0	[CLS]	O
0	the	O
0	systematic	O
0	availability	O
0	of	O
0	im	O
0	can	O
0	be	O
0	determined	O
0	by	O
0	comparison	O
0	of	O
0	the	O
0	area	B-PK
0	under	I-PK
0	the	I-PK
0	plasma	I-PK
0	concentration	I-PK
0	(	I-PK
0	au	I-PK
0	##c	I-PK
0	)	I-PK
0	versus	I-PK
0	time	I-PK
0	curves	I-PK
0	.	O
0	[SEP]	O
1	[CLS]	O
1	the	O
1	mean	O
1	au	B-PK
1	##c	I-PK
1	##0	I-PK
1	–	I-PK
1	24	I-PK
1	values	O
1	for	O
1	micro	O
1	##cid	O
1	s	O
1	##r	O
1	and	O
1	formulation	O
1	f	O
1	##3	O
1	were	O
1	124	O
1	##7	O
1	##8	O
1	±	O
1	104	O
1	.	O
1	21	O
1	ng	O
1	/	O
1	m	O
1	##l	O
1	h	O
1	##−	O
1	##1	O
1	and	O
1	121	O
1	##45	O
1	±	O
1	87	O
1	.	O
1	32	O
1	ng	O
1	/	O
1	m	O
1	##l	O
1	h	O
1	##−	O
1	##1	O
1	,	O
1	respectively	O
1	.	O
1	[SEP]	O
2	[CLS]	O
2	slow	O
2	in	O
2	v	O
2	##it	O
2	##ro	O
2	release	O
2	of	O
2	im	O
2	from	O
2	the	O
2	products	O
2	micro	O
2	##cid	O
2	s	O
2	##r	O
2	and	O
2	f	O
2	##3	O
2	formulation	O
2	##s	O
2	may	O
2	be	O
2	responsible	O
2	for	O
2	the	O
2	decreased	O
2	au	B-PK
2	##c	I-PK
2	values	O
2	when	O
2	compared	O
2	to	O
2	the	O
2	reported	O
2	conventional	O
2	dos	O
2	##age	O
2	forms	O
2	[	O
2	19	O
2	]	O
2	.	O
2	[SEP]	O
3	[CLS]	O
3	the	O
3	average	O
3	value	O
3	of	O
3	the	O
3	individual	O
3	and	O
3	mean	O
3	au	B-PK
3	##c	I-PK
3	##0	I-PK
3	–	I-PK
3	24	I-PK
3	ratio	I-PK
3	at	O
3	95	O
3	%	O
3	confidence	O
3	limit	O
3	(	O
3	0	O
3	.	O
3	8	O
3	–	O
3	1	O
3	.	O
3	25	O
3	)	O
3	was	O
3	within	O
3	acceptable	O
3	limits	O
3	for	O
3	bio	O
3	##e	O
3	##qui	O
3	##valent	O
3	products	O
3	[	O
3	19	O
3	]	O
3	.	O
3	[SEP]	O
4	[CLS]	O
4	in	O
4	order	O
4	to	O
4	obtain	O
4	in	O
4	v	O
4	##it	O
4	##ro	O
4	-	O
4	in	O
4	v	O
4	##ivo	O
4	correlation	O
4	,	O
4	drug	O
4	absorption	O
4	profiles	O
4	were	O
4	compared	O
4	for	O
4	micro	O
4	##cid	O
4	s	O
4	##r	O
4	and	O
4	formulation	O
4	f	O
4	##3	O
4	using	O
4	the	O
4	cumulative	B-PK
4	fraction	I-PK
4	of	I-PK
4	the	I-PK
4	drug	I-PK
4	absorbed	I-PK
4	in	O
4	v	O
4	##ivo	O
4	against	O
4	cumulative	B-PK
4	fraction	I-PK
4	of	I-PK
4	the	I-PK
4	drug	I-PK
4	dissolved	I-PK
4	in	O
4	v	O
4	##it	O
4	##ro	O
4	up	O
4	to	O
4	8	O
4	h	O
4	.	O
4	from	O
4	the	O
4	study	O
4	it	O
4	was	O
4	noticed	O
4	that	O
4	both	O
4	products	O
4	showed	O
4	an	O
4	adequate	O
4	correlation	O
4	.	O
4	[SEP]	O
5	[CLS]	O
5	currently	O
5	accepted	O
5	criteria	O
5	in	O
5	the	O
5	us	O
5	for	O
5	bio	O
5	##e	O
5	##qui	O
5	##valence	O
5	for	O
5	most	O
5	dos	O
5	##age	O
5	forms	O
5	require	O
5	that	O
5	the	O
5	mean	O
5	p	O
5	##har	O
5	##ma	O
5	##co	O
5	##kin	O
5	##etic	O
5	parameters	O
5	of	O
5	the	O
5	test	O
5	dos	O
5	##age	O
5	forms	O
5	should	O
5	be	O
5	within	O
5	80	O
5	–	O
5	120	O
5	%	O
5	of	O
5	the	O
5	reference	O
5	dos	O
5	##age	O
5	form	O
5	using	O
5	90	O
5	%	O
5	confidence	O
5	interval	O
5	.	O
5	[SEP]	O
6	[CLS]	O
6	the	O
6	observed	O
6	mean	O
6	au	B-PK
6	##c	I-PK
6	##0	I-PK
6	–	I-PK
6	∞	I-PK
6	##val	O
6	##ues	O
6	for	O
6	micro	O
6	##cid	O
6	s	O
6	##r	O
6	and	O
6	formulation	O
6	f	O
6	##3	O
6	were	O
6	126	O
6	##32	O
6	±	O
6	132	O
6	.	O
6	12	O
6	ng	O
6	/	O
6	m	O
6	##l	O
6	.	O
6	h	O
6	##−	O
6	##1	O
6	and	O
6	124	O
6	##5	O
6	##2	O
6	±	O
6	96	O
6	.	O
6	32	O
6	ng	O
6	/	O
6	m	O
6	##l	O
6	.	O
6	h	O
6	##−	O
6	##1	O
6	which	O
6	does	O
6	not	O
6	show	O
6	any	O
6	significant	O
6	statistical	O
6	difference	O
6	between	O
6	the	O
6	products	O
6	.	O
6	[SEP]	O
7	[CLS]	O
7	however	O
7	,	O
7	rapid	B-PK
7	##mu	I-PK
7	##co	I-PK
7	##ci	I-PK
7	##lia	I-PK
7	##ry	I-PK
7	clearance	I-PK
7	in	O
7	nasal	O
7	cavity	O
7	is	O
7	a	O
7	major	O
7	h	O
7	##ur	O
7	##dle	O
7	.	O
7	[SEP]	O
8	[CLS]	O
8	the	O
8	total	B-PK
8	area	I-PK
8	under	I-PK
8	the	I-PK
8	curve	I-PK
8	(	I-PK
8	au	I-PK
8	##c	I-PK
8	)	I-PK
8	of	O
8	the	O
8	serum	O
8	concentration	O
8	of	O
8	25	O
8	(	O
8	oh	O
8	)	O
8	d	O
8	up	O
8	to	O
8	day	O
8	28	O
8	[SEP]	O
9	[CLS]	O
9	a	O
9	one	O
9	-	O
9	compartment	O
9	model	O
9	with	O
9	an	O
9	absorption	B-PK
9	la	I-PK
9	##g	I-PK
9	-	I-PK
9	time	I-PK
9	(	I-PK
9	t	I-PK
9	##lag	I-PK
9	)	I-PK
9	best	O
9	described	O
9	the	O
9	data	O
9	.	O
9	[SEP]	O
10	[CLS]	O
10	the	O
10	final	O
10	model	O
10	included	O
10	age	O
10	(	O
10	adult	O
10	;	O
10	aged	O
10	)	O
10	on	O
10	apparent	B-PK
10	volume	I-PK
10	of	I-PK
10	distribution	I-PK
10	(	I-PK
10	v	I-PK
10	##d	I-PK
10	/	I-PK
10	f	I-PK
10	)	I-PK
10	,	O
10	apparent	B-PK
10	elimination	I-PK
10	rate	I-PK
10	(	I-PK
10	k	I-PK
10	##e	I-PK
10	/	I-PK
10	f	I-PK
10	)	I-PK
10	,	O
10	and	O
10	t	B-PK
10	##lag	I-PK
10	;	O
10	sex	O
10	(	O
10	female	O
10	;	O
10	male	O
10	)	O
10	on	O
10	k	B-PK
10	##e	I-PK
10	/	I-PK
10	f	I-PK
10	,	O
10	and	O
10	breed	O
10	(	O
10	be	O
10	##ag	O
10	##le	O
10	;	O
10	mixed	O
10	-	O
10	breed	O
10	)	O
10	on	O
10	v	B-PK
10	##d	I-PK
10	/	I-PK
10	f	I-PK
10	.	O
10	addition	O
10	of	O
10	the	O
10	co	O
10	##var	O
10	##iate	O
10	##s	O
10	to	O
10	the	O
10	model	O
10	explained	O
10	78	O
10	%	O
10	of	O
10	the	O
10	inter	O
10	##ind	O
10	##iv	O
10	##idal	O
10	var	O
10	##iability	O
10	(	O
10	ii	O
10	##v	O
10	)	O
10	in	O
10	v	B-PK
10	##d	I-PK
10	/	I-PK
10	f	I-PK
10	,	O
10	36	O
10	%	O
10	in	O
10	k	B-PK
10	##e	I-PK
10	/	I-PK
10	f	I-PK
10	,	O
10	and	O
10	24	O
10	%	O
10	in	O
10	t	B-PK
10	##lag	I-PK
10	,	O
10	respectively	O
10	.	O
10	[SEP]	O
11	[CLS]	O
11	the	O
11	recovery	O
11	rates	O
11	of	O
11	different	O
11	groups	O
11	were	O
11	similar	O
11	,	O
11	which	O
11	indicated	O
11	that	O
11	there	O
11	was	O
11	no	O
11	relationship	O
11	between	O
11	concentration	O
11	and	O
11	recovery	O
11	(	O
11	table	O
11	3	O
11	)	O
11	.	O
11	[SEP]	O
12	[CLS]	O
12	t	B-PK
12	##lag	I-PK
12	was	O
12	longer	O
12	,	O
12	whereas	O
12	v	B-PK
12	##d	I-PK
12	/	I-PK
12	f	I-PK
12	and	O
12	k	B-PK
12	##e	I-PK
12	/	I-PK
12	f	I-PK
12	were	O
12	lower	O
12	in	O
12	aged	O
12	compared	O
12	to	O
12	adult	O
12	animals	O
12	;	O
12	in	O
12	female	O
12	aged	O
12	dogs	O
12	k	B-PK
12	##e	I-PK
12	/	I-PK
12	f	I-PK
12	was	O
12	lower	O
12	than	O
12	in	O
12	male	O
12	aged	O
12	dogs	O
12	;	O
12	however	O
12	,	O
12	the	O
12	differences	O
12	were	O
12	of	O
12	low	O
12	magnitude	O
12	.	O
12	[SEP]	O
13	[CLS]	O
13	this	O
13	study	O
13	was	O
13	conducted	O
13	in	O
13	order	O
13	to	O
13	character	O
13	##ize	O
13	the	O
13	p	O
13	##har	O
13	##ma	O
13	##co	O
13	##kin	O
13	##etics	O
13	of	O
13	oral	O
13	##ly	O
13	administered	O
13	c	O
13	##ep	O
13	##hale	O
13	##xin	O
13	to	O
13	healthy	O
13	adult	O
13	and	O
13	aged	O
13	dogs	O
13	,	O
13	using	O
13	a	O
13	population	O
13	p	O
13	##har	O
13	##ma	O
13	##co	O
13	##kin	O
13	##etic	O
13	approach	O
13	.	O
13	[SEP]	O
14	[CLS]	O
14	different	O
14	disposition	O
14	of	O
14	c	O
14	##ep	O
14	##hale	O
14	##xin	O
14	may	O
14	be	O
14	expected	O
14	in	O
14	aged	O
14	dogs	O
14	.	O
14	[SEP]	O
15	[CLS]	O
15	finally	O
15	,	O
15	the	O
15	average	O
15	fluorescent	O
15	-	O
15	counts	O
15	in	O
15	each	O
15	experiment	O
15	were	O
15	compared	O
15	with	O
15	non	O
15	-	O
15	trans	O
15	##fected	O
15	cells	O
15	.	O
15	[SEP]	O
16	[CLS]	O
16	when	O
16	the	O
16	per	O
16	##fusion	O
16	rate	O
16	was	O
16	1	O
16	.	O
16	5	O
16	μ	O
16	##l	O
16	/	O
16	min	O
16	,	O
16	the	O
16	average	O
16	recover	O
16	##ies	O
16	measured	O
16	by	O
16	in	O
16	##cre	O
16	##ment	O
16	and	O
16	de	O
16	##cre	O
16	##ment	O
16	method	O
16	were	O
16	47	O
16	.	O
16	22	O
16	##±	O
16	##1	O
16	.	O
16	97	O
16	%	O
16	and	O
16	49	O
16	.	O
16	48	O
16	##±	O
16	##2	O
16	.	O
16	25	O
16	%	O
16	,	O
16	respectively	O
16	.	O
16	[SEP]	O
17	[CLS]	O
17	two	O
17	hundred	O
17	and	O
17	eighty	O
17	-	O
17	six	O
17	c	O
17	##ep	O
17	##hale	O
17	##xin	O
17	plasma	O
17	concentrations	O
17	obtained	O
17	from	O
17	previous	O
17	p	O
17	##har	O
17	##ma	O
17	##co	O
17	##kin	O
17	##etic	O
17	studies	O
17	were	O
17	used	O
17	.	O
17	[SEP]	O
18	[CLS]	O
18	after	O
18	a	O
18	wash	O
18	##out	O
18	period	O
18	of	O
18	1	O
18	week	O
18	,	O
18	the	O
18	next	O
18	cycle	O
18	of	O
18	administration	O
18	was	O
18	carried	O
18	out	O
18	.	O
18	[SEP]	O
19	[CLS]	O
19	each	O
19	of	O
19	the	O
19	les	O
19	##ion	O
19	r	O
19	##oi	O
19	’	O
19	s	O
19	and	O
19	background	O
19	r	O
19	##oi	O
19	’	O
19	s	O
19	mean	O
19	counts	O
19	were	O
19	used	O
19	as	O
19	p	O
19	##ois	O
19	##son	O
19	distribution	O
19	mean	O
19	values	O
19	.	O
19	[SEP]	O
20	[CLS]	O
20	the	O
20	e	O
20	##ff	O
20	##lux	O
20	transfer	B-PK
20	constant	I-PK
20	k	I-PK
20	##out	I-PK
20	was	O
20	calculated	O
20	as	O
20	0	O
20	.	O
20	05	O
20	min	O
20	##−	O
20	##1	O
20	,	O
20	equal	O
20	to	O
20	t	B-PK
20	##1	I-PK
20	/	I-PK
20	2	I-PK
20	,	I-PK
20	brain	I-PK
20	of	O
20	13	O
20	.	O
20	8	O
20	min	O
20	.	O
20	[SEP]	O
21	[CLS]	O
21	a	O
21	two	O
21	-	O
21	part	O
21	,	O
21	phase	O
21	i	O
21	,	O
21	random	O
21	##ized	O
21	,	O
21	five	O
21	-	O
21	period	O
21	crossover	O
21	trial	O
21	in	O
21	healthy	O
21	adults	O
21	(	O
21	aged	O
21	18	O
21	–	O
21	55	O
21	years	O
21	)	O
21	was	O
21	conducted	O
21	to	O
21	determine	O
21	the	O
21	dose	O
21	-	O
21	proportional	O
21	##ity	O
21	of	O
21	five	O
21	doses	O
21	of	O
21	f	O
21	##ent	O
21	##any	O
21	##l	O
21	sub	O
21	##ling	O
21	##ual	O
21	spray	O
21	(	O
21	100	O
21	,	O
21	200	O
21	,	O
21	400	O
21	,	O
21	600	O
21	,	O
21	and	O
21	800	O
21	μ	O
21	##g	O
21	)	O
21	under	O
21	fast	O
21	##ed	O
21	conditions	O
21	(	O
21	part	O
21	a	O
21	)	O
21	,	O
21	and	O
21	determine	O
21	the	O
21	effects	O
21	of	O
21	temperature	O
21	and	O
21	p	O
21	##h	O
21	in	O
21	the	O
21	oral	O
21	cavity	O
21	on	O
21	the	O
21	bio	B-PK
21	##ava	I-PK
21	##ila	I-PK
21	##bility	I-PK
21	of	O
21	f	O
21	##ent	O
21	##any	O
21	##l	O
21	after	O
21	administration	O
21	of	O
21	f	O
21	##ent	O
21	##any	O
21	##l	O
21	sub	O
21	##ling	O
21	##ual	O
21	spray	O
21	200	O
21	μ	O
21	##g	O
21	(	O
21	part	O
21	b	O
21	)	O
21	.	O
21	55	O
21	a	O
21	total	O
21	of	O
21	53	O
21	subjects	O
21	(	O
21	38	O
21	female	O
21	,	O
21	15	O
21	male	O
21	)	O
21	were	O
21	enrolled	O
21	in	O
21	part	O
21	a	O
21	and	O
21	14	O
21	subjects	O
21	(	O
21	3	O
21	female	O
21	,	O
21	11	O
21	male	O
21	)	O
21	were	O
21	enrolled	O
21	in	O
21	part	O
21	b	O
21	.	O
21	subjects	O
21	withdrew	O
21	due	O
21	to	O
21	positive	O
21	urine	O
21	drug	O
21	screen	O
21	(	O
21	n	O
21	=	O
21	2	O
21	)	O
21	,	O
21	positive	O
21	urine	O
21	alcohol	O
21	screen	O
21	(	O
21	n	O
21	=	O
21	1	O
21	)	O
21	,	O
21	and	O
21	withdrawal	O
21	of	O
21	consent	O
21	(	O
21	n	O
21	=	O
21	9	O
21	)	O
21	.	O
21	[SEP]	O
22	[CLS]	O
22	the	O
22	reliability	O
22	of	O
22	the	O
22	ex	O
22	##po	O
22	##nent	O
22	##ial	O
22	fitting	O
22	procedure	O
22	for	O
22	half	B-PK
22	-	I-PK
22	life	I-PK
22	calculations	O
22	was	O
22	assessed	O
22	using	O
22	mon	O
22	##te	O
22	car	O
22	##lo	O
22	simulation	O
22	of	O
22	error	O
22	propagation	O
22	.	O
22	[SEP]	O
23	[CLS]	O
23	a	B-PK
23	##0	I-PK
23	and	O
23	t	B-PK
23	##1	I-PK
23	/	I-PK
23	2	I-PK
23	values	O
23	were	O
23	fitted	O
23	for	O
23	every	O
23	time	O
23	series	O
23	,	O
23	and	O
23	mean	O
23	and	O
23	standard	O
23	de	O
23	##viation	O
23	##s	O
23	of	O
23	the	O
23	fitted	O
23	parameters	O
23	were	O
23	calculated	O
23	.	O
23	[SEP]	O
24	[CLS]	O
24	[UNK]	O
24	the	O
24	p	O
24	##k	O
24	model	O
24	predict	O
24	##s	O
24	the	O
24	concentrations	O
24	of	O
24	l	O
24	##y	O
24	##25	O
24	##10	O
24	##9	O
24	##24	O
24	for	O
24	various	O
24	doses	O
24	of	O
24	the	O
24	drug	O
24	.	O
24	[SEP]	O
25	[CLS]	O
25	the	O
25	p	O
25	##k	O
25	/	O
25	p	O
25	##d	O
25	model	O
25	predict	O
25	##s	O
25	the	O
25	c	O
25	##d	O
25	##34	O
25	+	O
25	cell	O
25	response	O
25	to	O
25	repeated	O
25	l	O
25	##y	O
25	##25	O
25	##10	O
25	##9	O
25	##24	O
25	dos	O
25	##ing	O
25	.	O
25	[SEP]	O
26	[CLS]	O
26	sample	O
26	size	O
26	was	O
26	the	O
26	size	O
26	of	O
26	the	O
26	respective	O
26	r	O
26	##oi	O
26	.	O
26	[SEP]	O
27	[CLS]	O
27	the	O
27	a	O
27	##ero	O
27	##si	O
27	##l	O
27	suspension	O
27	thus	O
27	obtained	O
27	was	O
27	freeze	O
27	dried	O
27	to	O
27	remove	O
27	water	O
27	by	O
27	sub	O
27	##lim	O
27	##ation	O
27	methods	O
27	.	O
27	[SEP]	O
28	[CLS]	O
28	10	O
28	,	O
28	000	O
28	random	O
28	numbers	O
28	for	O
28	all	O
28	three	O
28	imaging	O
28	time	O
28	points	O
28	were	O
28	generated	O
28	,	O
28	and	O
28	le	O
28	##ven	O
28	##berg	O
28	-	O
28	ma	O
28	##r	O
28	##qua	O
28	##rd	O
28	##t	O
28	non	O
28	##linear	O
28	fit	O
28	was	O
28	performed	O
28	for	O
28	all	O
28	10	O
28	,	O
28	000	O
28	time	O
28	series	O
28	generated	O
28	.	O
28	[SEP]	O
29	[CLS]	O
29	the	O
29	micro	O
29	##em	O
29	##ul	O
29	##sion	O
29	containing	O
29	solid	O
29	ads	O
29	##or	O
29	##bent	O
29	was	O
29	prepared	O
29	as	O
29	described	O
29	in	O
29	spray	O
29	drying	O
29	method	O
29	.	O
29	[SEP]	O
30	[CLS]	O
30	this	O
30	allowed	O
30	us	O
30	to	O
30	assess	O
30	the	O
30	reliability	O
30	of	O
30	the	O
30	a	B-PK
30	##0	I-PK
30	and	O
30	t	B-PK
30	##1	I-PK
30	/	I-PK
30	2	I-PK
30	values	O
30	.	O
30	[SEP]	O
31	[CLS]	O
31	choosing	O
31	op	O
31	##ti	O
31	##mum	O
31	imaging	O
31	times	O
31	,	O
31	as	O
31	stated	O
31	above	O
31	,	O
31	will	O
31	provide	O
31	more	O
31	reliable	O
31	a	B-PK
31	##0	I-PK
31	and	O
31	t	B-PK
31	##1	I-PK
31	/	I-PK
31	2	I-PK
31	data	O
31	.	O
31	[SEP]	O
32	[CLS]	O
32	the	O
32	study	O
32	was	O
32	designed	O
32	as	O
32	a	O
32	single	O
32	‐	O
32	center	O
32	,	O
32	5	O
32	‐	O
32	part	O
32	study	O
32	in	O
32	healthy	O
32	subjects	O
32	to	O
32	compare	O
32	the	O
32	bio	B-PK
32	##ava	I-PK
32	##ila	I-PK
32	##bility	I-PK
32	of	O
32	single	O
32	and	O
32	multiple	O
32	doses	O
32	of	O
32	the	O
32	up	O
32	##ada	O
32	##ci	O
32	##tin	O
32	##ib	O
32	er	O
32	formulation	O
32	with	O
32	the	O
32	i	O
32	##r	O
32	formulation	O
32	under	O
32	fast	O
32	##ing	O
32	conditions	O
32	,	O
32	to	O
32	evaluate	O
32	the	O
32	p	O
32	##har	O
32	##ma	O
32	##co	O
32	##kin	O
32	##etics	O
32	,	O
32	safety	O
32	,	O
32	and	O
32	to	O
32	##ler	O
32	##ability	O
32	of	O
32	multiple	O
32	doses	O
32	of	O
32	the	O
32	er	O
32	formulation	O
32	,	O
32	and	O
32	to	O
32	assess	O
32	the	O
32	effect	O
32	of	O
32	a	O
32	high	O
32	‐	O
32	fat	O
32	meal	O
32	on	O
32	the	O
32	p	O
32	##har	O
32	##ma	O
32	##co	O
32	##kin	O
32	##etics	O
32	of	O
32	the	O
32	er	O
32	formulation	O
32	.	O
32	[SEP]	O
33	[CLS]	O
33	geometric	O
33	mean	O
33	f	O
33	##xi	O
33	##ii	O
33	t	B-PK
33	##rough	I-PK
33	level	I-PK
33	was	O
33	0	O
33	.	O
33	17	O
33	i	O
33	##u	O
33	/	O
33	m	O
33	##l	O
33	.	O
33	geometric	O
33	terminal	B-PK
33	half	I-PK
33	-	I-PK
33	life	I-PK
33	was	O
33	13	O
33	.	O
33	7	O
33	days	O
33	.	O
33	[SEP]	O
34	[CLS]	O
34	sixty	O
34	patients	O
34	were	O
34	exposed	O
34	to	O
34	r	O
34	##f	O
34	##xi	O
34	##ii	O
34	-	O
34	a	O
34	##2	O
34	;	O
34	their	O
34	median	O
34	age	O
34	was	O
34	26	O
34	.	O
34	0	O
34	years	O
34	(	O
34	range	O
34	:	O
34	7	O
34	.	O
34	0	O
34	–	O
34	77	O
34	.	O
34	0	O
34	)	O
34	.	O
34	[SEP]	O
35	[CLS]	O
35	the	O
35	precision	O
35	(	O
35	c	O
35	##v	O
35	%	O
35	)	O
35	did	O
35	not	O
35	exceed	O
35	20	O
35	%	O
35	for	O
35	ll	O
35	##o	O
35	##q	O
35	and	O
35	15	O
35	%	O
35	for	O
35	the	O
35	other	O
35	concentrations	O
35	,	O
35	which	O
35	prove	O
35	the	O
35	close	O
35	##ness	O
35	of	O
35	the	O
35	measurements	O
35	.	O
35	[SEP]	O
36	[CLS]	O
36	the	O
36	quality	O
36	of	O
36	images	O
36	was	O
36	assessed	O
36	using	O
36	a	O
36	3	O
36	-	O
36	point	O
36	scale	O
36	(	O
36	poor	O
36	,	O
36	fair	O
36	,	O
36	and	O
36	good	O
36	)	O
36	.	O
36	[SEP]	O
37	[CLS]	O
37	re	O
37	##comb	O
37	##ina	O
37	##nt	O
37	factor	O
37	x	O
37	##ii	O
37	##i	O
37	-	O
37	a	O
37	##2	O
37	(	O
37	r	O
37	##f	O
37	##xi	O
37	##ii	O
37	-	O
37	a	O
37	##2	O
37	)	O
37	was	O
37	developed	O
37	for	O
37	prop	O
37	##hyl	O
37	##ax	O
37	##is	O
37	and	O
37	treatment	O
37	of	O
37	bleed	O
37	##s	O
37	in	O
37	patients	O
37	with	O
37	con	O
37	##gen	O
37	##ital	O
37	f	O
37	##xi	O
37	##ii	O
37	a	O
37	-	O
37	subunit	O
37	deficiency	O
37	.	O
37	[SEP]	O
38	[CLS]	O
38	a	O
38	##gi	O
38	##lent	O
38	bond	O
38	el	O
38	##ute	O
38	c	O
38	##18	O
38	,	O
38	50	O
38	mg	O
38	per	O
38	1	O
38	m	O
38	##l	O
38	cartridges	O
38	were	O
38	from	O
38	a	O
38	##gi	O
38	##lent	O
38	(	O
38	sa	O
38	##nta	O
38	c	O
38	##lar	O
38	##a	O
38	,	O
38	ca	O
38	)	O
38	.	O
38	[SEP]	O
39	[CLS]	O
39	we	O
39	also	O
39	know	O
39	that	O
39	medium	O
39	energy	O
39	co	O
39	##lli	O
39	##mat	O
39	##ors	O
39	have	O
39	about	O
39	10	O
39	mm	O
39	resolution	O
39	as	O
39	compared	O
39	to	O
39	0	O
39	.	O
39	1	O
39	mm	O
39	range	O
39	of	O
39	alpha	O
39	particles	O
39	.	O
39	[SEP]	O
40	[CLS]	O
40	no	O
40	patients	O
40	withdrew	O
40	due	O
40	to	O
40	lack	O
40	of	O
40	efficacy	O
40	.	O
40	[SEP]	O
41	[CLS]	O
41	all	O
41	other	O
41	re	O
41	##age	O
41	##nts	O
41	were	O
41	of	O
41	analytical	O
41	grade	O
41	and	O
41	obtained	O
41	from	O
41	standard	O
41	commercial	O
41	suppliers	O
41	.	O
41	[SEP]	O
42	[CLS]	O
42	mean	O
42	annual	O
42	##ized	O
42	bleeding	O
42	rate	O
42	(	O
42	a	O
42	##b	O
42	##r	O
42	)	O
42	was	O
42	0	O
42	.	O
42	04	O
42	##3	O
42	/	O
42	patient	O
42	-	O
42	year	O
42	.	O
42	[SEP]	O
43	[CLS]	O
43	figure	O
43	7	O
43	shows	O
43	the	O
43	plasma	O
43	ram	O
43	##ip	O
43	##ril	O
43	and	O
43	ram	O
43	##ip	O
43	##ril	O
43	##at	O
43	following	O
43	an	O
43	oral	O
43	dose	O
43	of	O
43	2	O
43	.	O
43	5	O
43	mg	O
43	ram	O
43	##ip	O
43	##ril	O
43	in	O
43	the	O
43	same	O
43	subject	O
43	.	O
43	[SEP]	O
44	[CLS]	O
44	seven	O
44	parameters	O
44	are	O
44	required	O
44	to	O
44	model	O
44	the	O
44	i	O
44	##v	O
44	ram	O
44	##ip	O
44	##ril	O
44	experiments	O
44	(	O
44	see	O
44	methods	O
44	)	O
44	:	O
44	c	B-PK
44	##lint	I-PK
44	_	I-PK
44	l	I-PK
44	,	O
44	c	B-PK
44	##lint	I-PK
44	_	I-PK
44	k	I-PK
44	and	O
44	f	B-PK
44	##rl	I-PK
44	describe	O
44	the	O
44	liver	O
44	and	O
44	kidney	O
44	metabolism	O
44	of	O
44	ram	O
44	##ip	O
44	##ril	O
44	and	O
44	its	O
44	conversion	O
44	to	O
44	ram	O
44	##ip	O
44	##ril	O
44	##at	O
44	;	O
44	ps	B-PK
44	##l	I-PK
44	and	O
44	ps	B-PK
44	##k	I-PK
44	describe	O
44	the	O
44	rate	O
44	that	O
44	this	O
44	ram	O
44	##ip	O
44	##ril	O
44	##at	O
44	leaves	O
44	the	O
44	liver	O
44	and	O
44	kidney	O
44	and	O
44	enters	O
44	the	O
44	systemic	O
44	circulation	O
44	;	O
44	ps	B-PK
44	##t	I-PK
44	describes	O
44	the	O
44	rate	O
44	that	O
44	ram	O
44	##ip	O
44	##ril	O
44	enters	O
44	the	O
44	in	O
44	##tra	O
44	##cellular	O
44	water	O
44	of	O
44	the	O
44	peripheral	O
44	tissues	O
44	and	O
44	f	B-PK
44	##u	I-PK
44	_	I-PK
44	cell	I-PK
44	describes	O
44	the	O
44	in	B-PK
44	##tra	I-PK
44	##cellular	I-PK
44	fraction	I-PK
44	un	I-PK
44	##bound	I-PK
44	which	O
44	determines	O
44	the	O
44	ram	O
44	##ip	O
44	##ril	O
44	equilibrium	O
44	volume	B-PK
44	of	I-PK
44	distribution	I-PK
44	.	O
44	[SEP]	O
45	[CLS]	O
45	five	O
45	additional	O
45	parameters	O
45	(	O
45	ad	B-PK
45	,	O
45	a	B-PK
45	,	O
45	t	B-PK
45	,	O
45	a	B-PK
45	##r	I-PK
45	,	O
45	as	B-PK
45	##low	I-PK
45	)	O
45	are	O
45	required	O
45	to	O
45	model	O
45	the	O
45	oral	O
45	ram	O
45	##ip	O
45	##ril	O
45	in	O
45	##test	O
45	##inal	O
45	absorption	O
45	.	O
45	[SEP]	O
46	[CLS]	O
46	none	O
46	of	O
46	the	O
46	reduction	O
46	##s	O
46	in	O
46	im	O
46	##mu	O
46	##no	O
46	##g	O
46	##lo	O
46	##bul	O
46	##in	O
46	is	O
46	##otype	O
46	##s	O
46	were	O
46	considered	O
46	to	O
46	be	O
46	an	O
46	a	O
46	##e	O
46	by	O
46	the	O
46	principal	O
46	investigators	O
46	.	O
46	[SEP]	O
47	[CLS]	O
47	the	O
47	rest	O
47	of	O
47	the	O
47	plasma	O
47	samples	O
47	were	O
47	stored	O
47	at	O
47	−	O
47	##20	O
47	##°	O
47	##f	O
47	until	O
47	ready	O
47	for	O
47	insulin	O
47	measurements	O
47	and	O
47	[	O
47	3	O
47	-	O
47	3	O
47	##h	O
47	]	O
47	glucose	O
47	trace	O
47	##r	O
47	ass	O
47	##ay	O
47	in	O
47	the	O
47	case	O
47	of	O
47	the	O
47	h	O
47	##yper	O
47	##ins	O
47	##ulin	O
47	##em	O
47	##ic	O
47	-	O
47	e	O
47	##ug	O
47	##ly	O
47	##ce	O
47	##mic	O
47	c	O
47	##lamp	O
47	(	O
47	e	O
47	##g	O
47	##c	O
47	)	O
47	.	O
47	[SEP]	O
48	[CLS]	O
48	p	O
48	##d	O
48	markers	O
48	were	O
48	measured	O
48	by	O
48	valid	O
48	##ated	O
48	methods	O
48	.	O
48	[SEP]	O
49	[CLS]	O
49	the	O
49	activated	O
49	factor	O
49	x	O
49	then	O
49	h	O
49	##ydro	O
49	##ly	O
49	##zed	O
49	a	O
49	ch	O
49	##rom	O
49	##ogenic	O
49	substrate	O
49	(	O
49	s	O
49	##23	O
49	##37	O
49	)	O
49	,	O
49	releasing	O
49	a	O
49	ch	O
49	##rom	O
49	##op	O
49	##hore	O
49	(	O
49	para	O
49	##ni	O
49	##tro	O
49	##ani	O
49	##line	O
49	)	O
49	,	O
49	which	O
49	was	O
49	detected	O
49	by	O
49	monitoring	O
49	light	O
49	absorb	O
49	##ance	O
49	at	O
49	405	O
49	nm	O
49	.	O
49	17	O
49	the	O
49	factor	O
49	x	O
49	##a	O
49	inhibitor	O
49	ass	O
49	##ay	O
49	consists	O
49	of	O
49	measuring	O
49	the	O
49	difference	O
49	in	O
49	factor	O
49	x	O
49	activity	O
49	(	O
49	p	O
49	##t	O
49	ass	O
49	##ay	O
49	)	O
49	before	O
49	and	O
49	after	O
49	in	O
49	##cu	O
49	##bation	O
49	of	O
49	a	O
49	mixture	O
49	of	O
49	normal	O
49	plasma	O
49	and	O
49	the	O
49	patient	O
49	'	O
49	s	O
49	plasma	O
49	for	O
49	1	O
49	hour	O
49	at	O
49	37	O
49	##°	O
49	##c	O
49	.	O
49	[SEP]	O
50	[CLS]	O
50	there	O
50	was	O
50	no	O
50	statistical	O
50	##ly	O
50	significant	O
50	relationship	O
50	(	O
50	zero	O
50	slope	O
50	re	O
50	##gression	O
50	)	O
50	between	O
50	δ	O
50	##δ	O
50	##q	O
50	##t	O
50	##ci	O
50	and	O
50	log	O
50	8	O
50	-	O
50	oh	O
50	-	O
50	lo	O
50	##xa	O
50	##pine	O
50	concentration	O
50	(	O
50	figure	O
50	4	O
50	)	O
50	.	O
50	[SEP]	O
51	[CLS]	O
51	r	O
51	##f	O
51	##xi	O
51	##ii	O
51	-	O
51	a	O
51	##2	O
51	##p	O
51	##rop	O
51	##hyl	O
51	##ax	O
51	##is	O
51	provided	O
51	sufficient	O
51	ha	O
51	##em	O
51	##ost	O
51	##atic	O
51	coverage	O
51	for	O
51	12	O
51	minor	O
51	surge	O
51	##ries	O
51	without	O
51	the	O
51	need	O
51	for	O
51	additional	O
51	f	O
51	##xi	O
51	##ii	O
51	therapy	O
51	;	O
51	eight	O
51	procedures	O
51	were	O
51	performed	O
51	within	O
51	7	O
51	days	O
51	of	O
51	the	O
51	patient	O
51	'	O
51	s	O
51	last	O
51	scheduled	O
51	r	O
51	##f	O
51	##xi	O
51	##ii	O
51	-	O
51	a	O
51	##2	O
51	##dos	O
51	##e	O
51	,	O
51	and	O
51	four	O
51	were	O
51	performed	O
51	10	O
51	to	O
51	21	O
51	days	O
51	after	O
51	the	O
51	last	O
51	dose	O
51	.	O
51	[SEP]	O
52	[CLS]	O
52	plasma	O
52	concentration	O
52	-	O
52	time	O
52	profiles	O
52	for	O
52	h	O
52	##c	O
52	in	O
52	the	O
52	fed	O
52	and	O
52	fast	O
52	##ed	O
52	state	O
52	are	O
52	shown	O
52	in	O
52	figure	O
52	1	O
52	and	O
52	p	O
52	##har	O
52	##ma	O
52	##co	O
52	##kin	O
52	##etic	O
52	parameters	O
52	in	O
52	table	O
52	1	O
52	.	O
52	[SEP]	O
53	[CLS]	O
53	the	O
53	fraction	O
53	##al	O
53	values	O
53	for	O
53	oral	O
53	administration	O
53	(	O
53	unless	O
53	otherwise	O
53	indicated	O
53	)	O
53	of	O
53	f	B-PK
53	for	O
53	each	O
53	of	O
53	the	O
53	op	O
53	##io	O
53	##ids	O
53	studied	O
53	were	O
53	as	O
53	follows	O
53	:	O
53	m	O
53	##or	O
53	##phine	O
53	averaged	O
53	0	O
53	.	O
53	38	O
53	with	O
53	a	O
53	range	O
53	of	O
53	0	O
53	.	O
53	15	O
53	to	O
53	0	O
53	.	O
53	64	O
53	;	O
53	tram	O
53	##ado	O
53	##l	O
53	was	O
53	0	O
53	.	O
53	73	O
53	males	O
53	and	O
53	0	O
53	.	O
53	79	O
53	in	O
53	females	O
53	;	O
53	code	O
53	##ine	O
53	was	O
53	0	O
53	.	O
53	50	O
53	;	O
53	me	O
53	##per	O
53	##id	O
53	##ine	O
53	had	O
53	a	O
53	range	O
53	of	O
53	0	O
53	.	O
53	40	O
53	to	O
53	0	O
53	.	O
53	60	O
53	with	O
53	an	O
53	average	O
53	of	O
53	0	O
53	.	O
53	50	O
53	;	O
53	h	O
53	##ydro	O
53	##co	O
53	##don	O
53	##e	O
53	was	O
53	0	O
53	.	O
53	80	O
53	;	O
53	o	O
53	##xy	O
53	##co	O
53	##don	O
53	##e	O
53	i	O
53	##r	O
53	had	O
53	a	O
53	range	O
53	of	O
53	0	O
53	.	O
53	60	O
53	to	O
53	0	O
53	.	O
53	87	O
53	with	O
53	an	O
53	average	O
53	of	O
53	0	O
53	.	O
53	74	O
53	,	O
53	which	O
53	was	O
53	similar	O
53	for	O
53	o	O
53	##xy	O
53	##co	O
53	##don	O
53	##e	O
53	c	O
53	##r	O
53	;	O
53	h	O
53	##ydro	O
53	##mor	O
53	##phone	O
53	had	O
53	a	O
53	range	O
53	of	O
53	0	O
53	.	O
53	52	O
53	to	O
53	0	O
53	.	O
53	58	O
53	with	O
53	an	O
53	average	O
53	of	O
53	0	O
53	.	O
53	55	O
53	;	O
53	o	O
53	##xy	O
53	##mor	O
53	##phone	O
53	was	O
53	0	O
53	.	O
53	10	O
53	;	O
53	met	O
53	##had	O
53	##one	O
53	was	O
53	0	O
53	.	O
53	80	O
53	with	O
53	a	O
53	range	O
53	of	O
53	0	O
53	.	O
53	10	O
53	to	O
53	0	O
53	.	O
53	90	O
53	;	O
53	f	O
53	##ent	O
53	##any	O
53	##l	O
53	was	O
53	0	O
53	.	O
53	33	O
53	for	O
53	the	O
53	oral	O
53	preparation	O
53	,	O
53	0	O
53	.	O
53	50	O
53	for	O
53	the	O
53	b	O
53	##uc	O
53	##cal	O
53	,	O
53	and	O
53	0	O
53	.	O
53	92	O
53	for	O
53	the	O
53	patch	O
53	;	O
53	and	O
53	b	O
53	##up	O
53	##ren	O
53	##or	O
53	##phine	O
53	averaged	O
53	0	O
53	.	O
53	63	O
53	with	O
53	a	O
53	range	O
53	of	O
53	0	O
53	.	O
53	50	O
53	to	O
53	0	O
53	.	O
53	75	O
53	.	O
53	[SEP]	O
54	[CLS]	O
54	overall	O
54	,	O
54	systemic	O
54	absorption	O
54	of	O
54	single	O
54	oral	O
54	doses	O
54	of	O
54	h	O
54	##c	O
54	-	O
54	er	O
54	20	O
54	mg	O
54	was	O
54	comparable	O
54	in	O
54	the	O
54	fed	O
54	and	O
54	fast	O
54	##ed	O
54	states	O
54	.	O
54	[SEP]	O
55	[CLS]	O
55	au	B-PK
55	##c	I-PK
55	estimates	O
55	for	O
55	h	O
55	##c	O
55	in	O
55	the	O
55	fed	O
55	and	O
55	fast	O
55	##ed	O
55	states	O
55	were	O
55	similar	O
55	,	O
55	and	O
55	the	O
55	f	B-PK
55	##rel	I-PK
55	based	O
55	on	O
55	these	O
55	estimates	O
55	was	O
55	close	O
55	to	O
55	100	O
55	%	O
55	.	O
55	[SEP]	O
56	[CLS]	O
56	the	O
56	mean	O
56	cm	B-PK
56	##ax	I-PK
56	for	O
56	h	O
56	##c	O
56	was	O
56	higher	O
56	in	O
56	the	O
56	fed	O
56	state	O
56	compared	O
56	with	O
56	the	O
56	fast	O
56	##ed	O
56	state	O
56	(	O
56	28	O
56	.	O
56	86	O
56	versus	O
56	22	O
56	.	O
56	74	O
56	ng	O
56	/	O
56	m	O
56	##l	O
56	)	O
56	.	O
56	[SEP]	O
57	[CLS]	O
57	the	O
57	median	O
57	t	B-PK
57	##max	I-PK
57	in	O
57	the	O
57	fed	O
57	and	O
57	fast	O
57	##ed	O
57	states	O
57	was	O
57	approximately	O
57	6	O
57	and	O
57	8	O
57	hours	O
57	,	O
57	respectively	O
57	,	O
57	and	O
57	mean	O
57	t	B-PK
57	##½	I-PK
57	was	O
57	4	O
57	.	O
57	9	O
57	and	O
57	6	O
57	.	O
57	5	O
57	hours	O
57	,	O
57	respectively	O
57	(	O
57	table	O
57	1	O
57	)	O
57	.	O
57	[SEP]	O
58	[CLS]	O
58	for	O
58	h	O
58	##ydro	O
58	##mor	O
58	##phone	O
58	,	O
58	cm	B-PK
58	##ax	I-PK
58	and	O
58	au	B-PK
58	##c	I-PK
58	values	O
58	were	O
58	approximately	O
58	6	O
58	%	O
58	of	O
58	those	O
58	for	O
58	h	O
58	##c	O
58	and	O
58	were	O
58	similar	O
58	in	O
58	both	O
58	the	O
58	fed	O
58	and	O
58	fast	O
58	##ed	O
58	states	O
58	;	O
58	median	O
58	t	B-PK
58	##max	I-PK
58	was	O
58	approximately	O
58	9	O
58	hours	O
58	in	O
58	the	O
58	fed	O
58	state	O
58	and	O
58	7	O
58	hours	O
58	in	O
58	the	O
58	fast	O
58	##ed	O
58	state	O
58	(	O
58	table	O
58	1	O
58	)	O
58	.	O
58	[SEP]	O
59	[CLS]	O
59	copper	O
59	sheet	O
59	(	O
59	0	O
59	.	O
59	76	O
59	##2	O
59	mm	O
59	thick	O
59	,	O
59	99	O
59	.	O
59	9	O
59	%	O
59	purity	O
59	)	O
59	was	O
59	purchased	O
59	from	O
59	es	O
59	##pi	O
59	metals	O
59	(	O
59	ash	O
59	##land	O
59	,	O
59	ore	O
59	##gon	O
59	,	O
59	united	O
59	states	O
59	)	O
59	,	O
59	and	O
59	natural	O
59	abundance	O
59	ch	O
59	##rom	O
59	##ium	O
59	was	O
59	electro	O
59	##plate	O
59	##d	O
59	by	O
59	four	O
59	star	O
59	finishing	O
59	(	O
59	saint	O
59	lo	O
59	##ui	O
59	##s	O
59	,	O
59	miss	O
59	##our	O
59	##i	O
59	,	O
59	united	O
59	states	O
59	)	O
59	.	O
59	[SEP]	O
60	[CLS]	O
60	six	O
60	patients	O
60	experienced	O
60	11	O
60	sa	O
60	##es	O
60	,	O
60	which	O
60	were	O
60	di	O
60	##ar	O
60	##r	O
60	##hoe	O
60	##a	O
60	(	O
60	n	O
60	=	O
60	3	O
60	)	O
60	,	O
60	mac	O
60	##ulo	O
60	##pa	O
60	##pu	O
60	##lar	O
60	r	O
60	##ash	O
60	(	O
60	n	O
60	=	O
60	2	O
60	)	O
60	,	O
60	pneumonia	O
60	,	O
60	h	O
60	##yper	O
60	##gly	O
60	##ca	O
60	##emia	O
60	,	O
60	d	O
60	##ys	O
60	##p	O
60	##no	O
60	##ea	O
60	,	O
60	s	O
60	##tom	O
60	##ati	O
60	##tis	O
60	,	O
60	vomit	O
60	##ing	O
60	,	O
60	and	O
60	p	O
60	##ap	O
60	##ular	O
60	r	O
60	##ash	O
60	(	O
60	each	O
60	n	O
60	=	O
60	1	O
60	)	O
60	.	O
60	[SEP]	O
61	[CLS]	O
61	the	O
61	analytical	O
61	column	O
61	was	O
61	a	O
61	c	O
61	##18	O
61	column	O
61	(	O
61	ve	O
61	##nus	O
61	##il	O
61	x	O
61	##b	O
61	##p	O
61	,	O
61	5	O
61	μ	O
61	##m	O
61	,	O
61	4	O
61	.	O
61	6	O
61	##×	O
61	##15	O
61	##0	O
61	mm	O
61	;	O
61	age	O
61	##la	O
61	,	O
61	t	O
61	##ian	O
61	##jin	O
61	,	O
61	people	O
61	’	O
61	s	O
61	republic	O
61	of	O
61	chin	O
61	##a	O
61	)	O
61	guarded	O
61	with	O
61	a	O
61	re	O
61	##fill	O
61	##able	O
61	pre	O
61	##co	O
61	##lum	O
61	##n	O
61	(	O
61	c	O
61	##18	O
61	,	O
61	2	O
61	.	O
61	0	O
61	##×	O
61	##20	O
61	mm	O
61	;	O
61	all	O
61	##tech	O
61	,	O
61	le	O
61	##xing	O
61	##ton	O
61	,	O
61	k	O
61	##y	O
61	,	O
61	us	O
61	##a	O
61	)	O
61	.	O
61	[SEP]	O
62	[CLS]	O
62	fifteen	O
62	men	O
62	(	O
62	28	O
62	±	O
62	6	O
62	years	O
62	,	O
62	b	O
62	##mi	O
62	24	O
62	±	O
62	2	O
62	kg	O
62	/	O
62	m	O
62	##2	O
62	)	O
62	and	O
62	15	O
62	women	O
62	(	O
62	29	O
62	±	O
62	7	O
62	years	O
62	,	O
62	b	O
62	##mi	O
62	21	O
62	±	O
62	2	O
62	kg	O
62	/	O
62	m	O
62	##2	O
62	)	O
62	of	O
62	ca	O
62	##uca	O
62	##sian	O
62	origin	O
62	,	O
62	aged	O
62	22	O
62	–	O
62	46	O
62	years	O
62	,	O
62	participated	O
62	in	O
62	this	O
62	study	O
62	.	O
62	[SEP]	O
63	[CLS]	O
63	sensitivity	O
63	is	O
63	evaluated	O
63	by	O
63	the	O
63	ll	O
63	##o	O
63	##q	O
63	determination	O
63	##s	O
63	,	O
63	which	O
63	are	O
63	defined	O
63	as	O
63	the	O
63	lowest	O
63	concentration	O
63	that	O
63	can	O
63	be	O
63	re	O
63	##lia	O
63	##bly	O
63	and	O
63	re	O
63	##p	O
63	##rod	O
63	##uc	O
63	##ibly	O
63	measured	O
63	in	O
63	at	O
63	least	O
63	three	O
63	replica	O
63	##tes	O
63	.	O
63	[SEP]	O
64	[CLS]	O
64	the	O
64	cm	B-PK
64	##ax	I-PK
64	of	O
64	palm	O
64	##ati	O
64	##ne	O
64	in	O
64	group	O
64	a	O
64	was	O
64	significantly	O
64	higher	O
64	than	O
64	those	O
64	of	O
64	groups	O
64	b	O
64	and	O
64	c	O
64	(	O
64	p	O
64	<	O
64	0	O
64	.	O
64	05	O
64	)	O
64	,	O
64	but	O
64	the	O
64	difference	O
64	in	O
64	cm	B-PK
64	##ax	I-PK
64	values	O
64	between	O
64	groups	O
64	b	O
64	and	O
64	c	O
64	was	O
64	not	O
64	significant	O
64	(	O
64	p	O
64	>	O
64	0	O
64	.	O
64	05	O
64	)	O
64	.	O
64	[SEP]	O
65	[CLS]	O
65	the	O
65	differences	O
65	with	O
65	regard	O
65	to	O
65	t	B-PK
65	##max	I-PK
65	and	O
65	t	B-PK
65	##1	I-PK
65	/	I-PK
65	2	I-PK
65	of	O
65	palm	O
65	##ati	O
65	##ne	O
65	among	O
65	the	O
65	three	O
65	groups	O
65	were	O
65	not	O
65	significant	O
65	.	O
65	[SEP]	O
66	[CLS]	O
66	meanwhile	O
66	,	O
66	the	O
66	au	B-PK
66	##c	I-PK
66	##0	I-PK
66	–	I-PK
66	t	I-PK
66	of	O
66	group	O
66	a	O
66	was	O
66	higher	O
66	than	O
66	groups	O
66	b	O
66	and	O
66	c	O
66	,	O
66	whereby	O
66	group	O
66	a	O
66	>	O
66	group	O
66	b	O
66	>	O
66	group	O
66	c	O
66	(	O
66	table	O
66	4	O
66	)	O
66	;	O
66	however	O
66	,	O
66	the	O
66	differences	O
66	were	O
66	not	O
66	significant	O
66	.	O
66	[SEP]	O
67	[CLS]	O
67	these	O
67	results	O
67	(	O
67	figure	O
67	3	O
67	(	O
67	c	O
67	)	O
67	)	O
67	indicated	O
67	that	O
67	both	O
67	c	O
67	##nc	O
67	and	O
67	a	O
67	##c	O
67	may	O
67	decrease	O
67	the	O
67	bio	B-PK
67	##ava	I-PK
67	##ila	I-PK
67	##bility	I-PK
67	of	O
67	palm	O
67	##ati	O
67	##ne	O
67	in	O
67	comparison	O
67	to	O
67	r	O
67	##ca	O
67	##e	O
67	alone	O
67	.	O
67	[SEP]	O
68	[CLS]	O
68	peak	O
68	areas	O
68	in	O
68	the	O
68	ch	O
68	##roma	O
68	##to	O
68	##gram	O
68	##s	O
68	for	O
68	the	O
68	spike	O
68	##d	O
68	plasma	O
68	samples	O
68	containing	O
68	the	O
68	above	O
68	lowest	O
68	concentrations	O
68	were	O
68	compared	O
68	with	O
68	the	O
68	signal	O
68	-	O
68	to	O
68	noise	O
68	ratio	O
68	≥	O
68	10	O
68	.	O
68	[SEP]	O
69	[CLS]	O
69	more	O
69	##over	O
69	,	O
69	cop	O
69	shows	O
69	that	O
69	plasma	O
69	m	O
69	##or	O
69	##phine	O
69	flu	O
69	##ct	O
69	##uations	O
69	about	O
69	remain	O
69	close	O
69	to	O
69	the	O
69	bounds	O
69	of	O
69	m	O
69	##or	O
69	##phine	O
69	'	O
69	s	O
69	therapeutic	O
69	window	O
69	for	O
69	anal	O
69	##ges	O
69	##ia	O
69	.	O
69	[SEP]	O
70	[CLS]	O
70	we	O
70	modeled	O
70	the	O
70	mi	O
70	##c	O
70	distribution	O
70	with	O
70	1	O
70	million	O
70	replica	O
70	##tes	O
70	using	O
70	a	O
70	normal	O
70	distribution	O
70	of	O
70	a	O
70	log	O
70	##2	O
70	geometric	O
70	mean	O
70	mi	O
70	##c	O
70	±	O
70	s	O
70	##d	O
70	and	O
70	then	O
70	back	O
70	transforming	O
70	into	O
70	the	O
70	geometric	O
70	mi	O
70	##c	O
70	.	O
70	[SEP]	O
71	[CLS]	O
71	twenty	O
71	-	O
71	four	O
71	hour	O
71	urine	O
71	collections	O
71	could	O
71	not	O
71	be	O
71	taken	O
71	until	O
71	subjects	O
71	had	O
71	given	O
71	consent	O
71	and	O
71	were	O
71	admitted	O
71	to	O
71	the	O
71	investigation	O
71	##al	O
71	site	O
71	,	O
71	therefore	O
71	estimated	O
71	c	O
71	##rea	O
71	##tin	O
71	##ine	O
71	clearance	O
71	values	O
71	using	O
71	the	O
71	cock	O
71	##croft	O
71	-	O
71	g	O
71	##ault	O
71	equation	O
71	were	O
71	used	O
71	at	O
71	screening	O
71	to	O
71	class	O
71	##ify	O
71	subjects	O
71	with	O
71	varying	O
71	degrees	O
71	of	O
71	re	O
71	##nal	O
71	imp	O
71	##air	O
71	##ment	O
71	,	O
71	to	O
71	achieve	O
71	12	O
71	subjects	O
71	per	O
71	group	O
71	.	O
71	[SEP]	O
72	[CLS]	O
72	subjects	O
72	were	O
72	subsequently	O
72	re	O
72	-	O
72	classified	O
72	within	O
72	the	O
72	re	O
72	##nal	O
72	imp	O
72	##air	O
72	##ment	O
72	categories	O
72	according	O
72	to	O
72	their	O
72	actual	O
72	serum	O
72	c	O
72	##rea	O
72	##tin	O
72	##ine	O
72	clearance	O
72	values	O
72	obtained	O
72	on	O
72	day	O
72	1	O
72	,	O
72	resulting	O
72	in	O
72	a	O
72	di	O
72	##sp	O
72	##rop	O
72	##ort	O
72	##ion	O
72	##ate	O
72	number	O
72	of	O
72	subjects	O
72	within	O
72	each	O
72	category	O
72	.	O
72	[SEP]	O
73	[CLS]	O
73	flu	O
73	##cona	O
73	##zo	O
73	##le	O
73	’	O
73	s	O
73	long	O
73	terminal	B-PK
73	half	I-PK
73	-	I-PK
73	life	I-PK
73	leads	O
73	to	O
73	little	O
73	var	O
73	##iability	O
73	across	O
73	the	O
73	dos	O
73	##ing	O
73	interval	O
73	[	O
73	20	O
73	]	O
73	,	O
73	so	O
73	the	O
73	au	B-PK
73	##c	I-PK
73	:	I-PK
73	mi	I-PK
73	##c	I-PK
73	ratio	I-PK
73	also	O
73	was	O
73	calculated	O
73	from	O
73	the	O
73	simulated	O
73	patients	O
73	using	O
73	flu	O
73	##cona	O
73	##zo	O
73	##le	O
73	concentration	O
73	multi	O
73	##plied	O
73	by	O
73	24	O
73	hours	O
73	and	O
73	divided	O
73	by	O
73	mi	O
73	##c	O
73	.	O
73	[SEP]	O
74	[CLS]	O
74	rats	O
74	had	O
74	been	O
74	bred	O
74	in	O
74	a	O
74	breeding	O
74	room	O
74	(	O
74	12	O
74	h	O
74	dark	O
74	-	O
74	light	O
74	cycle	O
74	;	O
74	temperature	O
74	was	O
74	23	O
74	##°	O
74	##c	O
74	±	O
74	2	O
74	##°	O
74	##c	O
74	and	O
74	humidity	O
74	was	O
74	50	O
74	±	O
74	5	O
74	%	O
74	)	O
74	and	O
74	fed	O
74	standard	O
74	laboratory	O
74	food	O
74	and	O
74	water	O
74	for	O
74	a	O
74	week	O
74	to	O
74	a	O
74	##cc	O
74	##lim	O
74	##ati	O
74	##zation	O
74	.	O
74	[SEP]	O
75	[CLS]	O
75	twenty	O
75	male	O
75	s	O
75	##pra	O
75	##gue	O
75	-	O
75	da	O
75	##wley	O
75	rats	O
75	(	O
75	220	O
75	–	O
75	250	O
75	)	O
75	g	O
75	were	O
75	obtained	O
75	from	O
75	s	O
75	##han	O
75	ch	O
75	##uan	O
75	##hong	O
75	experimental	O
75	animals	O
75	technology	O
75	co	O
75	.	O
75	,	O
75	l	O
75	##t	O
75	##d	O
75	.	O
75	(	O
75	be	O
75	##iji	O
75	##ng	O
75	,	O
75	chin	O
75	##a	O
75	)	O
75	.	O
75	[SEP]	O
76	[CLS]	O
76	in	O
76	the	O
76	multi	O
76	##var	O
76	##iable	O
76	re	O
76	##gression	O
76	analysis	O
76	only	O
76	at	O
76	##v	O
76	concentrations	O
76	(	O
76	p	O
76	<	O
76	0	O
76	.	O
76	01	O
76	)	O
76	and	O
76	r	O
76	##ito	O
76	##na	O
76	##vir	O
76	use	O
76	(	O
76	p	O
76	=	O
76	0	O
76	.	O
76	02	O
76	)	O
76	remained	O
76	independently	O
76	associated	O
76	with	O
76	d	O
76	##ys	O
76	##lip	O
76	##ide	O
76	##mia	O
76	.	O
76	[SEP]	O
77	[CLS]	O
77	the	O
77	enhanced	O
77	oral	O
77	absorption	O
77	of	O
77	pm	O
77	##x	O
77	in	O
77	hp	O
77	-	O
77	beta	O
77	-	O
77	c	O
77	##d	O
77	/	O
77	pm	O
77	##x	O
77	/	O
77	d	O
77	##ck	O
77	/	O
77	p	O
77	##18	O
77	##8	O
77	-	O
77	ne	O
77	might	O
77	be	O
77	at	O
77	##tri	O
77	##but	O
77	##able	O
77	to	O
77	the	O
77	following	O
77	factors	O
77	:	O
77	1	O
77	)	O
77	d	O
77	##ck	O
77	complex	O
77	increased	O
77	the	O
77	lip	O
77	##op	O
77	##hil	O
77	##icit	O
77	##y	O
77	,	O
77	partition	O
77	coefficient	O
77	,	O
77	and	O
77	apparent	O
77	lip	O
77	##oso	O
77	##lub	O
77	##ility	O
77	of	O
77	the	O
77	drug	O
77	in	O
77	the	O
77	in	O
77	##test	O
77	##inal	O
77	membrane	O
77	.	O
77	[SEP]	O
78	[CLS]	O
78	2	O
78	)	O
78	do	O
78	##ca	O
78	in	O
78	the	O
78	d	O
78	##ck	O
78	can	O
78	disrupt	O
78	the	O
78	in	O
78	##test	O
78	##inal	O
78	barrier	O
78	via	O
78	o	O
78	##cc	O
78	##lu	O
78	##din	O
78	de	O
78	##ph	O
78	##os	O
78	##ph	O
78	##ory	O
78	##lation	O
78	and	O
78	c	O
78	##yt	O
78	##os	O
78	##kel	O
78	##etal	O
78	rear	O
78	##rang	O
78	##ement	O
78	at	O
78	the	O
78	e	O
78	##pit	O
78	##hel	O
78	##ial	O
78	lining	O
78	tight	O
78	junction	O
78	level	O
78	,	O
78	followed	O
78	by	O
78	promotion	O
78	of	O
78	the	O
78	para	O
78	##cellular	O
78	transport	O
78	of	O
78	drug	O
78	;	O
78	more	O
78	##over	O
78	,	O
78	selective	O
78	interaction	O
78	with	O
78	the	O
78	bi	O
78	##le	O
78	acid	O
78	transport	O
78	##ers	O
78	on	O
78	the	O
78	in	O
78	##test	O
78	##inal	O
78	membrane	O
78	may	O
78	facilitate	O
78	trans	O
78	##cellular	O
78	transport	O
78	of	O
78	the	O
78	drug	O
78	.	O
78	18	O
78	,	O
78	51	O
78	,	O
78	65	O
78	3	O
78	)	O
78	na	O
78	##no	O
78	-	O
78	sized	O
78	drop	O
78	##lets	O
78	so	O
78	##lub	O
78	##ili	O
78	##zing	O
78	the	O
78	hp	O
78	-	O
78	beta	O
78	-	O
78	c	O
78	##d	O
78	/	O
78	pm	O
78	##x	O
78	/	O
78	d	O
78	##ck	O
78	/	O
78	p	O
78	##18	O
78	##8	O
78	in	O
78	a	O
78	su	O
78	##pra	O
78	##mo	O
78	##le	O
78	##cular	O
78	state	O
78	also	O
78	improved	O
78	the	O
78	oral	O
78	absorption	O
78	of	O
78	the	O
78	drug	O
78	by	O
78	increasing	O
78	the	O
78	di	O
78	##sper	O
78	##si	O
78	##bility	O
78	of	O
78	the	O
78	drug	O
78	complex	O
78	and	O
78	protecting	O
78	the	O
78	complex	O
78	form	O
78	from	O
78	di	O
78	##sso	O
78	##ciation	O
78	,	O
78	thereby	O
78	f	O
78	##ac	O
78	##ilitating	O
78	its	O
78	diffusion	O
78	across	O
78	the	O
78	un	O
78	##st	O
78	##ir	O
78	##red	O
78	water	O
78	layer	O
78	and	O
78	access	O
78	to	O
78	the	O
78	brush	O
78	border	O
78	membrane	O
78	of	O
78	enter	O
78	##ocytes	O
78	.	O
78	66	O
78	4	O
78	)	O
78	surf	O
78	##act	O
78	##ant	O
78	-	O
78	induced	O
78	membrane	O
78	fluid	O
78	##ity	O
78	and	O
78	thus	O
78	per	B-PK
78	##me	I-PK
78	##ability	I-PK
78	changes	O
78	potentially	O
78	afforded	O
78	the	O
78	enhanced	O
78	drug	O
78	absorption	O
78	.	O
78	62	O
78	,	O
78	67	O
78	[SEP]	O
79	[CLS]	O
79	for	O
79	measuring	O
79	the	O
79	f	B-PK
79	##eca	I-PK
79	##l	I-PK
79	ex	I-PK
79	##cre	I-PK
79	##tion	I-PK
79	rate	I-PK
79	,	O
79	weighing	O
79	the	O
79	f	O
79	##ec	O
79	##es	O
79	collected	O
79	during	O
79	0	O
79	–	O
79	24	O
79	,	O
79	24	O
79	–	O
79	48	O
79	,	O
79	48	O
79	–	O
79	72	O
79	,	O
79	72	O
79	–	O
79	96	O
79	,	O
79	96	O
79	–	O
79	120	O
79	,	O
79	120	O
79	–	O
79	144	O
79	,	O
79	and	O
79	144	O
79	–	O
79	168	O
79	hours	O
79	after	O
79	14	O
79	##c	O
79	-	O
79	h	O
79	##yal	O
79	##uron	O
79	##ic	O
79	acid	O
79	administration	O
79	,	O
79	adding	O
79	di	O
79	##st	O
79	##ille	O
79	##d	O
79	water	O
79	,	O
79	stirring	O
79	to	O
79	make	O
79	ho	O
79	##mogeneous	O
79	with	O
79	the	O
79	p	O
79	##oly	O
79	##tron	O
79	ho	O
79	##mo	O
79	##gen	O
79	##izer	O
79	(	O
79	kin	O
79	##ema	O
79	##tica	O
79	in	O
79	##c	O
79	.	O
79	)	O
79	,	O
79	and	O
79	further	O
79	di	O
79	##lut	O
79	##ing	O
79	to	O
79	100	O
79	m	O
79	##l	O
79	with	O
79	di	O
79	##st	O
79	##ille	O
79	##d	O
79	water	O
79	,	O
79	the	O
79	0	O
79	.	O
79	2	O
79	m	O
79	##l	O
79	was	O
79	transferred	O
79	to	O
79	via	O
79	##ls	O
79	as	O
79	radio	O
79	##act	O
79	##ivity	O
79	samples	O
79	.	O
79	[SEP]	O
80	[CLS]	O
80	neither	O
80	d	O
80	##ha	O
80	nor	O
80	its	O
80	meta	O
80	##bol	O
80	##ites	O
80	(	O
80	m	O
80	##1	O
80	and	O
80	d	O
80	##ha	O
80	-	O
80	g	O
80	)	O
80	changed	O
80	significantly	O
80	(	O
80	p	O
80	>	O
80	0	O
80	.	O
80	05	O
80	)	O
80	in	O
80	au	B-PK
80	##c	I-PK
80	##0	I-PK
80	-	I-PK
80	t	I-PK
80	after	O
80	5	O
80	-	O
80	day	O
80	oral	O
80	doses	O
80	of	O
80	d	O
80	##ha	O
80	or	O
80	a	O
80	##rs	O
80	.	O
80	[SEP]	O
81	[CLS]	O
81	plasma	B-PK
81	concentration	I-PK
81	ma	I-PK
81	##xi	I-PK
81	##ma	I-PK
81	occurred	O
81	at	O
81	a	O
81	median	O
81	t	B-PK
81	##max	I-PK
81	of	O
81	40	O
81	minutes	O
81	to	O
81	1	O
81	hour	O
81	after	O
81	all	O
81	treatments	O
81	,	O
81	and	O
81	the	O
81	u	O
81	##rina	O
81	##ry	O
81	ex	O
81	##cre	O
81	##tion	O
81	parameters	O
81	f	B-PK
81	##e	I-PK
81	##0	I-PK
81	‐	I-PK
81	36	I-PK
81	and	O
81	c	B-PK
81	##l	I-PK
81	##r	I-PK
81	,	I-PK
81	0	I-PK
81	‐	I-PK
81	36	I-PK
81	were	O
81	comparable	O
81	between	O
81	the	O
81	treatments	O
81	(	O
81	table	O
81	s	O
81	##1	O
81	)	O
81	.	O
81	[SEP]	O
82	[CLS]	O
82	graphical	O
82	comparisons	O
82	of	O
82	individual	O
82	and	O
82	geometric	O
82	mean	O
82	au	B-PK
82	##c	I-PK
82	##0	I-PK
82	‐	I-PK
82	t	I-PK
82	##z	I-PK
82	and	O
82	cm	B-PK
82	##ax	I-PK
82	values	O
82	are	O
82	given	O
82	in	O
82	figure	O
82	s	O
82	##3	O
82	.	O
82	[SEP]	O
83	[CLS]	O
83	excluded	O
83	from	O
83	the	O
83	study	O
83	were	O
83	:	O
83	women	O
83	of	O
83	child	O
83	-	O
83	bearing	O
83	potential	O
83	without	O
83	reliable	O
83	con	O
83	##tra	O
83	##ception	O
83	,	O
83	pregnant	O
83	or	O
83	la	O
83	##ct	O
83	##ating	O
83	women	O
83	,	O
83	persons	O
83	with	O
83	any	O
83	disease	O
83	likely	O
83	to	O
83	disturb	O
83	the	O
83	vitamin	O
83	k	O
83	metabolism	O
83	such	O
83	as	O
83	bleeding	O
83	or	O
83	th	O
83	##rom	O
83	##boe	O
83	##mbo	O
83	##lic	O
83	history	O
83	(	O
83	acute	O
83	or	O
83	persistent	O
83	)	O
83	or	O
83	d	O
83	##ys	O
83	##function	O
83	##s	O
83	of	O
83	in	O
83	##test	O
83	##inal	O
83	lip	O
83	##id	O
83	absorption	O
83	(	O
83	c	O
83	##ro	O
83	##hn	O
83	’	O
83	s	O
83	disease	O
83	,	O
83	ch	O
83	##ole	O
83	##static	O
83	liver	O
83	diseases	O
83	)	O
83	.	O
83	[SEP]	O
84	[CLS]	O
84	ta	O
84	and	O
84	me	O
84	##p	O
84	##b	O
84	treatment	O
84	significantly	O
84	increased	O
84	s	O
84	##b	O
84	##ma	O
84	fly	O
84	via	O
84	##bility	O
84	in	O
84	ad	O
84	##ose	O
84	-	O
84	dependent	O
84	manner	O
84	(	O
84	fi	O
84	##g	O
84	.	O
84	1	O
84	##b	O
84	,	O
84	c	O
84	)	O
84	,	O
84	similar	O
84	##to	O
84	the	O
84	known	O
84	a	O
84	##r	O
84	antagonist	O
84	bi	O
84	##cal	O
84	##uta	O
84	##mi	O
84	##de	O
84	,	O
84	whereas	O
84	an	O
84	a	O
84	##r	O
84	-	O
84	unrelated	O
84	compound	O
84	,	O
84	i	O
84	##bu	O
84	##p	O
84	##ro	O
84	##fen	O
84	,	O
84	did	O
84	not	O
84	(	O
84	supplement	O
84	##ary	O
84	fi	O
84	##g	O
84	.	O
84	1	O
84	)	O
84	.	O
84	[SEP]	O
85	[CLS]	O
85	the	O
85	u	O
85	##v	O
85	absorption	O
85	was	O
85	measured	O
85	at	O
85	full	O
85	spectrum	O
85	(	O
85	200	O
85	‐	O
85	300	O
85	nm	O
85	)	O
85	and	O
85	at	O
85	215	O
85	nm	O
85	.	O
85	[SEP]	O
86	[CLS]	O
86	the	O
86	primary	O
86	end	O
86	##point	O
86	was	O
86	the	O
86	natural	O
86	log	O
86	parasite	O
86	reduction	O
86	rate	O
86	per	O
86	24	O
86	h	O
86	.	O
86	secondary	O
86	end	O
86	##points	O
86	were	O
86	the	O
86	first	O
86	-	O
86	order	O
86	parasite	O
86	clearance	O
86	rate	O
86	constant	O
86	and	O
86	derived	O
86	half	O
86	-	O
86	life	O
86	(	O
86	estimated	O
86	with	O
86	the	O
86	online	O
86	worldwide	O
86	anti	O
86	##mal	O
86	##aria	O
86	##l	O
86	resistance	O
86	network	O
86	[	O
86	w	O
86	##war	O
86	##n	O
86	]	O
86	tool	O
86	##ki	O
86	##t	O
86	)	O
86	,	O
86	para	O
86	##si	O
86	##ta	O
86	##emia	O
86	reduction	O
86	times	O
86	(	O
86	50	O
86	%	O
86	,	O
86	80	O
86	%	O
86	,	O
86	90	O
86	%	O
86	,	O
86	and	O
86	99	O
86	%	O
86	)	O
86	,	O
86	parasite	O
86	clearance	O
86	time	O
86	,	O
86	26	O
86	,	O
86	27	O
86	,	O
86	28	O
86	game	O
86	##to	O
86	##cy	O
86	##ta	O
86	##emia	O
86	reduction	O
86	,	O
86	and	O
86	fever	O
86	clearance	O
86	time	O
86	.	O
86	[SEP]	O
87	[CLS]	O
87	consistent	O
87	with	O
87	these	O
87	results	O
87	,	O
87	both	O
87	ta	O
87	and	O
87	##me	O
87	##p	O
87	##b	O
87	significantly	O
87	restored	O
87	lo	O
87	##com	O
87	##oto	O
87	##r	O
87	function	O
87	in	O
87	flies	O
87	expressing	O
87	##pol	O
87	##y	O
87	##q	O
87	-	O
87	expanded	O
87	a	O
87	##r	O
87	in	O
87	motor	O
87	neurons	O
87	(	O
87	ok	O
87	##37	O
87	##1	O
87	>	O
87	u	O
87	##as	O
87	-	O
87	a	O
87	##r	O
87	##5	O
87	##2	O
87	##q	O
87	)	O
87	,	O
87	measured	O
87	as	O
87	##in	O
87	##cre	O
87	##ase	O
87	##d	O
87	displacement	O
87	and	O
87	velocity	O
87	of	O
87	walking	O
87	in	O
87	adult	O
87	flies	O
87	(	O
87	fi	O
87	##g	O
87	.	O
87	1	O
87	##d	O
87	–	O
87	f	O
87	)	O
87	,	O
87	to	O
87	similar	O
87	levels	O
87	observed	O
87	in	O
87	flies	O
87	##ex	O
87	##pressing	O
87	a	O
87	##r	O
87	variants	O
87	that	O
87	m	O
87	##od	O
87	##ulate	O
87	core	O
87	##gu	O
87	##lator	O
87	binding	O
87	to	O
87	the	O
87	a	O
87	##f	O
87	##2	O
87	domain	O
87	(	O
87	ok	O
87	##37	O
87	##1	O
87	>	O
87	u	O
87	##as	O
87	-	O
87	a	O
87	##r	O
87	##5	O
87	##2	O
87	##q	O
87	-	O
87	k	O
87	##7	O
87	##20	O
87	##a	O
87	and	O
87	ok	O
87	##37	O
87	##1	O
87	>	O
87	u	O
87	##as	O
87	-	O
87	a	O
87	##r	O
87	##6	O
87	##6	O
87	##q	O
87	-	O
87	e	O
87	##8	O
87	##9	O
87	##7	O
87	##k	O
87	)	O
87	.	O
87	[SEP]	O
88	[CLS]	O
88	the	O
88	hp	O
88	##l	O
88	##c	O
88	system	O
88	consisted	O
88	of	O
88	a	O
88	be	O
88	##ckman	O
88	system	O
88	gold	O
88	equipped	O
88	with	O
88	a	O
88	50	O
88	##7	O
88	auto	O
88	##sa	O
88	##mple	O
88	##r	O
88	fitted	O
88	with	O
88	a	O
88	50	O
88	μ	O
88	##l	O
88	loop	O
88	,	O
88	coupled	O
88	to	O
88	an	O
88	ultra	O
88	##vio	O
88	##let	O
88	(	O
88	u	O
88	##v	O
88	)	O
88	‐	O
88	photo	O
88	##dio	O
88	##de	O
88	array	O
88	be	O
88	##ckman	O
88	168	O
88	detector	O
88	and	O
88	gold	O
88	release	O
88	4	O
88	.	O
88	0	O
88	software	O
88	(	O
88	be	O
88	##ckman	O
88	ins	O
88	##t	O
88	.	O
88	[SEP]	O
89	[CLS]	O
89	the	O
89	ma	O
89	##ximal	O
89	##ly	O
89	tolerate	O
89	##d	O
89	dos	O
89	##age	O
89	rate	O
89	for	O
89	a	O
89	single	O
89	treatment	O
89	of	O
89	v	O
89	##in	O
89	##c	O
89	##rist	O
89	##ine	O
89	in	O
89	ta	O
89	##sman	O
89	##ian	O
89	devil	O
89	##s	O
89	was	O
89	0	O
89	.	O
89	105	O
89	mg	O
89	/	O
89	kg	O
89	.	O
89	[SEP]	O
90	[CLS]	O
90	bio	B-PK
90	##ava	I-PK
90	##ila	I-PK
90	##bility	I-PK
90	for	O
90	l	O
90	‐	O
90	p	O
90	##z	O
90	##q	O
90	of	O
90	o	O
90	##dt	O
90	r	O
90	##ac	O
90	‐	O
90	p	O
90	##z	O
90	##q	O
90	and	O
90	c	O
90	##ys	O
90	##tic	O
90	##ide	O
90	at	O
90	40	O
90	mg	O
90	/	O
90	kg	O
90	was	O
90	comparable	O
90	(	O
90	l	O
90	‐	O
90	p	O
90	##z	O
90	##q	O
90	area	B-PK
90	under	I-PK
90	the	I-PK
90	concentration	I-PK
90	‐	I-PK
90	time	I-PK
90	curve	I-PK
90	from	I-PK
90	zero	I-PK
90	to	I-PK
90	in	I-PK
90	##finity	I-PK
90	(	I-PK
90	au	I-PK
90	##c	I-PK
90	##0	I-PK
90	–	I-PK
90	∞	I-PK
90	)	I-PK
90	test	I-PK
90	/	I-PK
90	reference	I-PK
90	ratio	I-PK
90	(	O
90	90	O
90	%	O
90	confidence	O
90	interval	O
90	(	O
90	c	O
90	##i	O
90	)	O
90	)	O
90	:	O
90	96	O
90	%	O
90	(	O
90	84	O
90	–	O
90	111	O
90	%	O
90	)	O
90	)	O
90	,	O
90	whereas	O
90	relative	B-PK
90	bio	I-PK
90	##ava	I-PK
90	##ila	I-PK
90	##bility	I-PK
90	of	O
90	o	O
90	##dt	O
90	l	O
90	‐	O
90	p	O
90	##z	O
90	##q	O
90	20	O
90	mg	O
90	/	O
90	kg	O
90	was	O
90	~	O
90	40	O
90	%	O
90	that	O
90	of	O
90	c	O
90	##ys	O
90	##tic	O
90	##ide	O
90	40	O
90	mg	O
90	/	O
90	kg	O
90	(	O
90	test	O
90	/	O
90	reference	O
90	:	O
90	40	O
90	%	O
90	(	O
90	35	O
90	–	O
90	46	O
90	%	O
90	)	O
90	)	O
90	.	O
90	[SEP]	O
91	[CLS]	O
91	two	O
91	crossover	O
91	studies	O
91	(	O
91	n	O
91	=	O
91	32	O
91	and	O
91	36	O
91	,	O
91	respectively	O
91	)	O
91	assessed	O
91	the	O
91	relative	B-PK
91	bio	I-PK
91	##ava	I-PK
91	##ila	I-PK
91	##bility	I-PK
91	of	O
91	these	O
91	o	O
91	##dt	O
91	##s	O
91	vs	O
91	.	O
91	c	O
91	##ys	O
91	##tic	O
91	##ide	O
91	in	O
91	adults	O
91	.	O
91	[SEP]	O
92	[CLS]	O
92	au	B-PK
92	##c	I-PK
92	##0	I-PK
92	‐	I-PK
92	∞	I-PK
92	and	O
92	peak	B-PK
92	plasma	I-PK
92	concentration	I-PK
92	(	I-PK
92	cm	I-PK
92	##ax	I-PK
92	)	I-PK
92	were	O
92	highly	O
92	variable	O
92	in	O
92	both	O
92	studies	O
92	.	O
92	[SEP]	O
93	[CLS]	O
93	for	O
93	both	O
93	o	O
93	##dt	O
93	##s	O
93	,	O
93	l	O
93	‐	O
93	p	O
93	##z	O
93	##q	O
93	au	B-PK
93	##c	I-PK
93	##0	I-PK
93	–	I-PK
93	∞	I-PK
93	showed	O
93	greater	O
93	than	O
93	dose	O
93	‐	O
93	proportional	O
93	increase	O
93	over	O
93	the	O
93	ranges	O
93	tested	O
93	and	O
93	a	O
93	significant	O
93	food	O
93	effect	O
93	.	O
93	[SEP]	O
94	[CLS]	O
94	as	O
94	shown	O
94	in	O
94	table	O
94	1	O
94	,	O
94	the	O
94	lowest	O
94	mean	O
94	time	B-PK
94	to	I-PK
94	reach	I-PK
94	peak	I-PK
94	plasma	I-PK
94	concentration	I-PK
94	(	I-PK
94	t	I-PK
94	##max	I-PK
94	)	I-PK
94	of	O
94	0	O
94	.	O
94	83	O
94	h	O
94	was	O
94	observed	O
94	for	O
94	the	O
94	dog	O
94	and	O
94	the	O
94	highest	O
94	value	O
94	of	O
94	3	O
94	.	O
94	25	O
94	h	O
94	for	O
94	the	O
94	monkey	O
94	.	O
94	[SEP]	O
95	[CLS]	O
95	the	O
95	mean	O
95	estimated	O
95	plasma	B-PK
95	clearance	I-PK
95	(	I-PK
95	c	I-PK
95	##l	I-PK
95	/	I-PK
95	f	I-PK
95	)	I-PK
95	increased	O
95	across	O
95	species	O
95	,	O
95	from	O
95	0	O
95	.	O
95	05	O
95	l	O
95	/	O
95	h	O
95	for	O
95	mouse	O
95	to	O
95	42	O
95	.	O
95	52	O
95	l	O
95	/	O
95	h	O
95	for	O
95	dog	O
95	as	O
95	displayed	O
95	in	O
95	table	O
95	1	O
95	.	O
95	[SEP]	O
96	[CLS]	O
96	after	O
96	single	O
96	p	O
96	.	O
96	o	O
96	.	O
96	administration	O
96	of	O
96	cap	O
96	##mat	O
96	##ini	O
96	##b	O
96	using	O
96	capsule	O
96	formulation	O
96	on	O
96	day	O
96	1	O
96	,	O
96	cap	O
96	##mat	O
96	##ini	O
96	##b	O
96	was	O
96	rapidly	O
96	absorbed	O
96	with	O
96	median	O
96	t	B-PK
96	##max	I-PK
96	of	O
96	1	O
96	.	O
96	5	O
96	‐	O
96	2	O
96	hours	O
96	,	O
96	with	O
96	the	O
96	exception	O
96	of	O
96	100	O
96	mg	O
96	q	O
96	.	O
96	d	O
96	.	O
96	following	O
96	repeated	O
96	daily	O
96	dos	O
96	##ing	O
96	up	O
96	to	O
96	day	O
96	15	O
96	following	O
96	the	O
96	q	O
96	.	O
96	d	O
96	.	O
96	or	O
96	b	O
96	.	O
96	i	O
96	.	O
96	d	O
96	.	O
96	regime	O
96	##n	O
96	using	O
96	capsule	O
96	##s	O
96	,	O
96	median	O
96	t	B-PK
96	##max	I-PK
96	ranged	O
96	1	O
96	.	O
96	0	O
96	‐	O
96	4	O
96	.	O
96	0	O
96	hours	O
96	(	O
96	table	O
96	4	O
96	,	O
96	figures	O
96	1	O
96	and	O
96	2	O
96	)	O
96	,	O
96	whereas	O
96	absorption	O
96	was	O
96	more	O
96	rapid	O
96	after	O
96	dos	O
96	##ing	O
96	using	O
96	a	O
96	tablet	O
96	with	O
96	median	O
96	t	B-PK
96	##max	I-PK
96	of	O
96	1	O
96	.	O
96	0	O
96	hour	O
96	on	O
96	both	O
96	day	O
96	1	O
96	and	O
96	day	O
96	15	O
96	.	O
96	[SEP]	O
97	[CLS]	O
97	plate	O
97	##let	O
97	count	O
97	≥	O
97	##75	O
97	×	O
97	109	O
97	/	O
97	l	O
97	(	O
97	or	O
97	≥	O
97	30	O
97	×	O
97	109	O
97	/	O
97	l	O
97	if	O
97	bone	O
97	ma	O
97	##rrow	O
97	involvement	O
97	)	O
97	serum	O
97	bi	O
97	##li	O
97	##ru	O
97	##bin	O
97	≤	O
97	##1	O
97	.	O
97	5	O
97	×	O
97	upper	O
97	limit	O
97	of	O
97	normal	O
97	unless	O
97	raised	O
97	due	O
97	to	O
97	g	O
97	##il	O
97	##bert	O
97	’	O
97	s	O
97	syndrome	O
97	,	O
97	in	O
97	which	O
97	case	O
97	up	O
97	to	O
97	3	O
97	×	O
97	upper	O
97	limit	O
97	of	O
97	normal	O
97	is	O
97	per	O
97	##missible	O
97	##alan	O
97	##ine	O
97	amino	O
97	##tra	O
97	##ns	O
97	##fer	O
97	##ase	O
97	and	O
97	as	O
97	##par	O
97	##tate	O
97	amino	O
97	##tra	O
97	##ns	O
97	##fer	O
97	##ase	O
97	≤	O
97	##2	O
97	.	O
97	5	O
97	×	O
97	upper	O
97	limit	O
97	of	O
97	normal	O
97	unless	O
97	raised	O
97	due	O
97	to	O
97	he	O
97	##pa	O
97	##tic	O
97	involvement	O
97	##cal	O
97	##culate	O
97	##d	O
97	c	O
97	##rea	O
97	##tin	O
97	##ine	O
97	clearance	O
97	(	O
97	cock	O
97	##roft	O
97	–	O
97	g	O
97	##ault	O
97	formula	O
97	)	O
97	≥	O
97	##30	O
97	m	O
97	##l	O
97	/	O
97	min	O
97	(	O
97	un	O
97	##cor	O
97	##re	O
97	##cted	O
97	value	O
97	)	O
97	ability	O
97	to	O
97	understand	O
97	the	O
97	purpose	O
97	and	O
97	risks	O
97	of	O
97	the	O
97	study	O
97	and	O
97	provide	O
97	written	O
97	informed	O
97	consent	O
97	##will	O
97	##ing	O
97	and	O
97	able	O
97	to	O
97	participate	O
97	in	O
97	all	O
97	required	O
97	evaluation	O
97	##s	O
97	and	O
97	procedures	O
97	in	O
97	the	O
97	study	O
97	protocol	O
97	##will	O
97	##ing	O
97	to	O
97	participate	O
97	in	O
97	appropriate	O
97	pregnancy	O
97	prevention	O
97	measures	O
97	:	O
97	women	O
97	with	O
97	child	O
97	##be	O
97	##aring	O
97	potential	O
97	who	O
97	have	O
97	a	O
97	negative	O
97	serum	O
97	or	O
97	urine	O
97	pregnancy	O
97	test	O
97	during	O
97	screening	O
97	(	O
97	within	O
97	14	O
97	days	O
97	prior	O
97	to	O
97	the	O
97	start	O
97	of	O
97	trial	O
97	treatment	O
97	)	O
97	and	O
97	who	O
97	agree	O
97	to	O
97	use	O
97	one	O
97	highly	O
97	effective	O
97	form	O
97	of	O
97	con	O
97	##tra	O
97	##ception	O
97	combined	O
97	with	O
97	an	O
97	effective	O
97	form	O
97	of	O
97	con	O
97	##tra	O
97	##ception	O
97	from	O
97	the	O
97	first	O
97	administration	O
97	of	O
97	all	O
97	study	O
97	drugs	O
97	throughout	O
97	the	O
97	trial	O
97	and	O
97	for	O
97	12	O
97	months	O
97	after	O
97	the	O
97	last	O
97	dose	O
97	of	O
97	all	O
97	study	O
97	drugs	O
97	.	O
97	[SEP]	O
98	[CLS]	O
98	simulated	O
98	l	O
98	##n	O
98	au	B-PK
98	##c	I-PK
98	##0	I-PK
98	–	I-PK
98	∞	I-PK
98	values	O
98	for	O
98	the	O
98	g	O
98	##ran	O
98	##ule	O
98	dos	O
98	##age	O
98	administration	O
98	for	O
98	subjects	O
98	weighing	O
98	<	O
98	20	O
98	kg	O
98	and	O
98	the	O
98	tablet	O
98	dos	O
98	##age	O
98	administration	O
98	for	O
98	subjects	O
98	weighing	O
98	≥	O
98	##20	O
98	kg	O
98	are	O
98	presented	O
98	in	O
98	fi	O
98	##g	O
98	.	O
98	5	O
98	to	O
98	illustrate	O
98	uniform	O
98	exposure	O
98	across	O
98	the	O
98	weight	O
98	ranges	O
98	for	O
98	the	O
98	proposed	O
98	labeled	O
98	dos	O
98	##ing	O
98	of	O
98	g	O
98	##ran	O
98	##ules	O
98	and	O
98	tablets	O
98	.	O
98	[SEP]	O
99	[CLS]	O
99	the	O
99	literature	O
99	on	O
99	the	O
99	p	O
99	##har	O
99	##ma	O
99	##co	O
99	##kin	O
99	##etics	O
99	of	O
99	van	O
99	##com	O
99	##y	O
99	##cin	O
99	in	O
99	patients	O
99	undergoing	O
99	extra	O
99	##cor	O
99	##pore	O
99	##al	O
99	membrane	O
99	oxygen	O
99	##ation	O
99	(	O
99	e	O
99	##c	O
99	##mo	O
99	)	O
99	therapy	O
99	is	O
99	sparse	O
99	.	O
99	[SEP]	O
100	[CLS]	O
100	samples	O
100	were	O
100	compared	O
100	to	O
100	no	O
100	##ve	O
100	##x	O
100	sharp	O
100	pre	O
100	-	O
100	stained	O
100	markers	O
100	(	O
100	in	O
100	##vi	O
100	##tro	O
100	##gen	O
100	)	O
100	.	O
100	[SEP]	O
101	[CLS]	O
101	au	B-PK
101	##c	I-PK
101	improved	O
101	from	O
101	0	O
101	.	O
101	62	O
101	##7	O
101	(	O
101	set	O
101	14	O
101	)	O
101	to	O
101	0	O
101	.	O
101	83	O
101	##4	O
101	(	O
101	set	O
101	3	O
101	)	O
101	with	O
101	a	O
101	33	O
101	%	O
101	increase	O
101	.	O
101	[SEP]	O
102	[CLS]	O
102	parameters	O
102	included	O
102	clearance	B-PK
102	of	O
102	2	O
102	.	O
102	83	O
102	l	O
102	/	O
102	h	O
102	##r	O
102	,	O
102	limited	O
102	central	B-PK
102	volume	I-PK
102	of	I-PK
102	distribution	I-PK
102	24	O
102	.	O
102	2	O
102	l	O
102	,	O
102	and	O
102	low	O
102	residual	O
102	var	O
102	##iability	O
102	0	O
102	.	O
102	67	O
102	%	O
102	.	O
102	[SEP]	O
103	[CLS]	O
103	our	O
103	study	O
103	showed	O
103	that	O
103	the	O
103	peak	B-PK
103	time	I-PK
103	,	O
103	half	B-PK
103	-	I-PK
103	life	I-PK
103	time	I-PK
103	,	O
103	mean	O
103	residence	B-PK
103	time	I-PK
103	and	O
103	area	B-PK
103	under	I-PK
103	the	I-PK
103	curve	I-PK
103	of	O
103	g	O
103	##a	O
103	-	O
103	c	O
103	##ts	O
103	/	O
103	5	O
103	-	O
103	f	O
103	##u	O
103	were	O
103	longer	O
103	or	O
103	more	O
103	than	O
103	those	O
103	of	O
103	the	O
103	5	O
103	-	O
103	f	O
103	##u	O
103	group	O
103	,	O
103	but	O
103	the	O
103	maximum	B-PK
103	concentration	I-PK
103	(	I-PK
103	cm	I-PK
103	##ax	I-PK
103	)	I-PK
103	was	O
103	lower	O
103	.	O
103	[SEP]	O
104	[CLS]	O
104	the	O
104	p	O
104	##har	O
104	##ma	O
104	##co	O
104	##kin	O
104	##etic	O
104	parameters	O
104	(	O
104	p	O
104	##k	O
104	)	O
104	cm	B-PK
104	##ax	I-PK
104	,	O
104	au	B-PK
104	##c	I-PK
104	##0	I-PK
104	-	I-PK
104	24	I-PK
104	##h	I-PK
104	and	O
104	t	B-PK
104	##max	I-PK
104	obtained	O
104	from	O
104	the	O
104	curve	O
104	of	O
104	plasma	O
104	concentrations	O
104	,	O
104	are	O
104	shown	O
104	in	O
104	table	O
104	8	O
104	.	O
104	[SEP]	O
105	[CLS]	O
105	three	O
105	parameters	O
105	character	O
105	##ize	O
105	this	O
105	metabolism	O
105	:	O
105	the	O
105	intrinsic	B-PK
105	liver	I-PK
105	(	I-PK
105	c	I-PK
105	##lint	I-PK
105	_	I-PK
105	l	I-PK
105	)	I-PK
105	and	O
105	kidney	B-PK
105	(	I-PK
105	c	I-PK
105	##lint	I-PK
105	_	I-PK
105	k	I-PK
105	)	I-PK
105	clearance	I-PK
105	and	O
105	the	O
105	fraction	B-PK
105	of	I-PK
105	total	I-PK
105	liver	I-PK
105	ram	I-PK
105	##ip	I-PK
105	##ril	I-PK
105	metabolism	I-PK
105	that	I-PK
105	is	I-PK
105	converted	I-PK
105	to	I-PK
105	ram	I-PK
105	##ip	I-PK
105	##ril	I-PK
105	##at	I-PK
105	(	I-PK
105	f	I-PK
105	##rl	I-PK
105	)	I-PK
105	.	O
105	[SEP]	O
106	[CLS]	O
106	clearance	B-PK
106	(	I-PK
106	c	I-PK
106	##l	I-PK
106	)	I-PK
106	was	O
106	calculated	O
106	as	O
106	0	O
106	.	O
106	69	O
106	##3	O
106	×	O
106	v	O
106	##d	O
106	/	O
106	t	O
106	##1	O
106	/	O
106	2	O
106	where	O
106	v	B-PK
106	##d	I-PK
106	is	O
106	the	O
106	apparent	B-PK
106	volume	I-PK
106	of	I-PK
106	distribution	I-PK
106	and	O
106	t	B-PK
106	##1	I-PK
106	/	I-PK
106	2	I-PK
106	is	O
106	the	O
106	elimination	B-PK
106	half	I-PK
106	-	I-PK
106	life	I-PK
106	.	O
106	[SEP]	O
107	[CLS]	O
107	because	O
107	there	O
107	was	O
107	no	O
107	in	O
107	##tra	O
107	##ven	O
107	##ous	O
107	com	O
107	##par	O
107	##ator	O
107	arm	O
107	in	O
107	this	O
107	study	O
107	,	O
107	equivalent	O
107	bio	B-PK
107	##ava	I-PK
107	##ila	I-PK
107	##bility	I-PK
107	was	O
107	assumed	O
107	for	O
107	comparisons	O
107	of	O
107	apparent	B-PK
107	volume	I-PK
107	of	I-PK
107	distribution	I-PK
107	(	I-PK
107	v	I-PK
107	##d	I-PK
107	/	I-PK
107	f	I-PK
107	)	I-PK
107	and	O
107	clearance	B-PK
107	(	I-PK
107	c	I-PK
107	##l	I-PK
107	/	I-PK
107	f	I-PK
107	)	I-PK
107	,	O
107	where	O
107	f	B-PK
107	is	O
107	the	O
107	oral	B-PK
107	bio	I-PK
107	##ava	I-PK
107	##ila	I-PK
107	##bility	I-PK
107	or	O
107	fraction	B-PK
107	of	I-PK
107	the	I-PK
107	drug	I-PK
107	absorbed	I-PK
107	(	O
107	unknown	O
107	)	O
107	.	O
107	[SEP]	O
108	[CLS]	O
108	single	O
108	-	O
108	dose	O
108	p	O
108	##k	O
108	studies	O
108	of	O
108	til	O
108	##di	O
108	##pi	O
108	##ros	O
108	##in	O
108	were	O
108	performed	O
108	with	O
108	ne	O
108	##ut	O
108	##rop	O
108	##eni	O
108	##c	O
108	lung	O
108	-	O
108	infected	O
108	mice	O
108	following	O
108	sub	O
108	##cut	O
108	##aneous	O
108	administration	O
108	(	O
108	dose	O
108	volume	O
108	:	O
108	0	O
108	.	O
108	2	O
108	m	O
108	##l	O
108	)	O
108	of	O
108	til	O
108	##di	O
108	##pi	O
108	##ros	O
108	##in	O
108	(	O
108	1	O
108	,	O
108	2	O
108	,	O
108	4	O
108	,	O
108	6	O
108	,	O
108	and	O
108	8	O
108	mg	O
108	/	O
108	kg	O
108	)	O
108	.	O
108	[SEP]	O
109	[CLS]	O
109	t	O
109	##m	O
109	##z	O
109	alone	O
109	had	O
109	no	O
109	significant	O
109	effect	O
109	on	O
109	the	O
109	release	O
109	of	O
109	l	O
109	##dh	O
109	by	O
109	the	O
109	u	O
109	##8	O
109	##7	O
109	/	O
109	t	O
109	##r	O
109	cells	O
109	(	O
109	fi	O
109	##g	O
109	.	O
109	5	O
109	##c	O
109	)	O
109	.	O
109	[SEP]	O
110	[CLS]	O
110	urine	O
110	samples	O
110	were	O
110	taken	O
110	from	O
110	a	O
110	24	O
110	-	O
110	hour	O
110	collection	O
110	to	O
110	measure	O
110	c	O
110	##rea	O
110	##tin	O
110	##ine	O
110	clearance	O
110	.	O
110	[SEP]	O
111	[CLS]	O
111	we	O
111	also	O
111	tested	O
111	the	O
111	effect	O
111	of	O
111	and	O
111	##rog	O
111	##rap	O
111	##hol	O
111	##ide	O
111	on	O
111	m	O
111	##c	O
111	##f	O
111	-	O
111	7	O
111	cells	O
111	and	O
111	observed	O
111	similar	O
111	dose	O
111	-	O
111	and	O
111	time	O
111	-	O
111	dependent	O
111	effect	O
111	on	O
111	mm	O
111	##p	O
111	loss	O
111	(	O
111	additional	O
111	file	O
111	2	O
111	:	O
111	figure	O
111	s	O
111	##2	O
111	##b	O
111	)	O
111	.	O
111	[SEP]	O
112	[CLS]	O
112	no	O
112	p	O
112	##har	O
112	##ma	O
112	##co	O
112	##kin	O
112	##etic	O
112	and	O
112	bio	B-PK
112	##ava	I-PK
112	##ila	I-PK
112	##bility	I-PK
112	data	O
112	on	O
112	g	O
112	##eran	O
112	##iol	O
112	are	O
112	currently	O
112	available	O
112	.	O
112	[SEP]	O
113	[CLS]	O
113	after	O
113	in	O
113	##tra	O
113	##ven	O
113	##ous	O
113	administration	O
113	of	O
113	g	O
113	##eran	O
113	##iol	O
113	to	O
113	rats	O
113	(	O
113	50	O
113	mg	O
113	/	O
113	kg	O
113	)	O
113	,	O
113	its	O
113	concentration	O
113	in	O
113	whole	O
113	blood	O
113	(	O
113	detected	O
113	via	O
113	hp	O
113	##l	O
113	##c	O
113	)	O
113	decreased	O
113	following	O
113	an	O
113	apparent	O
113	pseudo	O
113	-	O
113	first	O
113	order	O
113	kinetic	O
113	##s	O
113	with	O
113	a	O
113	half	B-PK
113	-	I-PK
113	life	I-PK
113	of	O
113	12	O
113	.	O
113	5	O
113	±	O
113	1	O
113	.	O
113	5	O
113	min	O
113	.	O
113	[SEP]	O
114	[CLS]	O
114	the	O
114	absolute	B-PK
114	bio	I-PK
114	##ava	I-PK
114	##ila	I-PK
114	##bility	I-PK
114	values	O
114	of	O
114	oral	O
114	formulation	O
114	##s	O
114	(	O
114	50	O
114	mg	O
114	/	O
114	kg	O
114	)	O
114	of	O
114	em	O
114	##ul	O
114	##si	O
114	##fied	O
114	g	O
114	##eran	O
114	##iol	O
114	or	O
114	fiber	O
114	-	O
114	ads	O
114	##or	O
114	##bed	O
114	g	O
114	##eran	O
114	##iol	O
114	were	O
114	92	O
114	and	O
114	16	O
114	%	O
114	,	O
114	respectively	O
114	.	O
114	[SEP]	O
115	[CLS]	O
115	low	O
115	temperature	O
115	decreased	O
115	the	O
115	intrinsic	B-PK
115	clearance	I-PK
115	of	O
115	liver	O
115	micro	O
115	##some	O
115	##s	O
115	,	O
115	with	O
115	no	O
115	change	O
115	in	O
115	protein	O
115	binding	O
115	or	O
115	he	O
115	##pa	O
115	##to	O
115	##cy	O
115	##te	O
115	up	O
115	##take	O
115	of	O
115	ni	O
115	##mo	O
115	##di	O
115	##pine	O
115	.	O
115	[SEP]	O
116	[CLS]	O
116	the	O
116	concentration	O
116	vs	O
116	time	O
116	curves	O
116	for	O
116	fl	O
116	##b	O
116	##z	O
116	and	O
116	/	O
116	or	O
116	its	O
116	meta	O
116	##bol	O
116	##ites	O
116	in	O
116	plasma	O
116	for	O
116	each	O
116	individual	O
116	animal	O
116	were	O
116	fitted	O
116	with	O
116	the	O
116	p	O
116	##ks	O
116	##ol	O
116	##ution	O
116	##st	O
116	##m	O
116	computer	O
116	program	O
116	(	O
116	summit	O
116	research	O
116	service	O
116	,	O
116	oh	O
116	,	O
116	us	O
116	##a	O
116	)	O
116	.	O
116	[SEP]	O
117	[CLS]	O
117	forest	O
117	plots	O
117	for	O
117	the	O
117	final	O
117	model	O
117	showing	O
117	the	O
117	relationships	O
117	between	O
117	parameters	O
117	and	O
117	co	O
117	##var	O
117	##iate	O
117	##s	O
117	for	O
117	c	B-PK
117	##l	I-PK
117	,	O
117	v	B-PK
117	##1	I-PK
117	,	O
117	and	O
117	im	B-PK
117	##ax	I-PK
117	are	O
117	shown	O
117	in	O
117	figure	O
117	1	O
117	.	O
117	[SEP]	O
118	[CLS]	O
118	visual	O
118	predict	O
118	##ive	O
118	checks	O
118	for	O
118	the	O
118	10	O
118	mg	O
118	/	O
118	kg	O
118	dose	O
118	group	O
118	are	O
118	shown	O
118	in	O
118	figure	O
118	2	O
118	,	O
118	and	O
118	figure	O
118	3	O
118	shows	O
118	the	O
118	predicted	O
118	variation	O
118	in	O
118	c	B-PK
118	##l	I-PK
118	over	O
118	time	O
118	by	O
118	patient	O
118	and	O
118	tumor	O
118	type	O
118	.	O
118	[SEP]	O
119	[CLS]	O
119	the	O
119	pop	O
119	##p	O
119	##k	O
119	model	O
119	in	O
119	adults	O
119	showed	O
119	a	O
119	median	O
119	au	B-PK
119	##c	I-PK
119	estimated	O
119	at	O
119	96	O
119	##2	O
119	μ	O
119	##mo	O
119	##l	O
119	h	O
119	/	O
119	l	O
119	(	O
119	5th	O
119	–	O
119	95	O
119	##th	O
119	percent	O
119	##iles	O
119	,	O
119	76	O
119	##5	O
119	–	O
119	140	O
119	##3	O
119	μ	O
119	##mo	O
119	##l	O
119	h	O
119	/	O
119	l	O
119	)	O
119	and	O
119	b	O
119	##w	O
119	normal	B-PK
119	##ized	I-PK
119	c	I-PK
119	##l	I-PK
119	and	O
119	v	B-PK
119	##dt	I-PK
119	##ota	I-PK
119	##l	I-PK
119	of	O
119	0	O
119	.	O
119	10	O
119	l	O
119	/	O
119	h	O
119	per	O
119	kg	O
119	(	O
119	0	O
119	.	O
119	08	O
119	–	O
119	0	O
119	.	O
119	13	O
119	l	O
119	/	O
119	h	O
119	)	O
119	and	O
119	0	O
119	.	O
119	20	O
119	l	O
119	/	O
119	kg	O
119	(	O
119	0	O
119	.	O
119	16	O
119	–	O
119	0	O
119	.	O
119	25	O
119	l	O
119	/	O
119	kg	O
119	)	O
119	,	O
119	respectively	O
119	.	O
119	[SEP]	O
120	[CLS]	O
120	therefore	O
120	,	O
120	a	O
120	slightly	O
120	lower	O
120	b	O
120	##w	O
120	normal	B-PK
120	##ized	I-PK
120	c	I-PK
120	##l	I-PK
120	was	O
120	observed	O
120	in	O
120	children	O
120	than	O
120	in	O
120	adults	O
120	(	O
120	0	O
120	.	O
120	06	O
120	vs	O
120	0	O
120	.	O
120	10	O
120	l	O
120	/	O
120	h	O
120	/	O
120	kg	O
120	)	O
120	.	O
120	[SEP]	O
121	[CLS]	O
121	volumes	B-PK
121	of	I-PK
121	distribution	I-PK
121	of	O
121	both	O
121	pop	O
121	##p	O
121	##k	O
121	models	O
121	could	O
121	not	O
121	be	O
121	formally	O
121	compared	O
121	since	O
121	the	O
121	pop	O
121	##p	O
121	##k	O
121	model	O
121	for	O
121	children	O
121	was	O
121	parameter	O
121	##ized	O
121	with	O
121	vs	B-PK
121	##s	I-PK
121	,	O
121	while	O
121	it	O
121	was	O
121	parameter	O
121	##ized	O
121	with	O
121	v	B-PK
121	##dt	I-PK
121	##ota	I-PK
121	##l	I-PK
121	for	O
121	adults	O
121	.	O
121	[SEP]	O
122	[CLS]	O
122	nevertheless	O
122	,	O
122	the	O
122	vs	B-PK
122	##s	I-PK
122	in	O
122	children	O
122	could	O
122	be	O
122	compared	O
122	with	O
122	the	O
122	vs	B-PK
122	##s	I-PK
122	obtained	O
122	in	O
122	adults	O
122	by	O
122	non	O
122	##com	O
122	##par	O
122	##tment	O
122	##al	O
122	analysis	O
122	and	O
122	was	O
122	found	O
122	also	O
122	to	O
122	be	O
122	different	O
122	(	O
122	0	O
122	.	O
122	04	O
122	##7	O
122	l	O
122	/	O
122	kg	O
122	for	O
122	children	O
122	and	O
122	ca	O
122	.	O
122	[SEP]	O
123	[CLS]	O
123	this	O
123	difference	O
123	can	O
123	be	O
123	explained	O
123	by	O
123	the	O
123	difference	O
123	in	O
123	c	B-PK
123	##l	I-PK
123	and	O
123	the	O
123	fact	O
123	that	O
123	re	O
123	##nal	O
123	function	O
123	mat	O
123	##uration	O
123	was	O
123	not	O
123	completely	O
123	achieved	O
123	in	O
123	children	O
123	younger	O
123	than	O
123	2	O
123	years	O
123	.	O
123	29	O
123	the	O
123	proportion	O
123	of	O
123	children	O
123	'	O
123	s	O
123	values	O
123	outside	O
123	adults	O
123	'	O
123	95	O
123	%	O
123	percent	O
123	##ile	O
123	interval	O
123	was	O
123	64	O
123	%	O
123	to	O
123	76	O
123	%	O
123	for	O
123	concentrations	O
123	and	O
123	79	O
123	%	O
123	for	O
123	au	B-PK
123	##c	I-PK
123	.	O
123	[SEP]	O
124	[CLS]	O
124	the	O
124	clearance	B-PK
124	rate	I-PK
124	and	O
124	serum	B-PK
124	half	I-PK
124	-	I-PK
124	life	I-PK
124	were	O
124	obtained	O
124	from	O
124	a	O
124	non	O
124	-	O
124	compartment	O
124	##al	O
124	model	O
124	##14	O
124	of	O
124	the	O
124	anti	O
124	##body	O
124	concentration	O
124	as	O
124	a	O
124	function	O
124	of	O
124	time	O
124	using	O
124	the	O
124	p	O
124	##hoe	O
124	##ni	O
124	##x	O
124	software	O
124	(	O
124	c	O
124	##ert	O
124	##ara	O
124	)	O
124	.	O
124	[SEP]	O
125	[CLS]	O
125	compound	O
125	-	O
125	specific	O
125	p	O
125	##hy	O
125	##si	O
125	##co	O
125	##chemical	O
125	properties	O
125	and	O
125	the	O
125	un	B-PK
125	##bound	I-PK
125	fraction	I-PK
125	of	I-PK
125	the	I-PK
125	drug	I-PK
125	in	I-PK
125	plasma	I-PK
125	(	I-PK
125	f	I-PK
125	##u	I-PK
125	)	I-PK
125	were	O
125	used	O
125	to	O
125	para	O
125	##met	O
125	##riz	O
125	##e	O
125	the	O
125	initial	O
125	reference	O
125	p	O
125	##b	O
125	##p	O
125	##k	O
125	model	O
125	for	O
125	humans	O
125	(	O
125	fi	O
125	##g	O
125	.	O
125	4	O
125	;	O
125	table	O
125	1	O
125	)	O
125	.	O
125	[SEP]	O
126	[CLS]	O
126	in	O
126	h	O
126	##cy	O
126	##p	O
126	##1	O
126	##a	O
126	##1	O
126	/	O
126	1	O
126	##a	O
126	##2	O
126	mice	O
126	treated	O
126	with	O
126	3	O
126	-	O
126	m	O
126	##c	O
126	,	O
126	significant	O
126	reduction	O
126	##s	O
126	in	O
126	both	O
126	the	O
126	au	B-PK
126	##c	I-PK
126	##0	I-PK
126	–	I-PK
126	8	I-PK
126	hours	I-PK
126	(	O
126	54	O
126	%	O
126	)	O
126	and	O
126	half	B-PK
126	-	I-PK
126	life	I-PK
126	(	O
126	67	O
126	%	O
126	)	O
126	values	O
126	for	O
126	p	O
126	##ona	O
126	##tin	O
126	##ib	O
126	were	O
126	also	O
126	observed	O
126	(	O
126	fi	O
126	##g	O
126	.	O
126	4	O
126	##b	O
126	;	O
126	table	O
126	1	O
126	)	O
126	.	O
126	[SEP]	O
127	[CLS]	O
127	the	O
127	absolute	O
127	level	O
127	of	O
127	the	O
127	p	O
127	-	O
127	g	O
127	##sh	O
127	con	O
127	##ju	O
127	##gate	O
127	formed	O
127	could	O
127	not	O
127	be	O
127	determined	O
127	because	O
127	relevant	O
127	standards	O
127	were	O
127	not	O
127	available	O
127	.	O
127	[SEP]	O
128	[CLS]	O
128	the	O
128	amount	O
128	of	O
128	pet	O
128	-	O
128	id	O
128	##7	O
128	protein	O
128	was	O
128	determined	O
128	by	O
128	sat	O
128	##uration	O
128	of	O
128	a	O
128	his	O
128	-	O
128	bind	O
128	##®	O
128	column	O
128	(	O
128	no	O
128	##vage	O
128	##n	O
128	)	O
128	with	O
128	a	O
128	theoretical	O
128	capacity	O
128	of	O
128	20	O
128	mg	O
128	protein	O
128	.	O
128	[SEP]	O
129	[CLS]	O
129	the	O
129	average	O
129	cm	B-PK
129	##ax	I-PK
129	of	O
129	r	O
129	-	O
129	al	O
129	##o	O
129	was	O
129	greater	O
129	than	O
129	s	O
129	-	O
129	al	O
129	##o	O
129	by	O
129	4	O
129	.	O
129	96	O
129	times	O
129	.	O
129	[SEP]	O
130	[CLS]	O
130	the	O
130	bio	B-PK
130	##ava	I-PK
130	##ila	I-PK
130	##bility	I-PK
130	of	O
130	the	O
130	p	O
130	##t	O
130	-	O
130	drug	O
130	is	O
130	calculated	O
130	by	O
130	the	O
130	area	B-PK
130	under	I-PK
130	the	I-PK
130	curve	I-PK
130	(	I-PK
130	au	I-PK
130	##c	I-PK
130	)	I-PK
130	,	O
130	namely	O
130	the	O
130	integral	O
130	of	O
130	the	O
130	p	O
130	##t	O
130	concentration	O
130	-	O
130	time	O
130	curve	O
130	,	O
130	using	O
130	the	O
130	trap	O
130	##ez	O
130	##oid	O
130	##al	O
130	rule	O
130	.	O
130	[SEP]	O
131	[CLS]	O
131	a	O
131	single	O
131	administration	O
131	of	O
131	in	O
131	##tral	O
131	##ip	O
131	##id	O
131	can	O
131	increase	O
131	the	O
131	bio	B-PK
131	##ava	I-PK
131	##ila	I-PK
131	##bility	I-PK
131	of	O
131	the	O
131	p	O
131	##t	O
131	drug	O
131	by	O
131	18	O
131	.	O
131	7	O
131	%	O
131	during	O
131	the	O
131	first	O
131	5	O
131	h	O
131	##r	O
131	(	O
131	p	O
131	<	O
131	0	O
131	.	O
131	000	O
131	##1	O
131	)	O
131	and	O
131	by	O
131	9	O
131	.	O
131	4	O
131	%	O
131	during	O
131	24	O
131	h	O
131	##r	O
131	(	O
131	p	O
131	<	O
131	0	O
131	.	O
131	00	O
131	##1	O
131	)	O
131	(	O
131	fi	O
131	##g	O
131	.	O
131	s	O
131	##3	O
131	)	O
131	.	O
131	[SEP]	O
132	[CLS]	O
132	this	O
132	finding	O
132	indicates	O
132	that	O
132	in	O
132	##tral	O
132	##ip	O
132	##id	O
132	can	O
132	change	O
132	the	O
132	clearance	B-PK
132	and	O
132	increase	O
132	the	O
132	bio	B-PK
132	##ava	I-PK
132	##ila	I-PK
132	##bility	I-PK
132	of	O
132	the	O
132	na	O
132	##no	O
132	##dr	O
132	##ug	O
132	.	O
132	[SEP]	O
133	[CLS]	O
133	d	O
133	##ms	O
133	##55	O
133	##40	O
133	was	O
133	expressed	O
133	in	O
133	e	O
133	.	O
133	co	O
133	##li	O
133	and	O
133	pu	O
133	##rified	O
133	from	O
133	culture	O
133	super	O
133	##nat	O
133	##ant	O
133	by	O
133	protein	O
133	-	O
133	a	O
133	affinity	O
133	capture	O
133	followed	O
133	by	O
133	cat	O
133	##ion	O
133	exchange	O
133	ch	O
133	##roma	O
133	##tography	O
133	.	O
133	[SEP]	O
134	[CLS]	O
134	the	O
134	di	O
134	##sso	O
134	##ciation	O
134	equilibrium	O
134	constant	O
134	(	O
134	k	O
134	##d	O
134	)	O
134	for	O
134	the	O
134	d	O
134	##ms	O
134	##55	O
134	##40	O
134	-	O
134	m	O
134	##t	O
134	##n	O
134	##f	O
134	##r	O
134	##1	O
134	interaction	O
134	was	O
134	determined	O
134	to	O
134	be	O
134	270	O
134	pm	O
134	(	O
134	ka	O
134	7	O
134	.	O
134	98	O
134	105	O
134	m	O
134	-	O
134	1	O
134	##s	O
134	-	O
134	1	O
134	;	O
134	k	O
134	##off	O
134	2	O
134	.	O
134	17	O
134	10	O
134	##−	O
134	##4	O
134	s	O
134	-	O
134	1	O
134	)	O
134	.	O
134	[SEP]	O
135	[CLS]	O
135	the	O
135	plasma	O
135	concentration	O
135	vs	O
135	time	O
135	pro	O
135	##ﬁ	O
135	##le	O
135	of	O
135	r	O
135	-	O
135	al	O
135	##o	O
135	and	O
135	s	O
135	-	O
135	al	O
135	##o	O
135	in	O
135	rats	O
135	is	O
135	shown	O
135	in	O
135	figure	O
135	5	O
135	.	O
135	[SEP]	O
136	[CLS]	O
136	till	O
136	now	O
136	the	O
136	stereo	O
136	##sel	O
136	##ec	O
136	##tive	O
136	bio	O
136	##tra	O
136	##ns	O
136	##formation	O
136	of	O
136	al	O
136	##o	O
136	and	O
136	their	O
136	effect	O
136	on	O
136	al	O
136	##o	O
136	quantities	O
136	in	O
136	plasma	O
136	is	O
136	not	O
136	known	O
136	in	O
136	published	O
136	literature	O
136	.	O
136	[SEP]	O
137	[CLS]	O
137	the	O
137	t	B-PK
137	##1	I-PK
137	/	I-PK
137	2	I-PK
137	of	O
137	r	O
137	-	O
137	al	O
137	##o	O
137	and	O
137	s	O
137	-	O
137	al	O
137	##o	O
137	was	O
137	9	O
137	.	O
137	175	O
137	and	O
137	9	O
137	.	O
137	169	O
137	hours	O
137	respectively	O
137	.	O
137	[SEP]	O
138	[CLS]	O
138	the	O
138	higher	O
138	plasma	O
138	concentration	O
138	of	O
138	the	O
138	r	O
138	-	O
138	en	O
138	##anti	O
138	##omer	O
138	as	O
138	compared	O
138	to	O
138	the	O
138	s	O
138	-	O
138	al	O
138	##o	O
138	may	O
138	be	O
138	because	O
138	of	O
138	greater	O
138	rate	B-PK
138	of	I-PK
138	absorption	I-PK
138	of	O
138	the	O
138	r	O
138	-	O
138	al	O
138	##o	O
138	and	O
138	/	O
138	or	O
138	extensive	O
138	metabolism	O
138	of	O
138	the	O
138	s	O
138	-	O
138	al	O
138	##o	O
138	than	O
138	r	O
138	-	O
138	al	O
138	##o	O
138	.	O
138	[SEP]	O
139	[CLS]	O
139	the	O
139	results	O
139	illustrated	O
139	a	O
139	gradual	O
139	dose	O
139	-	O
139	dependent	O
139	activation	O
139	of	O
139	ca	O
139	##sp	O
139	##ase	O
139	-	O
139	9	O
139	(	O
139	fi	O
139	##g	O
139	.	O
139	7	O
139	##a	O
139	)	O
139	and	O
139	ca	O
139	##sp	O
139	##ase	O
139	-	O
139	3	O
139	(	O
139	fi	O
139	##g	O
139	.	O
139	7	O
139	##b	O
139	)	O
139	.	O
139	[SEP]	O
140	[CLS]	O
140	it	O
140	was	O
140	indicated	O
140	that	O
140	the	O
140	absorption	O
140	##s	O
140	of	O
140	these	O
140	5	O
140	components	O
140	in	O
140	v	O
140	##ivo	O
140	were	O
140	promoted	O
140	with	O
140	the	O
140	increase	O
140	of	O
140	the	O
140	oral	O
140	dose	O
140	of	O
140	administration	O
140	of	O
140	n	O
140	##x	O
140	##t	O
140	##c	O
140	.	O
140	[SEP]	O
141	[CLS]	O
141	table	O
141	9	O
141	shows	O
141	the	O
141	results	O
141	of	O
141	the	O
141	au	B-PK
141	##c	I-PK
141	##0	I-PK
141	-	I-PK
141	24	I-PK
141	##h	I-PK
141	/	I-PK
141	mi	I-PK
141	##c	I-PK
141	index	O
141	for	O
141	each	O
141	dose	O
141	studied	O
141	.	O
141	[SEP]	O
142	[CLS]	O
142	the	O
142	partial	O
142	main	O
142	p	O
142	##har	O
142	##ma	O
142	##co	O
142	##kin	O
142	##etic	O
142	parameters	O
142	of	O
142	ca	O
142	##ffe	O
142	##ic	O
142	acid	O
142	,	O
142	f	O
142	##er	O
142	##uli	O
142	##c	O
142	acid	O
142	,	O
142	form	O
142	##ono	O
142	##net	O
142	##in	O
142	,	O
142	cry	O
142	##pt	O
142	##ota	O
142	##ns	O
142	##hino	O
142	##ne	O
142	,	O
142	and	O
142	tan	O
142	##shin	O
142	##one	O
142	ii	O
142	##a	O
142	in	O
142	rats	O
142	are	O
142	shown	O
142	in	O
142	table	O
142	6	O
142	.	O
142	[SEP]	O
143	[CLS]	O
143	the	O
143	result	O
143	indicated	O
143	that	O
143	some	O
143	more	O
143	sensitive	O
143	methods	O
143	would	O
143	be	O
143	established	O
143	and	O
143	valid	O
143	##ated	O
143	to	O
143	focus	O
143	on	O
143	the	O
143	mechanism	O
143	of	O
143	absorption	O
143	and	O
143	metabolism	O
143	of	O
143	these	O
143	six	O
143	components	O
143	.	O
143	[SEP]	O
144	[CLS]	O
144	it	O
144	was	O
144	observed	O
144	that	O
144	t	B-PK
144	##max	I-PK
144	of	O
144	3	O
144	components	O
144	(	O
144	ca	O
144	##ffe	O
144	##ic	O
144	acid	O
144	,	O
144	f	O
144	##er	O
144	##uli	O
144	##c	O
144	acid	O
144	,	O
144	and	O
144	form	O
144	##ono	O
144	##net	O
144	##in	O
144	)	O
144	were	O
144	less	O
144	than	O
144	1	O
144	h	O
144	,	O
144	which	O
144	implied	O
144	that	O
144	they	O
144	were	O
144	rapidly	O
144	absorbed	O
144	in	O
144	rat	O
144	plasma	O
144	after	O
144	oral	O
144	administration	O
144	of	O
144	n	O
144	##x	O
144	##t	O
144	##c	O
144	at	O
144	doses	O
144	of	O
144	0	O
144	.	O
144	5	O
144	g	O
144	kg	O
144	##−	O
144	##1	O
144	and	O
144	1	O
144	.	O
144	5	O
144	g	O
144	kg	O
144	##−	O
144	##1	O
144	.	O
144	[SEP]	O
145	[CLS]	O
145	the	O
145	p	O
145	##har	O
145	##ma	O
145	##co	O
145	##kin	O
145	##etic	O
145	results	O
145	indicated	O
145	that	O
145	the	O
145	mean	O
145	t	B-PK
145	##max	I-PK
145	after	O
145	single	O
145	dose	O
145	administration	O
145	of	O
145	n	O
145	##x	O
145	##t	O
145	capsule	O
145	was	O
145	0	O
145	.	O
145	17	O
145	h	O
145	.	O
145	[SEP]	O
146	[CLS]	O
146	it	O
146	is	O
146	used	O
146	for	O
146	treating	O
146	age	O
146	-	O
146	related	O
146	diseases	O
146	such	O
146	as	O
146	ne	O
146	##uro	O
146	##de	O
146	##gene	O
146	##rative	O
146	disorders	O
146	and	O
146	card	O
146	##iovascular	O
146	disease	O
146	[	O
146	20	O
146	]	O
146	.	O
146	[SEP]	O
147	[CLS]	O
147	all	O
147	cm	B-PK
147	##ax	I-PK
147	and	O
147	au	B-PK
147	##c	I-PK
147	(	I-PK
147	0	I-PK
147	–	I-PK
147	24	I-PK
147	h	I-PK
147	)	I-PK
147	values	O
147	of	O
147	5	O
147	components	O
147	(	O
147	ca	O
147	##ffe	O
147	##ic	O
147	acid	O
147	,	O
147	f	O
147	##er	O
147	##uli	O
147	##c	O
147	acid	O
147	,	O
147	form	O
147	##ono	O
147	##net	O
147	##in	O
147	,	O
147	cry	O
147	##pt	O
147	##ota	O
147	##ns	O
147	##hino	O
147	##ne	O
147	,	O
147	and	O
147	tan	O
147	##shin	O
147	##one	O
147	ii	O
147	##a	O
147	)	O
147	after	O
147	oral	O
147	administration	O
147	of	O
147	n	O
147	##x	O
147	##t	O
147	capsule	O
147	at	O
147	triple	O
147	doses	O
147	of	O
147	1	O
147	.	O
147	5	O
147	g	O
147	kg	O
147	##−	O
147	##1	O
147	were	O
147	higher	O
147	than	O
147	those	O
147	after	O
147	oral	O
147	administration	O
147	at	O
147	normal	O
147	doses	O
147	of	O
147	0	O
147	.	O
147	5	O
147	g	O
147	kg	O
147	##−	O
147	##1	O
147	.	O
147	[SEP]	O
148	[CLS]	O
148	this	O
148	was	O
148	the	O
148	first	O
148	p	O
148	##har	O
148	##ma	O
148	##co	O
148	##kin	O
148	##etic	O
148	study	O
148	in	O
148	humans	O
148	,	O
148	which	O
148	demonstrated	O
148	linear	O
148	##ity	O
148	and	O
148	was	O
148	consistent	O
148	with	O
148	the	O
148	oral	O
148	two	O
148	-	O
148	compartment	O
148	model	O
148	with	O
148	a	O
148	terminal	B-PK
148	half	I-PK
148	-	I-PK
148	life	I-PK
148	of	O
148	about	O
148	1	O
148	day	O
148	.	O
148	[SEP]	O
149	[CLS]	O
149	no	O
149	severe	O
149	adverse	O
149	events	O
149	requiring	O
149	the	O
149	disco	O
149	##ntin	O
149	##uation	O
149	of	O
149	treatment	O
149	were	O
149	recorded	O
149	.	O
149	[SEP]	O
150	[CLS]	O
150	the	O
150	new	O
150	understanding	O
150	sum	O
150	##mar	O
150	##ised	O
150	in	O
150	the	O
150	present	O
150	article	O
150	was	O
150	directly	O
150	translated	O
150	to	O
150	human	O
150	liver	O
150	imaging	O
150	in	O
150	two	O
150	recent	O
150	publications	O
150	.	O
150	[SEP]	O
151	[CLS]	O
151	t	B-PK
151	##1	I-PK
151	/	I-PK
151	2	I-PK
151	values	O
151	of	O
151	cry	O
151	##pt	O
151	##ota	O
151	##ns	O
151	##hino	O
151	##ne	O
151	(	O
151	17	O
151	.	O
151	8	O
151	±	O
151	17	O
151	.	O
151	1	O
151	h	O
151	)	O
151	and	O
151	tan	O
151	##shin	O
151	##one	O
151	ii	O
151	##a	O
151	(	O
151	17	O
151	.	O
151	8	O
151	±	O
151	17	O
151	.	O
151	1	O
151	h	O
151	)	O
151	indicated	O
151	that	O
151	the	O
151	action	O
151	time	O
151	of	O
151	both	O
151	cry	O
151	##pt	O
151	##ota	O
151	##ns	O
151	##hino	O
151	##ne	O
151	and	O
151	tan	O
151	##shin	O
151	##one	O
151	ii	O
151	##a	O
151	were	O
151	significantly	O
151	longer	O
151	in	O
151	body	O
151	than	O
151	the	O
151	other	O
151	three	O
151	components	O
151	.	O
151	[SEP]	O
152	[CLS]	O
152	the	O
152	developed	O
152	hp	O
152	##l	O
152	##c	O
152	-	O
152	m	O
152	##s	O
152	/	O
152	m	O
152	##s	O
152	method	O
152	was	O
152	successfully	O
152	used	O
152	to	O
152	determine	O
152	the	O
152	plasma	O
152	concentrations	O
152	of	O
152	11	O
152	components	O
152	after	O
152	oral	O
152	administration	O
152	of	O
152	n	O
152	##x	O
152	##t	O
152	##c	O
152	at	O
152	doses	O
152	of	O
152	0	O
152	.	O
152	5	O
152	g	O
152	kg	O
152	##−	O
152	##1	O
152	and	O
152	1	O
152	.	O
152	5	O
152	g	O
152	kg	O
152	##−	O
152	##1	O
152	,	O
152	respectively	O
152	.	O
152	[SEP]	O
153	[CLS]	O
153	the	O
153	most	O
153	common	O
153	recorded	O
153	adverse	O
153	events	O
153	were	O
153	vomit	O
153	##ing	O
153	,	O
153	headache	O
153	and	O
153	di	O
153	##ar	O
153	##r	O
153	##hoe	O
153	##a	O
153	(	O
153	table	O
153	6	O
153	)	O
153	.	O
153	[SEP]	O
154	[CLS]	O
154	more	O
154	recently	O
154	,	O
154	we	O
154	published	O
154	the	O
154	p	O
154	##har	O
154	##ma	O
154	##co	O
154	##kin	O
154	##etic	O
154	modelling	O
154	of	O
154	liver	O
154	images	O
154	to	O
154	q	O
154	##uant	O
154	##ify	O
154	the	O
154	liver	O
154	per	O
154	##fusion	O
154	and	O
154	he	O
154	##pa	O
154	##to	O
154	##cy	O
154	##te	O
154	transport	O
154	function	O
154	of	O
154	patients	O
154	with	O
154	chronic	O
154	liver	O
154	diseases	O
154	[	O
154	36	O
154	]	O
154	.	O
154	[SEP]	O
155	[CLS]	O
155	we	O
155	used	O
155	the	O
155	final	O
155	model	O
155	and	O
155	performed	O
155	a	O
155	simulation	O
155	to	O
155	determine	O
155	the	O
155	dos	O
155	##ing	O
155	regime	O
155	##n	O
155	in	O
155	patients	O
155	with	O
155	re	O
155	##nal	O
155	imp	O
155	##air	O
155	##ment	O
155	and	O
155	in	O
155	those	O
155	with	O
155	con	O
155	##com	O
155	##ita	O
155	##nt	O
155	administration	O
155	of	O
155	am	O
155	##io	O
155	##dar	O
155	##one	O
155	.	O
155	[SEP]	O
156	[CLS]	O
156	from	O
156	table	O
156	6	O
156	,	O
156	it	O
156	was	O
156	found	O
156	that	O
156	values	O
156	of	O
156	t	B-PK
156	##max	I-PK
156	and	O
156	t	B-PK
156	##1	I-PK
156	/	I-PK
156	2	I-PK
156	of	O
156	ca	O
156	##ffe	O
156	##ic	O
156	acid	O
156	and	O
156	f	O
156	##er	O
156	##uli	O
156	##c	O
156	acid	O
156	were	O
156	much	O
156	closer	O
156	,	O
156	demonstrating	O
156	that	O
156	they	O
156	have	O
156	similar	O
156	absorption	B-PK
156	and	O
156	elimination	B-PK
156	rate	I-PK
156	.	O
156	[SEP]	O
157	[CLS]	O
157	antibodies	O
157	were	O
157	el	O
157	##uted	O
157	using	O
157	100	O
157	mm	O
157	ace	O
157	##tic	O
157	acid	O
157	p	O
157	##h	O
157	3	O
157	.	O
157	2	O
157	and	O
157	the	O
157	el	O
157	##ution	O
157	pools	O
157	were	O
157	brought	O
157	to	O
157	p	O
157	##h	O
157	5	O
157	.	O
157	0	O
157	using	O
157	1	O
157	m	O
157	na	O
157	##oh	O
157	.	O
157	[SEP]	O
158	[CLS]	O
158	the	O
158	cm	B-PK
158	##ax	I-PK
158	values	O
158	were	O
158	15	O
158	.	O
158	24	O
158	±	O
158	3	O
158	.	O
158	08	O
158	ng	O
158	m	O
158	##l	O
158	##−	O
158	##1	O
158	and	O
158	12	O
158	.	O
158	07	O
158	±	O
158	4	O
158	.	O
158	61	O
158	ng	O
158	m	O
158	##l	O
158	##−	O
158	##1	O
158	and	O
158	values	O
158	of	O
158	au	B-PK
158	##c	I-PK
158	(	I-PK
158	0	I-PK
158	–	I-PK
158	24	I-PK
158	h	I-PK
158	)	I-PK
158	were	O
158	25	O
158	.	O
158	99	O
158	±	O
158	18	O
158	.	O
158	62	O
158	ng	O
158	m	O
158	##l	O
158	-	O
158	1	O
158	h	O
158	##−	O
158	##1	O
158	##and	O
158	8	O
158	.	O
158	33	O
158	±	O
158	3	O
158	.	O
158	87	O
158	ng	O
158	m	O
158	##l	O
158	##−	O
158	##1	O
158	h	O
158	##−	O
158	##1	O
158	for	O
158	ca	O
158	##ffe	O
158	##ic	O
158	acid	O
158	and	O
158	f	O
158	##er	O
158	##uli	O
158	##c	O
158	acid	O
158	at	O
158	triple	O
158	doses	O
158	,	O
158	respectively	O
158	.	O
158	[SEP]	O
159	[CLS]	O
159	the	O
159	pro	O
159	##ba	O
159	##bilities	O
159	of	O
159	t	B-PK
159	##rough	I-PK
159	dig	I-PK
159	##ox	I-PK
159	##in	I-PK
159	concentrations	I-PK
159	being	O
159	in	O
159	the	O
159	range	O
159	of	O
159	0	O
159	.	O
159	5	O
159	–	O
159	0	O
159	.	O
159	8	O
159	ng	O
159	/	O
159	m	O
159	##l	O
159	in	O
159	the	O
159	steady	O
159	state	O
159	are	O
159	shown	O
159	in	O
159	fi	O
159	##g	O
159	.	O
159	3	O
159	.	O
159	[SEP]	O
160	[CLS]	O
160	in	O
160	the	O
160	present	O
160	studies	O
160	,	O
160	cm	B-PK
160	##ax	I-PK
160	of	O
160	form	O
160	##ono	O
160	##net	O
160	##in	O
160	was	O
160	less	O
160	than	O
160	1	O
160	ng	O
160	m	O
160	##l	O
160	##−	O
160	##1	O
160	.	O
160	[SEP]	O
161	[CLS]	O
161	the	O
161	au	B-PK
161	##c	I-PK
161	(	I-PK
161	0	I-PK
161	–	I-PK
161	24	I-PK
161	h	I-PK
161	)	I-PK
161	values	O
161	were	O
161	lower	O
161	than	O
161	1	O
161	ng	O
161	m	O
161	##l	O
161	##−	O
161	##1	O
161	.	O
161	[SEP]	O
162	[CLS]	O
162	apparent	B-PK
162	per	I-PK
162	##me	I-PK
162	##ability	I-PK
162	coefficients	I-PK
162	(	I-PK
162	p	I-PK
162	##ap	I-PK
162	##p	I-PK
162	)	I-PK
162	were	O
162	calculated	O
162	using	O
162	the	O
162	following	O
162	equation	O
162	:	O
162	(	O
162	3	O
162	)	O
162	p	O
162	##ap	O
162	##p	O
162	=	O
162	q	O
162	##ac	O
162	##0	O
162	##t	O
162	,	O
162	where	O
162	p	B-PK
162	##ap	I-PK
162	##p	I-PK
162	is	O
162	the	O
162	apparent	B-PK
162	per	I-PK
162	##me	I-PK
162	##ability	I-PK
162	coefficient	I-PK
162	(	O
162	cm	O
162	/	O
162	s	O
162	)	O
162	,	O
162	q	O
162	is	O
162	the	O
162	total	O
162	amount	O
162	per	O
162	##me	O
162	##ated	O
162	throughout	O
162	the	O
162	in	O
162	##cu	O
162	##bation	O
162	time	O
162	(	O
162	μ	O
162	##g	O
162	)	O
162	,	O
162	a	O
162	is	O
162	the	O
162	diffusion	O
162	area	O
162	of	O
162	the	O
162	mon	O
162	##ola	O
162	##yer	O
162	(	O
162	cm	O
162	##2	O
162	)	O
162	,	O
162	c	O
162	##0	O
162	is	O
162	the	O
162	initial	O
162	concentration	O
162	of	O
162	the	O
162	d	O
162	##t	O
162	##x	O
162	in	O
162	the	O
162	a	O
162	##pical	O
162	part	O
162	(	O
162	μ	O
162	##g	O
162	/	O
162	cm	O
162	##3	O
162	)	O
162	,	O
162	and	O
162	t	O
162	is	O
162	the	O
162	total	O
162	time	O
162	of	O
162	the	O
162	experiments	O
162	.	O
162	[SEP]	O
163	[CLS]	O
163	differences	O
163	in	O
163	ca	O
163	##ffe	O
163	##ine	O
163	serum	O
163	concentrations	O
163	between	O
163	dos	O
163	##ing	O
163	regime	O
163	##n	O
163	groups	O
163	were	O
163	determined	O
163	by	O
163	man	O
163	##n	O
163	–	O
163	w	O
163	##hit	O
163	##ney	O
163	u	O
163	test	O
163	.	O
163	[SEP]	O
164	[CLS]	O
164	based	O
164	on	O
164	the	O
164	above	O
164	results	O
164	,	O
164	the	O
164	newly	O
164	established	O
164	l	O
164	##c	O
164	-	O
164	m	O
164	##s	O
164	/	O
164	m	O
164	##s	O
164	method	O
164	was	O
164	sufficiently	O
164	sensitive	O
164	for	O
164	the	O
164	determination	O
164	of	O
164	multiple	O
164	components	O
164	in	O
164	rat	O
164	plasma	O
164	and	O
164	was	O
164	suitable	O
164	to	O
164	simultaneously	O
164	evaluate	O
164	the	O
164	p	O
164	##har	O
164	##ma	O
164	##co	O
164	##kin	O
164	##etic	O
164	properties	O
164	of	O
164	the	O
164	multiple	O
164	bio	O
164	##active	O
164	components	O
164	after	O
164	oral	O
164	administration	O
164	of	O
164	n	O
164	##x	O
164	##t	O
164	##c	O
164	.	O
164	[SEP]	O
165	[CLS]	O
165	severe	O
165	:	O
165	causing	O
165	inability	O
165	to	O
165	carry	O
165	out	O
165	usual	O
165	activities	O
165	;	O
165	the	O
165	subject	O
165	may	O
165	experience	O
165	into	O
165	##ler	O
165	##able	O
165	discomfort	O
165	or	O
165	pain	O
165	.	O
165	[SEP]	O
166	[CLS]	O
166	the	O
166	pool	O
166	##ed	O
166	antibodies	O
166	were	O
166	then	O
166	concentrated	O
166	and	O
166	buffer	O
166	exchanged	O
166	into	O
166	10	O
166	mm	O
166	ace	O
166	##tic	O
166	acid	O
166	,	O
166	9	O
166	%	O
166	su	O
166	##c	O
166	##rose	O
166	,	O
166	p	O
166	##h	O
166	5	O
166	.	O
166	2	O
166	,	O
166	and	O
166	al	O
166	##iq	O
166	##uo	O
166	##ts	O
166	were	O
166	stored	O
166	at	O
166	-	O
166	70	O
166	##°	O
166	##c	O
166	until	O
166	needed	O
166	.	O
166	[SEP]	O
167	[CLS]	O
167	the	O
167	possible	O
167	reason	O
167	may	O
167	be	O
167	that	O
167	some	O
167	of	O
167	the	O
167	ca	O
167	##ffe	O
167	##ic	O
167	acid	O
167	detected	O
167	in	O
167	rat	O
167	plasma	O
167	was	O
167	the	O
167	meta	O
167	##bol	O
167	##ites	O
167	of	O
167	the	O
167	components	O
167	in	O
167	n	O
167	##x	O
167	##t	O
167	##c	O
167	.	O
167	[SEP]	O
168	[CLS]	O
168	the	O
168	results	O
168	were	O
168	not	O
168	correspondent	O
168	with	O
168	their	O
168	dose	O
168	administered	O
168	to	O
168	the	O
168	rats	O
168	(	O
168	7	O
168	.	O
168	1	O
168	μ	O
168	##g	O
168	kg	O
168	##−	O
168	##1	O
168	ca	O
168	##ffe	O
168	##ic	O
168	acid	O
168	and	O
168	53	O
168	.	O
168	7	O
168	μ	O
168	##g	O
168	kg	O
168	##−	O
168	##1	O
168	f	O
168	##er	O
168	##uli	O
168	##c	O
168	acid	O
168	)	O
168	.	O
168	[SEP]	O
169	[CLS]	O
169	the	O
169	relationships	O
169	between	O
169	treatment	O
169	efficacy	O
169	and	O
169	patient	O
169	demographic	O
169	##s	O
169	were	O
169	also	O
169	evaluated	O
169	by	O
169	linear	O
169	re	O
169	##gression	O
169	.	O
169	[SEP]	O
170	[CLS]	O
170	–	O
170	sample	O
170	size	O
170	,	O
170	mean	O
170	,	O
170	standard	O
170	de	O
170	##viation	O
170	,	O
170	median	O
170	,	O
170	minimum	O
170	,	O
170	and	O
170	maximum	O
170	for	O
170	or	O
170	##dina	O
170	##l	O
170	variables	O
170	[SEP]	O
171	[CLS]	O
171	ca	O
171	##ffe	O
171	##ic	O
171	acid	O
171	has	O
171	very	O
171	excellent	O
171	anti	O
171	##ox	O
171	##ida	O
171	##nt	O
171	and	O
171	anti	O
171	##vir	O
171	##al	O
171	activity	O
171	[	O
171	25	O
171	]	O
171	.	O
171	[SEP]	O
172	[CLS]	O
172	da	O
172	##pi	O
172	stain	O
172	##ing	O
172	by	O
172	con	O
172	##fo	O
172	##cal	O
172	micro	O
172	##sco	O
172	##py	O
172	also	O
172	revealed	O
172	a	O
172	con	O
172	##den	O
172	##sed	O
172	and	O
172	s	O
172	##hr	O
172	##unk	O
172	nucleus	O
172	with	O
172	the	O
172	fragment	O
172	##ed	O
172	ch	O
172	##roma	O
172	##tin	O
172	.	O
172	[SEP]	O
173	[CLS]	O
173	the	O
173	study	O
173	compared	O
173	the	O
173	area	B-PK
173	under	I-PK
173	the	I-PK
173	curve	I-PK
173	(	I-PK
173	au	I-PK
173	##c	I-PK
173	)	I-PK
173	of	O
173	the	O
173	serum	O
173	25	O
173	(	O
173	oh	O
173	)	O
173	d	O
173	concentration	O
173	between	O
173	the	O
173	two	O
173	treatment	O
173	groups	O
173	.	O
173	[SEP]	O
174	[CLS]	O
174	if	O
174	the	O
174	cells	O
174	were	O
174	treated	O
174	with	O
174	1	O
174	%	O
174	p	O
174	##c	O
174	##ms	O
174	for	O
174	2	O
174	h	O
174	(	O
174	data	O
174	not	O
174	shown	O
174	)	O
174	prior	O
174	to	O
174	the	O
174	ethanol	O
174	addition	O
174	,	O
174	the	O
174	damage	O
174	was	O
174	more	O
174	pronounced	O
174	.	O
174	[SEP]	O
175	[CLS]	O
175	r	O
175	##t	O
175	##v	O
175	was	O
175	given	O
175	either	O
175	as	O
175	an	O
175	80	O
175	mg	O
175	/	O
175	m	O
175	##l	O
175	oral	O
175	solution	O
175	or	O
175	as	O
175	100	O
175	mg	O
175	capsule	O
175	##s	O
175	(	O
175	permitted	O
175	for	O
175	children	O
175	≥	O
175	##33	O
175	kg	O
175	)	O
175	.	O
175	[SEP]	O
176	[CLS]	O
176	male	O
176	s	O
176	##pra	O
176	##gue	O
176	da	O
176	##wley	O
176	rats	O
176	(	O
176	225	O
176	–	O
176	275	O
176	g	O
176	,	O
176	central	O
176	animal	O
176	laboratory	O
176	of	O
176	the	O
176	second	O
176	x	O
176	##ian	O
176	##gy	O
176	##a	O
176	hospital	O
176	of	O
176	central	O
176	south	O
176	university	O
176	,	O
176	h	O
176	##una	O
176	##n	O
176	,	O
176	people	O
176	’	O
176	s	O
176	republic	O
176	of	O
176	chin	O
176	##a	O
176	)	O
176	were	O
176	used	O
176	to	O
176	perform	O
176	the	O
176	l	O
176	##ymph	O
176	##atic	O
176	transport	O
176	study	O
176	.	O
176	[SEP]	O
177	[CLS]	O
177	a	O
177	sample	O
177	size	O
177	of	O
177	28	O
177	subjects	O
177	was	O
177	required	O
177	to	O
177	provide	O
177	at	O
177	least	O
177	80	O
177	%	O
177	power	O
177	to	O
177	conclude	O
177	an	O
177	absence	O
177	of	O
177	effect	O
177	of	O
177	er	O
177	##yt	O
177	##hr	O
177	##omy	O
177	##cin	O
177	on	O
177	ed	O
177	##ox	O
177	##aba	O
177	##n	O
177	p	O
177	##har	O
177	##ma	O
177	##co	O
177	##kin	O
177	##etics	O
177	using	O
177	a	O
177	90	O
177	%	O
177	c	O
177	##i	O
177	with	O
177	no	O
177	‐	O
177	effect	O
177	boundaries	O
177	of	O
177	80	O
177	–	O
177	125	O
177	%	O
177	.	O
177	[SEP]	O
178	[CLS]	O
178	human	O
178	serum	O
178	album	O
178	##in	O
178	clearance	O
178	studies	O
178	were	O
178	performed	O
178	to	O
178	determine	O
178	the	O
178	effect	O
178	of	O
178	end	O
178	##ogen	O
178	##ous	O
178	m	O
178	##sa	O
178	on	O
178	the	O
178	p	O
178	##har	O
178	##ma	O
178	##co	O
178	##kin	O
178	##etic	O
178	behavior	O
178	of	O
178	administered	O
178	human	O
178	album	O
178	##in	O
178	.	O
178	[SEP]	O
179	[CLS]	O
179	men	O
179	and	O
179	non	O
179	##p	O
179	##re	O
179	##gnant	O
179	,	O
179	non	O
179	##la	O
179	##ct	O
179	##ating	O
179	women	O
179	aged	O
179	18	O
179	–	O
179	55	O
179	years	O
179	old	O
179	who	O
179	were	O
179	healthy	O
179	(	O
179	i	O
179	##e	O
179	,	O
179	with	O
179	no	O
179	evidence	O
179	of	O
179	active	O
179	or	O
179	chronic	O
179	disease	O
179	after	O
179	a	O
179	detailed	O
179	review	O
179	of	O
179	medical	O
179	and	O
179	surgical	O
179	histories	O
179	and	O
179	a	O
179	complete	O
179	physical	O
179	examination	O
179	)	O
179	were	O
179	eligible	O
179	to	O
179	participate	O
179	.	O
179	[SEP]	O
180	[CLS]	O
180	only	O
180	,	O
180	the	O
180	cells	O
180	showed	O
180	a	O
180	loss	O
180	of	O
180	ad	O
180	##herence	O
180	,	O
180	became	O
180	distorted	O
180	and	O
180	a	O
180	##pop	O
180	##to	O
180	##tic	O
180	,	O
180	which	O
180	is	O
180	reflected	O
180	as	O
180	a	O
180	yellow	O
180	mark	O
180	in	O
180	the	O
180	a	O
180	##o	O
180	/	O
180	et	O
180	##b	O
180	##r	O
180	stain	O
180	##ing	O
180	.	O
180	[SEP]	O
181	[CLS]	O
181	two	O
181	mice	O
181	of	O
181	each	O
181	co	O
181	##hor	O
181	##t	O
181	also	O
181	received	O
181	5	O
181	mg	O
181	/	O
181	kg	O
181	human	O
181	i	O
181	##gg	O
181	in	O
181	the	O
181	same	O
181	i	O
181	##v	O
181	injection	O
181	##s	O
181	.	O
181	[SEP]	O
182	[CLS]	O
182	the	O
182	primary	O
182	end	O
182	##point	O
182	was	O
182	serum	O
182	25	O
182	(	O
182	oh	O
182	)	O
182	d	O
182	level	O
182	measured	O
182	from	O
182	day	O
182	0	O
182	to	O
182	day	O
182	112	O
182	.	O
182	[SEP]	O
183	[CLS]	O
183	cat	O
183	##ego	O
183	##rical	O
183	data	O
183	were	O
183	evaluated	O
183	using	O
183	ch	O
183	##i	O
183	-	O
183	square	O
183	test	O
183	.	O
183	[SEP]	O
184	[CLS]	O
184	en	O
184	##fu	O
184	##vir	O
184	##tide	O
184	was	O
184	permitted	O
184	in	O
184	addition	O
184	to	O
184	n	O
184	##rt	O
184	##is	O
184	for	O
184	children	O
184	>	O
184	6	O
184	years	O
184	old	O
184	,	O
184	providing	O
184	its	O
184	use	O
184	was	O
184	within	O
184	the	O
184	locally	O
184	approved	O
184	product	O
184	label	O
184	.	O
184	[SEP]	O
185	[CLS]	O
185	study	O
185	participants	O
185	also	O
185	needed	O
185	to	O
185	be	O
185	able	O
185	to	O
185	swallow	O
185	a	O
185	dose	O
185	of	O
185	the	O
185	study	O
185	drug	O
185	according	O
185	to	O
185	the	O
185	study	O
185	conditions	O
185	and	O
185	to	O
185	comply	O
185	with	O
185	study	O
185	procedures	O
185	.	O
185	[SEP]	O
186	[CLS]	O
186	a	O
186	total	O
186	of	O
186	36	O
186	subjects	O
186	were	O
186	enrolled	O
186	to	O
186	compensate	O
186	for	O
186	potential	O
186	drop	O
186	##outs	O
186	.	O
186	[SEP]	O
187	[CLS]	O
187	k	O
187	##olm	O
187	##ogo	O
187	##rov	O
187	–	O
187	s	O
187	##mir	O
187	##nov	O
187	test	O
187	was	O
187	used	O
187	to	O
187	check	O
187	for	O
187	the	O
187	normal	O
187	distribution	O
187	of	O
187	data	O
187	.	O
187	[SEP]	O
188	[CLS]	O
188	subjects	O
188	were	O
188	given	O
188	f	O
188	##p	O
188	##v	O
188	##±	O
188	##rt	O
188	##v	O
188	with	O
188	a	O
188	background	O
188	regime	O
188	##n	O
188	of	O
188	2	O
188	or	O
188	3	O
188	active	O
188	n	O
188	##rt	O
188	##is	O
188	.	O
188	[SEP]	O
189	[CLS]	O
189	on	O
189	t	O
189	##ues	O
189	##day	O
189	of	O
189	the	O
189	second	O
189	week	O
189	,	O
189	group	O
189	1	O
189	was	O
189	exposed	O
189	without	O
189	hood	O
189	##s	O
189	and	O
189	breathing	O
189	chamber	O
189	air	O
189	;	O
189	hence	O
189	,	O
189	exposure	O
189	was	O
189	via	O
189	both	O
189	the	O
189	der	O
189	##mal	O
189	and	O
189	the	O
189	in	O
189	##hala	O
189	##tion	O
189	pathway	O
189	.	O
189	[SEP]	O
190	[CLS]	O
190	ace	O
190	##ton	O
190	##it	O
190	##ril	O
190	##e	O
190	and	O
190	water	O
190	containing	O
190	0	O
190	.	O
190	1	O
190	%	O
190	(	O
190	v	O
190	/	O
190	v	O
190	)	O
190	form	O
190	##ic	O
190	acid	O
190	was	O
190	adopted	O
190	as	O
190	the	O
190	mobile	O
190	phase	O
190	,	O
190	the	O
190	flow	O
190	rate	O
190	was	O
190	0	O
190	.	O
190	3	O
190	m	O
190	##l	O
190	/	O
190	mi	O
190	.	O
190	[SEP]	O
191	[CLS]	O
191	participants	O
191	provided	O
191	informed	O
191	consent	O
191	before	O
191	participation	O
191	.	O
191	[SEP]	O
192	[CLS]	O
192	a	O
192	s	O
192	##med	O
192	##ds	O
192	sample	O
192	was	O
192	di	O
192	##lut	O
192	##ed	O
192	with	O
192	di	O
192	##st	O
192	##ille	O
192	##d	O
192	water	O
192	at	O
192	25	O
192	##°	O
192	##c	O
192	under	O
192	gentle	O
192	agitation	O
192	immediately	O
192	before	O
192	measurement	O
192	.	O
192	[SEP]	O
193	[CLS]	O
193	patients	O
193	were	O
193	(	O
193	mean	O
193	±	O
193	standard	O
193	de	O
193	##viation	O
193	(	O
193	s	O
193	##d	O
193	)	O
193	)	O
193	53	O
193	±	O
193	11	O
193	years	O
193	old	O
193	,	O
193	50	O
193	%	O
193	male	O
193	,	O
193	81	O
193	±	O
193	14	O
193	kg	O
193	,	O
193	and	O
193	had	O
193	acute	O
193	p	O
193	##hy	O
193	##sio	O
193	##log	O
193	##ic	O
193	and	O
193	chronic	O
193	health	O
193	evaluation	O
193	ii	O
193	score	O
193	(	O
193	a	O
193	##pa	O
193	##che	O
193	ii	O
193	)	O
193	scores	O
193	of	O
193	31	O
193	.	O
193	5	O
193	±	O
193	3	O
193	.	O
193	8	O
193	.	O
193	[SEP]	O
194	[CLS]	O
194	after	O
194	reaching	O
194	the	O
194	peak	B-PK
194	concentration	I-PK
194	of	I-PK
194	cm	I-PK
194	##ax	I-PK
194	,	O
194	the	O
194	o	O
194	##xy	O
194	##co	O
194	##don	O
194	##e	O
194	plasma	O
194	concentrations	O
194	followed	O
194	a	O
194	mon	O
194	##oe	O
194	##x	O
194	##po	O
194	##nent	O
194	##ial	O
194	decline	O
194	.	O
194	[SEP]	O
195	[CLS]	O
195	patients	O
195	had	O
195	minimal	O
195	residual	O
195	re	O
195	##nal	O
195	function	O
195	and	O
195	remained	O
195	an	O
195	##uri	O
195	##c	O
195	or	O
195	o	O
195	##li	O
195	##gu	O
195	##ric	O
195	during	O
195	the	O
195	entire	O
195	study	O
195	period	O
195	.	O
195	[SEP]	O
196	[CLS]	O
196	patients	O
196	were	O
196	enrolled	O
196	in	O
196	the	O
196	study	O
196	for	O
196	a	O
196	mean	O
196	of	O
196	5	O
196	±	O
196	3	O
196	days	O
196	(	O
196	range	O
196	2	O
196	to	O
196	11	O
196	days	O
196	)	O
196	.	O
196	[SEP]	O
197	[CLS]	O
197	participants	O
197	were	O
197	eligible	O
197	if	O
197	they	O
197	were	O
197	aged	O
197	between	O
197	18	O
197	and	O
197	55	O
197	years	O
197	,	O
197	had	O
197	a	O
197	mean	O
197	body	O
197	weight	O
197	of	O
197	72	O
197	.	O
197	3	O
197	kg	O
197	(	O
197	range	O
197	53	O
197	.	O
197	6	O
197	–	O
197	88	O
197	.	O
197	9	O
197	kg	O
197	)	O
197	,	O
197	and	O
197	had	O
197	a	O
197	mean	O
197	body	O
197	mass	O
197	index	O
197	between	O
197	19	O
197	.	O
197	5	O
197	and	O
197	28	O
197	.	O
197	3	O
197	kg	O
197	/	O
197	m	O
197	.	O
197	2	O
197	[SEP]	O
198	[CLS]	O
198	the	O
198	terminal	O
198	phases	O
198	of	O
198	the	O
198	plasma	O
198	concentration	O
198	–	O
198	time	O
198	profiles	O
198	had	O
198	distinct	O
198	half	B-PK
198	‐	I-PK
198	lives	I-PK
198	with	O
198	p	O
198	##o	O
198	administration	O
198	of	O
198	immediate	O
198	‐	O
198	release	O
198	(	O
198	i	O
198	##r	O
198	)	O
198	and	O
198	controlled	O
198	‐	O
198	release	O
198	(	O
198	c	O
198	##r	O
198	)	O
198	or	O
198	with	O
198	in	O
198	##tra	O
198	##nas	O
198	##al	O
198	administration	O
198	.	O
198	[SEP]	O
199	[CLS]	O
199	ten	O
199	patients	O
199	were	O
199	enrolled	O
199	.	O
199	[SEP]	O
200	[CLS]	O
200	p	O
200	##har	O
200	##ma	O
200	##cological	O
200	experiments	O
200	based	O
200	on	O
200	the	O
200	study	O
200	found	O
200	that	O
200	the	O
200	topic	O
200	##al	O
200	pig	O
200	##mentation	O
200	model	O
200	of	O
200	g	O
200	##uin	O
200	##ea	O
200	pigs	O
200	showed	O
200	a	O
200	better	O
200	therapeutic	O
200	effect	O
200	.	O
200	[SEP]	O
201	[CLS]	O
201	these	O
201	results	O
201	implied	O
201	s	O
201	##med	O
201	##ds	O
201	could	O
201	not	O
201	spontaneous	O
201	##ly	O
201	form	O
201	transparent	O
201	and	O
201	stable	O
201	micro	O
201	##em	O
201	##ul	O
201	##sion	O
201	systems	O
201	upon	O
201	a	O
201	##que	O
201	##ous	O
201	di	O
201	##lution	O
201	any	O
201	longer	O
201	beyond	O
201	c	O
201	##rem	O
201	##op	O
201	##hor	O
201	r	O
201	##h	O
201	40	O
201	:	O
201	na	O
201	##t	O
201	##c	O
201	,	O
201	c	O
201	##rem	O
201	##op	O
201	##hor	O
201	r	O
201	##h	O
201	40	O
201	:	O
201	na	O
201	##d	O
201	##c	O
201	,	O
201	or	O
201	c	O
201	##rem	O
201	##op	O
201	##hor	O
201	r	O
201	##h	O
201	40	O
201	:	O
201	na	O
201	##c	O
201	mass	O
201	ratios	O
201	of	O
201	2	O
201	:	O
201	8	O
201	,	O
201	2	O
201	:	O
201	8	O
201	,	O
201	and	O
201	3	O
201	:	O
201	7	O
201	,	O
201	respect	O
201	##vel	O
201	##y	O
201	.	O
201	[SEP]	O
202	[CLS]	O
202	the	O
202	following	O
202	parameters	O
202	were	O
202	estimated	O
202	:	O
202	maximum	B-PK
202	(	I-PK
202	peak	I-PK
202	)	I-PK
202	observed	I-PK
202	concentration	I-PK
202	in	I-PK
202	plasma	I-PK
202	(	I-PK
202	cm	I-PK
202	##ax	I-PK
202	)	I-PK
202	,	O
202	time	B-PK
202	from	I-PK
202	dos	I-PK
202	##ing	I-PK
202	to	I-PK
202	the	I-PK
202	maximum	I-PK
202	(	I-PK
202	peak	I-PK
202	)	I-PK
202	observed	I-PK
202	concentration	I-PK
202	in	I-PK
202	plasma	I-PK
202	(	I-PK
202	t	I-PK
202	##max	I-PK
202	)	I-PK
202	,	O
202	area	B-PK
202	under	I-PK
202	the	I-PK
202	concentration	I-PK
202	‐	I-PK
202	time	I-PK
202	curve	I-PK
202	from	I-PK
202	time	I-PK
202	extra	I-PK
202	##pol	I-PK
202	##ated	I-PK
202	to	I-PK
202	in	I-PK
202	##finity	I-PK
202	(	I-PK
202	au	I-PK
202	##c	I-PK
202	)	I-PK
202	,	O
202	apparent	B-PK
202	terminal	I-PK
202	elimination	I-PK
202	half	I-PK
202	‐	I-PK
202	life	I-PK
202	(	I-PK
202	t	I-PK
202	##1	I-PK
202	/	I-PK
202	2	I-PK
202	)	I-PK
202	,	O
202	and	O
202	apparent	B-PK
202	clearance	I-PK
202	from	I-PK
202	plasma	I-PK
202	after	I-PK
202	oral	I-PK
202	administration	I-PK
202	(	I-PK
202	c	I-PK
202	##l	I-PK
202	/	I-PK
202	f	I-PK
202	)	I-PK
202	.	O
202	[SEP]	O
203	[CLS]	O
203	re	O
203	##e	O
203	##qui	O
203	##li	O
203	##bra	O
203	##tion	O
203	time	O
203	after	O
203	gradient	O
203	el	O
203	##ution	O
203	was	O
203	5	O
203	min	O
203	.	O
203	[SEP]	O
204	[CLS]	O
204	the	O
204	mixed	O
204	h	O
204	##l	O
204	##b	O
204	values	O
204	of	O
204	c	O
204	##rem	O
204	##eo	O
204	##ph	O
204	##or	O
204	40	O
204	/	O
204	bi	O
204	##le	O
204	salts	O
204	were	O
204	in	O
204	the	O
204	range	O
204	of	O
204	13	O
204	–	O
204	39	O
204	.	O
204	18	O
204	.	O
204	[SEP]	O
205	[CLS]	O
205	plasma	O
205	concentration	O
205	–	O
205	time	O
205	data	O
205	were	O
205	anal	O
205	##ys	O
205	##ed	O
205	by	O
205	non	O
205	##com	O
205	##par	O
205	##tment	O
205	##al	O
205	methods	O
205	using	O
205	win	O
205	##non	O
205	##lin	O
205	professional	O
205	software	O
205	(	O
205	versions	O
205	4	O
205	.	O
205	0	O
205	or	O
205	higher	O
205	)	O
205	.	O
205	[SEP]	O
206	[CLS]	O
206	the	O
206	population	O
206	p	O
206	##k	O
206	models	O
206	were	O
206	evaluated	O
206	using	O
206	diagnostic	O
206	plots	O
206	[	O
206	19	O
206	,	O
206	20	O
206	]	O
206	,	O
206	visual	O
206	predict	O
206	##ive	O
206	check	O
206	(	O
206	v	O
206	##p	O
206	##c	O
206	)	O
206	[	O
206	20	O
206	,	O
206	21	O
206	]	O
206	,	O
206	prediction	O
206	-	O
206	corrected	O
206	v	O
206	##p	O
206	##c	O
206	(	O
206	p	O
206	##c	O
206	##v	O
206	##p	O
206	##c	O
206	)	O
206	[	O
206	22	O
206	]	O
206	,	O
206	boots	O
206	##tra	O
206	##pping	O
206	[	O
206	23	O
206	]	O
206	and	O
206	shrink	O
206	##age	O
206	[	O
206	24	O
206	]	O
206	assessments	O
206	.	O
206	[SEP]	O
207	[CLS]	O
207	exposure	O
207	including	O
207	the	O
207	t	B-PK
207	##rough	I-PK
207	(	I-PK
207	cm	I-PK
207	##in	I-PK
207	)	I-PK
207	and	O
207	peak	B-PK
207	(	I-PK
207	cm	I-PK
207	##ax	I-PK
207	)	I-PK
207	concentration	I-PK
207	was	O
207	com	O
207	##puted	O
207	at	O
207	steady	O
207	state	O
207	given	O
207	be	O
207	##va	O
207	##ci	O
207	##zu	O
207	##ma	O
207	##b	O
207	of	O
207	10	O
207	mg	O
207	/	O
207	kg	O
207	once	O
207	every	O
207	2	O
207	weeks	O
207	using	O
207	the	O
207	final	O
207	model	O
207	.	O
207	[SEP]	O
208	[CLS]	O
208	the	O
208	statistical	O
208	significance	O
208	of	O
208	difference	O
208	in	O
208	the	O
208	mean	O
208	of	O
208	the	O
208	variables	O
208	,	O
208	such	O
208	as	O
208	cm	B-PK
208	##ax	I-PK
208	,	O
208	t	B-PK
208	##max	I-PK
208	and	O
208	au	B-PK
208	##c	I-PK
208	##last	I-PK
208	,	O
208	between	O
208	two	O
208	groups	O
208	was	O
208	assessed	O
208	using	O
208	the	O
208	independent	O
208	samples	O
208	student	O
208	’	O
208	s	O
208	t	O
208	-	O
208	test	O
208	used	O
208	to	O
208	identify	O
208	significance	O
208	in	O
208	p	O
208	##har	O
208	##ma	O
208	##co	O
208	##kin	O
208	##etic	O
208	parameters	O
208	using	O
208	95	O
208	%	O
208	confidence	O
208	interval	O
208	.	O
208	[SEP]	O
209	[CLS]	O
209	image	O
209	##j	O
209	(	O
209	gel	O
209	analyze	O
209	##r	O
209	plug	O
209	##in	O
209	)	O
209	was	O
209	used	O
209	for	O
209	q	O
209	##uant	O
209	##ification	O
209	of	O
209	western	O
209	b	O
209	##lot	O
209	##s	O
209	and	O
209	im	O
209	##mu	O
209	##nos	O
209	##taining	O
209	,	O
209	and	O
209	data	O
209	were	O
209	presented	O
209	as	O
209	mean	O
209	±	O
209	s	O
209	##d	O
209	(	O
209	or	O
209	9	O
209	##se	O
209	##m	O
209	)	O
209	by	O
209	graph	O
209	##pad	O
209	p	O
209	##rism	O
209	5	O
209	(	O
209	graph	O
209	##pad	O
209	p	O
209	##rism	O
209	software	O
209	version	O
209	5	O
209	.	O
209	01	O
209	)	O
209	.	O
209	[SEP]	O
210	[CLS]	O
210	the	O
210	relative	O
210	impact	O
210	of	O
210	each	O
210	co	O
210	##var	O
210	##iate	O
210	included	O
210	in	O
210	the	O
210	final	O
210	model	O
210	alone	O
210	on	O
210	p	O
210	##k	O
210	parameters	O
210	and	O
210	exposure	O
210	was	O
210	explored	O
210	.	O
210	[SEP]	O
211	[CLS]	O
211	the	O
211	full	O
211	-	O
211	scan	O
211	single	O
211	-	O
211	mass	O
211	spectrum	O
211	and	O
211	the	O
211	daughter	O
211	ion	O
211	-	O
211	mass	O
211	spectrum	O
211	for	O
211	m	O
211	##1	O
211	were	O
211	(	O
211	m	O
211	/	O
211	z	O
211	)	O
211	250	O
211	.	O
211	64	O
211	>	O
211	58	O
211	.	O
211	50	O
211	.	O
211	[SEP]	O
212	[CLS]	O
212	so	O
212	##lub	O
212	##ility	O
212	trials	O
212	,	O
212	em	O
212	##ul	O
212	##si	O
212	##fying	O
212	studies	O
212	,	O
212	and	O
212	pseudo	O
212	-	O
212	te	O
212	##rna	O
212	##ry	O
212	phase	O
212	diagram	O
212	##s	O
212	were	O
212	used	O
212	to	O
212	screen	O
212	the	O
212	s	O
212	##ned	O
212	##ds	O
212	formulation	O
212	##s	O
212	.	O
212	[SEP]	O
213	[CLS]	O
213	blood	O
213	(	O
213	~	O
213	1	O
213	m	O
213	##l	O
213	)	O
213	samples	O
213	were	O
213	collected	O
213	at	O
213	the	O
213	same	O
213	time	O
213	points	O
213	as	O
213	described	O
213	for	O
213	c	O
213	##s	O
213	##f	O
213	sampling	O
213	.	O
213	[SEP]	O
214	[CLS]	O
214	each	O
214	tube	O
214	was	O
214	v	O
214	##ortex	O
214	##ed	O
214	for	O
214	1	O
214	min	O
214	for	O
214	extraction	O
214	,	O
214	followed	O
214	by	O
214	cent	O
214	##ri	O
214	##fu	O
214	##gation	O
214	for	O
214	5	O
214	min	O
214	at	O
214	13	O
214	,	O
214	000	O
214	g	O
214	.	O
214	the	O
214	organic	O
214	s	O
214	##tra	O
214	##tum	O
214	was	O
214	then	O
214	transferred	O
214	to	O
214	a	O
214	clean	O
214	sample	O
214	bottle	O
214	,	O
214	and	O
214	10	O
214	μ	O
214	##l	O
214	specimens	O
214	was	O
214	introduced	O
214	into	O
214	the	O
214	ultra	O
214	-	O
214	fast	O
214	liquid	O
214	ch	O
214	##roma	O
214	##tography	O
214	/	O
214	tandem	O
214	mass	O
214	s	O
214	##pect	O
214	##rome	O
214	##try	O
214	(	O
214	u	O
214	##f	O
214	##l	O
214	##c	O
214	-	O
214	m	O
214	##s	O
214	/	O
214	m	O
214	##s	O
214	)	O
214	system	O
214	for	O
214	analysis	O
214	of	O
214	ni	O
214	##fe	O
214	##di	O
214	##pine	O
214	and	O
214	oxidation	O
214	ni	O
214	##fe	O
214	##di	O
214	##pine	O
214	.	O
214	[SEP]	O
215	[CLS]	O
215	the	O
215	integral	O
215	of	O
215	the	O
215	concentration	O
215	of	O
215	p	O
215	##elli	O
215	##tor	O
215	##ine	O
215	in	O
215	serum	O
215	from	O
215	zero	O
215	to	O
215	time	O
215	t	O
215	is	O
215	the	O
215	area	B-PK
215	under	I-PK
215	the	I-PK
215	curve	I-PK
215	until	I-PK
215	time	I-PK
215	t	I-PK
215	.	O
215	[SEP]	O
216	[CLS]	O
216	capture	O
216	and	O
216	detection	O
216	re	O
216	##age	O
216	##nts	O
216	were	O
216	applied	O
216	at	O
216	100	O
216	μ	O
216	##g	O
216	/	O
216	m	O
216	##l	O
216	of	O
216	bio	O
216	##tin	O
216	-	O
216	con	O
216	##ju	O
216	##gated	O
216	goat	O
216	anti	O
216	-	O
216	human	O
216	i	O
216	##gg	O
216	(	O
216	h	O
216	##c	O
216	+	O
216	l	O
216	##c	O
216	,	O
216	monkey	O
216	ads	O
216	##or	O
216	##bed	O
216	,	O
216	bet	O
216	##hyl	O
216	)	O
216	in	O
216	p	O
216	##bs	O
216	/	O
216	0	O
216	.	O
216	01	O
216	%	O
216	p	O
216	##oly	O
216	##sor	O
216	##bate	O
216	-	O
216	20	O
216	/	O
216	0	O
216	.	O
216	02	O
216	%	O
216	na	O
216	##n	O
216	##3	O
216	and	O
216	ale	O
216	##xa	O
216	##64	O
216	##7	O
216	-	O
216	anti	O
216	-	O
216	c	O
216	##dr	O
216	(	O
216	clone	O
216	242	O
216	,	O
216	gene	O
216	##nte	O
216	##ch	O
216	)	O
216	at	O
216	25	O
216	nm	O
216	in	O
216	re	O
216	##x	O
216	##xi	O
216	##p	O
216	f	O
216	(	O
216	g	O
216	##yr	O
216	##os	O
216	)	O
216	.	O
216	[SEP]	O
217	[CLS]	O
217	treatment	O
217	with	O
217	si	O
217	##vel	O
217	##esta	O
217	##t	O
217	increases	O
217	the	O
217	expression	O
217	of	O
217	ng	O
217	-	O
217	2	O
217	,	O
217	α	O
217	-	O
217	s	O
217	##ma	O
217	and	O
217	v	O
217	##w	O
217	##f	O
217	.	O
217	[SEP]	O
218	[CLS]	O
218	s	O
218	##ci	O
218	substantially	O
218	disrupt	O
218	##s	O
218	the	O
218	v	O
218	##as	O
218	##cula	O
218	##ture	O
218	,	O
218	especially	O
218	at	O
218	the	O
218	epic	O
218	##enter	O
218	of	O
218	the	O
218	injury	O
218	,	O
218	where	O
218	blood	O
218	vessels	O
218	undergo	O
218	re	O
218	##mo	O
218	##del	O
218	##ing	O
218	and	O
218	structural	O
218	changes	O
218	before	O
218	they	O
218	become	O
218	functional	O
218	.	O
218	[SEP]	O
219	[CLS]	O
219	de	O
219	##c	O
219	(	O
219	purity	O
219	,	O
219	≥	O
219	##9	O
219	##8	O
219	%	O
219	)	O
219	,	O
219	a	O
219	##b	O
219	##z	O
219	(	O
219	purity	O
219	,	O
219	≥	O
219	##9	O
219	##8	O
219	%	O
219	)	O
219	,	O
219	a	O
219	##b	O
219	##z	O
219	-	O
219	o	O
219	##x	O
219	(	O
219	purity	O
219	,	O
219	≥	O
219	##9	O
219	##9	O
219	.	O
219	9	O
219	%	O
219	)	O
219	,	O
219	a	O
219	##b	O
219	##z	O
219	-	O
219	on	O
219	(	O
219	purity	O
219	,	O
219	≥	O
219	##9	O
219	##9	O
219	.	O
219	6	O
219	%	O
219	)	O
219	,	O
219	o	O
219	##xi	O
219	##ben	O
219	##da	O
219	##zo	O
219	##le	O
219	(	O
219	o	O
219	##b	O
219	##z	O
219	)	O
219	(	O
219	purity	O
219	,	O
219	≥	O
219	##9	O
219	##9	O
219	.	O
219	9	O
219	%	O
219	)	O
219	,	O
219	and	O
219	d	O
219	##3	O
219	-	O
219	de	O
219	##c	O
219	(	O
219	purity	O
219	,	O
219	≥	O
219	##9	O
219	##8	O
219	%	O
219	)	O
219	,	O
219	(	O
219	fi	O
219	##g	O
219	.	O
219	1	O
219	)	O
219	of	O
219	pharmaceutical	O
219	grade	O
219	were	O
219	purchased	O
219	from	O
219	si	O
219	##gma	O
219	-	O
219	al	O
219	##dric	O
219	##h	O
219	,	O
219	s	O
219	##t	O
219	lo	O
219	##ui	O
219	##s	O
219	,	O
219	m	O
219	##o	O
219	,	O
219	us	O
219	##a	O
219	.	O
219	[SEP]	O
220	[CLS]	O
220	the	O
220	c	O
220	##ip	O
220	##ro	O
220	##f	O
220	##lo	O
220	##xa	O
220	##cin	O
220	p	O
220	##b	O
220	##p	O
220	##k	O
220	model	O
220	for	O
220	adults	O
220	was	O
220	verified	O
220	by	O
220	comparing	O
220	independent	O
220	data	O
220	##sets	O
220	that	O
220	were	O
220	not	O
220	used	O
220	for	O
220	model	O
220	building	O
220	,	O
220	with	O
220	corresponding	O
220	simulation	O
220	##s	O
220	.	O
220	[SEP]	O
221	[CLS]	O
221	all	O
221	other	O
221	chemical	O
221	re	O
221	##age	O
221	##nts	O
221	were	O
221	from	O
221	si	O
221	##gma	O
221	(	O
221	s	O
221	##t	O
221	.	O
221	lo	O
221	##ui	O
221	##s	O
221	,	O
221	m	O
221	##o	O
221	)	O
221	.	O
221	[SEP]	O
222	[CLS]	O
222	hp	O
222	##l	O
222	##c	O
222	-	O
222	grade	O
222	met	O
222	##han	O
222	##ol	O
222	(	O
222	me	O
222	##oh	O
222	)	O
222	,	O
222	ace	O
222	##ton	O
222	##it	O
222	##ril	O
222	##e	O
222	(	O
222	a	O
222	##c	O
222	##n	O
222	)	O
222	,	O
222	form	O
222	##ic	O
222	acid	O
222	(	O
222	f	O
222	##a	O
222	)	O
222	,	O
222	and	O
222	ace	O
222	##tic	O
222	acid	O
222	were	O
222	obtained	O
222	from	O
222	fish	O
222	##er	O
222	scientific	O
222	(	O
222	fair	O
222	lawn	O
222	,	O
222	n	O
222	##j	O
222	)	O
222	.	O
222	[SEP]	O
223	[CLS]	O
223	mean	O
223	spontaneous	O
223	a	O
223	##b	O
223	##r	O
223	was	O
223	0	O
223	.	O
223	01	O
223	##1	O
223	/	O
223	patient	O
223	-	O
223	year	O
223	.	O
223	[SEP]	O
224	[CLS]	O
224	if	O
224	the	O
224	inhibitor	O
224	screen	O
224	was	O
224	positive	O
224	for	O
224	an	O
224	inhibitor	O
224	of	O
224	factor	O
224	x	O
224	,	O
224	the	O
224	inhibitor	O
224	was	O
224	q	O
224	##uant	O
224	##itated	O
224	by	O
224	the	O
224	bet	O
224	##hes	O
224	##da	O
224	ass	O
224	##ay	O
224	.	O
224	18	O
224	in	O
224	l	O
224	##m	O
224	##w	O
224	##h	O
224	ass	O
224	##ay	O
224	,	O
224	residual	O
224	free	O
224	factor	O
224	x	O
224	##a	O
224	was	O
224	measured	O
224	in	O
224	plasma	O
224	by	O
224	ch	O
224	##rom	O
224	##ogenic	O
224	substrate	O
224	ass	O
224	##ay	O
224	after	O
224	addition	O
224	of	O
224	b	O
224	##ov	O
224	##ine	O
224	at	O
224	ii	O
224	##i	O
224	and	O
224	factor	O
224	x	O
224	##a	O
224	,	O
224	which	O
224	forms	O
224	an	O
224	inactive	O
224	factor	O
224	x	O
224	##a	O
224	‐	O
224	at	O
224	ii	O
224	##i	O
224	‐	O
224	he	O
224	##par	O
224	##in	O
224	complex	O
224	.	O
224	18	O
224	[SEP]	O
225	[CLS]	O
225	the	O
225	el	O
225	##isa	O
225	has	O
225	an	O
225	identical	O
225	sensitivity	O
225	to	O
225	p	O
225	##or	O
225	##cine	O
225	and	O
225	can	O
225	##ine	O
225	insulin	O
225	.	O
225	[SEP]	O
226	[CLS]	O
226	collected	O
226	samples	O
226	were	O
226	immediately	O
226	cent	O
226	##ri	O
226	##fu	O
226	##ged	O
226	,	O
226	plasma	O
226	was	O
226	al	O
226	##iq	O
226	##uo	O
226	##ted	O
226	,	O
226	and	O
226	glucose	O
226	concentrations	O
226	were	O
226	measured	O
226	with	O
226	a	O
226	y	O
226	##si	O
226	270	O
226	##0	O
226	auto	O
226	##ana	O
226	##ly	O
226	##zer	O
226	(	O
226	yellow	O
226	springs	O
226	instruments	O
226	,	O
226	yellow	O
226	springs	O
226	,	O
226	oh	O
226	)	O
226	.	O
226	[SEP]	O
227	[CLS]	O
227	the	O
227	in	O
227	##tra	O
227	-	O
227	and	O
227	inter	O
227	##ass	O
227	##ay	O
227	coefficient	O
227	of	O
227	variance	O
227	of	O
227	insulin	O
227	was	O
227	2	O
227	.	O
227	3	O
227	±	O
227	0	O
227	.	O
227	3	O
227	%	O
227	and	O
227	2	O
227	.	O
227	9	O
227	±	O
227	1	O
227	.	O
227	3	O
227	%	O
227	,	O
227	respectively	O
227	.	O
227	[SEP]	O
228	[CLS]	O
228	one	O
228	mill	O
228	##ili	O
228	##ter	O
228	of	O
228	blood	O
228	was	O
228	taken	O
228	at	O
228	each	O
228	time	O
228	point	O
228	from	O
228	a	O
228	peripheral	O
228	vein	O
228	into	O
228	chilled	O
228	1	O
228	.	O
228	5	O
228	-	O
228	m	O
228	##l	O
228	e	O
228	##ppe	O
228	##ndo	O
228	##rf	O
228	tubes	O
228	coated	O
228	with	O
228	lit	O
228	##hium	O
228	flu	O
228	##ori	O
228	##de	O
228	,	O
228	he	O
228	##par	O
228	##in	O
228	,	O
228	and	O
228	1	O
228	μ	O
228	##g	O
228	/	O
228	50	O
228	μ	O
228	##l	O
228	ed	O
228	##ta	O
228	.	O
228	[SEP]	O
229	[CLS]	O
229	there	O
229	were	O
229	no	O
229	significant	O
229	changes	O
229	in	O
229	c	O
229	##4	O
229	or	O
229	c	O
229	##3	O
229	across	O
229	treatment	O
229	groups	O
229	.	O
229	[SEP]	O
230	[CLS]	O
230	in	O
230	plots	O
230	of	O
230	tan	O
230	##δ	O
230	versus	O
230	stress	O
230	in	O
230	fi	O
230	##g	O
230	.	O
230	1	O
230	##a	O
230	##3	O
230	,	O
230	b	O
230	##3	O
230	and	O
230	c	O
230	##3	O
230	,	O
230	only	O
230	those	O
230	h	O
230	##ydro	O
230	##gel	O
230	##s	O
230	with	O
230	a	O
230	10	O
230	%	O
230	concentration	O
230	and	O
230	a	O
230	r	O
230	##op	O
230	##v	O
230	##p	O
230	/	O
230	c	O
230	##s	O
230	ratio	O
230	of	O
230	20	O
230	:	O
230	5	O
230	showed	O
230	tan	O
230	##δ	O
230	values	O
230	of	O
230	<	O
230	1	O
230	,	O
230	indicating	O
230	that	O
230	those	O
230	h	O
230	##ydro	O
230	##gel	O
230	##s	O
230	with	O
230	g	O
230	′	O
230	>	O
230	[SEP]	O
231	[CLS]	O
231	all	O
231	tea	O
231	##es	O
231	resolved	O
231	,	O
231	with	O
231	medication	O
231	for	O
231	14	O
231	of	O
231	them	O
231	(	O
231	in	O
231	9	O
231	subjects	O
231	)	O
231	.	O
231	[SEP]	O
232	[CLS]	O
232	g	O
232	″	O
232	had	O
232	gel	O
232	v	O
232	##isco	O
232	##ela	O
232	##stic	O
232	behaviors	O
232	dominated	O
232	by	O
232	elastic	O
232	##ity	O
232	.	O
232	[SEP]	O
233	[CLS]	O
233	k	O
233	##ona	O
233	##ki	O
233	##on	O
233	##®	O
233	mm	O
233	2	O
233	mg	O
233	is	O
233	approved	O
233	for	O
233	prop	O
233	##hyl	O
233	##ax	O
233	##is	O
233	and	O
233	therapy	O
233	of	O
233	vitamin	O
233	k	O
233	deficiency	O
233	bleeding	O
233	in	O
233	newborn	O
233	##s	O
233	.	O
233	[SEP]	O
234	[CLS]	O
234	standardized	O
234	food	O
234	was	O
234	served	O
234	no	O
234	earlier	O
234	than	O
234	10	O
234	h	O
234	after	O
234	dos	O
234	##ing	O
234	.	O
234	[SEP]	O
235	[CLS]	O
235	six	O
235	patients	O
235	had	O
235	dose	O
235	interrupt	O
235	##ions	O
235	,	O
235	which	O
235	were	O
235	a	O
235	result	O
235	of	O
235	a	O
235	##es	O
235	in	O
235	five	O
235	patients	O
235	.	O
235	[SEP]	O
236	[CLS]	O
236	there	O
236	were	O
236	no	O
236	clinical	O
236	##ly	O
236	important	O
236	,	O
236	treatment	O
236	-	O
236	related	O
236	trends	O
236	in	O
236	clinical	O
236	chemistry	O
236	parameters	O
236	.	O
236	[SEP]	O
237	[CLS]	O
237	the	O
237	column	O
237	temperature	O
237	was	O
237	set	O
237	to	O
237	70	O
237	##°	O
237	##c	O
237	.	O
237	[SEP]	O
238	[CLS]	O
238	however	O
238	,	O
238	the	O
238	mobile	O
238	phase	O
238	was	O
238	a	O
238	mixture	O
238	of	O
238	ace	O
238	##ton	O
238	##it	O
238	##ril	O
238	##e	O
238	/	O
238	water	O
238	/	O
238	te	O
238	##rt	O
238	-	O
238	but	O
238	##yl	O
238	met	O
238	##hyl	O
238	et	O
238	##her	O
238	/	O
238	p	O
238	##hos	O
238	##ph	O
238	##ori	O
238	##c	O
238	acid	O
238	(	O
238	52	O
238	##5	O
238	/	O
238	425	O
238	/	O
238	50	O
238	/	O
238	1	O
238	,	O
238	v	O
238	/	O
238	v	O
238	/	O
238	v	O
238	/	O
238	v	O
238	)	O
238	at	O
238	a	O
238	flow	O
238	rate	O
238	of	O
238	1	O
238	.	O
238	5	O
238	m	O
238	##l	O
238	/	O
238	minute	O
238	for	O
238	in	O
238	v	O
238	##ivo	O
238	determination	O
238	.	O
238	16	O
238	[SEP]	O
239	[CLS]	O
239	in	O
239	this	O
239	clinical	O
239	trial	O
239	,	O
239	vitamin	O
239	k	O
239	##1	O
239	p	O
239	##har	O
239	##ma	O
239	##co	O
239	##kin	O
239	##etics	O
239	was	O
239	investigated	O
239	in	O
239	healthy	O
239	volunteers	O
239	after	O
239	oral	O
239	and	O
239	in	O
239	##tra	O
239	##ven	O
239	##ous	O
239	route	O
239	of	O
239	administration	O
239	.	O
239	[SEP]	O
240	[CLS]	O
240	all	O
240	subjects	O
240	were	O
240	healthy	O
240	according	O
240	to	O
240	their	O
240	medical	O
240	history	O
240	,	O
240	physical	O
240	examination	O
240	,	O
240	and	O
240	standard	O
240	laboratory	O
240	procedures	O
240	.	O
240	[SEP]	O
241	[CLS]	O
241	according	O
241	to	O
241	the	O
241	manufacturer	O
241	'	O
241	s	O
241	product	O
241	information	O
241	,	O
241	me	O
241	##rop	O
241	##ene	O
241	##m	O
241	dose	O
241	reduction	O
241	is	O
241	required	O
241	when	O
241	the	O
241	g	O
241	##f	O
241	##r	O
241	is	O
241	<	O
241	50	O
241	m	O
241	##l	O
241	/	O
241	min	O
241	.	O
241	[	O
241	14	O
241	]	O
241	[SEP]	O
242	[CLS]	O
242	identification	O
242	of	O
242	anti	O
242	##mic	O
242	##ro	O
242	##bial	O
242	su	O
242	##s	O
242	##ce	O
242	##pt	O
242	##ibility	O
242	and	O
242	mi	O
242	##c	O
242	testing	O
242	were	O
242	performed	O
242	in	O
242	the	O
242	clinical	O
242	micro	O
242	##biology	O
242	laboratory	O
242	using	O
242	the	O
242	v	O
242	##ite	O
242	##k	O
242	2	O
242	automated	O
242	system	O
242	(	O
242	bio	O
242	##mer	O
242	##ieu	O
242	##x	O
242	,	O
242	ma	O
242	##rc	O
242	##y	O
242	l	O
242	’	O
242	et	O
242	##oil	O
242	##e	O
242	,	O
242	f	O
242	##rance	O
242	)	O
242	.	O
242	[SEP]	O
243	[CLS]	O
243	the	O
243	linear	O
243	##ity	O
243	of	O
243	the	O
243	method	O
243	was	O
243	assessed	O
243	by	O
243	plotting	O
243	ca	O
243	##li	O
243	##bra	O
243	##tion	O
243	curves	O
243	in	O
243	plasma	O
243	at	O
243	seven	O
243	concentration	O
243	levels	O
243	in	O
243	trip	O
243	##lica	O
243	##te	O
243	on	O
243	three	O
243	consecutive	O
243	days	O
243	.	O
243	[SEP]	O
244	[CLS]	O
244	however	O
244	,	O
244	towards	O
244	the	O
244	end	O
244	of	O
244	the	O
244	dos	O
244	##ing	O
244	interval	O
244	,	O
244	the	O
244	concentration	O
244	falls	O
244	slightly	O
244	below	O
244	the	O
244	evidence	O
244	-	O
244	based	O
244	plasma	O
244	m	O
244	##or	O
244	##phine	O
244	concentration	O
244	for	O
244	anal	O
244	##ges	O
244	##ia	O
244	of	O
244	20	O
244	μ	O
244	##g	O
244	/	O
244	l	O
244	.	O
244	cop	O
244	indicates	O
244	that	O
244	an	O
244	adjustment	O
244	in	O
244	the	O
244	dos	O
244	##ing	O
244	interval	O
244	can	O
244	be	O
244	made	O
244	if	O
244	the	O
244	patient	O
244	complain	O
244	##s	O
244	of	O
244	pain	O
244	towards	O
244	the	O
244	end	O
244	of	O
244	the	O
244	dos	O
244	##ing	O
244	interval	O
244	.	O
244	[SEP]	O
245	[CLS]	O
245	the	O
245	inclusion	O
245	criteria	O
245	included	O
245	a	O
245	diagnosis	O
245	of	O
245	un	O
245	##com	O
245	##plicate	O
245	##d	O
245	malaria	O
245	(	O
245	defined	O
245	as	O
245	a	O
245	fever	O
245	[	O
245	t	O
245	##ym	O
245	##pan	O
245	##ic	O
245	temperature	O
245	of	O
245	≥	O
245	##38	O
245	##°	O
245	##c	O
245	or	O
245	history	O
245	of	O
245	fever	O
245	within	O
245	the	O
245	past	O
245	24	O
245	h	O
245	)	O
245	and	O
245	micro	O
245	##sco	O
245	##py	O
245	-	O
245	confirmed	O
245	p	O
245	.	O
245	f	O
245	##al	O
245	##ci	O
245	##par	O
245	##um	O
245	mon	O
245	##oi	O
245	##n	O
245	##fect	O
245	##ion	O
245	)	O
245	,	O
245	age	O
245	≥	O
245	##16	O
245	years	O
245	,	O
245	and	O
245	a	O
245	confirmed	O
245	pregnancy	O
245	of	O
245	12	O
245	to	O
245	38	O
245	weeks	O
245	g	O
245	##esta	O
245	##tional	O
245	age	O
245	.	O
245	[SEP]	O
246	[CLS]	O
246	the	O
246	proportion	O
246	of	O
246	flu	O
246	##cona	O
246	##zo	O
246	##le	O
246	concentration	O
246	relative	O
246	to	O
246	mi	O
246	##c	O
246	then	O
246	was	O
246	calculated	O
246	from	O
246	the	O
246	1	O
246	million	O
246	replica	O
246	##tes	O
246	.	O
246	[SEP]	O
247	[CLS]	O
247	analyses	O
247	were	O
247	performed	O
247	using	O
247	ex	O
247	##cel	O
247	2016	O
247	(	O
247	micro	O
247	##so	O
247	##ft	O
247	,	O
247	red	O
247	##mond	O
247	,	O
247	wa	O
247	)	O
247	.	O
247	[SEP]	O
248	[CLS]	O
248	then	O
248	the	O
248	plasma	O
248	samples	O
248	obtained	O
248	were	O
248	stored	O
248	at	O
248	−	O
248	##20	O
248	##°	O
248	##c	O
248	.	O
248	[SEP]	O
249	[CLS]	O
249	the	O
249	q	O
249	##c	O
249	samples	O
249	were	O
249	within	O
249	15	O
249	%	O
249	of	O
249	the	O
249	nominal	O
249	concentrations	O
249	,	O
249	meeting	O
249	the	O
249	acceptance	O
249	criteria	O
249	of	O
249	the	O
249	us	O
249	food	O
249	and	O
249	drug	O
249	administration	O
249	(	O
249	f	O
249	##da	O
249	)	O
249	for	O
249	the	O
249	valid	O
249	##ation	O
249	of	O
249	bio	O
249	##ana	O
249	##ly	O
249	##tical	O
249	methods	O
249	[	O
249	31	O
249	]	O
249	.	O
249	[SEP]	O
250	[CLS]	O
250	the	O
250	in	O
250	v	O
250	##it	O
250	##ro	O
250	release	O
250	data	O
250	were	O
250	applied	O
250	to	O
250	various	O
250	kinetic	O
250	##s	O
250	models	O
250	to	O
250	predict	O
250	the	O
250	drug	O
250	release	O
250	mechanism	O
250	and	O
250	kinetic	O
250	##s	O
250	[	O
250	table	O
250	1	O
250	]	O
250	.	O
250	[SEP]	O
251	[CLS]	O
251	after	O
251	a	O
251	single	O
251	oral	O
251	dose	O
251	,	O
251	blood	O
251	samples	O
251	will	O
251	be	O
251	drawn	O
251	at	O
251	0	O
251	.	O
251	25	O
251	,	O
251	0	O
251	.	O
251	5	O
251	,	O
251	1	O
251	,	O
251	2	O
251	,	O
251	4	O
251	,	O
251	and	O
251	8	O
251	h	O
251	.	O
251	samples	O
251	will	O
251	be	O
251	collected	O
251	,	O
251	processed	O
251	,	O
251	and	O
251	shipped	O
251	according	O
251	to	O
251	standard	O
251	operating	O
251	procedures	O
251	.	O
251	[SEP]	O
252	[CLS]	O
252	the	O
252	drug	O
252	release	O
252	was	O
252	proportional	O
252	to	O
252	square	O
252	root	O
252	of	O
252	time	O
252	.	O
252	[SEP]	O
253	[CLS]	O
253	we	O
253	will	O
253	recruit	O
253	approximately	O
253	6	O
253	–	O
253	8	O
253	subjects	O
253	per	O
253	dose	O
253	(	O
253	100	O
253	mg	O
253	,	O
253	200	O
253	mg	O
253	or	O
253	300	O
253	mg	O
253	ni	O
253	-	O
253	03	O
253	)	O
253	in	O
253	this	O
253	phase	O
253	i	O
253	study	O
253	,	O
253	giving	O
253	a	O
253	total	O
253	of	O
253	18	O
253	–	O
253	24	O
253	subjects	O
253	.	O
253	[SEP]	O
254	[CLS]	O
254	these	O
254	data	O
254	support	O
254	the	O
254	p	O
254	##har	O
254	##ma	O
254	##co	O
254	##dynamic	O
254	similarity	O
254	of	O
254	the	O
254	proposed	O
254	p	O
254	##eg	O
254	##fi	O
254	##l	O
254	##gra	O
254	##st	O
254	##im	O
254	bio	O
254	##si	O
254	##mi	O
254	##lar	O
254	and	O
254	the	O
254	reference	O
254	product	O
254	.	O
254	[SEP]	O
255	[CLS]	O
255	as	O
255	shown	O
255	in	O
255	figure	O
255	2	O
255	##a	O
255	,	O
255	an	O
255	##c	O
255	increased	O
255	as	O
255	expected	O
255	after	O
255	single	O
255	‐	O
255	dose	O
255	sub	O
255	##cut	O
255	##aneous	O
255	administration	O
255	,	O
255	with	O
255	peak	B-PK
255	levels	I-PK
255	occurring	O
255	approximately	O
255	64	O
255	and	O
255	61	O
255	hours	O
255	post	O
255	##dos	O
255	##e	O
255	for	O
255	the	O
255	proposed	O
255	p	O
255	##eg	O
255	##fi	O
255	##l	O
255	##gra	O
255	##st	O
255	##im	O
255	bio	O
255	##si	O
255	##mi	O
255	##lar	O
255	and	O
255	the	O
255	reference	O
255	product	O
255	,	O
255	respectively	O
255	,	O
255	and	O
255	returning	O
255	to	O
255	base	O
255	##line	O
255	levels	O
255	by	O
255	approximately	O
255	360	O
255	hours	O
255	post	O
255	##dos	O
255	##e	O
255	.	O
255	[SEP]	O
256	[CLS]	O
256	this	O
256	would	O
256	be	O
256	considered	O
256	the	O
256	dos	O
256	##age	O
256	rate	O
256	to	O
256	be	O
256	used	O
256	in	O
256	clinical	O
256	evaluation	O
256	.	O
256	[SEP]	O
257	[CLS]	O
257	12	O
257	%	O
257	bi	O
257	##s	O
257	t	O
257	##ris	O
257	n	O
257	##up	O
257	##age	O
257	gel	O
257	##s	O
257	(	O
257	in	O
257	##vi	O
257	##tro	O
257	##gen	O
257	)	O
257	were	O
257	run	O
257	in	O
257	me	O
257	##s	O
257	running	O
257	buffer	O
257	as	O
257	per	O
257	manufacturer	O
257	’	O
257	s	O
257	protocol	O
257	.	O
257	[SEP]	O
258	[CLS]	O
258	re	O
258	##comb	O
258	##ina	O
258	##nt	O
258	mouse	O
258	and	O
258	human	O
258	t	O
258	##n	O
258	##f	O
258	##r	O
258	##1	O
258	ch	O
258	##ime	O
258	##ras	O
258	and	O
258	single	O
258	point	O
258	mutant	O
258	##s	O
258	were	O
258	expressed	O
258	from	O
258	pp	O
258	##icz	O
258	##al	O
258	##pha	O
258	expression	O
258	vector	O
258	in	O
258	p	O
258	##ichi	O
258	##a	O
258	pastor	O
258	##is	O
258	km	O
258	##7	O
258	##1	O
258	##h	O
258	strain	O
258	using	O
258	met	O
258	##han	O
258	##ol	O
258	induction	O
258	.	O
258	[SEP]	O
259	[CLS]	O
259	it	O
259	was	O
259	six	O
259	times	O
259	higher	O
259	than	O
259	the	O
259	mean	O
259	t	B-PK
259	##max	I-PK
259	of	O
259	0	O
259	.	O
259	03	O
259	h	O
259	after	O
259	a	O
259	single	O
259	oral	O
259	administration	O
259	of	O
259	f	O
259	##er	O
259	##uli	O
259	##c	O
259	acid	O
259	[	O
259	21	O
259	]	O
259	,	O
259	which	O
259	implies	O
259	other	O
259	components	O
259	in	O
259	n	O
259	##x	O
259	##t	O
259	##c	O
259	might	O
259	affect	O
259	the	O
259	absorption	O
259	of	O
259	f	O
259	##er	O
259	##uli	O
259	##c	O
259	acid	O
259	.	O
259	[SEP]	O
260	[CLS]	O
260	further	O
260	details	O
260	on	O
260	the	O
260	experimental	O
260	design	O
260	and	O
260	results	O
260	can	O
260	be	O
260	found	O
260	in	O
260	we	O
260	##sch	O
260	##ler	O
260	et	O
260	al	O
260	.	O
260	10	O
260	[SEP]	O
261	[CLS]	O
261	the	O
261	au	B-PK
261	##c	I-PK
261	was	O
261	estimated	O
261	using	O
261	the	O
261	trap	O
261	##ez	O
261	##oid	O
261	##al	O
261	rule	O
261	with	O
261	log	O
261	‐	O
261	extension	O
261	to	O
261	in	O
261	##finity	O
261	based	O
261	on	O
261	the	O
261	last	O
261	three	O
261	points	O
261	.	O
261	[SEP]	O
262	[CLS]	O
262	the	O
262	half	B-PK
262	‐	I-PK
262	life	I-PK
262	(	I-PK
262	t	I-PK
262	##1	I-PK
262	/	I-PK
262	2	I-PK
262	)	I-PK
262	was	O
262	calculated	O
262	as	O
262	l	O
262	##n	O
262	##2	O
262	/	O
262	k	O
262	and	O
262	the	O
262	elimination	B-PK
262	rate	I-PK
262	constant	I-PK
262	k	I-PK
262	was	O
262	estimated	O
262	as	O
262	the	O
262	negative	O
262	of	O
262	the	O
262	slope	O
262	from	O
262	a	O
262	linear	O
262	re	O
262	##gression	O
262	of	O
262	log	O
262	concentration	O
262	of	O
262	time	O
262	.	O
262	[SEP]	O
263	[CLS]	O
263	drug	O
263	clearance	B-PK
263	(	I-PK
263	c	I-PK
263	##l	I-PK
263	)	I-PK
263	and	O
263	the	O
263	volume	B-PK
263	of	I-PK
263	distribution	I-PK
263	(	I-PK
263	v	I-PK
263	##d	I-PK
263	)	I-PK
263	were	O
263	estimated	O
263	as	O
263	dose	B-PK
263	/	I-PK
263	au	I-PK
263	##c	I-PK
263	and	O
263	c	B-PK
263	##l	I-PK
263	/	I-PK
263	k	I-PK
263	,	O
263	respectively	O
263	.	O
263	[SEP]	O
264	[CLS]	O
264	inter	O
264	##ind	O
264	##iv	O
264	##id	O
264	##ual	O
264	var	O
264	##iability	O
264	and	O
264	in	O
264	##tra	O
264	‐	O
264	individual	O
264	var	O
264	##iability	O
264	of	O
264	do	O
264	##ce	O
264	##ta	O
264	##xe	O
264	##l	O
264	clearance	B-PK
264	,	O
264	volume	B-PK
264	of	I-PK
264	distribution	I-PK
264	,	O
264	and	O
264	half	B-PK
264	‐	I-PK
264	life	I-PK
264	were	O
264	estimated	O
264	with	O
264	multi	O
264	##lev	O
264	##el	O
264	modeling	O
264	for	O
264	repeat	O
264	measures	O
264	in	O
264	which	O
264	the	O
264	fixed	O
264	effects	O
264	and	O
264	residual	O
264	variance	O
264	represents	O
264	the	O
264	inter	O
264	‐	O
264	and	O
264	in	O
264	##tra	O
264	‐	O
264	individual	O
264	variance	O
264	,	O
264	respectively	O
264	.	O
264	[SEP]	O
265	[CLS]	O
265	high	O
265	peak	B-PK
265	plasma	I-PK
265	concentrations	I-PK
265	(	I-PK
265	cm	I-PK
265	##ax	I-PK
265	)	I-PK
265	>	O
265	80	O
265	mg	O
265	/	O
265	m	O
265	##l	O
265	were	O
265	achieved	O
265	with	O
265	i	O
265	##v	O
265	injection	O
265	of	O
265	the	O
265	negative	O
265	(	O
265	t	O
265	##co	O
265	##oh	O
265	)	O
265	,	O
265	neutral	O
265	(	O
265	te	O
265	##go	O
265	##h	O
265	)	O
265	and	O
265	z	O
265	##wi	O
265	##tter	O
265	##ion	O
265	##ic	O
265	(	O
265	t	O
265	##z	O
265	##wi	O
265	##t	O
265	)	O
265	particles	O
265	,	O
265	while	O
265	a	O
265	10	O
265	-	O
265	fold	O
265	lower	O
265	peak	B-PK
265	plasma	I-PK
265	concentration	I-PK
265	was	O
265	achieved	O
265	with	O
265	the	O
265	positive	O
265	(	O
265	t	O
265	##t	O
265	##ma	O
265	)	O
265	particles	O
265	(	O
265	table	O
265	1	O
265	)	O
265	.	O
265	[SEP]	O
266	[CLS]	O
266	following	O
266	i	O
266	##v	O
266	injection	O
266	,	O
266	high	O
266	plasma	B-PK
266	clearance	I-PK
266	was	O
266	observed	O
266	for	O
266	the	O
266	negative	O
266	(	O
266	t	O
266	##co	O
266	##oh	O
266	)	O
266	and	O
266	positive	O
266	(	O
266	t	O
266	##t	O
266	##ma	O
266	)	O
266	charged	O
266	au	O
266	##n	O
266	##ps	O
266	(	O
266	0	O
266	.	O
266	07	O
266	##39	O
266	µ	O
266	##g	O
266	/	O
266	m	O
266	##l	O
266	/	O
266	min	O
266	and	O
266	0	O
266	.	O
266	170	O
266	µ	O
266	##g	O
266	/	O
266	m	O
266	##l	O
266	/	O
266	min	O
266	,	O
266	respectively	O
266	)	O
266	such	O
266	that	O
266	the	O
266	plasma	O
266	concentrations	O
266	fell	O
266	below	O
266	1	O
266	mg	O
266	/	O
266	m	O
266	##l	O
266	within	O
266	15	O
266	minutes	O
266	after	O
266	injection	O
266	(	O
266	figure	O
266	1	O
266	##a	O
266	)	O
266	.	O
266	[SEP]	O
267	[CLS]	O
267	the	O
267	results	O
267	of	O
267	recovery	O
267	rate	O
267	in	O
267	v	O
267	##ivo	O
267	are	O
267	summarized	O
267	in	O
267	table	O
267	4	O
267	.	O
267	[SEP]	O
268	[CLS]	O
268	the	O
268	relationship	O
268	between	O
268	raw	O
268	q	O
268	##t	O
268	interval	O
268	and	O
268	r	O
268	##r	O
268	interval	O
268	showed	O
268	a	O
268	steep	O
268	positive	O
268	slope	O
268	(	O
268	slope	O
268	p	O
268	<	O
268	0	O
268	.	O
268	000	O
268	##1	O
268	)	O
268	,	O
268	as	O
268	expected	O
268	based	O
268	on	O
268	normal	O
268	physiology	O
268	.	O
268	[SEP]	O
269	[CLS]	O
269	the	O
269	lines	O
269	in	O
269	fi	O
269	##g	O
269	.	O
269	6	O
269	are	O
269	the	O
269	p	O
269	##b	O
269	##p	O
269	##k	O
269	model	O
269	predictions	O
269	using	O
269	the	O
269	op	O
269	##ti	O
269	##mized	O
269	standard	O
269	parameters	O
269	in	O
269	tables	O
269	1	O
269	and	O
269	2	O
269	.	O
269	[SEP]	O
270	[CLS]	O
270	thus	O
270	,	O
270	the	O
270	in	O
270	v	O
270	##ivo	O
270	recovery	O
270	rate	O
270	can	O
270	be	O
270	used	O
270	to	O
270	correct	O
270	the	O
270	data	O
270	in	O
270	the	O
270	micro	O
270	##dial	O
270	##ys	O
270	##is	O
270	test	O
270	.	O
270	[SEP]	O
271	[CLS]	O
271	p	O
271	##lu	O
271	##rip	O
271	##ote	O
271	##ncy	O
271	was	O
271	confirmed	O
271	through	O
271	quantitative	O
271	p	O
271	##c	O
271	##r	O
271	gene	O
271	expression	O
271	analysis	O
271	of	O
271	the	O
271	p	O
271	##lu	O
271	##rip	O
271	##ote	O
271	##ncy	O
271	genes	O
271	na	O
271	##no	O
271	##g	O
271	,	O
271	o	O
271	##ct	O
271	##3	O
271	/	O
271	4	O
271	and	O
271	so	O
271	##x	O
271	##2	O
271	.	O
271	[SEP]	O
272	[CLS]	O
272	most	O
272	tea	O
272	##es	O
272	(	O
272	16	O
272	/	O
272	26	O
272	,	O
272	61	O
272	.	O
272	5	O
272	%	O
272	)	O
272	were	O
272	of	O
272	mild	O
272	intensity	O
272	,	O
272	38	O
272	.	O
272	5	O
272	%	O
272	were	O
272	of	O
272	moderate	O
272	intensity	O
272	,	O
272	and	O
272	none	O
272	was	O
272	severe	O
272	.	O
272	[SEP]	O
273	[CLS]	O
273	enrolled	O
273	patients	O
273	were	O
273	screened	O
273	for	O
273	t	O
273	##b	O
273	using	O
273	a	O
273	q	O
273	##uant	O
273	##ifer	O
273	##on	O
273	-	O
273	t	O
273	##b	O
273	gold	O
273	in	O
273	-	O
273	tube	O
273	test	O
273	and	O
273	chest	O
273	x	O
273	-	O
273	ray	O
273	(	O
273	or	O
273	chest	O
273	c	O
273	##t	O
273	scan	O
273	at	O
273	the	O
273	investigator	O
273	'	O
273	s	O
273	discretion	O
273	)	O
273	.	O
273	[SEP]	O
274	[CLS]	O
274	re	O
274	##p	O
274	##rog	O
274	##ram	O
274	##med	O
274	p	O
274	##b	O
274	##m	O
274	##cs	O
274	were	O
274	transferred	O
274	to	O
274	me	O
274	##f	O
274	feeder	O
274	cells	O
274	on	O
274	mat	O
274	##rig	O
274	##el	O
274	-	O
274	coated	O
274	plates	O
274	at	O
274	day	O
274	3	O
274	after	O
274	trans	O
274	##fect	O
274	##ion	O
274	and	O
274	culture	O
274	##d	O
274	in	O
274	te	O
274	##s	O
274	##r	O
274	-	O
274	e	O
274	##7	O
274	and	O
274	sodium	O
274	but	O
274	##yra	O
274	##te	O
274	re	O
274	##p	O
274	##rog	O
274	##ram	O
274	##ming	O
274	medium	O
274	(	O
274	stem	O
274	##cell	O
274	technologies	O
274	)	O
274	.	O
274	[SEP]	O
275	[CLS]	O
275	each	O
275	200	O
275	μ	O
275	##l	O
275	sample	O
275	contained	O
275	0	O
275	.	O
275	35	O
275	%	O
275	met	O
275	##hyl	O
275	cell	O
275	##ulos	O
275	##e	O
275	(	O
275	protein	O
275	simple	O
275	)	O
275	,	O
275	4	O
275	%	O
275	p	O
275	##har	O
275	##mal	O
275	##yte	O
275	3	O
275	–	O
275	10	O
275	(	O
275	g	O
275	##e	O
275	healthcare	O
275	)	O
275	,	O
275	10	O
275	mm	O
275	a	O
275	##rg	O
275	##ini	O
275	##ne	O
275	(	O
275	protein	O
275	simple	O
275	)	O
275	,	O
275	0	O
275	.	O
275	2	O
275	mg	O
275	m	O
275	##l	O
275	##−	O
275	##1	O
275	anti	O
275	##body	O
275	and	O
275	the	O
275	4	O
275	.	O
275	05	O
275	and	O
275	9	O
275	.	O
275	99	O
275	p	O
275	##i	O
275	markers	O
275	(	O
275	protein	O
275	simple	O
275	)	O
275	.	O
275	[SEP]	O
276	[CLS]	O
276	for	O
276	in	O
276	v	O
276	##it	O
276	##ro	O
276	determination	O
276	of	O
276	c	O
276	##ya	O
276	,	O
276	the	O
276	mobile	O
276	phase	O
276	consists	O
276	of	O
276	ace	O
276	##ton	O
276	##it	O
276	##ril	O
276	##e	O
276	/	O
276	water	O
276	/	O
276	te	O
276	##rt	O
276	-	O
276	but	O
276	##yl	O
276	met	O
276	##hyl	O
276	et	O
276	##her	O
276	/	O
276	p	O
276	##hos	O
276	##ph	O
276	##ori	O
276	##c	O
276	acid	O
276	(	O
276	60	O
276	/	O
276	35	O
276	/	O
276	5	O
276	/	O
276	0	O
276	.	O
276	1	O
276	,	O
276	v	O
276	/	O
276	v	O
276	/	O
276	v	O
276	/	O
276	v	O
276	)	O
276	at	O
276	a	O
276	flow	O
276	rate	O
276	of	O
276	1	O
276	.	O
276	0	O
276	m	O
276	##l	O
276	/	O
276	minute	O
276	.	O
276	[SEP]	O
277	[CLS]	O
277	day	O
277	1	O
277	:	O
277	r	O
277	##it	O
277	##ux	O
277	##ima	O
277	##b	O
277	375	O
277	mg	O
277	/	O
277	m	O
277	##2	O
277	in	O
277	##tra	O
277	##ven	O
277	##ously	O
277	(	O
277	i	O
277	##v	O
277	)	O
277	[SEP]	O
278	[CLS]	O
278	animals	O
278	were	O
278	a	O
278	##cc	O
278	##lim	O
278	##ated	O
278	for	O
278	at	O
278	least	O
278	a	O
278	week	O
278	prior	O
278	to	O
278	study	O
278	initiation	O
278	.	O
278	[SEP]	O
279	[CLS]	O
279	the	O
279	linear	O
279	##ity	O
279	of	O
279	the	O
279	proposed	O
279	method	O
279	in	O
279	rabbit	O
279	plasma	O
279	was	O
279	55	O
279	–	O
279	330	O
279	×	O
279	10	O
279	##−	O
279	##7	O
279	m	O
279	with	O
279	a	O
279	correlation	O
279	coefficient	O
279	of	O
279	0	O
279	.	O
279	99	O
279	##8	O
279	##9	O
279	±	O
279	0	O
279	.	O
279	00	O
279	##9	O
279	(	O
279	table	O
279	5	O
279	)	O
279	.	O
279	[SEP]	O
280	[CLS]	O
280	it	O
280	also	O
280	implies	O
280	that	O
280	for	O
280	those	O
280	complex	O
280	h	O
280	##ydro	O
280	##gel	O
280	##s	O
280	with	O
280	a	O
280	r	O
280	##op	O
280	##v	O
280	##p	O
280	/	O
280	c	O
280	##s	O
280	ratio	O
280	of	O
280	20	O
280	:	O
280	5	O
280	,	O
280	a	O
280	h	O
280	##ydro	O
280	##gel	O
280	concentration	O
280	of	O
280	7	O
280	.	O
280	5	O
280	~	O
280	10	O
280	%	O
280	was	O
280	desirable	O
280	to	O
280	form	O
280	a	O
280	solid	O
280	-	O
280	like	O
280	h	O
280	##ydro	O
280	##gel	O
280	with	O
280	a	O
280	higher	O
280	gel	O
280	strength	O
280	.	O
280	[SEP]	O
281	[CLS]	O
281	an	O
281	in	O
281	##cision	O
281	was	O
281	made	O
281	on	O
281	the	O
281	lateral	O
281	side	O
281	of	O
281	the	O
281	neck	O
281	to	O
281	expose	O
281	the	O
281	j	O
281	##ug	O
281	##ular	O
281	vein	O
281	,	O
281	which	O
281	was	O
281	isolated	O
281	and	O
281	a	O
281	two	O
281	-	O
281	l	O
281	##ume	O
281	##n	O
281	central	O
281	ve	O
281	##nous	O
281	cat	O
281	##he	O
281	##ter	O
281	was	O
281	inserted	O
281	into	O
281	the	O
281	l	O
281	##ume	O
281	##n	O
281	of	O
281	the	O
281	vein	O
281	.	O
281	[SEP]	O
282	[CLS]	O
282	the	O
282	p	O
282	##k	O
282	analysis	O
282	set	O
282	comprised	O
282	subjects	O
282	in	O
282	the	O
282	safety	O
282	analysis	O
282	set	O
282	for	O
282	whom	O
282	p	O
282	##k	O
282	data	O
282	were	O
282	adequate	O
282	for	O
282	the	O
282	calculation	O
282	of	O
282	at	O
282	least	O
282	1	O
282	of	O
282	the	O
282	primary	O
282	p	O
282	##k	O
282	parameters	O
282	.	O
282	[SEP]	O
283	[CLS]	O
283	the	O
283	interval	O
283	between	O
283	treatments	O
283	at	O
283	the	O
283	same	O
283	dos	O
283	##age	O
283	level	O
283	was	O
283	1	O
283	week	O
283	.	O
283	[SEP]	O
284	[CLS]	O
284	the	O
284	ll	O
284	##o	O
284	##q	O
284	values	O
284	for	O
284	the	O
284	four	O
284	components	O
284	in	O
284	rat	O
284	plasma	O
284	were	O
284	g	O
284	##ent	O
284	##io	O
284	##pic	O
284	##ros	O
284	##ide	O
284	(	O
284	10	O
284	ng	O
284	/	O
284	m	O
284	##l	O
284	)	O
284	,	O
284	g	O
284	##eni	O
284	##po	O
284	##side	O
284	(	O
284	5	O
284	ng	O
284	/	O
284	m	O
284	##l	O
284	)	O
284	,	O
284	b	O
284	##aic	O
284	##ali	O
284	##n	O
284	(	O
284	10	O
284	ng	O
284	/	O
284	m	O
284	##l	O
284	)	O
284	,	O
284	and	O
284	s	O
284	##wer	O
284	##tia	O
284	##mar	O
284	##in	O
284	(	O
284	5	O
284	ng	O
284	/	O
284	m	O
284	##l	O
284	)	O
284	.	O
284	[SEP]	O
285	[CLS]	O
285	descriptive	O
285	statistics	O
285	were	O
285	used	O
285	to	O
285	sum	O
285	##mar	O
285	##ize	O
285	continuous	O
285	and	O
285	cat	O
285	##ego	O
285	##rical	O
285	variables	O
285	.	O
285	[SEP]	O
286	[CLS]	O
286	all	O
286	animal	O
286	experiments	O
286	and	O
286	experimental	O
286	protocols	O
286	were	O
286	conducted	O
286	in	O
286	accordance	O
286	with	O
286	the	O
286	guide	O
286	for	O
286	the	O
286	care	O
286	and	O
286	use	O
286	of	O
286	laboratory	O
286	animals	O
286	of	O
286	h	O
286	##ui	O
286	##bei	O
286	provincial	O
286	laboratory	O
286	animal	O
286	public	O
286	service	O
286	center	O
286	(	O
286	permit	O
286	number	O
286	s	O
286	##yx	O
286	##k	O
286	2013	O
286	-	O
286	00	O
286	##44	O
286	)	O
286	and	O
286	approved	O
286	by	O
286	the	O
286	ethics	O
286	committee	O
286	of	O
286	h	O
286	##ua	O
286	##z	O
286	##hong	O
286	agricultural	O
286	un	O
286	##iver	O
286	##ist	O
286	##y	O
286	,	O
286	w	O
286	##uh	O
286	##an	O
286	,	O
286	chin	O
286	##a	O
286	.	O
286	[SEP]	O
287	[CLS]	O
287	this	O
287	was	O
287	not	O
287	possible	O
287	due	O
287	to	O
287	limited	O
287	numbers	O
287	of	O
287	animals	O
287	available	O
287	for	O
287	this	O
287	trial	O
287	(	O
287	table	O
287	1	O
287	)	O
287	.	O
287	[SEP]	O
288	[CLS]	O
288	when	O
288	dos	O
288	##age	O
288	levels	O
288	were	O
288	changed	O
288	in	O
288	an	O
288	individual	O
288	,	O
288	a	O
288	minimum	O
288	break	O
288	of	O
288	3	O
288	weeks	O
288	between	O
288	treatments	O
288	was	O
288	used	O
288	.	O
288	[SEP]	O
289	[CLS]	O
289	blood	O
289	samples	O
289	(	O
289	200	O
289	μ	O
289	##l	O
289	)	O
289	were	O
289	collected	O
289	from	O
289	the	O
289	vein	O
289	of	O
289	the	O
289	eye	O
289	socket	O
289	##s	O
289	into	O
289	he	O
289	##par	O
289	##ini	O
289	##zed	O
289	tubes	O
289	after	O
289	the	O
289	rats	O
289	were	O
289	an	O
289	##est	O
289	##he	O
289	##tized	O
289	with	O
289	et	O
289	##hyl	O
289	et	O
289	##her	O
289	.	O
289	[SEP]	O
290	[CLS]	O
290	subjects	O
290	received	O
290	a	O
290	single	O
290	dose	O
290	of	O
290	4	O
290	spray	O
290	##s	O
290	th	O
290	##c	O
290	/	O
290	c	O
290	##b	O
290	##d	O
290	on	O
290	day	O
290	1	O
290	.	O
290	[SEP]	O
291	[CLS]	O
291	we	O
291	performed	O
291	a	O
291	mon	O
291	##te	O
291	car	O
291	##lo	O
291	simulation	O
291	with	O
291	1	O
291	million	O
291	replica	O
291	##tes	O
291	based	O
291	on	O
291	the	O
291	normal	O
291	distribution	O
291	of	O
291	steady	O
291	-	O
291	state	O
291	flu	O
291	##cona	O
291	##zo	O
291	##le	O
291	concentrations	O
291	from	O
291	the	O
291	different	O
291	doses	O
291	.	O
291	[SEP]	O
292	[CLS]	O
292	subjects	O
292	received	O
292	once	O
292	daily	O
292	o	O
292	##me	O
292	##pra	O
292	##zo	O
292	##le	O
292	on	O
292	days	O
292	2	O
292	-	O
292	6	O
292	,	O
292	and	O
292	then	O
292	th	O
292	##c	O
292	/	O
292	c	O
292	##b	O
292	##d	O
292	spray	O
292	and	O
292	o	O
292	##me	O
292	##pra	O
292	##zo	O
292	##le	O
292	on	O
292	day	O
292	7	O
292	.	O
292	[SEP]	O
293	[CLS]	O
293	sex	O
293	difference	O
293	was	O
293	observed	O
293	for	O
293	d	O
293	##ha	O
293	and	O
293	its	O
293	meta	O
293	##bol	O
293	##ites	O
293	(	O
293	m	O
293	##1	O
293	and	O
293	d	O
293	##ha	O
293	-	O
293	g	O
293	)	O
293	,	O
293	whereas	O
293	its	O
293	pro	O
293	##dr	O
293	##ug	O
293	a	O
293	##rs	O
293	did	O
293	not	O
293	show	O
293	similar	O
293	characteristics	O
293	for	O
293	the	O
293	corresponding	O
293	meta	O
293	##bol	O
293	##ites	O
293	(	O
293	d	O
293	##ha	O
293	,	O
293	m	O
293	##1	O
293	and	O
293	d	O
293	##ha	O
293	-	O
293	g	O
293	)	O
293	.	O
293	[SEP]	O
294	[CLS]	O
294	the	O
294	drug	O
294	release	O
294	mechanism	O
294	from	O
294	the	O
294	micro	O
294	##sp	O
294	##here	O
294	##s	O
294	thus	O
294	can	O
294	be	O
294	described	O
294	as	O
294	diffusion	O
294	controlled	O
294	.	O
294	[SEP]	O
295	[CLS]	O
295	in	O
295	this	O
295	phase	O
295	,	O
295	ta	O
295	##s	O
295	-	O
295	121	O
295	was	O
295	administered	O
295	oral	O
295	##ly	O
295	q	O
295	##d	O
295	with	O
295	a	O
295	starting	O
295	dos	O
295	##age	O
295	of	O
295	2	O
295	mg	O
295	/	O
295	day	O
295	.	O
295	[SEP]	O
296	[CLS]	O
296	the	O
296	dos	O
296	##ing	O
296	rational	O
296	##e	O
296	was	O
296	derived	O
296	from	O
296	a	O
296	4	O
296	-	O
296	weeks	O
296	repeated	O
296	oral	O
296	-	O
296	dose	O
296	toxic	O
296	##ology	O
296	study	O
296	in	O
296	monkeys	O
296	.	O
296	[SEP]	O
297	[CLS]	O
297	a	O
297	theoretical	O
297	calculation	O
297	was	O
297	performed	O
297	to	O
297	estimate	O
297	the	O
297	target	O
297	particle	O
297	size	O
297	at	O
297	which	O
297	a	O
297	na	O
297	##no	O
297	##par	O
297	##tic	O
297	##le	O
297	should	O
297	rapidly	O
297	dissolve	O
297	in	O
297	the	O
297	blood	O
297	##stream	O
297	(	O
297	i	O
297	.	O
297	e	O
297	.	O
297	,	O
297	<	O
297	10	O
297	s	O
297	under	O
297	non	O
297	-	O
297	stirred	O
297	condition	O
297	)	O
297	upon	O
297	in	O
297	##tra	O
297	##ven	O
297	##ous	O
297	administration	O
297	.	O
297	[SEP]	O
298	[CLS]	O
298	the	O
298	study	O
298	was	O
298	registered	O
298	in	O
298	the	O
298	euro	O
298	##pe	O
298	##an	O
298	clinical	O
298	trials	O
298	database	O
298	(	O
298	e	O
298	##ud	O
298	##rac	O
298	##t	O
298	number	O
298	2008	O
298	-	O
298	00	O
298	##36	O
298	##43	O
298	-	O
298	36	O
298	)	O
298	and	O
298	conducted	O
298	in	O
298	accordance	O
298	with	O
298	good	O
298	clinical	O
298	practice	O
298	(	O
298	g	O
298	##c	O
298	##p	O
298	)	O
298	,	O
298	the	O
298	current	O
298	requirements	O
298	of	O
298	em	O
298	##a	O
298	(	O
298	euro	O
298	##pe	O
298	##an	O
298	medicines	O
298	agency	O
298	)	O
298	[	O
298	23	O
298	]	O
298	,	O
298	the	O
298	declaration	O
298	of	O
298	he	O
298	##ls	O
298	##ink	O
298	##i	O
298	and	O
298	local	O
298	and	O
298	euro	O
298	##pe	O
298	##an	O
298	law	O
298	.	O
298	[SEP]	O
299	[CLS]	O
299	the	O
299	injection	O
299	volume	O
299	was	O
299	50	O
299	μ	O
299	##l	O
299	and	O
299	the	O
299	total	O
299	run	O
299	time	O
299	was	O
299	30	O
299	min	O
299	.	O
299	[SEP]	O
300	[CLS]	O
300	the	O
300	analyses	O
300	were	O
300	carried	O
300	out	O
300	at	O
300	room	O
300	temperature	O
300	on	O
300	a	O
300	l	O
300	##una	O
300	c	O
300	##18	O
300	column	O
300	(	O
300	particle	O
300	size	O
300	:	O
300	5	O
300	μ	O
300	##m	O
300	,	O
300	250	O
300	×	O
300	4	O
300	.	O
300	6	O
300	mm	O
300	,	O
300	p	O
300	##hen	O
300	##ome	O
300	##nex	O
300	)	O
300	protected	O
300	with	O
300	a	O
300	guard	O
300	column	O
300	(	O
300	p	O
300	##hen	O
300	##ome	O
300	##nex	O
300	security	O
300	##guard	O
300	4	O
300	×	O
300	2	O
300	.	O
300	0	O
300	mm	O
300	)	O
300	.	O
300	[SEP]	O
301	[CLS]	O
301	the	O
301	external	O
301	standard	O
301	method	O
301	was	O
301	used	O
301	for	O
301	quantitative	O
301	analysis	O
301	.	O
301	16	O
301	[SEP]	O
302	[CLS]	O
302	the	O
302	dose	O
302	limiting	O
302	toxicity	O
302	was	O
302	ne	O
302	##ut	O
302	##rop	O
302	##enia	O
302	,	O
302	with	O
302	3	O
302	of	O
302	5	O
302	animals	O
302	treated	O
302	at	O
302	that	O
302	dos	O
302	##age	O
302	rate	O
302	showing	O
302	grade	O
302	2	O
302	to	O
302	4	O
302	ne	O
302	##ut	O
302	##rop	O
302	##enia	O
302	(	O
302	table	O
302	1	O
302	)	O
302	.	O
302	[SEP]	O
303	[CLS]	O
303	safety	O
303	end	O
303	##points	O
303	were	O
303	incidence	O
303	,	O
303	severity	O
303	,	O
303	drug	O
303	-	O
303	related	O
303	##ness	O
303	,	O
303	and	O
303	serious	O
303	##ness	O
303	of	O
303	adverse	O
303	events	O
303	and	O
303	of	O
303	laboratory	O
303	abnormal	O
303	##ities	O
303	.	O
303	[SEP]	O
304	[CLS]	O
304	the	O
304	same	O
304	sections	O
304	were	O
304	ex	O
304	##cise	O
304	##d	O
304	from	O
304	the	O
304	control	O
304	pig	O
304	and	O
304	fixed	O
304	in	O
304	neutral	O
304	buffer	O
304	##ed	O
304	formal	O
304	##in	O
304	in	O
304	order	O
304	to	O
304	preserve	O
304	the	O
304	tissues	O
304	.	O
304	[SEP]	O
305	[CLS]	O
305	covers	O
305	##lip	O
305	##ping	O
305	was	O
305	undertaken	O
305	to	O
305	prevent	O
305	the	O
305	tissue	O
305	from	O
305	being	O
305	scratched	O
305	and	O
305	to	O
305	provide	O
305	better	O
305	optical	O
305	quality	O
305	during	O
305	micro	O
305	##scopic	O
305	viewing	O
305	.	O
305	[SEP]	O
306	[CLS]	O
306	descriptions	O
306	of	O
306	the	O
306	micro	O
306	##scopic	O
306	features	O
306	were	O
306	made	O
306	and	O
306	a	O
306	final	O
306	micro	O
306	##scopic	O
306	diagnosis	O
306	was	O
306	reported	O
306	.	O
306	[SEP]	O
307	[CLS]	O
307	each	O
307	volunteer	O
307	participating	O
307	in	O
307	this	O
307	study	O
307	was	O
307	informed	O
307	by	O
307	the	O
307	clinical	O
307	investigator	O
307	about	O
307	the	O
307	m	O
307	##oda	O
307	##lity	O
307	and	O
307	the	O
307	possible	O
307	risks	O
307	of	O
307	the	O
307	trial	O
307	and	O
307	consent	O
307	##ed	O
307	to	O
307	study	O
307	participation	O
307	in	O
307	writing	O
307	before	O
307	undergoing	O
307	the	O
307	first	O
307	study	O
307	-	O
307	related	O
307	procedure	O
307	.	O
307	[SEP]	O
308	[CLS]	O
308	also	O
308	,	O
308	as	O
308	listed	O
308	in	O
308	table	O
308	1	O
308	,	O
308	the	O
308	dog	O
308	showed	O
308	the	O
308	lowest	O
308	mean	O
308	terminal	B-PK
308	half	I-PK
308	-	I-PK
308	life	I-PK
308	of	O
308	3	O
308	.	O
308	10	O
308	h	O
308	and	O
308	the	O
308	monkey	O
308	,	O
308	the	O
308	highest	O
308	value	O
308	of	O
308	9	O
308	.	O
308	94	O
308	h	O
308	.	O
308	[SEP]	O
309	[CLS]	O
309	a	O
309	dose	O
309	-	O
309	and	O
309	time	O
309	-	O
309	dependent	O
309	reduction	O
309	in	O
309	the	O
309	cell	O
309	proliferation	O
309	rate	O
309	was	O
309	evident	O
309	with	O
309	a	O
309	c	O
309	##yt	O
309	##ost	O
309	##atic	O
309	effect	O
309	up	O
309	to	O
309	24	O
309	h	O
309	post	O
309	-	O
309	treatment	O
309	followed	O
309	by	O
309	growth	O
309	in	O
309	##hibition	O
309	(	O
309	fi	O
309	##g	O
309	.	O
309	1	O
309	##c	O
309	)	O
309	except	O
309	in	O
309	cells	O
309	treated	O
309	with	O
309	60	O
309	μ	O
309	##m	O
309	and	O
309	##rog	O
309	##rap	O
309	##hol	O
309	##ide	O
309	.	O
309	[SEP]	O
310	[CLS]	O
310	after	O
310	topic	O
310	##al	O
310	application	O
310	of	O
310	the	O
310	26	O
310	##al	O
310	‐	O
310	a	O
310	##ch	O
310	anti	O
310	##pers	O
310	##pi	O
310	##rant	O
310	,	O
310	a	O
310	cotton	O
310	t	O
310	‐	O
310	shirt	O
310	was	O
310	dispatched	O
310	to	O
310	the	O
310	subjects	O
310	to	O
310	wear	O
310	for	O
310	the	O
310	rest	O
310	of	O
310	the	O
310	day	O
310	and	O
310	during	O
310	the	O
310	night	O
310	to	O
310	minimize	O
310	loss	O
310	of	O
310	radio	O
310	##la	O
310	##bel	O
310	to	O
310	the	O
310	environment	O
310	.	O
310	[SEP]	O
311	[CLS]	O
311	to	O
311	provide	O
311	some	O
311	evidence	O
311	on	O
311	u	O
311	##rina	O
311	##ry	O
311	ex	O
311	##cre	O
311	##tion	O
311	,	O
311	spot	O
311	urine	O
311	samples	O
311	were	O
311	taken	O
311	in	O
311	the	O
311	study	O
311	at	O
311	24	O
311	hours	O
311	,	O
311	3	O
311	,	O
311	4	O
311	,	O
311	18	O
311	,	O
311	15	O
311	,	O
311	22	O
311	,	O
311	and	O
311	29	O
311	days	O
311	post	O
311	##dos	O
311	##e	O
311	and	O
311	normal	O
311	##ized	O
311	to	O
311	c	O
311	##rea	O
311	##tin	O
311	##ine	O
311	concentration	O
311	.	O
311	[SEP]	O
312	[CLS]	O
312	(	O
312	a	O
312	)	O
312	drafting	O
312	the	O
312	manuscript	O
312	[SEP]	O
313	[CLS]	O
313	figure	O
313	##3	O
313	compares	O
313	the	O
313	time	O
313	course	O
313	of	O
313	linear	O
313	/	O
313	non	O
313	##linear	O
313	fraction	B-PK
313	##al	I-PK
313	drug	I-PK
313	elimination	I-PK
313	(	O
313	1	O
313	/	O
313	day	O
313	)	O
313	and	O
313	measures	O
313	b	O
313	‐	O
313	/	O
313	t	O
313	‐	O
313	cell	O
313	dynamics	O
313	in	O
313	blood	O
313	.	O
313	[SEP]	O
314	[CLS]	O
314	the	O
314	do	O
314	##x	O
314	group	O
314	was	O
314	given	O
314	an	O
314	i	O
314	.	O
314	v	O
314	.	O
314	single	O
314	dose	O
314	of	O
314	5	O
314	.	O
314	0	O
314	mg	O
314	/	O
314	kg	O
314	do	O
314	##x	O
314	via	O
314	the	O
314	tail	O
314	vein	O
314	.	O
314	[SEP]	O
315	[CLS]	O
315	dose	O
315	‐	O
315	depend	O
315	##ency	O
315	of	O
315	peripheral	O
315	blood	O
315	b	O
315	‐	O
315	cell	O
315	de	O
315	##ple	O
315	##tion	O
315	could	O
315	not	O
315	be	O
315	detected	O
315	in	O
315	the	O
315	pre	O
315	##c	O
315	##lini	O
315	##cal	O
315	studies	O
315	,	O
315	possibly	O
315	due	O
315	to	O
315	the	O
315	bulk	O
315	of	O
315	b	O
315	‐	O
315	cell	O
315	de	O
315	##ple	O
315	##tion	O
315	occurring	O
315	prior	O
315	to	O
315	the	O
315	first	O
315	sampling	O
315	time	O
315	##point	O
315	at	O
315	2	O
315	h	O
315	post	O
315	##dos	O
315	##e	O
315	.	O
315	[SEP]	O
316	[CLS]	O
316	male	O
316	subjects	O
316	must	O
316	also	O
316	refrain	O
316	from	O
316	don	O
316	##ating	O
316	sperm	O
316	during	O
316	this	O
316	period	O
316	.	O
316	[SEP]	O
317	[CLS]	O
317	in	O
317	##tra	O
317	-	O
317	and	O
317	inter	O
317	##day	O
317	variations	O
317	were	O
317	for	O
317	determining	O
317	the	O
317	precision	O
317	of	O
317	the	O
317	developed	O
317	method	O
317	.	O
317	[SEP]	O
318	[CLS]	O
318	additionally	O
318	,	O
318	across	O
318	the	O
318	pre	O
318	##c	O
318	##lini	O
318	##cal	O
318	range	O
318	of	O
318	doses	O
318	evaluated	O
318	,	O
318	a	O
318	pronounced	O
318	dose	O
318	‐	O
318	depend	O
318	##ency	O
318	was	O
318	observed	O
318	in	O
318	both	O
318	the	O
318	non	O
318	##linear	O
318	drug	O
318	elimination	O
318	term	O
318	and	O
318	the	O
318	t	O
318	‐	O
318	cell	O
318	response	O
318	,	O
318	particularly	O
318	in	O
318	the	O
318	first	O
318	7	O
318	days	O
318	post	O
318	##dos	O
318	##e	O
318	.	O
318	[SEP]	O
319	[CLS]	O
319	methods	O
319	for	O
319	radio	O
319	##la	O
319	##bel	O
319	##ing	O
319	and	O
319	pu	O
319	##rification	O
319	of	O
319	a	O
319	m	O
319	##f	O
319	##w	O
319	solution	O
319	of	O
319	s	O
319	##w	O
319	##c	O
319	##nt	O
319	-	O
319	(	O
319	dot	O
319	##a	O
319	)	O
319	(	O
319	h	O
319	##nh	O
319	)	O
319	with	O
319	225	O
319	##ac	O
319	at	O
319	p	O
319	##h	O
319	5	O
319	are	O
319	similar	O
319	to	O
319	those	O
319	described	O
319	previously	O
319	.	O
319	48	O
319	briefly	O
319	,	O
319	0	O
319	.	O
319	18	O
319	mg	O
319	of	O
319	s	O
319	##w	O
319	##c	O
319	##nt	O
319	-	O
319	(	O
319	dot	O
319	##a	O
319	)	O
319	(	O
319	h	O
319	##nh	O
319	)	O
319	in	O
319	0	O
319	.	O
319	02	O
319	m	O
319	##l	O
319	of	O
319	m	O
319	##f	O
319	##w	O
319	was	O
319	reacted	O
319	with	O
319	0	O
319	.	O
319	00	O
319	##5	O
319	m	O
319	##l	O
319	of	O
319	225	O
319	##ac	O
319	in	O
319	50	O
319	mm	O
319	op	O
319	##ti	O
319	##ma	O
319	grade	O
319	h	O
319	##ydro	O
319	##ch	O
319	##lor	O
319	##ic	O
319	acid	O
319	(	O
319	h	O
319	##c	O
319	##l	O
319	;	O
319	fish	O
319	##er	O
319	scientific	O
319	,	O
319	pit	O
319	##ts	O
319	##burgh	O
319	,	O
319	p	O
319	##a	O
319	,	O
319	us	O
319	##a	O
319	)	O
319	along	O
319	with	O
319	0	O
319	.	O
319	02	O
319	m	O
319	##l	O
319	of	O
319	150	O
319	g	O
319	/	O
319	l	O
319	l	O
319	-	O
319	as	O
319	##cor	O
319	##bic	O
319	acid	O
319	(	O
319	si	O
319	##gma	O
319	-	O
319	al	O
319	##dric	O
319	##h	O
319	)	O
319	and	O
319	0	O
319	.	O
319	2	O
319	m	O
319	##l	O
319	of	O
319	3	O
319	m	O
319	te	O
319	##tra	O
319	##met	O
319	##hyl	O
319	##am	O
319	##mon	O
319	##ium	O
319	ace	O
319	##tate	O
319	(	O
319	fish	O
319	##er	O
319	scientific	O
319	)	O
319	buffer	O
319	,	O
319	p	O
319	##h	O
319	5	O
319	.	O
319	5	O
319	,	O
319	at	O
319	60	O
319	##°	O
319	##c	O
319	for	O
319	60	O
319	minutes	O
319	(	O
319	reaction	O
319	1	O
319	)	O
319	.	O
319	[SEP]	O
320	[CLS]	O
320	relative	O
320	purity	O
320	of	O
320	protein	O
320	samples	O
320	were	O
320	assessed	O
320	on	O
320	a	O
320	non	O
320	-	O
320	reducing	O
320	s	O
320	##ds	O
320	-	O
320	page	O
320	.	O
320	[SEP]	O
321	[CLS]	O
321	purpose	O
321	:	O
321	to	O
321	examine	O
321	the	O
321	p	O
321	##har	O
321	##ma	O
321	##co	O
321	##kin	O
321	##etic	O
321	characteristics	O
321	of	O
321	sustained	O
321	-	O
321	release	O
321	de	O
321	##xa	O
321	##met	O
321	##has	O
321	##one	O
321	depot	O
321	##s	O
321	in	O
321	two	O
321	separate	O
321	can	O
321	##ine	O
321	studies	O
321	.	O
321	[SEP]	O
322	[CLS]	O
322	responses	O
322	of	O
322	c	O
322	-	O
322	fiber	O
322	no	O
322	##ci	O
322	##ceptor	O
322	##s	O
322	e	O
322	##voked	O
322	by	O
322	heat	O
322	were	O
322	reduced	O
322	by	O
322	compound	O
322	52	O
322	.	O
322	[SEP]	O
323	[CLS]	O
323	all	O
323	were	O
323	pu	O
323	##rified	O
323	from	O
323	culture	O
323	super	O
323	##nat	O
323	##ants	O
323	by	O
323	protein	O
323	-	O
323	a	O
323	(	O
323	g	O
323	##e	O
323	healthcare	O
323	)	O
323	affinity	O
323	capture	O
323	followed	O
323	by	O
323	cat	O
323	##ion	O
323	exchange	O
323	ch	O
323	##roma	O
323	##tography	O
323	and	O
323	polished	O
323	using	O
323	size	O
323	exclusion	O
323	ch	O
323	##roma	O
323	##tography	O
323	when	O
323	necessary	O
323	.	O
323	[SEP]	O
324	[CLS]	O
324	for	O
324	the	O
324	descriptive	O
324	cat	O
324	##ego	O
324	##rical	O
324	data	O
324	the	O
324	comparisons	O
324	were	O
324	explored	O
324	with	O
324	log	O
324	##istic	O
324	re	O
324	##gression	O
324	analyses	O
324	.	O
324	[SEP]	O
325	[CLS]	O
325	solutions	O
325	of	O
325	50	O
325	mm	O
325	diet	O
325	##hyl	O
325	##ene	O
325	##tri	O
325	##amine	O
325	##pent	O
325	##aa	O
325	##ce	O
325	##tic	O
325	acid	O
325	(	O
325	d	O
325	##t	O
325	##pa	O
325	;	O
325	si	O
325	##gma	O
325	-	O
325	al	O
325	##dric	O
325	##h	O
325	)	O
325	were	O
325	s	O
325	##ter	O
325	##ile	O
325	filtered	O
325	and	O
325	used	O
325	to	O
325	que	O
325	##nch	O
325	the	O
325	label	O
325	##ing	O
325	reaction	O
325	prior	O
325	to	O
325	se	O
325	##c	O
325	.	O
325	[SEP]	O
326	[CLS]	O
326	there	O
326	was	O
326	a	O
326	large	O
326	increase	O
326	in	O
326	au	B-PK
326	##c	I-PK
326	for	O
326	set	O
326	1	O
326	through	O
326	set	O
326	6	O
326	when	O
326	the	O
326	p	O
326	##d	O
326	-	O
326	related	O
326	information	O
326	was	O
326	integrated	O
326	to	O
326	the	O
326	enzyme	O
326	information	O
326	(	O
326	set	O
326	20	O
326	)	O
326	.	O
326	[SEP]	O
327	[CLS]	O
327	on	O
327	schedule	O
327	2	O
327	/	O
327	1	O
327	,	O
327	at	O
327	the	O
327	next	O
327	highest	O
327	dose	O
327	level	O
327	(	O
327	sun	O
327	##iti	O
327	##ni	O
327	##b	O
327	50	O
327	mg	O
327	with	O
327	p	O
327	##em	O
327	##et	O
327	##re	O
327	##xed	O
327	500	O
327	mg	O
327	/	O
327	m	O
327	##2	O
327	;	O
327	n	O
327	=	O
327	7	O
327	)	O
327	,	O
327	only	O
327	one	O
327	d	O
327	##lt	O
327	was	O
327	observed	O
327	.	O
327	[SEP]	O
328	[CLS]	O
328	specific	O
328	r	O
328	##rf	O
328	##c	O
328	##1	O
328	anti	O
328	##ser	O
328	##um	O
328	was	O
328	added	O
328	at	O
328	a	O
328	1	O
328	:	O
328	500	O
328	di	O
328	##lution	O
328	for	O
328	72	O
328	h	O
328	at	O
328	4	O
328	##°	O
328	##c	O
328	.	O
328	[SEP]	O
329	[CLS]	O
329	figure	O
329	3	O
329	##c	O
329	shows	O
329	g	O
329	##a	O
329	-	O
329	c	O
329	##ts	O
329	/	O
329	5	O
329	-	O
329	f	O
329	##u	O
329	na	O
329	##no	O
329	##par	O
329	##tic	O
329	##le	O
329	with	O
329	b	O
329	##ov	O
329	##ine	O
329	serum	O
329	;	O
329	the	O
329	size	O
329	of	O
329	g	O
329	##a	O
329	-	O
329	c	O
329	##ts	O
329	/	O
329	5	O
329	-	O
329	f	O
329	##u	O
329	na	O
329	##no	O
329	##par	O
329	##tic	O
329	##les	O
329	(	O
329	206	O
329	.	O
329	0	O
329	nm	O
329	)	O
329	was	O
329	increased	O
329	a	O
329	little	O
329	and	O
329	the	O
329	charge	O
329	(	O
329	+	O
329	14	O
329	.	O
329	3	O
329	m	O
329	##v	O
329	)	O
329	was	O
329	decreased	O
329	obviously	O
329	,	O
329	and	O
329	the	O
329	p	O
329	##i	O
329	was	O
329	0	O
329	.	O
329	135	O
329	.	O
329	[SEP]	O
330	[CLS]	O
330	s	O
330	##tri	O
330	##ata	O
330	##l	O
330	d	O
330	##2	O
330	receptor	O
330	o	O
330	##cc	O
330	##up	O
330	##ancy	O
330	was	O
330	calculated	O
330	using	O
330	the	O
330	simplified	O
330	reference	O
330	tissue	O
330	model	O
330	.	O
330	[SEP]	O
331	[CLS]	O
331	t	O
331	##rough	O
331	d	O
331	##2	O
331	receptor	O
331	o	O
331	##cc	O
331	##up	O
331	##ancy	O
331	was	O
331	similarly	O
331	low	O
331	for	O
331	both	O
331	formulation	O
331	##s	O
331	(	O
331	i	O
331	##r	O
331	7	O
331	##±	O
331	##7	O
331	%	O
331	,	O
331	x	O
331	##r	O
331	8	O
331	##±	O
331	##6	O
331	%	O
331	)	O
331	.	O
331	[SEP]	O
332	[CLS]	O
332	assuming	O
332	that	O
332	our	O
332	findings	O
332	in	O
332	control	O
332	subjects	O
332	are	O
332	valid	O
332	for	O
332	patients	O
332	with	O
332	s	O
332	##chi	O
332	##zophrenia	O
332	,	O
332	the	O
332	study	O
332	supports	O
332	the	O
332	view	O
332	that	O
332	que	O
332	##tia	O
332	##pine	O
332	,	O
332	like	O
332	the	O
332	prototype	O
332	at	O
332	##y	O
332	##pical	O
332	anti	O
332	##psy	O
332	##cho	O
332	##tic	O
332	c	O
332	##lo	O
332	##za	O
332	##pine	O
332	,	O
332	may	O
332	show	O
332	anti	O
332	##psy	O
332	##cho	O
332	##tic	O
332	effect	O
332	at	O
332	lower	O
332	d	O
332	##2	O
332	receptor	O
332	o	O
332	##cc	O
332	##up	O
332	##ancy	O
332	than	O
332	typical	O
332	anti	O
332	##psy	O
332	##cho	O
332	##tics	O
332	.	O
332	[SEP]	O
333	[CLS]	O
333	after	O
333	base	O
333	##line	O
333	examination	O
333	,	O
333	que	O
333	##tia	O
333	##pine	O
333	x	O
333	##r	O
333	was	O
333	administered	O
333	once	O
333	-	O
333	daily	O
333	for	O
333	8	O
333	d	O
333	t	O
333	##it	O
333	##rated	O
333	to	O
333	300	O
333	mg	O
333	/	O
333	d	O
333	on	O
333	days	O
333	5	O
333	–	O
333	8	O
333	,	O
333	followed	O
333	by	O
333	300	O
333	mg	O
333	/	O
333	d	O
333	que	O
333	##tia	O
333	##pine	O
333	i	O
333	##r	O
333	on	O
333	days	O
333	9	O
333	–	O
333	12	O
333	.	O
333	[SEP]	O
334	[CLS]	O
334	while	O
334	initially	O
334	manufactured	O
334	as	O
334	an	O
334	immediate	O
334	-	O
334	release	O
334	(	O
334	i	O
334	##r	O
334	)	O
334	formulation	O
334	,	O
334	an	O
334	extended	O
334	-	O
334	release	O
334	(	O
334	x	O
334	##r	O
334	)	O
334	formulation	O
334	has	O
334	recently	O
334	been	O
334	introduced	O
334	.	O
334	[SEP]	O
335	[CLS]	O
335	peak	O
335	d	O
335	##2	O
335	receptor	O
335	o	O
335	##cc	O
335	##up	O
335	##ancy	O
335	was	O
335	significantly	O
335	higher	O
335	with	O
335	que	O
335	##tia	O
335	##pine	O
335	i	O
335	##r	O
335	than	O
335	x	O
335	##r	O
335	in	O
335	all	O
335	subjects	O
335	(	O
335	50	O
335	##±	O
335	##4	O
335	%	O
335	and	O
335	32	O
335	##±	O
335	##11	O
335	%	O
335	,	O
335	respectively	O
335	)	O
335	,	O
335	consistent	O
335	with	O
335	lower	O
335	peak	B-PK
335	plasma	I-PK
335	concentrations	I-PK
335	for	O
335	the	O
335	x	O
335	##r	O
335	formulation	O
335	.	O
335	[SEP]	O
336	[CLS]	O
336	here	O
336	,	O
336	we	O
336	used	O
336	ch	O
336	##ito	O
336	##san	O
336	(	O
336	c	O
336	##ts	O
336	)	O
336	and	O
336	he	O
336	##pa	O
336	##tom	O
336	##a	O
336	cell	O
336	-	O
336	specific	O
336	binding	O
336	molecule	O
336	g	O
336	##ly	O
336	##cy	O
336	##rr	O
336	##he	O
336	##tin	O
336	##ic	O
336	acid	O
336	to	O
336	s	O
336	##ynth	O
336	##esi	O
336	##ze	O
336	g	O
336	##ly	O
336	##cy	O
336	##rr	O
336	##he	O
336	##tin	O
336	##ic	O
336	acid	O
336	-	O
336	modified	O
336	ch	O
336	##ito	O
336	##san	O
336	(	O
336	g	O
336	##a	O
336	-	O
336	c	O
336	##ts	O
336	)	O
336	.	O
336	[SEP]	O
337	[CLS]	O
337	data	O
337	s	O
337	##2	O
337	correlation	O
337	results	O
337	for	O
337	significantly	O
337	regulated	O
337	pathways	O
337	and	O
337	cellular	O
337	processes	O
337	in	O
337	rats	O
337	.	O
337	[SEP]	O
338	[CLS]	O
338	the	O
338	interactions	O
338	were	O
338	tested	O
338	by	O
338	examining	O
338	the	O
338	impact	O
338	of	O
338	one	O
338	s	O
338	##n	O
338	##p	O
338	in	O
338	two	O
338	separate	O
338	subgroup	O
338	##s	O
338	of	O
338	participants	O
338	,	O
338	ho	O
338	##mo	O
338	##zy	O
338	##got	O
338	##es	O
338	for	O
338	the	O
338	reference	O
338	,	O
338	and	O
338	variant	O
338	all	O
338	##ele	O
338	of	O
338	a	O
338	potential	O
338	con	O
338	##found	O
338	##ing	O
338	s	O
338	##n	O
338	##p	O
338	.	O
338	[SEP]	O
339	[CLS]	O
339	these	O
339	ex	O
339	##p	O
339	##lora	O
339	##tory	O
339	subgroup	O
339	analyses	O
339	revealed	O
339	no	O
339	significant	O
339	interactions	O
339	between	O
339	the	O
339	s	O
339	##n	O
339	##ps	O
339	that	O
339	affect	O
339	met	O
339	##form	O
339	##in	O
339	g	O
339	##ly	O
339	##ce	O
339	##mic	O
339	response	O
339	.	O
339	[SEP]	O
340	[CLS]	O
340	both	O
340	the	O
340	liver	O
340	and	O
340	kidney	O
340	meta	O
340	##bol	O
340	##ize	O
340	the	O
340	in	O
340	##tra	O
340	##cellular	O
340	ram	O
340	##ip	O
340	##ril	O
340	(	O
340	d	O
340	'	O
340	)	O
340	.	O
340	[SEP]	O
341	[CLS]	O
341	study	O
341	recruitment	O
341	will	O
341	occur	O
341	at	O
341	45	O
341	centers	O
341	in	O
341	the	O
341	us	O
341	##a	O
341	.	O
341	[SEP]	O
342	[CLS]	O
342	all	O
342	the	O
342	analyses	O
342	were	O
342	carried	O
342	out	O
342	by	O
342	the	O
342	mixed	O
342	or	O
342	n	O
342	##par	O
342	##1	O
342	##way	O
342	procedure	O
342	(	O
342	sa	O
342	##s	O
342	9	O
342	.	O
342	4	O
342	,	O
342	sa	O
342	##s	O
342	institute	O
342	,	O
342	in	O
342	##c	O
342	.	O
342	,	O
342	car	O
342	##y	O
342	,	O
342	n	O
342	##c	O
342	,	O
342	united	O
342	states	O
342	)	O
342	.	O
342	[SEP]	O
343	[CLS]	O
343	trained	O
343	study	O
343	personnel	O
343	at	O
343	each	O
343	site	O
343	will	O
343	recruit	O
343	subjects	O
343	.	O
343	[SEP]	O
344	[CLS]	O
344	the	O
344	flow	O
344	rate	O
344	was	O
344	programmed	O
344	as	O
344	follows	O
344	:	O
344	1	O
344	.	O
344	0	O
344	m	O
344	##l	O
344	min	O
344	##−	O
344	##1	O
344	(	O
344	0	O
344	–	O
344	68	O
344	min	O
344	)	O
344	,	O
344	0	O
344	.	O
344	2	O
344	m	O
344	##l	O
344	min	O
344	##−	O
344	##1	O
344	(	O
344	68	O
344	–	O
344	78	O
344	min	O
344	)	O
344	,	O
344	1	O
344	.	O
344	0	O
344	m	O
344	##l	O
344	min	O
344	##−	O
344	##1	O
344	(	O
344	78	O
344	–	O
344	100	O
344	min	O
344	)	O
344	.	O
344	[SEP]	O
345	[CLS]	O
345	eligible	O
345	patients	O
345	were	O
345	men	O
345	or	O
345	non	O
345	##p	O
345	##re	O
345	##gnant	O
345	and	O
345	non	O
345	##la	O
345	##ct	O
345	##ating	O
345	women	O
345	,	O
345	20	O
345	–	O
345	64	O
345	years	O
345	of	O
345	age	O
345	,	O
345	body	O
345	mass	O
345	index	O
345	≥	O
345	##18	O
345	.	O
345	5	O
345	and	O
345	<	O
345	30	O
345	.	O
345	0	O
345	kg	O
345	m	O
345	–	O
345	2	O
345	,	O
345	with	O
345	cc	O
345	of	O
345	at	O
345	least	O
345	6	O
345	months	O
345	'	O
345	duration	O
345	.	O
345	[SEP]	O
346	[CLS]	O
346	there	O
346	was	O
346	no	O
346	statistical	O
346	##ly	O
346	significant	O
346	difference	O
346	in	O
346	n	O
346	##ugen	O
346	##t	O
346	score	O
346	prior	O
346	to	O
346	pod	O
346	-	O
346	i	O
346	##v	O
346	##r	O
346	placement	O
346	compared	O
346	to	O
346	pod	O
346	-	O
346	i	O
346	##v	O
346	##r	O
346	:	O
346	t	O
346	##d	O
346	##f	O
346	pod	O
346	-	O
346	i	O
346	##v	O
346	##r	O
346	,	O
346	p	O
346	=	O
346	0	O
346	.	O
346	60	O
346	##6	O
346	##8	O
346	;	O
346	t	O
346	##d	O
346	##f	O
346	-	O
346	ft	O
346	##c	O
346	pod	O
346	-	O
346	i	O
346	##v	O
346	##r	O
346	,	O
346	p	O
346	=	O
346	0	O
346	.	O
346	56	O
346	##11	O
346	.	O
346	[SEP]	O
347	[CLS]	O
347	the	O
347	effect	O
347	of	O
347	and	O
347	##rog	O
347	##rap	O
347	##hol	O
347	##ide	O
347	on	O
347	mm	O
347	##p	O
347	in	O
347	m	O
347	##da	O
347	-	O
347	m	O
347	##b	O
347	-	O
347	231	O
347	cells	O
347	was	O
347	also	O
347	investigated	O
347	to	O
347	determine	O
347	whether	O
347	and	O
347	##rog	O
347	##rap	O
347	##hol	O
347	##ide	O
347	induced	O
347	-	O
347	r	O
347	##os	O
347	production	O
347	coincide	O
347	##s	O
347	with	O
347	loss	O
347	of	O
347	mm	O
347	##p	O
347	(	O
347	[UNK]	O
347	)	O
347	,	O
347	which	O
347	is	O
347	considered	O
347	as	O
347	an	O
347	early	O
347	in	O
347	##tra	O
347	##cellular	O
347	event	O
347	during	O
347	onset	O
347	of	O
347	a	O
347	##pop	O
347	##tosis	O
347	.	O
347	[SEP]	O
348	[CLS]	O
348	this	O
348	represents	O
348	a	O
348	trade	O
348	##off	O
348	between	O
348	precision	O
348	and	O
348	safety	O
348	.	O
348	[SEP]	O
349	[CLS]	O
349	these	O
349	results	O
349	indicate	O
349	that	O
349	the	O
349	que	O
349	/	O
349	t	O
349	##m	O
349	##z	O
349	-	O
349	n	O
349	##ls	O
349	have	O
349	superior	O
349	anti	O
349	##can	O
349	##cer	O
349	effects	O
349	on	O
349	t	O
349	##m	O
349	##z	O
349	-	O
349	resistant	O
349	g	O
349	##lio	O
349	##ma	O
349	cells	O
349	.	O
349	[SEP]	O
350	[CLS]	O
350	we	O
350	use	O
350	a	O
350	minimum	O
350	δ	O
350	%	O
350	co	O
350	##h	O
350	##b	O
350	of	O
350	4	O
350	.	O
350	5	O
350	%	O
350	to	O
350	avoid	O
350	over	O
350	##est	O
350	##imating	O
350	th	O
350	##b	O
350	‐	O
350	mass	O
350	.	O
350	[SEP]	O
351	[CLS]	O
351	the	O
351	remaining	O
351	anal	O
351	##yte	O
351	##s	O
351	were	O
351	determined	O
351	by	O
351	protein	O
351	precipitation	O
351	of	O
351	50	O
351	.	O
351	0	O
351	μ	O
351	##l	O
351	plasma	O
351	with	O
351	300	O
351	μ	O
351	##l	O
351	ace	O
351	##ton	O
351	##it	O
351	##ril	O
351	##e	O
351	followed	O
351	by	O
351	a	O
351	ch	O
351	##roma	O
351	##to	O
351	##graphic	O
351	separation	O
351	on	O
351	a	O
351	c	O
351	##18	O
351	column	O
351	(	O
351	the	O
351	same	O
351	as	O
351	for	O
351	flu	O
351	##rb	O
351	##ip	O
351	##ro	O
351	##fen	O
351	)	O
351	under	O
351	gradient	O
351	conditions	O
351	and	O
351	liquid	O
351	ch	O
351	##roma	O
351	##tography	O
351	‐	O
351	tandem	O
351	mass	O
351	s	O
351	##pect	O
351	##rome	O
351	##try	O
351	detection	O
351	of	O
351	positive	O
351	ions	O
351	.	O
351	[SEP]	O
352	[CLS]	O
352	the	O
352	safety	O
352	limit	O
352	of	O
352	10	O
352	%	O
352	is	O
352	based	O
352	on	O
352	previous	O
352	work	O
352	by	O
352	our	O
352	group	O
352	and	O
352	professor	O
352	s	O
352	##ch	O
352	##mi	O
352	##dt	O
352	who	O
352	developed	O
352	the	O
352	o	O
352	##cor	O
352	test	O
352	.	O
352	[SEP]	O
353	[CLS]	O
353	relevant	O
353	data	O
353	were	O
353	drawn	O
353	from	O
353	the	O
353	electronic	O
353	patient	O
353	file	O
353	and	O
353	the	O
353	intensive	O
353	care	O
353	information	O
353	system	O
353	.	O
353	[SEP]	O
354	[CLS]	O
354	the	O
354	following	O
354	equation	O
354	[	O
354	36	O
354	]	O
354	was	O
354	used	O
354	to	O
354	describe	O
354	the	O
354	bi	O
354	##ex	O
354	##po	O
354	##nent	O
354	##ial	O
354	concentration	O
354	–	O
354	time	O
354	curves	O
354	for	O
354	fl	O
354	##b	O
354	##z	O
354	and	O
354	r	O
354	-	O
354	fl	O
354	##b	O
354	##z	O
354	after	O
354	the	O
354	i	O
354	.	O
354	r	O
354	.	O
354	/	O
354	i	O
354	.	O
354	a	O
354	treatments	O
354	:	O
354	[SEP]	O
355	[CLS]	O
355	the	O
355	recovered	O
355	depot	O
355	##s	O
355	were	O
355	collected	O
355	for	O
355	photography	O
355	and	O
355	drug	O
355	content	O
355	analysis	O
355	.	O
355	[SEP]	O
356	[CLS]	O
356	the	O
356	concentration	O
356	of	O
356	each	O
356	variant	O
356	at	O
356	each	O
356	time	O
356	point	O
356	was	O
356	determined	O
356	by	O
356	a	O
356	bottom	O
356	-	O
356	up	O
356	l	O
356	##c	O
356	-	O
356	m	O
356	##s	O
356	/	O
356	m	O
356	##s	O
356	ass	O
356	##ay	O
356	.	O
356	[SEP]	O
357	[CLS]	O
357	a	O
357	urine	O
357	-	O
357	collection	O
357	experiment	O
357	of	O
357	(	O
357	5	O
357	)	O
357	,	O
357	via	O
357	bladder	O
357	pu	O
357	##nc	O
357	##ture	O
357	after	O
357	an	O
357	i	O
357	##v	O
357	injection	O
357	,	O
357	was	O
357	performed	O
357	on	O
357	three	O
357	additional	O
357	mice	O
357	.	O
357	[SEP]	O
358	[CLS]	O
358	an	O
358	en	O
358	##rich	O
358	##ed	O
358	young	O
358	t	O
358	##rop	O
358	##ho	O
358	##zo	O
358	##ite	O
358	-	O
358	stage	O
358	culture	O
358	of	O
358	p	O
358	.	O
358	f	O
358	##al	O
358	##ci	O
358	##par	O
358	##um	O
358	d	O
358	##d	O
358	##2	O
358	was	O
358	obtain	O
358	by	O
358	magnetic	O
358	pu	O
358	##rification	O
358	and	O
358	allowed	O
358	to	O
358	recover	O
358	for	O
358	1	O
358	h	O
358	at	O
358	37	O
358	°	O
358	##c	O
358	in	O
358	rpm	O
358	##i	O
358	1640	O
358	medium	O
358	(	O
358	life	O
358	technologies	O
358	)	O
358	en	O
358	##rich	O
358	##ed	O
358	with	O
358	1	O
358	%	O
358	h	O
358	##y	O
358	##pox	O
358	##ant	O
358	##hine	O
358	(	O
358	c	O
358	.	O
358	c	O
358	.	O
358	pro	O
358	g	O
358	##mb	O
358	##h	O
358	)	O
358	and	O
358	10	O
358	%	O
358	album	O
358	##ax	O
358	(	O
358	life	O
358	technologies	O
358	)	O
358	.	O
358	[SEP]	O
359	[CLS]	O
359	affinity	O
359	pu	O
359	##rification	O
359	of	O
359	soluble	O
359	his	O
359	##6	O
359	-	O
359	tag	O
359	##ged	O
359	pet	O
359	-	O
359	id	O
359	##7	O
359	fusion	O
359	proteins	O
359	was	O
359	performed	O
359	using	O
359	ni	O
359	-	O
359	n	O
359	##ta	O
359	his	O
359	-	O
359	bind	O
359	##®	O
359	re	O
359	##sin	O
359	(	O
359	no	O
359	##vage	O
359	##n	O
359	)	O
359	.	O
359	[SEP]	O
360	[CLS]	O
360	the	O
360	purity	O
360	of	O
360	protein	O
360	was	O
360	assessed	O
360	by	O
360	s	O
360	##ds	O
360	-	O
360	page	O
360	(	O
360	16	O
360	%	O
360	)	O
360	and	O
360	co	O
360	##oma	O
360	##ssie	O
360	stain	O
360	##ing	O
360	(	O
360	co	O
360	##oma	O
360	##ssie	O
360	brilliant	O
360	blue	O
360	r	O
360	-	O
360	250	O
360	,	O
360	rot	O
360	##h	O
360	,	O
360	ka	O
360	##rls	O
360	##ru	O
360	##he	O
360	,	O
360	g	O
360	##erman	O
360	##y	O
360	)	O
360	.	O
360	[SEP]	O
361	[CLS]	O
361	changes	O
361	in	O
361	the	O
361	p	O
361	##t	O
361	concentrations	O
361	in	O
361	blood	O
361	upon	O
361	in	O
361	##tral	O
361	##ip	O
361	##id	O
361	pre	O
361	-	O
361	treatment	O
361	are	O
361	shown	O
361	in	O
361	fi	O
361	##g	O
361	.	O
361	7	O
361	.	O
361	[SEP]	O
362	[CLS]	O
362	the	O
362	predicted	O
362	structure	O
362	of	O
362	the	O
362	r	O
362	##rf	O
362	##c	O
362	##1	O
362	protein	O
362	has	O
362	been	O
362	previously	O
362	described	O
362	.	O
362	7	O
362	highly	O
362	anti	O
362	##genic	O
362	regions	O
362	in	O
362	the	O
362	r	O
362	##rf	O
362	##c	O
362	##1	O
362	protein	O
362	sequence	O
362	were	O
362	identified	O
362	by	O
362	determination	O
362	of	O
362	the	O
362	anti	O
362	##genic	O
362	index	O
362	##24	O
362	using	O
362	pro	O
362	##te	O
362	##an	O
362	5	O
362	.	O
362	06	O
362	(	O
362	d	O
362	##nast	O
362	##ar	O
362	software	O
362	,	O
362	in	O
362	##c	O
362	.	O
362	,	O
362	mad	O
362	##ison	O
362	,	O
362	w	O
362	##i	O
362	,	O
362	us	O
362	##a	O
362	)	O
362	.	O
362	[SEP]	O
363	[CLS]	O
363	product	O
363	integrity	O
363	and	O
363	purity	O
363	were	O
363	confirmed	O
363	by	O
363	s	O
363	##ds	O
363	-	O
363	page	O
363	analysis	O
363	(	O
363	fi	O
363	##g	O
363	1	O
363	##b	O
363	)	O
363	,	O
363	confirming	O
363	a	O
363	product	O
363	in	O
363	the	O
363	25	O
363	##k	O
363	##da	O
363	range	O
363	,	O
363	and	O
363	size	O
363	exclusion	O
363	ch	O
363	##roma	O
363	##tography	O
363	(	O
363	fi	O
363	##g	O
363	1	O
363	##c	O
363	)	O
363	.	O
363	[SEP]	O
364	[CLS]	O
364	the	O
364	pet	O
364	-	O
364	41	O
364	##a	O
364	vector	O
364	contains	O
364	a	O
364	g	O
364	##lut	O
364	##ath	O
364	##ione	O
364	-	O
364	s	O
364	-	O
364	transfer	O
364	##ase	O
364	(	O
364	g	O
364	##st	O
364	)	O
364	and	O
364	his	O
364	##ti	O
364	##dine	O
364	(	O
364	his	O
364	)	O
364	6	O
364	gene	O
364	as	O
364	fusion	O
364	tags	O
364	to	O
364	aid	O
364	in	O
364	pu	O
364	##rification	O
364	steps	O
364	.	O
364	[SEP]	O
365	[CLS]	O
365	the	O
365	excellent	O
365	select	O
365	##ivity	O
365	of	O
365	solid	O
365	-	O
365	phase	O
365	extraction	O
365	helped	O
365	to	O
365	improve	O
365	the	O
365	l	O
365	##c	O
365	-	O
365	m	O
365	##s	O
365	/	O
365	m	O
365	##s	O
365	analysis	O
365	.	O
365	[SEP]	O
366	[CLS]	O
366	male	O
366	participants	O
366	with	O
366	partners	O
366	of	O
366	child	O
366	##be	O
366	##aring	O
366	potential	O
366	who	O
366	agree	O
366	to	O
366	take	O
366	measures	O
366	not	O
366	to	O
366	father	O
366	children	O
366	by	O
366	using	O
366	one	O
366	form	O
366	of	O
366	highly	O
366	effective	O
366	con	O
366	##tra	O
366	##ception	O
366	from	O
366	the	O
366	first	O
366	administration	O
366	of	O
366	all	O
366	study	O
366	drugs	O
366	,	O
366	throughout	O
366	the	O
366	trial	O
366	and	O
366	for	O
366	12	O
366	months	O
366	after	O
366	the	O
366	last	O
366	dose	O
366	of	O
366	all	O
366	study	O
366	drugs	O
366	.	O
366	[SEP]	O
367	[CLS]	O
367	the	O
367	d	O
367	##lts	O
367	were	O
367	drug	O
367	-	O
367	induced	O
367	liver	O
367	injury	O
367	,	O
367	plate	O
367	##let	O
367	count	O
367	decreased	O
367	,	O
367	u	O
367	##rt	O
367	##ica	O
367	##ria	O
367	,	O
367	inter	O
367	##st	O
367	##iti	O
367	##al	O
367	lung	O
367	disease	O
367	,	O
367	and	O
367	left	O
367	vent	O
367	##ric	O
367	##ular	O
367	failure	O
367	.	O
367	[SEP]	O
368	[CLS]	O
368	responses	O
368	e	O
368	##voked	O
368	by	O
368	the	O
368	most	O
368	intense	O
368	heat	O
368	stimuli	O
368	,	O
368	48	O
368	##°	O
368	##c	O
368	and	O
368	50	O
368	##°	O
368	##c	O
368	,	O
368	were	O
368	reduced	O
368	at	O
368	30	O
368	minutes	O
368	following	O
368	compound	O
368	52	O
368	(	O
368	new	O
368	##man	O
368	-	O
368	k	O
368	##uel	O
368	##s	O
368	tests	O
368	,	O
368	p	O
368	<	O
368	0	O
368	.	O
368	05	O
368	and	O
368	p	O
368	<	O
368	0	O
368	.	O
368	01	O
368	,	O
368	respectively	O
368	)	O
368	.	O
368	[SEP]	O
369	[CLS]	O
369	re	O
369	##comb	O
369	##ina	O
369	##nt	O
369	human	O
369	t	O
369	##n	O
369	##f	O
369	-	O
369	α	O
369	(	O
369	cat	O
369	no	O
369	.	O
369	300	O
369	-	O
369	1	O
369	##a	O
369	)	O
369	was	O
369	from	O
369	p	O
369	##ep	O
369	##rote	O
369	##ch	O
369	(	O
369	n	O
369	##j	O
369	,	O
369	us	O
369	##a	O
369	)	O
369	.	O
369	[SEP]	O
370	[CLS]	O
370	descriptive	O
370	group	O
370	data	O
370	are	O
370	given	O
370	as	O
370	median	O
370	(	O
370	minimum	O
370	–	O
370	maximum	O
370	)	O
370	values	O
370	.	O
370	[SEP]	O
371	[CLS]	O
371	225	O
371	##ac	O
371	radio	O
371	##nu	O
371	##c	O
371	##lide	O
371	was	O
371	obtained	O
371	from	O
371	the	O
371	us	O
371	department	O
371	of	O
371	energy	O
371	’	O
371	s	O
371	oak	O
371	ridge	O
371	national	O
371	laboratory	O
371	(	O
371	oak	O
371	ridge	O
371	,	O
371	t	O
371	##n	O
371	,	O
371	us	O
371	##a	O
371	)	O
371	.	O
371	[SEP]	O
372	[CLS]	O
372	a	O
372	population	O
372	p	O
372	##har	O
372	##ma	O
372	##co	O
372	##kin	O
372	##etic	O
372	(	O
372	p	O
372	##k	O
372	)	O
372	model	O
372	for	O
372	van	O
372	##com	O
372	##y	O
372	##cin	O
372	in	O
372	e	O
372	##c	O
372	##mo	O
372	patients	O
372	was	O
372	developed	O
372	using	O
372	a	O
372	non	O
372	##linear	O
372	mixed	O
372	effects	O
372	modeling	O
372	on	O
372	the	O
372	concentration	O
372	–	O
372	time	O
372	profiles	O
372	of	O
372	14	O
372	e	O
372	##c	O
372	##mo	O
372	patients	O
372	who	O
372	received	O
372	in	O
372	##tra	O
372	##ven	O
372	##ous	O
372	van	O
372	##com	O
372	##y	O
372	##cin	O
372	.	O
372	[SEP]	O
373	[CLS]	O
373	se	O
373	##m	O
373	of	O
373	g	O
373	##a	O
373	-	O
373	c	O
373	##ts	O
373	/	O
373	5	O
373	-	O
373	f	O
373	##u	O
373	showed	O
373	the	O
373	presence	O
373	of	O
373	spherical	O
373	na	O
373	##no	O
373	##par	O
373	##tic	O
373	##les	O
373	(	O
373	size	O
373	193	O
373	.	O
373	7	O
373	nm	O
373	)	O
373	with	O
373	smooth	O
373	surfaces	O
373	(	O
373	figure	O
373	3	O
373	##a	O
373	)	O
373	.	O
373	[SEP]	O
374	[CLS]	O
374	then	O
374	,	O
374	the	O
374	reaction	O
374	was	O
374	stopped	O
374	by	O
374	several	O
374	washing	O
374	steps	O
374	with	O
374	p	O
374	##bs	O
374	,	O
374	samples	O
374	were	O
374	counters	O
374	##tain	O
374	##ed	O
374	with	O
374	may	O
374	##er	O
374	'	O
374	s	O
374	hem	O
374	##ato	O
374	##xy	O
374	##lin	O
374	and	O
374	mounted	O
374	in	O
374	flu	O
374	##or	O
374	save	O
374	re	O
374	##age	O
374	##nt	O
374	(	O
374	ca	O
374	##l	O
374	##bio	O
374	##che	O
374	##m	O
374	,	O
374	bad	O
374	so	O
374	##den	O
374	,	O
374	g	O
374	##erman	O
374	##y	O
374	)	O
374	.	O
374	[SEP]	O
375	[CLS]	O
375	mean	O
375	pulse	O
375	increased	O
375	to	O
375	maximum	O
375	levels	O
375	at	O
375	12	O
375	hours	O
375	after	O
375	treatment	O
375	and	O
375	returned	O
375	to	O
375	pre	O
375	##tre	O
375	##at	O
375	##ment	O
375	levels	O
375	by	O
375	48	O
375	hours	O
375	after	O
375	dose	O
375	.	O
375	[SEP]	O
376	[CLS]	O
376	these	O
376	results	O
376	suggested	O
376	that	O
376	both	O
376	p	O
376	##k	O
376	and	O
376	p	O
376	##d	O
376	of	O
376	de	O
376	are	O
376	critical	O
376	for	O
376	d	O
376	##di	O
376	prediction	O
376	.	O
376	[SEP]	O
377	[CLS]	O
377	the	O
377	g	O
377	##a	O
377	-	O
377	c	O
377	##ts	O
377	/	O
377	5	O
377	-	O
377	f	O
377	##u	O
377	na	O
377	##no	O
377	##par	O
377	##tic	O
377	##le	O
377	had	O
377	a	O
377	protective	O
377	effect	O
377	on	O
377	the	O
377	drug	O
377	against	O
377	plasma	O
377	de	O
377	##grading	O
377	enzyme	O
377	,	O
377	and	O
377	provided	O
377	a	O
377	sustained	O
377	release	O
377	system	O
377	comprising	O
377	three	O
377	distinct	O
377	phases	O
377	of	O
377	quick	O
377	,	O
377	steady	O
377	,	O
377	and	O
377	slow	O
377	release	O
377	.	O
377	[SEP]	O
378	[CLS]	O
378	the	O
378	dual	O
378	action	O
378	of	O
378	el	O
378	##ob	O
378	##ix	O
378	##iba	O
378	##t	O
378	–	O
378	enhancing	O
378	co	O
378	##lon	O
378	##ic	O
378	secret	O
378	##ion	O
378	and	O
378	m	O
378	##ot	O
378	##ility	O
378	–	O
378	has	O
378	garnered	O
378	interest	O
378	in	O
378	the	O
378	treatment	O
378	of	O
378	con	O
378	##st	O
378	##ip	O
378	##ation	O
378	.	O
378	[SEP]	O
379	[CLS]	O
379	for	O
379	more	O
379	information	O
379	,	O
379	see	O
379	s	O
379	##3	O
379	table	O
379	.	O
379	[SEP]	O
380	[CLS]	O
380	an	O
380	early	O
380	phase	O
380	clinical	O
380	trial	O
380	with	O
380	the	O
380	same	O
380	device	O
380	and	O
380	doses	O
380	found	O
380	excellent	O
380	to	O
380	##ler	O
380	##ability	O
380	with	O
380	high	O
380	response	O
380	rates	O
380	and	O
380	rapid	O
380	onset	O
380	of	O
380	pain	O
380	relief	O
380	,	O
380	approaching	O
380	the	O
380	benefits	O
380	of	O
380	injection	O
380	despite	O
380	significantly	O
380	lower	O
380	predicted	O
380	drug	O
380	levels	O
380	.	O
380	[SEP]	O
381	[CLS]	O
381	it	O
381	is	O
381	assume	O
381	that	O
381	all	O
381	the	O
381	ram	O
381	##ip	O
381	##ril	O
381	meta	O
381	##bol	O
381	##ized	O
381	by	O
381	the	O
381	kidney	O
381	is	O
381	converted	O
381	to	O
381	ram	O
381	##ip	O
381	##ril	O
381	##at	O
381	.	O
381	[SEP]	O
382	[CLS]	O
382	comparisons	O
382	of	O
382	p	O
382	##har	O
382	##ma	O
382	##co	O
382	##kin	O
382	##etic	O
382	parameters	O
382	between	O
382	the	O
382	two	O
382	groups	O
382	of	O
382	rats	O
382	or	O
382	between	O
382	two	O
382	doses	O
382	of	O
382	r	O
382	##hu	O
382	##ep	O
382	##o	O
382	were	O
382	carried	O
382	out	O
382	using	O
382	w	O
382	##il	O
382	##co	O
382	##xon	O
382	rank	O
382	sum	O
382	tests	O
382	.	O
382	[SEP]	O
383	[CLS]	O
383	the	O
383	hp	O
383	##l	O
383	##c	O
383	apparatus	O
383	included	O
383	a	O
383	pump	O
383	(	O
383	l	O
383	##c	O
383	-	O
383	10	O
383	##at	O
383	,	O
383	s	O
383	##hima	O
383	##d	O
383	##zu	O
383	,	O
383	k	O
383	##yo	O
383	##to	O
383	,	O
383	j	O
383	##apa	O
383	##n	O
383	)	O
383	,	O
383	an	O
383	u	O
383	##v	O
383	detector	O
383	(	O
383	s	O
383	##p	O
383	##d	O
383	-	O
383	10	O
383	##av	O
383	##p	O
383	,	O
383	s	O
383	##hima	O
383	##d	O
383	##zu	O
383	)	O
383	and	O
383	an	O
383	automatic	O
383	in	O
383	##ject	O
383	##or	O
383	(	O
383	series	O
383	200	O
383	auto	O
383	##sa	O
383	##mple	O
383	##r	O
383	,	O
383	per	O
383	##kin	O
383	el	O
383	##mer	O
383	,	O
383	us	O
383	##a	O
383	)	O
383	.	O
383	[SEP]	O
384	[CLS]	O
384	the	O
384	decrease	O
384	in	O
384	plasma	O
384	concentrations	O
384	displayed	O
384	a	O
384	bi	O
384	##pha	O
384	##si	O
384	##c	O
384	profile	O
384	(	O
384	see	O
384	fi	O
384	##g	O
384	.	O
384	2	O
384	##a	O
384	,	O
384	c	O
384	)	O
384	.	O
384	[SEP]	O
385	[CLS]	O
385	the	O
385	diagnosis	O
385	of	O
385	cc	O
385	was	O
385	defined	O
385	as	O
385	a	O
385	history	O
385	of	O
385	fewer	O
385	than	O
385	three	O
385	spontaneous	O
385	b	O
385	##ms	O
385	(	O
385	s	O
385	##b	O
385	##ms	O
385	)	O
385	per	O
385	week	O
385	,	O
385	with	O
385	at	O
385	least	O
385	one	O
385	of	O
385	the	O
385	following	O
385	symptoms	O
385	:	O
385	(	O
385	1	O
385	)	O
385	straining	O
385	during	O
385	≥	O
385	##25	O
385	%	O
385	of	O
385	b	O
385	##ms	O
385	,	O
385	(	O
385	2	O
385	)	O
385	lump	O
385	##y	O
385	or	O
385	hard	O
385	stool	O
385	##s	O
385	during	O
385	≥	O
385	##25	O
385	%	O
385	of	O
385	b	O
385	##ms	O
385	and	O
385	(	O
385	3	O
385	)	O
385	sensation	O
385	of	O
385	incomplete	O
385	evacuation	O
385	during	O
385	≥	O
385	##25	O
385	%	O
385	of	O
385	b	O
385	##ms	O
385	.	O
385	[SEP]	O
386	[CLS]	O
386	the	O
386	rat	O
386	and	O
386	pool	O
386	##ed	O
386	human	O
386	liver	O
386	micro	O
386	##some	O
386	##s	O
386	were	O
386	carefully	O
386	th	O
386	##awed	O
386	on	O
386	ice	O
386	before	O
386	the	O
386	experiment	O
386	.	O
386	[SEP]	O
387	[CLS]	O
387	serial	O
387	blood	O
387	samples	O
387	were	O
387	collected	O
387	to	O
387	describe	O
387	the	O
387	anti	O
387	##biotic	O
387	p	O
387	##har	O
387	##ma	O
387	##co	O
387	##kin	O
387	##etics	O
387	.	O
387	[SEP]	O
388	[CLS]	O
388	the	O
388	que	O
388	/	O
388	t	O
388	##m	O
388	##z	O
388	-	O
388	n	O
388	##ls	O
388	significantly	O
388	up	O
388	##re	O
388	##gu	O
388	##lated	O
388	the	O
388	release	O
388	of	O
388	l	O
388	##dh	O
388	by	O
388	the	O
388	u	O
388	##8	O
388	##7	O
388	/	O
388	t	O
388	##r	O
388	cells	O
388	(	O
388	p	O
388	<	O
388	0	O
388	.	O
388	01	O
388	)	O
388	,	O
388	compared	O
388	with	O
388	the	O
388	control	O
388	n	O
388	##ls	O
388	and	O
388	the	O
388	d	O
388	##ms	O
388	##o	O
388	control	O
388	.	O
388	[SEP]	O
389	[CLS]	O
389	the	O
389	extraction	O
389	was	O
389	repeated	O
389	twice	O
389	.	O
389	[SEP]	O
390	[CLS]	O
390	after	O
390	undergoing	O
390	in	O
390	##cu	O
390	##bation	O
390	for	O
390	60	O
390	min	O
390	,	O
390	the	O
390	reactions	O
390	were	O
390	terminated	O
390	by	O
390	adding	O
390	an	O
390	equal	O
390	volume	O
390	of	O
390	et	O
390	##hyl	O
390	ace	O
390	##tate	O
390	.	O
390	[SEP]	O
391	[CLS]	O
391	a	O
391	complete	O
391	list	O
391	of	O
391	model	O
391	parameter	O
391	estimates	O
391	is	O
391	provided	O
391	in	O
391	table	O
391	2	O
391	.	O
391	[SEP]	O
392	[CLS]	O
392	per	O
392	##me	O
392	##ation	O
392	studies	O
392	performed	O
392	via	O
392	hp	O
392	##l	O
392	##c	O
392	evidenced	O
392	g	O
392	##eran	O
392	##iol	O
392	per	O
392	##me	O
392	##ability	O
392	coefficients	O
392	across	O
392	an	O
392	in	O
392	v	O
392	##it	O
392	##ro	O
392	model	O
392	of	O
392	the	O
392	human	O
392	in	O
392	##test	O
392	##inal	O
392	wall	O
392	for	O
392	a	O
392	##pical	O
392	to	O
392	b	O
392	##as	O
392	##olate	O
392	##ral	O
392	and	O
392	b	O
392	##as	O
392	##olate	O
392	##ral	O
392	to	O
392	a	O
392	##pical	O
392	transport	O
392	of	O
392	13	O
392	.	O
392	10	O
392	±	O
392	2	O
392	.	O
392	3	O
392	×	O
392	10	O
392	-	O
392	3	O
392	and	O
392	2	O
392	.	O
392	1	O
392	±	O
392	0	O
392	.	O
392	1	O
392	##⋅	O
392	##×	O
392	10	O
392	-	O
392	3	O
392	cm	O
392	/	O
392	min	O
392	,	O
392	respectively	O
392	.	O
392	[SEP]	O
393	[CLS]	O
393	overall	O
393	,	O
393	simulated	O
393	concentrations	O
393	at	O
393	10	O
393	,	O
393	20	O
393	,	O
393	and	O
393	30	O
393	minutes	O
393	were	O
393	lower	O
393	than	O
393	that	O
393	of	O
393	adults	O
393	,	O
393	with	O
393	ratios	O
393	between	O
393	geometric	O
393	means	O
393	(	O
393	adults	O
393	/	O
393	children	O
393	)	O
393	varying	O
393	from	O
393	1	O
393	.	O
393	8	O
393	(	O
393	c	O
393	##10	O
393	)	O
393	to	O
393	1	O
393	.	O
393	5	O
393	(	O
393	c	O
393	##30	O
393	)	O
393	(	O
393	fi	O
393	##g	O
393	.	O
393	2	O
393	)	O
393	,	O
393	whereas	O
393	simulated	O
393	au	B-PK
393	##c	I-PK
393	was	O
393	higher	O
393	than	O
393	that	O
393	of	O
393	adults	O
393	with	O
393	a	O
393	ratio	O
393	between	O
393	geometric	O
393	means	O
393	(	O
393	adults	O
393	/	O
393	children	O
393	)	O
393	of	O
393	0	O
393	.	O
393	62	O
393	(	O
393	fi	O
393	##g	O
393	.	O
393	3	O
393	)	O
393	.	O
393	[SEP]	O
394	[CLS]	O
394	mice	O
394	treated	O
394	with	O
394	120	O
394	mg	O
394	/	O
394	kg	O
394	of	O
394	g	O
394	##eran	O
394	##iol	O
394	for	O
394	4	O
394	weeks	O
394	showed	O
394	increased	O
394	anti	O
394	-	O
394	o	O
394	##xi	O
394	##da	O
394	##tive	O
394	defenses	O
394	with	O
394	no	O
394	signs	O
394	of	O
394	liver	O
394	toxicity	O
394	.	O
394	[SEP]	O
395	[CLS]	O
395	serum	O
395	be	O
395	##va	O
395	##ci	O
395	##zu	O
395	##ma	O
395	##b	O
395	concentrations	O
395	were	O
395	determined	O
395	at	O
395	gene	O
395	##nte	O
395	##ch	O
395	,	O
395	in	O
395	##c	O
395	.	O
395	,	O
395	using	O
395	an	O
395	enzyme	O
395	-	O
395	linked	O
395	im	O
395	##mu	O
395	##nos	O
395	##or	O
395	##bent	O
395	ass	O
395	##ay	O
395	that	O
395	used	O
395	re	O
395	##comb	O
395	##ina	O
395	##nt	O
395	human	O
395	ve	O
395	##g	O
395	##f	O
395	for	O
395	capture	O
395	and	O
395	a	O
395	goat	O
395	anti	O
395	##body	O
395	to	O
395	human	O
395	i	O
395	##gg	O
395	con	O
395	##ju	O
395	##gated	O
395	to	O
395	horse	O
395	##rad	O
395	##ish	O
395	per	O
395	##ox	O
395	##idas	O
395	##e	O
395	for	O
395	detection	O
395	.	O
395	[SEP]	O
396	[CLS]	O
396	plasma	O
396	concentrations	O
396	of	O
396	ni	O
396	##mo	O
396	##di	O
396	##pine	O
396	were	O
396	significantly	O
396	higher	O
396	in	O
396	h	O
396	##y	O
396	##pot	O
396	##her	O
396	##mia	O
396	than	O
396	in	O
396	norm	O
396	##oth	O
396	##er	O
396	##mia	O
396	.	O
396	[SEP]	O
397	[CLS]	O
397	g	O
397	##eran	O
397	##iol	O
397	is	O
397	a	O
397	natural	O
397	mon	O
397	##oter	O
397	##pen	O
397	##e	O
397	showing	O
397	anti	O
397	-	O
397	inflammatory	O
397	,	O
397	anti	O
397	##ox	O
397	##ida	O
397	##nt	O
397	,	O
397	ne	O
397	##uro	O
397	##p	O
397	##rote	O
397	##ctive	O
397	and	O
397	anti	O
397	##can	O
397	##cer	O
397	effects	O
397	.	O
397	[SEP]	O
398	[CLS]	O
398	diagnostic	O
398	plots	O
398	are	O
398	shown	O
398	in	O
398	figure	O
398	s	O
398	##1	O
398	and	O
398	s	O
398	##2	O
398	(	O
398	figure	O
398	supplement	O
398	##ary	O
398	material	O
398	)	O
398	.	O
398	[SEP]	O
399	[CLS]	O
399	values	O
399	of	O
399	co	O
399	##var	O
399	##iate	O
399	##s	O
399	that	O
399	follow	O
399	log	O
399	##nor	O
399	##mal	O
399	distribution	O
399	were	O
399	log	O
399	-	O
399	transformed	O
399	.	O
399	[SEP]	O
400	[CLS]	O
400	patients	O
400	with	O
400	at	O
400	least	O
400	one	O
400	p	O
400	##k	O
400	sample	O
400	were	O
400	evaluated	O
400	.	O
400	[SEP]	O
401	[CLS]	O
401	in	O
401	##hibition	O
401	profiles	O
401	and	O
401	50	B-PK
401	%	I-PK
401	inhibitor	I-PK
401	##y	I-PK
401	concentration	I-PK
401	(	I-PK
401	i	I-PK
401	##c	I-PK
401	##50	I-PK
401	)	I-PK
401	values	O
401	were	O
401	determined	O
401	using	O
401	a	O
401	normal	O
401	##ized	O
401	response	O
401	(	O
401	variable	O
401	-	O
401	slope	O
401	)	O
401	curve	O
401	-	O
401	fitting	O
401	algorithm	O
401	with	O
401	the	O
401	graph	O
401	##pad	O
401	p	O
401	##rism	O
401	software	O
401	.	O
401	[SEP]	O
402	[CLS]	O
402	the	O
402	study	O
402	was	O
402	conducted	O
402	on	O
402	16	O
402	w	O
402	##ista	O
402	##r	O
402	rats	O
402	,	O
402	which	O
402	were	O
402	divided	O
402	into	O
402	four	O
402	groups	O
402	each	O
402	group	O
402	containing	O
402	four	O
402	rats	O
402	.	O
402	[SEP]	O
403	[CLS]	O
403	the	O
403	dwell	O
403	times	O
403	were	O
403	20	O
403	m	O
403	##s	O
403	and	O
403	the	O
403	entrance	O
403	potential	O
403	was	O
403	at	O
403	10	O
403	v	O
403	for	O
403	each	O
403	transition	O
403	.	O
403	[SEP]	O
404	[CLS]	O
404	the	O
404	multiple	O
404	reaction	O
404	monitoring	O
404	transitions	O
404	for	O
404	two	O
404	unique	O
404	sur	O
404	##rogate	O
404	p	O
404	##eptide	O
404	##s	O
404	of	O
404	the	O
404	ma	O
404	##b	O
404	##2	O
404	backbone	O
404	were	O
404	used	O
404	for	O
404	concentration	O
404	determination	O
404	relative	O
404	to	O
404	the	O
404	standards	O
404	and	O
404	controls	O
404	using	O
404	the	O
404	peak	O
404	area	O
404	from	O
404	the	O
404	m	O
404	##qi	O
404	##ii	O
404	integration	O
404	algorithm	O
404	of	O
404	the	O
404	analyst	O
404	software	O
404	.	O
404	[SEP]	O
405	[CLS]	O
405	then	O
405	,	O
405	g	O
405	##st	O
405	-	O
405	and	O
405	his	O
405	##tag	O
405	##s	O
405	were	O
405	c	O
405	##lea	O
405	##ved	O
405	from	O
405	the	O
405	r	O
405	##rf	O
405	##c	O
405	##1	O
405	specific	O
405	p	O
405	##eptide	O
405	(	O
405	r	O
405	##sp	O
405	)	O
405	by	O
405	means	O
405	of	O
405	enter	O
405	##oki	O
405	##nas	O
405	##e	O
405	(	O
405	30	O
405	µ	O
405	##g	O
405	/	O
405	mg	O
405	fusion	O
405	protein	O
405	)	O
405	over	O
405	6	O
405	h	O
405	in	O
405	dial	O
405	##ys	O
405	##is	O
405	buffer	O
405	(	O
405	200	O
405	mm	O
405	na	O
405	##c	O
405	##l	O
405	,	O
405	20	O
405	mm	O
405	t	O
405	##ris	O
405	-	O
405	h	O
405	##c	O
405	##l	O
405	,	O
405	200	O
405	mm	O
405	im	O
405	##ida	O
405	##zo	O
405	##le	O
405	p	O
405	##h	O
405	8	O
405	.	O
405	0	O
405	)	O
405	.	O
405	[SEP]	O
406	[CLS]	O
406	the	O
406	p	O
406	##c	O
406	##r	O
406	product	O
406	denoted	O
406	in	O
406	##tra	O
406	##cellular	O
406	domain	O
406	7	O
406	(	O
406	id	O
406	##7	O
406	)	O
406	was	O
406	clone	O
406	##d	O
406	into	O
406	the	O
406	expression	O
406	vector	O
406	pet	O
406	-	O
406	41	O
406	##a	O
406	(	O
406	no	O
406	##vage	O
406	##n	O
406	,	O
406	in	O
406	##c	O
406	.	O
406	,	O
406	mad	O
406	##ison	O
406	,	O
406	w	O
406	##i	O
406	,	O
406	us	O
406	##a	O
406	)	O
406	via	O
406	e	O
406	##cor	O
406	##i	O
406	/	O
406	hind	O
406	##ii	O
406	##i	O
406	(	O
406	ne	O
406	##b	O
406	,	O
406	i	O
406	##ps	O
406	##wich	O
406	,	O
406	ma	O
406	,	O
406	us	O
406	##a	O
406	)	O
406	.	O
406	[SEP]	O
407	[CLS]	O
407	the	O
407	extraction	O
407	recover	O
407	##ies	O
407	were	O
407	ranged	O
407	from	O
407	83	O
407	.	O
407	4	O
407	%	O
407	to	O
407	94	O
407	.	O
407	2	O
407	%	O
407	.	O
407	[SEP]	O
408	[CLS]	O
408	therefore	O
408	,	O
408	solid	O
408	-	O
408	phase	O
408	extraction	O
408	was	O
408	used	O
408	to	O
408	remove	O
408	excess	O
408	ingredients	O
408	in	O
408	plasma	O
408	and	O
408	achieve	O
408	good	O
408	select	O
408	##ivity	O
408	.	O
408	[SEP]	O
409	[CLS]	O
409	subsequently	O
409	,	O
409	fusion	O
409	proteins	O
409	were	O
409	el	O
409	##uted	O
409	with	O
409	im	O
409	##ida	O
409	##zo	O
409	##le	O
409	(	O
409	300	O
409	mm	O
409	)	O
409	in	O
409	el	O
409	##ution	O
409	buffer	O
409	(	O
409	0	O
409	.	O
409	5	O
409	m	O
409	na	O
409	##c	O
409	##l	O
409	,	O
409	20	O
409	mm	O
409	t	O
409	##ris	O
409	-	O
409	h	O
409	##c	O
409	##l	O
409	,	O
409	p	O
409	##h	O
409	7	O
409	.	O
409	9	O
409	)	O
409	.	O
409	[SEP]	O
410	[CLS]	O
410	this	O
410	finding	O
410	demonstrates	O
410	that	O
410	and	O
410	##rog	O
410	##rap	O
410	##hol	O
410	##ide	O
410	might	O
410	induce	O
410	activation	O
410	of	O
410	intrinsic	O
410	ca	O
410	##sp	O
410	##ase	O
410	pathway	O
410	in	O
410	m	O
410	##da	O
410	-	O
410	m	O
410	##b	O
410	-	O
410	231	O
410	cells	O
410	.	O
410	[SEP]	O
411	[CLS]	O
411	it	O
411	was	O
411	reported	O
411	that	O
411	the	O
411	medicinal	O
411	herbs	O
411	containing	O
411	form	O
411	##ono	O
411	##net	O
411	##in	O
411	often	O
411	have	O
411	been	O
411	used	O
411	to	O
411	treat	O
411	card	O
411	##iovascular	O
411	diseases	O
411	for	O
411	a	O
411	long	O
411	time	O
411	[	O
411	26	O
411	]	O
411	.	O
411	[SEP]	O
412	[CLS]	O
412	however	O
412	,	O
412	the	O
412	ll	O
412	##o	O
412	##q	O
412	##s	O
412	of	O
412	the	O
412	new	O
412	method	O
412	were	O
412	sufficient	O
412	to	O
412	character	O
412	##ize	O
412	the	O
412	p	O
412	##har	O
412	##ma	O
412	##co	O
412	##kin	O
412	##etics	O
412	of	O
412	the	O
412	other	O
412	5	O
412	components	O
412	(	O
412	ca	O
412	##ffe	O
412	##ic	O
412	acid	O
412	,	O
412	f	O
412	##er	O
412	##uli	O
412	##c	O
412	acid	O
412	,	O
412	form	O
412	##ono	O
412	##net	O
412	##in	O
412	,	O
412	cry	O
412	##pt	O
412	##ota	O
412	##ns	O
412	##hino	O
412	##ne	O
412	,	O
412	and	O
412	tan	O
412	##shin	O
412	##one	O
412	ii	O
412	##a	O
412	)	O
412	in	O
412	rats	O
412	.	O
412	[SEP]	O
413	[CLS]	O
413	as	O
413	shown	O
413	in	O
413	figure	O
413	2	O
413	,	O
413	two	O
413	plasma	B-PK
413	concentration	I-PK
413	peaks	I-PK
413	were	O
413	observed	O
413	in	O
413	the	O
413	mean	O
413	plasma	O
413	concentration	O
413	curves	O
413	profiles	O
413	of	O
413	cry	O
413	##pt	O
413	##ota	O
413	##ns	O
413	##hino	O
413	##ne	O
413	and	O
413	tan	O
413	##shin	O
413	##one	O
413	ii	O
413	##a	O
413	,	O
413	which	O
413	was	O
413	consistent	O
413	with	O
413	results	O
413	from	O
413	previous	O
413	studies	O
413	[	O
413	24	O
413	]	O
413	.	O
413	[SEP]	O
414	[CLS]	O
414	the	O
414	mean	O
414	plasma	O
414	concentration	O
414	-	O
414	time	O
414	profiles	O
414	of	O
414	ca	O
414	##ffe	O
414	##ic	O
414	acid	O
414	,	O
414	f	O
414	##er	O
414	##uli	O
414	##c	O
414	acid	O
414	,	O
414	form	O
414	##ono	O
414	##net	O
414	##in	O
414	,	O
414	cry	O
414	##pt	O
414	##ota	O
414	##ns	O
414	##hino	O
414	##ne	O
414	,	O
414	and	O
414	tan	O
414	##shin	O
414	##one	O
414	ii	O
414	##a	O
414	are	O
414	shown	O
414	in	O
414	figure	O
414	2	O
414	.	O
414	[SEP]	O
415	[CLS]	O
415	in	O
415	2016	O
415	,	O
415	we	O
415	reviewed	O
415	all	O
415	the	O
415	published	O
415	studies	O
415	that	O
415	co	O
415	##rrel	O
415	##ate	O
415	the	O
415	he	O
415	##pa	O
415	##to	O
415	##bil	O
415	##iary	O
415	m	O
415	##r	O
415	imaging	O
415	and	O
415	the	O
415	expression	O
415	of	O
415	he	O
415	##pa	O
415	##to	O
415	##cy	O
415	##te	O
415	transport	O
415	##ers	O
415	in	O
415	human	O
415	he	O
415	##pa	O
415	##to	O
415	##cellular	O
415	car	O
415	##cin	O
415	##oma	O
415	##s	O
415	[	O
415	35	O
415	]	O
415	.	O
415	[SEP]	O
416	[CLS]	O
416	we	O
416	showed	O
416	how	O
416	the	O
416	understanding	O
416	of	O
416	signal	O
416	intensity	O
416	in	O
416	these	O
416	focal	O
416	lesions	O
416	relies	O
416	on	O
416	the	O
416	transport	O
416	function	O
416	of	O
416	the	O
416	human	O
416	m	O
416	##rp	O
416	##2	O
416	.	O
416	[SEP]	O
417	[CLS]	O
417	dig	O
417	##ox	O
417	##in	O
417	concentration	O
417	was	O
417	simulated	O
417	for	O
417	1000	O
417	patients	O
417	with	O
417	c	O
417	##l	O
417	##c	O
417	##r	O
417	ranging	O
417	from	O
417	5	O
417	to	O
417	130	O
417	m	O
417	##l	O
417	/	O
417	min	O
417	with	O
417	or	O
417	without	O
417	am	O
417	##io	O
417	##dar	O
417	##one	O
417	administration	O
417	.	O
417	[SEP]	O
418	[CLS]	O
418	plasma	O
418	concentration	O
418	-	O
418	time	O
418	data	O
418	(	O
418	table	O
418	7	O
418	)	O
418	of	O
418	each	O
418	anal	O
418	##yte	O
418	were	O
418	analyzed	O
418	by	O
418	the	O
418	non	O
418	-	O
418	compartment	O
418	##al	O
418	method	O
418	using	O
418	p	O
418	##k	O
418	solve	O
418	##r	O
418	software	O
418	.	O
418	46	O
418	the	O
418	peak	B-PK
418	plasma	I-PK
418	concentration	I-PK
418	was	O
418	reached	O
418	by	O
418	both	O
418	r	O
418	and	O
418	s	O
418	-	O
418	al	O
418	##o	O
418	at	O
418	approximately	O
418	the	O
418	equal	O
418	time	O
418	(	O
418	in	O
418	1	O
418	hour	O
418	)	O
418	after	O
418	administration	O
418	of	O
418	the	O
418	oral	O
418	al	O
418	##o	O
418	dose	O
418	thus	O
418	showing	O
418	same	O
418	absorption	O
418	profile	O
418	.	O
418	[SEP]	O
419	[CLS]	O
419	a	O
419	total	O
419	of	O
419	22	O
419	healthy	O
419	subjects	O
419	(	O
419	11	O
419	male	O
419	and	O
419	11	O
419	female	O
419	;	O
419	age	O
419	18	O
419	–	O
419	65	O
419	years	O
419	)	O
419	participated	O
419	in	O
419	the	O
419	study	O
419	.	O
419	[SEP]	O
420	[CLS]	O
420	the	O
420	p	O
420	##har	O
420	##ma	O
420	##co	O
420	##kin	O
420	##etic	O
420	linear	O
420	##ity	O
420	and	O
420	parameters	O
420	reported	O
420	are	O
420	necessary	O
420	p	O
420	##har	O
420	##ma	O
420	##cological	O
420	information	O
420	of	O
420	k	O
420	##rato	O
420	##m	O
420	,	O
420	and	O
420	there	O
420	is	O
420	a	O
420	possibility	O
420	for	O
420	it	O
420	to	O
420	be	O
420	developed	O
420	medical	O
420	##ly	O
420	as	O
420	a	O
420	pain	O
420	killer	O
420	or	O
420	better	O
420	op	O
420	##io	O
420	##id	O
420	substitute	O
420	in	O
420	the	O
420	future	O
420	.	O
420	[SEP]	O
421	[CLS]	O
421	recommended	O
421	phase	O
421	ii	O
421	doses	O
421	were	O
421	determined	O
421	in	O
421	a	O
421	dose	O
421	es	O
421	##cal	O
421	##ation	O
421	study	O
421	in	O
421	advanced	O
421	solid	O
421	t	O
421	##umour	O
421	##s	O
421	.	O
421	[SEP]	O
422	[CLS]	O
422	the	O
422	vascular	O
422	disrupt	O
422	##ing	O
422	agent	O
422	o	O
422	##mb	O
422	##rab	O
422	##ulin	O
422	shows	O
422	s	O
422	##yne	O
422	##rgy	O
422	with	O
422	do	O
422	##ce	O
422	##ta	O
422	##xe	O
422	##l	O
422	in	O
422	v	O
422	##ivo	O
422	.	O
422	[SEP]	O
423	[CLS]	O
423	the	O
423	conditions	O
423	were	O
423	reversed	O
423	for	O
423	group	O
423	2	O
423	,	O
423	who	O
423	were	O
423	exposed	O
423	without	O
423	hood	O
423	##s	O
423	on	O
423	wed	O
423	##nes	O
423	##day	O
423	of	O
423	the	O
423	first	O
423	week	O
423	and	O
423	while	O
423	wearing	O
423	hood	O
423	##s	O
423	on	O
423	wed	O
423	##nes	O
423	##day	O
423	of	O
423	the	O
423	second	O
423	week	O
423	.	O
423	[SEP]	O
424	[CLS]	O
424	the	O
424	drop	O
424	##let	O
424	size	O
424	distribution	O
424	was	O
424	determined	O
424	by	O
424	dynamic	O
424	light	O
424	scattering	O
424	(	O
424	z	O
424	##eta	O
424	##si	O
424	##zer	O
424	,	O
424	na	O
424	##no	O
424	z	O
424	##s	O
424	-	O
424	90	O
424	,	O
424	ma	O
424	##lve	O
424	##rn	O
424	instruments	O
424	,	O
424	ma	O
424	##lve	O
424	##rn	O
424	,	O
424	uk	O
424	)	O
424	.	O
424	[SEP]	O
425	[CLS]	O
425	the	O
425	ma	O
425	##bs	O
425	##ele	O
425	##ct	O
425	sure	O
425	el	O
425	##ution	O
425	pools	O
425	were	O
425	then	O
425	di	O
425	##lut	O
425	##ed	O
425	with	O
425	two	O
425	volumes	O
425	of	O
425	water	O
425	and	O
425	loaded	O
425	on	O
425	to	O
425	a	O
425	s	O
425	##p	O
425	-	O
425	se	O
425	##pha	O
425	##rose	O
425	hp	O
425	column	O
425	(	O
425	g	O
425	##e	O
425	healthcare	O
425	,	O
425	p	O
425	##is	O
425	##cat	O
425	##away	O
425	n	O
425	##j	O
425	)	O
425	followed	O
425	washing	O
425	with	O
425	s	O
425	##p	O
425	-	O
425	buffer	O
425	a	O
425	(	O
425	20	O
425	mm	O
425	ace	O
425	##tic	O
425	acid	O
425	p	O
425	##h	O
425	5	O
425	.	O
425	0	O
425	)	O
425	.	O
425	[SEP]	O
426	[CLS]	O
426	six	O
426	male	O
426	volunteers	O
426	,	O
426	aged	O
426	27	O
426	to	O
426	66	O
426	years	O
426	,	O
426	were	O
426	divided	O
426	into	O
426	groups	O
426	1	O
426	and	O
426	2	O
426	.	O
426	[SEP]	O
427	[CLS]	O
427	more	O
427	con	O
427	##den	O
427	##sed	O
427	nucleus	O
427	with	O
427	significant	O
427	m	O
427	##or	O
427	##phological	O
427	der	O
427	##ang	O
427	##ement	O
427	in	O
427	the	O
427	da	O
427	##pi	O
427	stain	O
427	##ing	O
427	sign	O
427	##ifies	O
427	the	O
427	toxicity	O
427	of	O
427	p	O
427	##c	O
427	##ms	O
427	on	O
427	isolated	O
427	cells	O
427	.	O
427	[SEP]	O
428	[CLS]	O
428	each	O
428	3	O
428	-	O
428	member	O
428	group	O
428	was	O
428	exposed	O
428	to	O
428	elevated	O
428	concentrations	O
428	of	O
428	d	O
428	##n	O
428	##b	O
428	##p	O
428	in	O
428	a	O
428	55	O
428	m	O
428	##3	O
428	chamber	O
428	for	O
428	6	O
428	h	O
428	.	O
428	group	O
428	1	O
428	comprised	O
428	participants	O
428	who	O
428	are	O
428	identified	O
428	as	O
428	p	O
428	##1	O
428	,	O
428	p	O
428	##2	O
428	,	O
428	and	O
428	p	O
428	##3	O
428	in	O
428	this	O
428	paper	O
428	,	O
428	and	O
428	group	O
428	2	O
428	includes	O
428	p	O
428	##4	O
428	,	O
428	p	O
428	##5	O
428	,	O
428	and	O
428	p	O
428	##6	O
428	.	O
428	[SEP]	O
429	[CLS]	O
429	all	O
429	the	O
429	animal	O
429	experimental	O
429	procedures	O
429	were	O
429	approved	O
429	by	O
429	the	O
429	institutional	O
429	animal	O
429	ethical	O
429	committee	O
429	and	O
429	were	O
429	in	O
429	compliance	O
429	with	O
429	the	O
429	national	O
429	institutes	O
429	of	O
429	health	O
429	guide	O
429	for	O
429	care	O
429	and	O
429	use	O
429	of	O
429	laboratory	O
429	animals	O
429	.	O
429	[SEP]	O
430	[CLS]	O
430	a	O
430	two	O
430	-	O
430	sided	O
430	p	O
430	<	O
430	0	O
430	.	O
430	05	O
430	was	O
430	considered	O
430	statistical	O
430	##ly	O
430	significant	O
430	for	O
430	all	O
430	tests	O
430	.	O
430	[SEP]	O
431	[CLS]	O
431	protein	O
431	quality	O
431	was	O
431	assessed	O
431	by	O
431	co	O
431	##oma	O
431	##ssie	O
431	stained	O
431	sodium	O
431	do	O
431	##de	O
431	##cy	O
431	##l	O
431	su	O
431	##lf	O
431	##ate	O
431	p	O
431	##oly	O
431	##ac	O
431	##ryl	O
431	##ami	O
431	##de	O
431	gel	O
431	electro	O
431	##ph	O
431	##ores	O
431	##is	O
431	(	O
431	s	O
431	##ds	O
431	-	O
431	page	O
431	)	O
431	,	O
431	size	O
431	exclusion	O
431	high	O
431	performance	O
431	liquid	O
431	ch	O
431	##roma	O
431	##tography	O
431	se	O
431	-	O
431	hp	O
431	##l	O
431	##c	O
431	(	O
431	bio	O
431	##se	O
431	##p	O
431	s	O
431	##30	O
431	##00	O
431	column	O
431	,	O
431	p	O
431	##hen	O
431	##ome	O
431	##nex	O
431	,	O
431	to	O
431	##rra	O
431	##nce	O
431	,	O
431	ca	O
431	,	O
431	us	O
431	##a	O
431	)	O
431	and	O
431	liquid	O
431	ch	O
431	##roma	O
431	##tography	O
431	electro	O
431	##sp	O
431	##ray	O
431	ion	O
431	##ization	O
431	mass	O
431	-	O
431	s	O
431	##pect	O
431	##rome	O
431	##try	O
431	.	O
431	[SEP]	O
432	[CLS]	O
432	these	O
432	data	O
432	were	O
432	analyzed	O
432	using	O
432	non	O
432	##com	O
432	##par	O
432	##tment	O
432	##al	O
432	and	O
432	traditional	O
432	compartment	O
432	##al	O
432	analyses	O
432	by	O
432	way	O
432	of	O
432	one	O
432	‐	O
432	compartment	O
432	model	O
432	with	O
432	first	O
432	‐	O
432	order	O
432	rate	O
432	constant	O
432	##s	O
432	.	O
432	[SEP]	O
433	[CLS]	O
433	i	O
433	##ver	O
433	##me	O
433	##ct	O
433	##in	O
433	-	O
433	d	O
433	##2	O
433	was	O
433	synthesized	O
433	by	O
433	to	O
433	##ron	O
433	##to	O
433	research	O
433	chemicals	O
433	(	O
433	on	O
433	##tar	O
433	##io	O
433	,	O
433	can	O
433	##ada	O
433	)	O
433	.	O
433	[SEP]	O
434	[CLS]	O
434	the	O
434	study	O
434	was	O
434	approved	O
434	by	O
434	the	O
434	institutional	O
434	animal	O
434	care	O
434	and	O
434	use	O
434	committees	O
434	at	O
434	the	O
434	g	O
434	##e	O
434	global	O
434	research	O
434	center	O
434	and	O
434	s	O
434	##tan	O
434	##ford	O
434	university	O
434	.	O
434	[SEP]	O
435	[CLS]	O
435	all	O
435	enrolled	O
435	patients	O
435	were	O
435	critically	O
435	ill	O
435	with	O
435	multiple	O
435	com	O
435	##or	O
435	##bid	O
435	##ities	O
435	and	O
435	were	O
435	receiving	O
435	i	O
435	##v	O
435	v	O
435	##ori	O
435	##cona	O
435	##zo	O
435	##le	O
435	for	O
435	the	O
435	treatment	O
435	of	O
435	a	O
435	known	O
435	or	O
435	suspected	O
435	systemic	O
435	fun	O
435	##gal	O
435	infection	O
435	.	O
435	[SEP]	O
436	[CLS]	O
436	a	O
436	two	O
436	-	O
436	tailed	O
436	p	O
436	value	O
436	of	O
436	<	O
436	0	O
436	.	O
436	05	O
436	was	O
436	considered	O
436	statistical	O
436	##ly	O
436	significant	O
436	.	O
436	[SEP]	O
437	[CLS]	O
437	a	O
437	total	O
437	of	O
437	56	O
437	##3	O
437	reports	O
437	(	O
437	220	O
437	single	O
437	-	O
437	agent	O
437	and	O
437	34	O
437	##3	O
437	multi	O
437	##age	O
437	##nt	O
437	reports	O
437	)	O
437	involved	O
437	ma	O
437	##gne	O
437	##vist	O
437	.	O
437	[SEP]	O
438	[CLS]	O
438	imaging	O
438	studies	O
438	and	O
438	data	O
438	analyses	O
438	were	O
438	carried	O
438	out	O
438	at	O
438	s	O
438	##tan	O
438	##ford	O
438	university	O
438	.	O
438	[SEP]	O
439	[CLS]	O
439	further	O
439	analysis	O
439	was	O
439	performed	O
439	to	O
439	evaluate	O
439	the	O
439	gene	O
439	expression	O
439	differences	O
439	of	O
439	the	O
439	two	O
439	sexes	O
439	sub	O
439	-	O
439	grouped	O
439	by	O
439	ethnicity	O
439	(	O
439	a	O
439	##f	O
439	##rica	O
439	##n	O
439	am	O
439	##eric	O
439	##an	O
439	males	O
439	vs	O
439	.	O
439	euro	O
439	##pe	O
439	##an	O
439	am	O
439	##eric	O
439	##an	O
439	males	O
439	or	O
439	a	O
439	##f	O
439	##rica	O
439	##n	O
439	am	O
439	##eric	O
439	##an	O
439	females	O
439	vs	O
439	.	O
439	euro	O
439	##pe	O
439	##an	O
439	am	O
439	##eric	O
439	##an	O
439	females	O
439	)	O
439	.	O
439	[SEP]	O
440	[CLS]	O
440	the	O
440	mobile	O
440	phases	O
440	consisted	O
440	of	O
440	ace	O
440	##ton	O
440	##it	O
440	##ril	O
440	##e	O
440	(	O
440	a	O
440	)	O
440	and	O
440	form	O
440	##ic	O
440	acid	O
440	a	O
440	##que	O
440	##ous	O
440	solution	O
440	(	O
440	b	O
440	)	O
440	.	O
440	[SEP]	O
441	[CLS]	O
441	the	O
441	human	O
441	non	O
441	-	O
441	small	O
441	cell	O
441	lung	O
441	car	O
441	##cin	O
441	##oma	O
441	cell	O
441	line	O
441	n	O
441	##ci	O
441	-	O
441	h	O
441	##46	O
441	##0	O
441	(	O
441	at	O
441	##cc	O
441	:	O
441	h	O
441	##t	O
441	##b	O
441	-	O
441	177	O
441	)	O
441	,	O
441	and	O
441	m	O
441	##uri	O
441	##ne	O
441	le	O
441	##wi	O
441	##s	O
441	lung	O
441	car	O
441	##cin	O
441	##oma	O
441	cell	O
441	line	O
441	ll	O
441	/	O
441	2	O
441	(	O
441	at	O
441	##cc	O
441	:	O
441	c	O
441	##rl	O
441	-	O
441	1642	O
441	)	O
441	,	O
441	were	O
441	used	O
441	in	O
441	this	O
441	study	O
441	.	O
441	[SEP]	O
442	[CLS]	O
442	the	O
442	op	O
442	##ti	O
442	##mized	O
442	drug	O
442	-	O
442	loaded	O
442	s	O
442	##ned	O
442	##ds	O
442	was	O
442	prepared	O
442	at	O
442	a	O
442	mass	O
442	ratio	O
442	of	O
442	3	O
442	:	O
442	24	O
442	:	O
442	38	O
442	:	O
442	38	O
442	for	O
442	c	O
442	##y	O
442	##c	O
442	##lov	O
442	##iro	O
442	##bu	O
442	##xin	O
442	##e	O
442	d	O
442	,	O
442	o	O
442	##le	O
442	##ic	O
442	acid	O
442	,	O
442	so	O
442	##lut	O
442	##ol	O
442	s	O
442	##h	O
442	##15	O
442	,	O
442	and	O
442	prop	O
442	##yle	O
442	##ne	O
442	g	O
442	##ly	O
442	##co	O
442	##l	O
442	,	O
442	respectively	O
442	.	O
442	[SEP]	O
443	[CLS]	O
443	in	O
443	##eb	O
443	##ili	O
443	##zu	O
443	##ma	O
443	##b	O
443	had	O
443	an	O
443	acceptable	O
443	safety	O
443	profile	O
443	in	O
443	re	O
443	##lap	O
443	##sing	O
443	m	O
443	##s	O
443	patients	O
443	and	O
443	showed	O
443	a	O
443	trend	O
443	in	O
443	reduction	O
443	##s	O
443	in	O
443	new	O
443	/	O
443	newly	O
443	en	O
443	##lar	O
443	##ging	O
443	and	O
443	g	O
443	##ado	O
443	##lini	O
443	##um	O
443	-	O
443	enhancing	O
443	lesions	O
443	.	O
443	[SEP]	O
444	[CLS]	O
444	following	O
444	the	O
444	previous	O
444	report	O
444	of	O
444	ho	O
444	##u	O
444	et	O
444	al	O
444	.	O
444	[	O
444	25	O
444	]	O
444	,	O
444	three	O
444	sets	O
444	of	O
444	extraction	O
444	methods	O
444	were	O
444	prepared	O
444	to	O
444	evaluate	O
444	the	O
444	matrix	O
444	effect	O
444	and	O
444	recovery	O
444	in	O
444	the	O
444	quantitative	O
444	bio	O
444	##ana	O
444	##ly	O
444	##tical	O
444	method	O
444	.	O
444	[SEP]	O
445	[CLS]	O
445	the	O
445	minimum	O
445	q	O
445	##uant	O
445	##ifiable	O
445	concentration	O
445	was	O
445	8	O
445	.	O
445	24	O
445	ng	O
445	/	O
445	m	O
445	##l	O
445	in	O
445	c	O
445	##yn	O
445	##o	O
445	v	O
445	##it	O
445	##re	O
445	##ous	O
445	humor	O
445	.	O
445	[SEP]	O
446	[CLS]	O
446	phase	O
446	i	O
446	‐	O
446	dose	O
446	es	O
446	##cal	O
446	##ation	O
446	[SEP]	O
447	[CLS]	O
447	both	O
447	ii	O
447	##v	O
447	and	O
447	i	O
447	##ov	O
447	were	O
447	expressed	O
447	as	O
447	coefficients	O
447	of	O
447	variation	O
447	(	O
447	c	O
447	##v	O
447	%	O
447	)	O
447	by	O
447	taking	O
447	the	O
447	square	O
447	roots	O
447	of	O
447	the	O
447	estimates	O
447	divided	O
447	by	O
447	the	O
447	mean	O
447	parameter	O
447	value	O
447	.	O
447	[SEP]	O
448	[CLS]	O
448	forty	O
448	-	O
448	five	O
448	patients	O
448	younger	O
448	than	O
448	2	O
448	years	O
448	with	O
448	normal	O
448	estimated	O
448	g	O
448	##lo	O
448	##mer	O
448	##ular	O
448	fi	O
448	##ltration	O
448	rate	O
448	and	O
448	scheduled	O
448	to	O
448	undergo	O
448	routine	O
448	g	O
448	##ado	O
448	##lini	O
448	##um	O
448	-	O
448	enhanced	O
448	magnetic	O
448	resonance	O
448	imaging	O
448	(	O
448	m	O
448	##ri	O
448	)	O
448	of	O
448	any	O
448	organ	O
448	were	O
448	included	O
448	and	O
448	received	O
448	a	O
448	single	O
448	in	O
448	##tra	O
448	##ven	O
448	##ous	O
448	injection	O
448	of	O
448	g	O
448	##ado	O
448	##tera	O
448	##te	O
448	me	O
448	##g	O
448	##lum	O
448	##ine	O
448	(	O
448	0	O
448	.	O
448	1	O
448	mm	O
448	##ol	O
448	/	O
448	kg	O
448	)	O
448	.	O
448	[SEP]	O
449	[CLS]	O
449	in	O
449	contrast	O
449	,	O
449	plasma	B-PK
449	clearance	I-PK
449	for	O
449	the	O
449	neutral	O
449	(	O
449	te	O
449	##go	O
449	##h	O
449	)	O
449	and	O
449	z	O
449	##wi	O
449	##tter	O
449	##ion	O
449	##ic	O
449	(	O
449	t	O
449	##z	O
449	##wi	O
449	##t	O
449	)	O
449	particles	O
449	was	O
449	substantially	O
449	lower	O
449	(	O
449	0	O
449	.	O
449	00	O
449	##60	O
449	##5	O
449	µ	O
449	##g	O
449	/	O
449	m	O
449	##l	O
449	/	O
449	min	O
449	and	O
449	0	O
449	.	O
449	00	O
449	##5	O
449	##6	O
449	##1	O
449	µ	O
449	##g	O
449	/	O
449	m	O
449	##l	O
449	/	O
449	min	O
449	,	O
449	respectively	O
449	)	O
449	such	O
449	that	O
449	plasma	O
449	concentrations	O
449	remained	O
449	above	O
449	1	O
449	µ	O
449	##g	O
449	/	O
449	m	O
449	##l	O
449	24	O
449	hours	O
449	after	O
449	injection	O
449	(	O
449	figure	O
449	1	O
449	##a	O
449	)	O
449	.	O
449	[SEP]	O
450	[CLS]	O
450	the	O
450	significance	O
450	of	O
450	the	O
450	co	O
450	##var	O
450	##iate	O
450	was	O
450	tested	O
450	using	O
450	the	O
450	nest	O
450	##ed	O
450	model	O
450	criteria	O
450	at	O
450	a	O
450	more	O
450	string	O
450	##ent	O
450	p	O
450	value	O
450	of	O
450	0	O
450	.	O
450	00	O
450	##1	O
450	,	O
450	resulting	O
450	in	O
450	a	O
450	change	O
450	in	O
450	of	O
450	##v	O
450	of	O
450	10	O
450	.	O
450	83	O
450	,	O
450	to	O
450	avoid	O
450	false	O
450	positive	O
450	##s	O
450	.	O
450	[SEP]	O
451	[CLS]	O
451	the	O
451	plasma	O
451	disposition	O
451	##s	O
451	of	O
451	the	O
451	au	O
451	##n	O
451	##ps	O
451	were	O
451	characterized	O
451	in	O
451	male	O
451	c	O
451	##d	O
451	##1	O
451	mice	O
451	after	O
451	i	O
451	##v	O
451	and	O
451	i	O
451	##p	O
451	administration	O
451	.	O
451	[SEP]	O
452	[CLS]	O
452	what	O
452	is	O
452	the	O
452	current	O
452	knowledge	O
452	on	O
452	the	O
452	topic	O
452	?	O
452	[SEP]	O
453	[CLS]	O
453	in	O
453	the	O
453	present	O
453	study	O
453	,	O
453	the	O
453	select	O
453	##ivity	O
453	was	O
453	studied	O
453	by	O
453	using	O
453	rat	O
453	joint	O
453	cavity	O
453	washing	O
453	fluid	O
453	samples	O
453	from	O
453	six	O
453	different	O
453	rats	O
453	.	O
453	[SEP]	O
454	[CLS]	O
454	figure	O
454	1	O
454	shows	O
454	a	O
454	typical	O
454	ch	O
454	##roma	O
454	##to	O
454	##gram	O
454	for	O
454	the	O
454	drug	O
454	-	O
454	free	O
454	rat	O
454	joint	O
454	cavity	O
454	washing	O
454	fluid	O
454	and	O
454	drug	O
454	-	O
454	free	O
454	joint	O
454	cavity	O
454	washing	O
454	fluid	O
454	spike	O
454	##d	O
454	with	O
454	s	O
454	##n	O
454	and	O
454	is	O
454	.	O
454	[SEP]	O
455	[CLS]	O
455	to	O
455	determine	O
455	whether	O
455	all	O
455	the	O
455	co	O
455	##var	O
455	##iate	O
455	##s	O
455	included	O
455	in	O
455	the	O
455	fully	O
455	parameter	O
455	##ized	O
455	population	O
455	p	O
455	##har	O
455	##ma	O
455	##co	O
455	##kin	O
455	##etic	O
455	model	O
455	continued	O
455	to	O
455	provide	O
455	significant	O
455	influence	O
455	on	O
455	the	O
455	population	O
455	model	O
455	,	O
455	the	O
455	co	O
455	##var	O
455	##iate	O
455	##s	O
455	included	O
455	in	O
455	the	O
455	full	O
455	model	O
455	were	O
455	se	O
455	##quential	O
455	##ly	O
455	removed	O
455	and	O
455	the	O
455	resulting	O
455	reduced	O
455	model	O
455	evaluated	O
455	to	O
455	determine	O
455	whether	O
455	there	O
455	was	O
455	significant	O
455	model	O
455	degradation	O
455	.	O
455	[SEP]	O
456	[CLS]	O
456	the	O
456	7	O
456	-	O
456	hour	O
456	separation	O
456	between	O
456	doses	O
456	was	O
456	selected	O
456	on	O
456	the	O
456	basis	O
456	of	O
456	the	O
456	p	O
456	##k	O
456	and	O
456	p	O
456	##d	O
456	profiles	O
456	obtained	O
456	in	O
456	regime	O
456	##ns	O
456	b	O
456	and	O
456	c	O
456	.	O
456	figure	O
456	1	O
456	shows	O
456	the	O
456	resulting	O
456	p	O
456	##k	O
456	profiles	O
456	and	O
456	table	O
456	2	O
456	the	O
456	corresponding	O
456	p	O
456	##k	O
456	parameters	O
456	.	O
456	[SEP]	O
457	[CLS]	O
457	plasma	O
457	was	O
457	collected	O
457	after	O
457	cent	O
457	##ri	O
457	##fu	O
457	##gt	O
457	##ation	O
457	and	O
457	stored	O
457	at	O
457	-	O
457	20	O
457	##°	O
457	##c	O
457	in	O
457	micro	O
457	##fu	O
457	##ge	O
457	tubes	O
457	until	O
457	analysis	O
457	.	O
457	[SEP]	O
458	[CLS]	O
458	in	O
458	addition	O
458	,	O
458	the	O
458	cm	B-PK
458	##ax	I-PK
458	and	O
458	au	B-PK
458	##c	I-PK
458	##last	I-PK
458	values	O
458	of	O
458	oral	O
458	hp	O
458	-	O
458	beta	O
458	-	O
458	c	O
458	##d	O
458	/	O
458	pm	O
458	##x	O
458	/	O
458	d	O
458	##ck	O
458	/	O
458	p	O
458	##18	O
458	##8	O
458	-	O
458	ne	O
458	(	O
458	equivalent	O
458	to	O
458	20	O
458	mg	O
458	/	O
458	kg	O
458	pm	O
458	##x	O
458	)	O
458	were	O
458	1	O
458	.	O
458	75	O
458	-	O
458	and	O
458	1	O
458	.	O
458	57	O
458	-	O
458	fold	O
458	greater	O
458	than	O
458	that	O
458	of	O
458	oral	O
458	hp	O
458	-	O
458	beta	O
458	-	O
458	c	O
458	##d	O
458	/	O
458	pm	O
458	##x	O
458	/	O
458	d	O
458	##ck	O
458	/	O
458	p	O
458	##18	O
458	##8	O
458	,	O
458	respectively	O
458	,	O
458	and	O
458	3	O
458	.	O
458	22	O
458	-	O
458	and	O
458	2	O
458	.	O
458	23	O
458	-	O
458	fold	O
458	greater	O
458	than	O
458	that	O
458	of	O
458	oral	O
458	pm	O
458	##x	O
458	solution	O
458	(	O
458	figure	O
458	9	O
458	##b	O
458	)	O
458	.	O
458	[SEP]	O
459	[CLS]	O
459	the	O
459	in	O
459	v	O
459	##ivo	O
459	he	B-PK
459	##pa	I-PK
459	##tic	I-PK
459	intrinsic	I-PK
459	clearance	I-PK
459	(	I-PK
459	c	I-PK
459	##lint	I-PK
459	##in	I-PK
459	##vi	I-PK
459	##vo	I-PK
459	)	I-PK
459	was	O
459	estimated	O
459	from	O
459	c	B-PK
459	##lint	I-PK
459	##in	I-PK
459	##vi	I-PK
459	##tro	I-PK
459	using	O
459	the	O
459	following	O
459	equation	O
459	:	O
459	(	O
459	5	O
459	)	O
459	c	O
459	##lint	O
459	##in	O
459	##vi	O
459	##vo	O
459	=	O
459	c	O
459	##lint	O
459	##in	O
459	##vi	O
459	##tro	O
459	##×	O
459	(	O
459	mg	O
459	##mic	O
459	##ros	O
459	##oma	O
459	##l	O
459	##p	O
459	##rote	O
459	##in	O
459	/	O
459	g	O
459	##li	O
459	##ver	O
459	)	O
459	×	O
459	(	O
459	g	O
459	##li	O
459	##ver	O
459	/	O
459	kg	O
459	##body	O
459	##weight	O
459	)	O
459	[SEP]	O
460	[CLS]	O
460	the	O
460	lower	O
460	bio	B-PK
460	##ava	I-PK
460	##ila	I-PK
460	##bility	I-PK
460	of	O
460	o	O
460	##dt	O
460	l	O
460	‐	O
460	p	O
460	##z	O
460	##q	O
460	,	O
460	as	O
460	well	O
460	as	O
460	the	O
460	high	O
460	var	O
460	##iability	O
460	and	O
460	non	O
460	##dos	O
460	##e	O
460	‐	O
460	proportional	O
460	##ity	O
460	of	O
460	p	O
460	##har	O
460	##ma	O
460	##co	O
460	##kin	O
460	##etic	O
460	(	O
460	p	O
460	##k	O
460	)	O
460	parameters	O
460	,	O
460	highlighted	O
460	the	O
460	need	O
460	for	O
460	a	O
460	dedicated	O
460	p	O
460	##ediatric	O
460	dose	O
460	‐	O
460	finding	O
460	study	O
460	for	O
460	the	O
460	selection	O
460	of	O
460	the	O
460	most	O
460	appropriate	O
460	formulation	O
460	and	O
460	dose	O
460	(	O
460	l	O
460	‐	O
460	p	O
460	##z	O
460	##q	O
460	o	O
460	##dt	O
460	or	O
460	r	O
460	##ac	O
460	‐	O
460	p	O
460	##z	O
460	##q	O
460	o	O
460	##dt	O
460	)	O
460	.	O
460	[SEP]	O
461	[CLS]	O
461	au	B-PK
461	##c	I-PK
461	boost	O
461	##ed	O
461	from	O
461	0	O
461	.	O
461	59	O
461	##3	O
461	(	O
461	set	O
461	20	O
461	)	O
461	to	O
461	0	O
461	.	O
461	82	O
461	##7	O
461	(	O
461	set	O
461	6	O
461	)	O
461	with	O
461	a	O
461	39	O
461	%	O
461	increase	O
461	and	O
461	from	O
461	0	O
461	.	O
461	62	O
461	##7	O
461	(	O
461	set	O
461	14	O
461	)	O
461	to	O
461	0	O
461	.	O
461	82	O
461	##7	O
461	(	O
461	set	O
461	6	O
461	)	O
461	with	O
461	a	O
461	32	O
461	%	O
461	increase	O
461	.	O
461	[SEP]	O
462	[CLS]	O
462	the	O
462	second	O
462	largest	O
462	improvement	O
462	in	O
462	au	B-PK
462	##c	I-PK
462	was	O
462	observed	O
462	when	O
462	integrating	O
462	p	O
462	##k	O
462	-	O
462	related	O
462	information	O
462	with	O
462	p	O
462	##d	O
462	-	O
462	related	O
462	information	O
462	.	O
462	[SEP]	O
463	[CLS]	O
463	when	O
463	adding	O
463	p	O
463	##d	O
463	-	O
463	related	O
463	information	O
463	to	O
463	the	O
463	enzyme	O
463	and	O
463	transport	O
463	##er	O
463	information	O
463	(	O
463	score	O
463	set	O
463	11	O
463	)	O
463	,	O
463	au	B-PK
463	##c	I-PK
463	jumped	O
463	from	O
463	0	O
463	.	O
463	65	O
463	##7	O
463	(	O
463	set	O
463	11	O
463	)	O
463	to	O
463	0	O
463	.	O
463	83	O
463	##4	O
463	(	O
463	set	O
463	3	O
463	)	O
463	with	O
463	a	O
463	27	O
463	%	O
463	increase	O
463	.	O
463	[SEP]	O
464	[CLS]	O
464	method	O
464	a	O
464	was	O
464	as	O
464	follows	O
464	:	O
464	the	O
464	separation	O
464	was	O
464	carried	O
464	out	O
464	on	O
464	a	O
464	waters	O
464	co	O
464	##rte	O
464	##cs	O
464	column	O
464	(	O
464	2	O
464	.	O
464	1	O
464	mm	O
464	×	O
464	150	O
464	mm	O
464	,	O
464	1	O
464	.	O
464	6	O
464	μ	O
464	##m	O
464	)	O
464	at	O
464	35	O
464	##°	O
464	##c	O
464	.	O
464	[SEP]	O
465	[CLS]	O
465	unless	O
465	stated	O
465	otherwise	O
465	,	O
465	normally	O
465	distributed	O
465	data	O
465	are	O
465	presented	O
465	as	O
465	mean	O
465	±	O
465	standard	O
465	de	O
465	##viation	O
465	,	O
465	and	O
465	as	O
465	median	O
465	(	O
465	inter	O
465	##qua	O
465	##rt	O
465	##ile	O
465	ranges	O
465	)	O
465	where	O
465	non	O
465	##nor	O
465	##mal	O
465	##ly	O
465	distributed	O
465	.	O
465	[SEP]	O
466	[CLS]	O
466	pu	O
466	##rified	O
466	h	O
466	##sa	O
466	was	O
466	injected	O
466	in	O
466	##tra	O
466	##ven	O
466	##ously	O
466	(	O
466	i	O
466	##v	O
466	)	O
466	at	O
466	10	O
466	mg	O
466	/	O
466	kg	O
466	into	O
466	7	O
466	age	O
466	and	O
466	sex	O
466	-	O
466	matched	O
466	t	O
466	##g	O
466	##32	O
466	-	O
466	al	O
466	##b	O
466	-	O
466	/	O
466	-	O
466	,	O
466	b	O
466	##6	O
466	-	O
466	al	O
466	##b	O
466	-	O
466	/	O
466	-	O
466	,	O
466	b	O
466	##6	O
466	.	O
466	129	O
466	##×	O
466	##1	O
466	-	O
466	f	O
466	##c	O
466	##g	O
466	##rt	O
466	##t	O
466	##m	O
466	##1	O
466	##d	O
466	##c	O
466	##r	O
466	/	O
466	d	O
466	##c	O
466	##r	O
466	##j	O
466	(	O
466	abbreviated	O
466	here	O
466	to	O
466	b	O
466	##6	O
466	-	O
466	m	O
466	##f	O
466	##c	O
466	##rna	O
466	-	O
466	/	O
466	-	O
466	)	O
466	,	O
466	t	O
466	##g	O
466	##32	O
466	and	O
466	b	O
466	##6	O
466	mice	O
466	.	O
466	[SEP]	O
467	[CLS]	O
467	participants	O
467	were	O
467	excluded	O
467	who	O
467	(	O
467	1	O
467	)	O
467	were	O
467	pregnant	O
467	,	O
467	trying	O
467	to	O
467	become	O
467	pregnant	O
467	,	O
467	or	O
467	breast	O
467	##fe	O
467	##eding	O
467	;	O
467	(	O
467	2	O
467	)	O
467	experienced	O
467	clinical	O
467	##ly	O
467	significant	O
467	illness	O
467	within	O
467	30	O
467	days	O
467	of	O
467	the	O
467	screening	O
467	examination	O
467	;	O
467	(	O
467	3	O
467	)	O
467	received	O
467	any	O
467	investigation	O
467	##al	O
467	drug	O
467	within	O
467	30	O
467	days	O
467	of	O
467	study	O
467	day	O
467	1	O
467	or	O
467	were	O
467	scheduled	O
467	to	O
467	receive	O
467	any	O
467	investigation	O
467	##al	O
467	drug	O
467	during	O
467	the	O
467	course	O
467	of	O
467	the	O
467	study	O
467	;	O
467	(	O
467	4	O
467	)	O
467	participated	O
467	in	O
467	a	O
467	previous	O
467	study	O
467	of	O
467	the	O
467	same	O
467	product	O
467	;	O
467	(	O
467	5	O
467	)	O
467	had	O
467	a	O
467	history	O
467	of	O
467	any	O
467	condition	O
467	that	O
467	could	O
467	possibly	O
467	affect	O
467	the	O
467	absorption	O
467	of	O
467	the	O
467	drug	O
467	,	O
467	such	O
467	as	O
467	p	O
467	##ept	O
467	##ic	O
467	ul	O
467	##cer	O
467	disease	O
467	,	O
467	gas	O
467	##tre	O
467	##ct	O
467	##omy	O
467	,	O
467	or	O
467	in	O
467	##test	O
467	##inal	O
467	ma	O
467	##la	O
467	##bs	O
467	##or	O
467	##ption	O
467	;	O
467	(	O
467	6	O
467	)	O
467	had	O
467	a	O
467	history	O
467	of	O
467	an	O
467	##emia	O
467	,	O
467	iron	O
467	deficiency	O
467	,	O
467	or	O
467	iron	O
467	de	O
467	##ple	O
467	##tion	O
467	;	O
467	(	O
467	7	O
467	)	O
467	were	O
467	im	O
467	##mu	O
467	##no	O
467	##com	O
467	##p	O
467	##rom	O
467	##ised	O
467	or	O
467	had	O
467	a	O
467	history	O
467	of	O
467	drug	O
467	all	O
467	##er	O
467	##gies	O
467	;	O
467	(	O
467	8	O
467	)	O
467	presented	O
467	with	O
467	an	O
467	e	O
467	##c	O
467	##g	O
467	abnormal	O
467	##ity	O
467	or	O
467	e	O
467	##c	O
467	##g	O
467	findings	O
467	deemed	O
467	clinical	O
467	##ly	O
467	relevant	O
467	;	O
467	(	O
467	9	O
467	)	O
467	had	O
467	a	O
467	q	O
467	##t	O
467	interval	O
467	corrected	O
467	for	O
467	heart	O
467	rate	O
467	(	O
467	f	O
467	##ride	O
467	##ric	O
467	##ia	O
467	’	O
467	s	O
467	correction	O
467	formula	O
467	,	O
467	q	O
467	##t	O
467	##c	O
467	##f	O
467	)	O
467	>	O
467	450	O
467	m	O
467	##s	O
467	;	O
467	(	O
467	10	O
467	)	O
467	had	O
467	a	O
467	clinical	O
467	##ly	O
467	relevant	O
467	history	O
467	or	O
467	presence	O
467	of	O
467	respiratory	O
467	,	O
467	gas	O
467	##tro	O
467	##int	O
467	##est	O
467	##inal	O
467	,	O
467	re	O
467	##nal	O
467	,	O
467	he	O
467	##pa	O
467	##tic	O
467	,	O
467	hem	O
467	##ato	O
467	##log	O
467	##ic	O
467	,	O
467	l	O
467	##ymph	O
467	##atic	O
467	,	O
467	ne	O
467	##uro	O
467	##logical	O
467	,	O
467	card	O
467	##iovascular	O
467	,	O
467	psychiatric	O
467	,	O
467	m	O
467	##us	O
467	##cu	O
467	##los	O
467	##kel	O
467	##etal	O
467	,	O
467	g	O
467	##eni	O
467	##tour	O
467	##ina	O
467	##ry	O
467	,	O
467	im	O
467	##mu	O
467	##no	O
467	##log	O
467	##ic	O
467	,	O
467	der	O
467	##mat	O
467	##olo	O
467	##gic	O
467	,	O
467	or	O
467	connect	O
467	##ive	O
467	tissue	O
467	disease	O
467	or	O
467	disorders	O
467	;	O
467	(	O
467	11	O
467	)	O
467	had	O
467	a	O
467	known	O
467	into	O
467	##ler	O
467	##ance	O
467	to	O
467	the	O
467	product	O
467	’	O
467	s	O
467	ingredients	O
467	;	O
467	or	O
467	(	O
467	12	O
467	)	O
467	had	O
467	donated	O
467	blood	O
467	or	O
467	had	O
467	significant	O
467	(	O
467	≥	O
467	##25	O
467	##0	O
467	m	O
467	##l	O
467	)	O
467	blood	O
467	loss	O
467	within	O
467	30	O
467	days	O
467	of	O
467	dos	O
467	##ing	O
467	or	O
467	had	O
467	donated	O
467	plasma	O
467	within	O
467	7	O
467	days	O
467	of	O
467	dos	O
467	##ing	O
467	.	O
467	[SEP]	O
468	[CLS]	O
468	after	O
468	leaving	O
468	the	O
468	chamber	O
468	,	O
468	full	O
468	volumes	O
468	of	O
468	urine	O
468	were	O
468	collected	O
468	for	O
468	each	O
468	u	O
468	##rina	O
468	##tion	O
468	over	O
468	the	O
468	next	O
468	48	O
468	h	O
468	.	O
468	[SEP]	O
469	[CLS]	O
469	the	O
469	urine	O
469	was	O
469	subsequently	O
469	analyzed	O
469	for	O
469	d	O
469	##n	O
469	##b	O
469	##p	O
469	meta	O
469	##bol	O
469	##ites	O
469	,	O
469	mon	O
469	##o	O
469	-	O
469	n	O
469	-	O
469	but	O
469	##yl	O
469	p	O
469	##ht	O
469	##hala	O
469	##te	O
469	(	O
469	m	O
469	##n	O
469	##b	O
469	##p	O
469	)	O
469	,	O
469	and	O
469	3	O
469	-	O
469	h	O
469	##ydro	O
469	##xy	O
469	-	O
469	mon	O
469	##o	O
469	-	O
469	n	O
469	-	O
469	but	O
469	##yl	O
469	p	O
469	##ht	O
469	##hala	O
469	##te	O
469	(	O
469	3	O
469	##oh	O
469	-	O
469	m	O
469	##n	O
469	##b	O
469	##p	O
469	)	O
469	.	O
469	[SEP]	O
470	[CLS]	O
470	l	O
470	##c	O
470	-	O
470	m	O
470	##s	O
470	-	O
470	grade	O
470	solvent	O
470	##s	O
470	,	O
470	ace	O
470	##ton	O
470	##it	O
470	##ril	O
470	##e	O
470	and	O
470	is	O
470	##op	O
470	##rop	O
470	##ano	O
470	##l	O
470	,	O
470	and	O
470	what	O
470	##man	O
470	##®	O
470	protein	O
470	save	O
470	##r	O
470	cards	O
470	90	O
470	##3	O
470	were	O
470	purchased	O
470	from	O
470	me	O
470	##rc	O
470	##k	O
470	kg	O
470	##aa	O
470	(	O
470	da	O
470	##rms	O
470	##tadt	O
470	,	O
470	g	O
470	##erman	O
470	##y	O
470	)	O
470	.	O
470	[SEP]	O
471	[CLS]	O
471	the	O
471	results	O
471	from	O
471	non	O
471	##com	O
471	##par	O
471	##tment	O
471	##al	O
471	and	O
471	traditional	O
471	compartment	O
471	##al	O
471	analyses	O
471	were	O
471	ta	O
471	##bula	O
471	##ted	O
471	in	O
471	tables	O
471	2	O
471	,	O
471	3	O
471	,	O
471	together	O
471	with	O
471	the	O
471	p	O
471	##k	O
471	parameter	O
471	values	O
471	reported	O
471	from	O
471	the	O
471	original	O
471	manuscripts	O
471	.	O
471	[SEP]	O
472	[CLS]	O
472	figure	O
472	6	O
472	shows	O
472	the	O
472	distribution	O
472	of	O
472	g	O
472	##ado	O
472	##lini	O
472	##um	O
472	in	O
472	urine	O
472	,	O
472	liver	O
472	,	O
472	and	O
472	blood	O
472	at	O
472	60	O
472	min	O
472	after	O
472	the	O
472	administration	O
472	of	O
472	the	O
472	new	O
472	ca	O
472	##s	O
472	.	O
472	[SEP]	O
473	[CLS]	O
473	samples	O
473	(	O
473	2	O
473	m	O
473	##l	O
473	)	O
473	were	O
473	removed	O
473	at	O
473	various	O
473	time	O
473	intervals	O
473	and	O
473	filtered	O
473	using	O
473	a	O
473	1	O
473	.	O
473	2	O
473	µ	O
473	##m	O
473	s	O
473	##yr	O
473	##inge	O
473	filter	O
473	.	O
473	[SEP]	O
474	[CLS]	O
474	the	O
474	v	O
474	##ou	O
474	##cher	O
474	specimens	O
474	were	O
474	deposited	O
474	at	O
474	the	O
474	herb	O
474	##arium	O
474	of	O
474	the	O
474	ch	O
474	##eng	O
474	##du	O
474	q	O
474	##ih	O
474	##uang	O
474	bio	O
474	-	O
474	tech	O
474	institute	O
474	(	O
474	ch	O
474	##eng	O
474	##du	O
474	,	O
474	chin	O
474	##a	O
474	)	O
474	.	O
474	[SEP]	O
475	[CLS]	O
475	s	O
475	##med	O
475	##ds	O
475	using	O
475	c	O
475	##rem	O
475	##op	O
475	##hor	O
475	r	O
475	##h	O
475	40	O
475	as	O
475	a	O
475	surf	O
475	##act	O
475	##ant	O
475	without	O
475	bi	O
475	##le	O
475	salts	O
475	possessed	O
475	good	O
475	self	O
475	-	O
475	micro	O
475	##em	O
475	##ul	O
475	##si	O
475	##fying	O
475	performance	O
475	after	O
475	a	O
475	100	O
475	-	O
475	fold	O
475	di	O
475	##lution	O
475	with	O
475	dei	O
475	##onized	O
475	water	O
475	,	O
475	and	O
475	retained	O
475	a	O
475	transparent	O
475	blue	O
475	–	O
475	op	O
475	##ales	O
475	##cent	O
475	appearance	O
475	.	O
475	[SEP]	O
476	[CLS]	O
476	all	O
476	herbs	O
476	,	O
476	commercially	O
476	available	O
476	as	O
476	dried	O
476	matter	O
476	,	O
476	were	O
476	purchased	O
476	from	O
476	sic	O
476	##hua	O
476	##n	O
476	ben	O
476	##ca	O
476	##ota	O
476	##ng	O
476	pharmaceutical	O
476	co	O
476	.	O
476	,	O
476	l	O
476	##t	O
476	##d	O
476	.	O
476	(	O
476	ch	O
476	##eng	O
476	##du	O
476	,	O
476	chin	O
476	##a	O
476	)	O
476	.	O
476	[SEP]	O
477	[CLS]	O
477	statistical	O
477	significance	O
477	was	O
477	assessed	O
477	by	O
477	un	O
477	##pair	O
477	##ed	O
477	student	O
477	′	O
477	s	O
477	t	O
477	test	O
477	or	O
477	one	O
477	-	O
477	way	O
477	analysis	O
477	of	O
477	variance	O
477	(	O
477	an	O
477	##ova	O
477	)	O
477	with	O
477	post	O
477	ho	O
477	##c	O
477	analysis	O
477	using	O
477	t	O
477	##uke	O
477	##y	O
477	′	O
477	s	O
477	multiple	O
477	comparison	O
477	test	O
477	for	O
477	para	O
477	##metric	O
477	data	O
477	.	O
477	[SEP]	O
478	[CLS]	O
478	serum	O
478	samples	O
478	were	O
478	prepared	O
478	by	O
478	c	O
478	##lot	O
478	##ting	O
478	at	O
478	room	O
478	temperature	O
478	,	O
478	and	O
478	then	O
478	cent	O
478	##ri	O
478	##fu	O
478	##ged	O
478	for	O
478	15	O
478	min	O
478	.	O
478	[SEP]	O
479	[CLS]	O
479	the	O
479	other	O
479	procedures	O
479	were	O
479	the	O
479	same	O
479	used	O
479	in	O
479	t	O
479	##r	O
479	q	O
479	##uant	O
479	##ification	O
479	.	O
479	[SEP]	O
480	[CLS]	O
480	a	O
480	g	O
480	##yr	O
480	##ola	O
480	##b	O
480	x	O
480	##p	O
480	ass	O
480	##ay	O
480	was	O
480	used	O
480	to	O
480	q	O
480	##uant	O
480	##ify	O
480	f	O
480	##ab	O
480	concentrations	O
480	in	O
480	c	O
480	##yn	O
480	##o	O
480	monkey	O
480	v	O
480	##it	O
480	##re	O
480	##ous	O
480	humor	O
480	.	O
480	[SEP]	O
481	[CLS]	O
481	comparisons	O
481	between	O
481	groups	O
481	were	O
481	assessed	O
481	with	O
481	man	O
481	##n	O
481	–	O
481	w	O
481	##hit	O
481	##ney	O
481	test	O
481	,	O
481	and	O
481	correlation	O
481	##s	O
481	with	O
481	spear	O
481	##man	O
481	coefficient	O
481	.	O
481	[SEP]	O
482	[CLS]	O
482	the	O
482	activities	O
482	against	O
482	liver	O
482	and	O
482	insect	O
482	stages	O
482	were	O
482	not	O
482	determined	O
482	.	O
482	[SEP]	O
483	[CLS]	O
483	the	O
483	instrument	O
483	was	O
483	run	O
483	and	O
483	data	O
483	analyzed	O
483	as	O
483	described	O
483	by	O
483	the	O
483	manufacturer	O
483	with	O
483	a	O
483	1	O
483	%	O
483	pm	O
483	##t	O
483	setting	O
483	.	O
483	[SEP]	O
484	[CLS]	O
484	this	O
484	was	O
484	a	O
484	phase	O
484	i	O
484	##v	O
484	open	O
484	-	O
484	label	O
484	,	O
484	prospective	O
484	study	O
484	conducted	O
484	in	O
484	9	O
484	centers	O
484	(	O
484	4	O
484	countries	O
484	)	O
484	.	O
484	[SEP]	O
485	[CLS]	O
485	for	O
485	que	O
485	##tia	O
485	##pine	O
485	x	O
485	##r	O
485	,	O
485	samples	O
485	were	O
485	drawn	O
485	pre	O
485	-	O
485	dose	O
485	and	O
485	at	O
485	0	O
485	.	O
485	5	O
485	,	O
485	1	O
485	,	O
485	2	O
485	,	O
485	3	O
485	,	O
485	4	O
485	,	O
485	5	O
485	,	O
485	5	O
485	.	O
485	5	O
485	,	O
485	6	O
485	,	O
485	8	O
485	,	O
485	12	O
485	,	O
485	24	O
485	and	O
485	25	O
485	h	O
485	post	O
485	-	O
485	dose	O
485	.	O
485	[SEP]	O
486	[CLS]	O
486	inclusion	O
486	criteria	O
486	included	O
486	admission	O
486	to	O
486	the	O
486	i	O
486	##cu	O
486	,	O
486	ca	O
486	##sp	O
486	##of	O
486	##ung	O
486	##in	O
486	therapy	O
486	for	O
486	suspected	O
486	or	O
486	proven	O
486	infection	O
486	or	O
486	for	O
486	prop	O
486	##hyl	O
486	##ax	O
486	##is	O
486	,	O
486	age	O
486	>	O
486	18	O
486	years	O
486	when	O
486	starting	O
486	ca	O
486	##sp	O
486	##of	O
486	##ung	O
486	##in	O
486	,	O
486	started	O
486	therapy	O
486	a	O
486	maximum	O
486	of	O
486	2	O
486	days	O
486	before	O
486	inclusion	O
486	,	O
486	and	O
486	management	O
486	with	O
486	a	O
486	central	O
486	ve	O
486	##nous	O
486	cat	O
486	##he	O
486	##ter	O
486	.	O
486	[SEP]	O
487	[CLS]	O
487	in	O
487	marked	O
487	contrast	O
487	,	O
487	the	O
487	neutral	O
487	(	O
487	te	O
487	##go	O
487	##h	O
487	)	O
487	and	O
487	z	O
487	##wi	O
487	##tter	O
487	##ion	O
487	##ic	O
487	(	O
487	t	O
487	##z	O
487	##wi	O
487	##t	O
487	)	O
487	au	O
487	##n	O
487	##ps	O
487	rapidly	O
487	entered	O
487	into	O
487	circulation	O
487	,	O
487	with	O
487	peak	B-PK
487	concentrations	I-PK
487	above	O
487	10	O
487	µ	O
487	##g	O
487	/	O
487	m	O
487	##l	O
487	achieved	O
487	1	O
487	.	O
487	5	O
487	and	O
487	3	O
487	hours	O
487	,	O
487	respectively	O
487	.	O
487	[SEP]	O
488	[CLS]	O
488	the	O
488	differences	O
488	in	O
488	sampling	O
488	times	O
488	for	O
488	the	O
488	two	O
488	formulation	O
488	##s	O
488	were	O
488	to	O
488	allow	O
488	for	O
488	dense	O
488	sampling	O
488	at	O
488	expected	O
488	t	B-PK
488	##max	I-PK
488	.	O
488	[SEP]	O
489	[CLS]	O
489	as	O
489	with	O
489	the	O
489	i	O
489	##v	O
489	injection	O
489	,	O
489	plasma	O
489	concentrations	O
489	of	O
489	the	O
489	neutral	O
489	(	O
489	te	O
489	##go	O
489	##h	O
489	)	O
489	and	O
489	z	O
489	##wi	O
489	##tter	O
489	##ion	O
489	##ic	O
489	(	O
489	t	O
489	##z	O
489	##wi	O
489	##t	O
489	)	O
489	au	O
489	##n	O
489	##ps	O
489	remained	O
489	above	O
489	1	O
489	µ	O
489	##g	O
489	/	O
489	m	O
489	##l	O
489	24	O
489	hours	O
489	after	O
489	injection	O
489	(	O
489	figure	O
489	2	O
489	##b	O
489	)	O
489	and	O
489	bio	B-PK
489	##ava	I-PK
489	##ila	I-PK
489	##bility	I-PK
489	values	O
489	for	O
489	these	O
489	au	O
489	##n	O
489	##p	O
489	were	O
489	high	O
489	(	O
489	77	O
489	%	O
489	and	O
489	70	O
489	%	O
489	,	O
489	respectively	O
489	)	O
489	.	O
489	[SEP]	O
490	[CLS]	O
490	the	O
490	addition	O
490	of	O
490	co	O
490	##var	O
490	##iate	O
490	##s	O
490	into	O
490	the	O
490	model	O
490	was	O
490	continued	O
490	until	O
490	a	O
490	decrease	O
490	of	O
490	3	O
490	.	O
490	84	O
490	could	O
490	not	O
490	be	O
490	reached	O
490	any	O
490	longer	O
490	.	O
490	[SEP]	O
491	[CLS]	O
491	for	O
491	que	O
491	##tia	O
491	##pine	O
491	i	O
491	##r	O
491	,	O
491	samples	O
491	were	O
491	obtained	O
491	pre	O
491	-	O
491	dose	O
491	and	O
491	at	O
491	0	O
491	.	O
491	5	O
491	,	O
491	1	O
491	,	O
491	1	O
491	.	O
491	5	O
491	,	O
491	2	O
491	,	O
491	2	O
491	.	O
491	5	O
491	,	O
491	5	O
491	,	O
491	11	O
491	,	O
491	24	O
491	and	O
491	25	O
491	h	O
491	post	O
491	-	O
491	dose	O
491	.	O
491	[SEP]	O
492	[CLS]	O
492	plasma	O
492	concentrations	O
492	were	O
492	nearly	O
492	identical	O
492	for	O
492	all	O
492	patients	O
492	,	O
492	regardless	O
492	of	O
492	age	O
492	group	O
492	,	O
492	for	O
492	both	O
492	dose	O
492	levels	O
492	tested	O
492	,	O
492	which	O
492	may	O
492	be	O
492	due	O
492	to	O
492	an	O
492	extensive	O
492	overlap	O
492	between	O
492	the	O
492	g	O
492	##eria	O
492	##tric	O
492	(	O
492	>	O
492	65	O
492	years	O
492	)	O
492	and	O
492	p	O
492	##k	O
492	populations	O
492	(	O
492	refer	O
492	to	O
492	sample	O
492	size	O
492	table	O
492	,	O
492	figure	O
492	4	O
492	)	O
492	.	O
492	[SEP]	O
493	[CLS]	O
493	c	O
493	##p	O
493	##0	O
493	##24	O
493	was	O
493	administered	O
493	as	O
493	two	O
493	different	O
493	formulation	O
493	##s	O
493	(	O
493	a	O
493	and	O
493	b	O
493	)	O
493	at	O
493	a	O
493	dose	O
493	of	O
493	5	O
493	mg	O
493	per	O
493	no	O
493	##st	O
493	##ril	O
493	once	O
493	daily	O
493	compared	O
493	with	O
493	the	O
493	same	O
493	h	O
493	##gh	O
493	dose	O
493	administered	O
493	nasal	O
493	##ly	O
493	as	O
493	a	O
493	simple	O
493	solution	O
493	(	O
493	without	O
493	the	O
493	critical	O
493	##sor	O
493	##b	O
493	absorption	O
493	enhance	O
493	##r	O
493	)	O
493	and	O
493	1	O
493	mg	O
493	h	O
493	##gh	O
493	s	O
493	##c	O
493	.	O
493	[SEP]	O
494	[CLS]	O
494	therefore	O
494	,	O
494	the	O
494	relative	B-PK
494	bio	I-PK
494	##ava	I-PK
494	##ila	I-PK
494	##bility	I-PK
494	of	O
494	c	O
494	##p	O
494	##0	O
494	##24	O
494	is	O
494	likely	O
494	to	O
494	be	O
494	an	O
494	under	O
494	##est	O
494	##imate	O
494	of	O
494	the	O
494	true	B-PK
494	bio	I-PK
494	##ava	I-PK
494	##ila	I-PK
494	##bility	I-PK
494	.	O
494	[SEP]	O
495	[CLS]	O
495	data	O
495	are	O
495	presented	O
495	as	O
495	peaks	O
495	,	O
495	and	O
495	the	O
495	au	B-PK
495	##c	I-PK
495	represents	O
495	the	O
495	percentage	O
495	of	O
495	host	O
495	-	O
495	versus	O
495	-	O
495	donor	O
495	hem	O
495	##ato	O
495	##po	O
495	##ies	O
495	##is	O
495	.	O
495	[SEP]	O
496	[CLS]	O
496	the	O
496	plasma	O
496	el	O
496	##ob	O
496	##ix	O
496	##iba	O
496	##t	O
496	concentration	O
496	after	O
496	breakfast	O
496	was	O
496	much	O
496	lower	O
496	than	O
496	in	O
496	the	O
496	fast	O
496	##ed	O
496	state	O
496	,	O
496	and	O
496	there	O
496	was	O
496	no	O
496	major	O
496	difference	O
496	in	O
496	t	B-PK
496	##1	I-PK
496	/	I-PK
496	2	I-PK
496	(	O
496	figure	O
496	3	O
496	)	O
496	.	O
496	[SEP]	O
497	[CLS]	O
497	the	O
497	mean	O
497	areas	B-PK
497	under	I-PK
497	the	I-PK
497	en	I-PK
497	##rich	I-PK
497	##ment	I-PK
497	-	I-PK
497	time	I-PK
497	curve	I-PK
497	before	O
497	and	O
497	after	O
497	nutrition	O
497	##al	O
497	rehabilitation	O
497	were	O
497	0	O
497	.	O
497	53	O
497	##9	O
497	##±	O
497	##0	O
497	.	O
497	320	O
497	and	O
497	0	O
497	.	O
497	620	O
497	##±	O
497	##0	O
497	.	O
497	322	O
497	atom	O
497	per	O
497	cent	O
497	excess	O
497	minute	O
497	,	O
497	respectively	O
497	.	O
497	[SEP]	O
498	[CLS]	O
498	a	O
498	mixed	O
498	random	O
498	effects	O
498	model	O
498	demonstrated	O
498	significant	O
498	sequence	O
498	effects	O
498	for	O
498	both	O
498	ne	O
498	##vir	O
498	##ap	O
498	##ine	O
498	log	O
498	transformed	O
498	cm	B-PK
498	##ax	I-PK
498	(	O
498	p	O
498	<	O
498	0	O
498	.	O
498	000	O
498	##1	O
498	)	O
498	and	O
498	au	B-PK
498	##c	I-PK
498	(	O
498	p	O
498	<	O
498	0	O
498	.	O
498	000	O
498	##1	O
498	)	O
498	as	O
498	outcomes	O
498	.	O
498	[SEP]	O
499	[CLS]	O
499	inter	O
499	##su	O
499	##bject	O
499	var	O
499	##iability	O
499	for	O
499	log	O
499	transformed	O
499	cm	B-PK
499	##ax	I-PK
499	ranged	O
499	from	O
499	0	O
499	.	O
499	24	O
499	–	O
499	0	O
499	.	O
499	40	O
499	and	O
499	that	O
499	for	O
499	au	B-PK
499	##c	I-PK
499	ranged	O
499	from	O
499	0	O
499	.	O
499	23	O
499	–	O
499	0	O
499	.	O
499	42	O
499	.	O
499	[SEP]	O
500	[CLS]	O
500	in	O
500	##tras	O
500	##ub	O
500	##ject	O
500	var	O
500	##iability	O
500	for	O
500	cm	B-PK
500	##ax	I-PK
500	ranged	O
500	from	O
500	0	O
500	.	O
500	21	O
500	–	O
500	0	O
500	.	O
500	44	O
500	and	O
500	au	B-PK
500	##c	I-PK
500	ranged	O
500	from	O
500	0	O
500	.	O
500	25	O
500	–	O
500	0	O
500	.	O
500	36	O
500	(	O
500	table	O
500	4	O
500	)	O
500	.	O
500	[SEP]	O
501	[CLS]	O
501	inter	O
501	##su	O
501	##bject	O
501	var	O
501	##iability	O
501	accounts	O
501	for	O
501	approximately	O
501	half	O
501	of	O
501	the	O
501	var	O
501	##iability	O
501	in	O
501	the	O
501	cm	B-PK
501	##ax	I-PK
501	and	O
501	au	B-PK
501	##c	I-PK
501	estimates	O
501	.	O
501	[SEP]	O
502	[CLS]	O
502	regarding	O
502	the	O
502	in	O
502	v	O
502	##ivo	O
502	oral	O
502	absorption	O
502	in	O
502	rats	O
502	,	O
502	the	O
502	pm	O
502	##x	O
502	in	O
502	plasma	O
502	concentration	O
502	–	O
502	time	O
502	profiles	O
502	following	O
502	i	O
502	##v	O
502	and	O
502	oral	O
502	administration	O
502	are	O
502	shown	O
502	in	O
502	figure	O
502	9	O
502	.	O
502	[SEP]	O
503	[CLS]	O
503	after	O
503	oral	O
503	administration	O
503	of	O
503	20	O
503	mg	O
503	/	O
503	kg	O
503	pm	O
503	##x	O
503	alone	O
503	,	O
503	the	O
503	maximum	B-PK
503	plasma	I-PK
503	concentration	I-PK
503	(	I-PK
503	cm	I-PK
503	##ax	I-PK
503	)	I-PK
503	attained	O
503	was	O
503	1	O
503	.	O
503	49	O
503	##±	O
503	##0	O
503	.	O
503	33	O
503	##2	O
503	μ	O
503	##g	O
503	/	O
503	m	O
503	##l	O
503	,	O
503	the	O
503	area	B-PK
503	under	I-PK
503	the	I-PK
503	plasma	I-PK
503	concentration	I-PK
503	–	I-PK
503	time	I-PK
503	curve	I-PK
503	(	I-PK
503	au	I-PK
503	##c	I-PK
503	##last	I-PK
503	)	I-PK
503	was	O
503	7	O
503	.	O
503	55	O
503	##±	O
503	##0	O
503	.	O
503	93	O
503	##8	O
503	μ	O
503	##g	O
503	·	O
503	h	O
503	/	O
503	m	O
503	##l	O
503	,	O
503	and	O
503	the	O
503	oral	B-PK
503	bio	I-PK
503	##ava	I-PK
503	##ila	I-PK
503	##bility	I-PK
503	(	O
503	compared	O
503	with	O
503	the	O
503	i	O
503	##v	O
503	dose	O
503	)	O
503	was	O
503	12	O
503	.	O
503	0	O
503	%	O
503	±	O
503	##1	O
503	.	O
503	45	O
503	%	O
503	.	O
503	[SEP]	O
504	[CLS]	O
504	however	O
504	,	O
504	compared	O
504	with	O
504	the	O
504	oral	O
504	administration	O
504	of	O
504	pm	O
504	##x	O
504	alone	O
504	,	O
504	oral	O
504	hp	O
504	-	O
504	beta	O
504	-	O
504	c	O
504	##d	O
504	/	O
504	pm	O
504	##x	O
504	/	O
504	d	O
504	##ck	O
504	/	O
504	p	O
504	##18	O
504	##8	O
504	(	O
504	equivalent	O
504	to	O
504	20	O
504	mg	O
504	/	O
504	kg	O
504	pm	O
504	##x	O
504	)	O
504	afforded	O
504	a	O
504	1	O
504	.	O
504	85	O
504	-	O
504	fold	O
504	increase	O
504	in	O
504	cm	B-PK
504	##ax	I-PK
504	(	O
504	2	O
504	.	O
504	75	O
504	##±	O
504	##0	O
504	.	O
504	79	O
504	##3	O
504	μ	O
504	##g	O
504	/	O
504	m	O
504	##l	O
504	)	O
504	and	O
504	a	O
504	1	O
504	.	O
504	42	O
504	-	O
504	fold	O
504	increase	O
504	in	O
504	au	B-PK
504	##c	I-PK
504	##last	I-PK
504	(	O
504	10	O
504	.	O
504	7	O
504	##±	O
504	##0	O
504	.	O
504	84	O
504	##9	O
504	μ	O
504	##g	O
504	·	O
504	h	O
504	/	O
504	m	O
504	##l	O
504	)	O
504	,	O
504	resulting	O
504	in	O
504	a	O
504	1	O
504	.	O
504	42	O
504	-	O
504	fold	O
504	increase	O
504	in	O
504	oral	B-PK
504	bio	I-PK
504	##ava	I-PK
504	##ila	I-PK
504	##bility	I-PK
504	(	O
504	17	O
504	.	O
504	0	O
504	%	O
504	±	O
504	##1	O
504	.	O
504	35	O
504	%	O
504	;	O
504	table	O
504	2	O
504	)	O
504	.	O
504	[SEP]	O
505	[CLS]	O
505	the	O
505	time	B-PK
505	to	I-PK
505	maximum	I-PK
505	concentration	I-PK
505	(	I-PK
505	t	I-PK
505	##max	I-PK
505	)	I-PK
505	values	O
505	were	O
505	2	O
505	.	O
505	75	O
505	##±	O
505	##3	O
505	.	O
505	50	O
505	and	O
505	0	O
505	.	O
505	900	O
505	##±	O
505	##0	O
505	.	O
505	224	O
505	h	O
505	after	O
505	oral	O
505	administration	O
505	of	O
505	free	O
505	pm	O
505	##x	O
505	or	O
505	hp	O
505	-	O
505	beta	O
505	-	O
505	c	O
505	##d	O
505	/	O
505	pm	O
505	##x	O
505	/	O
505	d	O
505	##ck	O
505	/	O
505	p	O
505	##18	O
505	##8	O
505	-	O
505	ne	O
505	,	O
505	respectively	O
505	,	O
505	implying	O
505	that	O
505	the	O
505	pm	O
505	##x	O
505	/	O
505	d	O
505	##ck	O
505	complex	O
505	was	O
505	quickly	O
505	released	O
505	from	O
505	the	O
505	na	O
505	##no	O
505	##em	O
505	##ul	O
505	##sion	O
505	to	O
505	per	O
505	##me	O
505	##ate	O
505	through	O
505	the	O
505	in	O
505	##test	O
505	##inal	O
505	membrane	O
505	.	O
505	[SEP]	O
506	[CLS]	O
506	such	O
506	rapid	O
506	absorption	O
506	may	O
506	be	O
506	at	O
506	##tri	O
506	##but	O
506	##able	O
506	to	O
506	the	O
506	enhanced	O
506	membrane	O
506	per	B-PK
506	##me	I-PK
506	##ability	I-PK
506	of	O
506	the	O
506	pm	O
506	##x	O
506	/	O
506	d	O
506	##ck	O
506	complex	O
506	,	O
506	without	O
506	any	O
506	decrease	O
506	in	O
506	the	O
506	so	O
506	##lub	O
506	##ility	O
506	of	O
506	pm	O
506	##x	O
506	,	O
506	after	O
506	incorporation	O
506	of	O
506	hp	O
506	-	O
506	beta	O
506	-	O
506	c	O
506	##d	O
506	/	O
506	pm	O
506	##x	O
506	/	O
506	d	O
506	##ck	O
506	/	O
506	p	O
506	##18	O
506	##8	O
506	into	O
506	na	O
506	##no	O
506	-	O
506	sized	O
506	drop	O
506	##lets	O
506	.	O
506	[SEP]	O
507	[CLS]	O
507	however	O
507	,	O
507	the	O
507	terminal	B-PK
507	elimination	I-PK
507	half	I-PK
507	-	I-PK
507	lives	I-PK
507	(	I-PK
507	t	I-PK
507	##1	I-PK
507	/	I-PK
507	2	I-PK
507	values	I-PK
507	)	I-PK
507	after	O
507	oral	O
507	administration	O
507	of	O
507	pm	O
507	##x	O
507	,	O
507	hp	O
507	-	O
507	beta	O
507	-	O
507	c	O
507	##d	O
507	/	O
507	pm	O
507	##x	O
507	/	O
507	d	O
507	##ck	O
507	/	O
507	p	O
507	##18	O
507	##8	O
507	,	O
507	and	O
507	hp	O
507	-	O
507	beta	O
507	-	O
507	c	O
507	##d	O
507	/	O
507	pm	O
507	##x	O
507	/	O
507	d	O
507	##ck	O
507	/	O
507	p	O
507	##18	O
507	##8	O
507	-	O
507	ne	O
507	(	O
507	alone	O
507	)	O
507	were	O
507	significantly	O
507	longer	O
507	than	O
507	those	O
507	after	O
507	i	O
507	##v	O
507	administration	O
507	.	O
507	[SEP]	O
508	[CLS]	O
508	tan	O
508	possessed	O
508	a	O
508	moderate	O
508	apparent	B-PK
508	volume	I-PK
508	of	I-PK
508	distribution	I-PK
508	of	I-PK
508	the	I-PK
508	central	I-PK
508	compartment	I-PK
508	(	I-PK
508	v	I-PK
508	##c	I-PK
508	=	O
508	4	O
508	.	O
508	20	O
508	±	O
508	0	O
508	.	O
508	82	O
508	l	O
508	/	O
508	kg	O
508	)	O
508	,	O
508	a	O
508	rapid	O
508	clearance	B-PK
508	(	I-PK
508	c	I-PK
508	##l	I-PK
508	=	O
508	94	O
508	.	O
508	1	O
508	±	O
508	20	O
508	.	O
508	2	O
508	m	O
508	##l	O
508	/	O
508	min	O
508	/	O
508	kg	O
508	)	O
508	and	O
508	a	O
508	moderate	O
508	terminal	B-PK
508	elimination	I-PK
508	half	I-PK
508	-	I-PK
508	life	I-PK
508	(	I-PK
508	t	I-PK
508	##1	I-PK
508	/	I-PK
508	2	I-PK
508	λ	I-PK
508	##z	I-PK
508	=	O
508	166	O
508	±	O
508	42	O
508	min	O
508	)	O
508	.	O
508	[SEP]	O
509	[CLS]	O
509	its	O
509	c	B-PK
509	##l	I-PK
509	value	O
509	exceeded	O
509	the	O
509	he	B-PK
509	##pa	I-PK
509	##tic	I-PK
509	blood	I-PK
509	flow	I-PK
509	rate	I-PK
509	,	O
509	indicating	O
509	the	O
509	involvement	O
509	of	O
509	extra	O
509	-	O
509	he	O
509	##pa	O
509	##tic	O
509	elimination	O
509	of	O
509	tan	O
509	.	O
509	[SEP]	O
510	[CLS]	O
510	θ	O
510	##t	O
510	##v	O
510	##p	O
510	is	O
510	an	O
510	estimated	O
510	parameter	O
510	describing	O
510	the	O
510	typical	O
510	p	O
510	##har	O
510	##ma	O
510	##co	O
510	##kin	O
510	##etic	O
510	parameter	O
510	value	O
510	for	O
510	an	O
510	individual	O
510	with	O
510	weight	O
510	equal	O
510	to	O
510	the	O
510	reference	O
510	weight	O
510	and	O
510	θ	O
510	##allo	O
510	is	O
510	an	O
510	all	O
510	##ometric	O
510	power	O
510	parameter	O
510	(	O
510	which	O
510	can	O
510	be	O
510	estimated	O
510	or	O
510	fixed	O
510	to	O
510	a	O
510	value	O
510	of	O
510	0	O
510	.	O
510	75	O
510	for	O
510	clearance	B-PK
510	##s	I-PK
510	,	O
510	and	O
510	a	O
510	value	O
510	of	O
510	1	O
510	for	O
510	an	O
510	##ato	O
510	##mic	O
510	##al	O
510	volumes	O
510	)	O
510	.	O
510	[SEP]	O
511	[CLS]	O
511	in	O
511	this	O
511	work	O
511	,	O
511	we	O
511	used	O
511	the	O
511	total	B-PK
511	cumulative	I-PK
511	area	I-PK
511	under	I-PK
511	the	I-PK
511	log	I-PK
511	concentration	I-PK
511	-	I-PK
511	time	I-PK
511	curve	I-PK
511	(	I-PK
511	au	I-PK
511	##log	I-PK
511	##c	I-PK
511	)	I-PK
511	as	O
511	the	O
511	p	O
511	##har	O
511	##ma	O
511	##co	O
511	##kin	O
511	##etic	O
511	pro	O
511	##xy	O
511	for	O
511	drug	O
511	exposure	O
511	.	O
511	[SEP]	O
512	[CLS]	O
512	maximum	B-PK
512	metabolism	I-PK
512	rates	I-PK
512	(	I-PK
512	v	I-PK
512	##max	I-PK
512	)	I-PK
512	were	O
512	estimated	O
512	serial	O
512	##ly	O
512	;	O
512	then	O
512	the	O
512	fraction	O
512	of	O
512	either	O
512	di	O
512	##a	O
512	or	O
512	de	O
512	##a	O
512	produced	O
512	from	O
512	at	O
512	##z	O
512	was	O
512	estimated	O
512	.	O
512	[SEP]	O
513	[CLS]	O
513	v	B-PK
513	##max	I-PK
513	for	O
513	da	O
513	##ct	O
513	was	O
513	defined	O
513	as	O
513	the	O
513	sum	O
513	of	O
513	the	O
513	rates	O
513	of	O
513	metabolism	O
513	of	O
513	di	O
513	##a	O
513	and	O
513	de	O
513	##a	O
513	.	O
513	[SEP]	O
514	[CLS]	O
514	a	O
514	first	B-PK
514	-	I-PK
514	order	I-PK
514	elimination	I-PK
514	rate	I-PK
514	constant	I-PK
514	was	O
514	added	O
514	to	O
514	the	O
514	in	O
514	v	O
514	##it	O
514	##ro	O
514	metabolism	O
514	model	O
514	for	O
514	da	O
514	##ct	O
514	to	O
514	account	O
514	for	O
514	measured	O
514	loss	O
514	of	O
514	da	O
514	##ct	O
514	from	O
514	the	O
514	media	O
514	at	O
514	the	O
514	end	O
514	of	O
514	the	O
514	in	O
514	##cu	O
514	##bation	O
514	period	O
514	.	O
514	[SEP]	O
515	[CLS]	O
515	in	O
515	addition	O
515	,	O
515	the	O
515	parameters	O
515	controlling	O
515	the	O
515	time	O
515	variance	O
515	of	O
515	c	B-PK
515	##l	I-PK
515	(	O
515	im	B-PK
515	##ax	I-PK
515	,	O
515	t	B-PK
515	##50	I-PK
515	,	O
515	and	O
515	γ	B-PK
515	)	O
515	were	O
515	estimated	O
515	separately	O
515	by	O
515	tumor	O
515	type	O
515	in	O
515	the	O
515	full	O
515	model	O
515	.	O
515	[SEP]	O
516	[CLS]	O
516	for	O
516	all	O
516	four	O
516	studies	O
516	,	O
516	the	O
516	inclusion	O
516	/	O
516	exclusion	O
516	criteria	O
516	allowed	O
516	for	O
516	the	O
516	enrollment	O
516	of	O
516	healthy	O
516	men	O
516	and	O
516	women	O
516	of	O
516	non	O
516	##child	O
516	bearing	O
516	potential	O
516	aged	O
516	between	O
516	18	O
516	and	O
516	55	O
516	years	O
516	of	O
516	age	O
516	with	O
516	a	O
516	body	O
516	weight	O
516	≥	O
516	50	O
516	kg	O
516	for	O
516	men	O
516	and	O
516	≥	O
516	45	O
516	kg	O
516	for	O
516	women	O
516	,	O
516	body	O
516	mass	O
516	index	O
516	(	O
516	b	O
516	##mi	O
516	)	O
516	within	O
516	the	O
516	range	O
516	18	O
516	.	O
516	5	O
516	to	O
516	31	O
516	.	O
516	0	O
516	kg	O
516	/	O
516	m	O
516	##2	O
516	(	O
516	inclusive	O
516	)	O
516	,	O
516	and	O
516	c	O
516	##rea	O
516	##tin	O
516	##ine	O
516	clearance	O
516	>	O
516	80	O
516	m	O
516	##l	O
516	/	O
516	min	O
516	at	O
516	time	O
516	of	O
516	screening	O
516	.	O
516	[SEP]	O
517	[CLS]	O
517	for	O
517	rat	O
517	single	O
517	-	O
517	pass	O
517	in	O
517	##test	O
517	##inal	O
517	per	O
517	##fusion	O
517	in	O
517	sit	O
517	##u	O
517	model	O
517	,	O
517	the	O
517	concentration	O
517	of	O
517	per	O
517	##fusion	O
517	fluid	O
517	was	O
517	calculated	O
517	as	O
517	co	O
517	##ut	O
517	(	O
517	corrected	O
517	)	O
517	=	O
517	co	O
517	##ut	O
517	##p	O
517	##rin	O
517	/	O
517	pro	O
517	##ut	O
517	and	O
517	the	O
517	effective	B-PK
517	per	I-PK
517	##me	I-PK
517	##ability	I-PK
517	coefficient	I-PK
517	(	I-PK
517	p	I-PK
517	##ef	I-PK
517	##f	I-PK
517	)	I-PK
517	was	O
517	calculated	O
517	as	O
517	p	O
517	##ef	O
517	##f	O
517	=	O
517	q	O
517	##ln	O
517	[	O
517	c	O
517	##in	O
517	/	O
517	co	O
517	##ut	O
517	(	O
517	corrected	O
517	)	O
517	]	O
517	/	O
517	2	O
517	##π	O
517	##rl	O
517	.	O
517	co	O
517	##ut	O
517	(	O
517	corrected	O
517	)	O
517	was	O
517	e	O
517	##ff	O
517	##lue	O
517	##nt	O
517	drug	O
517	concentration	O
517	with	O
517	correction	O
517	;	O
517	co	O
517	##ut	O
517	was	O
517	e	O
517	##ff	O
517	##lue	O
517	##nt	O
517	drug	O
517	concentration	O
517	without	O
517	correction	O
517	;	O
517	c	O
517	##in	O
517	was	O
517	in	O
517	##f	O
517	##lue	O
517	##nt	O
517	drug	O
517	concentration	O
517	;	O
517	p	O
517	##rin	O
517	was	O
517	in	O
517	##f	O
517	##lue	O
517	##nt	O
517	p	O
517	##hen	O
517	##ol	O
517	red	O
517	concentration	O
517	;	O
517	pro	O
517	##ut	O
517	were	O
517	e	O
517	##ff	O
517	##lue	O
517	##nt	O
517	p	O
517	##hen	O
517	##ol	O
517	red	O
517	concentration	O
517	;	O
517	q	O
517	was	O
517	per	O
517	##fu	O
517	##sat	O
517	##e	O
517	flow	O
517	rate	O
517	;	O
517	r	O
517	was	O
517	radius	O
517	of	O
517	in	O
517	##test	O
517	##inal	O
517	segment	O
517	and	O
517	l	O
517	was	O
517	in	O
517	##test	O
517	##inal	O
517	segment	O
517	length	O
517	.	O
517	[SEP]	O
518	[CLS]	O
518	therefore	O
518	,	O
518	there	O
518	were	O
518	higher	O
518	p	O
518	##har	O
518	##ma	O
518	##co	O
518	##kin	O
518	##etic	O
518	parameters	O
518	—	O
518	au	B-PK
518	##c	I-PK
518	,	O
518	m	B-PK
518	##rt	I-PK
518	,	O
518	and	O
518	t	B-PK
518	##1	I-PK
518	/	I-PK
518	2	I-PK
518	of	O
518	the	O
518	two	O
518	compounds	O
518	in	O
518	radiation	O
518	-	O
518	injured	O
518	mouse	O
518	,	O
518	when	O
518	compared	O
518	with	O
518	normal	O
518	mouse	O
518	.	O
518	[SEP]	O
519	[CLS]	O
519	all	O
519	procedures	O
519	pertaining	O
519	to	O
519	the	O
519	p	O
519	##k	O
519	studies	O
519	were	O
519	in	O
519	compliance	O
519	with	O
519	the	O
519	g	O
519	##erman	O
519	animal	O
519	welfare	O
519	act	O
519	and	O
519	g	O
519	##erman	O
519	regulations	O
519	(	O
519	tier	O
519	##sch	O
519	##g	O
519	/	O
519	tier	O
519	##sch	O
519	##vers	O
519	##v	O
519	)	O
519	and	O
519	were	O
519	approved	O
519	by	O
519	the	O
519	re	O
519	##gie	O
519	##rung	O
519	von	O
519	o	O
519	##ber	O
519	##bay	O
519	##ern	O
519	,	O
519	m	O
519	##unch	O
519	##en	O
519	,	O
519	(	O
519	authorization	O
519	number	O
519	55	O
519	.	O
519	2	O
519	-	O
519	1	O
519	-	O
519	54	O
519	-	O
519	253	O
519	##2	O
519	.	O
519	2	O
519	-	O
519	9	O
519	-	O
519	11	O
519	;	O
519	studies	O
519	in	O
519	mice	O
519	and	O
519	rats	O
519	)	O
519	and	O
519	the	O
519	ni	O
519	##ede	O
519	##rsa	O
519	##chs	O
519	##ische	O
519	##s	O
519	land	O
519	##es	O
519	##am	O
519	##t	O
519	fur	O
519	verb	O
519	##ra	O
519	##uche	O
519	##rsch	O
519	##utz	O
519	und	O
519	le	O
519	##ben	O
519	##sm	O
519	##itte	O
519	##ls	O
519	##iche	O
519	##r	O
519	##he	O
519	##it	O
519	,	O
519	old	O
519	##enburg	O
519	(	O
519	authorization	O
519	numbers	O
519	:	O
519	33	O
519	.	O
519	2	O
519	-	O
519	425	O
519	##0	O
519	##2	O
519	-	O
519	05	O
519	-	O
519	l	O
519	##g	O
519	-	O
519	01	O
519	-	O
519	86	O
519	/	O
519	2012	O
519	and	O
519	33	O
519	.	O
519	2	O
519	-	O
519	425	O
519	##0	O
519	##2	O
519	-	O
519	05	O
519	-	O
519	l	O
519	##g	O
519	-	O
519	01	O
519	/	O
519	2014	O
519	/	O
519	04	O
519	sa	O
519	;	O
519	studies	O
519	in	O
519	c	O
519	##yn	O
519	##omo	O
519	##l	O
519	##gus	O
519	monkeys	O
519	and	O
519	dogs	O
519	)	O
519	.	O
519	[SEP]	O
520	[CLS]	O
520	these	O
520	formulation	O
520	##s	O
520	might	O
520	produce	O
520	a	O
520	la	B-PK
520	##g	I-PK
520	time	I-PK
520	in	O
520	drug	O
520	absorption	O
520	or	O
520	present	O
520	a	O
520	plasma	O
520	concentration	O
520	with	O
520	a	O
520	sharp	O
520	initial	O
520	slope	O
520	followed	O
520	by	O
520	a	O
520	sustained	O
520	release	O
520	phase	O
520	.	O
520	[SEP]	O
521	[CLS]	O
521	when	O
521	the	O
521	co	O
521	##var	O
521	##iate	O
521	of	O
521	weight	O
521	was	O
521	on	O
521	c	B-PK
521	##l	I-PK
521	,	O
521	of	O
521	##v	O
521	were	O
521	–	O
521	62	O
521	##3	O
521	.	O
521	95	O
521	##8	O
521	,	O
521	–	O
521	89	O
521	##8	O
521	.	O
521	78	O
521	##3	O
521	,	O
521	and	O
521	–	O
521	144	O
521	##9	O
521	.	O
521	40	O
521	for	O
521	war	O
521	##fari	O
521	##n	O
521	,	O
521	r	O
521	-	O
521	war	O
521	##fari	O
521	##n	O
521	,	O
521	and	O
521	s	O
521	-	O
521	war	O
521	##fari	O
521	##n	O
521	,	O
521	respectively	O
521	.	O
521	[SEP]	O
522	[CLS]	O
522	post	O
522	analysis	O
522	,	O
522	the	O
522	p	O
522	##har	O
522	##ma	O
522	##co	O
522	##kin	O
522	##etic	O
522	parameters	O
522	were	O
522	com	O
522	##puted	O
522	using	O
522	win	O
522	non	O
522	##lin	O
522	##®	O
522	software	O
522	version	O
522	5	O
522	.	O
522	2	O
522	and	O
522	90	O
522	%	O
522	confidence	O
522	interval	O
522	was	O
522	com	O
522	##puted	O
522	using	O
522	sa	O
522	##s	O
522	##®	O
522	software	O
522	version	O
522	9	O
522	.	O
522	2	O
522	.	O
522	[SEP]	O
523	[CLS]	O
523	br	O
523	-	O
523	c	O
523	##16	O
523	-	O
523	p	O
523	##x	O
523	had	O
523	a	O
523	49	O
523	.	O
523	6	O
523	-	O
523	fold	O
523	greater	O
523	au	B-PK
523	##c	I-PK
523	##0	I-PK
523	–	I-PK
523	96	I-PK
523	h	I-PK
523	and	O
523	longer	O
523	t	B-PK
523	##1	I-PK
523	/	I-PK
523	2	I-PK
523	(	O
523	80	O
523	.	O
523	9	O
523	h	O
523	##r	O
523	versus	O
523	30	O
523	.	O
523	3	O
523	h	O
523	##r	O
523	)	O
523	compared	O
523	to	O
523	tax	O
523	##ol	O
523	.	O
523	[SEP]	O
524	[CLS]	O
524	the	O
524	concentration	O
524	of	O
524	p	O
524	##x	O
524	converted	O
524	from	O
524	br	O
524	-	O
524	c	O
524	##16	O
524	-	O
524	p	O
524	##x	O
524	n	O
524	##ps	O
524	reached	O
524	higher	O
524	numbers	O
524	than	O
524	tax	O
524	##ol	O
524	at	O
524	4	O
524	hours	O
524	and	O
524	remained	O
524	higher	O
524	up	O
524	to	O
524	96	O
524	hours	O
524	with	O
524	a	O
524	much	O
524	longer	O
524	m	B-PK
524	##rt	I-PK
524	(	O
524	32	O
524	.	O
524	2	O
524	h	O
524	##r	O
524	versus	O
524	14	O
524	.	O
524	7	O
524	h	O
524	##r	O
524	)	O
524	.	O
524	[SEP]	O
525	[CLS]	O
525	the	O
525	au	B-PK
525	##c	I-PK
525	##0	I-PK
525	–	I-PK
525	96	I-PK
525	h	I-PK
525	and	O
525	au	B-PK
525	##c	I-PK
525	##48	I-PK
525	–	I-PK
525	96	I-PK
525	h	I-PK
525	of	O
525	p	O
525	##x	O
525	from	O
525	the	O
525	n	O
525	##ps	O
525	were	O
525	1	O
525	.	O
525	1	O
525	-	O
525	fold	O
525	and	O
525	2	O
525	.	O
525	7	O
525	-	O
525	fold	O
525	higher	O
525	than	O
525	tax	O
525	##ol	O
525	,	O
525	respectively	O
525	.	O
525	[SEP]	O
526	[CLS]	O
526	after	O
526	inspection	O
526	of	O
526	the	O
526	p	O
526	##k	O
526	profiles	O
526	,	O
526	a	O
526	one	O
526	-	O
526	compartment	O
526	model	O
526	with	O
526	first	O
526	-	O
526	order	O
526	absorption	O
526	was	O
526	adopted	O
526	as	O
526	the	O
526	optimal	O
526	base	O
526	model	O
526	for	O
526	war	O
526	##fari	O
526	##n	O
526	,	O
526	r	O
526	-	O
526	war	O
526	##fari	O
526	##n	O
526	,	O
526	and	O
526	s	O
526	-	O
526	war	O
526	##fari	O
526	##n	O
526	.	O
526	[SEP]	O
527	[CLS]	O
527	structural	O
527	p	O
527	##k	O
527	model	O
527	was	O
527	fit	O
527	to	O
527	plasma	O
527	concentrations	O
527	,	O
527	and	O
527	typical	O
527	values	O
527	of	O
527	absorption	B-PK
527	rate	I-PK
527	constant	I-PK
527	(	I-PK
527	ka	I-PK
527	)	I-PK
527	,	O
527	apparent	B-PK
527	volume	I-PK
527	of	I-PK
527	distribution	I-PK
527	(	I-PK
527	v	I-PK
527	/	I-PK
527	f	I-PK
527	)	I-PK
527	,	O
527	and	O
527	oral	B-PK
527	clearance	I-PK
527	(	I-PK
527	c	I-PK
527	##l	I-PK
527	/	I-PK
527	f	I-PK
527	)	I-PK
527	were	O
527	calculated	O
527	(	O
527	where	O
527	f	B-PK
527	denotes	O
527	bio	B-PK
527	##ava	I-PK
527	##ila	I-PK
527	##bility	I-PK
527	)	O
527	.	O
527	[SEP]	O
528	[CLS]	O
528	the	O
528	results	O
528	of	O
528	the	O
528	paired	O
528	t	O
528	-	O
528	test	O
528	of	O
528	p	O
528	##har	O
528	##ma	O
528	##co	O
528	##kin	O
528	##etics	O
528	data	O
528	showed	O
528	that	O
528	there	O
528	was	O
528	no	O
528	significant	O
528	difference	O
528	between	O
528	products	O
528	a	O
528	and	O
528	b	O
528	.	O
528	from	O
528	both	O
528	the	O
528	in	O
528	v	O
528	##it	O
528	##ro	O
528	dissolution	O
528	studies	O
528	and	O
528	in	O
528	v	O
528	##ivo	O
528	bio	B-PK
528	##ava	I-PK
528	##ila	I-PK
528	##bility	I-PK
528	studies	O
528	it	O
528	was	O
528	concluded	O
528	that	O
528	products	O
528	a	O
528	and	O
528	b	O
528	had	O
528	similar	O
528	bio	B-PK
528	##ava	I-PK
528	##ila	I-PK
528	##bility	I-PK
528	.	O
528	[SEP]	O
529	[CLS]	O
529	normal	O
529	##ized	O
529	sensitivity	O
529	coefficients	O
529	were	O
529	calculated	O
529	using	O
529	the	O
529	forward	O
529	-	O
529	difference	O
529	method	O
529	for	O
529	all	O
529	chemical	O
529	specific	O
529	parameters	O
529	in	O
529	the	O
529	model	O
529	,	O
529	the	O
529	oral	O
529	up	B-PK
529	##take	I-PK
529	rate	I-PK
529	constant	I-PK
529	##s	I-PK
529	,	O
529	the	O
529	elimination	B-PK
529	rate	I-PK
529	constant	I-PK
529	##s	I-PK
529	,	O
529	and	O
529	the	O
529	partition	O
529	coefficients	O
529	.	O
529	[SEP]	O
530	[CLS]	O
530	g	O
530	##eh	O
530	##12	O
530	##13	O
530	##33	O
530	was	O
530	injected	O
530	through	O
530	a	O
530	cat	O
530	##he	O
530	##ter	O
530	placed	O
530	in	O
530	the	O
530	lateral	O
530	tail	O
530	veins	O
530	of	O
530	adult	O
530	female	O
530	fish	O
530	##er	O
530	rats	O
530	(	O
530	ch	O
530	##ar	O
530	##les	O
530	river	O
530	laboratories	O
530	,	O
530	150	O
530	–	O
530	200	O
530	g	O
530	,	O
530	n	O
530	=	O
530	4	O
530	each	O
530	us	O
530	##pio	O
530	compound	O
530	)	O
530	,	O
530	and	O
530	was	O
530	dose	O
530	##d	O
530	at	O
530	5	O
530	mg	O
530	f	O
530	##e	O
530	kg	O
530	##−	O
530	##1	O
530	body	O
530	weight	O
530	.	O
530	[SEP]	O
531	[CLS]	O
531	the	O
531	peak	B-PK
531	plasma	I-PK
531	concentration	I-PK
531	(	I-PK
531	cm	I-PK
531	##ax	I-PK
531	)	I-PK
531	and	O
531	time	B-PK
531	to	I-PK
531	reach	I-PK
531	cm	I-PK
531	##ax	I-PK
531	(	I-PK
531	t	I-PK
531	##max	I-PK
531	)	I-PK
531	were	O
531	determined	O
531	directly	O
531	from	O
531	the	O
531	experimental	O
531	data	O
531	.	O
531	[SEP]	O
532	[CLS]	O
532	the	O
532	specific	O
532	radio	B-PK
532	##act	I-PK
532	##ivity	I-PK
532	was	O
532	calculated	O
532	as	O
532	the	O
532	ratio	O
532	of	O
532	the	O
532	radio	B-PK
532	##act	I-PK
532	##ivity	I-PK
532	el	O
532	##uti	O
532	##ng	O
532	at	O
532	the	O
532	retention	O
532	time	O
532	of	O
532	product	O
532	during	O
532	the	O
532	pre	O
532	##par	O
532	##ative	O
532	hp	O
532	##l	O
532	##c	O
532	pu	O
532	##rification	O
532	to	O
532	the	O
532	mass	O
532	corresponding	O
532	to	O
532	the	O
532	area	O
532	under	O
532	the	O
532	curve	O
532	of	O
532	the	O
532	u	O
532	##v	O
532	absorption	O
532	.	O
532	[SEP]	O
533	[CLS]	O
533	bio	B-PK
533	##ava	I-PK
533	##ila	I-PK
533	##bility	I-PK
533	of	O
533	de	O
533	##tom	O
533	##id	O
533	##ine	O
533	after	O
533	sub	O
533	##ling	O
533	##ual	O
533	administration	O
533	was	O
533	approximate	O
533	##d	O
533	by	O
533	using	O
533	the	O
533	formula	O
533	100	O
533	%	O
533	*	O
533	[SEP]	O
534	[CLS]	O
534	the	O
534	formulation	O
534	enhance	O
534	##s	O
534	so	O
534	##lub	O
534	##ility	O
534	and	O
534	fraction	O
534	of	O
534	lip	O
534	##op	O
534	##hil	O
534	##ic	O
534	drugs	O
534	transported	O
534	through	O
534	the	O
534	in	O
534	##test	O
534	##inal	O
534	l	O
534	##ymph	O
534	##atic	O
534	system	O
534	,	O
534	thus	O
534	increasing	O
534	absorption	O
534	through	O
534	the	O
534	g	O
534	##i	O
534	tract	O
534	.	O
534	[SEP]	O
535	[CLS]	O
535	b	O
535	##w	O
535	all	O
535	##ometric	O
535	s	O
535	##cal	O
535	##ing	O
535	on	O
535	c	B-PK
535	##lm	I-PK
535	and	O
535	v	B-PK
535	##m	I-PK
535	marked	O
535	##ly	O
535	decreased	O
535	the	O
535	objective	O
535	function	O
535	(	O
535	a	O
535	##ic	O
535	difference	O
535	of	O
535	−	O
535	22	O
535	with	O
535	respect	O
535	to	O
535	the	O
535	basic	O
535	structural	O
535	model	O
535	)	O
535	.	O
535	[SEP]	O
536	[CLS]	O
536	v	B-PK
536	##m	I-PK
536	was	O
536	significantly	O
536	impacted	O
536	by	O
536	sex	O
536	(	O
536	δ	O
536	##of	O
536	##v	O
536	=	O
536	−	O
536	8	O
536	.	O
536	8	O
536	,	O
536	p	O
536	<	O
536	0	O
536	.	O
536	01	O
536	)	O
536	.	O
536	[SEP]	O
537	[CLS]	O
537	the	O
537	effect	O
537	of	O
537	b	O
537	##w	O
537	on	O
537	c	B-PK
537	##lm	I-PK
537	and	O
537	v	B-PK
537	##m	I-PK
537	was	O
537	also	O
537	retained	O
537	.	O
537	[SEP]	O
538	[CLS]	O
538	the	O
538	ram	O
538	##ip	O
538	##ril	O
538	##at	O
538	p	O
538	##b	O
538	##p	O
538	##k	O
538	parameters	O
538	are	O
538	:	O
538	1	O
538	)	O
538	the	O
538	4	O
538	ace	O
538	binding	O
538	constant	O
538	##s	O
538	(	O
538	kn	O
538	,	O
538	k	O
538	##c	O
538	,	O
538	k	O
538	-	O
538	n	O
538	,	O
538	k	O
538	-	O
538	c	O
538	,	O
538	e	O
538	##q	O
538	.	O
538	(	O
538	2	O
538	)	O
538	)	O
538	;	O
538	2	O
538	)	O
538	the	O
538	re	B-PK
538	##nal	I-PK
538	intrinsic	I-PK
538	clearance	I-PK
538	(	I-PK
538	c	I-PK
538	##lu	I-PK
538	,	O
538	e	O
538	##q	O
538	.	O
538	(	O
538	9	O
538	)	O
538	)	O
538	and	O
538	3	O
538	)	O
538	the	O
538	total	O
538	ace	O
538	concentration	O
538	in	O
538	plasma	O
538	and	O
538	each	O
538	tissue	O
538	(	O
538	et	O
538	##i	O
538	,	O
538	1	O
538	=	O
538	1	O
538	.	O
538	.	O
538	12	O
538	)	O
538	.	O
538	[SEP]	O
539	[CLS]	O
539	to	O
539	determine	O
539	a	O
539	constant	O
539	rate	O
539	in	O
539	##tra	O
539	##ven	O
539	##ous	O
539	in	O
539	##fusion	O
539	of	O
539	m	O
539	##or	O
539	##phine	O
539	,	O
539	we	O
539	estimate	O
539	k	B-PK
539	##0	I-PK
539	based	O
539	on	O
539	a	O
539	desired	O
539	m	O
539	##or	O
539	##phine	O
539	c	O
539	##tar	O
539	##get	O
539	to	O
539	achieve	O
539	,	O
539	and	O
539	its	O
539	c	B-PK
539	##l	I-PK
539	,	O
539	so	O
539	that	O
539	k	O
539	##0	O
539	=	O
539	c	O
539	##tar	O
539	##get	O
539	·	O
539	c	O
539	##l	O
539	.	O
539	[SEP]	O
540	[CLS]	O
540	if	O
540	rapid	O
540	achievement	O
540	of	O
540	steady	O
540	-	O
540	state	O
540	m	O
540	##or	O
540	##phine	O
540	concentration	O
540	is	O
540	desired	O
540	,	O
540	an	O
540	in	O
540	##tra	O
540	##ven	O
540	##ous	O
540	loading	O
540	dose	O
540	may	O
540	be	O
540	calculated	O
540	using	O
540	equation	O
540	7	O
540	or	O
540	simply	O
540	d	O
540	##l	O
540	=	O
540	c	O
540	##tar	O
540	##get	O
540	·	O
540	v	O
540	##d	O
540	.	O
540	[SEP]	O
541	[CLS]	O
541	op	O
541	##io	O
541	##id	O
541	population	O
541	p	O
541	##har	O
541	##ma	O
541	##co	O
541	##kin	O
541	##etic	O
541	parameter	O
541	est	O
541	##imation	O
541	using	O
541	the	O
541	boots	O
541	##tra	O
541	##p	O
541	(	O
541	see	O
541	below	O
541	)	O
541	was	O
541	not	O
541	performed	O
541	for	O
541	f	B-PK
541	or	O
541	ka	B-PK
541	values	O
541	.	O
541	[SEP]	O
542	[CLS]	O
542	cap	O
542	##mu	O
542	##l	O
542	m	O
542	##c	O
542	##m	O
542	c	O
542	##8	O
542	(	O
542	mon	O
542	##o	O
542	-	O
542	/	O
542	dig	O
542	##ly	O
542	##cer	O
542	##ides	O
542	of	O
542	cap	O
542	##ryl	O
542	##ic	O
542	acid	O
542	)	O
542	and	O
542	cap	O
542	##te	O
542	##x	O
542	35	O
542	##5	O
542	(	O
542	cap	O
542	##ryl	O
542	##ic	O
542	/	O
542	cap	O
542	##ric	O
542	t	O
542	##rig	O
542	##ly	O
542	##cer	O
542	##ide	O
542	derivative	O
542	)	O
542	were	O
542	obtained	O
542	as	O
542	gift	O
542	sample	O
542	from	O
542	a	O
542	##bit	O
542	##ec	O
542	,	O
542	uk	O
542	,	O
542	mi	O
542	##gly	O
542	##ol	O
542	81	O
542	##2	O
542	(	O
542	cap	O
542	##ryl	O
542	##ic	O
542	/	O
542	cap	O
542	##ric	O
542	t	O
542	##rig	O
542	##ly	O
542	##cer	O
542	##ide	O
542	)	O
542	was	O
542	gifted	O
542	by	O
542	sa	O
542	##sol	O
542	g	O
542	##erman	O
542	##y	O
542	g	O
542	##mb	O
542	##h	O
542	.	O
542	[SEP]	O
543	[CLS]	O
543	f	O
543	##etal	O
543	trans	O
543	##place	O
543	##ntal	O
543	exposure	O
543	to	O
543	do	O
543	##lut	O
543	##eg	O
543	##ra	O
543	##vir	O
543	was	O
543	considerable	O
543	as	O
543	well	O
543	as	O
543	accumulation	O
543	in	O
543	place	O
543	##ntal	O
543	tissue	O
543	.	O
543	[SEP]	O
544	[CLS]	O
544	this	O
544	means	O
544	that	O
544	putting	O
544	the	O
544	various	O
544	co	O
544	##var	O
544	##iate	O
544	##s	O
544	into	O
544	the	O
544	model	O
544	one	O
544	by	O
544	one	O
544	,	O
544	the	O
544	difference	O
544	between	O
544	the	O
544	objective	O
544	function	O
544	of	O
544	the	O
544	2	O
544	models	O
544	−	O
544	##2	O
544	##log	O
544	##lma	O
544	##x	O
544	follow	O
544	f	O
544	distribution	O
544	,	O
544	similar	O
544	to	O
544	χ	O
544	##2	O
544	distribution	O
544	.	O
544	[SEP]	O
545	[CLS]	O
545	when	O
545	developing	O
545	oral	O
545	am	O
545	##or	O
545	##ph	O
545	##ous	O
545	solid	O
545	di	O
545	##sper	O
545	##sion	O
545	for	O
545	h	O
545	##ydro	O
545	##phobic	O
545	drugs	O
545	such	O
545	as	O
545	c	O
545	##sa	O
545	(	O
545	sa	O
545	##s	O
545	##d	O
545	/	O
545	c	O
545	##sa	O
545	)	O
545	,	O
545	it	O
545	is	O
545	important	O
545	to	O
545	control	O
545	the	O
545	dissolution	O
545	rate	O
545	in	O
545	order	O
545	to	O
545	avoid	O
545	precipitation	O
545	upon	O
545	di	O
545	##lution	O
545	in	O
545	the	O
545	gas	O
545	##tro	O
545	##int	O
545	##est	O
545	##inal	O
545	tract	O
545	and	O
545	ma	O
545	##xi	O
545	##mize	O
545	the	O
545	absorption	O
545	in	O
545	the	O
545	in	O
545	##test	O
545	##ine	O
545	.	O
545	[SEP]	O
546	[CLS]	O
546	no	O
546	significant	O
546	dose	O
546	-	O
546	dependent	O
546	differences	O
546	in	O
546	clearance	B-PK
546	,	O
546	half	B-PK
546	-	I-PK
546	life	I-PK
546	or	O
546	volume	B-PK
546	of	I-PK
546	distribution	I-PK
546	were	O
546	observed	O
546	(	O
546	p	O
546	>	O
546	0	O
546	.	O
546	05	O
546	)	O
546	.	O
546	[SEP]	O
547	[CLS]	O
547	sixty	O
547	‐	O
547	seven	O
547	of	O
547	71	O
547	(	O
547	94	O
547	.	O
547	4	O
547	%	O
547	)	O
547	and	O
547	70	O
547	of	O
547	71	O
547	(	O
547	98	O
547	.	O
547	6	O
547	%	O
547	)	O
547	patients	O
547	experienced	O
547	one	O
547	or	O
547	more	O
547	treatment	O
547	‐	O
547	emerge	O
547	##nt	O
547	a	O
547	##e	O
547	(	O
547	tea	O
547	##e	O
547	)	O
547	during	O
547	cycle	O
547	1	O
547	and	O
547	all	O
547	cycles	O
547	,	O
547	respectively	O
547	.	O
547	[SEP]	O
548	[CLS]	O
548	between	O
548	approximately	O
548	1	O
548	week	O
548	and	O
548	1	O
548	month	O
548	after	O
548	injection	O
548	,	O
548	despite	O
548	the	O
548	early	O
548	var	O
548	##iability	O
548	discussed	O
548	above	O
548	,	O
548	groups	O
548	show	O
548	remarkably	O
548	little	O
548	var	O
548	##iability	O
548	and	O
548	follow	O
548	a	O
548	consistent	O
548	down	O
548	-	O
548	s	O
548	##loping	O
548	curve	O
548	with	O
548	an	O
548	apparent	B-PK
548	t	I-PK
548	##1	I-PK
548	/	I-PK
548	2	I-PK
548	=	O
548	14	O
548	days	O
548	,	O
548	far	O
548	longer	O
548	than	O
548	the	O
548	elimination	B-PK
548	t	I-PK
548	##1	I-PK
548	/	I-PK
548	2	I-PK
548	seen	O
548	after	O
548	in	O
548	##tra	O
548	##ven	O
548	##ous	O
548	dos	O
548	##ing	O
548	in	O
548	mice	O
548	(	O
548	15	O
548	h	O
548	)	O
548	[	O
548	17	O
548	]	O
548	.	O
548	[SEP]	O
549	[CLS]	O
549	the	O
549	long	O
549	apparent	B-PK
549	t	I-PK
549	##1	I-PK
549	/	I-PK
549	2	I-PK
549	during	O
549	this	O
549	phase	O
549	is	O
549	a	O
549	strong	O
549	indication	O
549	that	O
549	absorption	O
549	of	O
549	el	O
549	##q	O
549	-	O
549	300	O
549	from	O
549	the	O
549	injection	O
549	site	O
549	into	O
549	blood	O
549	is	O
549	ongoing	O
549	.	O
549	[SEP]	O
550	[CLS]	O
550	the	O
550	next	O
550	phase	O
550	of	O
550	the	O
550	curve	O
550	shows	O
550	a	O
550	decrease	O
550	in	O
550	the	O
550	slope	O
550	of	O
550	the	O
550	concentration	O
550	vs	O
550	time	O
550	curve	O
550	,	O
550	which	O
550	remains	O
550	relatively	O
550	flat	O
550	between	O
550	1	O
550	and	O
550	3	O
550	months	O
550	after	O
550	injection	O
550	.	O
550	[SEP]	O
551	[CLS]	O
551	after	O
551	day	O
551	90	O
551	,	O
551	the	O
551	downward	O
551	slope	O
551	increases	O
551	for	O
551	the	O
551	final	O
551	phase	O
551	of	O
551	the	O
551	curve	O
551	with	O
551	an	O
551	apparent	B-PK
551	terminal	I-PK
551	t	I-PK
551	##1	I-PK
551	/	I-PK
551	2	I-PK
551	=	O
551	29	O
551	.	O
551	5	O
551	days	O
551	.	O
551	[SEP]	O
552	[CLS]	O
552	the	O
552	secondary	O
552	end	O
552	##points	O
552	were	O
552	:	O
552	the	O
552	ma	B-PK
552	##ximal	I-PK
552	concentration	I-PK
552	of	I-PK
552	25	I-PK
552	(	I-PK
552	oh	I-PK
552	)	I-PK
552	d	I-PK
552	(	I-PK
552	cm	I-PK
552	##ax	I-PK
552	)	I-PK
552	the	O
552	time	B-PK
552	required	I-PK
552	to	I-PK
552	reach	I-PK
552	the	I-PK
552	ma	I-PK
552	##ximal	I-PK
552	concentration	I-PK
552	(	I-PK
552	t	I-PK
552	##max	I-PK
552	)	I-PK
552	the	O
552	total	B-PK
552	area	I-PK
552	under	I-PK
552	the	I-PK
552	curve	I-PK
552	(	I-PK
552	au	I-PK
552	##c	I-PK
552	)	I-PK
552	of	O
552	the	O
552	serum	O
552	concentration	O
552	of	O
552	25	O
552	(	O
552	oh	O
552	)	O
552	d	O
552	up	O
552	to	O
552	day	O
552	28	O
552	[SEP]	O
553	[CLS]	O
553	man	O
553	##ni	O
553	##to	O
553	##l	O
553	did	O
553	not	O
553	enhance	O
553	the	O
553	stability	O
553	of	O
553	sir	O
553	##oli	O
553	##mus	O
553	.	O
553	[SEP]	O
554	[CLS]	O
554	matrix	O
554	effect	O
554	(	O
554	%	O
554	)	O
554	=	O
554	b	O
554	##a	O
554	##×	O
554	##100	O
554	[SEP]	O
555	[CLS]	O
555	the	O
555	image	O
555	processing	O
555	procedure	O
555	of	O
555	radio	O
555	##lum	O
555	##ines	O
555	##cence	O
555	images	O
555	is	O
555	described	O
555	in	O
555	our	O
555	previous	O
555	manuscript	O
555	[	O
555	20	O
555	]	O
555	.	O
555	[SEP]	O
556	[CLS]	O
556	comparisons	O
556	of	O
556	area	B-PK
556	under	I-PK
556	the	I-PK
556	curve	I-PK
556	(	I-PK
556	au	I-PK
556	##c	I-PK
556	)	I-PK
556	in	O
556	vein	O
556	,	O
556	per	O
556	##ito	O
556	##ne	O
556	##um	O
556	,	O
556	x	O
556	##p	O
556	,	O
556	and	O
556	muscle	O
556	after	O
556	i	O
556	.	O
556	v	O
556	.	O
556	and	O
556	i	O
556	.	O
556	p	O
556	.	O
556	in	O
556	##fusion	O
556	were	O
556	performed	O
556	using	O
556	the	O
556	man	O
556	##n	O
556	-	O
556	w	O
556	##hit	O
556	##ney	O
556	test	O
556	,	O
556	and	O
556	p	O
556	-	O
556	values	O
556	<	O
556	0	O
556	.	O
556	05	O
556	were	O
556	considered	O
556	significant	O
556	.	O
556	[SEP]	O
557	[CLS]	O
557	the	O
557	investigators	O
557	used	O
557	a	O
557	##e	O
557	terminology	O
557	and	O
557	accurate	O
557	medical	O
557	terminology	O
557	to	O
557	record	O
557	the	O
557	following	O
557	conditions	O
557	of	O
557	a	O
557	##e	O
557	components	O
557	on	O
557	the	O
557	adverse	O
557	-	O
557	reaction	O
557	observation	O
557	page	O
557	in	O
557	the	O
557	case	O
557	-	O
557	report	O
557	form	O
557	:	O
557	s	O
557	##ym	O
557	##pt	O
557	##om	O
557	description	O
557	,	O
557	date	O
557	of	O
557	occurrence	O
557	,	O
557	date	O
557	of	O
557	s	O
557	##ym	O
557	##pt	O
557	##om	O
557	disco	O
557	##ntin	O
557	##uation	O
557	,	O
557	degree	O
557	,	O
557	measures	O
557	taken	O
557	,	O
557	evaluation	O
557	of	O
557	the	O
557	relationship	O
557	with	O
557	the	O
557	drug	O
557	,	O
557	and	O
557	the	O
557	final	O
557	outcome	O
557	.	O
557	[SEP]	O
558	[CLS]	O
558	if	O
558	an	O
558	a	O
558	##e	O
558	or	O
558	its	O
558	consequences	O
558	persisted	O
558	,	O
558	follow	O
558	-	O
558	up	O
558	was	O
558	continued	O
558	until	O
558	the	O
558	a	O
558	##e	O
558	had	O
558	disappeared	O
558	or	O
558	stab	O
558	##ilized	O
558	.	O
558	[SEP]	O
559	[CLS]	O
559	secondary	O
559	p	O
559	##d	O
559	ex	O
559	##p	O
559	##lora	O
559	##tory	O
559	end	O
559	##points	O
559	included	O
559	changes	O
559	from	O
559	base	O
559	##line	O
559	to	O
559	end	O
559	of	O
559	treatment	O
559	for	O
559	b	O
559	##mi	O
559	z	O
559	score	O
559	,	O
559	body	O
559	weight	O
559	,	O
559	f	O
559	##p	O
559	##g	O
559	,	O
559	serum	O
559	insulin	O
559	,	O
559	and	O
559	serum	O
559	h	O
559	##ba	O
559	##1	O
559	##c	O
559	.	O
559	[SEP]	O
560	[CLS]	O
560	what	O
560	does	O
560	this	O
560	study	O
560	add	O
560	to	O
560	our	O
560	knowledge	O
560	?	O
560	[SEP]	O
561	[CLS]	O
561	these	O
561	symptoms	O
561	may	O
561	result	O
561	in	O
561	delays	O
561	or	O
561	in	O
561	##con	O
561	##sist	O
561	##encies	O
561	in	O
561	the	O
561	absorption	O
561	of	O
561	oral	O
561	treatments	O
561	.	O
561	[SEP]	O
562	[CLS]	O
562	the	O
562	proportion	O
562	of	O
562	patients	O
562	that	O
562	were	O
562	pain	O
562	-	O
562	free	O
562	at	O
562	2	O
562	h	O
562	post	O
562	-	O
562	treatment	O
562	was	O
562	18	O
562	%	O
562	for	O
562	the	O
562	sum	O
562	##at	O
562	##rip	O
562	##tan	O
562	patch	O
562	vs	O
562	9	O
562	%	O
562	for	O
562	place	O
562	##bo	O
562	(	O
562	p	O
562	=	O
562	0	O
562	.	O
562	00	O
562	##9	O
562	##2	O
562	;	O
562	number	O
562	needed	O
562	to	O
562	treat	O
562	=	O
562	11	O
562	.	O
562	1	O
562	)	O
562	.	O
562	[SEP]	O
563	[CLS]	O
563	upon	O
563	approval	O
563	from	O
563	the	O
563	food	O
563	and	O
563	drug	O
563	administration	O
563	and	O
563	other	O
563	regulatory	O
563	authorities	O
563	,	O
563	the	O
563	ion	O
563	##top	O
563	##hore	O
563	##tic	O
563	trans	O
563	##der	O
563	##mal	O
563	delivery	O
563	of	O
563	sum	O
563	##at	O
563	##rip	O
563	##tan	O
563	will	O
563	be	O
563	a	O
563	good	O
563	choice	O
563	for	O
563	patients	O
563	experiencing	O
563	poor	O
563	absorption	O
563	of	O
563	oral	O
563	medication	O
563	often	O
563	associated	O
563	with	O
563	mi	O
563	##gra	O
563	##ine	O
563	and	O
563	/	O
563	or	O
563	for	O
563	those	O
563	with	O
563	into	O
563	##ler	O
563	##able	O
563	trip	O
563	##tan	O
563	-	O
563	related	O
563	adverse	O
563	events	O
563	.	O
563	[SEP]	O
564	[CLS]	O
564	then	O
564	the	O
564	solvent	O
564	and	O
564	##ex	O
564	##tra	O
564	th	O
564	##ion	O
564	##yl	O
564	chloride	O
564	were	O
564	removed	O
564	by	O
564	vacuum	O
564	di	O
564	##st	O
564	##illa	O
564	##tion	O
564	.	O
564	[SEP]	O
565	[CLS]	O
565	after	O
565	the	O
565	first	O
565	d	O
565	##lt	O
565	,	O
565	es	O
565	##cal	O
565	##ation	O
565	steps	O
565	of	O
565	no	O
565	more	O
565	than	O
565	35	O
565	%	O
565	of	O
565	the	O
565	previous	O
565	dose	O
565	were	O
565	made	O
565	.	O
565	[SEP]	O
566	[CLS]	O
566	the	O
566	starting	O
566	dose	O
566	level	O
566	for	O
566	schedule	O
566	a	O
566	was	O
566	5	O
566	mg	O
566	estimated	O
566	according	O
566	to	O
566	the	O
566	food	O
566	and	O
566	drug	O
566	administration	O
566	(	O
566	f	O
566	##da	O
566	)	O
566	flow	O
566	diagram	O
566	“	O
566	general	O
566	guide	O
566	for	O
566	starting	O
566	dose	O
566	selection	O
566	for	O
566	a	O
566	c	O
566	##yt	O
566	##oto	O
566	##xi	O
566	##c	O
566	agent	O
566	in	O
566	cancer	O
566	patients	O
566	”	O
566	,	O
566	with	O
566	dose	O
566	es	O
566	##cal	O
566	##ation	O
566	in	O
566	steps	O
566	of	O
566	100	O
566	%	O
566	until	O
566	the	O
566	first	O
566	drug	O
566	-	O
566	related	O
566	a	O
566	##e	O
566	grade	O
566	≥	O
566	##2	O
566	.	O
566	[SEP]	O
567	[CLS]	O
567	to	O
567	reduce	O
567	the	O
567	overall	O
567	number	O
567	of	O
567	patients	O
567	in	O
567	the	O
567	study	O
567	,	O
567	initial	O
567	patient	O
567	co	O
567	##hor	O
567	##ts	O
567	were	O
567	assigned	O
567	only	O
567	to	O
567	the	O
567	4	O
567	-	O
567	week	O
567	treatment	O
567	cycle	O
567	(	O
567	schedule	O
567	a	O
567	)	O
567	,	O
567	until	O
567	the	O
567	first	O
567	occurrence	O
567	in	O
567	cycle	O
567	1	O
567	of	O
567	a	O
567	drug	O
567	-	O
567	related	O
567	a	O
567	##e	O
567	grade	O
567	≥	O
567	##2	O
567	.	O
567	[SEP]	O
568	[CLS]	O
568	the	O
568	starting	O
568	dose	O
568	level	O
568	in	O
568	schedule	O
568	b	O
568	was	O
568	the	O
568	dose	O
568	at	O
568	which	O
568	a	O
568	first	O
568	drug	O
568	-	O
568	related	O
568	grade	O
568	≥	O
568	##2	O
568	a	O
568	##e	O
568	occurred	O
568	in	O
568	schedule	O
568	a	O
568	.	O
568	after	O
568	determination	O
568	of	O
568	the	O
568	m	O
568	##t	O
568	##d	O
568	,	O
568	up	O
568	to	O
568	9	O
568	additional	O
568	patients	O
568	were	O
568	entered	O
568	at	O
568	this	O
568	dose	O
568	level	O
568	to	O
568	obtain	O
568	further	O
568	safety	O
568	data	O
568	.	O
568	[SEP]	O
569	[CLS]	O
569	the	O
569	remaining	O
569	super	O
569	##nat	O
569	##ant	O
569	specimen	O
569	was	O
569	used	O
569	for	O
569	meta	O
569	##bol	O
569	##ite	O
569	identification	O
569	by	O
569	m	O
569	##s	O
569	/	O
569	m	O
569	##s	O
569	.	O
569	[SEP]	O
570	[CLS]	O
570	click	O
570	here	O
570	for	O
570	additional	O
570	data	O
570	file	O
570	.	O
570	[SEP]	O
571	[CLS]	O
571	for	O
571	m	O
571	##1	O
571	detection	O
571	all	O
571	separation	O
571	instances	O
571	were	O
571	carried	O
571	out	O
571	with	O
571	a	O
571	c	O
571	##18	O
571	l	O
571	##una	O
571	(	O
571	100	O
571	×	O
571	6	O
571	mm	O
571	id	O
571	,	O
571	5	O
571	μ	O
571	##m	O
571	particle	O
571	size	O
571	)	O
571	.	O
571	[SEP]	O
572	[CLS]	O
572	the	O
572	ass	O
572	##ay	O
572	was	O
572	run	O
572	on	O
572	a	O
572	g	O
572	##yr	O
572	##ola	O
572	##b	O
572	bio	O
572	##af	O
572	##fy	O
572	200	O
572	c	O
572	##d	O
572	,	O
572	and	O
572	wash	O
572	steps	O
572	used	O
572	p	O
572	##bs	O
572	/	O
572	0	O
572	.	O
572	01	O
572	%	O
572	p	O
572	##oly	O
572	##sor	O
572	##bate	O
572	-	O
572	20	O
572	/	O
572	0	O
572	.	O
572	02	O
572	%	O
572	na	O
572	##n	O
572	##3	O
572	followed	O
572	by	O
572	g	O
572	##yr	O
572	##os	O
572	p	O
572	##h	O
572	11	O
572	wash	O
572	buffer	O
572	.	O
572	[SEP]	O
573	[CLS]	O
573	safety	O
573	assessments	O
573	were	O
573	performed	O
573	by	O
573	evaluating	O
573	the	O
573	number	O
573	/	O
573	proportions	O
573	of	O
573	patients	O
573	experiencing	O
573	a	O
573	##es	O
573	and	O
573	by	O
573	analysis	O
573	of	O
573	any	O
573	changes	O
573	from	O
573	base	O
573	##line	O
573	in	O
573	laboratory	O
573	tests	O
573	,	O
573	e	O
573	##c	O
573	##g	O
573	and	O
573	vital	O
573	signs	O
573	.	O
573	[SEP]	O
574	[CLS]	O
574	exclusion	O
574	criteria	O
574	included	O
574	all	O
574	##er	O
574	##gy	O
574	for	O
574	e	O
574	##chin	O
574	##oc	O
574	##and	O
574	##ins	O
574	or	O
574	ex	O
574	##ci	O
574	##pie	O
574	##nts	O
574	,	O
574	known	O
574	hi	O
574	##v	O
574	,	O
574	he	O
574	##pa	O
574	##titis	O
574	b	O
574	or	O
574	c	O
574	infection	O
574	,	O
574	or	O
574	a	O
574	history	O
574	of	O
574	drug	O
574	or	O
574	alcohol	O
574	abuse	O
574	.	O
574	[SEP]	O
575	[CLS]	O
575	all	O
575	p	O
575	values	O
575	were	O
575	two	O
575	-	O
575	sided	O
575	,	O
575	and	O
575	the	O
575	level	O
575	of	O
575	significance	O
575	was	O
575	set	O
575	at	O
575	p	O
575	<	O
575	0	O
575	.	O
575	05	O
575	.	O
575	[SEP]	O
576	[CLS]	O
576	samples	O
576	were	O
576	di	O
576	##lut	O
576	##ed	O
576	1	O
576	:	O
576	4	O
576	in	O
576	sample	O
576	buffer	O
576	(	O
576	p	O
576	##bs	O
576	p	O
576	##h	O
576	7	O
576	.	O
576	4	O
576	,	O
576	0	O
576	.	O
576	5	O
576	%	O
576	b	O
576	##ov	O
576	##ine	O
576	serum	O
576	album	O
576	##in	O
576	[	O
576	b	O
576	##sa	O
576	]	O
576	,	O
576	15	O
576	pp	O
576	##m	O
576	pro	O
576	##c	O
576	##lin	O
576	,	O
576	0	O
576	.	O
576	05	O
576	%	O
576	p	O
576	##oly	O
576	##sor	O
576	##bate	O
576	-	O
576	20	O
576	,	O
576	0	O
576	.	O
576	25	O
576	%	O
576	3	O
576	-	O
576	[	O
576	(	O
576	3	O
576	-	O
576	ch	O
576	##ola	O
576	##mi	O
576	##do	O
576	##p	O
576	##rop	O
576	##yl	O
576	)	O
576	dim	O
576	##eth	O
576	##yla	O
576	##mm	O
576	##oni	O
576	##o	O
576	]	O
576	-	O
576	1	O
576	-	O
576	prop	O
576	##ane	O
576	##sul	O
576	##fo	O
576	##nate	O
576	[	O
576	ch	O
576	##ap	O
576	##s	O
576	]	O
576	,	O
576	5	O
576	mm	O
576	et	O
576	##hyl	O
576	##ened	O
576	##iam	O
576	##inet	O
576	##et	O
576	##ra	O
576	##ace	O
576	##tic	O
576	acid	O
576	[	O
576	ed	O
576	##ta	O
576	]	O
576	and	O
576	0	O
576	.	O
576	35	O
576	m	O
576	na	O
576	##c	O
576	##l	O
576	)	O
576	.	O
576	[SEP]	O
577	[CLS]	O
577	plasma	O
577	concentration	O
577	-	O
577	time	O
577	profiles	O
577	for	O
577	each	O
577	au	O
577	##n	O
577	##p	O
577	are	O
577	illustrated	O
577	in	O
577	figure	O
577	2	O
577	,	O
577	with	O
577	the	O
577	p	O
577	##har	O
577	##ma	O
577	##co	O
577	##kin	O
577	##etic	O
577	parameters	O
577	are	O
577	summarized	O
577	in	O
577	table	O
577	1	O
577	.	O
577	[SEP]	O
578	[CLS]	O
578	plasma	O
578	h	O
578	##gh	O
578	and	O
578	i	O
578	##g	O
578	##f	O
578	-	O
578	1	O
578	levels	O
578	were	O
578	determined	O
578	by	O
578	el	O
578	##isa	O
578	##s	O
578	from	O
578	r	O
578	&	O
578	d	O
578	systems	O
578	(	O
578	product	O
578	numbers	O
578	d	O
578	##gh	O
578	##100	O
578	and	O
578	d	O
578	##g	O
578	##100	O
578	)	O
578	,	O
578	which	O
578	were	O
578	valid	O
578	##ated	O
578	prior	O
578	to	O
578	use	O
578	.	O
578	[SEP]	O
579	[CLS]	O
579	adult	O
579	patients	O
579	receiving	O
579	either	O
579	me	O
579	##rop	O
579	##ene	O
579	##m	O
579	(	O
579	me	O
579	##rone	O
579	##m	O
579	##®	O
579	,	O
579	as	O
579	##tra	O
579	##zen	O
579	##eca	O
579	)	O
579	or	O
579	pipe	O
579	##rac	O
579	##ill	O
579	##in	O
579	/	O
579	ta	O
579	##zo	O
579	##ba	O
579	##ct	O
579	##am	O
579	(	O
579	ta	O
579	##zo	O
579	##cin	O
579	##®	O
579	,	O
579	p	O
579	##fi	O
579	##zer	O
579	)	O
579	were	O
579	included	O
579	if	O
579	they	O
579	did	O
579	not	O
579	meet	O
579	exclusion	O
579	criteria	O
579	which	O
579	included	O
579	re	O
579	##nal	O
579	d	O
579	##ys	O
579	##function	O
579	(	O
579	defined	O
579	as	O
579	an	O
579	estimated	O
579	g	O
579	##lo	O
579	##mer	O
579	##ular	O
579	fi	O
579	##ltration	O
579	rate	O
579	(	O
579	e	O
579	##g	O
579	##f	O
579	##r	O
579	)	O
579	assessed	O
579	by	O
579	the	O
579	m	O
579	##dr	O
579	##d	O
579	equation	O
579	of	O
579	<	O
579	80	O
579	m	O
579	##l	O
579	/	O
579	min	O
579	/	O
579	1	O
579	.	O
579	73	O
579	m²	O
579	)	O
579	,	O
579	absence	O
579	of	O
579	an	O
579	art	O
579	##erial	O
579	cat	O
579	##he	O
579	##ter	O
579	,	O
579	or	O
579	absence	O
579	of	O
579	informed	O
579	consent	O
579	.	O
579	[SEP]	O
580	[CLS]	O
580	from	O
580	fi	O
580	##ck	O
580	'	O
580	s	O
580	first	O
580	law	O
580	,	O
580	j	O
580	=	O
580	−	O
580	##d	O
580	×	O
580	[	O
580	d	O
580	##c	O
580	(	O
580	x	O
580	)	O
580	]	O
580	/	O
580	d	O
580	##x	O
580	(	O
580	j	O
580	is	O
580	the	O
580	flux	O
580	or	O
580	transfer	O
580	rate	O
580	along	O
580	the	O
580	donor	O
580	-	O
580	to	O
580	-	O
580	receptor	O
580	side	O
580	,	O
580	d	O
580	is	O
580	the	O
580	diffusion	O
580	coefficient	O
580	,	O
580	x	O
580	is	O
580	the	O
580	distance	O
580	from	O
580	the	O
580	donor	O
580	compartment	O
580	,	O
580	and	O
580	c	O
580	(	O
580	x	O
580	)	O
580	is	O
580	the	O
580	concentration	O
580	in	O
580	the	O
580	barrier	O
580	at	O
580	the	O
580	coordinate	O
580	x	O
580	in	O
580	the	O
580	barrier	O
580	)	O
580	,	O
580	the	O
580	following	O
580	differential	O
580	equation	O
580	is	O
580	derived	O
580	:	O
580	d	O
580	##m	O
580	##r	O
580	(	O
580	t	O
580	)	O
580	/	O
580	d	O
580	##t	O
580	=	O
580	p	O
580	##ap	O
580	##p	O
580	×	O
580	a	O
580	×	O
580	[	O
580	c	O
580	##d	O
580	(	O
580	t	O
580	)	O
580	−	O
580	c	O
580	##r	O
580	(	O
580	t	O
580	)	O
580	]	O
580	,	O
580	in	O
580	which	O
580	p	B-PK
580	##ap	I-PK
580	##p	I-PK
580	is	O
580	the	O
580	apparent	B-PK
580	per	I-PK
580	##me	I-PK
580	##ability	I-PK
580	coefficient	I-PK
580	(	O
580	a	O
580	product	O
580	of	O
580	distribution	O
580	coefficient	O
580	with	O
580	diffusion	O
580	coefficient	O
580	divided	O
580	by	O
580	the	O
580	barrier	O
580	thickness	O
580	)	O
580	,	O
580	m	O
580	##r	O
580	is	O
580	the	O
580	amount	O
580	of	O
580	substance	O
580	in	O
580	the	O
580	receiver	O
580	chamber	O
580	,	O
580	a	O
580	is	O
580	the	O
580	cross	O
580	-	O
580	section	O
580	##al	O
580	area	O
580	of	O
580	the	O
580	barrier	O
580	,	O
580	c	O
580	##d	O
580	is	O
580	the	O
580	donor	O
580	concentration	O
580	,	O
580	and	O
580	c	O
580	##r	O
580	is	O
580	the	O
580	receiver	O
580	concentration	O
580	.	O
580	[SEP]	O
581	[CLS]	O
581	the	O
581	adverse	O
581	events	O
581	of	O
581	f	O
581	##er	O
581	##mented	O
581	red	O
581	g	O
581	##ins	O
581	##eng	O
581	and	O
581	the	O
581	probe	O
581	drugs	O
581	were	O
581	evaluated	O
581	in	O
581	all	O
581	15	O
581	subjects	O
581	.	O
581	[SEP]	O
582	[CLS]	O
582	the	O
582	lower	O
582	limit	O
582	of	O
582	q	O
582	##uant	O
582	##ification	O
582	is	O
582	<	O
582	0	O
582	.	O
582	70	O
582	ng	O
582	/	O
582	m	O
582	##l	O
582	(	O
582	corresponding	O
582	to	O
582	<	O
582	1	O
582	.	O
582	8	O
582	nm	O
582	##ol	O
582	/	O
582	l	O
582	que	O
582	##tia	O
582	##pine	O
582	)	O
582	(	O
582	da	O
582	##vis	O
582	et	O
582	al	O
582	.	O
582	2010	O
582	)	O
582	.	O
582	[SEP]	O
583	[CLS]	O
583	after	O
583	administration	O
583	of	O
583	me	O
583	##dicated	O
583	feed	O
583	,	O
583	blood	O
583	plasma	O
583	samples	O
583	were	O
583	taken	O
583	between	O
583	0	O
583	and	O
583	48	O
583	hours	O
583	,	O
583	by	O
583	ca	O
583	##uda	O
583	##l	O
583	ve	O
583	##ni	O
583	##pu	O
583	##nc	O
583	##ture	O
583	at	O
583	the	O
583	following	O
583	times	O
583	:	O
583	0	O
583	,	O
583	3	O
583	,	O
583	6	O
583	,	O
583	8	O
583	,	O
583	12	O
583	,	O
583	18	O
583	,	O
583	24	O
583	,	O
583	36	O
583	and	O
583	48	O
583	hours	O
583	after	O
583	the	O
583	introduction	O
583	of	O
583	me	O
583	##dicated	O
583	feed	O
583	.	O
583	[SEP]	O
584	[CLS]	O
584	in	O
584	##tra	O
584	-	O
584	ass	O
584	##ay	O
584	precision	O
584	and	O
584	bias	O
584	was	O
584	examined	O
584	using	O
584	spike	O
584	##d	O
584	control	O
584	samples	O
584	anal	O
584	##ys	O
584	##ed	O
584	in	O
584	replica	O
584	##tes	O
584	of	O
584	five	O
584	.	O
584	[SEP]	O
585	[CLS]	O
585	by	O
585	hour	O
585	72	O
585	,	O
585	median	O
585	plasma	O
585	concentrations	O
585	of	O
585	con	O
585	##iva	O
585	##pta	O
585	##n	O
585	were	O
585	nearly	O
585	dose	O
585	proportional	O
585	.	O
585	[SEP]	O
586	[CLS]	O
586	by	O
586	study	O
586	day	O
586	10	O
586	,	O
586	virtually	O
586	100	O
586	%	O
586	of	O
586	the	O
586	drug	O
586	had	O
586	been	O
586	cleared	O
586	.	O
586	[SEP]	O
587	[CLS]	O
587	inter	O
587	-	O
587	ass	O
587	##ay	O
587	precision	O
587	and	O
587	accuracy	O
587	were	O
587	anal	O
587	##ys	O
587	##ed	O
587	in	O
587	q	O
587	##uin	O
587	##tu	O
587	##ple	O
587	##t	O
587	at	O
587	three	O
587	concentrations	O
587	and	O
587	on	O
587	three	O
587	separate	O
587	occasions	O
587	.	O
587	[SEP]	O
588	[CLS]	O
588	table	O
588	2	O
588	shows	O
588	the	O
588	l	O
588	##sm	O
588	##s	O
588	of	O
588	the	O
588	inverse	O
588	log	O
588	‐	O
588	transformed	O
588	p	O
588	##k	O
588	values	O
588	(	O
588	breakfast	O
588	/	O
588	no	O
588	breakfast	O
588	)	O
588	and	O
588	the	O
588	90	O
588	%	O
588	c	O
588	##is	O
588	.	O
588	[SEP]	O
589	[CLS]	O
589	the	O
589	samples	O
589	were	O
589	collected	O
589	in	O
589	ed	O
589	##ta	O
589	tubes	O
589	and	O
589	cent	O
589	##ri	O
589	##fu	O
589	##ged	O
589	at	O
589	450	O
589	##0	O
589	rpm	O
589	for	O
589	10	O
589	minutes	O
589	.	O
589	[SEP]	O
590	[CLS]	O
590	bone	O
590	ma	O
590	##rrow	O
590	donor	O
590	-	O
590	recipient	O
590	total	O
590	cell	O
590	ch	O
590	##ime	O
590	##rism	O
590	analysis	O
590	was	O
590	performed	O
590	on	O
590	day	O
590	30	O
590	and	O
590	day	O
590	100	O
590	using	O
590	a	O
590	quantitative	O
590	flu	O
590	##ores	O
590	##cence	O
590	-	O
590	based	O
590	short	O
590	tandem	O
590	repeat	O
590	polymer	O
590	##ase	O
590	chain	O
590	reaction	O
590	with	O
590	cap	O
590	##illa	O
590	##ry	O
590	electro	O
590	##ph	O
590	##ores	O
590	##is	O
590	for	O
590	polymer	O
590	##ase	O
590	chain	O
590	reaction	O
590	product	O
590	resolution	O
590	.	O
590	[SEP]	O
591	[CLS]	O
591	the	O
591	oral	B-PK
591	bio	I-PK
591	##ava	I-PK
591	##ila	I-PK
591	##bility	I-PK
591	of	O
591	hp	O
591	-	O
591	beta	O
591	-	O
591	c	O
591	##d	O
591	/	O
591	pm	O
591	##x	O
591	/	O
591	d	O
591	##ck	O
591	/	O
591	p	O
591	##18	O
591	##8	O
591	-	O
591	ne	O
591	was	O
591	thus	O
591	2	O
591	.	O
591	23	O
591	-	O
591	fold	O
591	higher	O
591	than	O
591	that	O
591	of	O
591	pm	O
591	##x	O
591	solution	O
591	(	O
591	26	O
591	.	O
591	8	O
591	%	O
591	±	O
591	##2	O
591	.	O
591	98	O
591	%	O
591	;	O
591	table	O
591	2	O
591	)	O
591	.	O
591	[SEP]	O
592	[CLS]	O
592	therefore	O
592	,	O
592	in	O
592	##test	O
592	##inal	O
592	membrane	O
592	per	B-PK
592	##me	I-PK
592	##ability	I-PK
592	and	O
592	pm	O
592	##x	O
592	absorption	O
592	in	O
592	rats	O
592	were	O
592	significantly	O
592	improved	O
592	by	O
592	ion	O
592	-	O
592	pair	O
592	complex	O
592	formation	O
592	with	O
592	d	O
592	##ck	O
592	and	O
592	incorporation	O
592	of	O
592	the	O
592	complex	O
592	in	O
592	a	O
592	na	O
592	##no	O
592	##em	O
592	##ul	O
592	##sive	O
592	system	O
592	.	O
592	[SEP]	O
593	[CLS]	O
593	the	O
593	differences	O
593	in	O
593	half	B-PK
593	-	I-PK
593	lives	I-PK
593	after	O
593	i	O
593	##v	O
593	and	O
593	oral	O
593	administration	O
593	of	O
593	pm	O
593	##x	O
593	suggest	O
593	that	O
593	absorption	O
593	may	O
593	still	O
593	occur	O
593	during	O
593	the	O
593	elimination	O
593	phase	O
593	after	O
593	oral	O
593	intake	O
593	.	O
593	[SEP]	O
594	[CLS]	O
594	flip	O
594	-	O
594	fl	O
594	##op	O
594	occurs	O
594	when	O
594	the	O
594	rate	B-PK
594	of	I-PK
594	absorption	I-PK
594	is	O
594	slower	O
594	than	O
594	the	O
594	rate	B-PK
594	of	I-PK
594	elimination	I-PK
594	.	O
594	[SEP]	O
595	[CLS]	O
595	key	O
595	exclusion	O
595	criteria	O
595	included	O
595	:	O
595	(	O
595	a	O
595	)	O
595	prior	O
595	treatment	O
595	with	O
595	a	O
595	##f	O
595	##li	O
595	##ber	O
595	##ce	O
595	##pt	O
595	or	O
595	p	O
595	##em	O
595	##et	O
595	##re	O
595	##xed	O
595	;	O
595	(	O
595	b	O
595	)	O
595	patients	O
595	whose	O
595	disease	O
595	had	O
595	progressed	O
595	during	O
595	c	O
595	##is	O
595	##p	O
595	##lat	O
595	##in	O
595	administration	O
595	or	O
595	re	O
595	##lap	O
595	##sed	O
595	within	O
595	6	O
595	months	O
595	of	O
595	completion	O
595	of	O
595	c	O
595	##is	O
595	##p	O
595	##lat	O
595	##in	O
595	-	O
595	based	O
595	therapy	O
595	;	O
595	(	O
595	c	O
595	)	O
595	surgery	O
595	within	O
595	the	O
595	last	O
595	28	O
595	days	O
595	;	O
595	(	O
595	d	O
595	)	O
595	un	O
595	##con	O
595	##tro	O
595	##lled	O
595	h	O
595	##yper	O
595	##tens	O
595	##ion	O
595	defined	O
595	as	O
595	s	O
595	##ys	O
595	##to	O
595	##lic	O
595	blood	O
595	pressure	O
595	(	O
595	b	O
595	##p	O
595	)	O
595	[UNK]	O
595	mm	O
595	h	O
595	##g	O
595	and	O
595	/	O
595	or	O
595	di	O
595	##ast	O
595	##olic	O
595	pressure	O
595	[UNK]	O
595	mm	O
595	h	O
595	##g	O
595	(	O
595	prior	O
595	anti	O
595	##hy	O
595	##pert	O
595	##ens	O
595	##ive	O
595	medication	O
595	was	O
595	allowed	O
595	)	O
595	;	O
595	(	O
595	e	O
595	)	O
595	bleeding	O
595	di	O
595	##ath	O
595	##esis	O
595	or	O
595	co	O
595	##agu	O
595	##lop	O
595	##athy	O
595	;	O
595	(	O
595	f	O
595	)	O
595	brain	O
595	or	O
595	le	O
595	##pt	O
595	##ome	O
595	##ning	O
595	##eal	O
595	meta	O
595	##sta	O
595	##ses	O
595	(	O
595	brain	O
595	imaging	O
595	was	O
595	mandatory	O
595	for	O
595	study	O
595	participation	O
595	)	O
595	.	O
595	[SEP]	O
596	[CLS]	O
596	13	O
596	.	O
596	4	O
596	%	O
596	of	O
596	participants	O
596	had	O
596	one	O
596	or	O
596	more	O
596	therapeutic	O
596	para	O
596	##ce	O
596	##tam	O
596	##ol	O
596	concentrations	O
596	.	O
596	[SEP]	O
597	[CLS]	O
597	re	O
597	##current	O
597	malaria	O
597	within	O
597	42	O
597	days	O
597	of	O
597	follow	O
597	-	O
597	up	O
597	occurred	O
597	in	O
597	31	O
597	.	O
597	3	O
597	%	O
597	(	O
597	10	O
597	/	O
597	34	O
597	)	O
597	of	O
597	children	O
597	less	O
597	than	O
597	2	O
597	years	O
597	old	O
597	,	O
597	16	O
597	.	O
597	0	O
597	%	O
597	(	O
597	16	O
597	/	O
597	106	O
597	)	O
597	of	O
597	those	O
597	aged	O
597	2	O
597	–	O
597	5	O
597	years	O
597	,	O
597	9	O
597	.	O
597	4	O
597	%	O
597	(	O
597	15	O
597	/	O
597	160	O
597	)	O
597	of	O
597	those	O
597	aged	O
597	5	O
597	–	O
597	10	O
597	years	O
597	,	O
597	and	O
597	none	O
597	(	O
597	0	O
597	/	O
597	68	O
597	)	O
597	of	O
597	those	O
597	over	O
597	10	O
597	years	O
597	old	O
597	.	O
597	[SEP]	O
598	[CLS]	O
598	liquid	O
598	liquid	O
598	extraction	O
598	method	O
598	was	O
598	used	O
598	.	O
598	[SEP]	O
599	[CLS]	O
599	all	O
599	experiments	O
599	were	O
599	conducted	O
599	according	O
599	to	O
599	the	O
599	guidelines	O
599	for	O
599	care	O
599	and	O
599	use	O
599	of	O
599	laboratory	O
599	animals	O
599	of	O
599	ji	O
599	##lin	O
599	university	O
599	and	O
599	the	O
599	principles	O
599	of	O
599	laboratory	O
599	animal	O
599	care	O
599	of	O
599	ji	O
599	##lin	O
599	university	O
599	.	O
599	[SEP]	O
600	[CLS]	O
600	also	O
600	,	O
600	the	O
600	extraction	O
600	method	O
600	was	O
600	rugged	O
600	enough	O
600	and	O
600	gave	O
600	accurate	O
600	and	O
600	consistent	O
600	results	O
600	when	O
600	applied	O
600	to	O
600	real	O
600	subject	O
600	samples	O
600	.	O
600	[SEP]	O
601	[CLS]	O
601	pre	O
601	##des	O
601	##ign	O
601	##ed	O
601	ta	O
601	##q	O
601	##man	O
601	real	O
601	-	O
601	time	O
601	p	O
601	##c	O
601	##r	O
601	ass	O
601	##ays	O
601	(	O
601	insulin	O
601	receptor	O
601	[	O
601	ins	O
601	##r	O
601	]	O
601	,	O
601	c	O
601	##f	O
601	##0	O
601	##26	O
601	##47	O
601	##6	O
601	##25	O
601	_	O
601	m	O
601	##1	O
601	;	O
601	insulin	O
601	-	O
601	de	O
601	##grading	O
601	enzyme	O
601	[	O
601	id	O
601	##e	O
601	]	O
601	,	O
601	c	O
601	##f	O
601	##0	O
601	##26	O
601	##34	O
601	##27	O
601	##0	O
601	_	O
601	m	O
601	##1	O
601	;	O
601	car	O
601	##cin	O
601	##oe	O
601	##mb	O
601	##ryo	O
601	##nic	O
601	anti	O
601	##gen	O
601	–	O
601	related	O
601	cell	O
601	ad	O
601	##hesion	O
601	molecule	O
601	1	O
601	[	O
601	c	O
601	##ea	O
601	##cam	O
601	##1	O
601	]	O
601	,	O
601	c	O
601	##f	O
601	##0	O
601	##30	O
601	##5	O
601	##40	O
601	##9	O
601	##7	O
601	_	O
601	m	O
601	##1	O
601	;	O
601	and	O
601	18	O
601	##s	O
601	r	O
601	##rna	O
601	,	O
601	h	O
601	##s	O
601	##9	O
601	##9	O
601	##9	O
601	##9	O
601	##9	O
601	##90	O
601	##1	O
601	_	O
601	s	O
601	##1	O
601	[	O
601	applied	O
601	bio	O
601	##sy	O
601	##ste	O
601	##ms	O
601	,	O
601	foster	O
601	city	O
601	,	O
601	ca	O
601	]	O
601	)	O
601	with	O
601	a	O
601	light	O
601	##cycle	O
601	##r	O
601	4	O
601	.	O
601	8	O
601	instrument	O
601	(	O
601	r	O
601	##och	O
601	##e	O
601	life	O
601	science	O
601	,	O
601	in	O
601	##dian	O
601	##ap	O
601	##olis	O
601	,	O
601	in	O
601	)	O
601	were	O
601	used	O
601	to	O
601	assess	O
601	gene	O
601	expression	O
601	.	O
601	[SEP]	O
602	[CLS]	O
602	other	O
602	screening	O
602	assessments	O
602	included	O
602	24	O
602	‐	O
602	hour	O
602	ho	O
602	##lter	O
602	monitoring	O
602	and	O
602	base	O
602	##line	O
602	echo	O
602	##card	O
602	##io	O
602	##gram	O
602	##s	O
602	.	O
602	[SEP]	O
603	[CLS]	O
603	this	O
603	mixture	O
603	was	O
603	treated	O
603	as	O
603	above	O
603	.	O
603	[SEP]	O
604	[CLS]	O
604	non	O
604	-	O
604	para	O
604	##metric	O
604	boots	O
604	##tra	O
604	##p	O
604	sampling	O
604	was	O
604	s	O
604	##tra	O
604	##ti	O
604	##fied	O
604	on	O
604	the	O
604	treatment	O
604	arms	O
604	and	O
604	the	O
604	c	O
604	##y	O
604	##p	O
604	##2	O
604	##b	O
604	##6	O
604	*	O
604	6	O
604	g	O
604	##eno	O
604	##type	O
604	.	O
604	[SEP]	O
605	[CLS]	O
605	matrix	O
605	effect	O
605	assessment	O
605	was	O
605	done	O
605	with	O
605	the	O
605	aim	O
605	to	O
605	check	O
605	the	O
605	effect	O
605	of	O
605	different	O
605	lots	O
605	of	O
605	plasma	O
605	on	O
605	the	O
605	back	O
605	calculated	O
605	value	O
605	of	O
605	q	O
605	##c	O
605	’	O
605	s	O
605	nominal	O
605	concentration	O
605	.	O
605	[SEP]	O
606	[CLS]	O
606	the	O
606	active	O
606	compounds	O
606	in	O
606	a	O
606	##can	O
606	##th	O
606	##op	O
606	##ana	O
606	##x	O
606	sent	O
606	##ico	O
606	##sus	O
606	(	O
606	as	O
606	)	O
606	have	O
606	different	O
606	p	O
606	##har	O
606	##ma	O
606	##co	O
606	##kin	O
606	##etic	O
606	characteristics	O
606	in	O
606	mouse	O
606	models	O
606	.	O
606	[SEP]	O
607	[CLS]	O
607	blood	O
607	samples	O
607	were	O
607	collected	O
607	in	O
607	v	O
607	##ac	O
607	##uta	O
607	##iner	O
607	tubes	O
607	containing	O
607	ed	O
607	##ta	O
607	as	O
607	the	O
607	anti	O
607	##coa	O
607	##gu	O
607	##lant	O
607	.	O
607	[SEP]	O
608	[CLS]	O
608	the	O
608	study	O
608	design	O
608	was	O
608	a	O
608	random	O
608	##ized	O
608	,	O
608	two	O
608	-	O
608	period	O
608	,	O
608	two	O
608	-	O
608	sequence	O
608	,	O
608	two	O
608	-	O
608	treatment	O
608	single	O
608	dose	O
608	,	O
608	open	O
608	label	O
608	,	O
608	bio	O
608	##e	O
608	##qui	O
608	##valence	O
608	study	O
608	using	O
608	axe	O
608	##rt	O
608	##®	O
608	(	O
608	manufactured	O
608	by	O
608	or	O
608	##th	O
608	##o	O
608	-	O
608	m	O
608	##c	O
608	##ne	O
608	##il	O
608	-	O
608	j	O
608	##ans	O
608	##sen	O
608	pharmaceutical	O
608	##s	O
608	,	O
608	in	O
608	##c	O
608	.	O
608	,	O
608	us	O
608	##a	O
608	)	O
608	as	O
608	the	O
608	reference	O
608	formulation	O
608	.	O
608	[SEP]	O
609	[CLS]	O
609	whole	O
609	-	O
609	blood	O
609	concentrations	O
609	of	O
609	c	O
609	##y	O
609	##c	O
609	##los	O
609	##por	O
609	##ine	O
609	and	O
609	ta	O
609	##c	O
609	##rol	O
609	##imus	O
609	were	O
609	determined	O
609	by	O
609	previously	O
609	valid	O
609	##ated	O
609	liquid	O
609	ch	O
609	##roma	O
609	##tography	O
609	with	O
609	tandem	O
609	mass	O
609	s	O
609	##pect	O
609	##rome	O
609	##try	O
609	(	O
609	l	O
609	##c	O
609	–	O
609	m	O
609	##s	O
609	/	O
609	m	O
609	##s	O
609	)	O
609	methods	O
609	by	O
609	inter	O
609	##te	O
609	##k	O
609	pharmaceutical	O
609	services	O
609	(	O
609	el	O
609	do	O
609	##rado	O
609	hills	O
609	,	O
609	ca	O
609	,	O
609	us	O
609	##a	O
609	)	O
609	and	O
609	pp	O
609	##d	O
609	(	O
609	rich	O
609	##mond	O
609	,	O
609	v	O
609	##a	O
609	,	O
609	us	O
609	##a	O
609	)	O
609	,	O
609	respectively	O
609	;	O
609	da	O
609	##c	O
609	##lat	O
609	##as	O
609	##vir	O
609	plasma	O
609	concentrations	O
609	were	O
609	determined	O
609	using	O
609	previously	O
609	valid	O
609	##ated	O
609	l	O
609	##c	O
609	–	O
609	m	O
609	##s	O
609	/	O
609	m	O
609	##s	O
609	methods	O
609	by	O
609	tandem	O
609	labs	O
609	(	O
609	west	O
609	t	O
609	##rent	O
609	##on	O
609	,	O
609	n	O
609	##j	O
609	,	O
609	us	O
609	##a	O
609	)	O
609	.	O
609	[SEP]	O
610	[CLS]	O
610	γ	O
610	-	O
610	ben	O
610	##zy	O
610	##l	O
610	l	O
610	-	O
610	g	O
610	##lut	O
610	##ama	O
610	##te	O
610	n	O
610	-	O
610	car	O
610	##box	O
610	##y	O
610	an	O
610	##hy	O
610	##dr	O
610	##ide	O
610	was	O
610	polymer	O
610	##ised	O
610	in	O
610	n	O
610	,	O
610	n	O
610	-	O
610	dim	O
610	##eth	O
610	##yl	O
610	##form	O
610	##ami	O
610	##de	O
610	,	O
610	initiated	O
610	with	O
610	the	O
610	n	O
610	##h	O
610	##2	O
610	amino	O
610	group	O
610	of	O
610	ch	O
610	##3	O
610	##o	O
610	–	O
610	p	O
610	##eg	O
610	–	O
610	ch	O
610	##2	O
610	##ch	O
610	##2	O
610	##ch	O
610	##2	O
610	##nh	O
610	##2	O
610	,	O
610	to	O
610	obtain	O
610	p	O
610	##eg	O
610	–	O
610	p	O
610	##oly	O
610	(	O
610	γ	O
610	-	O
610	ben	O
610	##zy	O
610	##l	O
610	l	O
610	-	O
610	g	O
610	##lut	O
610	##ama	O
610	##te	O
610	)	O
610	block	O
610	cop	O
610	##oly	O
610	##mers	O
610	(	O
610	p	O
610	##eg	O
610	–	O
610	p	O
610	##b	O
610	##l	O
610	##g	O
610	)	O
610	.	O
610	[SEP]	O
611	[CLS]	O
611	the	O
611	recovery	O
611	of	O
611	radio	B-PK
611	##act	I-PK
611	##ivity	I-PK
611	in	O
611	the	O
611	comb	O
611	##ust	O
611	##ed	O
611	samples	O
611	was	O
611	96	O
611	.	O
611	9	O
611	%	O
611	or	O
611	greater	O
611	.	O
611	[SEP]	O
612	[CLS]	O
612	a	O
612	blood	B-PK
612	clearance	I-PK
612	time	I-PK
612	constant	I-PK
612	was	O
612	estimated	O
612	from	O
612	the	O
612	change	O
612	in	O
612	relaxation	O
612	rates	O
612	(	O
612	r	O
612	##1	O
612	,	O
612	2	O
612	=	O
612	1	O
612	/	O
612	t	O
612	##1	O
612	,	O
612	2	O
612	)	O
612	over	O
612	the	O
612	first	O
612	4	O
612	h	O
612	post	O
612	-	O
612	injection	O
612	,	O
612	after	O
612	sub	O
612	##tract	O
612	##ing	O
612	the	O
612	corresponding	O
612	relaxation	O
612	rate	O
612	for	O
612	agent	O
612	-	O
612	free	O
612	whole	O
612	blood	O
612	as	O
612	base	O
612	##line	O
612	.	O
612	[SEP]	O
613	[CLS]	O
613	the	O
613	so	O
613	##lub	O
613	##ility	O
613	of	O
613	c	O
613	##y	O
613	##c	O
613	##lov	O
613	##iro	O
613	##bu	O
613	##xin	O
613	##e	O
613	d	O
613	was	O
613	determined	O
613	using	O
613	the	O
613	following	O
613	equation	O
613	:	O
613	y	O
613	=	O
613	47	O
613	,	O
613	84	O
613	##1	O
613	##x	O
613	##−	O
613	##1	O
613	,	O
613	29	O
613	##7	O
613	,	O
613	75	O
613	##7	O
613	(	O
613	r	O
613	##2	O
613	=	O
613	0	O
613	.	O
613	99	O
613	##8	O
613	)	O
613	(	O
613	4	O
613	)	O
613	where	O
613	y	O
613	represents	O
613	the	O
613	peak	O
613	area	O
613	and	O
613	x	O
613	represents	O
613	the	O
613	concentration	O
613	(	O
613	μ	O
613	##g	O
613	/	O
613	m	O
613	##l	O
613	)	O
613	.	O
613	[SEP]	O
614	[CLS]	O
614	after	O
614	initial	O
614	en	O
614	##rol	O
614	##ment	O
614	,	O
614	children	O
614	returned	O
614	to	O
614	visit	O
614	the	O
614	study	O
614	clinic	O
614	monthly	O
614	for	O
614	clinical	O
614	examination	O
614	and	O
614	for	O
614	s	O
614	##m	O
614	##c	O
614	drugs	O
614	to	O
614	be	O
614	administered	O
614	.	O
614	[SEP]	O
615	[CLS]	O
615	mean	O
615	serum	O
615	concentration	O
615	of	O
615	me	O
615	##lo	O
615	##xi	O
615	##cam	O
615	in	O
615	6	O
615	buffalo	O
615	##es	O
615	is	O
615	shown	O
615	in	O
615	fi	O
615	##g	O
615	2	O
615	.	O
615	[SEP]	O
616	[CLS]	O
616	complete	O
616	multi	O
616	##var	O
616	##iate	O
616	analyses	O
616	allowed	O
616	for	O
616	the	O
616	effect	O
616	of	O
616	sex	O
616	on	O
616	v	B-PK
616	##m	I-PK
616	and	O
616	f	B-PK
616	##1	I-PK
616	to	O
616	be	O
616	discarded	O
616	,	O
616	as	O
616	well	O
616	as	O
616	that	O
616	of	O
616	mat	O
616	##uration	O
616	on	O
616	d	O
616	##ha	O
616	clearance	B-PK
616	.	O
616	[SEP]	O
617	[CLS]	O
617	secondary	O
617	objectives	O
617	included	O
617	measurement	O
617	of	O
617	clinical	O
617	re	O
617	##mission	O
617	(	O
617	c	O
617	##dai	O
617	<	O
617	150	O
617	)	O
617	,	O
617	clinical	O
617	response	O
617	(	O
617	c	O
617	##dai	O
617	decrease	O
617	of	O
617	at	O
617	least	O
617	70	O
617	points	O
617	from	O
617	base	O
617	##line	O
617	[	O
617	c	O
617	##r	O
617	-	O
617	70	O
617	]	O
617	)	O
617	,	O
617	c	O
617	##r	O
617	-	O
617	100	O
617	(	O
617	c	O
617	##dai	O
617	decrease	O
617	of	O
617	at	O
617	least	O
617	100	O
617	points	O
617	from	O
617	base	O
617	##line	O
617	)	O
617	,	O
617	and	O
617	changes	O
617	in	O
617	laboratory	O
617	values	O
617	(	O
617	h	O
617	##s	O
617	-	O
617	c	O
617	##rp	O
617	and	O
617	f	O
617	##c	O
617	)	O
617	over	O
617	time	O
617	.	O
617	[SEP]	O
618	[CLS]	O
618	are	O
618	taken	O
618	from	O
618	the	O
618	default	O
618	""""	O
618	standard	O
618	human	O
618	""""	O
618	data	O
618	set	O
618	that	O
618	was	O
618	determined	O
618	previously	O
618	by	O
618	application	O
618	of	O
618	p	O
618	##k	O
618	##quest	O
618	to	O
618	other	O
618	so	O
618	##lut	O
618	##es	O
618	.	O
618	[SEP]	O
619	[CLS]	O
619	we	O
619	chose	O
619	a	O
619	value	O
619	for	O
619	c	O
619	##tar	O
619	##get	O
619	within	O
619	m	O
619	##or	O
619	##phine	O
619	'	O
619	s	O
619	therapeutic	O
619	window	O
619	.	O
619	[SEP]	O
620	[CLS]	O
620	four	O
620	of	O
620	5	O
620	pregnant	O
620	women	O
620	experiencing	O
620	re	O
620	##current	O
620	malaria	O
620	had	O
620	a	O
620	day	O
620	7	O
620	l	O
620	##ume	O
620	##fant	O
620	##rine	O
620	level	O
620	of	O
620	<	O
620	280	O
620	ng	O
620	/	O
620	m	O
620	##l	O
620	.	O
620	[SEP]	O
621	[CLS]	O
621	using	O
621	a	O
621	l	O
621	##ume	O
621	##fant	O
621	##rine	O
621	level	O
621	of	O
621	280	O
621	ng	O
621	/	O
621	m	O
621	##l	O
621	on	O
621	day	O
621	7	O
621	as	O
621	a	O
621	target	O
621	,	O
621	12	O
621	pregnant	O
621	women	O
621	(	O
621	40	O
621	%	O
621	)	O
621	and	O
621	9	O
621	non	O
621	##p	O
621	##re	O
621	##gnant	O
621	adults	O
621	(	O
621	30	O
621	%	O
621	)	O
621	were	O
621	below	O
621	this	O
621	threshold	O
621	concentration	O
621	.	O
621	[SEP]	O
622	[CLS]	O
622	all	O
622	subjects	O
622	(	O
622	n	O
622	=	O
622	22	O
622	subjects	O
622	completed	O
622	the	O
622	study	O
622	out	O
622	of	O
622	30	O
622	included	O
622	subjects	O
622	)	O
622	were	O
622	healthy	O
622	male	O
622	volunteers	O
622	,	O
622	with	O
622	both	O
622	parents	O
622	of	O
622	each	O
622	volunteer	O
622	being	O
622	of	O
622	sub	O
622	-	O
622	sa	O
622	##hara	O
622	##n	O
622	a	O
622	##f	O
622	##rica	O
622	##n	O
622	origin	O
622	.	O
622	[SEP]	O
623	[CLS]	O
623	for	O
623	all	O
623	ages	O
623	,	O
623	the	O
623	between	O
623	‐	O
623	drug	O
623	extra	O
623	##pol	O
623	##ation	O
623	potential	O
623	increases	O
623	with	O
623	decreasing	O
623	extraction	B-PK
623	ratio	I-PK
623	values	O
623	of	O
623	the	O
623	model	O
623	drug	O
623	,	O
623	with	O
623	this	O
623	effect	O
623	being	O
623	most	O
623	pronounced	O
623	in	O
623	younger	O
623	children	O
623	(	O
623	see	O
623	supplement	O
623	##ary	O
623	material	O
623	s	O
623	##2	O
623	and	O
623	s	O
623	##3	O
623	)	O
623	.	O
623	[SEP]	O
624	[CLS]	O
624	the	O
624	ne	O
624	##mat	O
624	##ode	O
624	counts	O
624	of	O
624	0	O
624	.	O
624	5	O
624	%	O
624	w	O
624	/	O
624	v	O
624	e	O
624	##p	O
624	##rino	O
624	##me	O
624	##ct	O
624	##in	O
624	-	O
624	treated	O
624	animals	O
624	and	O
624	the	O
624	un	O
624	##tre	O
624	##ated	O
624	control	O
624	animals	O
624	and	O
624	percentage	O
624	efficacy	O
624	are	O
624	summarized	O
624	in	O
624	table	O
624	2	O
624	for	O
624	those	O
624	parasite	O
624	##s	O
624	which	O
624	were	O
624	recovered	O
624	from	O
624	at	O
624	least	O
624	four	O
624	control	O
624	animals	O
624	in	O
624	one	O
624	of	O
624	the	O
624	two	O
624	studies	O
624	.	O
624	[SEP]	O
625	[CLS]	O
625	lb	O
625	used	O
625	in	O
625	this	O
625	study	O
625	(	O
625	95	O
625	%	O
625	)	O
625	was	O
625	prepared	O
625	by	O
625	the	O
625	east	O
625	chin	O
625	##a	O
625	university	O
625	of	O
625	science	O
625	and	O
625	technology	O
625	(	O
625	s	O
625	##hang	O
625	##hai	O
625	,	O
625	chin	O
625	##a	O
625	)	O
625	.	O
625	11	O
625	a	O
625	modified	O
625	ethanol	O
625	-	O
625	dripping	O
625	method	O
625	was	O
625	used	O
625	to	O
625	prepare	O
625	lb	O
625	.	O
625	12	O
625	an	O
625	ethanol	O
625	solution	O
625	of	O
625	lip	O
625	##id	O
625	(	O
625	le	O
625	##ci	O
625	##thin	O
625	:	O
625	ch	O
625	##ole	O
625	##ster	O
625	##ol	O
625	=	O
625	6	O
625	:	O
625	1	O
625	w	O
625	/	O
625	w	O
625	)	O
625	,	O
625	sodium	O
625	de	O
625	##ox	O
625	##ych	O
625	##olate	O
625	,	O
625	t	O
625	##we	O
625	##en	O
625	-	O
625	80	O
625	,	O
625	and	O
625	br	O
625	##uc	O
625	##ine	O
625	(	O
625	16	O
625	:	O
625	4	O
625	:	O
625	4	O
625	:	O
625	1	O
625	,	O
625	w	O
625	/	O
625	w	O
625	)	O
625	was	O
625	dripped	O
625	into	O
625	man	O
625	##ni	O
625	##to	O
625	##l	O
625	solution	O
625	(	O
625	5	O
625	.	O
625	3	O
625	mg	O
625	/	O
625	m	O
625	##l	O
625	)	O
625	.	O
625	[SEP]	O
626	[CLS]	O
626	p	O
626	##or	O
626	##cine	O
626	pan	O
626	##cre	O
626	##as	O
626	lip	O
626	##ase	O
626	was	O
626	provided	O
626	by	O
626	si	O
626	##gma	O
626	(	O
626	100	O
626	–	O
626	500	O
626	units	O
626	/	O
626	mg	O
626	,	O
626	si	O
626	##gma	O
626	-	O
626	al	O
626	##dric	O
626	##h	O
626	,	O
626	s	O
626	##t	O
626	.	O
626	lo	O
626	##ui	O
626	##s	O
626	,	O
626	m	O
626	##o	O
626	,	O
626	us	O
626	##a	O
626	)	O
626	.	O
626	[SEP]	O
627	[CLS]	O
627	c	O
627	##y	O
627	##c	O
627	##lo	O
627	##he	O
627	##xi	O
627	##mi	O
627	##de	O
627	was	O
627	purchased	O
627	from	O
627	s	O
627	##hang	O
627	##hai	O
627	y	O
627	##uan	O
627	##ye	O
627	biological	O
627	technology	O
627	co	O
627	.	O
627	,	O
627	l	O
627	##t	O
627	##d	O
627	.	O
627	(	O
627	s	O
627	##hang	O
627	##hai	O
627	,	O
627	chin	O
627	##a	O
627	)	O
627	.	O
627	[SEP]	O
628	[CLS]	O
628	the	O
628	linear	O
628	##ity	O
628	of	O
628	the	O
628	relationship	O
628	between	O
628	peak	O
628	area	O
628	ratio	O
628	or	O
628	peak	O
628	area	O
628	and	O
628	concentration	O
628	was	O
628	demonstrated	O
628	by	O
628	the	O
628	determination	O
628	coefficient	O
628	(	O
628	r	O
628	##2	O
628	)	O
628	obtained	O
628	for	O
628	the	O
628	p	O
628	##ae	O
628	##ono	O
628	##l	O
628	re	O
628	##gression	O
628	lines	O
628	.	O
628	[SEP]	O
629	[CLS]	O
629	the	O
629	maintenance	O
629	dose	O
629	should	O
629	be	O
629	reduced	O
629	to	O
629	35	O
629	mg	O
629	for	O
629	patients	O
629	classified	O
629	as	O
629	child	O
629	-	O
629	pu	O
629	##gh	O
629	b	O
629	or	O
629	c	O
629	.	O
629	ca	O
629	##sp	O
629	##of	O
629	##ung	O
629	##in	O
629	was	O
629	administered	O
629	in	O
629	##tra	O
629	##ven	O
629	##ously	O
629	over	O
629	approximately	O
629	1	O
629	h	O
629	.	O
629	patients	O
629	were	O
629	treated	O
629	as	O
629	long	O
629	as	O
629	clinical	O
629	##ly	O
629	relevant	O
629	but	O
629	the	O
629	duration	O
629	of	O
629	the	O
629	study	O
629	(	O
629	i	O
629	.	O
629	e	O
629	.	O
629	,	O
629	sampling	O
629	of	O
629	patients	O
629	)	O
629	was	O
629	limited	O
629	to	O
629	14	O
629	days	O
629	of	O
629	ca	O
629	##sp	O
629	##of	O
629	##ung	O
629	##in	O
629	treatment	O
629	.	O
629	[SEP]	O
630	[CLS]	O
630	all	O
630	other	O
630	chemicals	O
630	were	O
630	analytical	O
630	grade	O
630	and	O
630	used	O
630	without	O
630	further	O
630	pu	O
630	##rification	O
630	.	O
630	[SEP]	O
631	[CLS]	O
631	two	O
631	deaths	O
631	in	O
631	phase	O
631	1	O
631	##b	O
631	(	O
631	sudden	O
631	death	O
631	and	O
631	sub	O
631	##du	O
631	##ral	O
631	hem	O
631	##ato	O
631	##ma	O
631	)	O
631	were	O
631	considered	O
631	treatment	O
631	-	O
631	related	O
631	,	O
631	while	O
631	the	O
631	third	O
631	(	O
631	pneumonia	O
631	)	O
631	was	O
631	considered	O
631	unrelated	O
631	.	O
631	[SEP]	O
632	[CLS]	O
632	in	O
632	addition	O
632	,	O
632	the	O
632	c	O
632	##sa	O
632	dissolution	O
632	profile	O
632	of	O
632	sand	O
632	##im	O
632	##mu	O
632	##ne	O
632	##®	O
632	presented	O
632	after	O
632	30	O
632	min	O
632	a	O
632	progressive	O
632	increase	O
632	in	O
632	the	O
632	drug	O
632	dissolution	O
632	rate	O
632	reaching	O
632	95	O
632	%	O
632	c	O
632	##sa	O
632	after	O
632	90	O
632	min	O
632	.	O
632	[SEP]	O
633	[CLS]	O
633	in	O
633	this	O
633	evaluation	O
633	,	O
633	the	O
633	c	B-PK
633	##l	I-PK
633	/	I-PK
633	f	I-PK
633	and	O
633	v	B-PK
633	##d	I-PK
633	/	I-PK
633	f	I-PK
633	were	O
633	plot	O
633	##ted	O
633	against	O
633	animal	O
633	body	O
633	weight	O
633	on	O
633	a	O
633	log	O
633	-	O
633	log	O
633	scale	O
633	[	O
633	16	O
633	]	O
633	.	O
633	[SEP]	O
634	[CLS]	O
634	linear	O
634	re	O
634	##gression	O
634	analysis	O
634	was	O
634	then	O
634	performed	O
634	using	O
634	graph	O
634	##pad	O
634	p	O
634	##rism	O
634	5	O
634	.	O
634	0	O
634	,	O
634	graph	O
634	##pad	O
634	software	O
634	,	O
634	in	O
634	##c	O
634	.	O
634	la	O
634	j	O
634	##oll	O
634	##a	O
634	,	O
634	ca	O
634	,	O
634	us	O
634	##a	O
634	,	O
634	according	O
634	to	O
634	the	O
634	log	O
634	##ari	O
634	##th	O
634	##mic	O
634	transformations	O
634	of	O
634	the	O
634	simple	O
634	all	O
634	##ometric	O
634	equations	O
634	as	O
634	shown	O
634	below	O
634	for	O
634	:	O
634	[SEP]	O
635	[CLS]	O
635	plasma	B-PK
635	clearance	I-PK
635	rate	I-PK
635	was	O
635	71	O
635	–	O
635	79	O
635	m	O
635	##l	O
635	kg	O
635	##−	O
635	##1	O
635	h	O
635	##−	O
635	##1	O
635	and	O
635	hence	O
635	higher	O
635	than	O
635	that	O
635	observed	O
635	in	O
635	adult	O
635	patients	O
635	with	O
635	ha	O
635	##em	O
635	##op	O
635	##hil	O
635	##ia	O
635	and	O
635	in	O
635	healthy	O
635	subjects	O
635	.	O
635	[SEP]	O
636	[CLS]	O
636	in	O
636	v	O
636	##it	O
636	##ro	O
636	dissolution	O
636	studies	O
636	were	O
636	performed	O
636	for	O
636	raw	O
636	sir	O
636	##oli	O
636	##mus	O
636	powder	O
636	,	O
636	liquid	O
636	s	O
636	##med	O
636	##ds	O
636	,	O
636	and	O
636	solid	O
636	s	O
636	##med	O
636	##ds	O
636	.	O
636	[SEP]	O
637	[CLS]	O
637	the	O
637	severity	O
637	of	O
637	all	O
637	a	O
637	##es	O
637	was	O
637	either	O
637	mild	O
637	or	O
637	moderate	O
637	,	O
637	and	O
637	all	O
637	were	O
637	resolved	O
637	without	O
637	medical	O
637	intervention	O
637	.	O
637	[SEP]	O
638	[CLS]	O
638	matrix	O
638	effect	O
638	was	O
638	calculated	O
638	by	O
638	the	O
638	following	O
638	equation	O
638	using	O
638	the	O
638	peak	O
638	anal	O
638	##yte	O
638	areas	O
638	obtained	O
638	by	O
638	direct	O
638	injection	O
638	of	O
638	di	O
638	##lut	O
638	##ed	O
638	(	O
638	or	O
638	neat	O
638	)	O
638	standard	O
638	solutions	O
638	(	O
638	a	O
638	)	O
638	and	O
638	the	O
638	corresponding	O
638	peak	O
638	areas	O
638	of	O
638	di	O
638	##lut	O
638	##ed	O
638	(	O
638	or	O
638	neat	O
638	)	O
638	standard	O
638	solutions	O
638	spike	O
638	##d	O
638	into	O
638	plasma	O
638	de	O
638	##p	O
638	##rote	O
638	##ni	O
638	##zed	O
638	ace	O
638	##ton	O
638	##it	O
638	##ril	O
638	##e	O
638	(	O
638	b	O
638	)	O
638	.	O
638	[SEP]	O
639	[CLS]	O
639	p	O
639	##har	O
639	##ma	O
639	##co	O
639	##kin	O
639	##etic	O
639	parameters	O
639	were	O
639	determined	O
639	by	O
639	non	O
639	-	O
639	compartment	O
639	##al	O
639	analysis	O
639	using	O
639	kinetic	O
639	##a	O
639	ve	O
639	##r	O
639	4	O
639	.	O
639	4	O
639	.	O
639	1	O
639	(	O
639	the	O
639	##rm	O
639	##o	O
639	fish	O
639	##er	O
639	scientific	O
639	in	O
639	##c	O
639	,	O
639	p	O
639	##hil	O
639	##ade	O
639	##l	O
639	##phi	O
639	##a	O
639	,	O
639	p	O
639	##a	O
639	,	O
639	us	O
639	##a	O
639	)	O
639	.	O
639	[SEP]	O
640	[CLS]	O
640	a	O
640	solution	O
640	##of	O
640	3	O
640	-	O
640	ch	O
640	##lor	O
640	##o	O
640	-	O
640	4	O
640	-	O
640	ni	O
640	##tro	O
640	##ani	O
640	##line	O
640	(	O
640	6	O
640	,	O
640	10	O
640	.	O
640	2	O
640	mm	O
640	##ol	O
640	,	O
640	1	O
640	.	O
640	75	O
640	g	O
640	)	O
640	(	O
640	al	O
640	##fa	O
640	##ae	O
640	##sar	O
640	)	O
640	and	O
640	t	O
640	##rie	O
640	##thy	O
640	##lam	O
640	##ine	O
640	(	O
640	122	O
640	mm	O
640	##ol	O
640	,	O
640	17	O
640	.	O
640	0	O
640	m	O
640	##l	O
640	)	O
640	in	O
640	30	O
640	m	O
640	##l	O
640	of	O
640	th	O
640	##f	O
640	was	O
640	then	O
640	##ad	O
640	##ded	O
640	to	O
640	the	O
640	gray	O
640	salt	O
640	powder	O
640	in	O
640	30	O
640	m	O
640	##l	O
640	of	O
640	th	O
640	##f	O
640	.	O
640	[SEP]	O
641	[CLS]	O
641	j	O
641	##ak	O
641	##1	O
641	in	O
641	##hibition	O
641	was	O
641	investigated	O
641	using	O
641	flu	O
641	##ores	O
641	##cence	O
641	-	O
641	activated	O
641	cell	O
641	sorting	O
641	analysis	O
641	on	O
641	blood	O
641	samples	O
641	from	O
641	healthy	O
641	volunteers	O
641	after	O
641	administration	O
641	of	O
641	fi	O
641	##l	O
641	##got	O
641	##ini	O
641	##b	O
641	or	O
641	place	O
641	##bo	O
641	,	O
641	after	O
641	single	O
641	dose	O
641	(	O
641	day	O
641	1	O
641	)	O
641	or	O
641	at	O
641	steady	O
641	state	O
641	(	O
641	day	O
641	10	O
641	)	O
641	,	O
641	by	O
641	measuring	O
641	s	O
641	##tat	O
641	##1	O
641	p	O
641	##hos	O
641	##ph	O
641	##ory	O
641	##lation	O
641	(	O
641	ps	O
641	##tat	O
641	##1	O
641	)	O
641	in	O
641	il	O
641	-	O
641	6	O
641	-	O
641	stimulate	O
641	##d	O
641	blood	O
641	.	O
641	[SEP]	O
642	[CLS]	O
642	measurements	O
642	of	O
642	il	O
642	-	O
642	6	O
642	-	O
642	induced	O
642	s	O
642	##tat	O
642	##1	O
642	p	O
642	##hos	O
642	##ph	O
642	##ory	O
642	##lation	O
642	were	O
642	performed	O
642	as	O
642	described	O
642	in	O
642	van	O
642	r	O
642	##om	O
642	##pa	O
642	##ey	O
642	et	O
642	al	O
642	.	O
642	[	O
642	8	O
642	]	O
642	.	O
642	[SEP]	O
643	[CLS]	O
643	treatment	O
643	was	O
643	also	O
643	terminated	O
643	if	O
643	a	O
643	patient	O
643	had	O
643	an	O
643	into	O
643	##ler	O
643	##able	O
643	a	O
643	##e	O
643	or	O
643	withdrew	O
643	consent	O
643	,	O
643	or	O
643	if	O
643	a	O
643	treatment	O
643	cycle	O
643	was	O
643	delayed	O
643	for	O
643	>	O
643	2	O
643	weeks	O
643	.	O
643	[SEP]	O
644	[CLS]	O
644	these	O
644	differences	O
644	can	O
644	be	O
644	explained	O
644	by	O
644	the	O
644	fact	O
644	that	O
644	body	O
644	weight	O
644	was	O
644	the	O
644	only	O
644	co	O
644	##var	O
644	##iate	O
644	of	O
644	importance	O
644	for	O
644	l	O
644	##ira	O
644	##g	O
644	##lut	O
644	##ide	O
644	exposure	O
644	.	O
644	[SEP]	O
645	[CLS]	O
645	the	O
645	population	O
645	p	O
645	##k	O
645	analysis	O
645	allowed	O
645	for	O
645	comparison	O
645	of	O
645	l	O
645	##ira	O
645	##g	O
645	##lut	O
645	##ide	O
645	exposure	O
645	between	O
645	children	O
645	participating	O
645	in	O
645	the	O
645	current	O
645	trial	O
645	and	O
645	previous	O
645	trials	O
645	including	O
645	adolescent	O
645	##s	O
645	##21	O
645	and	O
645	adults	O
645	.	O
645	22	O
645	the	O
645	mean	O
645	estimate	O
645	of	O
645	c	B-PK
645	##l	I-PK
645	/	I-PK
645	f	I-PK
645	in	O
645	children	O
645	was	O
645	lower	O
645	than	O
645	that	O
645	in	O
645	both	O
645	adolescent	O
645	##s	O
645	and	O
645	adults	O
645	(	O
645	table	O
645	4	O
645	)	O
645	.	O
645	[SEP]	O
646	[CLS]	O
646	a	O
646	third	O
646	of	O
646	patients	O
646	on	O
646	the	O
646	p	O
646	##n	O
646	##40	O
646	##0	O
646	/	O
646	e	O
646	##10	O
646	treatment	O
646	were	O
646	affected	O
646	.	O
646	[SEP]	O
647	[CLS]	O
647	our	O
647	results	O
647	suggest	O
647	that	O
647	candidate	O
647	transport	O
647	##er	O
647	gene	O
647	variants	O
647	have	O
647	little	O
647	contribution	O
647	to	O
647	var	O
647	##iability	O
647	in	O
647	g	O
647	##ly	O
647	##ce	O
647	##mic	O
647	response	O
647	to	O
647	met	O
647	##form	O
647	##in	O
647	in	O
647	t	O
647	##2	O
647	##d	O
647	.	O
647	[SEP]	O
648	[CLS]	O
648	the	O
648	mean	O
648	clearance	B-PK
648	of	O
648	i	O
648	##gg	O
648	##1	O
648	anti	O
648	##body	O
648	a	O
648	##1	O
648	was	O
648	elevated	O
648	relative	O
648	to	O
648	c	O
648	##1	O
648	and	O
648	d	O
648	##1	O
648	by	O
648	10	O
648	.	O
648	3	O
648	and	O
648	13	O
648	.	O
648	8	O
648	mg	O
648	•	O
648	h	O
648	/	O
648	kg	O
648	,	O
648	respectively	O
648	in	O
648	the	O
648	s	O
648	##c	O
648	group	O
648	.	O
648	[SEP]	O
649	[CLS]	O
649	in	O
649	the	O
649	i	O
649	##v	O
649	group	O
649	mean	O
649	clearance	B-PK
649	levels	O
649	were	O
649	elevated	O
649	between	O
649	i	O
649	##gg	O
649	##1	O
649	anti	O
649	##body	O
649	b	O
649	##1	O
649	and	O
649	antibodies	O
649	c	O
649	##1	O
649	(	O
649	0	O
649	.	O
649	29	O
649	m	O
649	##l	O
649	/	O
649	h	O
649	/	O
649	kg	O
649	)	O
649	and	O
649	d	O
649	##1	O
649	(	O
649	0	O
649	.	O
649	31	O
649	m	O
649	##l	O
649	/	O
649	h	O
649	/	O
649	kg	O
649	)	O
649	)	O
649	,	O
649	along	O
649	with	O
649	elevated	O
649	levels	O
649	between	O
649	the	O
649	i	O
649	##gg	O
649	##2	O
649	anti	O
649	##body	O
649	b	O
649	##2	O
649	and	O
649	antibodies	O
649	c	O
649	##2	O
649	(	O
649	0	O
649	.	O
649	15	O
649	mg	O
649	•	O
649	h	O
649	/	O
649	kg	O
649	)	O
649	and	O
649	d	O
649	##2	O
649	(	O
649	0	O
649	.	O
649	15	O
649	mg	O
649	•	O
649	h	O
649	/	O
649	kg	O
649	)	O
649	.	O
649	[SEP]	O
650	[CLS]	O
650	after	O
650	s	O
650	.	O
650	c	O
650	.	O
650	administration	O
650	in	O
650	a	O
650	non	O
650	##de	O
650	##pot	O
650	formulation	O
650	to	O
650	mice	O
650	,	O
650	p	O
650	##f	O
650	##1	O
650	exhibited	O
650	an	O
650	extended	O
650	half	B-PK
650	-	I-PK
650	life	I-PK
650	in	O
650	comparison	O
650	with	O
650	o	O
650	##t	O
650	,	O
650	3	O
650	.	O
650	2	O
650	hours	O
650	versus	O
650	0	O
650	.	O
650	5	O
650	hour	O
650	,	O
650	respectively	O
650	(	O
650	fi	O
650	##g	O
650	.	O
650	2	O
650	##b	O
650	)	O
650	.	O
650	[SEP]	O
651	[CLS]	O
651	administration	O
651	of	O
651	p	O
651	##f	O
651	##1	O
651	at	O
651	1	O
651	mg	O
651	/	O
651	kg	O
651	in	O
651	the	O
651	non	O
651	##de	O
651	##pot	O
651	formulation	O
651	resulted	O
651	in	O
651	a	O
651	total	B-PK
651	ma	I-PK
651	##ximal	I-PK
651	plasma	I-PK
651	concentration	I-PK
651	(	I-PK
651	cm	I-PK
651	##ax	I-PK
651	)	I-PK
651	of	O
651	33	O
651	##1	O
651	nm	O
651	(	O
651	free	B-PK
651	cm	I-PK
651	##ax	I-PK
651	=	O
651	0	O
651	.	O
651	6	O
651	nm	O
651	)	O
651	at	O
651	2	O
651	hours	O
651	post	O
651	##dos	O
651	##e	O
651	.	O
651	[SEP]	O
652	[CLS]	O
652	the	O
652	total	B-PK
652	cm	I-PK
652	##ax	I-PK
652	of	O
652	o	O
652	##t	O
652	at	O
652	1	O
652	mg	O
652	/	O
652	kg	O
652	was	O
652	216	O
652	nm	O
652	(	O
652	free	B-PK
652	cm	I-PK
652	##ax	I-PK
652	=	O
652	191	O
652	nm	O
652	)	O
652	and	O
652	occurred	O
652	at	O
652	0	O
652	.	O
652	25	O
652	hour	O
652	post	O
652	##dos	O
652	##e	O
652	.	O
652	[SEP]	O
653	[CLS]	O
653	a	O
653	positive	O
653	association	O
653	of	O
653	au	B-PK
653	##c	I-PK
653	or	O
653	cm	B-PK
653	##ax	I-PK
653	with	O
653	dose	O
653	was	O
653	observed	O
653	in	O
653	both	O
653	age	O
653	groups	O
653	.	O
653	[SEP]	O
654	[CLS]	O
654	measured	O
654	p	O
654	##k	O
654	values	O
654	were	O
654	5	O
654	.	O
654	72	O
654	and	O
654	9	O
654	.	O
654	78	O
654	for	O
654	s	O
654	##c	O
654	##8	O
654	##14	O
654	##5	O
654	##8	O
654	and	O
654	9	O
654	.	O
654	82	O
654	for	O
654	s	O
654	##c	O
654	##8	O
654	##32	O
654	##8	O
654	##8	O
654	.	O
654	[SEP]	O
655	[CLS]	O
655	under	O
655	##nut	O
655	##rit	O
655	##ion	O
655	might	O
655	influence	O
655	the	O
655	au	B-PK
655	##c	I-PK
655	of	O
655	i	O
655	##ver	O
655	##me	O
655	##ct	O
655	##in	O
655	in	O
655	ps	O
655	##ac	O
655	.	O
655	[SEP]	O
656	[CLS]	O
656	the	O
656	bio	B-PK
656	##ava	I-PK
656	##ila	I-PK
656	##bility	I-PK
656	studies	O
656	for	O
656	tablets	O
656	with	O
656	pure	O
656	p	O
656	##io	O
656	(	O
656	t	O
656	##1	O
656	)	O
656	,	O
656	solid	O
656	di	O
656	##sper	O
656	##sion	O
656	of	O
656	p	O
656	##io	O
656	(	O
656	t	O
656	##4	O
656	)	O
656	,	O
656	and	O
656	m	O
656	##f	O
656	(	O
656	p	O
656	##io	O
656	##gli	O
656	##tr	O
656	)	O
656	were	O
656	carried	O
656	out	O
656	using	O
656	male	O
656	w	O
656	##ista	O
656	##r	O
656	rats	O
656	(	O
656	200	O
656	-	O
656	250	O
656	g	O
656	)	O
656	.	O
656	[SEP]	O
657	[CLS]	O
657	the	O
657	institutional	O
657	animal	O
657	ethical	O
657	clearance	O
657	(	O
657	v	O
657	##ide	O
657	letter	O
657	no	O
657	.	O
657	a	O
657	##ac	O
657	##p	O
657	/	O
657	i	O
657	##ae	O
657	##c	O
657	/	O
657	p	O
657	-	O
657	46	O
657	/	O
657	2007	O
657	)	O
657	was	O
657	obtained	O
657	before	O
657	conducting	O
657	the	O
657	studies	O
657	.	O
657	[SEP]	O
658	[CLS]	O
658	a	O
658	sample	O
658	size	O
658	of	O
658	18	O
658	subjects	O
658	was	O
658	estimated	O
658	using	O
658	a	O
658	formula	O
658	by	O
658	z	O
658	##hang	O
658	et	O
658	al	O
658	.	O
658	[	O
658	6	O
658	]	O
658	to	O
658	provide	O
658	80	O
658	%	O
658	power	O
658	to	O
658	detect	O
658	approximately	O
658	a	O
658	20	O
658	%	O
658	difference	O
658	on	O
658	a	O
658	log	O
658	scale	O
658	in	O
658	au	B-PK
658	##c	I-PK
658	##0	I-PK
658	–	I-PK
658	12	I-PK
658	##h	I-PK
658	and	O
658	cm	B-PK
658	##ax	I-PK
658	between	O
658	the	O
658	brand	O
658	formulation	O
658	and	O
658	the	O
658	generic	O
658	formulation	O
658	.	O
658	[SEP]	O
659	[CLS]	O
659	the	O
659	saturated	O
659	lip	O
659	##id	O
659	solution	O
659	was	O
659	further	O
659	cent	O
659	##ri	O
659	##fu	O
659	##ged	O
659	at	O
659	1500	O
659	##0	O
659	rpm	O
659	for	O
659	15	O
659	minutes	O
659	to	O
659	remove	O
659	ins	O
659	##ol	O
659	##ub	O
659	##le	O
659	drug	O
659	.	O
659	[SEP]	O
660	[CLS]	O
660	the	O
660	samples	O
660	were	O
660	cent	O
660	##ri	O
660	##fu	O
660	##ged	O
660	at	O
660	3	O
660	,	O
660	000	O
660	rpm	O
660	for	O
660	10	O
660	min	O
660	and	O
660	stored	O
660	at	O
660	−	O
660	##70	O
660	##°	O
660	##c	O
660	for	O
660	ass	O
660	##ays	O
660	.	O
660	[SEP]	O
661	[CLS]	O
661	a	O
661	total	O
661	of	O
661	28	O
661	patients	O
661	with	O
661	re	O
661	##nal	O
661	lesions	O
661	underwent	O
661	d	O
661	##ce	O
661	-	O
661	m	O
661	##ri	O
661	scanning	O
661	.	O
661	[SEP]	O
662	[CLS]	O
662	a	O
662	total	O
662	of	O
662	40	O
662	subjects	O
662	(	O
662	35	O
662	men	O
662	,	O
662	5	O
662	women	O
662	)	O
662	with	O
662	a	O
662	mean	O
662	age	O
662	of	O
662	30	O
662	.	O
662	9	O
662	years	O
662	(	O
662	range	O
662	20	O
662	–	O
662	45	O
662	years	O
662	)	O
662	and	O
662	b	O
662	##mi	O
662	ranging	O
662	from	O
662	19	O
662	.	O
662	9	O
662	kg	O
662	m	O
662	–	O
662	2	O
662	to	O
662	31	O
662	.	O
662	8	O
662	kg	O
662	m	O
662	–	O
662	2	O
662	were	O
662	enrolled	O
662	in	O
662	the	O
662	study	O
662	.	O
662	[SEP]	O
663	[CLS]	O
663	median	O
663	parameter	O
663	values	O
663	with	O
663	their	O
663	95	O
663	%	O
663	confidence	O
663	interval	O
663	(	O
663	c	O
663	##i	O
663	##9	O
663	##5	O
663	%	O
663	)	O
663	were	O
663	derived	O
663	from	O
663	2000	O
663	replica	O
663	##tes	O
663	of	O
663	the	O
663	initial	O
663	data	O
663	##sets	O
663	and	O
663	compared	O
663	with	O
663	the	O
663	original	O
663	estimates	O
663	.	O
663	[SEP]	O
664	[CLS]	O
664	the	O
664	stability	O
664	of	O
664	the	O
664	final	O
664	m	O
664	##q	O
664	and	O
664	as	O
664	/	O
664	d	O
664	##ha	O
664	models	O
664	was	O
664	assessed	O
664	by	O
664	means	O
664	of	O
664	the	O
664	boots	O
664	##tra	O
664	##p	O
664	method	O
664	implemented	O
664	in	O
664	ps	O
664	##n	O
664	-	O
664	tool	O
664	##ki	O
664	##t	O
664	[	O
664	15	O
664	]	O
664	.	O
664	[SEP]	O
665	[CLS]	O
665	the	O
665	accuracy	O
665	and	O
665	precision	O
665	of	O
665	the	O
665	model	O
665	were	O
665	estimated	O
665	by	O
665	means	O
665	of	O
665	prediction	O
665	error	O
665	(	O
665	m	O
665	##pe	O
665	)	O
665	and	O
665	root	O
665	mean	O
665	square	O
665	error	O
665	(	O
665	r	O
665	##ms	O
665	##e	O
665	)	O
665	,	O
665	using	O
665	log	O
665	-	O
665	transformed	O
665	concentrations	O
665	,	O
665	for	O
665	the	O
665	entire	O
665	data	O
665	##set	O
665	and	O
665	also	O
665	for	O
665	each	O
665	study	O
665	site	O
665	[	O
665	25	O
665	]	O
665	.	O
665	[SEP]	O
666	[CLS]	O
666	the	O
666	so	O
666	##lub	O
666	##ility	O
666	study	O
666	was	O
666	performed	O
666	to	O
666	select	O
666	the	O
666	suitable	O
666	oil	O
666	(	O
666	o	O
666	)	O
666	,	O
666	surf	O
666	##act	O
666	##ant	O
666	(	O
666	s	O
666	)	O
666	,	O
666	and	O
666	co	O
666	##su	O
666	##rf	O
666	##act	O
666	##ant	O
666	(	O
666	co	O
666	-	O
666	s	O
666	)	O
666	that	O
666	possesses	O
666	high	O
666	so	O
666	##lub	O
666	##ili	O
666	##zing	O
666	capacity	O
666	for	O
666	v	O
666	##als	O
666	##art	O
666	##an	O
666	.	O
666	[SEP]	O
667	[CLS]	O
667	more	O
667	##over	O
667	,	O
667	the	O
667	final	O
667	m	O
667	##q	O
667	p	O
667	##har	O
667	##ma	O
667	##co	O
667	##kin	O
667	##etic	O
667	model	O
667	was	O
667	valid	O
667	##ated	O
667	using	O
667	concentrations	O
667	collected	O
667	from	O
667	participants	O
667	not	O
667	used	O
667	in	O
667	initial	O
667	model	O
667	development	O
667	.	O
667	[SEP]	O
668	[CLS]	O
668	the	O
668	size	O
668	of	O
668	particles	O
668	for	O
668	nasal	O
668	delivery	O
668	should	O
668	be	O
668	above	O
668	10	O
668	µ	O
668	##m	O
668	because	O
668	the	O
668	smaller	O
668	particles	O
668	(	O
668	<	O
668	10	O
668	µ	O
668	##m	O
668	)	O
668	can	O
668	be	O
668	transferred	O
668	to	O
668	the	O
668	t	O
668	##rac	O
668	##he	O
668	##ob	O
668	##ron	O
668	##chia	O
668	##l	O
668	with	O
668	the	O
668	airs	O
668	##tre	O
668	##am	O
668	,	O
668	while	O
668	larger	O
668	particles	O
668	will	O
668	mostly	O
668	deposit	O
668	in	O
668	the	O
668	nose	O
668	.	O
668	[SEP]	O
669	[CLS]	O
669	s	O
669	##cal	O
669	##ing	O
669	of	O
669	parameters	O
669	by	O
669	weight	O
669	was	O
669	evaluated	O
669	using	O
669	the	O
669	all	O
669	##ometric	O
669	relationship	O
669	(	O
669	weight	O
669	/	O
669	median	O
669	weight	O
669	)	O
669	0	O
669	.	O
669	75	O
669	for	O
669	clearance	B-PK
669	##s	I-PK
669	and	O
669	a	O
669	linear	O
669	relationship	O
669	(	O
669	ratio	O
669	of	O
669	weight	O
669	to	O
669	median	O
669	weight	O
669	)	O
669	for	O
669	volumes	B-PK
669	.	O
669	[SEP]	O
670	[CLS]	O
670	the	O
670	size	O
670	of	O
670	particles	O
670	prepared	O
670	in	O
670	the	O
670	present	O
670	study	O
670	ranged	O
670	from	O
670	45	O
670	–	O
670	58	O
670	µ	O
670	##m	O
670	.	O
670	[SEP]	O
671	[CLS]	O
671	a	O
671	food	O
671	effect	O
671	was	O
671	also	O
671	introduced	O
671	as	O
671	a	O
671	co	O
671	##var	O
671	##iate	O
671	for	O
671	the	O
671	volume	B-PK
671	of	I-PK
671	distribution	I-PK
671	(	O
671	in	O
671	some	O
671	phase	O
671	1	O
671	studies	O
671	,	O
671	the	O
671	drug	O
671	was	O
671	given	O
671	to	O
671	fast	O
671	##ing	O
671	subjects	O
671	,	O
671	whereas	O
671	in	O
671	all	O
671	field	O
671	trials	O
671	the	O
671	drugs	O
671	were	O
671	administered	O
671	after	O
671	the	O
671	ing	O
671	##est	O
671	##ion	O
671	of	O
671	food	O
671	)	O
671	.	O
671	[SEP]	O
672	[CLS]	O
672	variations	O
672	between	O
672	these	O
672	phase	O
672	1	O
672	and	O
672	treatment	O
672	trials	O
672	(	O
672	study	O
672	and	O
672	disease	O
672	effects	O
672	)	O
672	were	O
672	considered	O
672	only	O
672	as	O
672	changes	O
672	to	O
672	the	O
672	relative	O
672	absorption	O
672	parameter	O
672	f	B-PK
672	(	O
672	s	O
672	##cal	O
672	##ing	O
672	parameter	O
672	on	O
672	f	B-PK
672	)	O
672	.	O
672	[SEP]	O
673	[CLS]	O
673	the	O
673	data	O
673	from	O
673	both	O
673	the	O
673	g	O
673	-	O
673	hat	O
673	and	O
673	ch	O
673	##aga	O
673	##s	O
673	disease	O
673	field	O
673	trials	O
673	were	O
673	too	O
673	sparse	O
673	to	O
673	estimate	O
673	changes	O
673	in	O
673	the	O
673	absorption	B-PK
673	rate	I-PK
673	,	O
673	clearance	B-PK
673	,	O
673	or	O
673	volume	B-PK
673	accurately	O
673	.	O
673	[SEP]	O
674	[CLS]	O
674	also	O
674	,	O
674	it	O
674	has	O
674	been	O
674	found	O
674	that	O
674	the	O
674	surface	O
674	charge	O
674	density	O
674	of	O
674	lip	O
674	##oso	O
674	##mes	O
674	influences	O
674	their	O
674	distribution	O
674	in	O
674	an	O
674	in	O
674	v	O
674	##ivo	O
674	environment	O
674	##5	O
674	##9	O
674	.	O
674	[SEP]	O
675	[CLS]	O
675	multiple	O
675	candidate	O
675	structural	O
675	models	O
675	were	O
675	evaluated	O
675	for	O
675	the	O
675	formation	O
675	of	O
675	the	O
675	drug	O
675	,	O
675	using	O
675	0	O
675	,	O
675	1	O
675	,	O
675	2	O
675	,	O
675	or	O
675	3	O
675	transit	O
675	compartment	O
675	##s	O
675	.	O
675	[SEP]	O
676	[CLS]	O
676	such	O
676	stability	O
676	is	O
676	determined	O
676	by	O
676	different	O
676	factors	O
676	,	O
676	such	O
676	as	O
676	the	O
676	##rm	O
676	##ody	O
676	##nam	O
676	##ics	O
676	and	O
676	co	O
676	##llo	O
676	##idal	O
676	properties	O
676	of	O
676	the	O
676	system	O
676	##5	O
676	##4	O
676	.	O
676	[SEP]	O
677	[CLS]	O
677	we	O
677	have	O
677	developed	O
677	three	O
677	different	O
677	cell	O
677	lines	O
677	for	O
677	this	O
677	experiment	O
677	to	O
677	test	O
677	the	O
677	p	O
677	##har	O
677	##ma	O
677	##co	O
677	##kin	O
677	##etics	O
677	of	O
677	two	O
677	different	O
677	imaging	O
677	molecules	O
677	##─	O
677	##18	O
677	##f	O
677	-	O
677	f	O
677	##d	O
677	##g	O
677	(	O
677	radio	O
677	##lum	O
677	##ines	O
677	##cence	O
677	)	O
677	and	O
677	6	O
677	-	O
677	n	O
677	##b	O
677	##d	O
677	##g	O
677	(	O
677	flu	O
677	##ores	O
677	##cence	O
677	)	O
677	.	O
677	[SEP]	O
678	[CLS]	O
678	the	O
678	procedure	O
678	for	O
678	cult	O
678	##uring	O
678	the	O
678	different	O
678	cell	O
678	lines	O
678	is	O
678	described	O
678	below	O
678	.	O
678	[SEP]	O
679	[CLS]	O
679	therefore	O
679	,	O
679	the	O
679	size	O
679	range	O
679	of	O
679	40	O
679	–	O
679	60	O
679	µ	O
679	##m	O
679	is	O
679	appropriate	O
679	for	O
679	nasal	O
679	delivery	O
679	##6	O
679	##1	O
679	.	O
679	[SEP]	O
680	[CLS]	O
680	the	O
680	cm	B-PK
680	##ax	I-PK
680	and	O
680	area	B-PK
680	under	I-PK
680	the	I-PK
680	curve	I-PK
680	(	I-PK
680	au	I-PK
680	##c	I-PK
680	)	I-PK
680	were	O
680	17	O
680	.	O
680	9	O
680	±	O
680	2	O
680	.	O
680	4	O
680	ng	O
680	/	O
680	m	O
680	##l	O
680	and	O
680	70	O
680	.	O
680	7	O
680	±	O
680	11	O
680	.	O
680	2	O
680	ng	O
680	##×	O
680	##h	O
680	/	O
680	m	O
680	##l	O
680	at	O
680	3	O
680	mg	O
680	/	O
680	kg	O
680	,	O
680	and	O
680	44	O
680	.	O
680	1	O
680	±	O
680	7	O
680	.	O
680	9	O
680	ng	O
680	/	O
680	m	O
680	##l	O
680	and	O
680	240	O
680	.	O
680	5	O
680	±	O
680	31	O
680	.	O
680	5	O
680	ng	O
680	##×	O
680	##h	O
680	/	O
680	m	O
680	##l	O
680	at	O
680	10	O
680	mg	O
680	/	O
680	kg	O
680	,	O
680	respectively	O
680	.	O
680	[SEP]	O
681	[CLS]	O
681	this	O
681	was	O
681	completed	O
681	via	O
681	a	O
681	combination	O
681	of	O
681	visual	O
681	inspection	O
681	and	O
681	application	O
681	of	O
681	an	O
681	algorithm	O
681	applied	O
681	to	O
681	a	O
681	linear	O
681	re	O
681	##gression	O
681	of	O
681	dose	O
681	and	O
681	au	B-PK
681	##c	I-PK
681	to	O
681	test	O
681	for	O
681	de	O
681	##viation	O
681	of	O
681	the	O
681	slope	O
681	from	O
681	1	O
681	(	O
681	fi	O
681	##g	O
681	.	O
681	1	O
681	)	O
681	.	O
681	[SEP]	O
682	[CLS]	O
682	the	O
682	cm	B-PK
682	##ax	I-PK
682	and	O
682	au	B-PK
682	##c	I-PK
682	were	O
682	114	O
682	##7	O
682	.	O
682	3	O
682	±	O
682	233	O
682	.	O
682	4	O
682	ng	O
682	/	O
682	m	O
682	##l	O
682	and	O
682	1995	O
682	.	O
682	3	O
682	±	O
682	173	O
682	##5	O
682	.	O
682	3	O
682	ng	O
682	##×	O
682	##h	O
682	/	O
682	m	O
682	##l	O
682	,	O
682	respectively	O
682	,	O
682	at	O
682	3	O
682	mg	O
682	/	O
682	kg	O
682	(	O
682	table	O
682	2	O
682	)	O
682	.	O
682	[SEP]	O
683	[CLS]	O
683	after	O
683	oral	O
683	treatment	O
683	(	O
683	3	O
683	and	O
683	10	O
683	mg	O
683	/	O
683	kg	O
683	)	O
683	,	O
683	a	O
683	maximum	B-PK
683	concentration	I-PK
683	(	I-PK
683	cm	I-PK
683	##ax	I-PK
683	)	I-PK
683	was	O
683	reached	O
683	after	O
683	approximately	O
683	1	O
683	.	O
683	2	O
683	±	O
683	0	O
683	.	O
683	4	O
683	h	O
683	and	O
683	1	O
683	.	O
683	4	O
683	±	O
683	0	O
683	.	O
683	5	O
683	h	O
683	,	O
683	respectively	O
683	,	O
683	and	O
683	gradually	O
683	decreased	O
683	(	O
683	fi	O
683	##g	O
683	.	O
683	1	O
683	##b	O
683	)	O
683	.	O
683	[SEP]	O
684	[CLS]	O
684	to	O
684	calculate	O
684	the	O
684	absolute	B-PK
684	bio	I-PK
684	##ava	I-PK
684	##ila	I-PK
684	##bility	I-PK
684	of	O
684	done	O
684	##pe	O
684	##zi	O
684	##l	O
684	,	O
684	an	O
684	in	O
684	##tra	O
684	##ven	O
684	##ous	O
684	b	O
684	##ol	O
684	##us	O
684	treatment	O
684	of	O
684	3	O
684	mg	O
684	/	O
684	kg	O
684	was	O
684	administered	O
684	to	O
684	hair	O
684	##less	O
684	rats	O
684	via	O
684	the	O
684	tail	O
684	vein	O
684	(	O
684	fi	O
684	##g	O
684	.	O
684	2	O
684	)	O
684	.	O
684	[SEP]	O
685	[CLS]	O
685	absolute	B-PK
685	bio	I-PK
685	##ava	I-PK
685	##ila	I-PK
685	##bility	I-PK
685	was	O
685	calculated	O
685	according	O
685	to	O
685	a	O
685	slightly	O
685	modified	O
685	method	O
685	described	O
685	by	O
685	sa	O
685	##lu	O
685	##ja	O
685	et	O
685	al	O
685	.	O
685	(	O
685	2013	O
685	)	O
685	,	O
685	and	O
685	was	O
685	determined	O
685	to	O
685	be	O
685	3	O
685	.	O
685	6	O
685	%	O
685	,	O
685	indicating	O
685	that	O
685	the	O
685	absolute	B-PK
685	bio	I-PK
685	##ava	I-PK
685	##ila	I-PK
685	##bility	I-PK
685	of	O
685	done	O
685	##pe	O
685	##zi	O
685	##l	O
685	is	O
685	low	O
685	.	O
685	[SEP]	O
686	[CLS]	O
686	total	B-PK
686	(	I-PK
686	i	I-PK
686	.	I-PK
686	e	I-PK
686	.	I-PK
686	,	I-PK
686	bound	I-PK
686	and	I-PK
686	un	I-PK
686	##bound	I-PK
686	)	I-PK
686	he	I-PK
686	##pa	I-PK
686	##tic	I-PK
686	metabolic	I-PK
686	plasma	I-PK
686	clearance	I-PK
686	will	O
686	be	O
686	referred	O
686	to	O
686	as	O
686	c	B-PK
686	##l	I-PK
686	##p	I-PK
686	in	O
686	this	O
686	paper	O
686	.	O
686	[SEP]	O
687	[CLS]	O
687	con	O
687	##ju	O
687	##gation	O
687	or	O
687	fusion	O
687	to	O
687	[UNK]	O
687	(	O
687	album	O
687	##in	O
687	-	O
687	binding	O
687	domain	O
687	antibodies	O
687	)	O
687	is	O
687	a	O
687	novel	O
687	approach	O
687	to	O
687	extend	O
687	the	O
687	half	B-PK
687	-	I-PK
687	life	I-PK
687	and	O
687	alter	O
687	the	O
687	tissue	O
687	distribution	O
687	of	O
687	biological	O
687	and	O
687	small	O
687	molecule	O
687	therapeutic	O
687	##s	O
687	.	O
687	[SEP]	O
688	[CLS]	O
688	following	O
688	single	O
688	and	O
688	multiple	O
688	doses	O
688	of	O
688	al	O
688	##iser	O
688	##ti	O
688	##b	O
688	,	O
688	median	O
688	t	B-PK
688	##max	I-PK
688	for	O
688	al	O
688	##iser	O
688	##ti	O
688	##b	O
688	was	O
688	achieved	O
688	at	O
688	4	O
688	and	O
688	3	O
688	h	O
688	,	O
688	respectively	O
688	(	O
688	table	O
688	1	O
688	)	O
688	.	O
688	[SEP]	O
689	[CLS]	O
689	we	O
689	investigate	O
689	the	O
689	extra	O
689	##pol	O
689	##ation	O
689	potential	O
689	of	O
689	p	O
689	##ediatric	O
689	co	O
689	##var	O
689	##iate	O
689	functions	O
689	s	O
689	##cal	O
689	##ing	O
689	c	B-PK
689	##l	I-PK
689	##p	I-PK
689	from	O
689	adults	O
689	to	O
689	p	O
689	##ediatric	O
689	patients	O
689	between	O
689	a	O
689	model	O
689	drug	O
689	and	O
689	a	O
689	test	O
689	drug	O
689	both	O
689	exclusively	O
689	eliminated	O
689	by	O
689	the	O
689	same	O
689	he	O
689	##pa	O
689	##tic	O
689	is	O
689	##oe	O
689	##nz	O
689	##yme	O
689	.	O
689	[SEP]	O
690	[CLS]	O
690	c	O
690	##ere	O
690	##bro	O
690	##sp	O
690	##inal	O
690	fluid	O
690	(	O
690	c	O
690	##s	O
690	##f	O
690	)	O
690	samples	O
690	were	O
690	collected	O
690	at	O
690	base	O
690	##line	O
690	and	O
690	at	O
690	approximately	O
690	week	O
690	32	O
690	(	O
690	or	O
690	early	O
690	withdrawal	O
690	)	O
690	from	O
690	a	O
690	subset	O
690	of	O
690	subjects	O
690	who	O
690	provided	O
690	consent	O
690	from	O
690	the	O
690	2	O
690	mg	O
690	/	O
690	kg	O
690	,	O
690	4	O
690	mg	O
690	/	O
690	kg	O
690	and	O
690	8	O
690	mg	O
690	/	O
690	kg	O
690	co	O
690	##hor	O
690	##ts	O
690	in	O
690	the	O
690	fi	O
690	##h	O
690	.	O
690	[SEP]	O
691	[CLS]	O
691	the	O
691	mean	O
691	t	B-PK
691	##1	I-PK
691	/	I-PK
691	2	I-PK
691	of	O
691	al	O
691	##iser	O
691	##ti	O
691	##b	O
691	following	O
691	single	O
691	-	O
691	dose	O
691	al	O
691	##iser	O
691	##ti	O
691	##b	O
691	was	O
691	approximately	O
691	16	O
691	h	O
691	.	O
691	median	O
691	t	B-PK
691	##max	I-PK
691	and	O
691	mean	O
691	t	B-PK
691	##1	I-PK
691	/	I-PK
691	2	I-PK
691	for	O
691	the	O
691	meta	O
691	##bol	O
691	##ite	O
691	m	O
691	##1	O
691	were	O
691	similar	O
691	to	O
691	al	O
691	##iser	O
691	##ti	O
691	##b	O
691	.	O
691	[SEP]	O
692	[CLS]	O
692	the	O
692	median	O
692	t	B-PK
692	##max	I-PK
692	for	O
692	meta	O
692	##bol	O
692	##ite	O
692	m	O
692	##2	O
692	was	O
692	achieved	O
692	at	O
692	10	O
692	and	O
692	4	O
692	h	O
692	,	O
692	following	O
692	single	O
692	and	O
692	multiple	O
692	doses	O
692	of	O
692	al	O
692	##iser	O
692	##ti	O
692	##b	O
692	,	O
692	respectively	O
692	and	O
692	the	O
692	mean	O
692	t	B-PK
692	##1	I-PK
692	/	I-PK
692	2	I-PK
692	of	O
692	m	O
692	##2	O
692	was	O
692	approximately	O
692	22	O
692	h	O
692	.	O
692	[SEP]	O
693	[CLS]	O
693	the	O
693	mean	O
693	ratios	B-PK
693	of	I-PK
693	au	I-PK
693	##c	I-PK
693	##0	I-PK
693	-	I-PK
693	last	I-PK
693	for	O
693	m	O
693	##1	O
693	and	O
693	m	O
693	##2	O
693	compared	O
693	to	O
693	al	O
693	##iser	O
693	##ti	O
693	##b	O
693	following	O
693	a	O
693	single	O
693	dose	O
693	of	O
693	al	O
693	##iser	O
693	##ti	O
693	##b	O
693	were	O
693	0	O
693	.	O
693	45	O
693	and	O
693	0	O
693	.	O
693	41	O
693	,	O
693	respectively	O
693	and	O
693	the	O
693	mean	O
693	ratios	B-PK
693	of	I-PK
693	au	I-PK
693	##c	I-PK
693	##0	I-PK
693	-	I-PK
693	10	I-PK
693	##h	I-PK
693	for	O
693	m	O
693	##1	O
693	and	O
693	m	O
693	##2	O
693	compared	O
693	to	O
693	al	O
693	##iser	O
693	##ti	O
693	##b	O
693	following	O
693	multiple	O
693	doses	O
693	of	O
693	al	O
693	##iser	O
693	##ti	O
693	##b	O
693	were	O
693	0	O
693	.	O
693	44	O
693	and	O
693	0	O
693	.	O
693	42	O
693	,	O
693	respectively	O
693	.	O
693	[SEP]	O
694	[CLS]	O
694	the	O
694	mean	O
694	ratios	B-PK
694	of	I-PK
694	cm	I-PK
694	##ax	I-PK
694	for	O
694	m	O
694	##1	O
694	and	O
694	m	O
694	##2	O
694	compared	O
694	to	O
694	al	O
694	##iser	O
694	##ti	O
694	##b	O
694	were	O
694	0	O
694	.	O
694	30	O
694	and	O
694	0	O
694	.	O
694	13	O
694	,	O
694	respectively	O
694	on	O
694	day	O
694	1	O
694	and	O
694	0	O
694	.	O
694	40	O
694	and	O
694	0	O
694	.	O
694	37	O
694	,	O
694	respectively	O
694	on	O
694	day	O
694	10	O
694	.	O
694	[SEP]	O
695	[CLS]	O
695	o	O
695	##xy	O
695	##to	O
695	##cin	O
695	(	O
695	o	O
695	##t	O
695	)	O
695	m	O
695	##od	O
695	##ulates	O
695	the	O
695	expression	O
695	of	O
695	social	O
695	and	O
695	emotional	O
695	behaviors	O
695	and	O
695	consequently	O
695	has	O
695	been	O
695	proposed	O
695	as	O
695	a	O
695	p	O
695	##har	O
695	##ma	O
695	##co	O
695	##log	O
695	##ic	O
695	treatment	O
695	of	O
695	psychiatric	O
695	diseases	O
695	,	O
695	including	O
695	autism	O
695	spectrum	O
695	disorders	O
695	and	O
695	s	O
695	##chi	O
695	##zophrenia	O
695	;	O
695	however	O
695	,	O
695	end	O
695	##ogen	O
695	##ous	O
695	o	O
695	##t	O
695	has	O
695	a	O
695	short	O
695	half	B-PK
695	-	I-PK
695	life	I-PK
695	in	O
695	plasma	O
695	and	O
695	poor	O
695	per	B-PK
695	##me	I-PK
695	##ability	I-PK
695	across	O
695	the	O
695	blood	O
695	-	O
695	brain	O
695	barrier	O
695	.	O
695	[SEP]	O
696	[CLS]	O
696	recent	O
696	efforts	O
696	have	O
696	focused	O
696	on	O
696	the	O
696	development	O
696	of	O
696	novel	O
696	drug	O
696	delivery	O
696	methods	O
696	to	O
696	enhance	O
696	brain	O
696	penetration	O
696	,	O
696	but	O
696	few	O
696	efforts	O
696	have	O
696	aimed	O
696	at	O
696	improving	O
696	its	O
696	half	B-PK
696	-	I-PK
696	life	I-PK
696	.	O
696	[SEP]	O
697	[CLS]	O
697	the	O
697	p	O
697	##k	O
697	properties	O
697	of	O
697	se	O
697	##cu	O
697	##kin	O
697	##uma	O
697	##b	O
697	were	O
697	linear	O
697	,	O
697	with	O
697	no	O
697	evidence	O
697	of	O
697	a	O
697	dose	O
697	dependence	O
697	of	O
697	clearance	B-PK
697	;	O
697	there	O
697	was	O
697	also	O
697	no	O
697	evidence	O
697	of	O
697	a	O
697	time	O
697	‐	O
697	dependent	O
697	change	O
697	in	O
697	the	O
697	clearance	B-PK
697	.	O
697	[SEP]	O
698	[CLS]	O
698	clearance	B-PK
698	and	O
698	volume	B-PK
698	varied	O
698	with	O
698	body	O
698	weight	O
698	in	O
698	an	O
698	all	O
698	##ometric	O
698	relationship	O
698	.	O
698	[SEP]	O
699	[CLS]	O
699	for	O
699	clearance	B-PK
699	and	O
699	central	B-PK
699	volume	I-PK
699	of	I-PK
699	distribution	I-PK
699	,	O
699	the	O
699	all	O
699	##ometric	O
699	ex	O
699	##ponents	O
699	were	O
699	estimated	O
699	to	O
699	be	O
699	between	O
699	0	O
699	.	O
699	8	O
699	and	O
699	1	O
699	.	O
699	0	O
699	;	O
699	in	O
699	other	O
699	words	O
699	,	O
699	a	O
699	doubling	O
699	of	O
699	body	O
699	weight	O
699	could	O
699	lead	O
699	to	O
699	a	O
699	nearly	O
699	2	O
699	‐	O
699	fold	O
699	increase	O
699	in	O
699	clearance	B-PK
699	and	O
699	distribution	B-PK
699	volume	I-PK
699	.	O
699	[SEP]	O
700	[CLS]	O
700	age	O
700	,	O
700	sex	O
700	,	O
700	race	O
700	(	O
700	as	O
700	##ian	O
700	vs	O
700	non	O
700	‐	O
700	as	O
700	##ian	O
700	)	O
700	,	O
700	geographic	O
700	region	O
700	,	O
700	and	O
700	base	O
700	##line	O
700	p	O
700	##asi	O
700	score	O
700	did	O
700	not	O
700	have	O
700	a	O
700	clinical	O
700	##ly	O
700	relevant	O
700	effect	O
700	on	O
700	se	O
700	##cu	O
700	##kin	O
700	##uma	O
700	##b	O
700	clearance	B-PK
700	after	O
700	adjusting	O
700	for	O
700	body	O
700	weight	O
700	.	O
700	[SEP]	O
701	[CLS]	O
701	the	O
701	relative	B-PK
701	bio	I-PK
701	##ava	I-PK
701	##ila	I-PK
701	##bility	I-PK
701	of	O
701	a	O
701	##c	O
701	##v	O
701	-	O
701	ne	O
701	h	O
701	##ydro	O
701	##gel	O
701	was	O
701	53	O
701	##5	O
701	.	O
701	2	O
701	%	O
701	and	O
701	244	O
701	.	O
701	6	O
701	%	O
701	with	O
701	respect	O
701	to	O
701	the	O
701	raw	O
701	a	O
701	##c	O
701	##v	O
701	h	O
701	##ydro	O
701	##gel	O
701	and	O
701	marketed	O
701	a	O
701	##c	O
701	##v	O
701	cream	O
701	,	O
701	respectively	O
701	.	O
701	[SEP]	O
702	[CLS]	O
702	thus	O
702	,	O
702	there	O
702	is	O
702	a	O
702	5	O
702	.	O
702	35	O
702	-	O
702	fold	O
702	and	O
702	2	O
702	.	O
702	44	O
702	-	O
702	fold	O
702	increase	O
702	in	O
702	the	O
702	bio	B-PK
702	##ava	I-PK
702	##ila	I-PK
702	##bility	I-PK
702	of	O
702	a	O
702	##c	O
702	##v	O
702	,	O
702	with	O
702	the	O
702	expectation	O
702	to	O
702	decrease	O
702	the	O
702	administered	O
702	dose	O
702	of	O
702	drug	O
702	to	O
702	the	O
702	patient	O
702	,	O
702	and	O
702	subsequently	O
702	minimize	O
702	the	O
702	the	O
702	und	O
702	##esi	O
702	##rable	O
702	effects	O
702	present	O
702	with	O
702	the	O
702	administration	O
702	of	O
702	the	O
702	large	O
702	dose	O
702	.	O
702	[SEP]	O
703	[CLS]	O
703	therefore	O
703	,	O
703	compositions	O
703	intended	O
703	for	O
703	absorption	O
703	through	O
703	the	O
703	oral	O
703	m	O
703	##uc	O
703	##osa	O
703	are	O
703	prefer	O
703	##ably	O
703	of	O
703	high	O
703	purity	O
703	,	O
703	as	O
703	con	O
703	##tam	O
703	##ina	O
703	##nts	O
703	may	O
703	be	O
703	absorbed	O
703	similarly	O
703	to	O
703	g	O
703	##lut	O
703	##ath	O
703	##ione	O
703	,	O
703	and	O
703	as	O
703	relatively	O
703	small	O
703	,	O
703	un	O
703	##charged	O
703	molecules	O
703	[	O
703	21	O
703	]	O
703	.	O
703	[SEP]	O
704	[CLS]	O
704	this	O
704	study	O
704	aimed	O
704	to	O
704	formula	O
704	##te	O
704	an	O
704	op	O
704	##ti	O
704	##mized	O
704	a	O
704	##cy	O
704	##c	O
704	##lov	O
704	##ir	O
704	(	O
704	a	O
704	##c	O
704	##v	O
704	)	O
704	na	O
704	##no	O
704	##em	O
704	##ul	O
704	##sion	O
704	h	O
704	##ydro	O
704	##gel	O
704	in	O
704	order	O
704	to	O
704	provide	O
704	a	O
704	solution	O
704	for	O
704	the	O
704	slow	O
704	,	O
704	variable	O
704	,	O
704	and	O
704	incomplete	O
704	oral	O
704	drug	O
704	absorption	O
704	in	O
704	patient	O
704	suffering	O
704	from	O
704	her	O
704	##pes	O
704	simple	O
704	##x	O
704	viral	O
704	infection	O
704	.	O
704	[SEP]	O
705	[CLS]	O
705	the	O
705	effective	O
705	formation	O
705	of	O
705	[	O
705	69	O
705	##ga	O
705	]	O
705	g	O
705	##a	O
705	-	O
705	1	O
705	na	O
705	##no	O
705	##mic	O
705	##elles	O
705	was	O
705	further	O
705	confirmed	O
705	by	O
705	transmission	O
705	electron	O
705	micro	O
705	##sco	O
705	##py	O
705	(	O
705	te	O
705	##m	O
705	)	O
705	imaging	O
705	,	O
705	which	O
705	showed	O
705	small	O
705	and	O
705	spherical	O
705	na	O
705	##no	O
705	##par	O
705	##tic	O
705	##les	O
705	(	O
705	fi	O
705	##g	O
705	.	O
705	3	O
705	##b	O
705	)	O
705	.	O
705	[SEP]	O
706	[CLS]	O
706	it	O
706	also	O
706	followed	O
706	the	O
706	good	O
706	clinical	O
706	practices	O
706	guidelines	O
706	[	O
706	14	O
706	]	O
706	,	O
706	the	O
706	ethical	O
706	principles	O
706	for	O
706	medical	O
706	research	O
706	for	O
706	humans	O
706	stated	O
706	in	O
706	the	O
706	declaration	O
706	of	O
706	he	O
706	##ls	O
706	##ink	O
706	##i	O
706	[	O
706	15	O
706	]	O
706	,	O
706	the	O
706	general	O
706	health	O
706	law	O
706	of	O
706	me	O
706	##xi	O
706	##co	O
706	(	O
706	le	O
706	##y	O
706	general	O
706	de	O
706	sa	O
706	##lu	O
706	##d	O
706	,	O
706	me	O
706	##xi	O
706	##co	O
706	)	O
706	[	O
706	16	O
706	]	O
706	,	O
706	and	O
706	the	O
706	regulations	O
706	of	O
706	the	O
706	general	O
706	health	O
706	law	O
706	for	O
706	health	O
706	research	O
706	(	O
706	re	O
706	##g	O
706	##lam	O
706	##ent	O
706	##o	O
706	de	O
706	la	O
706	le	O
706	##y	O
706	general	O
706	de	O
706	sa	O
706	##lu	O
706	##d	O
706	en	O
706	mater	O
706	##ia	O
706	de	O
706	invest	O
706	##iga	O
706	##cion	O
706	para	O
706	la	O
706	sa	O
706	##lu	O
706	##d	O
706	,	O
706	me	O
706	##xi	O
706	##co	O
706	)	O
706	[	O
706	17	O
706	]	O
706	.	O
706	[SEP]	O
707	[CLS]	O
707	a	O
707	ca	O
707	##d	O
707	product	O
707	ion	O
707	spectrum	O
707	for	O
707	al	O
707	##mot	O
707	##rip	O
707	##tan	O
707	and	O
707	al	O
707	##mot	O
707	##rip	O
707	##tan	O
707	-	O
707	d	O
707	##6	O
707	yielded	O
707	high	O
707	-	O
707	abundance	O
707	fragment	O
707	ions	O
707	at	O
707	m	O
707	/	O
707	z	O
707	33	O
707	##6	O
707	.	O
707	1	O
707	##→	O
707	##20	O
707	##1	O
707	.	O
707	1	O
707	and	O
707	34	O
707	##2	O
707	.	O
707	2	O
707	##→	O
707	##20	O
707	##7	O
707	.	O
707	2	O
707	in	O
707	multiple	O
707	reaction	O
707	monitoring	O
707	(	O
707	m	O
707	##rm	O
707	)	O
707	positive	O
707	mode	O
707	,	O
707	respectively	O
707	.	O
707	[SEP]	O
708	[CLS]	O
708	we	O
708	also	O
708	examined	O
708	the	O
708	formation	O
708	of	O
708	[	O
708	69	O
708	##ga	O
708	]	O
708	g	O
708	##a	O
708	-	O
708	1	O
708	na	O
708	##no	O
708	##mic	O
708	##elles	O
708	using	O
708	atom	O
708	##istic	O
708	molecular	O
708	-	O
708	dynamics	O
708	(	O
708	m	O
708	##d	O
708	)	O
708	simulation	O
708	##s	O
708	(	O
708	24	O
708	,	O
708	25	O
708	)	O
708	.	O
708	[SEP]	O
709	[CLS]	O
709	also	O
709	,	O
709	we	O
709	tried	O
709	different	O
709	column	O
709	packing	O
709	,	O
709	even	O
709	from	O
709	normal	O
709	phase	O
709	.	O
709	[SEP]	O
710	[CLS]	O
710	the	O
710	following	O
710	pieces	O
710	of	O
710	equipment	O
710	were	O
710	used	O
710	:	O
710	ultra	O
710	##vio	O
710	##let	O
710	-	O
710	visible	O
710	(	O
710	u	O
710	##v	O
710	-	O
710	v	O
710	##is	O
710	)	O
710	detector	O
710	(	O
710	s	O
710	##p	O
710	##d	O
710	-	O
710	10	O
710	##av	O
710	##p	O
710	)	O
710	and	O
710	high	O
710	performance	O
710	liquid	O
710	ch	O
710	##roma	O
710	##to	O
710	##graph	O
710	(	O
710	hp	O
710	##l	O
710	##c	O
710	,	O
710	l	O
710	##c	O
710	-	O
710	10	O
710	##at	O
710	##v	O
710	##p	O
710	)	O
710	(	O
710	s	O
710	##hima	O
710	##d	O
710	##zu	O
710	corporation	O
710	,	O
710	j	O
710	##apa	O
710	##n	O
710	)	O
710	;	O
710	f	O
710	##a	O
710	##100	O
710	##4	O
710	electronic	O
710	scales	O
710	(	O
710	s	O
710	##hang	O
710	##hai	O
710	l	O
710	##ian	O
710	##g	O
710	##ping	O
710	instrument	O
710	co	O
710	.	O
710	,	O
710	l	O
710	##t	O
710	##d	O
710	.	O
710	s	O
710	##hang	O
710	##hai	O
710	,	O
710	chin	O
710	##a	O
710	)	O
710	;	O
710	l	O
710	##g	O
710	##15	O
710	-	O
710	w	O
710	high	O
710	speed	O
710	micro	O
710	cent	O
710	##ri	O
710	##fu	O
710	##ge	O
710	(	O
710	be	O
710	##iji	O
710	##ng	O
710	medical	O
710	cent	O
710	##ri	O
710	##fu	O
710	##ge	O
710	factory	O
710	,	O
710	be	O
710	##iji	O
710	##ng	O
710	,	O
710	chin	O
710	##a	O
710	)	O
710	.	O
710	[SEP]	O
711	[CLS]	O
711	a	O
711	p	O
711	##har	O
711	##ma	O
711	##co	O
711	##kin	O
711	##etic	O
711	study	O
711	of	O
711	the	O
711	op	O
711	##ti	O
711	##mized	O
711	a	O
711	##c	O
711	##v	O
711	na	O
711	##no	O
711	##em	O
711	##ul	O
711	##sion	O
711	h	O
711	##ydro	O
711	##gel	O
711	was	O
711	conducted	O
711	in	O
711	rats	O
711	.	O
711	[SEP]	O
712	[CLS]	O
712	the	O
712	relative	B-PK
712	bio	I-PK
712	##ava	I-PK
712	##ila	I-PK
712	##bility	I-PK
712	of	O
712	the	O
712	op	O
712	##ti	O
712	##mized	O
712	a	O
712	##c	O
712	##v	O
712	na	O
712	##no	O
712	##em	O
712	##ul	O
712	##sion	O
712	h	O
712	##ydro	O
712	##gel	O
712	improved	O
712	to	O
712	53	O
712	##5	O
712	.	O
712	2	O
712	%	O
712	and	O
712	244	O
712	.	O
712	6	O
712	%	O
712	with	O
712	respect	O
712	to	O
712	the	O
712	raw	O
712	a	O
712	##c	O
712	##v	O
712	h	O
712	##ydro	O
712	##gel	O
712	and	O
712	marketed	O
712	cream	O
712	,	O
712	respectively	O
712	,	O
712	confirming	O
712	improvement	O
712	of	O
712	the	O
712	relative	B-PK
712	bio	I-PK
712	##ava	I-PK
712	##ila	I-PK
712	##bility	I-PK
712	of	O
712	a	O
712	##c	O
712	##v	O
712	in	O
712	the	O
712	formulated	O
712	na	O
712	##no	O
712	##em	O
712	##ul	O
712	##sion	O
712	h	O
712	##ydro	O
712	##gel	O
712	.	O
712	[SEP]	O
713	[CLS]	O
713	x	O
713	-	O
713	ray	O
713	imaging	O
713	was	O
713	employed	O
713	as	O
713	a	O
713	non	O
713	##in	O
713	##vasive	O
713	method	O
713	of	O
713	determining	O
713	the	O
713	residence	O
713	time	O
713	without	O
713	affecting	O
713	gas	O
713	##tro	O
713	##int	O
713	##est	O
713	##inal	O
713	(	O
713	g	O
713	##it	O
713	)	O
713	m	O
713	##ot	O
713	##ility	O
713	.	O
713	[SEP]	O
714	[CLS]	O
714	measurement	O
714	of	O
714	the	O
714	gas	O
714	##tric	O
714	residence	O
714	time	O
714	of	O
714	a	O
714	drug	O
714	delivery	O
714	system	O
714	at	O
714	the	O
714	application	O
714	site	O
714	is	O
714	to	O
714	provide	O
714	information	O
714	on	O
714	the	O
714	gas	O
714	##tro	O
714	##ret	O
714	##ent	O
714	##ive	O
714	ability	O
714	of	O
714	the	O
714	drug	O
714	delivery	O
714	system	O
714	.	O
714	[SEP]	O
715	[CLS]	O
715	to	O
715	assess	O
715	the	O
715	in	O
715	v	O
715	##ivo	O
715	behavior	O
715	of	O
715	pro	O
715	##dr	O
715	##ug	O
715	under	O
715	testing	O
715	,	O
715	an	O
715	open	O
715	label	O
715	random	O
715	##ized	O
715	two	O
715	-	O
715	way	O
715	cross	O
715	over	O
715	design	O
715	using	O
715	twelve	O
715	healthy	O
715	rabbits	O
715	was	O
715	adopted	O
715	.	O
715	[SEP]	O
716	[CLS]	O
716	a	O
716	radio	O
716	-	O
716	op	O
716	##aque	O
716	marker	O
716	,	O
716	bar	O
716	##ium	O
716	su	O
716	##l	O
716	##phate	O
716	,	O
716	was	O
716	incorporated	O
716	into	O
716	the	O
716	g	O
716	##dd	O
716	##s	O
716	and	O
716	p	O
716	##x	O
716	##ln	O
716	##et	O
716	formulation	O
716	##s	O
716	to	O
716	determine	O
716	the	O
716	extent	O
716	of	O
716	gas	O
716	##tro	O
716	##ret	O
716	##ent	O
716	##ion	O
716	.	O
716	[SEP]	O
717	[CLS]	O
717	the	O
717	d	O
717	##s	O
717	##c	O
717	curves	O
717	for	O
717	physical	O
717	mixture	O
717	of	O
717	m	O
717	##t	O
717	##x	O
717	,	O
717	p	O
717	##l	O
717	##ga	O
717	,	O
717	and	O
717	p	O
717	##eg	O
717	##40	O
717	##00	O
717	(	O
717	figure	O
717	3	O
717	##d	O
717	)	O
717	and	O
717	m	O
717	##t	O
717	##x	O
717	-	O
717	loaded	O
717	imp	O
717	##lants	O
717	(	O
717	figure	O
717	3	O
717	##e	O
717	)	O
717	showed	O
717	a	O
717	thermal	O
717	behavior	O
717	similar	O
717	to	O
717	that	O
717	identified	O
717	for	O
717	pure	O
717	m	O
717	##t	O
717	##x	O
717	and	O
717	the	O
717	polymer	O
717	##s	O
717	.	O
717	[SEP]	O
718	[CLS]	O
718	dogs	O
718	were	O
718	3	O
718	‐	O
718	12	O
718	years	O
718	of	O
718	age	O
718	(	O
718	median	O
718	,	O
718	6	O
718	years	O
718	)	O
718	with	O
718	a	O
718	duration	O
718	of	O
718	e	O
718	##pile	O
718	##psy	O
718	of	O
718	0	O
718	.	O
718	5	O
718	‐	O
718	0	O
718	.	O
718	6	O
718	years	O
718	(	O
718	median	O
718	,	O
718	1	O
718	year	O
718	)	O
718	.	O
718	[SEP]	O
719	[CLS]	O
719	a	O
719	g	O
719	##eno	O
719	##type	O
719	and	O
719	im	O
719	##ax	O
719	(	O
719	figure	O
719	3	O
719	##d	O
719	,	O
719	p	O
719	<	O
719	0	O
719	.	O
719	000	O
719	##1	O
719	)	O
719	was	O
719	observed	O
719	.	O
719	[SEP]	O
720	[CLS]	O
720	in	O
720	addition	O
720	,	O
720	sensitivity	O
720	analysis	O
720	showed	O
720	that	O
720	m	O
720	##or	O
720	##phine	O
720	c	B-PK
720	##l	I-PK
720	is	O
720	influenced	O
720	by	O
720	changes	O
720	in	O
720	cardiac	O
720	output	O
720	,	O
720	which	O
720	links	O
720	to	O
720	he	B-PK
720	##pa	I-PK
720	##tic	I-PK
720	blood	I-PK
720	flow	I-PK
720	.	O
720	[SEP]	O
721	[CLS]	O
721	thus	O
721	,	O
721	dim	O
721	##eri	O
721	##zation	O
721	of	O
721	l	O
721	##ys	O
721	##ost	O
721	##aph	O
721	##in	O
721	had	O
721	no	O
721	effect	O
721	on	O
721	its	O
721	cat	O
721	##alytic	O
721	efficacy	O
721	but	O
721	decreased	O
721	its	O
721	s	O
721	##ta	O
721	##phy	O
721	##lo	O
721	##ly	O
721	##tic	O
721	activity	O
721	,	O
721	which	O
721	was	O
721	evident	O
721	from	O
721	both	O
721	mi	O
721	##c	O
721	and	O
721	t	O
721	##ur	O
721	##bid	O
721	##ity	O
721	measurements	O
721	.	O
721	[SEP]	O
722	[CLS]	O
722	a	O
722	portable	O
722	co	O
722	gas	O
722	detector	O
722	(	O
722	drag	O
722	##er	O
722	p	O
722	##ac	O
722	700	O
722	##0	O
722	,	O
722	drag	O
722	##er	O
722	##wer	O
722	##k	O
722	a	O
722	##g	O
722	&	O
722	co	O
722	.	O
722	kg	O
722	##aa	O
722	,	O
722	g	O
722	##erman	O
722	##y	O
722	)	O
722	was	O
722	used	O
722	during	O
722	the	O
722	re	O
722	##bre	O
722	##ath	O
722	##ing	O
722	period	O
722	to	O
722	check	O
722	for	O
722	possible	O
722	co	O
722	leak	O
722	##age	O
722	at	O
722	the	O
722	nose	O
722	,	O
722	mouth	O
722	##piece	O
722	,	O
722	and	O
722	s	O
722	##pi	O
722	##rome	O
722	##ter	O
722	.	O
722	[SEP]	O
723	[CLS]	O
723	another	O
723	strategy	O
723	to	O
723	improve	O
723	the	O
723	o	B-PK
723	##cular	I-PK
723	bio	I-PK
723	##ava	I-PK
723	##ila	I-PK
723	##bility	I-PK
723	of	O
723	drugs	O
723	after	O
723	topic	O
723	##al	O
723	administration	O
723	is	O
723	to	O
723	use	O
723	na	O
723	##no	O
723	##med	O
723	##ici	O
723	##ne	O
723	and	O
723	na	O
723	##note	O
723	##ch	O
723	##nology	O
723	that	O
723	allow	O
723	the	O
723	drug	O
723	molecules	O
723	to	O
723	intimate	O
723	##ly	O
723	interact	O
723	with	O
723	specific	O
723	o	O
723	##cular	O
723	tissues	O
723	,	O
723	to	O
723	overcome	O
723	the	O
723	corn	O
723	##eal	O
723	barrier	O
723	,	O
723	and	O
723	to	O
723	increase	O
723	the	O
723	penetration	O
723	of	O
723	drugs	O
723	across	O
723	corn	O
723	##eal	O
723	tissue	O
723	##5	O
723	##6	O
723	##7	O
723	##8	O
723	##17	O
723	##18	O
723	.	O
723	[SEP]	O
724	[CLS]	O
724	protocols	O
724	were	O
724	approved	O
724	by	O
724	the	O
724	institutional	O
724	animal	O
724	care	O
724	and	O
724	use	O
724	committee	O
724	of	O
724	the	O
724	veterinary	O
724	science	O
724	school	O
724	,	O
724	university	O
724	of	O
724	b	O
724	##uen	O
724	##os	O
724	air	O
724	##es	O
724	(	O
724	protocol	O
724	number	O
724	2010	O
724	/	O
724	20	O
724	)	O
724	.	O
724	[SEP]	O
725	[CLS]	O
725	thus	O
725	,	O
725	83	O
725	patients	O
725	remained	O
725	to	O
725	be	O
725	studied	O
725	.	O
725	[SEP]	O
726	[CLS]	O
726	the	O
726	second	O
726	patient	O
726	entered	O
726	in	O
726	this	O
726	co	O
726	##hor	O
726	##t	O
726	experienced	O
726	grade	O
726	3	O
726	di	O
726	##ar	O
726	##r	O
726	##hoe	O
726	##a	O
726	and	O
726	nausea	O
726	.	O
726	[SEP]	O
727	[CLS]	O
727	this	O
727	analysis	O
727	included	O
727	p	O
727	##har	O
727	##ma	O
727	##co	O
727	##kin	O
727	##etic	O
727	data	O
727	from	O
727	114	O
727	patients	O
727	.	O
727	[SEP]	O
728	[CLS]	O
728	according	O
728	to	O
728	protocol	O
728	,	O
728	a	O
728	total	O
728	of	O
728	six	O
728	patients	O
728	had	O
728	to	O
728	be	O
728	a	O
728	##cc	O
728	##rue	O
728	##d	O
728	at	O
728	the	O
728	same	O
728	d	O
728	##l	O
728	.	O
728	[SEP]	O
729	[CLS]	O
729	blood	O
729	##stream	O
729	infections	O
729	were	O
729	identified	O
729	in	O
729	50	O
729	%	O
729	of	O
729	mice	O
729	(	O
729	5	O
729	/	O
729	10	O
729	)	O
729	from	O
729	the	O
729	vehicle	O
729	control	O
729	group	O
729	,	O
729	while	O
729	no	O
729	is	O
729	##olate	O
729	##s	O
729	were	O
729	recovered	O
729	from	O
729	the	O
729	blood	O
729	of	O
729	any	O
729	mouse	O
729	treated	O
729	with	O
729	5	O
729	or	O
729	20	O
729	mg	O
729	/	O
729	kg	O
729	ca	O
729	##sp	O
729	##of	O
729	##ung	O
729	##in	O
729	(	O
729	fi	O
729	##g	O
729	.	O
729	3	O
729	##c	O
729	)	O
729	.	O
729	[SEP]	O
730	[CLS]	O
730	thirty	O
730	-	O
730	six	O
730	healthy	O
730	subjects	O
730	were	O
730	randomly	O
730	assigned	O
730	in	O
730	a	O
730	3	O
730	:	O
730	1	O
730	ratio	O
730	to	O
730	receive	O
730	either	O
730	fi	O
730	##da	O
730	##x	O
730	##omi	O
730	##cin	O
730	or	O
730	place	O
730	##bo	O
730	.	O
730	[SEP]	O
731	[CLS]	O
731	all	O
731	electro	O
731	##card	O
731	##io	O
731	##gram	O
731	##s	O
731	were	O
731	without	O
731	any	O
731	clinical	O
731	##ly	O
731	significant	O
731	findings	O
731	.	O
731	[SEP]	O
732	[CLS]	O
732	therefore	O
732	110	O
732	mg	O
732	m	O
732	##−	O
732	##2	O
732	was	O
732	considered	O
732	the	O
732	m	O
732	##t	O
732	##d	O
732	of	O
732	b	O
732	##ms	O
732	-	O
732	1887	O
732	##9	O
732	##7	O
732	in	O
732	combination	O
732	with	O
732	c	O
732	##is	O
732	##p	O
732	##lat	O
732	##in	O
732	(	O
732	75	O
732	mg	O
732	m	O
732	##−	O
732	##2	O
732	)	O
732	.	O
732	[SEP]	O
733	[CLS]	O
733	none	O
733	of	O
733	the	O
733	additional	O
733	patients	O
733	experienced	O
733	a	O
733	d	O
733	##lt	O
733	,	O
733	so	O
733	the	O
733	study	O
733	could	O
733	proceed	O
733	to	O
733	150	O
733	mg	O
733	m	O
733	##−	O
733	##2	O
733	.	O
733	[SEP]	O
734	[CLS]	O
734	this	O
734	concentration	O
734	declined	O
734	gradually	O
734	to	O
734	0	O
734	.	O
734	9	O
734	±	O
734	0	O
734	.	O
734	1	O
734	µ	O
734	##g	O
734	/	O
734	m	O
734	##l	O
734	at	O
734	8	O
734	h	O
734	post	O
734	-	O
734	administration	O
734	.	O
734	[SEP]	O
735	[CLS]	O
735	these	O
735	small	O
735	increases	O
735	were	O
735	consistent	O
735	with	O
735	the	O
735	calculated	O
735	accumulation	B-PK
735	ratio	I-PK
735	(	I-PK
735	r	I-PK
735	##0	I-PK
735	)	I-PK
735	for	O
735	au	B-PK
735	##c	I-PK
735	(	I-PK
735	0	I-PK
735	-	I-PK
735	t	I-PK
735	)	I-PK
735	.	O
735	[SEP]	O
736	[CLS]	O
736	exclusion	O
736	criteria	O
736	were	O
736	:	O
736	intake	O
736	of	O
736	a	O
736	##b	O
736	##z	O
736	or	O
736	other	O
736	b	O
736	##z	O
736	##d	O
736	drugs	O
736	within	O
736	the	O
736	last	O
736	30	O
736	days	O
736	;	O
736	ma	O
736	##la	O
736	##bs	O
736	##or	O
736	##ption	O
736	or	O
736	other	O
736	syndrome	O
736	##s	O
736	that	O
736	could	O
736	compromise	O
736	the	O
736	to	O
736	##ler	O
736	##ability	O
736	or	O
736	absorption	O
736	of	O
736	a	O
736	##b	O
736	##z	O
736	;	O
736	history	O
736	of	O
736	h	O
736	##yper	O
736	##sen	O
736	##si	O
736	##ti	O
736	##vity	O
736	or	O
736	into	O
736	##ler	O
736	##ance	O
736	to	O
736	a	O
736	##b	O
736	##z	O
736	or	O
736	its	O
736	inactive	O
736	ingredients	O
736	;	O
736	acute	O
736	clinical	O
736	condition	O
736	;	O
736	pregnancy	O
736	or	O
736	breast	O
736	feeding	O
736	.	O
736	[SEP]	O
737	[CLS]	O
737	compared	O
737	to	O
737	the	O
737	controls	O
737	,	O
737	the	O
737	mean	O
737	serum	O
737	concentration	O
737	of	O
737	am	O
737	##ox	O
737	##ici	O
737	##llin	O
737	was	O
737	significantly	O
737	higher	O
737	in	O
737	lead	O
737	-	O
737	into	O
737	##xi	O
737	##cated	O
737	goats	O
737	during	O
737	the	O
737	first	O
737	hour	O
737	after	O
737	lead	O
737	administration	O
737	and	O
737	significantly	O
737	lower	O
737	at	O
737	4	O
737	h	O
737	post	O
737	-	O
737	administration	O
737	.	O
737	[SEP]	O
738	[CLS]	O
738	am	O
738	##ox	O
738	##ici	O
738	##llin	O
738	was	O
738	slowly	O
738	eliminated	O
738	from	O
738	the	O
738	control	O
738	goats	O
738	with	O
738	t	B-PK
738	##1	I-PK
738	/	I-PK
738	2	I-PK
738	##β	I-PK
738	of	O
738	4	O
738	.	O
738	14	O
738	±	O
738	0	O
738	.	O
738	82	O
738	h	O
738	compared	O
738	to	O
738	1	O
738	.	O
738	26	O
738	±	O
738	0	O
738	.	O
738	09	O
738	h	O
738	for	O
738	the	O
738	lead	O
738	-	O
738	into	O
738	##xi	O
738	##cated	O
738	goats	O
738	(	O
738	p	O
738	<	O
738	0	O
738	.	O
738	05	O
738	)	O
738	.	O
738	[SEP]	O
739	[CLS]	O
739	simulated	O
739	concentration	O
739	-	O
739	time	O
739	profiles	O
739	were	O
739	compared	O
739	to	O
739	experimental	O
739	data	O
739	.	O
739	[SEP]	O
740	[CLS]	O
740	statistical	O
740	data	O
740	analysis	O
740	was	O
740	performed	O
740	using	O
740	graph	O
740	##pad	O
740	##p	O
740	##rism	O
740	software	O
740	where	O
740	one	O
740	-	O
740	way	O
740	analysis	O
740	of	O
740	variance	O
740	followed	O
740	by	O
740	b	O
740	##on	O
740	##fer	O
740	##ron	O
740	##i	O
740	[UNK]	O
740	s	O
740	##test	O
740	was	O
740	applied	O
740	and	O
740	p	O
740	##≤	O
740	##0	O
740	.	O
740	05	O
740	was	O
740	considered	O
740	as	O
740	them	O
740	##ini	O
740	##mal	O
740	level	O
740	of	O
740	significance	O
740	unless	O
740	indicated	O
740	otherwise	O
740	.	O
740	[SEP]	O
741	[CLS]	O
741	d	O
741	=	O
741	pre	O
741	##det	O
741	##ermined	O
741	composition	O
741	(	O
741	%	O
741	)	O
741	of	O
741	t	O
741	##p	O
741	##gs	O
741	.	O
741	[SEP]	O
742	[CLS]	O
742	fl	O
742	so	O
742	##lub	O
742	##ility	O
742	(	O
742	%	O
742	)	O
742	was	O
742	calculated	O
742	for	O
742	the	O
742	varied	O
742	composition	O
742	at	O
742	the	O
742	10	O
742	%	O
742	weight	O
742	ratio	O
742	interval	O
742	between	O
742	k	O
742	##oll	O
742	##is	O
742	##ol	O
742	##v	O
742	m	O
742	##ct	O
742	70	O
742	and	O
742	t	O
742	##p	O
742	##gs	O
742	within	O
742	the	O
742	pseudo	O
742	-	O
742	te	O
742	##rna	O
742	##ry	O
742	phase	O
742	diagram	O
742	.	O
742	[SEP]	O
743	[CLS]	O
743	b	O
743	=	O
743	fl	O
743	so	O
743	##lub	O
743	##ility	O
743	(	O
743	%	O
743	)	O
743	in	O
743	t	O
743	##p	O
743	##gs	O
743	from	O
743	table	O
743	3	O
743	.	O
743	c	O
743	=	O
743	pre	O
743	##det	O
743	##ermined	O
743	composition	O
743	(	O
743	%	O
743	)	O
743	of	O
743	k	O
743	##oll	O
743	##is	O
743	##ol	O
743	##v	O
743	m	O
743	##ct	O
743	70	O
743	.	O
743	[SEP]	O
744	[CLS]	O
744	the	O
744	following	O
744	equations	O
744	were	O
744	used	O
744	to	O
744	predict	O
744	the	O
744	x	O
744	##ant	O
744	##hot	O
744	##ox	O
744	##ol	O
744	clearance	B-PK
744	in	O
744	human	O
744	[	O
744	13	O
744	]	O
744	:	O
744	(	O
744	2	O
744	)	O
744	c	O
744	##lint	O
744	in	O
744	v	O
744	##it	O
744	##ro	O
744	=	O
744	v	O
744	##max	O
744	##k	O
744	##m	O
744	,	O
744	c	O
744	##lint	O
744	in	O
744	v	O
744	##ivo	O
744	=	O
744	c	O
744	##lint	O
744	in	O
744	v	O
744	##it	O
744	##ro	O
744	·	O
744	s	O
744	##f	O
744	,	O
744	c	O
744	##l	O
744	##h	O
744	=	O
744	q	O
744	##h	O
744	·	O
744	f	O
744	##u	O
744	·	O
744	c	O
744	##lint	O
744	in	O
744	v	O
744	##ivo	O
744	##q	O
744	##h	O
744	+	O
744	f	O
744	##u	O
744	·	O
744	c	O
744	##lint	O
744	in	O
744	v	O
744	##ivo	O
744	,	O
744	where	O
744	s	O
744	##f	O
744	(	O
744	s	O
744	##cal	O
744	##ing	O
744	factor	O
744	)	O
744	represents	O
744	the	O
744	mill	O
744	##ig	O
744	##rams	O
744	of	O
744	micro	O
744	##so	O
744	##mal	O
744	protein	O
744	per	O
744	gram	O
744	of	O
744	liver	O
744	multi	O
744	##plied	O
744	by	O
744	the	O
744	grams	O
744	of	O
744	liver	O
744	weight	O
744	;	O
744	c	B-PK
744	##lint	I-PK
744	is	O
744	the	O
744	intrinsic	B-PK
744	metabolic	I-PK
744	clearance	I-PK
744	;	O
744	c	B-PK
744	##l	I-PK
744	##h	I-PK
744	is	O
744	he	B-PK
744	##pa	I-PK
744	##tic	I-PK
744	clearance	I-PK
744	;	O
744	f	B-PK
744	##u	I-PK
744	is	O
744	the	O
744	free	B-PK
744	fraction	I-PK
744	in	I-PK
744	blood	I-PK
744	(	O
744	there	O
744	are	O
744	no	O
744	data	O
744	of	O
744	x	O
744	##ant	O
744	##hot	O
744	##ox	O
744	##ol	O
744	;	O
744	here	O
744	f	B-PK
744	##u	I-PK
744	was	O
744	a	O
744	##rb	O
744	##it	O
744	##rar	O
744	##ily	O
744	proposed	O
744	to	O
744	be	O
744	1	O
744	)	O
744	;	O
744	q	B-PK
744	##h	I-PK
744	is	O
744	the	O
744	he	B-PK
744	##pa	I-PK
744	##tic	I-PK
744	blood	I-PK
744	flow	I-PK
744	.	O
744	[SEP]	O
745	[CLS]	O
745	to	O
745	prevent	O
745	solvent	O
745	drop	O
745	##lets	O
745	from	O
745	entering	O
745	and	O
745	con	O
745	##tam	O
745	##inating	O
745	the	O
745	ion	O
745	op	O
745	##tics	O
745	,	O
745	a	O
745	curtain	O
745	n	O
745	##2	O
745	gas	O
745	of	O
745	45	O
745	ps	O
745	##i	O
745	was	O
745	applied	O
745	between	O
745	the	O
745	curtain	O
745	plate	O
745	and	O
745	the	O
745	or	O
745	##ifice	O
745	.	O
745	[SEP]	O
746	[CLS]	O
746	these	O
746	data	O
746	indicated	O
746	that	O
746	the	O
746	daily	O
746	,	O
746	but	O
746	not	O
746	weekly	O
746	,	O
746	administration	O
746	of	O
746	t	O
746	##pt	O
746	##d	O
746	in	O
746	our	O
746	regime	O
746	##n	O
746	settings	O
746	stimulate	O
746	##d	O
746	the	O
746	per	O
746	##ios	O
746	##te	O
746	##al	O
746	bone	O
746	formation	O
746	of	O
746	the	O
746	t	O
746	##ibi	O
746	##al	O
746	co	O
746	##rt	O
746	##ices	O
746	.	O
746	[SEP]	O
747	[CLS]	O
747	the	O
747	rats	O
747	were	O
747	fast	O
747	##ed	O
747	for	O
747	12	O
747	h	O
747	but	O
747	allowed	O
747	water	O
747	ad	O
747	l	O
747	##ibi	O
747	##tum	O
747	before	O
747	the	O
747	z	O
747	##hi	O
747	##gan	O
747	##ca	O
747	##o	O
747	extract	O
747	was	O
747	oral	O
747	##ly	O
747	administered	O
747	at	O
747	a	O
747	dose	O
747	of	O
747	1	O
747	.	O
747	21	O
747	g	O
747	/	O
747	kg	O
747	.	O
747	[SEP]	O
748	[CLS]	O
748	these	O
748	calculations	O
748	were	O
748	performed	O
748	using	O
748	p	O
748	##rism	O
748	5	O
748	.	O
748	0	O
748	(	O
748	graph	O
748	##pad	O
748	,	O
748	us	O
748	##a	O
748	)	O
748	.	O
748	[SEP]	O
749	[CLS]	O
749	data	O
749	were	O
749	expressed	O
749	as	O
749	mean	O
749	±	O
749	the	O
749	standard	O
749	error	O
749	(	O
749	se	O
749	)	O
749	.	O
749	[SEP]	O
750	[CLS]	O
750	a	O
750	pseudo	O
750	-	O
750	te	O
750	##rna	O
750	##ry	O
750	phase	O
750	diagram	O
750	was	O
750	constructed	O
750	with	O
750	fl	O
750	,	O
750	k	O
750	##oll	O
750	##is	O
750	##ol	O
750	##v	O
750	m	O
750	##ct	O
750	70	O
750	,	O
750	and	O
750	t	O
750	##p	O
750	##gs	O
750	.	O
750	[SEP]	O
751	[CLS]	O
751	the	O
751	he	B-PK
751	##pa	I-PK
751	##tic	I-PK
751	clearance	I-PK
751	of	O
751	x	O
751	##ant	O
751	##hot	O
751	##ox	O
751	##ol	O
751	was	O
751	calculated	O
751	using	O
751	(	O
751	2	O
751	)	O
751	,	O
751	and	O
751	physiological	O
751	parameters	O
751	in	O
751	human	O
751	were	O
751	described	O
751	as	O
751	follows	O
751	:	O
751	micro	O
751	##so	O
751	##mal	O
751	protein	O
751	per	O
751	gram	O
751	of	O
751	liver	O
751	,	O
751	liver	O
751	weight	O
751	per	O
751	k	O
751	##ilo	O
751	##gram	O
751	of	O
751	body	O
751	,	O
751	and	O
751	liver	B-PK
751	blood	I-PK
751	flow	I-PK
751	for	O
751	human	O
751	were	O
751	48	O
751	.	O
751	8	O
751	mg	O
751	,	O
751	25	O
751	.	O
751	7	O
751	g	O
751	,	O
751	and	O
751	20	O
751	.	O
751	7	O
751	m	O
751	##l	O
751	·	O
751	min	O
751	##−	O
751	##1	O
751	·	O
751	kg	O
751	##−	O
751	##1	O
751	,	O
751	respectively	O
751	[	O
751	14	O
751	]	O
751	.	O
751	[SEP]	O
752	[CLS]	O
752	the	O
752	full	O
752	range	O
752	of	O
752	p	O
752	##har	O
752	##ma	O
752	##co	O
752	##kin	O
752	##etic	O
752	parameters	O
752	could	O
752	therefore	O
752	only	O
752	be	O
752	derived	O
752	for	O
752	the	O
752	14	O
752	subjects	O
752	who	O
752	received	O
752	all	O
752	three	O
752	doses	O
752	.	O
752	[SEP]	O
753	[CLS]	O
753	the	O
753	time	B-PK
753	to	I-PK
753	reach	I-PK
753	steady	I-PK
753	state	I-PK
753	for	O
753	m	O
753	##or	O
753	##phine	O
753	is	O
753	t	O
753	##ss	O
753	=	O
753	5	O
753	×	O
753	t	O
753	##1	O
753	/	O
753	2	O
753	=	O
753	20	O
753	hours	O
753	.	O
753	[SEP]	O
754	[CLS]	O
754	thus	O
754	,	O
754	the	O
754	m	O
754	##or	O
754	##phine	O
754	maintenance	O
754	dose	O
754	to	O
754	achieve	O
754	a	O
754	steady	O
754	state	O
754	in	O
754	t	B-PK
754	##ss	I-PK
754	is	O
754	given	O
754	by	O
754	[SEP]	O
755	[CLS]	O
755	both	O
755	clearance	B-PK
755	and	O
755	volume	B-PK
755	of	I-PK
755	distribution	I-PK
755	(	I-PK
755	v	I-PK
755	##d	I-PK
755	)	I-PK
755	were	O
755	decreased	O
755	by	O
755	15	O
755	-	O
755	fold	O
755	(	O
755	0	O
755	.	O
755	57	O
755	##±	O
755	##0	O
755	.	O
755	2	O
755	m	O
755	##l	O
755	/	O
755	h	O
755	versus	O
755	7	O
755	.	O
755	98	O
755	##±	O
755	##1	O
755	.	O
755	2	O
755	m	O
755	##l	O
755	/	O
755	h	O
755	,	O
755	for	O
755	[	O
755	p	O
755	##t	O
755	(	O
755	o	O
755	,	O
755	o	O
755	'	O
755	-	O
755	a	O
755	##ca	O
755	##c	O
755	)	O
755	(	O
755	γ	O
755	-	O
755	a	O
755	##ca	O
755	##c	O
755	)	O
755	(	O
755	d	O
755	##ms	O
755	)	O
755	]	O
755	and	O
755	c	O
755	##is	O
755	##p	O
755	##lat	O
755	##in	O
755	,	O
755	respectively	O
755	p	O
755	<	O
755	0	O
755	.	O
755	00	O
755	##1	O
755	n	O
755	=	O
755	6	O
755	;	O
755	table	O
755	1	O
755	)	O
755	and	O
755	46	O
755	-	O
755	fold	O
755	(	O
755	1	O
755	.	O
755	8	O
755	##±	O
755	##0	O
755	.	O
755	2	O
755	m	O
755	##l	O
755	/	O
755	kg	O
755	versus	O
755	82	O
755	.	O
755	67	O
755	##±	O
755	##2	O
755	.	O
755	2	O
755	m	O
755	##l	O
755	/	O
755	kg	O
755	,	O
755	for	O
755	[	O
755	p	O
755	##t	O
755	(	O
755	o	O
755	,	O
755	o	O
755	'	O
755	-	O
755	a	O
755	##ca	O
755	##c	O
755	)	O
755	(	O
755	γ	O
755	-	O
755	a	O
755	##ca	O
755	##c	O
755	)	O
755	(	O
755	d	O
755	##ms	O
755	)	O
755	]	O
755	and	O
755	c	O
755	##is	O
755	##p	O
755	##lat	O
755	##in	O
755	,	O
755	respectively	O
755	p	O
755	<	O
755	0	O
755	.	O
755	00	O
755	##1	O
755	n	O
755	=	O
755	6	O
755	;	O
755	table	O
755	1	O
755	)	O
755	,	O
755	in	O
755	the	O
755	[	O
755	p	O
755	##t	O
755	(	O
755	o	O
755	,	O
755	o	O
755	'	O
755	-	O
755	a	O
755	##ca	O
755	##c	O
755	)	O
755	(	O
755	γ	O
755	-	O
755	a	O
755	##ca	O
755	##c	O
755	)	O
755	(	O
755	d	O
755	##ms	O
755	)	O
755	]	O
755	treatment	O
755	group	O
755	compared	O
755	with	O
755	the	O
755	c	O
755	##is	O
755	##p	O
755	##lat	O
755	##in	O
755	-	O
755	treatment	O
755	group	O
755	.	O
755	[SEP]	O
756	[CLS]	O
756	the	O
756	criteria	O
756	for	O
756	successful	O
756	runs	O
756	were	O
756	restricted	O
756	to	O
756	successful	O
756	convergence	O
756	using	O
756	f	O
756	##oc	O
756	##e	O
756	with	O
756	interaction	O
756	,	O
756	good	O
756	diagnostic	O
756	##s	O
756	for	O
756	the	O
756	model	O
756	-	O
756	fit	O
756	for	O
756	all	O
756	data	O
756	of	O
756	the	O
756	different	O
756	treatment	O
756	periods	O
756	,	O
756	and	O
756	reasonable	O
756	estimates	O
756	for	O
756	fixed	O
756	and	O
756	random	O
756	effect	O
756	parameters	O
756	.	O
756	[SEP]	O
757	[CLS]	O
757	the	O
757	latter	O
757	is	O
757	especially	O
757	problematic	O
757	for	O
757	then	O
757	##asa	O
757	##l	O
757	absorption	O
757	of	O
757	high	O
757	molecular	O
757	-	O
757	weight	O
757	and	O
757	h	O
757	##ydro	O
757	##phi	O
757	##lic	O
757	drugs	O
757	##10	O
757	,	O
757	20	O
757	,	O
757	21	O
757	,	O
757	22	O
757	.	O
757	[SEP]	O
758	[CLS]	O
758	the	O
758	serum	O
758	concentration	O
758	-	O
758	time	O
758	profiles	O
758	for	O
758	each	O
758	dos	O
758	##ing	O
758	group	O
758	are	O
758	shown	O
758	in	O
758	figure	O
758	3	O
758	.	O
758	[SEP]	O
759	[CLS]	O
759	based	O
759	on	O
759	d	O
759	##lts	O
759	observed	O
759	on	O
759	-	O
759	study	O
759	,	O
759	d	O
759	##lt	O
759	criteria	O
759	were	O
759	revised	O
759	to	O
759	establish	O
759	a	O
759	more	O
759	clinical	O
759	##ly	O
759	relevant	O
759	m	O
759	##t	O
759	##d	O
759	(	O
759	additional	O
759	file	O
759	1	O
759	:	O
759	table	O
759	s	O
759	##1	O
759	)	O
759	.	O
759	[SEP]	O
760	[CLS]	O
760	three	O
760	hours	O
760	after	O
760	the	O
760	s	O
760	##c	O
760	injection	O
760	of	O
760	h	O
760	##gh	O
760	,	O
760	there	O
760	was	O
760	a	O
760	significant	O
760	(	O
760	p	O
760	<	O
760	.	O
760	00	O
760	##3	O
760	)	O
760	induction	O
760	of	O
760	i	O
760	##g	O
760	##f	O
760	-	O
760	1	O
760	that	O
760	was	O
760	sustained	O
760	up	O
760	to	O
760	the	O
760	24	O
760	-	O
760	hour	O
760	time	O
760	point	O
760	(	O
760	figure	O
760	2	O
760	)	O
760	.	O
760	[SEP]	O
761	[CLS]	O
761	while	O
761	the	O
761	exact	O
761	mechanism	O
761	of	O
761	##thi	O
761	##s	O
761	effect	O
761	has	O
761	not	O
761	been	O
761	determined	O
761	,	O
761	it	O
761	is	O
761	known	O
761	that	O
761	m	O
761	##uc	O
761	##oa	O
761	##dh	O
761	##esi	O
761	##ve	O
761	add	O
761	##itive	O
761	##sma	O
761	##y	O
761	improve	O
761	drug	O
761	absorption	O
761	by	O
761	reducing	O
761	the	O
761	m	O
761	##uc	O
761	##oc	O
761	##ilia	O
761	##ry	O
761	clearance	B-PK
761	rate	I-PK
761	and	O
761	by	O
761	##in	O
761	##cre	O
761	##asing	O
761	the	O
761	residence	B-PK
761	time	I-PK
761	of	O
761	the	O
761	drug	O
761	formulation	O
761	in	O
761	the	O
761	nasal	O
761	##ca	O
761	##vity	O
761	##25	O
761	,	O
761	26	O
761	.	O
761	[SEP]	O
762	[CLS]	O
762	hp	O
762	##tr	O
762	and	O
762	hp	O
762	##to	O
762	##l	O
762	tended	O
762	to	O
762	increase	O
762	more	O
762	after	O
762	d	O
762	##w	O
762	##p	O
762	##0	O
762	##51	O
762	##9	O
762	##5	O
762	administration	O
762	than	O
762	after	O
762	place	O
762	##bo	O
762	administration	O
762	.	O
762	[SEP]	O
763	[CLS]	O
763	more	O
763	##over	O
763	,	O
763	the	O
763	use	O
763	of	O
763	both	O
763	lab	O
763	##ras	O
763	##ola	O
763	##nd	O
763	cap	O
763	##mu	O
763	##l	O
763	m	O
763	##c	O
763	##m	O
763	(	O
763	both	O
763	of	O
763	which	O
763	are	O
763	reported	O
763	to	O
763	in	O
763	##hibit	O
763	p	O
763	-	O
763	g	O
763	##ly	O
763	##co	O
763	##p	O
763	##rote	O
763	##ina	O
763	##ct	O
763	##ivity	O
763	##27	O
763	,	O
763	28	O
763	)	O
763	might	O
763	also	O
763	be	O
763	responsible	O
763	forth	O
763	##e	O
763	observed	O
763	improved	O
763	bio	B-PK
763	##ava	I-PK
763	##ila	I-PK
763	##bility	I-PK
763	of	O
763	ni	O
763	##mo	O
763	##di	O
763	##pine	O
763	from	O
763	the	O
763	developed	O
763	##form	O
763	##ulation	O
763	.	O
763	[SEP]	O
764	[CLS]	O
764	further	O
764	##more	O
764	,	O
764	some	O
764	m	O
764	##uc	O
764	##oa	O
764	##dh	O
764	##esi	O
764	##ve	O
764	polymer	O
764	-	O
764	containing	O
764	systems	O
764	may	O
764	##dir	O
764	##ec	O
764	##tly	O
764	change	O
764	e	O
764	##pit	O
764	##hel	O
764	##ial	O
764	tight	O
764	junction	O
764	##s	O
764	and	O
764	increase	O
764	drug	O
764	absorption	O
764	and	B-PK
764	##bio	I-PK
764	##ava	I-PK
764	##ila	I-PK
764	##bility	I-PK
764	##23	O
764	,	O
764	29	O
764	.	O
764	[SEP]	O
765	[CLS]	O
765	the	O
765	maximum	B-PK
765	plasma	I-PK
765	concentrations	I-PK
765	and	O
765	area	B-PK
765	under	I-PK
765	the	I-PK
765	plasma	I-PK
765	concentration	I-PK
765	–	I-PK
765	time	I-PK
765	curve	I-PK
765	from	I-PK
765	zero	I-PK
765	to	I-PK
765	the	I-PK
765	last	I-PK
765	me	I-PK
765	##as	I-PK
765	##urable	I-PK
765	time	I-PK
765	dose	O
765	-	O
765	dependent	O
765	##ly	O
765	increased	O
765	.	O
765	[SEP]	O
766	[CLS]	O
766	the	O
766	in	O
766	##tra	O
766	##nas	O
766	##al	O
766	h	O
766	##gh	O
766	control	O
766	formulated	O
766	without	O
766	the	O
766	critical	O
766	##sor	O
766	##b	O
766	absorption	O
766	enhance	O
766	##r	O
766	had	O
766	no	O
766	effect	O
766	on	O
766	i	O
766	##g	O
766	##f	O
766	-	O
766	1	O
766	levels	O
766	.	O
766	[SEP]	O
767	[CLS]	O
767	when	O
767	c	O
767	##p	O
767	##0	O
767	##24	O
767	was	O
767	dose	O
767	##d	O
767	twice	O
767	daily	O
767	,	O
767	it	O
767	strongly	O
767	and	O
767	significantly	O
767	induced	O
767	i	O
767	##g	O
767	##f	O
767	-	O
767	1	O
767	up	O
767	to	O
767	at	O
767	least	O
767	19	O
767	hours	O
767	after	O
767	the	O
767	first	O
767	dose	O
767	(	O
767	p	O
767	<	O
767	.	O
767	00	O
767	##2	O
767	)	O
767	,	O
767	achieving	O
767	a	O
767	similar	O
767	i	O
767	##g	O
767	##f	O
767	-	O
767	1	O
767	cm	B-PK
767	##ax	I-PK
767	and	O
767	au	B-PK
767	##c	I-PK
767	##0	I-PK
767	–	I-PK
767	10	I-PK
767	##h	I-PK
767	to	O
767	the	O
767	s	O
767	##c	O
767	injection	O
767	.	O
767	[SEP]	O
768	[CLS]	O
768	despite	O
768	the	O
768	low	O
768	incidence	O
768	,	O
768	patients	O
768	who	O
768	develop	O
768	ad	O
768	##as	O
768	from	O
768	ex	O
768	##ogen	O
768	##ous	O
768	e	O
768	##po	O
768	may	O
768	have	O
768	a	O
768	serious	O
768	a	O
768	##e	O
768	called	O
768	pure	O
768	red	O
768	-	O
768	cell	O
768	a	O
768	##p	O
768	##lasia	O
768	(	O
768	p	O
768	##rca	O
768	)	O
768	.	O
768	34	O
768	p	O
768	##rca	O
768	patients	O
768	become	O
768	severely	O
768	an	O
768	##em	O
768	##ic	O
768	with	O
768	a	O
768	rapidly	O
768	decreasing	O
768	h	O
768	##b	O
768	level	O
768	and	O
768	eventually	O
768	become	O
768	dependent	O
768	on	O
768	trans	O
768	##fusion	O
768	##s	O
768	.	O
768	35	O
768	according	O
768	to	O
768	one	O
768	retrospective	O
768	study	O
768	,	O
768	reported	O
768	cases	O
768	of	O
768	p	O
768	##rca	O
768	mostly	O
768	occurred	O
768	in	O
768	hem	O
768	##od	O
768	##ial	O
768	##ys	O
768	##is	O
768	patients	O
768	who	O
768	received	O
768	sub	O
768	##cut	O
768	##aneous	O
768	e	O
768	##po	O
768	##eti	O
768	##n	O
768	al	O
768	##fa	O
768	.	O
768	[SEP]	O
769	[CLS]	O
769	dial	O
769	##ys	O
769	##is	O
769	tub	O
769	##ing	O
769	procedure	O
769	is	O
769	a	O
769	fast	O
769	and	O
769	low	O
769	cost	O
769	method	O
769	to	O
769	evaluate	O
769	the	O
769	bio	B-PK
769	##ava	I-PK
769	##ila	I-PK
769	##bility	I-PK
769	of	O
769	different	O
769	kinds	O
769	of	O
769	compounds	O
769	and	O
769	,	O
769	in	O
769	this	O
769	study	O
769	,	O
769	it	O
769	was	O
769	used	O
769	in	O
769	the	O
769	aim	O
769	to	O
769	evaluate	O
769	the	O
769	bio	B-PK
769	##ava	I-PK
769	##ila	I-PK
769	##bility	I-PK
769	of	O
769	native	O
769	ha	O
769	and	O
769	ha	O
769	-	O
769	ace	O
769	##t	O
769	.	O
769	[SEP]	O
770	[CLS]	O
770	bio	B-PK
770	##ava	I-PK
770	##ila	I-PK
770	##bility	I-PK
770	was	O
770	defined	O
770	as	O
770	the	O
770	percentage	O
770	of	O
770	tested	O
770	ha	O
770	and	O
770	ha	O
770	-	O
770	ace	O
770	##t	O
770	recovered	O
770	in	O
770	the	O
770	bio	O
770	##ac	O
770	##cess	O
770	##ible	O
770	fraction	O
770	,	O
770	after	O
770	in	O
770	v	O
770	##it	O
770	##ro	O
770	dig	O
770	##est	O
770	##ion	O
770	,	O
770	in	O
770	relation	O
770	to	O
770	the	O
770	original	O
770	non	O
770	##di	O
770	##ges	O
770	##ted	O
770	samples	O
770	.	O
770	[SEP]	O
771	[CLS]	O
771	fully	O
771	processed	O
771	r	O
771	##f	O
771	##vi	O
771	##ii	O
771	##f	O
771	##c	O
771	(	O
771	figure	O
771	1	O
771	##a	O
771	,	O
771	lane	O
771	3	O
771	)	O
771	was	O
771	produced	O
771	by	O
771	co	O
771	-	O
771	trans	O
771	##fect	O
771	##ion	O
771	of	O
771	r	O
771	##f	O
771	##vi	O
771	##ii	O
771	##f	O
771	##c	O
771	with	O
771	human	O
771	p	O
771	##c	O
771	##5	O
771	,	O
771	a	O
771	member	O
771	of	O
771	the	O
771	prop	O
771	##rote	O
771	##in	O
771	convert	O
771	##ase	O
771	sub	O
771	##til	O
771	##isi	O
771	##n	O
771	/	O
771	k	O
771	##ex	O
771	##in	O
771	(	O
771	p	O
771	##cs	O
771	##k	O
771	)	O
771	type	O
771	pro	O
771	##te	O
771	##ases	O
771	,	O
771	as	O
771	described	O
771	[	O
771	10	O
771	]	O
771	.	O
771	[SEP]	O
772	[CLS]	O
772	the	O
772	geometric	O
772	least	O
772	square	O
772	mean	O
772	(	O
772	l	O
772	##sm	O
772	)	O
772	ratios	O
772	and	O
772	90	O
772	%	O
772	confidence	O
772	interval	O
772	(	O
772	c	O
772	##i	O
772	)	O
772	for	O
772	the	O
772	primary	O
772	p	O
772	##har	O
772	##ma	O
772	##co	O
772	##kin	O
772	##etic	O
772	parameters	O
772	[	O
772	cm	B-PK
772	##ax	I-PK
772	and	O
772	au	B-PK
772	##c	I-PK
772	##0	I-PK
772	-	I-PK
772	72	I-PK
772	]	O
772	of	O
772	done	O
772	##pe	O
772	##zi	O
772	##l	O
772	under	O
772	both	O
772	fast	O
772	##ing	O
772	and	O
772	fed	O
772	states	O
772	are	O
772	presented	O
772	in	O
772	table	O
772	4	O
772	.	O
772	[SEP]	O
773	[CLS]	O
773	most	O
773	importantly	O
773	,	O
773	oral	O
773	ing	O
773	##est	O
773	##ion	O
773	of	O
773	g	O
773	##ins	O
773	##eno	O
773	##side	O
773	##s	O
773	from	O
773	g	O
773	##be	O
773	yielded	O
773	significantly	O
773	higher	O
773	ratios	O
773	and	O
773	slow	O
773	rates	B-PK
773	of	I-PK
773	absorption	I-PK
773	of	O
773	pp	O
773	##d	O
773	-	O
773	type	O
773	g	O
773	##ins	O
773	##eno	O
773	##side	O
773	##s	O
773	(	O
773	e	O
773	.	O
773	g	O
773	.	O
773	,	O
773	r	O
773	##b	O
773	##1	O
773	.	O
773	[SEP]	O
774	[CLS]	O
774	r	O
774	##b	O
774	##2	O
774	,	O
774	r	O
774	##c	O
774	and	O
774	r	O
774	##d	O
774	)	O
774	,	O
774	suggesting	O
774	that	O
774	g	O
774	##ins	O
774	##eno	O
774	##side	O
774	structures	O
774	facilitated	O
774	the	O
774	prediction	O
774	of	O
774	their	O
774	p	O
774	##har	O
774	##ma	O
774	##co	O
774	##kin	O
774	##etic	O
774	profiles	O
774	including	O
774	absorption	O
774	in	O
774	herb	O
774	##al	O
774	medicines	O
774	.	O
774	[SEP]	O
775	[CLS]	O
775	the	O
775	proteins	O
775	were	O
775	analyzed	O
775	by	O
775	non	O
775	-	O
775	reducing	O
775	sodium	O
775	do	O
775	##de	O
775	##cy	O
775	##l	O
775	su	O
775	##lf	O
775	##ate	O
775	p	O
775	##oly	O
775	##ac	O
775	##ryl	O
775	##ami	O
775	##de	O
775	gel	O
775	electro	O
775	##ph	O
775	##ores	O
775	##is	O
775	(	O
775	s	O
775	##ds	O
775	-	O
775	page	O
775	)	O
775	and	O
775	the	O
775	mass	O
775	concentrations	O
775	determined	O
775	by	O
775	measuring	O
775	u	O
775	##v	O
775	absorb	O
775	##ance	O
775	at	O
775	280	O
775	nm	O
775	.	O
775	[SEP]	O
776	[CLS]	O
776	sa	O
776	##es	O
776	will	O
776	be	O
776	reported	O
776	until	O
776	180	O
776	days	O
776	after	O
776	the	O
776	last	O
776	administration	O
776	of	O
776	trial	O
776	drugs	O
776	.	O
776	[SEP]	O
777	[CLS]	O
777	first	O
777	,	O
777	the	O
777	in	O
777	##hala	O
777	##tion	O
777	exposure	O
777	intake	O
777	was	O
777	simply	O
777	calculated	O
777	as	O
777	in	O
777	the	O
777	hood	O
777	-	O
777	off	O
777	simulation	O
777	##s	O
777	:	O
777	an	O
777	air	O
777	concentration	O
777	times	O
777	an	O
777	individual	O
777	-	O
777	specific	O
777	in	O
777	##hala	O
777	##tion	O
777	rate	O
777	.	O
777	[SEP]	O
778	[CLS]	O
778	the	O
778	trial	O
778	also	O
778	has	O
778	a	O
778	uk	O
778	regulatory	O
778	com	O
778	##pliant	O
778	real	O
778	-	O
778	time	O
778	sa	O
778	##e	O
778	reporting	O
778	process	O
778	to	O
778	identify	O
778	serious	O
778	adverse	O
778	reactions	O
778	and	O
778	suspected	O
778	unexpected	O
778	serious	O
778	adverse	O
778	reactions	O
778	that	O
778	could	O
778	lead	O
778	to	O
778	the	O
778	suspension	O
778	or	O
778	c	O
778	##ess	O
778	##ation	O
778	of	O
778	the	O
778	trial	O
778	if	O
778	warrant	O
778	##ed	O
778	.	O
778	[SEP]	O
779	[CLS]	O
779	for	O
779	z	O
779	##eta	O
779	potential	O
779	measurement	O
779	na	O
779	##no	O
779	##par	O
779	##tic	O
779	##les	O
779	formulation	O
779	##s	O
779	were	O
779	di	O
779	##lut	O
779	##ed	O
779	with	O
779	water	O
779	.	O
779	[SEP]	O
780	[CLS]	O
780	average	O
780	particle	O
780	diameter	O
780	,	O
780	p	O
780	##oly	O
780	##dis	O
780	##pers	O
780	##ity	O
780	index	O
780	and	O
780	z	O
780	##eta	O
780	potential	O
780	for	O
780	each	O
780	batch	O
780	of	O
780	prepared	O
780	na	O
780	##no	O
780	##par	O
780	##tic	O
780	##les	O
780	was	O
780	determined	O
780	by	O
780	using	O
780	z	O
780	##eta	O
780	##si	O
780	##zer	O
780	3000	O
780	##hs	O
780	(	O
780	ma	O
780	##lve	O
780	##rn	O
780	instruments	O
780	,	O
780	uk	O
780	)	O
780	.	O
780	[SEP]	O
781	[CLS]	O
781	the	O
781	lo	O
781	##d	O
781	and	O
781	lo	O
781	##q	O
781	are	O
781	presented	O
781	in	O
781	table	O
781	1	O
781	.	O
781	[SEP]	O
782	[CLS]	O
782	the	O
782	mechanism	O
782	for	O
782	the	O
782	interaction	O
782	was	O
782	identified	O
782	(	O
782	an	O
782	increase	O
782	in	O
782	bio	B-PK
782	##ava	I-PK
782	##ila	I-PK
782	##bility	I-PK
782	in	O
782	one	O
782	sub	O
782	##pop	O
782	##ulation	O
782	)	O
782	.	O
782	[SEP]	O
783	[CLS]	O
783	the	O
783	oral	O
783	data	O
783	were	O
783	best	O
783	described	O
783	with	O
783	a	O
783	first	O
783	order	O
783	absorption	O
783	without	O
783	la	B-PK
783	##g	I-PK
783	time	I-PK
783	.	O
783	[SEP]	O
784	[CLS]	O
784	the	O
784	estimated	O
784	value	O
784	for	O
784	the	O
784	absorption	B-PK
784	rate	I-PK
784	constant	I-PK
784	was	O
784	1	O
784	.	O
784	31	O
784	hour	O
784	-	O
784	1	O
784	with	O
784	r	O
784	##se	O
784	14	O
784	%	O
784	.	O
784	[SEP]	O
785	[CLS]	O
785	as	O
785	bio	B-PK
785	##ava	I-PK
785	##ila	I-PK
785	##bility	I-PK
785	and	O
785	inter	O
785	##ind	O
785	##iv	O
785	##id	O
785	##ual	O
785	var	O
785	##iability	O
785	in	O
785	f	B-PK
785	were	O
785	of	O
785	particular	O
785	interest	O
785	,	O
785	some	O
785	additional	O
785	investigation	O
785	was	O
785	performed	O
785	.	O
785	[SEP]	O
786	[CLS]	O
786	figure	O
786	8	O
786	has	O
786	shown	O
786	a	O
786	linear	O
786	ca	O
786	##li	O
786	##bra	O
786	##tion	O
786	plot	O
786	over	O
786	the	O
786	concentration	O
786	range	O
786	under	O
786	the	O
786	op	O
786	##ti	O
786	##mum	O
786	conditions	O
786	.	O
786	[SEP]	O
787	[CLS]	O
787	this	O
787	is	O
787	the	O
787	first	O
787	p	O
787	##har	O
787	##ma	O
787	##co	O
787	##kin	O
787	##etic	O
787	model	O
787	of	O
787	i	O
787	##ver	O
787	##me	O
787	##ct	O
787	##in	O
787	.	O
787	[SEP]	O
788	[CLS]	O
788	this	O
788	procedure	O
788	was	O
788	followed	O
788	for	O
788	all	O
788	participants	O
788	,	O
788	p	O
788	##1	O
788	to	O
788	p	O
788	##6	O
788	.	O
788	[SEP]	O
789	[CLS]	O
789	table	O
789	1	O
789	shows	O
789	good	O
789	values	O
789	of	O
789	the	O
789	correlation	O
789	coefficient	O
789	(	O
789	r	O
789	)	O
789	with	O
789	small	O
789	intercept	O
789	,	O
789	small	O
789	value	O
789	of	O
789	standard	O
789	de	O
789	##viation	O
789	(	O
789	s	O
789	.	O
789	d	O
789	.	O
789	)	O
789	and	O
789	relative	O
789	standard	O
789	de	O
789	##viation	O
789	(	O
789	r	O
789	##s	O
789	##d	O
789	)	O
789	that	O
789	point	O
789	out	O
789	high	O
789	accuracy	O
789	and	O
789	precision	O
789	of	O
789	the	O
789	proposed	O
789	method	O
789	.	O
789	[SEP]	O
790	[CLS]	O
790	it	O
790	demonstrates	O
790	the	O
790	utility	O
790	of	O
790	two	O
790	modeling	O
790	approaches	O
790	to	O
790	explore	O
790	drug	O
790	interactions	O
790	,	O
790	especially	O
790	where	O
790	there	O
790	may	O
790	be	O
790	population	O
790	he	O
790	##tero	O
790	##gene	O
790	##ity	O
790	.	O
790	[SEP]	O
791	[CLS]	O
791	first	O
791	,	O
791	the	O
791	95	O
791	%	O
791	confidence	O
791	interval	O
791	for	O
791	inter	O
791	##ind	O
791	##iv	O
791	##id	O
791	##ual	O
791	var	O
791	##iability	O
791	in	O
791	f	B-PK
791	was	O
791	obtained	O
791	using	O
791	likelihood	O
791	pro	O
791	##fi	O
791	##ling	O
791	.	O
791	[SEP]	O
792	[CLS]	O
792	the	O
792	estimated	O
792	c	B-PK
792	##l	I-PK
792	for	O
792	the	O
792	in	O
792	##tra	O
792	##ven	O
792	##ous	O
792	route	O
792	was	O
792	39	O
792	.	O
792	7	O
792	l	O
792	/	O
792	h	O
792	(	O
792	r	O
792	##se	O
792	8	O
792	%	O
792	)	O
792	while	O
792	the	O
792	estimates	O
792	of	O
792	the	O
792	oral	B-PK
792	c	I-PK
792	##l	I-PK
792	(	O
792	or	O
792	rather	O
792	c	B-PK
792	##l	I-PK
792	/	I-PK
792	f	I-PK
792	)	O
792	was	O
792	105	O
792	l	O
792	/	O
792	h	O
792	(	O
792	r	O
792	##se	O
792	13	O
792	%	O
792	)	O
792	.	O
792	[SEP]	O
793	[CLS]	O
793	the	O
793	drug	O
793	en	O
793	##tra	O
793	##pment	O
793	efficiency	O
793	was	O
793	determined	O
793	by	O
793	gel	O
793	per	O
793	##me	O
793	##ation	O
793	ch	O
793	##roma	O
793	##tography	O
793	(	O
793	g	O
793	##p	O
793	##c	O
793	)	O
793	with	O
793	se	O
793	##pha	O
793	##rose	O
793	c	O
793	##l	O
793	-	O
793	4	O
793	##b	O
793	.	O
793	[SEP]	O
794	[CLS]	O
794	second	O
794	,	O
794	in	O
794	order	O
794	to	O
794	get	O
794	a	O
794	broader	O
794	insight	O
794	into	O
794	the	O
794	first	O
794	pass	O
794	metabolism	O
794	,	O
794	bio	B-PK
794	##ava	I-PK
794	##ila	I-PK
794	##bility	I-PK
794	and	O
794	var	O
794	##iability	O
794	in	O
794	c	B-PK
794	##l	I-PK
794	following	O
794	different	O
794	administration	O
794	routes	O
794	,	O
794	f	B-PK
794	was	O
794	omitted	O
794	from	O
794	the	O
794	model	O
794	and	O
794	instead	O
794	apparent	B-PK
794	c	I-PK
794	##l	I-PK
794	and	O
794	its	O
794	inter	O
794	##ind	O
794	##iv	O
794	##id	O
794	##ual	O
794	var	O
794	##iability	O
794	was	O
794	estimated	O
794	separately	O
794	for	O
794	each	O
794	route	O
794	of	O
794	administration	O
794	(	O
794	other	O
794	disposition	O
794	parameters	O
794	were	O
794	still	O
794	estimated	O
794	jointly	O
794	)	O
794	.	O
794	[SEP]	O
795	[CLS]	O
795	the	O
795	composition	O
795	of	O
795	high	O
795	fat	O
795	high	O
795	ca	O
795	##lor	O
795	##ie	O
795	breakfast	O
795	is	O
795	the	O
795	same	O
795	in	O
795	both	O
795	the	O
795	periods	O
795	.	O
795	[SEP]	O
796	[CLS]	O
796	a	O
796	sample	O
796	size	O
796	of	O
796	30	O
796	in	O
796	each	O
796	group	O
796	was	O
796	targeted	O
796	to	O
796	detect	O
796	a	O
796	35	O
796	%	O
796	difference	O
796	in	O
796	the	O
796	au	B-PK
796	##c	I-PK
796	of	O
796	all	O
796	anal	O
796	##yte	O
796	##s	O
796	with	O
796	80	O
796	%	O
796	power	O
796	and	O
796	5	O
796	%	O
796	significance	O
796	level	O
796	.	O
796	[SEP]	O
797	[CLS]	O
797	the	O
797	estimated	O
797	inter	O
797	##ind	O
797	##iv	O
797	##id	O
797	##ual	O
797	var	O
797	##iability	O
797	in	O
797	c	B-PK
797	##l	I-PK
797	for	O
797	the	O
797	in	O
797	##tra	O
797	##ven	O
797	##ous	O
797	and	O
797	oral	O
797	routes	O
797	were	O
797	59	O
797	%	O
797	(	O
797	r	O
797	##se	O
797	22	O
797	%	O
797	)	O
797	and	O
797	55	O
797	(	O
797	50	O
797	%	O
797	)	O
797	respectively	O
797	.	O
797	[SEP]	O
798	[CLS]	O
798	third	O
798	,	O
798	a	O
798	model	O
798	allowing	O
798	correlation	O
798	between	O
798	f	B-PK
798	and	O
798	c	B-PK
798	##l	I-PK
798	was	O
798	tested	O
798	,	O
798	but	O
798	it	O
798	did	O
798	not	O
798	result	O
798	in	O
798	any	O
798	improvements	O
798	and	O
798	var	O
798	##iability	O
798	in	O
798	f	B-PK
798	was	O
798	still	O
798	not	O
798	app	O
798	##re	O
798	##cia	O
798	##ble	O
798	.	O
798	[SEP]	O
799	[CLS]	O
799	the	O
799	percentage	O
799	of	O
799	ha	O
799	##em	O
799	##oly	O
799	##sis	O
799	=	O
799	[	O
799	(	O
799	a	O
799	##45	O
799	##0	O
799	##n	O
799	##m	O
799	of	O
799	test	O
799	compound	O
799	treated	O
799	sample	O
799	-	O
799	a	O
799	##45	O
799	##0	O
799	##n	O
799	##m	O
799	of	O
799	buffer	O
799	treated	O
799	sample	O
799	)	O
799	/	O
799	(	O
799	a	O
799	##45	O
799	##0	O
799	##n	O
799	##m	O
799	of	O
799	4	O
799	%	O
799	t	O
799	##rito	O
799	##nx	O
799	-	O
799	100	O
799	treated	O
799	samples	O
799	-	O
799	a	O
799	##45	O
799	##0	O
799	##n	O
799	##m	O
799	of	O
799	buffer	O
799	treated	O
799	sample	O
799	)	O
799	]	O
799	[SEP]	O
800	[CLS]	O
800	el	O
800	##uted	O
800	compounds	O
800	were	O
800	detected	O
800	at	O
800	227	O
800	nm	O
800	.	O
800	[SEP]	O
801	[CLS]	O
801	membrane	O
801	##less	O
801	dissolution	O
801	model	O
801	was	O
801	used	O
801	to	O
801	determine	O
801	in	O
801	v	O
801	##it	O
801	##ro	O
801	drug	O
801	release	O
801	behavior	O
801	of	O
801	in	O
801	sit	O
801	##u	O
801	h	O
801	##ydro	O
801	##gel	O
801	of	O
801	g	O
801	##c	O
801	##v	O
801	.	O
801	[SEP]	O
802	[CLS]	O
802	the	O
802	con	O
802	##ju	O
802	##gated	O
802	meta	O
802	##bol	O
802	##ites	O
802	in	O
802	serum	O
802	were	O
802	determined	O
802	through	O
802	h	O
802	##ydro	O
802	##lysis	O
802	with	O
802	g	O
802	##lu	O
802	##cu	O
802	##ron	O
802	##idas	O
802	##e	O
802	and	O
802	su	O
802	##lf	O
802	##ata	O
802	##se	O
802	.	O
802	[SEP]	O
803	[CLS]	O
803	we	O
803	therefore	O
803	compared	O
803	the	O
803	p	O
803	##har	O
803	##ma	O
803	##co	O
803	##kin	O
803	##etic	O
803	(	O
803	p	O
803	##k	O
803	)	O
803	end	O
803	points	O
803	(	O
803	area	B-PK
803	under	I-PK
803	the	I-PK
803	curve	I-PK
803	from	I-PK
803	time	I-PK
803	0	I-PK
803	to	I-PK
803	the	I-PK
803	last	I-PK
803	sample	I-PK
803	drawn	I-PK
803	(	I-PK
803	au	I-PK
803	##c	I-PK
803	##0	I-PK
803	–	I-PK
803	t	I-PK
803	)	I-PK
803	and	O
803	metabolic	B-PK
803	ratios	I-PK
803	)	O
803	of	O
803	selective	O
803	substrates	O
803	for	O
803	specific	O
803	c	O
803	##y	O
803	##ps	O
803	and	O
803	p	O
803	‐	O
803	g	O
803	##p	O
803	administered	O
803	as	O
803	a	O
803	cocktail	O
803	obtained	O
803	on	O
803	day	O
803	8	O
803	(	O
803	reflecting	O
803	in	O
803	##hibition	O
803	)	O
803	and	O
803	on	O
803	day	O
803	17	O
803	(	O
803	reflecting	O
803	induction	O
803	)	O
803	with	O
803	day	O
803	1	O
803	.	O
803	[SEP]	O
804	[CLS]	O
804	the	O
804	minimum	O
804	required	O
804	di	O
804	##lution	O
804	for	O
804	the	O
804	samples	O
804	was	O
804	1	O
804	:	O
804	13	O
804	.	O
804	3	O
804	(	O
804	sad	O
804	)	O
804	or	O
804	1	O
804	:	O
804	40	O
804	(	O
804	mad	O
804	)	O
804	.	O
804	[SEP]	O
805	[CLS]	O
805	we	O
805	selected	O
805	eight	O
805	fl	O
805	##av	O
805	##ono	O
805	##ids	O
805	represented	O
805	in	O
805	table	O
805	1	O
805	,	O
805	g	O
805	##ly	O
805	##cy	O
805	##rr	O
805	##hi	O
805	##zi	O
805	##c	O
805	acid	O
805	,	O
805	g	O
805	##ly	O
805	##cy	O
805	##rr	O
805	##he	O
805	##tin	O
805	##ic	O
805	acid	O
805	and	O
805	be	O
805	##rber	O
805	##ine	O
805	,	O
805	and	O
805	conducted	O
805	their	O
805	p	O
805	##har	O
805	##ma	O
805	##co	O
805	##kin	O
805	##etic	O
805	study	O
805	using	O
805	the	O
805	plasma	O
805	of	O
805	rats	O
805	given	O
805	oral	O
805	##ly	O
805	with	O
805	2	O
805	g	O
805	/	O
805	kg	O
805	k	O
805	##rt	O
805	.	O
805	[SEP]	O
806	[CLS]	O
806	however	O
806	,	O
806	β	O
806	-	O
806	g	O
806	##lu	O
806	##cu	O
806	##ron	O
806	##idas	O
806	##e	O
806	treatment	O
806	increased	O
806	concentrations	O
806	of	O
806	almost	O
806	all	O
806	fl	O
806	##av	O
806	##ono	O
806	##ids	O
806	(	O
806	e	O
806	.	O
806	g	O
806	.	O
806	,	O
806	maximum	B-PK
806	concentration	I-PK
806	of	O
806	b	O
806	##aic	O
806	##ale	O
806	##in	O
806	was	O
806	132	O
806	##0	O
806	ng	O
806	/	O
806	m	O
806	##l	O
806	after	O
806	β	O
806	-	O
806	g	O
806	##lu	O
806	##cu	O
806	##ron	O
806	##idas	O
806	##e	O
806	treatment	O
806	,	O
806	while	O
806	the	O
806	concentration	O
806	was	O
806	b	O
806	##q	O
806	##l	O
806	in	O
806	un	O
806	##tre	O
806	##ated	O
806	plasma	O
806	from	O
806	k	O
806	##rt	O
806	-	O
806	administered	O
806	rats	O
806	)	O
806	.	O
806	[SEP]	O
807	[CLS]	O
807	finally	O
807	the	O
807	he	O
807	##par	O
807	##in	O
807	was	O
807	neutral	O
807	##ized	O
807	by	O
807	administer	O
807	##ing	O
807	1400	O
807	##0	O
807	i	O
807	##u	O
807	of	O
807	pro	O
807	##tamine	O
807	su	O
807	##l	O
807	##phate	O
807	(	O
807	pro	O
807	##tam	O
807	##in	O
807	,	O
807	le	O
807	##o	O
807	p	O
807	##har	O
807	##ma	O
807	,	O
807	ball	O
807	##er	O
807	##up	O
807	,	O
807	den	O
807	##mark	O
807	)	O
807	.	O
807	[SEP]	O
808	[CLS]	O
808	b	O
808	##u	O
808	p	O
808	##k	O
808	parameters	O
808	(	O
808	cm	B-PK
808	##ax	I-PK
808	,	O
808	au	B-PK
808	##c	I-PK
808	,	O
808	c	B-PK
808	##ss	I-PK
808	and	O
808	c	B-PK
808	##l	I-PK
808	)	O
808	and	O
808	dose	O
808	adjustment	O
808	(	O
808	ratio	O
808	of	O
808	adjusted	O
808	vs	O
808	un	O
808	##ad	O
808	##ju	O
808	##sted	O
808	dose	O
808	)	O
808	were	O
808	compared	O
808	between	O
808	g	O
808	##eno	O
808	##type	O
808	##s	O
808	or	O
808	between	O
808	carriers	O
808	and	O
808	non	O
808	-	O
808	carriers	O
808	of	O
808	g	O
808	##sta	O
808	##1	O
808	ha	O
808	##p	O
808	##lot	O
808	##ype	O
808	##s	O
808	using	O
808	linear	O
808	re	O
808	##gression	O
808	analysis	O
808	.	O
808	[SEP]	O
809	[CLS]	O
809	rats	O
809	were	O
809	habit	O
809	##uated	O
809	to	O
809	the	O
809	an	O
809	##a	O
809	testing	O
809	chambers	O
809	for	O
809	at	O
809	least	O
809	30	O
809	minutes	O
809	prior	O
809	to	O
809	the	O
809	formal	O
809	##in	O
809	injection	O
809	.	O
809	[SEP]	O
810	[CLS]	O
810	the	O
810	cartridge	O
810	was	O
810	r	O
810	##ins	O
810	##ed	O
810	with	O
810	0	O
810	.	O
810	5	O
810	m	O
810	##l	O
810	of	O
810	0	O
810	.	O
810	1	O
810	m	O
810	phosphate	O
810	buffer	O
810	(	O
810	p	O
810	##h	O
810	3	O
810	.	O
810	0	O
810	)	O
810	,	O
810	followed	O
810	by	O
810	0	O
810	.	O
810	5	O
810	m	O
810	##l	O
810	20	O
810	%	O
810	met	O
810	##han	O
810	##ol	O
810	and	O
810	dried	O
810	under	O
810	vacuum	O
810	.	O
810	[SEP]	O
811	[CLS]	O
811	the	O
811	anal	O
811	##yte	O
811	##s	O
811	were	O
811	el	O
811	##uted	O
811	with	O
811	1	O
811	m	O
811	##l	O
811	of	O
811	met	O
811	##han	O
811	##ol	O
811	-	O
811	am	O
811	##monia	O
811	(	O
811	[UNK]	O
811	v	O
811	/	O
811	v	O
811	)	O
811	at	O
811	a	O
811	low	O
811	rate	O
811	of	O
811	no	O
811	more	O
811	than	O
811	1	O
811	m	O
811	##l	O
811	/	O
811	min	O
811	.	O
811	[SEP]	O
812	[CLS]	O
812	after	O
812	60	O
812	minutes	O
812	,	O
812	the	O
812	animals	O
812	were	O
812	e	O
812	##uth	O
812	##ani	O
812	##zed	O
812	and	O
812	the	O
812	g	O
812	##i	O
812	tract	O
812	was	O
812	harvested	O
812	.	O
812	[SEP]	O
813	[CLS]	O
813	other	O
813	imaging	O
813	data	O
813	(	O
813	figure	O
813	8	O
813	##a	O
813	)	O
813	was	O
813	taken	O
813	from	O
813	dynamic	O
813	pet	O
813	measurements	O
813	in	O
813	the	O
813	first	O
813	hour	O
813	after	O
813	administration	O
813	which	O
813	showed	O
813	clearly	O
813	the	O
813	rapid	O
813	blood	B-PK
813	compartment	I-PK
813	clearance	I-PK
813	(	O
813	t	B-PK
813	##1	I-PK
813	/	I-PK
813	2	I-PK
813	=	O
813	15	O
813	minutes	O
813	)	O
813	.	O
813	[SEP]	O
814	[CLS]	O
814	we	O
814	have	O
814	developed	O
814	a	O
814	novel	O
814	nasal	O
814	h	O
814	##gh	O
814	product	O
814	(	O
814	c	O
814	##p	O
814	##0	O
814	##24	O
814	)	O
814	that	O
814	showed	O
814	excellent	O
814	nasal	O
814	absorption	O
814	in	O
814	animal	O
814	models	O
814	;	O
814	however	O
814	,	O
814	the	O
814	translation	O
814	of	O
814	these	O
814	results	O
814	into	O
814	the	O
814	clinical	O
814	setting	O
814	is	O
814	essential	O
814	because	O
814	past	O
814	attempts	O
814	to	O
814	develop	O
814	such	O
814	formulation	O
814	##s	O
814	by	O
814	other	O
814	groups	O
814	have	O
814	been	O
814	unable	O
814	to	O
814	induce	O
814	i	O
814	##g	O
814	##f	O
814	-	O
814	1	O
814	in	O
814	man	O
814	.	O
814	[SEP]	O
815	[CLS]	O
815	the	O
815	ability	O
815	of	O
815	p	O
815	##rid	O
815	##op	O
815	##id	O
815	##ine	O
815	and	O
815	t	O
815	##v	O
815	‐	O
815	450	O
815	##65	O
815	to	O
815	in	O
815	##hibit	O
815	and	O
815	/	O
815	or	O
815	induce	O
815	the	O
815	in	O
815	v	O
815	##it	O
815	##ro	O
815	activity	O
815	of	O
815	major	O
815	drug	O
815	meta	O
815	##bol	O
815	##izing	O
815	enzymes	O
815	was	O
815	assessed	O
815	according	O
815	to	O
815	standard	O
815	practices	O
815	18	O
815	,	O
815	19	O
815	,	O
815	20	O
815	.	O
815	[SEP]	O
816	[CLS]	O
816	all	O
816	participants	O
816	underwent	O
816	pre	O
816	##oper	O
816	##ative	O
816	m	O
816	##ri	O
816	and	O
816	d	O
816	##ce	O
816	-	O
816	m	O
816	##ri	O
816	,	O
816	and	O
816	were	O
816	scheduled	O
816	for	O
816	surgical	O
816	re	O
816	##section	O
816	within	O
816	40	O
816	days	O
816	of	O
816	imaging	O
816	.	O
816	[SEP]	O
817	[CLS]	O
817	dose	O
817	proportional	O
817	##ity	O
817	was	O
817	tested	O
817	using	O
817	cm	B-PK
817	##ax	I-PK
817	,	O
817	au	B-PK
817	##c	I-PK
817	##0	I-PK
817	–	I-PK
817	24	I-PK
817	##h	I-PK
817	,	O
817	cm	B-PK
817	##ax	I-PK
817	,	I-PK
817	s	I-PK
817	##s	I-PK
817	,	O
817	and	O
817	au	B-PK
817	##c	I-PK
817	##τ	I-PK
817	,	I-PK
817	s	I-PK
817	##s	I-PK
817	with	O
817	linear	O
817	re	O
817	##gression	O
817	by	O
817	using	O
817	log	O
817	-	O
817	transformed	O
817	values	O
817	based	O
817	on	O
817	the	O
817	power	O
817	model	O
817	.	O
817	19	O
817	fish	O
817	##er	O
817	’	O
817	s	O
817	exact	O
817	test	O
817	was	O
817	used	O
817	to	O
817	compare	O
817	the	O
817	continuous	O
817	variables	O
817	of	O
817	the	O
817	safety	O
817	test	O
817	among	O
817	the	O
817	treatment	O
817	groups	O
817	.	O
817	[SEP]	O
818	[CLS]	O
818	p	O
818	##har	O
818	##ma	O
818	##co	O
818	##kin	O
818	##etic	O
818	study	O
818	revealed	O
818	low	O
818	plasma	O
818	levels	O
818	of	O
818	fl	O
818	##av	O
818	##ono	O
818	##id	O
818	a	O
818	##gly	O
818	##con	O
818	##es	O
818	after	O
818	k	O
818	##rt	O
818	administration	O
818	;	O
818	however	O
818	,	O
818	plasma	O
818	concentrations	O
818	were	O
818	enhanced	O
818	marked	O
818	##ly	O
818	by	O
818	β	O
818	-	O
818	g	O
818	##lu	O
818	##cu	O
818	##ron	O
818	##idas	O
818	##e	O
818	treatment	O
818	,	O
818	with	O
818	b	O
818	##aic	O
818	##ale	O
818	##in	O
818	the	O
818	most	O
818	abundant	O
818	(	O
818	cm	B-PK
818	##ax	I-PK
818	,	O
818	1	O
818	.	O
818	32	O
818	µ	O
818	##g	O
818	/	O
818	m	O
818	##l	O
818	)	O
818	.	O
818	[SEP]	O
819	[CLS]	O
819	drug	O
819	and	O
819	drug	O
819	meta	O
819	##bol	O
819	##ite	O
819	concentrations	O
819	in	O
819	plasma	O
819	,	O
819	c	O
819	##er	O
819	##vic	O
819	##ova	O
819	##gin	O
819	##al	O
819	fluids	O
819	(	O
819	c	O
819	##v	O
819	##fs	O
819	)	O
819	,	O
819	c	O
819	##er	O
819	##vic	O
819	##ova	O
819	##gin	O
819	##al	O
819	lava	O
819	##ges	O
819	(	O
819	c	O
819	##v	O
819	##ls	O
819	)	O
819	,	O
819	and	O
819	v	O
819	##agi	O
819	##nal	O
819	tissue	O
819	(	O
819	v	O
819	##t	O
819	)	O
819	bio	O
819	##ps	O
819	##ies	O
819	were	O
819	determined	O
819	via	O
819	liquid	O
819	ch	O
819	##roma	O
819	##to	O
819	##graphic	O
819	-	O
819	tandem	O
819	mass	O
819	s	O
819	##pect	O
819	##rome	O
819	##try	O
819	(	O
819	l	O
819	##c	O
819	-	O
819	m	O
819	##s	O
819	/	O
819	m	O
819	##s	O
819	)	O
819	.	O
819	[SEP]	O
820	[CLS]	O
820	male	O
820	and	O
820	female	O
820	patients	O
820	aged	O
820	≥	O
820	##20	O
820	years	O
820	who	O
820	required	O
820	hospital	O
820	##ization	O
820	and	O
820	treatment	O
820	with	O
820	systemic	O
820	anti	O
820	##ba	O
820	##cter	O
820	##ial	O
820	agents	O
820	and	O
820	gave	O
820	consent	O
820	to	O
820	participate	O
820	in	O
820	the	O
820	study	O
820	were	O
820	included	O
820	.	O
820	[SEP]	O
821	[CLS]	O
821	per	O
821	##ce	O
821	##pt	O
821	##ibility	O
821	and	O
821	accept	O
821	##ability	O
821	were	O
821	assessed	O
821	by	O
821	surveys	O
821	and	O
821	interviews	O
821	.	O
821	[SEP]	O
822	[CLS]	O
822	post	O
822	ho	O
822	##c	O
822	bay	O
822	##esi	O
822	##an	O
822	estimates	O
822	of	O
822	c	B-PK
822	##l	I-PK
822	and	O
822	v	B-PK
822	##1	I-PK
822	in	O
822	the	O
822	model	O
822	-	O
822	building	O
822	population	O
822	(	O
822	mostly	O
822	non	O
822	-	O
822	as	O
822	##ian	O
822	patients	O
822	)	O
822	and	O
822	external	O
822	valid	O
822	##ation	O
822	population	O
822	(	O
822	j	O
822	##apa	O
822	##nese	O
822	patients	O
822	only	O
822	)	O
822	were	O
822	also	O
822	similar	O
822	after	O
822	normal	O
822	##ization	O
822	by	O
822	individual	O
822	co	O
822	##var	O
822	##iate	O
822	values	O
822	that	O
822	were	O
822	included	O
822	in	O
822	the	O
822	final	O
822	model	O
822	(	O
822	fi	O
822	##g	O
822	.	O
822	4	O
822	##c	O
822	,	O
822	d	O
822	)	O
822	.	O
822	[SEP]	O
823	[CLS]	O
823	the	O
823	dose	O
823	es	O
823	##cal	O
823	##ation	O
823	and	O
823	d	O
823	##lt	O
823	are	O
823	listed	O
823	in	O
823	table	O
823	2	O
823	.	O
823	[SEP]	O
824	[CLS]	O
824	the	O
824	normal	O
824	##ization	O
824	was	O
824	done	O
824	by	O
824	dividing	O
824	the	O
824	post	O
824	ho	O
824	##c	O
824	bay	O
824	##esi	O
824	##an	O
824	estimates	O
824	of	O
824	c	B-PK
824	##l	I-PK
824	and	O
824	v	B-PK
824	##1	I-PK
824	by	O
824	the	O
824	individual	O
824	co	O
824	##var	O
824	##iate	O
824	values	O
824	in	O
824	the	O
824	form	O
824	that	O
824	appeared	O
824	in	O
824	the	O
824	equations	O
824	of	O
824	the	O
824	final	O
824	model	O
824	.	O
824	[SEP]	O
825	[CLS]	O
825	the	O
825	observed	O
825	maximum	B-PK
825	concentration	I-PK
825	(	I-PK
825	cm	I-PK
825	##ax	I-PK
825	)	I-PK
825	and	O
825	the	O
825	time	B-PK
825	to	I-PK
825	reach	I-PK
825	the	I-PK
825	maximum	I-PK
825	concentration	I-PK
825	(	I-PK
825	t	I-PK
825	##max	I-PK
825	)	I-PK
825	were	O
825	obtained	O
825	by	O
825	visual	O
825	inspection	O
825	of	O
825	the	O
825	experimental	O
825	data	O
825	.	O
825	[SEP]	O
826	[CLS]	O
826	in	O
826	this	O
826	model	O
826	,	O
826	the	O
826	effect	O
826	of	O
826	l	O
826	##y	O
826	##25	O
826	##10	O
826	##9	O
826	##24	O
826	was	O
826	mediated	O
826	by	O
826	a	O
826	sat	O
826	##urable	O
826	concentration	O
826	‐	O
826	dependent	O
826	stimulation	O
826	of	O
826	c	O
826	##d	O
826	##34	O
826	+	O
826	cell	O
826	mob	O
826	##ilization	O
826	to	O
826	the	O
826	response	O
826	compartment	O
826	.	O
826	[SEP]	O
827	[CLS]	O
827	area	B-PK
827	under	I-PK
827	the	I-PK
827	s	I-PK
827	##yn	I-PK
827	##ov	I-PK
827	##ial	I-PK
827	fluid	I-PK
827	concentration	I-PK
827	-	I-PK
827	time	I-PK
827	curve	I-PK
827	(	I-PK
827	au	I-PK
827	##c	I-PK
827	)	I-PK
827	from	I-PK
827	time	I-PK
827	zero	I-PK
827	to	I-PK
827	the	I-PK
827	last	I-PK
827	q	I-PK
827	##uant	I-PK
827	##ifiable	I-PK
827	concentration	I-PK
827	was	O
827	calculated	O
827	using	O
827	linear	O
827	trap	O
827	##ez	O
827	##oid	O
827	##al	O
827	rule	O
827	.	O
827	[SEP]	O
828	[CLS]	O
828	the	O
828	m	B-PK
828	##rt	I-PK
828	is	O
828	calculated	O
828	as	O
828	area	B-PK
828	under	I-PK
828	the	I-PK
828	first	I-PK
828	moment	I-PK
828	curve	I-PK
828	(	I-PK
828	au	I-PK
828	##m	I-PK
828	##c	I-PK
828	)	I-PK
828	/	I-PK
828	au	I-PK
828	##c	I-PK
828	.	O
828	[SEP]	O
829	[CLS]	O
829	steady	O
829	state	O
829	with	O
829	respect	O
829	to	O
829	cc	O
829	##c	O
829	was	O
829	assumed	O
829	prior	O
829	to	O
829	the	O
829	first	O
829	dose	O
829	of	O
829	l	O
829	##y	O
829	##25	O
829	##10	O
829	##9	O
829	##24	O
829	and	O
829	/	O
829	or	O
829	so	O
829	##c	O
829	,	O
829	and	O
829	kin	B-PK
829	was	O
829	calculated	O
829	as	O
829	follows	O
829	:	O
829	(	O
829	6	O
829	)	O
829	kin	O
829	=	O
829	c	O
829	##d	O
829	##34	O
829	##0	O
829	##×	O
829	##ko	O
829	##ut	O
829	[SEP]	O
830	[CLS]	O
830	the	O
830	change	O
830	in	O
830	cc	O
830	##c	O
830	in	O
830	the	O
830	pool	O
830	(	O
830	p	O
830	)	O
830	and	O
830	response	O
830	(	O
830	r	O
830	)	O
830	compartment	O
830	##s	O
830	and	O
830	the	O
830	dynamics	O
830	of	O
830	the	O
830	s	O
830	##ti	O
830	##mu	O
830	##lator	O
830	##y	O
830	signal	O
830	(	O
830	s	O
830	)	O
830	were	O
830	defined	O
830	by	O
830	the	O
830	following	O
830	system	O
830	of	O
830	differential	O
830	equations	O
830	:	O
830	(	O
830	5	O
830	)	O
830	d	O
830	##p	O
830	##dt	O
830	=	O
830	kin	O
830	##−	O
830	##k	O
830	##p	O
830	##c	O
830	##×	O
830	##1	O
830	+	O
830	s	O
830	##max	O
830	##×	O
830	##c	O
830	##ps	O
830	##c	O
830	##50	O
830	+	O
830	c	O
830	##p	O
830	+	O
830	[UNK]	O
830	+	O
830	k	O
830	##c	O
830	##p	O
830	##×	O
830	##r	O
830	,	O
830	p	O
830	##0	O
830	=	O
830	c	O
830	##d	O
830	##34	O
830	##0	O
830	##×	O
830	##ko	O
830	##ut	O
830	+	O
830	k	O
830	##c	O
830	##p	O
830	##k	O
830	##p	O
830	##c	O
830	##dr	O
830	##dt	O
830	=	O
830	k	O
830	##p	O
830	##c	O
830	##×	O
830	##1	O
830	+	O
830	s	O
830	##max	O
830	##×	O
830	##c	O
830	##ps	O
830	##c	O
830	##50	O
830	+	O
830	c	O
830	##p	O
830	+	O
830	[UNK]	O
830	+	O
830	k	O
830	##c	O
830	##p	O
830	+	O
830	k	O
830	##out	O
830	##×	O
830	##r	O
830	,	O
830	r	O
830	##0	O
830	=	O
830	c	O
830	##d	O
830	##34	O
830	##0	O
830	##ds	O
830	##dt	O
830	=	O
830	k	O
830	##t	O
830	##×	O
830	##f	O
830	##c	O
830	##xa	O
830	##c	O
830	##×	O
830	##1	O
830	##−	O
830	##s	O
830	,	O
830	s	O
830	##0	O
830	=	O
830	0	O
830	##where	O
830	c	O
830	##d	O
830	##34	O
830	##0	O
830	is	O
830	the	O
830	estimated	O
830	cc	O
830	##c	O
830	at	O
830	time	O
830	zero	O
830	,	O
830	k	B-PK
830	##p	I-PK
830	##c	I-PK
830	is	O
830	the	O
830	first	B-PK
830	‐	I-PK
830	order	I-PK
830	rate	I-PK
830	of	I-PK
830	transfer	I-PK
830	of	O
830	c	O
830	##d	O
830	##34	O
830	+	O
830	cells	O
830	from	O
830	the	O
830	pool	O
830	to	O
830	the	O
830	response	O
830	compartment	O
830	,	O
830	k	B-PK
830	##c	I-PK
830	##p	I-PK
830	is	O
830	the	O
830	first	B-PK
830	‐	I-PK
830	order	I-PK
830	rate	I-PK
830	of	I-PK
830	transfer	I-PK
830	of	O
830	c	O
830	##d	O
830	##34	O
830	+	O
830	cells	O
830	from	O
830	the	O
830	response	O
830	back	O
830	to	O
830	the	O
830	pool	O
830	compartment	O
830	,	O
830	k	B-PK
830	##out	I-PK
830	is	O
830	the	O
830	first	B-PK
830	‐	I-PK
830	order	I-PK
830	rate	I-PK
830	of	I-PK
830	c	I-PK
830	##d	I-PK
830	##34	I-PK
830	+	I-PK
830	cell	I-PK
830	elimination	I-PK
830	,	O
830	k	O
830	##t	O
830	is	O
830	the	O
830	first	B-PK
830	‐	I-PK
830	order	I-PK
830	signal	I-PK
830	transit	I-PK
830	rate	I-PK
830	,	O
830	which	O
830	is	O
830	null	O
830	for	O
830	patients	O
830	which	O
830	were	O
830	not	O
830	enrolled	O
830	in	O
830	study	O
830	c	O
830	##xa	O
830	##c	O
830	,	O
830	s	O
830	##max	O
830	is	O
830	the	O
830	maximum	O
830	s	O
830	##ti	O
830	##mu	O
830	##lator	O
830	##y	O
830	effect	O
830	of	O
830	l	O
830	##y	O
830	##25	O
830	##10	O
830	##9	O
830	##24	O
830	,	O
830	s	O
830	##c	O
830	##50	O
830	is	O
830	the	O
830	l	O
830	##y	O
830	##25	O
830	##10	O
830	##9	O
830	##24	O
830	concentration	O
830	at	O
830	which	O
830	half	O
830	of	O
830	the	O
830	maximum	O
830	s	O
830	##ti	O
830	##mu	O
830	##lator	O
830	##y	O
830	effect	O
830	is	O
830	achieved	O
830	,	O
830	c	O
830	##p	O
830	is	O
830	the	O
830	l	O
830	##y	O
830	##25	O
830	##10	O
830	##9	O
830	##24	O
830	concentration	O
830	in	O
830	the	O
830	central	O
830	compartment	O
830	,	O
830	[UNK]	O
830	is	O
830	the	O
830	signal	O
830	s	O
830	##ti	O
830	##mu	O
830	##lator	O
830	##y	O
830	factor	O
830	,	O
830	and	O
830	f	O
830	##c	O
830	##xa	O
830	##c	O
830	is	O
830	set	O
830	to	O
830	1	O
830	after	O
830	the	O
830	first	O
830	dose	O
830	for	O
830	patients	O
830	enrolled	O
830	in	O
830	study	O
830	c	O
830	##xa	O
830	##c	O
830	and	O
830	zero	O
830	otherwise	O
830	.	O
830	[SEP]	O
831	[CLS]	O
831	the	O
831	accumulation	O
831	ratio	O
831	in	O
831	the	O
831	presence	O
831	of	O
831	r	O
831	##t	O
831	##v	O
831	was	O
831	between	O
831	2	O
831	‐	O
831	and	O
831	4	O
831	‐	O
831	fold	O
831	,	O
831	consistent	O
831	with	O
831	the	O
831	reduction	O
831	in	O
831	c	O
831	##y	O
831	##p	O
831	##3	O
831	##a	O
831	##4	O
831	‐	O
831	mediated	O
831	metabolic	B-PK
831	clearance	I-PK
831	of	O
831	g	O
831	##sk	O
831	##28	O
831	##38	O
831	##23	O
831	##2	O
831	.	O
831	[SEP]	O
832	[CLS]	O
832	h	O
832	##00	O
832	##1	O
832	,	O
832	an	O
832	analogue	O
832	of	O
832	h	O
832	##00	O
832	##2	O
832	,	O
832	was	O
832	used	O
832	as	O
832	the	O
832	internal	O
832	standard	O
832	.	O
832	[SEP]	O
833	[CLS]	O
833	multiple	O
833	dos	O
833	##ing	O
833	of	O
833	the	O
833	micro	O
833	##ni	O
833	##zed	O
833	a	O
833	##pi	O
833	form	O
833	of	O
833	g	O
833	##sk	O
833	##28	O
833	##38	O
833	##23	O
833	##2	O
833	q	O
833	##d	O
833	for	O
833	11	O
833	days	O
833	in	O
833	the	O
833	presence	O
833	of	O
833	r	O
833	##t	O
833	##v	O
833	appeared	O
833	to	O
833	be	O
833	dose	O
833	proportional	O
833	through	O
833	200	O
833	mg	O
833	with	O
833	either	O
833	powder	O
833	‐	O
833	in	O
833	‐	O
833	bottle	O
833	or	O
833	given	O
833	as	O
833	capsule	O
833	##s	O
833	(	O
833	study	O
833	204	O
833	##9	O
833	##53	O
833	,	O
833	table	O
833	3	O
833	,	O
833	figure	O
833	3	O
833	)	O
833	.	O
833	[SEP]	O
834	[CLS]	O
834	currently	O
834	,	O
834	topic	O
834	##al	O
834	administration	O
834	is	O
834	the	O
834	first	O
834	choice	O
834	for	O
834	treatment	O
834	of	O
834	o	O
834	##cular	O
834	diseases	O
834	because	O
834	of	O
834	its	O
834	convenience	O
834	and	O
834	patient	O
834	compliance	O
834	##12	O
834	##34	O
834	.	O
834	[SEP]	O
835	[CLS]	O
835	further	O
835	##more	O
835	,	O
835	s	O
835	##nc	O
835	##v	O
835	##s	O
835	in	O
835	animals	O
835	given	O
835	5	O
835	%	O
835	glucose	O
835	,	O
835	c	O
835	##dd	O
835	##p	O
835	,	O
835	and	O
835	n	O
835	##c	O
835	-	O
835	600	O
835	##4	O
835	were	O
835	42	O
835	.	O
835	86	O
835	##±	O
835	##8	O
835	.	O
835	07	O
835	,	O
835	35	O
835	.	O
835	48	O
835	##±	O
835	##4	O
835	.	O
835	91	O
835	,	O
835	and	O
835	43	O
835	.	O
835	74	O
835	##±	O
835	##5	O
835	.	O
835	3	O
835	m	O
835	s	O
835	##−	O
835	##1	O
835	,	O
835	respectively	O
835	.	O
835	[SEP]	O
836	[CLS]	O
836	a	O
836	good	O
836	correlation	O
836	was	O
836	found	O
836	between	O
836	the	O
836	l	O
836	##ymph	O
836	##atic	O
836	transport	O
836	of	O
836	vitamin	O
836	d	O
836	in	O
836	the	O
836	conscious	O
836	,	O
836	me	O
836	##sent	O
836	##eric	O
836	l	O
836	##ymph	O
836	-	O
836	can	O
836	##nu	O
836	##lated	O
836	rat	O
836	model	O
836	and	O
836	in	O
836	the	O
836	ch	O
836	##yl	O
836	##omi	O
836	##c	O
836	##ron	O
836	flow	O
836	blocking	O
836	model	O
836	using	O
836	c	O
836	##y	O
836	##c	O
836	##lo	O
836	##he	O
836	##xi	O
836	##mi	O
836	##de	O
836	.	O
836	19	O
836	it	O
836	has	O
836	been	O
836	reported	O
836	that	O
836	the	O
836	fraction	O
836	transported	O
836	by	O
836	the	O
836	l	O
836	##ymph	O
836	##atic	O
836	pathway	O
836	can	O
836	be	O
836	determined	O
836	by	O
836	sub	O
836	##tract	O
836	##ing	O
836	the	O
836	fraction	O
836	transported	O
836	to	O
836	the	O
836	systemic	O
836	circulation	O
836	in	O
836	the	O
836	rats	O
836	pre	O
836	##tre	O
836	##ated	O
836	with	O
836	c	O
836	##y	O
836	##c	O
836	##lo	O
836	##he	O
836	##xi	O
836	##mi	O
836	##de	O
836	from	O
836	the	O
836	total	B-PK
836	bio	I-PK
836	##ava	I-PK
836	##ila	I-PK
836	##bility	I-PK
836	in	O
836	animals	O
836	pre	O
836	##tre	O
836	##ated	O
836	with	O
836	sa	O
836	##line	O
836	.	O
836	16	O
836	,	O
836	18	O
836	[SEP]	O
837	[CLS]	O
837	secondary	O
837	end	O
837	points	O
837	included	O
837	investigator	O
837	-	O
837	assessed	O
837	r	O
837	##pf	O
837	##s	O
837	,	O
837	time	O
837	to	O
837	initiation	O
837	of	O
837	ch	O
837	##em	O
837	##otherapy	O
837	,	O
837	time	O
837	to	O
837	pro	O
837	##state	O
837	-	O
837	specific	O
837	anti	O
837	##gen	O
837	(	O
837	ps	O
837	##a	O
837	)	O
837	progression	O
837	,	O
837	ps	O
837	##a	O
837	response	O
837	(	O
837	≥	O
837	##50	O
837	%	O
837	decline	O
837	)	O
837	,	O
837	and	O
837	time	O
837	to	O
837	skeletal	O
837	-	O
837	related	O
837	event	O
837	.	O
837	[SEP]	O
838	[CLS]	O
838	however	O
838	,	O
838	fatty	O
838	in	O
838	##fi	O
838	##ltration	O
838	had	O
838	been	O
838	seen	O
838	in	O
838	all	O
838	groups	O
838	without	O
838	significant	O
838	difference	O
838	.	O
838	[SEP]	O
839	[CLS]	O
839	it	O
839	is	O
839	well	O
839	established	O
839	that	O
839	p	O
839	##ha	O
839	##go	O
839	##cy	O
839	##tes	O
839	,	O
839	which	O
839	are	O
839	abundant	O
839	in	O
839	the	O
839	re	O
839	##tic	O
839	##ulo	O
839	##end	O
839	##oth	O
839	##eli	O
839	##al	O
839	system	O
839	,	O
839	in	O
839	liver	O
839	,	O
839	kidney	O
839	,	O
839	s	O
839	##ple	O
839	##en	O
839	and	O
839	lung	O
839	tissues	O
839	,	O
839	can	O
839	trigger	O
839	the	O
839	process	O
839	of	O
839	p	O
839	##ha	O
839	##go	O
839	##cy	O
839	##tic	O
839	recognition	O
839	and	O
839	subsequent	O
839	blood	B-PK
839	clearance	I-PK
839	.	O
839	[SEP]	O
840	[CLS]	O
840	the	O
840	area	B-PK
840	under	I-PK
840	the	I-PK
840	time	I-PK
840	curve	I-PK
840	extra	I-PK
840	##pol	I-PK
840	##ated	I-PK
840	to	I-PK
840	an	I-PK
840	infinite	I-PK
840	time	I-PK
840	(	I-PK
840	au	I-PK
840	##c	I-PK
840	##0	I-PK
840	-	I-PK
840	in	I-PK
840	##f	I-PK
840	)	I-PK
840	approximately	O
840	doubled	O
840	,	O
840	maximum	B-PK
840	concentration	I-PK
840	(	I-PK
840	cm	I-PK
840	##ax	I-PK
840	)	I-PK
840	increased	O
840	at	O
840	a	O
840	rate	O
840	greater	O
840	than	O
840	the	O
840	dose	O
840	(	O
840	~	O
840	2	O
840	.	O
840	4	O
840	fold	O
840	)	O
840	;	O
840	and	O
840	the	O
840	time	B-PK
840	to	I-PK
840	cm	I-PK
840	##ax	I-PK
840	(	I-PK
840	t	I-PK
840	##max	I-PK
840	)	I-PK
840	,	O
840	apparent	B-PK
840	clearance	I-PK
840	(	I-PK
840	c	I-PK
840	##l	I-PK
840	/	I-PK
840	f	I-PK
840	)	I-PK
840	and	O
840	apparent	B-PK
840	volume	I-PK
840	of	I-PK
840	distribution	I-PK
840	(	I-PK
840	v	I-PK
840	##d	I-PK
840	/	I-PK
840	f	I-PK
840	)	I-PK
840	were	O
840	approximately	O
840	the	O
840	same	O
840	for	O
840	both	O
840	p	O
840	##f	O
840	-	O
840	51	O
840	##90	O
840	##45	O
840	##7	O
840	50	O
840	mg	O
840	b	O
840	.	O
840	i	O
840	.	O
840	d	O
840	.	O
840	and	O
840	100	O
840	mg	O
840	b	O
840	.	O
840	i	O
840	.	O
840	d	O
840	.	O
840	doses	O
840	.	O
840	[SEP]	O
841	[CLS]	O
841	twenty	O
841	participants	O
841	took	O
841	four	O
841	100	O
841	-	O
841	mg	O
841	al	O
841	##ba	O
841	##cona	O
841	##zo	O
841	##le	O
841	capsule	O
841	##s	O
841	before	O
841	crossing	O
841	over	O
841	to	O
841	a	O
841	single	O
841	400	O
841	-	O
841	mg	O
841	al	O
841	##ba	O
841	##cona	O
841	##zo	O
841	##le	O
841	tablet	O
841	.	O
841	[SEP]	O
842	[CLS]	O
842	p	O
842	##lu	O
842	##ronic	O
842	f	O
842	68	O
842	was	O
842	purchased	O
842	from	O
842	si	O
842	##gma	O
842	-	O
842	al	O
842	##dric	O
842	##h	O
842	chemicals	O
842	,	O
842	us	O
842	##a	O
842	.	O
842	[SEP]	O
843	[CLS]	O
843	this	O
843	study	O
843	was	O
843	conducted	O
843	at	O
843	a	O
843	single	O
843	site	O
843	(	O
843	co	O
843	##vance	O
843	clinical	O
843	research	O
843	unit	O
843	,	O
843	da	O
843	##llas	O
843	,	O
843	te	O
843	##xa	O
843	##s	O
843	)	O
843	under	O
843	a	O
843	single	O
843	principal	O
843	investigator	O
843	(	O
843	j	O
843	.	O
843	k	O
843	.	O
843	)	O
843	;	O
843	institutional	O
843	review	O
843	board	O
843	approval	O
843	was	O
843	obtained	O
843	for	O
843	the	O
843	study	O
843	protocol	O
843	and	O
843	consent	O
843	forms	O
843	(	O
843	s	O
843	##chu	O
843	##lman	O
843	associates	O
843	i	O
843	##rb	O
843	,	O
843	in	O
843	##c	O
843	.	O
843	,	O
843	c	O
843	##in	O
843	##cin	O
843	##nat	O
843	##i	O
843	,	O
843	oh	O
843	##io	O
843	)	O
843	.	O
843	[SEP]	O
844	[CLS]	O
844	to	O
844	adjust	O
844	for	O
844	multi	O
844	##p	O
844	##licity	O
844	in	O
844	the	O
844	ass	O
844	##ay	O
844	sensitivity	O
844	analysis	O
844	,	O
844	a	O
844	re	O
844	##sa	O
844	##mp	O
844	##ling	O
844	‐	O
844	based	O
844	multiple	O
844	test	O
844	was	O
844	carried	O
844	out	O
844	.	O
844	[SEP]	O
845	[CLS]	O
845	y	O
845	=	O
845	α	O
845	##0	O
845	+	O
845	α	O
845	##1	O
845	##x	O
845	##1	O
845	+	O
845	α	O
845	##2	O
845	##x	O
845	##2	O
845	+	O
845	α	O
845	##3	O
845	##x	O
845	##3	O
845	+	O
845	α	O
845	##12	O
845	##x	O
845	##1	O
845	##x	O
845	##2	O
845	+	O
845	α	O
845	##13	O
845	##x	O
845	##1	O
845	##x	O
845	##3	O
845	+	O
845	α	O
845	##23	O
845	##x	O
845	##2	O
845	##x	O
845	##3	O
845	+	O
845	α	O
845	##11	O
845	##x	O
845	##12	O
845	+	O
845	α	O
845	##22	O
845	##x	O
845	##22	O
845	+	O
845	α	O
845	##33	O
845	##x	O
845	##32	O
845	+	O
845	·	O
845	·	O
845	·	O
845	[SEP]	O
846	[CLS]	O
846	in	O
846	the	O
846	context	O
846	of	O
846	p	O
846	##har	O
846	##ma	O
846	##co	O
846	##kin	O
846	##etic	O
846	/	O
846	p	O
846	##har	O
846	##ma	O
846	##co	O
846	##dynamic	O
846	goal	O
846	of	O
846	area	B-PK
846	under	I-PK
846	the	I-PK
846	time	I-PK
846	concentration	I-PK
846	curve	I-PK
846	to	I-PK
846	minimum	I-PK
846	inhibitor	I-PK
846	##y	I-PK
846	concentration	I-PK
846	(	I-PK
846	au	I-PK
846	##c	I-PK
846	/	I-PK
846	mi	I-PK
846	##c	I-PK
846	)	I-PK
846	≥	O
846	##40	O
846	##0	O
846	and	O
846	also	O
846	to	O
846	obtain	O
846	t	B-PK
846	##rough	I-PK
846	serum	I-PK
846	concentration	I-PK
846	of	O
846	van	O
846	##com	O
846	##y	O
846	##cin	O
846	of	O
846	≥	O
846	##15	O
846	mg	O
846	/	O
846	l	O
846	,	O
846	it	O
846	is	O
846	necessary	O
846	to	O
846	individual	O
846	##ize	O
846	doses	O
846	of	O
846	van	O
846	##com	O
846	##y	O
846	##cin	O
846	in	O
846	critically	O
846	ill	O
846	patients	O
846	.	O
846	[SEP]	O
847	[CLS]	O
847	the	O
847	apparent	B-PK
847	terminal	I-PK
847	half	I-PK
847	-	I-PK
847	life	I-PK
847	(	I-PK
847	t	I-PK
847	##1	I-PK
847	/	I-PK
847	2	I-PK
847	)	I-PK
847	of	O
847	ng	O
847	##r	O
847	–	O
847	h	O
847	##t	O
847	##n	O
847	##f	O
847	was	O
847	relatively	O
847	short	O
847	,	O
847	with	O
847	means	O
847	##±	O
847	##s	O
847	.	O
847	d	O
847	.	O
847	[SEP]	O
848	[CLS]	O
848	all	O
848	of	O
848	the	O
848	a	O
848	##es	O
848	were	O
848	judged	O
848	to	O
848	be	O
848	due	O
848	to	O
848	the	O
848	b	O
848	##al	O
848	procedure	O
848	and	O
848	not	O
848	considered	O
848	drug	O
848	related	O
848	,	O
848	except	O
848	for	O
848	one	O
848	a	O
848	##e	O
848	(	O
848	vomit	O
848	##ing	O
848	)	O
848	,	O
848	which	O
848	occurred	O
848	just	O
848	after	O
848	drug	O
848	administration	O
848	.	O
848	[SEP]	O
849	[CLS]	O
849	all	O
849	a	O
849	##es	O
849	were	O
849	mild	O
849	in	O
849	severity	O
849	,	O
849	except	O
849	for	O
849	one	O
849	moderate	O
849	a	O
849	##e	O
849	(	O
849	respiratory	O
849	tract	O
849	infection	O
849	)	O
849	.	O
849	[SEP]	O
850	[CLS]	O
850	the	O
850	standard	O
850	de	O
850	##viation	O
850	##s	O
850	of	O
850	the	O
850	au	B-PK
850	##c	I-PK
850	ranged	O
850	from	O
850	0	O
850	.	O
850	000	O
850	to	O
850	0	O
850	.	O
850	01	O
850	##9	O
850	suggesting	O
850	that	O
850	the	O
850	models	O
850	were	O
850	stable	O
850	,	O
850	i	O
850	.	O
850	e	O
850	.	O
850	the	O
850	selection	O
850	of	O
850	non	O
850	-	O
850	d	O
850	##di	O
850	drugs	O
850	did	O
850	not	O
850	affect	O
850	the	O
850	results	O
850	.	O
850	[SEP]	O
851	[CLS]	O
851	the	O
851	results	O
851	of	O
851	4	O
851	-	O
851	fold	O
851	cross	O
851	-	O
851	valid	O
851	##ation	O
851	showed	O
851	that	O
851	the	O
851	standard	O
851	de	O
851	##viation	O
851	##s	O
851	of	O
851	au	B-PK
851	##c	I-PK
851	ranged	O
851	from	O
851	0	O
851	.	O
851	00	O
851	##2	O
851	to	O
851	0	O
851	.	O
851	01	O
851	##9	O
851	(	O
851	additional	O
851	file	O
851	1	O
851	:	O
851	table	O
851	s	O
851	##3	O
851	,	O
851	figure	O
851	s	O
851	##1	O
851	)	O
851	.	O
851	[SEP]	O
852	[CLS]	O
852	however	O
852	,	O
852	their	O
852	au	B-PK
852	##c	I-PK
852	values	O
852	were	O
852	clearly	O
852	higher	O
852	than	O
852	those	O
852	of	O
852	oral	O
852	administration	O
852	(	O
852	0	O
852	.	O
852	27	O
852	##16	O
852	–	O
852	2	O
852	.	O
852	222	O
852	ng	O
852	h	O
852	/	O
852	m	O
852	##l	O
852	)	O
852	.	O
852	[SEP]	O
853	[CLS]	O
853	since	O
853	we	O
853	chose	O
853	drugs	O
853	from	O
853	a	O
853	pool	O
853	of	O
853	a	O
853	large	O
853	number	O
853	of	O
853	drugs	O
853	with	O
853	non	O
853	-	O
853	d	O
853	##di	O
853	for	O
853	d	O
853	##q	O
853	to	O
853	construct	O
853	a	O
853	balanced	O
853	classification	O
853	(	O
853	d	O
853	##di	O
853	pairs	O
853	:	O
853	non	O
853	-	O
853	d	O
853	##di	O
853	pairs	O
853	=	O
853	1	O
853	:	O
853	1	O
853	)	O
853	,	O
853	we	O
853	were	O
853	concerned	O
853	about	O
853	the	O
853	bias	O
853	brought	O
853	by	O
853	the	O
853	selection	O
853	of	O
853	the	O
853	non	O
853	-	O
853	d	O
853	##di	O
853	drugs	O
853	.	O
853	[SEP]	O
854	[CLS]	O
854	the	O
854	model	O
854	was	O
854	repeated	O
854	using	O
854	different	O
854	age	O
854	threshold	O
854	variables	O
854	(	O
854	e	O
854	##g	O
854	,	O
854	≥	O
854	##6	O
854	vs	O
854	<	O
854	6	O
854	years	O
854	of	O
854	age	O
854	)	O
854	until	O
854	the	O
854	threshold	O
854	that	O
854	indicated	O
854	a	O
854	statistical	O
854	##ly	O
854	significant	O
854	increase	O
854	in	O
854	the	O
854	odds	O
854	of	O
854	having	O
854	a	O
854	half	B-PK
854	-	I-PK
854	life	I-PK
854	at	O
854	2	O
854	hours	O
854	or	O
854	higher	O
854	was	O
854	detected	O
854	.	O
854	[SEP]	O
855	[CLS]	O
855	calculated	O
855	area	B-PK
855	under	I-PK
855	the	I-PK
855	time	I-PK
855	–	I-PK
855	concentration	I-PK
855	curve	I-PK
855	(	I-PK
855	au	I-PK
855	##c	I-PK
855	)	I-PK
855	0	I-PK
855	–	I-PK
855	t	I-PK
855	values	O
855	was	O
855	slightly	O
855	higher	O
855	by	O
855	i	O
855	.	O
855	p	O
855	.	O
855	dos	O
855	##ing	O
855	than	O
855	by	O
855	i	O
855	.	O
855	v	O
855	.	O
855	dos	O
855	##ing	O
855	(	O
855	15	O
855	.	O
855	01	O
855	and	O
855	10	O
855	.	O
855	36	O
855	ng	O
855	h	O
855	/	O
855	m	O
855	##l	O
855	,	O
855	respectively	O
855	)	O
855	.	O
855	[SEP]	O
856	[CLS]	O
856	all	O
856	of	O
856	the	O
856	three	O
856	patients	O
856	(	O
856	100	O
856	%	O
856	)	O
856	receiving	O
856	8	O
856	mg	O
856	/	O
856	day	O
856	developed	O
856	a	O
856	r	O
856	##ash	O
856	,	O
856	a	O
856	well	O
856	-	O
856	known	O
856	a	O
856	##e	O
856	related	O
856	with	O
856	in	O
856	##hibition	O
856	of	O
856	wild	O
856	-	O
856	type	O
856	e	O
856	##g	O
856	##f	O
856	##r	O
856	.	O
856	[SEP]	O
857	[CLS]	O
857	adjusting	O
857	both	O
857	e	O
857	##f	O
857	and	O
857	f	O
857	##u	O
857	in	O
857	the	O
857	pp	O
857	##k	O
857	model	O
857	again	O
857	resulted	O
857	in	O
857	a	O
857	strong	O
857	bias	O
857	toward	O
857	over	O
857	##p	O
857	##red	O
857	##ict	O
857	##ing	O
857	u	O
857	##tero	O
857	##tro	O
857	##phic	O
857	le	O
857	##ls	O
857	(	O
857	m	O
857	##r	O
857	##v	O
857	=	O
857	1	O
857	.	O
857	24	O
857	log	O
857	units	O
857	)	O
857	,	O
857	whereas	O
857	all	O
857	single	O
857	-	O
857	adjustment	O
857	models	O
857	had	O
857	m	O
857	##r	O
857	##v	O
857	values	O
857	between	O
857	−	O
857	##0	O
857	.	O
857	21	O
857	and	O
857	−	O
857	##0	O
857	.	O
857	68	O
857	log	O
857	units	O
857	,	O
857	“	O
857	all	O
857	”	O
857	group	O
857	,	O
857	figure	O
857	3	O
857	##b	O
857	.	O
857	[SEP]	O
858	[CLS]	O
858	the	O
858	only	O
858	co	O
858	##var	O
858	##iate	O
858	that	O
858	improved	O
858	the	O
858	fit	O
858	of	O
858	the	O
858	model	O
858	was	O
858	,	O
858	for	O
858	pipe	O
858	##rac	O
858	##ill	O
858	##in	O
858	c	B-PK
858	##l	I-PK
858	,	O
858	c	O
858	##l	O
858	##c	O
858	##r	O
858	normal	O
858	##ized	O
858	to	O
858	100	O
858	m	O
858	##l	O
858	/	O
858	min	O
858	,	O
858	which	O
858	decreased	O
858	the	O
858	of	O
858	##v	O
858	by	O
858	18	O
858	.	O
858	62	O
858	(	O
858	p	O
858	<	O
858	0	O
858	.	O
858	01	O
858	)	O
858	.	O
858	[SEP]	O
859	[CLS]	O
859	the	O
859	time	O
859	course	O
859	of	O
859	un	O
859	##bound	O
859	plasma	O
859	pipe	O
859	##rac	O
859	##ill	O
859	##in	O
859	concentrations	O
859	was	O
859	best	O
859	described	O
859	by	O
859	a	O
859	two	O
859	-	O
859	compartment	O
859	linear	O
859	model	O
859	with	O
859	combined	O
859	residual	O
859	error	O
859	and	O
859	b	O
859	##s	O
859	##v	O
859	on	O
859	the	O
859	volume	B-PK
859	of	I-PK
859	the	I-PK
859	central	I-PK
859	(	I-PK
859	v	I-PK
859	##c	I-PK
859	)	I-PK
859	and	I-PK
859	peripheral	I-PK
859	compartment	I-PK
859	##s	I-PK
859	(	I-PK
859	v	I-PK
859	##p	I-PK
859	)	I-PK
859	,	O
859	drug	B-PK
859	clearance	I-PK
859	(	I-PK
859	c	I-PK
859	##l	I-PK
859	)	I-PK
859	and	O
859	an	O
859	in	B-PK
859	##fusion	I-PK
859	la	I-PK
859	##g	I-PK
859	des	I-PK
859	##cript	I-PK
859	##or	I-PK
859	(	I-PK
859	al	I-PK
859	##ag	I-PK
859	;	O
859	defined	O
859	as	O
859	the	O
859	time	O
859	taken	O
859	for	O
859	the	O
859	residual	O
859	drug	O
859	to	O
859	get	O
859	through	O
859	the	O
859	i	O
859	##v	O
859	line	O
859	after	O
859	completion	O
859	of	O
859	the	O
859	20	O
859	-	O
859	minute	O
859	in	O
859	##fusion	O
859	,	O
859	which	O
859	was	O
859	included	O
859	as	O
859	zero	O
859	order	O
859	input	O
859	)	O
859	.	O
859	[SEP]	O
860	[CLS]	O
860	after	O
860	5	O
860	min	O
860	of	O
860	in	O
860	##cu	O
860	##bation	O
860	at	O
860	37	O
860	##°	O
860	##c	O
860	,	O
860	the	O
860	reaction	O
860	was	O
860	stopped	O
860	by	O
860	the	O
860	addition	O
860	of	O
860	0	O
860	.	O
860	85	O
860	m	O
860	##l	O
860	of	O
860	t	O
860	##rich	O
860	##lor	O
860	##oa	O
860	##ce	O
860	##tic	O
860	acid	O
860	(	O
860	t	O
860	##ca	O
860	)	O
860	0	O
860	.	O
860	31	O
860	m	O
860	.	O
860	the	O
860	p	O
860	##h	O
860	of	O
860	the	O
860	mixture	O
860	was	O
860	brought	O
860	to	O
860	about	O
860	10	O
860	by	O
860	adding	O
860	0	O
860	.	O
860	65	O
860	m	O
860	##l	O
860	of	O
860	1	O
860	.	O
860	6	O
860	m	O
860	na	O
860	##oh	O
860	-	O
860	g	O
860	##ly	O
860	##cine	O
860	buffer	O
860	(	O
860	p	O
860	##h	O
860	10	O
860	.	O
860	3	O
860	)	O
860	;	O
860	the	O
860	amount	O
860	of	O
860	um	O
860	##bell	O
860	##ifer	O
860	##one	O
860	was	O
860	measured	O
860	flu	O
860	##ori	O
860	##metric	O
860	##ally	O
860	(	O
860	ex	O
860	##citation	O
860	390	O
860	nm	O
860	;	O
860	emission	O
860	440	O
860	nm	O
860	)	O
860	(	O
860	v	O
860	##iva	O
860	##relli	O
860	et	O
860	al	O
860	.	O
860	,	O
860	2016	O
860	##b	O
860	)	O
860	.	O
860	[SEP]	O
861	[CLS]	O
861	the	O
861	terminal	B-PK
861	half	I-PK
861	-	I-PK
861	life	I-PK
861	was	O
861	relatively	O
861	long	O
861	,	O
861	16	O
861	hours	O
861	.	O
861	[SEP]	O
862	[CLS]	O
862	the	O
862	half	B-PK
862	-	I-PK
862	life	I-PK
862	for	O
862	the	O
862	first	O
862	distribution	O
862	phase	O
862	was	O
862	calculated	O
862	to	O
862	be	O
862	0	O
862	.	O
862	2	O
862	hour	O
862	and	O
862	the	O
862	corresponding	O
862	half	B-PK
862	-	I-PK
862	life	I-PK
862	for	O
862	the	O
862	second	O
862	distribution	O
862	phase	O
862	was	O
862	1	O
862	.	O
862	3	O
862	hours	O
862	.	O
862	[SEP]	O
863	[CLS]	O
863	this	O
863	is	O
863	in	O
863	##dicative	O
863	of	O
863	a	O
863	stable	O
863	physically	O
863	cross	O
863	-	O
863	linked	O
863	network	O
863	showing	O
863	little	O
863	change	O
863	in	O
863	v	O
863	##isco	O
863	##ela	O
863	##stic	O
863	characteristics	O
863	.	O
863	[SEP]	O
864	[CLS]	O
864	for	O
864	quantitative	O
864	analysis	O
864	of	O
864	the	O
864	co	O
864	##rona	O
864	##l	O
864	imaging	O
864	planes	O
864	,	O
864	one	O
864	region	O
864	of	O
864	interest	O
864	(	O
864	r	O
864	##oi	O
864	)	O
864	was	O
864	placed	O
864	in	O
864	air	O
864	in	O
864	the	O
864	upper	O
864	left	O
864	q	O
864	##uad	O
864	##rant	O
864	outside	O
864	the	O
864	animal	O
864	and	O
864	defined	O
864	as	O
864	background	O
864	.	O
864	[SEP]	O
865	[CLS]	O
865	the	O
865	high	O
865	-	O
865	dose	O
865	to	O
865	##ler	O
865	##ability	O
865	study	O
865	with	O
865	g	O
865	##eh	O
865	##12	O
865	##13	O
865	##33	O
865	(	O
865	200	O
865	mg	O
865	f	O
865	##e	O
865	kg	O
865	##−	O
865	##1	O
865	)	O
865	did	O
865	not	O
865	reveal	O
865	any	O
865	weight	O
865	loss	O
865	in	O
865	g	O
865	##eh	O
865	##12	O
865	##13	O
865	##33	O
865	-	O
865	injected	O
865	rats	O
865	compared	O
865	with	O
865	controls	O
865	.	O
865	[SEP]	O
866	[CLS]	O
866	in	O
866	summary	O
866	,	O
866	no	O
866	significant	O
866	adverse	O
866	effects	O
866	were	O
866	observed	O
866	in	O
866	animals	O
866	treated	O
866	with	O
866	g	O
866	##eh	O
866	##12	O
866	##13	O
866	##33	O
866	at	O
866	a	O
866	high	O
866	dose	O
866	of	O
866	200	O
866	mg	O
866	f	O
866	##e	O
866	kg	O
866	##−	O
866	##1	O
866	.	O
866	[SEP]	O
867	[CLS]	O
867	em	O
867	:	O
867	those	O
867	cat	O
867	##ego	O
867	##rise	O
867	##d	O
867	as	O
867	having	O
867	two	O
867	of	O
867	the	O
867	wild	O
867	-	O
867	type	O
867	all	O
867	##ele	O
867	(	O
867	c	O
867	##y	O
867	##p	O
867	##2	O
867	##d	O
867	##6	O
867	*	O
867	1	O
867	ho	O
867	##mo	O
867	##zy	O
867	##got	O
867	##e	O
867	em	O
867	)	O
867	,	O
867	and	O
867	in	O
867	addition	O
867	patients	O
867	with	O
867	one	O
867	functional	O
867	all	O
867	##ele	O
867	and	O
867	one	O
867	non	O
867	-	O
867	functional	O
867	all	O
867	##ele	O
867	or	O
867	an	O
867	all	O
867	##ele	O
867	with	O
867	decreased	O
867	function	O
867	(	O
867	he	O
867	##tero	O
867	##zy	O
867	##got	O
867	##e	O
867	em	O
867	)	O
867	.	O
867	[SEP]	O
868	[CLS]	O
868	m	O
868	##r	O
868	images	O
868	were	O
868	exported	O
868	as	O
868	di	O
868	##com	O
868	files	O
868	and	O
868	analyzed	O
868	with	O
868	the	O
868	o	O
868	##sir	O
868	##ix	O
868	software	O
868	(	O
868	32	O
868	-	O
868	bit	O
868	open	O
868	source	O
868	,	O
868	http	O
868	:	O
868	/	O
868	/	O
868	www	O
868	.	O
868	o	O
868	##sir	O
868	##ix	O
868	-	O
868	viewer	O
868	.	O
868	com	O
868	)	O
868	.	O
868	[SEP]	O
869	[CLS]	O
869	the	O
869	random	O
869	##ized	O
869	volunteers	O
869	included	O
869	66	O
869	healthy	O
869	subjects	O
869	(	O
869	49	O
869	men	O
869	and	O
869	17	O
869	women	O
869	)	O
869	from	O
869	1	O
869	study	O
869	site	O
869	(	O
869	a	O
869	##pot	O
869	##ex	O
869	,	O
869	in	O
869	##c	O
869	.	O
869	,	O
869	bio	O
869	##c	O
869	##lini	O
869	##cal	O
869	development	O
869	,	O
869	clinical	O
869	operations	O
869	)	O
869	in	O
869	to	O
869	##ron	O
869	##to	O
869	,	O
869	on	O
869	##tar	O
869	##io	O
869	,	O
869	can	O
869	##ada	O
869	,	O
869	who	O
869	had	O
869	signed	O
869	informed	O
869	consent	O
869	and	O
869	had	O
869	passed	O
869	the	O
869	screening	O
869	processes	O
869	for	O
869	eligibility	O
869	.	O
869	[SEP]	O
870	[CLS]	O
870	the	O
870	study	O
870	was	O
870	approved	O
870	by	O
870	health	O
870	can	O
870	##ada	O
870	and	O
870	can	O
870	##adia	O
870	##n	O
870	research	O
870	ethics	O
870	board	O
870	and	O
870	was	O
870	conducted	O
870	in	O
870	compliance	O
870	with	O
870	good	O
870	clinical	O
870	practice	O
870	guidelines	O
870	.	O
870	[SEP]	O
871	[CLS]	O
871	there	O
871	were	O
871	no	O
871	apparent	O
871	relationships	O
871	between	O
871	the	O
871	levels	O
871	or	O
871	changes	O
871	of	O
871	these	O
871	bio	O
871	##mark	O
871	##ers	O
871	and	O
871	tumor	O
871	responses	O
871	.	O
871	[SEP]	O
872	[CLS]	O
872	pregnant	O
872	and	O
872	la	O
872	##ct	O
872	##ating	O
872	females	O
872	were	O
872	excluded	O
872	.	O
872	[SEP]	O
873	[CLS]	O
873	use	O
873	of	O
873	drug	O
873	meta	O
873	##bol	O
873	##izing	O
873	enzyme	O
873	(	O
873	c	O
873	##y	O
873	##p	O
873	-	O
873	450	O
873	)	O
873	induce	O
873	##rs	O
873	within	O
873	28	O
873	days	O
873	prior	O
873	to	O
873	dos	O
873	##ing	O
873	or	O
873	inhibitor	O
873	##s	O
873	within	O
873	14	O
873	days	O
873	prior	O
873	to	O
873	dos	O
873	##ing	O
873	,	O
873	use	O
873	of	O
873	any	O
873	mon	O
873	##oam	O
873	##ine	O
873	o	O
873	##xi	O
873	##das	O
873	##e	O
873	inhibitor	O
873	##s	O
873	within	O
873	28	O
873	days	O
873	prior	O
873	to	O
873	dos	O
873	##ing	O
873	,	O
873	use	O
873	of	O
873	any	O
873	prescription	O
873	medications	O
873	/	O
873	products	O
873	,	O
873	except	O
873	ho	O
873	##rmon	O
873	##al	O
873	con	O
873	##tra	O
873	##ceptive	O
873	##s	O
873	in	O
873	female	O
873	subjects	O
873	of	O
873	child	O
873	##be	O
873	##aring	O
873	potential	O
873	,	O
873	and	O
873	use	O
873	of	O
873	any	O
873	over	O
873	-	O
873	the	O
873	-	O
873	counter	O
873	non	O
873	-	O
873	prescription	O
873	preparations	O
873	(	O
873	except	O
873	i	O
873	##bu	O
873	##p	O
873	##ro	O
873	##fen	O
873	and	O
873	ace	O
873	##tam	O
873	##ino	O
873	##phe	O
873	##n	O
873	used	O
873	at	O
873	recommended	O
873	doses	O
873	)	O
873	within	O
873	14	O
873	days	O
873	of	O
873	study	O
873	entry	O
873	all	O
873	resulted	O
873	in	O
873	exclusion	O
873	.	O
873	[SEP]	O
874	[CLS]	O
874	no	O
874	id	O
874	##urs	O
874	##ulf	O
874	##ase	O
874	-	O
874	related	O
874	m	O
874	##or	O
874	##bid	O
874	##ity	O
874	or	O
874	mortality	O
874	was	O
874	observed	O
874	during	O
874	the	O
874	study	O
874	.	O
874	[SEP]	O
875	[CLS]	O
875	the	O
875	lower	O
875	limit	O
875	of	O
875	q	O
875	##uant	O
875	##itation	O
875	was	O
875	2	O
875	.	O
875	50	O
875	p	O
875	##g	O
875	/	O
875	m	O
875	##l	O
875	for	O
875	e	O
875	##e	O
875	and	O
875	50	O
875	.	O
875	0	O
875	p	O
875	##g	O
875	/	O
875	m	O
875	##l	O
875	for	O
875	l	O
875	##n	O
875	.	O
875	[SEP]	O
876	[CLS]	O
876	the	O
876	inter	B-PK
876	##com	I-PK
876	##par	I-PK
876	##tment	I-PK
876	##al	I-PK
876	rate	I-PK
876	constant	I-PK
876	##s	I-PK
876	were	O
876	defined	O
876	as	O
876	k	O
876	##12	O
876	=	O
876	q	O
876	##1	O
876	×	O
876	p	O
876	##c	O
876	/	O
876	v	O
876	##1	O
876	,	O
876	k	O
876	##21	O
876	=	O
876	q	O
876	##1	O
876	/	O
876	v	O
876	##2	O
876	,	O
876	and	O
876	k	O
876	##20	O
876	=	O
876	daily	O
876	c	O
876	##s	O
876	##f	O
876	drainage	O
876	volume	O
876	/	O
876	24	O
876	.	O
876	[SEP]	O
877	[CLS]	O
877	p	B-PK
877	##c	I-PK
877	is	O
877	defined	O
877	as	O
877	transfer	O
877	multi	O
877	##p	O
877	##lier	O
877	between	O
877	the	O
877	central	O
877	and	O
877	c	O
877	##s	O
877	##f	O
877	compartment	O
877	##s	O
877	.	O
877	[SEP]	O
878	[CLS]	O
878	ass	O
878	##ay	O
878	precision	O
878	,	O
878	expressed	O
878	as	O
878	the	O
878	between	O
878	‐	O
878	day	O
878	percent	O
878	coefficient	O
878	of	O
878	variation	O
878	(	O
878	%	O
878	c	O
878	##v	O
878	)	O
878	of	O
878	the	O
878	quality	O
878	control	O
878	(	O
878	q	O
878	##c	O
878	)	O
878	samples	O
878	was	O
878	<	O
878	14	O
878	.	O
878	7	O
878	%	O
878	for	O
878	e	O
878	##e	O
878	and	O
878	<	O
878	6	O
878	.	O
878	0	O
878	%	O
878	for	O
878	l	O
878	##n	O
878	for	O
878	the	O
878	low	O
878	,	O
878	medium	O
878	,	O
878	and	O
878	high	O
878	q	O
878	##c	O
878	samples	O
878	.	O
878	[SEP]	O
879	[CLS]	O
879	the	O
879	cumulative	O
879	transmission	O
879	per	O
879	unit	O
879	area	O
879	of	O
879	q	O
879	(	O
879	μ	O
879	##g	O
879	cm	O
879	##−	O
879	##2	O
879	)	O
879	and	O
879	the	O
879	steady	O
879	-	O
879	state	O
879	trans	O
879	##der	O
879	##mal	O
879	rate	O
879	j	O
879	##s	O
879	(	O
879	μ	O
879	##g	O
879	cm	O
879	##−	O
879	##2	O
879	h	O
879	##−	O
879	##1	O
879	)	O
879	were	O
879	calculated	O
879	.	O
879	[SEP]	O
880	[CLS]	O
880	for	O
880	quantitative	O
880	comparison	O
880	with	O
880	p	O
880	##ediatric	O
880	population	O
880	,	O
880	the	O
880	proportion	O
880	of	O
880	p	O
880	##ediatric	O
880	subjects	O
880	falling	O
880	outside	O
880	the	O
880	adult	O
880	95	O
880	%	O
880	percent	O
880	##ile	O
880	interval	O
880	was	O
880	com	O
880	##puted	O
880	for	O
880	distribution	O
880	of	O
880	concentrations	O
880	and	O
880	au	B-PK
880	##c	I-PK
880	.	O
880	[SEP]	O
881	[CLS]	O
881	the	O
881	following	O
881	p	O
881	##har	O
881	##ma	O
881	##co	O
881	##kin	O
881	##etic	O
881	parameters	O
881	from	O
881	plasma	O
881	samples	O
881	were	O
881	determined	O
881	from	O
881	typical	O
881	and	O
881	individual	O
881	g	O
881	##ado	O
881	##ter	O
881	##ic	O
881	acid	O
881	concentration	O
881	-	O
881	time	O
881	profiles	O
881	:	O
881	area	B-PK
881	under	I-PK
881	the	I-PK
881	curve	I-PK
881	(	I-PK
881	au	I-PK
881	##c	I-PK
881	)	I-PK
881	,	O
881	rate	B-PK
881	constant	I-PK
881	of	I-PK
881	the	I-PK
881	terminal	I-PK
881	phase	I-PK
881	(	I-PK
881	β	I-PK
881	)	I-PK
881	,	O
881	elimination	B-PK
881	half	I-PK
881	-	I-PK
881	life	I-PK
881	(	I-PK
881	t	I-PK
881	##½	I-PK
881	##β	I-PK
881	)	I-PK
881	,	O
881	total	B-PK
881	clearance	I-PK
881	(	I-PK
881	c	I-PK
881	##l	I-PK
881	;	O
881	per	O
881	subject	O
881	and	O
881	normal	O
881	##ized	O
881	for	O
881	b	O
881	##w	O
881	)	O
881	,	O
881	and	O
881	volume	B-PK
881	of	I-PK
881	distribution	I-PK
881	(	I-PK
881	v	I-PK
881	##d	I-PK
881	;	O
881	per	O
881	subject	O
881	and	O
881	normal	O
881	##ized	O
881	for	O
881	b	O
881	##w	O
881	)	O
881	.	O
881	[SEP]	O
882	[CLS]	O
882	it	O
882	is	O
882	obvious	O
882	that	O
882	the	O
882	2d	O
882	method	O
882	has	O
882	successfully	O
882	en	O
882	##rich	O
882	##ed	O
882	the	O
882	peak	O
882	capacity	O
882	and	O
882	improved	O
882	the	O
882	resolution	O
882	as	O
882	well	O
882	.	O
882	[SEP]	O
883	[CLS]	O
883	for	O
883	c	B-PK
883	##l	I-PK
883	and	O
883	v	B-PK
883	##d	I-PK
883	,	O
883	the	O
883	significant	O
883	co	O
883	##var	O
883	##iable	O
883	##s	O
883	responsible	O
883	for	O
883	the	O
883	variations	O
883	of	O
883	the	O
883	parameters	O
883	were	O
883	studied	O
883	.	O
883	[SEP]	O
884	[CLS]	O
884	sa	O
884	##rog	O
884	##lit	O
884	##azar	O
884	was	O
884	rapidly	O
884	and	O
884	well	O
884	absorbed	O
884	across	O
884	all	O
884	doses	O
884	in	O
884	the	O
884	single	O
884	-	O
884	dose	O
884	p	O
884	##har	O
884	##ma	O
884	##co	O
884	##kin	O
884	##etic	O
884	study	O
884	,	O
884	with	O
884	a	O
884	median	O
884	time	B-PK
884	to	I-PK
884	the	I-PK
884	peak	I-PK
884	plasma	I-PK
884	concentration	I-PK
884	(	I-PK
884	t	I-PK
884	##max	I-PK
884	)	I-PK
884	of	O
884	less	O
884	than	O
884	1	O
884	h	O
884	(	O
884	range	O
884	0	O
884	.	O
884	63	O
884	–	O
884	1	O
884	h	O
884	)	O
884	under	O
884	fast	O
884	##ing	O
884	conditions	O
884	across	O
884	the	O
884	doses	O
884	studied	O
884	.	O
884	[SEP]	O
885	[CLS]	O
885	the	O
885	average	O
885	terminal	B-PK
885	half	I-PK
885	-	I-PK
885	life	I-PK
885	of	O
885	sa	O
885	##rog	O
885	##lit	O
885	##azar	O
885	was	O
885	5	O
885	.	O
885	6	O
885	h	O
885	.	O
885	sa	O
885	##rog	O
885	##lit	O
885	##azar	O
885	was	O
885	not	O
885	eliminated	O
885	via	O
885	the	O
885	re	O
885	##nal	O
885	route	O
885	.	O
885	[SEP]	O
886	[CLS]	O
886	there	O
886	was	O
886	no	O
886	effect	O
886	of	O
886	sex	O
886	on	O
886	the	O
886	p	O
886	##har	O
886	##ma	O
886	##co	O
886	##kin	O
886	##etics	O
886	of	O
886	sa	O
886	##rog	O
886	##lit	O
886	##azar	O
886	,	O
886	except	O
886	for	O
886	the	O
886	terminal	B-PK
886	half	I-PK
886	-	I-PK
886	life	I-PK
886	,	O
886	which	O
886	was	O
886	significantly	O
886	shorter	O
886	in	O
886	females	O
886	than	O
886	in	O
886	males	O
886	.	O
886	[SEP]	O
887	[CLS]	O
887	the	O
887	bio	O
887	##e	O
887	##qui	O
887	##valence	O
887	between	O
887	both	O
887	products	O
887	was	O
887	determined	O
887	by	O
887	calculation	O
887	of	O
887	the	O
887	confidence	O
887	intervals	O
887	(	O
887	c	O
887	##is	O
887	)	O
887	at	O
887	90	O
887	%	O
887	of	O
887	the	O
887	log	O
887	##ari	O
887	##th	O
887	##m	O
887	of	O
887	the	O
887	coefficient	O
887	test	O
887	/	O
887	reference	O
887	such	O
887	as	O
887	cm	B-PK
887	##ax	I-PK
887	,	O
887	au	B-PK
887	##c	I-PK
887	##0	I-PK
887	–	I-PK
887	t	I-PK
887	,	O
887	and	O
887	au	B-PK
887	##c	I-PK
887	##0	I-PK
887	–	I-PK
887	∞	I-PK
887	in	O
887	terms	O
887	of	O
887	ace	O
887	##tam	O
887	##ino	O
887	##phe	O
887	##n	O
887	p	O
887	##har	O
887	##ma	O
887	##co	O
887	##kin	O
887	##etic	O
887	metric	O
887	##s	O
887	.	O
887	[SEP]	O
888	[CLS]	O
888	the	O
888	p	O
888	##har	O
888	##ma	O
888	##co	O
888	##kin	O
888	##etics	O
888	of	O
888	the	O
888	active	O
888	m	O
888	##oi	O
888	##ety	O
888	after	O
888	oral	O
888	r	O
888	##is	O
888	##per	O
888	##ido	O
888	##ne	O
888	administration	O
888	has	O
888	been	O
888	described	O
888	using	O
888	a	O
888	two	O
888	-	O
888	compartment	O
888	disposition	O
888	model	O
888	with	O
888	linear	O
888	elimination	O
888	from	O
888	the	O
888	central	O
888	compartment	O
888	.	O
888	25	O
888	oral	O
888	absorption	O
888	was	O
888	modeled	O
888	using	O
888	a	O
888	first	O
888	-	O
888	order	O
888	process	O
888	with	O
888	a	O
888	la	B-PK
888	##g	I-PK
888	time	I-PK
888	from	O
888	the	O
888	gut	O
888	to	O
888	the	O
888	central	O
888	compartment	O
888	.	O
888	[SEP]	O
889	[CLS]	O
889	the	O
889	terminal	B-PK
889	elimination	I-PK
889	rate	I-PK
889	constant	I-PK
889	(	I-PK
889	λ	I-PK
889	##z	I-PK
889	)	I-PK
889	was	O
889	estimated	O
889	by	O
889	linear	O
889	re	O
889	##gression	O
889	of	O
889	log	O
889	##ari	O
889	##th	O
889	##mic	O
889	##ally	O
889	‐	O
889	transformed	O
889	concentration	O
889	–	O
889	time	O
889	data	O
889	.	O
889	[SEP]	O
890	[CLS]	O
890	terminal	B-PK
890	elimination	I-PK
890	t	I-PK
890	##1	I-PK
890	/	I-PK
890	2	I-PK
890	was	O
890	calculated	O
890	as	O
890	l	O
890	##n	O
890	(	O
890	2	O
890	)	O
890	/	O
890	λ	O
890	##z	O
890	.	O
890	[SEP]	O
891	[CLS]	O
891	the	O
891	accumulation	B-PK
891	ratio	I-PK
891	(	I-PK
891	r	I-PK
891	##ac	I-PK
891	##c	I-PK
891	)	I-PK
891	was	O
891	calculated	O
891	as	O
891	au	B-PK
891	##c	I-PK
891	##0	I-PK
891	–	I-PK
891	24	I-PK
891	##pm	I-PK
891	,	I-PK
891	s	I-PK
891	##s	I-PK
891	/	I-PK
891	au	I-PK
891	##c	I-PK
891	##0	I-PK
891	–	I-PK
891	24	I-PK
891	,	I-PK
891	s	I-PK
891	##d	I-PK
891	.	O
891	[SEP]	O
892	[CLS]	O
892	the	O
892	maximum	B-PK
892	observed	I-PK
892	plasma	I-PK
892	concentration	I-PK
892	(	I-PK
892	cm	I-PK
892	##ax	I-PK
892	)	I-PK
892	and	O
892	time	B-PK
892	to	I-PK
892	reach	I-PK
892	cm	I-PK
892	##ax	I-PK
892	(	I-PK
892	t	I-PK
892	##max	I-PK
892	)	I-PK
892	were	O
892	obtained	O
892	directly	O
892	from	O
892	the	O
892	concentration	O
892	–	O
892	time	O
892	data	O
892	.	O
892	[SEP]	O
893	[CLS]	O
893	the	O
893	au	B-PK
893	##c	I-PK
893	from	I-PK
893	time	I-PK
893	zero	I-PK
893	to	I-PK
893	in	I-PK
893	##finity	I-PK
893	(	I-PK
893	au	I-PK
893	##c	I-PK
893	##0	I-PK
893	–	I-PK
893	∞	I-PK
893	)	I-PK
893	after	O
893	a	O
893	single	O
893	dose	O
893	was	O
893	calculated	O
893	as	O
893	the	O
893	sum	O
893	of	O
893	au	B-PK
893	##c	I-PK
893	##0	I-PK
893	–	I-PK
893	last	I-PK
893	and	O
893	au	B-PK
893	##ce	I-PK
893	##x	I-PK
893	##tra	I-PK
893	##p	I-PK
893	where	O
893	au	B-PK
893	##ce	I-PK
893	##x	I-PK
893	##tra	I-PK
893	##p	I-PK
893	is	O
893	c	B-PK
893	##last	I-PK
893	/	I-PK
893	λ	I-PK
893	##z	I-PK
893	.	O
893	[SEP]	O
894	[CLS]	O
894	the	O
894	area	B-PK
894	under	I-PK
894	the	I-PK
894	plasma	I-PK
894	concentration	I-PK
894	–	I-PK
894	time	I-PK
894	curve	I-PK
894	from	I-PK
894	time	I-PK
894	zero	I-PK
894	to	I-PK
894	the	I-PK
894	end	I-PK
894	of	I-PK
894	the	I-PK
894	dos	I-PK
894	##ing	I-PK
894	interval	I-PK
894	,	I-PK
894	ta	I-PK
894	##u	I-PK
894	,	O
894	for	O
894	the	O
894	morning	O
894	and	O
894	evening	O
894	dose	O
894	(	O
894	au	B-PK
894	##cam	I-PK
894	,	O
894	au	B-PK
894	##c	I-PK
894	##pm	I-PK
894	)	O
894	was	O
894	calculated	O
894	by	O
894	means	O
894	of	O
894	the	O
894	mixed	O
894	log	O
894	‐	O
894	linear	O
894	trap	O
894	##ez	O
894	##oid	O
894	##al	O
894	rule	O
894	.	O
894	[SEP]	O
895	[CLS]	O
895	the	O
895	steady	B-PK
895	‐	I-PK
895	state	I-PK
895	equilibrium	I-PK
895	ratio	I-PK
895	was	O
895	calculated	O
895	as	O
895	au	B-PK
895	##c	I-PK
895	##0	I-PK
895	–	I-PK
895	24	I-PK
895	##pm	I-PK
895	,	I-PK
895	s	I-PK
895	##s	I-PK
895	/	I-PK
895	au	I-PK
895	##c	I-PK
895	##0	I-PK
895	–	I-PK
895	∞	I-PK
895	,	I-PK
895	s	I-PK
895	##d	I-PK
895	.	O
895	[SEP]	O
896	[CLS]	O
896	the	O
896	half	B-PK
896	-	I-PK
896	life	I-PK
896	in	O
896	the	O
896	first	O
896	les	O
896	##ion	O
896	varied	O
896	from	O
896	1	O
896	.	O
896	8	O
896	days	O
896	to	O
896	3	O
896	.	O
896	6	O
896	days	O
896	(	O
896	mean	O
896	2	O
896	.	O
896	4	O
896	days	O
896	,	O
896	s	O
896	##d	O
896	0	O
896	.	O
896	8	O
896	days	O
896	)	O
896	during	O
896	the	O
896	six	O
896	cycles	O
896	,	O
896	and	O
896	from	O
896	3	O
896	.	O
896	0	O
896	days	O
896	to	O
896	4	O
896	.	O
896	5	O
896	days	O
896	(	O
896	mean	O
896	3	O
896	.	O
896	7	O
896	days	O
896	,	O
896	s	O
896	##d	O
896	0	O
896	.	O
896	6	O
896	days	O
896	)	O
896	in	O
896	the	O
896	second	O
896	les	O
896	##ion	O
896	,	O
896	respectively	O
896	.	O
896	[SEP]	O
897	[CLS]	O
897	distribution	O
897	of	O
897	exposure	O
897	over	O
897	a	O
897	24	O
897	‐	O
897	h	O
897	dos	O
897	##ing	O
897	interval	O
897	at	O
897	steady	O
897	state	O
897	was	O
897	q	O
897	##uant	O
897	##ified	O
897	by	O
897	est	O
897	##imating	O
897	the	O
897	ratio	O
897	between	O
897	the	O
897	au	B-PK
897	##c	I-PK
897	for	I-PK
897	the	I-PK
897	first	I-PK
897	12	I-PK
897	‐	I-PK
897	h	I-PK
897	interval	I-PK
897	over	O
897	the	O
897	total	B-PK
897	au	I-PK
897	##c	I-PK
897	for	I-PK
897	the	I-PK
897	entire	I-PK
897	24	I-PK
897	‐	I-PK
897	h	I-PK
897	dos	I-PK
897	##ing	I-PK
897	interval	I-PK
897	under	O
897	the	O
897	g	O
897	##ir	O
897	(	O
897	au	B-PK
897	##c	I-PK
897	##gi	I-PK
897	##r	I-PK
897	,	I-PK
897	0	I-PK
897	–	I-PK
897	12	I-PK
897	##h	I-PK
897	,	I-PK
897	s	I-PK
897	##s	I-PK
897	/	I-PK
897	au	I-PK
897	##c	I-PK
897	##gi	I-PK
897	##r	I-PK
897	,	I-PK
897	τ	I-PK
897	,	I-PK
897	s	I-PK
897	##s	I-PK
897	)	O
897	.	O
897	[SEP]	O
898	[CLS]	O
898	the	O
898	au	B-PK
898	##c	I-PK
898	##24	I-PK
898	##h	I-PK
898	/	I-PK
898	mi	I-PK
898	##c	I-PK
898	and	O
898	cm	B-PK
898	##ax	I-PK
898	/	I-PK
898	mi	I-PK
898	##c	I-PK
898	were	O
898	used	O
898	as	O
898	the	O
898	combined	O
898	p	O
898	##k	O
898	/	O
898	p	O
898	##d	O
898	parameters	O
898	.	O
898	[SEP]	O
899	[CLS]	O
899	using	O
899	the	O
899	following	O
899	inhibitor	O
899	##y	O
899	si	O
899	##g	O
899	##mo	O
899	##id	O
899	em	B-PK
899	##ax	I-PK
899	model	O
899	to	O
899	integrate	O
899	the	O
899	ex	O
899	v	O
899	##ivo	O
899	au	B-PK
899	##c	I-PK
899	##24	I-PK
899	##h	I-PK
899	/	I-PK
899	mi	I-PK
899	##c	I-PK
899	ratio	I-PK
899	and	O
899	bacteria	O
899	count	O
899	change	O
899	(	O
899	c	O
899	##fu	O
899	/	O
899	m	O
899	##l	O
899	)	O
899	in	O
899	il	O
899	##eum	O
899	content	O
899	during	O
899	24	O
899	h	O
899	in	O
899	##cu	O
899	##bation	O
899	(	O
899	al	O
899	##ia	O
899	##bad	O
899	##i	O
899	and	O
899	le	O
899	##es	O
899	,	O
899	2001	O
899	;	O
899	al	O
899	##ia	O
899	##bad	O
899	##i	O
899	,	O
899	2002	O
899	;	O
899	al	O
899	##ia	O
899	##bad	O
899	##i	O
899	et	O
899	al	O
899	.	O
899	,	O
899	2003	O
899	)	O
899	.	O
899	[SEP]	O
900	[CLS]	O
900	the	O
900	(	O
900	%	O
900	)	O
900	is	O
900	##c	O
900	##v	O
900	was	O
900	slightly	O
900	higher	O
900	under	O
900	fast	O
900	##ing	O
900	conditions	O
900	(	O
900	15	O
900	.	O
900	6	O
900	and	O
900	11	O
900	.	O
900	4	O
900	for	O
900	cm	B-PK
900	##ax	I-PK
900	and	O
900	au	B-PK
900	##c	I-PK
900	##0	I-PK
900	-	I-PK
900	72	I-PK
900	)	O
900	than	O
900	that	O
900	observed	O
900	under	O
900	fed	O
900	conditions	O
900	(	O
900	11	O
900	.	O
900	5	O
900	for	O
900	cm	B-PK
900	##ax	I-PK
900	and	O
900	5	O
900	.	O
900	3	O
900	for	O
900	au	B-PK
900	##c	I-PK
900	##0	I-PK
900	-	I-PK
900	72	I-PK
900	)	O
900	.	O
900	[SEP]	O
901	[CLS]	O
901	to	O
901	maintain	O
901	a	O
901	stable	O
901	state	O
901	in	O
901	p	O
901	##h	O
901	1	O
901	.	O
901	2	O
901	dissolution	O
901	conditions	O
901	,	O
901	a	O
901	high	O
901	concentration	O
901	of	O
901	surf	O
901	##act	O
901	##ant	O
901	was	O
901	required	O
901	.	O
901	[SEP]	O
902	[CLS]	O
902	steady	B-PK
902	state	I-PK
902	au	I-PK
902	##cs	I-PK
902	were	O
902	significantly	O
902	higher	O
902	in	O
902	group	O
902	2	O
902	(	O
902	66	O
902	##5	O
902	.	O
902	9	O
902	±	O
902	136	O
902	.	O
902	5	O
902	)	O
902	comparing	O
902	with	O
902	group	O
902	1	O
902	(	O
902	490	O
902	.	O
902	7	O
902	±	O
902	101	O
902	.	O
902	1	O
902	)	O
902	,	O
902	respectively	O
902	(	O
902	p	O
902	=	O
902	0	O
902	.	O
902	00	O
902	##8	O
902	)	O
902	.	O
902	[SEP]	O
903	[CLS]	O
903	c	O
903	##t	O
903	-	O
903	p	O
903	##13	O
903	and	O
903	r	O
903	##p	O
903	were	O
903	comparable	O
903	in	O
903	terms	O
903	of	O
903	efficacy	O
903	(	O
903	including	O
903	radio	O
903	##graphic	O
903	progression	O
903	)	O
903	,	O
903	im	O
903	##mu	O
903	##no	O
903	##genic	O
903	##ity	O
903	and	O
903	p	O
903	##k	O
903	/	O
903	p	O
903	##d	O
903	up	O
903	to	O
903	week	O
903	54	O
903	.	O
903	[SEP]	O
904	[CLS]	O
904	the	O
904	residue	O
904	was	O
904	further	O
904	re	O
904	##con	O
904	##stituted	O
904	by	O
904	200	O
904	μ	O
904	##l	O
904	of	O
904	mobile	O
904	phase	O
904	.	O
904	[SEP]	O
905	[CLS]	O
905	what	O
905	question	O
905	does	O
905	this	O
905	study	O
905	address	O
905	?	O
905	[SEP]	O
906	[CLS]	O
906	following	O
906	the	O
906	treatment	O
906	,	O
906	participants	O
906	will	O
906	attend	O
906	post	O
906	-	O
906	treatment	O
906	and	O
906	progression	O
906	follow	O
906	-	O
906	up	O
906	visits	O
906	where	O
906	data	O
906	will	O
906	be	O
906	collected	O
906	on	O
906	a	O
906	##es	O
906	,	O
906	disease	O
906	status	O
906	and	O
906	survival	O
906	status	O
906	(	O
906	fi	O
906	##gs	O
906	.	O
906	5	O
906	and	O
906	6	O
906	)	O
906	.	O
906	[SEP]	O
907	[CLS]	O
907	in	O
907	our	O
907	present	O
907	study	O
907	,	O
907	the	O
907	in	O
907	##tra	O
907	##cellular	O
907	p	O
907	##har	O
907	##ma	O
907	##co	O
907	##kin	O
907	##etics	O
907	of	O
907	the	O
907	r	O
907	##h	O
907	##α	O
907	-	O
907	g	O
907	##la	O
907	,	O
907	i	O
907	.	O
907	e	O
907	.	O
907	,	O
907	f	O
907	##ab	O
907	##raz	O
907	##yme	O
907	and	O
907	re	O
907	##p	O
907	##lag	O
907	##al	O
907	,	O
907	are	O
907	consistent	O
907	with	O
907	the	O
907	previous	O
907	studies	O
907	that	O
907	the	O
907	half	B-PK
907	-	I-PK
907	life	I-PK
907	of	O
907	the	O
907	ad	O
907	##mini	O
907	##stra	O
907	##ted	O
907	r	O
907	##h	O
907	##α	O
907	-	O
907	g	O
907	##las	O
907	was	O
907	around	O
907	24	O
907	h	O
907	,	O
907	and	O
907	the	O
907	r	O
907	##h	O
907	##α	O
907	-	O
907	g	O
907	##la	O
907	up	O
907	##take	O
907	of	O
907	f	O
907	##ab	O
907	##raz	O
907	##yme	O
907	was	O
907	obviously	O
907	higher	O
907	than	O
907	that	O
907	of	O
907	re	O
907	##p	O
907	##lag	O
907	##al	O
907	in	O
907	the	O
907	g	O
907	##la	O
907	-	O
907	null	O
907	cells	O
907	(	O
907	figure	O
907	2d	O
907	,	O
907	e	O
907	)	O
907	.	O
907	[SEP]	O
908	[CLS]	O
908	t	B-PK
908	##1	I-PK
908	/	I-PK
908	2	I-PK
908	,	O
908	c	B-PK
908	##l	I-PK
908	/	I-PK
908	w	I-PK
908	##t	I-PK
908	,	O
908	au	B-PK
908	##c	I-PK
908	##0	I-PK
908	–	I-PK
908	24	I-PK
908	h	I-PK
908	,	O
908	and	O
908	cm	B-PK
908	##ax	I-PK
908	were	O
908	calculated	O
908	and	O
908	are	O
908	shown	O
908	after	O
908	s	O
908	##tra	O
908	##ti	O
908	##fication	O
908	for	O
908	re	O
908	##nal	O
908	function	O
908	(	O
908	c	O
908	##l	O
908	##c	O
908	##r	O
908	)	O
908	at	O
908	base	O
908	##line	O
908	.	O
908	[SEP]	O
909	[CLS]	O
909	the	O
909	lower	O
909	limit	O
909	of	O
909	q	O
909	##uant	O
909	##ification	O
909	for	O
909	the	O
909	ass	O
909	##ay	O
909	is	O
909	0	O
909	.	O
909	06	O
909	u	O
909	m	O
909	##l	O
909	##−	O
909	##1	O
909	,	O
909	and	O
909	the	O
909	ass	O
909	##ay	O
909	precision	O
909	is	O
909	10	O
909	%	O
909	c	O
909	##v	O
909	.	O
909	[SEP]	O
910	[CLS]	O
910	although	O
910	the	O
910	o	O
910	##2	O
910	supply	O
910	was	O
910	nearly	O
910	doubled	O
910	by	O
910	ni	O
910	##fe	O
910	##di	O
910	##pine	O
910	application	O
910	,	O
910	the	O
910	art	O
910	##eri	O
910	##o	O
910	-	O
910	ve	O
910	##nous	O
910	o	O
910	##2	O
910	concentration	O
910	difference	O
910	(	O
910	a	O
910	##v	O
910	##do	O
910	##2	O
910	)	O
910	remained	O
910	almost	O
910	constant	O
910	(	O
910	table	O
910	12	O
910	up	O
910	##take	O
910	following	O
910	the	O
910	improved	O
910	o	O
910	##2	O
910	delivery	O
910	caused	O
910	by	O
910	ni	O
910	##fe	O
910	##di	O
910	##pine	O
910	administration	O
910	.	O
910	[SEP]	O
911	[CLS]	O
911	the	O
911	fi	O
911	##lt	O
911	##rate	O
911	was	O
911	collected	O
911	,	O
911	and	O
911	the	O
911	residue	O
911	was	O
911	boiled	O
911	again	O
911	in	O
911	di	O
911	##st	O
911	##ille	O
911	##d	O
911	water	O
911	(	O
911	1	O
911	:	O
911	6	O
911	,	O
911	w	O
911	/	O
911	v	O
911	)	O
911	for	O
911	0	O
911	.	O
911	5	O
911	h	O
911	.	O
911	[SEP]	O
912	[CLS]	O
912	for	O
912	re	B-PK
912	##nal	I-PK
912	clearance	I-PK
912	,	O
912	the	O
912	agent	O
912	’	O
912	s	O
912	ex	B-PK
912	##cre	I-PK
912	##tion	I-PK
912	rate	I-PK
912	is	O
912	dependent	O
912	upon	O
912	the	O
912	rate	O
912	at	O
912	which	O
912	it	O
912	is	O
912	passive	O
912	##ly	O
912	filtered	O
912	through	O
912	the	O
912	kidney	O
912	’	O
912	s	O
912	f	O
912	##ene	O
912	##stra	O
912	##ted	O
912	g	O
912	##lo	O
912	##mer	O
912	##ular	O
912	cap	O
912	##illa	O
912	##ries	O
912	and	O
912	the	O
912	rates	O
912	of	O
912	secret	O
912	##ion	O
912	and	O
912	re	O
912	##ab	O
912	##sor	O
912	##ption	O
912	across	O
912	the	O
912	kidney	O
912	tub	O
912	##ular	O
912	e	O
912	##pit	O
912	##hel	O
912	##ium	O
912	.	O
912	[SEP]	O
913	[CLS]	O
913	p	O
913	##d	O
913	evaluation	O
913	##s	O
913	included	O
913	c	O
913	##rp	O
913	and	O
913	es	O
913	##r	O
913	.	O
913	[SEP]	O
914	[CLS]	O
914	for	O
914	su	O
914	##lt	O
914	##1	O
914	##a	O
914	##1	O
914	,	O
914	maturity	O
914	was	O
914	taken	O
914	to	O
914	have	O
914	been	O
914	reached	O
914	at	O
914	birth	O
914	,	O
914	22	O
914	and	O
914	,	O
914	therefore	O
914	,	O
914	is	O
914	##oe	O
914	##nz	O
914	##yme	O
914	onto	O
914	##geny	O
914	of	O
914	su	O
914	##lt	O
914	##1	O
914	##a	O
914	##1	O
914	,	O
914	defined	O
914	as	O
914	the	O
914	p	O
914	##ediatric	O
914	to	O
914	adult	O
914	ratio	B-PK
914	of	I-PK
914	micro	I-PK
914	##so	I-PK
914	##mal	I-PK
914	intrinsic	I-PK
914	clearance	I-PK
914	,	O
914	was	O
914	set	O
914	to	O
914	1	O
914	.	O
914	[SEP]	O
915	[CLS]	O
915	glucose	O
915	levels	O
915	were	O
915	forced	O
915	to	O
915	decrease	O
915	in	O
915	all	O
915	groups	O
915	at	O
915	the	O
915	same	O
915	rate	O
915	in	O
915	the	O
915	first	O
915	3	O
915	hours	O
915	due	O
915	to	O
915	repeated	O
915	insulin	O
915	administration	O
915	.	O
915	[SEP]	O
916	[CLS]	O
916	across	O
916	all	O
916	treatment	O
916	regime	O
916	##ns	O
916	,	O
916	73	O
916	.	O
916	3	O
916	%	O
916	of	O
916	participants	O
916	(	O
916	22	O
916	/	O
916	30	O
916	)	O
916	reported	O
916	a	O
916	treatment	O
916	-	O
916	emerge	O
916	##nt	O
916	a	O
916	##e	O
916	(	O
916	tea	O
916	##e	O
916	)	O
916	;	O
916	the	O
916	frequency	O
916	of	O
916	tea	O
916	##es	O
916	by	O
916	treatment	O
916	is	O
916	summarized	O
916	in	O
916	table	O
916	4	O
916	.	O
916	[SEP]	O
917	[CLS]	O
917	but	O
917	t	B-PK
917	##max	I-PK
917	was	O
917	further	O
917	increased	O
917	to	O
917	4	O
917	h	O
917	in	O
917	the	O
917	1	O
917	mg	O
917	/	O
917	m	O
917	##l	O
917	s	O
917	-	O
917	b	O
917	##o	O
917	group	O
917	compared	O
917	to	O
917	5	O
917	min	O
917	in	O
917	s	O
917	##n	O
917	-	O
917	38	O
917	-	O
917	lips	O
917	group	O
917	with	O
917	85	O
917	.	O
917	09	O
917	##3	O
917	μ	O
917	##g	O
917	/	O
917	kg	O
917	of	O
917	cm	B-PK
917	##ax	I-PK
917	and	O
917	30	O
917	min	O
917	in	O
917	2	O
917	and	O
917	5	O
917	mg	O
917	/	O
917	m	O
917	##l	O
917	s	O
917	-	O
917	b	O
917	##o	O
917	group	O
917	with	O
917	217	O
917	.	O
917	385	O
917	and	O
917	251	O
917	.	O
917	64	O
917	##4	O
917	μ	O
917	##g	O
917	/	O
917	kg	O
917	of	O
917	cm	B-PK
917	##ax	I-PK
917	.	O
917	[SEP]	O
918	[CLS]	O
918	au	B-PK
918	##c	I-PK
918	##0	I-PK
918	–	I-PK
918	24	I-PK
918	h	I-PK
918	of	O
918	2	O
918	mg	O
918	/	O
918	m	O
918	##l	O
918	s	O
918	-	O
918	b	O
918	##o	O
918	group	O
918	were	O
918	290	O
918	.	O
918	345	O
918	μ	O
918	##g	O
918	/	O
918	kg	O
918	·	O
918	h	O
918	which	O
918	were	O
918	significantly	O
918	higher	O
918	(	O
918	p	O
918	<	O
918	.	O
918	05	O
918	)	O
918	than	O
918	s	O
918	##n	O
918	-	O
918	38	O
918	-	O
918	lips	O
918	group	O
918	(	O
918	1	O
918	.	O
918	44	O
918	-	O
918	fold	O
918	)	O
918	,	O
918	1	O
918	mg	O
918	/	O
918	m	O
918	##l	O
918	s	O
918	-	O
918	b	O
918	##o	O
918	group	O
918	(	O
918	2	O
918	.	O
918	97	O
918	-	O
918	fold	O
918	)	O
918	and	O
918	5	O
918	mg	O
918	/	O
918	m	O
918	##l	O
918	s	O
918	-	O
918	b	O
918	##o	O
918	group	O
918	(	O
918	1	O
918	.	O
918	78	O
918	-	O
918	fold	O
918	)	O
918	,	O
918	showing	O
918	that	O
918	2	O
918	mg	O
918	/	O
918	m	O
918	##l	O
918	s	O
918	-	O
918	b	O
918	##o	O
918	group	O
918	enhanced	O
918	systematic	O
918	exposure	O
918	of	O
918	s	O
918	##n	O
918	-	O
918	38	O
918	-	O
918	lips	O
918	.	O
918	[SEP]	O
919	[CLS]	O
919	and	O
919	2	O
919	mg	O
919	/	O
919	m	O
919	##l	O
919	s	O
919	-	O
919	b	O
919	##o	O
919	significantly	O
919	(	O
919	p	O
919	<	O
919	.	O
919	05	O
919	)	O
919	prolonged	O
919	plasma	O
919	exposure	O
919	of	O
919	s	O
919	##n	O
919	-	O
919	38	O
919	-	O
919	lips	O
919	after	O
919	s	O
919	.	O
919	c	O
919	.	O
919	administration	O
919	,	O
919	m	B-PK
919	##rt	I-PK
919	##0	I-PK
919	–	I-PK
919	24	I-PK
919	h	I-PK
919	and	O
919	t	B-PK
919	##1	I-PK
919	/	I-PK
919	2	I-PK
919	of	O
919	which	O
919	were	O
919	increased	O
919	to	O
919	11	O
919	.	O
919	38	O
919	##7	O
919	and	O
919	2	O
919	.	O
919	43	O
919	##6	O
919	h	O
919	and	O
919	c	B-PK
919	##l	I-PK
919	of	O
919	which	O
919	were	O
919	decreased	O
919	to	O
919	9	O
919	.	O
919	84	O
919	##6	O
919	l	O
919	/	O
919	h	O
919	/	O
919	kg	O
919	.	O
919	[SEP]	O
920	[CLS]	O
920	the	O
920	au	B-PK
920	##c	I-PK
920	and	O
920	cm	B-PK
920	##ax	I-PK
920	and	O
920	t	B-PK
920	##max	I-PK
920	p	O
920	##har	O
920	##ma	O
920	##co	O
920	##kin	O
920	##etic	O
920	parameters	O
920	were	O
920	calculated	O
920	with	O
920	the	O
920	p	O
920	##hoe	O
920	##ni	O
920	##x	O
920	win	O
920	##non	O
920	##lin	O
920	software	O
920	(	O
920	version	O
920	8	O
920	.	O
920	0	O
920	,	O
920	p	O
920	##har	O
920	##sight	O
920	corporation	O
920	,	O
920	mountain	O
920	view	O
920	,	O
920	ca	O
920	,	O
920	us	O
920	##a	O
920	)	O
920	using	O
920	non	O
920	-	O
920	compartment	O
920	##al	O
920	analysis	O
920	.	O
920	[SEP]	O
921	[CLS]	O
921	the	O
921	relationships	O
921	between	O
921	la	O
921	##ct	O
921	##ate	O
921	accumulation	O
921	and	O
921	work	O
921	intensity	O
921	and	O
921	capacity	O
921	as	O
921	well	O
921	as	O
921	the	O
921	correlation	O
921	between	O
921	la	O
921	##ct	O
921	##ate	O
921	accumulation	O
921	and	O
921	muscular	O
921	fatigue	O
921	have	O
921	long	O
921	been	O
921	a	O
921	major	O
921	research	O
921	topic	O
921	[	O
921	38	O
921	]	O
921	.	O
921	[SEP]	O
922	[CLS]	O
922	in	O
922	patients	O
922	with	O
922	advanced	O
922	solid	O
922	ma	O
922	##li	O
922	##gna	O
922	##ncies	O
922	,	O
922	the	O
922	m	O
922	##t	O
922	##d	O
922	of	O
922	sun	O
922	##iti	O
922	##ni	O
922	##b	O
922	plus	O
922	500	O
922	mg	O
922	/	O
922	m	O
922	##2	O
922	p	O
922	##em	O
922	##et	O
922	##re	O
922	##xed	O
922	was	O
922	37	O
922	.	O
922	5	O
922	mg	O
922	/	O
922	day	O
922	(	O
922	c	O
922	##dd	O
922	schedule	O
922	)	O
922	or	O
922	50	O
922	mg	O
922	/	O
922	day	O
922	(	O
922	schedule	O
922	2	O
922	/	O
922	1	O
922	)	O
922	.	O
922	[SEP]	O
923	[CLS]	O
923	the	O
923	d	O
923	##l	O
923	of	O
923	ch	O
923	##20	O
923	-	O
923	g	O
923	##sh	O
923	and	O
923	ch	O
923	##50	O
923	-	O
923	g	O
923	##sh	O
923	n	O
923	##ps	O
923	was	O
923	18	O
923	.	O
923	4	O
923	%	O
923	and	O
923	18	O
923	.	O
923	2	O
923	%	O
923	,	O
923	respectively	O
923	.	O
923	[SEP]	O
924	[CLS]	O
924	the	O
924	c	O
924	##dd	O
924	schedule	O
924	m	O
924	##t	O
924	##d	O
924	was	O
924	to	O
924	##ler	O
924	##able	O
924	and	O
924	demonstrated	O
924	promising	O
924	clinical	O
924	benefit	O
924	in	O
924	n	O
924	##s	O
924	##c	O
924	##l	O
924	##c	O
924	.	O
924	[SEP]	O
925	[CLS]	O
925	the	O
925	median	O
925	clearance	B-PK
925	rate	I-PK
925	constant	I-PK
925	for	O
925	p	O
925	v	O
925	##iva	O
925	##x	O
925	ranged	O
925	from	O
925	0	O
925	·	O
925	22	O
925	to	O
925	0	O
925	·	O
925	30	O
925	per	O
925	hour	O
925	leading	O
925	to	O
925	a	O
925	99	O
925	·	O
925	6	O
925	%	O
925	reduction	O
925	in	O
925	parasite	O
925	den	O
925	##sities	O
925	by	O
925	36	O
925	h	O
925	.	O
925	estimated	O
925	median	O
925	parasite	O
925	clearance	O
925	half	O
925	-	O
925	life	O
925	estimates	O
925	ranged	O
925	from	O
925	4	O
925	·	O
925	1	O
925	h	O
925	to	O
925	5	O
925	·	O
925	6	O
925	h	O
925	for	O
925	p	O
925	f	O
925	##al	O
925	##ci	O
925	##par	O
925	##um	O
925	and	O
925	2	O
925	·	O
925	3	O
925	h	O
925	to	O
925	3	O
925	·	O
925	2	O
925	h	O
925	for	O
925	p	O
925	v	O
925	##iva	O
925	##x	O
925	(	O
925	table	O
925	2	O
925	)	O
925	.	O
925	[SEP]	O
926	[CLS]	O
926	it	O
926	should	O
926	be	O
926	noted	O
926	that	O
926	variations	O
926	in	O
926	the	O
926	half	B-PK
926	-	I-PK
926	life	I-PK
926	accounts	O
926	for	O
926	the	O
926	most	O
926	part	O
926	of	O
926	the	O
926	relative	O
926	dose	O
926	differences	O
926	.	O
926	[SEP]	O
927	[CLS]	O
927	complex	O
927	h	O
927	##ydro	O
927	##gel	O
927	##s	O
927	formed	O
927	with	O
927	ch	O
927	##ito	O
927	##san	O
927	(	O
927	c	O
927	##s	O
927	)	O
927	and	O
927	ring	O
927	-	O
927	opened	O
927	p	O
927	##oly	O
927	##vin	O
927	##yl	O
927	p	O
927	##yr	O
927	##rol	O
927	##ido	O
927	##ne	O
927	(	O
927	r	O
927	##op	O
927	##v	O
927	##p	O
927	)	O
927	as	O
927	a	O
927	swell	O
927	##able	O
927	m	O
927	##uc	O
927	##oa	O
927	##dh	O
927	##esi	O
927	##ve	O
927	gas	O
927	##tro	O
927	##ret	O
927	##ent	O
927	##ive	O
927	drug	O
927	dos	O
927	##age	O
927	form	O
927	(	O
927	s	O
927	##m	O
927	##g	O
927	##rd	O
927	##d	O
927	##f	O
927	)	O
927	were	O
927	prepared	O
927	and	O
927	characterized	O
927	.	O
927	[SEP]	O
928	[CLS]	O
928	them	O
928	##ob	O
928	##ile	O
928	phase	O
928	was	O
928	prepared	O
928	daily	O
928	and	O
928	de	O
928	##gas	O
928	##sed	O
928	before	O
928	use	O
928	.	O
928	[SEP]	O
929	[CLS]	O
929	a	O
929	p	O
929	##har	O
929	##ma	O
929	##co	O
929	##kin	O
929	##etic	O
929	study	O
929	exhibited	O
929	that	O
929	the	O
929	plasma	O
929	profile	O
929	of	O
929	ale	O
929	##nd	O
929	##rona	O
929	##te	O
929	followed	O
929	a	O
929	sustained	O
929	manner	O
929	with	O
929	3	O
929	-	O
929	fold	O
929	enhance	O
929	##ment	O
929	of	O
929	the	O
929	oral	B-PK
929	bio	I-PK
929	##ava	I-PK
929	##ila	I-PK
929	##bility	I-PK
929	.	O
929	[SEP]	O
930	[CLS]	O
930	this	O
930	is	O
930	a	O
930	prospective	O
930	study	O
930	from	O
930	j	O
930	##anu	O
930	##ary	O
930	2013	O
930	to	O
930	de	O
930	##ce	O
930	##mber	O
930	2014	O
930	for	O
930	c	O
930	##f	O
930	patients	O
930	admitted	O
930	to	O
930	university	O
930	of	O
930	mi	O
930	##chi	O
930	##gan	O
930	m	O
930	##ott	O
930	’	O
930	s	O
930	children	O
930	hospital	O
930	.	O
930	[SEP]	O
931	[CLS]	O
931	the	O
931	bacteria	O
931	were	O
931	di	O
931	##lut	O
931	##ed	O
931	to	O
931	a	O
931	density	O
931	of	O
931	1	O
931	×	O
931	106	O
931	c	O
931	##fu	O
931	/	O
931	m	O
931	##l	O
931	in	O
931	m	O
931	##h	O
931	br	O
931	##oth	O
931	or	O
931	artificial	O
931	s	O
931	##put	O
931	##um	O
931	medium	O
931	(	O
931	as	O
931	##m	O
931	)	O
931	,	O
931	which	O
931	was	O
931	prepared	O
931	by	O
931	use	O
931	of	O
931	the	O
931	recipe	O
931	by	O
931	s	O
931	##ri	O
931	##ram	O
931	##ulu	O
931	et	O
931	al	O
931	.	O
931	(	O
931	48	O
931	)	O
931	.	O
931	[SEP]	O
932	[CLS]	O
932	the	O
932	anti	O
932	##biotic	O
932	selection	O
932	was	O
932	determined	O
932	by	O
932	the	O
932	primary	O
932	pu	O
932	##lm	O
932	##ono	O
932	##logist	O
932	and	O
932	was	O
932	based	O
932	on	O
932	the	O
932	most	O
932	recent	O
932	s	O
932	##put	O
932	##um	O
932	or	O
932	throat	O
932	culture	O
932	and	O
932	sensitivity	O
932	results	O
932	for	O
932	each	O
932	patient	O
932	.	O
932	[SEP]	O
933	[CLS]	O
933	part	O
933	1	O
933	##b	O
933	studied	O
933	the	O
933	relative	O
933	bio	O
933	##ava	O
933	##ila	O
933	##bility	O
933	of	O
933	g	O
933	##sk	O
933	##28	O
933	##38	O
933	##23	O
933	##2	O
933	given	O
933	as	O
933	100	O
933	mg	O
933	(	O
933	2	O
933	×	O
933	50	O
933	mg	O
933	)	O
933	capsule	O
933	##s	O
933	versus	O
933	the	O
933	reference	O
933	a	O
933	##pi	O
933	(	O
933	p	O
933	##ib	O
933	)	O
933	in	O
933	a	O
933	two	O
933	‐	O
933	period	O
933	crossover	O
933	design	O
933	with	O
933	r	O
933	##t	O
933	##v	O
933	,	O
933	following	O
933	2	O
933	days	O
933	of	O
933	r	O
933	##t	O
933	##v	O
933	pre	O
933	##dos	O
933	##ing	O
933	.	O
933	[SEP]	O
934	[CLS]	O
934	re	O
934	##ct	O
934	##al	O
934	administration	O
934	resulted	O
934	in	O
934	a	O
934	delayed	O
934	t	B-PK
934	##max	I-PK
934	,	O
934	a	O
934	lower	O
934	cm	B-PK
934	##ax	I-PK
934	,	O
934	and	O
934	an	O
934	au	B-PK
934	##c	I-PK
934	##0	I-PK
934	–	I-PK
934	24	I-PK
934	value	O
934	that	O
934	was	O
934	70	O
934	%	O
934	of	O
934	that	O
934	observed	O
934	following	O
934	oral	O
934	administration	O
934	.	O
934	[SEP]	O
935	[CLS]	O
935	after	O
935	oral	O
935	administration	O
935	,	O
935	the	O
935	plasma	O
935	mi	O
935	##ans	O
935	##eri	O
935	##n	O
935	level	O
935	reached	O
935	cm	B-PK
935	##ax	I-PK
935	at	O
935	30	O
935	min	O
935	and	O
935	then	O
935	rapidly	O
935	decreased	O
935	.	O
935	[SEP]	O
936	[CLS]	O
936	based	O
936	on	O
936	physiological	O
936	p	O
936	##laus	O
936	##ibility	O
936	and	O
936	extensive	O
936	previous	O
936	evidence	O
936	,	O
936	b	O
936	##w	O
936	was	O
936	incorporated	O
936	a	O
936	prior	O
936	##i	O
936	as	O
936	a	O
936	co	O
936	##var	O
936	##iate	O
936	,	O
936	both	O
936	on	O
936	c	B-PK
936	##l	I-PK
936	(	O
936	all	O
936	##ometric	O
936	##ally	O
936	with	O
936	a	O
936	power	O
936	ex	O
936	##po	O
936	##nent	O
936	of	O
936	0	O
936	.	O
936	75	O
936	)	O
936	and	O
936	on	O
936	v	B-PK
936	##d	I-PK
936	(	O
936	power	O
936	ex	O
936	##po	O
936	##nent	O
936	of	O
936	1	O
936	)	O
936	and	O
936	was	O
936	standardized	O
936	to	O
936	a	O
936	typical	O
936	70	O
936	kg	O
936	patient	O
936	[	O
936	15	O
936	–	O
936	18	O
936	]	O
936	.	O
936	[SEP]	O
937	[CLS]	O
937	in	O
937	the	O
937	safety	O
937	analysis	O
937	set	O
937	,	O
937	97	O
937	.	O
937	6	O
937	%	O
937	of	O
937	patients	O
937	experienced	O
937	at	O
937	least	O
937	one	O
937	a	O
937	##e	O
937	,	O
937	of	O
937	which	O
937	95	O
937	.	O
937	1	O
937	%	O
937	were	O
937	judged	O
937	by	O
937	the	O
937	local	O
937	investigator	O
937	to	O
937	be	O
937	related	O
937	to	O
937	a	O
937	##z	O
937	##d	O
937	##53	O
937	##6	O
937	##3	O
937	(	O
937	table	O
937	2	O
937	)	O
937	.	O
937	[SEP]	O
938	[CLS]	O
938	a	O
938	total	O
938	of	O
938	63	O
938	.	O
938	4	O
938	%	O
938	of	O
938	patients	O
938	experienced	O
938	an	O
938	a	O
938	##e	O
938	of	O
938	c	O
938	##t	O
938	##ca	O
938	##e	O
938	grade	O
938	≥	O
938	##3	O
938	,	O
938	with	O
938	h	O
938	##yper	O
938	##gly	O
938	##ce	O
938	##mia	O
938	(	O
938	39	O
938	.	O
938	0	O
938	%	O
938	)	O
938	and	O
938	di	O
938	##ar	O
938	##r	O
938	##hea	O
938	(	O
938	17	O
938	.	O
938	1	O
938	%	O
938	)	O
938	being	O
938	the	O
938	most	O
938	common	O
938	;	O
938	58	O
938	.	O
938	5	O
938	%	O
938	of	O
938	patients	O
938	experienced	O
938	a	O
938	grade	O
938	≥	O
938	##3	O
938	a	O
938	##e	O
938	considered	O
938	to	O
938	be	O
938	treatment	O
938	related	O
938	.	O
938	[SEP]	O
939	[CLS]	O
939	disco	O
939	##ntin	O
939	##uations	O
939	due	O
939	to	O
939	an	O
939	a	O
939	##e	O
939	occurred	O
939	in	O
939	12	O
939	.	O
939	2	O
939	%	O
939	of	O
939	patients	O
939	,	O
939	while	O
939	39	O
939	.	O
939	0	O
939	%	O
939	of	O
939	patients	O
939	had	O
939	a	O
939	##es	O
939	leading	O
939	to	O
939	dose	O
939	interrupt	O
939	##ion	O
939	.	O
939	[SEP]	O
940	[CLS]	O
940	administration	O
940	of	O
940	d	O
940	##t	O
940	##n	O
940	in	O
940	combination	O
940	with	O
940	k	O
940	##tz	O
940	resulted	O
940	in	O
940	at	O
940	##ten	O
940	##uated	O
940	liver	O
940	injury	O
940	,	O
940	including	O
940	lower	O
940	al	O
940	##ani	O
940	##ne	O
940	trans	O
940	##ami	O
940	##nas	O
940	##e	O
940	and	O
940	as	O
940	##par	O
940	##tate	O
940	trans	O
940	##ami	O
940	##nas	O
940	##e	O
940	activities	O
940	and	O
940	greater	O
940	au	B-PK
940	##c	I-PK
940	and	O
940	cm	B-PK
940	##ax	I-PK
940	of	O
940	serum	O
940	d	O
940	##t	O
940	##n	O
940	,	O
940	whereas	O
940	,	O
940	pre	O
940	##tre	O
940	##at	O
940	##ment	O
940	with	O
940	de	O
940	##xa	O
940	##met	O
940	##has	O
940	##one	O
940	a	O
940	##gg	O
940	##ra	O
940	##vated	O
940	the	O
940	injury	O
940	.	O
940	[SEP]	O
941	[CLS]	O
941	primary	O
941	outcomes	O
941	were	O
941	p	O
941	##har	O
941	##ma	O
941	##co	O
941	##kin	O
941	##etic	O
941	parameters	O
941	(	O
941	maximum	B-PK
941	plasma	I-PK
941	mi	I-PK
941	##ans	I-PK
941	##eri	I-PK
941	##n	I-PK
941	concentration	I-PK
941	[	I-PK
941	cm	I-PK
941	##ax	I-PK
941	]	I-PK
941	,	O
941	time	B-PK
941	of	I-PK
941	cm	I-PK
941	##ax	I-PK
941	[	I-PK
941	t	I-PK
941	##max	I-PK
941	]	I-PK
941	,	O
941	and	O
941	area	B-PK
941	under	I-PK
941	the	I-PK
941	plasma	I-PK
941	concentration	I-PK
941	-	I-PK
941	time	I-PK
941	curve	I-PK
941	from	I-PK
941	0	I-PK
941	to	I-PK
941	24	I-PK
941	h	I-PK
941	[	I-PK
941	au	I-PK
941	##c	I-PK
941	##0	I-PK
941	-	I-PK
941	24	I-PK
941	]	I-PK
941	)	O
941	.	O
941	[SEP]	O
942	[CLS]	O
942	disposition	O
942	p	O
942	##k	O
942	parameters	O
942	were	O
942	similar	O
942	between	O
942	g	O
942	##cc	O
942	‐	O
942	440	O
942	##1	O
942	##c	O
942	and	O
942	r	O
942	##iva	O
942	##ro	O
942	##xa	O
942	##ban	O
942	,	O
942	with	O
942	slightly	O
942	larger	O
942	steady	B-PK
942	‐	I-PK
942	state	I-PK
942	volume	I-PK
942	of	I-PK
942	distribution	I-PK
942	and	O
942	total	B-PK
942	clearance	I-PK
942	in	O
942	g	O
942	##cc	O
942	‐	O
942	440	O
942	##1	O
942	##c	O
942	.	O
942	[SEP]	O
943	[CLS]	O
943	the	O
943	absorption	O
943	process	O
943	was	O
943	described	O
943	by	O
943	a	O
943	we	O
943	##ib	O
943	##ull	O
943	model	O
943	with	O
943	mixed	O
943	first	O
943	and	O
943	zero	O
943	order	O
943	absorption	O
943	.	O
943	[SEP]	O
944	[CLS]	O
944	for	O
944	op	O
944	##ti	O
944	##mizing	O
944	above	O
944	parameters	O
944	at	O
944	each	O
944	time	O
944	point	O
944	,	O
944	quality	O
944	control	O
944	tests	O
944	were	O
944	carried	O
944	out	O
944	by	O
944	t	O
944	##l	O
944	##c	O
944	using	O
944	it	O
944	##l	O
944	##c	O
944	strips	O
944	.	O
944	[	O
944	101	O
944	##7	O
944	##18	O
944	##19	O
944	]	O
944	[SEP]	O
945	[CLS]	O
945	in	O
945	females	O
945	,	O
945	the	O
945	only	O
945	change	O
945	that	O
945	was	O
945	observed	O
945	was	O
945	a	O
945	significant	O
945	reduction	O
945	in	O
945	au	B-PK
945	##c	I-PK
945	under	O
945	fed	O
945	conditions	O
945	.	O
945	[SEP]	O
946	[CLS]	O
946	the	O
946	non	O
946	-	O
946	bio	O
946	##e	O
946	##qui	O
946	##valence	O
946	(	O
946	non	O
946	-	O
946	be	O
946	)	O
946	tablet	O
946	group	O
946	achieved	O
946	higher	O
946	plasma	O
946	cm	B-PK
946	##ax	I-PK
946	and	O
946	area	B-PK
946	under	I-PK
946	the	I-PK
946	curve	I-PK
946	(	I-PK
946	au	I-PK
946	##c	I-PK
946	)	I-PK
946	than	O
946	the	O
946	reference	O
946	and	O
946	be	O
946	tablets	O
946	groups	O
946	,	O
946	with	O
946	only	O
946	one	O
946	difference	O
946	in	O
946	tablet	O
946	composition	O
946	,	O
946	which	O
946	was	O
946	the	O
946	presence	O
946	of	O
946	calcium	O
946	mon	O
946	##oh	O
946	##ydro	O
946	##gen	O
946	phosphate	O
946	,	O
946	an	O
946	al	O
946	##kal	O
946	##ini	O
946	##zing	O
946	ex	O
946	##ci	O
946	##pie	O
946	##nt	O
946	,	O
946	in	O
946	the	O
946	tablet	O
946	core	O
946	of	O
946	the	O
946	non	O
946	-	O
946	be	O
946	formulation	O
946	.	O
946	[SEP]	O
947	[CLS]	O
947	a	O
947	similar	O
947	proportion	O
947	of	O
947	e	O
947	##u	O
947	##vo	O
947	##lem	O
947	##ic	O
947	patients	O
947	treated	O
947	with	O
947	either	O
947	20	O
947	or	O
947	40	O
947	mg	O
947	/	O
947	day	O
947	con	O
947	##iva	O
947	##pta	O
947	##n	O
947	attained	O
947	this	O
947	treatment	O
947	goal	O
947	(	O
947	82	O
947	.	O
947	6	O
947	%	O
947	vs	O
947	74	O
947	.	O
947	8	O
947	%	O
947	,	O
947	respectively	O
947	)	O
947	.	O
947	[SEP]	O
948	[CLS]	O
948	the	O
948	un	B-PK
948	##bound	I-PK
948	fraction	I-PK
948	ratio	I-PK
948	(	I-PK
948	f	I-PK
948	##u	I-PK
948	)	I-PK
948	of	O
948	ni	O
948	##mo	O
948	##di	O
948	##pine	O
948	in	O
948	rabbit	O
948	plasma	O
948	was	O
948	calculated	O
948	using	O
948	the	O
948	following	O
948	equation	O
948	:	O
948	(	O
948	1	O
948	)	O
948	f	O
948	##u	O
948	=	O
948	c	O
948	##bu	O
948	##ffer	O
948	##ct	O
948	##ota	O
948	##l	O
948	##where	O
948	c	O
948	##bu	O
948	##ffer	O
948	and	O
948	c	O
948	##to	O
948	##tal	O
948	are	O
948	the	O
948	ni	O
948	##mo	O
948	##di	O
948	##pine	O
948	concentrations	O
948	in	O
948	the	O
948	buffer	O
948	chamber	O
948	and	O
948	the	O
948	sample	O
948	chamber	O
948	,	O
948	respectively	O
948	.	O
948	[SEP]	O
949	[CLS]	O
949	since	O
949	the	O
949	specific	O
949	transport	O
949	##ers	O
949	contributing	O
949	to	O
949	the	O
949	absorption	O
949	and	O
949	elimination	O
949	of	O
949	c	O
949	##ip	O
949	##ro	O
949	##f	O
949	##lo	O
949	##xa	O
949	##cin	O
949	have	O
949	not	O
949	yet	O
949	been	O
949	fully	O
949	el	O
949	##uc	O
949	##idated	O
949	,	O
949	the	O
949	effect	O
949	of	O
949	the	O
949	mat	O
949	##uration	O
949	and	O
949	aging	O
949	process	O
949	on	O
949	these	O
949	pathways	O
949	is	O
949	unknown	O
949	.	O
949	[SEP]	O
950	[CLS]	O
950	this	O
950	would	O
950	potentially	O
950	lead	O
950	to	O
950	repression	O
950	of	O
950	selected	O
950	##tar	O
950	##get	O
950	genes	O
950	driving	O
950	s	O
950	##b	O
950	##ma	O
950	-	O
950	associated	O
950	toxicity	O
950	,	O
950	while	O
950	allowing	O
950	transcription	O
950	##ala	O
950	##ct	O
950	##ivation	O
950	of	O
950	other	O
950	target	O
950	genes	O
950	.	O
950	[SEP]	O
951	[CLS]	O
951	mean	B-PK
951	residence	I-PK
951	time	I-PK
951	(	I-PK
951	m	I-PK
951	##rt	I-PK
951	)	I-PK
951	of	O
951	products	O
951	a	O
951	and	O
951	b	O
951	was	O
951	found	O
951	to	O
951	be	O
951	3	O
951	.	O
951	6	O
951	±	O
951	0	O
951	.	O
951	10	O
951	h	O
951	and	O
951	4	O
951	.	O
951	76	O
951	±	O
951	0	O
951	.	O
951	10	O
951	h	O
951	,	O
951	respectively	O
951	.	O
951	[SEP]	O
952	[CLS]	O
952	mean	O
952	(	O
952	c	O
952	##v	O
952	%	O
952	)	O
952	cm	B-PK
952	##ax	I-PK
952	and	O
952	au	B-PK
952	##c	I-PK
952	##24	I-PK
952	increased	O
952	from	O
952	20	O
952	.	O
952	2	O
952	ng	O
952	/	O
952	m	O
952	##l	O
952	(	O
952	18	O
952	.	O
952	8	O
952	%	O
952	)	O
952	to	O
952	195	O
952	.	O
952	0	O
952	ng	O
952	/	O
952	m	O
952	##l	O
952	(	O
952	26	O
952	.	O
952	7	O
952	%	O
952	)	O
952	and	O
952	from	O
952	31	O
952	##4	O
952	.	O
952	0	O
952	hour	O
952	*	O
952	ng	O
952	/	O
952	m	O
952	##l	O
952	(	O
952	11	O
952	.	O
952	2	O
952	%	O
952	)	O
952	to	O
952	3	O
952	,	O
952	53	O
952	##8	O
952	.	O
952	0	O
952	hour	O
952	*	O
952	ng	O
952	/	O
952	m	O
952	##l	O
952	(	O
952	33	O
952	.	O
952	5	O
952	%	O
952	)	O
952	across	O
952	the	O
952	10	O
952	‐	O
952	to	O
952	100	O
952	‐	O
952	mg	O
952	dose	O
952	levels	O
952	,	O
952	respectively	O
952	.	O
952	[SEP]	O
953	[CLS]	O
953	eleven	O
953	percent	O
953	(	O
953	12	O
953	/	O
953	109	O
953	)	O
953	of	O
953	subjects	O
953	experienced	O
953	at	O
953	least	O
953	1	O
953	drug	O
953	-	O
953	related	O
953	grade	O
953	2	O
953	–	O
953	4	O
953	a	O
953	##e	O
953	,	O
953	11	O
953	%	O
953	(	O
953	10	O
953	/	O
953	89	O
953	)	O
953	of	O
953	subjects	O
953	in	O
953	the	O
953	f	O
953	##p	O
953	##v	O
953	/	O
953	r	O
953	##t	O
953	##v	O
953	group	O
953	and	O
953	10	O
953	%	O
953	(	O
953	2	O
953	/	O
953	20	O
953	)	O
953	of	O
953	subjects	O
953	in	O
953	the	O
953	f	O
953	##p	O
953	##v	O
953	group	O
953	.	O
953	[SEP]	O
954	[CLS]	O
954	the	O
954	difference	O
954	in	O
954	mean	O
954	values	O
954	of	O
954	m	B-PK
954	##rt	I-PK
954	in	O
954	both	O
954	the	O
954	formulation	O
954	##s	O
954	was	O
954	statistical	O
954	##ly	O
954	ins	O
954	##ign	O
954	##ificant	O
954	.	O
954	[SEP]	O
955	[CLS]	O
955	a	O
955	correlation	O
955	between	O
955	total	B-PK
955	and	O
955	free	B-PK
955	au	I-PK
955	##c	I-PK
955	/	I-PK
955	mi	I-PK
955	##c	I-PK
955	levels	O
955	vs	O
955	.	O
955	total	B-PK
955	t	I-PK
955	##rough	I-PK
955	concentrations	I-PK
955	predicted	O
955	by	O
955	the	O
955	p	O
955	##b	O
955	##p	O
955	##k	O
955	model	O
955	of	O
955	van	O
955	##com	O
955	##y	O
955	##cin	O
955	captured	O
955	the	O
955	clinical	O
955	observations	O
955	,	O
955	in	O
955	which	O
955	the	O
955	free	B-PK
955	fraction	I-PK
955	of	O
955	van	O
955	##com	O
955	##y	O
955	##cin	O
955	was	O
955	fixed	O
955	at	O
955	the	O
955	value	O
955	reported	O
955	in	O
955	the	O
955	clinical	O
955	study	O
955	##31	O
955	(	O
955	figure	O
955	##6	O
955	##c	O
955	,	O
955	left	O
955	)	O
955	.	O
955	[SEP]	O
956	[CLS]	O
956	after	O
956	the	O
956	first	O
956	dose	O
956	of	O
956	r	O
956	##p	O
956	##50	O
956	##6	O
956	##3	O
956	,	O
956	cm	B-PK
956	##ax	I-PK
956	and	O
956	au	B-PK
956	##c	I-PK
956	##24	I-PK
956	increased	O
956	in	O
956	a	O
956	dose	O
956	‐	O
956	proportional	O
956	manner	O
956	from	O
956	10	O
956	–	O
956	100	O
956	mg	O
956	.	O
956	[SEP]	O
957	[CLS]	O
957	median	O
957	t	B-PK
957	##max	I-PK
957	(	O
957	12	O
957	.	O
957	0	O
957	–	O
957	16	O
957	.	O
957	0	O
957	hours	O
957	)	O
957	and	O
957	mean	O
957	t	B-PK
957	##1	I-PK
957	/	I-PK
957	2	I-PK
957	(	O
957	10	O
957	.	O
957	6	O
957	–	O
957	11	O
957	.	O
957	0	O
957	hours	O
957	)	O
957	were	O
957	found	O
957	to	O
957	be	O
957	independent	O
957	of	O
957	dose	O
957	.	O
957	[SEP]	O
958	[CLS]	O
958	re	O
958	##gression	O
958	analyses	O
958	of	O
958	cm	B-PK
958	##ax	I-PK
958	,	O
958	au	B-PK
958	##c	I-PK
958	##0	I-PK
958	–	I-PK
958	48	I-PK
958	,	O
958	and	O
958	au	B-PK
958	##c	I-PK
958	##0	I-PK
958	–	I-PK
958	∞	I-PK
958	by	O
958	dose	O
958	indicated	O
958	that	O
958	the	O
958	relationship	O
958	was	O
958	linear	O
958	(	O
958	slope	O
958	,	O
958	p	O
958	≤	O
958	0	O
958	.	O
958	05	O
958	)	O
958	and	O
958	that	O
958	the	O
958	intercept	O
958	did	O
958	not	O
958	differ	O
958	significantly	O
958	from	O
958	zero	O
958	(	O
958	p	O
958	>	O
958	0	O
958	.	O
958	05	O
958	)	O
958	.	O
958	[SEP]	O
959	[CLS]	O
959	normal	O
959	##ized	O
959	efficacy	O
959	was	O
959	determined	O
959	by	O
959	dividing	O
959	t	O
959	##gi	O
959	by	O
959	either	O
959	plasma	O
959	or	O
959	tumor	O
959	au	B-PK
959	##c	I-PK
959	##0	I-PK
959	-	I-PK
959	8	I-PK
959	.	O
959	[SEP]	O
960	[CLS]	O
960	gas	O
960	##tric	O
960	empty	O
960	##ing	O
960	is	O
960	also	O
960	affected	O
960	by	O
960	the	O
960	physical	O
960	and	O
960	chemical	O
960	properties	O
960	of	O
960	the	O
960	meal	O
960	,	O
960	body	O
960	movement	O
960	,	O
960	and	O
960	position	O
960	during	O
960	empty	O
960	##ing	O
960	[	O
960	30	O
960	]	O
960	.	O
960	[SEP]	O
961	[CLS]	O
961	it	O
961	is	O
961	also	O
961	en	O
961	##vis	O
961	##aged	O
961	that	O
961	it	O
961	could	O
961	also	O
961	be	O
961	a	O
961	meta	O
961	##bol	O
961	##ite	O
961	that	O
961	may	O
961	be	O
961	responsible	O
961	for	O
961	delayed	O
961	gas	O
961	##tric	O
961	empty	O
961	##ing	O
961	[	O
961	27	O
961	]	O
961	;	O
961	however	O
961	,	O
961	which	O
961	##ever	O
961	it	O
961	is	O
961	,	O
961	it	O
961	affects	O
961	both	O
961	the	O
961	absorption	O
961	of	O
961	l	O
961	-	O
961	do	O
961	##pa	O
961	and	O
961	its	O
961	meta	O
961	##bol	O
961	##ite	O
961	as	O
961	this	O
961	may	O
961	also	O
961	ex	O
961	##plicate	O
961	the	O
961	multiple	O
961	peaks	O
961	of	O
961	met	O
961	##hyl	O
961	##do	O
961	##pa	O
961	as	O
961	well	O
961	.	O
961	[SEP]	O
962	[CLS]	O
962	although	O
962	the	O
962	mean	O
962	p	O
962	##har	O
962	##ma	O
962	##co	O
962	##kin	O
962	##etic	O
962	curve	O
962	of	O
962	i	O
962	##p	O
962	##b	O
962	matrices	O
962	has	O
962	a	O
962	single	O
962	peak	O
962	,	O
962	some	O
962	of	O
962	individual	O
962	pigs	O
962	had	O
962	double	O
962	peaks	O
962	and	O
962	this	O
962	may	O
962	also	O
962	explain	O
962	the	O
962	mean	O
962	t	B-PK
962	##max	I-PK
962	of	O
962	i	O
962	##p	O
962	##b	O
962	matrices	O
962	being	O
962	at	O
962	the	O
962	4th	O
962	hour	O
962	.	O
962	[SEP]	O
963	[CLS]	O
963	after	O
963	fi	O
963	##ltration	O
963	(	O
963	mill	O
963	##ip	O
963	##ore	O
963	mill	O
963	##ex	O
963	##®	O
963	l	O
963	##g	O
963	0	O
963	.	O
963	20	O
963	μ	O
963	##m	O
963	;	O
963	me	O
963	##rc	O
963	##k	O
963	kg	O
963	##aa	O
963	,	O
963	da	O
963	##rms	O
963	##tadt	O
963	,	O
963	g	O
963	##erman	O
963	##y	O
963	)	O
963	,	O
963	the	O
963	g	O
963	##ado	O
963	##lini	O
963	##um	O
963	concentration	O
963	in	O
963	these	O
963	fi	O
963	##lt	O
963	##rates	O
963	was	O
963	determined	O
963	with	O
963	a	O
963	##as	O
963	,	O
963	and	O
963	the	O
963	total	O
963	amount	O
963	of	O
963	ch	O
963	##ira	O
963	##l	O
963	den	O
963	##dr	O
963	##ime	O
963	##r	O
963	g	O
963	##d	O
963	-	O
963	m	O
963	##ri	O
963	ca	O
963	##s	O
963	in	O
963	liver	O
963	and	O
963	kidney	O
963	was	O
963	estimated	O
963	from	O
963	the	O
963	weight	O
963	of	O
963	the	O
963	tissues	O
963	.	O
963	[SEP]	O
964	[CLS]	O
964	c	B-PK
964	##l	I-PK
964	and	O
964	v	B-PK
964	##1	I-PK
964	calculated	O
964	based	O
964	on	O
964	the	O
964	equations	O
964	in	O
964	the	O
964	final	O
964	model	O
964	(	O
964	p	O
964	##ip	O
964	##red	O
964	)	O
964	were	O
964	similar	O
964	to	O
964	those	O
964	estimated	O
964	based	O
964	on	O
964	observed	O
964	concentrations	O
964	(	O
964	p	O
964	##est	O
964	)	O
964	(	O
964	fi	O
964	##g	O
964	.	O
964	4	O
964	##a	O
964	,	O
964	b	O
964	)	O
964	.	O
964	[SEP]	O
965	[CLS]	O
965	mean	O
965	p	O
965	##e	O
965	for	O
965	be	O
965	##va	O
965	##ci	O
965	##zu	O
965	##ma	O
965	##b	O
965	serum	O
965	concentrations	O
965	,	O
965	c	B-PK
965	##l	I-PK
965	and	O
965	v	B-PK
965	##1	I-PK
965	were	O
965	−	O
965	##2	O
965	.	O
965	1	O
965	,	O
965	3	O
965	.	O
965	1	O
965	and	O
965	1	O
965	.	O
965	0	O
965	%	O
965	,	O
965	respectively	O
965	.	O
965	[SEP]	O
966	[CLS]	O
966	the	O
966	toxicity	O
966	index	O
966	is	O
966	a	O
966	measure	O
966	of	O
966	the	O
966	toxic	O
966	events	O
966	experienced	O
966	due	O
966	to	O
966	exposure	O
966	to	O
966	the	O
966	toxic	O
966	meta	O
966	##bol	O
966	##ites	O
966	h	O
966	##z	O
966	and	O
966	a	O
966	##ch	O
966	##z	O
966	.	O
966	[SEP]	O
967	[CLS]	O
967	as	O
967	one	O
967	patient	O
967	died	O
967	because	O
967	of	O
967	a	O
967	non	O
967	-	O
967	treatment	O
967	-	O
967	related	O
967	cause	O
967	(	O
967	cardiac	O
967	failure	O
967	)	O
967	between	O
967	weeks	O
967	4	O
967	and	O
967	16	O
967	,	O
967	the	O
967	l	O
967	##pi	O
967	data	O
967	presented	O
967	are	O
967	from	O
967	13	O
967	patients	O
967	.	O
967	[SEP]	O
968	[CLS]	O
968	r	O
968	##ms	O
968	##e	O
968	for	O
968	be	O
968	##va	O
968	##ci	O
968	##zu	O
968	##ma	O
968	##b	O
968	serum	O
968	concentrations	O
968	,	O
968	c	B-PK
968	##l	I-PK
968	and	O
968	v	B-PK
968	##1	I-PK
968	were	O
968	0	O
968	.	O
968	28	O
968	##3	O
968	,	O
968	0	O
968	.	O
968	01	O
968	##7	O
968	and	O
968	2	O
968	.	O
968	60	O
968	,	O
968	respectively	O
968	.	O
968	[SEP]	O
969	[CLS]	O
969	exposure	O
969	to	O
969	the	O
969	two	O
969	toxic	O
969	meta	O
969	##bol	O
969	##ites	O
969	h	O
969	##z	O
969	and	O
969	a	O
969	##ch	O
969	##z	O
969	was	O
969	defined	O
969	as	O
969	the	O
969	area	B-PK
969	under	I-PK
969	the	I-PK
969	concentration	I-PK
969	-	I-PK
969	time	I-PK
969	curve	I-PK
969	(	I-PK
969	au	I-PK
969	##c	I-PK
969	)	I-PK
969	in	O
969	the	O
969	in	O
969	##tra	O
969	##cellular	O
969	space	O
969	in	O
969	the	O
969	off	O
969	-	O
969	target	O
969	organ	O
969	,	O
969	the	O
969	liver	O
969	,	O
969	and	O
969	was	O
969	estimated	O
969	from	O
969	the	O
969	p	O
969	##b	O
969	##p	O
969	##k	O
969	model	O
969	.	O
969	(	O
969	5	O
969	)	O
969	t	O
969	##i	O
969	=	O
969	[	O
969	au	O
969	##c	O
969	(	O
969	h	O
969	##z	O
969	)	O
969	id	O
969	##ag	O
969	+	O
969	au	O
969	##c	O
969	(	O
969	a	O
969	##ch	O
969	##z	O
969	)	O
969	id	O
969	##ag	O
969	]	O
969	[	O
969	au	O
969	##c	O
969	(	O
969	h	O
969	##z	O
969	)	O
969	i	O
969	##30	O
969	##0	O
969	##m	O
969	##g	O
969	##q	O
969	##ds	O
969	##low	O
969	+	O
969	au	O
969	##c	O
969	(	O
969	a	O
969	##ch	O
969	##z	O
969	)	O
969	i	O
969	##30	O
969	##0	O
969	##m	O
969	##g	O
969	##q	O
969	##ds	O
969	##low	O
969	]	O
969	both	O
969	clinical	O
969	in	O
969	##dices	O
969	can	O
969	exceed	O
969	100	O
969	%	O
969	,	O
969	if	O
969	a	O
969	combination	O
969	of	O
969	dose	O
969	and	O
969	ace	O
969	##ty	O
969	##lator	O
969	p	O
969	##hen	O
969	##otype	O
969	results	O
969	in	O
969	a	O
969	larger	O
969	e	O
969	##ba	O
969	after	O
969	2	O
969	days	O
969	of	O
969	treatment	O
969	for	O
969	treatment	O
969	efficacy	O
969	or	O
969	higher	O
969	exposure	O
969	to	O
969	toxic	O
969	meta	O
969	##bol	O
969	##ites	O
969	for	O
969	the	O
969	toxicity	O
969	index	O
969	.	O
969	[SEP]	O
970	[CLS]	O
970	the	O
970	optimal	O
970	dos	O
970	##ing	O
970	regime	O
970	##n	O
970	was	O
970	selected	O
970	on	O
970	the	O
970	basis	O
970	of	O
970	target	O
970	effect	O
970	which	O
970	was	O
970	defined	O
970	as	O
970	maintenance	O
970	of	O
970	a	O
970	m	O
970	##oa	O
970	##a	O
970	/	O
970	s	O
970	score	O
970	<	O
970	2	O
970	for	O
970	at	O
970	least	O
970	1	O
970	.	O
970	5	O
970	h	O
970	.	O
970	one	O
970	thousand	O
970	virtual	O
970	subjects	O
970	were	O
970	simulated	O
970	each	O
970	time	O
970	,	O
970	and	O
970	the	O
970	p	O
970	##har	O
970	##ma	O
970	##co	O
970	##kin	O
970	##etic	O
970	and	O
970	p	O
970	##har	O
970	##ma	O
970	##co	O
970	##dynamic	O
970	values	O
970	for	O
970	the	O
970	1	O
970	,	O
970	000	O
970	subjects	O
970	were	O
970	simulated	O
970	using	O
970	the	O
970	parameters	O
970	from	O
970	the	O
970	final	O
970	models	O
970	,	O
970	of	O
970	which	O
970	the	O
970	var	O
970	##iability	O
970	were	O
970	randomly	O
970	sampled	O
970	from	O
970	the	O
970	log	O
970	-	O
970	normal	O
970	distributions	O
970	obtained	O
970	from	O
970	the	O
970	modeling	O
970	.	O
970	[SEP]	O
971	[CLS]	O
971	one	O
971	-	O
971	way	O
971	analysis	O
971	of	O
971	variance	O
971	(	O
971	an	O
971	##ova	O
971	)	O
971	with	O
971	du	O
971	##nc	O
971	##an	O
971	’	O
971	s	O
971	test	O
971	was	O
971	used	O
971	for	O
971	inter	O
971	-	O
971	group	O
971	comparisons	O
971	.	O
971	[SEP]	O
972	[CLS]	O
972	art	O
972	##hr	O
972	##itis	O
972	was	O
972	induced	O
972	with	O
972	the	O
972	injection	O
972	of	O
972	2	O
972	%	O
972	λ	O
972	-	O
972	car	O
972	##rage	O
972	##enan	O
972	and	O
972	4	O
972	%	O
972	ka	O
972	##olin	O
972	into	O
972	the	O
972	right	O
972	knee	O
972	joints	O
972	of	O
972	male	O
972	s	O
972	##pra	O
972	##gue	O
972	da	O
972	##wley	O
972	rats	O
972	.	O
972	[SEP]	O
973	[CLS]	O
973	relative	B-PK
973	bio	I-PK
973	##ava	I-PK
973	##ila	I-PK
973	##bility	I-PK
973	(	I-PK
973	f	I-PK
973	##r	I-PK
973	)	I-PK
973	and	O
973	absolute	B-PK
973	bio	I-PK
973	##ava	I-PK
973	##ila	I-PK
973	##bility	I-PK
973	(	I-PK
973	f	I-PK
973	##a	I-PK
973	)	I-PK
973	were	O
973	calculated	O
973	as	O
973	follows	O
973	:	O
973	f	O
973	##r	O
973	=	O
973	au	O
973	##c	O
973	##0	O
973	-	O
973	∞	O
973	(	O
973	o	O
973	##bas	O
973	)	O
973	/	O
973	au	O
973	##c	O
973	##0	O
973	-	O
973	∞	O
973	(	O
973	b	O
973	##h	O
973	)	O
973	×	O
973	100	O
973	%	O
973	,	O
973	f	O
973	##a	O
973	=	O
973	au	O
973	##c	O
973	##0	O
973	-	O
973	∞	O
973	(	O
973	i	O
973	##g	O
973	)	O
973	×	O
973	di	O
973	##v	O
973	/	O
973	au	O
973	##c	O
973	##0	O
973	-	O
973	∞	O
973	(	O
973	i	O
973	##v	O
973	)	O
973	×	O
973	dig	O
973	×	O
973	100	O
973	%	O
973	.	O
973	[SEP]	O
974	[CLS]	O
974	formulation	O
974	2	O
974	showed	O
974	a	O
974	significantly	O
974	higher	O
974	cm	B-PK
974	##ax	I-PK
974	(	O
974	p	O
974	value	O
974	<	O
974	0	O
974	.	O
974	00	O
974	##1	O
974	)	O
974	and	O
974	faster	O
974	initial	O
974	drop	O
974	after	O
974	reaching	O
974	peak	B-PK
974	concentrations	I-PK
974	(	O
974	p	O
974	value	O
974	<	O
974	0	O
974	.	O
974	01	O
974	for	O
974	slope	O
974	of	O
974	log	O
974	##ari	O
974	##th	O
974	##mic	O
974	plasma	O
974	concentration	O
974	-	O
974	time	O
974	profiles	O
974	between	O
974	t	B-PK
974	##max	I-PK
974	and	O
974	24	O
974	h	O
974	)	O
974	than	O
974	formulation	O
974	1	O
974	,	O
974	suggesting	O
974	a	O
974	faster	O
974	drug	O
974	absorption	O
974	or	O
974	release	O
974	rate	O
974	.	O
974	[SEP]	O
975	[CLS]	O
975	for	O
975	all	O
975	im	O
975	formulation	O
975	##s	O
975	,	O
975	the	O
975	slopes	O
975	of	O
975	the	O
975	log	O
975	##ari	O
975	##th	O
975	##mic	O
975	plasma	O
975	concentration	O
975	-	O
975	time	O
975	profiles	O
975	between	O
975	t	B-PK
975	##max	I-PK
975	and	O
975	24	O
975	h	O
975	were	O
975	significantly	O
975	lower	O
975	than	O
975	for	O
975	formulation	O
975	5	O
975	(	O
975	i	O
975	##v	O
975	)	O
975	between	O
975	6	O
975	and	O
975	24	O
975	h	O
975	(	O
975	p	O
975	value	O
975	<	O
975	0	O
975	.	O
975	00	O
975	##1	O
975	for	O
975	formulation	O
975	1	O
975	,	O
975	p	O
975	value	O
975	<	O
975	0	O
975	.	O
975	01	O
975	for	O
975	formulation	O
975	##s	O
975	2	O
975	and	O
975	5	O
975	(	O
975	im	O
975	)	O
975	)	O
975	.	O
975	[SEP]	O
976	[CLS]	O
976	the	O
976	half	B-PK
976	-	I-PK
976	life	I-PK
976	calculated	O
976	for	O
976	formulation	O
976	5	O
976	(	O
976	im	O
976	and	O
976	i	O
976	##v	O
976	)	O
976	was	O
976	much	O
976	shorter	O
976	due	O
976	to	O
976	the	O
976	earlier	O
976	t	B-PK
976	##last	I-PK
976	and	O
976	can	O
976	therefore	O
976	not	O
976	be	O
976	compared	O
976	to	O
976	the	O
976	half	B-PK
976	-	I-PK
976	life	I-PK
976	of	O
976	formulation	O
976	##s	O
976	1	O
976	and	O
976	2	O
976	.	O
976	[SEP]	O
977	[CLS]	O
977	however	O
977	,	O
977	log	O
977	##ari	O
977	##th	O
977	##mic	O
977	plasma	O
977	concentration	O
977	-	O
977	time	O
977	profiles	O
977	of	O
977	formulation	O
977	##s	O
977	1	O
977	and	O
977	2	O
977	(	O
977	im	O
977	)	O
977	declined	O
977	parallel	O
977	to	O
977	the	O
977	ones	O
977	of	O
977	formulation	O
977	5	O
977	(	O
977	im	O
977	and	O
977	i	O
977	##v	O
977	)	O
977	between	O
977	24	O
977	and	O
977	80	O
977	h	O
977	after	O
977	dos	O
977	##ing	O
977	,	O
977	suggesting	O
977	a	O
977	similar	O
977	half	B-PK
977	-	I-PK
977	life	I-PK
977	for	O
977	all	O
977	formulation	O
977	##s	O
977	within	O
977	that	O
977	time	O
977	##frame	O
977	.	O
977	[SEP]	O
978	[CLS]	O
978	as	O
978	shown	O
978	in	O
978	table	O
978	2	O
978	,	O
978	the	O
978	time	B-PK
978	to	I-PK
978	reach	I-PK
978	to	I-PK
978	maximum	I-PK
978	concentration	I-PK
978	(	I-PK
978	t	I-PK
978	##max	I-PK
978	)	I-PK
978	,	O
978	the	O
978	peak	B-PK
978	drug	I-PK
978	concentration	I-PK
978	(	I-PK
978	cm	I-PK
978	##ax	I-PK
978	)	I-PK
978	,	O
978	and	O
978	the	O
978	area	B-PK
978	under	I-PK
978	the	I-PK
978	curve	I-PK
978	at	I-PK
978	24	I-PK
978	h	I-PK
978	(	I-PK
978	au	I-PK
978	##c	I-PK
978	##24	I-PK
978	)	I-PK
978	were	O
978	3	O
978	.	O
978	52	O
978	±	O
978	0	O
978	.	O
978	34	O
978	h	O
978	,	O
978	1	O
978	.	O
978	57	O
978	±	O
978	0	O
978	.	O
978	46	O
978	μ	O
978	##g	O
978	/	O
978	m	O
978	##l	O
978	,	O
978	and	O
978	20	O
978	.	O
978	13	O
978	±	O
978	5	O
978	.	O
978	26	O
978	μ	O
978	##g	O
978	.	O
978	[SEP]	O
979	[CLS]	O
979	the	O
979	mean	B-PK
979	residence	I-PK
979	time	I-PK
979	(	I-PK
979	m	I-PK
979	##rt	I-PK
979	)	I-PK
979	was	O
979	16	O
979	.	O
979	45	O
979	±	O
979	1	O
979	.	O
979	67	O
979	h	O
979	.	O
979	[SEP]	O
980	[CLS]	O
980	the	O
980	intercept	O
980	for	O
980	the	O
980	distribution	O
980	phase	O
980	(	O
980	a	O
980	)	O
980	and	O
980	for	O
980	the	O
980	elimination	O
980	phase	O
980	(	O
980	b	O
980	)	O
980	were	O
980	2	O
980	.	O
980	67	O
980	±	O
980	0	O
980	.	O
980	99	O
980	μ	O
980	##g	O
980	/	O
980	m	O
980	##l	O
980	and	O
980	0	O
980	.	O
980	09	O
980	±	O
980	0	O
980	.	O
980	01	O
980	μ	O
980	##g	O
980	/	O
980	m	O
980	##l	O
980	.	O
980	the	O
980	distribution	B-PK
980	rate	I-PK
980	constant	I-PK
980	(	I-PK
980	α	I-PK
980	)	I-PK
980	and	O
980	elimination	B-PK
980	rate	I-PK
980	constant	I-PK
980	(	I-PK
980	β	I-PK
980	)	I-PK
980	were	O
980	0	O
980	.	O
980	11	O
980	±	O
980	0	O
980	.	O
980	01	O
980	l	O
980	/	O
980	h	O
980	and	O
980	0	O
980	.	O
980	00	O
980	##2	O
980	±	O
980	0	O
980	.	O
980	00	O
980	##1	O
980	l	O
980	/	O
980	h	O
980	.	O
980	[SEP]	O
981	[CLS]	O
981	this	O
981	anterior	O
981	segment	O
981	is	O
981	largely	O
981	lined	O
981	with	O
981	non	O
981	-	O
981	c	O
981	##iliated	O
981	sq	O
981	##ua	O
981	##mous	O
981	e	O
981	##pit	O
981	##hel	O
981	##ium	O
981	that	O
981	is	O
981	less	O
981	efficient	O
981	at	O
981	medication	O
981	absorption	O
981	than	O
981	the	O
981	respiratory	O
981	m	O
981	##uc	O
981	##osa	O
981	beyond	O
981	the	O
981	nasal	O
981	valve	O
981	.	O
981	12	O
981	,	O
981	13	O
981	anterior	O
981	deposition	O
981	following	O
981	a	O
981	conventional	O
981	nasal	O
981	spray	O
981	also	O
981	results	O
981	in	O
981	a	O
981	substantial	O
981	portion	O
981	of	O
981	the	O
981	delivered	O
981	dose	O
981	either	O
981	dripping	O
981	out	O
981	of	O
981	the	O
981	no	O
981	##st	O
981	##ril	O
981	or	O
981	being	O
981	wiped	O
981	off	O
981	.	O
981	[SEP]	O
982	[CLS]	O
982	importantly	O
982	,	O
982	a	O
982	large	O
982	fraction	O
982	of	O
982	the	O
982	remaining	O
982	drug	O
982	that	O
982	is	O
982	believed	O
982	to	O
982	enter	O
982	the	O
982	“	O
982	deep	O
982	”	O
982	nasal	O
982	cavity	O
982	following	O
982	standard	O
982	nasal	O
982	spray	O
982	administration	O
982	is	O
982	actually	O
982	drawn	O
982	along	O
982	the	O
982	floor	O
982	of	O
982	the	O
982	nasal	O
982	cavity	O
982	into	O
982	the	O
982	p	O
982	##har	O
982	##ynx	O
982	where	O
982	it	O
982	is	O
982	swallowed	O
982	.	O
982	12	O
982	swallowing	O
982	affects	O
982	such	O
982	a	O
982	significant	O
982	portion	O
982	of	O
982	the	O
982	medication	O
982	delivered	O
982	by	O
982	conventional	O
982	nasal	O
982	spray	O
982	##s	O
982	that	O
982	a	O
982	higher	O
982	plasma	O
982	peak	O
982	can	O
982	be	O
982	produced	O
982	via	O
982	the	O
982	un	O
982	##int	O
982	##ended	O
982	g	O
982	##i	O
982	route	O
982	than	O
982	by	O
982	nasal	O
982	absorption	O
982	.	O
982	14	O
982	this	O
982	phenomenon	O
982	is	O
982	clearly	O
982	observed	O
982	with	O
982	sum	O
982	##at	O
982	##rip	O
982	##tan	O
982	in	O
982	the	O
982	bi	O
982	##mo	O
982	##dal	O
982	absorption	O
982	profile	O
982	following	O
982	nasal	O
982	spray	O
982	administration	O
982	:	O
982	a	O
982	lower	O
982	early	O
982	peak	O
982	,	O
982	likely	O
982	related	O
982	to	O
982	in	O
982	##tra	O
982	##nas	O
982	##al	O
982	absorption	O
982	,	O
982	is	O
982	produced	O
982	after	O
982	20	O
982	minutes	O
982	and	O
982	is	O
982	followed	O
982	by	O
982	a	O
982	higher	O
982	absorption	O
982	peak	O
982	consistent	O
982	with	O
982	g	O
982	##i	O
982	absorption	O
982	around	O
982	90	O
982	minutes	O
982	.	O
982	14	O
982	[SEP]	O
983	[CLS]	O
983	the	O
983	km	B-PK
983	and	O
983	v	B-PK
983	##max	I-PK
983	at	O
983	37	O
983	,	O
983	32	O
983	or	O
983	[UNK]	O
983	were	O
983	obtained	O
983	from	O
983	the	O
983	mi	O
983	##cha	O
983	##eli	O
983	##s	O
983	–	O
983	men	O
983	##ten	O
983	equation	O
983	.	O
983	[SEP]	O
984	[CLS]	O
984	however	O
984	,	O
984	the	O
984	v	B-PK
984	##max	I-PK
984	of	O
984	ni	O
984	##mo	O
984	##di	O
984	##pine	O
984	was	O
984	[UNK]	O
984	%	O
984	lower	O
984	at	O
984	[UNK]	O
984	and	O
984	[UNK]	O
984	%	O
984	lower	O
984	at	O
984	[UNK]	O
984	than	O
984	that	O
984	at	O
984	[UNK]	O
984	.	O
984	[SEP]	O
985	[CLS]	O
985	no	O
985	significant	O
985	changes	O
985	were	O
985	observed	O
985	in	O
985	km	B-PK
985	at	O
985	37	O
985	,	O
985	32	O
985	or	O
985	[UNK]	O
985	(	O
985	table	O
985	3	O
985	)	O
985	.	O
985	[SEP]	O
986	[CLS]	O
986	the	O
986	extremely	O
986	low	O
986	oral	B-PK
986	bio	I-PK
986	##ava	I-PK
986	##ila	I-PK
986	##bility	I-PK
986	of	O
986	re	O
986	##s	O
986	is	O
986	primarily	O
986	due	O
986	to	O
986	its	O
986	low	O
986	so	O
986	##lub	O
986	##ility	O
986	and	O
986	extensive	O
986	in	O
986	##test	O
986	##inal	O
986	first	O
986	-	O
986	pass	O
986	metabolism	O
986	[	O
986	17	O
986	]	O
986	.	O
986	[SEP]	O
987	[CLS]	O
987	in	O
987	addition	O
987	,	O
987	the	O
987	developed	O
987	s	O
987	##ned	O
987	##ds	O
987	improved	O
987	the	O
987	oral	B-PK
987	bio	I-PK
987	##ava	I-PK
987	##ila	I-PK
987	##bility	I-PK
987	of	O
987	re	O
987	##s	O
987	.	O
987	[SEP]	O
988	[CLS]	O
988	previous	O
988	studies	O
988	have	O
988	also	O
988	reported	O
988	that	O
988	such	O
988	a	O
988	system	O
988	for	O
988	delivering	O
988	h	O
988	##ydro	O
988	##phobic	O
988	compounds	O
988	could	O
988	be	O
988	an	O
988	effective	O
988	oral	O
988	dos	O
988	##age	O
988	form	O
988	for	O
988	enhancing	O
988	oral	B-PK
988	bio	I-PK
988	##ava	I-PK
988	##ila	I-PK
988	##bility	I-PK
988	[	O
988	29	O
988	,	O
988	30	O
988	]	O
988	.	O
988	[SEP]	O
989	[CLS]	O
989	many	O
989	studies	O
989	have	O
989	shown	O
989	that	O
989	reducing	O
989	the	O
989	particle	O
989	size	O
989	increases	O
989	the	O
989	absorption	O
989	of	O
989	the	O
989	active	O
989	ingredient	O
989	and	O
989	the	O
989	particle	O
989	up	O
989	##take	O
989	by	O
989	enhancing	O
989	the	O
989	mechanisms	O
989	of	O
989	passive	O
989	transport	O
989	through	O
989	the	O
989	in	O
989	##test	O
989	##inal	O
989	walls	O
989	[	O
989	31	O
989	]	O
989	.	O
989	[SEP]	O
990	[CLS]	O
990	more	O
990	##over	O
990	,	O
990	the	O
990	l	O
990	##ymph	O
990	##atic	O
990	transport	O
990	substantially	O
990	contributes	O
990	to	O
990	the	O
990	total	O
990	oral	O
990	absorption	O
990	of	O
990	drugs	O
990	because	O
990	the	O
990	oil	O
990	phase	O
990	,	O
990	which	O
990	promotes	O
990	lip	O
990	##op	O
990	##hil	O
990	##ic	O
990	drug	O
990	absorption	O
990	,	O
990	constitutes	O
990	more	O
990	than	O
990	25	O
990	%	O
990	of	O
990	the	O
990	self	O
990	-	O
990	em	O
990	##ul	O
990	##si	O
990	##fying	O
990	drug	O
990	delivery	O
990	system	O
990	[	O
990	32	O
990	]	O
990	.	O
990	[SEP]	O
991	[CLS]	O
991	receiver	O
991	operating	O
991	characteristic	O
991	(	O
991	r	O
991	##oc	O
991	)	O
991	curve	O
991	analysis	O
991	was	O
991	also	O
991	performed	O
991	to	O
991	evaluate	O
991	diagnostic	O
991	characteristics	O
991	of	O
991	each	O
991	d	O
991	##ce	O
991	-	O
991	m	O
991	##ri	O
991	parameter	O
991	in	O
991	different	O
991	##iating	O
991	border	O
991	##line	O
991	/	O
991	ma	O
991	##li	O
991	##gnant	O
991	tumors	O
991	from	O
991	ben	O
991	##ign	O
991	lesions	O
991	and	O
991	,	O
991	to	O
991	provide	O
991	the	O
991	optimal	O
991	cut	O
991	##off	O
991	values	O
991	for	O
991	these	O
991	variables	O
991	.	O
991	[SEP]	O
992	[CLS]	O
992	the	O
992	elimination	B-PK
992	rate	I-PK
992	constant	I-PK
992	for	O
992	album	O
992	##in	O
992	was	O
992	set	O
992	equivalent	O
992	to	O
992	the	O
992	half	B-PK
992	-	I-PK
992	life	I-PK
992	of	O
992	album	O
992	##in	O
992	in	O
992	blood	O
992	for	O
992	the	O
992	rat	O
992	(	O
992	≈	O
992	##46	O
992	h	O
992	)	O
992	,	O
992	as	O
992	described	O
992	in	O
992	m	O
992	##c	O
992	##mu	O
992	##llin	O
992	et	O
992	al	O
992	.	O
992	(	O
992	2003	O
992	)	O
992	.	O
992	[SEP]	O
993	[CLS]	O
993	additionally	O
993	,	O
993	an	O
993	electro	O
993	##card	O
993	##io	O
993	##gram	O
993	was	O
993	conducted	O
993	and	O
993	a	O
993	general	O
993	examination	O
993	of	O
993	the	O
993	subject	O
993	was	O
993	performed	O
993	to	O
993	exclude	O
993	any	O
993	illness	O
993	or	O
993	abnormal	O
993	##ity	O
993	.	O
993	[SEP]	O
994	[CLS]	O
994	p	O
994	##har	O
994	##ma	O
994	##co	O
994	##kin	O
994	##etic	O
994	samples	O
994	were	O
994	taken	O
994	on	O
994	day	O
994	0	O
994	(	O
994	pre	O
994	##dos	O
994	##ing	O
994	)	O
994	,	O
994	on	O
994	day	O
994	1	O
994	,	O
994	and	O
994	then	O
994	weekly	O
994	for	O
994	weeks	O
994	2	O
994	to	O
994	5	O
994	and	O
994	then	O
994	on	O
994	weeks	O
994	9	O
994	and	O
994	10	O
994	.	O
994	[SEP]	O
995	[CLS]	O
995	s	O
995	##tag	O
995	=	O
995	ma	O
995	##x	O
995	(	O
995	s	O
995	##tag	O
995	##1	O
995	,	O
995	s	O
995	##tag	O
995	##2	O
995	)	O
995	in	O
995	fi	O
995	##g	O
995	.	O
995	4	O
995	.	O
995	[SEP]	O
996	[CLS]	O
996	we	O
996	found	O
996	that	O
996	plasma	O
996	parent	O
996	ya	O
996	##ku	O
996	##chin	O
996	##one	O
996	a	O
996	observed	O
996	only	O
996	up	O
996	to	O
996	0	O
996	.	O
996	5	O
996	h	O
996	after	O
996	dos	O
996	##ing	O
996	and	O
996	the	O
996	concentrations	O
996	were	O
996	quite	O
996	low	O
996	with	O
996	the	O
996	mean	O
996	cm	B-PK
996	##ax	I-PK
996	at	O
996	4	O
996	.	O
996	62	O
996	ng	O
996	/	O
996	m	O
996	##l	O
996	.	O
996	the	O
996	plasma	O
996	parent	O
996	ya	O
996	##ku	O
996	##chin	O
996	##one	O
996	a	O
996	peaked	O
996	at	O
996	0	O
996	.	O
996	08	O
996	##3	O
996	h	O
996	post	O
996	##dos	O
996	##e	O
996	and	O
996	declined	O
996	rapidly	O
996	(	O
996	mean	O
996	m	B-PK
996	##rt	I-PK
996	value	O
996	,	O
996	0	O
996	.	O
996	63	O
996	h	O
996	)	O
996	.	O
996	[SEP]	O
997	[CLS]	O
997	the	O
997	mean	O
997	au	B-PK
997	##c	I-PK
997	##0	I-PK
997	##→	I-PK
997	##t	I-PK
997	value	O
997	was	O
997	0	O
997	.	O
997	72	O
997	h	O
997	·	O
997	ng	O
997	/	O
997	m	O
997	##l	O
997	.	O
997	meanwhile	O
997	,	O
997	the	O
997	significant	O
997	individual	O
997	differences	O
997	were	O
997	observed	O
997	.	O
997	[SEP]	O
998	[CLS]	O
998	ft	O
998	##ir	O
998	s	O
998	##pect	O
998	##ra	O
998	analysis	O
998	of	O
998	m	O
998	##t	O
998	##x	O
998	,	O
998	p	O
998	##l	O
998	##ga	O
998	,	O
998	p	O
998	##eg	O
998	##40	O
998	##00	O
998	,	O
998	physical	O
998	mixture	O
998	of	O
998	m	O
998	##t	O
998	##x	O
998	,	O
998	p	O
998	##l	O
998	##ga	O
998	,	O
998	and	O
998	p	O
998	##eg	O
998	##40	O
998	##00	O
998	,	O
998	and	O
998	m	O
998	##t	O
998	##x	O
998	-	O
998	loaded	O
998	imp	O
998	##lants	O
998	revealed	O
998	characteristic	O
998	absorption	O
998	bands	O
998	at	O
998	different	O
998	frequencies	O
998	(	O
998	figure	O
998	4	O
998	)	O
998	.	O
998	[SEP]	O
999	[CLS]	O
999	as	O
999	shown	O
999	in	O
999	the	O
999	ft	O
999	##ir	O
999	spectrum	O
999	of	O
999	m	O
999	##t	O
999	##x	O
999	(	O
999	figure	O
999	4	O
999	##a	O
999	)	O
999	,	O
999	a	O
999	broad	O
999	band	O
999	at	O
999	3	O
999	,	O
999	36	O
999	##7	O
999	cm	O
999	##−	O
999	##1	O
999	was	O
999	attributed	O
999	to	O
999	the	O
999	stretching	O
999	vibration	O
999	of	O
999	n	O
999	–	O
999	h	O
999	.	O
999	9	O
999	,	O
999	21	O
999	,	O
999	22	O
999	typical	O
999	infrared	O
999	absorption	O
999	bands	O
999	observed	O
999	in	O
999	p	O
999	##l	O
999	##ga	O
999	(	O
999	figure	O
999	4	O
999	##b	O
999	)	O
999	and	O
999	p	O
999	##eg	O
999	##40	O
999	##00	O
999	(	O
999	figure	O
999	4	O
999	##c	O
999	)	O
999	were	O
999	detected	O
999	in	O
999	the	O
999	s	O
999	##pect	O
999	##ra	O
999	of	O
999	physical	O
999	mixture	O
999	of	O
999	m	O
999	##t	O
999	##x	O
999	,	O
999	p	O
999	##l	O
999	##ga	O
999	,	O
999	and	O
999	p	O
999	##eg	O
999	##40	O
999	##00	O
999	(	O
999	figure	O
999	4	O
999	##d	O
999	)	O
999	and	O
999	m	O
999	##t	O
999	##x	O
999	-	O
999	loaded	O
999	imp	O
999	##lants	O
999	(	O
999	figure	O
999	4	O
999	##e	O
999	)	O
999	.	O
999	[SEP]	O
1000	[CLS]	O
1000	ca	O
1000	##sp	O
1000	##of	O
1000	##ung	O
1000	##in	O
1000	levels	O
1000	in	O
1000	plasma	O
1000	and	O
1000	g	O
1000	##i	O
1000	compartment	O
1000	##s	O
1000	were	O
1000	measured	O
1000	by	O
1000	liquid	O
1000	ch	O
1000	##roma	O
1000	##tography	O
1000	-	O
1000	tandem	O
1000	mass	O
1000	s	O
1000	##pect	O
1000	##rome	O
1000	##try	O
1000	(	O
1000	l	O
1000	##c	O
1000	-	O
1000	m	O
1000	##s	O
1000	/	O
1000	m	O
1000	##s	O
1000	)	O
1000	in	O
1000	electro	O
1000	##sp	O
1000	##ray	O
1000	positive	O
1000	-	O
1000	ion	O
1000	##ization	O
1000	mode	O
1000	(	O
1000	es	O
1000	##i	O
1000	+	O
1000	)	O
1000	on	O
1000	an	O
1000	a	O
1000	##b	O
1000	s	O
1000	##cie	O
1000	##x	O
1000	q	O
1000	##tra	O
1000	##p	O
1000	4000	O
1000	triple	O
1000	-	O
1000	q	O
1000	##uad	O
1000	##rup	O
1000	##ole	O
1000	mass	O
1000	s	O
1000	##pect	O
1000	##rome	O
1000	##ter	O
1000	combined	O
1000	with	O
1000	an	O
1000	a	O
1000	##gi	O
1000	##lent	O
1000	126	O
1000	##0	O
1000	high	O
1000	-	O
1000	performance	O
1000	liquid	O
1000	ch	O
1000	##roma	O
1000	##to	O
1000	##graph	O
1000	(	O
1000	hp	O
1000	##l	O
1000	##c	O
1000	)	O
1000	using	O
1000	the	O
1000	analyst	O
1000	software	O
1000	and	O
1000	multiple	O
1000	-	O
1000	reaction	O
1000	monitoring	O
1000	(	O
1000	m	O
1000	##rm	O
1000	)	O
1000	of	O
1000	precursor	O
1000	/	O
1000	product	O
1000	transitions	O
1000	.	O
1000	[SEP]	O
1001	[CLS]	O
1001	the	O
1001	si	O
1001	##m	O
1001	##cy	O
1001	##p	O
1001	si	O
1001	##mu	O
1001	##lator	O
1001	incorporated	O
1001	a	O
1001	physiological	O
1001	##ly	O
1001	based	O
1001	method	O
1001	to	O
1001	si	O
1001	##mu	O
1001	##late	O
1001	changes	O
1001	in	O
1001	c	B-PK
1001	##l	I-PK
1001	associated	O
1001	with	O
1001	various	O
1001	c	O
1001	##y	O
1001	##p	O
1001	##2	O
1001	##c	O
1001	##9	O
1001	g	O
1001	##eno	O
1001	##type	O
1001	##s	O
1001	.	O
1001	[SEP]	O
1002	[CLS]	O
1002	the	O
1002	experimental	O
1002	protocol	O
1002	was	O
1002	approved	O
1002	by	O
1002	the	O
1002	animal	O
1002	experiment	O
1002	ethics	O
1002	committee	O
1002	of	O
1002	show	O
1002	##a	O
1002	university	O
1002	.	O
1002	[SEP]	O
1003	[CLS]	O
1003	the	O
1003	enzyme	O
1003	contribution	O
1003	for	O
1003	sip	O
1003	##oni	O
1003	##mo	O
1003	##d	O
1003	metabolism	O
1003	in	O
1003	the	O
1003	different	O
1003	c	O
1003	##y	O
1003	##p	O
1003	##2	O
1003	##c	O
1003	##9	O
1003	g	O
1003	##eno	O
1003	##type	O
1003	##s	O
1003	was	O
1003	predicted	O
1003	from	O
1003	in	O
1003	v	O
1003	##it	O
1003	##ro	O
1003	enzyme	O
1003	p	O
1003	##hen	O
1003	##ot	O
1003	##y	O
1003	##ping	O
1003	[	O
1003	unpublished	O
1003	data	O
1003	]	O
1003	,	O
1003	and	O
1003	metabolism	O
1003	data	O
1003	derived	O
1003	from	O
1003	h	O
1003	##lm	O
1003	ho	O
1003	##mo	O
1003	##zy	O
1003	##got	O
1003	##es	O
1003	were	O
1003	used	O
1003	to	O
1003	predict	O
1003	the	O
1003	c	O
1003	##py	O
1003	##2	O
1003	##c	O
1003	##9	O
1003	intrinsic	B-PK
1003	clearance	I-PK
1003	(	I-PK
1003	c	I-PK
1003	##lint	I-PK
1003	)	I-PK
1003	.	O
1003	[SEP]	O
1004	[CLS]	O
1004	a	O
1004	d	O
1004	##lt	O
1004	was	O
1004	defined	O
1004	as	O
1004	a	O
1004	significant	O
1004	adverse	O
1004	event	O
1004	(	O
1004	a	O
1004	##e	O
1004	)	O
1004	or	O
1004	abnormal	O
1004	laboratory	O
1004	parameter	O
1004	ad	O
1004	##ju	O
1004	##dged	O
1004	to	O
1004	be	O
1004	common	O
1004	terminology	O
1004	criteria	O
1004	for	O
1004	adverse	O
1004	events	O
1004	(	O
1004	version	O
1004	3	O
1004	.	O
1004	0	O
1004	)	O
1004	grade	O
1004	3	O
1004	or	O
1004	4	O
1004	in	O
1004	severity	O
1004	and	O
1004	considered	O
1004	unrelated	O
1004	to	O
1004	disease	O
1004	progression	O
1004	,	O
1004	inter	O
1004	##current	O
1004	illness	O
1004	,	O
1004	or	O
1004	con	O
1004	##com	O
1004	##ita	O
1004	##nt	O
1004	medications	O
1004	.	O
1004	[SEP]	O
1005	[CLS]	O
1005	in	O
1005	addition	O
1005	,	O
1005	all	O
1005	patients	O
1005	must	O
1005	have	O
1005	had	O
1005	adequate	O
1005	bone	O
1005	ma	O
1005	##rrow	O
1005	(	O
1005	absolute	O
1005	ne	O
1005	##ut	O
1005	##rop	O
1005	##hil	O
1005	count	O
1005	[	O
1005	1	O
1005	.	O
1005	5	O
1005	×	O
1005	109	O
1005	/	O
1005	l	O
1005	]	O
1005	,	O
1005	hem	O
1005	##og	O
1005	##lo	O
1005	##bin	O
1005	[	O
1005	9	O
1005	g	O
1005	/	O
1005	d	O
1005	##l	O
1005	]	O
1005	,	O
1005	and	O
1005	plate	O
1005	##lets	O
1005	[	O
1005	100	O
1005	×	O
1005	109	O
1005	/	O
1005	l	O
1005	]	O
1005	)	O
1005	,	O
1005	liver	O
1005	(	O
1005	serum	O
1005	total	O
1005	bi	O
1005	##li	O
1005	##ru	O
1005	##bin	O
1005	[	O
1005	1	O
1005	.	O
1005	5	O
1005	×	O
1005	upper	O
1005	limit	O
1005	of	O
1005	normal	O
1005	(	O
1005	ul	O
1005	##n	O
1005	)	O
1005	]	O
1005	,	O
1005	as	O
1005	##par	O
1005	##tate	O
1005	amino	O
1005	##tra	O
1005	##ns	O
1005	##fer	O
1005	##ase	O
1005	,	O
1005	and	O
1005	al	O
1005	##ani	O
1005	##ne	O
1005	amino	O
1005	##tra	O
1005	##ns	O
1005	##fer	O
1005	##ase	O
1005	[	O
1005	2	O
1005	.	O
1005	5	O
1005	×	O
1005	ul	O
1005	##n	O
1005	or	O
1005	5	O
1005	.	O
1005	0	O
1005	×	O
1005	ul	O
1005	##n	O
1005	if	O
1005	liver	O
1005	meta	O
1005	##sta	O
1005	##ses	O
1005	are	O
1005	present	O
1005	]	O
1005	)	O
1005	,	O
1005	and	O
1005	kidney	O
1005	function	O
1005	(	O
1005	serum	O
1005	c	O
1005	##rea	O
1005	##tin	O
1005	##ine	O
1005	[	O
1005	1	O
1005	.	O
1005	5	O
1005	×	O
1005	ul	O
1005	##n	O
1005	]	O
1005	or	O
1005	24	O
1005	‐	O
1005	h	O
1005	c	O
1005	##rea	O
1005	##tin	O
1005	##ine	O
1005	clearance	O
1005	[	O
1005	50	O
1005	m	O
1005	##l	O
1005	/	O
1005	min	O
1005	]	O
1005	)	O
1005	.	O
1005	[SEP]	O
1006	[CLS]	O
1006	patients	O
1006	were	O
1006	excluded	O
1006	if	O
1006	they	O
1006	had	O
1006	a	O
1006	history	O
1006	of	O
1006	a	O
1006	brain	O
1006	tumor	O
1006	or	O
1006	brain	O
1006	meta	O
1006	##sta	O
1006	##ses	O
1006	(	O
1006	except	O
1006	re	O
1006	##lap	O
1006	##sed	O
1006	m	O
1006	##b	O
1006	)	O
1006	,	O
1006	clinical	O
1006	##ly	O
1006	significant	O
1006	cardiac	O
1006	disease	O
1006	,	O
1006	or	O
1006	gas	O
1006	##tro	O
1006	##int	O
1006	##est	O
1006	##inal	O
1006	d	O
1006	##ys	O
1006	##function	O
1006	that	O
1006	might	O
1006	imp	O
1006	##air	O
1006	son	O
1006	##ide	O
1006	##gi	O
1006	##b	O
1006	absorption	O
1006	.	O
1006	[SEP]	O
1007	[CLS]	O
1007	son	O
1007	##ide	O
1007	##gi	O
1007	##b	O
1007	concentrations	O
1007	in	O
1007	plasma	O
1007	were	O
1007	measured	O
1007	using	O
1007	a	O
1007	valid	O
1007	##ated	O
1007	liquid	O
1007	ch	O
1007	##roma	O
1007	##tography	O
1007	–	O
1007	tandem	O
1007	mass	O
1007	s	O
1007	##pect	O
1007	##rome	O
1007	##try	O
1007	method	O
1007	##7	O
1007	with	O
1007	the	O
1007	lower	O
1007	limit	O
1007	of	O
1007	q	O
1007	##uant	O
1007	##ification	O
1007	of	O
1007	25	O
1007	.	O
1007	4	O
1007	p	O
1007	##g	O
1007	/	O
1007	m	O
1007	##l	O
1007	.	O
1007	p	O
1007	##har	O
1007	##ma	O
1007	##co	O
1007	##kin	O
1007	##etic	O
1007	parameters	O
1007	were	O
1007	estimated	O
1007	for	O
1007	each	O
1007	patient	O
1007	using	O
1007	a	O
1007	non	O
1007	‐	O
1007	compartment	O
1007	##al	O
1007	method	O
1007	with	O
1007	p	O
1007	##hoe	O
1007	##ni	O
1007	##x	O
1007	win	O
1007	##non	O
1007	##lin	O
1007	(	O
1007	p	O
1007	##har	O
1007	##sight	O
1007	,	O
1007	mountain	O
1007	view	O
1007	,	O
1007	ca	O
1007	,	O
1007	us	O
1007	##a	O
1007	)	O
1007	using	O
1007	a	O
1007	linear	O
1007	trap	O
1007	##ez	O
1007	##oid	O
1007	##al	O
1007	method	O
1007	for	O
1007	area	B-PK
1007	under	I-PK
1007	the	I-PK
1007	concentration	I-PK
1007	–	I-PK
1007	time	I-PK
1007	curve	I-PK
1007	(	I-PK
1007	au	I-PK
1007	##c	I-PK
1007	)	I-PK
1007	calculation	O
1007	.	O
1007	[SEP]	O
1008	[CLS]	O
1008	in	O
1008	both	O
1008	groups	O
1008	,	O
1008	most	O
1008	patients	O
1008	(	O
1008	86	O
1008	%	O
1008	[	O
1008	n	O
1008	=	O
1008	18	O
1008	]	O
1008	in	O
1008	group	O
1008	1	O
1008	and	O
1008	75	O
1008	%	O
1008	[	O
1008	n	O
1008	=	O
1008	18	O
1008	]	O
1008	in	O
1008	group	O
1008	2	O
1008	)	O
1008	experienced	O
1008	at	O
1008	least	O
1008	one	O
1008	a	O
1008	##e	O
1008	,	O
1008	which	O
1008	was	O
1008	suspected	O
1008	to	O
1008	be	O
1008	related	O
1008	to	O
1008	son	O
1008	##ide	O
1008	##gi	O
1008	##b	O
1008	.	O
1008	[SEP]	O
1009	[CLS]	O
1009	the	O
1009	most	O
1009	common	O
1009	drug	O
1009	‐	O
1009	related	O
1009	a	O
1009	##e	O
1009	in	O
1009	both	O
1009	groups	O
1009	was	O
1009	increase	O
1009	in	O
1009	c	O
1009	##k	O
1009	levels	O
1009	(	O
1009	33	O
1009	%	O
1009	in	O
1009	group	O
1009	1	O
1009	vs	O
1009	50	O
1009	%	O
1009	in	O
1009	group	O
1009	2	O
1009	)	O
1009	.	O
1009	[SEP]	O
1010	[CLS]	O
1010	the	O
1010	ma	B-PK
1010	##ximal	I-PK
1010	plasma	I-PK
1010	concentration	I-PK
1010	(	I-PK
1010	cm	I-PK
1010	##ax	I-PK
1010	)	I-PK
1010	was	O
1010	observed	O
1010	at	O
1010	approximately	O
1010	2	O
1010	–	O
1010	4	O
1010	h	O
1010	(	O
1010	t	B-PK
1010	##max	I-PK
1010	)	O
1010	after	O
1010	a	O
1010	single	O
1010	dose	O
1010	in	O
1010	the	O
1010	p	O
1010	##har	O
1010	##ma	O
1010	##co	O
1010	##kin	O
1010	##etic	O
1010	run	O
1010	‐	O
1010	in	O
1010	period	O
1010	and	O
1010	repeated	O
1010	dos	O
1010	##ing	O
1010	in	O
1010	cycle	O
1010	1	O
1010	day	O
1010	15	O
1010	.	O
1010	[SEP]	O
1011	[CLS]	O
1011	exposure	O
1011	(	O
1011	cm	B-PK
1011	##ax	I-PK
1011	and	O
1011	au	B-PK
1011	##c	I-PK
1011	)	O
1011	increased	O
1011	as	O
1011	the	O
1011	dose	O
1011	es	O
1011	##calated	O
1011	in	O
1011	both	O
1011	groups	O
1011	.	O
1011	[SEP]	O
1012	[CLS]	O
1012	after	O
1012	repeated	O
1012	dos	O
1012	##ing	O
1012	in	O
1012	group	O
1012	1	O
1012	,	O
1012	exposure	O
1012	accumulation	O
1012	in	O
1012	cycle	O
1012	1	O
1012	day	O
1012	15	O
1012	was	O
1012	4	O
1012	.	O
1012	9	O
1012	‐	O
1012	and	O
1012	4	O
1012	.	O
1012	6	O
1012	‐	O
1012	fold	O
1012	at	O
1012	400	O
1012	and	O
1012	600	O
1012	mg	O
1012	,	O
1012	respectively	O
1012	,	O
1012	as	O
1012	the	O
1012	au	B-PK
1012	##c	I-PK
1012	ratio	I-PK
1012	.	O
1012	[SEP]	O
1013	[CLS]	O
1013	in	O
1013	group	O
1013	2	O
1013	,	O
1013	au	B-PK
1013	##c	I-PK
1013	accumulation	I-PK
1013	at	O
1013	400	O
1013	,	O
1013	600	O
1013	,	O
1013	and	O
1013	800	O
1013	mg	O
1013	in	O
1013	cycle	O
1013	1	O
1013	day	O
1013	15	O
1013	was	O
1013	approximately	O
1013	4	O
1013	.	O
1013	3	O
1013	‐	O
1013	,	O
1013	4	O
1013	.	O
1013	2	O
1013	‐	O
1013	,	O
1013	and	O
1013	6	O
1013	.	O
1013	0	O
1013	‐	O
1013	fold	O
1013	,	O
1013	respectively	O
1013	.	O
1013	[SEP]	O
1014	[CLS]	O
1014	a	O
1014	large	O
1014	inter	O
1014	##ind	O
1014	##iv	O
1014	##id	O
1014	##ual	O
1014	var	O
1014	##iability	O
1014	was	O
1014	observed	O
1014	(	O
1014	for	O
1014	example	O
1014	,	O
1014	the	O
1014	percentage	O
1014	of	O
1014	coefficient	O
1014	of	O
1014	variation	O
1014	in	O
1014	au	B-PK
1014	##c	I-PK
1014	is	O
1014	50	O
1014	%	O
1014	or	O
1014	more	O
1014	when	O
1014	n	O
1014	≥	O
1014	3	O
1014	)	O
1014	in	O
1014	this	O
1014	study	O
1014	,	O
1014	and	O
1014	there	O
1014	was	O
1014	no	O
1014	obvious	O
1014	difference	O
1014	or	O
1014	trend	O
1014	in	O
1014	exposure	O
1014	(	O
1014	cm	B-PK
1014	##ax	I-PK
1014	and	O
1014	au	B-PK
1014	##c	I-PK
1014	)	O
1014	of	O
1014	son	O
1014	##ide	O
1014	##gi	O
1014	##b	O
1014	between	O
1014	the	O
1014	two	O
1014	groups	O
1014	.	O
1014	[SEP]	O
1015	[CLS]	O
1015	in	O
1015	cycle	O
1015	1	O
1015	day	O
1015	15	O
1015	,	O
1015	nine	O
1015	of	O
1015	12	O
1015	patients	O
1015	with	O
1015	grade	O
1015	3	O
1015	or	O
1015	4	O
1015	c	O
1015	##k	O
1015	elevations	O
1015	showed	O
1015	a	O
1015	higher	O
1015	individual	O
1015	au	B-PK
1015	##c	I-PK
1015	compared	O
1015	to	O
1015	the	O
1015	geometric	O
1015	mean	O
1015	observed	O
1015	for	O
1015	their	O
1015	respective	O
1015	groups	O
1015	.	O
1015	[SEP]	O
1016	[CLS]	O
1016	further	O
1016	##more	O
1016	,	O
1016	two	O
1016	of	O
1016	nine	O
1016	patients	O
1016	who	O
1016	experienced	O
1016	grade	O
1016	3	O
1016	c	O
1016	##k	O
1016	elevations	O
1016	after	O
1016	the	O
1016	last	O
1016	treatment	O
1016	showed	O
1016	smaller	O
1016	au	B-PK
1016	##c	I-PK
1016	compared	O
1016	to	O
1016	the	O
1016	other	O
1016	patients	O
1016	with	O
1016	or	O
1016	without	O
1016	c	O
1016	##k	O
1016	elevation	O
1016	.	O
1016	[SEP]	O
1017	[CLS]	O
1017	the	O
1017	p	O
1017	##har	O
1017	##ma	O
1017	##co	O
1017	##kin	O
1017	##etic	O
1017	profile	O
1017	of	O
1017	the	O
1017	drug	O
1017	including	O
1017	area	B-PK
1017	under	I-PK
1017	the	I-PK
1017	curve	I-PK
1017	,	O
1017	volume	B-PK
1017	of	I-PK
1017	distribution	I-PK
1017	and	O
1017	clearance	B-PK
1017	was	O
1017	greater	O
1017	(	O
1017	p	O
1017	<	O
1017	0	O
1017	.	O
1017	05	O
1017	)	O
1017	in	O
1017	p	O
1017	##o	O
1017	than	O
1017	s	O
1017	##c	O
1017	ca	O
1017	##lves	O
1017	.	O
1017	[SEP]	O
1018	[CLS]	O
1018	the	O
1018	slope	B-PK
1018	of	I-PK
1018	terminal	I-PK
1018	phase	I-PK
1018	(	I-PK
1018	λ	I-PK
1018	##z	I-PK
1018	)	I-PK
1018	of	O
1018	the	O
1018	log	O
1018	plasma	O
1018	concentration	O
1018	vs	O
1018	.	O
1018	time	O
1018	curve	O
1018	was	O
1018	estimated	O
1018	by	O
1018	means	O
1018	of	O
1018	linear	O
1018	re	O
1018	##gression	O
1018	;	O
1018	while	O
1018	the	O
1018	half	B-PK
1018	-	I-PK
1018	life	I-PK
1018	of	I-PK
1018	the	I-PK
1018	terminal	I-PK
1018	phase	I-PK
1018	(	I-PK
1018	λ	I-PK
1018	##z	I-PK
1018	-	I-PK
1018	h	I-PK
1018	##l	I-PK
1018	)	I-PK
1018	was	O
1018	calculated	O
1018	using	O
1018	the	O
1018	following	O
1018	equation	O
1018	:	O
1018	λ	O
1018	##z	O
1018	-	O
1018	h	O
1018	##l	O
1018	=	O
1018	0	O
1018	.	O
1018	69	O
1018	##3	O
1018	##λ	O
1018	##z	O
1018	.	O
1018	[SEP]	O
1019	[CLS]	O
1019	area	B-PK
1019	under	I-PK
1019	the	I-PK
1019	plasma	I-PK
1019	concentration	I-PK
1019	vs	I-PK
1019	.	I-PK
1019	time	I-PK
1019	curve	I-PK
1019	(	I-PK
1019	au	I-PK
1019	##c	I-PK
1019	)	I-PK
1019	and	O
1019	area	B-PK
1019	under	I-PK
1019	the	I-PK
1019	first	I-PK
1019	moment	I-PK
1019	of	I-PK
1019	the	I-PK
1019	plasma	I-PK
1019	concentration	I-PK
1019	vs	I-PK
1019	.	I-PK
1019	time	I-PK
1019	curve	I-PK
1019	(	I-PK
1019	au	I-PK
1019	##m	I-PK
1019	##c	I-PK
1019	)	I-PK
1019	were	O
1019	calculated	O
1019	by	O
1019	use	O
1019	of	O
1019	the	O
1019	log	O
1019	-	O
1019	linear	O
1019	trap	O
1019	##ez	O
1019	##oid	O
1019	##al	O
1019	method	O
1019	[	O
1019	14	O
1019	]	O
1019	.	O
1019	[SEP]	O
1020	[CLS]	O
1020	time	O
1020	range	O
1020	from	O
1020	the	O
1020	first	O
1020	measurement	O
1020	(	O
1020	t	O
1020	##0	O
1020	)	O
1020	to	O
1020	the	O
1020	last	O
1020	measurement	O
1020	(	O
1020	d	O
1020	7	O
1020	)	O
1020	of	O
1020	drug	O
1020	concentration	O
1020	was	O
1020	used	O
1020	for	O
1020	the	O
1020	calculation	O
1020	of	O
1020	au	B-PK
1020	##c	I-PK
1020	##0	I-PK
1020	-	I-PK
1020	last	I-PK
1020	and	O
1020	au	B-PK
1020	##m	I-PK
1020	##c	I-PK
1020	##0	I-PK
1020	-	I-PK
1020	last	I-PK
1020	.	O
1020	[SEP]	O
1021	[CLS]	O
1021	the	O
1021	au	B-PK
1021	##c	I-PK
1021	and	O
1021	au	B-PK
1021	##m	I-PK
1021	##c	I-PK
1021	were	O
1021	extra	O
1021	##pol	O
1021	##ated	O
1021	to	O
1021	in	O
1021	##finity	O
1021	to	O
1021	determine	O
1021	au	B-PK
1021	##c	I-PK
1021	##0	I-PK
1021	-	I-PK
1021	∞	I-PK
1021	and	O
1021	au	B-PK
1021	##m	I-PK
1021	##c	I-PK
1021	##0	I-PK
1021	-	I-PK
1021	∞	I-PK
1021	to	O
1021	account	O
1021	for	O
1021	the	O
1021	total	O
1021	me	O
1021	##lo	O
1021	##xi	O
1021	##cam	O
1021	exposure	O
1021	to	O
1021	ca	O
1021	##lves	O
1021	[	O
1021	14	O
1021	]	O
1021	.	O
1021	[SEP]	O
1022	[CLS]	O
1022	apparent	B-PK
1022	volume	I-PK
1022	of	I-PK
1022	distribution	I-PK
1022	during	I-PK
1022	terminal	I-PK
1022	phase	I-PK
1022	(	I-PK
1022	v	I-PK
1022	##z	I-PK
1022	/	I-PK
1022	f	I-PK
1022	)	I-PK
1022	and	O
1022	total	B-PK
1022	systemic	I-PK
1022	clearance	I-PK
1022	scaled	I-PK
1022	by	I-PK
1022	bio	I-PK
1022	##ava	I-PK
1022	##ila	I-PK
1022	##bility	I-PK
1022	(	I-PK
1022	c	I-PK
1022	##l	I-PK
1022	/	I-PK
1022	f	I-PK
1022	)	I-PK
1022	and	O
1022	mean	B-PK
1022	residence	I-PK
1022	time	I-PK
1022	(	I-PK
1022	m	I-PK
1022	##rt	I-PK
1022	)	I-PK
1022	of	O
1022	drug	O
1022	were	O
1022	also	O
1022	determined	O
1022	.	O
1022	[SEP]	O
1023	[CLS]	O
1023	peak	B-PK
1023	plasma	I-PK
1023	concentration	I-PK
1023	(	I-PK
1023	cm	I-PK
1023	##ax	I-PK
1023	)	I-PK
1023	and	O
1023	time	B-PK
1023	to	I-PK
1023	achieve	I-PK
1023	peak	I-PK
1023	concentration	I-PK
1023	(	I-PK
1023	t	I-PK
1023	##max	I-PK
1023	)	I-PK
1023	were	O
1023	determined	O
1023	directly	O
1023	from	O
1023	the	O
1023	observed	O
1023	data	O
1023	.	O
1023	[SEP]	O
1024	[CLS]	O
1024	behaviour	O
1024	##s	O
1024	were	O
1024	defined	O
1024	as	O
1024	:	O
1024	a	O
1024	)	O
1024	eating	O
1024	:	O
1024	ing	O
1024	##est	O
1024	##ing	O
1024	hay	O
1024	or	O
1024	straw	O
1024	from	O
1024	the	O
1024	ground	O
1024	or	O
1024	the	O
1024	feeder	O
1024	,	O
1024	b	O
1024	)	O
1024	lying	O
1024	:	O
1024	either	O
1024	lateral	O
1024	(	O
1024	laying	O
1024	with	O
1024	hip	O
1024	and	O
1024	shoulder	O
1024	on	O
1024	the	O
1024	ground	O
1024	with	O
1024	at	O
1024	least	O
1024	3	O
1024	limbs	O
1024	extended	O
1024	)	O
1024	or	O
1024	ventral	O
1024	(	O
1024	laying	O
1024	in	O
1024	stern	O
1024	##al	O
1024	re	O
1024	##cum	O
1024	##ben	O
1024	##cy	O
1024	with	O
1024	legs	O
1024	folded	O
1024	under	O
1024	the	O
1024	body	O
1024	or	O
1024	one	O
1024	hind	O
1024	or	O
1024	front	O
1024	leg	O
1024	extended	O
1024	)	O
1024	lying	O
1024	,	O
1024	c	O
1024	)	O
1024	walking	O
1024	:	O
1024	walking	O
1024	forward	O
1024	more	O
1024	than	O
1024	2	O
1024	steps	O
1024	,	O
1024	d	O
1024	)	O
1024	standing	O
1024	:	O
1024	standing	O
1024	on	O
1024	all	O
1024	four	O
1024	legs	O
1024	,	O
1024	e	O
1024	)	O
1024	foot	O
1024	stamp	O
1024	##ing	O
1024	:	O
1024	hind	O
1024	legs	O
1024	are	O
1024	lifted	O
1024	and	O
1024	forcefully	O
1024	placed	O
1024	on	O
1024	the	O
1024	ground	O
1024	or	O
1024	kicked	O
1024	outward	O
1024	##s	O
1024	while	O
1024	standing	O
1024	,	O
1024	f	O
1024	)	O
1024	head	O
1024	turning	O
1024	:	O
1024	head	O
1024	is	O
1024	turned	O
1024	and	O
1024	touches	O
1024	the	O
1024	side	O
1024	of	O
1024	the	O
1024	calf	O
1024	’	O
1024	s	O
1024	body	O
1024	when	O
1024	standing	O
1024	,	O
1024	including	O
1024	head	O
1024	turning	O
1024	to	O
1024	groom	O
1024	,	O
1024	g	O
1024	)	O
1024	tail	O
1024	flick	O
1024	##ing	O
1024	:	O
1024	force	O
1024	##ful	O
1024	tail	O
1024	movement	O
1024	beyond	O
1024	the	O
1024	wide	O
1024	##st	O
1024	part	O
1024	of	O
1024	the	O
1024	r	O
1024	##ump	O
1024	when	O
1024	standing	O
1024	,	O
1024	movement	O
1024	to	O
1024	one	O
1024	side	O
1024	is	O
1024	counted	O
1024	as	O
1024	one	O
1024	action	O
1024	,	O
1024	h	O
1024	)	O
1024	les	O
1024	##ion	O
1024	licking	O
1024	:	O
1024	head	O
1024	turning	O
1024	to	O
1024	lick	O
1024	the	O
1024	les	O
1024	##ion	O
1024	caused	O
1024	by	O
1024	cast	O
1024	##ration	O
1024	while	O
1024	standing	O
1024	[	O
1024	17	O
1024	]	O
1024	.	O
1024	[SEP]	O
1025	[CLS]	O
1025	the	O
1025	p	O
1025	##k	O
1025	data	O
1025	are	O
1025	clinical	O
1025	##ly	O
1025	useful	O
1025	as	O
1025	the	O
1025	terminal	B-PK
1025	half	I-PK
1025	-	I-PK
1025	life	I-PK
1025	of	O
1025	p	O
1025	##o	O
1025	me	O
1025	##lo	O
1025	##xi	O
1025	##cam	O
1025	at	O
1025	a	O
1025	dose	O
1025	of	O
1025	1	O
1025	.	O
1025	0	O
1025	mg	O
1025	/	O
1025	kg	O
1025	suggested	O
1025	that	O
1025	once	O
1025	a	O
1025	day	O
1025	administration	O
1025	provides	O
1025	anal	O
1025	##ges	O
1025	##ic	O
1025	efficacy	O
1025	in	O
1025	ca	O
1025	##lves	O
1025	[	O
1025	3	O
1025	]	O
1025	.	O
1025	[SEP]	O
1026	[CLS]	O
1026	limitations	O
1026	of	O
1026	p	O
1026	##o	O
1026	administration	O
1026	include	O
1026	a	O
1026	prolonged	O
1026	time	O
1026	of	O
1026	onset	O
1026	of	O
1026	anal	O
1026	##ges	O
1026	##ia	O
1026	after	O
1026	administration	O
1026	and	O
1026	unpredictable	O
1026	absorption	O
1026	due	O
1026	to	O
1026	varying	O
1026	gas	O
1026	##tric	O
1026	conditions	O
1026	and	O
1026	first	O
1026	pass	O
1026	he	O
1026	##pa	O
1026	##tic	O
1026	bio	O
1026	##tra	O
1026	##ns	O
1026	##formation	O
1026	[	O
1026	33	O
1026	]	O
1026	.	O
1026	[SEP]	O
1027	[CLS]	O
1027	in	O
1027	contrast	O
1027	,	O
1027	s	O
1027	##c	O
1027	administration	O
1027	offers	O
1027	the	O
1027	advantage	O
1027	of	O
1027	faster	O
1027	absorption	O
1027	and	O
1027	ease	O
1027	of	O
1027	administration	O
1027	.	O
1027	[SEP]	O
1028	[CLS]	O
1028	the	O
1028	time	B-PK
1028	to	I-PK
1028	reach	I-PK
1028	peak	I-PK
1028	plasma	I-PK
1028	drug	I-PK
1028	concentrations	I-PK
1028	(	I-PK
1028	t	I-PK
1028	##max	I-PK
1028	=	O
1028	24	O
1028	.	O
1028	0	O
1028	hour	O
1028	,	O
1028	p	O
1028	##o	O
1028	;	O
1028	t	B-PK
1028	##max	I-PK
1028	=	O
1028	3	O
1028	.	O
1028	7	O
1028	hour	O
1028	,	O
1028	s	O
1028	##c	O
1028	)	O
1028	after	O
1028	drug	O
1028	administration	O
1028	##s	O
1028	differed	O
1028	(	O
1028	p	O
1028	≤	O
1028	0	O
1028	.	O
1028	05	O
1028	)	O
1028	between	O
1028	treatments	O
1028	while	O
1028	no	O
1028	differences	O
1028	(	O
1028	p	O
1028	≥	O
1028	0	O
1028	.	O
1028	10	O
1028	)	O
1028	were	O
1028	observed	O
1028	for	O
1028	peak	B-PK
1028	plasma	I-PK
1028	drug	I-PK
1028	concentration	I-PK
1028	(	I-PK
1028	cm	I-PK
1028	##ax	I-PK
1028	=	O
1028	2	O
1028	.	O
1028	32	O
1028	μ	O
1028	##g	O
1028	/	O
1028	m	O
1028	##l	O
1028	,	O
1028	p	O
1028	##o	O
1028	;	O
1028	cm	B-PK
1028	##ax	I-PK
1028	=	O
1028	2	O
1028	.	O
1028	37	O
1028	μ	O
1028	##g	O
1028	/	O
1028	m	O
1028	##l	O
1028	,	O
1028	s	O
1028	##c	O
1028	)	O
1028	(	O
1028	table	O
1028	1	O
1028	)	O
1028	.	O
1028	[SEP]	O
1029	[CLS]	O
1029	similar	O
1029	t	B-PK
1029	##max	I-PK
1029	and	O
1029	cm	B-PK
1029	##ax	I-PK
1029	values	O
1029	were	O
1029	observed	O
1029	in	O
1029	ca	O
1029	##lves	O
1029	receiving	O
1029	s	O
1029	##c	O
1029	me	O
1029	##lo	O
1029	##xi	O
1029	##cam	O
1029	with	O
1029	or	O
1029	without	O
1029	a	O
1029	lid	O
1029	##oc	O
1029	##aine	O
1029	ring	O
1029	block	O
1029	prior	O
1029	to	O
1029	knife	O
1029	cast	O
1029	##ration	O
1029	[	O
1029	2	O
1029	]	O
1029	.	O
1029	[SEP]	O
1030	[CLS]	O
1030	similar	O
1030	findings	O
1030	were	O
1030	also	O
1030	reported	O
1030	in	O
1030	goats	O
1030	,	O
1030	where	O
1030	s	O
1030	##c	O
1030	me	O
1030	##lo	O
1030	##xi	O
1030	##cam	O
1030	administration	O
1030	had	O
1030	a	O
1030	significantly	O
1030	shorter	O
1030	t	B-PK
1030	##max	I-PK
1030	(	O
1030	3	O
1030	.	O
1030	20	O
1030	hour	O
1030	)	O
1030	compared	O
1030	to	O
1030	p	O
1030	##o	O
1030	me	O
1030	##lo	O
1030	##xi	O
1030	##cam	O
1030	administration	O
1030	(	O
1030	14	O
1030	.	O
1030	3	O
1030	hour	O
1030	)	O
1030	[	O
1030	31	O
1030	]	O
1030	.	O
1030	[SEP]	O
1031	[CLS]	O
1031	in	O
1031	contrast	O
1031	,	O
1031	mean	O
1031	cm	B-PK
1031	##ax	I-PK
1031	following	O
1031	s	O
1031	##c	O
1031	me	O
1031	##lo	O
1031	##xi	O
1031	##cam	O
1031	administration	O
1031	in	O
1031	the	O
1031	present	O
1031	study	O
1031	was	O
1031	higher	O
1031	than	O
1031	the	O
1031	value	O
1031	(	O
1031	cm	B-PK
1031	##ax	I-PK
1031	=	O
1031	1	O
1031	.	O
1031	91	O
1031	μ	O
1031	##g	O
1031	/	O
1031	m	O
1031	##l	O
1031	)	O
1031	obtained	O
1031	for	O
1031	goats	O
1031	[	O
1031	31	O
1031	]	O
1031	,	O
1031	while	O
1031	a	O
1031	lower	O
1031	cm	B-PK
1031	##ax	I-PK
1031	was	O
1031	observed	O
1031	following	O
1031	p	O
1031	##o	O
1031	administration	O
1031	in	O
1031	comparison	O
1031	to	O
1031	the	O
1031	cm	B-PK
1031	##ax	I-PK
1031	(	O
1031	3	O
1031	.	O
1031	10	O
1031	μ	O
1031	##g	O
1031	/	O
1031	m	O
1031	##l	O
1031	)	O
1031	previously	O
1031	reported	O
1031	in	O
1031	ca	O
1031	##lves	O
1031	[	O
1031	3	O
1031	]	O
1031	.	O
1031	[SEP]	O
1032	[CLS]	O
1032	the	O
1032	area	B-PK
1032	under	I-PK
1032	the	I-PK
1032	curve	I-PK
1032	(	I-PK
1032	au	I-PK
1032	##c	I-PK
1032	=	O
1032	95	O
1032	.	O
1032	16	O
1032	μ	O
1032	##g	O
1032	×	O
1032	h	O
1032	/	O
1032	m	O
1032	##l	O
1032	)	O
1032	,	O
1032	v	B-PK
1032	##z	I-PK
1032	/	I-PK
1032	f	I-PK
1032	=	O
1032	244	O
1032	m	O
1032	##l	O
1032	/	O
1032	kg	O
1032	and	O
1032	c	B-PK
1032	##l	I-PK
1032	/	I-PK
1032	f	I-PK
1032	=	O
1032	11	O
1032	.	O
1032	11	O
1032	m	O
1032	##l	O
1032	/	O
1032	h	O
1032	/	O
1032	kg	O
1032	were	O
1032	greater	O
1032	(	O
1032	p	O
1032	≤	O
1032	0	O
1032	.	O
1032	05	O
1032	)	O
1032	in	O
1032	the	O
1032	ca	O
1032	##lves	O
1032	receiving	O
1032	p	O
1032	##o	O
1032	compared	O
1032	to	O
1032	s	O
1032	##c	O
1032	me	O
1032	##lo	O
1032	##xi	O
1032	##cam	O
1032	administration	O
1032	.	O
1032	[SEP]	O
1033	[CLS]	O
1033	the	O
1033	au	B-PK
1033	##c	I-PK
1033	is	O
1033	an	O
1033	indicator	O
1033	of	O
1033	the	O
1033	total	O
1033	drug	O
1033	exposure	O
1033	and	O
1033	it	O
1033	is	O
1033	dependent	O
1033	on	O
1033	dose	O
1033	and	O
1033	rate	B-PK
1033	of	I-PK
1033	elimination	I-PK
1033	.	O
1033	[SEP]	O
1034	[CLS]	O
1034	a	O
1034	higher	O
1034	dose	O
1034	of	O
1034	me	O
1034	##lo	O
1034	##xi	O
1034	##cam	O
1034	given	O
1034	to	O
1034	the	O
1034	p	O
1034	##o	O
1034	ca	O
1034	##lves	O
1034	seems	O
1034	to	O
1034	be	O
1034	the	O
1034	major	O
1034	contributing	O
1034	factor	O
1034	for	O
1034	a	O
1034	greater	O
1034	au	B-PK
1034	##c	I-PK
1034	as	O
1034	the	O
1034	elimination	B-PK
1034	rate	I-PK
1034	(	I-PK
1034	λ	I-PK
1034	##z	I-PK
1034	=	O
1034	0	O
1034	.	O
1034	04	O
1034	##3	O
1034	–	O
1034	0	O
1034	.	O
1034	04	O
1034	##5	O
1034	1	O
1034	/	O
1034	h	O
1034	)	O
1034	is	O
1034	approximately	O
1034	the	O
1034	same	O
1034	for	O
1034	both	O
1034	treatment	O
1034	groups	O
1034	.	O
1034	[SEP]	O
1035	[CLS]	O
1035	the	O
1035	s	O
1035	##c	O
1035	ca	O
1035	##lves	O
1035	had	O
1035	lower	O
1035	(	O
1035	p	O
1035	≤	O
1035	0	O
1035	.	O
1035	05	O
1035	)	O
1035	clearance	B-PK
1035	(	I-PK
1035	c	I-PK
1035	##l	I-PK
1035	/	I-PK
1035	f	I-PK
1035	=	O
1035	7	O
1035	.	O
1035	98	O
1035	m	O
1035	##l	O
1035	/	O
1035	h	O
1035	/	O
1035	kg	O
1035	)	O
1035	of	O
1035	me	O
1035	##lo	O
1035	##xi	O
1035	##cam	O
1035	than	O
1035	the	O
1035	p	O
1035	##o	O
1035	ca	O
1035	##lves	O
1035	,	O
1035	which	O
1035	is	O
1035	in	O
1035	agreement	O
1035	with	O
1035	the	O
1035	longer	O
1035	elimination	B-PK
1035	half	I-PK
1035	-	I-PK
1035	life	I-PK
1035	(	I-PK
1035	λ	I-PK
1035	##z	I-PK
1035	-	I-PK
1035	h	I-PK
1035	##l	I-PK
1035	=	O
1035	16	O
1035	.	O
1035	2	O
1035	h	O
1035	)	O
1035	of	O
1035	the	O
1035	s	O
1035	##c	O
1035	treatment	O
1035	than	O
1035	the	O
1035	p	O
1035	##o	O
1035	(	O
1035	15	O
1035	.	O
1035	2	O
1035	h	O
1035	)	O
1035	administration	O
1035	.	O
1035	[SEP]	O
1036	[CLS]	O
1036	the	O
1036	λ	B-PK
1036	##z	I-PK
1036	-	I-PK
1036	h	I-PK
1036	##l	I-PK
1036	(	O
1036	16	O
1036	.	O
1036	2	O
1036	h	O
1036	)	O
1036	in	O
1036	ca	O
1036	##lves	O
1036	was	O
1036	slightly	O
1036	higher	O
1036	than	O
1036	that	O
1036	reported	O
1036	for	O
1036	goats	O
1036	(	O
1036	15	O
1036	.	O
1036	1	O
1036	h	O
1036	)	O
1036	after	O
1036	s	O
1036	##c	O
1036	me	O
1036	##lo	O
1036	##xi	O
1036	##cam	O
1036	administration	O
1036	using	O
1036	the	O
1036	same	O
1036	dose	O
1036	of	O
1036	0	O
1036	.	O
1036	5	O
1036	mg	O
1036	/	O
1036	kg	O
1036	[	O
1036	31	O
1036	]	O
1036	,	O
1036	while	O
1036	higher	O
1036	values	O
1036	for	O
1036	λ	B-PK
1036	##z	I-PK
1036	-	I-PK
1036	h	I-PK
1036	##l	I-PK
1036	(	O
1036	27	O
1036	.	O
1036	5	O
1036	h	O
1036	)	O
1036	and	O
1036	au	B-PK
1036	##c	I-PK
1036	(	O
1036	164	O
1036	.	O
1036	4	O
1036	μ	O
1036	##g	O
1036	.	O
1036	h	O
1036	/	O
1036	m	O
1036	##l	O
1036	)	O
1036	have	O
1036	been	O
1036	reported	O
1036	following	O
1036	p	O
1036	##o	O
1036	administration	O
1036	of	O
1036	me	O
1036	##lo	O
1036	##xi	O
1036	##cam	O
1036	in	O
1036	ca	O
1036	##lves	O
1036	[	O
1036	3	O
1036	]	O
1036	.	O
1036	[SEP]	O
1037	[CLS]	O
1037	in	O
1037	the	O
1037	previously	O
1037	mentioned	O
1037	trial	O
1037	p	O
1037	##k	O
1037	analysis	O
1037	showed	O
1037	that	O
1037	the	O
1037	au	B-PK
1037	##c	I-PK
1037	extra	O
1037	##pol	O
1037	##ation	O
1037	range	O
1037	was	O
1037	23	O
1037	.	O
1037	0	O
1037	–	O
1037	39	O
1037	.	O
1037	4	O
1037	%	O
1037	in	O
1037	four	O
1037	ca	O
1037	##lves	O
1037	and	O
1037	4	O
1037	.	O
1037	14	O
1037	–	O
1037	5	O
1037	.	O
1037	85	O
1037	%	O
1037	in	O
1037	two	O
1037	ca	O
1037	##lves	O
1037	.	O
1037	[SEP]	O
1038	[CLS]	O
1038	in	O
1038	contrast	O
1038	,	O
1038	p	O
1038	##k	O
1038	analysis	O
1038	for	O
1038	the	O
1038	current	O
1038	study	O
1038	was	O
1038	done	O
1038	with	O
1038	au	B-PK
1038	##c	I-PK
1038	extra	O
1038	##pol	O
1038	##ation	O
1038	of	O
1038	0	O
1038	.	O
1038	18	O
1038	%	O
1038	.	O
1038	[SEP]	O
1039	[CLS]	O
1039	insufficient	O
1039	sampling	O
1039	times	O
1039	in	O
1039	the	O
1039	descending	O
1039	part	O
1039	of	O
1039	the	O
1039	curve	O
1039	may	O
1039	lead	O
1039	to	O
1039	over	O
1039	##est	O
1039	##imation	O
1039	of	O
1039	au	B-PK
1039	##c	I-PK
1039	[	O
1039	34	O
1039	]	O
1039	.	O
1039	[SEP]	O
1040	[CLS]	O
1040	this	O
1040	could	O
1040	be	O
1040	the	O
1040	reason	O
1040	for	O
1040	a	O
1040	greater	O
1040	au	B-PK
1040	##c	I-PK
1040	in	O
1040	the	O
1040	previous	O
1040	study	O
1040	compared	O
1040	to	O
1040	the	O
1040	au	B-PK
1040	##c	I-PK
1040	obtained	O
1040	in	O
1040	the	O
1040	current	O
1040	study	O
1040	.	O
1040	[SEP]	O
1041	[CLS]	O
1041	the	O
1041	au	B-PK
1041	##c	I-PK
1041	in	O
1041	ca	O
1041	##lves	O
1041	was	O
1041	greater	O
1041	than	O
1041	the	O
1041	au	B-PK
1041	##c	I-PK
1041	reported	O
1041	in	O
1041	sheep	O
1041	(	O
1041	75	O
1041	.	O
1041	09	O
1041	μ	O
1041	##g	O
1041	×	O
1041	h	O
1041	/	O
1041	m	O
1041	##l	O
1041	)	O
1041	[	O
1041	30	O
1041	]	O
1041	and	O
1041	goats	O
1041	(	O
1041	23	O
1041	.	O
1041	24	O
1041	μ	O
1041	##g	O
1041	×	O
1041	h	O
1041	/	O
1041	m	O
1041	##l	O
1041	)	O
1041	[	O
1041	29	O
1041	]	O
1041	,	O
1041	indicating	O
1041	that	O
1041	me	O
1041	##lo	O
1041	##xi	O
1041	##cam	O
1041	is	O
1041	eliminated	O
1041	at	O
1041	a	O
1041	slower	O
1041	rate	O
1041	in	O
1041	ca	O
1041	##lves	O
1041	than	O
1041	small	O
1041	r	O
1041	##umi	O
1041	##nant	O
1041	species	O
1041	.	O
1041	[SEP]	O
1042	[CLS]	O
1042	the	O
1042	limited	O
1042	v	B-PK
1042	##z	I-PK
1042	/	I-PK
1042	f	I-PK
1042	=	O
1042	244	O
1042	m	O
1042	##l	O
1042	/	O
1042	kg	O
1042	observed	O
1042	in	O
1042	the	O
1042	present	O
1042	study	O
1042	after	O
1042	p	O
1042	##o	O
1042	me	O
1042	##lo	O
1042	##xi	O
1042	##cam	O
1042	administration	O
1042	is	O
1042	similar	O
1042	to	O
1042	previous	O
1042	values	O
1042	reported	O
1042	for	O
1042	ca	O
1042	##lves	O
1042	(	O
1042	242	O
1042	m	O
1042	##l	O
1042	/	O
1042	kg	O
1042	)	O
1042	[	O
1042	3	O
1042	]	O
1042	and	O
1042	sheep	O
1042	(	O
1042	29	O
1042	##3	O
1042	m	O
1042	##l	O
1042	/	O
1042	kg	O
1042	)	O
1042	[	O
1042	30	O
1042	]	O
1042	.	O
1042	[SEP]	O
1043	[CLS]	O
1043	a	O
1043	low	O
1043	v	B-PK
1043	##z	I-PK
1043	/	I-PK
1043	f	I-PK
1043	indicates	O
1043	that	O
1043	the	O
1043	drug	O
1043	is	O
1043	mainly	O
1043	found	O
1043	in	O
1043	the	O
1043	vascular	O
1043	space	O
1043	as	O
1043	opposed	O
1043	to	O
1043	the	O
1043	extra	O
1043	##vas	O
1043	##cular	O
1043	space	O
1043	.	O
1043	[SEP]	O
1044	[CLS]	O
1044	however	O
1044	,	O
1044	low	O
1044	values	O
1044	of	O
1044	clearance	B-PK
1044	and	O
1044	a	O
1044	terminal	B-PK
1044	half	I-PK
1044	-	I-PK
1044	life	I-PK
1044	of	O
1044	16	O
1044	.	O
1044	2	O
1044	hours	O
1044	following	O
1044	s	O
1044	##c	O
1044	administration	O
1044	suggests	O
1044	that	O
1044	once	O
1044	a	O
1044	day	O
1044	dos	O
1044	##ing	O
1044	might	O
1044	prove	O
1044	effective	O
1044	to	O
1044	maintain	O
1044	anal	O
1044	##ges	O
1044	##ic	O
1044	effect	O
1044	in	O
1044	ca	O
1044	##lves	O
1044	.	O
1044	[SEP]	O
1045	[CLS]	O
1045	a	O
1045	possible	O
1045	explanation	O
1045	for	O
1045	the	O
1045	reduction	O
1045	in	O
1045	s	O
1045	##c	O
1045	##rot	O
1045	##al	O
1045	inflammation	O
1045	observed	O
1045	in	O
1045	p	O
1045	##o	O
1045	ca	O
1045	##lves	O
1045	could	O
1045	be	O
1045	due	O
1045	to	O
1045	the	O
1045	greater	O
1045	exposure	O
1045	to	O
1045	me	O
1045	##lo	O
1045	##xi	O
1045	##cam	O
1045	as	O
1045	p	O
1045	##o	O
1045	ca	O
1045	##lves	O
1045	had	O
1045	greater	O
1045	au	B-PK
1045	##c	I-PK
1045	than	O
1045	s	O
1045	##c	O
1045	ca	O
1045	##lves	O
1045	.	O
1045	[SEP]	O
1046	[CLS]	O
1046	the	O
1046	greater	O
1046	exposure	O
1046	to	O
1046	me	O
1046	##lo	O
1046	##xi	O
1046	##cam	O
1046	(	O
1046	au	B-PK
1046	##c	I-PK
1046	)	O
1046	observed	O
1046	can	O
1046	explain	O
1046	lower	O
1046	standing	O
1046	duration	O
1046	and	O
1046	s	O
1046	##c	O
1046	##rot	O
1046	##al	O
1046	inflammation	O
1046	,	O
1046	and	O
1046	the	O
1046	greater	O
1046	lying	O
1046	percentage	O
1046	observed	O
1046	in	O
1046	the	O
1046	p	O
1046	##o	O
1046	ca	O
1046	##lves	O
1046	.	O
1046	[SEP]	O
1047	[CLS]	O
1047	treatment	O
1047	with	O
1047	g	O
1047	##l	O
1047	extract	O
1047	##s	O
1047	did	O
1047	not	O
1047	alter	O
1047	the	O
1047	levels	O
1047	of	O
1047	fast	O
1047	##ing	O
1047	plasma	O
1047	glucose	O
1047	and	O
1047	insulin	O
1047	,	O
1047	but	O
1047	significantly	O
1047	reduced	O
1047	the	O
1047	levels	O
1047	of	O
1047	plasma	O
1047	glucose	O
1047	at	O
1047	60	O
1047	and	O
1047	120	O
1047	min	O
1047	post	O
1047	glucose	O
1047	challenge	O
1047	,	O
1047	also	O
1047	reduced	O
1047	the	O
1047	values	O
1047	of	O
1047	au	B-PK
1047	##c	I-PK
1047	and	O
1047	quantitative	O
1047	insulin	O
1047	sensitivity	O
1047	check	O
1047	index	O
1047	(	O
1047	quick	O
1047	##i	O
1047	)	O
1047	at	O
1047	42	O
1047	days	O
1047	post	O
1047	treatment	O
1047	.	O
1047	[SEP]	O
1048	[CLS]	O
1048	the	O
1048	area	B-PK
1048	under	I-PK
1048	the	I-PK
1048	curve	I-PK
1048	(	I-PK
1048	au	I-PK
1048	##c	I-PK
1048	)	I-PK
1048	over	I-PK
1048	the	I-PK
1048	levels	I-PK
1048	of	I-PK
1048	blood	I-PK
1048	glucose	I-PK
1048	in	O
1048	individual	O
1048	rats	O
1048	was	O
1048	calculated	O
1048	by	O
1048	the	O
1048	trap	O
1048	##ez	O
1048	##oid	O
1048	##al	O
1048	rule	O
1048	:	O
1048	{	O
1048	[	O
1048	15	O
1048	×	O
1048	log	O
1048	(	O
1048	g	O
1048	##lu	O
1048	##c	O
1048	##0	O
1048	min	O
1048	)	O
1048	]	O
1048	+	O
1048	[	O
1048	30	O
1048	×	O
1048	log	O
1048	(	O
1048	g	O
1048	##lu	O
1048	##c	O
1048	##30	O
1048	min	O
1048	)	O
1048	]	O
1048	+	O
1048	[	O
1048	45	O
1048	×	O
1048	log	O
1048	(	O
1048	g	O
1048	##lu	O
1048	##c	O
1048	##60	O
1048	min	O
1048	)	O
1048	]	O
1048	+	O
1048	[	O
1048	30	O
1048	×	O
1048	log	O
1048	(	O
1048	g	O
1048	##lu	O
1048	##c	O
1048	##12	O
1048	##0	O
1048	min	O
1048	)	O
1048	]	O
1048	/	O
1048	120	O
1048	}	O
1048	[	O
1048	19	O
1048	]	O
1048	.	O
1048	[SEP]	O
1049	[CLS]	O
1049	as	O
1049	a	O
1049	result	O
1049	,	O
1049	the	O
1049	values	O
1049	of	O
1049	the	O
1049	au	B-PK
1049	##c	I-PK
1049	over	I-PK
1049	the	I-PK
1049	first	I-PK
1049	2	I-PK
1049	-	I-PK
1049	h	I-PK
1049	after	I-PK
1049	glucose	I-PK
1049	challenge	I-PK
1049	(	I-PK
1049	g	I-PK
1049	##au	I-PK
1049	##c	I-PK
1049	##0	I-PK
1049	-	I-PK
1049	2	I-PK
1049	)	I-PK
1049	in	O
1049	the	O
1049	g	O
1049	##l	O
1049	-	O
1049	treated	O
1049	rats	O
1049	were	O
1049	significantly	O
1049	less	O
1049	than	O
1049	that	O
1049	of	O
1049	the	O
1049	controls	O
1049	(	O
1049	210	O
1049	.	O
1049	53	O
1049	±	O
1049	5	O
1049	.	O
1049	15	O
1049	vs	O
1049	.	O
1049	203	O
1049	.	O
1049	08	O
1049	±	O
1049	4	O
1049	.	O
1049	33	O
1049	mg	O
1049	/	O
1049	d	O
1049	##l	O
1049	/	O
1049	min	O
1049	,	O
1049	p	O
1049	=	O
1049	0	O
1049	.	O
1049	02	O
1049	,	O
1049	n	O
1049	=	O
1049	6	O
1049	,	O
1049	figure	O
1049	1	O
1049	##g	O
1049	)	O
1049	,	O
1049	and	O
1049	the	O
1049	quick	O
1049	##i	O
1049	values	O
1049	in	O
1049	the	O
1049	g	O
1049	##l	O
1049	-	O
1049	treated	O
1049	rats	O
1049	were	O
1049	significantly	O
1049	less	O
1049	than	O
1049	that	O
1049	in	O
1049	the	O
1049	control	O
1049	rats	O
1049	(	O
1049	3	O
1049	.	O
1049	40	O
1049	±	O
1049	0	O
1049	.	O
1049	28	O
1049	vs	O
1049	.	O
1049	3	O
1049	.	O
1049	01	O
1049	±	O
1049	0	O
1049	.	O
1049	12	O
1049	,	O
1049	p	O
1049	=	O
1049	0	O
1049	.	O
1049	04	O
1049	,	O
1049	n	O
1049	=	O
1049	6	O
1049	,	O
1049	figure	O
1049	1	O
1049	##h	O
1049	)	O
1049	.	O
1049	[SEP]	O
1050	[CLS]	O
1050	as	O
1050	shown	O
1050	in	O
1050	figure	O
1050	2	O
1050	,	O
1050	the	O
1050	relative	O
1050	levels	O
1050	of	O
1050	total	O
1050	a	O
1050	##kt	O
1050	(	O
1050	0	O
1050	.	O
1050	44	O
1050	±	O
1050	0	O
1050	.	O
1050	09	O
1050	vs	O
1050	.	O
1050	0	O
1050	.	O
1050	84	O
1050	±	O
1050	0	O
1050	.	O
1050	11	O
1050	,	O
1050	p	O
1050	=	O
1050	0	O
1050	.	O
1050	00	O
1050	##1	O
1050	,	O
1050	n	O
1050	=	O
1050	4	O
1050	,	O
1050	figure	O
1050	2	O
1050	##e	O
1050	and	O
1050	f	O
1050	)	O
1050	and	O
1050	p	O
1050	##hos	O
1050	##ph	O
1050	##ory	O
1050	##lated	O
1050	a	O
1050	##kt	O
1050	308	O
1050	(	O
1050	0	O
1050	.	O
1050	29	O
1050	±	O
1050	0	O
1050	.	O
1050	17	O
1050	vs	O
1050	.	O
1050	0	O
1050	.	O
1050	74	O
1050	±	O
1050	0	O
1050	.	O
1050	10	O
1050	,	O
1050	p	O
1050	=	O
1050	0	O
1050	.	O
1050	00	O
1050	##5	O
1050	,	O
1050	n	O
1050	=	O
1050	4	O
1050	,	O
1050	figure	O
1050	2	O
1050	##e	O
1050	and	O
1050	g	O
1050	)	O
1050	,	O
1050	but	O
1050	not	O
1050	a	O
1050	##kt	O
1050	47	O
1050	##3	O
1050	(	O
1050	figure	O
1050	2	O
1050	##e	O
1050	and	O
1050	h	O
1050	)	O
1050	in	O
1050	the	O
1050	muscles	O
1050	form	O
1050	the	O
1050	g	O
1050	##l	O
1050	-	O
1050	treated	O
1050	rats	O
1050	were	O
1050	significantly	O
1050	higher	O
1050	than	O
1050	that	O
1050	in	O
1050	the	O
1050	controls	O
1050	.	O
1050	[SEP]	O
1051	[CLS]	O
1051	the	O
1051	area	B-PK
1051	under	I-PK
1051	the	I-PK
1051	curve	I-PK
1051	(	I-PK
1051	au	I-PK
1051	##c	I-PK
1051	)	I-PK
1051	,	O
1051	maximum	B-PK
1051	plasma	I-PK
1051	concentration	I-PK
1051	(	I-PK
1051	cm	I-PK
1051	##ax	I-PK
1051	)	I-PK
1051	,	O
1051	and	O
1051	time	B-PK
1051	needed	I-PK
1051	to	I-PK
1051	reach	I-PK
1051	the	I-PK
1051	maximum	I-PK
1051	plasma	I-PK
1051	concentration	I-PK
1051	(	I-PK
1051	t	I-PK
1051	##max	I-PK
1051	)	I-PK
1051	were	O
1051	determined	O
1051	by	O
1051	the	O
1051	software	O
1051	.	O
1051	[SEP]	O
1052	[CLS]	O
1052	the	O
1052	half	B-PK
1052	-	I-PK
1052	life	I-PK
1052	(	I-PK
1052	t	I-PK
1052	##1	I-PK
1052	/	I-PK
1052	2	I-PK
1052	)	I-PK
1052	of	O
1052	the	O
1052	drug	O
1052	was	O
1052	calculated	O
1052	by	O
1052	use	O
1052	of	O
1052	the	O
1052	relationship	O
1052	t	O
1052	##1	O
1052	/	O
1052	2	O
1052	=	O
1052	0	O
1052	.	O
1052	69	O
1052	##3	O
1052	/	O
1052	k	O
1052	##el	O
1052	.	O
1052	[SEP]	O
1053	[CLS]	O
1053	the	O
1053	elimination	B-PK
1053	rate	I-PK
1053	constant	I-PK
1053	(	I-PK
1053	k	I-PK
1053	##el	I-PK
1053	)	I-PK
1053	was	O
1053	obtained	O
1053	from	O
1053	the	O
1053	terminal	O
1053	slope	O
1053	by	O
1053	use	O
1053	of	O
1053	re	O
1053	##gression	O
1053	analysis	O
1053	.	O
1053	[SEP]	O
1054	[CLS]	O
1054	con	O
1054	##com	O
1054	##ita	O
1054	##nt	O
1054	can	O
1054	##na	O
1054	##bid	O
1054	##iol	O
1054	had	O
1054	little	O
1054	effect	O
1054	on	O
1054	c	O
1054	##lo	O
1054	##ba	O
1054	##zam	O
1054	exposure	O
1054	(	O
1054	maximum	B-PK
1054	concentration	I-PK
1054	[	I-PK
1054	cm	I-PK
1054	##ax	I-PK
1054	]	I-PK
1054	and	O
1054	area	B-PK
1054	under	I-PK
1054	the	I-PK
1054	concentration	I-PK
1054	‐	I-PK
1054	time	I-PK
1054	curve	I-PK
1054	[	I-PK
1054	au	I-PK
1054	##c	I-PK
1054	]	I-PK
1054	,	O
1054	1	O
1054	.	O
1054	2	O
1054	‐	O
1054	fold	O
1054	)	O
1054	,	O
1054	n	O
1054	‐	O
1054	des	O
1054	##met	O
1054	##hyl	O
1054	##c	O
1054	##lo	O
1054	##ba	O
1054	##zam	O
1054	exposure	O
1054	increased	O
1054	(	O
1054	cm	B-PK
1054	##ax	I-PK
1054	and	O
1054	au	B-PK
1054	##c	I-PK
1054	,	O
1054	3	O
1054	.	O
1054	4	O
1054	‐	O
1054	fold	O
1054	)	O
1054	,	O
1054	stir	O
1054	##ip	O
1054	##ent	O
1054	##ol	O
1054	exposure	O
1054	increased	O
1054	slightly	O
1054	(	O
1054	cm	B-PK
1054	##ax	I-PK
1054	,	O
1054	1	O
1054	.	O
1054	3	O
1054	‐	O
1054	fold	O
1054	;	O
1054	au	B-PK
1054	##c	I-PK
1054	,	O
1054	1	O
1054	.	O
1054	6	O
1054	‐	O
1054	fold	O
1054	)	O
1054	,	O
1054	while	O
1054	no	O
1054	clinical	O
1054	##ly	O
1054	relevant	O
1054	effect	O
1054	on	O
1054	v	O
1054	##al	O
1054	##p	O
1054	##roa	O
1054	##te	O
1054	exposure	O
1054	was	O
1054	observed	O
1054	.	O
1054	[SEP]	O
1055	[CLS]	O
1055	con	O
1055	##com	O
1055	##ita	O
1055	##nt	O
1055	c	O
1055	##lo	O
1055	##ba	O
1055	##zam	O
1055	with	O
1055	can	O
1055	##na	O
1055	##bid	O
1055	##iol	O
1055	increased	O
1055	7	O
1055	‐	O
1055	oh	O
1055	‐	O
1055	c	O
1055	##b	O
1055	##d	O
1055	exposure	O
1055	(	O
1055	cm	B-PK
1055	##ax	I-PK
1055	,	O
1055	1	O
1055	.	O
1055	7	O
1055	‐	O
1055	fold	O
1055	;	O
1055	au	B-PK
1055	##c	I-PK
1055	,	O
1055	1	O
1055	.	O
1055	5	O
1055	‐	O
1055	fold	O
1055	)	O
1055	,	O
1055	without	O
1055	notable	O
1055	7	O
1055	‐	O
1055	co	O
1055	##oh	O
1055	‐	O
1055	c	O
1055	##b	O
1055	##d	O
1055	or	O
1055	can	O
1055	##na	O
1055	##bid	O
1055	##iol	O
1055	increases	O
1055	.	O
1055	[SEP]	O
1056	[CLS]	O
1056	in	O
1056	patients	O
1056	,	O
1056	con	O
1056	##com	O
1056	##ita	O
1056	##nt	O
1056	administration	O
1056	of	O
1056	can	O
1056	##na	O
1056	##bid	O
1056	##iol	O
1056	with	O
1056	c	O
1056	##lo	O
1056	##ba	O
1056	##zam	O
1056	resulted	O
1056	in	O
1056	an	O
1056	increase	O
1056	in	O
1056	the	O
1056	plasma	O
1056	concentration	O
1056	of	O
1056	n	O
1056	‐	O
1056	c	O
1056	##l	O
1056	##b	O
1056	##30	O
1056	,	O
1056	31	O
1056	,	O
1056	32	O
1056	often	O
1056	associated	O
1056	with	O
1056	increased	O
1056	se	O
1056	##dation	O
1056	,	O
1056	a	O
1056	recognized	O
1056	adverse	O
1056	event	O
1056	(	O
1056	a	O
1056	##e	O
1056	)	O
1056	noted	O
1056	with	O
1056	c	O
1056	##lo	O
1056	##ba	O
1056	##zam	O
1056	administration	O
1056	for	O
1056	the	O
1056	treatment	O
1056	of	O
1056	l	O
1056	##gs	O
1056	.	O
1056	33	O
1056	increases	O
1056	in	O
1056	liver	O
1056	trans	O
1056	##ami	O
1056	##nas	O
1056	##es	O
1056	are	O
1056	more	O
1056	common	O
1056	in	O
1056	patients	O
1056	who	O
1056	are	O
1056	taking	O
1056	can	O
1056	##na	O
1056	##bid	O
1056	##iol	O
1056	with	O
1056	v	O
1056	##al	O
1056	##p	O
1056	##roa	O
1056	##te	O
1056	(	O
1056	which	O
1056	is	O
1056	associated	O
1056	with	O
1056	he	O
1056	##pa	O
1056	##to	O
1056	##to	O
1056	##xi	O
1056	##city	O
1056	##34	O
1056	)	O
1056	than	O
1056	in	O
1056	those	O
1056	who	O
1056	are	O
1056	not	O
1056	.	O
1056	31	O
1056	given	O
1056	that	O
1056	in	O
1056	these	O
1056	patient	O
1056	trials	O
1056	,	O
1056	the	O
1056	majority	O
1056	of	O
1056	patients	O
1056	were	O
1056	on	O
1056	multiple	O
1056	con	O
1056	##com	O
1056	##ita	O
1056	##nt	O
1056	a	O
1056	##eds	O
1056	,	O
1056	the	O
1056	importance	O
1056	of	O
1056	this	O
1056	phase	O
1056	1	O
1056	trial	O
1056	was	O
1056	evident	O
1056	:	O
1056	to	O
1056	understand	O
1056	the	O
1056	potential	O
1056	for	O
1056	p	O
1056	##k	O
1056	interactions	O
1056	between	O
1056	can	O
1056	##na	O
1056	##bid	O
1056	##iol	O
1056	and	O
1056	3	O
1056	commonly	O
1056	used	O
1056	other	O
1056	a	O
1056	##eds	O
1056	in	O
1056	a	O
1056	healthy	O
1056	population	O
1056	who	O
1056	were	O
1056	not	O
1056	taking	O
1056	other	O
1056	a	O
1056	##eds	O
1056	.	O
1056	[SEP]	O
1057	[CLS]	O
1057	a	O
1057	treatment	O
1057	‐	O
1057	emerge	O
1057	##nt	O
1057	a	O
1057	##e	O
1057	was	O
1057	defined	O
1057	as	O
1057	any	O
1057	event	O
1057	not	O
1057	present	O
1057	before	O
1057	(	O
1057	the	O
1057	first	O
1057	)	O
1057	administration	O
1057	of	O
1057	the	O
1057	imp	O
1057	,	O
1057	or	O
1057	any	O
1057	event	O
1057	already	O
1057	present	O
1057	that	O
1057	worse	O
1057	##ned	O
1057	in	O
1057	either	O
1057	severity	O
1057	or	O
1057	frequency	O
1057	following	O
1057	exposure	O
1057	to	O
1057	the	O
1057	imp	O
1057	.	O
1057	[SEP]	O
1058	[CLS]	O
1058	an	O
1058	a	O
1058	##e	O
1058	that	O
1058	occurred	O
1058	before	O
1058	(	O
1058	the	O
1058	first	O
1058	)	O
1058	administration	O
1058	of	O
1058	the	O
1058	imp	O
1058	was	O
1058	considered	O
1058	a	O
1058	pre	O
1058	##tre	O
1058	##at	O
1058	##ment	O
1058	a	O
1058	##e	O
1058	.	O
1058	[SEP]	O
1059	[CLS]	O
1059	for	O
1059	can	O
1059	##na	O
1059	##bid	O
1059	##iol	O
1059	(	O
1059	and	O
1059	7	O
1059	‐	O
1059	oh	O
1059	‐	O
1059	c	O
1059	##b	O
1059	##d	O
1059	,	O
1059	7	O
1059	‐	O
1059	co	O
1059	##oh	O
1059	‐	O
1059	c	O
1059	##b	O
1059	##d	O
1059	)	O
1059	,	O
1059	c	O
1059	##lo	O
1059	##ba	O
1059	##zam	O
1059	(	O
1059	and	O
1059	n	O
1059	‐	O
1059	c	O
1059	##l	O
1059	##b	O
1059	)	O
1059	,	O
1059	stir	O
1059	##ip	O
1059	##ent	O
1059	##ol	O
1059	,	O
1059	and	O
1059	v	O
1059	##al	O
1059	##p	O
1059	##roa	O
1059	##te	O
1059	(	O
1059	and	O
1059	4	O
1059	‐	O
1059	en	O
1059	##e	O
1059	‐	O
1059	v	O
1059	##pa	O
1059	)	O
1059	,	O
1059	the	O
1059	following	O
1059	p	O
1059	##k	O
1059	parameters	O
1059	were	O
1059	estimated	O
1059	by	O
1059	non	O
1059	##com	O
1059	##par	O
1059	##tment	O
1059	##al	O
1059	methods	O
1059	using	O
1059	p	O
1059	##hoe	O
1059	##ni	O
1059	##x	O
1059	win	O
1059	##non	O
1059	##lin	O
1059	version	O
1059	6	O
1059	.	O
1059	3	O
1059	(	O
1059	c	O
1059	##ert	O
1059	##ara	O
1059	,	O
1059	prince	O
1059	##ton	O
1059	,	O
1059	new	O
1059	jersey	O
1059	)	O
1059	:	O
1059	maximum	B-PK
1059	observed	I-PK
1059	plasma	I-PK
1059	concentration	I-PK
1059	(	I-PK
1059	cm	I-PK
1059	##ax	I-PK
1059	)	I-PK
1059	,	O
1059	time	B-PK
1059	to	I-PK
1059	attain	I-PK
1059	maximum	I-PK
1059	observed	I-PK
1059	plasma	I-PK
1059	concentration	I-PK
1059	,	O
1059	and	O
1059	area	B-PK
1059	under	I-PK
1059	the	I-PK
1059	plasma	I-PK
1059	concentration	I-PK
1059	–	I-PK
1059	time	I-PK
1059	curve	I-PK
1059	over	I-PK
1059	a	I-PK
1059	dos	I-PK
1059	##ing	I-PK
1059	interval	I-PK
1059	,	O
1059	where	O
1059	ta	O
1059	##u	O
1059	is	O
1059	the	O
1059	dos	O
1059	##ing	O
1059	interval	O
1059	(	O
1059	au	B-PK
1059	##ct	I-PK
1059	##au	I-PK
1059	)	O
1059	.	O
1059	[SEP]	O
1060	[CLS]	O
1060	seventy	O
1060	subjects	O
1060	completed	O
1060	the	O
1060	trial	O
1060	,	O
1060	and	O
1060	7	O
1060	subjects	O
1060	were	O
1060	withdrawn	O
1060	—	O
1060	6	O
1060	were	O
1060	due	O
1060	to	O
1060	an	O
1060	a	O
1060	##e	O
1060	and	O
1060	1	O
1060	withdrew	O
1060	consent	O
1060	to	O
1060	participate	O
1060	.	O
1060	[SEP]	O
1061	[CLS]	O
1061	(	O
1061	e	O
1061	)	O
1061	d	O
1061	##di	O
1061	v	O
1061	##al	O
1061	##p	O
1061	##roa	O
1061	##te	O
1061	.	O
1061	[SEP]	O
1062	[CLS]	O
1062	(	O
1062	f	O
1062	)	O
1062	the	O
1062	effect	O
1062	of	O
1062	con	O
1062	##com	O
1062	##ita	O
1062	##nt	O
1062	administration	O
1062	of	O
1062	750	O
1062	mg	O
1062	of	O
1062	v	O
1062	##al	O
1062	##p	O
1062	##roa	O
1062	##te	O
1062	,	O
1062	on	O
1062	plasma	O
1062	concentrations	O
1062	of	O
1062	(	O
1062	i	O
1062	)	O
1062	can	O
1062	##na	O
1062	##bid	O
1062	##iol	O
1062	,	O
1062	(	O
1062	ii	O
1062	)	O
1062	7	O
1062	‐	O
1062	oh	O
1062	‐	O
1062	c	O
1062	##b	O
1062	##d	O
1062	,	O
1062	and	O
1062	(	O
1062	ii	O
1062	##i	O
1062	)	O
1062	7	O
1062	‐	O
1062	co	O
1062	##oh	O
1062	‐	O
1062	c	O
1062	##b	O
1062	##d	O
1062	(	O
1062	arithmetic	O
1062	mean	O
1062	±	O
1062	s	O
1062	##d	O
1062	[	O
1062	lower	O
1062	tail	O
1062	is	O
1062	not	O
1062	shown	O
1062	if	O
1062	greater	O
1062	than	O
1062	mean	O
1062	value	O
1062	]	O
1062	)	O
1062	.	O
1062	[SEP]	O
1063	[CLS]	O
1063	(	O
1063	i	O
1063	)	O
1063	the	O
1063	effect	O
1063	of	O
1063	con	O
1063	##com	O
1063	##ita	O
1063	##nt	O
1063	administration	O
1063	of	O
1063	750	O
1063	mg	O
1063	of	O
1063	can	O
1063	##na	O
1063	##bid	O
1063	##iol	O
1063	bid	O
1063	on	O
1063	individual	O
1063	and	O
1063	geometric	O
1063	mean	O
1063	steady	O
1063	‐	O
1063	state	O
1063	exposure	O
1063	(	O
1063	top	O
1063	panel	O
1063	:	O
1063	cm	B-PK
1063	##ax	I-PK
1063	;	O
1063	middle	O
1063	panel	O
1063	:	O
1063	au	B-PK
1063	##ct	I-PK
1063	##au	I-PK
1063	;	O
1063	bottom	O
1063	panel	O
1063	:	O
1063	treatment	O
1063	ratios	O
1063	with	O
1063	90	O
1063	%	O
1063	confidence	O
1063	intervals	O
1063	[	O
1063	c	O
1063	##is	O
1063	]	O
1063	)	O
1063	to	O
1063	c	O
1063	##lo	O
1063	##ba	O
1063	##zam	O
1063	and	O
1063	n	O
1063	‐	O
1063	c	O
1063	##l	O
1063	##b	O
1063	.	O
1063	[SEP]	O
1064	[CLS]	O
1064	(	O
1064	ii	O
1064	)	O
1064	the	O
1064	effect	O
1064	of	O
1064	con	O
1064	##com	O
1064	##ita	O
1064	##nt	O
1064	administration	O
1064	of	O
1064	5	O
1064	mg	O
1064	of	O
1064	c	O
1064	##lo	O
1064	##ba	O
1064	##zam	O
1064	bid	O
1064	,	O
1064	on	O
1064	individual	O
1064	and	O
1064	geometric	O
1064	mean	O
1064	steady	O
1064	‐	O
1064	state	O
1064	exposure	O
1064	(	O
1064	top	O
1064	panel	O
1064	:	O
1064	cm	B-PK
1064	##ax	I-PK
1064	;	O
1064	middle	O
1064	panel	O
1064	:	O
1064	au	B-PK
1064	##ct	I-PK
1064	##au	I-PK
1064	;	O
1064	bottom	O
1064	panel	O
1064	:	O
1064	treatment	O
1064	ratios	O
1064	with	O
1064	90	O
1064	%	O
1064	c	O
1064	##i	O
1064	)	O
1064	to	O
1064	can	O
1064	##na	O
1064	##bid	O
1064	##iol	O
1064	,	O
1064	7	O
1064	‐	O
1064	oh	O
1064	‐	O
1064	c	O
1064	##b	O
1064	##d	O
1064	,	O
1064	and	O
1064	7	O
1064	‐	O
1064	co	O
1064	##oh	O
1064	‐	O
1064	c	O
1064	##b	O
1064	##d	O
1064	.	O
1064	[SEP]	O
1065	[CLS]	O
1065	(	O
1065	i	O
1065	)	O
1065	the	O
1065	effect	O
1065	of	O
1065	con	O
1065	##com	O
1065	##ita	O
1065	##nt	O
1065	administration	O
1065	of	O
1065	750	O
1065	mg	O
1065	of	O
1065	can	O
1065	##na	O
1065	##bid	O
1065	##iol	O
1065	bid	O
1065	on	O
1065	individual	O
1065	and	O
1065	geometric	O
1065	mean	O
1065	steady	O
1065	‐	O
1065	state	O
1065	exposure	O
1065	(	O
1065	top	O
1065	panel	O
1065	:	O
1065	cm	B-PK
1065	##ax	I-PK
1065	;	O
1065	middle	O
1065	panel	O
1065	:	O
1065	au	B-PK
1065	##ct	I-PK
1065	##au	I-PK
1065	;	O
1065	bottom	O
1065	panel	O
1065	:	O
1065	treatment	O
1065	ratios	O
1065	with	O
1065	90	O
1065	%	O
1065	c	O
1065	##i	O
1065	)	O
1065	to	O
1065	stir	O
1065	##ip	O
1065	##ent	O
1065	##ol	O
1065	.	O
1065	[SEP]	O
1066	[CLS]	O
1066	(	O
1066	ii	O
1066	)	O
1066	the	O
1066	effect	O
1066	of	O
1066	con	O
1066	##com	O
1066	##ita	O
1066	##nt	O
1066	administration	O
1066	of	O
1066	750	O
1066	mg	O
1066	of	O
1066	stir	O
1066	##ip	O
1066	##ent	O
1066	##ol	O
1066	bid	O
1066	,	O
1066	on	O
1066	individual	O
1066	and	O
1066	geometric	O
1066	mean	O
1066	steady	O
1066	‐	O
1066	state	O
1066	exposure	O
1066	(	O
1066	top	O
1066	panel	O
1066	:	O
1066	cm	B-PK
1066	##ax	I-PK
1066	;	O
1066	middle	O
1066	panel	O
1066	:	O
1066	au	B-PK
1066	##ct	I-PK
1066	##au	I-PK
1066	;	O
1066	bottom	O
1066	panel	O
1066	:	O
1066	treatment	O
1066	ratios	O
1066	with	O
1066	90	O
1066	%	O
1066	c	O
1066	##i	O
1066	)	O
1066	to	O
1066	can	O
1066	##na	O
1066	##bid	O
1066	##iol	O
1066	,	O
1066	7	O
1066	‐	O
1066	oh	O
1066	‐	O
1066	c	O
1066	##b	O
1066	##d	O
1066	,	O
1066	and	O
1066	7	O
1066	‐	O
1066	co	O
1066	##oh	O
1066	‐	O
1066	c	O
1066	##b	O
1066	##d	O
1066	.	O
1066	[SEP]	O
1067	[CLS]	O
1067	(	O
1067	i	O
1067	)	O
1067	the	O
1067	effect	O
1067	of	O
1067	con	O
1067	##com	O
1067	##ita	O
1067	##nt	O
1067	administration	O
1067	of	O
1067	750	O
1067	mg	O
1067	of	O
1067	can	O
1067	##na	O
1067	##bid	O
1067	##iol	O
1067	bid	O
1067	on	O
1067	individual	O
1067	and	O
1067	geometric	O
1067	mean	O
1067	steady	O
1067	‐	O
1067	state	O
1067	exposure	O
1067	(	O
1067	top	O
1067	panel	O
1067	:	O
1067	cm	B-PK
1067	##ax	I-PK
1067	;	O
1067	middle	O
1067	panel	O
1067	:	O
1067	au	B-PK
1067	##ct	I-PK
1067	##au	I-PK
1067	;	O
1067	bottom	O
1067	panel	O
1067	:	O
1067	treatment	O
1067	ratios	O
1067	with	O
1067	90	O
1067	%	O
1067	c	O
1067	##i	O
1067	)	O
1067	to	O
1067	v	O
1067	##al	O
1067	##p	O
1067	##roa	O
1067	##te	O
1067	.	O
1067	[SEP]	O
1068	[CLS]	O
1068	(	O
1068	ii	O
1068	)	O
1068	the	O
1068	effect	O
1068	of	O
1068	con	O
1068	##com	O
1068	##ita	O
1068	##nt	O
1068	administration	O
1068	of	O
1068	750	O
1068	mg	O
1068	of	O
1068	v	O
1068	##al	O
1068	##p	O
1068	##roa	O
1068	##te	O
1068	bid	O
1068	on	O
1068	individual	O
1068	and	O
1068	geometric	O
1068	mean	O
1068	steady	O
1068	‐	O
1068	state	O
1068	exposure	O
1068	(	O
1068	top	O
1068	panel	O
1068	:	O
1068	cm	B-PK
1068	##ax	I-PK
1068	;	O
1068	middle	O
1068	panel	O
1068	:	O
1068	au	B-PK
1068	##ct	I-PK
1068	##au	I-PK
1068	;	O
1068	bottom	O
1068	panel	O
1068	:	O
1068	treatment	O
1068	ratios	O
1068	with	O
1068	90	O
1068	%	O
1068	c	O
1068	##i	O
1068	)	O
1068	to	O
1068	can	O
1068	##na	O
1068	##bid	O
1068	##iol	O
1068	,	O
1068	7	O
1068	‐	O
1068	oh	O
1068	‐	O
1068	c	O
1068	##b	O
1068	##d	O
1068	,	O
1068	and	O
1068	7	O
1068	‐	O
1068	co	O
1068	##oh	O
1068	‐	O
1068	c	O
1068	##b	O
1068	##d	O
1068	.	O
1068	[SEP]	O
1069	[CLS]	O
1069	7	O
1069	‐	O
1069	oh	O
1069	‐	O
1069	c	O
1069	##b	O
1069	##d	O
1069	,	O
1069	7	O
1069	‐	O
1069	h	O
1069	##ydro	O
1069	##xy	O
1069	‐	O
1069	can	O
1069	##na	O
1069	##bid	O
1069	##iol	O
1069	;	O
1069	7	O
1069	‐	O
1069	co	O
1069	##oh	O
1069	‐	O
1069	c	O
1069	##b	O
1069	##d	O
1069	,	O
1069	7	O
1069	‐	O
1069	car	O
1069	##box	O
1069	##y	O
1069	‐	O
1069	can	O
1069	##na	O
1069	##bid	O
1069	##iol	O
1069	;	O
1069	au	B-PK
1069	##ct	I-PK
1069	##au	I-PK
1069	,	O
1069	area	B-PK
1069	under	I-PK
1069	the	I-PK
1069	plasma	I-PK
1069	concentration	I-PK
1069	–	I-PK
1069	time	I-PK
1069	curve	I-PK
1069	over	I-PK
1069	a	I-PK
1069	dos	I-PK
1069	##ing	I-PK
1069	interval	I-PK
1069	,	O
1069	where	O
1069	ta	O
1069	##u	O
1069	is	O
1069	the	O
1069	dos	O
1069	##ing	O
1069	interval	O
1069	;	O
1069	c	O
1069	##i	O
1069	,	O
1069	confidence	O
1069	interval	O
1069	;	O
1069	cm	B-PK
1069	##ax	I-PK
1069	,	I-PK
1069	maximum	I-PK
1069	concentration	I-PK
1069	;	O
1069	d	O
1069	##di	O
1069	,	O
1069	drug	O
1069	‐	O
1069	drug	O
1069	interaction	O
1069	;	O
1069	n	O
1069	‐	O
1069	c	O
1069	##l	O
1069	##b	O
1069	,	O
1069	n	O
1069	‐	O
1069	des	O
1069	##met	O
1069	##hyl	O
1069	##c	O
1069	##lo	O
1069	##ba	O
1069	##zam	O
1069	;	O
1069	s	O
1069	##d	O
1069	,	O
1069	standard	O
1069	de	O
1069	##viation	O
1069	.	O
1069	[SEP]	O
1070	[CLS]	O
1070	following	O
1070	repeated	O
1070	con	O
1070	##com	O
1070	##ita	O
1070	##nt	O
1070	dos	O
1070	##ing	O
1070	of	O
1070	can	O
1070	##na	O
1070	##bid	O
1070	##iol	O
1070	(	O
1070	750	O
1070	mg	O
1070	bid	O
1070	)	O
1070	with	O
1070	c	O
1070	##lo	O
1070	##ba	O
1070	##zam	O
1070	(	O
1070	5	O
1070	mg	O
1070	bid	O
1070	)	O
1070	for	O
1070	7	O
1070	days	O
1070	(	O
1070	no	O
1070	t	O
1070	##it	O
1070	##ration	O
1070	)	O
1070	and	O
1070	14	O
1070	days	O
1070	(	O
1070	10	O
1070	‐	O
1070	day	O
1070	t	O
1070	##it	O
1070	##ration	O
1070	)	O
1070	,	O
1070	there	O
1070	was	O
1070	a	O
1070	slight	O
1070	increase	O
1070	in	O
1070	the	O
1070	exposure	O
1070	of	O
1070	c	O
1070	##lo	O
1070	##ba	O
1070	##zam	O
1070	with	O
1070	the	O
1070	point	O
1070	estimate	O
1070	for	O
1070	the	O
1070	t	O
1070	##r	O
1070	for	O
1070	cm	B-PK
1070	##ax	I-PK
1070	of	O
1070	1	O
1070	.	O
1070	20	O
1070	(	O
1070	90	O
1070	%	O
1070	c	O
1070	##i	O
1070	,	O
1070	1	O
1070	.	O
1070	05	O
1070	–	O
1070	1	O
1070	.	O
1070	38	O
1070	)	O
1070	and	O
1070	for	O
1070	au	B-PK
1070	##ct	I-PK
1070	##au	I-PK
1070	of	O
1070	1	O
1070	.	O
1070	21	O
1070	(	O
1070	90	O
1070	%	O
1070	c	O
1070	##i	O
1070	,	O
1070	1	O
1070	.	O
1070	05	O
1070	–	O
1070	1	O
1070	.	O
1070	39	O
1070	)	O
1070	.	O
1070	[SEP]	O
1071	[CLS]	O
1071	there	O
1071	was	O
1071	an	O
1071	increase	O
1071	in	O
1071	systemic	O
1071	exposure	O
1071	to	O
1071	n	O
1071	‐	O
1071	c	O
1071	##l	O
1071	##b	O
1071	,	O
1071	whereby	O
1071	the	O
1071	geometric	O
1071	mean	O
1071	cm	B-PK
1071	##ax	I-PK
1071	increased	O
1071	3	O
1071	.	O
1071	39	O
1071	‐	O
1071	fold	O
1071	(	O
1071	90	O
1071	%	O
1071	c	O
1071	##i	O
1071	,	O
1071	2	O
1071	.	O
1071	61	O
1071	–	O
1071	4	O
1071	.	O
1071	39	O
1071	)	O
1071	and	O
1071	au	B-PK
1071	##ct	I-PK
1071	##au	I-PK
1071	increased	O
1071	3	O
1071	.	O
1071	38	O
1071	‐	O
1071	fold	O
1071	(	O
1071	90	O
1071	%	O
1071	c	O
1071	##i	O
1071	,	O
1071	2	O
1071	.	O
1071	62	O
1071	–	O
1071	4	O
1071	.	O
1071	36	O
1071	)	O
1071	.	O
1071	[SEP]	O
1072	[CLS]	O
1072	following	O
1072	21	O
1072	days	O
1072	of	O
1072	con	O
1072	##com	O
1072	##ita	O
1072	##nt	O
1072	administration	O
1072	of	O
1072	5	O
1072	mg	O
1072	of	O
1072	c	O
1072	##lo	O
1072	##ba	O
1072	##zam	O
1072	bid	O
1072	with	O
1072	750	O
1072	mg	O
1072	of	O
1072	can	O
1072	##na	O
1072	##bid	O
1072	##iol	O
1072	bid	O
1072	,	O
1072	there	O
1072	was	O
1072	a	O
1072	slight	O
1072	increase	O
1072	in	O
1072	can	O
1072	##na	O
1072	##bid	O
1072	##iol	O
1072	exposure	O
1072	(	O
1072	t	O
1072	##r	O
1072	for	O
1072	can	O
1072	##na	O
1072	##bid	O
1072	##iol	O
1072	cm	B-PK
1072	##ax	I-PK
1072	and	O
1072	au	B-PK
1072	##ct	I-PK
1072	##au	I-PK
1072	;	O
1072	1	O
1072	.	O
1072	34	O
1072	[	O
1072	90	O
1072	%	O
1072	c	O
1072	##i	O
1072	,	O
1072	0	O
1072	.	O
1072	93	O
1072	–	O
1072	1	O
1072	.	O
1072	95	O
1072	]	O
1072	and	O
1072	1	O
1072	.	O
1072	30	O
1072	[	O
1072	90	O
1072	%	O
1072	c	O
1072	##i	O
1072	,	O
1072	1	O
1072	.	O
1072	00	O
1072	–	O
1072	1	O
1072	.	O
1072	70	O
1072	]	O
1072	respectively	O
1072	)	O
1072	and	O
1072	for	O
1072	7	O
1072	‐	O
1072	co	O
1072	##oh	O
1072	‐	O
1072	c	O
1072	##b	O
1072	##d	O
1072	(	O
1072	cm	B-PK
1072	##ax	I-PK
1072	t	O
1072	##r	O
1072	1	O
1072	.	O
1072	35	O
1072	[	O
1072	90	O
1072	%	O
1072	c	O
1072	##i	O
1072	,	O
1072	1	O
1072	.	O
1072	12	O
1072	–	O
1072	1	O
1072	.	O
1072	63	O
1072	]	O
1072	and	O
1072	au	B-PK
1072	##ct	I-PK
1072	##au	I-PK
1072	t	O
1072	##r	O
1072	1	O
1072	.	O
1072	31	O
1072	[	O
1072	90	O
1072	%	O
1072	c	O
1072	##i	O
1072	,	O
1072	1	O
1072	.	O
1072	04	O
1072	–	O
1072	1	O
1072	.	O
1072	64	O
1072	]	O
1072	)	O
1072	.	O
1072	[SEP]	O
1073	[CLS]	O
1073	the	O
1073	t	O
1073	##r	O
1073	point	O
1073	estimate	O
1073	for	O
1073	cm	B-PK
1073	##ax	I-PK
1073	of	O
1073	7	O
1073	‐	O
1073	oh	O
1073	‐	O
1073	c	O
1073	##b	O
1073	##d	O
1073	increased	O
1073	by	O
1073	1	O
1073	.	O
1073	73	O
1073	‐	O
1073	fold	O
1073	(	O
1073	90	O
1073	%	O
1073	c	O
1073	##i	O
1073	,	O
1073	1	O
1073	.	O
1073	36	O
1073	–	O
1073	2	O
1073	.	O
1073	20	O
1073	)	O
1073	and	O
1073	au	B-PK
1073	##ct	I-PK
1073	##au	I-PK
1073	increased	O
1073	with	O
1073	a	O
1073	t	O
1073	##r	O
1073	of	O
1073	1	O
1073	.	O
1073	47	O
1073	(	O
1073	90	O
1073	%	O
1073	c	O
1073	##i	O
1073	,	O
1073	1	O
1073	.	O
1073	26	O
1073	–	O
1073	1	O
1073	.	O
1073	70	O
1073	)	O
1073	.	O
1073	[SEP]	O
1074	[CLS]	O
1074	there	O
1074	were	O
1074	also	O
1074	no	O
1074	obvious	O
1074	effects	O
1074	on	O
1074	the	O
1074	exposure	O
1074	to	O
1074	the	O
1074	active	O
1074	meta	O
1074	##bol	O
1074	##ite	O
1074	7	O
1074	‐	O
1074	oh	O
1074	‐	O
1074	c	O
1074	##b	O
1074	##d	O
1074	with	O
1074	cm	B-PK
1074	##ax	I-PK
1074	t	O
1074	##r	O
1074	0	O
1074	.	O
1074	97	O
1074	(	O
1074	90	O
1074	%	O
1074	c	O
1074	##i	O
1074	,	O
1074	0	O
1074	.	O
1074	67	O
1074	–	O
1074	1	O
1074	.	O
1074	41	O
1074	)	O
1074	and	O
1074	au	B-PK
1074	##ct	I-PK
1074	##au	I-PK
1074	t	O
1074	##r	O
1074	1	O
1074	.	O
1074	22	O
1074	(	O
1074	90	O
1074	%	O
1074	c	O
1074	##i	O
1074	,	O
1074	0	O
1074	.	O
1074	96	O
1074	–	O
1074	1	O
1074	.	O
1074	55	O
1074	)	O
1074	or	O
1074	to	O
1074	7	O
1074	‐	O
1074	co	O
1074	##oh	O
1074	‐	O
1074	c	O
1074	##b	O
1074	##d	O
1074	with	O
1074	cm	B-PK
1074	##ax	I-PK
1074	t	O
1074	##r	O
1074	1	O
1074	.	O
1074	25	O
1074	‐	O
1074	fold	O
1074	(	O
1074	90	O
1074	%	O
1074	c	O
1074	##i	O
1074	,	O
1074	1	O
1074	.	O
1074	07	O
1074	–	O
1074	1	O
1074	.	O
1074	45	O
1074	)	O
1074	and	O
1074	au	B-PK
1074	##ct	I-PK
1074	##au	I-PK
1074	t	O
1074	##r	O
1074	1	O
1074	.	O
1074	22	O
1074	(	O
1074	90	O
1074	%	O
1074	c	O
1074	##i	O
1074	,	O
1074	0	O
1074	.	O
1074	96	O
1074	–	O
1074	1	O
1074	.	O
1074	55	O
1074	)	O
1074	(	O
1074	figure	O
1074	4	O
1074	##c	O
1074	(	O
1074	ii	O
1074	)	O
1074	)	O
1074	.	O
1074	[SEP]	O
1075	[CLS]	O
1075	there	O
1075	were	O
1075	3	O
1075	withdrawal	O
1075	##s	O
1075	due	O
1075	to	O
1075	a	O
1075	##es	O
1075	in	O
1075	subjects	O
1075	in	O
1075	the	O
1075	can	O
1075	##na	O
1075	##bid	O
1075	##iol	O
1075	(	O
1075	victim	O
1075	)	O
1075	+	O
1075	c	O
1075	##lo	O
1075	##ba	O
1075	##zam	O
1075	(	O
1075	per	O
1075	##pet	O
1075	##rator	O
1075	)	O
1075	subgroup	O
1075	:	O
1075	a	O
1075	moderate	O
1075	a	O
1075	##e	O
1075	of	O
1075	a	O
1075	##v	O
1075	block	O
1075	first	O
1075	degree	O
1075	was	O
1075	recorded	O
1075	for	O
1075	1	O
1075	(	O
1075	8	O
1075	.	O
1075	3	O
1075	%	O
1075	)	O
1075	subject	O
1075	that	O
1075	occurred	O
1075	while	O
1075	receiving	O
1075	can	O
1075	##na	O
1075	##bid	O
1075	##iol	O
1075	alone	O
1075	(	O
1075	no	O
1075	t	O
1075	##it	O
1075	##ration	O
1075	)	O
1075	and	O
1075	2	O
1075	severe	O
1075	a	O
1075	##es	O
1075	of	O
1075	r	O
1075	##ash	O
1075	p	O
1075	##ap	O
1075	##ular	O
1075	(	O
1075	without	O
1075	m	O
1075	##uc	O
1075	##osa	O
1075	##l	O
1075	involvement	O
1075	)	O
1075	were	O
1075	reported	O
1075	in	O
1075	2	O
1075	(	O
1075	16	O
1075	.	O
1075	7	O
1075	%	O
1075	)	O
1075	subjects	O
1075	during	O
1075	the	O
1075	first	O
1075	2	O
1075	days	O
1075	of	O
1075	receiving	O
1075	can	O
1075	##na	O
1075	##bid	O
1075	##iol	O
1075	(	O
1075	no	O
1075	t	O
1075	##it	O
1075	##ration	O
1075	)	O
1075	+	O
1075	c	O
1075	##lo	O
1075	##ba	O
1075	##zam	O
1075	.	O
1075	[SEP]	O
1076	[CLS]	O
1076	details	O
1076	of	O
1076	the	O
1076	r	O
1076	##ash	O
1076	##es	O
1076	,	O
1076	including	O
1076	severity	O
1076	of	O
1076	the	O
1076	a	O
1076	##e	O
1076	and	O
1076	action	O
1076	taken	O
1076	,	O
1076	as	O
1076	well	O
1076	as	O
1076	details	O
1076	of	O
1076	treatment	O
1076	administered	O
1076	and	O
1076	whether	O
1076	any	O
1076	can	O
1076	##na	O
1076	##bid	O
1076	##iol	O
1076	t	O
1076	##it	O
1076	##ration	O
1076	period	O
1076	was	O
1076	included	O
1076	,	O
1076	are	O
1076	provided	O
1076	in	O
1076	table	O
1076	5	O
1076	.	O
1076	[SEP]	O
1077	[CLS]	O
1077	one	O
1077	subject	O
1077	experienced	O
1077	a	O
1077	moderate	O
1077	a	O
1077	##e	O
1077	of	O
1077	first	O
1077	‐	O
1077	degree	O
1077	at	O
1077	##rio	O
1077	##vent	O
1077	##ric	O
1077	##ular	O
1077	block	O
1077	(	O
1077	p	O
1077	##r	O
1077	interval	O
1077	pro	O
1077	##long	O
1077	##ation	O
1077	of	O
1077	149	O
1077	–	O
1077	152	O
1077	mill	O
1077	##ise	O
1077	##con	O
1077	##ds	O
1077	relative	O
1077	to	O
1077	base	O
1077	##line	O
1077	)	O
1077	on	O
1077	day	O
1077	8	O
1077	while	O
1077	taking	O
1077	can	O
1077	##na	O
1077	##bid	O
1077	##iol	O
1077	alone	O
1077	(	O
1077	no	O
1077	t	O
1077	##it	O
1077	##ration	O
1077	)	O
1077	.	O
1077	[SEP]	O
1078	[CLS]	O
1078	although	O
1078	the	O
1078	p	O
1078	##r	O
1078	interval	O
1078	had	O
1078	returned	O
1078	to	O
1078	base	O
1078	##line	O
1078	value	O
1078	50	O
1078	minutes	O
1078	later	O
1078	,	O
1078	the	O
1078	a	O
1078	##e	O
1078	was	O
1078	classified	O
1078	as	O
1078	ongoing	O
1078	at	O
1078	the	O
1078	follow	O
1078	‐	O
1078	up	O
1078	visit	O
1078	(	O
1078	1	O
1078	week	O
1078	later	O
1078	)	O
1078	,	O
1078	when	O
1078	the	O
1078	p	O
1078	##r	O
1078	interval	O
1078	was	O
1078	153	O
1078	mill	O
1078	##ise	O
1078	##con	O
1078	##ds	O
1078	above	O
1078	base	O
1078	##line	O
1078	.	O
1078	[SEP]	O
1079	[CLS]	O
1079	an	O
1079	a	O
1079	##e	O
1079	of	O
1079	men	O
1079	##st	O
1079	##ru	O
1079	##al	O
1079	discomfort	O
1079	was	O
1079	reported	O
1079	by	O
1079	1	O
1079	subject	O
1079	on	O
1079	day	O
1079	8	O
1079	of	O
1079	taking	O
1079	can	O
1079	##na	O
1079	##bid	O
1079	##iol	O
1079	(	O
1079	no	O
1079	t	O
1079	##it	O
1079	##ration	O
1079	;	O
1079	victim	O
1079	)	O
1079	+	O
1079	stir	O
1079	##ip	O
1079	##ent	O
1079	##ol	O
1079	(	O
1079	per	O
1079	##pet	O
1079	##rator	O
1079	)	O
1079	,	O
1079	which	O
1079	was	O
1079	mild	O
1079	in	O
1079	severity	O
1079	and	O
1079	resolved	O
1079	on	O
1079	the	O
1079	same	O
1079	day	O
1079	it	O
1079	appeared	O
1079	with	O
1079	no	O
1079	action	O
1079	taken	O
1079	.	O
1079	[SEP]	O
1080	[CLS]	O
1080	the	O
1080	t	B-PK
1080	##rough	I-PK
1080	drug	I-PK
1080	concentration	I-PK
1080	,	O
1080	defined	O
1080	as	O
1080	the	O
1080	concentration	O
1080	at	O
1080	the	O
1080	end	O
1080	of	O
1080	the	O
1080	dos	O
1080	##ing	O
1080	interval	O
1080	(	O
1080	c	O
1080	##12	O
1080	)	O
1080	,	O
1080	maximum	B-PK
1080	concentration	I-PK
1080	(	I-PK
1080	cm	I-PK
1080	##ax	I-PK
1080	)	I-PK
1080	,	O
1080	time	B-PK
1080	to	I-PK
1080	reach	I-PK
1080	cm	I-PK
1080	##ax	I-PK
1080	(	I-PK
1080	t	I-PK
1080	##max	I-PK
1080	)	I-PK
1080	,	O
1080	and	O
1080	area	B-PK
1080	under	I-PK
1080	the	I-PK
1080	plasma	I-PK
1080	concentration	I-PK
1080	–	I-PK
1080	time	I-PK
1080	curve	I-PK
1080	from	I-PK
1080	0	I-PK
1080	to	I-PK
1080	12	I-PK
1080	h	I-PK
1080	(	I-PK
1080	au	I-PK
1080	##c	I-PK
1080	##0	I-PK
1080	–	I-PK
1080	12	I-PK
1080	##h	I-PK
1080	)	I-PK
1080	for	O
1080	sa	O
1080	##quin	O
1080	##avi	O
1080	##r	O
1080	and	O
1080	r	O
1080	##ito	O
1080	##na	O
1080	##vir	O
1080	,	O
1080	were	O
1080	estimated	O
1080	using	O
1080	non	O
1080	##com	O
1080	##par	O
1080	##tment	O
1080	##al	O
1080	methods	O
1080	using	O
1080	win	O
1080	##non	O
1080	##lin	O
1080	software	O
1080	(	O
1080	version	O
1080	5	O
1080	.	O
1080	2	O
1080	,	O
1080	p	O
1080	##har	O
1080	##sight	O
1080	corporation	O
1080	,	O
1080	mountain	O
1080	view	O
1080	,	O
1080	ca	O
1080	,	O
1080	us	O
1080	##a	O
1080	)	O
1080	for	O
1080	days	O
1080	3	O
1080	,	O
1080	4	O
1080	,	O
1080	7	O
1080	,	O
1080	10	O
1080	,	O
1080	and	O
1080	14	O
1080	.	O
1080	[SEP]	O
1081	[CLS]	O
1081	consistent	O
1081	with	O
1081	the	O
1081	mean	O
1081	plasma	O
1081	concentrations	O
1081	,	O
1081	the	O
1081	highest	O
1081	sa	O
1081	##quin	O
1081	##avi	O
1081	##r	O
1081	mean	O
1081	cm	B-PK
1081	##ax	I-PK
1081	and	O
1081	au	B-PK
1081	##c	I-PK
1081	##0	I-PK
1081	–	I-PK
1081	12	I-PK
1081	##h	I-PK
1081	following	O
1081	administration	O
1081	of	O
1081	sa	O
1081	##quin	O
1081	##avi	O
1081	##r	O
1081	/	O
1081	r	O
1081	##ito	O
1081	##na	O
1081	##vir	O
1081	500	O
1081	/	O
1081	100	O
1081	mg	O
1081	bid	O
1081	was	O
1081	observed	O
1081	on	O
1081	day	O
1081	3	O
1081	(	O
1081	40	O
1081	##30	O
1081	ng	O
1081	/	O
1081	m	O
1081	##l	O
1081	and	O
1081	27	O
1081	,	O
1081	100	O
1081	ng	O
1081	·	O
1081	h	O
1081	/	O
1081	m	O
1081	##l	O
1081	,	O
1081	respectively	O
1081	)	O
1081	and	O
1081	declined	O
1081	on	O
1081	days	O
1081	4	O
1081	and	O
1081	7	O
1081	,	O
1081	with	O
1081	the	O
1081	lowest	O
1081	exposure	O
1081	on	O
1081	day	O
1081	7	O
1081	.	O
1081	[SEP]	O
1082	[CLS]	O
1082	similarly	O
1082	,	O
1082	doubling	O
1082	the	O
1082	dose	O
1082	of	O
1082	sa	O
1082	##quin	O
1082	##avi	O
1082	##r	O
1082	to	O
1082	1000	O
1082	/	O
1082	100	O
1082	mg	O
1082	bid	O
1082	during	O
1082	the	O
1082	second	O
1082	week	O
1082	resulted	O
1082	in	O
1082	higher	O
1082	mean	O
1082	cm	B-PK
1082	##ax	I-PK
1082	and	O
1082	au	B-PK
1082	##c	I-PK
1082	##0	I-PK
1082	–	I-PK
1082	12	I-PK
1082	##h	I-PK
1082	on	O
1082	days	O
1082	10	O
1082	and	O
1082	14	O
1082	with	O
1082	highest	O
1082	cm	B-PK
1082	##ax	I-PK
1082	and	O
1082	au	B-PK
1082	##c	I-PK
1082	##0	I-PK
1082	–	I-PK
1082	12	I-PK
1082	##h	I-PK
1082	on	O
1082	day	O
1082	10	O
1082	(	O
1082	530	O
1082	##0	O
1082	ng	O
1082	/	O
1082	m	O
1082	##l	O
1082	and	O
1082	34	O
1082	,	O
1082	200	O
1082	ng	O
1082	·	O
1082	h	O
1082	/	O
1082	m	O
1082	##l	O
1082	,	O
1082	respectively	O
1082	)	O
1082	.	O
1082	[SEP]	O
1083	[CLS]	O
1083	median	O
1083	time	B-PK
1083	to	I-PK
1083	cm	I-PK
1083	##ax	I-PK
1083	(	I-PK
1083	i	I-PK
1083	.	I-PK
1083	e	I-PK
1083	.	I-PK
1083	,	I-PK
1083	t	I-PK
1083	##max	I-PK
1083	)	I-PK
1083	for	O
1083	sa	O
1083	##quin	O
1083	##avi	O
1083	##r	O
1083	was	O
1083	reached	O
1083	approximately	O
1083	2	O
1083	–	O
1083	4	O
1083	h	O
1083	after	O
1083	dos	O
1083	##ing	O
1083	(	O
1083	table	O
1083	3	O
1083	)	O
1083	.	O
1083	[SEP]	O
1084	[CLS]	O
1084	mean	O
1084	r	O
1084	##ito	O
1084	##na	O
1084	##vir	O
1084	plasma	O
1084	concentrations	O
1084	and	O
1084	mean	O
1084	r	O
1084	##ito	O
1084	##na	O
1084	##vir	O
1084	exposure	O
1084	##s	O
1084	(	O
1084	cm	B-PK
1084	##ax	I-PK
1084	and	O
1084	au	B-PK
1084	##c	I-PK
1084	##0	I-PK
1084	–	I-PK
1084	12	I-PK
1084	##h	I-PK
1084	)	O
1084	flu	O
1084	##ct	O
1084	##uated	O
1084	across	O
1084	study	O
1084	days	O
1084	but	O
1084	were	O
1084	generally	O
1084	similar	O
1084	when	O
1084	considering	O
1084	the	O
1084	inter	O
1084	##ind	O
1084	##iv	O
1084	##id	O
1084	##ual	O
1084	var	O
1084	##iability	O
1084	(	O
1084	table	O
1084	3	O
1084	)	O
1084	.	O
1084	[SEP]	O
1085	[CLS]	O
1085	median	O
1085	t	B-PK
1085	##max	I-PK
1085	was	O
1085	reached	O
1085	approximately	O
1085	3	O
1085	–	O
1085	4	O
1085	h	O
1085	after	O
1085	dos	O
1085	##ing	O
1085	(	O
1085	table	O
1085	3	O
1085	)	O
1085	.	O
1085	[SEP]	O
1086	[CLS]	O
1086	the	O
1086	relationship	O
1086	between	O
1086	sa	O
1086	##quin	O
1086	##avi	O
1086	##r	O
1086	concentration	O
1086	and	O
1086	q	O
1086	##t	O
1086	##c	O
1086	##f	O
1086	was	O
1086	evaluated	O
1086	using	O
1086	cm	B-PK
1086	##ax	I-PK
1086	because	O
1086	a	O
1086	delay	O
1086	in	O
1086	maximum	O
1086	[UNK]	O
1086	compared	O
1086	with	O
1086	maximum	O
1086	sa	O
1086	##quin	O
1086	##avi	O
1086	##r	O
1086	plasma	O
1086	concentrations	O
1086	is	O
1086	observed	O
1086	manifest	O
1086	##ing	O
1086	as	O
1086	a	O
1086	counter	O
1086	-	O
1086	clockwise	O
1086	h	O
1086	##yster	O
1086	##esis	O
1086	(	O
1086	data	O
1086	not	O
1086	shown	O
1086	)	O
1086	.	O
1086	[SEP]	O
1087	[CLS]	O
1087	no	O
1087	strong	O
1087	correlation	O
1087	was	O
1087	observed	O
1087	between	O
1087	the	O
1087	maximum	O
1087	[UNK]	O
1087	and	O
1087	cm	B-PK
1087	##ax	I-PK
1087	of	O
1087	sa	O
1087	##quin	O
1087	##avi	O
1087	##r	O
1087	(	O
1087	fi	O
1087	##g	O
1087	.	O
1087	3	O
1087	)	O
1087	.	O
1087	[SEP]	O
1088	[CLS]	O
1088	one	O
1088	patient	O
1088	discontinued	O
1088	study	O
1088	drug	O
1088	due	O
1088	to	O
1088	go	O
1088	##no	O
1088	##co	O
1088	##cca	O
1088	##l	O
1088	pro	O
1088	##ct	O
1088	##itis	O
1088	which	O
1088	was	O
1088	classified	O
1088	as	O
1088	a	O
1088	serious	O
1088	a	O
1088	##e	O
1088	but	O
1088	was	O
1088	not	O
1088	considered	O
1088	to	O
1088	be	O
1088	drug	O
1088	-	O
1088	related	O
1088	.	O
1088	[SEP]	O
1089	[CLS]	O
1089	the	O
1089	application	O
1089	of	O
1089	bet	O
1089	##ulin	O
1089	##ic	O
1089	acid	O
1089	(	O
1089	b	O
1089	)	O
1089	,	O
1089	a	O
1089	potent	O
1089	anti	O
1089	##ne	O
1089	##op	O
1089	##lastic	O
1089	agent	O
1089	,	O
1089	is	O
1089	limited	O
1089	due	O
1089	to	O
1089	poor	O
1089	bio	B-PK
1089	##ava	I-PK
1089	##ila	I-PK
1089	##bility	I-PK
1089	,	O
1089	short	O
1089	plasma	B-PK
1089	half	I-PK
1089	-	I-PK
1089	life	I-PK
1089	and	O
1089	inappropriate	O
1089	tissue	O
1089	distribution	O
1089	.	O
1089	[SEP]	O
1090	[CLS]	O
1090	later	O
1090	,	O
1090	in	O
1090	v	O
1090	##it	O
1090	##ro	O
1090	cell	O
1090	culture	O
1090	analysis	O
1090	using	O
1090	he	O
1090	##p	O
1090	-	O
1090	g	O
1090	##2	O
1090	cells	O
1090	and	O
1090	con	O
1090	##fo	O
1090	##cal	O
1090	micro	O
1090	##sco	O
1090	##py	O
1090	studies	O
1090	revealed	O
1090	that	O
1090	b	O
1090	##n	O
1090	##p	O
1090	had	O
1090	the	O
1090	highest	O
1090	in	O
1090	##hibition	O
1090	and	O
1090	penetration	O
1090	properties	O
1090	than	O
1090	parent	O
1090	b	O
1090	.	O
1090	oral	O
1090	p	O
1090	##har	O
1090	##ma	O
1090	##co	O
1090	##kin	O
1090	##etics	O
1090	studies	O
1090	using	O
1090	al	O
1090	##bino	O
1090	w	O
1090	##ista	O
1090	##r	O
1090	rats	O
1090	at	O
1090	single	O
1090	100	O
1090	mg	O
1090	dose	O
1090	again	O
1090	exhibited	O
1090	b	O
1090	##n	O
1090	##p	O
1090	had	O
1090	the	O
1090	higher	O
1090	50	O
1090	%	O
1090	of	O
1090	plasma	O
1090	concentration	O
1090	(	O
1090	t	B-PK
1090	##1	I-PK
1090	/	I-PK
1090	2	I-PK
1090	)	O
1090	,	O
1090	a	O
1090	higher	O
1090	maximum	B-PK
1090	plasma	I-PK
1090	concentration	I-PK
1090	(	I-PK
1090	cm	I-PK
1090	##ax	I-PK
1090	)	I-PK
1090	and	O
1090	took	O
1090	longer	O
1090	to	O
1090	reach	O
1090	the	O
1090	maximum	B-PK
1090	plasma	I-PK
1090	concentration	I-PK
1090	(	I-PK
1090	t	I-PK
1090	##max	I-PK
1090	)	I-PK
1090	than	O
1090	parent	O
1090	b	O
1090	.	O
1090	next	O
1090	,	O
1090	our	O
1090	in	O
1090	v	O
1090	##ivo	O
1090	study	O
1090	using	O
1090	ni	O
1090	##tro	O
1090	##so	O
1090	##die	O
1090	##thy	O
1090	##l	O
1090	am	O
1090	##ine	O
1090	(	O
1090	n	O
1090	##dea	O
1090	)	O
1090	-	O
1090	induced	O
1090	h	O
1090	##cc	O
1090	model	O
1090	documented	O
1090	b	O
1090	##n	O
1090	##p	O
1090	decreased	O
1090	in	O
1090	number	O
1090	of	O
1090	nod	O
1090	##ules	O
1090	,	O
1090	restored	O
1090	body	O
1090	weight	O
1090	,	O
1090	o	O
1090	##xi	O
1090	##da	O
1090	##tive	O
1090	stress	O
1090	parameters	O
1090	,	O
1090	liver	O
1090	marker	O
1090	enzymes	O
1090	and	O
1090	his	O
1090	##to	O
1090	##logical	O
1090	architecture	O
1090	than	O
1090	parent	O
1090	b	O
1090	.	O
1090	last	O
1090	##ly	O
1090	,	O
1090	q	O
1090	##rt	O
1090	-	O
1090	p	O
1090	##c	O
1090	##r	O
1090	studies	O
1090	further	O
1090	demonstrated	O
1090	that	O
1090	anti	O
1090	-	O
1090	h	O
1090	##cc	O
1090	properties	O
1090	of	O
1090	b	O
1090	##n	O
1090	##p	O
1090	may	O
1090	be	O
1090	due	O
1090	to	O
1090	over	O
1090	expression	O
1090	of	O
1090	anti	O
1090	##ap	O
1090	##op	O
1090	##to	O
1090	##tic	O
1090	ca	O
1090	##sp	O
1090	##ases	O
1090	i	O
1090	.	O
1090	e	O
1090	.	O
1090	,	O
1090	ca	O
1090	##sp	O
1090	##ase	O
1090	3	O
1090	and	O
1090	8	O
1090	.	O
1090	[SEP]	O
1091	[CLS]	O
1091	this	O
1091	mixture	O
1091	was	O
1091	son	O
1091	##ica	O
1091	##ted	O
1091	for	O
1091	15	O
1091	or	O
1091	30	O
1091	min	O
1091	with	O
1091	addition	O
1091	of	O
1091	12	O
1091	m	O
1091	##l	O
1091	of	O
1091	different	O
1091	concentrations	O
1091	(	O
1091	w	O
1091	/	O
1091	v	O
1091	)	O
1091	of	O
1091	a	O
1091	##que	O
1091	##ous	O
1091	p	O
1091	##oly	O
1091	##vin	O
1091	##yl	O
1091	alcohol	O
1091	(	O
1091	p	O
1091	##va	O
1091	)	O
1091	at	O
1091	10	O
1091	k	O
1091	##h	O
1091	##z	O
1091	(	O
1091	2	O
1091	%	O
1091	p	O
1091	##va	O
1091	formulation	O
1091	##s	O
1091	a	O
1091	and	O
1091	b	O
1091	with	O
1091	son	O
1091	##ica	O
1091	##tion	O
1091	times	O
1091	15	O
1091	and	O
1091	30	O
1091	min	O
1091	,	O
1091	4	O
1091	%	O
1091	p	O
1091	##va	O
1091	formulation	O
1091	##s	O
1091	c	O
1091	and	O
1091	d	O
1091	with	O
1091	son	O
1091	##ica	O
1091	##tion	O
1091	times	O
1091	15	O
1091	and	O
1091	30	O
1091	min	O
1091	,	O
1091	6	O
1091	%	O
1091	p	O
1091	##va	O
1091	formulation	O
1091	##s	O
1091	e	O
1091	and	O
1091	f	O
1091	with	O
1091	son	O
1091	##ica	O
1091	##tion	O
1091	times	O
1091	15	O
1091	and	O
1091	30	O
1091	min	O
1091	;	O
1091	table	O
1091	1	O
1091	)	O
1091	.	O
1091	[SEP]	O
1092	[CLS]	O
1092	limited	O
1092	so	O
1092	##lub	O
1092	##ility	O
1092	and	O
1092	poor	O
1092	oral	B-PK
1092	bio	I-PK
1092	##ava	I-PK
1092	##ila	I-PK
1092	##bility	I-PK
1092	are	O
1092	the	O
1092	major	O
1092	draw	O
1092	##backs	O
1092	for	O
1092	b	O
1092	,	O
1092	and	O
1092	therefore	O
1092	,	O
1092	it	O
1092	has	O
1092	limited	O
1092	therapeutic	O
1092	index	O
1092	during	O
1092	p	O
1092	##har	O
1092	##ma	O
1092	##cological	O
1092	responses	O
1092	.	O
1092	8	O
1092	–	O
1092	14	O
1092	this	O
1092	problem	O
1092	may	O
1092	be	O
1092	overcome	O
1092	through	O
1092	enhancing	O
1092	the	O
1092	so	O
1092	##lub	O
1092	##ility	O
1092	in	O
1092	biological	O
1092	matrix	O
1092	##es	O
1092	and	O
1092	increasing	O
1092	the	O
1092	oral	B-PK
1092	bio	I-PK
1092	##ava	I-PK
1092	##ila	I-PK
1092	##bility	I-PK
1092	.	O
1092	[SEP]	O
1093	[CLS]	O
1093	as	O
1093	depicted	O
1093	in	O
1093	table	O
1093	2	O
1093	and	O
1093	figure	O
1093	4	O
1093	##b	O
1093	,	O
1093	the	O
1093	maximum	B-PK
1093	plasma	I-PK
1093	concentration	I-PK
1093	(	I-PK
1093	cm	I-PK
1093	##ax	I-PK
1093	)	I-PK
1093	and	O
1093	time	B-PK
1093	required	I-PK
1093	to	I-PK
1093	reach	I-PK
1093	the	I-PK
1093	maximum	I-PK
1093	plasma	I-PK
1093	concentration	I-PK
1093	(	I-PK
1093	t	I-PK
1093	##max	I-PK
1093	)	I-PK
1093	were	O
1093	10	O
1093	.	O
1093	34	O
1093	µ	O
1093	##g	O
1093	/	O
1093	m	O
1093	##l	O
1093	and	O
1093	4	O
1093	h	O
1093	for	O
1093	b	O
1093	and	O
1093	47	O
1093	.	O
1093	43	O
1093	µ	O
1093	##g	O
1093	/	O
1093	m	O
1093	##l	O
1093	and	O
1093	8	O
1093	h	O
1093	for	O
1093	b	O
1093	##n	O
1093	##p	O
1093	,	O
1093	respectively	O
1093	.	O
1093	[SEP]	O
1094	[CLS]	O
1094	the	O
1094	plasma	O
1094	concentration	O
1094	reached	O
1094	50	O
1094	%	O
1094	(	O
1094	t	B-PK
1094	##1	I-PK
1094	/	I-PK
1094	2	I-PK
1094	)	O
1094	at	O
1094	10	O
1094	.	O
1094	73	O
1094	and	O
1094	11	O
1094	.	O
1094	11	O
1094	h	O
1094	for	O
1094	b	O
1094	and	O
1094	b	O
1094	##n	O
1094	##p	O
1094	,	O
1094	respectively	O
1094	.	O
1094	[SEP]	O
1095	[CLS]	O
1095	the	O
1095	total	B-PK
1095	area	I-PK
1095	under	I-PK
1095	the	I-PK
1095	curve	I-PK
1095	(	I-PK
1095	au	I-PK
1095	##c	I-PK
1095	)	I-PK
1095	after	O
1095	48	O
1095	h	O
1095	was	O
1095	133	O
1095	.	O
1095	81	O
1095	and	O
1095	83	O
1095	##8	O
1095	.	O
1095	43	O
1095	µ	O
1095	##g	O
1095	##⋅	O
1095	##h	O
1095	/	O
1095	m	O
1095	##l	O
1095	for	O
1095	b	O
1095	and	O
1095	b	O
1095	##n	O
1095	##p	O
1095	,	O
1095	respectively	O
1095	.	O
1095	[SEP]	O
1096	[CLS]	O
1096	the	O
1096	following	O
1096	p	O
1096	##har	O
1096	##ma	O
1096	##co	O
1096	##kin	O
1096	##etic	O
1096	parameters	O
1096	were	O
1096	calculated	O
1096	:	O
1096	cm	B-PK
1096	##ax	I-PK
1096	,	O
1096	t	B-PK
1096	##max	I-PK
1096	,	O
1096	and	O
1096	au	B-PK
1096	##c	I-PK
1096	values	O
1096	.	O
1096	[SEP]	O
1097	[CLS]	O
1097	all	O
1097	sub	O
1097	##cut	O
1097	##aneous	O
1097	f	O
1097	##b	O
1097	##z	O
1097	treatment	O
1097	regime	O
1097	##ns	O
1097	tested	O
1097	were	O
1097	most	O
1097	successful	O
1097	and	O
1097	mediated	O
1097	a	O
1097	complete	O
1097	clearance	O
1097	of	O
1097	the	O
1097	peripheral	O
1097	micro	O
1097	##fi	O
1097	##lar	O
1097	##emia	O
1097	.	O
1097	[SEP]	O
1098	[CLS]	O
1098	using	O
1098	p	O
1098	##har	O
1098	##ma	O
1098	##co	O
1098	##kin	O
1098	##etic	O
1098	analysis	O
1098	we	O
1098	compared	O
1098	cm	B-PK
1098	##ax	I-PK
1098	and	O
1098	au	B-PK
1098	##c	I-PK
1098	values	O
1098	of	O
1098	f	O
1098	##b	O
1098	##z	O
1098	between	O
1098	the	O
1098	different	O
1098	treatment	O
1098	regime	O
1098	##ns	O
1098	and	O
1098	route	O
1098	of	O
1098	administration	O
1098	##s	O
1098	.	O
1098	[SEP]	O
1099	[CLS]	O
1099	mean	O
1099	cm	B-PK
1099	##ax	I-PK
1099	and	O
1099	au	B-PK
1099	##c	I-PK
1099	##0	I-PK
1099	-	I-PK
1099	24	I-PK
1099	##h	I-PK
1099	values	O
1099	increased	O
1099	roughly	O
1099	dose	O
1099	proportional	O
1099	##ly	O
1099	between	O
1099	2	O
1099	##m	O
1099	##g	O
1099	/	O
1099	kg	O
1099	/	O
1099	day	O
1099	up	O
1099	to	O
1099	40	O
1099	##m	O
1099	##g	O
1099	/	O
1099	kg	O
1099	(	O
1099	table	O
1099	1	O
1099	,	O
1099	s	O
1099	##1	O
1099	##a	O
1099	fi	O
1099	##g	O
1099	)	O
1099	.	O
1099	[SEP]	O
1100	[CLS]	O
1100	no	O
1100	changes	O
1100	in	O
1100	cm	B-PK
1100	##ax	I-PK
1100	and	O
1100	au	B-PK
1100	##c	I-PK
1100	##0	I-PK
1100	-	I-PK
1100	24	I-PK
1100	##h	I-PK
1100	values	O
1100	were	O
1100	observed	O
1100	with	O
1100	longer	O
1100	duration	O
1100	of	O
1100	dos	O
1100	##ing	O
1100	with	O
1100	values	O
1100	similar	O
1100	between	O
1100	day	O
1100	5	O
1100	and	O
1100	day	O
1100	10	O
1100	(	O
1100	table	O
1100	1	O
1100	,	O
1100	s	O
1100	##1	O
1100	##a	O
1100	fi	O
1100	##g	O
1100	)	O
1100	.	O
1100	[SEP]	O
1101	[CLS]	O
1101	at	O
1101	2	O
1101	and	O
1101	10	O
1101	##m	O
1101	##g	O
1101	/	O
1101	kg	O
1101	single	O
1101	dose	O
1101	,	O
1101	the	O
1101	cm	B-PK
1101	##ax	I-PK
1101	was	O
1101	similar	O
1101	and	O
1101	au	B-PK
1101	##c	I-PK
1101	##0	I-PK
1101	-	I-PK
1101	days	I-PK
1101	57	I-PK
1101	increased	O
1101	less	O
1101	than	O
1101	dose	O
1101	proportional	O
1101	##ly	O
1101	between	O
1101	the	O
1101	2	O
1101	doses	O
1101	(	O
1101	table	O
1101	1	O
1101	,	O
1101	s	O
1101	##1	O
1101	##b	O
1101	fi	O
1101	##g	O
1101	)	O
1101	.	O
1101	[SEP]	O
1102	[CLS]	O
1102	after	O
1102	comparison	O
1102	of	O
1102	10	O
1102	##m	O
1102	##g	O
1102	/	O
1102	kg	O
1102	single	O
1102	dose	O
1102	and	O
1102	after	O
1102	5	O
1102	days	O
1102	of	O
1102	administration	O
1102	,	O
1102	no	O
1102	increase	O
1102	in	O
1102	cm	B-PK
1102	##ax	I-PK
1102	values	O
1102	was	O
1102	seen	O
1102	and	O
1102	exposure	O
1102	(	O
1102	au	B-PK
1102	##c	I-PK
1102	##0	I-PK
1102	-	I-PK
1102	day	I-PK
1102	##5	I-PK
1102	##2	I-PK
1102	)	O
1102	increased	O
1102	by	O
1102	two	O
1102	(	O
1102	table	O
1102	1	O
1102	,	O
1102	s	O
1102	##1	O
1102	##b	O
1102	fi	O
1102	##g	O
1102	)	O
1102	.	O
1102	[SEP]	O
1103	[CLS]	O
1103	the	O
1103	au	B-PK
1103	##c	I-PK
1103	##0	I-PK
1103	-	I-PK
1103	120	I-PK
1103	##h	I-PK
1103	was	O
1103	14	O
1103	%	O
1103	of	O
1103	the	O
1103	au	B-PK
1103	##c	I-PK
1103	##0	I-PK
1103	-	I-PK
1103	d	I-PK
1103	##5	I-PK
1103	##7	I-PK
1103	(	O
1103	s	O
1103	##1	O
1103	##b	O
1103	fi	O
1103	##g	O
1103	)	O
1103	.	O
1103	[SEP]	O
1104	[CLS]	O
1104	the	O
1104	mi	O
1104	##rta	O
1104	##za	O
1104	##pine	O
1104	serum	O
1104	concentration	O
1104	versus	O
1104	time	O
1104	data	O
1104	for	O
1104	10	O
1104	healthy	O
1104	cats	O
1104	administered	O
1104	a	O
1104	fixed	O
1104	oral	O
1104	1	O
1104	.	O
1104	88	O
1104	mg	O
1104	dose	O
1104	in	O
1104	two	O
1104	earlier	O
1104	studies	O
1104	was	O
1104	used	O
1104	for	O
1104	calculation	O
1104	of	O
1104	drug	O
1104	exposure	O
1104	(	O
1104	au	B-PK
1104	##c	I-PK
1104	##0	I-PK
1104	–	I-PK
1104	24	I-PK
1104	h	I-PK
1104	)	O
1104	by	O
1104	non	O
1104	##com	O
1104	##par	O
1104	##tment	O
1104	##al	O
1104	methods	O
1104	.	O
1104	3	O
1104	,	O
1104	4	O
1104	the	O
1104	resulting	O
1104	au	B-PK
1104	##c	I-PK
1104	values	O
1104	were	O
1104	found	O
1104	to	O
1104	be	O
1104	normally	O
1104	distributed	O
1104	by	O
1104	q	O
1104	–	O
1104	q	O
1104	plot	O
1104	and	O
1104	subsequently	O
1104	analyzed	O
1104	as	O
1104	a	O
1104	response	O
1104	to	O
1104	time	O
1104	point	O
1104	mi	O
1104	##rta	O
1104	##za	O
1104	##pine	O
1104	concentration	O
1104	values	O
1104	as	O
1104	predict	O
1104	##ors	O
1104	by	O
1104	best	O
1104	subset	O
1104	multiple	O
1104	linear	O
1104	re	O
1104	##gression	O
1104	.	O
1104	[SEP]	O
1105	[CLS]	O
1105	this	O
1105	method	O
1105	evaluate	O
1105	##s	O
1105	all	O
1105	single	O
1105	time	O
1105	points	O
1105	as	O
1105	well	O
1105	as	O
1105	all	O
1105	possible	O
1105	combinations	O
1105	of	O
1105	multiple	O
1105	time	O
1105	points	O
1105	as	O
1105	predict	O
1105	##ors	O
1105	of	O
1105	the	O
1105	outcome	O
1105	(	O
1105	au	B-PK
1105	##c	I-PK
1105	##0	I-PK
1105	–	I-PK
1105	24	I-PK
1105	h	I-PK
1105	)	O
1105	.	O
1105	[SEP]	O
1106	[CLS]	O
1106	the	O
1106	results	O
1106	of	O
1106	best	O
1106	subset	O
1106	multiple	O
1106	linear	O
1106	re	O
1106	##gression	O
1106	revealed	O
1106	that	O
1106	using	O
1106	2	O
1106	points	O
1106	as	O
1106	predict	O
1106	##ors	O
1106	of	O
1106	au	B-PK
1106	##c	I-PK
1106	##0	I-PK
1106	‐	I-PK
1106	in	I-PK
1106	##finity	I-PK
1106	(	O
1106	1	O
1106	and	O
1106	4	O
1106	hours	O
1106	)	O
1106	could	O
1106	provide	O
1106	the	O
1106	best	O
1106	combination	O
1106	of	O
1106	statistical	O
1106	correlation	O
1106	(	O
1106	r	O
1106	##2	O
1106	=	O
1106	0	O
1106	.	O
1106	98	O
1106	##9	O
1106	)	O
1106	while	O
1106	mini	O
1106	##mizing	O
1106	sample	O
1106	number	O
1106	and	O
1106	time	O
1106	post	O
1106	##ad	O
1106	##mini	O
1106	##stra	O
1106	##tion	O
1106	.	O
1106	[SEP]	O
1107	[CLS]	O
1107	the	O
1107	final	O
1107	model	O
1107	using	O
1107	the	O
1107	identified	O
1107	time	O
1107	points	O
1107	is	O
1107	described	O
1107	by	O
1107	the	O
1107	equation	O
1107	##au	O
1107	##c	O
1107	##0	O
1107	##−	O
1107	##in	O
1107	##finity	O
1107	=	O
1107	−	O
1107	##12	O
1107	##9	O
1107	+	O
1107	(	O
1107	3	O
1107	.	O
1107	25	O
1107	##∗	O
1107	##c	O
1107	##1	O
1107	##hou	O
1107	##r	O
1107	)	O
1107	+	O
1107	(	O
1107	12	O
1107	.	O
1107	0	O
1107	##∗	O
1107	##c	O
1107	##4	O
1107	##hou	O
1107	##rs	O
1107	)	O
1107	where	O
1107	c	O
1107	##1	O
1107	hour	O
1107	and	O
1107	c	O
1107	##4	O
1107	hours	O
1107	represent	O
1107	the	O
1107	serum	O
1107	concentrations	O
1107	at	O
1107	1	O
1107	and	O
1107	4	O
1107	hours	O
1107	,	O
1107	respectively	O
1107	,	O
1107	after	O
1107	oral	O
1107	administration	O
1107	.	O
1107	[SEP]	O
1108	[CLS]	O
1108	this	O
1108	equation	O
1108	was	O
1108	used	O
1108	to	O
1108	estimate	O
1108	au	B-PK
1108	##c	I-PK
1108	in	O
1108	study	O
1108	samples	O
1108	.	O
1108	[SEP]	O
1109	[CLS]	O
1109	a	O
1109	24	O
1109	hours	O
1109	time	O
1109	point	O
1109	was	O
1109	included	O
1109	when	O
1109	possible	O
1109	for	O
1109	the	O
1109	est	O
1109	##imation	O
1109	of	O
1109	elimination	B-PK
1109	rate	I-PK
1109	(	I-PK
1109	k	I-PK
1109	##el	I-PK
1109	)	I-PK
1109	,	O
1109	which	O
1109	was	O
1109	calculated	O
1109	with	O
1109	the	O
1109	4	O
1109	and	O
1109	24	O
1109	hours	O
1109	time	O
1109	points	O
1109	using	O
1109	the	O
1109	equation	O
1109	:	O
1109	k	O
1109	##el	O
1109	=	O
1109	l	O
1109	##n	O
1109	(	O
1109	c	O
1109	##24	O
1109	##hou	O
1109	##rs	O
1109	/	O
1109	c	O
1109	##4	O
1109	##hou	O
1109	##rs	O
1109	)	O
1109	/	O
1109	(	O
1109	24	O
1109	##−	O
1109	##4	O
1109	)	O
1109	[SEP]	O
1110	[CLS]	O
1110	cm	B-PK
1110	##ax	I-PK
1110	was	O
1110	reported	O
1110	as	O
1110	the	O
1110	highest	B-PK
1110	measured	I-PK
1110	serum	I-PK
1110	concentration	I-PK
1110	(	O
1110	either	O
1110	1	O
1110	or	O
1110	4	O
1110	hours	O
1110	)	O
1110	and	O
1110	t	B-PK
1110	##max	I-PK
1110	was	O
1110	reported	O
1110	as	O
1110	the	O
1110	time	B-PK
1110	point	I-PK
1110	corresponding	I-PK
1110	to	I-PK
1110	the	I-PK
1110	highest	I-PK
1110	measured	I-PK
1110	serum	I-PK
1110	concentration	I-PK
1110	.	O
1110	[SEP]	O
1111	[CLS]	O
1111	parameters	O
1111	compared	O
1111	included	O
1111	au	B-PK
1111	##c	I-PK
1111	,	O
1111	cm	B-PK
1111	##ax	I-PK
1111	(	I-PK
1111	maximum	I-PK
1111	serum	I-PK
1111	concentration	I-PK
1111	)	I-PK
1111	,	O
1111	and	O
1111	t	B-PK
1111	##max	I-PK
1111	(	I-PK
1111	time	I-PK
1111	to	I-PK
1111	maximum	I-PK
1111	serum	I-PK
1111	concentration	I-PK
1111	)	I-PK
1111	,	O
1111	and	O
1111	in	O
1111	the	O
1111	cats	O
1111	where	O
1111	a	O
1111	24	O
1111	hours	O
1111	sample	O
1111	was	O
1111	obtained	O
1111	,	O
1111	half	B-PK
1111	‐	I-PK
1111	life	I-PK
1111	.	O
1111	[SEP]	O
1112	[CLS]	O
1112	a	O
1112	repeated	O
1112	measures	O
1112	two	O
1112	‐	O
1112	way	O
1112	an	O
1112	##ova	O
1112	was	O
1112	used	O
1112	to	O
1112	compare	O
1112	the	O
1112	in	O
1112	v	O
1112	##it	O
1112	##ro	O
1112	k	B-PK
1112	##el	I-PK
1112	(	O
1112	slope	O
1112	of	O
1112	the	O
1112	line	O
1112	in	O
1112	least	O
1112	squares	O
1112	non	O
1112	##linear	O
1112	re	O
1112	##gression	O
1112	)	O
1112	of	O
1112	mi	O
1112	##rta	O
1112	##za	O
1112	##pine	O
1112	between	O
1112	l	O
1112	##d	O
1112	cats	O
1112	and	O
1112	non	O
1112	‐	O
1112	l	O
1112	##d	O
1112	cats	O
1112	.	O
1112	[SEP]	O
1113	[CLS]	O
1113	calculation	O
1113	of	O
1113	the	O
1113	in	O
1113	v	O
1113	##it	O
1113	##ro	O
1113	half	B-PK
1113	‐	I-PK
1113	life	I-PK
1113	was	O
1113	performed	O
1113	by	O
1113	dividing	O
1113	0	O
1113	.	O
1113	69	O
1113	##3	O
1113	by	O
1113	the	O
1113	in	O
1113	v	O
1113	##it	O
1113	##ro	O
1113	k	O
1113	##el	O
1113	:	O
1113	t	O
1113	##1	O
1113	/	O
1113	2	O
1113	=	O
1113	0	O
1113	.	O
1113	69	O
1113	##3	O
1113	/	O
1113	k	O
1113	##el	O
1113	.	O
1113	[SEP]	O
1114	[CLS]	O
1114	the	O
1114	apparent	B-PK
1114	intrinsic	I-PK
1114	he	I-PK
1114	##pa	I-PK
1114	##tic	I-PK
1114	clearance	I-PK
1114	(	I-PK
1114	c	I-PK
1114	##lint	I-PK
1114	,	I-PK
1114	app	I-PK
1114	)	I-PK
1114	of	O
1114	mi	O
1114	##rta	O
1114	##za	O
1114	##pine	O
1114	was	O
1114	then	O
1114	calculated	O
1114	using	O
1114	the	O
1114	in	O
1114	v	O
1114	##it	O
1114	##ro	O
1114	half	B-PK
1114	‐	I-PK
1114	life	I-PK
1114	as	O
1114	follows	O
1114	:	O
1114	[SEP]	O
1115	[CLS]	O
1115	c	O
1115	##lint	O
1115	,	O
1115	app	O
1115	=	O
1115	(	O
1115	0	O
1115	.	O
1115	69	O
1115	##3	O
1115	/	O
1115	in	O
1115	v	O
1115	##it	O
1115	##ro	O
1115	t	O
1115	##1	O
1115	/	O
1115	2	O
1115	)	O
1115	[SEP]	O
1116	[CLS]	O
1116	there	O
1116	was	O
1116	a	O
1116	statistical	O
1116	##ly	O
1116	significant	O
1116	difference	O
1116	in	O
1116	t	B-PK
1116	##max	I-PK
1116	between	O
1116	l	O
1116	##d	O
1116	cats	O
1116	and	O
1116	age	O
1116	‐	O
1116	matched	O
1116	control	O
1116	cats	O
1116	(	O
1116	p	O
1116	=	O
1116	.	O
1116	03	O
1116	)	O
1116	.	O
1116	[SEP]	O
1117	[CLS]	O
1117	au	B-PK
1117	##c	I-PK
1117	was	O
1117	not	O
1117	significantly	O
1117	different	O
1117	between	O
1117	the	O
1117	two	O
1117	groups	O
1117	;	O
1117	however	O
1117	,	O
1117	the	O
1117	calculated	O
1117	half	B-PK
1117	‐	I-PK
1117	life	I-PK
1117	of	O
1117	l	O
1117	##d	O
1117	cats	O
1117	was	O
1117	significantly	O
1117	increased	O
1117	(	O
1117	p	O
1117	<	O
1117	.	O
1117	00	O
1117	##2	O
1117	)	O
1117	compared	O
1117	with	O
1117	age	O
1117	‐	O
1117	matched	O
1117	control	O
1117	cats	O
1117	(	O
1117	figure	O
1117	2	O
1117	)	O
1117	.	O
1117	[SEP]	O
1118	[CLS]	O
1118	when	O
1118	liver	O
1118	micro	O
1118	##some	O
1118	##s	O
1118	from	O
1118	cats	O
1118	without	O
1118	and	O
1118	without	O
1118	l	O
1118	##d	O
1118	were	O
1118	in	O
1118	##cu	O
1118	##bate	O
1118	##d	O
1118	with	O
1118	mi	O
1118	##rta	O
1118	##za	O
1118	##pine	O
1118	,	O
1118	there	O
1118	was	O
1118	a	O
1118	significant	O
1118	difference	O
1118	in	O
1118	the	O
1118	slope	O
1118	of	O
1118	the	O
1118	line	O
1118	representing	O
1118	the	O
1118	rate	B-PK
1118	of	I-PK
1118	loss	I-PK
1118	(	I-PK
1118	k	I-PK
1118	##el	I-PK
1118	)	I-PK
1118	of	O
1118	mi	O
1118	##rta	O
1118	##za	O
1118	##pine	O
1118	between	O
1118	l	O
1118	##d	O
1118	cats	O
1118	(	O
1118	–	O
1118	0	O
1118	.	O
1118	00	O
1118	##22	O
1118	min	O
1118	##−	O
1118	##1	O
1118	,	O
1118	c	O
1118	##i	O
1118	:	O
1118	−	O
1118	##0	O
1118	.	O
1118	00	O
1118	##50	O
1118	to	O
1118	0	O
1118	.	O
1118	000	O
1118	##5	O
1118	##4	O
1118	min	O
1118	##−	O
1118	##1	O
1118	)	O
1118	and	O
1118	cats	O
1118	without	O
1118	l	O
1118	##d	O
1118	(	O
1118	0	O
1118	.	O
1118	01	O
1118	##8	O
1118	##4	O
1118	##9	O
1118	min	O
1118	##−	O
1118	##1	O
1118	,	O
1118	c	O
1118	##i	O
1118	:	O
1118	−	O
1118	##0	O
1118	.	O
1118	02	O
1118	##5	O
1118	to	O
1118	−	O
1118	##0	O
1118	.	O
1118	01	O
1118	##2	O
1118	min	O
1118	##−	O
1118	##1	O
1118	;	O
1118	p	O
1118	=	O
1118	.	O
1118	00	O
1118	##2	O
1118	;	O
1118	figure	O
1118	3	O
1118	)	O
1118	.	O
1118	[SEP]	O
1119	[CLS]	O
1119	93	O
1119	%	O
1119	of	O
1119	the	O
1119	predicted	O
1119	area	B-PK
1119	under	I-PK
1119	the	I-PK
1119	plasma	I-PK
1119	concentration	I-PK
1119	‐	I-PK
1119	time	I-PK
1119	curve	I-PK
1119	(	I-PK
1119	au	I-PK
1119	##c	I-PK
1119	)	I-PK
1119	ratios	I-PK
1119	and	O
1119	94	O
1119	%	O
1119	of	O
1119	the	O
1119	peak	B-PK
1119	plasma	I-PK
1119	concentration	I-PK
1119	(	I-PK
1119	cm	I-PK
1119	##ax	I-PK
1119	)	I-PK
1119	ratios	I-PK
1119	are	O
1119	within	O
1119	two	O
1119	##fold	O
1119	of	O
1119	the	O
1119	observed	O
1119	values	O
1119	.	O
1119	[SEP]	O
1120	[CLS]	O
1120	the	O
1120	models	O
1120	were	O
1120	evaluated	O
1120	by	O
1120	comparison	O
1120	of	O
1120	concentration	O
1120	‐	O
1120	time	O
1120	profiles	O
1120	,	O
1120	area	B-PK
1120	under	I-PK
1120	the	I-PK
1120	plasma	I-PK
1120	concentration	I-PK
1120	‐	I-PK
1120	time	I-PK
1120	curve	I-PK
1120	(	I-PK
1120	au	I-PK
1120	##c	I-PK
1120	)	I-PK
1120	,	O
1120	and	O
1120	peak	B-PK
1120	plasma	I-PK
1120	concentration	I-PK
1120	(	I-PK
1120	cm	I-PK
1120	##ax	I-PK
1120	)	I-PK
1120	values	O
1120	resulting	O
1120	from	O
1120	our	O
1120	simulation	O
1120	##s	O
1120	to	O
1120	the	O
1120	values	O
1120	observed	O
1120	during	O
1120	clinical	O
1120	studies	O
1120	.	O
1120	[SEP]	O
1121	[CLS]	O
1121	as	O
1121	a	O
1121	quantitative	O
1121	measure	O
1121	of	O
1121	the	O
1121	descriptive	O
1121	and	O
1121	predict	O
1121	##ive	O
1121	performance	O
1121	of	O
1121	each	O
1121	model	O
1121	,	O
1121	the	O
1121	geometric	O
1121	mean	O
1121	fold	O
1121	error	O
1121	was	O
1121	calculated	O
1121	according	O
1121	to	O
1121	e	O
1121	##q	O
1121	.	O
1121	(	O
1121	1	O
1121	)	O
1121	:	O
1121	(	O
1121	1	O
1121	)	O
1121	g	O
1121	##m	O
1121	##fe	O
1121	=	O
1121	10	O
1121	(	O
1121	σ	O
1121	|	O
1121	log	O
1121	##10	O
1121	(	O
1121	pre	O
1121	##d	O
1121	##p	O
1121	##k	O
1121	##par	O
1121	##ame	O
1121	##ter	O
1121	/	O
1121	o	O
1121	##bs	O
1121	##p	O
1121	##k	O
1121	##par	O
1121	##ame	O
1121	##ter	O
1121	)	O
1121	|	O
1121	)	O
1121	/	O
1121	n	O
1121	,	O
1121	with	O
1121	g	O
1121	##m	O
1121	##fe	O
1121	=	O
1121	geometric	O
1121	mean	O
1121	fold	O
1121	error	O
1121	of	O
1121	all	O
1121	au	B-PK
1121	##c	I-PK
1121	or	O
1121	cm	B-PK
1121	##ax	I-PK
1121	predictions	O
1121	of	O
1121	the	O
1121	respective	O
1121	model	O
1121	,	O
1121	pre	O
1121	##d	O
1121	p	O
1121	##k	O
1121	parameter	O
1121	=	O
1121	predicted	O
1121	au	B-PK
1121	##c	I-PK
1121	or	O
1121	cm	B-PK
1121	##ax	I-PK
1121	,	O
1121	o	O
1121	##bs	O
1121	p	O
1121	##k	O
1121	parameter	O
1121	=	O
1121	observed	O
1121	au	B-PK
1121	##c	I-PK
1121	or	O
1121	cm	B-PK
1121	##ax	I-PK
1121	,	O
1121	and	O
1121	n	O
1121	=	O
1121	number	O
1121	of	O
1121	studies	O
1121	.	O
1121	[SEP]	O
1122	[CLS]	O
1122	the	O
1122	d	O
1122	##di	O
1122	modeling	O
1122	performance	O
1122	was	O
1122	assessed	O
1122	by	O
1122	comparison	O
1122	of	O
1122	predicted	O
1122	vs	O
1122	.	O
1122	observed	O
1122	victim	O
1122	drug	O
1122	plasma	O
1122	concentration	O
1122	‐	O
1122	time	O
1122	profiles	O
1122	during	O
1122	co	O
1122	‐	O
1122	administration	O
1122	,	O
1122	d	O
1122	##di	O
1122	au	B-PK
1122	##c	I-PK
1122	ratios	I-PK
1122	(	O
1122	e	O
1122	##q	O
1122	.	O
1122	(	O
1122	2	O
1122	)	O
1122	)	O
1122	,	O
1122	and	O
1122	d	O
1122	##di	O
1122	cm	B-PK
1122	##ax	I-PK
1122	ratios	I-PK
1122	(	O
1122	e	O
1122	##q	O
1122	.	O
1122	(	O
1122	3	O
1122	)	O
1122	)	O
1122	:	O
1122	(	O
1122	2	O
1122	)	O
1122	d	O
1122	##di	O
1122	au	O
1122	##c	O
1122	ratio	O
1122	=	O
1122	au	O
1122	##c	O
1122	##vic	O
1122	##ti	O
1122	##m	O
1122	##dr	O
1122	##ug	O
1122	##du	O
1122	##ring	O
1122	##co	O
1122	##−	O
1122	##ad	O
1122	##mini	O
1122	##stra	O
1122	##tion	O
1122	##au	O
1122	##c	O
1122	##vic	O
1122	##ti	O
1122	##m	O
1122	##dr	O
1122	##ug	O
1122	(	O
1122	3	O
1122	)	O
1122	d	O
1122	##dic	O
1122	##max	O
1122	##rat	O
1122	##io	O
1122	=	O
1122	cm	O
1122	##ax	O
1122	##vic	O
1122	##ti	O
1122	##m	O
1122	##dr	O
1122	##ug	O
1122	##du	O
1122	##ring	O
1122	##co	O
1122	##−	O
1122	##ad	O
1122	##mini	O
1122	##stra	O
1122	##tion	O
1122	##c	O
1122	##max	O
1122	##vic	O
1122	##ti	O
1122	##m	O
1122	##dr	O
1122	##ug	O
1122	[SEP]	O
1123	[CLS]	O
1123	as	O
1123	a	O
1123	quantitative	O
1123	measure	O
1123	of	O
1123	the	O
1123	prediction	O
1123	accuracy	O
1123	of	O
1123	each	O
1123	d	O
1123	##di	O
1123	interaction	O
1123	,	O
1123	g	O
1123	##m	O
1123	##fe	O
1123	##s	O
1123	of	O
1123	the	O
1123	predicted	O
1123	d	O
1123	##di	O
1123	au	B-PK
1123	##c	I-PK
1123	ratios	I-PK
1123	and	O
1123	d	O
1123	##di	O
1123	cm	B-PK
1123	##ax	I-PK
1123	ratios	I-PK
1123	were	O
1123	calculated	O
1123	according	O
1123	to	O
1123	e	O
1123	##q	O
1123	.	O
1123	(	O
1123	1	O
1123	)	O
1123	.	O
1123	[SEP]	O
1124	[CLS]	O
1124	sensitivity	O
1124	of	O
1124	the	O
1124	final	O
1124	models	O
1124	to	O
1124	single	O
1124	parameters	O
1124	(	O
1124	local	O
1124	sensitivity	O
1124	analysis	O
1124	)	O
1124	was	O
1124	calculated	O
1124	,	O
1124	measured	O
1124	as	O
1124	changes	O
1124	of	O
1124	the	O
1124	au	B-PK
1124	##c	I-PK
1124	extra	I-PK
1124	##pol	I-PK
1124	##ated	I-PK
1124	to	I-PK
1124	in	I-PK
1124	##finity	I-PK
1124	(	O
1124	for	O
1124	single	O
1124	‐	O
1124	dose	O
1124	administration	O
1124	drugs	O
1124	)	O
1124	or	O
1124	of	O
1124	the	O
1124	au	B-PK
1124	##c	I-PK
1124	of	I-PK
1124	one	I-PK
1124	dos	I-PK
1124	##ing	I-PK
1124	interval	I-PK
1124	in	I-PK
1124	steady	I-PK
1124	‐	I-PK
1124	state	I-PK
1124	conditions	I-PK
1124	(	O
1124	for	O
1124	multiple	O
1124	‐	O
1124	dose	O
1124	administration	O
1124	drugs	O
1124	)	O
1124	of	O
1124	a	O
1124	simulation	O
1124	with	O
1124	administration	O
1124	of	O
1124	the	O
1124	highest	O
1124	common	O
1124	dose	O
1124	.	O
1124	[SEP]	O
1125	[CLS]	O
1125	sensitivity	O
1125	to	O
1125	a	O
1125	parameter	O
1125	is	O
1125	calculated	O
1125	as	O
1125	the	O
1125	ratio	O
1125	of	O
1125	the	O
1125	relative	O
1125	change	O
1125	of	O
1125	the	O
1125	simulated	O
1125	au	B-PK
1125	##c	I-PK
1125	to	O
1125	the	O
1125	relative	O
1125	variation	O
1125	of	O
1125	the	O
1125	parameter	O
1125	around	O
1125	the	O
1125	value	O
1125	used	O
1125	in	O
1125	the	O
1125	final	O
1125	model	O
1125	(	O
1125	e	O
1125	##q	O
1125	.	O
1125	(	O
1125	4	O
1125	)	O
1125	)	O
1125	:	O
1125	(	O
1125	4	O
1125	)	O
1125	s	O
1125	=	O
1125	δ	O
1125	##au	O
1125	##ca	O
1125	##uc	O
1125	·	O
1125	p	O
1125	##δ	O
1125	##p	O
1125	,	O
1125	with	O
1125	s	O
1125	=	O
1125	sensitivity	O
1125	of	O
1125	the	O
1125	au	B-PK
1125	##c	I-PK
1125	to	O
1125	the	O
1125	examined	O
1125	model	O
1125	parameter	O
1125	,	O
1125	δ	O
1125	##au	O
1125	##c	O
1125	=	O
1125	change	O
1125	of	O
1125	the	O
1125	au	O
1125	##c	O
1125	,	O
1125	au	O
1125	##c	O
1125	=	O
1125	simulated	O
1125	au	O
1125	##c	O
1125	with	O
1125	the	O
1125	original	O
1125	parameter	O
1125	value	O
1125	,	O
1125	δ	O
1125	##p	O
1125	=	O
1125	change	O
1125	of	O
1125	the	O
1125	examined	O
1125	model	O
1125	parameter	O
1125	value	O
1125	,	O
1125	and	O
1125	p	O
1125	=	O
1125	original	O
1125	model	O
1125	parameter	O
1125	value	O
1125	.	O
1125	[SEP]	O
1126	[CLS]	O
1126	a	O
1126	sensitivity	O
1126	value	O
1126	of	O
1126	+	O
1126	1	O
1126	.	O
1126	0	O
1126	sign	O
1126	##ifies	O
1126	that	O
1126	a	O
1126	10	O
1126	%	O
1126	increase	O
1126	of	O
1126	the	O
1126	examined	O
1126	parameter	O
1126	causes	O
1126	a	O
1126	10	O
1126	%	O
1126	increase	O
1126	of	O
1126	the	O
1126	simulated	O
1126	au	B-PK
1126	##c	I-PK
1126	.	O
1126	[SEP]	O
1127	[CLS]	O
1127	in	O
1127	addition	O
1127	,	O
1127	predicted	O
1127	compared	O
1127	to	O
1127	observed	O
1127	au	B-PK
1127	##c	I-PK
1127	and	O
1127	cm	B-PK
1127	##ax	I-PK
1127	values	O
1127	with	O
1127	calculated	O
1127	g	O
1127	##m	O
1127	##fe	O
1127	##s	O
1127	(	O
1127	also	O
1127	listed	O
1127	in	O
1127	tables	O
1127	s	O
1127	##1	O
1127	##a	O
1127	,	O
1127	s	O
1127	##2	O
1127	##a	O
1127	,	O
1127	s	O
1127	##3	O
1127	##a	O
1127	,	O
1127	s	O
1127	##4	O
1127	##a	O
1127	,	O
1127	s	O
1127	##5	O
1127	##a	O
1127	,	O
1127	s	O
1127	##6	O
1127	##a	O
1127	in	O
1127	app	O
1127	##end	O
1127	##ix	O
1127	##s	O
1127	##1	O
1127	)	O
1127	and	O
1127	sensitivity	O
1127	analysis	O
1127	results	O
1127	(	O
1127	figures	O
1127	s	O
1127	##1	O
1127	##e	O
1127	,	O
1127	s	O
1127	##2	O
1127	##e	O
1127	,	O
1127	s	O
1127	##3	O
1127	##e	O
1127	,	O
1127	s	O
1127	##4	O
1127	##e	O
1127	,	O
1127	s	O
1127	##5	O
1127	##e	O
1127	,	O
1127	s	O
1127	##6	O
1127	##e	O
1127	in	O
1127	app	O
1127	##end	O
1127	##ix	O
1127	##s	O
1127	##1	O
1127	)	O
1127	are	O
1127	presented	O
1127	.	O
1127	[SEP]	O
1128	[CLS]	O
1128	predicted	O
1128	compared	O
1128	with	O
1128	observed	O
1128	d	O
1128	##di	O
1128	au	B-PK
1128	##c	I-PK
1128	ratios	I-PK
1128	and	O
1128	cm	B-PK
1128	##ax	I-PK
1128	ratios	I-PK
1128	with	O
1128	calculated	O
1128	g	O
1128	##m	O
1128	##fe	O
1128	##s	O
1128	for	O
1128	each	O
1128	per	O
1128	##pet	O
1128	##rator	O
1128	‐	O
1128	victim	O
1128	pair	O
1128	are	O
1128	summarized	O
1128	in	O
1128	table	O
1128	##1	O
1128	.	O
1128	[SEP]	O
1129	[CLS]	O
1129	correlation	O
1129	of	O
1129	predicted	O
1129	to	O
1129	observed	O
1129	d	O
1129	##di	O
1129	au	B-PK
1129	##c	I-PK
1129	ratios	I-PK
1129	and	O
1129	cm	B-PK
1129	##ax	I-PK
1129	ratios	I-PK
1129	of	O
1129	all	O
1129	57	O
1129	modeled	O
1129	interaction	O
1129	studies	O
1129	,	O
1129	ill	O
1129	##ust	O
1129	##rating	O
1129	the	O
1129	performance	O
1129	of	O
1129	the	O
1129	entire	O
1129	d	O
1129	##di	O
1129	network	O
1129	,	O
1129	is	O
1129	presented	O
1129	in	O
1129	figure	O
1129	##5	O
1129	.	O
1129	[SEP]	O
1130	[CLS]	O
1130	the	O
1130	objective	O
1130	of	O
1130	the	O
1130	present	O
1130	study	O
1130	was	O
1130	to	O
1130	evaluate	O
1130	the	O
1130	p	O
1130	##har	O
1130	##ma	O
1130	##co	O
1130	##kin	O
1130	##etic	O
1130	parameters	O
1130	and	O
1130	bio	B-PK
1130	##ava	I-PK
1130	##ila	I-PK
1130	##bility	I-PK
1130	of	O
1130	a	O
1130	selective	O
1130	his	O
1130	##tamine	O
1130	(	O
1130	h	O
1130	##1	O
1130	)	O
1130	-	O
1130	receptor	O
1130	antagonist	O
1130	,	O
1130	c	O
1130	##eti	O
1130	##riz	O
1130	##ine	O
1130	h	O
1130	##ydro	O
1130	##ch	O
1130	##lor	O
1130	##ide	O
1130	(	O
1130	c	O
1130	##tz	O
1130	)	O
1130	,	O
1130	following	O
1130	administration	O
1130	of	O
1130	a	O
1130	single	O
1130	oral	O
1130	dose	O
1130	of	O
1130	the	O
1130	drug	O
1130	.	O
1130	[SEP]	O
1131	[CLS]	O
1131	p	O
1131	##har	O
1131	##ma	O
1131	##co	O
1131	##kin	O
1131	##etic	O
1131	parameters	O
1131	including	O
1131	t	B-PK
1131	##1	I-PK
1131	/	I-PK
1131	2	I-PK
1131	,	O
1131	t	B-PK
1131	##1	I-PK
1131	/	I-PK
1131	2	I-PK
1131	(	I-PK
1131	a	I-PK
1131	##bs	I-PK
1131	)	I-PK
1131	,	O
1131	k	B-PK
1131	,	O
1131	ka	B-PK
1131	,	O
1131	t	B-PK
1131	##max	I-PK
1131	,	O
1131	cm	B-PK
1131	##ax	I-PK
1131	,	O
1131	v	B-PK
1131	##d	I-PK
1131	/	I-PK
1131	f	I-PK
1131	,	O
1131	c	B-PK
1131	##l	I-PK
1131	/	I-PK
1131	f	I-PK
1131	,	O
1131	au	B-PK
1131	##c	I-PK
1131	##0	I-PK
1131	-	I-PK
1131	24	I-PK
1131	,	O
1131	au	B-PK
1131	##c	I-PK
1131	0	I-PK
1131	-	I-PK
1131	∞	I-PK
1131	and	O
1131	m	B-PK
1131	##rt	I-PK
1131	were	O
1131	determined	O
1131	from	O
1131	plasma	O
1131	concentration	O
1131	-	O
1131	time	O
1131	profiles	O
1131	for	O
1131	tested	O
1131	products	O
1131	and	O
1131	found	O
1131	to	O
1131	be	O
1131	in	O
1131	good	O
1131	agreement	O
1131	with	O
1131	previous	O
1131	reports	O
1131	.	O
1131	[SEP]	O
1132	[CLS]	O
1132	the	O
1132	confidence	O
1132	intervals	O
1132	for	O
1132	the	O
1132	ratio	B-PK
1132	of	I-PK
1132	cm	I-PK
1132	##ax	I-PK
1132	(	O
1132	95	O
1132	-	O
1132	110	O
1132	%	O
1132	)	O
1132	,	O
1132	au	B-PK
1132	##c	I-PK
1132	##0	I-PK
1132	-	I-PK
1132	24	I-PK
1132	(	O
1132	91	O
1132	-	O
1132	112	O
1132	%	O
1132	)	O
1132	and	O
1132	au	B-PK
1132	##c	I-PK
1132	##0	I-PK
1132	-	I-PK
1132	∞	I-PK
1132	(	O
1132	92	O
1132	-	O
1132	109	O
1132	%	O
1132	)	O
1132	for	O
1132	the	O
1132	test	O
1132	and	O
1132	reference	O
1132	products	O
1132	were	O
1132	within	O
1132	the	O
1132	acceptable	O
1132	interval	O
1132	of	O
1132	80	O
1132	-	O
1132	125	O
1132	%	O
1132	.	O
1132	[SEP]	O
1133	[CLS]	O
1133	the	O
1133	elimination	B-PK
1133	rate	I-PK
1133	constant	I-PK
1133	(	I-PK
1133	k	I-PK
1133	)	I-PK
1133	was	O
1133	estimated	O
1133	by	O
1133	the	O
1133	least	O
1133	-	O
1133	square	O
1133	re	O
1133	##gression	O
1133	of	O
1133	plasma	O
1133	concentration	O
1133	-	O
1133	time	O
1133	data	O
1133	points	O
1133	lying	O
1133	in	O
1133	the	O
1133	terminal	O
1133	log	O
1133	-	O
1133	linear	O
1133	region	O
1133	of	O
1133	the	O
1133	curves	O
1133	.	O
1133	[SEP]	O
1134	[CLS]	O
1134	the	O
1134	elimination	B-PK
1134	half	I-PK
1134	life	I-PK
1134	was	O
1134	calculated	O
1134	as	O
1134	0	O
1134	.	O
1134	69	O
1134	##3	O
1134	divided	O
1134	by	O
1134	k	B-PK
1134	.	O
1134	the	O
1134	area	B-PK
1134	under	I-PK
1134	the	I-PK
1134	plasma	I-PK
1134	concentration	I-PK
1134	-	I-PK
1134	time	I-PK
1134	curve	I-PK
1134	from	I-PK
1134	time	I-PK
1134	zero	I-PK
1134	to	I-PK
1134	the	I-PK
1134	last	I-PK
1134	me	I-PK
1134	##as	I-PK
1134	##urable	I-PK
1134	concentration	I-PK
1134	at	I-PK
1134	time	I-PK
1134	t	I-PK
1134	(	I-PK
1134	au	I-PK
1134	##c	I-PK
1134	##0	I-PK
1134	-	I-PK
1134	t	I-PK
1134	)	I-PK
1134	was	O
1134	calculated	O
1134	using	O
1134	the	O
1134	trap	O
1134	##ez	O
1134	##oid	O
1134	##al	O
1134	rule	O
1134	.	O
1134	[SEP]	O
1135	[CLS]	O
1135	the	O
1135	area	B-PK
1135	was	I-PK
1135	extra	I-PK
1135	##pol	I-PK
1135	##ated	I-PK
1135	to	I-PK
1135	in	I-PK
1135	##finity	I-PK
1135	(	I-PK
1135	au	I-PK
1135	##c	I-PK
1135	##0	I-PK
1135	-	I-PK
1135	∞	I-PK
1135	)	I-PK
1135	by	O
1135	addition	O
1135	of	O
1135	c	B-PK
1135	##t	I-PK
1135	/	I-PK
1135	k	I-PK
1135	to	O
1135	au	B-PK
1135	##c	I-PK
1135	##0	I-PK
1135	-	I-PK
1135	t	I-PK
1135	where	O
1135	c	B-PK
1135	##t	I-PK
1135	is	O
1135	the	O
1135	last	O
1135	measured	O
1135	drug	O
1135	concentration	O
1135	.	O
1135	[SEP]	O
1136	[CLS]	O
1136	peak	B-PK
1136	plasma	I-PK
1136	concentration	I-PK
1136	(	I-PK
1136	cm	I-PK
1136	##ax	I-PK
1136	)	I-PK
1136	and	O
1136	time	B-PK
1136	to	I-PK
1136	peak	I-PK
1136	con	I-PK
1136	##ce	I-PK
1136	##n	I-PK
1136	-	I-PK
1136	t	I-PK
1136	##ration	I-PK
1136	(	I-PK
1136	t	I-PK
1136	##max	I-PK
1136	)	I-PK
1136	were	O
1136	determined	O
1136	by	O
1136	inspection	O
1136	of	O
1136	the	O
1136	individual	O
1136	subject	O
1136	concentration	O
1136	time	O
1136	curves	O
1136	.	O
1136	[SEP]	O
1137	[CLS]	O
1137	apparent	B-PK
1137	oral	I-PK
1137	clearance	I-PK
1137	(	I-PK
1137	c	I-PK
1137	##l	I-PK
1137	/	I-PK
1137	f	I-PK
1137	)	I-PK
1137	and	O
1137	apparent	B-PK
1137	volume	I-PK
1137	of	I-PK
1137	distribution	I-PK
1137	(	I-PK
1137	v	I-PK
1137	##d	I-PK
1137	/	I-PK
1137	f	I-PK
1137	)	I-PK
1137	were	O
1137	calculated	O
1137	by	O
1137	e	O
1137	##q	O
1137	.	O
1137	2	O
1137	and	O
1137	3	O
1137	,	O
1137	respectively	O
1137	:	O
1137	[SEP]	O
1138	[CLS]	O
1138	the	O
1138	relative	B-PK
1138	bio	I-PK
1138	##ava	I-PK
1138	##ila	I-PK
1138	##bility	I-PK
1138	of	O
1138	the	O
1138	test	O
1138	formulation	O
1138	was	O
1138	estimated	O
1138	as	O
1138	the	O
1138	au	B-PK
1138	##c	I-PK
1138	##0	I-PK
1138	-	I-PK
1138	∞	I-PK
1138	##rat	I-PK
1138	##io	I-PK
1138	of	O
1138	the	O
1138	test	O
1138	to	O
1138	the	O
1138	reference	O
1138	product	O
1138	.	O
1138	[SEP]	O
1139	[CLS]	O
1139	absorption	B-PK
1139	half	I-PK
1139	-	I-PK
1139	life	I-PK
1139	(	I-PK
1139	t	I-PK
1139	##1	I-PK
1139	/	I-PK
1139	2	I-PK
1139	(	I-PK
1139	a	I-PK
1139	##bs	I-PK
1139	)	I-PK
1139	)	I-PK
1139	was	O
1139	calculated	O
1139	by	O
1139	0	O
1139	.	O
1139	69	O
1139	##3	O
1139	/	O
1139	ka	O
1139	.	O
1139	[SEP]	O
1140	[CLS]	O
1140	where	O
1140	au	B-PK
1140	##m	I-PK
1140	##c	I-PK
1140	is	O
1140	the	O
1140	area	B-PK
1140	under	I-PK
1140	the	I-PK
1140	first	I-PK
1140	moment	I-PK
1140	of	I-PK
1140	plasma	I-PK
1140	drug	I-PK
1140	concentration	I-PK
1140	.	O
1140	[SEP]	O
1141	[CLS]	O
1141	mean	B-PK
1141	residence	I-PK
1141	time	I-PK
1141	(	I-PK
1141	m	I-PK
1141	##rt	I-PK
1141	)	I-PK
1141	,	O
1141	the	O
1141	average	O
1141	time	O
1141	for	O
1141	all	O
1141	the	O
1141	drug	O
1141	molecules	O
1141	to	O
1141	reside	O
1141	in	O
1141	the	O
1141	body	O
1141	was	O
1141	estimated	O
1141	according	O
1141	to	O
1141	the	O
1141	following	O
1141	equation	O
1141	(	O
1141	12	O
1141	)	O
1141	:	O
1141	[SEP]	O
1142	[CLS]	O
1142	in	O
1142	spite	O
1142	of	O
1142	a	O
1142	significant	O
1142	difference	O
1142	between	O
1142	the	O
1142	m	O
1142	##dt	O
1142	and	O
1142	f	B-PK
1142	values	O
1142	of	O
1142	the	O
1142	two	O
1142	products	O
1142	,	O
1142	the	O
1142	drug	O
1142	content	O
1142	of	O
1142	both	O
1142	formulation	O
1142	##s	O
1142	was	O
1142	largely	O
1142	released	O
1142	within	O
1142	20	O
1142	min	O
1142	.	O
1142	[SEP]	O
1143	[CLS]	O
1143	in	O
1143	order	O
1143	to	O
1143	confirm	O
1143	the	O
1143	bio	O
1143	##e	O
1143	##qui	O
1143	##vale	O
1143	##ncy	O
1143	of	O
1143	the	O
1143	two	O
1143	products	O
1143	,	O
1143	the	O
1143	90	O
1143	%	O
1143	confidence	O
1143	intervals	O
1143	for	O
1143	arithmetic	O
1143	mean	O
1143	of	O
1143	test	O
1143	/	O
1143	reference	O
1143	,	O
1143	in	O
1143	##di	O
1143	##vi	O
1143	-	O
1143	dual	O
1143	ratios	O
1143	of	O
1143	cm	B-PK
1143	##ax	I-PK
1143	,	O
1143	au	B-PK
1143	##c	I-PK
1143	##0	I-PK
1143	-	I-PK
1143	24	I-PK
1143	,	O
1143	au	B-PK
1143	##c	I-PK
1143	##0	I-PK
1143	-	I-PK
1143	∞	I-PK
1143	,	O
1143	and	O
1143	cm	B-PK
1143	##ax	I-PK
1143	/	I-PK
1143	au	I-PK
1143	##c	I-PK
1143	##0	I-PK
1143	-	I-PK
1143	∞	I-PK
1143	were	O
1143	calculated	O
1143	.	O
1143	[SEP]	O
1144	[CLS]	O
1144	w	O
1144	##il	O
1144	##co	O
1144	##xon	O
1144	signed	O
1144	rank	O
1144	non	O
1144	-	O
1144	para	O
1144	##metric	O
1144	analysis	O
1144	did	O
1144	not	O
1144	reveal	O
1144	significant	O
1144	differences	O
1144	between	O
1144	t	B-PK
1144	##max	I-PK
1144	values	O
1144	(	O
1144	p	O
1144	=	O
1144	0	O
1144	.	O
1144	137	O
1144	)	O
1144	.	O
1144	[SEP]	O
1145	[CLS]	O
1145	as	O
1145	shown	O
1145	in	O
1145	table	O
1145	6	O
1145	,	O
1145	the	O
1145	para	O
1145	##metric	O
1145	point	O
1145	estimate	O
1145	of	O
1145	the	O
1145	difference	O
1145	(	O
1145	t	O
1145	-	O
1145	r	O
1145	)	O
1145	for	O
1145	t	B-PK
1145	##max	I-PK
1145	is	O
1145	0	O
1145	.	O
1145	21	O
1145	h	O
1145	and	O
1145	thus	O
1145	within	O
1145	the	O
1145	s	O
1145	##tip	O
1145	##ulated	O
1145	bio	O
1145	##e	O
1145	##qui	O
1145	##valence	O
1145	range	O
1145	of	O
1145	±	O
1145	0	O
1145	.	O
1145	35	O
1145	h	O
1145	(	O
1145	±	O
1145	20	O
1145	%	O
1145	of	O
1145	the	O
1145	mean	O
1145	of	O
1145	the	O
1145	reference	O
1145	product	O
1145	)	O
1145	.	O
1145	[SEP]	O
1146	[CLS]	O
1146	no	O
1146	significant	O
1146	differences	O
1146	were	O
1146	observed	O
1146	between	O
1146	the	O
1146	cm	B-PK
1146	##ax	I-PK
1146	,	O
1146	t	B-PK
1146	##max	I-PK
1146	,	O
1146	au	B-PK
1146	##c	I-PK
1146	##0	I-PK
1146	-	I-PK
1146	24	I-PK
1146	,	O
1146	au	B-PK
1146	##c	I-PK
1146	##0	I-PK
1146	-	I-PK
1146	∞	I-PK
1146	,	O
1146	t	B-PK
1146	##1	I-PK
1146	/	I-PK
1146	2	I-PK
1146	,	O
1146	k	B-PK
1146	,	O
1146	c	B-PK
1146	##l	I-PK
1146	/	I-PK
1146	f	I-PK
1146	,	O
1146	v	B-PK
1146	##d	I-PK
1146	/	I-PK
1146	f	I-PK
1146	and	O
1146	m	B-PK
1146	##rt	I-PK
1146	of	O
1146	the	O
1146	two	O
1146	products	O
1146	(	O
1146	p	O
1146	>	O
1146	0	O
1146	.	O
1146	05	O
1146	)	O
1146	,	O
1146	however	O
1146	we	O
1146	observed	O
1146	some	O
1146	differences	O
1146	between	O
1146	ka	B-PK
1146	##and	I-PK
1146	t	B-PK
1146	##1	I-PK
1146	/	I-PK
1146	2	I-PK
1146	##α	I-PK
1146	(	O
1146	table	O
1146	4	O
1146	)	O
1146	.	O
1146	[SEP]	O
1147	[CLS]	O
1147	the	O
1147	area	B-PK
1147	under	I-PK
1147	the	I-PK
1147	concentration	I-PK
1147	‐	I-PK
1147	time	I-PK
1147	curve	I-PK
1147	(	I-PK
1147	au	I-PK
1147	##c	I-PK
1147	)	I-PK
1147	ratios	I-PK
1147	of	O
1147	mid	O
1147	##az	O
1147	##ola	O
1147	##m	O
1147	were	O
1147	above	O
1147	0	O
1147	.	O
1147	80	O
1147	,	O
1147	indicating	O
1147	that	O
1147	induction	O
1147	of	O
1147	c	O
1147	##y	O
1147	##p	O
1147	##3	O
1147	##a	O
1147	by	O
1147	e	O
1147	##vo	O
1147	##fo	O
1147	##s	O
1147	##fa	O
1147	##mi	O
1147	##de	O
1147	administered	O
1147	weekly	O
1147	is	O
1147	unlikely	O
1147	to	O
1147	occur	O
1147	in	O
1147	humans	O
1147	.	O
1147	[SEP]	O
1148	[CLS]	O
1148	numerous	O
1148	mathematical	O
1148	models	O
1148	have	O
1148	been	O
1148	developed	O
1148	to	O
1148	predict	O
1148	clinical	O
1148	d	O
1148	##di	O
1148	from	O
1148	in	O
1148	v	O
1148	##it	O
1148	##ro	O
1148	data	O
1148	.	O
1148	21	O
1148	,	O
1148	22	O
1148	,	O
1148	23	O
1148	,	O
1148	24	O
1148	the	O
1148	simplest	O
1148	model	O
1148	is	O
1148	one	O
1148	in	O
1148	which	O
1148	a	O
1148	static	O
1148	score	O
1148	of	O
1148	degree	O
1148	of	O
1148	induction	O
1148	is	O
1148	calculated	O
1148	from	O
1148	the	O
1148	average	O
1148	plasma	O
1148	concentration	O
1148	of	O
1148	an	O
1148	induce	O
1148	##r	O
1148	using	O
1148	in	O
1148	v	O
1148	##it	O
1148	##ro	O
1148	half	O
1148	‐	O
1148	ma	O
1148	##ximal	O
1148	effective	O
1148	concentration	O
1148	and	O
1148	maximum	B-PK
1148	effect	I-PK
1148	(	I-PK
1148	em	I-PK
1148	##ax	I-PK
1148	)	I-PK
1148	estimates	O
1148	.	O
1148	25	O
1148	,	O
1148	26	O
1148	,	O
1148	27	O
1148	the	O
1148	potential	O
1148	for	O
1148	induction	O
1148	‐	O
1148	based	O
1148	d	O
1148	##dis	O
1148	is	O
1148	then	O
1148	predicted	O
1148	based	O
1148	upon	O
1148	the	O
1148	extent	O
1148	of	O
1148	clearance	B-PK
1148	associated	O
1148	with	O
1148	each	O
1148	induced	O
1148	enzyme	O
1148	.	O
1148	[SEP]	O
1149	[CLS]	O
1149	in	O
1149	contrast	O
1149	,	O
1149	dynamic	O
1149	models	O
1149	consider	O
1149	differences	O
1149	in	O
1149	the	O
1149	levels	O
1149	of	O
1149	enzyme	O
1149	activity	O
1149	and	O
1149	,	O
1149	thus	O
1149	,	O
1149	clearance	B-PK
1149	of	O
1149	a	O
1149	drug	O
1149	as	O
1149	a	O
1149	result	O
1149	of	O
1149	increased	O
1149	enzyme	O
1149	synthesis	O
1149	in	O
1149	an	O
1149	induce	O
1149	##r	O
1149	‐	O
1149	concentration	O
1149	dependent	O
1149	manner	O
1149	.	O
1149	28	O
1149	,	O
1149	29	O
1149	,	O
1149	30	O
1149	[SEP]	O
1150	[CLS]	O
1150	the	O
1150	area	B-PK
1150	under	I-PK
1150	the	I-PK
1150	concentration	I-PK
1150	‐	I-PK
1150	time	I-PK
1150	curve	I-PK
1150	up	I-PK
1150	to	I-PK
1150	24	I-PK
1150	hours	I-PK
1150	(	I-PK
1150	au	I-PK
1150	##c	I-PK
1150	##0	I-PK
1150	–	I-PK
1150	24	I-PK
1150	)	I-PK
1150	and	O
1150	maximum	B-PK
1150	concentration	I-PK
1150	(	I-PK
1150	cm	I-PK
1150	##ax	I-PK
1150	)	I-PK
1150	of	O
1150	the	O
1150	probe	O
1150	substrates	O
1150	after	O
1150	administration	O
1150	on	O
1150	trial	O
1150	day	O
1150	1	O
1150	or	O
1150	15	O
1150	were	O
1150	used	O
1150	for	O
1150	evaluation	O
1150	##s	O
1150	,	O
1150	respectively	O
1150	.	O
1150	[SEP]	O
1151	[CLS]	O
1151	the	O
1151	per	O
1151	##pet	O
1151	##rator	O
1151	properties	O
1151	of	O
1151	e	O
1151	##vo	O
1151	##fo	O
1151	##s	O
1151	##fa	O
1151	##mi	O
1151	##de	O
1151	regarding	O
1151	c	O
1151	##y	O
1151	##p	O
1151	##3	O
1151	##a	O
1151	were	O
1151	applied	O
1151	to	O
1151	both	O
1151	c	O
1151	##y	O
1151	##p	O
1151	##3	O
1151	##a	O
1151	##4	O
1151	and	O
1151	c	O
1151	##y	O
1151	##p	O
1151	##3	O
1151	##a	O
1151	##5	O
1151	.	O
1151	[SEP]	O
1152	[CLS]	O
1152	standard	O
1152	approaches	O
1152	,	O
1152	as	O
1152	outlined	O
1152	in	O
1152	guidance	O
1152	documents	O
1152	,	O
1152	were	O
1152	designed	O
1152	as	O
1152	a	O
1152	worst	O
1152	‐	O
1152	case	O
1152	approach	O
1152	,	O
1152	putting	O
1152	the	O
1152	patient	O
1152	safety	O
1152	first	O
1152	by	O
1152	using	O
1152	the	O
1152	maximum	B-PK
1152	concentration	I-PK
1152	.	O
1152	[SEP]	O
1153	[CLS]	O
1153	the	O
1153	static	O
1153	calculation	O
1153	indicated	O
1153	that	O
1153	the	O
1153	interaction	O
1153	potential	O
1153	is	O
1153	ne	O
1153	##gli	O
1153	##gible	O
1153	,	O
1153	with	O
1153	au	B-PK
1153	##c	I-PK
1153	ratios	I-PK
1153	for	O
1153	the	O
1153	sensitive	O
1153	substrate	O
1153	de	O
1153	##x	O
1153	##trom	O
1153	##eth	O
1153	##or	O
1153	##pha	O
1153	##n	O
1153	of	O
1153	1	O
1153	.	O
1153	11	O
1153	and	O
1153	1	O
1153	.	O
1153	000	O
1153	##5	O
1153	based	O
1153	on	O
1153	im	B-PK
1153	##ax	I-PK
1153	and	O
1153	i	B-PK
1153	##av	I-PK
1153	,	O
1153	respectively	O
1153	.	O
1153	[SEP]	O
1154	[CLS]	O
1154	the	O
1154	geometric	O
1154	mean	O
1154	ratios	O
1154	(	O
1154	95	O
1154	%	O
1154	c	O
1154	##i	O
1154	)	O
1154	for	O
1154	au	B-PK
1154	##c	I-PK
1154	and	O
1154	cm	B-PK
1154	##ax	I-PK
1154	with	O
1154	and	O
1154	without	O
1154	e	O
1154	##vo	O
1154	##fo	O
1154	##s	O
1154	##fa	O
1154	##mi	O
1154	##de	O
1154	were	O
1154	1	O
1154	.	O
1154	04	O
1154	(	O
1154	1	O
1154	.	O
1154	03	O
1154	;	O
1154	1	O
1154	.	O
1154	04	O
1154	)	O
1154	,	O
1154	and	O
1154	1	O
1154	.	O
1154	04	O
1154	(	O
1154	1	O
1154	.	O
1154	03	O
1154	;	O
1154	1	O
1154	.	O
1154	04	O
1154	)	O
1154	,	O
1154	respectively	O
1154	.	O
1154	[SEP]	O
1155	[CLS]	O
1155	sensitivity	O
1155	analyses	O
1155	showed	O
1155	that	O
1155	the	O
1155	au	B-PK
1155	##c	I-PK
1155	ratio	I-PK
1155	(	O
1155	95	O
1155	%	O
1155	c	O
1155	##i	O
1155	)	O
1155	both	O
1155	at	O
1155	half	O
1155	the	O
1155	measured	O
1155	k	B-PK
1155	##i	I-PK
1155	value	O
1155	of	O
1155	1	O
1155	.	O
1155	07	O
1155	(	O
1155	1	O
1155	.	O
1155	06	O
1155	;	O
1155	1	O
1155	.	O
1155	08	O
1155	)	O
1155	and	O
1155	at	O
1155	a	O
1155	5	O
1155	‐	O
1155	fold	O
1155	increased	O
1155	in	O
1155	##tra	O
1155	##cellular	O
1155	concentration	O
1155	of	O
1155	e	O
1155	##vo	O
1155	##fo	O
1155	##s	O
1155	##fa	O
1155	##mi	O
1155	##de	O
1155	1	O
1155	.	O
1155	16	O
1155	(	O
1155	1	O
1155	.	O
1155	13	O
1155	;	O
1155	1	O
1155	.	O
1155	18	O
1155	)	O
1155	were	O
1155	well	O
1155	below	O
1155	the	O
1155	threshold	O
1155	of	O
1155	1	O
1155	.	O
1155	25	O
1155	.	O
1155	[SEP]	O
1156	[CLS]	O
1156	the	O
1156	results	O
1156	shown	O
1156	in	O
1156	table	O
1156	##3	O
1156	indicated	O
1156	a	O
1156	<	O
1156	1	O
1156	%	O
1156	change	O
1156	in	O
1156	both	O
1156	au	B-PK
1156	##c	I-PK
1156	and	O
1156	cm	B-PK
1156	##ax	I-PK
1156	values	O
1156	following	O
1156	e	O
1156	##vo	O
1156	##fo	O
1156	##s	O
1156	##fa	O
1156	##mi	O
1156	##de	O
1156	administration	O
1156	.	O
1156	[SEP]	O
1157	[CLS]	O
1157	the	O
1157	au	B-PK
1157	##c	I-PK
1157	ratios	I-PK
1157	stayed	O
1157	below	O
1157	1	O
1157	.	O
1157	02	O
1157	for	O
1157	all	O
1157	simulated	O
1157	scenarios	O
1157	,	O
1157	including	O
1157	sensitivity	O
1157	analyses	O
1157	.	O
1157	[SEP]	O
1158	[CLS]	O
1158	the	O
1158	au	B-PK
1158	##c	I-PK
1158	ratios	I-PK
1158	also	O
1158	stayed	O
1158	below	O
1158	1	O
1158	.	O
1158	02	O
1158	for	O
1158	repeat	O
1158	dos	O
1158	##ing	O
1158	of	O
1158	e	O
1158	##vo	O
1158	##fo	O
1158	##s	O
1158	##fa	O
1158	##mi	O
1158	##de	O
1158	,	O
1158	in	O
1158	which	O
1158	c	O
1158	##y	O
1158	##p	O
1158	##2	O
1158	##b	O
1158	##6	O
1158	was	O
1158	only	O
1158	minimal	O
1158	##ly	O
1158	in	O
1158	##hibit	O
1158	##ed	O
1158	.	O
1158	[SEP]	O
1159	[CLS]	O
1159	more	O
1159	than	O
1159	99	O
1159	.	O
1159	5	O
1159	%	O
1159	of	O
1159	is	O
1159	##oz	O
1159	##yme	O
1159	remained	O
1159	active	O
1159	,	O
1159	leading	O
1159	to	O
1159	b	O
1159	##up	O
1159	##rop	O
1159	##ion	O
1159	au	B-PK
1159	##c	I-PK
1159	ratios	I-PK
1159	of	O
1159	1	O
1159	.	O
1159	00	O
1159	(	O
1159	1	O
1159	.	O
1159	00	O
1159	;	O
1159	1	O
1159	.	O
1159	00	O
1159	)	O
1159	,	O
1159	indicating	O
1159	a	O
1159	lack	O
1159	of	O
1159	potential	O
1159	in	O
1159	##hibition	O
1159	of	O
1159	c	O
1159	##y	O
1159	##p	O
1159	##2	O
1159	##b	O
1159	##6	O
1159	by	O
1159	e	O
1159	##vo	O
1159	##fo	O
1159	##s	O
1159	##fa	O
1159	##mi	O
1159	##de	O
1159	in	O
1159	the	O
1159	clinic	O
1159	.	O
1159	[SEP]	O
1160	[CLS]	O
1160	static	O
1160	modeling	O
1160	predicted	O
1160	au	B-PK
1160	##c	I-PK
1160	ratios	I-PK
1160	above	O
1160	the	O
1160	threshold	O
1160	of	O
1160	1	O
1160	.	O
1160	25	O
1160	;	O
1160	the	O
1160	values	O
1160	are	O
1160	presented	O
1160	in	O
1160	table	O
1160	##4	O
1160	.	O
1160	[SEP]	O
1161	[CLS]	O
1161	no	O
1161	in	O
1161	##hibition	O
1161	by	O
1161	e	O
1161	##vo	O
1161	##fo	O
1161	##s	O
1161	##fa	O
1161	##mi	O
1161	##de	O
1161	was	O
1161	predicted	O
1161	for	O
1161	c	O
1161	##y	O
1161	##p	O
1161	##3	O
1161	##a	O
1161	##4	O
1161	/	O
1161	5	O
1161	with	O
1161	au	B-PK
1161	##c	I-PK
1161	ratios	I-PK
1161	close	O
1161	to	O
1161	unity	O
1161	(	O
1161	table	O
1161	##3	O
1161	)	O
1161	.	O
1161	[SEP]	O
1162	[CLS]	O
1162	sensitivity	O
1162	analyses	O
1162	for	O
1162	k	B-PK
1162	##i	I-PK
1162	(	O
1162	direct	O
1162	in	O
1162	##hibition	O
1162	)	O
1162	,	O
1162	and	O
1162	ka	B-PK
1162	##pp	I-PK
1162	and	O
1162	kin	B-PK
1162	##act	I-PK
1162	(	O
1162	mechanism	O
1162	‐	O
1162	based	O
1162	in	O
1162	##hibition	O
1162	(	O
1162	m	O
1162	##bi	O
1162	)	O
1162	)	O
1162	showed	O
1162	au	B-PK
1162	##c	I-PK
1162	ratios	I-PK
1162	below	O
1162	1	O
1162	.	O
1162	10	O
1162	,	O
1162	which	O
1162	is	O
1162	well	O
1162	below	O
1162	the	O
1162	threshold	O
1162	of	O
1162	1	O
1162	.	O
1162	25	O
1162	for	O
1162	e	O
1162	##vo	O
1162	##fo	O
1162	##s	O
1162	##fa	O
1162	##mi	O
1162	##de	O
1162	to	O
1162	be	O
1162	considered	O
1162	as	O
1162	a	O
1162	weak	O
1162	inhibitor	O
1162	.	O
1162	[SEP]	O
1163	[CLS]	O
1163	the	O
1163	au	B-PK
1163	##c	I-PK
1163	and	O
1163	cm	B-PK
1163	##ax	I-PK
1163	ratios	I-PK
1163	(	O
1163	table	O
1163	##3	O
1163	)	O
1163	of	O
1163	mid	O
1163	##az	O
1163	##ola	O
1163	##m	O
1163	are	O
1163	near	O
1163	unity	O
1163	and	O
1163	well	O
1163	above	O
1163	the	O
1163	threshold	O
1163	of	O
1163	0	O
1163	.	O
1163	80	O
1163	for	O
1163	consideration	O
1163	of	O
1163	e	O
1163	##vo	O
1163	##fo	O
1163	##s	O
1163	##fa	O
1163	##mi	O
1163	##de	O
1163	as	O
1163	a	O
1163	weak	O
1163	induce	O
1163	##r	O
1163	of	O
1163	c	O
1163	##y	O
1163	##p	O
1163	##3	O
1163	##a	O
1163	.	O
1163	[SEP]	O
1164	[CLS]	O
1164	the	O
1164	sensitivity	O
1164	analyses	O
1164	yielded	O
1164	au	B-PK
1164	##c	I-PK
1164	ratios	I-PK
1164	(	O
1164	95	O
1164	%	O
1164	c	O
1164	##i	O
1164	)	O
1164	of	O
1164	0	O
1164	.	O
1164	82	O
1164	(	O
1164	0	O
1164	.	O
1164	80	O
1164	;	O
1164	0	O
1164	.	O
1164	85	O
1164	)	O
1164	assuming	O
1164	2	O
1164	‐	O
1164	fold	O
1164	higher	O
1164	in	O
1164	##d	O
1164	##max	O
1164	and	O
1164	0	O
1164	.	O
1164	88	O
1164	(	O
1164	0	O
1164	.	O
1164	86	O
1164	;	O
1164	0	O
1164	.	O
1164	90	O
1164	)	O
1164	assuming	O
1164	2	O
1164	‐	O
1164	fold	O
1164	lower	O
1164	in	O
1164	##d	O
1164	##c	O
1164	##50	O
1164	,	O
1164	and	O
1164	are	O
1164	,	O
1164	therefore	O
1164	,	O
1164	above	O
1164	the	O
1164	regulatory	O
1164	threshold	O
1164	of	O
1164	0	O
1164	.	O
1164	80	O
1164	in	O
1164	the	O
1164	sensitivity	O
1164	analyses	O
1164	regarding	O
1164	the	O
1164	induction	O
1164	parameters	O
1164	.	O
1164	[SEP]	O
1165	[CLS]	O
1165	published	O
1165	work	O
1165	suggests	O
1165	that	O
1165	the	O
1165	clearance	B-PK
1165	of	O
1165	end	O
1165	##ogen	O
1165	##ous	O
1165	a	O
1165	##po	O
1165	##a	O
1165	-	O
1165	i	O
1165	may	O
1165	be	O
1165	accelerated	O
1165	in	O
1165	patients	O
1165	with	O
1165	risk	O
1165	factors	O
1165	for	O
1165	ch	O
1165	##d	O
1165	.	O
1165	13	O
1165	more	O
1165	importantly	O
1165	,	O
1165	several	O
1165	authors	O
1165	have	O
1165	reported	O
1165	that	O
1165	the	O
1165	h	O
1165	##dl	O
1165	from	O
1165	patients	O
1165	with	O
1165	ch	O
1165	##d	O
1165	may	O
1165	have	O
1165	impaired	O
1165	functionality	O
1165	and	O
1165	have	O
1165	further	O
1165	speculated	O
1165	that	O
1165	the	O
1165	physiological	O
1165	status	O
1165	of	O
1165	these	O
1165	patients	O
1165	may	O
1165	alter	O
1165	the	O
1165	h	O
1165	##dl	O
1165	to	O
1165	render	O
1165	it	O
1165	less	O
1165	functional	O
1165	or	O
1165	even	O
1165	d	O
1165	##ys	O
1165	##function	O
1165	##al	O
1165	.	O
1165	14	O
1165	for	O
1165	example	O
1165	,	O
1165	h	O
1165	##dl	O
1165	pu	O
1165	##rified	O
1165	from	O
1165	patients	O
1165	with	O
1165	stable	O
1165	at	O
1165	##her	O
1165	##os	O
1165	##cle	O
1165	##rot	O
1165	##ic	O
1165	disease	O
1165	exhibits	O
1165	lower	O
1165	c	O
1165	##ec	O
1165	than	O
1165	that	O
1165	from	O
1165	healthy	O
1165	subjects	O
1165	even	O
1165	after	O
1165	normal	O
1165	##ization	O
1165	for	O
1165	protein	O
1165	or	O
1165	ch	O
1165	##ole	O
1165	##ster	O
1165	##ol	O
1165	content	O
1165	.	O
1165	15	O
1165	,	O
1165	16	O
1165	recent	O
1165	work	O
1165	using	O
1165	both	O
1165	animal	O
1165	and	O
1165	human	O
1165	subjects	O
1165	suggests	O
1165	that	O
1165	the	O
1165	function	O
1165	of	O
1165	h	O
1165	##dl	O
1165	may	O
1165	be	O
1165	impaired	O
1165	by	O
1165	the	O
1165	action	O
1165	of	O
1165	serum	O
1165	am	O
1165	##yl	O
1165	##oid	O
1165	a	O
1165	,	O
1165	an	O
1165	h	O
1165	##dl	O
1165	-	O
1165	associated	O
1165	serum	O
1165	protein	O
1165	that	O
1165	is	O
1165	up	O
1165	##re	O
1165	##gu	O
1165	##lated	O
1165	in	O
1165	acute	O
1165	co	O
1165	##rona	O
1165	##ry	O
1165	syndrome	O
1165	,	O
1165	ch	O
1165	##d	O
1165	,	O
1165	and	O
1165	any	O
1165	condition	O
1165	that	O
1165	pro	O
1165	##voke	O
1165	##s	O
1165	a	O
1165	he	O
1165	##pa	O
1165	##tic	O
1165	acute	O
1165	phase	O
1165	response	O
1165	.	O
1165	17	O
1165	,	O
1165	18	O
1165	it	O
1165	is	O
1165	thus	O
1165	possible	O
1165	that	O
1165	the	O
1165	amount	O
1165	or	O
1165	functional	O
1165	activity	O
1165	of	O
1165	c	O
1165	##s	O
1165	##l	O
1165	##11	O
1165	##2	O
1165	might	O
1165	be	O
1165	altered	O
1165	in	O
1165	patients	O
1165	with	O
1165	card	O
1165	##iovascular	O
1165	disease	O
1165	.	O
1165	[SEP]	O
1166	[CLS]	O
1166	in	O
1166	addition	O
1166	,	O
1166	subjects	O
1166	were	O
1166	s	O
1166	##tra	O
1166	##ti	O
1166	##fied	O
1166	in	O
1166	equal	O
1166	proportions	O
1166	to	O
1166	have	O
1166	normal	O
1166	re	O
1166	##nal	O
1166	function	O
1166	(	O
1166	c	O
1166	##rea	O
1166	##tin	O
1166	##ine	O
1166	clearance	O
1166	≥	O
1166	##90	O
1166	m	O
1166	##l	O
1166	/	O
1166	min	O
1166	)	O
1166	or	O
1166	mild	O
1166	re	O
1166	##nal	O
1166	imp	O
1166	##air	O
1166	##ment	O
1166	(	O
1166	c	O
1166	##rea	O
1166	##tin	O
1166	##ine	O
1166	clearance	O
1166	≥	O
1166	##60	O
1166	and	O
1166	<	O
1166	90	O
1166	m	O
1166	##l	O
1166	/	O
1166	min	O
1166	)	O
1166	.	O
1166	[SEP]	O
1167	[CLS]	O
1167	p	O
1167	##har	O
1167	##ma	O
1167	##co	O
1167	##kin	O
1167	##etics	O
1167	parameters	O
1167	for	O
1167	base	O
1167	##line	O
1167	-	O
1167	corrected	O
1167	plasma	O
1167	concentrations	O
1167	of	O
1167	a	O
1167	##po	O
1167	##a	O
1167	-	O
1167	i	O
1167	were	O
1167	determined	O
1167	after	O
1167	single	O
1167	and	O
1167	multiple	O
1167	in	O
1167	##tra	O
1167	##ven	O
1167	##ous	O
1167	in	O
1167	##fusion	O
1167	##s	O
1167	of	O
1167	c	O
1167	##s	O
1167	##l	O
1167	##11	O
1167	##2	O
1167	and	O
1167	included	O
1167	area	B-PK
1167	under	I-PK
1167	the	I-PK
1167	plasma	I-PK
1167	concentration	I-PK
1167	time	I-PK
1167	curve	I-PK
1167	from	I-PK
1167	time	I-PK
1167	point	I-PK
1167	zero	I-PK
1167	(	I-PK
1167	before	I-PK
1167	dos	I-PK
1167	##ing	I-PK
1167	)	I-PK
1167	to	I-PK
1167	the	I-PK
1167	last	I-PK
1167	time	I-PK
1167	point	I-PK
1167	above	I-PK
1167	base	I-PK
1167	##line	I-PK
1167	(	I-PK
1167	au	I-PK
1167	##c	I-PK
1167	##0	I-PK
1167	–	I-PK
1167	last	I-PK
1167	)	I-PK
1167	,	O
1167	maximum	B-PK
1167	plasma	I-PK
1167	concentration	I-PK
1167	,	O
1167	and	O
1167	half	B-PK
1167	-	I-PK
1167	life	I-PK
1167	.	O
1167	[SEP]	O
1168	[CLS]	O
1168	a	O
1168	2	O
1168	-	O
1168	compartment	O
1168	in	O
1168	##tra	O
1168	##ven	O
1168	##ous	O
1168	model	O
1168	para	O
1168	##met	O
1168	##riz	O
1168	##ed	O
1168	in	O
1168	terms	O
1168	of	O
1168	elimination	B-PK
1168	clearance	I-PK
1168	,	O
1168	central	B-PK
1168	volume	I-PK
1168	of	I-PK
1168	distribution	I-PK
1168	(	I-PK
1168	v	I-PK
1168	##c	I-PK
1168	)	I-PK
1168	,	O
1168	inter	B-PK
1168	##com	I-PK
1168	##par	I-PK
1168	##tment	I-PK
1168	##al	I-PK
1168	clearance	I-PK
1168	(	I-PK
1168	q	I-PK
1168	)	I-PK
1168	,	O
1168	peripheral	B-PK
1168	volume	I-PK
1168	of	I-PK
1168	distribution	I-PK
1168	(	I-PK
1168	v	I-PK
1168	##p	I-PK
1168	)	I-PK
1168	,	O
1168	and	O
1168	base	O
1168	##line	O
1168	a	O
1168	##po	O
1168	##a	O
1168	-	O
1168	i	O
1168	serum	O
1168	concentration	O
1168	.	O
1168	[SEP]	O
1169	[CLS]	O
1169	the	O
1169	following	O
1169	p	O
1169	##har	O
1169	##ma	O
1169	##co	O
1169	##dynamic	O
1169	parameters	O
1169	were	O
1169	assessed	O
1169	:	O
1169	area	O
1169	under	O
1169	the	O
1169	effect	O
1169	curve	O
1169	for	O
1169	time	O
1169	point	O
1169	zero	O
1169	to	O
1169	the	O
1169	time	O
1169	point	O
1169	of	O
1169	the	O
1169	last	O
1169	q	O
1169	##uant	O
1169	##ifiable	O
1169	concentration	O
1169	/	O
1169	activity	O
1169	(	O
1169	au	O
1169	##ec	O
1169	##0	O
1169	–	O
1169	last	O
1169	)	O
1169	,	O
1169	maximum	B-PK
1169	bio	I-PK
1169	##mark	I-PK
1169	##er	I-PK
1169	concentration	I-PK
1169	/	I-PK
1169	activity	I-PK
1169	(	I-PK
1169	r	I-PK
1169	##max	I-PK
1169	)	I-PK
1169	,	O
1169	and	O
1169	time	B-PK
1169	to	I-PK
1169	reach	I-PK
1169	maximum	I-PK
1169	concentration	I-PK
1169	/	I-PK
1169	activity	I-PK
1169	(	I-PK
1169	t	I-PK
1169	##max	I-PK
1169	)	I-PK
1169	.	O
1169	[SEP]	O
1170	[CLS]	O
1170	comparison	O
1170	of	O
1170	the	O
1170	relationship	O
1170	of	O
1170	total	O
1170	c	O
1170	##ec	O
1170	au	O
1170	##ec	O
1170	##0	O
1170	–	O
1170	24	O
1170	,	O
1170	pre	O
1170	–	O
1170	β	O
1170	##1	O
1170	-	O
1170	h	O
1170	##dl	O
1170	au	O
1170	##ec	O
1170	##0	O
1170	–	O
1170	24	O
1170	,	O
1170	and	O
1170	h	O
1170	##dl	O
1170	-	O
1170	c	O
1170	au	O
1170	##ec	O
1170	##0	O
1170	##─	O
1170	##7	O
1170	##2	O
1170	versus	O
1170	a	O
1170	##po	O
1170	##a	O
1170	-	O
1170	i	O
1170	au	B-PK
1170	##c	I-PK
1170	between	O
1170	studies	O
1170	was	O
1170	done	O
1170	using	O
1170	random	O
1170	effects	O
1170	re	O
1170	##gression	O
1170	models	O
1170	with	O
1170	patient	O
1170	as	O
1170	the	O
1170	random	O
1170	effect	O
1170	and	O
1170	testing	O
1170	the	O
1170	parallel	O
1170	##ism	O
1170	of	O
1170	slopes	O
1170	hypothesis	O
1170	.	O
1170	[SEP]	O
1171	[CLS]	O
1171	c	O
1171	##s	O
1171	##l	O
1171	##11	O
1171	##2	O
1171	p	O
1171	##har	O
1171	##ma	O
1171	##co	O
1171	##kin	O
1171	##etics	O
1171	parameters	O
1171	were	O
1171	,	O
1171	therefore	O
1171	,	O
1171	determined	O
1171	from	O
1171	base	O
1171	##line	O
1171	-	O
1171	corrected	O
1171	plasma	O
1171	concentrations	O
1171	of	O
1171	a	O
1171	##po	O
1171	##a	O
1171	-	O
1171	i	O
1171	.	O
1171	as	O
1171	previously	O
1171	reported	O
1171	in	O
1171	healthy	O
1171	subjects	O
1171	##19	O
1171	and	O
1171	patients	O
1171	with	O
1171	at	O
1171	##her	O
1171	##os	O
1171	##cle	O
1171	##rot	O
1171	##ic	O
1171	disease	O
1171	,	O
1171	12	O
1171	the	O
1171	p	O
1171	##har	O
1171	##ma	O
1171	##co	O
1171	##kin	O
1171	##etics	O
1171	of	O
1171	a	O
1171	##po	O
1171	##a	O
1171	-	O
1171	i	O
1171	is	O
1171	characterized	O
1171	by	O
1171	dose	O
1171	-	O
1171	dependent	O
1171	increases	O
1171	in	O
1171	concentration	O
1171	(	O
1171	t	B-PK
1171	##max	I-PK
1171	≈	O
1171	##2	O
1171	hours	O
1171	)	O
1171	and	O
1171	a	O
1171	slow	O
1171	elimination	O
1171	(	O
1171	figure	O
1171	1	O
1171	##a	O
1171	)	O
1171	.	O
1171	[SEP]	O
1172	[CLS]	O
1172	after	O
1172	accounting	O
1172	for	O
1172	the	O
1172	effect	O
1172	of	O
1172	body	O
1172	weight	O
1172	on	O
1172	a	O
1172	##po	O
1172	##a	O
1172	-	O
1172	i	O
1172	clearance	B-PK
1172	in	O
1172	the	O
1172	model	O
1172	,	O
1172	there	O
1172	was	O
1172	no	O
1172	significant	O
1172	effect	O
1172	of	O
1172	population	O
1172	(	O
1172	healthy	O
1172	subject	O
1172	versus	O
1172	patients	O
1172	with	O
1172	stable	O
1172	at	O
1172	##her	O
1172	##os	O
1172	##cle	O
1172	##rot	O
1172	##ic	O
1172	disease	O
1172	)	O
1172	or	O
1172	other	O
1172	demographic	O
1172	##s	O
1172	that	O
1172	were	O
1172	tested	O
1172	in	O
1172	the	O
1172	model	O
1172	on	O
1172	the	O
1172	p	O
1172	##har	O
1172	##ma	O
1172	##co	O
1172	##kin	O
1172	##etics	O
1172	of	O
1172	a	O
1172	##po	O
1172	##a	O
1172	-	O
1172	i	O
1172	(	O
1172	manuscript	O
1172	in	O
1172	preparation	O
1172	)	O
1172	.	O
1172	22	O
1172	this	O
1172	is	O
1172	further	O
1172	demonstrated	O
1172	in	O
1172	figure	O
1172	1	O
1172	##b	O
1172	,	O
1172	which	O
1172	shows	O
1172	the	O
1172	similar	O
1172	model	O
1172	predicted	O
1172	exposure	O
1172	(	O
1172	au	B-PK
1172	##c	I-PK
1172	,	I-PK
1172	0	I-PK
1172	–	I-PK
1172	48	I-PK
1172	hours	I-PK
1172	)	O
1172	in	O
1172	healthy	O
1172	subjects	O
1172	and	O
1172	patients	O
1172	.	O
1172	[SEP]	O
1173	[CLS]	O
1173	these	O
1173	results	O
1173	suggest	O
1173	that	O
1173	the	O
1173	presence	O
1173	of	O
1173	stable	O
1173	at	O
1173	##her	O
1173	##os	O
1173	##cle	O
1173	##rot	O
1173	##ic	O
1173	disease	O
1173	does	O
1173	not	O
1173	affect	O
1173	the	O
1173	clearance	B-PK
1173	of	O
1173	in	O
1173	##fused	O
1173	c	O
1173	##s	O
1173	##l	O
1173	##11	O
1173	##2	O
1173	,	O
1173	its	O
1173	interaction	O
1173	with	O
1173	end	O
1173	##ogen	O
1173	##ous	O
1173	h	O
1173	##dl	O
1173	,	O
1173	or	O
1173	the	O
1173	formation	O
1173	of	O
1173	pre	O
1173	–	O
1173	β	O
1173	##1	O
1173	-	O
1173	h	O
1173	##dl	O
1173	.	O
1173	[SEP]	O
1174	[CLS]	O
1174	a	O
1174	similar	O
1174	pattern	O
1174	was	O
1174	seen	O
1174	also	O
1174	in	O
1174	both	O
1174	phase	O
1174	1	O
1174	studies	O
1174	.	O
1174	10	O
1174	to	O
1174	enable	O
1174	comparison	O
1174	between	O
1174	patients	O
1174	with	O
1174	stable	O
1174	at	O
1174	##her	O
1174	##os	O
1174	##cle	O
1174	##rot	O
1174	##ic	O
1174	disease	O
1174	and	O
1174	healthy	O
1174	subjects	O
1174	from	O
1174	2	O
1174	prior	O
1174	phase	O
1174	1	O
1174	studies	O
1174	,	O
1174	h	O
1174	##dl	O
1174	-	O
1174	c	O
1174	au	O
1174	##ec	O
1174	##0	O
1174	–	O
1174	72	O
1174	versus	O
1174	a	O
1174	##po	O
1174	##a	O
1174	-	O
1174	i	O
1174	au	B-PK
1174	##c	I-PK
1174	##0	I-PK
1174	–	I-PK
1174	72	I-PK
1174	was	O
1174	plot	O
1174	##ted	O
1174	.	O
1174	[SEP]	O
1175	[CLS]	O
1175	analysis	O
1175	of	O
1175	the	O
1175	total	O
1175	c	O
1175	##ec	O
1175	au	O
1175	##ec	O
1175	##0	O
1175	–	O
1175	24	O
1175	versus	O
1175	a	O
1175	##po	O
1175	##a	O
1175	-	O
1175	i	O
1175	au	B-PK
1175	##c	I-PK
1175	##0	I-PK
1175	–	I-PK
1175	24	I-PK
1175	(	O
1175	figure	O
1175	4	O
1175	##c	O
1175	)	O
1175	as	O
1175	well	O
1175	as	O
1175	a	O
1175	##b	O
1175	##ca	O
1175	##1	O
1175	-	O
1175	dependent	O
1175	and	O
1175	a	O
1175	##b	O
1175	##ca	O
1175	##1	O
1175	-	O
1175	independent	O
1175	c	O
1175	##ec	O
1175	(	O
1175	data	O
1175	not	O
1175	shown	O
1175	)	O
1175	showed	O
1175	these	O
1175	elevations	O
1175	to	O
1175	be	O
1175	linear	O
1175	dose	O
1175	dependent	O
1175	in	O
1175	all	O
1175	3	O
1175	study	O
1175	populations	O
1175	.	O
1175	[SEP]	O
1176	[CLS]	O
1176	the	O
1176	evidence	O
1176	of	O
1176	thee	O
1176	##x	O
1176	##pect	O
1176	##ed	O
1176	model	O
1176	was	O
1176	calculated	O
1176	by	O
1176	analyzing	O
1176	the	O
1176	p	O
1176	##hi	O
1176	(	O
1176	f	O
1176	)	O
1176	and	O
1176	ps	O
1176	##i	O
1176	(	O
1176	?	O
1176	)	O
1176	to	O
1176	##rs	O
1176	##ion	O
1176	angles	O
1176	using	O
1176	pro	O
1176	##che	O
1176	##ck	O
1176	online	O
1176	server	O
1176	.	O
1176	[SEP]	O
1177	[CLS]	O
1177	discovery	O
1177	studio	O
1177	3	O
1177	.	O
1177	5	O
1177	(	O
1177	a	O
1177	##cc	O
1177	##el	O
1177	##ry	O
1177	##s	O
1177	sa	O
1177	##n	O
1177	die	O
1177	##go	O
1177	,	O
1177	us	O
1177	##a	O
1177	)	O
1177	was	O
1177	used	O
1177	to	O
1177	##generate	O
1177	ad	O
1177	##met	O
1177	values	O
1177	.	O
1177	[SEP]	O
1178	[CLS]	O
1178	thus	O
1178	,	O
1178	in	O
1178	as	O
1178	##ili	O
1178	##con	O
1178	profile	O
1178	of	O
1178	p	O
1178	##har	O
1178	##ma	O
1178	##co	O
1178	##kin	O
1178	##etic	O
1178	selected	O
1178	compounds	O
1178	were	O
1178	##eval	O
1178	##uated	O
1178	for	O
1178	put	O
1178	##ative	O
1178	bio	B-PK
1178	##ava	I-PK
1178	##ila	I-PK
1178	##bility	I-PK
1178	for	O
1178	c	O
1178	##rz	O
1178	##1	O
1178	inhibitor	O
1178	##s	O
1178	(	O
1178	table	O
1178	2	O
1178	)	O
1178	.	O
1178	lip	O
1178	##op	O
1178	##hil	O
1178	##icit	O
1178	##y	O
1178	(	O
1178	c	O
1178	##log	O
1178	##p	O
1178	)	O
1178	,	O
1178	p	O
1178	##hy	O
1178	##si	O
1178	##co	O
1178	##chemical	O
1178	properties	O
1178	,	O
1178	polar	O
1178	surface	O
1178	##are	O
1178	##a	O
1178	,	O
1178	molecular	O
1178	weight	O
1178	(	O
1178	m	O
1178	##w	O
1178	)	O
1178	and	O
1178	primarily	O
1178	a	O
1178	##que	O
1178	##ous	O
1178	so	O
1178	##lub	O
1178	##ility	O
1178	(	O
1178	logs	O
1178	)	O
1178	are	O
1178	linear	O
1178	##ly	O
1178	connected	O
1178	to	O
1178	the	O
1178	bio	B-PK
1178	##ava	I-PK
1178	##ila	I-PK
1178	##bility	I-PK
1178	and	O
1178	absorption	O
1178	of	O
1178	##dr	O
1178	##ug	O
1178	molecule	O
1178	37	O
1178	,	O
1178	38	O
1178	.	O
1178	[SEP]	O
1179	[CLS]	O
1179	along	O
1179	with	O
1179	p	O
1179	value	O
1179	(	O
1179	lip	O
1179	##op	O
1179	##hil	O
1179	##icit	O
1179	##y	O
1179	)	O
1179	is	O
1179	a	O
1179	significant	O
1179	property	O
1179	for	O
1179	calculating	O
1179	per	O
1179	##oral	O
1179	bio	B-PK
1179	##ava	I-PK
1179	##ila	I-PK
1179	##bility	I-PK
1179	of	O
1179	them	O
1179	##ole	O
1179	##cule	O
1179	##s	O
1179	of	O
1179	the	O
1179	drug	O
1179	.	O
1179	[SEP]	O
1180	[CLS]	O
1180	the	O
1180	##com	O
1180	##po	O
1180	##und	O
1180	73	O
1180	##17	O
1180	##0	O
1180	also	O
1180	interact	O
1180	##s	O
1180	with	O
1180	the	O
1180	c	O
1180	##rz	O
1180	##1	O
1180	binding	O
1180	site	O
1180	by	O
1180	##int	O
1180	##era	O
1180	##cting	O
1180	with	O
1180	other	O
1180	residues	O
1180	(	O
1180	le	O
1180	##u	O
1180	##28	O
1180	,	O
1180	le	O
1180	##u	O
1180	##32	O
1180	,	O
1180	t	O
1180	##yr	O
1180	##39	O
1180	,	O
1180	th	O
1180	##r	O
1180	##40	O
1180	,	O
1180	pro	O
1180	##41	O
1180	,	O
1180	pro	O
1180	##5	O
1180	##8	O
1180	,	O
1180	pro	O
1180	##7	O
1180	##1	O
1180	,	O
1180	g	O
1180	##ly	O
1180	##7	O
1180	##4	O
1180	,	O
1180	a	O
1180	##rg	O
1180	##8	O
1180	##1	O
1180	,	O
1180	as	O
1180	##n	O
1180	##24	O
1180	##1	O
1180	,	O
1180	t	O
1180	##yr	O
1180	##24	O
1180	##4	O
1180	,	O
1180	pro	O
1180	##24	O
1180	##5	O
1180	,	O
1180	v	O
1180	##al	O
1180	##25	O
1180	##0	O
1180	,	O
1180	pro	O
1180	##26	O
1180	##0	O
1180	,	O
1180	and	O
1180	as	O
1180	##n	O
1180	##26	O
1180	##1	O
1180	)	O
1180	as	O
1180	compared	O
1180	to	O
1180	flu	O
1180	##dio	O
1180	##xon	O
1180	##il	O
1180	shown	O
1180	in	O
1180	figure	O
1180	##4	O
1180	##b	O
1180	.	O
1180	[SEP]	O
1181	[CLS]	O
1181	protein	O
1181	-	O
1181	l	O
1181	##igan	O
1181	##ds	O
1181	relationships	O
1181	##p	O
1181	##ro	O
1181	##fi	O
1181	##le	O
1181	unveiled	O
1181	that	O
1181	the	O
1181	inhibitor	O
1181	##s	O
1181	of	O
1181	compounds	O
1181	are	O
1181	found	O
1181	to	O
1181	be	O
1181	##most	O
1181	##ly	O
1181	reaching	O
1181	to	O
1181	the	O
1181	active	O
1181	site	O
1181	residues	O
1181	of	O
1181	c	O
1181	##rz	O
1181	##1	O
1181	like	O
1181	as	O
1181	##p	O
1181	##35	O
1181	,	O
1181	his	O
1181	##36	O
1181	,	O
1181	his	O
1181	##4	O
1181	##9	O
1181	,	O
1181	t	O
1181	##yr	O
1181	##6	O
1181	##1	O
1181	,	O
1181	g	O
1181	##lu	O
1181	##25	O
1181	,	O
1181	th	O
1181	##r	O
1181	##27	O
1181	,	O
1181	g	O
1181	##ln	O
1181	##60	O
1181	,	O
1181	pro	O
1181	##26	O
1181	##0	O
1181	,	O
1181	as	O
1181	##n	O
1181	##26	O
1181	##1	O
1181	,	O
1181	as	O
1181	##n	O
1181	##12	O
1181	##8	O
1181	,	O
1181	g	O
1181	##ln	O
1181	##15	O
1181	##6	O
1181	,	O
1181	pro	O
1181	##7	O
1181	##1	O
1181	,	O
1181	a	O
1181	##rg	O
1181	##8	O
1181	##1	O
1181	,	O
1181	g	O
1181	##ly	O
1181	##7	O
1181	##4	O
1181	and	O
1181	associated	O
1181	with	O
1181	hydrogen	O
1181	##bon	O
1181	##ding	O
1181	with	O
1181	bond	O
1181	distance	O
1181	lies	O
1181	within	O
1181	the	O
1181	range	O
1181	of	O
1181	4	O
1181	a	O
1181	(	O
1181	table	O
1181	1	O
1181	)	O
1181	.	O
1181	alpha	O
1181	am	O
1181	##yr	O
1181	##in	O
1181	(	O
1181	73	O
1181	##17	O
1181	##0	O
1181	)	O
1181	was	O
1181	found	O
1181	to	O
1181	be	O
1181	most	O
1181	potent	O
1181	and	O
1181	nicely	O
1181	##bound	O
1181	##ed	O
1181	into	O
1181	the	O
1181	active	O
1181	site	O
1181	of	O
1181	c	O
1181	##rz	O
1181	##1	O
1181	with	O
1181	minimum	O
1181	binding	O
1181	energy	O
1181	(	O
1181	delta	O
1181	##g	O
1181	)	O
1181	-	O
1181	9	O
1181	.	O
1181	8	O
1181	k	O
1181	##cal	O
1181	/	O
1181	m	O
1181	##ol	O
1181	as	O
1181	compared	O
1181	to	O
1181	flu	O
1181	##dio	O
1181	##xon	O
1181	##il	O
1181	(	O
1181	table	O
1181	3	O
1181	and	O
1181	(	O
1181	figure	O
1181	##4	O
1181	##a	O
1181	)	O
1181	.	O
1181	[SEP]	O
1182	[CLS]	O
1182	t	O
1182	##ps	O
1182	##a	O
1182	and	O
1182	the	O
1182	value	O
1182	of	O
1182	lip	O
1182	##op	O
1182	##hil	O
1182	##icit	O
1182	##y	O
1182	(	O
1182	log	O
1182	##p	O
1182	)	O
1182	are	O
1182	the	O
1182	two	O
1182	essential	O
1182	##p	O
1182	##roper	O
1182	##ties	O
1182	in	O
1182	analyzing	O
1182	per	B-PK
1182	##oral	I-PK
1182	bio	I-PK
1182	##ava	I-PK
1182	##ila	I-PK
1182	##bility	I-PK
1182	of	O
1182	drug	O
1182	molecule	O
1182	.	O
1182	[SEP]	O
1183	[CLS]	O
1183	for	O
1183	the	O
1183	compounds	O
1183	with	O
1183	=	O
1183	ten	O
1183	rot	O
1183	##ata	O
1183	##ble	O
1183	bonds	O
1183	and	O
1183	##als	O
1183	##o	O
1183	t	O
1183	##ps	O
1183	##a	O
1183	of	O
1183	≤	O
1183	140	O
1183	a	O
1183	can	O
1183	be	O
1183	said	O
1183	to	O
1183	have	O
1183	good	O
1183	bio	B-PK
1183	##ava	I-PK
1183	##ila	I-PK
1183	##bility	I-PK
1183	46	O
1183	.	O
1183	[SEP]	O
1184	[CLS]	O
1184	t	O
1184	##ps	O
1184	##a	O
1184	of	O
1184	all	O
1184	l	O
1184	##igan	O
1184	##ds	O
1184	exhibited	O
1184	20	O
1184	.	O
1184	23	O
1184	a	O
1184	to	O
1184	##14	O
1184	##0	O
1184	a	O
1184	ranges	O
1184	,	O
1184	which	O
1184	indicates	O
1184	good	O
1184	bio	B-PK
1184	##ava	I-PK
1184	##ila	I-PK
1184	##bility	I-PK
1184	by	O
1184	oral	O
1184	route	O
1184	##ex	O
1184	##ce	O
1184	##pt	O
1184	ka	O
1184	##em	O
1184	##fer	O
1184	##ol	O
1184	,	O
1184	c	O
1184	##yan	O
1184	##id	O
1184	##in	O
1184	3	O
1184	,	O
1184	5	O
1184	g	O
1184	##lu	O
1184	##cos	O
1184	##ide	O
1184	,	O
1184	and	O
1184	que	O
1184	##rc	O
1184	##eti	O
1184	##n	O
1184	.	O
1184	[SEP]	O
1185	[CLS]	O
1185	a	O
1185	two	O
1185	-	O
1185	compartment	O
1185	##al	O
1185	model	O
1185	with	O
1185	first	O
1185	-	O
1185	order	O
1185	absorption	O
1185	and	O
1185	elimination	O
1185	,	O
1185	with	O
1185	clearance	B-PK
1185	dependent	O
1185	on	O
1185	weight	O
1185	adequately	O
1185	described	O
1185	the	O
1185	p	O
1185	##k	O
1185	of	O
1185	r	O
1185	##up	O
1185	##ata	O
1185	##dine	O
1185	for	O
1185	6	O
1185	–	O
1185	11	O
1185	year	O
1185	olds	O
1185	.	O
1185	[SEP]	O
1186	[CLS]	O
1186	the	O
1186	tested	O
1186	models	O
1186	were	O
1186	described	O
1186	in	O
1186	terms	O
1186	of	O
1186	volume	B-PK
1186	of	I-PK
1186	distribution	I-PK
1186	of	I-PK
1186	the	I-PK
1186	central	I-PK
1186	compartment	I-PK
1186	(	I-PK
1186	v	I-PK
1186	##c	I-PK
1186	/	I-PK
1186	f	I-PK
1186	)	I-PK
1186	;	O
1186	volume	B-PK
1186	of	I-PK
1186	distribution	I-PK
1186	of	I-PK
1186	the	I-PK
1186	peripheral	I-PK
1186	compartment	I-PK
1186	(	I-PK
1186	v	I-PK
1186	##p	I-PK
1186	/	I-PK
1186	f	I-PK
1186	)	I-PK
1186	;	O
1186	total	B-PK
1186	body	I-PK
1186	clearance	I-PK
1186	(	I-PK
1186	c	I-PK
1186	##l	I-PK
1186	/	I-PK
1186	f	I-PK
1186	)	I-PK
1186	;	O
1186	inter	B-PK
1186	##com	I-PK
1186	##par	I-PK
1186	##tment	I-PK
1186	##al	I-PK
1186	clearance	I-PK
1186	(	I-PK
1186	c	I-PK
1186	##ld	I-PK
1186	/	I-PK
1186	f	I-PK
1186	)	I-PK
1186	;	O
1186	and	O
1186	the	O
1186	absorption	B-PK
1186	rate	I-PK
1186	constant	I-PK
1186	(	I-PK
1186	ka	I-PK
1186	)	I-PK
1186	.	O
1186	[SEP]	O
1187	[CLS]	O
1187	in	O
1187	addition	O
1187	,	O
1187	the	O
1187	inclusion	O
1187	of	O
1187	absorption	B-PK
1187	la	I-PK
1187	##g	I-PK
1187	time	I-PK
1187	(	I-PK
1187	t	I-PK
1187	##lag	I-PK
1187	)	I-PK
1187	was	O
1187	evaluated	O
1187	in	O
1187	order	O
1187	to	O
1187	help	O
1187	adjust	O
1187	the	O
1187	model	O
1187	to	O
1187	the	O
1187	data	O
1187	in	O
1187	the	O
1187	absorption	O
1187	phase	O
1187	.	O
1187	[SEP]	O
1188	[CLS]	O
1188	the	O
1188	two	O
1188	-	O
1188	compartment	O
1188	model	O
1188	with	O
1188	inter	O
1188	##ind	O
1188	##iv	O
1188	##id	O
1188	##ual	O
1188	var	O
1188	##iability	O
1188	in	O
1188	c	B-PK
1188	##l	I-PK
1188	and	O
1188	v	B-PK
1188	provided	O
1188	a	O
1188	significant	O
1188	decrease	O
1188	of	O
1188	13	O
1188	points	O
1188	in	O
1188	the	O
1188	of	O
1188	compared	O
1188	to	O
1188	the	O
1188	model	O
1188	with	O
1188	a	O
1188	single	O
1188	compartment	O
1188	of	O
1188	disposition	O
1188	(	O
1188	p	O
1188	<	O
1188	0	O
1188	.	O
1188	00	O
1188	##5	O
1188	)	O
1188	and	O
1188	predictions	O
1188	that	O
1188	were	O
1188	closer	O
1188	to	O
1188	the	O
1188	observations	O
1188	.	O
1188	[SEP]	O
1189	[CLS]	O
1189	although	O
1189	an	O
1189	all	O
1189	##ometric	O
1189	s	O
1189	##cal	O
1189	##ing	O
1189	model	O
1189	was	O
1189	tested	O
1189	,	O
1189	the	O
1189	function	O
1189	that	O
1189	best	O
1189	described	O
1189	the	O
1189	weight	O
1189	–	O
1189	c	B-PK
1189	##l	I-PK
1189	/	I-PK
1189	f	I-PK
1189	relationship	O
1189	was	O
1189	a	O
1189	linear	O
1189	model	O
1189	(	O
1189	equation	O
1189	below	O
1189	)	O
1189	.	O
1189	c	O
1189	##li	O
1189	=	O
1189	θ	O
1189	##1	O
1189	+	O
1189	θ	O
1189	##2	O
1189	*	O
1189	(	O
1189	weight	O
1189	/	O
1189	38	O
1189	.	O
1189	5	O
1189	)	O
1189	[SEP]	O
1190	[CLS]	O
1190	b	O
1190	##mi	O
1190	was	O
1190	tested	O
1190	for	O
1190	significance	O
1190	in	O
1190	non	O
1190	##me	O
1190	##m	O
1190	,	O
1190	but	O
1190	no	O
1190	clear	O
1190	improvement	O
1190	of	O
1190	the	O
1190	model	O
1190	was	O
1190	detected	O
1190	respect	O
1190	to	O
1190	the	O
1190	base	O
1190	model	O
1190	(	O
1190	of	O
1190	##v	O
1190	=	O
1190	-	O
1190	114	O
1190	vs	O
1190	-	O
1190	112	O
1190	,	O
1190	p	O
1190	>	O
1190	0	O
1190	.	O
1190	05	O
1190	)	O
1190	.	O
1190	[SEP]	O
1191	[CLS]	O
1191	the	O
1191	incorporation	O
1191	of	O
1191	weight	O
1191	into	O
1191	the	O
1191	r	O
1191	##up	O
1191	##ata	O
1191	##dine	O
1191	clearance	O
1191	model	O
1191	decreased	O
1191	the	O
1191	value	O
1191	of	O
1191	the	O
1191	of	O
1191	in	O
1191	3	O
1191	points	O
1191	(	O
1191	p	O
1191	=	O
1191	0	O
1191	.	O
1191	08	O
1191	)	O
1191	,	O
1191	generally	O
1191	improved	O
1191	the	O
1191	est	O
1191	##imation	O
1191	errors	O
1191	with	O
1191	respect	O
1191	to	O
1191	the	O
1191	base	O
1191	model	O
1191	and	O
1191	explained	O
1191	11	O
1191	.	O
1191	1	O
1191	%	O
1191	of	O
1191	the	O
1191	inter	O
1191	##ind	O
1191	##iv	O
1191	##id	O
1191	##ual	O
1191	var	O
1191	##iability	O
1191	in	O
1191	c	B-PK
1191	##l	I-PK
1191	/	I-PK
1191	f	I-PK
1191	.	O
1191	when	O
1191	the	O
1191	influence	O
1191	of	O
1191	weight	O
1191	on	O
1191	v	B-PK
1191	/	I-PK
1191	f	I-PK
1191	was	O
1191	evaluated	O
1191	,	O
1191	the	O
1191	results	O
1191	argued	O
1191	against	O
1191	its	O
1191	inclusion	O
1191	in	O
1191	the	O
1191	model	O
1191	.	O
1191	[SEP]	O
1192	[CLS]	O
1192	when	O
1192	age	O
1192	was	O
1192	included	O
1192	in	O
1192	the	O
1192	v	B-PK
1192	/	I-PK
1192	f	I-PK
1192	model	O
1192	as	O
1192	un	O
1192	##iva	O
1192	##ria	O
1192	##te	O
1192	,	O
1192	there	O
1192	was	O
1192	no	O
1192	change	O
1192	in	O
1192	the	O
1192	of	O
1192	and	O
1192	it	O
1192	was	O
1192	deemed	O
1192	appropriate	O
1192	to	O
1192	exclude	O
1192	age	O
1192	from	O
1192	the	O
1192	final	O
1192	model	O
1192	following	O
1192	the	O
1192	criterion	O
1192	of	O
1192	simplicity	O
1192	.	O
1192	[SEP]	O
1193	[CLS]	O
1193	the	O
1193	mean	O
1193	maximum	B-PK
1193	blood	I-PK
1193	concentration	I-PK
1193	and	O
1193	half	B-PK
1193	-	I-PK
1193	life	I-PK
1193	of	O
1193	g	O
1193	-	O
1193	c	O
1193	##e	O
1193	##6	O
1193	(	O
1193	2	O
1193	mg	O
1193	/	O
1193	kg	O
1193	)	O
1193	were	O
1193	15	O
1193	.	O
1193	19	O
1193	±	O
1193	4	O
1193	.	O
1193	44	O
1193	μ	O
1193	##g	O
1193	/	O
1193	m	O
1193	##l	O
1193	and	O
1193	3	O
1193	.	O
1193	02	O
1193	±	O
1193	0	O
1193	.	O
1193	58	O
1193	h	O
1193	,	O
1193	respectively	O
1193	.	O
1193	[SEP]	O
1194	[CLS]	O
1194	in	O
1194	the	O
1194	2	O
1194	mg	O
1194	/	O
1194	kg	O
1194	group	O
1194	(	O
1194	n	O
1194	=	O
1194	6	O
1194	)	O
1194	,	O
1194	mean	O
1194	cm	B-PK
1194	##ax	I-PK
1194	=	O
1194	15	O
1194	.	O
1194	19	O
1194	±	O
1194	4	O
1194	.	O
1194	44	O
1194	μ	O
1194	##g	O
1194	/	O
1194	m	O
1194	##l	O
1194	;	O
1194	mean	O
1194	t	B-PK
1194	##1	I-PK
1194	/	I-PK
1194	2	I-PK
1194	=	O
1194	3	O
1194	.	O
1194	02	O
1194	±	O
1194	0	O
1194	.	O
1194	58	O
1194	h	O
1194	;	O
1194	mean	O
1194	area	B-PK
1194	under	I-PK
1194	the	I-PK
1194	curve	I-PK
1194	(	I-PK
1194	au	I-PK
1194	##c	I-PK
1194	)	I-PK
1194	=	O
1194	12	O
1194	.	O
1194	03	O
1194	±	O
1194	3	O
1194	.	O
1194	18	O
1194	μ	O
1194	##g	O
1194	/	O
1194	m	O
1194	##l	O
1194	·	O
1194	h	O
1194	;	O
1194	mean	O
1194	c	B-PK
1194	##l	I-PK
1194	=	O
1194	175	O
1194	.	O
1194	9	O
1194	±	O
1194	45	O
1194	.	O
1194	68	O
1194	m	O
1194	##l	O
1194	/	O
1194	[UNK]	O
1194	;	O
1194	and	O
1194	v	B-PK
1194	##ds	I-PK
1194	##s	I-PK
1194	=	O
1194	52	O
1194	##9	O
1194	.	O
1194	19	O
1194	±	O
1194	188	O
1194	.	O
1194	67	O
1194	m	O
1194	##l	O
1194	/	O
1194	kg	O
1194	.	O
1194	[SEP]	O
1195	[CLS]	O
1195	at	O
1195	24	O
1195	h	O
1195	after	O
1195	the	O
1195	5	O
1195	-	O
1195	min	O
1195	-	O
1195	interval	O
1195	p	O
1195	##dt	O
1195	,	O
1195	widespread	O
1195	tumor	O
1195	cells	O
1195	appeared	O
1195	ne	O
1195	##c	O
1195	##rot	O
1195	##ic	O
1195	,	O
1195	and	O
1195	fi	O
1195	##bri	O
1195	##n	O
1195	th	O
1195	##rom	O
1195	##bus	O
1195	formation	O
1195	within	O
1195	the	O
1195	vessels	O
1195	was	O
1195	observed	O
1195	in	O
1195	the	O
1195	surrounding	O
1195	normal	O
1195	sub	O
1195	##cut	O
1195	##aneous	O
1195	tissues	O
1195	(	O
1195	figure	O
1195	14	O
1195	##b	O
1195	,	O
1195	e	O
1195	)	O
1195	.	O
1195	[SEP]	O
1196	[CLS]	O
1196	at	O
1196	24	O
1196	h	O
1196	after	O
1196	the	O
1196	3	O
1196	-	O
1196	h	O
1196	-	O
1196	interval	O
1196	p	O
1196	##dt	O
1196	,	O
1196	cells	O
1196	at	O
1196	the	O
1196	superficial	O
1196	tumor	O
1196	tissue	O
1196	appeared	O
1196	ne	O
1196	##c	O
1196	##rot	O
1196	##ic	O
1196	,	O
1196	whereas	O
1196	deep	O
1196	-	O
1196	seated	O
1196	tumor	O
1196	cells	O
1196	appeared	O
1196	intact	O
1196	(	O
1196	figure	O
1196	14	O
1196	##c	O
1196	,	O
1196	f	O
1196	)	O
1196	.	O
1196	[SEP]	O
1197	[CLS]	O
1197	in	O
1197	the	O
1197	5	O
1197	mg	O
1197	/	O
1197	kg	O
1197	group	O
1197	(	O
1197	n	O
1197	=	O
1197	6	O
1197	)	O
1197	,	O
1197	mean	O
1197	cm	B-PK
1197	##ax	I-PK
1197	=	O
1197	46	O
1197	.	O
1197	99	O
1197	±	O
1197	12	O
1197	.	O
1197	22	O
1197	μ	O
1197	##g	O
1197	/	O
1197	m	O
1197	##l	O
1197	;	O
1197	mean	O
1197	t	B-PK
1197	##1	I-PK
1197	/	I-PK
1197	2	I-PK
1197	=	O
1197	2	O
1197	.	O
1197	84	O
1197	±	O
1197	0	O
1197	.	O
1197	60	O
1197	h	O
1197	;	O
1197	mean	O
1197	au	B-PK
1197	##c	I-PK
1197	=	O
1197	59	O
1197	.	O
1197	66	O
1197	±	O
1197	7	O
1197	.	O
1197	87	O
1197	μ	O
1197	##g	O
1197	/	O
1197	m	O
1197	##l	O
1197	·	O
1197	h	O
1197	;	O
1197	mean	O
1197	c	B-PK
1197	##l	I-PK
1197	=	O
1197	84	O
1197	.	O
1197	75	O
1197	±	O
1197	10	O
1197	.	O
1197	73	O
1197	m	O
1197	##l	O
1197	/	O
1197	[UNK]	O
1197	;	O
1197	and	O
1197	v	B-PK
1197	##ds	I-PK
1197	##s	I-PK
1197	=	O
1197	258	O
1197	.	O
1197	11	O
1197	±	O
1197	65	O
1197	.	O
1197	57	O
1197	m	O
1197	##l	O
1197	/	O
1197	kg	O
1197	.	O
1197	[SEP]	O
1198	[CLS]	O
1198	in	O
1198	the	O
1198	20	O
1198	mg	O
1198	/	O
1198	kg	O
1198	group	O
1198	(	O
1198	n	O
1198	=	O
1198	1	O
1198	)	O
1198	,	O
1198	cm	B-PK
1198	##ax	I-PK
1198	=	O
1198	82	O
1198	.	O
1198	05	O
1198	μ	O
1198	##g	O
1198	/	O
1198	m	O
1198	##l	O
1198	;	O
1198	t	B-PK
1198	##1	I-PK
1198	/	I-PK
1198	2	I-PK
1198	=	O
1198	2	O
1198	.	O
1198	51	O
1198	h	O
1198	;	O
1198	au	B-PK
1198	##c	I-PK
1198	=	O
1198	234	O
1198	.	O
1198	75	O
1198	μ	O
1198	##g	O
1198	/	O
1198	m	O
1198	##l	O
1198	·	O
1198	h	O
1198	;	O
1198	c	B-PK
1198	##l	I-PK
1198	=	O
1198	85	O
1198	.	O
1198	2	O
1198	m	O
1198	##l	O
1198	/	O
1198	[UNK]	O
1198	;	O
1198	and	O
1198	v	B-PK
1198	##ds	I-PK
1198	##s	I-PK
1198	=	O
1198	28	O
1198	##4	O
1198	.	O
1198	40	O
1198	m	O
1198	##l	O
1198	/	O
1198	kg	O
1198	(	O
1198	table	O
1198	1	O
1198	)	O
1198	.	O
1198	[SEP]	O
1199	[CLS]	O
1199	after	O
1199	in	O
1199	##tra	O
1199	##ven	O
1199	##ous	O
1199	administration	O
1199	of	O
1199	g	O
1199	-	O
1199	c	O
1199	##e	O
1199	##6	O
1199	at	O
1199	a	O
1199	dose	O
1199	of	O
1199	2	O
1199	mg	O
1199	/	O
1199	kg	O
1199	to	O
1199	healthy	O
1199	be	O
1199	##ag	O
1199	##le	O
1199	dogs	O
1199	,	O
1199	drug	O
1199	distribution	O
1199	occurred	O
1199	in	O
1199	the	O
1199	first	O
1199	hour	O
1199	,	O
1199	followed	O
1199	by	O
1199	an	O
1199	elimination	O
1199	phase	O
1199	with	O
1199	a	O
1199	mean	O
1199	t	B-PK
1199	##1	I-PK
1199	/	I-PK
1199	2	I-PK
1199	of	O
1199	3	O
1199	.	O
1199	02	O
1199	±	O
1199	0	O
1199	.	O
1199	58	O
1199	h	O
1199	;	O
1199	the	O
1199	au	B-PK
1199	##c	I-PK
1199	of	O
1199	g	O
1199	-	O
1199	c	O
1199	##e	O
1199	##6	O
1199	at	O
1199	a	O
1199	dose	O
1199	of	O
1199	2	O
1199	mg	O
1199	/	O
1199	kg	O
1199	was	O
1199	12	O
1199	.	O
1199	03	O
1199	±	O
1199	3	O
1199	.	O
1199	18	O
1199	μ	O
1199	##g	O
1199	/	O
1199	m	O
1199	##l	O
1199	·	O
1199	h	O
1199	.	O
1199	[SEP]	O
1200	[CLS]	O
1200	in	O
1200	contrast	O
1200	,	O
1200	the	O
1200	t	B-PK
1200	##1	I-PK
1200	/	I-PK
1200	2	I-PK
1200	and	O
1200	au	B-PK
1200	##c	I-PK
1200	of	O
1200	p	O
1200	##orf	O
1200	##ime	O
1200	##r	O
1200	sodium	O
1200	were	O
1200	44	O
1200	.	O
1200	22	O
1200	±	O
1200	8	O
1200	.	O
1200	10	O
1200	h	O
1200	and	O
1200	167	O
1200	##0	O
1200	.	O
1200	2	O
1200	±	O
1200	71	O
1200	.	O
1200	6	O
1200	μ	O
1200	##g	O
1200	/	O
1200	[UNK]	O
1200	,	O
1200	respectively	O
1200	[	O
1200	39	O
1200	]	O
1200	.	O
1200	[SEP]	O
1201	[CLS]	O
1201	the	O
1201	p	O
1201	##har	O
1201	##ma	O
1201	##co	O
1201	##kin	O
1201	##etic	O
1201	parameters	O
1201	were	O
1201	calculated	O
1201	as	O
1201	follows	O
1201	:	O
1201	half	O
1201	-	O
1201	life	O
1201	(	O
1201	t	O
1201	##1	O
1201	/	O
1201	2	O
1201	)	O
1201	=	O
1201	l	O
1201	##n	O
1201	2	O
1201	/	O
1201	β	O
1201	,	O
1201	where	O
1201	β	O
1201	is	O
1201	the	O
1201	slope	O
1201	of	O
1201	the	O
1201	elimination	O
1201	phase	O
1201	;	O
1201	volume	O
1201	of	O
1201	distribution	O
1201	at	O
1201	steady	O
1201	state	O
1201	(	O
1201	v	O
1201	##ds	O
1201	##s	O
1201	)	O
1201	=	O
1201	dose	O
1201	(	O
1201	a	O
1201	/	O
1201	α	O
1201	##2	O
1201	+	O
1201	b	O
1201	/	O
1201	β	O
1201	##2	O
1201	)	O
1201	/	O
1201	(	O
1201	(	O
1201	a	O
1201	/	O
1201	α	O
1201	)	O
1201	+	O
1201	(	O
1201	b	O
1201	/	O
1201	β	O
1201	)	O
1201	)	O
1201	2	O
1201	,	O
1201	where	O
1201	a	O
1201	and	O
1201	b	O
1201	are	O
1201	the	O
1201	intercept	O
1201	##s	O
1201	of	O
1201	the	O
1201	distribution	O
1201	and	O
1201	elimination	O
1201	phases	O
1201	,	O
1201	respectively	O
1201	;	O
1201	α	O
1201	is	O
1201	the	O
1201	slope	O
1201	of	O
1201	the	O
1201	distribution	O
1201	phase	O
1201	;	O
1201	and	O
1201	clearance	O
1201	(	O
1201	c	O
1201	##l	O
1201	)	O
1201	=	O
1201	dose	O
1201	/	O
1201	au	O
1201	##c	O
1201	,	O
1201	where	O
1201	au	O
1201	##c	O
1201	is	O
1201	the	O
1201	area	O
1201	under	O
1201	the	O
1201	curve	O
1201	,	O
1201	which	O
1201	was	O
1201	calculated	O
1201	using	O
1201	the	O
1201	trap	O
1201	##ez	O
1201	##oid	O
1201	##al	O
1201	method	O
1201	.	O
1201	[SEP]	O
1202	[CLS]	O
1202	the	O
1202	p	O
1202	##har	O
1202	##ma	O
1202	##co	O
1202	##kin	O
1202	##etic	O
1202	studies	O
1202	showed	O
1202	that	O
1202	the	O
1202	cm	B-PK
1202	##ax	I-PK
1202	,	O
1202	t	B-PK
1202	##max	I-PK
1202	,	O
1202	au	B-PK
1202	##c	I-PK
1202	,	O
1202	t	B-PK
1202	##1	I-PK
1202	/	I-PK
1202	2	I-PK
1202	,	O
1202	and	O
1202	m	B-PK
1202	##rt	I-PK
1202	of	O
1202	the	O
1202	major	O
1202	compounds	O
1202	of	O
1202	different	O
1202	extracted	O
1202	parts	O
1202	were	O
1202	significantly	O
1202	different	O
1202	in	O
1202	rat	O
1202	plasma	O
1202	at	O
1202	same	O
1202	dos	O
1202	##age	O
1202	.	O
1202	[SEP]	O
1203	[CLS]	O
1203	the	O
1203	results	O
1203	showed	O
1203	that	O
1203	the	O
1203	cm	B-PK
1203	##ax	I-PK
1203	of	O
1203	h	O
1203	##d	O
1203	##p	O
1203	group	O
1203	was	O
1203	significantly	O
1203	higher	O
1203	,	O
1203	and	O
1203	m	B-PK
1203	##rt	I-PK
1203	and	O
1203	t	B-PK
1203	##1	I-PK
1203	/	I-PK
1203	2	I-PK
1203	were	O
1203	less	O
1203	than	O
1203	the	O
1203	te	O
1203	group	O
1203	.	O
1203	[SEP]	O
1204	[CLS]	O
1204	the	O
1204	dos	O
1204	##age	O
1204	of	O
1204	em	O
1204	##od	O
1204	##in	O
1204	in	O
1204	cap	O
1204	group	O
1204	was	O
1204	much	O
1204	lower	O
1204	than	O
1204	that	O
1204	in	O
1204	the	O
1204	total	O
1204	part	O
1204	and	O
1204	f	O
1204	##ap	O
1204	groups	O
1204	,	O
1204	but	O
1204	the	O
1204	cm	B-PK
1204	##ax	I-PK
1204	was	O
1204	much	O
1204	higher	O
1204	than	O
1204	those	O
1204	in	O
1204	the	O
1204	plasma	O
1204	after	O
1204	administration	O
1204	.	O
1204	[SEP]	O
1205	[CLS]	O
1205	first	O
1205	,	O
1205	the	O
1205	dos	O
1205	##age	O
1205	of	O
1205	em	O
1205	##od	O
1205	##in	O
1205	in	O
1205	f	O
1205	##ap	O
1205	group	O
1205	was	O
1205	similar	O
1205	to	O
1205	the	O
1205	te	O
1205	group	O
1205	,	O
1205	but	O
1205	the	O
1205	cm	B-PK
1205	##ax	I-PK
1205	,	O
1205	au	B-PK
1205	##c	I-PK
1205	##0	I-PK
1205	-	I-PK
1205	24	I-PK
1205	,	O
1205	and	O
1205	au	B-PK
1205	##c	I-PK
1205	##0	I-PK
1205	-	I-PK
1205	∞	I-PK
1205	were	O
1205	significantly	O
1205	lower	O
1205	than	O
1205	those	O
1205	in	O
1205	the	O
1205	te	O
1205	group	O
1205	.	O
1205	[SEP]	O
1206	[CLS]	O
1206	second	O
1206	,	O
1206	the	O
1206	dos	O
1206	##age	O
1206	of	O
1206	em	O
1206	##od	O
1206	##in	O
1206	in	O
1206	cap	O
1206	group	O
1206	was	O
1206	only	O
1206	0	O
1206	.	O
1206	23	O
1206	mg	O
1206	/	O
1206	kg	O
1206	,	O
1206	but	O
1206	the	O
1206	cm	B-PK
1206	##ax	I-PK
1206	,	O
1206	au	B-PK
1206	##c	I-PK
1206	##0	I-PK
1206	-	I-PK
1206	24	I-PK
1206	,	O
1206	and	O
1206	au	B-PK
1206	##c	I-PK
1206	##0	I-PK
1206	-	I-PK
1206	∞	I-PK
1206	were	O
1206	much	O
1206	higher	O
1206	than	O
1206	those	O
1206	in	O
1206	the	O
1206	d	O
1206	##c	O
1206	##m	O
1206	group	O
1206	.	O
1206	[SEP]	O
1207	[CLS]	O
1207	third	O
1207	,	O
1207	the	O
1207	numerical	O
1207	value	O
1207	of	O
1207	au	B-PK
1207	##c	I-PK
1207	##0	I-PK
1207	-	I-PK
1207	24	I-PK
1207	and	O
1207	au	B-PK
1207	##c	I-PK
1207	##0	I-PK
1207	-	I-PK
1207	∞	I-PK
1207	were	O
1207	the	O
1207	sum	O
1207	of	O
1207	h	O
1207	##d	O
1207	##p	O
1207	,	O
1207	cap	O
1207	,	O
1207	and	O
1207	f	O
1207	##ap	O
1207	groups	O
1207	.	O
1207	[SEP]	O
1208	[CLS]	O
1208	according	O
1208	to	O
1208	the	O
1208	dose	O
1208	and	O
1208	concentrations	O
1208	in	O
1208	rat	O
1208	plasma	O
1208	,	O
1208	the	O
1208	ed	O
1208	##g	O
1208	in	O
1208	these	O
1208	three	O
1208	groups	O
1208	might	O
1208	have	O
1208	a	O
1208	low	O
1208	bio	B-PK
1208	##ava	I-PK
1208	##ila	I-PK
1208	##bility	I-PK
1208	and	O
1208	fast	O
1208	elimination	O
1208	.	O
1208	[SEP]	O
1209	[CLS]	O
1209	the	O
1209	bio	B-PK
1209	##ava	I-PK
1209	##ila	I-PK
1209	##bility	I-PK
1209	of	O
1209	ed	O
1209	##g	O
1209	might	O
1209	be	O
1209	low	O
1209	and	O
1209	elimination	O
1209	was	O
1209	fast	O
1209	in	O
1209	rats	O
1209	after	O
1209	administration	O
1209	of	O
1209	these	O
1209	three	O
1209	extract	O
1209	##s	O
1209	,	O
1209	and	O
1209	the	O
1209	concentration	O
1209	point	O
1209	data	O
1209	in	O
1209	rat	O
1209	plasma	O
1209	are	O
1209	incomplete	O
1209	.	O
1209	[SEP]	O
1210	[CLS]	O
1210	to	O
1210	compare	O
1210	the	O
1210	time	O
1210	to	O
1210	parasite	O
1210	clearance	B-PK
1210	between	O
1210	sa	O
1210	##m	O
1210	and	O
1210	non	O
1210	-	O
1210	sa	O
1210	##m	O
1210	children	O
1210	[SEP]	O
1211	[CLS]	O
1211	in	O
1211	addition	O
1211	,	O
1211	the	O
1211	determination	O
1211	of	O
1211	parasite	O
1211	clearance	B-PK
1211	time	O
1211	will	O
1211	involve	O
1211	extra	O
1211	blood	O
1211	films	O
1211	at	O
1211	h	O
1211	##6	O
1211	,	O
1211	h	O
1211	##12	O
1211	,	O
1211	h	O
1211	##36	O
1211	.	O
1211	[SEP]	O
1212	[CLS]	O
1212	as	O
1212	an	O
1212	alternative	O
1212	,	O
1212	the	O
1212	parasite	O
1212	clearance	B-PK
1212	will	O
1212	be	O
1212	determined	O
1212	in	O
1212	all	O
1212	patients	O
1212	,	O
1212	as	O
1212	it	O
1212	is	O
1212	considered	O
1212	the	O
1212	best	O
1212	indicator	O
1212	of	O
1212	impaired	O
1212	efficacy	O
1212	of	O
1212	the	O
1212	art	O
1212	##em	O
1212	##isi	O
1212	##nin	O
1212	component	O
1212	of	O
1212	an	O
1212	act	O
1212	[	O
1212	30	O
1212	]	O
1212	.	O
1212	[SEP]	O
1213	[CLS]	O
1213	a	O
1213	prolonged	O
1213	parasite	O
1213	clearance	B-PK
1213	in	O
1213	children	O
1213	with	O
1213	sa	O
1213	##m	O
1213	would	O
1213	support	O
1213	an	O
1213	impaired	O
1213	efficacy	O
1213	of	O
1213	art	O
1213	##em	O
1213	##eth	O
1213	##er	O
1213	,	O
1213	one	O
1213	possible	O
1213	cause	O
1213	being	O
1213	inadequate	O
1213	exposure	O
1213	to	O
1213	art	O
1213	##em	O
1213	##isi	O
1213	##nin	O
1213	##s	O
1213	.	O
1213	[SEP]	O
1214	[CLS]	O
1214	on	O
1214	the	O
1214	other	O
1214	hand	O
1214	,	O
1214	an	O
1214	un	O
1214	##altered	O
1214	clearance	B-PK
1214	would	O
1214	suggest	O
1214	that	O
1214	art	O
1214	##em	O
1214	##isi	O
1214	##nin	O
1214	exposure	O
1214	and	O
1214	efficacy	O
1214	is	O
1214	adequate	O
1214	.	O
1214	[SEP]	O
1215	[CLS]	O
1215	the	O
1215	data	O
1215	safety	O
1215	monitoring	O
1215	board	O
1215	(	O
1215	d	O
1215	##sm	O
1215	##b	O
1215	)	O
1215	will	O
1215	have	O
1215	the	O
1215	responsibility	O
1215	to	O
1215	monitor	O
1215	closely	O
1215	parasite	O
1215	clearance	B-PK
1215	data	O
1215	,	O
1215	and	O
1215	to	O
1215	recommend	O
1215	a	O
1215	protocol	O
1215	amendment	O
1215	adding	O
1215	art	O
1215	##em	O
1215	##eth	O
1215	##er	O
1215	p	O
1215	##k	O
1215	assessment	O
1215	if	O
1215	deemed	O
1215	necessary	O
1215	.	O
1215	[SEP]	O
1216	[CLS]	O
1216	secondary	O
1216	outcomes	O
1216	are	O
1216	:	O
1216	regarding	O
1216	treatment	O
1216	[UNK]	O
1216	corrected	O
1216	a	O
1216	##c	O
1216	##p	O
1216	##r	O
1216	proportion	O
1216	on	O
1216	day	O
1216	[UNK]	O
1216	failure	O
1216	proportion	O
1216	by	O
1216	type	O
1216	(	O
1216	et	O
1216	##f	O
1216	,	O
1216	l	O
1216	##c	O
1216	##f	O
1216	,	O
1216	l	O
1216	##pf	O
1216	)	O
1216	by	O
1216	day	O
1216	28	O
1216	and	O
1216	42	O
1216	,	O
1216	as	O
1216	defined	O
1216	by	O
1216	who	O
1216	[	O
1216	14	O
1216	]	O
1216	[UNK]	O
1216	proportion	O
1216	of	O
1216	re	O
1216	##in	O
1216	##fect	O
1216	##ion	O
1216	and	O
1216	[UNK]	O
1216	time	O
1216	to	O
1216	parasite	O
1216	clearance	B-PK
1216	and	O
1216	parasite	O
1216	clearance	B-PK
1216	half	I-PK
1216	-	I-PK
1216	life	I-PK
1216	##regard	I-PK
1216	##ing	I-PK
1216	p	O
1216	##k	O
1216	of	O
1216	[UNK]	O
1216	area	B-PK
1216	under	I-PK
1216	curve	I-PK
1216	(	I-PK
1216	au	I-PK
1216	##c	I-PK
1216	)	I-PK
1216	and	O
1216	other	O
1216	p	O
1216	##k	O
1216	parameters	O
1216	(	O
1216	cm	B-PK
1216	##ax	I-PK
1216	,	O
1216	t	B-PK
1216	##max	I-PK
1216	,	O
1216	clearance	B-PK
1216	,	O
1216	volume	B-PK
1216	of	I-PK
1216	distribution	I-PK
1216	)	O
1216	[UNK]	O
1216	concentration	O
1216	on	O
1216	day	O
1216	[UNK]	O
1216	concentration	O
1216	on	O
1216	day	O
1216	of	O
1216	failure	O
1216	(	O
1216	in	O
1216	case	O
1216	of	O
1216	failure	O
1216	)	O
1216	regarding	O
1216	[UNK]	O
1216	type	O
1216	and	O
1216	frequency	O
1216	of	O
1216	adverse	O
1216	events	O
1216	[SEP]	O
1217	[CLS]	O
1217	regarding	O
1217	treatment	O
1217	[UNK]	O
1217	corrected	O
1217	a	O
1217	##c	O
1217	##p	O
1217	##r	O
1217	proportion	O
1217	on	O
1217	day	O
1217	[UNK]	O
1217	failure	O
1217	proportion	O
1217	by	O
1217	type	O
1217	(	O
1217	et	O
1217	##f	O
1217	,	O
1217	l	O
1217	##c	O
1217	##f	O
1217	,	O
1217	l	O
1217	##pf	O
1217	)	O
1217	by	O
1217	day	O
1217	28	O
1217	and	O
1217	42	O
1217	,	O
1217	as	O
1217	defined	O
1217	by	O
1217	who	O
1217	[	O
1217	14	O
1217	]	O
1217	[UNK]	O
1217	proportion	O
1217	of	O
1217	re	O
1217	##in	O
1217	##fect	O
1217	##ion	O
1217	and	O
1217	[UNK]	O
1217	time	O
1217	to	O
1217	parasite	O
1217	clearance	B-PK
1217	and	O
1217	parasite	O
1217	clearance	B-PK
1217	half	I-PK
1217	-	I-PK
1217	life	I-PK
1217	[SEP]	O
1218	[CLS]	O
1218	[UNK]	O
1218	time	O
1218	to	O
1218	parasite	O
1218	clearance	B-PK
1218	and	O
1218	parasite	O
1218	clearance	B-PK
1218	half	I-PK
1218	-	I-PK
1218	life	I-PK
1218	[SEP]	O
1219	[CLS]	O
1219	regarding	O
1219	p	O
1219	##k	O
1219	of	O
1219	[UNK]	O
1219	area	B-PK
1219	under	I-PK
1219	curve	I-PK
1219	(	I-PK
1219	au	I-PK
1219	##c	I-PK
1219	)	I-PK
1219	and	O
1219	other	O
1219	p	O
1219	##k	O
1219	parameters	O
1219	(	O
1219	cm	B-PK
1219	##ax	I-PK
1219	,	O
1219	t	B-PK
1219	##max	I-PK
1219	,	O
1219	clearance	B-PK
1219	,	O
1219	volume	B-PK
1219	of	I-PK
1219	distribution	I-PK
1219	)	O
1219	[UNK]	O
1219	concentration	O
1219	on	O
1219	day	O
1219	[UNK]	O
1219	concentration	O
1219	on	O
1219	day	O
1219	of	O
1219	failure	O
1219	(	O
1219	in	O
1219	case	O
1219	of	O
1219	failure	O
1219	)	O
1219	[SEP]	O
1220	[CLS]	O
1220	[UNK]	O
1220	area	B-PK
1220	under	I-PK
1220	curve	I-PK
1220	(	I-PK
1220	au	I-PK
1220	##c	I-PK
1220	)	I-PK
1220	and	O
1220	other	O
1220	p	O
1220	##k	O
1220	parameters	O
1220	(	O
1220	cm	B-PK
1220	##ax	I-PK
1220	,	O
1220	t	B-PK
1220	##max	I-PK
1220	,	O
1220	clearance	B-PK
1220	,	O
1220	volume	B-PK
1220	of	I-PK
1220	distribution	I-PK
1220	)	O
1220	[SEP]	O
1221	[CLS]	O
1221	p	O
1221	##k	O
1221	modeling	O
1221	will	O
1221	estimate	O
1221	the	O
1221	l	O
1221	##ume	O
1221	##fant	O
1221	##rine	O
1221	area	B-PK
1221	under	I-PK
1221	the	I-PK
1221	curve	I-PK
1221	,	O
1221	cm	B-PK
1221	##ax	I-PK
1221	,	O
1221	t	B-PK
1221	##max	I-PK
1221	,	O
1221	volume	B-PK
1221	of	I-PK
1221	distribution	I-PK
1221	and	O
1221	clearance	B-PK
1221	in	O
1221	sa	O
1221	##m	O
1221	and	O
1221	non	O
1221	-	O
1221	sa	O
1221	##m	O
1221	children	O
1221	using	O
1221	non	O
1221	##linear	O
1221	mixed	O
1221	effect	O
1221	models	O
1221	(	O
1221	non	O
1221	##ne	O
1221	##m	O
1221	)	O
1221	.	O
1221	[SEP]	O
1222	[CLS]	O
1222	re	O
1222	##gression	O
1222	models	O
1222	of	O
1222	the	O
1222	log	O
1222	-	O
1222	transformed	O
1222	parasite	O
1222	counts	O
1222	will	O
1222	be	O
1222	fitted	O
1222	in	O
1222	order	O
1222	to	O
1222	estimate	O
1222	parasite	O
1222	clearance	O
1222	using	O
1222	the	O
1222	parasite	O
1222	clearance	O
1222	est	O
1222	##imator	O
1222	tool	O
1222	(	O
1222	p	O
1222	##ce	O
1222	)	O
1222	developed	O
1222	by	O
1222	the	O
1222	worldwide	O
1222	anti	O
1222	##mal	O
1222	##aria	O
1222	##l	O
1222	resistance	O
1222	network	O
1222	(	O
1222	w	O
1222	##war	O
1222	##n	O
1222	)	O
1222	[	O
1222	30	O
1222	]	O
1222	.	O
1222	[SEP]	O
1223	[CLS]	O
1223	parasite	O
1223	clearance	O
1223	will	O
1223	be	O
1223	compared	O
1223	between	O
1223	groups	O
1223	of	O
1223	sa	O
1223	##m	O
1223	and	O
1223	non	O
1223	-	O
1223	sa	O
1223	##m	O
1223	children	O
1223	on	O
1223	a	O
1223	regular	O
1223	basis	O
1223	during	O
1223	the	O
1223	study	O
1223	.	O
1223	[SEP]	O
1224	[CLS]	O
1224	the	O
1224	reliability	O
1224	of	O
1224	the	O
1224	model	O
1224	was	O
1224	tested	O
1224	against	O
1224	published	O
1224	clinical	O
1224	studies	O
1224	monitoring	O
1224	different	O
1224	inhibitor	O
1224	##s	O
1224	and	O
1224	dose	O
1224	regime	O
1224	##ns	O
1224	,	O
1224	and	O
1224	all	O
1224	predicted	O
1224	area	B-PK
1224	under	I-PK
1224	the	I-PK
1224	concentration	I-PK
1224	–	I-PK
1224	time	I-PK
1224	curve	I-PK
1224	(	I-PK
1224	au	I-PK
1224	##c	I-PK
1224	)	I-PK
1224	ratios	I-PK
1224	were	O
1224	within	O
1224	the	O
1224	two	O
1224	##fold	O
1224	acceptance	O
1224	range	O
1224	.	O
1224	[SEP]	O
1225	[CLS]	O
1225	it	O
1225	has	O
1225	a	O
1225	significantly	O
1225	higher	O
1225	bio	B-PK
1225	##ava	I-PK
1225	##ila	I-PK
1225	##bility	I-PK
1225	(	O
1225	between	O
1225	42	O
1225	and	O
1225	87	O
1225	%	O
1225	)	O
1225	than	O
1225	m	O
1225	##or	O
1225	##phine	O
1225	with	O
1225	an	O
1225	estimated	O
1225	bio	B-PK
1225	##ava	I-PK
1225	##ila	I-PK
1225	##bility	I-PK
1225	range	O
1225	of	O
1225	22	O
1225	–	O
1225	48	O
1225	%	O
1225	.	O
1225	1	O
1225	the	O
1225	complete	O
1225	metabolism	O
1225	of	O
1225	o	O
1225	##xy	O
1225	##co	O
1225	##don	O
1225	##e	O
1225	has	O
1225	not	O
1225	yet	O
1225	been	O
1225	defined	O
1225	.	O
1225	[SEP]	O
1226	[CLS]	O
1226	lo	O
1226	##pina	O
1226	##vir	O
1226	/	O
1226	r	O
1226	##ito	O
1226	##na	O
1226	##vir	O
1226	treatment	O
1226	increased	O
1226	the	O
1226	au	B-PK
1226	##c	I-PK
1226	of	O
1226	o	O
1226	##xy	O
1226	##mor	O
1226	##phone	O
1226	by	O
1226	about	O
1226	two	O
1226	##fold	O
1226	and	O
1226	both	O
1226	treatments	O
1226	led	O
1226	to	O
1226	higher	O
1226	self	O
1226	-	O
1226	reported	O
1226	op	O
1226	##io	O
1226	##id	O
1226	effects	O
1226	.	O
1226	7	O
1226	on	O
1226	the	O
1226	other	O
1226	hand	O
1226	,	O
1226	induction	O
1226	of	O
1226	c	O
1226	##y	O
1226	##p	O
1226	##3	O
1226	##a	O
1226	by	O
1226	r	O
1226	##if	O
1226	##amp	O
1226	##ici	O
1226	##n	O
1226	has	O
1226	been	O
1226	studied	O
1226	by	O
1226	ni	O
1226	##en	O
1226	##mine	O
1226	##n	O
1226	et	O
1226	al	O
1226	.	O
1226	where	O
1226	r	O
1226	##if	O
1226	##amp	O
1226	##ici	O
1226	##n	O
1226	600	O
1226	mg	O
1226	was	O
1226	administered	O
1226	to	O
1226	12	O
1226	healthy	O
1226	volunteers	O
1226	for	O
1226	7	O
1226	days	O
1226	.	O
1226	[SEP]	O
1227	[CLS]	O
1227	the	O
1227	mean	O
1227	au	B-PK
1227	##c	I-PK
1227	values	O
1227	of	O
1227	both	O
1227	o	O
1227	##xy	O
1227	##co	O
1227	##don	O
1227	##e	O
1227	and	O
1227	o	O
1227	##xy	O
1227	##mor	O
1227	##phone	O
1227	were	O
1227	decreased	O
1227	by	O
1227	~	O
1227	86	O
1227	and	O
1227	90	O
1227	%	O
1227	.	O
1227	[SEP]	O
1228	[CLS]	O
1228	imp	O
1228	##lication	O
1228	of	O
1228	new	O
1228	pathways	O
1228	has	O
1228	been	O
1228	proposed	O
1228	for	O
1228	three	O
1228	compounds	O
1228	and	O
1228	remaining	O
1228	clearance	B-PK
1228	##s	I-PK
1228	were	O
1228	assigned	O
1228	to	O
1228	und	O
1228	##ef	O
1228	##ined	O
1228	pathways	O
1228	.	O
1228	[SEP]	O
1229	[CLS]	O
1229	the	O
1229	simulated	O
1229	mean	O
1229	au	B-PK
1229	##c	I-PK
1229	##24	I-PK
1229	h	I-PK
1229	of	O
1229	o	O
1229	##xy	O
1229	##mor	O
1229	##phone	O
1229	in	O
1229	c	O
1229	##y	O
1229	##p	O
1229	##2	O
1229	##d	O
1229	##6	O
1229	poor	O
1229	meta	O
1229	##bol	O
1229	##izer	O
1229	##s	O
1229	(	O
1229	pm	O
1229	##s	O
1229	)	O
1229	and	O
1229	extensive	O
1229	meta	O
1229	##bol	O
1229	##izer	O
1229	##s	O
1229	(	O
1229	em	O
1229	##s	O
1229	)	O
1229	were	O
1229	in	O
1229	close	O
1229	agreement	O
1229	with	O
1229	observed	O
1229	values	O
1229	in	O
1229	the	O
1229	same	O
1229	##r	O
1229	et	O
1229	al	O
1229	.	O
1229	study	O
1229	,	O
1229	namely	O
1229	31	O
1229	vs	O
1229	.	O
1229	44	O
1229	ng	O
1229	##⋅	O
1229	##min	O
1229	/	O
1229	m	O
1229	##l	O
1229	and	O
1229	229	O
1229	vs	O
1229	.	O
1229	26	O
1229	##8	O
1229	ng	O
1229	##⋅	O
1229	##min	O
1229	/	O
1229	m	O
1229	##l	O
1229	,	O
1229	respectively	O
1229	.	O
1229	[SEP]	O
1230	[CLS]	O
1230	accordingly	O
1230	,	O
1230	the	O
1230	simulated	O
1230	ratio	B-PK
1230	of	I-PK
1230	o	I-PK
1230	##xy	I-PK
1230	##mor	I-PK
1230	##phone	I-PK
1230	au	I-PK
1230	##c	I-PK
1230	in	O
1230	pm	O
1230	vs	O
1230	.	O
1230	em	O
1230	was	O
1230	0	O
1230	.	O
1230	13	O
1230	,	O
1230	which	O
1230	is	O
1230	in	O
1230	close	O
1230	agreement	O
1230	with	O
1230	the	O
1230	ratio	O
1230	observed	O
1230	in	O
1230	the	O
1230	clinical	O
1230	trial	O
1230	by	O
1230	same	O
1230	##r	O
1230	et	O
1230	al	O
1230	.	O
1230	(	O
1230	0	O
1230	.	O
1230	14	O
1230	)	O
1230	and	O
1230	s	O
1230	##tam	O
1230	##er	O
1230	et	O
1230	al	O
1230	.	O
1230	(	O
1230	0	O
1230	.	O
1230	12	O
1230	)	O
1230	.	O
1230	9	O
1230	,	O
1230	12	O
1230	the	O
1230	impact	O
1230	of	O
1230	co	O
1230	##tre	O
1230	##at	O
1230	##ment	O
1230	with	O
1230	k	O
1230	##eto	O
1230	##cona	O
1230	##zo	O
1230	##le	O
1230	observed	O
1230	by	O
1230	same	O
1230	##r	O
1230	et	O
1230	al	O
1230	.	O
1230	was	O
1230	used	O
1230	to	O
1230	re	O
1230	##fine	O
1230	the	O
1230	fraction	O
1230	of	O
1230	dose	O
1230	of	O
1230	the	O
1230	drug	O
1230	meta	O
1230	##bol	O
1230	##ized	O
1230	by	O
1230	c	O
1230	##y	O
1230	##p	O
1230	##3	O
1230	##a	O
1230	##4	O
1230	(	O
1230	f	O
1230	##m	O
1230	-	O
1230	3	O
1230	##a	O
1230	##4	O
1230	)	O
1230	.	O
1230	[SEP]	O
1231	[CLS]	O
1231	predicted	O
1231	au	B-PK
1231	##c	I-PK
1231	ratios	I-PK
1231	were	O
1231	90	O
1231	,	O
1231	100	O
1231	,	O
1231	and	O
1231	100	O
1231	%	O
1231	of	O
1231	the	O
1231	observed	O
1231	values	O
1231	for	O
1231	o	O
1231	##xy	O
1231	##co	O
1231	##don	O
1231	##e	O
1231	,	O
1231	o	O
1231	##xy	O
1231	##mor	O
1231	##phone	O
1231	,	O
1231	and	O
1231	nor	O
1231	##ox	O
1231	##y	O
1231	##co	O
1231	##don	O
1231	##e	O
1231	,	O
1231	respectively	O
1231	.	O
1231	[SEP]	O
1232	[CLS]	O
1232	concerning	O
1232	o	O
1232	##xy	O
1232	##co	O
1232	##don	O
1232	##e	O
1232	,	O
1232	observed	B-PK
1232	au	I-PK
1232	##c	I-PK
1232	ratio	I-PK
1232	/	I-PK
1232	simulated	I-PK
1232	au	I-PK
1232	##c	I-PK
1232	ratio	I-PK
1232	following	O
1232	k	O
1232	##eto	O
1232	##cona	O
1232	##zo	O
1232	##le	O
1232	,	O
1232	c	O
1232	##lar	O
1232	##ith	O
1232	##rom	O
1232	##y	O
1232	##cine	O
1232	,	O
1232	in	O
1232	##tra	O
1232	##ven	O
1232	##ous	O
1232	and	O
1232	oral	O
1232	it	O
1232	##rac	O
1232	##ona	O
1232	##zo	O
1232	##le	O
1232	,	O
1232	and	O
1232	combination	O
1232	of	O
1232	it	O
1232	##rac	O
1232	##ona	O
1232	##zo	O
1232	##le	O
1232	and	O
1232	par	O
1232	##ox	O
1232	##eti	O
1232	##ne	O
1232	were	O
1232	1	O
1232	.	O
1232	8	O
1232	,	O
1232	1	O
1232	.	O
1232	3	O
1232	,	O
1232	1	O
1232	.	O
1232	2	O
1232	,	O
1232	1	O
1232	.	O
1232	6	O
1232	,	O
1232	and	O
1232	1	O
1232	.	O
1232	7	O
1232	,	O
1232	respectively	O
1232	.	O
1232	[SEP]	O
1233	[CLS]	O
1233	with	O
1233	regards	O
1233	to	O
1233	2d	O
1233	##6	O
1233	in	O
1233	##hibition	O
1233	,	O
1233	clinical	B-PK
1233	au	I-PK
1233	##c	I-PK
1233	ratio	I-PK
1233	/	I-PK
1233	simulated	I-PK
1233	au	I-PK
1233	##c	I-PK
1233	ratio	I-PK
1233	following	O
1233	par	O
1233	##ox	O
1233	##eti	O
1233	##ne	O
1233	administration	O
1233	alone	O
1233	were	O
1233	0	O
1233	.	O
1233	9	O
1233	and	O
1233	1	O
1233	.	O
1233	[SEP]	O
1234	[CLS]	O
1234	regarding	O
1234	nor	O
1234	##ox	O
1234	##y	O
1234	##co	O
1234	##don	O
1234	##e	O
1234	,	O
1234	clinical	B-PK
1234	/	I-PK
1234	simulated	I-PK
1234	au	I-PK
1234	##c	I-PK
1234	ratio	I-PK
1234	following	O
1234	oral	O
1234	and	O
1234	in	O
1234	##tra	O
1234	##ven	O
1234	##ous	O
1234	it	O
1234	##rac	O
1234	##ona	O
1234	##zo	O
1234	##le	O
1234	,	O
1234	c	O
1234	##lar	O
1234	##ith	O
1234	##rom	O
1234	##y	O
1234	##cine	O
1234	,	O
1234	and	O
1234	par	O
1234	##ox	O
1234	##eti	O
1234	##ne	O
1234	administration	O
1234	were	O
1234	1	O
1234	.	O
1234	0	O
1234	,	O
1234	1	O
1234	.	O
1234	2	O
1234	,	O
1234	1	O
1234	.	O
1234	0	O
1234	,	O
1234	and	O
1234	1	O
1234	.	O
1234	1	O
1234	.	O
1234	[SEP]	O
1235	[CLS]	O
1235	with	O
1235	respect	O
1235	to	O
1235	o	O
1235	##xy	O
1235	##mor	O
1235	##phone	O
1235	,	O
1235	clinical	B-PK
1235	au	I-PK
1235	##c	I-PK
1235	ratio	I-PK
1235	/	I-PK
1235	simulated	I-PK
1235	au	I-PK
1235	##c	I-PK
1235	ratio	I-PK
1235	after	O
1235	c	O
1235	##y	O
1235	##p	O
1235	##3	O
1235	##a	O
1235	##4	O
1235	blockade	O
1235	following	O
1235	oral	O
1235	and	O
1235	in	O
1235	##tra	O
1235	##ven	O
1235	##ous	O
1235	administration	O
1235	of	O
1235	it	O
1235	##rac	O
1235	##ona	O
1235	##zo	O
1235	##le	O
1235	was	O
1235	1	O
1235	.	O
1235	8	O
1235	and	O
1235	1	O
1235	.	O
1235	6	O
1235	,	O
1235	respectively	O
1235	.	O
1235	[SEP]	O
1236	[CLS]	O
1236	in	O
1236	the	O
1236	si	O
1236	##m	O
1236	##cy	O
1236	##p	O
1236	si	O
1236	##mu	O
1236	##lator	O
1236	,	O
1236	the	O
1236	distribution	O
1236	of	O
1236	meta	O
1236	##bol	O
1236	##ites	O
1236	throughout	O
1236	the	O
1236	body	O
1236	is	O
1236	assumed	O
1236	to	O
1236	be	O
1236	instant	O
1236	##aneous	O
1236	and	O
1236	formed	O
1236	meta	O
1236	##bol	O
1236	##ites	O
1236	are	O
1236	instantly	O
1236	available	O
1236	for	O
1236	further	O
1236	metabolism	O
1236	.	O
1236	37	O
1236	some	O
1236	of	O
1236	meta	O
1236	##bol	O
1236	##ites	O
1236	parameters	O
1236	such	O
1236	as	O
1236	distribution	B-PK
1236	volume	I-PK
1236	and	O
1236	systemic	B-PK
1236	clearance	I-PK
1236	were	O
1236	estimated	O
1236	using	O
1236	parameter	O
1236	est	O
1236	##imation	O
1236	and	O
1236	sensitivity	O
1236	analysis	O
1236	functions	O
1236	provided	O
1236	in	O
1236	the	O
1236	si	O
1236	##mu	O
1236	##lator	O
1236	.	O
1236	[SEP]	O
1237	[CLS]	O
1237	with	O
1237	regards	O
1237	to	O
1237	clearance	B-PK
1237	,	O
1237	different	O
1237	in	O
1237	v	O
1237	##it	O
1237	##ro	O
1237	systems	O
1237	such	O
1237	as	O
1237	human	O
1237	liver	O
1237	micro	O
1237	##some	O
1237	##s	O
1237	(	O
1237	h	O
1237	##lm	O
1237	)	O
1237	or	O
1237	re	O
1237	##comb	O
1237	##ina	O
1237	##ntly	O
1237	expressed	O
1237	systems	O
1237	can	O
1237	be	O
1237	used	O
1237	to	O
1237	determine	O
1237	the	O
1237	intrinsic	B-PK
1237	clearance	I-PK
1237	(	I-PK
1237	c	I-PK
1237	##lint	I-PK
1237	)	I-PK
1237	of	O
1237	a	O
1237	compound	O
1237	by	O
1237	a	O
1237	specific	O
1237	c	O
1237	##y	O
1237	##p	O
1237	is	O
1237	##of	O
1237	##orm	O
1237	.	O
1237	[SEP]	O
1238	[CLS]	O
1238	obtained	O
1238	c	B-PK
1238	##lint	I-PK
1238	can	O
1238	be	O
1238	incorporated	O
1238	into	O
1238	si	O
1238	##m	O
1238	##cy	O
1238	##p	O
1238	to	O
1238	estimate	O
1238	the	O
1238	net	O
1238	intrinsic	B-PK
1238	clearance	I-PK
1238	of	O
1238	the	O
1238	total	O
1238	liver	O
1238	by	O
1238	s	O
1238	##cal	O
1238	##ing	O
1238	methods	O
1238	.	O
1238	[SEP]	O
1239	[CLS]	O
1239	for	O
1239	that	O
1239	,	O
1239	c	B-PK
1239	##lint	I-PK
1239	of	O
1239	different	O
1239	metabolic	O
1239	pathways	O
1239	for	O
1239	each	O
1239	enzyme	O
1239	involved	O
1239	in	O
1239	the	O
1239	metabolism	O
1239	of	O
1239	the	O
1239	compound	O
1239	will	O
1239	be	O
1239	added	O
1239	up	O
1239	after	O
1239	taking	O
1239	into	O
1239	account	O
1239	enzyme	O
1239	’	O
1239	s	O
1239	abundance	O
1239	in	O
1239	the	O
1239	studied	O
1239	population	O
1239	,	O
1239	mill	O
1239	##ig	O
1239	##rams	O
1239	of	O
1239	micro	O
1239	##so	O
1239	##mal	O
1239	protein	O
1239	per	O
1239	gram	O
1239	of	O
1239	liver	O
1239	and	O
1239	total	O
1239	liver	O
1239	weight	O
1239	for	O
1239	each	O
1239	individual	O
1239	.	O
1239	36	O
1239	besides	O
1239	common	O
1239	in	O
1239	v	O
1239	##it	O
1239	##ro	O
1239	-	O
1239	in	O
1239	v	O
1239	##ivo	O
1239	extra	O
1239	##pol	O
1239	##ation	O
1239	strategy	O
1239	,	O
1239	he	O
1239	##pa	O
1239	##tic	O
1239	first	O
1239	pass	O
1239	can	O
1239	also	O
1239	be	O
1239	estimated	O
1239	after	O
1239	de	O
1239	##com	O
1239	##po	O
1239	##sing	O
1239	the	O
1239	systemic	B-PK
1239	clearance	I-PK
1239	(	O
1239	oral	B-PK
1239	or	O
1239	in	B-PK
1239	##tra	I-PK
1239	##ven	I-PK
1239	##ous	I-PK
1239	clearance	I-PK
1239	)	O
1239	to	O
1239	its	O
1239	re	O
1239	##nal	O
1239	and	O
1239	he	O
1239	##pa	O
1239	##tic	O
1239	components	O
1239	.	O
1239	[SEP]	O
1240	[CLS]	O
1240	the	O
1240	estimated	O
1240	net	O
1240	intrinsic	B-PK
1240	clearance	I-PK
1240	will	O
1240	then	O
1240	be	O
1240	divided	O
1240	by	O
1240	the	O
1240	average	O
1240	liver	O
1240	weight	O
1240	,	O
1240	the	O
1240	micro	O
1240	##so	O
1240	##mal	O
1240	protein	O
1240	per	O
1240	gram	O
1240	of	O
1240	liver	O
1240	value	O
1240	for	O
1240	every	O
1240	is	O
1240	##oe	O
1240	##nz	O
1240	##yme	O
1240	and	O
1240	the	O
1240	fraction	O
1240	meta	O
1240	##bol	O
1240	##ized	O
1240	by	O
1240	each	O
1240	is	O
1240	##oe	O
1240	##nz	O
1240	##yme	O
1240	to	O
1240	obtain	O
1240	the	O
1240	intrinsic	B-PK
1240	clearance	I-PK
1240	value	O
1240	for	O
1240	each	O
1240	is	O
1240	##oe	O
1240	##nz	O
1240	##yme	O
1240	.	O
1240	[SEP]	O
1241	[CLS]	O
1241	therefore	O
1241	,	O
1241	the	O
1241	net	O
1241	intrinsic	B-PK
1241	he	I-PK
1241	##pa	I-PK
1241	##tic	I-PK
1241	clearance	I-PK
1241	(	I-PK
1241	c	I-PK
1241	##lu	I-PK
1241	##h	I-PK
1241	,	I-PK
1241	in	I-PK
1241	##t	I-PK
1241	)	I-PK
1241	will	O
1241	be	O
1241	back	O
1241	-	O
1241	calculated	O
1241	from	O
1241	in	B-PK
1241	v	I-PK
1241	##ivo	I-PK
1241	clearance	I-PK
1241	value	O
1241	by	O
1241	e	O
1241	##q	O
1241	##s	O
1241	.	O
1241	1	O
1241	–	O
1241	3	O
1241	using	O
1241	the	O
1241	re	O
1241	##tro	O
1241	##grade	O
1241	mode	O
1241	in	O
1241	the	O
1241	si	O
1241	##mu	O
1241	##lator	O
1241	:	O
1241	[SEP]	O
1242	[CLS]	O
1242	where	O
1242	c	B-PK
1242	##l	I-PK
1242	is	O
1242	the	O
1242	systemic	B-PK
1242	plasma	I-PK
1242	clearance	I-PK
1242	(	O
1242	l	O
1242	/	O
1242	h	O
1242	)	O
1242	,	O
1242	c	B-PK
1242	##l	I-PK
1242	##po	I-PK
1242	is	O
1242	the	O
1242	oral	B-PK
1242	clearance	I-PK
1242	(	O
1242	l	O
1242	/	O
1242	h	O
1242	)	O
1242	,	O
1242	f	B-PK
1242	##a	I-PK
1242	is	O
1242	the	O
1242	fraction	B-PK
1242	absorbed	I-PK
1242	,	O
1242	f	B-PK
1242	##h	I-PK
1242	and	O
1242	f	B-PK
1242	##g	I-PK
1242	are	O
1242	fraction	B-PK
1242	##s	I-PK
1242	meta	I-PK
1242	##bol	I-PK
1242	##ized	I-PK
1242	escaping	I-PK
1242	metabolism	I-PK
1242	,	O
1242	respectively	O
1242	in	O
1242	the	O
1242	liver	O
1242	and	O
1242	gut	O
1242	,	O
1242	c	B-PK
1242	##lm	I-PK
1242	##et	I-PK
1242	is	O
1242	the	O
1242	he	B-PK
1242	##pa	I-PK
1242	##tic	I-PK
1242	metabolic	I-PK
1242	clearance	I-PK
1242	in	I-PK
1242	blood	I-PK
1242	(	O
1242	l	O
1242	/	O
1242	h	O
1242	)	O
1242	,	O
1242	c	B-PK
1242	##l	I-PK
1242	##r	I-PK
1242	is	O
1242	the	O
1242	re	B-PK
1242	##nal	I-PK
1242	clearance	I-PK
1242	(	O
1242	l	O
1242	/	O
1242	h	O
1242	)	O
1242	,	O
1242	b	B-PK
1242	:	I-PK
1242	p	I-PK
1242	is	O
1242	the	O
1242	blood	B-PK
1242	to	I-PK
1242	plasma	I-PK
1242	partition	I-PK
1242	ratio	I-PK
1242	,	O
1242	f	B-PK
1242	##u	I-PK
1242	,	O
1242	b	B-PK
1242	is	O
1242	the	O
1242	fraction	B-PK
1242	un	I-PK
1242	##bound	I-PK
1242	in	I-PK
1242	blood	I-PK
1242	and	O
1242	q	B-PK
1242	##h	I-PK
1242	is	O
1242	the	O
1242	he	B-PK
1242	##pa	I-PK
1242	##tic	I-PK
1242	blood	I-PK
1242	flow	I-PK
1242	(	O
1242	84	O
1242	.	O
1242	8	O
1242	l	O
1242	/	O
1242	h	O
1242	)	O
1242	.	O
1242	[SEP]	O
1243	[CLS]	O
1243	in	O
1243	order	O
1243	to	O
1243	verify	O
1243	the	O
1243	validity	O
1243	of	O
1243	the	O
1243	final	O
1243	models	O
1243	of	O
1243	o	O
1243	##xy	O
1243	##co	O
1243	##don	O
1243	##e	O
1243	,	O
1243	o	O
1243	##xy	O
1243	##mor	O
1243	##phone	O
1243	and	O
1243	nor	O
1243	##ox	O
1243	##y	O
1243	##co	O
1243	##don	O
1243	##e	O
1243	for	O
1243	prediction	O
1243	of	O
1243	different	O
1243	d	O
1243	##dis	O
1243	,	O
1243	seven	O
1243	c	O
1243	##y	O
1243	##p	O
1243	##45	O
1243	##0	O
1243	-	O
1243	mediated	O
1243	interaction	O
1243	scenarios	O
1243	including	O
1243	k	O
1243	##eto	O
1243	##cona	O
1243	##zo	O
1243	##le	O
1243	,	O
1243	par	O
1243	##ox	O
1243	##eti	O
1243	##ne	O
1243	,	O
1243	it	O
1243	##rac	O
1243	##ona	O
1243	##zo	O
1243	##le	O
1243	,	O
1243	and	O
1243	c	O
1243	##lar	O
1243	##ith	O
1243	##rom	O
1243	##y	O
1243	##cine	O
1243	were	O
1243	simulated	O
1243	in	O
1243	healthy	O
1243	volunteers	O
1243	and	O
1243	results	O
1243	were	O
1243	compared	O
1243	to	O
1243	reference	O
1243	published	O
1243	data	O
1243	.	O
1243	13	O
1243	,	O
1243	39	O
1243	,	O
1243	40	O
1243	,	O
1243	41	O
1243	all	O
1243	studies	O
1243	were	O
1243	conducted	O
1243	with	O
1243	oral	O
1243	doses	O
1243	of	O
1243	o	O
1243	##xy	O
1243	##co	O
1243	##don	O
1243	##e	O
1243	except	O
1243	one	O
1243	where	O
1243	the	O
1243	impact	O
1243	of	O
1243	200	O
1243	mg	O
1243	oral	O
1243	it	O
1243	##rac	O
1243	##ona	O
1243	##zo	O
1243	##le	O
1243	on	O
1243	both	O
1243	oral	O
1243	and	O
1243	in	O
1243	##tra	O
1243	##ven	O
1243	##ous	O
1243	o	O
1243	##xy	O
1243	##co	O
1243	##don	O
1243	##e	O
1243	was	O
1243	assessed	O
1243	.	O
1243	13	O
1243	aforementioned	O
1243	inhibitor	O
1243	##s	O
1243	were	O
1243	chosen	O
1243	as	O
1243	they	O
1243	already	O
1243	exist	O
1243	in	O
1243	the	O
1243	default	O
1243	library	O
1243	of	O
1243	si	O
1243	##m	O
1243	##cy	O
1243	##p	O
1243	inhibitor	O
1243	##s	O
1243	and	O
1243	all	O
1243	their	O
1243	parameters	O
1243	were	O
1243	used	O
1243	as	O
1243	si	O
1243	##m	O
1243	##cy	O
1243	##p	O
1243	library	O
1243	files	O
1243	in	O
1243	v	O
1243	##12	O
1243	.	O
1243	[SEP]	O
1244	[CLS]	O
1244	an	O
1244	incurred	O
1244	sample	O
1244	re	O
1244	-	O
1244	analysis	O
1244	(	O
1244	is	O
1244	##r	O
1244	)	O
1244	was	O
1244	also	O
1244	conducted	O
1244	by	O
1244	selecting	O
1244	the	O
1244	12	O
1244	subject	O
1244	samples	O
1244	(	O
1244	two	O
1244	samples	O
1244	from	O
1244	each	O
1244	subject	O
1244	)	O
1244	near	O
1244	cm	B-PK
1244	##ax	I-PK
1244	and	O
1244	the	O
1244	elimination	O
1244	phase	O
1244	.	O
1244	[SEP]	O
1245	[CLS]	O
1245	the	O
1245	mean	O
1245	plasma	O
1245	concentrations	O
1245	vs	O
1245	time	O
1245	profile	O
1245	of	O
1245	at	O
1245	##or	O
1245	##vas	O
1245	##tat	O
1245	##in	O
1245	,	O
1245	met	O
1245	##form	O
1245	##in	O
1245	and	O
1245	g	O
1245	##lim	O
1245	##ep	O
1245	##iri	O
1245	##de	O
1245	are	O
1245	shown	O
1245	in	O
1245	fi	O
1245	##g	O
1245	.	O
1245	5	O
1245	.	O
1245	[SEP]	O
1246	[CLS]	O
1246	h	O
1246	##y	O
1246	##po	O
1246	##ar	O
1246	##gin	O
1246	##ine	O
1246	##mia	O
1246	and	O
1246	hem	O
1246	##oly	O
1246	##sis	O
1246	likely	O
1246	reduce	O
1246	no	O
1246	bio	B-PK
1246	##ava	I-PK
1246	##ila	I-PK
1246	##bility	I-PK
1246	.	O
1246	[SEP]	O
1247	[CLS]	O
1247	clinical	O
1247	trials	O
1247	in	O
1247	s	O
1247	##m	O
1247	of	O
1247	ad	O
1247	##junct	O
1247	##ive	O
1247	agents	O
1247	to	O
1247	improve	O
1247	end	O
1247	##oth	O
1247	##eli	O
1247	##al	O
1247	no	O
1247	bio	B-PK
1247	##ava	I-PK
1247	##ila	I-PK
1247	##bility	I-PK
1247	,	O
1247	including	O
1247	l	O
1247	-	O
1247	a	O
1247	##rg	O
1247	##ini	O
1247	##ne	O
1247	,	O
1247	are	O
1247	warrant	O
1247	##ed	O
1247	.	O
1247	[SEP]	O
1248	[CLS]	O
1248	er	O
1248	##yt	O
1248	##hr	O
1248	##oc	O
1248	##yte	O
1248	r	O
1248	##up	O
1248	##ture	O
1248	results	O
1248	in	O
1248	increased	O
1248	cell	O
1248	-	O
1248	free	O
1248	hem	O
1248	##og	O
1248	##lo	O
1248	##bin	O
1248	and	O
1248	plasma	O
1248	a	O
1248	##rg	O
1248	##inas	O
1248	##e	O
1248	(	O
1248	15	O
1248	,	O
1248	16	O
1248	)	O
1248	,	O
1248	leading	O
1248	to	O
1248	increased	O
1248	no	O
1248	consumption	O
1248	and	O
1248	plasma	O
1248	l	O
1248	-	O
1248	a	O
1248	##rg	O
1248	##ini	O
1248	##ne	O
1248	cat	O
1248	##ab	O
1248	##olis	O
1248	##m	O
1248	,	O
1248	respectively	O
1248	,	O
1248	and	O
1248	an	O
1248	overall	O
1248	reduction	O
1248	in	O
1248	no	O
1248	bio	B-PK
1248	##ava	I-PK
1248	##ila	I-PK
1248	##bility	I-PK
1248	(	O
1248	14	O
1248	)	O
1248	.	O
1248	[SEP]	O
1249	[CLS]	O
1249	we	O
1249	show	O
1249	here	O
1249	a	O
1249	10	O
1249	-	O
1249	fold	O
1249	increased	O
1249	oral	B-PK
1249	bio	I-PK
1249	##ava	I-PK
1249	##ila	I-PK
1249	##bility	I-PK
1249	of	O
1249	p	O
1249	##ac	O
1249	##lit	O
1249	##ax	O
1249	##el	O
1249	in	O
1249	mice	O
1249	treated	O
1249	with	O
1249	the	O
1249	p	O
1249	-	O
1249	g	O
1249	##ly	O
1249	##co	O
1249	##p	O
1249	##rote	O
1249	##in	O
1249	block	O
1249	##er	O
1249	s	O
1249	##d	O
1249	##z	O
1249	ps	O
1249	##c	O
1249	83	O
1249	##3	O
1249	.	O
1249	[SEP]	O
1250	[CLS]	O
1250	therefore	O
1250	,	O
1250	we	O
1250	established	O
1250	and	O
1250	characterized	O
1250	a	O
1250	liver	O
1250	im	O
1250	##mu	O
1250	##no	O
1250	##com	O
1250	##pet	O
1250	##ent	O
1250	co	O
1250	##culture	O
1250	model	O
1250	and	O
1250	evaluated	O
1250	di	O
1250	##c	O
1250	##lo	O
1250	##fen	O
1250	##ac	O
1250	(	O
1250	d	O
1250	##c	O
1250	##f	O
1250	)	O
1250	metabolic	O
1250	profiles	O
1250	,	O
1250	in	O
1250	v	O
1250	##it	O
1250	##ro	O
1250	–	O
1250	in	O
1250	v	O
1250	##ivo	O
1250	clearance	B-PK
1250	correlation	O
1250	##s	O
1250	,	O
1250	toxic	O
1250	##ological	O
1250	responses	O
1250	,	O
1250	and	O
1250	acute	O
1250	phase	O
1250	responses	O
1250	using	O
1250	liquid	O
1250	ch	O
1250	##roma	O
1250	##tography	O
1250	–	O
1250	tandem	O
1250	mass	O
1250	s	O
1250	##pect	O
1250	##rome	O
1250	##try	O
1250	.	O
1250	[SEP]	O
1251	[CLS]	O
1251	on	O
1251	day	O
1251	3	O
1251	,	O
1251	the	O
1251	medium	O
1251	was	O
1251	replaced	O
1251	with	O
1251	will	O
1251	##iam	O
1251	’	O
1251	s	O
1251	e	O
1251	medium	O
1251	(	O
1251	we	O
1251	##m	O
1251	)	O
1251	and	O
1251	maintenance	O
1251	supplement	O
1251	##s	O
1251	containing	O
1251	100	O
1251	nm	O
1251	h	O
1251	##ydro	O
1251	##cor	O
1251	##tis	O
1251	##one	O
1251	.	O
1251	[SEP]	O
1252	[CLS]	O
1252	for	O
1252	d	O
1252	##c	O
1252	##f	O
1252	clearance	B-PK
1252	studies	O
1252	,	O
1252	a	O
1252	complete	O
1252	medium	O
1252	change	O
1252	was	O
1252	performed	O
1252	and	O
1252	d	O
1252	##c	O
1252	##f	O
1252	(	O
1252	si	O
1252	##gma	O
1252	-	O
1252	al	O
1252	##dric	O
1252	##h	O
1252	,	O
1252	pool	O
1252	##e	O
1252	,	O
1252	uk	O
1252	)	O
1252	in	O
1252	d	O
1252	##ms	O
1252	##o	O
1252	[	O
1252	final	O
1252	concentration	O
1252	of	O
1252	0	O
1252	.	O
1252	5	O
1252	%	O
1252	(	O
1252	v	O
1252	/	O
1252	v	O
1252	)	O
1252	for	O
1252	all	O
1252	doses	O
1252	]	O
1252	was	O
1252	added	O
1252	in	O
1252	a	O
1252	volume	O
1252	of	O
1252	2	O
1252	m	O
1252	##l	O
1252	medium	O
1252	containing	O
1252	1	O
1252	.	O
1252	25	O
1252	mg	O
1252	/	O
1252	m	O
1252	##l	O
1252	to	O
1252	yield	O
1252	concentrations	O
1252	indicted	O
1252	in	O
1252	the	O
1252	text	O
1252	.	O
1252	[SEP]	O
1253	[CLS]	O
1253	based	O
1253	on	O
1253	the	O
1253	initial	O
1253	observation	O
1253	of	O
1253	the	O
1253	d	O
1253	##c	O
1253	##f	O
1253	concentration	O
1253	profile	O
1253	over	O
1253	time	O
1253	,	O
1253	a	O
1253	one	O
1253	-	O
1253	compartment	O
1253	##al	O
1253	p	O
1253	##k	O
1253	model	O
1253	was	O
1253	used	O
1253	to	O
1253	estimate	O
1253	the	O
1253	d	O
1253	##c	O
1253	##f	O
1253	elimination	B-PK
1253	rate	I-PK
1253	(	I-PK
1253	k	I-PK
1253	##el	I-PK
1253	)	I-PK
1253	and	O
1253	the	O
1253	volume	B-PK
1253	of	I-PK
1253	distribution	I-PK
1253	(	I-PK
1253	v	I-PK
1253	##d	I-PK
1253	)	I-PK
1253	.	O
1253	[SEP]	O
1254	[CLS]	O
1254	due	O
1254	to	O
1254	sampling	O
1254	from	O
1254	the	O
1254	bio	O
1254	##rea	O
1254	##ctor	O
1254	,	O
1254	v	B-PK
1254	##d	I-PK
1254	was	O
1254	used	O
1254	as	O
1254	the	O
1254	average	O
1254	of	O
1254	the	O
1254	volumes	O
1254	at	O
1254	t	O
1254	=	O
1254	0	O
1254	and	O
1254	the	O
1254	end	O
1254	point	O
1254	.	O
1254	[SEP]	O
1255	[CLS]	O
1255	the	O
1255	elimination	B-PK
1255	half	I-PK
1255	-	I-PK
1255	life	I-PK
1255	(	O
1255	)	O
1255	of	O
1255	d	O
1255	##c	O
1255	##f	O
1255	and	O
1255	the	O
1255	clearance	B-PK
1255	(	I-PK
1255	c	I-PK
1255	##l	I-PK
1255	)	I-PK
1255	were	O
1255	calculated	O
1255	using	O
1255	e	O
1255	##q	O
1255	##s	O
1255	.	O
1255	3	O
1255	and	O
1255	4	O
1255	:	O
1255	[SEP]	O
1256	[CLS]	O
1256	we	O
1256	thus	O
1256	assessed	O
1256	these	O
1256	e	O
1256	##qui	O
1256	##li	O
1256	##bria	O
1256	experimental	O
1256	##ly	O
1256	across	O
1256	our	O
1256	dose	O
1256	range	O
1256	to	O
1256	build	O
1256	appropriate	O
1256	p	O
1256	##k	O
1256	models	O
1256	of	O
1256	our	O
1256	experimental	O
1256	clearance	B-PK
1256	and	O
1256	metabolism	O
1256	data	O
1256	using	O
1256	our	O
1256	culture	O
1256	media	O
1256	,	O
1256	which	O
1256	contain	O
1256	other	O
1256	album	O
1256	##in	O
1256	-	O
1256	binding	O
1256	lip	O
1256	##op	O
1256	##hil	O
1256	##ic	O
1256	molecules	O
1256	including	O
1256	co	O
1256	##rt	O
1256	##is	O
1256	##ol	O
1256	.	O
1256	[SEP]	O
1257	[CLS]	O
1257	we	O
1257	then	O
1257	experimental	O
1257	##ly	O
1257	determined	O
1257	the	O
1257	d	O
1257	##c	O
1257	##f	O
1257	-	O
1257	album	O
1257	##in	O
1257	binding	O
1257	e	O
1257	##qui	O
1257	##li	O
1257	##bria	O
1257	in	O
1257	the	O
1257	culture	O
1257	medium	O
1257	used	O
1257	for	O
1257	the	O
1257	clearance	B-PK
1257	and	O
1257	metabolism	O
1257	studies	O
1257	in	O
1257	this	O
1257	work	O
1257	,	O
1257	and	O
1257	we	O
1257	found	O
1257	that	O
1257	measured	O
1257	outcomes	O
1257	were	O
1257	in	O
1257	agreement	O
1257	with	O
1257	the	O
1257	literature	O
1257	for	O
1257	the	O
1257	1	O
1257	.	O
1257	25	O
1257	g	O
1257	/	O
1257	l	O
1257	b	O
1257	##sa	O
1257	concentration	O
1257	used	O
1257	in	O
1257	these	O
1257	studies	O
1257	and	O
1257	total	O
1257	d	O
1257	##c	O
1257	##f	O
1257	concentrations	O
1257	up	O
1257	to	O
1257	100	O
1257	µ	O
1257	##m	O
1257	(	O
1257	fi	O
1257	##g	O
1257	.	O
1257	1	O
1257	##b	O
1257	)	O
1257	.	O
1257	[SEP]	O
1258	[CLS]	O
1258	drug	O
1258	clearance	B-PK
1258	was	O
1258	q	O
1258	##uant	O
1258	##ified	O
1258	after	O
1258	dos	O
1258	##ing	O
1258	with	O
1258	a	O
1258	p	O
1258	##har	O
1258	##ma	O
1258	##cological	O
1258	4	O
1258	.	O
1258	4	O
1258	-	O
1258	µ	O
1258	##m	O
1258	dose	O
1258	and	O
1258	a	O
1258	su	O
1258	##pra	O
1258	##pha	O
1258	##rma	O
1258	##cological	O
1258	440	O
1258	-	O
1258	µ	O
1258	##m	O
1258	dose	O
1258	of	O
1258	d	O
1258	##c	O
1258	##f	O
1258	in	O
1258	medium	O
1258	containing	O
1258	1	O
1258	.	O
1258	25	O
1258	g	O
1258	/	O
1258	l	O
1258	b	O
1258	##sa	O
1258	(	O
1258	fi	O
1258	##g	O
1258	.	O
1258	2	O
1258	;	O
1258	supplement	O
1258	##al	O
1258	table	O
1258	3	O
1258	)	O
1258	.	O
1258	[SEP]	O
1259	[CLS]	O
1259	clearance	B-PK
1259	parameters	O
1259	were	O
1259	calculated	O
1259	from	O
1259	the	O
1259	concentration	O
1259	profiles	O
1259	of	O
1259	total	O
1259	d	O
1259	##c	O
1259	##f	O
1259	as	O
1259	a	O
1259	function	O
1259	of	O
1259	time	O
1259	,	O
1259	taking	O
1259	into	O
1259	account	O
1259	the	O
1259	reactor	O
1259	mixing	O
1259	properties	O
1259	and	O
1259	album	O
1259	##in	O
1259	binding	O
1259	,	O
1259	using	O
1259	a	O
1259	p	O
1259	##k	O
1259	model	O
1259	as	O
1259	described	O
1259	in	O
1259	the	O
1259	materials	O
1259	and	O
1259	methods	O
1259	.	O
1259	[SEP]	O
1260	[CLS]	O
1260	the	O
1260	t	B-PK
1260	##1	I-PK
1260	/	I-PK
1260	2	I-PK
1260	of	O
1260	d	O
1260	##c	O
1260	##f	O
1260	at	O
1260	a	O
1260	p	O
1260	##har	O
1260	##ma	O
1260	##cological	O
1260	dose	O
1260	was	O
1260	estimated	O
1260	to	O
1260	be	O
1260	14	O
1260	.	O
1260	6	O
1260	hours	O
1260	in	O
1260	the	O
1260	liver	O
1260	##chi	O
1260	##p	O
1260	bio	O
1260	##rea	O
1260	##ctor	O
1260	.	O
1260	[SEP]	O
1261	[CLS]	O
1261	values	O
1261	of	O
1261	s	O
1261	##cal	O
1261	##ing	O
1261	parameters	O
1261	and	O
1261	intrinsic	B-PK
1261	clearance	I-PK
1261	are	O
1261	found	O
1261	in	O
1261	supplement	O
1261	##al	O
1261	table	O
1261	3	O
1261	.	O
1261	[SEP]	O
1262	[CLS]	O
1262	clearance	B-PK
1262	was	O
1262	also	O
1262	investigated	O
1262	at	O
1262	a	O
1262	higher	O
1262	dose	O
1262	(	O
1262	440	O
1262	µ	O
1262	##m	O
1262	)	O
1262	(	O
1262	fi	O
1262	##g	O
1262	.	O
1262	2	O
1262	##b	O
1262	)	O
1262	,	O
1262	as	O
1262	this	O
1262	condition	O
1262	was	O
1262	used	O
1262	to	O
1262	assess	O
1262	meta	O
1262	##bol	O
1262	##ite	O
1262	production	O
1262	in	O
1262	addition	O
1262	to	O
1262	clearance	B-PK
1262	.	O
1262	[SEP]	O
1263	[CLS]	O
1263	here	O
1263	,	O
1263	the	O
1263	retrospective	O
1263	in	O
1263	v	O
1263	##ivo	O
1263	–	O
1263	in	O
1263	v	O
1263	##it	O
1263	##ro	O
1263	correlation	O
1263	analysis	O
1263	of	O
1263	the	O
1263	d	O
1263	##c	O
1263	##f	O
1263	clearance	B-PK
1263	using	O
1263	t	B-PK
1263	##1	I-PK
1263	/	I-PK
1263	2	I-PK
1263	and	O
1263	v	B-PK
1263	##d	I-PK
1263	to	O
1263	calculate	O
1263	intrinsic	B-PK
1263	clearance	I-PK
1263	(	I-PK
1263	c	I-PK
1263	##lint	I-PK
1263	)	I-PK
1263	by	O
1263	accounting	O
1263	for	O
1263	the	O
1263	s	O
1263	##cal	O
1263	##ing	O
1263	factors	O
1263	detailed	O
1263	in	O
1263	e	O
1263	##q	O
1263	.	O
1263	7	O
1263	(	O
1263	da	O
1263	##vies	O
1263	and	O
1263	m	O
1263	##or	O
1263	##ris	O
1263	1993	O
1263	;	O
1263	o	O
1263	##bach	O
1263	et	O
1263	al	O
1263	.	O
1263	,	O
1263	1997	O
1263	;	O
1263	o	O
1263	##bach	O
1263	,	O
1263	1999	O
1263	;	O
1263	sa	O
1263	##rka	O
1263	##r	O
1263	et	O
1263	al	O
1263	.	O
1263	,	O
1263	2015	O
1263	)	O
1263	:	O
1263	[SEP]	O
1264	[CLS]	O
1264	the	O
1264	cm	B-PK
1264	##ax	I-PK
1264	for	O
1264	the	O
1264	recommended	O
1264	dose	O
1264	of	O
1264	d	O
1264	##c	O
1264	##f	O
1264	in	O
1264	humans	O
1264	is	O
1264	4	O
1264	.	O
1264	4	O
1264	µ	O
1264	##m	O
1264	and	O
1264	experiments	O
1264	were	O
1264	carried	O
1264	out	O
1264	up	O
1264	to	O
1264	100	O
1264	cm	B-PK
1264	##ax	I-PK
1264	.	O
1264	[SEP]	O
1265	[CLS]	O
1265	another	O
1265	23	O
1265	%	O
1265	were	O
1265	associated	O
1265	with	O
1265	high	O
1265	-	O
1265	density	O
1265	lip	O
1265	##op	O
1265	##rote	O
1265	##in	O
1265	particle	O
1265	clearance	O
1265	.	O
1265	[SEP]	O
1266	[CLS]	O
1266	b	O
1266	##w	O
1266	demonstrated	O
1266	the	O
1266	following	O
1266	effects	O
1266	:	O
1266	after	O
1266	i	O
1266	.	O
1266	v	O
1266	.	O
1266	administration	O
1266	,	O
1266	significant	O
1266	effects	O
1266	(	O
1266	p	O
1266	<	O
1266	0	O
1266	.	O
1266	05	O
1266	)	O
1266	were	O
1266	observed	O
1266	for	O
1266	exposure	O
1266	(	O
1266	area	B-PK
1266	under	I-PK
1266	the	I-PK
1266	concentration	I-PK
1266	–	I-PK
1266	time	I-PK
1266	curve	I-PK
1266	from	I-PK
1266	zero	I-PK
1266	to	I-PK
1266	in	I-PK
1266	##finity	I-PK
1266	(	I-PK
1266	au	I-PK
1266	##c	I-PK
1266	##0	I-PK
1266	–	I-PK
1266	∞	I-PK
1266	)	I-PK
1266	)	O
1266	,	O
1266	peak	B-PK
1266	plasma	I-PK
1266	concentration	I-PK
1266	(	I-PK
1266	cm	I-PK
1266	##ax	I-PK
1266	)	I-PK
1266	,	O
1266	volume	B-PK
1266	of	I-PK
1266	distribution	I-PK
1266	at	I-PK
1266	steady	I-PK
1266	state	I-PK
1266	,	O
1266	and	O
1266	clearance	B-PK
1266	;	O
1266	whereas	O
1266	after	O
1266	s	O
1266	.	O
1266	c	O
1266	.	O
1266	administration	O
1266	,	O
1266	significant	O
1266	effects	O
1266	(	O
1266	p	O
1266	<	O
1266	0	O
1266	.	O
1266	05	O
1266	)	O
1266	were	O
1266	observed	O
1266	for	O
1266	cm	B-PK
1266	##ax	I-PK
1266	,	O
1266	au	B-PK
1266	##c	I-PK
1266	##0	I-PK
1266	–	I-PK
1266	∞	I-PK
1266	,	O
1266	terminal	B-PK
1266	half	I-PK
1266	‐	I-PK
1266	life	I-PK
1266	,	O
1266	and	O
1266	estimated	O
1266	apparent	B-PK
1266	clearance	I-PK
1266	.	O
1266	[SEP]	O
1267	[CLS]	O
1267	b	O
1267	##mi	O
1267	increased	O
1267	clearance	B-PK
1267	for	O
1267	heavier	O
1267	subjects	O
1267	.	O
1267	[SEP]	O
1268	[CLS]	O
1268	for	O
1268	example	O
1268	,	O
1268	mean	O
1268	(	O
1268	s	O
1268	##d	O
1268	)	O
1268	plasma	B-PK
1268	clearance	I-PK
1268	of	O
1268	i	O
1268	.	O
1268	v	O
1268	.	O
1268	an	O
1268	##aki	O
1268	##n	O
1268	##ra	O
1268	increased	O
1268	from	O
1268	1	O
1268	.	O
1268	17	O
1268	±	O
1268	0	O
1268	.	O
1268	29	O
1268	to	O
1268	1	O
1268	.	O
1268	62	O
1268	±	O
1268	0	O
1268	.	O
1268	24	O
1268	m	O
1268	##l	O
1268	/	O
1268	minute	O
1268	/	O
1268	kg	O
1268	(	O
1268	p	O
1268	<	O
1268	0	O
1268	.	O
1268	05	O
1268	)	O
1268	for	O
1268	larger	O
1268	(	O
1268	>	O
1268	100	O
1268	kg	O
1268	)	O
1268	o	O
1268	##bes	O
1268	##e	O
1268	(	O
1268	b	O
1268	##mi	O
1268	>	O
1268	36	O
1268	)	O
1268	vs	O
1268	.	O
1268	larger	O
1268	(	O
1268	>	O
1268	100	O
1268	kg	O
1268	)	O
1268	less	O
1268	o	O
1268	##bes	O
1268	##e	O
1268	(	O
1268	b	O
1268	##mi	O
1268	<	O
1268	35	O
1268	)	O
1268	subjects	O
1268	,	O
1268	respectively	O
1268	.	O
1268	[SEP]	O
1269	[CLS]	O
1269	absolute	B-PK
1269	bio	I-PK
1269	##ava	I-PK
1269	##ila	I-PK
1269	##bility	I-PK
1269	ranged	O
1269	from	O
1269	80	O
1269	–	O
1269	92	O
1269	%	O
1269	and	O
1269	was	O
1269	unrelated	O
1269	to	O
1269	b	O
1269	##w	O
1269	or	O
1269	b	O
1269	##mi	O
1269	.	O
1269	[SEP]	O
1270	[CLS]	O
1270	[UNK]	O
1270	the	O
1270	study	O
1270	demonstrated	O
1270	that	O
1270	absolute	B-PK
1270	bio	I-PK
1270	##ava	I-PK
1270	##ila	I-PK
1270	##bility	I-PK
1270	was	O
1270	not	O
1270	altered	O
1270	in	O
1270	o	O
1270	##bes	O
1270	##e	O
1270	subjects	O
1270	.	O
1270	[SEP]	O
1271	[CLS]	O
1271	the	O
1271	p	O
1271	##k	O
1271	of	O
1271	an	O
1271	##aki	O
1271	##n	O
1271	##ra	O
1271	showed	O
1271	that	O
1271	,	O
1271	as	O
1271	anticipated	O
1271	,	O
1271	exposure	O
1271	was	O
1271	higher	O
1271	(	O
1271	and	O
1271	clearance	B-PK
1271	lower	O
1271	)	O
1271	in	O
1271	lighter	O
1271	‐	O
1271	weight	O
1271	subjects	O
1271	.	O
1271	[SEP]	O
1272	[CLS]	O
1272	b	O
1272	##mi	O
1272	altered	O
1272	clearance	B-PK
1272	and	O
1272	exposure	O
1272	in	O
1272	heavier	O
1272	subjects	O
1272	.	O
1272	[SEP]	O
1273	[CLS]	O
1273	the	O
1273	absolute	B-PK
1273	bio	I-PK
1273	##ava	I-PK
1273	##ila	I-PK
1273	##bility	I-PK
1273	(	I-PK
1273	f	I-PK
1273	)	I-PK
1273	after	O
1273	a	O
1273	70	O
1273	‐	O
1273	mg	O
1273	s	O
1273	.	O
1273	c	O
1273	.	O
1273	b	O
1273	##ol	O
1273	##us	O
1273	injection	O
1273	into	O
1273	healthy	O
1273	subjects	O
1273	is	O
1273	95	O
1273	%	O
1273	.	O
1273	8	O
1273	in	O
1273	subjects	O
1273	with	O
1273	r	O
1273	##a	O
1273	,	O
1273	maximum	B-PK
1273	observed	I-PK
1273	plasma	I-PK
1273	concentrations	I-PK
1273	(	I-PK
1273	cm	I-PK
1273	##ax	I-PK
1273	)	I-PK
1273	of	O
1273	an	O
1273	##aki	O
1273	##n	O
1273	##ra	O
1273	occurred	O
1273	within	O
1273	3	O
1273	–	O
1273	7	O
1273	hours	O
1273	after	O
1273	s	O
1273	.	O
1273	c	O
1273	.	O
1273	administration	O
1273	,	O
1273	with	O
1273	a	O
1273	terminal	B-PK
1273	half	I-PK
1273	‐	I-PK
1273	life	I-PK
1273	(	I-PK
1273	t	I-PK
1273	##1	I-PK
1273	/	I-PK
1273	2	I-PK
1273	)	I-PK
1273	ranging	O
1273	within	O
1273	4	O
1273	–	O
1273	6	O
1273	hours	O
1273	.	O
1273	[SEP]	O
1274	[CLS]	O
1274	population	O
1274	p	O
1274	##k	O
1274	analyses	O
1274	at	O
1274	doses	O
1274	of	O
1274	30	O
1274	mg	O
1274	,	O
1274	70	O
1274	mg	O
1274	,	O
1274	and	O
1274	150	O
1274	mg	O
1274	of	O
1274	s	O
1274	.	O
1274	c	O
1274	.	O
1274	injected	O
1274	an	O
1274	##aki	O
1274	##n	O
1274	##ra	O
1274	up	O
1274	to	O
1274	24	O
1274	weeks	O
1274	indicated	O
1274	that	O
1274	the	O
1274	estimated	O
1274	apparent	B-PK
1274	clearance	I-PK
1274	(	I-PK
1274	c	I-PK
1274	##l	I-PK
1274	/	I-PK
1274	f	I-PK
1274	)	I-PK
1274	of	O
1274	an	O
1274	##aki	O
1274	##n	O
1274	##ra	O
1274	after	O
1274	s	O
1274	.	O
1274	c	O
1274	.	O
1274	administration	O
1274	increased	O
1274	with	O
1274	increasing	O
1274	c	O
1274	##rea	O
1274	##tin	O
1274	##ine	O
1274	clearance	O
1274	and	O
1274	body	O
1274	weight	O
1274	(	O
1274	b	O
1274	##w	O
1274	)	O
1274	.	O
1274	9	O
1274	gender	O
1274	differences	O
1274	also	O
1274	occur	O
1274	,	O
1274	most	O
1274	likely	O
1274	related	O
1274	to	O
1274	differences	O
1274	in	O
1274	b	O
1274	##w	O
1274	.	O
1274	10	O
1274	plasma	B-PK
1274	clearance	I-PK
1274	of	O
1274	an	O
1274	##aki	O
1274	##n	O
1274	##ra	O
1274	occurs	O
1274	predominantly	O
1274	via	O
1274	g	O
1274	##lo	O
1274	##mer	O
1274	##ular	O
1274	fi	O
1274	##ltration	O
1274	and	O
1274	tub	O
1274	##ular	O
1274	re	O
1274	##ab	O
1274	##sor	O
1274	##ption	O
1274	.	O
1274	11	O
1274	[SEP]	O
1275	[CLS]	O
1275	the	O
1275	t	B-PK
1275	##1	I-PK
1275	/	I-PK
1275	2	I-PK
1275	of	O
1275	an	O
1275	##aki	O
1275	##n	O
1275	##ra	O
1275	is	O
1275	4	O
1275	–	O
1275	6	O
1275	hours	O
1275	;	O
1275	therefore	O
1275	,	O
1275	7	O
1275	days	O
1275	was	O
1275	considered	O
1275	an	O
1275	adequate	O
1275	wash	O
1275	##out	O
1275	period	O
1275	.	O
1275	[SEP]	O
1276	[CLS]	O
1276	the	O
1276	primary	O
1276	end	O
1276	points	O
1276	of	O
1276	this	O
1276	study	O
1276	were	O
1276	f	B-PK
1276	after	O
1276	s	O
1276	.	O
1276	c	O
1276	.	O
1276	administration	O
1276	of	O
1276	an	O
1276	##aki	O
1276	##n	O
1276	##ra	O
1276	,	O
1276	area	B-PK
1276	under	I-PK
1276	the	I-PK
1276	concentration	I-PK
1276	–	I-PK
1276	time	I-PK
1276	curve	I-PK
1276	(	I-PK
1276	au	I-PK
1276	##c	I-PK
1276	)	I-PK
1276	,	O
1276	and	O
1276	cm	B-PK
1276	##ax	I-PK
1276	.	O
1276	[SEP]	O
1277	[CLS]	O
1277	secondary	O
1277	p	O
1277	##k	O
1277	end	O
1277	points	O
1277	were	O
1277	time	B-PK
1277	of	I-PK
1277	maximum	I-PK
1277	plasma	I-PK
1277	concentration	I-PK
1277	(	I-PK
1277	t	I-PK
1277	##max	I-PK
1277	)	I-PK
1277	,	O
1277	t	B-PK
1277	##1	I-PK
1277	/	I-PK
1277	2	I-PK
1277	,	O
1277	c	B-PK
1277	##l	I-PK
1277	/	I-PK
1277	f	I-PK
1277	,	O
1277	volume	B-PK
1277	of	I-PK
1277	distribution	I-PK
1277	at	I-PK
1277	steady	I-PK
1277	state	I-PK
1277	(	I-PK
1277	vs	I-PK
1277	##s	I-PK
1277	)	I-PK
1277	,	O
1277	and	O
1277	clearance	B-PK
1277	(	I-PK
1277	c	I-PK
1277	##l	I-PK
1277	)	I-PK
1277	.	O
1277	[SEP]	O
1278	[CLS]	O
1278	pre	O
1278	##sp	O
1278	##ec	O
1278	##ified	O
1278	h	O
1278	##y	O
1278	##pot	O
1278	##heses	O
1278	tested	O
1278	in	O
1278	this	O
1278	study	O
1278	included	O
1278	whether	O
1278	o	O
1278	##besity	O
1278	altered	O
1278	absolute	B-PK
1278	bio	I-PK
1278	##ava	I-PK
1278	##ila	I-PK
1278	##bility	I-PK
1278	or	O
1278	clearance	B-PK
1278	.	O
1278	[SEP]	O
1279	[CLS]	O
1279	power	O
1279	analyses	O
1279	for	O
1279	numbers	O
1279	of	O
1279	subjects	O
1279	were	O
1279	based	O
1279	on	O
1279	data	O
1279	from	O
1279	a	O
1279	previous	O
1279	study	O
1279	of	O
1279	an	O
1279	##aki	O
1279	##n	O
1279	##ra	O
1279	(	O
1279	study	O
1279	2000	O
1279	##01	O
1279	##9	O
1279	##6	O
1279	)	O
1279	,	O
1279	in	O
1279	which	O
1279	the	O
1279	between	O
1279	‐	O
1279	subject	O
1279	var	O
1279	##iability	O
1279	for	O
1279	au	B-PK
1279	##c	I-PK
1279	,	O
1279	cm	B-PK
1279	##ax	I-PK
1279	,	O
1279	and	O
1279	the	O
1279	ratio	O
1279	of	O
1279	dose	O
1279	a	O
1279	to	O
1279	dose	O
1279	b	O
1279	for	O
1279	au	B-PK
1279	##c	I-PK
1279	and	O
1279	cm	B-PK
1279	##ax	I-PK
1279	does	O
1279	not	O
1279	exceed	O
1279	14	O
1279	%	O
1279	for	O
1279	au	B-PK
1279	##c	I-PK
1279	and	O
1279	27	O
1279	%	O
1279	for	O
1279	cm	B-PK
1279	##ax	I-PK
1279	.	O
1279	[SEP]	O
1280	[CLS]	O
1280	using	O
1280	these	O
1280	estimates	O
1280	,	O
1280	it	O
1280	was	O
1280	determined	O
1280	that	O
1280	a	O
1280	sample	O
1280	size	O
1280	of	O
1280	32	O
1280	would	O
1280	provide	O
1280	an	O
1280	80	O
1280	%	O
1280	chance	O
1280	(	O
1280	power	O
1280	)	O
1280	of	O
1280	detect	O
1280	##ing	O
1280	at	O
1280	the	O
1280	5	O
1280	%	O
1280	level	O
1280	of	O
1280	significance	O
1280	a	O
1280	14	O
1280	%	O
1280	difference	O
1280	in	O
1280	au	B-PK
1280	##c	I-PK
1280	parameters	O
1280	and	O
1280	a	O
1280	32	O
1280	%	O
1280	difference	O
1280	in	O
1280	cm	B-PK
1280	##ax	I-PK
1280	parameters	O
1280	between	O
1280	the	O
1280	two	O
1280	b	O
1280	##mi	O
1280	classification	O
1280	##s	O
1280	(	O
1280	≥	O
1280	36	O
1280	or	O
1280	<	O
1280	35	O
1280	;	O
1280	n	O
1280	=	O
1280	16	O
1280	)	O
1280	or	O
1280	the	O
1280	two	O
1280	b	O
1280	##w	O
1280	classification	O
1280	##s	O
1280	(	O
1280	≤	O
1280	90	O
1280	or	O
1280	≥	O
1280	100	O
1280	;	O
1280	n	O
1280	=	O
1280	16	O
1280	)	O
1280	.	O
1280	[SEP]	O
1281	[CLS]	O
1281	the	O
1281	primary	O
1281	contrasts	O
1281	of	O
1281	interest	O
1281	were	O
1281	the	O
1281	estimates	O
1281	of	O
1281	f	B-PK
1281	,	O
1281	au	B-PK
1281	##c	I-PK
1281	,	O
1281	and	O
1281	cm	B-PK
1281	##ax	I-PK
1281	for	O
1281	the	O
1281	two	O
1281	b	O
1281	##mi	O
1281	and	O
1281	two	O
1281	b	O
1281	##w	O
1281	classification	O
1281	##s	O
1281	.	O
1281	[SEP]	O
1282	[CLS]	O
1282	using	O
1282	the	O
1282	same	O
1282	estimates	O
1282	for	O
1282	the	O
1282	differences	O
1282	between	O
1282	any	O
1282	two	O
1282	groups	O
1282	(	O
1282	n	O
1282	=	O
1282	8	O
1282	)	O
1282	,	O
1282	this	O
1282	study	O
1282	had	O
1282	an	O
1282	80	O
1282	%	O
1282	chance	O
1282	of	O
1282	detect	O
1282	##ing	O
1282	at	O
1282	the	O
1282	5	O
1282	%	O
1282	level	O
1282	of	O
1282	significance	O
1282	,	O
1282	a	O
1282	22	O
1282	%	O
1282	difference	O
1282	in	O
1282	au	B-PK
1282	##c	I-PK
1282	,	O
1282	and	O
1282	a	O
1282	50	O
1282	%	O
1282	difference	O
1282	in	O
1282	cm	B-PK
1282	##ax	I-PK
1282	.	O
1282	[SEP]	O
1283	[CLS]	O
1283	secondary	O
1283	contrasts	O
1283	of	O
1283	interest	O
1283	were	O
1283	analysis	O
1283	of	O
1283	variance	O
1283	(	O
1283	an	O
1283	##ova	O
1283	)	O
1283	comparisons	O
1283	among	O
1283	the	O
1283	three	O
1283	s	O
1283	.	O
1283	c	O
1283	.	O
1283	doses	O
1283	(	O
1283	for	O
1283	each	O
1283	of	O
1283	the	O
1283	four	O
1283	b	O
1283	##w	O
1283	/	O
1283	b	O
1283	##mi	O
1283	classification	O
1283	##s	O
1283	)	O
1283	;	O
1283	a	O
1283	crossover	O
1283	an	O
1283	##ova	O
1283	was	O
1283	used	O
1283	to	O
1283	compare	O
1283	dose	O
1283	‐	O
1283	adjusted	O
1283	cm	B-PK
1283	##ax	I-PK
1283	and	O
1283	au	B-PK
1283	##c	I-PK
1283	after	O
1283	each	O
1283	s	O
1283	.	O
1283	c	O
1283	.	O
1283	dose	O
1283	.	O
1283	[SEP]	O
1284	[CLS]	O
1284	b	O
1284	##w	O
1284	demonstrated	O
1284	the	O
1284	following	O
1284	effects	O
1284	:	O
1284	after	O
1284	i	O
1284	.	O
1284	v	O
1284	.	O
1284	administration	O
1284	,	O
1284	significant	O
1284	effects	O
1284	(	O
1284	p	O
1284	<	O
1284	0	O
1284	.	O
1284	05	O
1284	)	O
1284	were	O
1284	observed	O
1284	for	O
1284	exposure	O
1284	(	O
1284	au	B-PK
1284	##c	I-PK
1284	##0	I-PK
1284	–	I-PK
1284	∞	I-PK
1284	)	O
1284	,	O
1284	cm	B-PK
1284	##ax	I-PK
1284	,	O
1284	vs	B-PK
1284	##s	I-PK
1284	,	O
1284	and	O
1284	c	B-PK
1284	##l	I-PK
1284	,	O
1284	whereas	O
1284	after	O
1284	s	O
1284	.	O
1284	c	O
1284	.	O
1284	administration	O
1284	,	O
1284	significant	O
1284	effects	O
1284	(	O
1284	p	O
1284	<	O
1284	0	O
1284	.	O
1284	05	O
1284	)	O
1284	were	O
1284	observed	O
1284	for	O
1284	cm	B-PK
1284	##ax	I-PK
1284	,	O
1284	au	B-PK
1284	##c	I-PK
1284	##0	I-PK
1284	–	I-PK
1284	∞	I-PK
1284	,	O
1284	t	B-PK
1284	##1	I-PK
1284	/	I-PK
1284	2	I-PK
1284	,	O
1284	and	O
1284	c	B-PK
1284	##l	I-PK
1284	/	I-PK
1284	f	I-PK
1284	.	O
1284	[SEP]	O
1285	[CLS]	O
1285	median	O
1285	plasma	O
1285	an	O
1285	##aki	O
1285	##n	O
1285	##ra	O
1285	concentration	O
1285	–	O
1285	time	O
1285	profiles	O
1285	after	O
1285	i	O
1285	.	O
1285	v	O
1285	.	O
1285	administration	O
1285	of	O
1285	100	O
1285	mg	O
1285	an	O
1285	##aki	O
1285	##n	O
1285	##ra	O
1285	declined	O
1285	with	O
1285	similar	O
1285	slopes	O
1285	and	O
1285	t	B-PK
1285	##1	I-PK
1285	/	I-PK
1285	2	I-PK
1285	values	O
1285	for	O
1285	the	O
1285	different	O
1285	b	O
1285	##w	O
1285	and	O
1285	b	O
1285	##mi	O
1285	groups	O
1285	,	O
1285	varying	O
1285	from	O
1285	1	O
1285	.	O
1285	67	O
1285	##−	O
1285	##1	O
1285	.	O
1285	86	O
1285	hours	O
1285	(	O
1285	figure	O
1285	##2	O
1285	##and	O
1285	table	O
1285	##2	O
1285	)	O
1285	.	O
1285	[SEP]	O
1286	[CLS]	O
1286	the	O
1286	c	B-PK
1286	##l	I-PK
1286	value	O
1286	,	O
1286	which	O
1286	is	O
1286	inverse	O
1286	##ly	O
1286	proportional	O
1286	to	O
1286	au	B-PK
1286	##c	I-PK
1286	,	O
1286	was	O
1286	higher	O
1286	for	O
1286	the	O
1286	heavier	O
1286	subjects	O
1286	than	O
1286	for	O
1286	the	O
1286	lighter	O
1286	subjects	O
1286	;	O
1286	however	O
1286	,	O
1286	after	O
1286	being	O
1286	normal	O
1286	##ized	O
1286	by	O
1286	b	O
1286	##w	O
1286	(	O
1286	c	B-PK
1286	##l	I-PK
1286	/	I-PK
1286	b	I-PK
1286	##w	I-PK
1286	)	O
1286	,	O
1286	it	O
1286	was	O
1286	16	O
1286	%	O
1286	higher	O
1286	for	O
1286	the	O
1286	lighter	O
1286	subjects	O
1286	than	O
1286	for	O
1286	the	O
1286	heavier	O
1286	subjects	O
1286	.	O
1286	[SEP]	O
1287	[CLS]	O
1287	the	O
1287	t	B-PK
1287	##1	I-PK
1287	/	I-PK
1287	2	I-PK
1287	was	O
1287	independent	O
1287	of	O
1287	b	O
1287	##w	O
1287	,	O
1287	as	O
1287	the	O
1287	vs	B-PK
1287	##s	I-PK
1287	value	O
1287	also	O
1287	increased	O
1287	with	O
1287	increasing	O
1287	b	O
1287	##w	O
1287	in	O
1287	a	O
1287	similar	O
1287	manner	O
1287	to	O
1287	c	B-PK
1287	##l	I-PK
1287	.	O
1287	[SEP]	O
1288	[CLS]	O
1288	therefore	O
1288	,	O
1288	concentration	O
1288	data	O
1288	after	O
1288	i	O
1288	.	O
1288	v	O
1288	.	O
1288	administration	O
1288	for	O
1288	these	O
1288	subjects	O
1288	were	O
1288	excluded	O
1288	from	O
1288	p	O
1288	##k	O
1288	and	O
1288	statistical	O
1288	analyses	O
1288	,	O
1288	and	O
1288	the	O
1288	absolute	B-PK
1288	bio	I-PK
1288	##ava	I-PK
1288	##ila	I-PK
1288	##bility	I-PK
1288	for	O
1288	these	O
1288	subjects	O
1288	was	O
1288	not	O
1288	estimated	O
1288	.	O
1288	[SEP]	O
1289	[CLS]	O
1289	the	O
1289	clearance	B-PK
1289	value	O
1289	of	O
1289	this	O
1289	subject	O
1289	was	O
1289	2	O
1289	.	O
1289	9	O
1289	‐	O
1289	fold	O
1289	higher	O
1289	than	O
1289	the	O
1289	mean	O
1289	value	O
1289	for	O
1289	the	O
1289	rest	O
1289	of	O
1289	the	O
1289	subjects	O
1289	.	O
1289	[SEP]	O
1290	[CLS]	O
1290	the	O
1290	estimated	O
1290	f	B-PK
1290	after	O
1290	s	O
1290	.	O
1290	c	O
1290	.	O
1290	administration	O
1290	for	O
1290	this	O
1290	subject	O
1290	was	O
1290	unexpectedly	O
1290	out	O
1290	of	O
1290	range	O
1290	:	O
1290	218	O
1290	%	O
1290	at	O
1290	100	O
1290	mg	O
1290	,	O
1290	225	O
1290	%	O
1290	at	O
1290	150	O
1290	mg	O
1290	,	O
1290	and	O
1290	at	O
1290	212	O
1290	%	O
1290	at	O
1290	300	O
1290	mg	O
1290	.	O
1290	[SEP]	O
1291	[CLS]	O
1291	based	O
1291	on	O
1291	the	O
1291	c	B-PK
1291	##l	I-PK
1291	and	O
1291	f	B-PK
1291	values	O
1291	,	O
1291	this	O
1291	subject	O
1291	'	O
1291	s	O
1291	p	O
1291	##k	O
1291	profile	O
1291	after	O
1291	i	O
1291	.	O
1291	v	O
1291	.	O
1291	administration	O
1291	was	O
1291	classified	O
1291	as	O
1291	an	O
1291	out	O
1291	##lier	O
1291	.	O
1291	[SEP]	O
1292	[CLS]	O
1292	therefore	O
1292	,	O
1292	the	O
1292	p	O
1292	##k	O
1292	parameters	O
1292	after	O
1292	i	O
1292	.	O
1292	v	O
1292	.	O
1292	administration	O
1292	and	O
1292	the	O
1292	f	B-PK
1292	after	O
1292	s	O
1292	.	O
1292	c	O
1292	.	O
1292	administration	O
1292	for	O
1292	this	O
1292	subject	O
1292	were	O
1292	also	O
1292	excluded	O
1292	from	O
1292	statistical	O
1292	analyses	O
1292	.	O
1292	[SEP]	O
1293	[CLS]	O
1293	mean	O
1293	c	B-PK
1293	##l	I-PK
1293	/	I-PK
1293	f	I-PK
1293	values	O
1293	were	O
1293	higher	O
1293	for	O
1293	subjects	O
1293	with	O
1293	b	O
1293	##w	O
1293	≥	O
1293	100	O
1293	kg	O
1293	than	O
1293	for	O
1293	subjects	O
1293	with	O
1293	b	O
1293	##w	O
1293	≤	O
1293	90	O
1293	kg	O
1293	,	O
1293	and	O
1293	b	O
1293	##mi	O
1293	seemed	O
1293	to	O
1293	have	O
1293	an	O
1293	impact	O
1293	only	O
1293	for	O
1293	heavier	O
1293	subjects	O
1293	.	O
1293	[SEP]	O
1294	[CLS]	O
1294	as	O
1294	seen	O
1294	in	O
1294	table	O
1294	##3	O
1294	,	O
1294	t	B-PK
1294	##1	I-PK
1294	/	I-PK
1294	2	I-PK
1294	increased	O
1294	with	O
1294	both	O
1294	higher	O
1294	b	O
1294	##w	O
1294	and	O
1294	higher	O
1294	b	O
1294	##mi	O
1294	ranging	O
1294	from	O
1294	3	O
1294	.	O
1294	63	O
1294	hours	O
1294	for	O
1294	less	O
1294	o	O
1294	##bes	O
1294	##e	O
1294	,	O
1294	lighter	O
1294	‐	O
1294	weight	O
1294	subjects	O
1294	to	O
1294	7	O
1294	.	O
1294	62	O
1294	hours	O
1294	for	O
1294	o	O
1294	##bes	O
1294	##e	O
1294	,	O
1294	heavier	O
1294	‐	O
1294	weight	O
1294	subjects	O
1294	.	O
1294	[SEP]	O
1295	[CLS]	O
1295	f	B-PK
1295	was	O
1295	independent	O
1295	of	O
1295	both	O
1295	b	O
1295	##w	O
1295	and	O
1295	b	O
1295	##mi	O
1295	and	O
1295	ranged	O
1295	from	O
1295	80	O
1295	##−	O
1295	##9	O
1295	##2	O
1295	%	O
1295	(	O
1295	table	O
1295	##3	O
1295	)	O
1295	.	O
1295	[SEP]	O
1296	[CLS]	O
1296	when	O
1296	the	O
1296	dose	O
1296	was	O
1296	normal	O
1296	##ized	O
1296	vs	O
1296	.	O
1296	the	O
1296	100	O
1296	‐	O
1296	mg	O
1296	dose	O
1296	,	O
1296	cm	B-PK
1296	##ax	I-PK
1296	and	O
1296	au	B-PK
1296	##c	I-PK
1296	##0	I-PK
1296	‐	I-PK
1296	∞	I-PK
1296	were	O
1296	similar	O
1296	in	O
1296	a	O
1296	dose	O
1296	range	O
1296	for	O
1296	100	O
1296	mg	O
1296	,	O
1296	150	O
1296	mg	O
1296	,	O
1296	and	O
1296	300	O
1296	mg	O
1296	(	O
1296	figure	O
1296	##4	O
1296	)	O
1296	.	O
1296	[SEP]	O
1297	[CLS]	O
1297	a	O
1297	total	O
1297	of	O
1297	21	O
1297	subjects	O
1297	(	O
1297	64	O
1297	%	O
1297	)	O
1297	experienced	O
1297	the	O
1297	most	O
1297	common	O
1297	a	O
1297	##e	O
1297	,	O
1297	a	O
1297	reaction	O
1297	at	O
1297	the	O
1297	site	O
1297	of	O
1297	s	O
1297	.	O
1297	c	O
1297	.	O
1297	injection	O
1297	.	O
1297	[SEP]	O
1298	[CLS]	O
1298	the	O
1298	absolute	B-PK
1298	bio	I-PK
1298	##ava	I-PK
1298	##ila	I-PK
1298	##bility	I-PK
1298	of	O
1298	del	O
1298	##sol	O
1298	##ine	O
1298	was	O
1298	20	O
1298	.	O
1298	9	O
1298	%	O
1298	.	O
1298	[SEP]	O
1299	[CLS]	O
1299	the	O
1299	area	B-PK
1299	under	I-PK
1299	the	I-PK
1299	blood	I-PK
1299	concentration	I-PK
1299	-	I-PK
1299	time	I-PK
1299	curve	I-PK
1299	(	I-PK
1299	au	I-PK
1299	##c	I-PK
1299	)	I-PK
1299	,	O
1299	mean	B-PK
1299	residence	I-PK
1299	time	I-PK
1299	(	I-PK
1299	m	I-PK
1299	##rt	I-PK
1299	)	I-PK
1299	,	O
1299	blood	B-PK
1299	clearance	I-PK
1299	(	I-PK
1299	c	I-PK
1299	##l	I-PK
1299	)	I-PK
1299	,	O
1299	apparent	B-PK
1299	volume	I-PK
1299	of	I-PK
1299	distribution	I-PK
1299	(	I-PK
1299	v	I-PK
1299	)	I-PK
1299	,	O
1299	maximum	B-PK
1299	blood	I-PK
1299	concentration	I-PK
1299	(	I-PK
1299	cm	I-PK
1299	##ax	I-PK
1299	)	I-PK
1299	,	O
1299	and	O
1299	half	B-PK
1299	-	I-PK
1299	life	I-PK
1299	(	I-PK
1299	t	I-PK
1299	##1	I-PK
1299	/	I-PK
1299	2	I-PK
1299	)	I-PK
1299	was	O
1299	analyzed	O
1299	.	O
1299	[SEP]	O
1300	[CLS]	O
1300	the	O
1300	equation	O
1300	for	O
1300	bio	B-PK
1300	##ava	I-PK
1300	##ila	I-PK
1300	##bility	I-PK
1300	is	O
1300	expressed	O
1300	as	O
1300	the	O
1300	following	O
1300	:	O
1300	absolute	O
1300	bio	O
1300	##ava	O
1300	##ila	O
1300	##bility	O
1300	=	O
1300	in	O
1300	##tra	O
1300	##gas	O
1300	##tric	O
1300	au	O
1300	##c	O
1300	/	O
1300	in	O
1300	##tra	O
1300	##ven	O
1300	##ous	O
1300	au	O
1300	##c	O
1300	×	O
1300	100	O
1300	%	O
1300	.	O
1300	[SEP]	O
1301	[CLS]	O
1301	the	O
1301	t	B-PK
1301	##1	I-PK
1301	/	I-PK
1301	2	I-PK
1301	of	O
1301	the	O
1301	in	O
1301	##tra	O
1301	##gas	O
1301	##tric	O
1301	administration	O
1301	(	O
1301	9	O
1301	,	O
1301	6	O
1301	,	O
1301	and	O
1301	3	O
1301	mg	O
1301	/	O
1301	kg	O
1301	)	O
1301	and	O
1301	in	O
1301	##tra	O
1301	##ven	O
1301	##ous	O
1301	administration	O
1301	(	O
1301	1	O
1301	mg	O
1301	/	O
1301	kg	O
1301	)	O
1301	was	O
1301	1	O
1301	.	O
1301	3	O
1301	+	O
1301	0	O
1301	.	O
1301	5	O
1301	h	O
1301	,	O
1301	1	O
1301	.	O
1301	6	O
1301	+	O
1301	0	O
1301	.	O
1301	7	O
1301	h	O
1301	,	O
1301	1	O
1301	.	O
1301	7	O
1301	+	O
1301	0	O
1301	.	O
1301	8	O
1301	h	O
1301	,	O
1301	and	O
1301	2	O
1301	.	O
1301	5	O
1301	+	O
1301	0	O
1301	.	O
1301	7	O
1301	h	O
1301	,	O
1301	respectively	O
1301	,	O
1301	indicating	O
1301	that	O
1301	its	O
1301	metabolism	O
1301	was	O
1301	rapid	O
1301	.	O
1301	[SEP]	O
1302	[CLS]	O
1302	the	O
1302	absolute	B-PK
1302	bio	I-PK
1302	##ava	I-PK
1302	##ila	I-PK
1302	##bility	I-PK
1302	of	O
1302	del	O
1302	##sol	O
1302	##ine	O
1302	(	O
1302	9	O
1302	,	O
1302	6	O
1302	,	O
1302	and	O
1302	3	O
1302	mg	O
1302	/	O
1302	kg	O
1302	)	O
1302	was	O
1302	26	O
1302	.	O
1302	2	O
1302	%	O
1302	,	O
1302	18	O
1302	.	O
1302	8	O
1302	%	O
1302	,	O
1302	and	O
1302	17	O
1302	.	O
1302	7	O
1302	%	O
1302	,	O
1302	respectively	O
1302	,	O
1302	with	O
1302	an	O
1302	average	O
1302	of	O
1302	20	O
1302	.	O
1302	9	O
1302	%	O
1302	.	O
1302	[SEP]	O
1303	[CLS]	O
1303	the	O
1303	absolute	B-PK
1303	bio	I-PK
1303	##ava	I-PK
1303	##ila	I-PK
1303	##bility	I-PK
1303	of	O
1303	these	O
1303	doses	O
1303	was	O
1303	not	O
1303	significantly	O
1303	different	O
1303	.	O
1303	[SEP]	O
1304	[CLS]	O
1304	plasma	O
1304	concentration	O
1304	of	O
1304	be	O
1304	##rgen	O
1304	##in	O
1304	was	O
1304	detect	O
1304	##able	O
1304	as	O
1304	early	O
1304	as	O
1304	10	O
1304	min	O
1304	after	O
1304	administration	O
1304	,	O
1304	with	O
1304	a	O
1304	mean	O
1304	peak	B-PK
1304	concentration	I-PK
1304	in	I-PK
1304	plasma	I-PK
1304	(	I-PK
1304	cm	I-PK
1304	##ax	I-PK
1304	)	I-PK
1304	of	O
1304	275	O
1304	##±	O
1304	##16	O
1304	##4	O
1304	ng	O
1304	/	O
1304	m	O
1304	##l	O
1304	and	O
1304	the	O
1304	time	B-PK
1304	to	I-PK
1304	peak	I-PK
1304	(	I-PK
1304	t	I-PK
1304	##max	I-PK
1304	)	I-PK
1304	of	O
1304	0	O
1304	.	O
1304	29	O
1304	##2	O
1304	##±	O
1304	##0	O
1304	.	O
1304	102	O
1304	h	O
1304	.	O
1304	[SEP]	O
1305	[CLS]	O
1305	the	O
1305	elimination	B-PK
1305	half	I-PK
1305	life	I-PK
1305	(	I-PK
1305	t	I-PK
1305	##1	I-PK
1305	/	I-PK
1305	2	I-PK
1305	)	I-PK
1305	,	O
1305	mean	B-PK
1305	residence	I-PK
1305	time	I-PK
1305	(	I-PK
1305	m	I-PK
1305	##rt	I-PK
1305	)	I-PK
1305	and	O
1305	area	B-PK
1305	under	I-PK
1305	the	I-PK
1305	concentration	I-PK
1305	–	I-PK
1305	time	I-PK
1305	curve	I-PK
1305	from	I-PK
1305	time	I-PK
1305	0	I-PK
1305	to	I-PK
1305	24	I-PK
1305	h	I-PK
1305	(	I-PK
1305	au	I-PK
1305	##c	I-PK
1305	##0	I-PK
1305	–	I-PK
1305	24	I-PK
1305	)	I-PK
1305	were	O
1305	8	O
1305	.	O
1305	03	O
1305	##±	O
1305	##3	O
1305	.	O
1305	24	O
1305	h	O
1305	,	O
1305	4	O
1305	.	O
1305	99	O
1305	##±	O
1305	##0	O
1305	.	O
1305	66	O
1305	h	O
1305	and	O
1305	54	O
1305	##8	O
1305	##±	O
1305	##40	O
1305	##8	O
1305	ng	O
1305	h	O
1305	/	O
1305	m	O
1305	##l	O
1305	,	O
1305	respectively	O
1305	.	O
1305	[SEP]	O
1306	[CLS]	O
1306	the	O
1306	elimination	B-PK
1306	rate	I-PK
1306	constant	I-PK
1306	(	O
1306	%	O
1306	relative	O
1306	standard	O
1306	error	O
1306	)	O
1306	of	O
1306	r	O
1306	##it	O
1306	##ux	O
1306	##ima	O
1306	##b	O
1306	effect	O
1306	decay	O
1306	was	O
1306	0	O
1306	.	O
1306	03	O
1306	##6	O
1306	(	O
1306	22	O
1306	.	O
1306	7	O
1306	%	O
1306	)	O
1306	days	O
1306	##−	O
1306	##1	O
1306	and	O
1306	c	O
1306	##d	O
1306	##19	O
1306	+	O
1306	turnover	O
1306	was	O
1306	0	O
1306	.	O
1306	02	O
1306	(	O
1306	41	O
1306	%	O
1306	)	O
1306	days	O
1306	##−	O
1306	##1	O
1306	corresponding	O
1306	to	O
1306	half	B-PK
1306	‐	I-PK
1306	lives	I-PK
1306	of	O
1306	19	O
1306	and	O
1306	35	O
1306	days	O
1306	respectively	O
1306	.	O
1306	[SEP]	O
1307	[CLS]	O
1307	here	O
1307	,	O
1307	a	B-PK
1307	##1	I-PK
1307	has	O
1307	initial	O
1307	conditions	O
1307	of	O
1307	0	O
1307	,	O
1307	with	O
1307	addition	O
1307	of	O
1307	a	O
1307	dose	O
1307	amount	O
1307	in	O
1307	mg	O
1307	added	O
1307	with	O
1307	every	O
1307	dose	O
1307	event	O
1307	,	O
1307	and	O
1307	k	B-PK
1307	##e	I-PK
1307	representing	O
1307	elimination	B-PK
1307	rate	I-PK
1307	constant	I-PK
1307	of	O
1307	r	O
1307	##it	O
1307	##ux	O
1307	##ima	O
1307	##b	O
1307	effect	O
1307	,	O
1307	kin	B-PK
1307	:	O
1307	production	O
1307	rate	O
1307	of	O
1307	c	O
1307	##d	O
1307	##19	O
1307	+	O
1307	l	O
1307	##ymph	O
1307	##ocytes	O
1307	,	O
1307	k	B-PK
1307	##out	I-PK
1307	:	O
1307	elimination	B-PK
1307	rate	I-PK
1307	constant	I-PK
1307	of	O
1307	c	O
1307	##d	O
1307	##19	O
1307	+	O
1307	l	O
1307	##ymph	O
1307	##ocytes	O
1307	,	O
1307	em	B-PK
1307	##ax	I-PK
1307	:	O
1307	maximum	O
1307	increase	O
1307	in	O
1307	cell	O
1307	elimination	O
1307	rate	O
1307	in	O
1307	the	O
1307	presence	O
1307	of	O
1307	r	O
1307	##it	O
1307	##ux	O
1307	##ima	O
1307	##b	O
1307	,	O
1307	ed	B-PK
1307	##50	I-PK
1307	:	O
1307	dose	B-PK
1307	at	I-PK
1307	which	I-PK
1307	produces	I-PK
1307	50	I-PK
1307	%	I-PK
1307	of	I-PK
1307	the	I-PK
1307	maximum	I-PK
1307	effect	I-PK
1307	,	O
1307	a	B-PK
1307	##2	I-PK
1307	represents	O
1307	c	O
1307	##d	O
1307	##19	O
1307	+	O
1307	l	O
1307	##ymph	O
1307	##ocytes	O
1307	.	O
1307	[SEP]	O
1308	[CLS]	O
1308	model	O
1308	evaluation	O
1308	consisted	O
1308	of	O
1308	plotting	O
1308	model	O
1308	predictions	O
1308	vs	O
1308	observed	O
1308	c	O
1308	##d	O
1308	##19	O
1308	+	O
1308	l	O
1308	##ymph	O
1308	##oc	O
1308	##yte	O
1308	counts	O
1308	for	O
1308	the	O
1308	population	O
1308	and	O
1308	for	O
1308	individual	O
1308	patients	O
1308	,	O
1308	relative	O
1308	standard	O
1308	error	O
1308	(	O
1308	r	O
1308	##se	O
1308	)	O
1308	of	O
1308	model	O
1308	parameters	O
1308	,	O
1308	and	O
1308	visual	O
1308	predict	O
1308	##ive	O
1308	check	O
1308	(	O
1308	v	O
1308	##p	O
1308	##c	O
1308	)	O
1308	.	O
1308	[SEP]	O
1309	[CLS]	O
1309	the	O
1309	elimination	B-PK
1309	rate	I-PK
1309	constant	I-PK
1309	##s	I-PK
1309	of	O
1309	r	O
1309	##it	O
1309	##ux	O
1309	##ima	O
1309	##b	O
1309	(	O
1309	k	B-PK
1309	##e	I-PK
1309	)	O
1309	and	O
1309	c	O
1309	##d	O
1309	##19	O
1309	+	O
1309	b	O
1309	cells	O
1309	(	O
1309	k	B-PK
1309	##out	I-PK
1309	)	O
1309	suggested	O
1309	half	B-PK
1309	‐	I-PK
1309	lives	I-PK
1309	of	O
1309	19	O
1309	days	O
1309	and	O
1309	35	O
1309	days	O
1309	,	O
1309	respectively	O
1309	.	O
1309	[SEP]	O
1310	[CLS]	O
1310	at	O
1310	a	O
1310	dose	O
1310	of	O
1310	2	O
1310	mum	O
1310	##ol	O
1310	kg	O
1310	-	O
1310	1	O
1310	and	O
1310	photo	O
1310	##ther	O
1310	##ap	O
1310	##y	O
1310	at	O
1310	24	O
1310	h	O
1310	p	O
1310	.	O
1310	i	O
1310	.	O
1310	,	O
1310	the	O
1310	t	O
1310	##umour	O
1310	volume	O
1310	doubling	O
1310	time	O
1310	increased	O
1310	to	O
1310	11	O
1310	days	O
1310	vs	O
1310	6	O
1310	days	O
1310	for	O
1310	the	O
1310	control	O
1310	t	O
1310	##umour	O
1310	##s	O
1310	.	O
1310	[SEP]	O
1311	[CLS]	O
1311	administration	O
1311	under	O
1311	fast	O
1311	##ing	O
1311	conditions	O
1311	resulted	O
1311	in	O
1311	decreases	O
1311	in	O
1311	the	O
1311	mean	O
1311	au	B-PK
1311	##cin	I-PK
1311	##f	I-PK
1311	of	O
1311	el	O
1311	##vi	O
1311	##te	O
1311	##gra	O
1311	##vir	O
1311	and	O
1311	ten	O
1311	##of	O
1311	##ov	O
1311	##ir	O
1311	by	O
1311	50	O
1311	%	O
1311	and	O
1311	28	O
1311	%	O
1311	,	O
1311	respectively	O
1311	,	O
1311	relative	O
1311	to	O
1311	administration	O
1311	with	O
1311	a	O
1311	standard	O
1311	breakfast	O
1311	,	O
1311	whereas	O
1311	the	O
1311	bio	B-PK
1311	##ava	I-PK
1311	##ila	I-PK
1311	##bilities	I-PK
1311	of	O
1311	el	O
1311	##vi	O
1311	##te	O
1311	##gra	O
1311	##vir	O
1311	and	O
1311	ten	O
1311	##of	O
1311	##ov	O
1311	##ir	O
1311	were	O
1311	comparable	O
1311	when	O
1311	administered	O
1311	with	O
1311	a	O
1311	standard	O
1311	breakfast	O
1311	or	O
1311	a	O
1311	nutrition	O
1311	##al	O
1311	protein	O
1311	-	O
1311	rich	O
1311	drink	O
1311	.	O
1311	[SEP]	O
1312	[CLS]	O
1312	under	O
1312	fast	O
1312	##ing	O
1312	conditions	O
1312	,	O
1312	it	O
1312	appears	O
1312	that	O
1312	the	O
1312	bio	B-PK
1312	##ava	I-PK
1312	##ila	I-PK
1312	##bilities	I-PK
1312	of	O
1312	el	O
1312	##vi	O
1312	##te	O
1312	##gra	O
1312	##vir	O
1312	and	O
1312	ten	O
1312	##of	O
1312	##ov	O
1312	##ir	O
1312	were	O
1312	not	O
1312	equivalent	O
1312	to	O
1312	those	O
1312	when	O
1312	they	O
1312	were	O
1312	administered	O
1312	with	O
1312	either	O
1312	type	O
1312	of	O
1312	food	O
1312	,	O
1312	although	O
1312	they	O
1312	were	O
1312	bio	O
1312	##e	O
1312	##qui	O
1312	##valent	O
1312	to	O
1312	each	O
1312	other	O
1312	under	O
1312	fed	O
1312	conditions	O
1312	.	O
1312	[SEP]	O
1313	[CLS]	O
1313	these	O
1313	findings	O
1313	suggest	O
1313	that	O
1313	el	O
1313	##vi	O
1313	##te	O
1313	##gra	O
1313	##vir	O
1313	/	O
1313	co	O
1313	##bic	O
1313	##ista	O
1313	##t	O
1313	/	O
1313	em	O
1313	##tric	O
1313	##ita	O
1313	##bine	O
1313	/	O
1313	ten	O
1313	##of	O
1313	##ov	O
1313	##ir	O
1313	di	O
1313	##so	O
1313	##p	O
1313	##ro	O
1313	##xi	O
1313	##l	O
1313	f	O
1313	##uma	O
1313	##rate	O
1313	should	O
1313	be	O
1313	administered	O
1313	with	O
1313	food	O
1313	,	O
1313	and	O
1313	that	O
1313	the	O
1313	bio	B-PK
1313	##ava	I-PK
1313	##ila	I-PK
1313	##bility	I-PK
1313	of	O
1313	el	O
1313	##vi	O
1313	##te	O
1313	##gra	O
1313	##vir	O
1313	and	O
1313	ten	O
1313	##of	O
1313	##ov	O
1313	##ir	O
1313	is	O
1313	not	O
1313	affected	O
1313	by	O
1313	the	O
1313	type	O
1313	of	O
1313	meal	O
1313	ing	O
1313	##ested	O
1313	.	O
1313	[SEP]	O
1314	[CLS]	O
1314	it	O
1314	enhance	O
1314	##s	O
1314	the	O
1314	bio	B-PK
1314	##ava	I-PK
1314	##ila	I-PK
1314	##bility	I-PK
1314	of	O
1314	co	O
1314	##ad	O
1314	##mini	O
1314	##stered	O
1314	drugs	O
1314	such	O
1314	as	O
1314	el	O
1314	##vi	O
1314	##te	O
1314	##gra	O
1314	##vir	O
1314	,	O
1314	which	O
1314	are	O
1314	meta	O
1314	##bol	O
1314	##ized	O
1314	by	O
1314	c	O
1314	##y	O
1314	##p	O
1314	##3	O
1314	##a	O
1314	and	O
1314	decreases	O
1314	their	O
1314	clearance	B-PK
1314	.	O
1314	[SEP]	O
1315	[CLS]	O
1315	the	O
1315	oral	B-PK
1315	bio	I-PK
1315	##ava	I-PK
1315	##ila	I-PK
1315	##bility	I-PK
1315	of	O
1315	el	O
1315	##vi	O
1315	##te	O
1315	##gra	O
1315	##vir	O
1315	and	O
1315	ten	O
1315	##of	O
1315	##ov	O
1315	##ir	O
1315	is	O
1315	affected	O
1315	by	O
1315	food	O
1315	intake	O
1315	.	O
1315	3	O
1315	,	O
1315	7	O
1315	a	O
1315	food	O
1315	interaction	O
1315	study	O
1315	showed	O
1315	that	O
1315	the	O
1315	mean	O
1315	au	B-PK
1315	##cin	I-PK
1315	##f	I-PK
1315	and	O
1315	cm	B-PK
1315	##ax	I-PK
1315	of	O
1315	these	O
1315	components	O
1315	of	O
1315	e	O
1315	##v	O
1315	##g	O
1315	/	O
1315	co	O
1315	##bi	O
1315	/	O
1315	ft	O
1315	##c	O
1315	/	O
1315	t	O
1315	##d	O
1315	##f	O
1315	s	O
1315	##tr	O
1315	administered	O
1315	oral	O
1315	##ly	O
1315	were	O
1315	increased	O
1315	by	O
1315	34	O
1315	%	O
1315	and	O
1315	24	O
1315	%	O
1315	,	O
1315	respectively	O
1315	,	O
1315	when	O
1315	administered	O
1315	with	O
1315	a	O
1315	meal	O
1315	(	O
1315	37	O
1315	##3	O
1315	k	O
1315	##cal	O
1315	,	O
1315	20	O
1315	%	O
1315	fat	O
1315	)	O
1315	,	O
1315	as	O
1315	compared	O
1315	with	O
1315	fast	O
1315	##ing	O
1315	conditions	O
1315	.	O
1315	7	O
1315	therefore	O
1315	,	O
1315	in	O
1315	a	O
1315	clinical	O
1315	setting	O
1315	,	O
1315	it	O
1315	is	O
1315	recommended	O
1315	that	O
1315	e	O
1315	##v	O
1315	##g	O
1315	/	O
1315	co	O
1315	##bi	O
1315	/	O
1315	ft	O
1315	##c	O
1315	/	O
1315	t	O
1315	##d	O
1315	##f	O
1315	s	O
1315	##tr	O
1315	be	O
1315	taken	O
1315	with	O
1315	a	O
1315	meal	O
1315	.	O
1315	3	O
1315	although	O
1315	e	O
1315	##v	O
1315	##g	O
1315	/	O
1315	co	O
1315	##bi	O
1315	/	O
1315	ft	O
1315	##c	O
1315	/	O
1315	t	O
1315	##d	O
1315	##f	O
1315	s	O
1315	##tr	O
1315	has	O
1315	been	O
1315	approved	O
1315	for	O
1315	marketing	O
1315	in	O
1315	j	O
1315	##apa	O
1315	##n	O
1315	and	O
1315	has	O
1315	already	O
1315	been	O
1315	administered	O
1315	to	O
1315	hi	O
1315	##v	O
1315	-	O
1315	1	O
1315	-	O
1315	infected	O
1315	patients	O
1315	,	O
1315	the	O
1315	p	O
1315	##har	O
1315	##ma	O
1315	##co	O
1315	##kin	O
1315	##etics	O
1315	of	O
1315	these	O
1315	components	O
1315	have	O
1315	not	O
1315	yet	O
1315	been	O
1315	evaluated	O
1315	in	O
1315	j	O
1315	##apa	O
1315	##nese	O
1315	subjects	O
1315	.	O
1315	[SEP]	O
1316	[CLS]	O
1316	the	O
1316	p	O
1316	##har	O
1316	##ma	O
1316	##co	O
1316	##kin	O
1316	##etic	O
1316	parameters	O
1316	estimated	O
1316	for	O
1316	each	O
1316	anal	O
1316	##yte	O
1316	were	O
1316	:	O
1316	maximum	B-PK
1316	plasma	I-PK
1316	concentration	I-PK
1316	(	I-PK
1316	cm	I-PK
1316	##ax	I-PK
1316	)	I-PK
1316	,	O
1316	concentration	O
1316	at	O
1316	24	O
1316	hours	O
1316	post	O
1316	-	O
1316	dose	O
1316	(	O
1316	c	O
1316	##24	O
1316	)	O
1316	,	O
1316	time	B-PK
1316	to	I-PK
1316	reach	I-PK
1316	cm	I-PK
1316	##ax	I-PK
1316	(	I-PK
1316	t	I-PK
1316	##max	I-PK
1316	)	I-PK
1316	,	O
1316	half	B-PK
1316	-	I-PK
1316	life	I-PK
1316	(	I-PK
1316	t	I-PK
1316	##1	I-PK
1316	/	I-PK
1316	2	I-PK
1316	)	I-PK
1316	,	O
1316	area	B-PK
1316	under	I-PK
1316	the	I-PK
1316	plasma	I-PK
1316	concentration	I-PK
1316	–	I-PK
1316	time	I-PK
1316	curve	I-PK
1316	from	I-PK
1316	the	I-PK
1316	time	I-PK
1316	of	I-PK
1316	administration	I-PK
1316	up	I-PK
1316	to	I-PK
1316	the	I-PK
1316	last	I-PK
1316	time	I-PK
1316	point	I-PK
1316	with	I-PK
1316	a	I-PK
1316	me	I-PK
1316	##as	I-PK
1316	##urable	I-PK
1316	concentration	I-PK
1316	post	I-PK
1316	-	I-PK
1316	dose	I-PK
1316	(	I-PK
1316	au	I-PK
1316	##c	I-PK
1316	##last	I-PK
1316	)	I-PK
1316	,	O
1316	and	O
1316	au	B-PK
1316	##c	I-PK
1316	extra	I-PK
1316	##pol	I-PK
1316	##ated	I-PK
1316	to	I-PK
1316	in	I-PK
1316	##finity	I-PK
1316	(	I-PK
1316	au	I-PK
1316	##cin	I-PK
1316	##f	I-PK
1316	)	I-PK
1316	.	O
1316	[SEP]	O
1317	[CLS]	O
1317	au	B-PK
1317	##cin	I-PK
1317	##f	I-PK
1317	was	O
1317	calculated	O
1317	as	O
1317	the	O
1317	sum	O
1317	of	O
1317	au	B-PK
1317	##c	I-PK
1317	##last	I-PK
1317	and	O
1317	c	B-PK
1317	##last	I-PK
1317	/	I-PK
1317	λ	I-PK
1317	##z	I-PK
1317	,	O
1317	where	O
1317	c	O
1317	##last	O
1317	denotes	O
1317	the	O
1317	last	O
1317	me	O
1317	##as	O
1317	##urable	O
1317	concentration	O
1317	and	O
1317	λ	B-PK
1317	##z	I-PK
1317	represents	O
1317	the	O
1317	elimination	B-PK
1317	rate	I-PK
1317	constant	I-PK
1317	determined	O
1317	by	O
1317	linear	O
1317	re	O
1317	##gression	O
1317	of	O
1317	the	O
1317	terminal	O
1317	points	O
1317	of	O
1317	the	O
1317	l	O
1317	##n	O
1317	-	O
1317	linear	O
1317	plasma	O
1317	concentration	O
1317	–	O
1317	time	O
1317	curve	O
1317	.	O
1317	[SEP]	O
1318	[CLS]	O
1318	the	O
1318	plasma	O
1318	el	O
1318	##vi	O
1318	##te	O
1318	##gra	O
1318	##vir	O
1318	concentration	O
1318	reached	O
1318	cm	B-PK
1318	##ax	I-PK
1318	within	O
1318	4	O
1318	hours	O
1318	post	O
1318	-	O
1318	dose	O
1318	in	O
1318	all	O
1318	of	O
1318	the	O
1318	treatment	O
1318	groups	O
1318	.	O
1318	[SEP]	O
1319	[CLS]	O
1319	for	O
1319	assessment	O
1319	of	O
1319	the	O
1319	l	O
1319	##s	O
1319	mean	O
1319	ratio	O
1319	,	O
1319	a	O
1319	single	O
1319	oral	O
1319	dose	O
1319	of	O
1319	e	O
1319	##v	O
1319	##g	O
1319	/	O
1319	co	O
1319	##bi	O
1319	/	O
1319	ft	O
1319	##c	O
1319	/	O
1319	t	O
1319	##d	O
1319	##f	O
1319	s	O
1319	##tr	O
1319	in	O
1319	a	O
1319	fast	O
1319	##ed	O
1319	state	O
1319	(	O
1319	treatment	O
1319	b	O
1319	)	O
1319	resulted	O
1319	in	O
1319	55	O
1319	%	O
1319	and	O
1319	50	O
1319	%	O
1319	decreases	O
1319	in	O
1319	cm	B-PK
1319	##ax	I-PK
1319	and	O
1319	au	B-PK
1319	##cin	I-PK
1319	##f	I-PK
1319	for	O
1319	el	O
1319	##vi	O
1319	##te	O
1319	##gra	O
1319	##vir	O
1319	,	O
1319	respectively	O
1319	,	O
1319	as	O
1319	compared	O
1319	with	O
1319	those	O
1319	following	O
1319	administration	O
1319	with	O
1319	a	O
1319	standard	O
1319	breakfast	O
1319	(	O
1319	treatment	O
1319	a	O
1319	)	O
1319	.	O
1319	[SEP]	O
1320	[CLS]	O
1320	the	O
1320	cm	B-PK
1320	##ax	I-PK
1320	and	O
1320	au	B-PK
1320	##cin	I-PK
1320	##f	I-PK
1320	values	O
1320	for	O
1320	el	O
1320	##vi	O
1320	##te	O
1320	##gra	O
1320	##vir	O
1320	in	O
1320	the	O
1320	protein	O
1320	-	O
1320	rich	O
1320	drink	O
1320	group	O
1320	(	O
1320	treatment	O
1320	c	O
1320	)	O
1320	were	O
1320	comparable	O
1320	to	O
1320	those	O
1320	in	O
1320	the	O
1320	standard	O
1320	breakfast	O
1320	group	O
1320	.	O
1320	[SEP]	O
1321	[CLS]	O
1321	the	O
1321	90	O
1321	%	O
1321	c	O
1321	##is	O
1321	of	O
1321	g	O
1321	##m	O
1321	##r	O
1321	for	O
1321	el	O
1321	##vi	O
1321	##te	O
1321	##gra	O
1321	##vir	O
1321	au	B-PK
1321	##cin	I-PK
1321	##f	I-PK
1321	were	O
1321	within	O
1321	the	O
1321	boundary	O
1321	of	O
1321	0	O
1321	.	O
1321	8	O
1321	–	O
1321	1	O
1321	.	O
1321	25	O
1321	,	O
1321	while	O
1321	the	O
1321	upper	O
1321	limit	O
1321	of	O
1321	the	O
1321	90	O
1321	%	O
1321	c	O
1321	##i	O
1321	of	O
1321	g	O
1321	##m	O
1321	##r	O
1321	for	O
1321	el	O
1321	##vi	O
1321	##te	O
1321	##gra	O
1321	##vir	O
1321	cm	B-PK
1321	##ax	I-PK
1321	was	O
1321	narrowly	O
1321	above	O
1321	the	O
1321	lack	O
1321	of	O
1321	a	O
1321	food	O
1321	effect	O
1321	boundary	O
1321	(	O
1321	1	O
1321	.	O
1321	27	O
1321	)	O
1321	after	O
1321	administration	O
1321	with	O
1321	a	O
1321	protein	O
1321	-	O
1321	rich	O
1321	drink	O
1321	,	O
1321	indicating	O
1321	that	O
1321	the	O
1321	two	O
1321	fed	O
1321	conditions	O
1321	were	O
1321	bio	O
1321	##e	O
1321	##qui	O
1321	##valent	O
1321	to	O
1321	each	O
1321	other	O
1321	.	O
1321	[SEP]	O
1322	[CLS]	O
1322	the	O
1322	plasma	O
1322	co	O
1322	##bic	O
1322	##ista	O
1322	##t	O
1322	concentration	O
1322	following	O
1322	administration	O
1322	with	O
1322	a	O
1322	standard	O
1322	breakfast	O
1322	(	O
1322	treatment	O
1322	a	O
1322	)	O
1322	reached	O
1322	cm	B-PK
1322	##ax	I-PK
1322	at	O
1322	2	O
1322	.	O
1322	5	O
1322	hours	O
1322	post	O
1322	-	O
1322	dose	O
1322	.	O
1322	[SEP]	O
1323	[CLS]	O
1323	the	O
1323	cm	B-PK
1323	##ax	I-PK
1323	and	O
1323	au	B-PK
1323	##cin	I-PK
1323	##f	I-PK
1323	values	O
1323	for	O
1323	co	O
1323	##bic	O
1323	##ista	O
1323	##t	O
1323	following	O
1323	administration	O
1323	in	O
1323	a	O
1323	fast	O
1323	##ed	O
1323	state	O
1323	(	O
1323	treatment	O
1323	b	O
1323	)	O
1323	and	O
1323	with	O
1323	a	O
1323	nutrition	O
1323	##al	O
1323	protein	O
1323	-	O
1323	rich	O
1323	drink	O
1323	(	O
1323	treatment	O
1323	c	O
1323	)	O
1323	were	O
1323	comparable	O
1323	to	O
1323	those	O
1323	following	O
1323	administration	O
1323	with	O
1323	a	O
1323	standard	O
1323	breakfast	O
1323	(	O
1323	treatment	O
1323	a	O
1323	)	O
1323	(	O
1323	table	O
1323	1	O
1323	)	O
1323	,	O
1323	the	O
1323	corresponding	O
1323	90	O
1323	%	O
1323	c	O
1323	##is	O
1323	of	O
1323	the	O
1323	g	O
1323	##m	O
1323	##r	O
1323	for	O
1323	co	O
1323	##bic	O
1323	##ista	O
1323	##t	O
1323	cm	B-PK
1323	##ax	I-PK
1323	and	O
1323	au	B-PK
1323	##cin	I-PK
1323	##f	I-PK
1323	falling	O
1323	within	O
1323	the	O
1323	bio	O
1323	##e	O
1323	##qui	O
1323	##valence	O
1323	limit	O
1323	,	O
1323	indicating	O
1323	the	O
1323	lack	O
1323	of	O
1323	any	O
1323	food	O
1323	effect	O
1323	.	O
1323	[SEP]	O
1324	[CLS]	O
1324	the	O
1324	plasma	O
1324	em	O
1324	##tric	O
1324	##ita	O
1324	##bine	O
1324	concentration	O
1324	following	O
1324	administration	O
1324	with	O
1324	a	O
1324	standard	O
1324	breakfast	O
1324	(	O
1324	treatment	O
1324	a	O
1324	)	O
1324	reached	O
1324	cm	B-PK
1324	##ax	I-PK
1324	at	O
1324	1	O
1324	.	O
1324	5	O
1324	hours	O
1324	post	O
1324	-	O
1324	dose	O
1324	.	O
1324	[SEP]	O
1325	[CLS]	O
1325	the	O
1325	cm	B-PK
1325	##ax	I-PK
1325	and	O
1325	au	B-PK
1325	##cin	I-PK
1325	##f	I-PK
1325	values	O
1325	for	O
1325	em	O
1325	##tric	O
1325	##ita	O
1325	##bine	O
1325	following	O
1325	administration	O
1325	with	O
1325	a	O
1325	standard	O
1325	breakfast	O
1325	were	O
1325	comparable	O
1325	to	O
1325	those	O
1325	following	O
1325	administration	O
1325	under	O
1325	fast	O
1325	##ing	O
1325	conditions	O
1325	(	O
1325	treatment	O
1325	b	O
1325	)	O
1325	and	O
1325	after	O
1325	ing	O
1325	##est	O
1325	##ion	O
1325	of	O
1325	a	O
1325	protein	O
1325	-	O
1325	rich	O
1325	drink	O
1325	(	O
1325	treatment	O
1325	c	O
1325	)	O
1325	.	O
1325	[SEP]	O
1326	[CLS]	O
1326	the	O
1326	plasma	O
1326	ten	O
1326	##of	O
1326	##ov	O
1326	##ir	O
1326	concentration	O
1326	following	O
1326	administration	O
1326	with	O
1326	a	O
1326	standard	O
1326	breakfast	O
1326	(	O
1326	treatment	O
1326	a	O
1326	)	O
1326	reached	O
1326	cm	B-PK
1326	##ax	I-PK
1326	at	O
1326	1	O
1326	.	O
1326	5	O
1326	hours	O
1326	post	O
1326	-	O
1326	dose	O
1326	.	O
1326	[SEP]	O
1327	[CLS]	O
1327	administration	O
1327	in	O
1327	a	O
1327	fast	O
1327	##ed	O
1327	state	O
1327	(	O
1327	treatment	O
1327	b	O
1327	)	O
1327	resulted	O
1327	in	O
1327	28	O
1327	%	O
1327	decreases	O
1327	in	O
1327	both	O
1327	cm	B-PK
1327	##ax	I-PK
1327	and	O
1327	au	B-PK
1327	##cin	I-PK
1327	##f	I-PK
1327	for	O
1327	ten	O
1327	##of	O
1327	##ov	O
1327	##ir	O
1327	,	O
1327	compared	O
1327	with	O
1327	those	O
1327	following	O
1327	administration	O
1327	with	O
1327	a	O
1327	standard	O
1327	breakfast	O
1327	(	O
1327	treatment	O
1327	a	O
1327	)	O
1327	,	O
1327	whereas	O
1327	the	O
1327	cm	B-PK
1327	##ax	I-PK
1327	and	O
1327	au	B-PK
1327	##cin	I-PK
1327	##f	I-PK
1327	values	O
1327	for	O
1327	ten	O
1327	##of	O
1327	##ov	O
1327	##ir	O
1327	following	O
1327	administration	O
1327	with	O
1327	a	O
1327	nutrition	O
1327	##al	O
1327	protein	O
1327	-	O
1327	rich	O
1327	drink	O
1327	(	O
1327	treatment	O
1327	c	O
1327	)	O
1327	were	O
1327	comparable	O
1327	to	O
1327	those	O
1327	following	O
1327	administration	O
1327	with	O
1327	a	O
1327	standard	O
1327	breakfast	O
1327	.	O
1327	[SEP]	O
1328	[CLS]	O
1328	in	O
1328	terms	O
1328	of	O
1328	the	O
1328	l	O
1328	##s	O
1328	mean	O
1328	ratio	O
1328	and	O
1328	the	O
1328	90	O
1328	%	O
1328	c	O
1328	##is	O
1328	,	O
1328	it	O
1328	appears	O
1328	that	O
1328	in	O
1328	a	O
1328	fast	O
1328	##ed	O
1328	state	O
1328	,	O
1328	the	O
1328	bio	B-PK
1328	##ava	I-PK
1328	##ila	I-PK
1328	##bility	I-PK
1328	of	O
1328	ten	O
1328	##of	O
1328	##ov	O
1328	##ir	O
1328	is	O
1328	not	O
1328	equivalent	O
1328	to	O
1328	that	O
1328	for	O
1328	either	O
1328	of	O
1328	the	O
1328	fed	O
1328	conditions	O
1328	.	O
1328	[SEP]	O
1329	[CLS]	O
1329	relative	O
1329	to	O
1329	the	O
1329	standard	O
1329	meal	O
1329	,	O
1329	the	O
1329	au	B-PK
1329	##cin	I-PK
1329	##f	I-PK
1329	for	O
1329	ten	O
1329	##of	O
1329	##ov	O
1329	##ir	O
1329	was	O
1329	within	O
1329	the	O
1329	lack	O
1329	of	O
1329	a	O
1329	food	O
1329	effect	O
1329	boundary	O
1329	after	O
1329	administration	O
1329	with	O
1329	a	O
1329	nutrition	O
1329	##al	O
1329	protein	O
1329	-	O
1329	rich	O
1329	drink	O
1329	,	O
1329	though	O
1329	cm	B-PK
1329	##ax	I-PK
1329	was	O
1329	slightly	O
1329	lower	O
1329	(	O
1329	0	O
1329	.	O
1329	76	O
1329	)	O
1329	,	O
1329	indicating	O
1329	that	O
1329	the	O
1329	two	O
1329	fed	O
1329	conditions	O
1329	were	O
1329	bio	O
1329	##e	O
1329	##qui	O
1329	##valent	O
1329	to	O
1329	each	O
1329	other	O
1329	.	O
1329	[SEP]	O
1330	[CLS]	O
1330	no	O
1330	significant	O
1330	period	O
1330	or	O
1330	sequence	O
1330	effects	O
1330	were	O
1330	seen	O
1330	for	O
1330	any	O
1330	of	O
1330	the	O
1330	comparisons	O
1330	,	O
1330	and	O
1330	the	O
1330	mean	O
1330	t	B-PK
1330	##1	I-PK
1330	/	I-PK
1330	2	I-PK
1330	of	O
1330	each	O
1330	anal	O
1330	##yte	O
1330	was	O
1330	generally	O
1330	comparable	O
1330	among	O
1330	all	O
1330	the	O
1330	treatments	O
1330	(	O
1330	tables	O
1330	##1	O
1330	and	O
1330	2	O
1330	)	O
1330	.	O
1330	[SEP]	O
1331	[CLS]	O
1331	p	O
1331	##har	O
1331	##ma	O
1331	##co	O
1331	##kin	O
1331	##etic	O
1331	parameters	O
1331	,	O
1331	including	O
1331	the	O
1331	half	B-PK
1331	-	I-PK
1331	life	I-PK
1331	of	I-PK
1331	distribution	I-PK
1331	phase	I-PK
1331	(	I-PK
1331	t	I-PK
1331	##1	I-PK
1331	/	I-PK
1331	2	I-PK
1331	α	I-PK
1331	)	I-PK
1331	,	O
1331	the	B-PK
1331	half	I-PK
1331	-	I-PK
1331	life	I-PK
1331	of	I-PK
1331	elimination	I-PK
1331	phase	I-PK
1331	(	I-PK
1331	t	I-PK
1331	##1	I-PK
1331	/	I-PK
1331	2	I-PK
1331	β	I-PK
1331	)	I-PK
1331	,	O
1331	volume	B-PK
1331	of	I-PK
1331	apparent	I-PK
1331	distribution	I-PK
1331	(	I-PK
1331	v	I-PK
1331	##d	I-PK
1331	)	I-PK
1331	,	O
1331	and	O
1331	area	B-PK
1331	under	I-PK
1331	the	I-PK
1331	concentration	I-PK
1331	-	I-PK
1331	time	I-PK
1331	curve	I-PK
1331	from	I-PK
1331	zero	I-PK
1331	to	I-PK
1331	infinite	I-PK
1331	time	I-PK
1331	(	I-PK
1331	au	I-PK
1331	##c	I-PK
1331	##0	I-PK
1331	–	I-PK
1331	t	I-PK
1331	)	I-PK
1331	were	O
1331	7	O
1331	.	O
1331	59	O
1331	min	O
1331	,	O
1331	46	O
1331	.	O
1331	99	O
1331	min	O
1331	,	O
1331	0	O
1331	.	O
1331	17	O
1331	l	O
1331	/	O
1331	kg	O
1331	,	O
1331	and	O
1331	204	O
1331	.	O
1331	5	O
1331	mg	O
1331	/	O
1331	l	O
1331	/	O
1331	min	O
1331	,	O
1331	respectively	O
1331	,	O
1331	as	O
1331	determined	O
1331	by	O
1331	ch	O
1331	##rom	O
1331	##ogenic	O
1331	substrate	O
1331	ass	O
1331	##ay	O
1331	;	O
1331	6	O
1331	.	O
1331	41	O
1331	min	O
1331	,	O
1331	47	O
1331	.	O
1331	28	O
1331	min	O
1331	,	O
1331	1	O
1331	.	O
1331	24	O
1331	l	O
1331	/	O
1331	kg	O
1331	,	O
1331	and	O
1331	57	O
1331	##5	O
1331	.	O
1331	18	O
1331	mg	O
1331	/	O
1331	l	O
1331	/	O
1331	min	O
1331	,	O
1331	respectively	O
1331	,	O
1331	as	O
1331	determined	O
1331	by	O
1331	el	O
1331	##isa	O
1331	;	O
1331	3	O
1331	.	O
1331	69	O
1331	min	O
1331	,	O
1331	70	O
1331	##1	O
1331	.	O
1331	90	O
1331	min	O
1331	,	O
1331	0	O
1331	.	O
1331	04	O
1331	l	O
1331	/	O
1331	kg	O
1331	,	O
1331	and	O
1331	41	O
1331	##8	O
1331	##9	O
1331	mg	O
1331	/	O
1331	l	O
1331	/	O
1331	min	O
1331	,	O
1331	respectively	O
1331	as	O
1331	determined	O
1331	by	O
1331	r	O
1331	##a	O
1331	;	O
1331	and	O
1331	4	O
1331	.	O
1331	57	O
1331	min	O
1331	,	O
1331	72	O
1331	##4	O
1331	.	O
1331	9	O
1331	min	O
1331	,	O
1331	0	O
1331	.	O
1331	09	O
1331	l	O
1331	/	O
1331	kg	O
1331	,	O
1331	and	O
1331	232	O
1331	##9	O
1331	mg	O
1331	/	O
1331	l	O
1331	/	O
1331	min	O
1331	,	O
1331	respectively	O
1331	,	O
1331	as	O
1331	determined	O
1331	by	O
1331	t	O
1331	##ca	O
1331	-	O
1331	r	O
1331	##a	O
1331	.	O
1331	[SEP]	O
1332	[CLS]	O
1332	more	O
1332	##over	O
1332	,	O
1332	the	O
1332	p	O
1332	##har	O
1332	##ma	O
1332	##co	O
1332	##kin	O
1332	##etic	O
1332	parameters	O
1332	determined	O
1332	by	O
1332	the	O
1332	ch	O
1332	##rom	O
1332	##ogenic	O
1332	substrate	O
1332	ass	O
1332	##ay	O
1332	and	O
1332	el	O
1332	##isa	O
1332	are	O
1332	con	O
1332	##g	O
1332	##rue	O
1332	##nt	O
1332	except	O
1332	for	O
1332	au	B-PK
1332	##c	I-PK
1332	.	O
1332	[SEP]	O
1333	[CLS]	O
1333	the	O
1333	distribution	B-PK
1333	half	I-PK
1333	-	I-PK
1333	life	I-PK
1333	(	I-PK
1333	t	I-PK
1333	##1	I-PK
1333	/	I-PK
1333	2	I-PK
1333	##α	I-PK
1333	)	I-PK
1333	was	O
1333	7	O
1333	.	O
1333	59	O
1333	##±	O
1333	##4	O
1333	.	O
1333	56	O
1333	minutes	O
1333	.	O
1333	[SEP]	O
1334	[CLS]	O
1334	the	O
1334	elimination	B-PK
1334	half	I-PK
1334	-	I-PK
1334	life	I-PK
1334	(	I-PK
1334	t	I-PK
1334	##1	I-PK
1334	/	I-PK
1334	2	I-PK
1334	##β	I-PK
1334	)	I-PK
1334	was	O
1334	47	O
1334	.	O
1334	0	O
1334	##±	O
1334	##22	O
1334	.	O
1334	2	O
1334	minutes	O
1334	.	O
1334	[SEP]	O
1335	[CLS]	O
1335	these	O
1335	results	O
1335	are	O
1335	similar	O
1335	to	O
1335	those	O
1335	of	O
1335	the	O
1335	ch	O
1335	##rom	O
1335	##ogenic	O
1335	substrate	O
1335	ass	O
1335	##ay	O
1335	below	O
1335	except	O
1335	that	O
1335	the	O
1335	area	B-PK
1335	under	I-PK
1335	the	I-PK
1335	curve	I-PK
1335	was	O
1335	204	O
1335	.	O
1335	5	O
1335	##±	O
1335	##19	O
1335	.	O
1335	9	O
1335	mg	O
1335	/	O
1335	l	O
1335	/	O
1335	min	O
1335	by	O
1335	the	O
1335	ch	O
1335	##rom	O
1335	##ogenic	O
1335	substrate	O
1335	ass	O
1335	##ay	O
1335	and	O
1335	57	O
1335	##5	O
1335	.	O
1335	2	O
1335	##±	O
1335	##39	O
1335	.	O
1335	4	O
1335	mg	O
1335	/	O
1335	l	O
1335	/	O
1335	min	O
1335	by	O
1335	el	O
1335	##isa	O
1335	.	O
1335	[SEP]	O
1336	[CLS]	O
1336	the	O
1336	distribution	B-PK
1336	half	I-PK
1336	-	I-PK
1336	life	I-PK
1336	(	I-PK
1336	t	I-PK
1336	##1	I-PK
1336	/	I-PK
1336	2	I-PK
1336	##α	I-PK
1336	)	I-PK
1336	was	O
1336	6	O
1336	.	O
1336	42	O
1336	##±	O
1336	##2	O
1336	.	O
1336	60	O
1336	minutes	O
1336	.	O
1336	[SEP]	O
1337	[CLS]	O
1337	the	O
1337	elimination	B-PK
1337	half	I-PK
1337	-	I-PK
1337	life	I-PK
1337	(	I-PK
1337	t	I-PK
1337	##1	I-PK
1337	/	I-PK
1337	2	I-PK
1337	##β	I-PK
1337	)	I-PK
1337	was	O
1337	47	O
1337	.	O
1337	3	O
1337	##±	O
1337	##13	O
1337	.	O
1337	1	O
1337	minutes	O
1337	.	O
1337	[SEP]	O
1338	[CLS]	O
1338	the	O
1338	distribution	B-PK
1338	half	I-PK
1338	-	I-PK
1338	life	I-PK
1338	(	I-PK
1338	t	I-PK
1338	##1	I-PK
1338	/	I-PK
1338	2	I-PK
1338	##α	I-PK
1338	)	I-PK
1338	was	O
1338	3	O
1338	.	O
1338	69	O
1338	##±	O
1338	##1	O
1338	.	O
1338	71	O
1338	minutes	O
1338	by	O
1338	the	O
1338	total	O
1338	radio	O
1338	##is	O
1338	##oto	O
1338	##pe	O
1338	ass	O
1338	##ay	O
1338	and	O
1338	4	O
1338	.	O
1338	58	O
1338	##±	O
1338	##1	O
1338	.	O
1338	73	O
1338	minutes	O
1338	by	O
1338	the	O
1338	t	O
1338	##rich	O
1338	##lor	O
1338	##oa	O
1338	##ce	O
1338	##tic	O
1338	acid	O
1338	pre	O
1338	-	O
1338	treated	O
1338	total	O
1338	radio	O
1338	##is	O
1338	##oto	O
1338	##pe	O
1338	ass	O
1338	##ay	O
1338	.	O
1338	[SEP]	O
1339	[CLS]	O
1339	the	O
1339	elimination	B-PK
1339	half	I-PK
1339	-	I-PK
1339	life	I-PK
1339	(	I-PK
1339	t	I-PK
1339	##1	I-PK
1339	/	I-PK
1339	2	I-PK
1339	##β	I-PK
1339	)	I-PK
1339	was	O
1339	70	O
1339	##1	O
1339	.	O
1339	9	O
1339	##±	O
1339	##19	O
1339	##8	O
1339	.	O
1339	8	O
1339	minutes	O
1339	and	O
1339	72	O
1339	##4	O
1339	.	O
1339	9	O
1339	##±	O
1339	##8	O
1339	##1	O
1339	.	O
1339	2	O
1339	minutes	O
1339	respectively	O
1339	.	O
1339	[SEP]	O
1340	[CLS]	O
1340	steady	O
1340	‐	O
1340	state	O
1340	exposure	O
1340	was	O
1340	higher	O
1340	with	O
1340	p	O
1340	##ila	O
1340	##ral	O
1340	##isi	O
1340	##b	O
1340	tablet	O
1340	formulation	O
1340	at	O
1340	400	O
1340	mg	O
1340	than	O
1340	with	O
1340	p	O
1340	##ila	O
1340	##ral	O
1340	##isi	O
1340	##b	O
1340	capsule	O
1340	formulation	O
1340	at	O
1340	400	O
1340	or	O
1340	600	O
1340	mg	O
1340	(	O
1340	mean	O
1340	area	B-PK
1340	under	I-PK
1340	the	I-PK
1340	curve	I-PK
1340	[	I-PK
1340	au	I-PK
1340	##c	I-PK
1340	##0	I-PK
1340	–	I-PK
1340	24	I-PK
1340	]	I-PK
1340	2	O
1340	,	O
1340	82	O
1340	##0	O
1340	,	O
1340	000	O
1340	ng	O
1340	×	O
1340	h	O
1340	/	O
1340	m	O
1340	##l	O
1340	vs	O
1340	.	O
1340	2	O
1340	,	O
1340	65	O
1340	##3	O
1340	,	O
1340	000	O
1340	and	O
1340	1	O
1340	,	O
1340	93	O
1340	##0	O
1340	,	O
1340	000	O
1340	ng	O
1340	×	O
1340	h	O
1340	/	O
1340	m	O
1340	##l	O
1340	,	O
1340	respectively	O
1340	)	O
1340	.	O
1340	[SEP]	O
1341	[CLS]	O
1341	the	O
1341	most	O
1341	common	O
1341	reasons	O
1341	for	O
1341	study	O
1341	disco	O
1341	##ntin	O
1341	##uation	O
1341	were	O
1341	disease	O
1341	progression	O
1341	as	O
1341	defined	O
1341	by	O
1341	re	O
1341	##cist	O
1341	version	O
1341	1	O
1341	.	O
1341	0	O
1341	(	O
1341	15	O
1341	patients	O
1341	,	O
1341	68	O
1341	.	O
1341	2	O
1341	%	O
1341	)	O
1341	,	O
1341	disease	O
1341	progression	O
1341	based	O
1341	on	O
1341	clinical	O
1341	de	O
1341	##ter	O
1341	##ior	O
1341	##ation	O
1341	(	O
1341	three	O
1341	patients	O
1341	,	O
1341	13	O
1341	.	O
1341	6	O
1341	%	O
1341	)	O
1341	,	O
1341	and	O
1341	adverse	O
1341	event	O
1341	(	O
1341	a	O
1341	##e	O
1341	;	O
1341	two	O
1341	patients	O
1341	,	O
1341	9	O
1341	.	O
1341	1	O
1341	%	O
1341	)	O
1341	.	O
1341	[SEP]	O
1342	[CLS]	O
1342	two	O
1342	patients	O
1342	(	O
1342	9	O
1342	.	O
1342	1	O
1342	%	O
1342	)	O
1342	permanently	O
1342	discontinued	O
1342	treatment	O
1342	because	O
1342	of	O
1342	an	O
1342	a	O
1342	##e	O
1342	(	O
1342	grade	O
1342	5	O
1342	en	O
1342	##ce	O
1342	##pha	O
1342	##lop	O
1342	##athy	O
1342	and	O
1342	grade	O
1342	4	O
1342	is	O
1342	##che	O
1342	##mic	O
1342	stroke	O
1342	)	O
1342	;	O
1342	both	O
1342	a	O
1342	##es	O
1342	were	O
1342	not	O
1342	treatment	O
1342	related	O
1342	.	O
1342	[SEP]	O
1343	[CLS]	O
1343	after	O
1343	repeated	O
1343	daily	O
1343	administration	O
1343	of	O
1343	p	O
1343	##ila	O
1343	##ral	O
1343	##isi	O
1343	##b	O
1343	tablets	O
1343	(	O
1343	100	O
1343	–	O
1343	600	O
1343	mg	O
1343	)	O
1343	,	O
1343	steady	O
1343	state	O
1343	was	O
1343	reached	O
1343	by	O
1343	cycle	O
1343	1	O
1343	,	O
1343	day	O
1343	28	O
1343	,	O
1343	and	O
1343	median	O
1343	time	B-PK
1343	to	I-PK
1343	maximum	I-PK
1343	concentration	I-PK
1343	ranged	O
1343	from	O
1343	1	O
1343	.	O
1343	99	O
1343	to	O
1343	23	O
1343	.	O
1343	1	O
1343	hours	O
1343	(	O
1343	table	O
1343	2	O
1343	)	O
1343	.	O
1343	[SEP]	O
1344	[CLS]	O
1344	the	O
1344	mean	O
1344	accumulation	B-PK
1344	ratio	I-PK
1344	for	I-PK
1344	maximum	I-PK
1344	concentration	I-PK
1344	(	I-PK
1344	cm	I-PK
1344	##ax	I-PK
1344	)	I-PK
1344	and	O
1344	area	B-PK
1344	under	I-PK
1344	the	I-PK
1344	curve	I-PK
1344	(	I-PK
1344	au	I-PK
1344	##c	I-PK
1344	##0	I-PK
1344	–	I-PK
1344	24	I-PK
1344	)	I-PK
1344	for	O
1344	cycle	O
1344	1	O
1344	,	O
1344	day	O
1344	28	O
1344	,	O
1344	compared	O
1344	with	O
1344	cycle	O
1344	1	O
1344	,	O
1344	day	O
1344	1	O
1344	,	O
1344	ranged	O
1344	from	O
1344	5	O
1344	.	O
1344	9	O
1344	‐	O
1344	fold	O
1344	to	O
1344	10	O
1344	.	O
1344	3	O
1344	‐	O
1344	fold	O
1344	and	O
1344	3	O
1344	.	O
1344	1	O
1344	‐	O
1344	fold	O
1344	to	O
1344	9	O
1344	.	O
1344	9	O
1344	‐	O
1344	fold	O
1344	,	O
1344	respectively	O
1344	.	O
1344	[SEP]	O
1345	[CLS]	O
1345	exposure	O
1345	(	O
1345	cm	B-PK
1345	##ax	I-PK
1345	and	O
1345	au	B-PK
1345	##c	I-PK
1345	##0	I-PK
1345	–	I-PK
1345	24	I-PK
1345	)	O
1345	did	O
1345	not	O
1345	appear	O
1345	to	O
1345	increase	O
1345	dose	O
1345	proportional	O
1345	##ly	O
1345	for	O
1345	the	O
1345	100	O
1345	–	O
1345	600	O
1345	mg	O
1345	dose	O
1345	levels	O
1345	,	O
1345	but	O
1345	conclusions	O
1345	were	O
1345	limited	O
1345	by	O
1345	the	O
1345	small	O
1345	patient	O
1345	numbers	O
1345	.	O
1345	[SEP]	O
1346	[CLS]	O
1346	on	O
1346	cycle	O
1346	1	O
1346	,	O
1346	day	O
1346	28	O
1346	,	O
1346	exposure	O
1346	was	O
1346	higher	O
1346	with	O
1346	p	O
1346	##ila	O
1346	##ral	O
1346	##isi	O
1346	##b	O
1346	400	O
1346	mg	O
1346	tablets	O
1346	administered	O
1346	q	O
1346	##d	O
1346	compared	O
1346	with	O
1346	600	O
1346	mg	O
1346	tablets	O
1346	q	O
1346	##d	O
1346	and	O
1346	the	O
1346	capsule	O
1346	formulation	O
1346	administered	O
1346	at	O
1346	400	O
1346	mg	O
1346	and	O
1346	600	O
1346	mg	O
1346	q	O
1346	##d	O
1346	(	O
1346	mean	O
1346	au	B-PK
1346	##c	I-PK
1346	##0	I-PK
1346	–	I-PK
1346	24	I-PK
1346	2	O
1346	,	O
1346	82	O
1346	##0	O
1346	,	O
1346	000	O
1346	[	O
1346	n	O
1346	=	O
1346	2	O
1346	]	O
1346	vs	O
1346	.	O
1346	au	B-PK
1346	##c	I-PK
1346	##0	I-PK
1346	–	I-PK
1346	24	I-PK
1346	1	O
1346	,	O
1346	470	O
1346	,	O
1346	000	O
1346	[	O
1346	n	O
1346	=	O
1346	2	O
1346	]	O
1346	,	O
1346	2	O
1346	,	O
1346	65	O
1346	##3	O
1346	,	O
1346	000	O
1346	[	O
1346	n	O
1346	=	O
1346	2	O
1346	]	O
1346	and	O
1346	1	O
1346	,	O
1346	93	O
1346	##0	O
1346	,	O
1346	000	O
1346	ng	O
1346	×	O
1346	h	O
1346	/	O
1346	m	O
1346	##l	O
1346	[	O
1346	n	O
1346	=	O
1346	14	O
1346	]	O
1346	,	O
1346	respectively	O
1346	)	O
1346	.	O
1346	[SEP]	O
1347	[CLS]	O
1347	the	O
1347	trial	O
1347	’	O
1347	s	O
1347	co	O
1347	-	O
1347	primary	O
1347	end	O
1347	##points	O
1347	were	O
1347	mean	O
1347	changes	O
1347	from	O
1347	base	O
1347	##line	O
1347	,	O
1347	as	O
1347	area	B-PK
1347	under	I-PK
1347	the	I-PK
1347	curve	I-PK
1347	(	I-PK
1347	au	I-PK
1347	##c	I-PK
1347	)	I-PK
1347	,	O
1347	in	O
1347	forced	O
1347	ex	O
1347	##pi	O
1347	##rator	O
1347	##y	O
1347	volume	O
1347	(	O
1347	f	O
1347	##ev	O
1347	##1	O
1347	)	O
1347	over	O
1347	0	O
1347	–	O
1347	12	O
1347	hours	O
1347	(	O
1347	au	B-PK
1347	##c	I-PK
1347	##0	I-PK
1347	–	I-PK
1347	12	I-PK
1347	h	I-PK
1347	f	O
1347	##ev	O
1347	##1	O
1347	)	O
1347	with	O
1347	m	O
1347	##f	O
1347	/	O
1347	f	O
1347	versus	O
1347	m	O
1347	##f	O
1347	,	O
1347	and	O
1347	in	O
1347	morning	O
1347	(	O
1347	am	O
1347	)	O
1347	pre	O
1347	-	O
1347	dose	O
1347	(	O
1347	t	O
1347	##rough	O
1347	)	O
1347	f	O
1347	##ev	O
1347	##1	O
1347	with	O
1347	m	O
1347	##f	O
1347	/	O
1347	f	O
1347	versus	O
1347	f	O
1347	after	O
1347	13	O
1347	weeks	O
1347	of	O
1347	treatment	O
1347	.	O
1347	[SEP]	O
1348	[CLS]	O
1348	the	O
1348	largest	O
1348	improvements	O
1348	in	O
1348	au	B-PK
1348	##c	I-PK
1348	##0	I-PK
1348	–	I-PK
1348	12	I-PK
1348	h	I-PK
1348	f	O
1348	##ev	O
1348	##1	O
1348	were	O
1348	observed	O
1348	with	O
1348	m	O
1348	##f	O
1348	/	O
1348	f	O
1348	400	O
1348	/	O
1348	10	O
1348	μ	O
1348	##g	O
1348	and	O
1348	m	O
1348	##f	O
1348	/	O
1348	f	O
1348	200	O
1348	/	O
1348	10	O
1348	μ	O
1348	##g	O
1348	.	O
1348	[SEP]	O
1349	[CLS]	O
1349	this	O
1349	was	O
1349	a	O
1349	random	O
1349	##ized	O
1349	,	O
1349	place	O
1349	##bo	O
1349	-	O
1349	controlled	O
1349	,	O
1349	double	O
1349	-	O
1349	blind	O
1349	,	O
1349	double	O
1349	-	O
1349	du	O
1349	##mmy	O
1349	,	O
1349	multi	O
1349	##cent	O
1349	##er	O
1349	study	O
1349	(	O
1349	clinical	O
1349	##tri	O
1349	##als	O
1349	.	O
1349	go	O
1349	##v	O
1349	id	O
1349	##ent	O
1349	##ifier	O
1349	:	O
1349	n	O
1349	##ct	O
1349	##00	O
1349	##38	O
1349	##37	O
1349	##21	O
1349	)	O
1349	of	O
1349	m	O
1349	##f	O
1349	/	O
1349	f	O
1349	400	O
1349	/	O
1349	10	O
1349	μ	O
1349	##g	O
1349	bid	O
1349	and	O
1349	m	O
1349	##f	O
1349	/	O
1349	f	O
1349	200	O
1349	/	O
1349	10	O
1349	μ	O
1349	##g	O
1349	bid	O
1349	compared	O
1349	with	O
1349	m	O
1349	##f	O
1349	400	O
1349	μ	O
1349	##g	O
1349	bid	O
1349	and	O
1349	f	O
1349	10	O
1349	μ	O
1349	##g	O
1349	bid	O
1349	in	O
1349	adults	O
1349	with	O
1349	moderate	O
1349	-	O
1349	to	O
1349	-	O
1349	very	O
1349	severe	O
1349	cop	O
1349	##d	O
1349	.	O
1349	[SEP]	O
1350	[CLS]	O
1350	total	O
1350	dose	O
1350	was	O
1350	delivered	O
1350	after	O
1350	two	O
1350	in	O
1350	##hala	O
1350	##tions	O
1350	bid	O
1350	of	O
1350	the	O
1350	following	O
1350	act	O
1350	##uated	O
1350	doses	O
1350	:	O
1350	m	O
1350	##f	O
1350	/	O
1350	f	O
1350	200	O
1350	/	O
1350	5	O
1350	μ	O
1350	##g	O
1350	,	O
1350	m	O
1350	##f	O
1350	/	O
1350	f	O
1350	100	O
1350	/	O
1350	5	O
1350	μ	O
1350	##g	O
1350	,	O
1350	m	O
1350	##f	O
1350	200	O
1350	μ	O
1350	##g	O
1350	,	O
1350	f	O
1350	5	O
1350	μ	O
1350	##g	O
1350	,	O
1350	or	O
1350	place	O
1350	##bo	O
1350	.	O
1350	[SEP]	O
1351	[CLS]	O
1351	at	O
1351	base	O
1351	##line	O
1351	,	O
1351	subjects	O
1351	were	O
1351	random	O
1351	##ized	O
1351	in	O
1351	a	O
1351	1	O
1351	:	O
1351	1	O
1351	:	O
1351	1	O
1351	:	O
1351	1	O
1351	:	O
1351	1	O
1351	ratio	O
1351	to	O
1351	26	O
1351	weeks	O
1351	of	O
1351	double	O
1351	-	O
1351	blind	O
1351	treatment	O
1351	with	O
1351	m	O
1351	##f	O
1351	/	O
1351	f	O
1351	400	O
1351	/	O
1351	10	O
1351	μ	O
1351	##g	O
1351	bid	O
1351	,	O
1351	m	O
1351	##f	O
1351	/	O
1351	f	O
1351	200	O
1351	/	O
1351	10	O
1351	μ	O
1351	##g	O
1351	bid	O
1351	,	O
1351	m	O
1351	##f	O
1351	400	O
1351	μ	O
1351	##g	O
1351	bid	O
1351	,	O
1351	f	O
1351	10	O
1351	μ	O
1351	##g	O
1351	bid	O
1351	,	O
1351	or	O
1351	place	O
1351	##bo	O
1351	.	O
1351	[SEP]	O
1352	[CLS]	O
1352	the	O
1352	active	O
1352	and	O
1352	place	O
1352	##bo	O
1352	m	O
1352	##f	O
1352	/	O
1352	f	O
1352	and	O
1352	m	O
1352	##f	O
1352	in	O
1352	##hale	O
1352	##rs	O
1352	were	O
1352	identical	O
1352	in	O
1352	appearance	O
1352	,	O
1352	as	O
1352	were	O
1352	the	O
1352	active	O
1352	and	O
1352	place	O
1352	##bo	O
1352	f	O
1352	in	O
1352	##hale	O
1352	##rs	O
1352	.	O
1352	[SEP]	O
1353	[CLS]	O
1353	the	O
1353	co	O
1353	-	O
1353	primary	O
1353	end	O
1353	##points	O
1353	were	O
1353	:	O
1353	1	O
1353	)	O
1353	m	O
1353	##f	O
1353	/	O
1353	f	O
1353	400	O
1353	/	O
1353	10	O
1353	μ	O
1353	##g	O
1353	compared	O
1353	with	O
1353	m	O
1353	##f	O
1353	400	O
1353	μ	O
1353	##g	O
1353	for	O
1353	f	O
1353	##ev	O
1353	##1	O
1353	area	O
1353	under	O
1353	the	O
1353	curve	O
1353	from	O
1353	0	O
1353	to	O
1353	12	O
1353	hours	O
1353	post	O
1353	-	O
1353	dose	O
1353	(	O
1353	au	O
1353	##c	O
1353	##0	O
1353	–	O
1353	12	O
1353	h	O
1353	)	O
1353	at	O
1353	the	O
1353	week	O
1353	13	O
1353	end	O
1353	##point	O
1353	(	O
1353	last	O
1353	observation	O
1353	carried	O
1353	forward	O
1353	[	O
1353	lo	O
1353	##c	O
1353	##f	O
1353	]	O
1353	)	O
1353	to	O
1353	assess	O
1353	the	O
1353	added	O
1353	benefit	O
1353	of	O
1353	f	O
1353	on	O
1353	br	O
1353	##on	O
1353	##cho	O
1353	##di	O
1353	##lation	O
1353	,	O
1353	and	O
1353	2	O
1353	)	O
1353	m	O
1353	##f	O
1353	/	O
1353	f	O
1353	400	O
1353	/	O
1353	10	O
1353	μ	O
1353	##g	O
1353	and	O
1353	m	O
1353	##f	O
1353	/	O
1353	f	O
1353	200	O
1353	/	O
1353	10	O
1353	μ	O
1353	##g	O
1353	compared	O
1353	with	O
1353	f	O
1353	10	O
1353	μ	O
1353	##g	O
1353	for	O
1353	am	O
1353	pre	O
1353	##dos	O
1353	##e	O
1353	(	O
1353	t	O
1353	##rough	O
1353	)	O
1353	f	O
1353	##ev	O
1353	##1	O
1353	at	O
1353	the	O
1353	week	O
1353	13	O
1353	end	O
1353	##point	O
1353	to	O
1353	assess	O
1353	the	O
1353	added	O
1353	benefit	O
1353	of	O
1353	m	O
1353	##f	O
1353	on	O
1353	t	O
1353	##rough	O
1353	f	O
1353	##ev	O
1353	##1	O
1353	.	O
1353	[SEP]	O
1354	[CLS]	O
1354	secondary	O
1354	efficacy	O
1354	end	O
1354	##points	O
1354	included	O
1354	assessment	O
1354	of	O
1354	changes	O
1354	from	O
1354	base	O
1354	##line	O
1354	in	O
1354	f	O
1354	##ev	O
1354	##1	O
1354	au	B-PK
1354	##c	I-PK
1354	##0	I-PK
1354	–	I-PK
1354	12	I-PK
1354	h	I-PK
1354	at	O
1354	day	O
1354	1	O
1354	,	O
1354	weeks	O
1354	1	O
1354	,	O
1354	13	O
1354	,	O
1354	26	O
1354	,	O
1354	and	O
1354	the	O
1354	26	O
1354	-	O
1354	week	O
1354	end	O
1354	##point	O
1354	(	O
1354	lo	O
1354	##c	O
1354	##f	O
1354	)	O
1354	,	O
1354	as	O
1354	well	O
1354	as	O
1354	assessment	O
1354	of	O
1354	changes	O
1354	from	O
1354	base	O
1354	##line	O
1354	in	O
1354	t	O
1354	##rough	O
1354	f	O
1354	##ev	O
1354	##1	O
1354	at	O
1354	each	O
1354	visit	O
1354	and	O
1354	at	O
1354	the	O
1354	26	O
1354	-	O
1354	week	O
1354	end	O
1354	##point	O
1354	.	O
1354	[SEP]	O
1355	[CLS]	O
1355	the	O
1355	first	O
1355	co	O
1355	-	O
1355	primary	O
1355	efficacy	O
1355	end	O
1355	##point	O
1355	was	O
1355	the	O
1355	mean	O
1355	au	B-PK
1355	##c	I-PK
1355	##0	I-PK
1355	–	I-PK
1355	12	I-PK
1355	h	I-PK
1355	of	O
1355	the	O
1355	change	O
1355	in	O
1355	f	O
1355	##ev	O
1355	##1	O
1355	from	O
1355	base	O
1355	##line	O
1355	to	O
1355	the	O
1355	week	O
1355	13	O
1355	end	O
1355	##point	O
1355	,	O
1355	measuring	O
1355	the	O
1355	contribution	O
1355	of	O
1355	f	O
1355	10	O
1355	μ	O
1355	##g	O
1355	bid	O
1355	to	O
1355	the	O
1355	combination	O
1355	.	O
1355	[SEP]	O
1356	[CLS]	O
1356	also	O
1356	,	O
1356	f	O
1356	##ev	O
1356	##1	O
1356	re	O
1356	##vers	O
1356	##ibility	O
1356	at	O
1356	screening	O
1356	tended	O
1356	to	O
1356	be	O
1356	higher	O
1356	in	O
1356	the	O
1356	f	O
1356	10	O
1356	μ	O
1356	##g	O
1356	group	O
1356	(	O
1356	10	O
1356	.	O
1356	37	O
1356	%	O
1356	)	O
1356	than	O
1356	it	O
1356	was	O
1356	in	O
1356	the	O
1356	m	O
1356	##f	O
1356	/	O
1356	f	O
1356	400	O
1356	/	O
1356	10	O
1356	μ	O
1356	##g	O
1356	and	O
1356	m	O
1356	##f	O
1356	/	O
1356	f	O
1356	200	O
1356	/	O
1356	10	O
1356	μ	O
1356	##g	O
1356	groups	O
1356	(	O
1356	8	O
1356	.	O
1356	69	O
1356	%	O
1356	and	O
1356	8	O
1356	.	O
1356	47	O
1356	%	O
1356	,	O
1356	respectively	O
1356	)	O
1356	.	O
1356	[SEP]	O
1357	[CLS]	O
1357	at	O
1357	the	O
1357	week	O
1357	13	O
1357	end	O
1357	##point	O
1357	,	O
1357	a	O
1357	significant	O
1357	difference	O
1357	of	O
1357	126	O
1357	m	O
1357	##l	O
1357	was	O
1357	observed	O
1357	in	O
1357	the	O
1357	mean	O
1357	change	O
1357	from	O
1357	base	O
1357	##line	O
1357	in	O
1357	f	O
1357	##ev	O
1357	##1	O
1357	au	B-PK
1357	##c	I-PK
1357	##0	I-PK
1357	–	I-PK
1357	12	I-PK
1357	h	I-PK
1357	between	O
1357	m	O
1357	##f	O
1357	/	O
1357	f	O
1357	400	O
1357	/	O
1357	10	O
1357	μ	O
1357	##g	O
1357	and	O
1357	m	O
1357	##f	O
1357	400	O
1357	μ	O
1357	##g	O
1357	groups	O
1357	(	O
1357	p	O
1357	<	O
1357	0	O
1357	.	O
1357	00	O
1357	##1	O
1357	)	O
1357	.	O
1357	[SEP]	O
1358	[CLS]	O
1358	m	O
1358	##f	O
1358	/	O
1358	f	O
1358	200	O
1358	/	O
1358	10	O
1358	μ	O
1358	##g	O
1358	also	O
1358	significantly	O
1358	improved	O
1358	f	O
1358	##ev	O
1358	##1	O
1358	au	B-PK
1358	##c	I-PK
1358	##0	I-PK
1358	–	I-PK
1358	12	I-PK
1358	h	I-PK
1358	versus	O
1358	m	O
1358	##f	O
1358	400	O
1358	μ	O
1358	##g	O
1358	(	O
1358	86	O
1358	m	O
1358	##l	O
1358	difference	O
1358	,	O
1358	p	O
1358	<	O
1358	0	O
1358	.	O
1358	00	O
1358	##1	O
1358	)	O
1358	.	O
1358	[SEP]	O
1359	[CLS]	O
1359	a	O
1359	significant	O
1359	improvement	O
1359	of	O
1359	74	O
1359	m	O
1359	##l	O
1359	was	O
1359	reported	O
1359	for	O
1359	f	O
1359	10	O
1359	μ	O
1359	##g	O
1359	compared	O
1359	with	O
1359	place	O
1359	##bo	O
1359	(	O
1359	p	O
1359	=	O
1359	0	O
1359	.	O
1359	00	O
1359	##4	O
1359	)	O
1359	(	O
1359	figure	O
1359	2	O
1359	)	O
1359	.	O
1359	[SEP]	O
1360	[CLS]	O
1360	results	O
1360	with	O
1360	m	O
1360	##f	O
1360	/	O
1360	f	O
1360	400	O
1360	/	O
1360	10	O
1360	μ	O
1360	##g	O
1360	and	O
1360	m	O
1360	##f	O
1360	/	O
1360	f	O
1360	200	O
1360	/	O
1360	10	O
1360	μ	O
1360	##g	O
1360	versus	O
1360	f	O
1360	10	O
1360	μ	O
1360	##g	O
1360	for	O
1360	the	O
1360	change	O
1360	from	O
1360	base	O
1360	##line	O
1360	in	O
1360	am	O
1360	pre	O
1360	-	O
1360	dose	O
1360	(	O
1360	t	O
1360	##rough	O
1360	)	O
1360	f	O
1360	##ev	O
1360	##1	O
1360	at	O
1360	the	O
1360	week	O
1360	13	O
1360	end	O
1360	##point	O
1360	indicate	O
1360	a	O
1360	contribution	O
1360	of	O
1360	m	O
1360	##f	O
1360	to	O
1360	the	O
1360	combination	O
1360	(	O
1360	figure	O
1360	4	O
1360	)	O
1360	.	O
1360	[SEP]	O
1361	[CLS]	O
1361	the	O
1361	significant	O
1361	improvement	O
1361	of	O
1361	f	O
1361	##ev	O
1361	##1	O
1361	au	B-PK
1361	##c	I-PK
1361	##0	I-PK
1361	–	I-PK
1361	12	I-PK
1361	h	I-PK
1361	with	O
1361	m	O
1361	##f	O
1361	/	O
1361	f	O
1361	400	O
1361	/	O
1361	10	O
1361	μ	O
1361	##g	O
1361	versus	O
1361	f	O
1361	10	O
1361	μ	O
1361	##g	O
1361	(	O
1361	87	O
1361	m	O
1361	##l	O
1361	,	O
1361	p	O
1361	<	O
1361	0	O
1361	.	O
1361	00	O
1361	##1	O
1361	)	O
1361	confirms	O
1361	the	O
1361	contribution	O
1361	of	O
1361	m	O
1361	##f	O
1361	to	O
1361	the	O
1361	combination	O
1361	.	O
1361	[SEP]	O
1362	[CLS]	O
1362	these	O
1362	results	O
1362	show	O
1362	the	O
1362	benefit	O
1362	of	O
1362	f	O
1362	in	O
1362	the	O
1362	combination	O
1362	formulation	O
1362	.	O
1362	[SEP]	O
1363	[CLS]	O
1363	in	O
1363	the	O
1363	second	O
1363	analysis	O
1363	of	O
1363	am	O
1363	pre	O
1363	-	O
1363	dose	O
1363	f	O
1363	##ev	O
1363	##1	O
1363	,	O
1363	performed	O
1363	after	O
1363	database	O
1363	lock	O
1363	and	O
1363	exclusion	O
1363	of	O
1363	these	O
1363	subjects	O
1363	,	O
1363	statistical	O
1363	significance	O
1363	was	O
1363	achieved	O
1363	for	O
1363	this	O
1363	co	O
1363	-	O
1363	primary	O
1363	end	O
1363	##point	O
1363	,	O
1363	with	O
1363	a	O
1363	difference	O
1363	of	O
1363	58	O
1363	m	O
1363	##l	O
1363	between	O
1363	m	O
1363	##f	O
1363	/	O
1363	f	O
1363	400	O
1363	/	O
1363	10	O
1363	μ	O
1363	##g	O
1363	and	O
1363	f	O
1363	10	O
1363	μ	O
1363	##g	O
1363	(	O
1363	p	O
1363	=	O
1363	0	O
1363	.	O
1363	03	O
1363	##0	O
1363	)	O
1363	,	O
1363	and	O
1363	a	O
1363	difference	O
1363	of	O
1363	105	O
1363	m	O
1363	##l	O
1363	between	O
1363	m	O
1363	##f	O
1363	/	O
1363	f	O
1363	400	O
1363	/	O
1363	10	O
1363	μ	O
1363	##g	O
1363	and	O
1363	place	O
1363	##bo	O
1363	(	O
1363	p	O
1363	<	O
1363	0	O
1363	.	O
1363	00	O
1363	##1	O
1363	)	O
1363	.	O
1363	[SEP]	O
1364	[CLS]	O
1364	compared	O
1364	with	O
1364	f	O
1364	10	O
1364	μ	O
1364	##g	O
1364	,	O
1364	m	O
1364	##f	O
1364	/	O
1364	f	O
1364	400	O
1364	/	O
1364	10	O
1364	μ	O
1364	##g	O
1364	had	O
1364	significantly	O
1364	greater	O
1364	increases	O
1364	in	O
1364	f	O
1364	##ev	O
1364	##1	O
1364	at	O
1364	all	O
1364	time	O
1364	points	O
1364	at	O
1364	week	O
1364	26	O
1364	(	O
1364	p	O
1364	≤	O
1364	0	O
1364	.	O
1364	01	O
1364	##6	O
1364	)	O
1364	,	O
1364	whereas	O
1364	m	O
1364	##f	O
1364	/	O
1364	f	O
1364	200	O
1364	/	O
1364	10	O
1364	μ	O
1364	##g	O
1364	had	O
1364	significantly	O
1364	greater	O
1364	increases	O
1364	versus	O
1364	f	O
1364	only	O
1364	at	O
1364	the	O
1364	4	O
1364	-	O
1364	and	O
1364	8	O
1364	-	O
1364	hour	O
1364	post	O
1364	-	O
1364	dose	O
1364	time	O
1364	points	O
1364	(	O
1364	p	O
1364	≤	O
1364	0	O
1364	.	O
1364	02	O
1364	##2	O
1364	)	O
1364	further	O
1364	##more	O
1364	,	O
1364	as	O
1364	would	O
1364	be	O
1364	expected	O
1364	,	O
1364	both	O
1364	m	O
1364	##f	O
1364	/	O
1364	f	O
1364	treatments	O
1364	were	O
1364	superior	O
1364	to	O
1364	place	O
1364	##bo	O
1364	(	O
1364	p	O
1364	≤	O
1364	0	O
1364	.	O
1364	01	O
1364	##9	O
1364	)	O
1364	at	O
1364	all	O
1364	time	O
1364	points	O
1364	during	O
1364	serial	O
1364	s	O
1364	##pi	O
1364	##rome	O
1364	##try	O
1364	assessments	O
1364	throughout	O
1364	the	O
1364	entire	O
1364	treatment	O
1364	period	O
1364	.	O
1364	[SEP]	O
1365	[CLS]	O
1365	the	O
1365	changes	O
1365	from	O
1365	base	O
1365	##line	O
1365	with	O
1365	m	O
1365	##f	O
1365	400	O
1365	μ	O
1365	##g	O
1365	(	O
1365	5	O
1365	.	O
1365	87	O
1365	)	O
1365	and	O
1365	f	O
1365	10	O
1365	μ	O
1365	##g	O
1365	(	O
1365	4	O
1365	.	O
1365	93	O
1365	)	O
1365	also	O
1365	surpassed	O
1365	the	O
1365	m	O
1365	##cid	O
1365	(	O
1365	figure	O
1365	5	O
1365	)	O
1365	.	O
1365	[SEP]	O
1366	[CLS]	O
1366	however	O
1366	,	O
1366	the	O
1366	difference	O
1366	between	O
1366	m	O
1366	##f	O
1366	/	O
1366	f	O
1366	400	O
1366	/	O
1366	10	O
1366	μ	O
1366	##g	O
1366	and	O
1366	f	O
1366	10	O
1366	μ	O
1366	##g	O
1366	(	O
1366	49	O
1366	m	O
1366	##l	O
1366	)	O
1366	was	O
1366	marginal	O
1366	##ly	O
1366	significant	O
1366	for	O
1366	the	O
1366	pre	O
1366	-	O
1366	specified	O
1366	lo	O
1366	##c	O
1366	##f	O
1366	analysis	O
1366	(	O
1366	p	O
1366	=	O
1366	0	O
1366	.	O
1366	06	O
1366	##2	O
1366	)	O
1366	.	O
1366	[SEP]	O
1367	[CLS]	O
1367	in	O
1367	analyses	O
1367	for	O
1367	observed	O
1367	cases	O
1367	(	O
1367	analyses	O
1367	based	O
1367	on	O
1367	observations	O
1367	at	O
1367	specified	O
1367	time	O
1367	points	O
1367	,	O
1367	as	O
1367	opposed	O
1367	to	O
1367	observations	O
1367	carried	O
1367	forward	O
1367	for	O
1367	end	O
1367	##point	O
1367	analyses	O
1367	)	O
1367	at	O
1367	weeks	O
1367	13	O
1367	and	O
1367	26	O
1367	,	O
1367	as	O
1367	well	O
1367	as	O
1367	the	O
1367	week	O
1367	26	O
1367	end	O
1367	##point	O
1367	,	O
1367	statistical	O
1367	significance	O
1367	was	O
1367	achieved	O
1367	,	O
1367	with	O
1367	differences	O
1367	between	O
1367	m	O
1367	##f	O
1367	/	O
1367	f	O
1367	400	O
1367	/	O
1367	10	O
1367	μ	O
1367	##g	O
1367	and	O
1367	f	O
1367	10	O
1367	μ	O
1367	##g	O
1367	of	O
1367	59	O
1367	m	O
1367	##l	O
1367	,	O
1367	101	O
1367	m	O
1367	##l	O
1367	,	O
1367	and	O
1367	82	O
1367	m	O
1367	##l	O
1367	,	O
1367	respectively	O
1367	(	O
1367	p	O
1367	≤	O
1367	0	O
1367	.	O
1367	03	O
1367	##3	O
1367	)	O
1367	.	O
1367	[SEP]	O
1368	[CLS]	O
1368	at	O
1368	the	O
1368	week	O
1368	13	O
1368	end	O
1368	##point	O
1368	in	O
1368	this	O
1368	subgroup	O
1368	,	O
1368	significant	O
1368	differences	O
1368	in	O
1368	mean	O
1368	changes	O
1368	from	O
1368	base	O
1368	##line	O
1368	in	O
1368	f	O
1368	##ev	O
1368	##1	O
1368	au	B-PK
1368	##c	I-PK
1368	##0	I-PK
1368	–	I-PK
1368	12	I-PK
1368	h	I-PK
1368	occurred	O
1368	,	O
1368	with	O
1368	a	O
1368	difference	O
1368	of	O
1368	101	O
1368	m	O
1368	##l	O
1368	between	O
1368	m	O
1368	##f	O
1368	/	O
1368	f	O
1368	400	O
1368	/	O
1368	10	O
1368	μ	O
1368	##g	O
1368	and	O
1368	m	O
1368	##f	O
1368	400	O
1368	μ	O
1368	##g	O
1368	(	O
1368	p	O
1368	<	O
1368	0	O
1368	.	O
1368	00	O
1368	##1	O
1368	)	O
1368	,	O
1368	88	O
1368	m	O
1368	##l	O
1368	between	O
1368	m	O
1368	##f	O
1368	/	O
1368	f	O
1368	200	O
1368	/	O
1368	10	O
1368	μ	O
1368	##g	O
1368	and	O
1368	m	O
1368	##f	O
1368	400	O
1368	μ	O
1368	##g	O
1368	(	O
1368	p	O
1368	<	O
1368	0	O
1368	.	O
1368	00	O
1368	##1	O
1368	)	O
1368	,	O
1368	and	O
1368	83	O
1368	m	O
1368	##l	O
1368	between	O
1368	f	O
1368	10	O
1368	μ	O
1368	##g	O
1368	and	O
1368	place	O
1368	##bo	O
1368	(	O
1368	p	O
1368	=	O
1368	0	O
1368	.	O
1368	00	O
1368	##1	O
1368	)	O
1368	.	O
1368	[SEP]	O
1369	[CLS]	O
1369	the	O
1369	proportions	O
1369	of	O
1369	subjects	O
1369	with	O
1369	moderate	O
1369	or	O
1369	severe	O
1369	first	O
1369	ex	O
1369	##ace	O
1369	##rb	O
1369	##ations	O
1369	in	O
1369	the	O
1369	m	O
1369	##f	O
1369	/	O
1369	f	O
1369	400	O
1369	/	O
1369	10	O
1369	μ	O
1369	##g	O
1369	,	O
1369	m	O
1369	##f	O
1369	/	O
1369	f	O
1369	200	O
1369	/	O
1369	10	O
1369	μ	O
1369	##g	O
1369	,	O
1369	m	O
1369	##f	O
1369	400	O
1369	μ	O
1369	##g	O
1369	,	O
1369	and	O
1369	f	O
1369	10	O
1369	μ	O
1369	##g	O
1369	groups	O
1369	were	O
1369	15	O
1369	.	O
1369	4	O
1369	%	O
1369	,	O
1369	12	O
1369	.	O
1369	8	O
1369	%	O
1369	,	O
1369	16	O
1369	.	O
1369	9	O
1369	%	O
1369	,	O
1369	and	O
1369	18	O
1369	.	O
1369	4	O
1369	%	O
1369	,	O
1369	respectively	O
1369	.	O
1369	[SEP]	O
1370	[CLS]	O
1370	only	O
1370	six	O
1370	subjects	O
1370	had	O
1370	l	O
1370	##s	O
1370	-	O
1370	b	O
1370	##m	O
1370	##d	O
1370	loss	O
1370	>	O
1370	6	O
1370	%	O
1370	during	O
1370	the	O
1370	study	O
1370	period	O
1370	:	O
1370	two	O
1370	subjects	O
1370	each	O
1370	in	O
1370	the	O
1370	m	O
1370	##f	O
1370	/	O
1370	f	O
1370	400	O
1370	/	O
1370	10	O
1370	μ	O
1370	##g	O
1370	and	O
1370	m	O
1370	##f	O
1370	400	O
1370	μ	O
1370	##g	O
1370	groups	O
1370	,	O
1370	one	O
1370	subject	O
1370	in	O
1370	the	O
1370	m	O
1370	##f	O
1370	/	O
1370	f	O
1370	200	O
1370	/	O
1370	10	O
1370	μ	O
1370	##g	O
1370	group	O
1370	,	O
1370	and	O
1370	one	O
1370	subject	O
1370	in	O
1370	the	O
1370	f	O
1370	10	O
1370	μ	O
1370	##g	O
1370	group	O
1370	.	O
1370	[SEP]	O
1371	[CLS]	O
1371	if	O
1371	cop	O
1371	##d	O
1371	ex	O
1371	##ace	O
1371	##rb	O
1371	##ation	O
1371	met	O
1371	the	O
1371	criteria	O
1371	for	O
1371	a	O
1371	serious	O
1371	a	O
1371	##e	O
1371	(	O
1371	e	O
1371	##g	O
1371	,	O
1371	was	O
1371	life	O
1371	-	O
1371	threatening	O
1371	,	O
1371	required	O
1371	hospital	O
1371	##ization	O
1371	,	O
1371	or	O
1371	prolonged	O
1371	hospital	O
1371	##ization	O
1371	)	O
1371	,	O
1371	it	O
1371	was	O
1371	recorded	O
1371	as	O
1371	an	O
1371	a	O
1371	##e	O
1371	.	O
1371	[SEP]	O
1372	[CLS]	O
1372	overall	O
1372	,	O
1372	90	O
1372	subjects	O
1372	(	O
1372	7	O
1372	.	O
1372	5	O
1372	%	O
1372	)	O
1372	reported	O
1372	a	O
1372	treatment	O
1372	-	O
1372	related	O
1372	a	O
1372	##e	O
1372	,	O
1372	the	O
1372	most	O
1372	frequent	O
1372	of	O
1372	which	O
1372	were	O
1372	lent	O
1372	##icular	O
1372	op	O
1372	##ac	O
1372	##ities	O
1372	(	O
1372	1	O
1372	subject	O
1372	m	O
1372	##f	O
1372	/	O
1372	f	O
1372	200	O
1372	/	O
1372	10	O
1372	μ	O
1372	##g	O
1372	,	O
1372	1	O
1372	subject	O
1372	m	O
1372	##f	O
1372	/	O
1372	f	O
1372	400	O
1372	/	O
1372	10	O
1372	μ	O
1372	##g	O
1372	,	O
1372	2	O
1372	subjects	O
1372	m	O
1372	##f	O
1372	400	O
1372	μ	O
1372	##g	O
1372	,	O
1372	3	O
1372	subjects	O
1372	f	O
1372	10	O
1372	μ	O
1372	##g	O
1372	,	O
1372	and	O
1372	1	O
1372	subject	O
1372	place	O
1372	##bo	O
1372	)	O
1372	,	O
1372	d	O
1372	##ys	O
1372	##phon	O
1372	##ia	O
1372	(	O
1372	2	O
1372	subjects	O
1372	m	O
1372	##f	O
1372	/	O
1372	f	O
1372	200	O
1372	/	O
1372	10	O
1372	μ	O
1372	##g	O
1372	,	O
1372	1	O
1372	subject	O
1372	m	O
1372	##f	O
1372	/	O
1372	f	O
1372	400	O
1372	/	O
1372	10	O
1372	μ	O
1372	##g	O
1372	,	O
1372	4	O
1372	subjects	O
1372	m	O
1372	##f	O
1372	400	O
1372	μ	O
1372	##g	O
1372	,	O
1372	and	O
1372	1	O
1372	subject	O
1372	place	O
1372	##bo	O
1372	)	O
1372	,	O
1372	and	O
1372	oral	O
1372	can	O
1372	##di	O
1372	##dia	O
1372	##sis	O
1372	,	O
1372	including	O
1372	the	O
1372	a	O
1372	##e	O
1372	terms	O
1372	of	O
1372	oral	O
1372	can	O
1372	##di	O
1372	##dia	O
1372	##sis	O
1372	,	O
1372	or	O
1372	##op	O
1372	##har	O
1372	##yn	O
1372	##ge	O
1372	##al	O
1372	can	O
1372	##di	O
1372	##dia	O
1372	##sis	O
1372	,	O
1372	and	O
1372	oral	O
1372	fun	O
1372	##gal	O
1372	infection	O
1372	(	O
1372	1	O
1372	subject	O
1372	m	O
1372	##f	O
1372	/	O
1372	f	O
1372	200	O
1372	/	O
1372	10	O
1372	μ	O
1372	##g	O
1372	,	O
1372	2	O
1372	subjects	O
1372	m	O
1372	##f	O
1372	/	O
1372	f	O
1372	400	O
1372	/	O
1372	10	O
1372	μ	O
1372	##g	O
1372	,	O
1372	6	O
1372	subjects	O
1372	m	O
1372	##f	O
1372	400	O
1372	μ	O
1372	##g	O
1372	,	O
1372	and	O
1372	1	O
1372	subject	O
1372	f	O
1372	10	O
1372	μ	O
1372	##g	O
1372	)	O
1372	.	O
1372	[SEP]	O
1373	[CLS]	O
1373	during	O
1373	the	O
1373	entire	O
1373	study	O
1373	period	O
1373	(	O
1373	treatment	O
1373	period	O
1373	plus	O
1373	safety	O
1373	extension	O
1373	)	O
1373	,	O
1373	23	O
1373	subjects	O
1373	(	O
1373	2	O
1373	.	O
1373	4	O
1373	%	O
1373	)	O
1373	reported	O
1373	pneumonia	O
1373	(	O
1373	including	O
1373	the	O
1373	a	O
1373	##e	O
1373	terms	O
1373	of	O
1373	pneumonia	O
1373	,	O
1373	pneumonia	O
1373	viral	O
1373	,	O
1373	pneumonia	O
1373	as	O
1373	##piration	O
1373	,	O
1373	and	O
1373	lo	O
1373	##bar	O
1373	pneumonia	O
1373	)	O
1373	across	O
1373	the	O
1373	four	O
1373	active	O
1373	treatment	O
1373	groups	O
1373	.	O
1373	[SEP]	O
1374	[CLS]	O
1374	single	O
1374	-	O
1374	dose	O
1374	in	O
1374	##tra	O
1374	##ven	O
1374	##ous	O
1374	and	O
1374	sub	O
1374	##cut	O
1374	##aneous	O
1374	p	O
1374	##har	O
1374	##ma	O
1374	##co	O
1374	##kin	O
1374	##etics	O
1374	studies	O
1374	indicate	O
1374	that	O
1374	a	O
1374	##bt	O
1374	-	O
1374	98	O
1374	##1	O
1374	has	O
1374	a	O
1374	half	B-PK
1374	-	I-PK
1374	life	I-PK
1374	of	O
1374	8	O
1374	.	O
1374	0	O
1374	to	O
1374	10	O
1374	.	O
1374	4	O
1374	d	O
1374	in	O
1374	c	O
1374	##yn	O
1374	##omo	O
1374	##l	O
1374	##gus	O
1374	monkey	O
1374	and	O
1374	10	O
1374	.	O
1374	0	O
1374	to	O
1374	20	O
1374	.	O
1374	3	O
1374	d	O
1374	in	O
1374	rode	O
1374	##nts	O
1374	.	O
1374	[SEP]	O
1375	[CLS]	O
1375	a	O
1375	##bt	O
1375	-	O
1375	98	O
1375	##1	O
1375	exhibits	O
1375	suitable	O
1375	drug	O
1375	-	O
1375	like	O
1375	-	O
1375	properties	O
1375	including	O
1375	affinity	O
1375	,	O
1375	pot	O
1375	##ency	O
1375	,	O
1375	specific	O
1375	##ity	O
1375	,	O
1375	half	B-PK
1375	-	I-PK
1375	life	I-PK
1375	,	O
1375	and	O
1375	stability	O
1375	for	O
1375	evaluation	O
1375	in	O
1375	human	O
1375	clinical	O
1375	trials	O
1375	.	O
1375	[SEP]	O
1376	[CLS]	O
1376	several	O
1376	affinity	O
1376	-	O
1376	mature	O
1376	##d	O
1376	s	O
1376	##k	O
1376	##48	O
1376	-	O
1376	e	O
1376	##26	O
1376	variant	O
1376	human	O
1376	i	O
1376	##gg	O
1376	##1	O
1376	/	O
1376	k	O
1376	antibodies	O
1376	(	O
1376	e	O
1376	##26	O
1376	.	O
1376	1	O
1376	,	O
1376	e	O
1376	##26	O
1376	.	O
1376	2	O
1376	,	O
1376	e	O
1376	##26	O
1376	.	O
1376	12	O
1376	,	O
1376	e	O
1376	##26	O
1376	.	O
1376	13	O
1376	,	O
1376	e	O
1376	##26	O
1376	.	O
1376	35	O
1376	and	O
1376	e	O
1376	##26	O
1376	.	O
1376	37	O
1376	)	O
1376	were	O
1376	generated	O
1376	by	O
1376	expression	O
1376	of	O
1376	a	O
1376	specific	O
1376	affinity	O
1376	-	O
1376	mature	O
1376	##d	O
1376	variable	O
1376	heavy	O
1376	chain	O
1376	(	O
1376	v	O
1376	##h	O
1376	)	O
1376	sequence	O
1376	(	O
1376	e	O
1376	##26	O
1376	.	O
1376	1	O
1376	v	O
1376	##h	O
1376	,	O
1376	e	O
1376	##26	O
1376	.	O
1376	2	O
1376	v	O
1376	##h	O
1376	,	O
1376	e	O
1376	##26	O
1376	.	O
1376	12	O
1376	v	O
1376	##h	O
1376	,	O
1376	e	O
1376	##26	O
1376	.	O
1376	13	O
1376	,	O
1376	v	O
1376	##h	O
1376	e	O
1376	##26	O
1376	.	O
1376	35	O
1376	v	O
1376	##h	O
1376	and	O
1376	e	O
1376	##26	O
1376	.	O
1376	37	O
1376	v	O
1376	##h	O
1376	)	O
1376	paired	O
1376	with	O
1376	the	O
1376	s	O
1376	##k	O
1376	##48	O
1376	-	O
1376	e	O
1376	##26	O
1376	variable	O
1376	light	O
1376	chain	O
1376	(	O
1376	v	O
1376	##l	O
1376	)	O
1376	sequence	O
1376	(	O
1376	s	O
1376	##k	O
1376	##48	O
1376	-	O
1376	e	O
1376	##26	O
1376	v	O
1376	##l	O
1376	)	O
1376	or	O
1376	the	O
1376	corresponding	O
1376	affinity	O
1376	-	O
1376	mature	O
1376	##d	O
1376	variable	O
1376	light	O
1376	chain	O
1376	sequence	O
1376	(	O
1376	e	O
1376	##26	O
1376	.	O
1376	1	O
1376	v	O
1376	##l	O
1376	and	O
1376	e	O
1376	##26	O
1376	.	O
1376	37	O
1376	v	O
1376	##l	O
1376	)	O
1376	.	O
1376	[SEP]	O
1377	[CLS]	O
1377	after	O
1377	i	O
1377	##v	O
1377	dos	O
1377	##ing	O
1377	in	O
1377	b	O
1377	##al	O
1377	##b	O
1377	/	O
1377	c	O
1377	mice	O
1377	,	O
1377	a	O
1377	##bt	O
1377	-	O
1377	98	O
1377	##1	O
1377	exhibited	O
1377	low	O
1377	clearance	B-PK
1377	(	O
1377	0	O
1377	.	O
1377	27	O
1377	m	O
1377	##l	O
1377	/	O
1377	h	O
1377	/	O
1377	kg	O
1377	)	O
1377	,	O
1377	a	O
1377	small	O
1377	volume	B-PK
1377	of	I-PK
1377	distribution	I-PK
1377	(	O
1377	95	O
1377	m	O
1377	##l	O
1377	/	O
1377	kg	O
1377	)	O
1377	,	O
1377	and	O
1377	a	O
1377	long	O
1377	half	B-PK
1377	-	I-PK
1377	life	I-PK
1377	of	O
1377	10	O
1377	.	O
1377	5	O
1377	d	O
1377	.	O
1377	after	O
1377	s	O
1377	##c	O
1377	administration	O
1377	of	O
1377	a	O
1377	##bt	O
1377	-	O
1377	98	O
1377	##1	O
1377	in	O
1377	mice	O
1377	,	O
1377	the	O
1377	cm	B-PK
1377	##ax	I-PK
1377	was	O
1377	29	O
1377	.	O
1377	2	O
1377	μ	O
1377	##g	O
1377	/	O
1377	m	O
1377	##l	O
1377	,	O
1377	the	O
1377	half	B-PK
1377	-	I-PK
1377	life	I-PK
1377	was	O
1377	20	O
1377	.	O
1377	3	O
1377	d	O
1377	and	O
1377	bio	B-PK
1377	##ava	I-PK
1377	##ila	I-PK
1377	##bility	I-PK
1377	was	O
1377	[UNK]	O
1377	%	O
1377	(	O
1377	fi	O
1377	##g	O
1377	.	O
1377	5	O
1377	##a	O
1377	)	O
1377	.	O
1377	[SEP]	O
1378	[CLS]	O
1378	after	O
1378	i	O
1378	##v	O
1378	dos	O
1378	##ing	O
1378	in	O
1378	s	O
1378	##pra	O
1378	##gue	O
1378	-	O
1378	da	O
1378	##wley	O
1378	rats	O
1378	,	O
1378	a	O
1378	##bt	O
1378	-	O
1378	98	O
1378	##1	O
1378	exhibited	O
1378	low	O
1378	clearance	B-PK
1378	(	O
1378	0	O
1378	.	O
1378	28	O
1378	m	O
1378	##l	O
1378	/	O
1378	h	O
1378	/	O
1378	kg	O
1378	)	O
1378	,	O
1378	small	O
1378	volume	B-PK
1378	of	I-PK
1378	distribution	I-PK
1378	(	O
1378	86	O
1378	m	O
1378	##l	O
1378	/	O
1378	kg	O
1378	)	O
1378	,	O
1378	with	O
1378	long	O
1378	half	B-PK
1378	-	I-PK
1378	life	I-PK
1378	of	O
1378	10	O
1378	.	O
1378	0	O
1378	d	O
1378	(	O
1378	fi	O
1378	##g	O
1378	.	O
1378	5	O
1378	##b	O
1378	and	O
1378	table	O
1378	7	O
1378	)	O
1378	.	O
1378	[SEP]	O
1379	[CLS]	O
1379	following	O
1379	s	O
1379	##c	O
1379	administration	O
1379	in	O
1379	rat	O
1379	,	O
1379	a	O
1379	cm	B-PK
1379	##ax	I-PK
1379	of	O
1379	16	O
1379	.	O
1379	0	O
1379	μ	O
1379	##g	O
1379	/	O
1379	m	O
1379	##l	O
1379	,	O
1379	with	O
1379	a	O
1379	half	B-PK
1379	-	I-PK
1379	life	I-PK
1379	of	O
1379	12	O
1379	.	O
1379	0	O
1379	d	O
1379	and	O
1379	52	O
1379	%	O
1379	bio	B-PK
1379	##ava	I-PK
1379	##ila	I-PK
1379	##bility	I-PK
1379	was	O
1379	observed	O
1379	(	O
1379	fi	O
1379	##g	O
1379	.	O
1379	5	O
1379	##b	O
1379	)	O
1379	.	O
1379	[SEP]	O
1380	[CLS]	O
1380	after	O
1380	i	O
1380	##v	O
1380	dos	O
1380	##ing	O
1380	in	O
1380	c	O
1380	##yn	O
1380	##omo	O
1380	##l	O
1380	##gus	O
1380	monkeys	O
1380	,	O
1380	a	O
1380	##bt	O
1380	-	O
1380	98	O
1380	##1	O
1380	exhibited	O
1380	low	O
1380	clearance	B-PK
1380	(	O
1380	0	O
1380	.	O
1380	22	O
1380	m	O
1380	##l	O
1380	/	O
1380	h	O
1380	/	O
1380	kg	O
1380	)	O
1380	,	O
1380	small	O
1380	volume	B-PK
1380	of	I-PK
1380	distribution	I-PK
1380	(	O
1380	61	O
1380	m	O
1380	##l	O
1380	/	O
1380	kg	O
1380	)	O
1380	and	O
1380	long	O
1380	half	B-PK
1380	-	I-PK
1380	life	I-PK
1380	of	O
1380	10	O
1380	.	O
1380	4	O
1380	d	O
1380	.	O
1380	after	O
1380	s	O
1380	##c	O
1380	administration	O
1380	,	O
1380	the	O
1380	half	B-PK
1380	-	I-PK
1380	life	I-PK
1380	of	O
1380	a	O
1380	##bt	O
1380	-	O
1380	98	O
1380	##1	O
1380	was	O
1380	8	O
1380	.	O
1380	0	O
1380	d	O
1380	and	O
1380	bio	B-PK
1380	##ava	I-PK
1380	##ila	I-PK
1380	##bility	I-PK
1380	was	O
1380	95	O
1380	%	O
1380	(	O
1380	fi	O
1380	##g	O
1380	.	O
1380	5	O
1380	##c	O
1380	)	O
1380	.	O
1380	[SEP]	O
1381	[CLS]	O
1381	to	O
1381	q	O
1381	##uant	O
1381	##itate	O
1381	the	O
1381	binding	O
1381	of	O
1381	ma	O
1381	##bs	O
1381	or	O
1381	d	O
1381	##v	O
1381	##d	O
1381	-	O
1381	i	O
1381	##gs	O
1381	to	O
1381	il	O
1381	-	O
1381	1	O
1381	##α	O
1381	or	O
1381	il	O
1381	-	O
1381	1	O
1381	##β	O
1381	,	O
1381	96	O
1381	-	O
1381	well	O
1381	el	O
1381	##isa	O
1381	plates	O
1381	were	O
1381	in	O
1381	##cu	O
1381	##bate	O
1381	##d	O
1381	overnight	O
1381	at	O
1381	4	O
1381	##°	O
1381	##c	O
1381	with	O
1381	anti	O
1381	-	O
1381	human	O
1381	f	O
1381	##c	O
1381	anti	O
1381	##body	O
1381	(	O
1381	jack	O
1381	##son	O
1381	im	O
1381	##mu	O
1381	##nor	O
1381	##ese	O
1381	##ar	O
1381	##ch	O
1381	,	O
1381	109	O
1381	-	O
1381	51	O
1381	##6	O
1381	-	O
1381	00	O
1381	##8	O
1381	)	O
1381	di	O
1381	##lut	O
1381	##ed	O
1381	in	O
1381	pier	O
1381	##ce	O
1381	buffer	O
1381	superb	O
1381	##lock	O
1381	(	O
1381	the	O
1381	##rm	O
1381	##o	O
1381	scientific	O
1381	,	O
1381	375	O
1381	##15	O
1381	)	O
1381	at	O
1381	a	O
1381	final	O
1381	concentration	O
1381	of	O
1381	2	O
1381	μ	O
1381	##g	O
1381	/	O
1381	m	O
1381	##l	O
1381	.	O
1381	plates	O
1381	were	O
1381	washed	O
1381	5	O
1381	times	O
1381	in	O
1381	washing	O
1381	buffer	O
1381	(	O
1381	p	O
1381	##bs	O
1381	containing	O
1381	0	O
1381	.	O
1381	05	O
1381	%	O
1381	t	O
1381	##we	O
1381	##en	O
1381	20	O
1381	)	O
1381	,	O
1381	and	O
1381	blocked	O
1381	for	O
1381	1	O
1381	hour	O
1381	at	O
1381	25	O
1381	##°	O
1381	##c	O
1381	with	O
1381	200	O
1381	μ	O
1381	##l	O
1381	per	O
1381	well	O
1381	with	O
1381	pier	O
1381	##ce	O
1381	buffer	O
1381	superb	O
1381	##lock	O
1381	.	O
1381	[SEP]	O
1382	[CLS]	O
1382	approximately	O
1382	5000	O
1382	r	O
1382	##u	O
1382	of	O
1382	goat	O
1382	anti	O
1382	-	O
1382	human	O
1382	i	O
1382	##gg	O
1382	f	O
1382	##c	O
1382	p	O
1382	##oly	O
1382	##c	O
1382	##lon	O
1382	##al	O
1382	anti	O
1382	##body	O
1382	(	O
1382	the	O
1382	##rm	O
1382	##o	O
1382	scientific	O
1382	,	O
1382	p	O
1382	##i	O
1382	-	O
1382	311	O
1382	##6	O
1382	##3	O
1382	)	O
1382	di	O
1382	##lut	O
1382	##ed	O
1382	in	O
1382	10	O
1382	mm	O
1382	sodium	O
1382	ace	O
1382	##tate	O
1382	(	O
1382	p	O
1382	##h	O
1382	4	O
1382	.	O
1382	5	O
1382	)	O
1382	was	O
1382	directly	O
1382	im	O
1382	##mo	O
1382	##bil	O
1382	##ized	O
1382	across	O
1382	a	O
1382	cm	O
1382	##5	O
1382	research	O
1382	grade	O
1382	bio	O
1382	##sen	O
1382	##sor	O
1382	chip	O
1382	using	O
1382	a	O
1382	standard	O
1382	am	O
1382	##ine	O
1382	coupling	O
1382	kit	O
1382	according	O
1382	to	O
1382	manufacturer	O
1382	'	O
1382	s	O
1382	instructions	O
1382	and	O
1382	procedures	O
1382	at	O
1382	25	O
1382	μ	O
1382	##g	O
1382	/	O
1382	m	O
1382	##l	O
1382	.	O
1382	un	O
1382	##rea	O
1382	##cted	O
1382	m	O
1382	##oi	O
1382	##eti	O
1382	##es	O
1382	on	O
1382	the	O
1382	bio	O
1382	##sen	O
1382	##sor	O
1382	surface	O
1382	were	O
1382	blocked	O
1382	with	O
1382	ethanol	O
1382	##amine	O
1382	,	O
1382	and	O
1382	modified	O
1382	car	O
1382	##box	O
1382	##yme	O
1382	##thy	O
1382	##l	O
1382	de	O
1382	##x	O
1382	##tra	O
1382	##n	O
1382	surface	O
1382	in	O
1382	flow	O
1382	##cell	O
1382	2	O
1382	and	O
1382	4	O
1382	was	O
1382	used	O
1382	as	O
1382	a	O
1382	reaction	O
1382	surface	O
1382	.	O
1382	[SEP]	O
1383	[CLS]	O
1383	a	O
1383	proportion	O
1383	of	O
1383	the	O
1383	isolated	O
1383	clone	O
1383	##s	O
1383	were	O
1383	sequence	O
1383	##d	O
1383	to	O
1383	obtain	O
1383	89	O
1383	unique	O
1383	v	O
1383	##h	O
1383	and	O
1383	41	O
1383	v	O
1383	##l	O
1383	variant	O
1383	sequences	O
1383	.	O
1383	[SEP]	O
1384	[CLS]	O
1384	rate	O
1384	constant	O
1384	##s	O
1384	were	O
1384	derived	O
1384	by	O
1384	making	O
1384	kinetic	O
1384	binding	O
1384	measurements	O
1384	of	O
1384	im	O
1384	##mu	O
1384	##no	O
1384	##g	O
1384	##lo	O
1384	##bul	O
1384	##ins	O
1384	using	O
1384	il	O
1384	-	O
1384	1	O
1384	concentrations	O
1384	ranging	O
1384	from	O
1384	10	O
1384	–	O
1384	200	O
1384	nm	O
1384	.	O
1384	un	O
1384	##mo	O
1384	##dified	O
1384	car	O
1384	##box	O
1384	##yme	O
1384	##thy	O
1384	##l	O
1384	de	O
1384	##x	O
1384	##tra	O
1384	##n	O
1384	without	O
1384	goat	O
1384	anti	O
1384	-	O
1384	mouse	O
1384	i	O
1384	##gg	O
1384	in	O
1384	flow	O
1384	cell	O
1384	1	O
1384	and	O
1384	3	O
1384	was	O
1384	used	O
1384	as	O
1384	the	O
1384	reference	O
1384	surface	O
1384	.	O
1384	[SEP]	O
1385	[CLS]	O
1385	goat	O
1385	anti	O
1385	-	O
1385	human	O
1385	i	O
1385	##gg	O
1385	f	O
1385	##c	O
1385	was	O
1385	co	O
1385	##valent	O
1385	##ly	O
1385	linked	O
1385	to	O
1385	the	O
1385	car	O
1385	##box	O
1385	##y	O
1385	met	O
1385	##hyl	O
1385	de	O
1385	##x	O
1385	##tra	O
1385	##n	O
1385	matrix	O
1385	on	O
1385	the	O
1385	cm	O
1385	##5	O
1385	bio	O
1385	##sen	O
1385	##sor	O
1385	chip	O
1385	(	O
1385	bi	O
1385	##aco	O
1385	##re	O
1385	a	O
1385	##b	O
1385	,	O
1385	br	O
1385	-	O
1385	100	O
1385	##5	O
1385	–	O
1385	30	O
1385	)	O
1385	via	O
1385	free	O
1385	am	O
1385	##ine	O
1385	groups	O
1385	using	O
1385	an	O
1385	am	O
1385	##ine	O
1385	coupling	O
1385	kit	O
1385	and	O
1385	the	O
1385	im	O
1385	##mo	O
1385	##bil	O
1385	##ization	O
1385	wizard	O
1385	option	O
1385	in	O
1385	the	O
1385	bi	O
1385	##aco	O
1385	##re	O
1385	t	O
1385	##20	O
1385	##0	O
1385	instrument	O
1385	'	O
1385	s	O
1385	controlling	O
1385	software	O
1385	.	O
1385	[SEP]	O
1386	[CLS]	O
1386	approximately	O
1386	1000	O
1386	##0	O
1386	r	O
1386	##u	O
1386	of	O
1386	goat	O
1386	anti	O
1386	‑	O
1386	human	O
1386	i	O
1386	##gg	O
1386	f	O
1386	##c	O
1386	antibodies	O
1386	were	O
1386	im	O
1386	##mo	O
1386	##bil	O
1386	##ized	O
1386	on	O
1386	the	O
1386	chip	O
1386	surface	O
1386	.	O
1386	[SEP]	O
1387	[CLS]	O
1387	a	O
1387	modified	O
1387	cm	O
1387	surface	O
1387	coated	O
1387	with	O
1387	goat	O
1387	anti	O
1387	-	O
1387	human	O
1387	f	O
1387	##c	O
1387	anti	O
1387	##body	O
1387	in	O
1387	flow	O
1387	##cell	O
1387	1	O
1387	was	O
1387	used	O
1387	as	O
1387	a	O
1387	reference	O
1387	surface	O
1387	.	O
1387	[SEP]	O
1388	[CLS]	O
1388	a	O
1388	##bt	O
1388	-	O
1388	98	O
1388	##1	O
1388	was	O
1388	di	O
1388	##lut	O
1388	##ed	O
1388	in	O
1388	h	O
1388	##bs	O
1388	-	O
1388	e	O
1388	##p	O
1388	(	O
1388	10	O
1388	mm	O
1388	he	O
1388	##pes	O
1388	[	O
1388	p	O
1388	##h	O
1388	7	O
1388	.	O
1388	4	O
1388	]	O
1388	,	O
1388	150	O
1388	mm	O
1388	na	O
1388	##c	O
1388	##l	O
1388	,	O
1388	3	O
1388	mm	O
1388	ed	O
1388	##ta	O
1388	,	O
1388	and	O
1388	0	O
1388	.	O
1388	00	O
1388	##5	O
1388	%	O
1388	surf	O
1388	##act	O
1388	##ant	O
1388	p	O
1388	##20	O
1388	)	O
1388	(	O
1388	bi	O
1388	##aco	O
1388	##re	O
1388	##®	O
1388	a	O
1388	##b	O
1388	,	O
1388	br	O
1388	##100	O
1388	##18	O
1388	##8	O
1388	)	O
1388	to	O
1388	a	O
1388	concentration	O
1388	of	O
1388	0	O
1388	.	O
1388	5	O
1388	μ	O
1388	##g	O
1388	/	O
1388	m	O
1388	##l	O
1388	and	O
1388	was	O
1388	injected	O
1388	over	O
1388	the	O
1388	goat	O
1388	anti	O
1388	-	O
1388	human	O
1388	i	O
1388	##gg	O
1388	f	O
1388	##c	O
1388	surface	O
1388	on	O
1388	flow	O
1388	cell	O
1388	3	O
1388	at	O
1388	a	O
1388	flow	O
1388	rate	O
1388	of	O
1388	5	O
1388	μ	O
1388	##l	O
1388	/	O
1388	min	O
1388	or	O
1388	10	O
1388	##ul	O
1388	/	O
1388	min	O
1388	for	O
1388	2	O
1388	minutes	O
1388	to	O
1388	achieve	O
1388	a	O
1388	capture	O
1388	level	O
1388	of	O
1388	[UNK]	O
1388	‑	O
1388	70	O
1388	##7	O
1388	r	O
1388	##u	O
1388	.	O
1388	[SEP]	O
1389	[CLS]	O
1389	maximum	B-PK
1389	plasma	I-PK
1389	concentration	I-PK
1389	(	I-PK
1389	cm	I-PK
1389	##ax	I-PK
1389	)	I-PK
1389	was	O
1389	similar	O
1389	between	O
1389	re	O
1389	##nal	O
1389	‐	O
1389	imp	O
1389	##air	O
1389	##ment	O
1389	groups	O
1389	and	O
1389	the	O
1389	normal	O
1389	‐	O
1389	re	O
1389	##nal	O
1389	‐	O
1389	function	O
1389	group	O
1389	.	O
1389	[SEP]	O
1390	[CLS]	O
1390	total	B-PK
1390	drug	I-PK
1390	clearance	I-PK
1390	from	I-PK
1390	plasma	I-PK
1390	(	I-PK
1390	c	I-PK
1390	##l	I-PK
1390	)	I-PK
1390	and	O
1390	terminal	B-PK
1390	half	I-PK
1390	‐	I-PK
1390	life	I-PK
1390	(	I-PK
1390	t	I-PK
1390	##1	I-PK
1390	/	I-PK
1390	2	I-PK
1390	)	I-PK
1390	correlated	O
1390	with	O
1390	re	O
1390	##nal	O
1390	function	O
1390	.	O
1390	[SEP]	O
1391	[CLS]	O
1391	ratios	B-PK
1391	(	I-PK
1391	90	I-PK
1391	%	I-PK
1391	confidence	I-PK
1391	intervals	I-PK
1391	)	I-PK
1391	of	I-PK
1391	area	I-PK
1391	under	I-PK
1391	the	I-PK
1391	plasma	I-PK
1391	concentration	I-PK
1391	‐	I-PK
1391	time	I-PK
1391	curve	I-PK
1391	from	I-PK
1391	0	I-PK
1391	to	I-PK
1391	in	I-PK
1391	##finity	I-PK
1391	(	I-PK
1391	au	I-PK
1391	##c	I-PK
1391	)	I-PK
1391	in	O
1391	mild	O
1391	,	O
1391	moderate	O
1391	,	O
1391	severe	O
1391	,	O
1391	and	O
1391	es	O
1391	##rd	O
1391	groups	O
1391	compared	O
1391	to	O
1391	those	O
1391	with	O
1391	normal	O
1391	re	O
1391	##nal	O
1391	function	O
1391	were	O
1391	1	O
1391	.	O
1391	0	O
1391	(	O
1391	0	O
1391	.	O
1391	8	O
1391	‐	O
1391	1	O
1391	.	O
1391	3	O
1391	)	O
1391	,	O
1391	1	O
1391	.	O
1391	5	O
1391	(	O
1391	1	O
1391	.	O
1391	2	O
1391	‐	O
1391	1	O
1391	.	O
1391	9	O
1391	)	O
1391	,	O
1391	2	O
1391	.	O
1391	5	O
1391	(	O
1391	2	O
1391	.	O
1391	0	O
1391	‐	O
1391	3	O
1391	.	O
1391	3	O
1391	)	O
1391	,	O
1391	and	O
1391	4	O
1391	.	O
1391	1	O
1391	(	O
1391	3	O
1391	.	O
1391	3	O
1391	‐	O
1391	5	O
1391	.	O
1391	2	O
1391	)	O
1391	,	O
1391	respectively	O
1391	.	O
1391	[SEP]	O
1392	[CLS]	O
1392	normal	O
1392	re	O
1392	##nal	O
1392	function	O
1392	was	O
1392	identified	O
1392	using	O
1392	the	O
1392	cock	O
1392	##croft	O
1392	‐	O
1392	g	O
1392	##ault	O
1392	equation	O
1392	calculation	O
1392	##9	O
1392	with	O
1392	c	O
1392	##rea	O
1392	##tin	O
1392	##ine	O
1392	clearance	O
1392	(	O
1392	c	O
1392	##l	O
1392	##c	O
1392	##r	O
1392	)	O
1392	≥	O
1392	90	O
1392	m	O
1392	##l	O
1392	/	O
1392	min	O
1392	without	O
1392	adjusting	O
1392	for	O
1392	body	O
1392	surface	O
1392	area	O
1392	.	O
1392	[SEP]	O
1393	[CLS]	O
1393	the	O
1393	following	O
1393	p	O
1393	##k	O
1393	parameters	O
1393	were	O
1393	calculated	O
1393	from	O
1393	the	O
1393	plasma	O
1393	concentration	O
1393	data	O
1393	for	O
1393	c	O
1393	##ef	O
1393	##ider	O
1393	##oc	O
1393	##ol	O
1393	using	O
1393	the	O
1393	non	O
1393	##com	O
1393	##par	O
1393	##tment	O
1393	##al	O
1393	methods	O
1393	in	O
1393	p	O
1393	##hoe	O
1393	##ni	O
1393	##x	O
1393	win	O
1393	##non	O
1393	##lin	O
1393	##®	O
1393	version	O
1393	6	O
1393	.	O
1393	3	O
1393	(	O
1393	c	O
1393	##ert	O
1393	##ara	O
1393	us	O
1393	##a	O
1393	,	O
1393	in	O
1393	##c	O
1393	,	O
1393	prince	O
1393	##ton	O
1393	,	O
1393	new	O
1393	jersey	O
1393	)	O
1393	:	O
1393	maximum	B-PK
1393	plasma	I-PK
1393	concentration	I-PK
1393	(	I-PK
1393	cm	I-PK
1393	##ax	I-PK
1393	)	I-PK
1393	,	O
1393	time	B-PK
1393	to	I-PK
1393	cm	I-PK
1393	##ax	I-PK
1393	(	I-PK
1393	t	I-PK
1393	##max	I-PK
1393	)	I-PK
1393	,	O
1393	area	B-PK
1393	under	I-PK
1393	the	I-PK
1393	plasma	I-PK
1393	concentration	I-PK
1393	‐	I-PK
1393	time	I-PK
1393	curve	I-PK
1393	from	I-PK
1393	0	I-PK
1393	to	I-PK
1393	the	I-PK
1393	time	I-PK
1393	of	I-PK
1393	the	I-PK
1393	last	I-PK
1393	q	I-PK
1393	##uant	I-PK
1393	##ifiable	I-PK
1393	concentration	I-PK
1393	(	I-PK
1393	au	I-PK
1393	##c	I-PK
1393	(	I-PK
1393	0	I-PK
1393	‐	I-PK
1393	t	I-PK
1393	)	I-PK
1393	)	I-PK
1393	,	O
1393	area	B-PK
1393	under	I-PK
1393	the	I-PK
1393	plasma	I-PK
1393	concentration	I-PK
1393	‐	I-PK
1393	time	I-PK
1393	curve	I-PK
1393	from	I-PK
1393	time	I-PK
1393	0	I-PK
1393	to	I-PK
1393	in	I-PK
1393	##finity	I-PK
1393	(	I-PK
1393	au	I-PK
1393	##c	I-PK
1393	)	I-PK
1393	,	O
1393	terminal	B-PK
1393	half	I-PK
1393	‐	I-PK
1393	life	I-PK
1393	(	I-PK
1393	t	I-PK
1393	##1	I-PK
1393	/	I-PK
1393	2	I-PK
1393	)	I-PK
1393	,	O
1393	total	B-PK
1393	drug	I-PK
1393	clearance	I-PK
1393	from	I-PK
1393	plasma	I-PK
1393	(	I-PK
1393	c	I-PK
1393	##l	I-PK
1393	)	I-PK
1393	,	O
1393	and	O
1393	volume	B-PK
1393	of	I-PK
1393	distribution	I-PK
1393	under	I-PK
1393	steady	I-PK
1393	‐	I-PK
1393	state	I-PK
1393	conditions	I-PK
1393	(	I-PK
1393	vs	I-PK
1393	##s	I-PK
1393	)	I-PK
1393	.	O
1393	[SEP]	O
1394	[CLS]	O
1394	au	B-PK
1394	##c	I-PK
1394	(	I-PK
1394	0	I-PK
1394	‐	I-PK
1394	t	I-PK
1394	)	I-PK
1394	and	O
1394	au	B-PK
1394	##c	I-PK
1394	were	O
1394	calculated	O
1394	with	O
1394	the	O
1394	linear	O
1394	‐	O
1394	up	O
1394	/	O
1394	log	O
1394	‐	O
1394	down	O
1394	trap	O
1394	##ez	O
1394	##oid	O
1394	##al	O
1394	method	O
1394	for	O
1394	the	O
1394	extra	O
1394	##pol	O
1394	##ation	O
1394	.	O
1394	[SEP]	O
1395	[CLS]	O
1395	fraction	B-PK
1395	of	I-PK
1395	total	I-PK
1395	drug	I-PK
1395	that	I-PK
1395	is	I-PK
1395	un	I-PK
1395	##bound	I-PK
1395	in	I-PK
1395	plasma	I-PK
1395	(	I-PK
1395	f	I-PK
1395	##u	I-PK
1395	)	I-PK
1395	was	O
1395	also	O
1395	assessed	O
1395	.	O
1395	[SEP]	O
1396	[CLS]	O
1396	cumulative	B-PK
1396	amount	I-PK
1396	of	I-PK
1396	drug	I-PK
1396	ex	I-PK
1396	##cre	I-PK
1396	##ted	I-PK
1396	unchanged	I-PK
1396	in	I-PK
1396	urine	I-PK
1396	(	I-PK
1396	a	I-PK
1396	##e	I-PK
1396	)	I-PK
1396	,	O
1396	fraction	B-PK
1396	of	I-PK
1396	dose	I-PK
1396	ex	I-PK
1396	##cre	I-PK
1396	##ted	I-PK
1396	unchanged	I-PK
1396	into	I-PK
1396	urine	I-PK
1396	(	I-PK
1396	f	I-PK
1396	##e	I-PK
1396	)	I-PK
1396	,	O
1396	and	O
1396	re	B-PK
1396	##nal	I-PK
1396	clearance	I-PK
1396	of	I-PK
1396	drug	I-PK
1396	(	I-PK
1396	c	I-PK
1396	##l	I-PK
1396	##r	I-PK
1396	)	I-PK
1396	were	O
1396	estimated	O
1396	for	O
1396	each	O
1396	subject	O
1396	with	O
1396	u	O
1396	##rina	O
1396	##ry	O
1396	ex	O
1396	##cre	O
1396	##tion	O
1396	data	O
1396	.	O
1396	[SEP]	O
1397	[CLS]	O
1397	one	O
1397	subject	O
1397	from	O
1397	the	O
1397	moderate	O
1397	imp	O
1397	##air	O
1397	##ment	O
1397	co	O
1397	##hor	O
1397	##t	O
1397	was	O
1397	premature	O
1397	##ly	O
1397	withdrawn	O
1397	from	O
1397	the	O
1397	study	O
1397	due	O
1397	to	O
1397	an	O
1397	a	O
1397	##e	O
1397	of	O
1397	u	O
1397	##rt	O
1397	##ica	O
1397	##ria	O
1397	;	O
1397	the	O
1397	subject	O
1397	received	O
1397	only	O
1397	74	O
1397	.	O
1397	2	O
1397	m	O
1397	##l	O
1397	of	O
1397	the	O
1397	re	O
1397	##con	O
1397	##stituted	O
1397	study	O
1397	drug	O
1397	instead	O
1397	of	O
1397	total	O
1397	100	O
1397	m	O
1397	##l	O
1397	.	O
1397	[SEP]	O
1398	[CLS]	O
1398	geometric	O
1398	mean	O
1398	values	O
1398	of	O
1398	cm	B-PK
1398	##ax	I-PK
1398	and	O
1398	vs	B-PK
1398	##s	I-PK
1398	were	O
1398	similar	O
1398	among	O
1398	re	O
1398	##nal	O
1398	function	O
1398	groups	O
1398	.	O
1398	[SEP]	O
1399	[CLS]	O
1399	the	O
1399	f	B-PK
1399	##u	I-PK
1399	at	O
1399	1	O
1399	and	O
1399	8	O
1399	hours	O
1399	was	O
1399	similar	O
1399	among	O
1399	re	O
1399	##nal	O
1399	function	O
1399	groups	O
1399	.	O
1399	[SEP]	O
1400	[CLS]	O
1400	by	O
1400	co	O
1400	##hor	O
1400	##t	O
1400	,	O
1400	half	O
1400	or	O
1400	fewer	O
1400	subjects	O
1400	experienced	O
1400	at	O
1400	least	O
1400	1	O
1400	a	O
1400	##e	O
1400	.	O
1400	[SEP]	O
1401	[CLS]	O
1401	the	O
1401	most	O
1401	frequently	O
1401	reported	O
1401	a	O
1401	##e	O
1401	was	O
1401	contact	O
1401	der	O
1401	##mat	O
1401	##itis	O
1401	(	O
1401	7	O
1401	.	O
1401	9	O
1401	%	O
1401	)	O
1401	,	O
1401	reported	O
1401	by	O
1401	1	O
1401	subject	O
1401	each	O
1401	in	O
1401	the	O
1401	mild	O
1401	,	O
1401	severe	O
1401	,	O
1401	and	O
1401	es	O
1401	##rd	O
1401	(	O
1401	period	O
1401	1	O
1401	)	O
1401	co	O
1401	##hor	O
1401	##ts	O
1401	.	O
1401	[SEP]	O
1402	[CLS]	O
1402	except	O
1402	for	O
1402	contact	O
1402	der	O
1402	##mat	O
1402	##itis	O
1402	,	O
1402	only	O
1402	nausea	O
1402	was	O
1402	reported	O
1402	as	O
1402	an	O
1402	a	O
1402	##e	O
1402	by	O
1402	more	O
1402	than	O
1402	1	O
1402	subject	O
1402	per	O
1402	co	O
1402	##hor	O
1402	##t	O
1402	.	O
1402	[SEP]	O
1403	[CLS]	O
1403	because	O
1403	the	O
1403	dose	O
1403	rate	O
1403	of	O
1403	de	O
1403	##x	O
1403	##med	O
1403	##eto	O
1403	##mi	O
1403	##dine	O
1403	remained	O
1403	constant	O
1403	for	O
1403	relatively	O
1403	long	O
1403	periods	O
1403	of	O
1403	time	O
1403	during	O
1403	three	O
1403	separate	O
1403	intervals	O
1403	,	O
1403	we	O
1403	calculated	O
1403	the	O
1403	plasma	B-PK
1403	clearance	I-PK
1403	of	O
1403	de	O
1403	##x	O
1403	##med	O
1403	##eto	O
1403	##mi	O
1403	##dine	O
1403	during	O
1403	these	O
1403	intervals	O
1403	by	O
1403	dividing	O
1403	the	O
1403	in	O
1403	##fusion	O
1403	rate	O
1403	by	O
1403	the	O
1403	plasma	O
1403	concentration	O
1403	.	O
1403	[SEP]	O
1404	[CLS]	O
1404	the	O
1404	calculated	O
1404	clearance	B-PK
1404	was	O
1404	55	O
1404	l	O
1404	/	O
1404	h	O
1404	,	O
1404	92	O
1404	l	O
1404	/	O
1404	h	O
1404	and	O
1404	87	O
1404	l	O
1404	/	O
1404	h	O
1404	during	O
1404	the	O
1404	2nd	O
1404	to	O
1404	6th	O
1404	,	O
1404	14th	O
1404	to	O
1404	20th	O
1404	and	O
1404	21st	O
1404	to	O
1404	23rd	O
1404	day	O
1404	of	O
1404	the	O
1404	de	O
1404	##x	O
1404	##med	O
1404	##eto	O
1404	##mi	O
1404	##dine	O
1404	in	O
1404	##fusion	O
1404	,	O
1404	respectively	O
1404	.	O
1404	[SEP]	O
1405	[CLS]	O
1405	in	O
1405	a	O
1405	two	O
1405	-	O
1405	step	O
1405	(	O
1405	parallel	O
1405	-	O
1405	group	O
1405	)	O
1405	p	O
1405	##har	O
1405	##ma	O
1405	##co	O
1405	##kin	O
1405	##etic	O
1405	trial	O
1405	with	O
1405	intensive	O
1405	blood	O
1405	sampling	O
1405	,	O
1405	we	O
1405	compared	O
1405	the	O
1405	area	B-PK
1405	under	I-PK
1405	the	I-PK
1405	concentration	I-PK
1405	-	I-PK
1405	time	I-PK
1405	curve	I-PK
1405	from	I-PK
1405	days	I-PK
1405	0	I-PK
1405	to	I-PK
1405	28	I-PK
1405	(	I-PK
1405	au	I-PK
1405	##c	I-PK
1405	##0	I-PK
1405	–	I-PK
1405	28	I-PK
1405	days	I-PK
1405	)	I-PK
1405	and	O
1405	the	O
1405	safety	O
1405	outcomes	O
1405	of	O
1405	pipe	O
1405	##ra	O
1405	##quin	O
1405	##e	O
1405	among	O
1405	malaria	O
1405	-	O
1405	un	O
1405	##in	O
1405	##fected	O
1405	hi	O
1405	##v	O
1405	+	O
1405	adults	O
1405	.	O
1405	[SEP]	O
1406	[CLS]	O
1406	pipe	O
1406	##ra	O
1406	##quin	O
1406	##e	O
1406	'	O
1406	s	O
1406	au	B-PK
1406	##c	I-PK
1406	##0	I-PK
1406	–	I-PK
1406	28	I-PK
1406	days	I-PK
1406	in	O
1406	both	O
1406	steps	O
1406	was	O
1406	43	O
1406	%	O
1406	lower	O
1406	among	O
1406	participants	O
1406	on	O
1406	e	O
1406	##fa	O
1406	##vir	O
1406	##en	O
1406	##z	O
1406	-	O
1406	based	O
1406	art	O
1406	than	O
1406	among	O
1406	art	O
1406	-	O
1406	naive	O
1406	participants	O
1406	.	O
1406	[SEP]	O
1407	[CLS]	O
1407	there	O
1407	were	O
1407	no	O
1407	significant	O
1407	differences	O
1407	in	O
1407	au	B-PK
1407	##c	I-PK
1407	##0	I-PK
1407	–	I-PK
1407	28	I-PK
1407	days	I-PK
1407	between	O
1407	the	O
1407	other	O
1407	art	O
1407	groups	O
1407	and	O
1407	the	O
1407	art	O
1407	-	O
1407	naive	O
1407	group	O
1407	in	O
1407	each	O
1407	of	O
1407	the	O
1407	two	O
1407	steps	O
1407	.	O
1407	[SEP]	O
1408	[CLS]	O
1408	participants	O
1408	in	O
1408	the	O
1408	e	O
1408	##f	O
1408	##v	O
1408	-	O
1408	art	O
1408	group	O
1408	had	O
1408	43	O
1408	%	O
1408	lower	O
1408	au	B-PK
1408	##c	I-PK
1408	##0	I-PK
1408	–	I-PK
1408	28	I-PK
1408	days	I-PK
1408	of	O
1408	pipe	O
1408	##ra	O
1408	##quin	O
1408	##e	O
1408	than	O
1408	those	O
1408	in	O
1408	the	O
1408	art	O
1408	-	O
1408	naive	O
1408	group	O
1408	(	O
1408	geometric	O
1408	mean	O
1408	ratio	O
1408	,	O
1408	0	O
1408	.	O
1408	57	O
1408	[	O
1408	90	O
1408	%	O
1408	confidence	O
1408	interval	O
1408	{	O
1408	c	O
1408	##i	O
1408	}	O
1408	,	O
1408	0	O
1408	.	O
1408	38	O
1408	to	O
1408	0	O
1408	.	O
1408	83	O
1408	]	O
1408	;	O
1408	p	O
1408	=	O
1408	0	O
1408	.	O
1408	02	O
1408	##9	O
1408	)	O
1408	.	O
1408	[SEP]	O
1409	[CLS]	O
1409	there	O
1409	were	O
1409	no	O
1409	significant	O
1409	differences	O
1409	in	O
1409	au	B-PK
1409	##c	I-PK
1409	##0	I-PK
1409	–	I-PK
1409	28	I-PK
1409	days	O
1409	among	O
1409	participants	O
1409	in	O
1409	the	O
1409	other	O
1409	art	O
1409	groups	O
1409	from	O
1409	those	O
1409	among	O
1409	participants	O
1409	in	O
1409	the	O
1409	art	O
1409	-	O
1409	naive	O
1409	group	O
1409	.	O
1409	[SEP]	O
1410	[CLS]	O
1410	pipe	O
1410	##ra	O
1410	##quin	O
1410	##e	O
1410	'	O
1410	s	O
1410	cm	B-PK
1410	##ax	I-PK
1410	was	O
1410	higher	O
1410	in	O
1410	the	O
1410	n	O
1410	##v	O
1410	##p	O
1410	-	O
1410	art	O
1410	group	O
1410	than	O
1410	in	O
1410	the	O
1410	art	O
1410	-	O
1410	naive	O
1410	group	O
1410	(	O
1410	geometric	O
1410	mean	O
1410	ratio	O
1410	,	O
1410	1	O
1410	.	O
1410	82	O
1410	[	O
1410	90	O
1410	%	O
1410	c	O
1410	##i	O
1410	,	O
1410	1	O
1410	.	O
1410	13	O
1410	to	O
1410	2	O
1410	.	O
1410	94	O
1410	]	O
1410	;	O
1410	p	O
1410	=	O
1410	0	O
1410	.	O
1410	06	O
1410	##1	O
1410	)	O
1410	,	O
1410	but	O
1410	no	O
1410	significant	O
1410	differences	O
1410	in	O
1410	cm	B-PK
1410	##ax	I-PK
1410	were	O
1410	observed	O
1410	between	O
1410	the	O
1410	rest	O
1410	of	O
1410	the	O
1410	art	O
1410	groups	O
1410	and	O
1410	the	O
1410	art	O
1410	-	O
1410	naive	O
1410	group	O
1410	.	O
1410	[SEP]	O
1411	[CLS]	O
1411	there	O
1411	were	O
1411	no	O
1411	significant	O
1411	differences	O
1411	in	O
1411	the	O
1411	t	B-PK
1411	##1	I-PK
1411	/	I-PK
1411	2	I-PK
1411	of	O
1411	pipe	O
1411	##ra	O
1411	##quin	O
1411	##e	O
1411	in	O
1411	all	O
1411	four	O
1411	study	O
1411	groups	O
1411	(	O
1411	as	O
1411	shown	O
1411	in	O
1411	table	O
1411	2	O
1411	)	O
1411	.	O
1411	[SEP]	O
1412	[CLS]	O
1412	however	O
1412	,	O
1412	the	O
1412	median	O
1412	t	B-PK
1412	##max	I-PK
1412	was	O
1412	higher	O
1412	in	O
1412	the	O
1412	l	O
1412	##p	O
1412	##v	O
1412	–	O
1412	r	O
1412	-	O
1412	art	O
1412	group	O
1412	than	O
1412	in	O
1412	the	O
1412	art	O
1412	-	O
1412	naive	O
1412	group	O
1412	(	O
1412	p	O
1412	=	O
1412	0	O
1412	.	O
1412	04	O
1412	##9	O
1412	)	O
1412	.	O
1412	[SEP]	O
1413	[CLS]	O
1413	in	O
1413	step	O
1413	2	O
1413	,	O
1413	pipe	O
1413	##ra	O
1413	##quin	O
1413	##e	O
1413	'	O
1413	s	O
1413	au	B-PK
1413	##c	I-PK
1413	##0	I-PK
1413	–	I-PK
1413	28	I-PK
1413	days	I-PK
1413	was	O
1413	43	O
1413	%	O
1413	lower	O
1413	in	O
1413	the	O
1413	e	O
1413	##f	O
1413	##v	O
1413	-	O
1413	art	O
1413	group	O
1413	than	O
1413	in	O
1413	the	O
1413	art	O
1413	-	O
1413	naive	O
1413	group	O
1413	(	O
1413	geometric	O
1413	mean	O
1413	ratio	O
1413	,	O
1413	0	O
1413	.	O
1413	57	O
1413	[	O
1413	95	O
1413	%	O
1413	c	O
1413	##i	O
1413	,	O
1413	0	O
1413	.	O
1413	44	O
1413	to	O
1413	0	O
1413	.	O
1413	74	O
1413	]	O
1413	;	O
1413	p	O
1413	=	O
1413	0	O
1413	.	O
1413	00	O
1413	##2	O
1413	)	O
1413	.	O
1413	[SEP]	O
1414	[CLS]	O
1414	there	O
1414	was	O
1414	no	O
1414	significant	O
1414	difference	O
1414	in	O
1414	pipe	O
1414	##ra	O
1414	##quin	O
1414	##e	O
1414	'	O
1414	s	O
1414	au	B-PK
1414	##c	I-PK
1414	##0	I-PK
1414	–	I-PK
1414	28	I-PK
1414	days	I-PK
1414	between	O
1414	the	O
1414	n	O
1414	##v	O
1414	##p	O
1414	-	O
1414	art	O
1414	and	O
1414	art	O
1414	-	O
1414	naive	O
1414	groups	O
1414	.	O
1414	[SEP]	O
1415	[CLS]	O
1415	further	O
1415	##more	O
1415	,	O
1415	participants	O
1415	in	O
1415	the	O
1415	e	O
1415	##f	O
1415	##v	O
1415	-	O
1415	art	O
1415	group	O
1415	had	O
1415	a	O
1415	43	O
1415	%	O
1415	lower	O
1415	cm	B-PK
1415	##ax	I-PK
1415	of	O
1415	pipe	O
1415	##ra	O
1415	##quin	O
1415	##e	O
1415	than	O
1415	the	O
1415	art	O
1415	-	O
1415	naive	O
1415	group	O
1415	(	O
1415	geometric	O
1415	mean	O
1415	ratio	O
1415	,	O
1415	0	O
1415	.	O
1415	57	O
1415	[	O
1415	95	O
1415	%	O
1415	c	O
1415	##i	O
1415	,	O
1415	0	O
1415	.	O
1415	36	O
1415	to	O
1415	0	O
1415	.	O
1415	90	O
1415	]	O
1415	;	O
1415	p	O
1415	=	O
1415	0	O
1415	.	O
1415	06	O
1415	##5	O
1415	)	O
1415	,	O
1415	and	O
1415	pipe	O
1415	##ra	O
1415	##quin	O
1415	##e	O
1415	'	O
1415	s	O
1415	t	B-PK
1415	##1	I-PK
1415	/	I-PK
1415	2	I-PK
1415	was	O
1415	64	O
1415	%	O
1415	lower	O
1415	in	O
1415	the	O
1415	e	O
1415	##f	O
1415	##v	O
1415	-	O
1415	art	O
1415	group	O
1415	than	O
1415	in	O
1415	the	O
1415	art	O
1415	-	O
1415	naive	O
1415	group	O
1415	(	O
1415	geometric	O
1415	mean	O
1415	ratio	O
1415	,	O
1415	0	O
1415	.	O
1415	36	O
1415	[	O
1415	95	O
1415	%	O
1415	c	O
1415	##i	O
1415	,	O
1415	0	O
1415	.	O
1415	15	O
1415	to	O
1415	0	O
1415	.	O
1415	87	O
1415	]	O
1415	;	O
1415	p	O
1415	=	O
1415	0	O
1415	.	O
1415	07	O
1415	##2	O
1415	)	O
1415	.	O
1415	[SEP]	O
1416	[CLS]	O
1416	however	O
1416	,	O
1416	there	O
1416	were	O
1416	no	O
1416	significant	O
1416	differences	O
1416	in	O
1416	the	O
1416	cm	B-PK
1416	##ax	I-PK
1416	and	O
1416	t	B-PK
1416	##1	I-PK
1416	/	I-PK
1416	2	I-PK
1416	of	O
1416	pipe	O
1416	##ra	O
1416	##quin	O
1416	##e	O
1416	between	O
1416	the	O
1416	n	O
1416	##v	O
1416	##p	O
1416	-	O
1416	art	O
1416	and	O
1416	the	O
1416	art	O
1416	-	O
1416	naive	O
1416	groups	O
1416	,	O
1416	as	O
1416	shown	O
1416	in	O
1416	table	O
1416	3	O
1416	.	O
1416	[SEP]	O
1417	[CLS]	O
1417	similarly	O
1417	,	O
1417	no	O
1417	significant	O
1417	differences	O
1417	in	O
1417	the	O
1417	median	O
1417	t	B-PK
1417	##max	I-PK
1417	between	O
1417	the	O
1417	two	O
1417	art	O
1417	groups	O
1417	and	O
1417	the	O
1417	art	O
1417	-	O
1417	naive	O
1417	group	O
1417	were	O
1417	observed	O
1417	.	O
1417	[SEP]	O
1418	[CLS]	O
1418	assuming	O
1418	a	O
1418	linear	O
1418	disposition	O
1418	of	O
1418	pipe	O
1418	##ra	O
1418	##quin	O
1418	##e	O
1418	,	O
1418	increasing	O
1418	the	O
1418	dose	O
1418	in	O
1418	step	O
1418	2	O
1418	should	O
1418	result	O
1418	in	O
1418	an	O
1418	increased	O
1418	au	B-PK
1418	##c	I-PK
1418	##0	I-PK
1418	–	I-PK
1418	28	I-PK
1418	days	I-PK
1418	in	O
1418	this	O
1418	step	O
1418	compared	O
1418	to	O
1418	that	O
1418	in	O
1418	step	O
1418	1	O
1418	.	O
1418	[SEP]	O
1419	[CLS]	O
1419	as	O
1419	part	O
1419	of	O
1419	an	O
1419	ex	O
1419	##p	O
1419	##lora	O
1419	##tory	O
1419	analysis	O
1419	,	O
1419	not	O
1419	determined	O
1419	a	O
1419	prior	O
1419	##i	O
1419	,	O
1419	we	O
1419	assessed	O
1419	dose	O
1419	proportional	O
1419	##ity	O
1419	between	O
1419	the	O
1419	art	O
1419	-	O
1419	naive	O
1419	groups	O
1419	in	O
1419	steps	O
1419	1	O
1419	and	O
1419	2	O
1419	using	O
1419	a	O
1419	linear	O
1419	q	O
1419	##uad	O
1419	##ratic	O
1419	re	O
1419	##gression	O
1419	approach	O
1419	by	O
1419	re	O
1419	##g	O
1419	##ress	O
1419	##ing	O
1419	dose	B-PK
1419	-	I-PK
1419	normal	I-PK
1419	##ized	I-PK
1419	au	I-PK
1419	##c	I-PK
1419	##0	I-PK
1419	–	I-PK
1419	28	I-PK
1419	days	I-PK
1419	(	I-PK
1419	au	I-PK
1419	##c	I-PK
1419	##0	I-PK
1419	–	I-PK
1419	28	I-PK
1419	days	I-PK
1419	/	I-PK
1419	dose	I-PK
1419	)	I-PK
1419	with	O
1419	the	O
1419	total	O
1419	dose	O
1419	received	O
1419	by	O
1419	each	O
1419	participant	O
1419	(	O
1419	20	O
1419	)	O
1419	.	O
1419	[SEP]	O
1420	[CLS]	O
1420	the	O
1420	fitted	O
1420	linear	O
1420	re	O
1420	##gression	O
1420	equation	O
1420	was	O
1420	(	O
1420	1	O
1420	)	O
1420	au	O
1420	##c	O
1420	##0	O
1420	##−	O
1420	##28	O
1420	days	O
1420	/	O
1420	dose	O
1420	=	O
1420	α	O
1420	+	O
1420	β	O
1420	##1	O
1420	##⋅	O
1420	##dos	O
1420	##e	O
1420	+	O
1420	β	O
1420	##2	O
1420	##⋅	O
1420	##dos	O
1420	##e	O
1420	##2	O
1420	[SEP]	O
1421	[CLS]	O
1421	equation	O
1421	1	O
1421	could	O
1421	be	O
1421	further	O
1421	simplified	O
1421	to	O
1421	equation	O
1421	3	O
1421	when	O
1421	β	O
1421	##2	O
1421	is	O
1421	not	O
1421	significantly	O
1421	different	O
1421	from	O
1421	zero	O
1421	:	O
1421	(	O
1421	2	O
1421	)	O
1421	au	O
1421	##c	O
1421	##0	O
1421	##−	O
1421	##28	O
1421	days	O
1421	/	O
1421	dose	O
1421	=	O
1421	α	O
1421	+	O
1421	β	O
1421	##⋅	O
1421	##dos	O
1421	##e	O
1421	[SEP]	O
1422	[CLS]	O
1422	this	O
1422	was	O
1422	calculated	O
1422	to	O
1422	detect	O
1422	a	O
1422	2	O
1422	-	O
1422	fold	O
1422	increase	O
1422	in	O
1422	the	O
1422	p	O
1422	##q	O
1422	au	B-PK
1422	##c	I-PK
1422	in	O
1422	any	O
1422	of	O
1422	the	O
1422	d	O
1422	##ha	O
1422	-	O
1422	p	O
1422	##q	O
1422	-	O
1422	art	O
1422	groups	O
1422	compared	O
1422	with	O
1422	that	O
1422	in	O
1422	the	O
1422	art	O
1422	-	O
1422	naive	O
1422	group	O
1422	,	O
1422	assuming	O
1422	a	O
1422	mean	O
1422	p	O
1422	##q	O
1422	au	B-PK
1422	##c	I-PK
1422	of	O
1422	19	O
1422	.	O
1422	4	O
1422	μ	O
1422	##g	O
1422	·	O
1422	h	O
1422	/	O
1422	m	O
1422	##l	O
1422	(	O
1422	standard	O
1422	de	O
1422	##viation	O
1422	,	O
1422	15	O
1422	.	O
1422	0	O
1422	μ	O
1422	##g	O
1422	·	O
1422	h	O
1422	/	O
1422	m	O
1422	##l	O
1422	)	O
1422	(	O
1422	17	O
1422	)	O
1422	in	O
1422	the	O
1422	art	O
1422	-	O
1422	naive	O
1422	group	O
1422	,	O
1422	with	O
1422	the	O
1422	power	O
1422	set	O
1422	at	O
1422	90	O
1422	%	O
1422	and	O
1422	the	O
1422	level	O
1422	of	O
1422	significance	O
1422	set	O
1422	at	O
1422	5	O
1422	%	O
1422	.	O
1422	[SEP]	O
1423	[CLS]	O
1423	for	O
1423	each	O
1423	study	O
1423	participant	O
1423	,	O
1423	the	O
1423	following	O
1423	p	O
1423	##k	O
1423	parameters	O
1423	were	O
1423	com	O
1423	##puted	O
1423	:	O
1423	au	B-PK
1423	##c	I-PK
1423	##0	I-PK
1423	–	I-PK
1423	28	I-PK
1423	days	I-PK
1423	,	O
1423	maximum	B-PK
1423	concentration	I-PK
1423	(	I-PK
1423	cm	I-PK
1423	##ax	I-PK
1423	)	I-PK
1423	,	O
1423	the	O
1423	time	B-PK
1423	to	I-PK
1423	the	I-PK
1423	maximum	I-PK
1423	concentration	I-PK
1423	(	I-PK
1423	t	I-PK
1423	##max	I-PK
1423	)	I-PK
1423	,	O
1423	and	O
1423	the	O
1423	terminal	B-PK
1423	elimination	I-PK
1423	half	I-PK
1423	-	I-PK
1423	life	I-PK
1423	(	I-PK
1423	t	I-PK
1423	##1	I-PK
1423	/	I-PK
1423	2	I-PK
1423	)	I-PK
1423	.	O
1423	[SEP]	O
1424	[CLS]	O
1424	so	O
1424	##y	O
1424	is	O
1424	##of	O
1424	##lav	O
1424	##ones	O
1424	have	O
1424	also	O
1424	been	O
1424	shown	O
1424	to	O
1424	reduce	O
1424	the	O
1424	efficacy	O
1424	of	O
1424	ta	O
1424	##mo	O
1424	##xi	O
1424	##fen	O
1424	##17	O
1424	.	O
1424	[SEP]	O
1425	[CLS]	O
1425	specifically	O
1425	,	O
1425	v	O
1425	##pa	O
1425	cm	B-PK
1425	##ax	I-PK
1425	values	O
1425	were	O
1425	decreased	O
1425	to	O
1425	57	O
1425	%	O
1425	for	O
1425	150	O
1425	mg	O
1425	so	O
1425	##y	O
1425	and	O
1425	65	O
1425	%	O
1425	for	O
1425	500	O
1425	mg	O
1425	so	O
1425	##y	O
1425	treatments	O
1425	.	O
1425	[SEP]	O
1426	[CLS]	O
1426	the	O
1426	v	O
1426	##pa	O
1426	t	B-PK
1426	##max	I-PK
1426	and	O
1426	m	B-PK
1426	##rt	I-PK
1426	were	O
1426	not	O
1426	different	O
1426	among	O
1426	the	O
1426	treatments	O
1426	.	O
1426	[SEP]	O
1427	[CLS]	O
1427	similarly	O
1427	,	O
1427	au	B-PK
1427	##c	I-PK
1427	decreased	O
1427	to	O
1427	83	O
1427	%	O
1427	and	O
1427	69	O
1427	%	O
1427	for	O
1427	150	O
1427	mg	O
1427	/	O
1427	kg	O
1427	and	O
1427	500	O
1427	mg	O
1427	/	O
1427	kg	O
1427	so	O
1427	##y	O
1427	treatments	O
1427	,	O
1427	respectively	O
1427	.	O
1427	[SEP]	O
1428	[CLS]	O
1428	clearance	B-PK
1428	increased	O
1428	by	O
1428	5	O
1428	%	O
1428	to	O
1428	34	O
1428	%	O
1428	and	O
1428	the	O
1428	volume	B-PK
1428	of	I-PK
1428	distribution	I-PK
1428	increased	O
1428	70	O
1428	%	O
1428	in	O
1428	the	O
1428	so	O
1428	##y	O
1428	treatment	O
1428	groups	O
1428	.	O
1428	[SEP]	O
1429	[CLS]	O
1429	there	O
1429	was	O
1429	a	O
1429	significant	O
1429	difference	O
1429	in	O
1429	cm	B-PK
1429	##ax	I-PK
1429	,	O
1429	t	B-PK
1429	##1	I-PK
1429	/	I-PK
1429	2	I-PK
1429	,	O
1429	au	B-PK
1429	##c	I-PK
1429	,	O
1429	clearance	B-PK
1429	,	O
1429	and	O
1429	distribution	B-PK
1429	volume	I-PK
1429	between	O
1429	the	O
1429	so	O
1429	##y	O
1429	treatment	O
1429	and	O
1429	control	O
1429	groups	O
1429	(	O
1429	table	O
1429	i	O
1429	)	O
1429	.	O
1429	[SEP]	O
1430	[CLS]	O
1430	v	O
1430	##pa	O
1430	is	O
1430	meta	O
1430	##bol	O
1430	##ized	O
1430	to	O
1430	a	O
1430	g	O
1430	##lu	O
1430	##cu	O
1430	##ron	O
1430	##ide	O
1430	for	O
1430	easy	O
1430	removal	O
1430	through	O
1430	the	O
1430	urine	O
1430	##24	O
1430	.	O
1430	[SEP]	O
1431	[CLS]	O
1431	the	O
1431	area	B-PK
1431	under	I-PK
1431	the	I-PK
1431	plasma	I-PK
1431	concentration	I-PK
1431	–	I-PK
1431	time	I-PK
1431	curve	I-PK
1431	(	I-PK
1431	au	I-PK
1431	##c	I-PK
1431	)	I-PK
1431	was	O
1431	calculated	O
1431	using	O
1431	the	O
1431	linear	O
1431	trap	O
1431	##ez	O
1431	##oid	O
1431	##al	O
1431	method	O
1431	.	O
1431	[SEP]	O
1432	[CLS]	O
1432	the	O
1432	maximum	B-PK
1432	plasma	I-PK
1432	concentration	I-PK
1432	(	I-PK
1432	cm	I-PK
1432	##ax	I-PK
1432	)	I-PK
1432	and	O
1432	the	O
1432	time	B-PK
1432	to	I-PK
1432	reach	I-PK
1432	the	I-PK
1432	maximum	I-PK
1432	plasma	I-PK
1432	concentration	I-PK
1432	(	I-PK
1432	t	I-PK
1432	##max	I-PK
1432	)	I-PK
1432	were	O
1432	calculated	O
1432	from	O
1432	the	O
1432	experimental	O
1432	data	O
1432	.	O
1432	[SEP]	O
1433	[CLS]	O
1433	the	O
1433	elimination	B-PK
1433	rate	I-PK
1433	constant	I-PK
1433	(	I-PK
1433	k	I-PK
1433	##el	I-PK
1433	)	I-PK
1433	was	O
1433	estimated	O
1433	by	O
1433	re	O
1433	##gression	O
1433	analysis	O
1433	from	O
1433	the	O
1433	slope	O
1433	the	O
1433	line	O
1433	of	O
1433	best	O
1433	fit	O
1433	,	O
1433	and	O
1433	the	O
1433	half	B-PK
1433	-	I-PK
1433	life	I-PK
1433	(	I-PK
1433	t	I-PK
1433	##1	I-PK
1433	/	I-PK
1433	2	I-PK
1433	)	I-PK
1433	of	O
1433	the	O
1433	drug	O
1433	was	O
1433	obtained	O
1433	as	O
1433	##0	O
1433	.	O
1433	69	O
1433	##3	O
1433	/	O
1433	k	O
1433	##el	O
1433	.	O
1433	[SEP]	O
1434	[CLS]	O
1434	the	O
1434	dose	B-PK
1434	/	I-PK
1434	au	I-PK
1434	##c	I-PK
1434	values	O
1434	were	O
1434	used	O
1434	to	O
1434	calculate	O
1434	total	B-PK
1434	plasma	I-PK
1434	clearance	I-PK
1434	.	O
1434	[SEP]	O
1435	[CLS]	O
1435	this	O
1435	example	O
1435	illustrate	O
1435	##s	O
1435	how	O
1435	the	O
1435	approach	O
1435	connects	O
1435	the	O
1435	ca	O
1435	##usal	O
1435	chain	O
1435	underlying	O
1435	drug	O
1435	distribution	O
1435	,	O
1435	starting	O
1435	with	O
1435	the	O
1435	technical	O
1435	aspect	O
1435	of	O
1435	drug	O
1435	delivery	O
1435	systems	O
1435	,	O
1435	through	O
1435	physiology	O
1435	-	O
1435	driven	O
1435	drug	O
1435	transport	O
1435	,	O
1435	then	O
1435	eventually	O
1435	linking	O
1435	to	O
1435	tissue	O
1435	penetration	O
1435	,	O
1435	binding	O
1435	,	O
1435	residence	O
1435	,	O
1435	and	O
1435	ultimately	O
1435	clearance	B-PK
1435	.	O
1435	[SEP]	O
1436	[CLS]	O
1436	the	O
1436	temporal	O
1436	distribution	O
1436	pattern	O
1436	could	O
1436	be	O
1436	described	O
1436	by	O
1436	a	O
1436	series	O
1436	of	O
1436	ex	O
1436	##po	O
1436	##nent	O
1436	##ial	O
1436	terms	O
1436	but	O
1436	e	O
1436	##qua	O
1436	##ting	O
1436	the	O
1436	ex	O
1436	##po	O
1436	##nent	O
1436	##ial	O
1436	terms	O
1436	to	O
1436	volumes	B-PK
1436	and	O
1436	clearance	B-PK
1436	##s	I-PK
1436	did	O
1436	not	O
1436	result	O
1436	in	O
1436	values	O
1436	that	O
1436	had	O
1436	p	O
1436	##hy	O
1436	##sio	O
1436	##log	O
1436	##ic	O
1436	meaning	O
1436	.	O
1436	[SEP]	O
1437	[CLS]	O
1437	in	O
1437	v	O
1437	##ivo	O
1437	skin	O
1437	micro	O
1437	##dial	O
1437	##ys	O
1437	##is	O
1437	showed	O
1437	that	O
1437	the	O
1437	peak	B-PK
1437	concentration	I-PK
1437	and	O
1437	area	B-PK
1437	under	I-PK
1437	the	I-PK
1437	curve	I-PK
1437	of	I-PK
1437	ps	I-PK
1437	##oral	I-PK
1437	##en	I-PK
1437	from	I-PK
1437	et	I-PK
1437	##hos	I-PK
1437	##ome	I-PK
1437	##s	I-PK
1437	were	O
1437	approximately	O
1437	3	O
1437	.	O
1437	37	O
1437	and	O
1437	2	O
1437	.	O
1437	34	O
1437	times	O
1437	higher	O
1437	,	O
1437	respectively	O
1437	,	O
1437	than	O
1437	those	O
1437	of	O
1437	ps	O
1437	##oral	O
1437	##en	O
1437	from	O
1437	the	O
1437	tin	O
1437	##cture	O
1437	.	O
1437	[SEP]	O
1438	[CLS]	O
1438	both	O
1438	values	O
1438	of	O
1438	f	O
1438	were	O
1438	less	O
1438	than	O
1438	f	O
1438	##0	O
1438	.	O
1438	05	O
1438	(	O
1438	2	O
1438	,	O
1438	2	O
1438	)	O
1438	,	O
1438	with	O
1438	the	O
1438	value	O
1438	19	O
1438	.	O
1438	00	O
1438	indicating	O
1438	that	O
1438	the	O
1438	re	O
1438	##gression	O
1438	equations	O
1438	were	O
1438	not	O
1438	statistical	O
1438	##ly	O
1438	significant	O
1438	,	O
1438	and	O
1438	the	O
1438	arranged	O
1438	et	O
1438	##hos	O
1438	##ome	O
1438	compositions	O
1438	had	O
1438	no	O
1438	significant	O
1438	effect	O
1438	on	O
1438	e	O
1438	##e	O
1438	or	O
1438	d	O
1438	##s	O
1438	##d	O
1438	.	O
1438	[SEP]	O
1439	[CLS]	O
1439	after	O
1439	30	O
1439	minutes	O
1439	,	O
1439	the	O
1439	higher	O
1439	drug	O
1439	concentration	O
1439	in	O
1439	the	O
1439	skin	O
1439	was	O
1439	obtained	O
1439	with	O
1439	the	O
1439	et	O
1439	##hos	O
1439	##ome	O
1439	formulation	O
1439	,	O
1439	with	O
1439	the	O
1439	peak	B-PK
1439	concentration	I-PK
1439	(	I-PK
1439	cm	I-PK
1439	##ax	I-PK
1439	)	I-PK
1439	observed	O
1439	3	O
1439	hours	O
1439	after	O
1439	application	O
1439	.	O
1439	[SEP]	O
1440	[CLS]	O
1440	during	O
1440	the	O
1440	study	O
1440	,	O
1440	compared	O
1440	to	O
1440	tin	O
1440	##cture	O
1440	application	O
1440	,	O
1440	et	O
1440	##hos	O
1440	##ome	O
1440	application	O
1440	was	O
1440	associated	O
1440	with	O
1440	a	O
1440	higher	O
1440	ps	O
1440	##oral	O
1440	##en	O
1440	concentration	O
1440	,	O
1440	and	O
1440	the	O
1440	topic	B-PK
1440	##al	I-PK
1440	area	I-PK
1440	under	I-PK
1440	the	I-PK
1440	concentration	I-PK
1440	-	I-PK
1440	time	I-PK
1440	curve	I-PK
1440	(	I-PK
1440	au	I-PK
1440	##c	I-PK
1440	##0	I-PK
1440	–	I-PK
1440	t	I-PK
1440	)	I-PK
1440	of	O
1440	the	O
1440	et	O
1440	##hos	O
1440	##ome	O
1440	##s	O
1440	was	O
1440	2	O
1440	.	O
1440	34	O
1440	-	O
1440	fold	O
1440	higher	O
1440	than	O
1440	that	O
1440	of	O
1440	the	O
1440	tin	O
1440	##cture	O
1440	(	O
1440	table	O
1440	3	O
1440	)	O
1440	.	O
1440	[SEP]	O
1441	[CLS]	O
1441	the	O
1441	au	B-PK
1441	##c	I-PK
1441	##0	I-PK
1441	–	I-PK
1441	t	I-PK
1441	in	O
1441	the	O
1441	abdomen	O
1441	was	O
1441	higher	O
1441	than	O
1441	those	O
1441	in	O
1441	the	O
1441	chest	O
1441	and	O
1441	s	O
1441	##cap	O
1441	##ular	O
1441	regions	O
1441	.	O
1441	[SEP]	O
1442	[CLS]	O
1442	figure	O
1442	2	O
1442	##e	O
1442	,	O
1442	f	O
1442	illustrate	O
1442	##s	O
1442	the	O
1442	in	O
1442	##test	O
1442	##inal	O
1442	stability	O
1442	of	O
1442	pm	O
1442	##x	O
1442	##53	O
1442	and	O
1442	pm	O
1442	##x	O
1442	##20	O
1442	##5	O
1442	when	O
1442	in	O
1442	##cu	O
1442	##bate	O
1442	##d	O
1442	at	O
1442	37	O
1442	°	O
1442	##c	O
1442	for	O
1442	up	O
1442	to	O
1442	60	O
1442	min	O
1442	.	O
1442	[SEP]	O
1443	[CLS]	O
1443	additionally	O
1443	,	O
1443	the	O
1443	half	B-PK
1443	-	I-PK
1443	life	I-PK
1443	and	O
1443	mean	B-PK
1443	residence	I-PK
1443	time	I-PK
1443	of	O
1443	pm	O
1443	##x	O
1443	##53	O
1443	and	O
1443	pm	O
1443	##x	O
1443	##20	O
1443	##5	O
1443	are	O
1443	relatively	O
1443	short	O
1443	(	O
1443	table	O
1443	5	O
1443	)	O
1443	.	O
1443	[SEP]	O
1444	[CLS]	O
1444	pm	O
1444	##x	O
1444	##20	O
1444	##5	O
1444	demonstrated	O
1444	overall	O
1444	higher	O
1444	concentrations	O
1444	in	O
1444	blood	O
1444	,	O
1444	brain	O
1444	and	O
1444	spinal	O
1444	cord	O
1444	,	O
1444	compared	O
1444	to	O
1444	pm	O
1444	##x	O
1444	##53	O
1444	,	O
1444	as	O
1444	reflected	O
1444	by	O
1444	its	O
1444	higher	O
1444	cm	B-PK
1444	##ax	I-PK
1444	values	O
1444	.	O
1444	[SEP]	O
1445	[CLS]	O
1445	however	O
1445	,	O
1445	pm	O
1445	##x	O
1445	##20	O
1445	##5	O
1445	also	O
1445	displayed	O
1445	faster	O
1445	clearance	B-PK
1445	compared	O
1445	to	O
1445	pm	O
1445	##x	O
1445	##53	O
1445	,	O
1445	potentially	O
1445	due	O
1445	to	O
1445	its	O
1445	more	O
1445	lip	O
1445	##op	O
1445	##hil	O
1445	##ic	O
1445	nature	O
1445	.	O
1445	[SEP]	O
1446	[CLS]	O
1446	the	O
1446	plasma	B-PK
1446	and	O
1446	tissue	B-PK
1446	volume	I-PK
1446	of	I-PK
1446	distribution	I-PK
1446	of	O
1446	pm	O
1446	##x	O
1446	##53	O
1446	was	O
1446	also	O
1446	higher	O
1446	compared	O
1446	to	O
1446	pm	O
1446	##x	O
1446	##20	O
1446	##5	O
1446	,	O
1446	however	O
1446	pm	O
1446	##x	O
1446	##20	O
1446	##5	O
1446	had	O
1446	higher	O
1446	absolute	O
1446	concentrations	O
1446	in	O
1446	the	O
1446	brain	O
1446	and	O
1446	spinal	O
1446	cord	O
1446	over	O
1446	the	O
1446	time	O
1446	-	O
1446	frame	O
1446	examined	O
1446	.	O
1446	[SEP]	O
1447	[CLS]	O
1447	me	O
1447	##rop	O
1447	##ene	O
1447	##m	O
1447	was	O
1447	cleared	O
1447	from	O
1447	the	O
1447	central	O
1447	compartment	O
1447	(	O
1447	clearance	B-PK
1447	in	O
1447	litre	O
1447	##s	O
1447	per	O
1447	hour	O
1447	)	O
1447	,	O
1447	which	O
1447	also	O
1447	has	O
1447	a	O
1447	volume	B-PK
1447	(	I-PK
1447	v	I-PK
1447	##c	I-PK
1447	;	O
1447	given	O
1447	in	O
1447	litre	O
1447	##s	O
1447	)	O
1447	.	O
1447	[SEP]	O
1448	[CLS]	O
1448	blood	O
1448	samples	O
1448	(	O
1448	4	O
1448	m	O
1448	##l	O
1448	)	O
1448	were	O
1448	collected	O
1448	using	O
1448	the	O
1448	in	O
1448	##d	O
1448	##well	O
1448	##ing	O
1448	art	O
1448	##erial	O
1448	cat	O
1448	##he	O
1448	##ter	O
1448	just	O
1448	before	O
1448	the	O
1448	start	O
1448	of	O
1448	the	O
1448	in	O
1448	##fusion	O
1448	(	O
1448	serum	B-PK
1448	t	I-PK
1448	##rough	I-PK
1448	concentration	I-PK
1448	[	I-PK
1448	cm	I-PK
1448	##in	I-PK
1448	]	I-PK
1448	)	O
1448	and	O
1448	after	O
1448	the	O
1448	end	O
1448	of	O
1448	the	O
1448	in	O
1448	##fusion	O
1448	(	O
1448	serum	B-PK
1448	peak	I-PK
1448	concentration	I-PK
1448	[	I-PK
1448	cm	I-PK
1448	##ax	I-PK
1448	]	I-PK
1448	)	O
1448	.	O
1448	[SEP]	O
1449	[CLS]	O
1449	k	B-PK
1449	##c	I-PK
1449	##p	I-PK
1449	,	O
1449	k	B-PK
1449	##p	I-PK
1449	##c	I-PK
1449	,	O
1449	k	B-PK
1449	##c	I-PK
1449	##b	I-PK
1449	and	O
1449	k	B-PK
1449	##b	I-PK
1449	##c	I-PK
1449	represent	O
1449	first	B-PK
1449	-	I-PK
1449	order	I-PK
1449	transfer	I-PK
1449	constant	I-PK
1449	##s	I-PK
1449	connecting	O
1449	the	O
1449	various	O
1449	compartment	O
1449	##s	O
1449	.	O
1449	[SEP]	O
1450	[CLS]	O
1450	the	O
1450	impact	O
1450	of	O
1450	weight	O
1450	,	O
1450	c	O
1450	##rc	O
1450	##l	O
1450	,	O
1450	bi	O
1450	##li	O
1450	##ru	O
1450	##bin	O
1450	,	O
1450	serum	O
1450	c	O
1450	##rp	O
1450	,	O
1450	serum	O
1450	il	O
1450	-	O
1450	6	O
1450	,	O
1450	serum	O
1450	p	O
1450	##ct	O
1450	,	O
1450	serum	O
1450	le	O
1450	##uc	O
1450	##ocytes	O
1450	,	O
1450	c	O
1450	##s	O
1450	##f	O
1450	cells	O
1450	,	O
1450	c	O
1450	##s	O
1450	##f	O
1450	er	O
1450	##yt	O
1450	##hr	O
1450	##ocytes	O
1450	,	O
1450	c	O
1450	##s	O
1450	##f	O
1450	il	O
1450	-	O
1450	6	O
1450	,	O
1450	c	O
1450	##s	O
1450	##f	O
1450	glucose	O
1450	,	O
1450	c	O
1450	##s	O
1450	##f	O
1450	protein	O
1450	,	O
1450	c	O
1450	##s	O
1450	##f	O
1450	drain	O
1450	in	O
1450	24	O
1450	h	O
1450	,	O
1450	sa	O
1450	##ps	O
1450	ii	O
1450	,	O
1450	sofa	O
1450	score	O
1450	and	O
1450	g	O
1450	##cs	O
1450	as	O
1450	co	O
1450	##var	O
1450	##iate	O
1450	##s	O
1450	was	O
1450	initially	O
1450	assessed	O
1450	by	O
1450	visual	O
1450	inspection	O
1450	.	O
1450	[SEP]	O
1451	[CLS]	O
1451	cm	B-PK
1451	##ax	I-PK
1451	and	O
1451	cm	B-PK
1451	##in	I-PK
1451	in	O
1451	serum	O
1451	and	O
1451	ca	O
1451	##fter	O
1451	4	O
1451	h	O
1451	and	O
1451	c	B-PK
1451	##tro	I-PK
1451	##ug	I-PK
1451	h	I-PK
1451	in	O
1451	c	O
1451	##s	O
1451	##f	O
1451	are	O
1451	the	O
1451	observed	O
1451	values	O
1451	.	O
1451	[SEP]	O
1452	[CLS]	O
1452	the	O
1452	average	O
1452	au	B-PK
1452	##c	I-PK
1452	for	O
1452	each	O
1452	patient	O
1452	was	O
1452	calculated	O
1452	using	O
1452	the	O
1452	bay	O
1452	##esi	O
1452	##an	O
1452	posterior	O
1452	para	O
1452	##metric	O
1452	estimates	O
1452	from	O
1452	the	O
1452	final	O
1452	model	O
1452	using	O
1452	the	O
1452	trap	O
1452	##ez	O
1452	##oid	O
1452	##al	O
1452	rule	O
1452	in	O
1452	pm	O
1452	##et	O
1452	##ric	O
1452	##s	O
1452	.	O
1452	[SEP]	O
1453	[CLS]	O
1453	we	O
1453	divided	O
1453	each	O
1453	subject	O
1453	’	O
1453	s	O
1453	cumulative	B-PK
1453	au	I-PK
1453	##c	I-PK
1453	(	I-PK
1453	au	I-PK
1453	##c	I-PK
1453	##f	I-PK
1453	)	I-PK
1453	by	O
1453	the	O
1453	total	O
1453	time	O
1453	in	O
1453	hours	O
1453	and	O
1453	multi	O
1453	##plied	O
1453	the	O
1453	result	O
1453	by	O
1453	24	O
1453	to	O
1453	estimate	O
1453	the	O
1453	daily	O
1453	average	O
1453	au	B-PK
1453	##c	I-PK
1453	(	I-PK
1453	au	I-PK
1453	##c	I-PK
1453	##0	I-PK
1453	–	I-PK
1453	24	I-PK
1453	)	I-PK
1453	.	O
1453	[SEP]	O
1454	[CLS]	O
1454	half	B-PK
1454	-	I-PK
1454	life	I-PK
1454	was	O
1454	calculated	O
1454	using	O
1454	transfer	B-PK
1454	rate	I-PK
1454	constant	I-PK
1454	##s	I-PK
1454	.	O
1454	[SEP]	O
1455	[CLS]	O
1455	c	O
1455	##rc	O
1455	##l	O
1455	was	O
1455	calculated	O
1455	using	O
1455	the	O
1455	cock	O
1455	##croft	O
1455	-	O
1455	g	O
1455	##ault	O
1455	equation	O
1455	[	O
1455	16	O
1455	]	O
1455	.	O
1455	[SEP]	O
1456	[CLS]	O
1456	briefly	O
1456	,	O
1456	the	O
1456	study	O
1456	population	O
1456	was	O
1456	relatively	O
1456	young	O
1456	(	O
1456	median	O
1456	age	O
1456	52	O
1456	years	O
1456	,	O
1456	range	O
1456	46	O
1456	–	O
1456	80	O
1456	years	O
1456	)	O
1456	and	O
1456	had	O
1456	well	O
1456	-	O
1456	preserved	O
1456	re	O
1456	##nal	O
1456	function	O
1456	on	O
1456	the	O
1456	day	O
1456	of	O
1456	inclusion	O
1456	(	O
1456	median	O
1456	c	O
1456	##rc	O
1456	##l	O
1456	120	O
1456	.	O
1456	1	O
1456	m	O
1456	##l	O
1456	/	O
1456	minute	O
1456	,	O
1456	range	O
1456	52	O
1456	.	O
1456	3	O
1456	–	O
1456	217	O
1456	.	O
1456	6	O
1456	m	O
1456	##l	O
1456	/	O
1456	minute	O
1456	)	O
1456	.	O
1456	[SEP]	O
1457	[CLS]	O
1457	in	O
1457	serum	O
1457	,	O
1457	the	O
1457	median	O
1457	cm	B-PK
1457	##ax	I-PK
1457	(	O
1457	range	O
1457	)	O
1457	was	O
1457	20	O
1457	.	O
1457	16	O
1457	(	O
1457	4	O
1457	.	O
1457	40	O
1457	–	O
1457	69	O
1457	.	O
1457	00	O
1457	)	O
1457	mg	O
1457	/	O
1457	l	O
1457	and	O
1457	the	O
1457	median	O
1457	cm	B-PK
1457	##in	I-PK
1457	(	O
1457	range	O
1457	)	O
1457	was	O
1457	2	O
1457	.	O
1457	54	O
1457	(	O
1457	0	O
1457	.	O
1457	00	O
1457	–	O
1457	31	O
1457	.	O
1457	40	O
1457	)	O
1457	mg	O
1457	/	O
1457	l	O
1457	.	O
1457	in	O
1457	c	O
1457	##s	O
1457	##f	O
1457	,	O
1457	the	O
1457	median	O
1457	ca	O
1457	##fter	O
1457	4	O
1457	##h	O
1457	(	O
1457	range	O
1457	)	O
1457	was	O
1457	1	O
1457	.	O
1457	20	O
1457	(	O
1457	0	O
1457	.	O
1457	00	O
1457	–	O
1457	6	O
1457	.	O
1457	20	O
1457	)	O
1457	mg	O
1457	/	O
1457	l	O
1457	and	O
1457	the	O
1457	median	O
1457	c	B-PK
1457	##tro	I-PK
1457	##ugh	I-PK
1457	(	O
1457	range	O
1457	)	O
1457	was	O
1457	1	O
1457	.	O
1457	28	O
1457	(	O
1457	0	O
1457	.	O
1457	00	O
1457	–	O
1457	4	O
1457	.	O
1457	10	O
1457	)	O
1457	mg	O
1457	/	O
1457	l	O
1457	.	O
1457	the	O
1457	median	O
1457	c	O
1457	##rc	O
1457	##l	O
1457	ranged	O
1457	from	O
1457	60	O
1457	.	O
1457	7	O
1457	to	O
1457	217	O
1457	.	O
1457	6	O
1457	m	O
1457	##l	O
1457	/	O
1457	minute	O
1457	(	O
1457	median	O
1457	122	O
1457	.	O
1457	5	O
1457	m	O
1457	##l	O
1457	/	O
1457	minute	O
1457	)	O
1457	.	O
1457	[SEP]	O
1458	[CLS]	O
1458	individual	O
1458	observed	O
1458	me	O
1458	##rop	O
1458	##ene	O
1458	##m	O
1458	concentrations	O
1458	and	O
1458	median	O
1458	c	O
1458	##rc	O
1458	##l	O
1458	values	O
1458	are	O
1458	shown	O
1458	in	O
1458	table	O
1458	2	O
1458	.	O
1458	[SEP]	O
1459	[CLS]	O
1459	the	O
1459	median	O
1459	au	B-PK
1459	##c	I-PK
1459	##0	I-PK
1459	–	I-PK
1459	24	I-PK
1459	in	O
1459	c	O
1459	##s	O
1459	##f	O
1459	was	O
1459	26	O
1459	.	O
1459	56	O
1459	[UNK]	O
1459	/	O
1459	l	O
1459	,	O
1459	and	O
1459	in	O
1459	serum	O
1459	it	O
1459	was	O
1459	350	O
1459	.	O
1459	22	O
1459	[UNK]	O
1459	/	O
1459	l	O
1459	.	O
1459	the	O
1459	values	O
1459	for	O
1459	the	O
1459	au	B-PK
1459	##c	I-PK
1459	##0	I-PK
1459	–	I-PK
1459	24	I-PK
1459	in	O
1459	c	O
1459	##s	O
1459	##f	O
1459	and	O
1459	serum	O
1459	ranged	O
1459	from	O
1459	7	O
1459	.	O
1459	44	O
1459	to	O
1459	85	O
1459	.	O
1459	53	O
1459	[UNK]	O
1459	/	O
1459	l	O
1459	and	O
1459	from	O
1459	112	O
1459	.	O
1459	95	O
1459	to	O
1459	76	O
1459	##8	O
1459	.	O
1459	63	O
1459	[UNK]	O
1459	/	O
1459	l	O
1459	,	O
1459	respectively	O
1459	.	O
1459	[SEP]	O
1460	[CLS]	O
1460	the	O
1460	present	O
1460	results	O
1460	,	O
1460	in	O
1460	fast	O
1460	##ed	O
1460	low	O
1460	-	O
1460	fat	O
1460	diet	O
1460	fed	O
1460	rats	O
1460	,	O
1460	are	O
1460	consistent	O
1460	with	O
1460	higher	O
1460	oral	B-PK
1460	bio	I-PK
1460	##ava	I-PK
1460	##ila	I-PK
1460	##bility	I-PK
1460	of	O
1460	o	O
1460	##m	O
1460	##3	O
1460	##ca	O
1460	versus	O
1460	o	O
1460	##m	O
1460	##3	O
1460	##ee	O
1460	forms	O
1460	of	O
1460	d	O
1460	##ha	O
1460	.	O
1460	[SEP]	O
1461	[CLS]	O
1461	in	O
1461	order	O
1461	to	O
1461	examine	O
1461	the	O
1461	contributions	O
1461	of	O
1461	the	O
1461	different	O
1461	forms	O
1461	of	O
1461	circulating	O
1461	d	O
1461	##ha	O
1461	(	O
1461	polar	O
1461	vs	O
1461	neutral	O
1461	lip	O
1461	##id	O
1461	species	O
1461	)	O
1461	to	O
1461	tissue	O
1461	up	O
1461	##take	O
1461	and	O
1461	retention	O
1461	of	O
1461	d	O
1461	##ha	O
1461	the	O
1461	following	O
1461	model	O
1461	(	O
1461	e	O
1461	##q	O
1461	1	O
1461	)	O
1461	was	O
1461	applied	O
1461	:	O
1461	r	O
1461	=	O
1461	k	O
1461	##p	O
1461	##l	O
1461	##×	O
1461	##au	O
1461	##c	O
1461	##p	O
1461	##l	O
1461	+	O
1461	kn	O
1461	##l	O
1461	##×	O
1461	##au	O
1461	##c	O
1461	##n	O
1461	##l	O
1461	(	O
1461	1	O
1461	)	O
1461	[SEP]	O
1462	[CLS]	O
1462	the	O
1462	unknown	O
1462	##s	O
1462	,	O
1462	k	B-PK
1462	##p	I-PK
1462	##l	I-PK
1462	and	O
1462	kn	B-PK
1462	##l	I-PK
1462	are	O
1462	the	O
1462	tissue	O
1462	specific	O
1462	clearance	B-PK
1462	rates	I-PK
1462	(	O
1462	m	O
1462	##l	O
1462	/	O
1462	100	O
1462	##g	O
1462	/	O
1462	min	O
1462	)	O
1462	of	O
1462	the	O
1462	polar	O
1462	and	O
1462	neutral	O
1462	lip	O
1462	##id	O
1462	species	O
1462	,	O
1462	respectively	O
1462	.	O
1462	[SEP]	O
1463	[CLS]	O
1463	model	O
1463	fitting	O
1463	and	O
1463	clearance	B-PK
1463	rate	I-PK
1463	est	O
1463	##imation	O
1463	were	O
1463	performed	O
1463	using	O
1463	multiple	O
1463	re	O
1463	##gression	O
1463	analysis	O
1463	(	O
1463	i	O
1463	##b	O
1463	##m	O
1463	s	O
1463	##ps	O
1463	##s	O
1463	statistics	O
1463	subscription	O
1463	,	O
1463	i	O
1463	##b	O
1463	##m	O
1463	co	O
1463	##rp	O
1463	,	O
1463	us	O
1463	##a	O
1463	)	O
1463	.	O
1463	[SEP]	O
1464	[CLS]	O
1464	14	O
1464	##c	O
1464	-	O
1464	d	O
1464	##ha	O
1464	/	O
1464	o	O
1464	##m	O
1464	##3	O
1464	##ca	O
1464	administration	O
1464	resulted	O
1464	in	O
1464	greater	O
1464	plasma	O
1464	14	O
1464	##c	O
1464	-	O
1464	neutral	O
1464	lip	O
1464	##id	O
1464	exposure	O
1464	##s	O
1464	,	O
1464	compared	O
1464	to	O
1464	14	O
1464	##c	O
1464	-	O
1464	d	O
1464	##ha	O
1464	-	O
1464	e	O
1464	##e	O
1464	/	O
1464	o	O
1464	##m	O
1464	##3	O
1464	##ee	O
1464	dos	O
1464	##ing	O
1464	consistent	O
1464	with	O
1464	higher	O
1464	bio	B-PK
1464	##ava	I-PK
1464	##ila	I-PK
1464	##bility	I-PK
1464	of	O
1464	the	O
1464	o	O
1464	##m	O
1464	##3	O
1464	##ca	O
1464	form	O
1464	of	O
1464	d	O
1464	##ha	O
1464	.	O
1464	[SEP]	O
1465	[CLS]	O
1465	thus	O
1465	,	O
1465	the	O
1465	area	B-PK
1465	under	I-PK
1465	the	I-PK
1465	14	I-PK
1465	##c	I-PK
1465	-	I-PK
1465	neutral	I-PK
1465	lip	I-PK
1465	##id	I-PK
1465	curve	I-PK
1465	,	I-PK
1465	from	I-PK
1465	0	I-PK
1465	to	I-PK
1465	240	I-PK
1465	min	I-PK
1465	(	I-PK
1465	au	I-PK
1465	##c	I-PK
1465	)	I-PK
1465	was	O
1465	significantly	O
1465	higher	O
1465	with	O
1465	o	O
1465	##m	O
1465	##3	O
1465	##ca	O
1465	compared	O
1465	to	O
1465	o	O
1465	##m	O
1465	##3	O
1465	##ee	O
1465	dos	O
1465	##ing	O
1465	(	O
1465	fi	O
1465	##g	O
1465	1	O
1465	,	O
1465	panel	O
1465	b	O
1465	,	O
1465	p	O
1465	<	O
1465	0	O
1465	.	O
1465	05	O
1465	,	O
1465	t	O
1465	-	O
1465	test	O
1465	)	O
1465	.	O
1465	[SEP]	O
1466	[CLS]	O
1466	correct	O
1466	##ing	O
1466	the	O
1466	trace	O
1466	##r	O
1466	appearance	O
1466	data	O
1466	for	O
1466	the	O
1466	nominal	O
1466	d	O
1466	##ha	O
1466	and	O
1466	d	O
1466	##ha	O
1466	-	O
1466	e	O
1466	##e	O
1466	specific	O
1466	activities	O
1466	of	O
1466	the	O
1466	dose	O
1466	formulation	O
1466	##s	O
1466	indicates	O
1466	greater	O
1466	oral	O
1466	exposure	O
1466	from	O
1466	the	O
1466	f	O
1466	##fa	O
1466	vs	O
1466	the	O
1466	est	O
1466	##er	O
1466	form	O
1466	of	O
1466	d	O
1466	##ha	O
1466	.	O
1466	[SEP]	O
1467	[CLS]	O
1467	thus	O
1467	,	O
1467	a	O
1467	lower	O
1467	nominal	O
1467	dose	O
1467	of	O
1467	o	O
1467	##m	O
1467	##3	O
1467	##ca	O
1467	(	O
1467	146	O
1467	μ	O
1467	##mo	O
1467	##l	O
1467	/	O
1467	rat	O
1467	versus	O
1467	an	O
1467	equivalent	O
1467	of	O
1467	256	O
1467	μ	O
1467	##mo	O
1467	##l	O
1467	/	O
1467	rat	O
1467	for	O
1467	o	O
1467	##m	O
1467	##3	O
1467	##ee	O
1467	)	O
1467	tended	O
1467	to	O
1467	result	O
1467	in	O
1467	a	O
1467	higher	O
1467	estimated	O
1467	d	O
1467	##ha	O
1467	au	O
1467	##c	O
1467	in	O
1467	the	O
1467	neutral	O
1467	lip	O
1467	##id	O
1467	fraction	O
1467	(	O
1467	fi	O
1467	##g	O
1467	1	O
1467	,	O
1467	panel	O
1467	c	O
1467	)	O
1467	.	O
1467	[SEP]	O
1468	[CLS]	O
1468	thus	O
1468	,	O
1468	the	O
1468	area	B-PK
1468	under	I-PK
1468	the	I-PK
1468	14	I-PK
1468	##c	I-PK
1468	-	I-PK
1468	polar	I-PK
1468	lip	I-PK
1468	##id	I-PK
1468	curve	I-PK
1468	,	I-PK
1468	from	I-PK
1468	0	I-PK
1468	to	I-PK
1468	240	I-PK
1468	min	I-PK
1468	(	I-PK
1468	au	I-PK
1468	##c	I-PK
1468	)	I-PK
1468	was	O
1468	significantly	O
1468	higher	O
1468	with	O
1468	o	O
1468	##m	O
1468	##3	O
1468	##ca	O
1468	compared	O
1468	to	O
1468	o	O
1468	##m	O
1468	##3	O
1468	##ee	O
1468	dos	O
1468	##ing	O
1468	(	O
1468	fi	O
1468	##g	O
1468	1	O
1468	,	O
1468	panel	O
1468	e	O
1468	,	O
1468	p	O
1468	<	O
1468	0	O
1468	.	O
1468	01	O
1468	,	O
1468	t	O
1468	-	O
1468	test	O
1468	)	O
1468	.	O
1468	[SEP]	O
1469	[CLS]	O
1469	14	O
1469	##c	O
1469	-	O
1469	d	O
1469	##ha	O
1469	/	O
1469	o	O
1469	##m	O
1469	##3	O
1469	##ca	O
1469	administration	O
1469	resulted	O
1469	in	O
1469	greater	O
1469	plasma	O
1469	14	O
1469	##c	O
1469	-	O
1469	polar	O
1469	lip	O
1469	##id	O
1469	exposure	O
1469	##s	O
1469	,	O
1469	compared	O
1469	to	O
1469	14	O
1469	##c	O
1469	-	O
1469	d	O
1469	##ha	O
1469	-	O
1469	e	O
1469	##e	O
1469	/	O
1469	o	O
1469	##m	O
1469	##3	O
1469	##ee	O
1469	dos	O
1469	##ing	O
1469	,	O
1469	again	O
1469	consistent	O
1469	with	O
1469	higher	O
1469	bio	B-PK
1469	##ava	I-PK
1469	##ila	I-PK
1469	##bility	I-PK
1469	of	O
1469	the	O
1469	o	O
1469	##m	O
1469	##3	O
1469	##ca	O
1469	versus	O
1469	the	O
1469	o	O
1469	##m	O
1469	##3	O
1469	##ee	O
1469	form	O
1469	.	O
1469	[SEP]	O
1470	[CLS]	O
1470	thus	O
1470	,	O
1470	a	O
1470	lower	O
1470	nominal	O
1470	dose	O
1470	of	O
1470	o	O
1470	##m	O
1470	##3	O
1470	##ca	O
1470	(	O
1470	see	O
1470	above	O
1470	)	O
1470	did	O
1470	not	O
1470	result	O
1470	in	O
1470	lower	O
1470	d	O
1470	##ha	O
1470	au	B-PK
1470	##c	I-PK
1470	in	O
1470	the	O
1470	polar	O
1470	lip	O
1470	##id	O
1470	fraction	O
1470	(	O
1470	fi	O
1470	##g	O
1470	1	O
1470	,	O
1470	panel	O
1470	f	O
1470	)	O
1470	.	O
1470	[SEP]	O
1471	[CLS]	O
1471	in	O
1471	the	O
1471	other	O
1471	tissues	O
1471	,	O
1471	the	O
1471	lower	O
1471	bio	B-PK
1471	##ava	I-PK
1471	##ila	I-PK
1471	##bility	I-PK
1471	of	O
1471	d	O
1471	##ha	O
1471	-	O
1471	e	O
1471	##e	O
1471	was	O
1471	compensate	O
1471	##d	O
1471	for	O
1471	by	O
1471	the	O
1471	higher	O
1471	equivalent	O
1471	dose	O
1471	of	O
1471	d	O
1471	##ha	O
1471	resulting	O
1471	in	O
1471	similar	O
1471	estimated	O
1471	d	O
1471	##ha	O
1471	retention	O
1471	##s	O
1471	for	O
1471	the	O
1471	two	O
1471	formulation	O
1471	##s	O
1471	.	O
1471	[SEP]	O
1472	[CLS]	O
1472	various	O
1472	pharmaceutical	O
1472	forms	O
1472	,	O
1472	i	O
1472	.	O
1472	e	O
1472	.	O
1472	re	O
1472	##ct	O
1472	##al	O
1472	suspension	O
1472	,	O
1472	two	O
1472	different	O
1472	re	O
1472	##ct	O
1472	##al	O
1472	gel	O
1472	##s	O
1472	,	O
1472	p	O
1472	##oly	O
1472	##eth	O
1472	##yle	O
1472	##ne	O
1472	g	O
1472	##ly	O
1472	##co	O
1472	##l	O
1472	(	O
1472	p	O
1472	##eg	O
1472	)	O
1472	su	O
1472	##pp	O
1472	##os	O
1472	##itor	O
1472	##y	O
1472	and	O
1472	hard	O
1472	gel	O
1472	##ati	O
1472	##n	O
1472	capsule	O
1472	(	O
1472	h	O
1472	##g	O
1472	##c	O
1472	)	O
1472	were	O
1472	assessed	O
1472	for	O
1472	in	O
1472	v	O
1472	##it	O
1472	##ro	O
1472	dissolution	O
1472	and	O
1472	in	O
1472	v	O
1472	##ivo	O
1472	bio	B-PK
1472	##ava	I-PK
1472	##ila	I-PK
1472	##bility	I-PK
1472	in	O
1472	the	O
1472	rabbit	O
1472	.	O
1472	[SEP]	O
1473	[CLS]	O
1473	hp	O
1473	##l	O
1473	##c	O
1473	analyses	O
1473	were	O
1473	performed	O
1473	on	O
1473	waters	O
1473	hp	O
1473	##l	O
1473	##c	O
1473	system	O
1473	with	O
1473	51	O
1473	##5	O
1473	hp	O
1473	##l	O
1473	##c	O
1473	pump	O
1473	,	O
1473	71	O
1473	##7	O
1473	##p	O
1473	##lus	O
1473	auto	O
1473	##sa	O
1473	##mple	O
1473	##r	O
1473	and	O
1473	248	O
1473	##7	O
1473	dual	O
1473	λ	O
1473	absorb	O
1473	##ance	O
1473	detector	O
1473	(	O
1473	waters	O
1473	,	O
1473	f	O
1473	##rance	O
1473	)	O
1473	.	O
1473	[SEP]	O
1474	[CLS]	O
1474	p	O
1474	##har	O
1474	##ma	O
1474	##co	O
1474	##kin	O
1474	##etic	O
1474	parameters	O
1474	,	O
1474	namely	O
1474	cm	B-PK
1474	##ax	I-PK
1474	,	O
1474	t	B-PK
1474	##max	I-PK
1474	and	O
1474	au	B-PK
1474	##c	I-PK
1474	of	O
1474	each	O
1474	condition	O
1474	were	O
1474	obtained	O
1474	from	O
1474	each	O
1474	individual	O
1474	plasma	O
1474	profile	O
1474	and	O
1474	then	O
1474	mean	O
1474	and	O
1474	standard	O
1474	de	O
1474	##viation	O
1474	(	O
1474	s	O
1474	##d	O
1474	)	O
1474	were	O
1474	calculated	O
1474	.	O
1474	[SEP]	O
1475	[CLS]	O
1475	au	B-PK
1475	##c	I-PK
1475	was	O
1475	calculated	O
1475	using	O
1475	trap	O
1475	##ez	O
1475	##oid	O
1475	rule	O
1475	.	O
1475	[SEP]	O
1476	[CLS]	O
1476	previous	O
1476	studies	O
1476	have	O
1476	shown	O
1476	that	O
1476	at	O
1476	p	O
1476	##h	O
1476	8	O
1476	,	O
1476	the	O
1476	half	B-PK
1476	-	I-PK
1476	life	I-PK
1476	of	O
1476	a	O
1476	##zi	O
1476	##th	O
1476	##rom	O
1476	##y	O
1476	##cin	O
1476	in	O
1476	buffer	O
1476	##ed	O
1476	solution	O
1476	was	O
1476	54	O
1476	days	O
1476	at	O
1476	20	O
1476	°	O
1476	##c	O
1476	and	O
1476	6	O
1476	days	O
1476	at	O
1476	40	O
1476	°	O
1476	##c	O
1476	(	O
1476	est	O
1476	##eb	O
1476	##an	O
1476	et	O
1476	al	O
1476	.	O
1476	,	O
1476	2009	O
1476	)	O
1476	.	O
1476	[SEP]	O
1477	[CLS]	O
1477	a	O
1477	m	O
1477	##uc	O
1477	##o	O
1477	-	O
1477	ad	O
1477	##hesive	O
1477	gel	O
1477	was	O
1477	tested	O
1477	in	O
1477	order	O
1477	to	O
1477	enhance	O
1477	re	B-PK
1477	##ct	I-PK
1477	##al	I-PK
1477	bio	I-PK
1477	##ava	I-PK
1477	##ila	I-PK
1477	##bility	I-PK
1477	by	O
1477	increasing	O
1477	the	O
1477	residence	B-PK
1477	time	I-PK
1477	in	O
1477	sit	O
1477	##u	O
1477	as	O
1477	compared	O
1477	to	O
1477	classical	O
1477	non	O
1477	m	O
1477	##uc	O
1477	##o	O
1477	-	O
1477	ad	O
1477	##hesive	O
1477	formulation	O
1477	##s	O
1477	.	O
1477	[SEP]	O
1478	[CLS]	O
1478	a	O
1478	##zi	O
1478	##th	O
1478	##rom	O
1478	##y	O
1478	##cin	O
1478	re	O
1478	##ct	O
1478	##al	O
1478	absorption	O
1478	was	O
1478	rapid	O
1478	for	O
1478	the	O
1478	suspension	O
1478	and	O
1478	car	O
1478	##bo	O
1478	##pol	O
1478	gel	O
1478	(	O
1478	t	B-PK
1478	##max	I-PK
1478	15	O
1478	min	O
1478	)	O
1478	,	O
1478	while	O
1478	it	O
1478	required	O
1478	30	O
1478	min	O
1478	to	O
1478	reach	O
1478	maximum	B-PK
1478	plasma	I-PK
1478	concentration	I-PK
1478	for	O
1478	the	O
1478	h	O
1478	##g	O
1478	##c	O
1478	and	O
1478	60	O
1478	min	O
1478	for	O
1478	the	O
1478	hp	O
1478	##m	O
1478	##c	O
1478	gel	O
1478	and	O
1478	the	O
1478	p	O
1478	##eg	O
1478	su	O
1478	##pp	O
1478	##os	O
1478	##itor	O
1478	##y	O
1478	.	O
1478	[SEP]	O
1479	[CLS]	O
1479	the	O
1479	highest	O
1479	re	O
1479	##ct	O
1479	##al	O
1479	cm	B-PK
1479	##ax	I-PK
1479	and	O
1479	re	B-PK
1479	##ct	I-PK
1479	##al	I-PK
1479	au	I-PK
1479	##c	I-PK
1479	##0	I-PK
1479	##−	I-PK
1479	##24	I-PK
1479	h	I-PK
1479	was	O
1479	obtained	O
1479	with	O
1479	the	O
1479	p	O
1479	##eg	O
1479	su	O
1479	##pp	O
1479	##os	O
1479	##itor	O
1479	##y	O
1479	;	O
1479	relative	B-PK
1479	bio	I-PK
1479	##ava	I-PK
1479	##ila	I-PK
1479	##bility	I-PK
1479	was	O
1479	[UNK]	O
1479	%	O
1479	of	O
1479	i	O
1479	##v	O
1479	and	O
1479	[UNK]	O
1479	.	O
1479	3	O
1479	times	O
1479	that	O
1479	of	O
1479	the	O
1479	re	O
1479	##ct	O
1479	##al	O
1479	suspension	O
1479	.	O
1479	[SEP]	O
1480	[CLS]	O
1480	the	O
1480	ratios	B-PK
1480	au	I-PK
1480	##c	I-PK
1480	##24	I-PK
1480	h	I-PK
1480	/	I-PK
1480	minimum	I-PK
1480	inhibitor	I-PK
1480	##y	I-PK
1480	concentration	I-PK
1480	(	I-PK
1480	mi	I-PK
1480	##c	I-PK
1480	)	I-PK
1480	and	O
1480	cm	B-PK
1480	##ax	I-PK
1480	/	I-PK
1480	mi	I-PK
1480	##c	I-PK
1480	are	O
1480	regarded	O
1480	as	O
1480	the	O
1480	main	O
1480	p	O
1480	##har	O
1480	##ma	O
1480	##co	O
1480	##kin	O
1480	##etic	O
1480	/	O
1480	p	O
1480	##har	O
1480	##ma	O
1480	##co	O
1480	##dynamic	O
1480	parameters	O
1480	for	O
1480	a	O
1480	##zi	O
1480	##th	O
1480	##rom	O
1480	##y	O
1480	##cin	O
1480	efficacy	O
1480	.	O
1480	[SEP]	O
1481	[CLS]	O
1481	differently	O
1481	from	O
1481	er	O
1481	##yt	O
1481	##hr	O
1481	##omy	O
1481	##cin	O
1481	,	O
1481	for	O
1481	a	O
1481	##zi	O
1481	##th	O
1481	##rom	O
1481	##y	O
1481	##cin	O
1481	the	O
1481	au	B-PK
1481	##c	I-PK
1481	##24	I-PK
1481	h	I-PK
1481	/	I-PK
1481	mi	I-PK
1481	##c	I-PK
1481	is	O
1481	more	O
1481	important	O
1481	than	O
1481	t	O
1481	/	O
1481	mi	O
1481	##c	O
1481	because	O
1481	of	O
1481	its	O
1481	long	O
1481	half	B-PK
1481	-	I-PK
1481	life	I-PK
1481	and	O
1481	good	O
1481	tissue	O
1481	penetration	O
1481	(	O
1481	van	O
1481	b	O
1481	##am	O
1481	##bek	O
1481	##e	O
1481	and	O
1481	t	O
1481	##ul	O
1481	##ken	O
1481	##s	O
1481	,	O
1481	2001	O
1481	)	O
1481	.	O
1481	[SEP]	O
1482	[CLS]	O
1482	of	O
1482	the	O
1482	formulation	O
1482	##s	O
1482	tested	O
1482	,	O
1482	the	O
1482	p	O
1482	##eg	O
1482	su	O
1482	##pp	O
1482	##os	O
1482	##itor	O
1482	##y	O
1482	appears	O
1482	to	O
1482	be	O
1482	the	O
1482	most	O
1482	promising	O
1482	candidate	O
1482	,	O
1482	but	O
1482	has	O
1482	a	O
1482	potential	O
1482	short	O
1482	##coming	O
1482	–	O
1482	the	O
1482	rather	O
1482	long	O
1482	t	B-PK
1482	##max	I-PK
1482	,	O
1482	which	O
1482	is	O
1482	of	O
1482	particular	O
1482	concern	O
1482	if	O
1482	early	O
1482	onset	O
1482	of	O
1482	action	O
1482	is	O
1482	needed	O
1482	.	O
1482	[SEP]	O
1483	[CLS]	O
1483	the	O
1483	bio	B-PK
1483	##ava	I-PK
1483	##ila	I-PK
1483	##bility	I-PK
1483	of	O
1483	the	O
1483	su	O
1483	##pp	O
1483	##os	O
1483	##itor	O
1483	##y	O
1483	formulation	O
1483	could	O
1483	be	O
1483	further	O
1483	improved	O
1483	by	O
1483	adding	O
1483	absorption	O
1483	enhance	O
1483	##rs	O
1483	or	O
1483	using	O
1483	a	O
1483	e	O
1483	##ute	O
1483	##ctic	O
1483	mixture	O
1483	of	O
1483	p	O
1483	##eg	O
1483	and	O
1483	a	O
1483	##zi	O
1483	##th	O
1483	##rom	O
1483	##y	O
1483	##cin	O
1483	.	O
1483	[SEP]	O
1484	[CLS]	O
1484	cm	B-PK
1484	##ax	I-PK
1484	remained	O
1484	unchanged	O
1484	for	O
1484	20	O
1484	and	O
1484	40	O
1484	mg	O
1484	/	O
1484	kg	O
1484	of	O
1484	a	O
1484	##zi	O
1484	##th	O
1484	##rom	O
1484	##y	O
1484	##cin	O
1484	(	O
1484	261	O
1484	and	O
1484	255	O
1484	ng	O
1484	/	O
1484	m	O
1484	##l	O
1484	respectively	O
1484	)	O
1484	and	O
1484	the	O
1484	extra	O
1484	##pol	O
1484	##ated	O
1484	au	B-PK
1484	##c	I-PK
1484	value	O
1484	ratio	O
1484	was	O
1484	1	O
1484	:	O
1484	1	O
1484	.	O
1484	5	O
1484	compared	O
1484	to	O
1484	1	O
1484	:	O
1484	2	O
1484	ratio	O
1484	for	O
1484	the	O
1484	a	O
1484	##zi	O
1484	##th	O
1484	##rom	O
1484	##y	O
1484	##cin	O
1484	dose	O
1484	.	O
1484	[SEP]	O
1485	[CLS]	O
1485	t	B-PK
1485	##max	I-PK
1485	remained	O
1485	unchanged	O
1485	.	O
1485	[SEP]	O
1486	[CLS]	O
1486	while	O
1486	both	O
1486	plasma	O
1486	and	O
1486	tissue	O
1486	concentrations	O
1486	were	O
1486	reportedly	O
1486	increased	O
1486	when	O
1486	doubling	O
1486	a	O
1486	##zi	O
1486	##th	O
1486	##rom	O
1486	##y	O
1486	##cin	O
1486	dose	O
1486	from	O
1486	500	O
1486	to	O
1486	1000	O
1486	mg	O
1486	per	O
1486	o	O
1486	##s	O
1486	in	O
1486	healthy	O
1486	adults	O
1486	(	O
1486	da	O
1486	##nes	O
1486	##i	O
1486	et	O
1486	al	O
1486	.	O
1486	,	O
1486	2003	O
1486	)	O
1486	,	O
1486	an	O
1486	oral	O
1486	dose	O
1486	of	O
1486	20	O
1486	mg	O
1486	/	O
1486	kg	O
1486	produced	O
1486	only	O
1486	a	O
1486	marginal	O
1486	increase	O
1486	in	O
1486	plasma	O
1486	au	B-PK
1486	##c	I-PK
1486	over	O
1486	10	O
1486	mg	O
1486	/	O
1486	kg	O
1486	(	O
1486	au	B-PK
1486	##c	I-PK
1486	ratio	I-PK
1486	1	O
1486	:	O
1486	18	O
1486	)	O
1486	,	O
1486	but	O
1486	a	O
1486	more	O
1486	significant	O
1486	increase	O
1486	of	O
1486	tons	O
1486	##il	O
1486	tissue	B-PK
1486	au	I-PK
1486	##c	I-PK
1486	(	O
1486	au	B-PK
1486	##c	I-PK
1486	ratio	I-PK
1486	1	O
1486	:	O
1486	53	O
1486	)	O
1486	(	O
1486	b	O
1486	##land	O
1486	##iz	O
1486	##zi	O
1486	et	O
1486	al	O
1486	.	O
1486	,	O
1486	2002	O
1486	)	O
1486	.	O
1486	[SEP]	O
1487	[CLS]	O
1487	their	O
1487	average	O
1487	areas	B-PK
1487	under	I-PK
1487	the	I-PK
1487	concentration	I-PK
1487	curves	I-PK
1487	,	I-PK
1487	au	I-PK
1487	##c	I-PK
1487	in	I-PK
1487	the	I-PK
1487	plasma	I-PK
1487	after	O
1487	a	O
1487	single	O
1487	oral	O
1487	administration	O
1487	of	O
1487	40	O
1487	m	O
1487	##l	O
1487	of	O
1487	k	O
1487	-	O
1487	60	O
1487	##1	O
1487	was	O
1487	also	O
1487	presented	O
1487	(	O
1487	fi	O
1487	##g	O
1487	.	O
1487	4	O
1487	)	O
1487	.	O
1487	[SEP]	O
1488	[CLS]	O
1488	p	O
1488	##har	O
1488	##ma	O
1488	##co	O
1488	##kin	O
1488	##etic	O
1488	parameters	O
1488	of	O
1488	e	O
1488	##uca	O
1488	##ly	O
1488	##pt	O
1488	##ol	O
1488	(	O
1488	fast	O
1488	##ed	O
1488	vs	O
1488	fed	O
1488	)	O
1488	were	O
1488	as	O
1488	follows	O
1488	:	O
1488	ma	B-PK
1488	##ximal	I-PK
1488	plasma	I-PK
1488	concentrations	I-PK
1488	(	I-PK
1488	cm	I-PK
1488	##ax	I-PK
1488	)	I-PK
1488	(	O
1488	167	O
1488	.	O
1488	60	O
1488	##±	O
1488	##11	O
1488	##4	O
1488	.	O
1488	69	O
1488	vs	O
1488	51	O
1488	##8	O
1488	.	O
1488	89	O
1488	##±	O
1488	##31	O
1488	##4	O
1488	.	O
1488	47	O
1488	ng	O
1488	·	O
1488	m	O
1488	##l	O
1488	##−	O
1488	##1	O
1488	)	O
1488	,	O
1488	time	B-PK
1488	of	I-PK
1488	maximum	I-PK
1488	concentration	I-PK
1488	(	I-PK
1488	t	I-PK
1488	##max	I-PK
1488	)	I-PK
1488	(	O
1488	3	O
1488	.	O
1488	7	O
1488	##±	O
1488	##1	O
1488	.	O
1488	1	O
1488	vs	O
1488	4	O
1488	.	O
1488	8	O
1488	##±	O
1488	##0	O
1488	.	O
1488	7	O
1488	h	O
1488	)	O
1488	,	O
1488	elimination	B-PK
1488	half	I-PK
1488	-	I-PK
1488	life	I-PK
1488	(	I-PK
1488	t	I-PK
1488	##1	I-PK
1488	/	I-PK
1488	2	I-PK
1488	)	I-PK
1488	(	O
1488	3	O
1488	.	O
1488	2	O
1488	##±	O
1488	##1	O
1488	.	O
1488	4	O
1488	vs	O
1488	2	O
1488	.	O
1488	6	O
1488	##±	O
1488	##0	O
1488	.	O
1488	7	O
1488	h	O
1488	)	O
1488	,	O
1488	area	B-PK
1488	under	I-PK
1488	the	I-PK
1488	plasma	I-PK
1488	concentration	I-PK
1488	–	I-PK
1488	time	I-PK
1488	curve	I-PK
1488	(	I-PK
1488	au	I-PK
1488	##c	I-PK
1488	##0	I-PK
1488	–	I-PK
1488	t	I-PK
1488	)	I-PK
1488	(	O
1488	58	O
1488	##4	O
1488	.	O
1488	91	O
1488	##±	O
1488	##36	O
1488	##9	O
1488	.	O
1488	90	O
1488	vs	O
1488	1	O
1488	,	O
1488	27	O
1488	##1	O
1488	.	O
1488	61	O
1488	##±	O
1488	##60	O
1488	##5	O
1488	.	O
1488	82	O
1488	ng	O
1488	·	O
1488	h	O
1488	·	O
1488	m	O
1488	##l	O
1488	##−	O
1488	##1	O
1488	)	O
1488	,	O
1488	and	O
1488	au	B-PK
1488	##c	I-PK
1488	##0	I-PK
1488	–	I-PK
1488	∞	I-PK
1488	(	O
1488	69	O
1488	##0	O
1488	.	O
1488	36	O
1488	##±	O
1488	##46	O
1488	##7	O
1488	.	O
1488	26	O
1488	vs	O
1488	1	O
1488	,	O
1488	45	O
1488	##8	O
1488	.	O
1488	02	O
1488	##±	O
1488	##7	O
1488	##20	O
1488	.	O
1488	21	O
1488	ng	O
1488	·	O
1488	h	O
1488	·	O
1488	m	O
1488	##l	O
1488	##−	O
1488	##1	O
1488	)	O
1488	.	O
1488	[SEP]	O
1489	[CLS]	O
1489	there	O
1489	was	O
1489	statistical	O
1489	##ly	O
1489	significant	O
1489	difference	O
1489	in	O
1489	cm	B-PK
1489	##ax	I-PK
1489	,	O
1489	au	B-PK
1489	##c	I-PK
1489	##0	I-PK
1489	–	I-PK
1489	t	I-PK
1489	,	O
1489	and	O
1489	au	B-PK
1489	##c	I-PK
1489	##0	I-PK
1489	–	I-PK
1489	∞	I-PK
1489	between	O
1489	the	O
1489	two	O
1489	dos	O
1489	##ing	O
1489	methods	O
1489	(	O
1489	p	O
1489	<	O
1489	0	O
1489	.	O
1489	05	O
1489	)	O
1489	.	O
1489	[SEP]	O
1490	[CLS]	O
1490	the	O
1490	90	O
1490	%	O
1490	confidence	O
1490	intervals	O
1490	for	O
1490	the	O
1490	ratio	O
1490	of	O
1490	cm	B-PK
1490	##ax	I-PK
1490	(	O
1490	18	O
1490	.	O
1490	4	O
1490	%	O
1490	~	O
1490	64	O
1490	.	O
1490	7	O
1490	%	O
1490	)	O
1490	,	O
1490	au	B-PK
1490	##c	I-PK
1490	##0	I-PK
1490	–	I-PK
1490	t	I-PK
1490	(	O
1490	28	O
1490	.	O
1490	9	O
1490	%	O
1490	~	O
1490	68	O
1490	.	O
1490	5	O
1490	%	O
1490	)	O
1490	,	O
1490	and	O
1490	au	B-PK
1490	##c	I-PK
1490	##0	I-PK
1490	–	I-PK
1490	∞	I-PK
1490	(	O
1490	31	O
1490	.	O
1490	1	O
1490	%	O
1490	~	O
1490	68	O
1490	.	O
1490	4	O
1490	%	O
1490	)	O
1490	values	O
1490	for	O
1490	the	O
1490	test	O
1490	(	O
1490	fast	O
1490	##ed	O
1490	)	O
1490	and	O
1490	reference	O
1490	(	O
1490	fed	O
1490	)	O
1490	were	O
1490	beyond	O
1490	the	O
1490	food	O
1490	and	O
1490	drug	O
1490	administration	O
1490	’	O
1490	s	O
1490	acceptable	O
1490	range	O
1490	of	O
1490	80	O
1490	%	O
1490	~	O
1490	125	O
1490	%	O
1490	.	O
1490	[SEP]	O
1491	[CLS]	O
1491	in	O
1491	addition	O
1491	,	O
1491	significant	O
1491	difference	O
1491	was	O
1491	obtained	O
1491	in	O
1491	t	B-PK
1491	##max	I-PK
1491	(	O
1491	p	O
1491	<	O
1491	0	O
1491	.	O
1491	05	O
1491	)	O
1491	.	O
1491	[SEP]	O
1492	[CLS]	O
1492	a	O
1492	high	O
1492	-	O
1492	fat	O
1492	and	O
1492	high	O
1492	-	O
1492	ca	O
1492	##lor	O
1492	##ie	O
1492	diet	O
1492	made	O
1492	of	O
1492	protein	O
1492	(	O
1492	about	O
1492	150	O
1492	ca	O
1492	##lor	O
1492	##ies	O
1492	)	O
1492	,	O
1492	car	O
1492	##bo	O
1492	##hy	O
1492	##dra	O
1492	##tes	O
1492	(	O
1492	250	O
1492	ca	O
1492	##lor	O
1492	##ies	O
1492	)	O
1492	,	O
1492	and	O
1492	fat	O
1492	(	O
1492	500	O
1492	–	O
1492	600	O
1492	ca	O
1492	##lor	O
1492	##ies	O
1492	)	O
1492	was	O
1492	provided	O
1492	and	O
1492	was	O
1492	treated	O
1492	as	O
1492	a	O
1492	standardized	O
1492	meal	O
1492	for	O
1492	food	O
1492	–	O
1492	effect	O
1492	bio	B-PK
1492	##ava	I-PK
1492	##ila	I-PK
1492	##bility	I-PK
1492	study	O
1492	.	O
1492	[SEP]	O
1493	[CLS]	O
1493	ma	B-PK
1493	##ximal	I-PK
1493	plasma	I-PK
1493	concentrations	I-PK
1493	(	I-PK
1493	cm	I-PK
1493	##ax	I-PK
1493	)	I-PK
1493	and	O
1493	the	O
1493	times	B-PK
1493	at	I-PK
1493	which	I-PK
1493	they	I-PK
1493	occurred	I-PK
1493	(	I-PK
1493	t	I-PK
1493	##max	I-PK
1493	)	I-PK
1493	were	O
1493	determined	O
1493	by	O
1493	inspection	O
1493	of	O
1493	the	O
1493	plasma	O
1493	concentration	O
1493	–	O
1493	time	O
1493	profile	O
1493	.	O
1493	[SEP]	O
1494	[CLS]	O
1494	the	O
1494	terminal	B-PK
1494	elimination	I-PK
1494	rate	I-PK
1494	constant	I-PK
1494	(	I-PK
1494	λ	I-PK
1494	##z	I-PK
1494	)	I-PK
1494	was	O
1494	determined	O
1494	by	O
1494	linear	O
1494	re	O
1494	##gression	O
1494	of	O
1494	the	O
1494	terminal	O
1494	portion	O
1494	of	O
1494	the	O
1494	log	O
1494	concentration	O
1494	–	O
1494	time	O
1494	profile	O
1494	.	O
1494	[SEP]	O
1495	[CLS]	O
1495	the	O
1495	elimination	B-PK
1495	half	I-PK
1495	-	I-PK
1495	life	I-PK
1495	(	I-PK
1495	t	I-PK
1495	##1	I-PK
1495	/	I-PK
1495	2	I-PK
1495	)	I-PK
1495	was	O
1495	calculated	O
1495	as	O
1495	0	O
1495	.	O
1495	69	O
1495	##3	O
1495	/	O
1495	λ	O
1495	##z	O
1495	.	O
1495	[SEP]	O
1496	[CLS]	O
1496	area	B-PK
1496	under	I-PK
1496	the	I-PK
1496	plasma	I-PK
1496	concentration	I-PK
1496	–	I-PK
1496	time	I-PK
1496	curve	I-PK
1496	(	I-PK
1496	au	I-PK
1496	##c	I-PK
1496	)	I-PK
1496	was	O
1496	determined	O
1496	by	O
1496	trap	O
1496	##ez	O
1496	##oid	O
1496	##al	O
1496	rule	O
1496	and	O
1496	was	O
1496	extra	O
1496	##pol	O
1496	##ated	O
1496	to	O
1496	in	O
1496	##finity	O
1496	by	O
1496	using	O
1496	the	O
1496	calculation	O
1496	of	O
1496	c	B-PK
1496	##t	I-PK
1496	/	I-PK
1496	λ	I-PK
1496	##z	I-PK
1496	.	O
1496	[SEP]	O
1497	[CLS]	O
1497	log	O
1497	transformed	O
1497	,	O
1497	cm	B-PK
1497	##ax	I-PK
1497	,	O
1497	au	B-PK
1497	##c	I-PK
1497	##0	I-PK
1497	–	I-PK
1497	t	I-PK
1497	,	O
1497	and	O
1497	au	B-PK
1497	##c	I-PK
1497	##0	I-PK
1497	–	I-PK
1497	∞	I-PK
1497	were	O
1497	analyzed	O
1497	using	O
1497	analysis	O
1497	of	O
1497	variance	O
1497	analysis	O
1497	and	O
1497	s	O
1497	##chu	O
1497	##ir	O
1497	##mann	O
1497	two	O
1497	one	O
1497	-	O
1497	sided	O
1497	t	O
1497	-	O
1497	test	O
1497	.	O
1497	[SEP]	O
1498	[CLS]	O
1498	t	B-PK
1498	##max	I-PK
1498	was	O
1498	analyzed	O
1498	by	O
1498	the	O
1498	non	O
1498	##par	O
1498	##ame	O
1498	##tric	O
1498	test	O
1498	,	O
1498	w	O
1498	##il	O
1498	##co	O
1498	##xon	O
1498	’	O
1498	s	O
1498	test	O
1498	.	O
1498	[SEP]	O
1499	[CLS]	O
1499	the	O
1499	p	O
1499	##har	O
1499	##ma	O
1499	##co	O
1499	##kin	O
1499	##etic	O
1499	parameters	O
1499	of	O
1499	dos	O
1499	##ing	O
1499	conditions	O
1499	(	O
1499	fast	O
1499	##ed	O
1499	vs	O
1499	after	O
1499	a	O
1499	meal	O
1499	)	O
1499	were	O
1499	as	O
1499	follows	O
1499	(	O
1499	table	O
1499	1	O
1499	)	O
1499	:	O
1499	cm	B-PK
1499	##ax	I-PK
1499	(	O
1499	167	O
1499	.	O
1499	6	O
1499	##±	O
1499	##11	O
1499	##4	O
1499	.	O
1499	69	O
1499	vs	O
1499	51	O
1499	##8	O
1499	.	O
1499	89	O
1499	##±	O
1499	##31	O
1499	##4	O
1499	.	O
1499	47	O
1499	ng	O
1499	·	O
1499	m	O
1499	##l	O
1499	##−	O
1499	##1	O
1499	)	O
1499	,	O
1499	t	B-PK
1499	##max	I-PK
1499	(	O
1499	3	O
1499	.	O
1499	7	O
1499	##±	O
1499	##1	O
1499	.	O
1499	1	O
1499	vs	O
1499	4	O
1499	.	O
1499	8	O
1499	##±	O
1499	##0	O
1499	.	O
1499	7	O
1499	h	O
1499	)	O
1499	,	O
1499	t	B-PK
1499	##1	I-PK
1499	/	I-PK
1499	2	I-PK
1499	(	O
1499	3	O
1499	.	O
1499	2	O
1499	##±	O
1499	##1	O
1499	.	O
1499	4	O
1499	vs	O
1499	2	O
1499	.	O
1499	6	O
1499	##±	O
1499	##0	O
1499	.	O
1499	7	O
1499	h	O
1499	)	O
1499	,	O
1499	au	B-PK
1499	##c	I-PK
1499	##0	I-PK
1499	–	I-PK
1499	t	I-PK
1499	(	O
1499	58	O
1499	##4	O
1499	.	O
1499	91	O
1499	##±	O
1499	##36	O
1499	##9	O
1499	.	O
1499	90	O
1499	vs	O
1499	127	O
1499	##1	O
1499	.	O
1499	61	O
1499	##±	O
1499	##60	O
1499	##5	O
1499	.	O
1499	82	O
1499	ng	O
1499	·	O
1499	h	O
1499	·	O
1499	m	O
1499	##l	O
1499	##−	O
1499	##1	O
1499	)	O
1499	,	O
1499	and	O
1499	au	B-PK
1499	##c	I-PK
1499	##0	I-PK
1499	–	I-PK
1499	∞	I-PK
1499	(	O
1499	69	O
1499	##0	O
1499	.	O
1499	36	O
1499	##±	O
1499	##46	O
1499	##7	O
1499	.	O
1499	26	O
1499	vs	O
1499	145	O
1499	##8	O
1499	.	O
1499	02	O
1499	##±	O
1499	##7	O
1499	##20	O
1499	.	O
1499	21	O
1499	ng	O
1499	·	O
1499	h	O
1499	·	O
1499	m	O
1499	##l	O
1499	##−	O
1499	##1	O
1499	)	O
1499	.	O
1499	[SEP]	O
1500	[CLS]	O
1500	statistical	O
1500	##ly	O
1500	significant	O
1500	difference	O
1500	was	O
1500	observed	O
1500	in	O
1500	cm	B-PK
1500	##ax	I-PK
1500	,	O
1500	au	B-PK
1500	##c	I-PK
1500	##0	I-PK
1500	–	I-PK
1500	t	I-PK
1500	,	O
1500	and	O
1500	au	B-PK
1500	##c	I-PK
1500	##0	I-PK
1500	–	I-PK
1500	∞	I-PK
1500	between	O
1500	two	O
1500	dos	O
1500	##ing	O
1500	methods	O
1500	(	O
1500	p	O
1500	<	O
1500	0	O
1500	.	O
1500	05	O
1500	)	O
1500	.	O
1500	[SEP]	O
1501	[CLS]	O
1501	the	O
1501	90	O
1501	%	O
1501	c	O
1501	##i	O
1501	for	O
1501	the	O
1501	ratio	B-PK
1501	of	I-PK
1501	cm	I-PK
1501	##ax	I-PK
1501	(	O
1501	18	O
1501	.	O
1501	4	O
1501	%	O
1501	~	O
1501	64	O
1501	.	O
1501	7	O
1501	%	O
1501	)	O
1501	,	O
1501	au	B-PK
1501	##c	I-PK
1501	##0	I-PK
1501	–	I-PK
1501	t	I-PK
1501	(	O
1501	28	O
1501	.	O
1501	9	O
1501	%	O
1501	~	O
1501	68	O
1501	.	O
1501	5	O
1501	%	O
1501	)	O
1501	,	O
1501	and	O
1501	au	B-PK
1501	##c	I-PK
1501	##0	I-PK
1501	–	I-PK
1501	∞	I-PK
1501	(	O
1501	31	O
1501	.	O
1501	1	O
1501	%	O
1501	~	O
1501	68	O
1501	.	O
1501	4	O
1501	%	O
1501	)	O
1501	values	O
1501	for	O
1501	the	O
1501	test	O
1501	(	O
1501	fast	O
1501	##ed	O
1501	)	O
1501	and	O
1501	reference	O
1501	(	O
1501	after	O
1501	a	O
1501	meal	O
1501	)	O
1501	were	O
1501	beyond	O
1501	the	O
1501	food	O
1501	and	O
1501	drug	O
1501	administration	O
1501	’	O
1501	s	O
1501	acceptable	O
1501	range	O
1501	of	O
1501	80	O
1501	%	O
1501	~	O
1501	125	O
1501	%	O
1501	.	O
1501	[SEP]	O
1502	[CLS]	O
1502	additionally	O
1502	,	O
1502	t	B-PK
1502	##max	I-PK
1502	value	O
1502	between	O
1502	two	O
1502	phases	O
1502	exhibited	O
1502	significant	O
1502	difference	O
1502	(	O
1502	p	O
1502	<	O
1502	0	O
1502	.	O
1502	05	O
1502	)	O
1502	.	O
1502	[SEP]	O
1503	[CLS]	O
1503	compared	O
1503	with	O
1503	s	O
1503	##ham	O
1503	-	O
1503	i	O
1503	##rra	O
1503	##dia	O
1503	##ted	O
1503	controls	O
1503	,	O
1503	whole	O
1503	p	O
1503	##el	O
1503	##vic	O
1503	i	O
1503	##rra	O
1503	##diation	O
1503	reduced	O
1503	the	O
1503	area	B-PK
1503	under	I-PK
1503	the	I-PK
1503	concentration	I-PK
1503	versus	I-PK
1503	time	I-PK
1503	curve	I-PK
1503	(	I-PK
1503	au	I-PK
1503	##c	I-PK
1503	)	I-PK
1503	of	O
1503	5	O
1503	-	O
1503	f	O
1503	##u	O
1503	in	O
1503	plasma	O
1503	and	O
1503	,	O
1503	in	O
1503	contrast	O
1503	,	O
1503	increased	O
1503	in	O
1503	bi	O
1503	##le	O
1503	with	O
1503	a	O
1503	radiation	O
1503	dose	O
1503	-	O
1503	dependent	O
1503	manner	O
1503	.	O
1503	[SEP]	O
1504	[CLS]	O
1504	pre	O
1504	##tre	O
1504	##at	O
1504	##ment	O
1504	with	O
1504	mm	O
1504	##p	O
1504	-	O
1504	8	O
1504	inhibitor	O
1504	reversed	O
1504	the	O
1504	effect	O
1504	of	O
1504	i	O
1504	##rra	O
1504	##diation	O
1504	on	O
1504	au	B-PK
1504	##c	I-PK
1504	of	O
1504	5	O
1504	-	O
1504	f	O
1504	##u	O
1504	in	O
1504	plasma	O
1504	.	O
1504	[SEP]	O
1505	[CLS]	O
1505	intriguing	O
1505	##ly	O
1505	,	O
1505	we	O
1505	found	O
1505	that	O
1505	p	O
1505	##el	O
1505	##vic	O
1505	i	O
1505	##rra	O
1505	##diation	O
1505	marked	O
1505	##ly	O
1505	reduced	O
1505	the	O
1505	au	B-PK
1505	##c	I-PK
1505	of	O
1505	5	O
1505	-	O
1505	f	O
1505	##u	O
1505	in	O
1505	rats	O
1505	by	O
1505	17	O
1505	.	O
1505	6	O
1505	%	O
1505	at	O
1505	0	O
1505	.	O
1505	5	O
1505	g	O
1505	##y	O
1505	(	O
1505	p	O
1505	=	O
1505	0	O
1505	.	O
1505	01	O
1505	##9	O
1505	)	O
1505	and	O
1505	21	O
1505	.	O
1505	5	O
1505	%	O
1505	at	O
1505	2	O
1505	g	O
1505	##y	O
1505	(	O
1505	p	O
1505	=	O
1505	0	O
1505	.	O
1505	00	O
1505	##8	O
1505	)	O
1505	(	O
1505	fi	O
1505	##g	O
1505	.	O
1505	1	O
1505	##a	O
1505	)	O
1505	.	O
1505	[SEP]	O
1506	[CLS]	O
1506	p	O
1506	##el	O
1506	##vic	O
1506	i	O
1506	##rra	O
1506	##diation	O
1506	significantly	O
1506	decreased	O
1506	cm	B-PK
1506	##ax	I-PK
1506	and	O
1506	clearance	B-PK
1506	value	O
1506	,	O
1506	and	O
1506	in	O
1506	contrast	O
1506	,	O
1506	increased	O
1506	m	B-PK
1506	##rt	I-PK
1506	and	O
1506	vs	B-PK
1506	##s	I-PK
1506	of	O
1506	5	O
1506	-	O
1506	f	O
1506	##u	O
1506	,	O
1506	when	O
1506	compared	O
1506	to	O
1506	non	O
1506	-	O
1506	i	O
1506	##rra	O
1506	##dia	O
1506	##ted	O
1506	controls	O
1506	.	O
1506	[SEP]	O
1507	[CLS]	O
1507	as	O
1507	shown	O
1507	in	O
1507	table	O
1507	1	O
1507	,	O
1507	p	O
1507	##el	O
1507	##vic	O
1507	i	O
1507	##rra	O
1507	##diation	O
1507	significantly	O
1507	decreased	O
1507	mean	B-PK
1507	residence	I-PK
1507	time	I-PK
1507	(	I-PK
1507	m	I-PK
1507	##rt	I-PK
1507	)	I-PK
1507	,	O
1507	and	O
1507	by	O
1507	contrast	O
1507	,	O
1507	increased	O
1507	the	O
1507	clearance	B-PK
1507	value	O
1507	of	O
1507	5	O
1507	-	O
1507	f	O
1507	##u	O
1507	when	O
1507	compared	O
1507	to	O
1507	non	O
1507	-	O
1507	i	O
1507	##rra	O
1507	##dia	O
1507	##ted	O
1507	controls	O
1507	.	O
1507	[SEP]	O
1508	[CLS]	O
1508	there	O
1508	was	O
1508	no	O
1508	significant	O
1508	difference	O
1508	in	O
1508	the	O
1508	values	O
1508	of	O
1508	half	B-PK
1508	-	I-PK
1508	life	I-PK
1508	(	I-PK
1508	t	I-PK
1508	##1	I-PK
1508	/	I-PK
1508	2	I-PK
1508	)	I-PK
1508	,	O
1508	maximum	B-PK
1508	observed	I-PK
1508	plasma	I-PK
1508	concentration	I-PK
1508	(	I-PK
1508	cm	I-PK
1508	##ax	I-PK
1508	)	I-PK
1508	or	O
1508	volume	B-PK
1508	of	I-PK
1508	distribution	I-PK
1508	at	I-PK
1508	steady	I-PK
1508	state	I-PK
1508	(	I-PK
1508	vs	I-PK
1508	##s	I-PK
1508	)	I-PK
1508	within	O
1508	the	O
1508	tested	O
1508	groups	O
1508	.	O
1508	[SEP]	O
1509	[CLS]	O
1509	of	O
1509	interest	O
1509	,	O
1509	2	O
1509	-	O
1509	g	O
1509	##y	O
1509	i	O
1509	##rra	O
1509	##diation	O
1509	decreased	O
1509	cm	B-PK
1509	##ax	I-PK
1509	,	O
1509	and	O
1509	in	O
1509	contrast	O
1509	,	O
1509	increased	O
1509	m	B-PK
1509	##rt	I-PK
1509	(	O
1509	p	O
1509	=	O
1509	0	O
1509	.	O
1509	00	O
1509	##8	O
1509	)	O
1509	and	O
1509	vs	B-PK
1509	##s	I-PK
1509	(	O
1509	p	O
1509	=	O
1509	0	O
1509	.	O
1509	01	O
1509	##5	O
1509	)	O
1509	of	O
1509	5	O
1509	-	O
1509	f	O
1509	##u	O
1509	to	O
1509	an	O
1509	extent	O
1509	greater	O
1509	than	O
1509	that	O
1509	of	O
1509	the	O
1509	0	O
1509	.	O
1509	5	O
1509	-	O
1509	g	O
1509	##y	O
1509	group	O
1509	.	O
1509	[SEP]	O
1510	[CLS]	O
1510	there	O
1510	was	O
1510	no	O
1510	statistical	O
1510	##ly	O
1510	significant	O
1510	difference	O
1510	between	O
1510	the	O
1510	0	O
1510	.	O
1510	5	O
1510	-	O
1510	g	O
1510	##y	O
1510	and	O
1510	control	O
1510	groups	O
1510	for	O
1510	cm	B-PK
1510	##ax	I-PK
1510	and	O
1510	vs	B-PK
1510	##s	I-PK
1510	.	O
1510	[SEP]	O
1511	[CLS]	O
1511	neither	O
1511	the	O
1511	mm	O
1511	##p	O
1511	-	O
1511	8	O
1511	inhibitor	O
1511	alone	O
1511	nor	O
1511	its	O
1511	vehicle	O
1511	had	O
1511	a	O
1511	significant	O
1511	effect	O
1511	on	O
1511	the	O
1511	au	B-PK
1511	##c	I-PK
1511	of	O
1511	5	O
1511	-	O
1511	f	O
1511	##u	O
1511	in	O
1511	comparison	O
1511	with	O
1511	the	O
1511	controls	O
1511	(	O
1511	fi	O
1511	##g	O
1511	.	O
1511	6	O
1511	)	O
1511	.	O
1511	[SEP]	O
1512	[CLS]	O
1512	we	O
1512	found	O
1512	that	O
1512	pre	O
1512	##tre	O
1512	##at	O
1512	##ment	O
1512	with	O
1512	mm	O
1512	##p	O
1512	-	O
1512	8	O
1512	inhibitor	O
1512	significantly	O
1512	at	O
1512	##ten	O
1512	##uated	O
1512	the	O
1512	decline	O
1512	in	O
1512	au	B-PK
1512	##c	I-PK
1512	of	O
1512	5	O
1512	-	O
1512	f	O
1512	##u	O
1512	caused	O
1512	by	O
1512	p	O
1512	##el	O
1512	##vic	O
1512	i	O
1512	##rra	O
1512	##diation	O
1512	(	O
1512	au	B-PK
1512	##ci	I-PK
1512	##rra	I-PK
1512	##diation	I-PK
1512	versus	O
1512	au	B-PK
1512	##c	I-PK
1512	##mm	I-PK
1512	##p	I-PK
1512	-	I-PK
1512	8	I-PK
1512	inhibitor	O
1512	+	O
1512	i	O
1512	##rra	O
1512	##diation	O
1512	was	O
1512	330	O
1512	##5	O
1512	versus	O
1512	39	O
1512	##6	O
1512	##3	O
1512	min	O
1512	µ	O
1512	##g	O
1512	/	O
1512	m	O
1512	##l	O
1512	,	O
1512	p	O
1512	<	O
1512	0	O
1512	.	O
1512	05	O
1512	)	O
1512	.	O
1512	[SEP]	O
1513	[CLS]	O
1513	more	O
1513	##over	O
1513	,	O
1513	the	O
1513	decreased	O
1513	m	B-PK
1513	##rt	I-PK
1513	and	O
1513	increased	O
1513	clearance	B-PK
1513	value	O
1513	caused	O
1513	by	O
1513	i	O
1513	##rra	O
1513	##diation	O
1513	were	O
1513	completely	O
1513	reversed	O
1513	by	O
1513	use	O
1513	of	O
1513	the	O
1513	mm	O
1513	##p	O
1513	-	O
1513	8	O
1513	inhibitor	O
1513	(	O
1513	table	O
1513	3	O
1513	)	O
1513	.	O
1513	[SEP]	O
1514	[CLS]	O
1514	jar	O
1514	##ug	O
1514	##ula	O
1514	et	O
1514	al	O
1514	.	O
1514	[	O
1514	42	O
1514	]	O
1514	proved	O
1514	that	O
1514	the	O
1514	dose	B-PK
1514	-	I-PK
1514	normal	I-PK
1514	##ized	I-PK
1514	area	I-PK
1514	under	I-PK
1514	the	I-PK
1514	curve	I-PK
1514	(	I-PK
1514	au	I-PK
1514	##c	I-PK
1514	)	I-PK
1514	was	O
1514	significantly	O
1514	higher	O
1514	after	O
1514	administration	O
1514	of	O
1514	100	O
1514	mg	O
1514	/	O
1514	kg	O
1514	(	O
1514	mean	O
1514	±	O
1514	standard	O
1514	de	O
1514	##viation	O
1514	,	O
1514	s	O
1514	##d	O
1514	,	O
1514	1	O
1514	.	O
1514	14	O
1514	##±	O
1514	##0	O
1514	.	O
1514	55	O
1514	mg	O
1514	·	O
1514	h	O
1514	/	O
1514	l	O
1514	/	O
1514	mg	O
1514	)	O
1514	than	O
1514	after	O
1514	50	O
1514	mg	O
1514	/	O
1514	kg	O
1514	(	O
1514	mean	O
1514	±	O
1514	s	O
1514	##d	O
1514	,	O
1514	0	O
1514	.	O
1514	50	O
1514	##±	O
1514	##0	O
1514	.	O
1514	16	O
1514	mg	O
1514	·	O
1514	h	O
1514	/	O
1514	l	O
1514	/	O
1514	mg	O
1514	)	O
1514	or	O
1514	10	O
1514	mg	O
1514	/	O
1514	kg	O
1514	(	O
1514	mean	O
1514	±	O
1514	s	O
1514	##d	O
1514	,	O
1514	0	O
1514	.	O
1514	43	O
1514	##±	O
1514	##0	O
1514	.	O
1514	11	O
1514	mg	O
1514	·	O
1514	h	O
1514	/	O
1514	l	O
1514	/	O
1514	mg	O
1514	)	O
1514	.	O
1514	[SEP]	O
1515	[CLS]	O
1515	p	O
1515	##har	O
1515	##ma	O
1515	##co	O
1515	##kin	O
1515	##etic	O
1515	parameters	O
1515	including	O
1515	the	O
1515	au	B-PK
1515	##c	I-PK
1515	for	O
1515	concentration	O
1515	versus	O
1515	time	O
1515	,	O
1515	terminal	B-PK
1515	elimination	I-PK
1515	phase	I-PK
1515	t	I-PK
1515	##1	I-PK
1515	/	I-PK
1515	2	I-PK
1515	,	O
1515	cm	B-PK
1515	##ax	I-PK
1515	,	O
1515	m	B-PK
1515	##rt	I-PK
1515	,	O
1515	total	B-PK
1515	plasma	I-PK
1515	clearance	I-PK
1515	and	O
1515	vs	B-PK
1515	##s	I-PK
1515	were	O
1515	calculated	O
1515	using	O
1515	the	O
1515	p	O
1515	##har	O
1515	##ma	O
1515	##co	O
1515	##kin	O
1515	##etics	O
1515	calculation	O
1515	software	O
1515	win	O
1515	##non	O
1515	##lin	O
1515	standard	O
1515	edition	O
1515	,	O
1515	version	O
1515	1	O
1515	.	O
1515	1	O
1515	(	O
1515	scientific	O
1515	consulting	O
1515	,	O
1515	apex	O
1515	,	O
1515	n	O
1515	##c	O
1515	,	O
1515	us	O
1515	##a	O
1515	)	O
1515	using	O
1515	a	O
1515	compartment	O
1515	##al	O
1515	method	O
1515	.	O
1515	[SEP]	O
1516	[CLS]	O
1516	maximum	B-PK
1516	observed	I-PK
1516	plasma	I-PK
1516	concentration	I-PK
1516	(	I-PK
1516	cm	I-PK
1516	##ax	I-PK
1516	)	I-PK
1516	,	O
1516	half	B-PK
1516	-	I-PK
1516	life	I-PK
1516	,	O
1516	area	B-PK
1516	under	I-PK
1516	plasma	I-PK
1516	concentration	I-PK
1516	time	I-PK
1516	curve	I-PK
1516	(	I-PK
1516	au	I-PK
1516	##c	I-PK
1516	)	I-PK
1516	,	O
1516	and	O
1516	mean	B-PK
1516	resident	I-PK
1516	time	I-PK
1516	(	I-PK
1516	m	I-PK
1516	##rt	I-PK
1516	)	I-PK
1516	were	O
1516	significantly	O
1516	(	O
1516	p	O
1516	<	O
1516	0	O
1516	.	O
1516	05	O
1516	)	O
1516	increased	O
1516	during	O
1516	multiple	O
1516	dose	O
1516	kinetic	O
1516	study	O
1516	and	O
1516	elimination	B-PK
1516	rate	I-PK
1516	constant	I-PK
1516	was	O
1516	significantly	O
1516	(	O
1516	p	O
1516	<	O
1516	0	O
1516	.	O
1516	05	O
1516	)	O
1516	decreased	O
1516	in	O
1516	comparison	O
1516	with	O
1516	their	O
1516	respective	O
1516	single	O
1516	-	O
1516	dose	O
1516	values	O
1516	,	O
1516	while	O
1516	there	O
1516	was	O
1516	no	O
1516	significant	O
1516	difference	O
1516	in	O
1516	time	O
1516	to	O
1516	achieve	O
1516	maximum	B-PK
1516	concentration	I-PK
1516	(	I-PK
1516	t	I-PK
1516	##max	I-PK
1516	)	I-PK
1516	in	O
1516	all	O
1516	groups	O
1516	during	O
1516	both	O
1516	phases	O
1516	of	O
1516	the	O
1516	study	O
1516	.	O
1516	[SEP]	O
1517	[CLS]	O
1517	the	O
1517	study	O
1517	revealed	O
1517	higher	O
1517	values	O
1517	[	O
1517	cm	B-PK
1517	##ax	I-PK
1517	,	O
1517	au	B-PK
1517	##c	I-PK
1517	,	O
1517	area	B-PK
1517	[SEP]	O
1518	[CLS]	O
1518	under	B-PK
1518	the	I-PK
1518	moment	I-PK
1518	curve	I-PK
1518	(	I-PK
1518	au	I-PK
1518	##m	I-PK
1518	##c	I-PK
1518	)	I-PK
1518	,	O
1518	m	B-PK
1518	##rt	I-PK
1518	,	O
1518	and	O
1518	half	B-PK
1518	-	I-PK
1518	life	I-PK
1518	]	O
1518	of	O
1518	at	O
1518	##or	O
1518	##vas	O
1518	##tat	O
1518	##in	O
1518	in	O
1518	garlic	O
1518	-	O
1518	treated	O
1518	groups	O
1518	.	O
1518	[SEP]	O
1519	[CLS]	O
1519	by	O
1519	using	O
1519	this	O
1519	program	O
1519	,	O
1519	parameters	O
1519	like	O
1519	cm	B-PK
1519	##ax	I-PK
1519	,	O
1519	t	B-PK
1519	##max	I-PK
1519	,	O
1519	elimination	B-PK
1519	rate	I-PK
1519	constant	I-PK
1519	,	O
1519	half	B-PK
1519	-	I-PK
1519	life	I-PK
1519	,	O
1519	au	B-PK
1519	##c	I-PK
1519	##0	I-PK
1519	-	I-PK
1519	t	I-PK
1519	,	O
1519	au	B-PK
1519	##c	I-PK
1519	##0	I-PK
1519	-	I-PK
1519	in	I-PK
1519	##f	I-PK
1519	,	O
1519	au	B-PK
1519	##m	I-PK
1519	##c	I-PK
1519	##0	I-PK
1519	-	I-PK
1519	t	I-PK
1519	,	O
1519	and	O
1519	au	B-PK
1519	##m	I-PK
1519	##c	I-PK
1519	##0	I-PK
1519	-	I-PK
1519	in	I-PK
1519	##f	I-PK
1519	were	O
1519	calculated	O
1519	.	O
1519	[SEP]	O
1520	[CLS]	O
1520	elimination	B-PK
1520	rate	I-PK
1520	constant	I-PK
1520	and	O
1520	half	B-PK
1520	-	I-PK
1520	life	I-PK
1520	were	O
1520	calculated	O
1520	using	O
1520	all	O
1520	terminal	O
1520	concentration	O
1520	-	O
1520	time	O
1520	points	O
1520	from	O
1520	the	O
1520	point	O
1520	of	O
1520	peak	B-PK
1520	concentration	I-PK
1520	.	O
1520	[SEP]	O
1521	[CLS]	O
1521	λ	B-PK
1521	##z	I-PK
1521	is	O
1521	elimination	B-PK
1521	rate	I-PK
1521	constant	I-PK
1521	[SEP]	O
1522	[CLS]	O
1522	maximum	B-PK
1522	observed	I-PK
1522	concentration	I-PK
1522	(	I-PK
1522	cm	I-PK
1522	##ax	I-PK
1522	)	I-PK
1522	(	O
1522	ng	O
1522	/	O
1522	m	O
1522	##l	O
1522	)	O
1522	values	O
1522	of	O
1522	groups	O
1522	1	O
1522	through	O
1522	5	O
1522	[	O
1522	figures	O
1522	1	O
1522	and	O
1522	5	O
1522	]	O
1522	during	O
1522	multiple	O
1522	-	O
1522	dose	O
1522	kinetic	O
1522	study	O
1522	(	O
1522	153	O
1522	.	O
1522	85	O
1522	±	O
1522	2	O
1522	.	O
1522	63	O
1522	,	O
1522	250	O
1522	.	O
1522	85	O
1522	±	O
1522	2	O
1522	.	O
1522	89	O
1522	,	O
1522	147	O
1522	.	O
1522	31	O
1522	±	O
1522	5	O
1522	.	O
1522	48	O
1522	,	O
1522	128	O
1522	.	O
1522	89	O
1522	±	O
1522	4	O
1522	.	O
1522	29	O
1522	,	O
1522	and	O
1522	71	O
1522	.	O
1522	24	O
1522	±	O
1522	2	O
1522	.	O
1522	11	O
1522	,	O
1522	respectively	O
1522	)	O
1522	were	O
1522	significantly	O
1522	(	O
1522	p	O
1522	<	O
1522	0	O
1522	.	O
1522	05	O
1522	)	O
1522	higher	O
1522	than	O
1522	those	O
1522	of	O
1522	their	O
1522	respective	O
1522	single	O
1522	-	O
1522	dose	O
1522	kinetic	O
1522	values	O
1522	.	O
1522	[SEP]	O
1523	[CLS]	O
1523	there	O
1523	was	O
1523	no	O
1523	significant	O
1523	difference	O
1523	in	O
1523	time	B-PK
1523	to	I-PK
1523	achieve	I-PK
1523	maximum	I-PK
1523	concentration	I-PK
1523	(	I-PK
1523	t	I-PK
1523	##max	I-PK
1523	)	I-PK
1523	(	O
1523	h	O
1523	)	O
1523	values	O
1523	in	O
1523	all	O
1523	groups	O
1523	during	O
1523	both	O
1523	phases	O
1523	of	O
1523	study	O
1523	.	O
1523	[SEP]	O
1524	[CLS]	O
1524	the	O
1524	cm	B-PK
1524	##ax	I-PK
1524	value	O
1524	observed	O
1524	during	O
1524	multiple	O
1524	dose	O
1524	study	O
1524	in	O
1524	group	O
1524	2	O
1524	was	O
1524	the	O
1524	highest	O
1524	(	O
1524	250	O
1524	.	O
1524	85	O
1524	±	O
1524	2	O
1524	.	O
1524	89	O
1524	)	O
1524	and	O
1524	significantly	O
1524	(	O
1524	p	O
1524	<	O
1524	0	O
1524	.	O
1524	05	O
1524	)	O
1524	higher	O
1524	as	O
1524	compared	O
1524	to	O
1524	its	O
1524	single	O
1524	-	O
1524	dose	O
1524	study	O
1524	value	O
1524	(	O
1524	162	O
1524	.	O
1524	14	O
1524	±	O
1524	2	O
1524	.	O
1524	90	O
1524	)	O
1524	and	O
1524	that	O
1524	of	O
1524	multiple	O
1524	-	O
1524	dose	O
1524	study	O
1524	value	O
1524	of	O
1524	group	O
1524	1	O
1524	(	O
1524	at	O
1524	##or	O
1524	##vas	O
1524	##tat	O
1524	##in	O
1524	control	O
1524	)	O
1524	.	O
1524	[SEP]	O
1525	[CLS]	O
1525	elimination	B-PK
1525	rate	I-PK
1525	constant	I-PK
1525	(	O
1525	h	O
1525	–	O
1525	1	O
1525	)	O
1525	in	O
1525	all	O
1525	groups	O
1525	showed	O
1525	a	O
1525	significant	O
1525	(	O
1525	p	O
1525	<	O
1525	0	O
1525	.	O
1525	05	O
1525	)	O
1525	decrease	O
1525	during	O
1525	multiple	O
1525	-	O
1525	dose	O
1525	study	O
1525	when	O
1525	compared	O
1525	to	O
1525	their	O
1525	respective	O
1525	values	O
1525	during	O
1525	single	O
1525	-	O
1525	dose	O
1525	study	O
1525	.	O
1525	[SEP]	O
1526	[CLS]	O
1526	elimination	B-PK
1526	rate	I-PK
1526	constant	I-PK
1526	value	O
1526	observed	O
1526	in	O
1526	group	O
1526	2	O
1526	during	O
1526	multiple	O
1526	-	O
1526	dose	O
1526	study	O
1526	was	O
1526	the	O
1526	least	O
1526	(	O
1526	0	O
1526	.	O
1526	131	O
1526	±	O
1526	0	O
1526	.	O
1526	00	O
1526	##6	O
1526	)	O
1526	followed	O
1526	by	O
1526	groups	O
1526	1	O
1526	,	O
1526	3	O
1526	,	O
1526	and	O
1526	4	O
1526	,	O
1526	while	O
1526	group	O
1526	5	O
1526	showed	O
1526	the	O
1526	highest	O
1526	elimination	B-PK
1526	rate	I-PK
1526	constant	I-PK
1526	(	O
1526	0	O
1526	.	O
1526	253	O
1526	±	O
1526	0	O
1526	.	O
1526	11	O
1526	)	O
1526	.	O
1526	[SEP]	O
1527	[CLS]	O
1527	elimination	B-PK
1527	rate	I-PK
1527	constant	I-PK
1527	observed	O
1527	in	O
1527	group	O
1527	2	O
1527	was	O
1527	significantly	O
1527	(	O
1527	p	O
1527	<	O
1527	0	O
1527	.	O
1527	05	O
1527	)	O
1527	lower	O
1527	than	O
1527	that	O
1527	observed	O
1527	in	O
1527	group	O
1527	1	O
1527	(	O
1527	at	O
1527	##or	O
1527	##vas	O
1527	##tat	O
1527	##in	O
1527	control	O
1527	)	O
1527	during	O
1527	multiple	O
1527	-	O
1527	dose	O
1527	study	O
1527	.	O
1527	[SEP]	O
1528	[CLS]	O
1528	the	O
1528	highest	O
1528	au	B-PK
1528	##c	I-PK
1528	(	I-PK
1528	0	I-PK
1528	-	I-PK
1528	t	I-PK
1528	)	I-PK
1528	(	O
1528	ng	O
1528	.	O
1528	h	O
1528	/	O
1528	m	O
1528	##l	O
1528	)	O
1528	and	O
1528	au	B-PK
1528	##c	I-PK
1528	(	I-PK
1528	0	I-PK
1528	-	I-PK
1528	∞	I-PK
1528	)	I-PK
1528	(	O
1528	ng	O
1528	.	O
1528	h	O
1528	/	O
1528	m	O
1528	##l	O
1528	)	O
1528	values	O
1528	were	O
1528	observed	O
1528	in	O
1528	group	O
1528	2	O
1528	during	O
1528	both	O
1528	phases	O
1528	of	O
1528	the	O
1528	study	O
1528	,	O
1528	followed	O
1528	by	O
1528	groups	O
1528	1	O
1528	and	O
1528	3	O
1528	.	O
1528	[SEP]	O
1529	[CLS]	O
1529	the	O
1529	au	B-PK
1529	##c	I-PK
1529	(	I-PK
1529	0	I-PK
1529	-	I-PK
1529	∞	I-PK
1529	)	I-PK
1529	value	O
1529	observed	O
1529	in	O
1529	group	O
1529	2	O
1529	during	O
1529	multiple	O
1529	-	O
1529	dose	O
1529	(	O
1529	27	O
1529	##18	O
1529	.	O
1529	68	O
1529	±	O
1529	63	O
1529	.	O
1529	40	O
1529	)	O
1529	studies	O
1529	was	O
1529	significantly	O
1529	(	O
1529	p	O
1529	<	O
1529	0	O
1529	.	O
1529	05	O
1529	)	O
1529	higher	O
1529	than	O
1529	its	O
1529	respective	O
1529	single	O
1529	-	O
1529	dose	O
1529	value	O
1529	(	O
1529	152	O
1529	##6	O
1529	.	O
1529	73	O
1529	±	O
1529	29	O
1529	.	O
1529	03	O
1529	)	O
1529	and	O
1529	also	O
1529	higher	O
1529	than	O
1529	the	O
1529	value	O
1529	of	O
1529	group	O
1529	1	O
1529	(	O
1529	at	O
1529	##or	O
1529	##vas	O
1529	##tat	O
1529	##in	O
1529	control	O
1529	)	O
1529	(	O
1529	140	O
1529	##1	O
1529	.	O
1529	48	O
1529	±	O
1529	31	O
1529	.	O
1529	01	O
1529	)	O
1529	.	O
1529	[SEP]	O
1530	[CLS]	O
1530	mean	B-PK
1530	resident	I-PK
1530	time	I-PK
1530	(	I-PK
1530	m	I-PK
1530	##rt	I-PK
1530	)	I-PK
1530	(	O
1530	h	O
1530	)	O
1530	during	O
1530	multiple	O
1530	-	O
1530	dose	O
1530	study	O
1530	in	O
1530	all	O
1530	groups	O
1530	was	O
1530	significantly	O
1530	(	O
1530	p	O
1530	<	O
1530	0	O
1530	.	O
1530	05	O
1530	)	O
1530	higher	O
1530	when	O
1530	compared	O
1530	to	O
1530	their	O
1530	respective	O
1530	single	O
1530	-	O
1530	dose	O
1530	study	O
1530	value	O
1530	.	O
1530	[SEP]	O
1531	[CLS]	O
1531	the	O
1531	highest	O
1531	m	B-PK
1531	##rt	I-PK
1531	was	O
1531	noted	O
1531	in	O
1531	group	O
1531	2	O
1531	(	O
1531	8	O
1531	.	O
1531	19	O
1531	±	O
1531	0	O
1531	.	O
1531	27	O
1531	)	O
1531	during	O
1531	multiple	O
1531	-	O
1531	dose	O
1531	study	O
1531	followed	O
1531	by	O
1531	groups	O
1531	1	O
1531	,	O
1531	4	O
1531	,	O
1531	and	O
1531	3	O
1531	,	O
1531	while	O
1531	m	B-PK
1531	##rt	I-PK
1531	of	O
1531	group	O
1531	5	O
1531	(	O
1531	4	O
1531	.	O
1531	57	O
1531	±	O
1531	0	O
1531	.	O
1531	11	O
1531	)	O
1531	was	O
1531	found	O
1531	to	O
1531	be	O
1531	the	O
1531	least	O
1531	.	O
1531	[SEP]	O
1532	[CLS]	O
1532	m	B-PK
1532	##rt	I-PK
1532	value	O
1532	of	O
1532	group	O
1532	2	O
1532	was	O
1532	also	O
1532	significantly	O
1532	(	O
1532	p	O
1532	<	O
1532	0	O
1532	.	O
1532	05	O
1532	)	O
1532	higher	O
1532	than	O
1532	that	O
1532	of	O
1532	group	O
1532	1	O
1532	at	O
1532	the	O
1532	end	O
1532	of	O
1532	multiple	O
1532	-	O
1532	dose	O
1532	study	O
1532	(	O
1532	7	O
1532	.	O
1532	31	O
1532	±	O
1532	0	O
1532	.	O
1532	07	O
1532	)	O
1532	[	O
1532	table	O
1532	2	O
1532	]	O
1532	.	O
1532	[SEP]	O
1533	[CLS]	O
1533	to	O
1533	the	O
1533	best	O
1533	of	O
1533	our	O
1533	knowledge	O
1533	,	O
1533	there	O
1533	are	O
1533	no	O
1533	available	O
1533	data	O
1533	concerning	O
1533	its	O
1533	pre	O
1533	##c	O
1533	##lini	O
1533	##cal	O
1533	p	O
1533	##har	O
1533	##ma	O
1533	##co	O
1533	##kin	O
1533	##etics	O
1533	and	O
1533	bio	B-PK
1533	##ava	I-PK
1533	##ila	I-PK
1533	##bility	I-PK
1533	in	O
1533	be	O
1533	##ag	O
1533	##le	O
1533	dogs	O
1533	.	O
1533	[SEP]	O
1534	[CLS]	O
1534	to	O
1534	support	O
1534	pre	O
1534	##c	O
1534	##lini	O
1534	##cal	O
1534	p	O
1534	##har	O
1534	##ma	O
1534	##co	O
1534	##kin	O
1534	##etic	O
1534	and	O
1534	bio	B-PK
1534	##ava	I-PK
1534	##ila	I-PK
1534	##bility	I-PK
1534	study	O
1534	,	O
1534	a	O
1534	reliable	O
1534	l	O
1534	##c	O
1534	-	O
1534	m	O
1534	##s	O
1534	/	O
1534	m	O
1534	##s	O
1534	method	O
1534	was	O
1534	developed	O
1534	for	O
1534	k	O
1534	##d	O
1534	concentration	O
1534	measurements	O
1534	in	O
1534	be	O
1534	##ag	O
1534	##le	O
1534	dog	O
1534	plasma	O
1534	.	O
1534	[SEP]	O
1535	[CLS]	O
1535	the	O
1535	currently	O
1535	developed	O
1535	method	O
1535	was	O
1535	valid	O
1535	##ated	O
1535	and	O
1535	applied	O
1535	to	O
1535	a	O
1535	p	O
1535	##har	O
1535	##ma	O
1535	##co	O
1535	##kin	O
1535	##etic	O
1535	and	O
1535	bio	B-PK
1535	##ava	I-PK
1535	##ila	I-PK
1535	##bility	I-PK
1535	study	O
1535	of	O
1535	k	O
1535	##d	O
1535	in	O
1535	be	O
1535	##ag	O
1535	##le	O
1535	dogs	O
1535	following	O
1535	oral	O
1535	administration	O
1535	at	O
1535	a	O
1535	dose	O
1535	of	O
1535	3	O
1535	mg	O
1535	/	O
1535	kg	O
1535	.	O
1535	[SEP]	O
1536	[CLS]	O
1536	the	O
1536	absolute	B-PK
1536	oral	I-PK
1536	bio	I-PK
1536	##ava	I-PK
1536	##ila	I-PK
1536	##bility	I-PK
1536	for	O
1536	k	O
1536	##d	O
1536	was	O
1536	determined	O
1536	to	O
1536	be	O
1536	27	O
1536	.	O
1536	6	O
1536	%	O
1536	.	O
1536	[SEP]	O
1537	[CLS]	O
1537	compared	O
1537	with	O
1537	typical	O
1537	g	O
1537	##ly	O
1537	##cos	O
1537	##ides	O
1537	,	O
1537	k	O
1537	##d	O
1537	has	O
1537	a	O
1537	better	O
1537	bio	B-PK
1537	##ava	I-PK
1537	##ila	I-PK
1537	##bility	I-PK
1537	and	O
1537	is	O
1537	suitable	O
1537	for	O
1537	developing	O
1537	an	O
1537	oral	O
1537	dos	O
1537	##age	O
1537	form	O
1537	.	O
1537	[SEP]	O
1538	[CLS]	O
1538	the	O
1538	valid	O
1538	##ated	O
1538	method	O
1538	was	O
1538	applied	O
1538	to	O
1538	a	O
1538	pre	O
1538	##c	O
1538	##lini	O
1538	##cal	O
1538	p	O
1538	##har	O
1538	##ma	O
1538	##co	O
1538	##kin	O
1538	##etic	O
1538	and	O
1538	bio	B-PK
1538	##ava	I-PK
1538	##ila	I-PK
1538	##bility	I-PK
1538	study	O
1538	of	O
1538	k	O
1538	##d	O
1538	in	O
1538	be	O
1538	##ag	O
1538	##le	O
1538	dogs	O
1538	following	O
1538	in	O
1538	##tra	O
1538	##ven	O
1538	##ous	O
1538	and	O
1538	oral	O
1538	administration	O
1538	.	O
1538	[SEP]	O
1539	[CLS]	O
1539	the	O
1539	maximum	B-PK
1539	plasma	I-PK
1539	concentration	I-PK
1539	(	I-PK
1539	cm	I-PK
1539	##ax	I-PK
1539	)	I-PK
1539	and	O
1539	time	B-PK
1539	to	I-PK
1539	reach	I-PK
1539	cm	I-PK
1539	##ax	I-PK
1539	(	I-PK
1539	t	I-PK
1539	##max	I-PK
1539	)	I-PK
1539	were	O
1539	obtained	O
1539	directly	O
1539	from	O
1539	the	O
1539	plasma	O
1539	concentration	O
1539	time	O
1539	course	O
1539	.	O
1539	[SEP]	O
1540	[CLS]	O
1540	the	O
1540	area	B-PK
1540	under	I-PK
1540	the	I-PK
1540	plasma	I-PK
1540	concentration	I-PK
1540	versus	I-PK
1540	time	I-PK
1540	curve	I-PK
1540	(	I-PK
1540	au	I-PK
1540	##c	I-PK
1540	)	I-PK
1540	from	I-PK
1540	time	I-PK
1540	zero	I-PK
1540	to	I-PK
1540	the	I-PK
1540	last	I-PK
1540	measured	I-PK
1540	time	I-PK
1540	point	I-PK
1540	(	I-PK
1540	au	I-PK
1540	##c	I-PK
1540	##0	I-PK
1540	–	I-PK
1540	t	I-PK
1540	)	I-PK
1540	and	O
1540	from	O
1540	time	O
1540	zero	O
1540	to	O
1540	in	O
1540	##finity	O
1540	(	O
1540	au	B-PK
1540	##c	I-PK
1540	##0	I-PK
1540	–	I-PK
1540	∞	I-PK
1540	)	O
1540	were	O
1540	estimated	O
1540	using	O
1540	the	O
1540	log	O
1540	-	O
1540	linear	O
1540	trap	O
1540	##ez	O
1540	##oid	O
1540	##al	O
1540	rule	O
1540	,	O
1540	while	O
1540	the	O
1540	elimination	B-PK
1540	half	I-PK
1540	-	I-PK
1540	life	I-PK
1540	(	I-PK
1540	t	I-PK
1540	##1	I-PK
1540	/	I-PK
1540	2	I-PK
1540	)	I-PK
1540	,	O
1540	the	O
1540	total	B-PK
1540	body	I-PK
1540	clearance	I-PK
1540	(	I-PK
1540	c	I-PK
1540	##l	I-PK
1540	)	I-PK
1540	,	O
1540	and	O
1540	the	O
1540	apparent	B-PK
1540	volume	I-PK
1540	of	I-PK
1540	distribution	I-PK
1540	(	I-PK
1540	v	I-PK
1540	##d	I-PK
1540	)	I-PK
1540	were	O
1540	processed	O
1540	by	O
1540	p	O
1540	##hoe	O
1540	##ni	O
1540	##x	O
1540	win	O
1540	##non	O
1540	##lin	O
1540	software	O
1540	.	O
1540	[SEP]	O
1541	[CLS]	O
1541	oral	B-PK
1541	bio	I-PK
1541	##ava	I-PK
1541	##ila	I-PK
1541	##bility	I-PK
1541	(	I-PK
1541	f	I-PK
1541	)	I-PK
1541	was	O
1541	calculated	O
1541	using	O
1541	the	O
1541	formula	O
1541	f	O
1541	=	O
1541	(	O
1541	au	O
1541	##c	O
1541	##po	O
1541	/	O
1541	au	O
1541	##ci	O
1541	##v	O
1541	)	O
1541	×	O
1541	(	O
1541	dose	O
1541	##iv	O
1541	/	O
1541	dose	O
1541	##po	O
1541	)	O
1541	.	O
1541	[SEP]	O
1542	[CLS]	O
1542	after	O
1542	an	O
1542	oral	O
1542	dose	O
1542	of	O
1542	3	O
1542	mg	O
1542	/	O
1542	kg	O
1542	,	O
1542	k	O
1542	##d	O
1542	was	O
1542	quickly	O
1542	absorbed	O
1542	and	O
1542	the	O
1542	cm	B-PK
1542	##ax	I-PK
1542	was	O
1542	reached	O
1542	at	O
1542	around	O
1542	1	O
1542	.	O
1542	04	O
1542	h	O
1542	,	O
1542	followed	O
1542	by	O
1542	a	O
1542	rapid	O
1542	elimination	O
1542	with	O
1542	a	O
1542	half	B-PK
1542	-	I-PK
1542	life	I-PK
1542	of	O
1542	0	O
1542	.	O
1542	91	O
1542	##5	O
1542	h	O
1542	.	O
1542	the	O
1542	mean	O
1542	au	B-PK
1542	##c	I-PK
1542	##0	I-PK
1542	-	I-PK
1542	t	I-PK
1542	values	O
1542	were	O
1542	68	O
1542	##20	O
1542	and	O
1542	1880	O
1542	ng	O
1542	·	O
1542	min	O
1542	/	O
1542	m	O
1542	##l	O
1542	for	O
1542	in	O
1542	##tra	O
1542	##ven	O
1542	##ous	O
1542	and	O
1542	oral	O
1542	doses	O
1542	of	O
1542	3	O
1542	mg	O
1542	/	O
1542	kg	O
1542	k	O
1542	##d	O
1542	.	O
1542	[SEP]	O
1543	[CLS]	O
1543	based	O
1543	upon	O
1543	such	O
1543	data	O
1543	,	O
1543	the	O
1543	bio	B-PK
1543	##ava	I-PK
1543	##ila	I-PK
1543	##bility	I-PK
1543	of	O
1543	k	O
1543	##d	O
1543	following	O
1543	oral	O
1543	administration	O
1543	(	O
1543	3	O
1543	mg	O
1543	/	O
1543	kg	O
1543	)	O
1543	was	O
1543	found	O
1543	to	O
1543	be	O
1543	27	O
1543	.	O
1543	6	O
1543	%	O
1543	.	O
1543	[SEP]	O
1544	[CLS]	O
1544	compared	O
1544	with	O
1544	those	O
1544	of	O
1544	the	O
1544	majority	O
1544	of	O
1544	extensively	O
1544	researched	O
1544	is	O
1544	##of	O
1544	##lav	O
1544	##one	O
1544	g	O
1544	##ly	O
1544	##cos	O
1544	##ides	O
1544	,	O
1544	the	O
1544	bio	B-PK
1544	##ava	I-PK
1544	##ila	I-PK
1544	##bility	I-PK
1544	of	O
1544	k	O
1544	##d	O
1544	was	O
1544	at	O
1544	least	O
1544	4	O
1544	-	O
1544	fold	O
1544	higher	O
1544	[	O
1544	24	O
1544	,	O
1544	25	O
1544	,	O
1544	26	O
1544	]	O
1544	.	O
1544	[SEP]	O
1545	[CLS]	O
1545	although	O
1545	this	O
1545	study	O
1545	provides	O
1545	the	O
1545	ground	O
1545	##work	O
1545	for	O
1545	knowing	O
1545	the	O
1545	oral	B-PK
1545	bio	I-PK
1545	##ava	I-PK
1545	##ila	I-PK
1545	##bility	I-PK
1545	of	O
1545	k	O
1545	##d	O
1545	,	O
1545	comprehensive	O
1545	studies	O
1545	are	O
1545	required	O
1545	to	O
1545	further	O
1545	investigate	O
1545	absorption	O
1545	,	O
1545	distribution	O
1545	,	O
1545	metabolism	O
1545	,	O
1545	and	O
1545	ex	O
1545	##cre	O
1545	##tion	O
1545	processes	O
1545	in	O
1545	pre	O
1545	##c	O
1545	##lini	O
1545	##cal	O
1545	animal	O
1545	models	O
1545	.	O
1545	[SEP]	O
1546	[CLS]	O
1546	delivery	O
1546	of	O
1546	hug	O
1546	##t	O
1546	##1	O
1546	##a	O
1546	##1	O
1546	‐	O
1546	m	O
1546	##od	O
1546	##rna	O
1546	(	O
1546	a	O
1546	modified	O
1546	messenger	O
1546	r	O
1546	##na	O
1546	encoding	O
1546	for	O
1546	u	O
1546	##gt	O
1546	##1	O
1546	##a	O
1546	##1	O
1546	)	O
1546	as	O
1546	a	O
1546	lip	O
1546	##id	O
1546	na	O
1546	##no	O
1546	##par	O
1546	##tic	O
1546	##le	O
1546	is	O
1546	anticipated	O
1546	to	O
1546	restore	O
1546	he	O
1546	##pa	O
1546	##tic	O
1546	expression	O
1546	of	O
1546	u	O
1546	##gt	O
1546	##1	O
1546	##a	O
1546	##1	O
1546	,	O
1546	allowing	O
1546	normal	O
1546	g	O
1546	##lu	O
1546	##cu	O
1546	##ron	O
1546	##ida	O
1546	##tion	O
1546	and	O
1546	clearance	B-PK
1546	of	O
1546	bi	O
1546	##li	O
1546	##ru	O
1546	##bin	O
1546	in	O
1546	patients	O
1546	.	O
1546	[SEP]	O
1547	[CLS]	O
1547	a	O
1547	new	O
1547	hug	O
1547	##t	O
1547	##1	O
1547	##a	O
1547	##1	O
1547	‐	O
1547	m	O
1547	##od	O
1547	##rna	O
1547	therapy	O
1547	discussed	O
1547	in	O
1547	this	O
1547	report	O
1547	aims	O
1547	to	O
1547	enable	O
1547	he	O
1547	##pa	O
1547	##tic	O
1547	expression	O
1547	of	O
1547	functional	O
1547	u	O
1547	##gt	O
1547	##1	O
1547	##a	O
1547	##1	O
1547	enzyme	O
1547	to	O
1547	restore	O
1547	the	O
1547	normal	O
1547	bi	O
1547	##li	O
1547	##ru	O
1547	##bin	O
1547	clearance	B-PK
1547	pathway	O
1547	.	O
1547	[SEP]	O
1548	[CLS]	O
1548	non	O
1548	##com	O
1548	##par	O
1548	##tment	O
1548	p	O
1548	##k	O
1548	analysis	O
1548	was	O
1548	performed	O
1548	to	O
1548	obtain	O
1548	exposure	O
1548	(	O
1548	peak	B-PK
1548	plasma	I-PK
1548	concentration	I-PK
1548	(	I-PK
1548	cm	I-PK
1548	##ax	I-PK
1548	)	I-PK
1548	and	O
1548	area	B-PK
1548	under	I-PK
1548	the	I-PK
1548	curve	I-PK
1548	(	I-PK
1548	au	I-PK
1548	##c	I-PK
1548	)	I-PK
1548	)	O
1548	information	O
1548	in	O
1548	plasma	O
1548	and	O
1548	liver	O
1548	(	O
1548	data	O
1548	not	O
1548	shown	O
1548	)	O
1548	.	O
1548	[SEP]	O
1549	[CLS]	O
1549	specifically	O
1549	,	O
1549	the	O
1549	model	O
1549	includes	O
1549	:	O
1549	(	O
1549	1	O
1549	)	O
1549	elimination	O
1549	of	O
1549	l	O
1549	##n	O
1549	##p	O
1549	from	O
1549	the	O
1549	plasma	O
1549	due	O
1549	to	O
1549	lip	O
1549	##oso	O
1549	##mal	O
1549	instability	O
1549	;	O
1549	(	O
1549	2	O
1549	)	O
1549	the	O
1549	up	O
1549	##take	O
1549	of	O
1549	l	O
1549	##n	O
1549	##p	O
1549	by	O
1549	end	O
1549	##oc	O
1549	##yt	O
1549	##osis	O
1549	into	O
1549	liver	O
1549	he	O
1549	##pa	O
1549	##to	O
1549	##cy	O
1549	##tes	O
1549	;	O
1549	(	O
1549	3	O
1549	)	O
1549	release	O
1549	of	O
1549	m	O
1549	##rna	O
1549	from	O
1549	the	O
1549	end	O
1549	##oso	O
1549	##me	O
1549	into	O
1549	the	O
1549	c	O
1549	##yt	O
1549	##op	O
1549	##las	O
1549	##m	O
1549	;	O
1549	(	O
1549	4	O
1549	)	O
1549	the	O
1549	transcription	O
1549	of	O
1549	the	O
1549	m	O
1549	##rna	O
1549	to	O
1549	produce	O
1549	u	O
1549	##gt	O
1549	##1	O
1549	##a	O
1549	##1	O
1549	protein	O
1549	;	O
1549	and	O
1549	(	O
1549	5	O
1549	)	O
1549	g	O
1549	##lu	O
1549	##cu	O
1549	##ron	O
1549	##ida	O
1549	##tion	O
1549	of	O
1549	bi	O
1549	##li	O
1549	##ru	O
1549	##bin	O
1549	by	O
1549	u	O
1549	##gt	O
1549	##1	O
1549	##a	O
1549	##1	O
1549	leading	O
1549	to	O
1549	(	O
1549	6	O
1549	)	O
1549	increased	O
1549	clearance	B-PK
1549	of	O
1549	bi	O
1549	##li	O
1549	##ru	O
1549	##bin	O
1549	.	O
1549	[SEP]	O
1550	[CLS]	O
1550	further	O
1550	##more	O
1550	,	O
1550	a	O
1550	systematic	O
1550	sensitivity	O
1550	analysis	O
1550	based	O
1550	on	O
1550	area	O
1550	under	O
1550	the	O
1550	absolute	O
1550	se	O
1550	##ns	O
1550	##iti	O
1550	##vi	O
1550	##ties	O
1550	was	O
1550	performed	O
1550	to	O
1550	explore	O
1550	the	O
1550	impact	O
1550	of	O
1550	model	O
1550	parameters	O
1550	on	O
1550	the	O
1550	time	O
1550	course	O
1550	of	O
1550	total	O
1550	bi	O
1550	##li	O
1550	##ru	O
1550	##bin	O
1550	levels	O
1550	in	O
1550	rat	O
1550	studies	O
1550	(	O
1550	supplement	O
1550	##ary	O
1550	figure	O
1550	s	O
1550	##2	O
1550	)	O
1550	.	O
1550	[SEP]	O
1551	[CLS]	O
1551	the	O
1551	parameter	O
1551	vs	O
1551	.	O
1551	objective	O
1551	function	O
1551	curves	O
1551	for	O
1551	protein	O
1551	binding	O
1551	on	O
1551	‐	O
1551	rate	O
1551	constant	O
1551	(	O
1551	k	O
1551	##on	O
1551	)	O
1551	,	O
1551	protein	O
1551	binding	O
1551	di	O
1551	##sso	O
1551	##ciation	O
1551	rate	O
1551	constant	O
1551	(	O
1551	k	O
1551	##off	O
1551	)	O
1551	,	O
1551	and	O
1551	elimination	B-PK
1551	rate	I-PK
1551	of	O
1551	mon	O
1551	##og	O
1551	##lu	O
1551	##cu	O
1551	##ron	O
1551	##ide	O
1551	bi	O
1551	##li	O
1551	##ru	O
1551	##bin	O
1551	(	O
1551	k	B-PK
1551	##cle	I-PK
1551	##arm	I-PK
1551	##gt	I-PK
1551	)	O
1551	were	O
1551	found	O
1551	to	O
1551	be	O
1551	flat	O
1551	indicating	O
1551	that	O
1551	the	O
1551	model	O
1551	fit	O
1551	is	O
1551	not	O
1551	sensitive	O
1551	to	O
1551	the	O
1551	value	O
1551	of	O
1551	these	O
1551	parameters	O
1551	over	O
1551	this	O
1551	range	O
1551	.	O
1551	[SEP]	O
1552	[CLS]	O
1552	whereas	O
1552	,	O
1552	the	O
1552	elimination	B-PK
1552	rate	I-PK
1552	of	I-PK
1552	bi	I-PK
1552	##li	I-PK
1552	##ru	I-PK
1552	##bin	I-PK
1552	(	I-PK
1552	k	I-PK
1552	##cle	I-PK
1552	##ar	I-PK
1552	##bil	I-PK
1552	)	I-PK
1552	and	O
1552	elimination	B-PK
1552	rate	I-PK
1552	of	I-PK
1552	d	I-PK
1552	##gt	I-PK
1552	bi	I-PK
1552	##li	I-PK
1552	##ru	I-PK
1552	##bin	I-PK
1552	(	I-PK
1552	k	I-PK
1552	##cle	I-PK
1552	##ard	I-PK
1552	##gt	I-PK
1552	)	I-PK
1552	are	O
1552	highly	O
1552	sensitive	O
1552	.	O
1552	[SEP]	O
1553	[CLS]	O
1553	there	O
1553	are	O
1553	one	O
1553	‐	O
1553	sided	O
1553	sensitive	O
1553	##s	O
1553	for	O
1553	first	B-PK
1553	order	I-PK
1553	elimination	I-PK
1553	rate	I-PK
1553	of	I-PK
1553	l	I-PK
1553	##n	I-PK
1553	##p	I-PK
1553	(	I-PK
1553	k	I-PK
1553	##w	I-PK
1553	)	I-PK
1553	and	O
1553	drug	B-PK
1553	distribution	I-PK
1553	rate	I-PK
1553	constant	I-PK
1553	from	I-PK
1553	plasma	I-PK
1553	to	I-PK
1553	tissue	I-PK
1553	(	I-PK
1553	k	I-PK
1553	##12	I-PK
1553	)	I-PK
1553	indicating	O
1553	that	O
1553	a	O
1553	higher	O
1553	value	O
1553	for	O
1553	these	O
1553	parameters	O
1553	is	O
1553	less	O
1553	likely	O
1553	than	O
1553	a	O
1553	lower	O
1553	value	O
1553	.	O
1553	[SEP]	O
1554	[CLS]	O
1554	the	O
1554	plasma	B-PK
1554	half	I-PK
1554	‐	I-PK
1554	life	I-PK
1554	of	O
1554	l	O
1554	##n	O
1554	##p	O
1554	was	O
1554	determined	O
1554	to	O
1554	be	O
1554	[UNK]	O
1554	hours	O
1554	(	O
1554	k	O
1554	##w	O
1554	=	O
1554	2	O
1554	.	O
1554	41	O
1554	##e	O
1554	‐	O
1554	05	O
1554	1	O
1554	/	O
1554	s	O
1554	)	O
1554	.	O
1554	[SEP]	O
1555	[CLS]	O
1555	the	O
1555	main	O
1555	parameters	O
1555	that	O
1555	are	O
1555	anticipated	O
1555	to	O
1555	be	O
1555	different	O
1555	between	O
1555	gun	O
1555	##n	O
1555	rats	O
1555	and	O
1555	patients	O
1555	with	O
1555	c	O
1555	##n	O
1555	##1	O
1555	are	O
1555	the	O
1555	production	O
1555	and	O
1555	clearance	B-PK
1555	rates	I-PK
1555	of	O
1555	un	O
1555	##mo	O
1555	##dified	O
1555	bi	O
1555	##li	O
1555	##ru	O
1555	##bin	O
1555	.	O
1555	[SEP]	O
1556	[CLS]	O
1556	in	O
1556	contrast	O
1556	to	O
1556	the	O
1556	bi	O
1556	##li	O
1556	##ru	O
1556	##bin	O
1556	synthesis	O
1556	and	O
1556	clearance	B-PK
1556	rate	I-PK
1556	,	O
1556	other	O
1556	parameters	O
1556	used	O
1556	in	O
1556	the	O
1556	q	O
1556	##sp	O
1556	model	O
1556	represent	O
1556	bio	O
1556	##physical	O
1556	interactions	O
1556	or	O
1556	cellular	O
1556	processes	O
1556	that	O
1556	are	O
1556	expected	O
1556	to	O
1556	be	O
1556	preserved	O
1556	between	O
1556	humans	O
1556	and	O
1556	rats	O
1556	and	O
1556	fixed	O
1556	as	O
1556	such	O
1556	in	O
1556	the	O
1556	human	O
1556	model	O
1556	(	O
1556	table	O
1556	##1	O
1556	)	O
1556	.	O
1556	[SEP]	O
1557	[CLS]	O
1557	for	O
1557	example	O
1557	,	O
1557	as	O
1557	the	O
1557	major	O
1557	clearance	B-PK
1557	route	O
1557	of	O
1557	plasma	O
1557	l	O
1557	##n	O
1557	##p	O
1557	is	O
1557	thought	O
1557	to	O
1557	be	O
1557	l	O
1557	##n	O
1557	##p	O
1557	instability	O
1557	,	O
1557	8	O
1557	,	O
1557	9	O
1557	the	O
1557	elimination	B-PK
1557	rate	I-PK
1557	was	O
1557	assumed	O
1557	to	O
1557	be	O
1557	the	O
1557	same	O
1557	in	O
1557	humans	O
1557	and	O
1557	gun	O
1557	##n	O
1557	rats	O
1557	.	O
1557	[SEP]	O
1558	[CLS]	O
1558	the	O
1558	primary	O
1558	end	O
1558	##point	O
1558	was	O
1558	systemic	O
1558	o	O
1558	##xy	O
1558	##mor	O
1558	##phone	O
1558	exposure	O
1558	;	O
1558	the	O
1558	bio	O
1558	##e	O
1558	##qui	O
1558	##valence	O
1558	criterion	O
1558	was	O
1558	met	O
1558	if	O
1558	the	O
1558	90	O
1558	%	O
1558	confidence	O
1558	intervals	O
1558	of	O
1558	the	O
1558	geometric	O
1558	mean	O
1558	ratio	O
1558	(	O
1558	o	O
1558	##xy	O
1558	-	O
1558	c	O
1558	##rf	O
1558	/	O
1558	o	O
1558	##xy	O
1558	-	O
1558	er	O
1558	)	O
1558	for	O
1558	o	O
1558	##xy	O
1558	##mor	O
1558	##phone	O
1558	area	B-PK
1558	under	I-PK
1558	the	I-PK
1558	curve	I-PK
1558	from	I-PK
1558	time	I-PK
1558	0	I-PK
1558	to	I-PK
1558	the	I-PK
1558	last	I-PK
1558	measured	I-PK
1558	concentration	I-PK
1558	(	I-PK
1558	au	I-PK
1558	##c	I-PK
1558	##0	I-PK
1558	–	I-PK
1558	t	I-PK
1558	)	I-PK
1558	,	O
1558	au	B-PK
1558	##c	I-PK
1558	from	I-PK
1558	time	I-PK
1558	0	I-PK
1558	to	I-PK
1558	in	I-PK
1558	##finity	I-PK
1558	(	I-PK
1558	au	I-PK
1558	##c	I-PK
1558	##0	I-PK
1558	–	I-PK
1558	in	I-PK
1558	##f	I-PK
1558	)	I-PK
1558	,	O
1558	and	O
1558	maximum	B-PK
1558	plasma	I-PK
1558	concentration	I-PK
1558	(	I-PK
1558	cm	I-PK
1558	##ax	I-PK
1558	)	I-PK
1558	were	O
1558	within	O
1558	0	O
1558	.	O
1558	8	O
1558	–	O
1558	1	O
1558	.	O
1558	25	O
1558	.	O
1558	[SEP]	O
1559	[CLS]	O
1559	the	O
1559	90	O
1559	%	O
1559	confidence	O
1559	intervals	O
1559	for	O
1559	plasma	O
1559	o	O
1559	##xy	O
1559	##mor	O
1559	##phone	O
1559	au	B-PK
1559	##c	I-PK
1559	##0	I-PK
1559	–	I-PK
1559	t	I-PK
1559	,	O
1559	au	B-PK
1559	##c	I-PK
1559	##0	I-PK
1559	–	I-PK
1559	in	I-PK
1559	##f	I-PK
1559	,	O
1559	and	O
1559	cm	B-PK
1559	##ax	I-PK
1559	fulfilled	O
1559	the	O
1559	bio	O
1559	##e	O
1559	##qui	O
1559	##valence	O
1559	criterion	O
1559	.	O
1559	[SEP]	O
1560	[CLS]	O
1560	o	O
1560	##xy	O
1560	-	O
1560	er	O
1560	and	O
1560	o	O
1560	##xy	O
1560	-	O
1560	c	O
1560	##rf	O
1560	produced	O
1560	similar	O
1560	mean	O
1560	±	O
1560	standard	O
1560	de	O
1560	##viation	O
1560	o	O
1560	##xy	O
1560	##mor	O
1560	##phone	O
1560	au	B-PK
1560	##c	I-PK
1560	##0	I-PK
1560	–	I-PK
1560	t	I-PK
1560	(	O
1560	study	O
1560	1	O
1560	,	O
1560	5	O
1560	.	O
1560	05	O
1560	±	O
1560	1	O
1560	.	O
1560	55	O
1560	versus	O
1560	5	O
1560	.	O
1560	29	O
1560	±	O
1560	1	O
1560	.	O
1560	52	O
1560	ng	O
1560	·	O
1560	h	O
1560	/	O
1560	m	O
1560	##l	O
1560	;	O
1560	study	O
1560	2	O
1560	,	O
1560	31	O
1560	.	O
1560	51	O
1560	±	O
1560	10	O
1560	.	O
1560	95	O
1560	versus	O
1560	31	O
1560	.	O
1560	23	O
1560	±	O
1560	10	O
1560	.	O
1560	33	O
1560	ng	O
1560	·	O
1560	h	O
1560	/	O
1560	m	O
1560	##l	O
1560	;	O
1560	study	O
1560	3	O
1560	,	O
1560	50	O
1560	.	O
1560	16	O
1560	±	O
1560	14	O
1560	.	O
1560	91	O
1560	versus	O
1560	49	O
1560	.	O
1560	01	O
1560	±	O
1560	14	O
1560	.	O
1560	03	O
1560	ng	O
1560	·	O
1560	h	O
1560	/	O
1560	m	O
1560	##l	O
1560	)	O
1560	and	O
1560	cm	B-PK
1560	##ax	I-PK
1560	(	O
1560	0	O
1560	.	O
1560	38	O
1560	±	O
1560	0	O
1560	.	O
1560	11	O
1560	versus	O
1560	0	O
1560	.	O
1560	37	O
1560	±	O
1560	0	O
1560	.	O
1560	12	O
1560	ng	O
1560	/	O
1560	m	O
1560	##l	O
1560	;	O
1560	2	O
1560	.	O
1560	37	O
1560	±	O
1560	1	O
1560	.	O
1560	20	O
1560	versus	O
1560	2	O
1560	.	O
1560	41	O
1560	±	O
1560	0	O
1560	.	O
1560	94	O
1560	ng	O
1560	/	O
1560	m	O
1560	##l	O
1560	;	O
1560	5	O
1560	.	O
1560	87	O
1560	±	O
1560	1	O
1560	.	O
1560	99	O
1560	versus	O
1560	5	O
1560	.	O
1560	63	O
1560	±	O
1560	2	O
1560	.	O
1560	26	O
1560	ng	O
1560	/	O
1560	m	O
1560	##l	O
1560	)	O
1560	under	O
1560	all	O
1560	conditions	O
1560	.	O
1560	[SEP]	O
1561	[CLS]	O
1561	o	O
1561	##xy	O
1561	##mor	O
1561	##phone	O
1561	and	O
1561	6	O
1561	-	O
1561	h	O
1561	##ydro	O
1561	##xy	O
1561	-	O
1561	o	O
1561	##xy	O
1561	##mor	O
1561	##phone	O
1561	(	O
1561	6	O
1561	-	O
1561	oh	O
1561	-	O
1561	o	O
1561	##xy	O
1561	##mor	O
1561	##phone	O
1561	)	O
1561	concentrations	O
1561	were	O
1561	determined	O
1561	using	O
1561	a	O
1561	simultaneous	O
1561	liquid	O
1561	ch	O
1561	##roma	O
1561	##tography	O
1561	-	O
1561	tandem	O
1561	mass	O
1561	s	O
1561	##pect	O
1561	##rome	O
1561	##try	O
1561	method	O
1561	valid	O
1561	##ated	O
1561	for	O
1561	the	O
1561	range	O
1561	of	O
1561	0	O
1561	.	O
1561	02	O
1561	##5	O
1561	–	O
1561	10	O
1561	.	O
1561	00	O
1561	ng	O
1561	/	O
1561	m	O
1561	##l	O
1561	.	O
1561	p	O
1561	##har	O
1561	##ma	O
1561	##co	O
1561	##kin	O
1561	##etic	O
1561	parameters	O
1561	(	O
1561	area	B-PK
1561	under	I-PK
1561	the	I-PK
1561	concentration	I-PK
1561	versus	I-PK
1561	time	I-PK
1561	curve	I-PK
1561	from	I-PK
1561	time	I-PK
1561	0	I-PK
1561	to	I-PK
1561	in	I-PK
1561	##finity	I-PK
1561	[	I-PK
1561	au	I-PK
1561	##c	I-PK
1561	##0	I-PK
1561	–	I-PK
1561	in	I-PK
1561	##f	I-PK
1561	]	I-PK
1561	,	O
1561	au	B-PK
1561	##c	I-PK
1561	from	I-PK
1561	time	I-PK
1561	0	I-PK
1561	to	I-PK
1561	the	I-PK
1561	last	I-PK
1561	measured	I-PK
1561	concentration	I-PK
1561	[	I-PK
1561	au	I-PK
1561	##c	I-PK
1561	##0	I-PK
1561	–	I-PK
1561	t	I-PK
1561	]	I-PK
1561	,	O
1561	maximum	B-PK
1561	plasma	I-PK
1561	concentration	I-PK
1561	[	I-PK
1561	cm	I-PK
1561	##ax	I-PK
1561	]	I-PK
1561	,	O
1561	and	O
1561	time	B-PK
1561	to	I-PK
1561	cm	I-PK
1561	##ax	I-PK
1561	[	I-PK
1561	t	I-PK
1561	##max	I-PK
1561	]	I-PK
1561	)	O
1561	were	O
1561	derived	O
1561	from	O
1561	the	O
1561	plasma	O
1561	concentration	O
1561	data	O
1561	using	O
1561	non	O
1561	##com	O
1561	##par	O
1561	##tment	O
1561	##al	O
1561	methods	O
1561	and	O
1561	actual	O
1561	sample	O
1561	times	O
1561	.	O
1561	[SEP]	O
1562	[CLS]	O
1562	the	O
1562	terminal	B-PK
1562	rate	I-PK
1562	constant	I-PK
1562	(	I-PK
1562	λ	I-PK
1562	##z	I-PK
1562	)	I-PK
1562	was	O
1562	calculated	O
1562	by	O
1562	linear	O
1562	re	O
1562	##gression	O
1562	of	O
1562	the	O
1562	terminal	O
1562	portion	O
1562	of	O
1562	the	O
1562	linear	O
1562	concentration	O
1562	versus	O
1562	time	O
1562	curve	O
1562	,	O
1562	and	O
1562	the	O
1562	terminal	B-PK
1562	half	I-PK
1562	-	I-PK
1562	life	I-PK
1562	[	I-PK
1562	t	I-PK
1562	##1	I-PK
1562	/	I-PK
1562	2	I-PK
1562	]	I-PK
1562	was	O
1562	calculated	O
1562	as	O
1562	l	O
1562	##n	O
1562	2	O
1562	/	O
1562	λ	O
1562	##z	O
1562	.	O
1562	[SEP]	O
1563	[CLS]	O
1563	au	B-PK
1563	##c	I-PK
1563	##0	I-PK
1563	–	I-PK
1563	t	I-PK
1563	was	O
1563	calculated	O
1563	using	O
1563	the	O
1563	linear	O
1563	trap	O
1563	##ez	O
1563	##oid	O
1563	rule	O
1563	,	O
1563	and	O
1563	au	B-PK
1563	##c	I-PK
1563	##0	I-PK
1563	–	I-PK
1563	in	I-PK
1563	##f	I-PK
1563	was	O
1563	calculated	O
1563	as	O
1563	au	B-PK
1563	##c	I-PK
1563	##0	I-PK
1563	–	I-PK
1563	t	I-PK
1563	plus	O
1563	last	O
1563	measured	O
1563	plasma	O
1563	concentration	O
1563	/	O
1563	terminal	B-PK
1563	rate	I-PK
1563	constant	I-PK
1563	.	O
1563	[SEP]	O
1564	[CLS]	O
1564	medication	O
1564	was	O
1564	administered	O
1564	according	O
1564	to	O
1564	one	O
1564	of	O
1564	two	O
1564	treatment	O
1564	sequences	O
1564	with	O
1564	alternating	O
1564	treatment	O
1564	periods	O
1564	(	O
1564	a	O
1564	##ba	O
1564	##b	O
1564	or	O
1564	b	O
1564	##aba	O
1564	)	O
1564	based	O
1564	on	O
1564	a	O
1564	computer	O
1564	-	O
1564	generated	O
1564	random	O
1564	##ization	O
1564	schedule	O
1564	.	O
1564	[SEP]	O
1565	[CLS]	O
1565	p	O
1565	##har	O
1565	##ma	O
1565	##co	O
1565	##kin	O
1565	##etic	O
1565	parameters	O
1565	were	O
1565	summarized	O
1565	descriptive	O
1565	##ly	O
1565	,	O
1565	using	O
1565	the	O
1565	number	O
1565	of	O
1565	subjects	O
1565	,	O
1565	mean	O
1565	,	O
1565	standard	O
1565	de	O
1565	##viation	O
1565	,	O
1565	and	O
1565	coefficient	O
1565	of	O
1565	variation	O
1565	(	O
1565	au	B-PK
1565	##c	I-PK
1565	##0	I-PK
1565	–	I-PK
1565	t	I-PK
1565	,	O
1565	au	B-PK
1565	##c	I-PK
1565	##0	I-PK
1565	–	I-PK
1565	in	I-PK
1565	##f	I-PK
1565	,	O
1565	cm	B-PK
1565	##ax	I-PK
1565	,	O
1565	and	O
1565	t	B-PK
1565	##1	I-PK
1565	/	I-PK
1565	2	I-PK
1565	)	O
1565	or	O
1565	the	O
1565	median	O
1565	and	O
1565	range	O
1565	(	O
1565	t	B-PK
1565	##max	I-PK
1565	)	O
1565	.	O
1565	[SEP]	O
1566	[CLS]	O
1566	the	O
1566	criterion	O
1566	for	O
1566	bio	O
1566	##e	O
1566	##qui	O
1566	##valence	O
1566	was	O
1566	met	O
1566	if	O
1566	the	O
1566	90	O
1566	%	O
1566	c	O
1566	##is	O
1566	of	O
1566	the	O
1566	geometric	O
1566	mean	O
1566	ratio	O
1566	(	O
1566	o	O
1566	##xy	O
1566	-	O
1566	c	O
1566	##rf	O
1566	/	O
1566	o	O
1566	##xy	O
1566	-	O
1566	er	O
1566	)	O
1566	for	O
1566	o	O
1566	##xy	O
1566	##mor	O
1566	##phone	O
1566	au	B-PK
1566	##c	I-PK
1566	##0	I-PK
1566	–	I-PK
1566	t	I-PK
1566	,	O
1566	au	B-PK
1566	##c	I-PK
1566	##0	I-PK
1566	–	I-PK
1566	in	I-PK
1566	##f	I-PK
1566	,	O
1566	and	O
1566	cm	B-PK
1566	##ax	I-PK
1566	were	O
1566	within	O
1566	0	O
1566	.	O
1566	8	O
1566	–	O
1566	1	O
1566	.	O
1566	25	O
1566	.	O
1566	[SEP]	O
1567	[CLS]	O
1567	systemic	O
1567	plasma	O
1567	o	O
1567	##xy	O
1567	##mor	O
1567	##phone	O
1567	exposure	O
1567	(	O
1567	au	B-PK
1567	##c	I-PK
1567	and	O
1567	cm	B-PK
1567	##ax	I-PK
1567	)	O
1567	was	O
1567	also	O
1567	similar	O
1567	after	O
1567	single	O
1567	doses	O
1567	of	O
1567	o	O
1567	##xy	O
1567	-	O
1567	er	O
1567	and	O
1567	o	O
1567	##xy	O
1567	-	O
1567	c	O
1567	##rf	O
1567	(	O
1567	table	O
1567	2	O
1567	)	O
1567	.	O
1567	[SEP]	O
1568	[CLS]	O
1568	mean	O
1568	±	O
1568	s	O
1568	##d	O
1568	o	O
1568	##xy	O
1568	##mor	O
1568	##phone	O
1568	au	B-PK
1568	##c	I-PK
1568	##0	I-PK
1568	–	I-PK
1568	t	I-PK
1568	for	O
1568	o	O
1568	##xy	O
1568	-	O
1568	er	O
1568	and	O
1568	o	O
1568	##xy	O
1568	-	O
1568	c	O
1568	##rf	O
1568	,	O
1568	respectively	O
1568	,	O
1568	was	O
1568	5	O
1568	.	O
1568	05	O
1568	±	O
1568	1	O
1568	.	O
1568	55	O
1568	and	O
1568	5	O
1568	.	O
1568	29	O
1568	±	O
1568	1	O
1568	.	O
1568	52	O
1568	ng	O
1568	·	O
1568	h	O
1568	/	O
1568	m	O
1568	##l	O
1568	after	O
1568	a	O
1568	5	O
1568	mg	O
1568	dose	O
1568	administered	O
1568	under	O
1568	fast	O
1568	##ed	O
1568	conditions	O
1568	,	O
1568	31	O
1568	.	O
1568	51	O
1568	±	O
1568	10	O
1568	.	O
1568	95	O
1568	and	O
1568	31	O
1568	.	O
1568	23	O
1568	±	O
1568	10	O
1568	.	O
1568	33	O
1568	ng	O
1568	·	O
1568	h	O
1568	/	O
1568	m	O
1568	##l	O
1568	after	O
1568	a	O
1568	40	O
1568	mg	O
1568	dose	O
1568	administered	O
1568	under	O
1568	fast	O
1568	##ed	O
1568	conditions	O
1568	,	O
1568	and	O
1568	50	O
1568	.	O
1568	16	O
1568	±	O
1568	14	O
1568	.	O
1568	91	O
1568	and	O
1568	49	O
1568	.	O
1568	01	O
1568	±	O
1568	14	O
1568	.	O
1568	03	O
1568	ng	O
1568	·	O
1568	h	O
1568	/	O
1568	m	O
1568	##l	O
1568	after	O
1568	a	O
1568	40	O
1568	mg	O
1568	dose	O
1568	administered	O
1568	following	O
1568	a	O
1568	high	O
1568	-	O
1568	fat	O
1568	breakfast	O
1568	.	O
1568	[SEP]	O
1569	[CLS]	O
1569	mean	O
1569	±	O
1569	s	O
1569	##d	O
1569	o	O
1569	##xy	O
1569	##mor	O
1569	##phone	O
1569	cm	B-PK
1569	##ax	I-PK
1569	for	O
1569	o	O
1569	##xy	O
1569	-	O
1569	er	O
1569	and	O
1569	o	O
1569	##xy	O
1569	-	O
1569	c	O
1569	##rf	O
1569	,	O
1569	respectively	O
1569	,	O
1569	was	O
1569	0	O
1569	.	O
1569	38	O
1569	±	O
1569	0	O
1569	.	O
1569	11	O
1569	and	O
1569	0	O
1569	.	O
1569	37	O
1569	±	O
1569	0	O
1569	.	O
1569	12	O
1569	ng	O
1569	/	O
1569	m	O
1569	##l	O
1569	after	O
1569	a	O
1569	5	O
1569	mg	O
1569	dose	O
1569	administered	O
1569	under	O
1569	fast	O
1569	##ed	O
1569	conditions	O
1569	,	O
1569	2	O
1569	.	O
1569	37	O
1569	±	O
1569	1	O
1569	.	O
1569	20	O
1569	and	O
1569	2	O
1569	.	O
1569	41	O
1569	±	O
1569	0	O
1569	.	O
1569	94	O
1569	ng	O
1569	/	O
1569	m	O
1569	##l	O
1569	after	O
1569	a	O
1569	40	O
1569	mg	O
1569	dose	O
1569	administered	O
1569	under	O
1569	fast	O
1569	##ed	O
1569	conditions	O
1569	,	O
1569	and	O
1569	5	O
1569	.	O
1569	87	O
1569	±	O
1569	1	O
1569	.	O
1569	99	O
1569	and	O
1569	5	O
1569	.	O
1569	63	O
1569	±	O
1569	2	O
1569	.	O
1569	26	O
1569	ng	O
1569	/	O
1569	m	O
1569	##l	O
1569	after	O
1569	a	O
1569	40	O
1569	mg	O
1569	dose	O
1569	administered	O
1569	following	O
1569	a	O
1569	high	O
1569	-	O
1569	fat	O
1569	breakfast	O
1569	.	O
1569	[SEP]	O
1570	[CLS]	O
1570	median	O
1570	o	O
1570	##xy	O
1570	##mor	O
1570	##phone	O
1570	t	B-PK
1570	##max	I-PK
1570	was	O
1570	the	O
1570	only	O
1570	p	O
1570	##har	O
1570	##ma	O
1570	##co	O
1570	##kin	O
1570	##etic	O
1570	parameter	O
1570	to	O
1570	differ	O
1570	between	O
1570	o	O
1570	##xy	O
1570	-	O
1570	er	O
1570	and	O
1570	o	O
1570	##xy	O
1570	-	O
1570	c	O
1570	##rf	O
1570	,	O
1570	being	O
1570	shorter	O
1570	for	O
1570	o	O
1570	##xy	O
1570	-	O
1570	er	O
1570	versus	O
1570	o	O
1570	##xy	O
1570	-	O
1570	c	O
1570	##rf	O
1570	40	O
1570	mg	O
1570	(	O
1570	table	O
1570	2	O
1570	)	O
1570	,	O
1570	with	O
1570	differences	O
1570	of	O
1570	2	O
1570	hours	O
1570	under	O
1570	fast	O
1570	##ed	O
1570	conditions	O
1570	(	O
1570	3	O
1570	.	O
1570	0	O
1570	versus	O
1570	5	O
1570	.	O
1570	0	O
1570	)	O
1570	and	O
1570	1	O
1570	.	O
1570	5	O
1570	hours	O
1570	under	O
1570	fed	O
1570	conditions	O
1570	(	O
1570	3	O
1570	.	O
1570	5	O
1570	versus	O
1570	5	O
1570	.	O
1570	0	O
1570	)	O
1570	.	O
1570	[SEP]	O
1571	[CLS]	O
1571	the	O
1571	difference	O
1571	in	O
1571	median	O
1571	t	B-PK
1571	##max	I-PK
1571	was	O
1571	smaller	O
1571	when	O
1571	5	O
1571	mg	O
1571	doses	O
1571	of	O
1571	o	O
1571	##xy	O
1571	-	O
1571	er	O
1571	and	O
1571	o	O
1571	##xy	O
1571	-	O
1571	c	O
1571	##rf	O
1571	were	O
1571	compared	O
1571	(	O
1571	6	O
1571	.	O
1571	0	O
1571	versus	O
1571	5	O
1571	.	O
1571	0	O
1571	hours	O
1571	)	O
1571	.	O
1571	[SEP]	O
1572	[CLS]	O
1572	the	O
1572	t	B-PK
1572	##max	I-PK
1572	values	O
1572	roughly	O
1572	correspond	O
1572	##ed	O
1572	to	O
1572	the	O
1572	time	O
1572	at	O
1572	which	O
1572	the	O
1572	two	O
1572	early	O
1572	peaks	O
1572	occurred	O
1572	in	O
1572	the	O
1572	plasma	O
1572	concentration	O
1572	versus	O
1572	time	O
1572	profiles	O
1572	(	O
1572	figure	O
1572	2	O
1572	)	O
1572	.	O
1572	[SEP]	O
1573	[CLS]	O
1573	the	O
1573	range	O
1573	of	O
1573	t	B-PK
1573	##max	I-PK
1573	was	O
1573	similar	O
1573	for	O
1573	the	O
1573	two	O
1573	formulation	O
1573	##s	O
1573	in	O
1573	each	O
1573	of	O
1573	the	O
1573	three	O
1573	studies	O
1573	.	O
1573	[SEP]	O
1574	[CLS]	O
1574	systemic	O
1574	plasma	O
1574	6	O
1574	-	O
1574	oh	O
1574	-	O
1574	o	O
1574	##xy	O
1574	##mor	O
1574	##phone	O
1574	exposure	O
1574	did	O
1574	not	O
1574	differ	O
1574	between	O
1574	the	O
1574	two	O
1574	formulation	O
1574	##s	O
1574	(	O
1574	table	O
1574	3	O
1574	)	O
1574	,	O
1574	but	O
1574	median	O
1574	t	B-PK
1574	##max	I-PK
1574	was	O
1574	1	O
1574	.	O
1574	0	O
1574	(	O
1574	40	O
1574	mg	O
1574	,	O
1574	fed	O
1574	)	O
1574	to	O
1574	1	O
1574	.	O
1574	5	O
1574	hours	O
1574	(	O
1574	5	O
1574	mg	O
1574	,	O
1574	fast	O
1574	##ed	O
1574	;	O
1574	40	O
1574	mg	O
1574	,	O
1574	fast	O
1574	##ed	O
1574	)	O
1574	shorter	O
1574	for	O
1574	o	O
1574	##xy	O
1574	-	O
1574	er	O
1574	versus	O
1574	o	O
1574	##xy	O
1574	-	O
1574	c	O
1574	##rf	O
1574	.	O
1574	[SEP]	O
1575	[CLS]	O
1575	within	O
1575	-	O
1575	subject	O
1575	var	O
1575	##iability	O
1575	in	O
1575	o	O
1575	##xy	O
1575	##mor	O
1575	##phone	O
1575	au	B-PK
1575	##c	I-PK
1575	and	O
1575	cm	B-PK
1575	##ax	I-PK
1575	ranged	O
1575	from	O
1575	11	O
1575	%	O
1575	to	O
1575	24	O
1575	%	O
1575	and	O
1575	was	O
1575	comparable	O
1575	between	O
1575	the	O
1575	two	O
1575	o	O
1575	##xy	O
1575	##mor	O
1575	##phone	O
1575	formulation	O
1575	##s	O
1575	(	O
1575	data	O
1575	not	O
1575	shown	O
1575	)	O
1575	.	O
1575	[SEP]	O
1576	[CLS]	O
1576	for	O
1576	all	O
1576	doses	O
1576	and	O
1576	under	O
1576	both	O
1576	fast	O
1576	##ed	O
1576	and	O
1576	fed	O
1576	conditions	O
1576	,	O
1576	the	O
1576	90	O
1576	%	O
1576	c	O
1576	##i	O
1576	for	O
1576	the	O
1576	comparisons	O
1576	of	O
1576	o	O
1576	##xy	O
1576	-	O
1576	er	O
1576	and	O
1576	o	O
1576	##xy	O
1576	-	O
1576	c	O
1576	##rf	O
1576	plasma	O
1576	o	O
1576	##xy	O
1576	##mor	O
1576	##phone	O
1576	au	B-PK
1576	##c	I-PK
1576	##0	I-PK
1576	–	I-PK
1576	t	I-PK
1576	,	O
1576	au	B-PK
1576	##c	I-PK
1576	##0	I-PK
1576	–	I-PK
1576	in	I-PK
1576	##f	I-PK
1576	,	O
1576	and	O
1576	cm	B-PK
1576	##ax	I-PK
1576	were	O
1576	within	O
1576	0	O
1576	.	O
1576	8	O
1576	–	O
1576	1	O
1576	.	O
1576	25	O
1576	(	O
1576	table	O
1576	4	O
1576	)	O
1576	,	O
1576	fulfilling	O
1576	the	O
1576	bio	O
1576	##e	O
1576	##qui	O
1576	##valence	O
1576	criterion	O
1576	.	O
1576	[SEP]	O
1577	[CLS]	O
1577	one	O
1577	subject	O
1577	(	O
1577	p	O
1577	##f	O
1577	-	O
1577	06	O
1577	##64	O
1577	##9	O
1577	##75	O
1577	##1	O
1577	9	O
1577	mg	O
1577	)	O
1577	had	O
1577	a	O
1577	pre	O
1577	-	O
1577	dose	O
1577	concentration	O
1577	of	O
1577	9	O
1577	.	O
1577	5	O
1577	%	O
1577	of	O
1577	peak	B-PK
1577	concentration	I-PK
1577	(	I-PK
1577	cm	I-PK
1577	##ax	I-PK
1577	)	I-PK
1577	and	O
1577	was	O
1577	included	O
1577	in	O
1577	the	O
1577	analysis	O
1577	.	O
1577	[SEP]	O
1578	[CLS]	O
1578	following	O
1578	administration	O
1578	of	O
1578	single	O
1578	oral	O
1578	doses	O
1578	of	O
1578	p	O
1578	##f	O
1578	-	O
1578	06	O
1578	##64	O
1578	##9	O
1578	##75	O
1578	##1	O
1578	from	O
1578	0	O
1578	.	O
1578	75	O
1578	mg	O
1578	to	O
1578	9	O
1578	mg	O
1578	under	O
1578	fast	O
1578	##ed	O
1578	conditions	O
1578	,	O
1578	p	O
1578	##f	O
1578	-	O
1578	06	O
1578	##64	O
1578	##9	O
1578	##75	O
1578	##1	O
1578	cm	B-PK
1578	##ax	I-PK
1578	occurred	O
1578	at	O
1578	approximately	O
1578	3	O
1578	.	O
1578	0	O
1578	–	O
1578	4	O
1578	.	O
1578	0	O
1578	h	O
1578	post	O
1578	dose	O
1578	(	O
1578	supplement	O
1578	##ary	O
1578	fi	O
1578	##g	O
1578	.	O
1578	1	O
1578	top	O
1578	panel	O
1578	and	O
1578	supplement	O
1578	##ary	O
1578	table	O
1578	3	O
1578	)	O
1578	.	O
1578	[SEP]	O
1579	[CLS]	O
1579	the	O
1579	half	B-PK
1579	-	I-PK
1579	life	I-PK
1579	(	I-PK
1579	t	I-PK
1579	##1	I-PK
1579	/	I-PK
1579	2	I-PK
1579	)	I-PK
1579	of	O
1579	p	O
1579	##f	O
1579	-	O
1579	06	O
1579	##64	O
1579	##9	O
1579	##75	O
1579	##1	O
1579	for	O
1579	the	O
1579	3	O
1579	-	O
1579	mg	O
1579	group	O
1579	in	O
1579	co	O
1579	##hor	O
1579	##t	O
1579	2	O
1579	was	O
1579	approximately	O
1579	16	O
1579	h	O
1579	.	O
1579	[SEP]	O
1580	[CLS]	O
1580	the	O
1580	t	B-PK
1580	##1	I-PK
1580	/	I-PK
1580	2	I-PK
1580	was	O
1580	not	O
1580	report	O
1580	##able	O
1580	for	O
1580	most	O
1580	treatments	O
1580	because	O
1580	the	O
1580	data	O
1580	were	O
1580	not	O
1580	sufficient	O
1580	for	O
1580	adequate	O
1580	characterization	O
1580	of	O
1580	the	O
1580	elimination	O
1580	phase	O
1580	.	O
1580	[SEP]	O
1581	[CLS]	O
1581	inter	O
1581	-	O
1581	subject	O
1581	var	O
1581	##iability	O
1581	for	O
1581	p	O
1581	##f	O
1581	-	O
1581	06	O
1581	##64	O
1581	##9	O
1581	##75	O
1581	##1	O
1581	exposure	O
1581	,	O
1581	based	O
1581	on	O
1581	geometric	O
1581	percent	O
1581	coefficient	O
1581	of	O
1581	variation	O
1581	(	O
1581	%	O
1581	c	O
1581	##v	O
1581	)	O
1581	,	O
1581	ranged	O
1581	from	O
1581	21	O
1581	%	O
1581	to	O
1581	44	O
1581	%	O
1581	for	O
1581	au	B-PK
1581	##c	I-PK
1581	##last	I-PK
1581	and	O
1581	26	O
1581	%	O
1581	to	O
1581	42	O
1581	%	O
1581	for	O
1581	cm	B-PK
1581	##ax	I-PK
1581	across	O
1581	all	O
1581	treatments	O
1581	.	O
1581	[SEP]	O
1582	[CLS]	O
1582	on	O
1582	day	O
1582	22	O
1582	(	O
1582	steady	O
1582	-	O
1582	state	O
1582	)	O
1582	,	O
1582	following	O
1582	administration	O
1582	of	O
1582	multiple	O
1582	oral	O
1582	doses	O
1582	of	O
1582	p	O
1582	##f	O
1582	-	O
1582	06	O
1582	##64	O
1582	##9	O
1582	##75	O
1582	##1	O
1582	from	O
1582	5	O
1582	mg	O
1582	to	O
1582	25	O
1582	mg	O
1582	,	O
1582	mean	O
1582	cm	B-PK
1582	##ax	I-PK
1582	for	O
1582	p	O
1582	##f	O
1582	-	O
1582	06	O
1582	##64	O
1582	##9	O
1582	##75	O
1582	##1	O
1582	occurred	O
1582	at	O
1582	approximately	O
1582	2	O
1582	.	O
1582	0	O
1582	–	O
1582	4	O
1582	.	O
1582	0	O
1582	h	O
1582	post	O
1582	dose	O
1582	.	O
1582	[SEP]	O
1583	[CLS]	O
1583	on	O
1583	the	O
1583	basis	O
1583	of	O
1583	average	O
1583	values	O
1583	in	O
1583	park	O
1583	##ins	O
1583	##on	O
1583	’	O
1583	s	O
1583	disease	O
1583	subjects	O
1583	with	O
1583	motor	O
1583	flu	O
1583	##ct	O
1583	##uations	O
1583	(	O
1583	co	O
1583	##hor	O
1583	##t	O
1583	4	O
1583	vs	O
1583	co	O
1583	##hor	O
1583	##t	O
1583	6	O
1583	)	O
1583	,	O
1583	the	O
1583	increase	O
1583	in	O
1583	au	B-PK
1583	##ct	I-PK
1583	##au	I-PK
1583	was	O
1583	less	O
1583	than	O
1583	dose	O
1583	proportional	O
1583	between	O
1583	15	O
1583	mg	O
1583	and	O
1583	25	O
1583	mg	O
1583	.	O
1583	[SEP]	O
1584	[CLS]	O
1584	the	O
1584	mean	O
1584	apparent	B-PK
1584	clearance	I-PK
1584	values	O
1584	ranged	O
1584	from	O
1584	2	O
1584	.	O
1584	4	O
1584	l	O
1584	/	O
1584	h	O
1584	to	O
1584	3	O
1584	.	O
1584	5	O
1584	l	O
1584	/	O
1584	h	O
1584	.	O
1584	[SEP]	O
1585	[CLS]	O
1585	a	O
1585	##es	O
1585	in	O
1585	all	O
1585	treatment	O
1585	groups	O
1585	occurred	O
1585	in	O
1585	the	O
1585	up	O
1585	-	O
1585	t	O
1585	##it	O
1585	##ration	O
1585	phase	O
1585	(	O
1585	days	O
1585	3	O
1585	–	O
1585	24	O
1585	and	O
1585	follow	O
1585	-	O
1585	up	O
1585	)	O
1585	and	O
1585	appeared	O
1585	related	O
1585	to	O
1585	pace	O
1585	and	O
1585	in	O
1585	##cre	O
1585	##ment	O
1585	of	O
1585	up	O
1585	-	O
1585	t	O
1585	##it	O
1585	##ration	O
1585	rather	O
1585	than	O
1585	maximum	O
1585	exposure	O
1585	,	O
1585	and	O
1585	they	O
1585	were	O
1585	generally	O
1585	self	O
1585	-	O
1585	limited	O
1585	.	O
1585	[SEP]	O
1586	[CLS]	O
1586	co	O
1586	-	O
1586	administration	O
1586	with	O
1586	o	O
1586	##sel	O
1586	##tam	O
1586	##iv	O
1586	##ir	O
1586	had	O
1586	no	O
1586	clinical	O
1586	##ly	O
1586	significant	O
1586	effect	O
1586	on	O
1586	the	O
1586	p	O
1586	##har	O
1586	##ma	O
1586	##co	O
1586	##kin	O
1586	##etics	O
1586	(	O
1586	p	O
1586	##k	O
1586	)	O
1586	of	O
1586	am	O
1586	##ant	O
1586	##adi	O
1586	##ne	O
1586	[	O
1586	mean	O
1586	ratios	O
1586	(	O
1586	90	O
1586	%	O
1586	c	O
1586	##i	O
1586	)	O
1586	for	O
1586	au	B-PK
1586	##c	I-PK
1586	##0	I-PK
1586	-	I-PK
1586	12	I-PK
1586	0	O
1586	.	O
1586	93	O
1586	(	O
1586	0	O
1586	.	O
1586	89	O
1586	,	O
1586	0	O
1586	.	O
1586	98	O
1586	)	O
1586	and	O
1586	cm	B-PK
1586	##ax	I-PK
1586	0	O
1586	.	O
1586	96	O
1586	(	O
1586	0	O
1586	.	O
1586	90	O
1586	,	O
1586	1	O
1586	.	O
1586	02	O
1586	)	O
1586	]	O
1586	.	O
1586	[SEP]	O
1587	[CLS]	O
1587	similarly	O
1587	,	O
1587	am	O
1587	##ant	O
1587	##adi	O
1587	##ne	O
1587	co	O
1587	-	O
1587	administration	O
1587	did	O
1587	not	O
1587	affect	O
1587	o	O
1587	##sel	O
1587	##tam	O
1587	##iv	O
1587	##ir	O
1587	p	O
1587	##k	O
1587	[	O
1587	au	B-PK
1587	##c	I-PK
1587	##0	I-PK
1587	-	I-PK
1587	12	I-PK
1587	0	O
1587	.	O
1587	92	O
1587	(	O
1587	0	O
1587	.	O
1587	86	O
1587	,	O
1587	0	O
1587	.	O
1587	99	O
1587	)	O
1587	and	O
1587	cm	B-PK
1587	##ax	I-PK
1587	0	O
1587	.	O
1587	85	O
1587	(	O
1587	0	O
1587	.	O
1587	73	O
1587	,	O
1587	0	O
1587	.	O
1587	99	O
1587	)	O
1587	]	O
1587	or	O
1587	the	O
1587	p	O
1587	##k	O
1587	of	O
1587	the	O
1587	meta	O
1587	##bol	O
1587	##ite	O
1587	,	O
1587	o	O
1587	##sel	O
1587	##tam	O
1587	##iv	O
1587	##ir	O
1587	car	O
1587	##box	O
1587	##yla	O
1587	##te	O
1587	[	O
1587	au	O
1587	##c	O
1587	##0	O
1587	-	O
1587	12	O
1587	0	O
1587	.	O
1587	98	O
1587	(	O
1587	0	O
1587	.	O
1587	95	O
1587	,	O
1587	1	O
1587	.	O
1587	02	O
1587	)	O
1587	and	O
1587	cm	B-PK
1587	##ax	I-PK
1587	0	O
1587	.	O
1587	95	O
1587	(	O
1587	0	O
1587	.	O
1587	89	O
1587	,	O
1587	1	O
1587	.	O
1587	01	O
1587	)	O
1587	]	O
1587	.	O
1587	[SEP]	O
1588	[CLS]	O
1588	to	O
1588	compare	O
1588	the	O
1588	results	O
1588	of	O
1588	the	O
1588	individual	O
1588	versus	O
1588	combination	O
1588	therapy	O
1588	arms	O
1588	for	O
1588	both	O
1588	am	O
1588	##ant	O
1588	##adi	O
1588	##ne	O
1588	and	O
1588	o	O
1588	##sel	O
1588	##tam	O
1588	##iv	O
1588	##ir	O
1588	,	O
1588	log	O
1588	-	O
1588	transformed	O
1588	p	O
1588	##k	O
1588	parameters	O
1588	au	B-PK
1588	##c	I-PK
1588	and	O
1588	cm	B-PK
1588	##ax	I-PK
1588	were	O
1588	analyzed	O
1588	by	O
1588	a	O
1588	linear	O
1588	mixed	O
1588	effect	O
1588	model	O
1588	,	O
1588	with	O
1588	fixed	O
1588	effects	O
1588	from	O
1588	sequence	O
1588	,	O
1588	treatment	O
1588	,	O
1588	and	O
1588	period	O
1588	,	O
1588	and	O
1588	random	O
1588	effects	O
1588	from	O
1588	subject	O
1588	nest	O
1588	##ed	O
1588	in	O
1588	sequence	O
1588	.	O
1588	[SEP]	O
1589	[CLS]	O
1589	am	O
1589	##ant	O
1589	##adi	O
1589	##ne	O
1589	au	B-PK
1589	##c	I-PK
1589	##0	I-PK
1589	-	I-PK
1589	12	I-PK
1589	and	O
1589	cm	B-PK
1589	##ax	I-PK
1589	decreased	O
1589	slightly	O
1589	when	O
1589	co	O
1589	##ad	O
1589	##mini	O
1589	##stered	O
1589	with	O
1589	o	O
1589	##sel	O
1589	##tam	O
1589	##iv	O
1589	##ir	O
1589	compared	O
1589	to	O
1589	am	O
1589	##ant	O
1589	##adi	O
1589	##ne	O
1589	administration	O
1589	alone	O
1589	(	O
1589	table	O
1589	2	O
1589	)	O
1589	.	O
1589	[SEP]	O
1590	[CLS]	O
1590	o	O
1590	##sel	O
1590	##tam	O
1590	##iv	O
1590	##ir	O
1590	au	B-PK
1590	##c	I-PK
1590	##0	I-PK
1590	-	I-PK
1590	12	I-PK
1590	and	O
1590	cm	B-PK
1590	##ax	I-PK
1590	decreased	O
1590	slightly	O
1590	when	O
1590	co	O
1590	##ad	O
1590	##mini	O
1590	##stered	O
1590	with	O
1590	am	O
1590	##ant	O
1590	##adi	O
1590	##ne	O
1590	compared	O
1590	to	O
1590	o	O
1590	##sel	O
1590	##tam	O
1590	##iv	O
1590	##ir	O
1590	administration	O
1590	alone	O
1590	(	O
1590	table	O
1590	3	O
1590	and	O
1590	4	O
1590	)	O
1590	.	O
1590	[SEP]	O
1591	[CLS]	O
1591	the	O
1591	geometric	O
1591	mean	O
1591	ratio	O
1591	(	O
1591	g	O
1591	##m	O
1591	##r	O
1591	)	O
1591	of	O
1591	the	O
1591	au	B-PK
1591	##c	I-PK
1591	##0	I-PK
1591	-	I-PK
1591	12	I-PK
1591	of	O
1591	am	O
1591	##ant	O
1591	##adi	O
1591	##ne	O
1591	,	O
1591	co	O
1591	##ad	O
1591	##mini	O
1591	##stered	O
1591	with	O
1591	o	O
1591	##sel	O
1591	##tam	O
1591	##iv	O
1591	##ir	O
1591	compared	O
1591	to	O
1591	am	O
1591	##ant	O
1591	##adi	O
1591	##ne	O
1591	alone	O
1591	,	O
1591	was	O
1591	0	O
1591	.	O
1591	93	O
1591	.	O
1591	[SEP]	O
1592	[CLS]	O
1592	as	O
1592	expected	O
1592	for	O
1592	am	O
1592	##ant	O
1592	##adi	O
1592	##ne	O
1592	,	O
1592	the	O
1592	geometric	O
1592	mean	O
1592	values	O
1592	for	O
1592	apparent	B-PK
1592	clearance	I-PK
1592	(	O
1592	15	O
1592	.	O
1592	6	O
1592	vs	O
1592	16	O
1592	.	O
1592	7	O
1592	l	O
1592	/	O
1592	h	O
1592	##r	O
1592	)	O
1592	,	O
1592	apparent	B-PK
1592	volume	I-PK
1592	of	I-PK
1592	distribution	I-PK
1592	(	O
1592	33	O
1592	##2	O
1592	vs	O
1592	32	O
1592	##6	O
1592	l	O
1592	)	O
1592	,	O
1592	half	B-PK
1592	-	I-PK
1592	life	I-PK
1592	(	O
1592	14	O
1592	.	O
1592	7	O
1592	vs	O
1592	13	O
1592	.	O
1592	6	O
1592	h	O
1592	##r	O
1592	)	O
1592	and	O
1592	t	B-PK
1592	##max	I-PK
1592	(	O
1592	2	O
1592	.	O
1592	1	O
1592	vs	O
1592	2	O
1592	.	O
1592	4	O
1592	h	O
1592	##r	O
1592	)	O
1592	were	O
1592	also	O
1592	similar	O
1592	between	O
1592	am	O
1592	##ant	O
1592	##adi	O
1592	##ne	O
1592	mon	O
1592	##otherapy	O
1592	versus	O
1592	combination	O
1592	therapy	O
1592	with	O
1592	o	O
1592	##sel	O
1592	##tam	O
1592	##iv	O
1592	##ir	O
1592	.	O
1592	[SEP]	O
1593	[CLS]	O
1593	the	O
1593	geometric	O
1593	mean	O
1593	ratio	O
1593	(	O
1593	g	O
1593	##m	O
1593	##r	O
1593	)	O
1593	of	O
1593	the	O
1593	au	B-PK
1593	##c	I-PK
1593	##0	I-PK
1593	-	I-PK
1593	12	I-PK
1593	of	O
1593	o	O
1593	##sel	O
1593	##tam	O
1593	##iv	O
1593	##ir	O
1593	,	O
1593	co	O
1593	##ad	O
1593	##mini	O
1593	##stered	O
1593	with	O
1593	o	O
1593	##sel	O
1593	##tam	O
1593	##iv	O
1593	##ir	O
1593	compared	O
1593	to	O
1593	am	O
1593	##ant	O
1593	##adi	O
1593	##ne	O
1593	alone	O
1593	,	O
1593	was	O
1593	0	O
1593	.	O
1593	92	O
1593	.	O
1593	[SEP]	O
1594	[CLS]	O
1594	g	O
1594	##m	O
1594	##r	O
1594	of	O
1594	the	O
1594	c	B-PK
1594	##tro	I-PK
1594	##ugh	I-PK
1594	and	O
1594	cm	B-PK
1594	##ax	I-PK
1594	were	O
1594	0	O
1594	.	O
1594	95	O
1594	(	O
1594	with	O
1594	a	O
1594	lower	O
1594	confidence	O
1594	interval	O
1594	of	O
1594	.	O
1594	73	O
1594	)	O
1594	and	O
1594	0	O
1594	.	O
1594	85	O
1594	(	O
1594	with	O
1594	a	O
1594	lower	O
1594	confidence	O
1594	interval	O
1594	of	O
1594	0	O
1594	.	O
1594	79	O
1594	)	O
1594	,	O
1594	respectively	O
1594	.	O
1594	[SEP]	O
1595	[CLS]	O
1595	the	O
1595	au	B-PK
1595	##c	I-PK
1595	##0	I-PK
1595	-	I-PK
1595	12	I-PK
1595	and	O
1595	cm	B-PK
1595	##ax	I-PK
1595	of	O
1595	the	O
1595	active	O
1595	o	O
1595	##sel	O
1595	##tam	O
1595	##iv	O
1595	##ir	O
1595	car	O
1595	##box	O
1595	##yla	O
1595	##te	O
1595	also	O
1595	decreased	O
1595	slightly	O
1595	when	O
1595	co	O
1595	##ad	O
1595	##mini	O
1595	##stered	O
1595	with	O
1595	am	O
1595	##ant	O
1595	##adi	O
1595	##ne	O
1595	compared	O
1595	to	O
1595	o	O
1595	##sel	O
1595	##tam	O
1595	##iv	O
1595	##ir	O
1595	administration	O
1595	alone	O
1595	(	O
1595	table	O
1595	4	O
1595	)	O
1595	.	O
1595	[SEP]	O
1596	[CLS]	O
1596	the	O
1596	geometric	O
1596	mean	O
1596	ratio	O
1596	(	O
1596	g	O
1596	##m	O
1596	##r	O
1596	)	O
1596	(	O
1596	90	O
1596	%	O
1596	confidence	O
1596	interval	O
1596	[	O
1596	c	O
1596	##i	O
1596	]	O
1596	)	O
1596	of	O
1596	the	O
1596	au	B-PK
1596	##c	I-PK
1596	##0	I-PK
1596	-	I-PK
1596	12	I-PK
1596	of	O
1596	o	O
1596	##sel	O
1596	##tam	O
1596	##iv	O
1596	##ir	O
1596	car	O
1596	##box	O
1596	##yla	O
1596	##te	O
1596	,	O
1596	co	O
1596	##ad	O
1596	##mini	O
1596	##stered	O
1596	with	O
1596	o	O
1596	##sel	O
1596	##tam	O
1596	##iv	O
1596	##ir	O
1596	compared	O
1596	to	O
1596	am	O
1596	##ant	O
1596	##adi	O
1596	##ne	O
1596	alone	O
1596	,	O
1596	was	O
1596	0	O
1596	.	O
1596	98	O
1596	.	O
1596	[SEP]	O
1597	[CLS]	O
1597	g	O
1597	##m	O
1597	##r	O
1597	of	O
1597	the	O
1597	cm	B-PK
1597	##ax	I-PK
1597	and	O
1597	c	B-PK
1597	##tro	I-PK
1597	##ugh	I-PK
1597	were	O
1597	0	O
1597	.	O
1597	95	O
1597	and	O
1597	1	O
1597	.	O
1597	03	O
1597	,	O
1597	respectively	O
1597	.	O
1597	[SEP]	O
1598	[CLS]	O
1598	as	O
1598	expected	O
1598	,	O
1598	the	O
1598	geometric	O
1598	mean	O
1598	values	O
1598	for	O
1598	o	O
1598	##sel	O
1598	##tam	O
1598	##iv	O
1598	##ir	O
1598	apparent	B-PK
1598	clearance	I-PK
1598	(	O
1598	46	O
1598	##5	O
1598	vs	O
1598	50	O
1598	##5	O
1598	l	O
1598	/	O
1598	h	O
1598	##r	O
1598	)	O
1598	,	O
1598	apparent	B-PK
1598	distribution	I-PK
1598	volume	I-PK
1598	(	O
1598	124	O
1598	##5	O
1598	vs	O
1598	132	O
1598	##9	O
1598	l	O
1598	)	O
1598	,	O
1598	half	B-PK
1598	-	I-PK
1598	life	I-PK
1598	(	O
1598	1	O
1598	.	O
1598	85	O
1598	vs	O
1598	1	O
1598	.	O
1598	83	O
1598	h	O
1598	##r	O
1598	)	O
1598	and	O
1598	t	B-PK
1598	##max	I-PK
1598	(	O
1598	0	O
1598	.	O
1598	76	O
1598	vs	O
1598	0	O
1598	.	O
1598	85	O
1598	h	O
1598	##r	O
1598	)	O
1598	were	O
1598	also	O
1598	similar	O
1598	between	O
1598	o	O
1598	##sel	O
1598	##tam	O
1598	##iv	O
1598	##ir	O
1598	mon	O
1598	##otherapy	O
1598	versus	O
1598	combination	O
1598	therapy	O
1598	with	O
1598	am	O
1598	##ant	O
1598	##adi	O
1598	##ne	O
1598	.	O
1598	[SEP]	O
1599	[CLS]	O
1599	in	O
1599	addition	O
1599	,	O
1599	geometric	O
1599	mean	O
1599	values	O
1599	for	O
1599	o	O
1599	##sel	O
1599	##tam	O
1599	##iv	O
1599	##ir	O
1599	car	O
1599	##box	O
1599	##yla	O
1599	##te	O
1599	apparent	B-PK
1599	clearance	I-PK
1599	(	O
1599	21	O
1599	.	O
1599	9	O
1599	vs	O
1599	22	O
1599	.	O
1599	3	O
1599	l	O
1599	/	O
1599	h	O
1599	##r	O
1599	)	O
1599	,	O
1599	apparent	B-PK
1599	distribution	I-PK
1599	volume	I-PK
1599	(	O
1599	192	O
1599	vs	O
1599	197	O
1599	l	O
1599	)	O
1599	,	O
1599	half	B-PK
1599	-	I-PK
1599	life	I-PK
1599	(	O
1599	6	O
1599	.	O
1599	09	O
1599	vs	O
1599	6	O
1599	.	O
1599	15	O
1599	h	O
1599	##r	O
1599	)	O
1599	and	O
1599	t	B-PK
1599	##max	I-PK
1599	(	O
1599	3	O
1599	.	O
1599	22	O
1599	vs	O
1599	3	O
1599	.	O
1599	07	O
1599	h	O
1599	##r	O
1599	)	O
1599	were	O
1599	similar	O
1599	between	O
1599	o	O
1599	##sel	O
1599	##tam	O
1599	##iv	O
1599	##ir	O
1599	mon	O
1599	##otherapy	O
1599	versus	O
1599	combination	O
1599	therapy	O
1599	with	O
1599	am	O
1599	##ant	O
1599	##adi	O
1599	##ne	O
1599	.	O
1599	[SEP]	O
1600	[CLS]	O
1600	k	O
1600	##pt	O
1600	-	O
1600	95	O
1600	##11	O
1600	was	O
1600	[UNK]	O
1600	fold	O
1600	less	O
1600	potent	O
1600	in	O
1600	re	O
1600	##v	O
1600	-	O
1600	g	O
1600	##f	O
1600	##p	O
1600	compared	O
1600	to	O
1600	k	O
1600	##pt	O
1600	-	O
1600	86	O
1600	##0	O
1600	##2	O
1600	(	O
1600	230	O
1600	nm	O
1600	vs	O
1600	42	O
1600	nm	O
1600	)	O
1600	and	O
1600	[UNK]	O
1600	fold	O
1600	less	O
1600	c	O
1600	##yt	O
1600	##oto	O
1600	##xi	O
1600	##c	O
1600	(	O
1600	280	O
1600	vs	O
1600	19	O
1600	nm	O
1600	)	O
1600	.	O
1600	[SEP]	O
1601	[CLS]	O
1601	f	O
1601	##oly	O
1601	##l	O
1601	##pol	O
1601	##y	O
1601	##g	O
1601	##lut	O
1601	##ama	O
1601	##te	O
1601	s	O
1601	##ynth	O
1601	##eta	O
1601	##se	O
1601	(	O
1601	f	O
1601	##p	O
1601	##gs	O
1601	)	O
1601	activity	O
1601	was	O
1601	higher	O
1601	in	O
1601	b	O
1601	vs	O
1601	t	O
1601	lineage	O
1601	all	O
1601	(	O
1601	p	O
1601	<	O
1601	0	O
1601	.	O
1601	00	O
1601	##5	O
1601	)	O
1601	,	O
1601	m	O
1601	##t	O
1601	##x	O
1601	influx	O
1601	and	O
1601	f	O
1601	##p	O
1601	##gs	O
1601	activity	O
1601	were	O
1601	higher	O
1601	in	O
1601	h	O
1601	##yper	O
1601	##di	O
1601	##p	O
1601	##lo	O
1601	##id	O
1601	vs	O
1601	non	O
1601	-	O
1601	h	O
1601	##yper	O
1601	##di	O
1601	##p	O
1601	##lo	O
1601	##id	O
1601	all	O
1601	(	O
1601	p	O
1601	<	O
1601	0	O
1601	.	O
1601	03	O
1601	)	O
1601	,	O
1601	m	O
1601	##t	O
1601	##x	O
1601	influx	O
1601	and	O
1601	f	O
1601	##p	O
1601	##gs	O
1601	activity	O
1601	were	O
1601	lower	O
1601	in	O
1601	the	O
1601	t	O
1601	(	O
1601	12	O
1601	;	O
1601	21	O
1601	)	O
1601	(	O
1601	et	O
1601	##v	O
1601	##6	O
1601	-	O
1601	run	O
1601	##x	O
1601	##1	O
1601	)	O
1601	sub	O
1601	##type	O
1601	(	O
1601	p	O
1601	<	O
1601	0	O
1601	.	O
1601	05	O
1601	)	O
1601	,	O
1601	and	O
1601	the	O
1601	ratio	O
1601	of	O
1601	f	O
1601	##p	O
1601	##gs	O
1601	to	O
1601	γ	O
1601	-	O
1601	g	O
1601	##lut	O
1601	##am	O
1601	##yl	O
1601	h	O
1601	##ydro	O
1601	##lase	O
1601	(	O
1601	g	O
1601	##gh	O
1601	)	O
1601	activity	O
1601	was	O
1601	lower	O
1601	in	O
1601	the	O
1601	t	O
1601	(	O
1601	1	O
1601	;	O
1601	19	O
1601	)	O
1601	(	O
1601	t	O
1601	##c	O
1601	##f	O
1601	##3	O
1601	-	O
1601	p	O
1601	##b	O
1601	##x	O
1601	##1	O
1601	)	O
1601	sub	O
1601	##type	O
1601	(	O
1601	p	O
1601	<	O
1601	0	O
1601	.	O
1601	03	O
1601	)	O
1601	than	O
1601	other	O
1601	genetic	O
1601	sub	O
1601	##type	O
1601	##s	O
1601	.	O
1601	[SEP]	O
1602	[CLS]	O
1602	figure	O
1602	1	O
1602	##a	O
1602	shows	O
1602	the	O
1602	concentration	O
1602	vs	O
1602	time	O
1602	plot	O
1602	of	O
1602	these	O
1602	data	O
1602	along	O
1602	with	O
1602	the	O
1602	population	O
1602	average	O
1602	model	O
1602	fit	O
1602	of	O
1602	the	O
1602	data	O
1602	sub	O
1602	-	O
1602	grouped	O
1602	by	O
1602	in	O
1602	##fusion	O
1602	length	O
1602	.	O
1602	[SEP]	O
1603	[CLS]	O
1603	the	O
1603	median	O
1603	clearance	B-PK
1603	of	O
1603	m	O
1603	##t	O
1603	##x	O
1603	was	O
1603	higher	O
1603	in	O
1603	the	O
1603	24	O
1603	h	O
1603	##r	O
1603	in	O
1603	##fusion	O
1603	group	O
1603	compared	O
1603	to	O
1603	the	O
1603	4	O
1603	h	O
1603	##r	O
1603	in	O
1603	##fusion	O
1603	group	O
1603	(	O
1603	122	O
1603	.	O
1603	6	O
1603	m	O
1603	##l	O
1603	/	O
1603	min	O
1603	/	O
1603	m	O
1603	##2	O
1603	vs	O
1603	108	O
1603	.	O
1603	6	O
1603	m	O
1603	##l	O
1603	/	O
1603	min	O
1603	/	O
1603	m	O
1603	##2	O
1603	;	O
1603	p	O
1603	<	O
1603	0	O
1603	.	O
1603	00	O
1603	##1	O
1603	)	O
1603	.	O
1603	[SEP]	O
1604	[CLS]	O
1604	figure	O
1604	1	O
1604	shows	O
1604	the	O
1604	concentration	O
1604	vs	O
1604	time	O
1604	plot	O
1604	of	O
1604	in	O
1604	##tra	O
1604	##cellular	O
1604	m	O
1604	##t	O
1604	##x	O
1604	(	O
1604	or	O
1604	m	O
1604	##t	O
1604	##x	O
1604	##p	O
1604	##g	O
1604	##1	O
1604	)	O
1604	(	O
1604	figure	O
1604	1	O
1604	##b	O
1604	)	O
1604	and	O
1604	total	O
1604	in	O
1604	##tra	O
1604	##cellular	O
1604	m	O
1604	##t	O
1604	##x	O
1604	##p	O
1604	##g	O
1604	##2	O
1604	-	O
1604	7	O
1604	(	O
1604	figure	O
1604	1	O
1604	##c	O
1604	)	O
1604	along	O
1604	with	O
1604	the	O
1604	population	O
1604	average	O
1604	model	O
1604	fit	O
1604	(	O
1604	for	O
1604	non	O
1604	-	O
1604	h	O
1604	##yper	O
1604	##di	O
1604	##p	O
1604	##lo	O
1604	##id	O
1604	b	O
1604	-	O
1604	lineage	O
1604	all	O
1604	)	O
1604	of	O
1604	the	O
1604	data	O
1604	.	O
1604	[SEP]	O
1605	[CLS]	O
1605	next	O
1605	we	O
1605	used	O
1605	simulation	O
1605	##s	O
1605	to	O
1605	compare	O
1605	the	O
1605	44	O
1605	h	O
1605	##r	O
1605	post	O
1605	m	O
1605	##t	O
1605	##x	O
1605	treatment	O
1605	in	O
1605	##hibition	O
1605	of	O
1605	d	O
1605	##n	O
1605	##ps	O
1605	between	O
1605	different	O
1605	doses	O
1605	(	O
1605	100	O
1605	mg	O
1605	/	O
1605	m	O
1605	##2	O
1605	to	O
1605	5	O
1605	g	O
1605	/	O
1605	m	O
1605	##2	O
1605	)	O
1605	and	O
1605	schedules	O
1605	(	O
1605	4	O
1605	vs	O
1605	24	O
1605	hour	O
1605	in	O
1605	##fusion	O
1605	##s	O
1605	)	O
1605	.	O
1605	[SEP]	O
1606	[CLS]	O
1606	a	O
1606	diagram	O
1606	of	O
1606	the	O
1606	model	O
1606	is	O
1606	shown	O
1606	in	O
1606	(	O
1606	figure	O
1606	8	O
1606	##a	O
1606	)	O
1606	and	O
1606	the	O
1606	model	O
1606	is	O
1606	described	O
1606	by	O
1606	the	O
1606	following	O
1606	system	O
1606	of	O
1606	ordinary	O
1606	differential	O
1606	equations	O
1606	:	O
1606	(	O
1606	1	O
1606	)	O
1606	the	O
1606	parameters	O
1606	are	O
1606	defined	O
1606	as	O
1606	follows	O
1606	:	O
1606	k	B-PK
1606	##e	I-PK
1606	,	O
1606	k	B-PK
1606	##12	I-PK
1606	,	O
1606	and	O
1606	k	B-PK
1606	##21	I-PK
1606	(	O
1606	1	O
1606	/	O
1606	h	O
1606	##r	O
1606	)	O
1606	are	O
1606	the	O
1606	first	O
1606	-	O
1606	order	O
1606	parameters	O
1606	describing	O
1606	the	O
1606	elimination	O
1606	of	O
1606	plasma	O
1606	m	O
1606	##t	O
1606	##x	O
1606	and	O
1606	the	O
1606	transition	O
1606	between	O
1606	the	O
1606	central	O
1606	(	O
1606	m	O
1606	##t	O
1606	##x	O
1606	)	O
1606	and	O
1606	peripheral	O
1606	(	O
1606	m	O
1606	##t	O
1606	##x	O
1606	##p	O
1606	)	O
1606	compartment	O
1606	##s	O
1606	respectively	O
1606	;	O
1606	v	B-PK
1606	(	O
1606	l	O
1606	/	O
1606	m	O
1606	##2	O
1606	)	O
1606	is	O
1606	the	O
1606	systemic	B-PK
1606	volume	I-PK
1606	;	O
1606	v	B-PK
1606	##max	I-PK
1606	-	I-PK
1606	in	I-PK
1606	(	O
1606	pm	O
1606	##ol	O
1606	/	O
1606	109	O
1606	cells	O
1606	/	O
1606	h	O
1606	##r	O
1606	)	O
1606	and	O
1606	km	B-PK
1606	-	I-PK
1606	in	I-PK
1606	(	O
1606	µ	O
1606	##m	O
1606	)	O
1606	are	O
1606	the	O
1606	mi	O
1606	##cha	O
1606	##eli	O
1606	##s	O
1606	-	O
1606	men	O
1606	##ten	O
1606	parameters	O
1606	describing	O
1606	the	O
1606	active	O
1606	influx	O
1606	of	O
1606	m	O
1606	##t	O
1606	##x	O
1606	into	O
1606	the	O
1606	le	O
1606	##uke	O
1606	##mic	O
1606	blast	O
1606	##s	O
1606	via	O
1606	the	O
1606	reduced	O
1606	f	O
1606	##olate	O
1606	carrier	O
1606	and	O
1606	various	O
1606	a	O
1606	##b	O
1606	##c	O
1606	transport	O
1606	##ers	O
1606	;	O
1606	k	B-PK
1606	##p	I-PK
1606	(	O
1606	1	O
1606	/	O
1606	h	O
1606	##r	O
1606	)	O
1606	is	O
1606	the	O
1606	first	B-PK
1606	-	I-PK
1606	order	I-PK
1606	passive	I-PK
1606	influx	I-PK
1606	parameter	I-PK
1606	;	O
1606	k	B-PK
1606	##ef	I-PK
1606	##f	I-PK
1606	(	O
1606	1	O
1606	/	O
1606	h	O
1606	##r	O
1606	)	O
1606	is	O
1606	the	O
1606	first	B-PK
1606	-	I-PK
1606	order	I-PK
1606	e	I-PK
1606	##ff	I-PK
1606	##lux	I-PK
1606	parameter	I-PK
1606	;	O
1606	v	B-PK
1606	##max	I-PK
1606	-	I-PK
1606	f	I-PK
1606	##p	I-PK
1606	##gs	I-PK
1606	(	O
1606	pm	O
1606	##ol	O
1606	/	O
1606	109	O
1606	cells	O
1606	/	O
1606	h	O
1606	##r	O
1606	)	O
1606	and	O
1606	km	B-PK
1606	-	I-PK
1606	f	I-PK
1606	##p	I-PK
1606	##gs	I-PK
1606	(	O
1606	pm	O
1606	##ol	O
1606	/	O
1606	109	O
1606	cells	O
1606	)	O
1606	are	O
1606	the	O
1606	mi	O
1606	##cha	O
1606	##eli	O
1606	##s	O
1606	-	O
1606	men	O
1606	##ten	O
1606	parameters	O
1606	describing	O
1606	the	O
1606	f	O
1606	##p	O
1606	##gs	O
1606	activity	O
1606	;	O
1606	and	O
1606	kg	B-PK
1606	##gh	I-PK
1606	(	O
1606	1	O
1606	/	O
1606	h	O
1606	##r	O
1606	)	O
1606	is	O
1606	the	O
1606	first	O
1606	-	O
1606	order	O
1606	parameter	O
1606	describing	O
1606	the	O
1606	g	O
1606	##gh	O
1606	activity	O
1606	.	O
1606	[SEP]	O
1607	[CLS]	O
1607	within	O
1607	each	O
1607	race	O
1607	group	O
1607	,	O
1607	however	O
1607	,	O
1607	the	O
1607	two	O
1607	treatment	O
1607	groups	O
1607	(	O
1607	l	O
1607	##ina	O
1607	##gli	O
1607	##pt	O
1607	##in	O
1607	vs	O
1607	place	O
1607	##bo	O
1607	)	O
1607	were	O
1607	generally	O
1607	similar	O
1607	.	O
1607	[SEP]	O
1608	[CLS]	O
1608	overall	O
1608	,	O
1608	the	O
1608	proportion	O
1608	of	O
1608	patients	O
1608	in	O
1608	both	O
1608	treatment	O
1608	groups	O
1608	reporting	O
1608	any	O
1608	a	O
1608	##e	O
1608	was	O
1608	similar	O
1608	in	O
1608	each	O
1608	race	O
1608	group	O
1608	.	O
1608	[SEP]	O
1609	[CLS]	O
1609	overall	O
1609	,	O
1609	the	O
1609	a	O
1609	##e	O
1609	profile	O
1609	by	O
1609	race	O
1609	in	O
1609	study	O
1609	2	O
1609	showed	O
1609	a	O
1609	similar	O
1609	trend	O
1609	between	O
1609	treatment	O
1609	groups	O
1609	to	O
1609	that	O
1609	seen	O
1609	in	O
1609	the	O
1609	original	O
1609	parent	O
1609	trial	O
1609	##11	O
1609	.	O
1609	[SEP]	O
1610	[CLS]	O
1610	na	O
1610	##so	O
1610	##pha	O
1610	##ryn	O
1610	##git	O
1610	##is	O
1610	was	O
1610	the	O
1610	most	O
1610	frequently	O
1610	reported	O
1610	a	O
1610	##e	O
1610	in	O
1610	study	O
1610	1	O
1610	;	O
1610	h	O
1610	##yper	O
1610	##gly	O
1610	##ce	O
1610	##mia	O
1610	was	O
1610	the	O
1610	most	O
1610	frequently	O
1610	reported	O
1610	a	O
1610	##e	O
1610	occurring	O
1610	in	O
1610	as	O
1610	##ian	O
1610	and	O
1610	white	O
1610	patients	O
1610	(	O
1610	study	O
1610	2	O
1610	)	O
1610	.	O
1610	[SEP]	O
1611	[CLS]	O
1611	the	O
1611	results	O
1611	demonstrated	O
1611	that	O
1611	all	O
1611	four	O
1611	cat	O
1611	##ech	O
1611	##ins	O
1611	showed	O
1611	a	O
1611	tendency	O
1611	for	O
1611	increased	O
1611	area	B-PK
1611	under	I-PK
1611	the	I-PK
1611	concentration	I-PK
1611	curve	I-PK
1611	from	I-PK
1611	the	I-PK
1611	zero	I-PK
1611	time	I-PK
1611	-	I-PK
1611	point	I-PK
1611	to	I-PK
1611	the	I-PK
1611	last	I-PK
1611	measurement	I-PK
1611	(	I-PK
1611	au	I-PK
1611	##c	I-PK
1611	##0	I-PK
1611	–	I-PK
1611	9	I-PK
1611	)	I-PK
1611	,	O
1611	the	O
1611	au	B-PK
1611	##c	I-PK
1611	from	I-PK
1611	the	I-PK
1611	zero	I-PK
1611	time	I-PK
1611	-	I-PK
1611	point	I-PK
1611	to	I-PK
1611	in	I-PK
1611	##finity	I-PK
1611	(	I-PK
1611	au	I-PK
1611	##c	I-PK
1611	##0	I-PK
1611	–	I-PK
1611	∞	I-PK
1611	)	I-PK
1611	,	O
1611	and	O
1611	the	O
1611	maximum	B-PK
1611	observed	I-PK
1611	concentration	I-PK
1611	(	I-PK
1611	cm	I-PK
1611	##ax	I-PK
1611	)	I-PK
1611	after	O
1611	repeated	O
1611	administration	O
1611	for	O
1611	15	O
1611	days	O
1611	,	O
1611	but	O
1611	the	O
1611	difference	O
1611	was	O
1611	not	O
1611	statistical	O
1611	##ly	O
1611	significant	O
1611	.	O
1611	[SEP]	O
1612	[CLS]	O
1612	interesting	O
1612	##ly	O
1612	,	O
1612	after	O
1612	repeated	O
1612	dos	O
1612	##ing	O
1612	of	O
1612	630	O
1612	mg	O
1612	green	O
1612	tea	O
1612	extract	O
1612	,	O
1612	the	O
1612	elimination	B-PK
1612	half	I-PK
1612	-	I-PK
1612	life	I-PK
1612	(	I-PK
1612	t	I-PK
1612	##1	I-PK
1612	/	I-PK
1612	2	I-PK
1612	)	I-PK
1612	of	O
1612	e	O
1612	##g	O
1612	##c	O
1612	and	O
1612	e	O
1612	##c	O
1612	was	O
1612	decreased	O
1612	to	O
1612	0	O
1612	.	O
1612	74	O
1612	-	O
1612	and	O
1612	0	O
1612	.	O
1612	70	O
1612	-	O
1612	fold	O
1612	the	O
1612	values	O
1612	obtained	O
1612	on	O
1612	day	O
1612	1	O
1612	,	O
1612	respectively	O
1612	.	O
1612	[SEP]	O
1613	[CLS]	O
1613	a	O
1613	recent	O
1613	study	O
1613	suggested	O
1613	that	O
1613	p	O
1613	-	O
1613	g	O
1613	##p	O
1613	could	O
1613	involve	O
1613	the	O
1613	absorption	O
1613	and	O
1613	elimination	O
1613	of	O
1613	green	O
1613	tea	O
1613	[	O
1613	30	O
1613	]	O
1613	,	O
1613	and	O
1613	in	O
1613	the	O
1613	current	O
1613	study	O
1613	,	O
1613	repeated	O
1613	dos	O
1613	##ing	O
1613	of	O
1613	the	O
1613	cat	O
1613	##ech	O
1613	##ins	O
1613	appeared	O
1613	to	O
1613	reduce	O
1613	the	O
1613	t	B-PK
1613	##1	I-PK
1613	/	I-PK
1613	2	I-PK
1613	of	O
1613	e	O
1613	##c	O
1613	##g	O
1613	and	O
1613	e	O
1613	##c	O
1613	.	O
1613	[SEP]	O
1614	[CLS]	O
1614	the	O
1614	carry	O
1614	##over	O
1614	was	O
1614	considered	O
1614	not	O
1614	to	O
1614	affect	O
1614	the	O
1614	analysis	O
1614	when	O
1614	the	O
1614	detection	O
1614	area	O
1614	of	O
1614	the	O
1614	anal	O
1614	##yte	O
1614	interference	O
1614	peak	O
1614	was	O
1614	within	O
1614	20	O
1614	%	O
1614	of	O
1614	the	O
1614	ll	O
1614	##o	O
1614	##q	O
1614	and	O
1614	within	O
1614	5	O
1614	%	O
1614	of	O
1614	the	O
1614	i	O
1614	.	O
1614	s	O
1614	.	O
1614	peak	O
1614	area	O
1614	.	O
1614	[SEP]	O
1615	[CLS]	O
1615	the	O
1615	cm	B-PK
1615	##ax	I-PK
1615	and	O
1615	the	O
1615	time	B-PK
1615	to	I-PK
1615	cm	I-PK
1615	##ax	I-PK
1615	(	I-PK
1615	t	I-PK
1615	##max	I-PK
1615	)	I-PK
1615	were	O
1615	obtained	O
1615	from	O
1615	the	O
1615	observed	O
1615	data	O
1615	.	O
1615	[SEP]	O
1616	[CLS]	O
1616	the	O
1616	au	B-PK
1616	##c	I-PK
1616	##0	I-PK
1616	–	I-PK
1616	t	I-PK
1616	and	O
1616	au	B-PK
1616	##c	I-PK
1616	##0	I-PK
1616	–	I-PK
1616	∞	I-PK
1616	were	O
1616	calculated	O
1616	using	O
1616	the	O
1616	linear	O
1616	/	O
1616	log	O
1616	trap	O
1616	##ez	O
1616	##oid	O
1616	##al	O
1616	method	O
1616	.	O
1616	[SEP]	O
1617	[CLS]	O
1617	the	O
1617	t	B-PK
1617	##1	I-PK
1617	/	I-PK
1617	2	I-PK
1617	was	O
1617	calculated	O
1617	as	O
1617	l	O
1617	##n	O
1617	(	O
1617	2	O
1617	)	O
1617	/	O
1617	λ	O
1617	##z	O
1617	.	O
1617	[SEP]	O
1618	[CLS]	O
1618	λ	B-PK
1618	##z	I-PK
1618	was	O
1618	the	O
1618	elimination	B-PK
1618	rate	I-PK
1618	constant	I-PK
1618	slope	I-PK
1618	of	O
1618	the	O
1618	plasma	O
1618	concentration	O
1618	-	O
1618	time	O
1618	plot	O
1618	calculated	O
1618	using	O
1618	linear	O
1618	re	O
1618	##gression	O
1618	.	O
1618	[SEP]	O
1619	[CLS]	O
1619	the	O
1619	t	B-PK
1619	##max	I-PK
1619	,	O
1619	cm	B-PK
1619	##ax	I-PK
1619	,	O
1619	au	B-PK
1619	##c	I-PK
1619	##0	I-PK
1619	–	I-PK
1619	t	I-PK
1619	,	O
1619	au	B-PK
1619	##c	I-PK
1619	##0	I-PK
1619	–	I-PK
1619	∞	I-PK
1619	,	O
1619	and	O
1619	t	B-PK
1619	##1	I-PK
1619	/	I-PK
1619	2	I-PK
1619	of	O
1619	the	O
1619	four	O
1619	cat	O
1619	##ech	O
1619	##ins	O
1619	were	O
1619	compared	O
1619	on	O
1619	day	O
1619	1	O
1619	(	O
1619	single	O
1619	-	O
1619	dose	O
1619	green	O
1619	tea	O
1619	with	O
1619	dig	O
1619	##ox	O
1619	##in	O
1619	)	O
1619	and	O
1619	day	O
1619	15	O
1619	(	O
1619	repeated	O
1619	-	O
1619	dose	O
1619	green	O
1619	tea	O
1619	with	O
1619	dig	O
1619	##ox	O
1619	##in	O
1619	)	O
1619	.	O
1619	[SEP]	O
1620	[CLS]	O
1620	during	O
1620	ha	O
1620	##em	O
1620	##od	O
1620	##ial	O
1620	##ys	O
1620	##is	O
1620	,	O
1620	the	O
1620	central	B-PK
1620	volume	I-PK
1620	v	I-PK
1620	##1	I-PK
1620	was	O
1620	estimated	O
1620	to	O
1620	be	O
1620	reduced	O
1620	by	O
1620	0	O
1620	.	O
1620	198	O
1620	l	O
1620	/	O
1620	h	O
1620	.	O
1620	[SEP]	O
1621	[CLS]	O
1621	a	O
1621	positive	O
1621	relationship	O
1621	was	O
1621	identified	O
1621	between	O
1621	initial	O
1621	v	B-PK
1621	##1	I-PK
1621	and	O
1621	observed	O
1621	weight	O
1621	loss	O
1621	during	O
1621	ha	O
1621	##em	O
1621	##od	O
1621	##ial	O
1621	##ys	O
1621	##is	O
1621	.	O
1621	[SEP]	O
1622	[CLS]	O
1622	v	B-PK
1622	##1	I-PK
1622	increased	O
1622	by	O
1622	0	O
1622	.	O
1622	61	O
1622	##4	O
1622	%	O
1622	per	O
1622	k	O
1622	##ilo	O
1622	##gram	O
1622	of	O
1622	body	O
1622	weight	O
1622	,	O
1622	and	O
1622	females	O
1622	had	O
1622	an	O
1622	18	O
1622	.	O
1622	3	O
1622	%	O
1622	lower	O
1622	v	B-PK
1622	##1	I-PK
1622	than	O
1622	males	O
1622	.	O
1622	[SEP]	O
1623	[CLS]	O
1623	differences	O
1623	between	O
1623	simulated	O
1623	profiles	O
1623	for	O
1623	different	O
1623	populations	O
1623	were	O
1623	marginal	O
1623	:	O
1623	maximum	B-PK
1623	concentration	I-PK
1623	(	I-PK
1623	cm	I-PK
1623	##ax	I-PK
1623	)	I-PK
1623	of	O
1623	209	O
1623	vs	O
1623	.	O
1623	204	O
1623	ng	O
1623	/	O
1623	m	O
1623	##l	O
1623	and	O
1623	area	B-PK
1623	under	I-PK
1623	the	I-PK
1623	curve	I-PK
1623	from	I-PK
1623	time	I-PK
1623	zero	I-PK
1623	to	I-PK
1623	in	I-PK
1623	##finity	I-PK
1623	(	I-PK
1623	au	I-PK
1623	##cin	I-PK
1623	##f	I-PK
1623	)	I-PK
1623	of	O
1623	5	O
1623	,	O
1623	98	O
1623	##0	O
1623	vs	O
1623	.	O
1623	5	O
1623	,	O
1623	92	O
1623	##0	O
1623	ng	O
1623	·	O
1623	h	O
1623	/	O
1623	m	O
1623	##l	O
1623	in	O
1623	h	O
1623	##v	O
1623	##s	O
1623	and	O
1623	c	O
1623	##k	O
1623	##d	O
1623	non	O
1623	-	O
1623	ha	O
1623	##em	O
1623	##od	O
1623	##ial	O
1623	##ys	O
1623	##is	O
1623	patients	O
1623	,	O
1623	respectively	O
1623	,	O
1623	for	O
1623	a	O
1623	single	O
1623	dose	O
1623	of	O
1623	510	O
1623	mg	O
1623	.	O
1623	[SEP]	O
1624	[CLS]	O
1624	in	O
1624	addition	O
1624	,	O
1624	physiological	O
1624	##ly	O
1624	plausible	O
1624	relations	O
1624	(	O
1624	e	O
1624	.	O
1624	g	O
1624	.	O
1624	measures	O
1624	of	O
1624	iron	O
1624	against	O
1624	parameters	O
1624	related	O
1624	to	O
1624	f	O
1624	##er	O
1624	##um	O
1624	##ox	O
1624	##yt	O
1624	##ol	O
1624	clearance	B-PK
1624	from	O
1624	the	O
1624	circulation	O
1624	,	O
1624	body	O
1624	weight	O
1624	on	O
1624	volume	B-PK
1624	,	O
1624	ha	O
1624	##em	O
1624	##od	O
1624	##ial	O
1624	##ys	O
1624	##is	O
1624	on	O
1624	clearance	B-PK
1624	or	O
1624	volume	B-PK
1624	)	O
1624	were	O
1624	tested	O
1624	i	O
1624	##rre	O
1624	##spective	O
1624	of	O
1624	the	O
1624	visual	O
1624	plot	O
1624	assessment	O
1624	.	O
1624	[SEP]	O
1625	[CLS]	O
1625	as	O
1625	previously	O
1625	described	O
1625	[	O
1625	12	O
1625	]	O
1625	,	O
1625	a	O
1625	linear	O
1625	relation	O
1625	between	O
1625	body	O
1625	weight	O
1625	and	O
1625	central	B-PK
1625	volume	I-PK
1625	(	I-PK
1625	v	I-PK
1625	##1	I-PK
1625	)	I-PK
1625	was	O
1625	included	O
1625	,	O
1625	whereas	O
1625	b	O
1625	##s	O
1625	##v	O
1625	on	O
1625	the	O
1625	mi	O
1625	##cha	O
1625	##eli	O
1625	##s	O
1625	–	O
1625	men	O
1625	##ten	O
1625	constant	O
1625	km	B-PK
1625	was	O
1625	not	O
1625	supported	O
1625	.	O
1625	[SEP]	O
1626	[CLS]	O
1626	after	O
1626	adding	O
1626	data	O
1626	from	O
1626	the	O
1626	c	O
1626	##k	O
1626	##d	O
1626	study	O
1626	,	O
1626	a	O
1626	slope	O
1626	(	O
1626	vs	O
1626	##lop	O
1626	##e	O
1626	)	O
1626	parameter	O
1626	was	O
1626	included	O
1626	for	O
1626	ha	O
1626	##em	O
1626	##od	O
1626	##ial	O
1626	##ys	O
1626	##is	O
1626	subjects	O
1626	to	O
1626	describe	O
1626	volume	O
1626	change	O
1626	over	O
1626	time	O
1626	,	O
1626	so	O
1626	as	O
1626	to	O
1626	account	O
1626	for	O
1626	the	O
1626	effects	O
1626	of	O
1626	ha	O
1626	##em	O
1626	##od	O
1626	##ial	O
1626	##ys	O
1626	##is	O
1626	on	O
1626	central	B-PK
1626	volume	I-PK
1626	of	I-PK
1626	distribution	I-PK
1626	.	O
1626	[SEP]	O
1627	[CLS]	O
1627	some	O
1627	shrink	O
1627	##age	O
1627	was	O
1627	present	O
1627	in	O
1627	the	O
1627	b	O
1627	##s	O
1627	##v	O
1627	of	O
1627	the	O
1627	peripheral	B-PK
1627	volume	I-PK
1627	v	I-PK
1627	##2	I-PK
1627	,	O
1627	indicating	O
1627	that	O
1627	visual	O
1627	inspection	O
1627	of	O
1627	individual	O
1627	bay	O
1627	##es	O
1627	estimates	O
1627	against	O
1627	co	O
1627	##var	O
1627	##iate	O
1627	values	O
1627	might	O
1627	not	O
1627	be	O
1627	inform	O
1627	##ative	O
1627	[	O
1627	21	O
1627	]	O
1627	.	O
1627	[SEP]	O
1628	[CLS]	O
1628	co	O
1628	##var	O
1628	##iate	O
1628	##s	O
1628	were	O
1628	therefore	O
1628	tested	O
1628	on	O
1628	v	B-PK
1628	##2	I-PK
1628	based	O
1628	on	O
1628	physiological	O
1628	p	O
1628	##laus	O
1628	##ibility	O
1628	,	O
1628	only	O
1628	.	O
1628	[SEP]	O
1629	[CLS]	O
1629	v	B-PK
1629	##1	I-PK
1629	and	O
1629	v	B-PK
1629	##2	I-PK
1629	were	O
1629	estimated	O
1629	to	O
1629	be	O
1629	small	O
1629	(	O
1629	2	O
1629	.	O
1629	8	O
1629	and	O
1629	0	O
1629	.	O
1629	35	O
1629	l	O
1629	,	O
1629	respectively	O
1629	)	O
1629	.	O
1629	[SEP]	O
1630	[CLS]	O
1630	during	O
1630	ha	O
1630	##em	O
1630	##od	O
1630	##ial	O
1630	##ys	O
1630	##is	O
1630	,	O
1630	v	B-PK
1630	##1	I-PK
1630	was	O
1630	estimated	O
1630	to	O
1630	be	O
1630	reduced	O
1630	by	O
1630	0	O
1630	.	O
1630	198	O
1630	l	O
1630	/	O
1630	h	O
1630	over	O
1630	a	O
1630	period	O
1630	of	O
1630	3	O
1630	h	O
1630	(	O
1630	total	O
1630	volume	O
1630	loss	O
1630	of	O
1630	0	O
1630	.	O
1630	59	O
1630	l	O
1630	)	O
1630	.	O
1630	[SEP]	O
1631	[CLS]	O
1631	it	O
1631	was	O
1631	also	O
1631	identified	O
1631	that	O
1631	patients	O
1631	with	O
1631	the	O
1631	highest	O
1631	observed	O
1631	weight	O
1631	loss	O
1631	during	O
1631	ha	O
1631	##em	O
1631	##od	O
1631	##ial	O
1631	##ys	O
1631	##is	O
1631	were	O
1631	those	O
1631	with	O
1631	the	O
1631	largest	O
1631	initial	O
1631	v	B-PK
1631	##1	I-PK
1631	.	O
1631	[SEP]	O
1632	[CLS]	O
1632	overall	O
1632	,	O
1632	v	B-PK
1632	##1	I-PK
1632	differed	O
1632	by	O
1632	0	O
1632	.	O
1632	61	O
1632	##4	O
1632	%	O
1632	per	O
1632	k	O
1632	##ilo	O
1632	##gram	O
1632	difference	O
1632	in	O
1632	body	O
1632	weight	O
1632	,	O
1632	and	O
1632	females	O
1632	had	O
1632	an	O
1632	18	O
1632	.	O
1632	3	O
1632	%	O
1632	lower	O
1632	v	B-PK
1632	##1	I-PK
1632	than	O
1632	males	O
1632	.	O
1632	[SEP]	O
1633	[CLS]	O
1633	this	O
1633	result	O
1633	is	O
1633	an	O
1633	effect	O
1633	of	O
1633	the	O
1633	co	O
1633	##var	O
1633	##iate	O
1633	influence	O
1633	w	O
1633	##lo	O
1633	on	O
1633	central	B-PK
1633	volume	I-PK
1633	of	I-PK
1633	distribution	I-PK
1633	.	O
1633	[SEP]	O
1634	[CLS]	O
1634	as	O
1634	a	O
1634	result	O
1634	of	O
1634	the	O
1634	changes	O
1634	in	O
1634	v	B-PK
1634	##1	I-PK
1634	during	O
1634	dial	O
1634	##ys	O
1634	##is	O
1634	,	O
1634	concentrations	O
1634	increase	O
1634	in	O
1634	the	O
1634	ha	O
1634	##em	O
1634	##od	O
1634	##ial	O
1634	##ys	O
1634	##is	O
1634	population	O
1634	.	O
1634	[SEP]	O
1635	[CLS]	O
1635	in	O
1635	addition	O
1635	,	O
1635	due	O
1635	to	O
1635	the	O
1635	sat	O
1635	##urable	O
1635	mi	O
1635	##cha	O
1635	##eli	O
1635	##s	O
1635	–	O
1635	men	O
1635	##ten	O
1635	elimination	O
1635	behaviour	O
1635	of	O
1635	f	O
1635	##er	O
1635	##um	O
1635	##ox	O
1635	##yt	O
1635	##ol	O
1635	,	O
1635	differences	O
1635	in	O
1635	v	B-PK
1635	##1	I-PK
1635	also	O
1635	result	O
1635	in	O
1635	relatively	O
1635	small	O
1635	differences	O
1635	in	O
1635	au	B-PK
1635	##c	I-PK
1635	.	O
1635	[SEP]	O
1636	[CLS]	O
1636	following	O
1636	the	O
1636	shorter	O
1636	dos	O
1636	##ing	O
1636	interval	O
1636	of	O
1636	2	O
1636	days	O
1636	apart	O
1636	,	O
1636	the	O
1636	peak	O
1636	and	O
1636	total	O
1636	exposure	O
1636	of	O
1636	f	O
1636	##er	O
1636	##um	O
1636	##ox	O
1636	##yt	O
1636	##ol	O
1636	is	O
1636	slightly	O
1636	higher	O
1636	,	O
1636	with	O
1636	median	O
1636	maximum	B-PK
1636	concentration	I-PK
1636	(	I-PK
1636	cm	I-PK
1636	##ax	I-PK
1636	)	I-PK
1636	and	O
1636	median	O
1636	total	B-PK
1636	area	I-PK
1636	under	I-PK
1636	the	I-PK
1636	curve	I-PK
1636	from	I-PK
1636	time	I-PK
1636	zero	I-PK
1636	to	I-PK
1636	in	I-PK
1636	##finity	I-PK
1636	(	I-PK
1636	au	I-PK
1636	##cin	I-PK
1636	##f	I-PK
1636	)	I-PK
1636	of	O
1636	two	O
1636	doses	O
1636	being	O
1636	~	O
1636	21	O
1636	and	O
1636	~	O
1636	11	O
1636	%	O
1636	higher	O
1636	compared	O
1636	with	O
1636	red	O
1636	##os	O
1636	##ing	O
1636	after	O
1636	5	O
1636	–	O
1636	8	O
1636	days	O
1636	.	O
1636	[SEP]	O
1637	[CLS]	O
1637	after	O
1637	oral	O
1637	administration	O
1637	in	O
1637	rode	O
1637	##nts	O
1637	,	O
1637	trip	O
1637	##to	O
1637	##lide	O
1637	(	O
1637	t	O
1637	##p	O
1637	)	O
1637	,	O
1637	a	O
1637	di	O
1637	##ter	O
1637	##pen	O
1637	##oid	O
1637	t	O
1637	##rie	O
1637	##pox	O
1637	##ide	O
1637	compound	O
1637	,	O
1637	active	O
1637	as	O
1637	anti	O
1637	-	O
1637	inflammatory	O
1637	,	O
1637	im	O
1637	##mu	O
1637	##nos	O
1637	##up	O
1637	##pressive	O
1637	,	O
1637	anti	O
1637	-	O
1637	fertility	O
1637	,	O
1637	anti	O
1637	-	O
1637	c	O
1637	##ys	O
1637	##to	O
1637	##genesis	O
1637	,	O
1637	and	O
1637	anti	O
1637	##can	O
1637	##cer	O
1637	agent	O
1637	,	O
1637	is	O
1637	rapidly	O
1637	absorbed	O
1637	into	O
1637	the	O
1637	blood	O
1637	circulation	O
1637	(	O
1637	from	O
1637	5	O
1637	.	O
1637	0	O
1637	to	O
1637	19	O
1637	.	O
1637	5	O
1637	minutes	O
1637	after	O
1637	dos	O
1637	##ing	O
1637	,	O
1637	depending	O
1637	on	O
1637	the	O
1637	rode	O
1637	##nt	O
1637	species	O
1637	)	O
1637	followed	O
1637	by	O
1637	a	O
1637	short	O
1637	elimination	B-PK
1637	half	I-PK
1637	-	I-PK
1637	life	I-PK
1637	(	O
1637	from	O
1637	about	O
1637	20	O
1637	minutes	O
1637	to	O
1637	less	O
1637	than	O
1637	1	O
1637	hour	O
1637	)	O
1637	.	O
1637	[SEP]	O
1638	[CLS]	O
1638	further	O
1638	##more	O
1638	,	O
1638	t	O
1638	##p	O
1638	-	O
1638	n	O
1638	##l	O
1638	##cs	O
1638	prolonged	O
1638	mean	B-PK
1638	residence	I-PK
1638	time	I-PK
1638	(	I-PK
1638	m	I-PK
1638	##rt	I-PK
1638	)	I-PK
1638	0	I-PK
1638	–	I-PK
1638	t	I-PK
1638	(	O
1638	p	O
1638	<	O
1638	0	O
1638	.	O
1638	00	O
1638	##1	O
1638	,	O
1638	p	O
1638	<	O
1638	0	O
1638	.	O
1638	00	O
1638	##1	O
1638	)	O
1638	,	O
1638	delayed	O
1638	t	B-PK
1638	##max	I-PK
1638	(	O
1638	p	O
1638	<	O
1638	0	O
1638	.	O
1638	01	O
1638	,	O
1638	p	O
1638	<	O
1638	0	O
1638	.	O
1638	05	O
1638	)	O
1638	and	O
1638	decreased	O
1638	cm	B-PK
1638	##ax	I-PK
1638	(	O
1638	p	O
1638	<	O
1638	0	O
1638	.	O
1638	01	O
1638	,	O
1638	p	O
1638	<	O
1638	0	O
1638	.	O
1638	05	O
1638	)	O
1638	compared	O
1638	to	O
1638	free	O
1638	t	O
1638	##p	O
1638	and	O
1638	t	O
1638	##p	O
1638	-	O
1638	s	O
1638	##ln	O
1638	##s	O
1638	,	O
1638	respectively	O
1638	,	O
1638	which	O
1638	was	O
1638	associated	O
1638	with	O
1638	reduced	O
1638	sub	O
1638	##ac	O
1638	##ute	O
1638	toxicity	O
1638	in	O
1638	male	O
1638	rats	O
1638	.	O
1638	[SEP]	O
1639	[CLS]	O
1639	medium	O
1639	chain	O
1639	t	O
1639	##rig	O
1639	##ly	O
1639	##cer	O
1639	##ides	O
1639	(	O
1639	m	O
1639	##ct	O
1639	;	O
1639	liquid	O
1639	lip	O
1639	##id	O
1639	)	O
1639	and	O
1639	lip	O
1639	##oid	O
1639	##®	O
1639	e	O
1639	80	O
1639	(	O
1639	egg	O
1639	le	O
1639	##ci	O
1639	##thin	O
1639	)	O
1639	were	O
1639	purchased	O
1639	from	O
1639	lip	O
1639	##oid	O
1639	g	O
1639	##mb	O
1639	##h	O
1639	(	O
1639	l	O
1639	##ud	O
1639	##wig	O
1639	##sha	O
1639	##fen	O
1639	,	O
1639	g	O
1639	##erman	O
1639	##y	O
1639	)	O
1639	.	O
1639	[SEP]	O
1640	[CLS]	O
1640	t	O
1640	##p	O
1640	-	O
1640	n	O
1640	##l	O
1640	##cs	O
1640	were	O
1640	prepared	O
1640	using	O
1640	micro	O
1640	##em	O
1640	##ul	O
1640	##sion	O
1640	technique	O
1640	.	O
1640	13	O
1640	briefly	O
1640	,	O
1640	t	O
1640	##p	O
1640	,	O
1640	lip	O
1640	##ids	O
1640	(	O
1640	selected	O
1640	solid	O
1640	and	O
1640	liquid	O
1640	lip	O
1640	##ids	O
1640	,	O
1640	for	O
1640	details	O
1640	,	O
1640	see	O
1640	results	O
1640	section	O
1640	)	O
1640	,	O
1640	c	O
1640	##rem	O
1640	##op	O
1640	##hor	O
1640	r	O
1640	##h	O
1640	##40	O
1640	,	O
1640	lip	O
1640	##oid	O
1640	e	O
1640	80	O
1640	,	O
1640	and	O
1640	trans	O
1640	##cut	O
1640	##ol	O
1640	hp	O
1640	were	O
1640	mixed	O
1640	at	O
1640	a	O
1640	ratio	O
1640	of	O
1640	1	O
1640	:	O
1640	55	O
1640	:	O
1640	42	O
1640	:	O
1640	6	O
1640	.	O
1640	5	O
1640	:	O
1640	6	O
1640	.	O
1640	5	O
1640	(	O
1640	weight	O
1640	[	O
1640	w	O
1640	]	O
1640	/	O
1640	w	O
1640	)	O
1640	.	O
1640	[SEP]	O
1641	[CLS]	O
1641	finally	O
1641	,	O
1641	samples	O
1641	were	O
1641	examined	O
1641	by	O
1641	the	O
1641	hit	O
1641	##achi	O
1641	h	O
1641	-	O
1641	700	O
1641	##0	O
1641	##fa	O
1641	transmission	O
1641	electron	O
1641	micro	O
1641	##scope	O
1641	at	O
1641	75	O
1641	k	O
1641	##v	O
1641	(	O
1641	hit	O
1641	##achi	O
1641	l	O
1641	##t	O
1641	##d	O
1641	,	O
1641	to	O
1641	##ky	O
1641	##o	O
1641	,	O
1641	j	O
1641	##apa	O
1641	##n	O
1641	)	O
1641	.	O
1641	[SEP]	O
1642	[CLS]	O
1642	the	O
1642	t	B-PK
1642	##max	I-PK
1642	and	O
1642	t	B-PK
1642	##1	I-PK
1642	/	I-PK
1642	2	I-PK
1642	##z	I-PK
1642	of	O
1642	free	O
1642	t	O
1642	##p	O
1642	were	O
1642	0	O
1642	.	O
1642	200	O
1642	hours	O
1642	and	O
1642	0	O
1642	.	O
1642	70	O
1642	##6	O
1642	hours	O
1642	,	O
1642	respectively	O
1642	,	O
1642	similar	O
1642	to	O
1642	results	O
1642	reported	O
1642	in	O
1642	previous	O
1642	studies	O
1642	.	O
1642	8	O
1642	,	O
1642	9	O
1642	in	O
1642	this	O
1642	study	O
1642	,	O
1642	the	O
1642	time	B-PK
1642	to	I-PK
1642	achieve	I-PK
1642	maximum	I-PK
1642	concentration	I-PK
1642	of	O
1642	t	O
1642	##p	O
1642	was	O
1642	delayed	O
1642	to	O
1642	0	O
1642	.	O
1642	71	O
1642	##7	O
1642	hours	O
1642	and	O
1642	0	O
1642	.	O
1642	450	O
1642	hours	O
1642	in	O
1642	the	O
1642	case	O
1642	of	O
1642	t	O
1642	##p	O
1642	-	O
1642	n	O
1642	##l	O
1642	##cs	O
1642	(	O
1642	p	O
1642	<	O
1642	0	O
1642	.	O
1642	01	O
1642	)	O
1642	and	O
1642	t	O
1642	##p	O
1642	-	O
1642	s	O
1642	##ln	O
1642	##s	O
1642	(	O
1642	p	O
1642	>	O
1642	0	O
1642	.	O
1642	05	O
1642	)	O
1642	,	O
1642	respectively	O
1642	.	O
1642	[SEP]	O
1643	[CLS]	O
1643	interesting	O
1643	##ly	O
1643	,	O
1643	a	O
1643	significant	O
1643	decrease	O
1643	was	O
1643	found	O
1643	in	O
1643	the	O
1643	cm	B-PK
1643	##ax	I-PK
1643	from	O
1643	8	O
1643	.	O
1643	65	O
1643	##6	O
1643	μ	O
1643	##g	O
1643	/	O
1643	l	O
1643	for	O
1643	free	O
1643	t	O
1643	##p	O
1643	to	O
1643	3	O
1643	.	O
1643	36	O
1643	##1	O
1643	μ	O
1643	##g	O
1643	/	O
1643	l	O
1643	for	O
1643	t	O
1643	##p	O
1643	-	O
1643	n	O
1643	##l	O
1643	##cs	O
1643	(	O
1643	p	O
1643	<	O
1643	0	O
1643	.	O
1643	01	O
1643	)	O
1643	and	O
1643	to	O
1643	5	O
1643	.	O
1643	79	O
1643	##4	O
1643	μ	O
1643	##g	O
1643	/	O
1643	l	O
1643	for	O
1643	t	O
1643	##p	O
1643	-	O
1643	s	O
1643	##ln	O
1643	##s	O
1643	(	O
1643	p	O
1643	<	O
1643	0	O
1643	.	O
1643	05	O
1643	)	O
1643	.	O
1643	[SEP]	O
1644	[CLS]	O
1644	apparent	B-PK
1644	clearance	I-PK
1644	(	I-PK
1644	c	I-PK
1644	##l	I-PK
1644	##z	I-PK
1644	/	I-PK
1644	f	I-PK
1644	)	I-PK
1644	was	O
1644	also	O
1644	found	O
1644	to	O
1644	be	O
1644	reduced	O
1644	in	O
1644	t	O
1644	##p	O
1644	-	O
1644	n	O
1644	##l	O
1644	##cs	O
1644	(	O
1644	p	O
1644	<	O
1644	0	O
1644	.	O
1644	01	O
1644	)	O
1644	and	O
1644	t	O
1644	##p	O
1644	-	O
1644	s	O
1644	##ln	O
1644	##s	O
1644	(	O
1644	p	O
1644	<	O
1644	0	O
1644	.	O
1644	05	O
1644	)	O
1644	compared	O
1644	to	O
1644	free	O
1644	t	O
1644	##p	O
1644	.	O
1644	[SEP]	O
1645	[CLS]	O
1645	in	O
1645	addition	O
1645	,	O
1645	t	O
1645	##p	O
1645	-	O
1645	n	O
1645	##l	O
1645	##cs	O
1645	and	O
1645	t	O
1645	##p	O
1645	-	O
1645	s	O
1645	##ln	O
1645	##s	O
1645	gave	O
1645	mean	O
1645	values	O
1645	of	O
1645	the	O
1645	area	B-PK
1645	under	I-PK
1645	the	I-PK
1645	curve	I-PK
1645	from	I-PK
1645	the	I-PK
1645	time	I-PK
1645	of	I-PK
1645	dos	I-PK
1645	##ing	I-PK
1645	to	I-PK
1645	the	I-PK
1645	last	I-PK
1645	observation	I-PK
1645	(	I-PK
1645	au	I-PK
1645	##c	I-PK
1645	##0	I-PK
1645	–	I-PK
1645	t	I-PK
1645	)	I-PK
1645	9	O
1645	.	O
1645	01	O
1645	##2	O
1645	and	O
1645	7	O
1645	.	O
1645	31	O
1645	##8	O
1645	μ	O
1645	##g	O
1645	*	O
1645	hour	O
1645	/	O
1645	l	O
1645	,	O
1645	which	O
1645	were	O
1645	1	O
1645	.	O
1645	54	O
1645	-	O
1645	and	O
1645	1	O
1645	.	O
1645	25	O
1645	-	O
1645	fold	O
1645	higher	O
1645	,	O
1645	than	O
1645	that	O
1645	of	O
1645	free	O
1645	t	O
1645	##p	O
1645	,	O
1645	respectively	O
1645	.	O
1645	[SEP]	O
1646	[CLS]	O
1646	these	O
1646	results	O
1646	showed	O
1646	the	O
1646	superiority	O
1646	of	O
1646	t	O
1646	##p	O
1646	-	O
1646	n	O
1646	##l	O
1646	##cs	O
1646	over	O
1646	t	O
1646	##p	O
1646	-	O
1646	s	O
1646	##ln	O
1646	##s	O
1646	,	O
1646	as	O
1646	also	O
1646	supported	O
1646	by	O
1646	prominent	O
1646	difference	O
1646	on	O
1646	m	B-PK
1646	##rt	I-PK
1646	##0	I-PK
1646	–	I-PK
1646	t	I-PK
1646	(	O
1646	p	O
1646	<	O
1646	0	O
1646	.	O
1646	00	O
1646	##1	O
1646	)	O
1646	,	O
1646	t	B-PK
1646	##max	I-PK
1646	(	O
1646	p	O
1646	<	O
1646	0	O
1646	.	O
1646	05	O
1646	)	O
1646	,	O
1646	and	O
1646	cm	B-PK
1646	##ax	I-PK
1646	(	O
1646	p	O
1646	<	O
1646	0	O
1646	.	O
1646	05	O
1646	)	O
1646	.	O
1646	[SEP]	O
1647	[CLS]	O
1647	standard	O
1647	mi	O
1647	##cha	O
1647	##eli	O
1647	##s	O
1647	-	O
1647	men	O
1647	##ten	O
1647	sat	O
1647	##uration	O
1647	kinetic	O
1647	##s	O
1647	were	O
1647	used	O
1647	to	O
1647	q	O
1647	##uant	O
1647	##ify	O
1647	the	O
1647	process	O
1647	of	O
1647	a	O
1647	##pa	O
1647	##p	O
1647	metabolism	O
1647	for	O
1647	a	O
1647	##pa	O
1647	##p	O
1647	-	O
1647	g	O
1647	and	O
1647	a	O
1647	##pa	O
1647	##p	O
1647	-	O
1647	s	O
1647	in	O
1647	the	O
1647	liver	O
1647	,	O
1647	and	O
1647	were	O
1647	parameter	O
1647	##ized	O
1647	by	O
1647	the	O
1647	mi	B-PK
1647	##cha	I-PK
1647	##eli	I-PK
1647	##s	I-PK
1647	constant	I-PK
1647	km	I-PK
1647	and	O
1647	maximum	B-PK
1647	metabolism	I-PK
1647	rate	I-PK
1647	v	I-PK
1647	##max	I-PK
1647	.	O
1647	[SEP]	O
1648	[CLS]	O
1648	to	O
1648	investigate	O
1648	whether	O
1648	the	O
1648	different	O
1648	algorithms	O
1648	give	O
1648	consistent	O
1648	results	O
1648	as	O
1648	to	O
1648	direct	O
1648	and	O
1648	indirect	O
1648	parameter	O
1648	se	O
1648	##ns	O
1648	##iti	O
1648	##vi	O
1648	##ties	O
1648	,	O
1648	we	O
1648	used	O
1648	the	O
1648	p	O
1648	##ear	O
1648	##son	O
1648	and	O
1648	spear	O
1648	##man	O
1648	correlation	O
1648	coefficients	O
1648	to	O
1648	assess	O
1648	the	O
1648	consistency	O
1648	of	O
1648	the	O
1648	main	O
1648	effects	O
1648	(	O
1648	m	O
1648	##or	O
1648	##ris	O
1648	μ	O
1648	*	O
1648	and	O
1648	sob	O
1648	##ol	O
1648	main	O
1648	effect	O
1648	)	O
1648	and	O
1648	interaction	O
1648	effects	O
1648	(	O
1648	σ	O
1648	,	O
1648	and	O
1648	sob	O
1648	##ol	O
1648	interaction	O
1648	effect	O
1648	)	O
1648	among	O
1648	each	O
1648	tested	O
1648	parameter	O
1648	using	O
1648	its	O
1648	maximum	O
1648	sensitivity	O
1648	index	O
1648	.	O
1648	[SEP]	O
1649	[CLS]	O
1649	parallel	O
1649	##ized	O
1649	com	O
1649	##putation	O
1649	of	O
1649	the	O
1649	m	O
1649	##c	O
1649	##m	O
1649	##c	O
1649	was	O
1649	performed	O
1649	within	O
1649	the	O
1649	64	O
1649	-	O
1649	bit	O
1649	cent	O
1649	##os	O
1649	l	O
1649	##in	O
1649	##ux	O
1649	distribution	O
1649	on	O
1649	a	O
1649	high	O
1649	-	O
1649	performance	O
1649	computing	O
1649	cluster	O
1649	at	O
1649	te	O
1649	##xa	O
1649	##s	O
1649	a	O
1649	&	O
1649	m	O
1649	university	O
1649	,	O
1649	comprising	O
1649	machines	O
1649	with	O
1649	in	O
1649	##tel	O
1649	x	O
1649	##eon	O
1649	2	O
1649	.	O
1649	5	O
1649	##gh	O
1649	##z	O
1649	e	O
1649	##5	O
1649	-	O
1649	26	O
1649	##70	O
1649	v	O
1649	##2	O
1649	(	O
1649	i	O
1649	##vy	O
1649	bridge	O
1649	-	O
1649	e	O
1649	##p	O
1649	)	O
1649	10	O
1649	-	O
1649	core	O
1649	processors	O
1649	and	O
1649	64	O
1649	g	O
1649	##b	O
1649	of	O
1649	ram	O
1649	each	O
1649	.	O
1649	[SEP]	O
1650	[CLS]	O
1650	for	O
1650	m	O
1650	##or	O
1650	##ris	O
1650	in	O
1650	##dices	O
1650	,	O
1650	we	O
1650	normal	O
1650	##ized	O
1650	the	O
1650	index	O
1650	by	O
1650	maximum	O
1650	est	O
1650	##imation	O
1650	and	O
1650	set	O
1650	the	O
1650	threshold	O
1650	as	O
1650	10	O
1650	%	O
1650	of	O
1650	maximum	O
1650	est	O
1650	##imation	O
1650	across	O
1650	model	O
1650	parameters	O
1650	for	O
1650	the	O
1650	specific	O
1650	compound	O
1650	at	O
1650	time	O
1650	t	O
1650	.	O
1650	[SEP]	O
1651	[CLS]	O
1651	visual	O
1651	inspection	O
1651	of	O
1651	the	O
1651	data	O
1651	points	O
1651	relative	O
1651	to	O
1651	the	O
1651	s	O
1651	##cat	O
1651	##ter	O
1651	of	O
1651	the	O
1651	predictions	O
1651	suggests	O
1651	that	O
1651	each	O
1651	parameter	O
1651	set	O
1651	shows	O
1651	a	O
1651	consistent	O
1651	or	O
1651	similar	O
1651	predicted	O
1651	curve	O
1651	in	O
1651	the	O
1651	high	O
1651	-	O
1651	dos	O
1651	##age	O
1651	(	O
1651	20	O
1651	and	O
1651	80	O
1651	mg	O
1651	/	O
1651	kg	O
1651	)	O
1651	groups	O
1651	(	O
1651	e	O
1651	–	O
1651	h	O
1651	)	O
1651	.	O
1651	[SEP]	O
1652	[CLS]	O
1652	the	O
1652	treatment	O
1652	-	O
1652	related	O
1652	adverse	O
1652	events	O
1652	(	O
1652	a	O
1652	##e	O
1652	)	O
1652	≥	O
1652	grade	O
1652	3	O
1652	in	O
1652	more	O
1652	than	O
1652	2	O
1652	patients	O
1652	were	O
1652	ne	O
1652	##ut	O
1652	##rop	O
1652	##enia	O
1652	(	O
1652	35	O
1652	%	O
1652	)	O
1652	,	O
1652	th	O
1652	##rom	O
1652	##bo	O
1652	##cy	O
1652	##top	O
1652	##enia	O
1652	(	O
1652	30	O
1652	%	O
1652	)	O
1652	,	O
1652	and	O
1652	le	O
1652	##uc	O
1652	##ope	O
1652	##nia	O
1652	(	O
1652	20	O
1652	%	O
1652	)	O
1652	.	O
1652	[SEP]	O
1653	[CLS]	O
1653	the	O
1653	investigator	O
1653	determined	O
1653	a	O
1653	##e	O
1653	serious	O
1653	##ness	O
1653	,	O
1653	severity	O
1653	grade	O
1653	,	O
1653	and	O
1653	relationship	O
1653	to	O
1653	study	O
1653	treatment	O
1653	.	O
1653	[SEP]	O
1654	[CLS]	O
1654	the	O
1654	maximum	B-PK
1654	plasma	I-PK
1654	drug	I-PK
1654	concentration	I-PK
1654	(	I-PK
1654	cm	I-PK
1654	##ax	I-PK
1654	)	I-PK
1654	and	O
1654	time	B-PK
1654	to	I-PK
1654	reach	I-PK
1654	maximum	I-PK
1654	concentration	I-PK
1654	(	I-PK
1654	t	I-PK
1654	##max	I-PK
1654	)	I-PK
1654	were	O
1654	obtained	O
1654	from	O
1654	experimental	O
1654	observation	O
1654	.	O
1654	[SEP]	O
1655	[CLS]	O
1655	all	O
1655	20	O
1655	patients	O
1655	were	O
1655	assessed	O
1655	for	O
1655	toxicity	O
1655	.	O
1655	[SEP]	O
1656	[CLS]	O
1656	there	O
1656	was	O
1656	no	O
1656	significant	O
1656	difference	O
1656	in	O
1656	p	O
1656	##k	O
1656	parameters	O
1656	of	O
1656	ex	O
1656	##em	O
1656	##esta	O
1656	##ne	O
1656	before	O
1656	and	O
1656	after	O
1656	combination	O
1656	with	O
1656	ch	O
1656	##ida	O
1656	##mi	O
1656	##de	O
1656	,	O
1656	including	O
1656	the	O
1656	plasma	O
1656	exposure	O
1656	(	O
1656	32	O
1656	.	O
1656	5	O
1656	vs	O
1656	.	O
1656	31	O
1656	.	O
1656	4	O
1656	ng	O
1656	/	O
1656	m	O
1656	##l	O
1656	for	O
1656	cm	B-PK
1656	##ax	I-PK
1656	,	O
1656	and	O
1656	71	O
1656	.	O
1656	8	O
1656	vs	O
1656	.	O
1656	79	O
1656	.	O
1656	3	O
1656	ng	O
1656	·	O
1656	h	O
1656	/	O
1656	m	O
1656	##l	O
1656	for	O
1656	au	B-PK
1656	##c	I-PK
1656	##0	I-PK
1656	##−	I-PK
1656	##t	I-PK
1656	)	O
1656	.	O
1656	[SEP]	O
1657	[CLS]	O
1657	p	O
1657	##har	O
1657	##ma	O
1657	##co	O
1657	##kin	O
1657	##etic	O
1657	analysis	O
1657	of	O
1657	the	O
1657	con	O
1657	##ju	O
1657	##gate	O
1657	##s	O
1657	demonstrated	O
1657	that	O
1657	the	O
1657	con	O
1657	##ju	O
1657	##gate	O
1657	circulated	O
1657	for	O
1657	a	O
1657	longer	O
1657	time	O
1657	in	O
1657	the	O
1657	blood	O
1657	circulation	O
1657	system	O
1657	(	O
1657	t	B-PK
1657	##2	I-PK
1657	/	I-PK
1657	1	I-PK
1657	=	O
1657	10	O
1657	.	O
1657	51	O
1657	##6	O
1657	##±	O
1657	##1	O
1657	.	O
1657	158	O
1657	h	O
1657	)	O
1657	than	O
1657	did	O
1657	10	O
1657	-	O
1657	h	O
1657	##c	O
1657	##pt	O
1657	solution	O
1657	(	O
1657	t	B-PK
1657	##2	I-PK
1657	/	I-PK
1657	1	I-PK
1657	=	O
1657	1	O
1657	.	O
1657	85	O
1657	##9	O
1657	##±	O
1657	##1	O
1657	.	O
1657	385	O
1657	h	O
1657	)	O
1657	,	O
1657	and	O
1657	that	O
1657	it	O
1657	also	O
1657	enhanced	O
1657	the	O
1657	targeting	O
1657	and	O
1657	mean	B-PK
1657	residence	I-PK
1657	time	I-PK
1657	(	I-PK
1657	m	I-PK
1657	##rt	I-PK
1657	##0	I-PK
1657	–	I-PK
1657	in	I-PK
1657	##f	I-PK
1657	=	O
1657	39	O
1657	.	O
1657	87	O
1657	##3	O
1657	##±	O
1657	##4	O
1657	.	O
1657	54	O
1657	##9	O
1657	h	O
1657	)	O
1657	in	O
1657	the	O
1657	tumor	O
1657	site	O
1657	,	O
1657	compared	O
1657	with	O
1657	10	O
1657	-	O
1657	h	O
1657	##c	O
1657	##pt	O
1657	(	O
1657	m	B-PK
1657	##rt	I-PK
1657	##0	I-PK
1657	–	I-PK
1657	in	I-PK
1657	##f	I-PK
1657	=	O
1657	9	O
1657	.	O
1657	247	O
1657	##±	O
1657	##1	O
1657	.	O
1657	02	O
1657	##6	O
1657	h	O
1657	)	O
1657	.	O
1657	[SEP]	O
1658	[CLS]	O
1658	compound	O
1658	e	O
1658	was	O
1658	kept	O
1658	at	O
1658	4	O
1658	##°	O
1658	##c	O
1658	under	O
1658	n	O
1658	##2	O
1658	.	O
1658	[SEP]	O
1659	[CLS]	O
1659	compound	O
1659	e	O
1659	(	O
1659	205	O
1659	mg	O
1659	,	O
1659	0	O
1659	.	O
1659	1	O
1659	mm	O
1659	##ol	O
1659	)	O
1659	was	O
1659	dissolved	O
1659	in	O
1659	50	O
1659	m	O
1659	##l	O
1659	an	O
1659	##hy	O
1659	##dr	O
1659	##ous	O
1659	d	O
1659	##m	O
1659	##f	O
1659	and	O
1659	to	O
1659	it	O
1659	were	O
1659	added	O
1659	compound	O
1659	c	O
1659	(	O
1659	55	O
1659	mg	O
1659	,	O
1659	0	O
1659	.	O
1659	1	O
1659	mm	O
1659	##ol	O
1659	)	O
1659	drop	O
1659	by	O
1659	drop	O
1659	at	O
1659	0	O
1659	##°	O
1659	##c	O
1659	under	O
1659	n	O
1659	##2	O
1659	.	O
1659	35	O
1659	k	O
1659	##2	O
1659	##co	O
1659	##3	O
1659	was	O
1659	added	O
1659	to	O
1659	the	O
1659	reaction	O
1659	to	O
1659	maintain	O
1659	a	O
1659	basic	O
1659	p	O
1659	##h	O
1659	.	O
1659	after	O
1659	stirring	O
1659	for	O
1659	3	O
1659	h	O
1659	in	O
1659	an	O
1659	ice	O
1659	-	O
1659	bath	O
1659	,	O
1659	the	O
1659	solvent	O
1659	was	O
1659	e	O
1659	##va	O
1659	##porated	O
1659	under	O
1659	reduced	O
1659	pressure	O
1659	to	O
1659	concentrate	O
1659	the	O
1659	mixture	O
1659	.	O
1659	[SEP]	O
1660	[CLS]	O
1660	after	O
1660	24	O
1660	h	O
1660	culture	O
1660	,	O
1660	cells	O
1660	were	O
1660	treated	O
1660	with	O
1660	compound	O
1660	f	O
1660	and	O
1660	10	O
1660	-	O
1660	h	O
1660	##c	O
1660	##pt	O
1660	solution	O
1660	for	O
1660	1	O
1660	,	O
1660	2	O
1660	,	O
1660	or	O
1660	4	O
1660	h	O
1660	under	O
1660	5	O
1660	%	O
1660	co	O
1660	##2	O
1660	at	O
1660	37	O
1660	##°	O
1660	##c	O
1660	.	O
1660	[SEP]	O
1661	[CLS]	O
1661	mice	O
1661	were	O
1661	administered	O
1661	a	O
1661	single	O
1661	dose	O
1661	of	O
1661	10	O
1661	-	O
1661	h	O
1661	##c	O
1661	##pt	O
1661	(	O
1661	5	O
1661	mg	O
1661	/	O
1661	kg	O
1661	)	O
1661	and	O
1661	compound	O
1661	f	O
1661	solution	O
1661	(	O
1661	equal	O
1661	to	O
1661	10	O
1661	-	O
1661	h	O
1661	##c	O
1661	##pt	O
1661	5	O
1661	mg	O
1661	/	O
1661	kg	O
1661	)	O
1661	in	O
1661	##tra	O
1661	##ven	O
1661	##ously	O
1661	.	O
1661	[SEP]	O
1662	[CLS]	O
1662	in	O
1662	v	O
1662	##ivo	O
1662	anti	O
1662	##tum	O
1662	##or	O
1662	efficacy	O
1662	of	O
1662	compound	O
1662	f	O
1662	was	O
1662	assessed	O
1662	using	O
1662	tumor	O
1662	-	O
1662	bearing	O
1662	nude	O
1662	mouse	O
1662	models	O
1662	.	O
1662	[SEP]	O
1663	[CLS]	O
1663	tumor	O
1663	-	O
1663	bearing	O
1663	mice	O
1663	were	O
1663	divided	O
1663	into	O
1663	three	O
1663	groups	O
1663	(	O
1663	n	O
1663	=	O
1663	8	O
1663	)	O
1663	in	O
1663	such	O
1663	a	O
1663	way	O
1663	as	O
1663	to	O
1663	minimize	O
1663	weight	O
1663	and	O
1663	tumor	O
1663	size	O
1663	differences	O
1663	among	O
1663	the	O
1663	groups	O
1663	:	O
1663	the	O
1663	control	O
1663	group	O
1663	received	O
1663	sa	O
1663	##line	O
1663	;	O
1663	one	O
1663	treatment	O
1663	group	O
1663	received	O
1663	10	O
1663	-	O
1663	h	O
1663	##c	O
1663	##pt	O
1663	solution	O
1663	,	O
1663	which	O
1663	is	O
1663	a	O
1663	commercial	O
1663	injection	O
1663	(	O
1663	5	O
1663	.	O
1663	0	O
1663	mg	O
1663	/	O
1663	kg	O
1663	)	O
1663	;	O
1663	the	O
1663	other	O
1663	treatment	O
1663	group	O
1663	received	O
1663	compound	O
1663	f	O
1663	solution	O
1663	(	O
1663	35	O
1663	.	O
1663	1	O
1663	mg	O
1663	/	O
1663	kg	O
1663	,	O
1663	equivalent	O
1663	to	O
1663	5	O
1663	.	O
1663	0	O
1663	mg	O
1663	/	O
1663	kg	O
1663	10	O
1663	-	O
1663	h	O
1663	##c	O
1663	##pt	O
1663	)	O
1663	.	O
1663	[SEP]	O
1664	[CLS]	O
1664	the	O
1664	following	O
1664	abbreviation	O
1664	##s	O
1664	are	O
1664	used	O
1664	for	O
1664	spin	O
1664	multi	O
1664	##p	O
1664	##licity	O
1664	:	O
1664	s	O
1664	=	O
1664	single	O
1664	##t	O
1664	,	O
1664	d	O
1664	=	O
1664	double	O
1664	##t	O
1664	,	O
1664	t	O
1664	=	O
1664	triple	O
1664	##t	O
1664	,	O
1664	q	O
1664	=	O
1664	quartet	O
1664	,	O
1664	m	O
1664	=	O
1664	multiple	O
1664	##t	O
1664	,	O
1664	d	O
1664	##d	O
1664	=	O
1664	double	O
1664	double	O
1664	##t	O
1664	,	O
1664	d	O
1664	##t	O
1664	=	O
1664	double	O
1664	triple	O
1664	##t	O
1664	.	O
1664	[SEP]	O
1665	[CLS]	O
1665	the	O
1665	flu	O
1665	##ores	O
1665	##cence	O
1665	s	O
1665	##pect	O
1665	##ra	O
1665	of	O
1665	compound	O
1665	f	O
1665	are	O
1665	shown	O
1665	in	O
1665	figure	O
1665	7	O
1665	.	O
1665	[SEP]	O
1666	[CLS]	O
1666	we	O
1666	can	O
1666	see	O
1666	that	O
1666	the	O
1666	maximum	O
1666	ex	O
1666	##citation	O
1666	wavelength	O
1666	of	O
1666	compound	O
1666	f	O
1666	is	O
1666	365	O
1666	nm	O
1666	,	O
1666	and	O
1666	the	O
1666	maximum	O
1666	emission	O
1666	wave	O
1666	-	O
1666	length	O
1666	of	O
1666	compound	O
1666	f	O
1666	is	O
1666	47	O
1666	##2	O
1666	nm	O
1666	.	O
1666	[SEP]	O
1667	[CLS]	O
1667	the	O
1667	anti	O
1667	##tum	O
1667	##or	O
1667	activities	O
1667	of	O
1667	10	O
1667	-	O
1667	h	O
1667	##c	O
1667	##pt	O
1667	and	O
1667	compound	O
1667	f	O
1667	were	O
1667	tested	O
1667	on	O
1667	three	O
1667	cancer	O
1667	cell	O
1667	lines	O
1667	using	O
1667	m	O
1667	##tt	O
1667	ass	O
1667	##ay	O
1667	.	O
1667	[SEP]	O
1668	[CLS]	O
1668	co	O
1668	##uma	O
1668	##rin	O
1668	-	O
1668	6	O
1668	was	O
1668	used	O
1668	as	O
1668	fluorescent	O
1668	marker	O
1668	by	O
1668	being	O
1668	incorporated	O
1668	into	O
1668	compound	O
1668	f	O
1668	mice	O
1668	.	O
1668	[SEP]	O
1669	[CLS]	O
1669	in	O
1669	addition	O
1669	,	O
1669	flu	O
1669	##ores	O
1669	##cence	O
1669	of	O
1669	co	O
1669	##uma	O
1669	##rin	O
1669	-	O
1669	6	O
1669	was	O
1669	observed	O
1669	in	O
1669	the	O
1669	nuclei	O
1669	of	O
1669	m	O
1669	##c	O
1669	##f	O
1669	-	O
1669	7	O
1669	cells	O
1669	after	O
1669	1	O
1669	h	O
1669	,	O
1669	suggesting	O
1669	the	O
1669	rapid	O
1669	internal	O
1669	##ization	O
1669	and	O
1669	nuclear	O
1669	transport	O
1669	of	O
1669	compound	O
1669	f	O
1669	mice	O
1669	##lles	O
1669	.	O
1669	[SEP]	O
1670	[CLS]	O
1670	additionally	O
1670	,	O
1670	compared	O
1670	with	O
1670	10	O
1670	-	O
1670	h	O
1670	##c	O
1670	##pt	O
1670	solution	O
1670	,	O
1670	the	O
1670	m	B-PK
1670	##rt	I-PK
1670	##0	I-PK
1670	–	I-PK
1670	in	I-PK
1670	##f	I-PK
1670	values	O
1670	of	O
1670	compound	O
1670	f	O
1670	were	O
1670	4	O
1670	.	O
1670	31	O
1670	-	O
1670	fold	O
1670	in	O
1670	tumors	O
1670	.	O
1670	[SEP]	O
1671	[CLS]	O
1671	the	O
1671	au	B-PK
1671	##c	I-PK
1671	##0	I-PK
1671	–	I-PK
1671	in	I-PK
1671	##f	I-PK
1671	values	O
1671	of	O
1671	compound	O
1671	f	O
1671	in	O
1671	tumor	O
1671	were	O
1671	7	O
1671	.	O
1671	76	O
1671	-	O
1671	fold	O
1671	higher	O
1671	than	O
1671	those	O
1671	of	O
1671	10	O
1671	-	O
1671	h	O
1671	##c	O
1671	##pt	O
1671	solution	O
1671	.	O
1671	[SEP]	O
1672	[CLS]	O
1672	as	O
1672	can	O
1672	be	O
1672	seen	O
1672	,	O
1672	the	O
1672	total	B-PK
1672	area	I-PK
1672	under	I-PK
1672	the	I-PK
1672	curve	I-PK
1672	(	I-PK
1672	au	I-PK
1672	##c	I-PK
1672	)	I-PK
1672	and	O
1672	mean	B-PK
1672	residence	I-PK
1672	time	I-PK
1672	(	I-PK
1672	m	I-PK
1672	##rt	I-PK
1672	)	I-PK
1672	of	O
1672	compound	O
1672	f	O
1672	were	O
1672	significantly	O
1672	higher	O
1672	than	O
1672	those	O
1672	of	O
1672	10	O
1672	-	O
1672	h	O
1672	##c	O
1672	##pt	O
1672	solution	O
1672	in	O
1672	plasma	O
1672	(	O
1672	figure	O
1672	12	O
1672	)	O
1672	.	O
1672	[SEP]	O
1673	[CLS]	O
1673	therefore	O
1673	,	O
1673	compound	O
1673	f	O
1673	could	O
1673	reduce	O
1673	the	O
1673	corresponding	O
1673	toxic	O
1673	effects	O
1673	.	O
1673	[SEP]	O
1674	[CLS]	O
1674	compound	O
1674	f	O
1674	also	O
1674	exhibited	O
1674	a	O
1674	higher	O
1674	accumulation	O
1674	in	O
1674	the	O
1674	liver	O
1674	,	O
1674	s	O
1674	##ple	O
1674	##en	O
1674	,	O
1674	and	O
1674	lung	O
1674	.	O
1674	[SEP]	O
1675	[CLS]	O
1675	to	O
1675	provide	O
1675	in	O
1675	v	O
1675	##ivo	O
1675	evidence	O
1675	for	O
1675	the	O
1675	anti	O
1675	##tum	O
1675	##or	O
1675	potential	O
1675	of	O
1675	compound	O
1675	f	O
1675	,	O
1675	anti	O
1675	##tum	O
1675	##or	O
1675	efficacy	O
1675	was	O
1675	evaluated	O
1675	using	O
1675	an	O
1675	in	O
1675	v	O
1675	##ivo	O
1675	nude	O
1675	mouse	O
1675	model	O
1675	.	O
1675	[SEP]	O
1676	[CLS]	O
1676	as	O
1676	shown	O
1676	in	O
1676	figure	O
1676	13	O
1676	,	O
1676	the	O
1676	tumor	O
1676	volume	O
1676	of	O
1676	the	O
1676	group	O
1676	treated	O
1676	with	O
1676	compound	O
1676	f	O
1676	solution	O
1676	was	O
1676	significantly	O
1676	smaller	O
1676	than	O
1676	that	O
1676	of	O
1676	the	O
1676	group	O
1676	treated	O
1676	with	O
1676	either	O
1676	sa	O
1676	##line	O
1676	or	O
1676	10	O
1676	-	O
1676	h	O
1676	##c	O
1676	##pt	O
1676	solution	O
1676	(	O
1676	p	O
1676	<	O
1676	0	O
1676	.	O
1676	05	O
1676	)	O
1676	.	O
1676	[SEP]	O
1677	[CLS]	O
1677	as	O
1677	can	O
1677	be	O
1677	seen	O
1677	,	O
1677	compound	O
1677	f	O
1677	did	O
1677	not	O
1677	cause	O
1677	significant	O
1677	loss	O
1677	of	O
1677	body	O
1677	weight	O
1677	,	O
1677	whereas	O
1677	10	O
1677	-	O
1677	h	O
1677	##c	O
1677	##pt	O
1677	solution	O
1677	exhibited	O
1677	significant	O
1677	body	O
1677	weight	O
1677	loss	O
1677	(	O
1677	p	O
1677	<	O
1677	0	O
1677	.	O
1677	05	O
1677	)	O
1677	,	O
1677	which	O
1677	means	O
1677	that	O
1677	compound	O
1677	f	O
1677	has	O
1677	lower	O
1677	toxicity	O
1677	than	O
1677	10	O
1677	-	O
1677	h	O
1677	##c	O
1677	##pt	O
1677	.	O
1677	[SEP]	O
1678	[CLS]	O
1678	the	O
1678	main	O
1678	p	O
1678	##har	O
1678	##ma	O
1678	##co	O
1678	##kin	O
1678	##etic	O
1678	(	O
1678	p	O
1678	##k	O
1678	)	O
1678	parameters	O
1678	including	O
1678	the	O
1678	area	B-PK
1678	under	I-PK
1678	the	I-PK
1678	curve	I-PK
1678	at	I-PK
1678	24	I-PK
1678	h	I-PK
1678	(	I-PK
1678	au	I-PK
1678	##c	I-PK
1678	##24	I-PK
1678	h	I-PK
1678	)	I-PK
1678	,	O
1678	au	B-PK
1678	##c	I-PK
1678	,	O
1678	terminal	B-PK
1678	half	I-PK
1678	-	I-PK
1678	life	I-PK
1678	(	I-PK
1678	t	I-PK
1678	##1	I-PK
1678	/	I-PK
1678	2	I-PK
1678	)	I-PK
1678	,	O
1678	the	B-PK
1678	time	I-PK
1678	to	I-PK
1678	peak	I-PK
1678	concentration	I-PK
1678	(	I-PK
1678	t	I-PK
1678	##max	I-PK
1678	)	I-PK
1678	,	O
1678	peak	B-PK
1678	concentration	I-PK
1678	(	I-PK
1678	cm	I-PK
1678	##ax	I-PK
1678	)	I-PK
1678	,	O
1678	relative	B-PK
1678	total	I-PK
1678	systemic	I-PK
1678	clearance	I-PK
1678	(	I-PK
1678	c	I-PK
1678	##l	I-PK
1678	##b	I-PK
1678	)	I-PK
1678	,	O
1678	and	O
1678	the	O
1678	last	B-PK
1678	mean	I-PK
1678	residence	I-PK
1678	time	I-PK
1678	(	I-PK
1678	m	I-PK
1678	##rt	I-PK
1678	##last	I-PK
1678	)	I-PK
1678	were	O
1678	calculated	O
1678	to	O
1678	be	O
1678	7	O
1678	.	O
1678	10	O
1678	,	O
1678	7	O
1678	.	O
1678	94	O
1678	μ	O
1678	##g	O
1678	##∗	O
1678	##h	O
1678	/	O
1678	m	O
1678	##l	O
1678	,	O
1678	24	O
1678	.	O
1678	02	O
1678	,	O
1678	na	O
1678	h	O
1678	,	O
1678	na	O
1678	μ	O
1678	##g	O
1678	/	O
1678	m	O
1678	##l	O
1678	,	O
1678	0	O
1678	.	O
1678	46	O
1678	l	O
1678	/	O
1678	h	O
1678	##∗	O
1678	##k	O
1678	##g	O
1678	,	O
1678	8	O
1678	.	O
1678	06	O
1678	h	O
1678	and	O
1678	3	O
1678	.	O
1678	94	O
1678	,	O
1678	6	O
1678	.	O
1678	79	O
1678	μ	O
1678	##g	O
1678	##∗	O
1678	##h	O
1678	/	O
1678	m	O
1678	##l	O
1678	,	O
1678	44	O
1678	.	O
1678	04	O
1678	,	O
1678	0	O
1678	.	O
1678	25	O
1678	h	O
1678	,	O
1678	0	O
1678	.	O
1678	98	O
1678	μ	O
1678	##g	O
1678	/	O
1678	m	O
1678	##l	O
1678	,	O
1678	0	O
1678	.	O
1678	43	O
1678	l	O
1678	/	O
1678	h	O
1678	##∗	O
1678	##k	O
1678	##g	O
1678	,	O
1678	22	O
1678	.	O
1678	85	O
1678	h	O
1678	after	O
1678	i	O
1678	.	O
1678	v	O
1678	.	O
1678	and	O
1678	i	O
1678	.	O
1678	m	O
1678	.	O
1678	induction	O
1678	,	O
1678	respectively	O
1678	.	O
1678	[SEP]	O
1679	[CLS]	O
1679	more	O
1679	##over	O
1679	,	O
1679	the	O
1679	bio	B-PK
1679	##ava	I-PK
1679	##ila	I-PK
1679	##bility	I-PK
1679	of	O
1679	i	O
1679	.	O
1679	m	O
1679	.	O
1679	route	O
1679	was	O
1679	85	O
1679	.	O
1679	5	O
1679	%	O
1679	,	O
1679	and	O
1679	the	O
1679	un	O
1679	##bin	O
1679	##ding	O
1679	of	O
1679	til	O
1679	##di	O
1679	##pi	O
1679	##ros	O
1679	##in	O
1679	to	O
1679	serum	O
1679	protein	O
1679	was	O
1679	78	O
1679	%	O
1679	.	O
1679	[SEP]	O
1680	[CLS]	O
1680	although	O
1680	most	O
1680	mac	O
1680	##rol	O
1680	##ides	O
1680	were	O
1680	classified	O
1680	as	O
1680	time	O
1680	-	O
1680	dependent	O
1680	killing	O
1680	drugs	O
1680	,	O
1680	til	O
1680	##di	O
1680	##pi	O
1680	##ros	O
1680	##in	O
1680	was	O
1680	concentration	O
1680	-	O
1680	dependent	O
1680	,	O
1680	and	O
1680	the	O
1680	p	O
1680	##k	O
1680	/	O
1680	p	O
1680	##d	O
1680	index	O
1680	were	O
1680	the	O
1680	au	B-PK
1680	##c	I-PK
1680	##24	I-PK
1680	h	I-PK
1680	/	I-PK
1680	mi	I-PK
1680	##c	I-PK
1680	and	O
1680	the	O
1680	cm	B-PK
1680	##ax	I-PK
1680	/	I-PK
1680	mi	I-PK
1680	##c	I-PK
1680	(	O
1680	m	O
1680	##out	O
1680	##on	O
1680	et	O
1680	al	O
1680	.	O
1680	,	O
1680	2002	O
1680	;	O
1680	ch	O
1680	##ig	O
1680	##uts	O
1680	##a	O
1680	et	O
1680	al	O
1680	.	O
1680	,	O
1680	2012	O
1680	;	O
1680	rose	O
1680	et	O
1680	al	O
1680	.	O
1680	,	O
1680	2013	O
1680	;	O
1680	x	O
1680	##ia	O
1680	##o	O
1680	et	O
1680	al	O
1680	.	O
1680	,	O
1680	2015	O
1680	)	O
1680	.	O
1680	[SEP]	O
1681	[CLS]	O
1681	the	O
1681	au	B-PK
1681	##c	I-PK
1681	##24	I-PK
1681	h	I-PK
1681	/	I-PK
1681	mi	I-PK
1681	##c	I-PK
1681	and	O
1681	cm	B-PK
1681	##ax	I-PK
1681	/	I-PK
1681	mi	I-PK
1681	##c	I-PK
1681	were	O
1681	considered	O
1681	as	O
1681	paired	O
1681	p	O
1681	##k	O
1681	/	O
1681	p	O
1681	##d	O
1681	parameters	O
1681	which	O
1681	were	O
1681	calculated	O
1681	in	O
1681	each	O
1681	dose	O
1681	of	O
1681	the	O
1681	time	O
1681	-	O
1681	killing	O
1681	curve	O
1681	.	O
1681	[SEP]	O
1682	[CLS]	O
1682	the	O
1682	inhibitor	O
1682	##y	O
1682	si	O
1682	##g	O
1682	##mo	O
1682	##id	O
1682	em	B-PK
1682	##ax	I-PK
1682	model	O
1682	was	O
1682	applied	O
1682	to	O
1682	evaluate	O
1682	the	O
1682	ass	O
1682	##im	O
1682	##ilation	O
1682	of	O
1682	correlation	O
1682	of	O
1682	au	B-PK
1682	##c	I-PK
1682	##24	I-PK
1682	h	I-PK
1682	/	I-PK
1682	mi	I-PK
1682	##c	I-PK
1682	ratio	I-PK
1682	in	O
1682	v	O
1682	##it	O
1682	##ro	O
1682	and	O
1682	bacteria	O
1682	count	O
1682	change	O
1682	(	O
1682	c	O
1682	##fu	O
1682	/	O
1682	m	O
1682	##l	O
1682	)	O
1682	in	O
1682	serum	O
1682	during	O
1682	24	O
1682	h	O
1682	in	O
1682	##cu	O
1682	##bation	O
1682	with	O
1682	win	O
1682	##non	O
1682	##lin	O
1682	software	O
1682	(	O
1682	al	O
1682	##ia	O
1682	##bad	O
1682	##i	O
1682	and	O
1682	le	O
1682	##es	O
1682	,	O
1682	2000	O
1682	,	O
1682	2001	O
1682	,	O
1682	2002	O
1682	;	O
1682	si	O
1682	##dh	O
1682	##u	O
1682	et	O
1682	al	O
1682	.	O
1682	,	O
1682	2011	O
1682	)	O
1682	.	O
1682	[SEP]	O
1683	[CLS]	O
1683	e	O
1683	,	O
1683	presented	O
1683	the	O
1683	effect	O
1683	of	O
1683	anti	O
1683	##mic	O
1683	##ro	O
1683	##bial	O
1683	agent	O
1683	counted	O
1683	as	O
1683	log	O
1683	##10	O
1683	difference	O
1683	of	O
1683	bacterial	O
1683	number	O
1683	before	O
1683	and	O
1683	after	O
1683	the	O
1683	24	O
1683	h	O
1683	in	O
1683	##cu	O
1683	##bation	O
1683	in	O
1683	v	O
1683	##it	O
1683	##ro	O
1683	;	O
1683	em	B-PK
1683	##ax	I-PK
1683	,	O
1683	measured	O
1683	the	O
1683	de	O
1683	##viation	O
1683	##s	O
1683	in	O
1683	log	O
1683	##10	O
1683	difference	O
1683	between	O
1683	0	O
1683	and	O
1683	24	O
1683	h	O
1683	in	O
1683	the	O
1683	control	O
1683	and	O
1683	til	O
1683	##di	O
1683	##pi	O
1683	##ros	O
1683	##in	O
1683	samples	O
1683	;	O
1683	e	B-PK
1683	##c	I-PK
1683	##50	I-PK
1683	,	O
1683	the	O
1683	au	B-PK
1683	##c	I-PK
1683	##24	I-PK
1683	/	I-PK
1683	mi	I-PK
1683	##c	I-PK
1683	value	O
1683	reached	O
1683	50	O
1683	%	O
1683	of	O
1683	the	O
1683	em	B-PK
1683	##ax	I-PK
1683	;	O
1683	c	O
1683	,	O
1683	presented	O
1683	the	O
1683	au	B-PK
1683	##c	I-PK
1683	##24	I-PK
1683	/	I-PK
1683	mi	I-PK
1683	##c	I-PK
1683	ratio	O
1683	;	O
1683	n	O
1683	,	O
1683	presented	O
1683	the	O
1683	hill	B-PK
1683	coefficient	I-PK
1683	.	O
1683	[SEP]	O
1684	[CLS]	O
1684	the	O
1684	given	O
1684	formula	O
1684	was	O
1684	performed	O
1684	to	O
1684	calculate	O
1684	the	O
1684	doses	O
1684	in	O
1684	different	O
1684	magnitude	O
1684	##s	O
1684	of	O
1684	efficiency	O
1684	containing	O
1684	(	O
1684	e	O
1684	=	O
1684	0	O
1684	,	O
1684	no	O
1684	change	O
1684	in	O
1684	bacterial	O
1684	count	O
1684	,	O
1684	e	O
1684	=	O
1684	-	O
1684	1	O
1684	,	O
1684	99	O
1684	.	O
1684	9	O
1684	%	O
1684	reduction	O
1684	in	O
1684	the	O
1684	count	O
1684	,	O
1684	e	O
1684	=	O
1684	-	O
1684	3	O
1684	,	O
1684	99	O
1684	.	O
1684	99	O
1684	%	O
1684	reduction	O
1684	)	O
1684	for	O
1684	est	O
1684	##imating	O
1684	an	O
1684	op	O
1684	##ti	O
1684	##mum	O
1684	regime	O
1684	##n	O
1684	.	O
1684	[SEP]	O
1685	[CLS]	O
1685	the	O
1685	mon	O
1685	##te	O
1685	car	O
1685	##lo	O
1685	simulation	O
1685	(	O
1685	including	O
1685	10	O
1685	,	O
1685	000	O
1685	it	O
1685	##eration	O
1685	##s	O
1685	)	O
1685	was	O
1685	performed	O
1685	using	O
1685	the	O
1685	crystal	O
1685	ball	O
1685	software	O
1685	(	O
1685	version	O
1685	7	O
1685	.	O
1685	2	O
1685	.	O
1685	2	O
1685	,	O
1685	or	O
1685	##acle	O
1685	,	O
1685	united	O
1685	states	O
1685	)	O
1685	based	O
1685	on	O
1685	the	O
1685	selected	O
1685	p	O
1685	##k	O
1685	/	O
1685	p	O
1685	##d	O
1685	target	O
1685	index	O
1685	(	O
1685	au	B-PK
1685	##c	I-PK
1685	##24	I-PK
1685	/	I-PK
1685	mi	I-PK
1685	##c	I-PK
1685	,	O
1685	e	O
1685	=	O
1685	-	O
1685	3	O
1685	,	O
1685	b	O
1685	##act	O
1685	##eric	O
1685	##idal	O
1685	activity	O
1685	)	O
1685	(	O
1685	le	O
1685	##i	O
1685	et	O
1685	al	O
1685	.	O
1685	,	O
1685	2017	O
1685	##a	O
1685	,	O
1685	b	O
1685	,	O
1685	c	O
1685	,	O
1685	2018	O
1685	##b	O
1685	)	O
1685	.	O
1685	[SEP]	O
1686	[CLS]	O
1686	the	O
1686	results	O
1686	for	O
1686	the	O
1686	au	B-PK
1686	##c	I-PK
1686	##24	I-PK
1686	h	I-PK
1686	,	O
1686	au	B-PK
1686	##c	I-PK
1686	,	O
1686	t	B-PK
1686	##max	I-PK
1686	,	O
1686	t	B-PK
1686	##1	I-PK
1686	/	I-PK
1686	2	I-PK
1686	of	O
1686	til	O
1686	##di	O
1686	##pi	O
1686	##ros	O
1686	##in	O
1686	,	O
1686	cm	B-PK
1686	##ax	I-PK
1686	,	O
1686	c	B-PK
1686	##l	I-PK
1686	##b	I-PK
1686	,	O
1686	and	O
1686	the	O
1686	mean	B-PK
1686	resistance	I-PK
1686	time	I-PK
1686	(	I-PK
1686	m	I-PK
1686	##rt	I-PK
1686	)	I-PK
1686	in	O
1686	the	O
1686	serum	O
1686	after	O
1686	i	O
1686	.	O
1686	v	O
1686	.	O
1686	and	O
1686	i	O
1686	.	O
1686	m	O
1686	.	O
1686	administration	O
1686	##s	O
1686	were	O
1686	shown	O
1686	in	O
1686	table	O
1686	2	O
1686	.	O
1686	[SEP]	O
1687	[CLS]	O
1687	the	O
1687	bio	B-PK
1687	##ava	I-PK
1687	##ila	I-PK
1687	##bility	I-PK
1687	for	O
1687	til	O
1687	##di	O
1687	##pi	O
1687	##ros	O
1687	##in	O
1687	after	O
1687	i	O
1687	.	O
1687	m	O
1687	.	O
1687	administration	O
1687	was	O
1687	determined	O
1687	as	O
1687	85	O
1687	.	O
1687	5	O
1687	%	O
1687	(	O
1687	table	O
1687	2	O
1687	)	O
1687	.	O
1687	[SEP]	O
1688	[CLS]	O
1688	the	O
1688	ratios	O
1688	of	O
1688	cm	B-PK
1688	##ax	I-PK
1688	/	I-PK
1688	mi	I-PK
1688	##c	I-PK
1688	,	O
1688	au	B-PK
1688	##c	I-PK
1688	##24	I-PK
1688	##h	I-PK
1688	/	I-PK
1688	mi	I-PK
1688	##c	I-PK
1688	and	O
1688	t	O
1688	>	O
1688	mi	O
1688	##c	O
1688	were	O
1688	1	O
1688	.	O
1688	96	O
1688	,	O
1688	7	O
1688	.	O
1688	88	O
1688	,	O
1688	and	O
1688	0	O
1688	.	O
1688	97	O
1688	h	O
1688	,	O
1688	respectively	O
1688	,	O
1688	on	O
1688	the	O
1688	basis	O
1688	of	O
1688	p	O
1688	##k	O
1688	/	O
1688	p	O
1688	##d	O
1688	data	O
1688	ex	O
1688	v	O
1688	##ivo	O
1688	(	O
1688	table	O
1688	2	O
1688	)	O
1688	.	O
1688	[SEP]	O
1689	[CLS]	O
1689	the	O
1689	relationship	O
1689	between	O
1689	anti	O
1689	##mic	O
1689	##ro	O
1689	##bial	O
1689	efficiency	O
1689	and	O
1689	the	O
1689	ex	O
1689	v	O
1689	##ivo	O
1689	p	O
1689	##k	O
1689	/	O
1689	p	O
1689	##d	O
1689	parameter	O
1689	of	O
1689	au	B-PK
1689	##c	I-PK
1689	##24	I-PK
1689	##h	I-PK
1689	/	I-PK
1689	mi	I-PK
1689	##c	I-PK
1689	ratios	O
1689	were	O
1689	simulated	O
1689	by	O
1689	using	O
1689	the	O
1689	inhibitor	O
1689	##y	O
1689	si	O
1689	##g	O
1689	##mo	O
1689	##id	O
1689	em	B-PK
1689	##ax	I-PK
1689	model	O
1689	.	O
1689	[SEP]	O
1690	[CLS]	O
1690	the	O
1690	model	O
1690	parameters	O
1690	of	O
1690	the	O
1690	hill	B-PK
1690	coefficient	I-PK
1690	n	I-PK
1690	,	O
1690	em	B-PK
1690	##ax	I-PK
1690	,	O
1690	and	O
1690	au	B-PK
1690	##c	I-PK
1690	##24	I-PK
1690	##h	I-PK
1690	/	I-PK
1690	mi	I-PK
1690	##c	I-PK
1690	values	O
1690	are	O
1690	presented	O
1690	for	O
1690	three	O
1690	levels	O
1690	of	O
1690	growth	O
1690	in	O
1690	##hibition	O
1690	in	O
1690	table	O
1690	4	O
1690	and	O
1690	figure	O
1690	5	O
1690	.	O
1690	[SEP]	O
1691	[CLS]	O
1691	the	O
1691	values	O
1691	of	O
1691	the	O
1691	au	B-PK
1691	##c	I-PK
1691	##24	I-PK
1691	##h	I-PK
1691	/	I-PK
1691	mi	I-PK
1691	##c	I-PK
1691	ratio	O
1691	required	O
1691	for	O
1691	b	O
1691	##act	O
1691	##eri	O
1691	##ost	O
1691	##atic	O
1691	activity	O
1691	(	O
1691	e	O
1691	=	O
1691	0	O
1691	)	O
1691	,	O
1691	b	O
1691	##act	O
1691	##eric	O
1691	##idal	O
1691	activity	O
1691	(	O
1691	e	O
1691	=	O
1691	-	O
1691	3	O
1691	)	O
1691	,	O
1691	and	O
1691	bacterial	O
1691	elimination	O
1691	(	O
1691	e	O
1691	=	O
1691	-	O
1691	4	O
1691	)	O
1691	were	O
1691	18	O
1691	.	O
1691	91	O
1691	,	O
1691	29	O
1691	.	O
1691	13	O
1691	,	O
1691	and	O
1691	34	O
1691	.	O
1691	03	O
1691	h	O
1691	,	O
1691	as	O
1691	presented	O
1691	in	O
1691	table	O
1691	4	O
1691	.	O
1691	[SEP]	O
1692	[CLS]	O
1692	the	O
1692	obtained	O
1692	results	O
1692	revealed	O
1692	the	O
1692	great	O
1692	ability	O
1692	of	O
1692	the	O
1692	produced	O
1692	n	O
1692	##f	O
1692	-	O
1692	loaded	O
1692	ni	O
1692	##o	O
1692	-	O
1692	some	O
1692	##s	O
1692	to	O
1692	enhance	O
1692	drug	O
1692	penetration	O
1692	through	O
1692	nasal	O
1692	m	O
1692	##uc	O
1692	##osa	O
1692	and	O
1692	improve	O
1692	its	O
1692	relative	B-PK
1692	bio	I-PK
1692	##ava	I-PK
1692	##ila	I-PK
1692	##bility	I-PK
1692	compared	O
1692	with	O
1692	n	O
1692	##f	O
1692	oral	O
1692	solution	O
1692	.	O
1692	[SEP]	O
1693	[CLS]	O
1693	the	O
1693	calculated	O
1693	cumulative	O
1693	target	O
1693	achievement	O
1693	for	O
1693	p	O
1693	##k	O
1693	/	O
1693	p	O
1693	##d	O
1693	parameter	O
1693	(	O
1693	au	B-PK
1693	##c	I-PK
1693	##24	I-PK
1693	h	I-PK
1693	/	I-PK
1693	mi	I-PK
1693	##c	I-PK
1693	)	O
1693	in	O
1693	serum	O
1693	(	O
1693	ex	O
1693	v	O
1693	##ivo	O
1693	)	O
1693	was	O
1693	29	O
1693	.	O
1693	13	O
1693	±	O
1693	2	O
1693	.	O
1693	44	O
1693	h	O
1693	,	O
1693	with	O
1693	assured	O
1693	b	O
1693	##act	O
1693	##eric	O
1693	##idal	O
1693	activity	O
1693	(	O
1693	e	O
1693	=	O
1693	-	O
1693	3	O
1693	)	O
1693	.	O
1693	[SEP]	O
1694	[CLS]	O
1694	the	O
1694	predicted	O
1694	daily	O
1694	doses	O
1694	were	O
1694	given	O
1694	in	O
1694	table	O
1694	6	O
1694	based	O
1694	on	O
1694	au	B-PK
1694	##c	I-PK
1694	##24	I-PK
1694	h	I-PK
1694	/	I-PK
1694	mi	I-PK
1694	##c	I-PK
1694	ratios	I-PK
1694	and	O
1694	c	B-PK
1694	##l	I-PK
1694	##b	I-PK
1694	for	O
1694	these	O
1694	three	O
1694	levels	O
1694	of	O
1694	anti	O
1694	##ba	O
1694	##cter	O
1694	##ial	O
1694	activity	O
1694	measured	O
1694	from	O
1694	the	O
1694	p	O
1694	##k	O
1694	/	O
1694	p	O
1694	##d	O
1694	integrating	O
1694	model	O
1694	and	O
1694	the	O
1694	distribution	O
1694	of	O
1694	ex	O
1694	v	O
1694	##ivo	O
1694	mi	O
1694	##c	O
1694	using	O
1694	mon	O
1694	##te	O
1694	car	O
1694	##lo	O
1694	simulation	O
1694	##s	O
1694	in	O
1694	or	O
1694	##acle	O
1694	crystal	O
1694	ball	O
1694	.	O
1694	[SEP]	O
1695	[CLS]	O
1695	the	O
1695	distributions	O
1695	of	O
1695	predicted	O
1695	population	O
1695	dose	O
1695	(	O
1695	au	B-PK
1695	##c	I-PK
1695	##24	I-PK
1695	h	I-PK
1695	/	I-PK
1695	mi	I-PK
1695	##c	I-PK
1695	)	O
1695	values	O
1695	of	O
1695	til	O
1695	##di	O
1695	##pi	O
1695	##ros	O
1695	##in	O
1695	cu	O
1695	##ring	O
1695	pm	O
1695	for	O
1695	50	O
1695	and	O
1695	90	O
1695	%	O
1695	targets	O
1695	were	O
1695	observed	O
1695	,	O
1695	respectively	O
1695	,	O
1695	and	O
1695	illustrated	O
1695	in	O
1695	figure	O
1695	6	O
1695	.	O
1695	[SEP]	O
1696	[CLS]	O
1696	one	O
1696	of	O
1696	the	O
1696	greatest	O
1696	challenges	O
1696	drug	O
1696	formulation	O
1696	is	O
1696	facing	O
1696	is	O
1696	poor	O
1696	bio	B-PK
1696	##ava	I-PK
1696	##ila	I-PK
1696	##bility	I-PK
1696	via	O
1696	oral	O
1696	route	O
1696	.	O
1696	[SEP]	O
1697	[CLS]	O
1697	in	O
1697	this	O
1697	regard	O
1697	,	O
1697	nasal	O
1697	drug	O
1697	delivery	O
1697	has	O
1697	been	O
1697	commonly	O
1697	used	O
1697	as	O
1697	an	O
1697	alternative	O
1697	route	O
1697	to	O
1697	improve	O
1697	drug	O
1697	bio	B-PK
1697	##ava	I-PK
1697	##ila	I-PK
1697	##bility	I-PK
1697	.	O
1697	[SEP]	O
1698	[CLS]	O
1698	ne	O
1698	##fo	O
1698	##pa	O
1698	##m	O
1698	h	O
1698	##ydro	O
1698	##ch	O
1698	##lor	O
1698	##ide	O
1698	(	O
1698	n	O
1698	##f	O
1698	)	O
1698	is	O
1698	an	O
1698	anal	O
1698	##ges	O
1698	##ic	O
1698	drug	O
1698	that	O
1698	suffers	O
1698	from	O
1698	poor	O
1698	bio	B-PK
1698	##ava	I-PK
1698	##ila	I-PK
1698	##bility	I-PK
1698	due	O
1698	to	O
1698	extensive	O
1698	metabolism	O
1698	in	O
1698	liver	O
1698	.	O
1698	[SEP]	O
1699	[CLS]	O
1699	accordingly	O
1699	,	O
1699	the	O
1699	goal	O
1699	of	O
1699	the	O
1699	present	O
1699	study	O
1699	was	O
1699	to	O
1699	improve	O
1699	n	O
1699	##f	O
1699	bio	B-PK
1699	##ava	I-PK
1699	##ila	I-PK
1699	##bility	I-PK
1699	via	O
1699	ni	O
1699	##oso	O
1699	##mal	O
1699	-	O
1699	based	O
1699	formulation	O
1699	designed	O
1699	for	O
1699	in	O
1699	##tra	O
1699	##nas	O
1699	##al	O
1699	delivery	O
1699	.	O
1699	[SEP]	O
1700	[CLS]	O
1700	the	O
1700	in	O
1700	-	O
1700	v	O
1700	##ivo	O
1700	studies	O
1700	showed	O
1700	a	O
1700	4	O
1700	.	O
1700	77	O
1700	-	O
1700	fold	O
1700	increase	O
1700	in	O
1700	bio	B-PK
1700	##ava	I-PK
1700	##ila	I-PK
1700	##bility	I-PK
1700	of	O
1700	op	O
1700	##ti	O
1700	##mized	O
1700	nasal	O
1700	ni	O
1700	##oso	O
1700	##mes	O
1700	compared	O
1700	with	O
1700	oral	O
1700	solution	O
1700	of	O
1700	drug	O
1700	.	O
1700	[SEP]	O
1701	[CLS]	O
1701	equation	O
1701	3	O
1701	was	O
1701	used	O
1701	to	O
1701	calculate	O
1701	au	B-PK
1701	##c	I-PK
1701	from	I-PK
1701	0	I-PK
1701	to	I-PK
1701	in	I-PK
1701	##finity	I-PK
1701	,	O
1701	au	O
1701	##c	O
1701	##0	O
1701	–	O
1701	∞	O
1701	(	O
1701	ng	O
1701	hour	O
1701	/	O
1701	m	O
1701	##l	O
1701	)	O
1701	:	O
1701	au	O
1701	##c	O
1701	##0	O
1701	##−	O
1701	##∞	O
1701	=	O
1701	au	O
1701	##c	O
1701	##0	O
1701	##−	O
1701	##24	O
1701	+	O
1701	c	O
1701	##t	O
1701	/	O
1701	k	O
1701	(	O
1701	3	O
1701	)	O
1701	where	O
1701	##ct	O
1701	is	O
1701	the	O
1701	last	O
1701	measured	O
1701	concentration	O
1701	at	O
1701	time	O
1701	t	O
1701	##k	O
1701	is	O
1701	the	O
1701	terminal	B-PK
1701	elimination	I-PK
1701	rate	I-PK
1701	constant	I-PK
1701	##final	I-PK
1701	##ly	I-PK
1701	,	O
1701	the	O
1701	apparent	B-PK
1701	terminal	I-PK
1701	elimination	I-PK
1701	half	I-PK
1701	-	I-PK
1701	life	I-PK
1701	(	I-PK
1701	t	I-PK
1701	##1	I-PK
1701	/	I-PK
1701	2	I-PK
1701	)	I-PK
1701	was	O
1701	determined	O
1701	using	O
1701	the	O
1701	relation	O
1701	t	O
1701	##1	O
1701	/	O
1701	2	O
1701	=	O
1701	0	O
1701	.	O
1701	69	O
1701	##3	O
1701	/	O
1701	k	O
1701	.	O
1701	[SEP]	O
1702	[CLS]	O
1702	parameters	O
1702	like	O
1702	maximum	B-PK
1702	drug	I-PK
1702	concentration	I-PK
1702	and	O
1702	the	O
1702	time	B-PK
1702	needed	I-PK
1702	to	I-PK
1702	reach	I-PK
1702	such	I-PK
1702	a	I-PK
1702	concentration	I-PK
1702	,	O
1702	namely	O
1702	,	O
1702	cm	B-PK
1702	##ax	I-PK
1702	(	O
1702	ng	O
1702	/	O
1702	m	O
1702	##l	O
1702	)	O
1702	and	O
1702	t	B-PK
1702	##max	I-PK
1702	(	O
1702	h	O
1702	)	O
1702	,	O
1702	respectively	O
1702	,	O
1702	were	O
1702	determined	O
1702	.	O
1702	[SEP]	O
1703	[CLS]	O
1703	more	O
1703	##over	O
1703	,	O
1703	the	O
1703	area	B-PK
1703	under	I-PK
1703	the	I-PK
1703	curve	I-PK
1703	,	I-PK
1703	au	I-PK
1703	##c	I-PK
1703	##0	I-PK
1703	–	I-PK
1703	24	I-PK
1703	(	O
1703	ng	O
1703	hour	O
1703	/	O
1703	m	O
1703	##l	O
1703	)	O
1703	,	O
1703	for	O
1703	each	O
1703	group	O
1703	was	O
1703	determined	O
1703	by	O
1703	employing	O
1703	the	O
1703	trap	O
1703	##ez	O
1703	##oid	O
1703	##al	O
1703	rule	O
1703	from	O
1703	time	O
1703	0	O
1703	to	O
1703	the	O
1703	last	O
1703	time	O
1703	interval	O
1703	used	O
1703	for	O
1703	withdrawing	O
1703	blood	O
1703	samples	O
1703	.	O
1703	[SEP]	O
1704	[CLS]	O
1704	transmission	O
1704	electron	O
1704	micro	O
1704	##sco	O
1704	##py	O
1704	showed	O
1704	the	O
1704	formation	O
1704	of	O
1704	spherical	O
1704	ni	O
1704	##oso	O
1704	##mes	O
1704	with	O
1704	closed	O
1704	bi	O
1704	##layer	O
1704	structure	O
1704	(	O
1704	figure	O
1704	1	O
1704	)	O
1704	.	O
1704	[SEP]	O
1705	[CLS]	O
1705	the	O
1705	t	B-PK
1705	##max	I-PK
1705	value	O
1705	for	O
1705	groups	O
1705	1	O
1705	and	O
1705	2	O
1705	was	O
1705	2	O
1705	he	O
1705	##ct	O
1705	##ose	O
1705	##con	O
1705	##ds	O
1705	,	O
1705	while	O
1705	that	O
1705	of	O
1705	group	O
1705	3	O
1705	was	O
1705	1	O
1705	he	O
1705	##ct	O
1705	##ose	O
1705	##con	O
1705	##ds	O
1705	.	O
1705	[SEP]	O
1706	[CLS]	O
1706	the	O
1706	mean	O
1706	area	B-PK
1706	under	I-PK
1706	the	I-PK
1706	plasma	I-PK
1706	concentration	I-PK
1706	-	I-PK
1706	time	I-PK
1706	curve	I-PK
1706	for	O
1706	oral	O
1706	solution	O
1706	was	O
1706	found	O
1706	to	O
1706	be	O
1706	61	O
1706	##5	O
1706	.	O
1706	7	O
1706	ng	O
1706	hours	O
1706	/	O
1706	m	O
1706	##l	O
1706	while	O
1706	that	O
1706	of	O
1706	op	O
1706	##ti	O
1706	##mum	O
1706	nasal	O
1706	formula	O
1706	was	O
1706	calculated	O
1706	to	O
1706	be	O
1706	2	O
1706	,	O
1706	94	O
1706	##0	O
1706	.	O
1706	7	O
1706	ng	O
1706	hours	O
1706	/	O
1706	m	O
1706	##l	O
1706	and	O
1706	that	O
1706	of	O
1706	n	O
1706	##f	O
1706	nasal	O
1706	solution	O
1706	was	O
1706	found	O
1706	to	O
1706	be	O
1706	1	O
1706	,	O
1706	56	O
1706	##2	O
1706	.	O
1706	3	O
1706	ng	O
1706	hours	O
1706	/	O
1706	m	O
1706	##l	O
1706	.	O
1706	the	O
1706	op	O
1706	##ti	O
1706	##mized	O
1706	n	O
1706	##f	O
1706	-	O
1706	loaded	O
1706	ni	O
1706	##oso	O
1706	##mes	O
1706	nasal	O
1706	formula	O
1706	had	O
1706	a	O
1706	percentage	O
1706	relative	B-PK
1706	bio	I-PK
1706	##ava	I-PK
1706	##ila	I-PK
1706	##bility	I-PK
1706	of	O
1706	47	O
1706	##7	O
1706	.	O
1706	5	O
1706	%	O
1706	when	O
1706	compared	O
1706	with	O
1706	the	O
1706	n	O
1706	##f	O
1706	oral	O
1706	solution	O
1706	.	O
1706	[SEP]	O
1707	[CLS]	O
1707	the	O
1707	current	O
1707	investigation	O
1707	revealed	O
1707	that	O
1707	the	O
1707	op	O
1707	##ti	O
1707	##mized	O
1707	nasal	O
1707	formulation	O
1707	exhibited	O
1707	a	O
1707	higher	O
1707	cm	B-PK
1707	##ax	I-PK
1707	value	O
1707	and	O
1707	an	O
1707	elongated	O
1707	mean	O
1707	elimination	B-PK
1707	half	I-PK
1707	-	I-PK
1707	life	I-PK
1707	compared	O
1707	with	O
1707	that	O
1707	of	O
1707	n	O
1707	##f	O
1707	oral	O
1707	solution	O
1707	and	O
1707	n	O
1707	##f	O
1707	nasal	O
1707	solution	O
1707	.	O
1707	[SEP]	O
1708	[CLS]	O
1708	the	O
1708	n	O
1708	##f	O
1708	oral	O
1708	solution	O
1708	had	O
1708	a	O
1708	t	B-PK
1708	##1	I-PK
1708	/	I-PK
1708	2	I-PK
1708	of	O
1708	4	O
1708	.	O
1708	12	O
1708	hours	O
1708	;	O
1708	in	O
1708	the	O
1708	meantime	O
1708	,	O
1708	the	O
1708	op	O
1708	##ti	O
1708	##mum	O
1708	n	O
1708	##f	O
1708	-	O
1708	loaded	O
1708	ni	O
1708	##oso	O
1708	##mal	O
1708	nasal	O
1708	suspension	O
1708	had	O
1708	a	O
1708	t	B-PK
1708	##1	I-PK
1708	/	I-PK
1708	2	I-PK
1708	of	O
1708	9	O
1708	.	O
1708	2	O
1708	hours	O
1708	and	O
1708	the	O
1708	nasal	O
1708	solution	O
1708	of	O
1708	drug	O
1708	had	O
1708	a	O
1708	t	B-PK
1708	##1	I-PK
1708	/	I-PK
1708	2	I-PK
1708	of	O
1708	2	O
1708	.	O
1708	3	O
1708	hours	O
1708	.	O
1708	[SEP]	O
1709	[CLS]	O
1709	for	O
1709	art	O
1709	##em	O
1709	##eth	O
1709	##er	O
1709	and	O
1709	d	O
1709	##ha	O
1709	,	O
1709	the	O
1709	two	O
1709	samples	O
1709	were	O
1709	taken	O
1709	at	O
1709	1	O
1709	and	O
1709	2	O
1709	h	O
1709	post	O
1709	first	O
1709	treatment	O
1709	dose	O
1709	(	O
1709	i	O
1709	.	O
1709	e	O
1709	.	O
1709	anticipated	O
1709	time	B-PK
1709	of	I-PK
1709	maximum	I-PK
1709	concentration	I-PK
1709	(	I-PK
1709	cm	I-PK
1709	##ax	I-PK
1709	)	I-PK
1709	)	O
1709	.	O
1709	[SEP]	O
1710	[CLS]	O
1710	cm	B-PK
1710	##ax	I-PK
1710	was	O
1710	determined	O
1710	from	O
1710	these	O
1710	two	O
1710	concentrations	O
1710	,	O
1710	which	O
1710	##ever	O
1710	was	O
1710	larger	O
1710	for	O
1710	a	O
1710	given	O
1710	patient	O
1710	.	O
1710	[SEP]	O
1711	[CLS]	O
1711	cm	B-PK
1711	##ax	I-PK
1711	and	O
1711	au	B-PK
1711	##c	I-PK
1711	##0	I-PK
1711	-	I-PK
1711	last	I-PK
1711	were	O
1711	derived	O
1711	from	O
1711	this	O
1711	population	O
1711	mean	O
1711	concentration	O
1711	-	O
1711	time	O
1711	curve	O
1711	.	O
1711	[SEP]	O
1712	[CLS]	O
1712	as	O
1712	reported	O
1712	elsewhere	O
1712	[	O
1712	24	O
1712	]	O
1712	,	O
1712	there	O
1712	were	O
1712	no	O
1712	clinical	O
1712	##ly	O
1712	relevant	O
1712	between	O
1712	-	O
1712	group	O
1712	differences	O
1712	in	O
1712	cm	B-PK
1712	##ax	I-PK
1712	for	O
1712	art	O
1712	##em	O
1712	##eth	O
1712	##er	O
1712	or	O
1712	d	O
1712	##ha	O
1712	;	O
1712	l	O
1712	##ume	O
1712	##fant	O
1712	##rine	O
1712	cm	B-PK
1712	##ax	I-PK
1712	and	O
1712	au	B-PK
1712	##c	I-PK
1712	0	I-PK
1712	-	I-PK
1712	last	I-PK
1712	appeared	O
1712	higher	O
1712	in	O
1712	the	O
1712	15	O
1712	to	O
1712	<	O
1712	25	O
1712	kg	O
1712	group	O
1712	compared	O
1712	to	O
1712	the	O
1712	5	O
1712	to	O
1712	<	O
1712	15	O
1712	kg	O
1712	body	O
1712	weight	O
1712	group	O
1712	,	O
1712	approximately	O
1712	in	O
1712	line	O
1712	with	O
1712	the	O
1712	increase	O
1712	in	O
1712	dose	O
1712	,	O
1712	in	O
1712	particular	O
1712	for	O
1712	au	B-PK
1712	##c	I-PK
1712	after	O
1712	crushed	O
1712	tablet	O
1712	.	O
1712	[SEP]	O
1713	[CLS]	O
1713	art	O
1713	##em	O
1713	##eth	O
1713	##er	O
1713	and	O
1713	d	O
1713	##ha	O
1713	cm	B-PK
1713	##ax	I-PK
1713	were	O
1713	2	O
1713	.	O
1713	15	O
1713	-	O
1713	to	O
1713	3	O
1713	.	O
1713	4	O
1713	-	O
1713	fold	O
1713	higher	O
1713	in	O
1713	the	O
1713	5	O
1713	to	O
1713	<	O
1713	10	O
1713	kg	O
1713	body	O
1713	weight	O
1713	group	O
1713	compared	O
1713	to	O
1713	the	O
1713	10	O
1713	to	O
1713	<	O
1713	15	O
1713	kg	O
1713	body	O
1713	weight	O
1713	group	O
1713	.	O
1713	[SEP]	O
1714	[CLS]	O
1714	there	O
1714	were	O
1714	no	O
1714	apparent	O
1714	differences	O
1714	for	O
1714	l	O
1714	##ume	O
1714	##fant	O
1714	##rine	O
1714	cm	B-PK
1714	##ax	I-PK
1714	or	O
1714	au	B-PK
1714	##c	I-PK
1714	between	O
1714	the	O
1714	two	O
1714	body	O
1714	weight	O
1714	groups	O
1714	.	O
1714	[SEP]	O
1715	[CLS]	O
1715	there	O
1715	was	O
1715	a	O
1715	tendency	O
1715	towards	O
1715	longer	O
1715	time	O
1715	to	O
1715	parasite	O
1715	and	O
1715	fever	O
1715	clearance	B-PK
1715	in	O
1715	the	O
1715	lower	O
1715	body	O
1715	weight	O
1715	groups	O
1715	(	O
1715	table	O
1715	4	O
1715	)	O
1715	.	O
1715	[SEP]	O
1716	[CLS]	O
1716	a	O
1716	meaningful	O
1716	assessment	O
1716	of	O
1716	game	O
1716	##to	O
1716	##cy	O
1716	##te	O
1716	clearance	B-PK
1716	according	O
1716	to	O
1716	body	O
1716	weight	O
1716	group	O
1716	was	O
1716	not	O
1716	possible	O
1716	due	O
1716	to	O
1716	the	O
1716	low	O
1716	number	O
1716	of	O
1716	patients	O
1716	with	O
1716	game	O
1716	##to	O
1716	##cy	O
1716	##ta	O
1716	##emia	O
1716	at	O
1716	base	O
1716	##line	O
1716	(	O
1716	n	O
1716	=	O
1716	41	O
1716	)	O
1716	.	O
1716	[SEP]	O
1717	[CLS]	O
1717	the	O
1717	national	O
1717	ethics	O
1717	review	O
1717	committee	O
1717	at	O
1717	et	O
1717	##hi	O
1717	##op	O
1717	##ian	O
1717	science	O
1717	and	O
1717	technology	O
1717	ministry	O
1717	as	O
1717	well	O
1717	as	O
1717	by	O
1717	the	O
1717	food	O
1717	and	O
1717	drug	O
1717	administration	O
1717	and	O
1717	control	O
1717	authority	O
1717	of	O
1717	et	O
1717	##hi	O
1717	##op	O
1717	##ia	O
1717	.	O
1717	[SEP]	O
1718	[CLS]	O
1718	a	O
1718	[	O
1718	c	O
1718	##y	O
1718	##p	O
1718	##3	O
1718	##a	O
1718	##5	O
1718	*	O
1718	6	O
1718	]	O
1718	,	O
1718	c	O
1718	_	O
1718	_	O
1718	322	O
1718	##8	O
1718	##7	O
1718	##18	O
1718	##8	O
1718	_	O
1718	10	O
1718	for	O
1718	c	O
1718	##y	O
1718	##p	O
1718	##3	O
1718	##a	O
1718	##5	O
1718	g	O
1718	.	O
1718	27	O
1718	##13	O
1718	##1	O
1718	_	O
1718	27	O
1718	##13	O
1718	##2	O
1718	##ins	O
1718	##t	O
1718	r	O
1718	##s	O
1718	##24	O
1718	##13	O
1718	##0	O
1718	##33	O
1718	##43	O
1718	[	O
1718	c	O
1718	##y	O
1718	##p	O
1718	##3	O
1718	##a	O
1718	##5	O
1718	*	O
1718	7	O
1718	]	O
1718	,	O
1718	c	O
1718	_	O
1718	_	O
1718	_	O
1718	1901	O
1718	##6	O
1718	##9	O
1718	##7	O
1718	_	O
1718	20	O
1718	for	O
1718	s	O
1718	##l	O
1718	##co	O
1718	##1	O
1718	##b	O
1718	##1	O
1718	38	O
1718	##8	O
1718	##a	O
1718	>	O
1718	g	O
1718	r	O
1718	##s	O
1718	##23	O
1718	##0	O
1718	##6	O
1718	##28	O
1718	##3	O
1718	(	O
1718	*	O
1718	1	O
1718	##b	O
1718	)	O
1718	and	O
1718	c	O
1718	_	O
1718	_	O
1718	306	O
1718	##33	O
1718	##90	O
1718	##6	O
1718	_	O
1718	10	O
1718	for	O
1718	s	O
1718	##l	O
1718	##co	O
1718	##1	O
1718	##b	O
1718	##1	O
1718	52	O
1718	##1	O
1718	##t	O
1718	>	O
1718	c	O
1718	r	O
1718	##s	O
1718	##41	O
1718	##4	O
1718	##90	O
1718	##5	O
1718	##6	O
1718	(	O
1718	*	O
1718	5	O
1718	)	O
1718	on	O
1718	a	O
1718	##bi	O
1718	750	O
1718	##0	O
1718	fast	O
1718	(	O
1718	applied	O
1718	bio	O
1718	##sy	O
1718	##ste	O
1718	##ms	O
1718	,	O
1718	foster	O
1718	city	O
1718	,	O
1718	ca	O
1718	)	O
1718	.	O
1718	[SEP]	O
1719	[CLS]	O
1719	se	O
1719	##quencing	O
1719	reaction	O
1719	was	O
1719	done	O
1719	using	O
1719	the	O
1719	a	O
1719	##bi	O
1719	[UNK]	O
1719	big	O
1719	##dy	O
1719	##e	O
1719	##®	O
1719	term	O
1719	##inator	O
1719	cycle	O
1719	se	O
1719	##quencing	O
1719	ready	O
1719	reaction	O
1719	kit	O
1719	v	O
1719	##3	O
1719	.	O
1719	1	O
1719	(	O
1719	applied	O
1719	bio	O
1719	##sy	O
1719	##ste	O
1719	##ms	O
1719	,	O
1719	foster	O
1719	city	O
1719	,	O
1719	ca	O
1719	)	O
1719	,	O
1719	and	O
1719	analyzed	O
1719	on	O
1719	an	O
1719	a	O
1719	##bi	O
1719	p	O
1719	##rism	O
1719	37	O
1719	##7	O
1719	d	O
1719	##na	O
1719	sequence	O
1719	##r	O
1719	.	O
1719	[SEP]	O
1720	[CLS]	O
1720	an	O
1720	all	O
1720	##ometric	O
1720	##ally	O
1720	scaled	O
1720	population	O
1720	-	O
1720	p	O
1720	##har	O
1720	##ma	O
1720	##co	O
1720	##kin	O
1720	##etic	O
1720	model	O
1720	was	O
1720	developed	O
1720	to	O
1720	investigate	O
1720	the	O
1720	effect	O
1720	of	O
1720	tablet	O
1720	and	O
1720	suspension	O
1720	relative	B-PK
1720	bio	I-PK
1720	##ava	I-PK
1720	##ila	I-PK
1720	##bility	I-PK
1720	,	O
1720	non	B-PK
1720	##linear	I-PK
1720	bio	I-PK
1720	##ava	I-PK
1720	##ila	I-PK
1720	##bility	I-PK
1720	of	O
1720	suspension	O
1720	,	O
1720	followed	O
1720	by	O
1720	a	O
1720	step	O
1720	-	O
1720	wise	O
1720	co	O
1720	##var	O
1720	##iate	O
1720	model	O
1720	building	O
1720	exercise	O
1720	to	O
1720	identify	O
1720	other	O
1720	important	O
1720	sources	O
1720	of	O
1720	var	O
1720	##iability	O
1720	.	O
1720	[SEP]	O
1721	[CLS]	O
1721	a	O
1721	one	O
1721	-	O
1721	compartment	O
1721	model	O
1721	was	O
1721	used	O
1721	,	O
1721	with	O
1721	tablet	O
1721	apparent	B-PK
1721	clearance	I-PK
1721	standard	O
1721	##ised	O
1721	to	O
1721	a	O
1721	70	O
1721	-	O
1721	kg	O
1721	individual	O
1721	of	O
1721	15	O
1721	l	O
1721	/	O
1721	h	O
1721	.	O
1721	[SEP]	O
1722	[CLS]	O
1722	suspension	O
1722	was	O
1722	found	O
1722	to	O
1722	have	O
1722	decreasing	O
1722	bio	B-PK
1722	##ava	I-PK
1722	##ila	I-PK
1722	##bility	I-PK
1722	with	O
1722	increasing	O
1722	dose	O
1722	;	O
1722	the	O
1722	estimated	O
1722	suspension	O
1722	dose	O
1722	to	O
1722	yield	O
1722	half	O
1722	the	O
1722	tablet	O
1722	bio	B-PK
1722	##ava	I-PK
1722	##ila	I-PK
1722	##bility	I-PK
1722	was	O
1722	99	O
1722	mg	O
1722	/	O
1722	m	O
1722	##2	O
1722	.	O
1722	[SEP]	O
1723	[CLS]	O
1723	association	O
1723	of	O
1723	di	O
1723	##li	O
1723	with	O
1723	female	O
1723	sex	O
1723	(	O
1723	p	O
1723	=	O
1723	0	O
1723	.	O
1723	00	O
1723	##1	O
1723	)	O
1723	and	O
1723	lower	O
1723	b	O
1723	##mi	O
1723	(	O
1723	p	O
1723	=	O
1723	0	O
1723	.	O
1723	09	O
1723	)	O
1723	was	O
1723	noted	O
1723	.	O
1723	[SEP]	O
1724	[CLS]	O
1724	in	O
1724	the	O
1724	largest	O
1724	population	O
1724	-	O
1724	p	O
1724	##har	O
1724	##ma	O
1724	##co	O
1724	##kin	O
1724	##etic	O
1724	study	O
1724	to	O
1724	date	O
1724	in	O
1724	children	O
1724	,	O
1724	we	O
1724	have	O
1724	found	O
1724	similar	O
1724	co	O
1724	##var	O
1724	##iate	O
1724	effects	O
1724	to	O
1724	those	O
1724	seen	O
1724	in	O
1724	adults	O
1724	,	O
1724	but	O
1724	low	O
1724	bio	B-PK
1724	##ava	I-PK
1724	##ila	I-PK
1724	##bility	I-PK
1724	of	O
1724	suspension	O
1724	in	O
1724	patients	O
1724	with	O
1724	di	O
1724	##ar	O
1724	##r	O
1724	##hoe	O
1724	##a	O
1724	or	O
1724	those	O
1724	taking	O
1724	concurrent	O
1724	pro	O
1724	##ton	O
1724	pump	O
1724	inhibitor	O
1724	##s	O
1724	,	O
1724	which	O
1724	may	O
1724	in	O
1724	particular	O
1724	limit	O
1724	the	O
1724	use	O
1724	of	O
1724	p	O
1724	##osa	O
1724	##cona	O
1724	##zo	O
1724	##le	O
1724	in	O
1724	these	O
1724	patients	O
1724	.	O
1724	[SEP]	O
1725	[CLS]	O
1725	co	O
1725	##x	O
1725	-	O
1725	re	O
1725	##gression	O
1725	analysis	O
1725	showed	O
1725	that	O
1725	there	O
1725	was	O
1725	a	O
1725	statistical	O
1725	##ly	O
1725	significant	O
1725	association	O
1725	di	O
1725	##li	O
1725	with	O
1725	c	O
1725	##y	O
1725	##p	O
1725	##2	O
1725	##b	O
1725	##6	O
1725	*	O
1725	6	O
1725	and	O
1725	a	O
1725	##b	O
1725	##c	O
1725	##b	O
1725	##1	O
1725	34	O
1725	##35	O
1725	##tt	O
1725	g	O
1725	##eno	O
1725	##type	O
1725	(	O
1725	table	O
1725	3	O
1725	)	O
1725	.	O
1725	[SEP]	O
1726	[CLS]	O
1726	because	O
1726	most	O
1726	samples	O
1726	were	O
1726	pre	O
1726	-	O
1726	dose	O
1726	t	O
1726	##rough	O
1726	##s	O
1726	and	O
1726	p	O
1726	##osa	O
1726	##cona	O
1726	##zo	O
1726	##le	O
1726	is	O
1726	known	O
1726	to	O
1726	have	O
1726	a	O
1726	long	O
1726	elimination	B-PK
1726	half	I-PK
1726	-	I-PK
1726	life	I-PK
1726	,	O
1726	a	O
1726	one	O
1726	-	O
1726	compartment	O
1726	model	O
1726	with	O
1726	first	O
1726	-	O
1726	order	O
1726	absorption	O
1726	was	O
1726	used	O
1726	.	O
1726	[SEP]	O
1727	[CLS]	O
1727	all	O
1727	##ometric	O
1727	s	O
1727	##cal	O
1727	##ing	O
1727	with	O
1727	ex	O
1727	##ponents	O
1727	of	O
1727	0	O
1727	.	O
1727	75	O
1727	,	O
1727	1	O
1727	and	O
1727	−	O
1727	0	O
1727	.	O
1727	25	O
1727	on	O
1727	clearance	B-PK
1727	(	I-PK
1727	c	I-PK
1727	##l	I-PK
1727	)	I-PK
1727	,	O
1727	central	B-PK
1727	volume	I-PK
1727	and	I-PK
1727	absorption	I-PK
1727	rate	I-PK
1727	constant	I-PK
1727	(	I-PK
1727	ka	I-PK
1727	)	I-PK
1727	were	O
1727	added	O
1727	a	O
1727	prior	O
1727	##i	O
1727	,	O
1727	and	O
1727	a	O
1727	si	O
1727	##g	O
1727	##mo	O
1727	##idal	O
1727	mat	O
1727	##uration	O
1727	function	O
1727	based	O
1727	on	O
1727	post	O
1727	##men	O
1727	##st	O
1727	##ru	O
1727	##al	O
1727	age	O
1727	was	O
1727	tested	O
1727	[	O
1727	12	O
1727	]	O
1727	.	O
1727	[SEP]	O
1728	[CLS]	O
1728	the	O
1728	following	O
1728	con	O
1728	##com	O
1728	##ita	O
1728	##nt	O
1728	medications	O
1728	were	O
1728	also	O
1728	tested	O
1728	on	O
1728	c	B-PK
1728	##l	I-PK
1728	:	O
1728	mac	O
1728	##rol	O
1728	##ides	O
1728	,	O
1728	e	O
1728	##chin	O
1728	##oc	O
1728	##and	O
1728	##ins	O
1728	,	O
1728	c	O
1728	##ic	O
1728	##los	O
1728	##por	O
1728	##in	O
1728	,	O
1728	ta	O
1728	##c	O
1728	##rol	O
1728	##imus	O
1728	,	O
1728	my	O
1728	##co	O
1728	##phe	O
1728	##no	O
1728	##late	O
1728	,	O
1728	r	O
1728	##if	O
1728	##amp	O
1728	##ici	O
1728	##n	O
1728	,	O
1728	car	O
1728	##ba	O
1728	##ma	O
1728	##ze	O
1728	##pine	O
1728	,	O
1728	p	O
1728	##hen	O
1728	##yt	O
1728	##oi	O
1728	##n	O
1728	or	O
1728	v	O
1728	##ala	O
1728	##ci	O
1728	##c	O
1728	##lov	O
1728	##ir	O
1728	.	O
1728	[SEP]	O
1729	[CLS]	O
1729	the	O
1729	base	O
1729	structural	O
1729	model	O
1729	with	O
1729	all	O
1729	##ometric	O
1729	s	O
1729	##cal	O
1729	##ing	O
1729	centred	O
1729	on	O
1729	70	O
1729	kg	O
1729	and	O
1729	inter	O
1729	-	O
1729	individual	O
1729	var	O
1729	##iability	O
1729	on	O
1729	c	B-PK
1729	##l	I-PK
1729	only	O
1729	gave	O
1729	parameter	O
1729	estimates	O
1729	of	O
1729	86	O
1729	.	O
1729	5	O
1729	l	O
1729	/	O
1729	h	O
1729	,	O
1729	143	O
1729	##9	O
1729	.	O
1729	6	O
1729	l	O
1729	and	O
1729	0	O
1729	.	O
1729	09	O
1729	/	O
1729	h	O
1729	for	O
1729	apparent	B-PK
1729	clearance	I-PK
1729	(	I-PK
1729	c	I-PK
1729	##l	I-PK
1729	/	I-PK
1729	f	I-PK
1729	)	I-PK
1729	,	O
1729	apparent	B-PK
1729	volume	I-PK
1729	and	O
1729	ka	B-PK
1729	,	O
1729	respectively	O
1729	.	O
1729	[SEP]	O
1730	[CLS]	O
1730	the	O
1730	addition	O
1730	of	O
1730	a	O
1730	si	O
1730	##g	O
1730	##mo	O
1730	##idal	O
1730	mat	O
1730	##uration	O
1730	function	O
1730	gave	O
1730	no	O
1730	improvement	O
1730	in	O
1730	fit	O
1730	,	O
1730	whereas	O
1730	adding	O
1730	a	O
1730	cat	O
1730	##ego	O
1730	##rical	O
1730	co	O
1730	##var	O
1730	##iate	O
1730	of	O
1730	a	O
1730	change	O
1730	in	O
1730	relative	B-PK
1730	bio	I-PK
1730	##ava	I-PK
1730	##ila	I-PK
1730	##bility	I-PK
1730	with	O
1730	suspension	O
1730	compared	O
1730	with	O
1730	a	O
1730	tablet	O
1730	yielded	O
1730	a	O
1730	decrease	O
1730	in	O
1730	of	O
1730	##v	O
1730	of	O
1730	10	O
1730	.	O
1730	11	O
1730	(	O
1730	p	O
1730	=	O
1730	0	O
1730	.	O
1730	00	O
1730	##15	O
1730	)	O
1730	.	O
1730	[SEP]	O
1731	[CLS]	O
1731	during	O
1731	model	O
1731	building	O
1731	,	O
1731	flip	O
1731	-	O
1731	fl	O
1731	##op	O
1731	kinetic	O
1731	##s	O
1731	became	O
1731	apparent	O
1731	(	O
1731	ka	B-PK
1731	being	O
1731	estimated	O
1731	to	O
1731	be	O
1731	larger	O
1731	than	O
1731	elimination	B-PK
1731	rate	I-PK
1731	constant	I-PK
1731	)	O
1731	.	O
1731	[SEP]	O
1732	[CLS]	O
1732	thereafter	O
1732	,	O
1732	ka	B-PK
1732	was	O
1732	fixed	O
1732	to	O
1732	literature	O
1732	values	O
1732	of	O
1732	0	O
1732	.	O
1732	58	O
1732	##8	O
1732	/	O
1732	h	O
1732	for	O
1732	tablets	O
1732	[	O
1732	19	O
1732	]	O
1732	,	O
1732	and	O
1732	0	O
1732	.	O
1732	197	O
1732	/	O
1732	h	O
1732	for	O
1732	suspension	O
1732	##s	O
1732	[	O
1732	15	O
1732	]	O
1732	.	O
1732	[SEP]	O
1733	[CLS]	O
1733	the	O
1733	difference	O
1733	in	O
1733	of	O
1733	##v	O
1733	between	O
1733	this	O
1733	model	O
1733	and	O
1733	the	O
1733	estimated	O
1733	ka	B-PK
1733	and	O
1733	v	B-PK
1733	models	O
1733	was	O
1733	7	O
1733	.	O
1733	63	O
1733	,	O
1733	indicating	O
1733	a	O
1733	very	O
1733	similar	O
1733	fit	O
1733	.	O
1733	[SEP]	O
1734	[CLS]	O
1734	o	O
1734	##mada	O
1734	##cy	O
1734	##cline	O
1734	plasma	B-PK
1734	clearance	I-PK
1734	was	O
1734	1	O
1734	.	O
1734	2	O
1734	liter	O
1734	##s	O
1734	/	O
1734	h	O
1734	/	O
1734	kg	O
1734	,	O
1734	and	O
1734	its	O
1734	half	B-PK
1734	-	I-PK
1734	life	I-PK
1734	was	O
1734	4	O
1734	.	O
1734	6	O
1734	h	O
1734	;	O
1734	the	O
1734	steady	B-PK
1734	-	I-PK
1734	state	I-PK
1734	volume	I-PK
1734	of	I-PK
1734	distribution	I-PK
1734	(	I-PK
1734	vs	I-PK
1734	##s	I-PK
1734	)	I-PK
1734	was	O
1734	6	O
1734	.	O
1734	89	O
1734	liter	O
1734	##s	O
1734	/	O
1734	kg	O
1734	.	O
1734	[SEP]	O
1735	[CLS]	O
1735	the	O
1735	predominant	O
1735	radioactive	O
1735	components	O
1735	in	O
1735	rat	O
1735	plasma	O
1735	after	O
1735	a	O
1735	single	O
1735	i	O
1735	.	O
1735	v	O
1735	.	O
1735	dose	O
1735	were	O
1735	unchanged	O
1735	(	O
1735	o	O
1735	##mada	O
1735	##cy	O
1735	##cline	O
1735	/	O
1735	c	O
1735	-	O
1735	4	O
1735	e	O
1735	##pi	O
1735	##mer	O
1735	,	O
1735	89	O
1735	.	O
1735	9	O
1735	%	O
1735	au	B-PK
1735	##c	I-PK
1735	)	O
1735	.	O
1735	[SEP]	O
1736	[CLS]	O
1736	following	O
1736	a	O
1736	90	O
1736	mg	O
1736	/	O
1736	kg	O
1736	oral	O
1736	dose	O
1736	of	O
1736	14	O
1736	##c	O
1736	-	O
1736	o	O
1736	##mada	O
1736	##cy	O
1736	##cline	O
1736	,	O
1736	the	O
1736	peak	B-PK
1736	radio	I-PK
1736	##act	I-PK
1736	##ivity	I-PK
1736	concentration	I-PK
1736	in	I-PK
1736	plasma	I-PK
1736	(	I-PK
1736	cm	I-PK
1736	##ax	I-PK
1736	,	O
1736	172	O
1736	ng	O
1736	·	O
1736	e	O
1736	##q	O
1736	/	O
1736	m	O
1736	##l	O
1736	)	O
1736	was	O
1736	attained	O
1736	at	O
1736	between	O
1736	0	O
1736	.	O
1736	25	O
1736	and	O
1736	2	O
1736	h	O
1736	(	O
1736	fi	O
1736	##g	O
1736	.	O
1736	1	O
1736	)	O
1736	.	O
1736	[SEP]	O
1737	[CLS]	O
1737	the	O
1737	peak	B-PK
1737	plasma	I-PK
1737	concentration	I-PK
1737	of	O
1737	unchanged	O
1737	o	O
1737	##mada	O
1737	##cy	O
1737	##cline	O
1737	(	O
1737	cm	B-PK
1737	##ax	I-PK
1737	,	O
1737	47	O
1737	.	O
1737	5	O
1737	ng	O
1737	/	O
1737	m	O
1737	##l	O
1737	)	O
1737	was	O
1737	attained	O
1737	at	O
1737	0	O
1737	.	O
1737	5	O
1737	h	O
1737	after	O
1737	oral	O
1737	dos	O
1737	##ing	O
1737	(	O
1737	fi	O
1737	##g	O
1737	.	O
1737	2	O
1737	)	O
1737	,	O
1737	further	O
1737	suggesting	O
1737	rapid	O
1737	absorption	O
1737	(	O
1737	table	O
1737	4	O
1737	)	O
1737	.	O
1737	[SEP]	O
1738	[CLS]	O
1738	ratio	O
1738	of	O
1738	the	O
1738	values	O
1738	corresponding	O
1738	to	O
1738	the	O
1738	dose	B-PK
1738	-	I-PK
1738	normal	I-PK
1738	##ized	I-PK
1738	area	I-PK
1738	under	I-PK
1738	the	I-PK
1738	concentration	I-PK
1738	/	I-PK
1738	time	I-PK
1738	curve	I-PK
1738	at	I-PK
1738	last	I-PK
1738	observation	I-PK
1738	(	I-PK
1738	au	I-PK
1738	##c	I-PK
1738	##last	I-PK
1738	)	I-PK
1738	of	O
1738	radio	B-PK
1738	##act	I-PK
1738	##ivity	I-PK
1738	in	O
1738	plasma	O
1738	.	O
1738	[SEP]	O
1739	[CLS]	O
1739	the	O
1739	oral	B-PK
1739	bio	I-PK
1739	##ava	I-PK
1739	##ila	I-PK
1739	##bility	I-PK
1739	was	O
1739	very	O
1739	low	O
1739	(	O
1739	0	O
1739	.	O
1739	23	O
1739	%	O
1739	)	O
1739	compared	O
1739	to	O
1739	the	O
1739	absorption	O
1739	(	O
1739	table	O
1739	4	O
1739	)	O
1739	,	O
1739	suggesting	O
1739	significant	O
1739	first	O
1739	-	O
1739	pass	O
1739	elimination	O
1739	.	O
1739	[SEP]	O
1740	[CLS]	O
1740	the	O
1740	oral	B-PK
1740	bio	I-PK
1740	##ava	I-PK
1740	##ila	I-PK
1740	##bility	I-PK
1740	was	O
1740	much	O
1740	lower	O
1740	than	O
1740	[UNK]	O
1740	%	O
1740	in	O
1740	humans	O
1740	(	O
1740	5	O
1740	)	O
1740	.	O
1740	[SEP]	O
1741	[CLS]	O
1741	systemic	B-PK
1741	plasma	I-PK
1741	clearance	I-PK
1741	(	I-PK
1741	c	I-PK
1741	##l	I-PK
1741	;	O
1741	1	O
1741	,	O
1741	200	O
1741	m	O
1741	##l	O
1741	/	O
1741	h	O
1741	/	O
1741	kg	O
1741	)	O
1741	appeared	O
1741	to	O
1741	be	O
1741	moderate	O
1741	compared	O
1741	to	O
1741	the	O
1741	level	O
1741	in	O
1741	the	O
1741	he	B-PK
1741	##pa	I-PK
1741	##tic	I-PK
1741	blood	I-PK
1741	flow	I-PK
1741	in	O
1741	the	O
1741	rat	O
1741	(	O
1741	3	O
1741	.	O
1741	3	O
1741	liter	O
1741	##s	O
1741	/	O
1741	h	O
1741	/	O
1741	kg	O
1741	)	O
1741	,	O
1741	assuming	O
1741	equal	O
1741	distributions	O
1741	of	O
1741	14	O
1741	##c	O
1741	-	O
1741	o	O
1741	##mada	O
1741	##cy	O
1741	##cline	O
1741	in	O
1741	the	O
1741	blood	O
1741	and	O
1741	plasma	O
1741	.	O
1741	[SEP]	O
1742	[CLS]	O
1742	the	O
1742	plasma	B-PK
1742	volume	I-PK
1742	of	I-PK
1742	distribution	I-PK
1742	at	I-PK
1742	the	I-PK
1742	steady	I-PK
1742	state	I-PK
1742	of	O
1742	the	O
1742	unchanged	O
1742	compound	O
1742	(	O
1742	vs	B-PK
1742	##s	I-PK
1742	;	O
1742	6	O
1742	.	O
1742	89	O
1742	liter	O
1742	##s	O
1742	/	O
1742	kg	O
1742	)	O
1742	was	O
1742	larger	O
1742	than	O
1742	the	O
1742	body	O
1742	water	O
1742	volume	O
1742	(	O
1742	0	O
1742	.	O
1742	6	O
1742	liter	O
1742	##s	O
1742	/	O
1742	kg	O
1742	)	O
1742	,	O
1742	suggesting	O
1742	that	O
1742	o	O
1742	##mada	O
1742	##cy	O
1742	##cline	O
1742	was	O
1742	extensively	O
1742	distributed	O
1742	to	O
1742	tissues	O
1742	.	O
1742	[SEP]	O
1743	[CLS]	O
1743	the	O
1743	highest	B-PK
1743	average	I-PK
1743	plasma	I-PK
1743	o	I-PK
1743	##mada	I-PK
1743	##cy	I-PK
1743	##cline	I-PK
1743	and	I-PK
1743	radio	I-PK
1743	##act	I-PK
1743	##ivity	I-PK
1743	concentrations	I-PK
1743	(	I-PK
1743	cm	I-PK
1743	##ax	I-PK
1743	)	I-PK
1743	and	O
1743	corresponding	O
1743	times	O
1743	(	O
1743	t	B-PK
1743	##max	I-PK
1743	)	O
1743	were	O
1743	recorded	O
1743	.	O
1743	[SEP]	O
1744	[CLS]	O
1744	a	O
1744	##ki	O
1744	was	O
1744	defined	O
1744	either	O
1744	as	O
1744	>	O
1744	50	O
1744	%	O
1744	increase	O
1744	in	O
1744	plasma	O
1744	c	O
1744	##rea	O
1744	##tin	O
1744	##ine	O
1744	from	O
1744	base	O
1744	##line	O
1744	,	O
1744	or	O
1744	>	O
1744	33	O
1744	.	O
1744	3	O
1744	%	O
1744	decrease	O
1744	in	O
1744	c	O
1744	##rea	O
1744	##tin	O
1744	##ine	O
1744	clearance	O
1744	.	O
1744	[SEP]	O
1745	[CLS]	O
1745	clearance	B-PK
1745	(	I-PK
1745	c	I-PK
1745	##l	I-PK
1745	)	I-PK
1745	and	O
1745	the	O
1745	steady	B-PK
1745	-	I-PK
1745	state	I-PK
1745	volume	I-PK
1745	of	I-PK
1745	distribution	I-PK
1745	(	I-PK
1745	vs	I-PK
1745	##s	I-PK
1745	)	I-PK
1745	of	O
1745	o	O
1745	##mada	O
1745	##cy	O
1745	##cline	O
1745	were	O
1745	calculated	O
1745	using	O
1745	data	O
1745	from	O
1745	the	O
1745	i	O
1745	.	O
1745	v	O
1745	.	O
1745	dose	O
1745	.	O
1745	[SEP]	O
1746	[CLS]	O
1746	amongst	O
1746	patients	O
1746	with	O
1746	plasma	O
1746	c	O
1746	##rea	O
1746	##tin	O
1746	##ine	O
1746	<	O
1746	1	O
1746	.	O
1746	24	O
1746	mg	O
1746	/	O
1746	d	O
1746	##l	O
1746	on	O
1746	entry	O
1746	,	O
1746	c	O
1746	##rea	O
1746	##tin	O
1746	##ine	O
1746	clearance	O
1746	improved	O
1746	the	O
1746	prediction	O
1746	of	O
1746	a	O
1746	##ki	O
1746	considerably	O
1746	(	O
1746	net	O
1746	re	O
1746	##c	O
1746	##lass	O
1746	##ification	O
1746	improvement	O
1746	83	O
1746	%	O
1746	,	O
1746	integrated	O
1746	discrimination	O
1746	improvement	O
1746	0	O
1746	.	O
1746	29	O
1746	)	O
1746	.	O
1746	[SEP]	O
1747	[CLS]	O
1747	for	O
1747	the	O
1747	major	O
1747	meta	O
1747	##bol	O
1747	##ites	O
1747	in	O
1747	plasma	O
1747	,	O
1747	cm	B-PK
1747	##ax	I-PK
1747	and	O
1747	t	B-PK
1747	##max	I-PK
1747	were	O
1747	recorded	O
1747	as	O
1747	observed	O
1747	.	O
1747	[SEP]	O
1748	[CLS]	O
1748	on	O
1748	-	O
1748	entry	O
1748	,	O
1748	c	O
1748	##rea	O
1748	##tin	O
1748	##ine	O
1748	clearance	O
1748	associated	O
1748	with	O
1748	a	O
1748	##ki	O
1748	severity	O
1748	and	O
1748	duration	O
1748	(	O
1748	p	O
1748	<	O
1748	0	O
1748	.	O
1748	000	O
1748	##1	O
1748	)	O
1748	predicted	O
1748	dial	O
1748	##ys	O
1748	##is	O
1748	need	O
1748	(	O
1748	area	O
1748	under	O
1748	the	O
1748	curve	O
1748	:	O
1748	0	O
1748	.	O
1748	75	O
1748	)	O
1748	and	O
1748	death	O
1748	(	O
1748	0	O
1748	.	O
1748	61	O
1748	)	O
1748	.	O
1748	[SEP]	O
1749	[CLS]	O
1749	patients	O
1749	were	O
1749	further	O
1749	classified	O
1749	into	O
1749	(	O
1749	i	O
1749	)	O
1749	no	O
1749	a	O
1749	##ki	O
1749	(	O
1749	δ	O
1749	##p	O
1749	##c	O
1749	##rno	O
1749	-	O
1749	a	O
1749	##ki	O
1749	and	O
1749	δ	O
1749	##cc	O
1749	##ln	O
1749	##o	O
1749	-	O
1749	a	O
1749	##ki	O
1749	)	O
1749	;	O
1749	(	O
1749	ii	O
1749	)	O
1749	a	O
1749	##ki	O
1749	by	O
1749	the	O
1749	clearance	B-PK
1749	criterion	O
1749	only	O
1749	(	O
1749	δ	O
1749	##p	O
1749	##c	O
1749	##rno	O
1749	-	O
1749	a	O
1749	##ki	O
1749	and	O
1749	δ	O
1749	##cc	O
1749	##lak	O
1749	##i	O
1749	)	O
1749	;	O
1749	(	O
1749	ii	O
1749	##i	O
1749	)	O
1749	a	O
1749	##ki	O
1749	by	O
1749	the	O
1749	p	O
1749	##c	O
1749	##r	O
1749	criterion	O
1749	only	O
1749	(	O
1749	δ	O
1749	##p	O
1749	##c	O
1749	##rak	O
1749	##i	O
1749	and	O
1749	δ	O
1749	##cc	O
1749	##ln	O
1749	##o	O
1749	-	O
1749	a	O
1749	##ki	O
1749	)	O
1749	or	O
1749	(	O
1749	i	O
1749	##v	O
1749	)	O
1749	a	O
1749	##ki	O
1749	by	O
1749	both	O
1749	criteria	O
1749	(	O
1749	δ	O
1749	##p	O
1749	##c	O
1749	##rak	O
1749	##i	O
1749	and	O
1749	δ	O
1749	##cc	O
1749	##lak	O
1749	##i	O
1749	)	O
1749	.	O
1749	[SEP]	O
1750	[CLS]	O
1750	the	O
1750	area	O
1750	under	O
1750	the	O
1750	receiver	O
1750	operator	O
1750	characteristic	O
1750	curve	O
1750	(	O
1750	au	O
1750	##c	O
1750	)	O
1750	was	O
1750	used	O
1750	to	O
1750	determine	O
1750	the	O
1750	predict	O
1750	##ive	O
1750	value	O
1750	of	O
1750	on	O
1750	-	O
1750	entry	O
1750	cc	O
1750	##l	O
1750	for	O
1750	δ	O
1750	##cc	O
1750	##lak	O
1750	##i	O
1750	and	O
1750	on	O
1750	-	O
1750	entry	O
1750	p	O
1750	##c	O
1750	##r	O
1750	for	O
1750	δ	O
1750	##p	O
1750	##c	O
1750	##rak	O
1750	##i	O
1750	.	O
1750	[SEP]	O
1751	[CLS]	O
1751	diagnostic	O
1751	and	O
1751	pro	O
1751	##gno	O
1751	##stic	O
1751	performance	O
1751	was	O
1751	assessed	O
1751	by	O
1751	calculating	O
1751	the	O
1751	au	B-PK
1751	##c	I-PK
1751	and	O
1751	odds	O
1751	ratios	O
1751	.	O
1751	[SEP]	O
1752	[CLS]	O
1752	the	O
1752	reference	O
1752	and	O
1752	new	O
1752	a	O
1752	##ki	O
1752	risk	O
1752	prediction	O
1752	models	O
1752	were	O
1752	compared	O
1752	by	O
1752	the	O
1752	continuous	O
1752	(	O
1752	category	O
1752	-	O
1752	free	O
1752	)	O
1752	net	O
1752	re	O
1752	##c	O
1752	##lass	O
1752	##ification	O
1752	improvement	O
1752	(	O
1752	n	O
1752	##ri	O
1752	)	O
1752	and	O
1752	integrated	O
1752	discrimination	O
1752	improvement	O
1752	statistics	O
1752	[	O
1752	19	O
1752	-	O
1752	21	O
1752	]	O
1752	and	O
1752	difference	O
1752	in	O
1752	au	B-PK
1752	##c	I-PK
1752	[	O
1752	22	O
1752	]	O
1752	.	O
1752	[SEP]	O
1753	[CLS]	O
1753	of	O
1753	the	O
1753	remainder	O
1753	,	O
1753	30	O
1753	were	O
1753	a	O
1753	sub	O
1753	-	O
1753	co	O
1753	##hor	O
1753	##t	O
1753	of	O
1753	high	O
1753	-	O
1753	risk	O
1753	patients	O
1753	who	O
1753	had	O
1753	undergone	O
1753	card	O
1753	##io	O
1753	-	O
1753	th	O
1753	##ora	O
1753	##ci	O
1753	##c	O
1753	surgery	O
1753	,	O
1753	and	O
1753	whose	O
1753	first	O
1753	clearance	B-PK
1753	measure	O
1753	was	O
1753	8	O
1753	to	O
1753	11	O
1753	h	O
1753	after	O
1753	entry	O
1753	to	O
1753	i	O
1753	##cu	O
1753	,	O
1753	and	O
1753	14	O
1753	patients	O
1753	had	O
1753	no	O
1753	clearance	B-PK
1753	measurement	O
1753	because	O
1753	they	O
1753	were	O
1753	an	O
1753	##uri	O
1753	##c	O
1753	or	O
1753	because	O
1753	clinical	O
1753	events	O
1753	prevented	O
1753	measurement	O
1753	.	O
1753	[SEP]	O
1754	[CLS]	O
1754	on	O
1754	entry	O
1754	to	O
1754	the	O
1754	i	O
1754	##cu	O
1754	,	O
1754	182	O
1754	patients	O
1754	had	O
1754	a	O
1754	pre	O
1754	-	O
1754	admission	O
1754	base	O
1754	##line	O
1754	c	O
1754	##rea	O
1754	##tin	O
1754	##ine	O
1754	from	O
1754	which	O
1754	the	O
1754	change	O
1754	in	O
1754	c	O
1754	##rea	O
1754	##tin	O
1754	##ine	O
1754	(	O
1754	δ	O
1754	##p	O
1754	##c	O
1754	##r	O
1754	)	O
1754	and	O
1754	change	O
1754	in	O
1754	c	O
1754	##rea	O
1754	##tin	O
1754	##ine	O
1754	clearance	O
1754	(	O
1754	δ	O
1754	##cc	O
1754	##l	O
1754	)	O
1754	to	O
1754	determine	O
1754	a	O
1754	##ki	O
1754	status	O
1754	on	O
1754	entry	O
1754	was	O
1754	calculated	O
1754	(	O
1754	figure	O
1754	1	O
1754	)	O
1754	.	O
1754	[SEP]	O
1755	[CLS]	O
1755	the	O
1755	optimal	O
1755	cut	O
1755	-	O
1755	point	O
1755	for	O
1755	cc	O
1755	##l	O
1755	to	O
1755	di	O
1755	##ag	O
1755	##nose	O
1755	δ	O
1755	##cc	O
1755	##lak	O
1755	##i	O
1755	was	O
1755	48	O
1755	.	O
1755	6	O
1755	m	O
1755	##l	O
1755	/	O
1755	min	O
1755	(	O
1755	au	O
1755	##c	O
1755	,	O
1755	0	O
1755	.	O
1755	87	O
1755	;	O
1755	95	O
1755	%	O
1755	c	O
1755	##i	O
1755	,	O
1755	0	O
1755	.	O
1755	81	O
1755	to	O
1755	0	O
1755	.	O
1755	94	O
1755	)	O
1755	calculated	O
1755	using	O
1755	1	O
1755	/	O
1755	cc	O
1755	##l	O
1755	)	O
1755	in	O
1755	the	O
1755	known	O
1755	base	O
1755	##line	O
1755	c	O
1755	##rea	O
1755	##tin	O
1755	##ine	O
1755	co	O
1755	##hor	O
1755	##t	O
1755	(	O
1755	figure	O
1755	3	O
1755	)	O
1755	.	O
1755	[SEP]	O
1756	[CLS]	O
1756	on	O
1756	entry	O
1756	to	O
1756	the	O
1756	i	O
1756	##cu	O
1756	,	O
1756	cc	O
1756	##l	O
1756	moderately	O
1756	predicted	O
1756	the	O
1756	need	O
1756	for	O
1756	dial	O
1756	##ys	O
1756	##is	O
1756	marginal	O
1756	##ly	O
1756	better	O
1756	(	O
1756	au	O
1756	##c	O
1756	,	O
1756	0	O
1756	.	O
1756	75	O
1756	;	O
1756	95	O
1756	%	O
1756	c	O
1756	##i	O
1756	,	O
1756	0	O
1756	.	O
1756	59	O
1756	to	O
1756	0	O
1756	.	O
1756	91	O
1756	;	O
1756	p	O
1756	=	O
1756	0	O
1756	.	O
1756	01	O
1756	##8	O
1756	)	O
1756	than	O
1756	p	O
1756	##c	O
1756	##r	O
1756	(	O
1756	au	O
1756	##c	O
1756	,	O
1756	0	O
1756	.	O
1756	72	O
1756	;	O
1756	95	O
1756	%	O
1756	c	O
1756	##i	O
1756	,	O
1756	0	O
1756	.	O
1756	56	O
1756	to	O
1756	0	O
1756	.	O
1756	89	O
1756	)	O
1756	;	O
1756	u	O
1756	##o	O
1756	was	O
1756	not	O
1756	predict	O
1756	##ive	O
1756	(	O
1756	au	O
1756	##c	O
1756	,	O
1756	0	O
1756	.	O
1756	50	O
1756	;	O
1756	95	O
1756	%	O
1756	c	O
1756	##i	O
1756	,	O
1756	0	O
1756	.	O
1756	41	O
1756	to	O
1756	0	O
1756	.	O
1756	75	O
1756	)	O
1756	.	O
1756	[SEP]	O
1757	[CLS]	O
1757	below	O
1757	this	O
1757	cut	O
1757	-	O
1757	point	O
1757	adding	O
1757	cc	O
1757	##l	O
1757	to	O
1757	a	O
1757	risk	O
1757	prediction	O
1757	model	O
1757	comprising	O
1757	p	O
1757	##c	O
1757	##r	O
1757	,	O
1757	u	O
1757	##o	O
1757	and	O
1757	acute	O
1757	physiology	O
1757	and	O
1757	chronic	O
1757	health	O
1757	evaluation	O
1757	(	O
1757	a	O
1757	##pa	O
1757	##che	O
1757	)	O
1757	ii	O
1757	scores	O
1757	(	O
1757	all	O
1757	p	O
1757	<	O
1757	0	O
1757	.	O
1757	1	O
1757	in	O
1757	a	O
1757	un	O
1757	##iva	O
1757	##ria	O
1757	##te	O
1757	analysis	O
1757	)	O
1757	for	O
1757	a	O
1757	##ki	O
1757	(	O
1757	δ	O
1757	##cc	O
1757	##lak	O
1757	##i	O
1757	or	O
1757	δ	O
1757	##p	O
1757	##c	O
1757	##rak	O
1757	##i	O
1757	)	O
1757	considerably	O
1757	improved	O
1757	the	O
1757	model	O
1757	:	O
1757	in	O
1757	the	O
1757	known	O
1757	base	O
1757	##line	O
1757	c	O
1757	##rea	O
1757	##tin	O
1757	##ine	O
1757	co	O
1757	##hor	O
1757	##t	O
1757	the	O
1757	au	O
1757	##c	O
1757	increased	O
1757	by	O
1757	0	O
1757	.	O
1757	23	O
1757	to	O
1757	a	O
1757	moderate	O
1757	0	O
1757	.	O
1757	77	O
1757	;	O
1757	a	O
1757	net	O
1757	23	O
1757	%	O
1757	of	O
1757	those	O
1757	with	O
1757	a	O
1757	##ki	O
1757	had	O
1757	greater	O
1757	risk	O
1757	whilst	O
1757	60	O
1757	%	O
1757	of	O
1757	those	O
1757	without	O
1757	a	O
1757	##ki	O
1757	had	O
1757	less	O
1757	risk	O
1757	,	O
1757	resulting	O
1757	in	O
1757	an	O
1757	n	O
1757	##ri	O
1757	of	O
1757	83	O
1757	%	O
1757	;	O
1757	the	O
1757	average	O
1757	increase	O
1757	in	O
1757	risk	O
1757	of	O
1757	those	O
1757	with	O
1757	a	O
1757	##ki	O
1757	was	O
1757	0	O
1757	.	O
1757	22	O
1757	(	O
1757	id	O
1757	##ia	O
1757	##ki	O
1757	)	O
1757	and	O
1757	the	O
1757	average	O
1757	decrease	O
1757	in	O
1757	risk	O
1757	of	O
1757	those	O
1757	without	O
1757	a	O
1757	##ki	O
1757	was	O
1757	0	O
1757	.	O
1757	07	O
1757	##4	O
1757	(	O
1757	id	O
1757	##ino	O
1757	-	O
1757	a	O
1757	##ki	O
1757	)	O
1757	indicating	O
1757	the	O
1757	model	O
1757	worked	O
1757	best	O
1757	to	O
1757	improve	O
1757	identification	O
1757	of	O
1757	those	O
1757	with	O
1757	a	O
1757	##ki	O
1757	rather	O
1757	than	O
1757	exclude	O
1757	those	O
1757	without	O
1757	(	O
1757	table	O
1757	4	O
1757	)	O
1757	.	O
1757	[SEP]	O
1758	[CLS]	O
1758	neither	O
1758	p	O
1758	##c	O
1758	##r	O
1758	(	O
1758	au	O
1758	##c	O
1758	,	O
1758	0	O
1758	.	O
1758	55	O
1758	;	O
1758	95	O
1758	%	O
1758	c	O
1758	##i	O
1758	,	O
1758	0	O
1758	.	O
1758	48	O
1758	to	O
1758	0	O
1758	.	O
1758	62	O
1758	)	O
1758	nor	O
1758	u	O
1758	##o	O
1758	(	O
1758	au	O
1758	##c	O
1758	,	O
1758	0	O
1758	.	O
1758	55	O
1758	;	O
1758	95	O
1758	%	O
1758	c	O
1758	##i	O
1758	,	O
1758	0	O
1758	.	O
1758	47	O
1758	to	O
1758	0	O
1758	.	O
1758	62	O
1758	)	O
1758	were	O
1758	predict	O
1758	##ive	O
1758	of	O
1758	death	O
1758	.	O
1758	[SEP]	O
1759	[CLS]	O
1759	cc	O
1759	##l	O
1759	was	O
1759	predict	O
1759	##ive	O
1759	of	O
1759	death	O
1759	within	O
1759	30	O
1759	days	O
1759	,	O
1759	but	O
1759	with	O
1759	a	O
1759	lower	O
1759	au	O
1759	##c	O
1759	value	O
1759	of	O
1759	0	O
1759	.	O
1759	61	O
1759	(	O
1759	95	O
1759	%	O
1759	c	O
1759	##i	O
1759	,	O
1759	0	O
1759	.	O
1759	54	O
1759	to	O
1759	0	O
1759	.	O
1759	68	O
1759	)	O
1759	.	O
1759	[SEP]	O
1760	[CLS]	O
1760	these	O
1760	patients	O
1760	were	O
1760	more	O
1760	likely	O
1760	to	O
1760	require	O
1760	dial	O
1760	##ys	O
1760	##is	O
1760	or	O
1760	die	O
1760	within	O
1760	30	O
1760	days	O
1760	than	O
1760	patients	O
1760	with	O
1760	smaller	O
1760	decreases	O
1760	(	O
1760	29	O
1760	%	O
1760	vs	O
1760	15	O
1760	%	O
1760	,	O
1760	p	O
1760	=	O
1760	0	O
1760	.	O
1760	00	O
1760	##5	O
1760	##7	O
1760	;	O
1760	r	O
1760	##r	O
1760	,	O
1760	2	O
1760	.	O
1760	0	O
1760	;	O
1760	95	O
1760	%	O
1760	c	O
1760	##i	O
1760	,	O
1760	1	O
1760	.	O
1760	3	O
1760	to	O
1760	3	O
1760	.	O
1760	0	O
1760	)	O
1760	.	O
1760	[SEP]	O
1761	[CLS]	O
1761	compared	O
1761	to	O
1761	the	O
1761	control	O
1761	group	O
1761	given	O
1761	oral	O
1761	pu	O
1761	##era	O
1761	##rin	O
1761	only	O
1761	,	O
1761	the	O
1761	combined	O
1761	use	O
1761	of	O
1761	pipe	O
1761	##rine	O
1761	(	O
1761	10	O
1761	or	O
1761	20	O
1761	mg	O
1761	/	O
1761	kg	O
1761	)	O
1761	increased	O
1761	the	O
1761	cm	B-PK
1761	##ax	I-PK
1761	of	O
1761	pu	O
1761	##era	O
1761	##rin	O
1761	by	O
1761	1	O
1761	.	O
1761	30	O
1761	-	O
1761	fold	O
1761	or	O
1761	1	O
1761	.	O
1761	64	O
1761	-	O
1761	fold	O
1761	and	O
1761	the	O
1761	au	B-PK
1761	##c	I-PK
1761	##0	I-PK
1761	–	I-PK
1761	∞	I-PK
1761	by	O
1761	133	O
1761	%	O
1761	or	O
1761	157	O
1761	%	O
1761	,	O
1761	respectively	O
1761	.	O
1761	[SEP]	O
1762	[CLS]	O
1762	the	O
1762	drug	O
1762	and	O
1762	statistics	O
1762	software	O
1762	(	O
1762	version	O
1762	3	O
1762	.	O
1762	1	O
1762	.	O
1762	5	O
1762	)	O
1762	was	O
1762	used	O
1762	to	O
1762	calculate	O
1762	the	O
1762	model	O
1762	-	O
1762	independent	O
1762	parameters	O
1762	,	O
1762	such	O
1762	as	O
1762	the	O
1762	area	B-PK
1762	under	I-PK
1762	the	I-PK
1762	plasma	I-PK
1762	concentration	I-PK
1762	-	I-PK
1762	time	I-PK
1762	curve	I-PK
1762	(	I-PK
1762	au	I-PK
1762	##c	I-PK
1762	)	I-PK
1762	,	O
1762	the	O
1762	volume	B-PK
1762	of	I-PK
1762	distribution	I-PK
1762	(	I-PK
1762	v	I-PK
1762	##d	I-PK
1762	)	I-PK
1762	,	O
1762	the	O
1762	clearance	B-PK
1762	(	I-PK
1762	c	I-PK
1762	##l	I-PK
1762	)	I-PK
1762	,	O
1762	and	O
1762	the	O
1762	half	B-PK
1762	-	I-PK
1762	life	I-PK
1762	(	I-PK
1762	t	I-PK
1762	##1	I-PK
1762	/	I-PK
1762	2	I-PK
1762	)	I-PK
1762	.	O
1762	[SEP]	O
1763	[CLS]	O
1763	other	O
1763	p	O
1763	##har	O
1763	##ma	O
1763	##co	O
1763	##kin	O
1763	##etic	O
1763	parameters	O
1763	such	O
1763	as	O
1763	c	B-PK
1763	##l	I-PK
1763	and	O
1763	t	B-PK
1763	##1	I-PK
1763	/	I-PK
1763	2	I-PK
1763	were	O
1763	not	O
1763	altered	O
1763	obviously	O
1763	.	O
1763	[SEP]	O
1764	[CLS]	O
1764	as	O
1764	is	O
1764	shown	O
1764	in	O
1764	table	O
1764	2	O
1764	,	O
1764	the	O
1764	c	B-PK
1764	##l	I-PK
1764	and	O
1764	v	B-PK
1764	##d	I-PK
1764	of	O
1764	pu	O
1764	##era	O
1764	##rin	O
1764	were	O
1764	not	O
1764	altered	O
1764	obviously	O
1764	after	O
1764	pre	O
1764	##tre	O
1764	##at	O
1764	##ment	O
1764	with	O
1764	pipe	O
1764	##rine	O
1764	.	O
1764	[SEP]	O
1765	[CLS]	O
1765	however	O
1765	,	O
1765	the	O
1765	combined	O
1765	use	O
1765	of	O
1765	white	O
1765	pepper	O
1765	(	O
1765	125	O
1765	and	O
1765	250	O
1765	mg	O
1765	/	O
1765	kg	O
1765	)	O
1765	with	O
1765	pu	O
1765	##era	O
1765	##rin	O
1765	increased	O
1765	the	O
1765	au	B-PK
1765	##c	I-PK
1765	##0	I-PK
1765	–	I-PK
1765	∞	I-PK
1765	of	O
1765	pu	O
1765	##era	O
1765	##rin	O
1765	by	O
1765	115	O
1765	%	O
1765	and	O
1765	128	O
1765	%	O
1765	(	O
1765	p	O
1765	<	O
1765	0	O
1765	.	O
1765	05	O
1765	)	O
1765	,	O
1765	respectively	O
1765	,	O
1765	as	O
1765	compared	O
1765	to	O
1765	the	O
1765	control	O
1765	group	O
1765	.	O
1765	[SEP]	O
1766	[CLS]	O
1766	the	O
1766	t	B-PK
1766	##1	I-PK
1766	/	I-PK
1766	2	I-PK
1766	of	O
1766	pu	O
1766	##era	O
1766	##rin	O
1766	was	O
1766	increased	O
1766	and	O
1766	c	B-PK
1766	##l	I-PK
1766	was	O
1766	reduced	O
1766	in	O
1766	the	O
1766	presence	O
1766	of	O
1766	white	O
1766	pepper	O
1766	,	O
1766	although	O
1766	there	O
1766	was	O
1766	no	O
1766	statistical	O
1766	significance	O
1766	(	O
1766	p	O
1766	>	O
1766	0	O
1766	.	O
1766	05	O
1766	)	O
1766	.	O
1766	[SEP]	O
1767	[CLS]	O
1767	the	O
1767	cm	B-PK
1767	##ax	I-PK
1767	and	O
1767	au	B-PK
1767	##c	I-PK
1767	in	O
1767	the	O
1767	a	O
1767	##f	O
1767	##rica	O
1767	##ns	O
1767	were	O
1767	2	O
1767	.	O
1767	67	O
1767	-	O
1767	fold	O
1767	and	O
1767	2	O
1767	.	O
1767	0	O
1767	-	O
1767	fold	O
1767	higher	O
1767	than	O
1767	the	O
1767	chin	O
1767	##ese	O
1767	,	O
1767	respectively	O
1767	.	O
1767	[SEP]	O
1768	[CLS]	O
1768	s	O
1768	##cat	O
1768	##ter	O
1768	plot	O
1768	showed	O
1768	a	O
1768	strong	O
1768	negative	O
1768	correlation	O
1768	between	O
1768	the	O
1768	micro	O
1768	##bio	O
1768	##tal	O
1768	abundance	O
1768	and	O
1768	the	O
1768	be	O
1768	##rber	O
1768	##ine	O
1768	au	B-PK
1768	##c	I-PK
1768	,	O
1768	especially	O
1768	for	O
1768	the	O
1768	genus	O
1768	pre	O
1768	##vo	O
1768	##tel	O
1768	##la	O
1768	(	O
1768	r	O
1768	=	O
1768	−	O
1768	##0	O
1768	.	O
1768	81	O
1768	##3	O
1768	)	O
1768	and	O
1768	its	O
1768	species	O
1768	.	O
1768	[SEP]	O
1769	[CLS]	O
1769	a	O
1769	more	O
1769	extensive	O
1769	metabolism	O
1769	was	O
1769	observed	O
1769	in	O
1769	chin	O
1769	##ese	O
1769	with	O
1769	1	O
1769	.	O
1769	83	O
1769	-	O
1769	fold	O
1769	higher	O
1769	meta	O
1769	##bol	O
1769	##ites	O
1769	,	O
1769	possibly	O
1769	contributing	O
1769	to	O
1769	the	O
1769	lower	O
1769	au	B-PK
1769	##c	I-PK
1769	than	O
1769	the	O
1769	a	O
1769	##f	O
1769	##rica	O
1769	##ns	O
1769	.	O
1769	[SEP]	O
1770	[CLS]	O
1770	the	O
1770	cm	B-PK
1770	##ax	I-PK
1770	were	O
1770	respectively	O
1770	0	O
1770	.	O
1770	16	O
1770	±	O
1770	0	O
1770	.	O
1770	08	O
1770	and	O
1770	0	O
1770	.	O
1770	06	O
1770	±	O
1770	0	O
1770	.	O
1770	02	O
1770	ng	O
1770	·	O
1770	m	O
1770	##l	O
1770	##−	O
1770	##1	O
1770	for	O
1770	the	O
1770	a	O
1770	##f	O
1770	##rica	O
1770	##ns	O
1770	and	O
1770	chin	O
1770	##ese	O
1770	(	O
1770	p	O
1770	=	O
1770	0	O
1770	.	O
1770	000	O
1770	##6	O
1770	)	O
1770	.	O
1770	[SEP]	O
1771	[CLS]	O
1771	significantly	O
1771	higher	O
1771	area	B-PK
1771	under	I-PK
1771	the	I-PK
1771	curve	I-PK
1771	(	I-PK
1771	au	I-PK
1771	##c	I-PK
1771	)	I-PK
1771	values	O
1771	were	O
1771	observed	O
1771	in	O
1771	the	O
1771	a	O
1771	##f	O
1771	##rica	O
1771	##ns	O
1771	(	O
1771	0	O
1771	.	O
1771	96	O
1771	±	O
1771	0	O
1771	.	O
1771	34	O
1771	ng	O
1771	·	O
1771	h	O
1771	·	O
1771	m	O
1771	##l	O
1771	##−	O
1771	##1	O
1771	)	O
1771	compared	O
1771	with	O
1771	the	O
1771	chin	O
1771	##ese	O
1771	subjects	O
1771	(	O
1771	0	O
1771	.	O
1771	47	O
1771	±	O
1771	0	O
1771	.	O
1771	13	O
1771	ng	O
1771	·	O
1771	h	O
1771	·	O
1771	m	O
1771	##l	O
1771	##−	O
1771	##1	O
1771	)	O
1771	with	O
1771	a	O
1771	p	O
1771	value	O
1771	of	O
1771	0	O
1771	.	O
1771	00	O
1771	##37	O
1771	,	O
1771	indicating	O
1771	a	O
1771	2	O
1771	.	O
1771	0	O
1771	-	O
1771	fold	O
1771	increase	O
1771	in	O
1771	the	O
1771	a	O
1771	##f	O
1771	##rica	O
1771	##ns	O
1771	(	O
1771	fi	O
1771	##g	O
1771	.	O
1771	1	O
1771	##a	O
1771	,	O
1771	b	O
1771	)	O
1771	.	O
1771	[SEP]	O
1772	[CLS]	O
1772	there	O
1772	was	O
1772	no	O
1772	significant	O
1772	difference	O
1772	in	O
1772	t	B-PK
1772	##max	I-PK
1772	between	O
1772	the	O
1772	two	O
1772	races	O
1772	,	O
1772	4	O
1772	.	O
1772	00	O
1772	±	O
1772	1	O
1772	.	O
1772	38	O
1772	h	O
1772	and	O
1772	4	O
1772	.	O
1772	00	O
1772	±	O
1772	1	O
1772	.	O
1772	34	O
1772	h	O
1772	for	O
1772	a	O
1772	##f	O
1772	##rica	O
1772	##ns	O
1772	and	O
1772	chin	O
1772	##ese	O
1772	,	O
1772	respectively	O
1772	.	O
1772	[SEP]	O
1773	[CLS]	O
1773	bacteria	O
1773	from	O
1773	two	O
1773	genera	O
1773	,	O
1773	r	O
1773	##c	O
1773	##9	O
1773	gut	O
1773	group	O
1773	(	O
1773	1	O
1773	.	O
1773	63	O
1773	%	O
1773	abundance	O
1773	)	O
1773	and	O
1773	su	O
1773	##cci	O
1773	##ni	O
1773	##vi	O
1773	##bri	O
1773	##o	O
1773	(	O
1773	1	O
1773	.	O
1773	56	O
1773	%	O
1773	abundance	O
1773	)	O
1773	were	O
1773	exclusively	O
1773	detected	O
1773	in	O
1773	the	O
1773	in	O
1773	##test	O
1773	##inal	O
1773	micro	O
1773	##bio	O
1773	##me	O
1773	of	O
1773	a	O
1773	##f	O
1773	##rica	O
1773	##ns	O
1773	.	O
1773	[SEP]	O
1774	[CLS]	O
1774	figure	O
1774	3	O
1774	presents	O
1774	a	O
1774	ho	O
1774	##listic	O
1774	representation	O
1774	of	O
1774	these	O
1774	bacteria	O
1774	genera	O
1774	in	O
1774	all	O
1774	the	O
1774	participants	O
1774	in	O
1774	relation	O
1774	to	O
1774	their	O
1774	link	O
1774	with	O
1774	the	O
1774	au	B-PK
1774	##c	I-PK
1774	of	O
1774	be	O
1774	##rber	O
1774	##ine	O
1774	.	O
1774	[SEP]	O
1775	[CLS]	O
1775	bacteria	O
1775	from	O
1775	the	O
1775	genus	O
1775	pre	O
1775	##vo	O
1775	##tel	O
1775	##la	O
1775	showed	O
1775	the	O
1775	highest	O
1775	correlation	O
1775	with	O
1775	au	B-PK
1775	##c	I-PK
1775	(	O
1775	r	O
1775	=	O
1775	−	O
1775	##0	O
1775	.	O
1775	81	O
1775	##3	O
1775	)	O
1775	while	O
1775	those	O
1775	belonging	O
1775	to	O
1775	me	O
1775	##gam	O
1775	##ona	O
1775	##s	O
1775	were	O
1775	least	O
1775	correlated	O
1775	with	O
1775	au	B-PK
1775	##c	I-PK
1775	(	O
1775	r	O
1775	=	O
1775	−	O
1775	##0	O
1775	.	O
1775	69	O
1775	##6	O
1775	)	O
1775	in	O
1775	both	O
1775	the	O
1775	a	O
1775	##f	O
1775	##rica	O
1775	##n	O
1775	and	O
1775	chin	O
1775	##ese	O
1775	groups	O
1775	.	O
1775	[SEP]	O
1776	[CLS]	O
1776	the	O
1776	negative	O
1776	correlation	O
1776	values	O
1776	sign	O
1776	##ify	O
1776	the	O
1776	existing	O
1776	inverse	O
1776	relationship	O
1776	of	O
1776	the	O
1776	bacterial	O
1776	abundance	O
1776	with	O
1776	the	O
1776	au	B-PK
1776	##c	I-PK
1776	of	O
1776	be	O
1776	##rber	O
1776	##ine	O
1776	.	O
1776	[SEP]	O
1777	[CLS]	O
1777	the	O
1777	contributions	O
1777	of	O
1777	these	O
1777	genera	O
1777	towards	O
1777	the	O
1777	metabolism	O
1777	of	O
1777	be	O
1777	##rber	O
1777	##ine	O
1777	,	O
1777	hence	O
1777	,	O
1777	its	O
1777	au	B-PK
1777	##c	I-PK
1777	in	O
1777	all	O
1777	participants	O
1777	from	O
1777	the	O
1777	results	O
1777	is	O
1777	follows	O
1777	:	O
1777	pre	O
1777	##vo	O
1777	##tel	O
1777	##la	O
1777	>	O
1777	[SEP]	O
1778	[CLS]	O
1778	the	O
1778	former	O
1778	pointed	O
1778	to	O
1778	m	O
1778	##od	O
1778	##ulation	O
1778	of	O
1778	try	O
1778	##pt	O
1778	##op	O
1778	##han	O
1778	h	O
1778	##ydro	O
1778	##xy	O
1778	##lase	O
1778	-	O
1778	1	O
1778	to	O
1778	enhance	O
1778	5	O
1778	-	O
1778	h	O
1778	##t	O
1778	synthesis	O
1778	,	O
1778	while	O
1778	the	O
1778	latter	O
1778	indicates	O
1778	an	O
1778	impact	O
1778	on	O
1778	clearance	B-PK
1778	into	O
1778	enter	O
1778	##ocytes	O
1778	through	O
1778	se	O
1778	##rt	O
1778	.	O
1778	[SEP]	O
1779	[CLS]	O
1779	taken	O
1779	together	O
1779	,	O
1779	these	O
1779	findings	O
1779	show	O
1779	e	O
1779	##c	O
1779	##n	O
1779	is	O
1779	able	O
1779	to	O
1779	enhance	O
1779	5	O
1779	-	O
1779	h	O
1779	##t	O
1779	bio	B-PK
1779	##ava	I-PK
1779	##ila	I-PK
1779	##bility	I-PK
1779	in	O
1779	il	O
1779	##eal	O
1779	tissues	O
1779	through	O
1779	interaction	O
1779	with	O
1779	compounds	O
1779	secret	O
1779	##ed	O
1779	from	O
1779	host	O
1779	tissues	O
1779	.	O
1779	[SEP]	O
1780	[CLS]	O
1780	taken	O
1780	together	O
1780	,	O
1780	the	O
1780	role	O
1780	of	O
1780	the	O
1780	se	O
1780	##rot	O
1780	##one	O
1780	##rg	O
1780	##ic	O
1780	system	O
1780	in	O
1780	both	O
1780	local	O
1780	and	O
1780	systemic	O
1780	disease	O
1780	,	O
1780	the	O
1780	g	O
1780	##i	O
1780	tract	O
1780	as	O
1780	the	O
1780	major	O
1780	site	O
1780	of	O
1780	5	O
1780	-	O
1780	h	O
1780	##t	O
1780	production	O
1780	in	O
1780	humans	O
1780	,	O
1780	and	O
1780	emerging	O
1780	evidence	O
1780	of	O
1780	gut	O
1780	micro	O
1780	##bio	O
1780	##me	O
1780	mediated	O
1780	regulation	O
1780	of	O
1780	5	O
1780	-	O
1780	h	O
1780	##t	O
1780	bio	B-PK
1780	##ava	I-PK
1780	##ila	I-PK
1780	##bility	I-PK
1780	,	O
1780	point	O
1780	to	O
1780	manipulation	O
1780	of	O
1780	se	O
1780	##rot	O
1780	##one	O
1780	##rg	O
1780	##ic	O
1780	signalling	O
1780	in	O
1780	particular	O
1780	as	O
1780	a	O
1780	prime	O
1780	target	O
1780	for	O
1780	development	O
1780	of	O
1780	pro	O
1780	##biotic	O
1780	interventions	O
1780	.	O
1780	[SEP]	O
1781	[CLS]	O
1781	however	O
1781	,	O
1781	relatively	O
1781	little	O
1781	is	O
1781	known	O
1781	regarding	O
1781	the	O
1781	impact	O
1781	of	O
1781	e	O
1781	##c	O
1781	##n	O
1781	or	O
1781	other	O
1781	species	O
1781	on	O
1781	5	O
1781	-	O
1781	h	O
1781	##t	O
1781	bio	B-PK
1781	##ava	I-PK
1781	##ila	I-PK
1781	##bility	I-PK
1781	or	O
1781	signalling	O
1781	in	O
1781	the	O
1781	g	O
1781	##i	O
1781	tract	O
1781	.	O
1781	[SEP]	O
1782	[CLS]	O
1782	although	O
1782	structural	O
1782	##ly	O
1782	and	O
1782	bio	O
1782	##chemical	O
1782	##ly	O
1782	similar	O
1782	,	O
1782	a	O
1782	major	O
1782	distinguishing	O
1782	feature	O
1782	of	O
1782	e	O
1782	##c	O
1782	##n	O
1782	and	O
1782	mg	O
1782	##16	O
1782	##55	O
1782	is	O
1782	the	O
1782	composition	O
1782	of	O
1782	the	O
1782	outer	O
1782	p	O
1782	##oly	O
1782	##sa	O
1782	##cc	O
1782	##hari	O
1782	##de	O
1782	capsule	O
1782	,	O
1782	with	O
1782	e	O
1782	##c	O
1782	##n	O
1782	generating	O
1782	a	O
1782	k	O
1782	##5	O
1782	type	O
1782	capsule	O
1782	compared	O
1782	to	O
1782	the	O
1782	mg	O
1782	##16	O
1782	##55	O
1782	k	O
1782	##12	O
1782	type	O
1782	capsule	O
1782	.	O
1782	[SEP]	O
1783	[CLS]	O
1783	recent	O
1783	studies	O
1783	have	O
1783	also	O
1783	indicated	O
1783	that	O
1783	a	O
1783	range	O
1783	of	O
1783	soluble	O
1783	meta	O
1783	##bol	O
1783	##ites	O
1783	generated	O
1783	by	O
1783	gut	O
1783	micro	O
1783	##bes	O
1783	increase	O
1783	5	O
1783	-	O
1783	h	O
1783	##t	O
1783	bio	B-PK
1783	##ava	I-PK
1783	##ila	I-PK
1783	##bility	I-PK
1783	in	O
1783	m	O
1783	##uri	O
1783	##ne	O
1783	models	O
1783	,	O
1783	and	O
1783	include	O
1783	those	O
1783	derived	O
1783	from	O
1783	the	O
1783	modification	O
1783	of	O
1783	host	O
1783	generated	O
1783	compounds	O
1783	##43	O
1783	.	O
1783	[SEP]	O
1784	[CLS]	O
1784	e	O
1784	.	O
1784	co	O
1784	##li	O
1784	ni	O
1784	##ss	O
1784	##le	O
1784	1917	O
1784	(	O
1784	e	O
1784	##c	O
1784	##n	O
1784	;	O
1784	a	O
1784	##rde	O
1784	##y	O
1784	##pha	O
1784	##rm	O
1784	g	O
1784	##mb	O
1784	##h	O
1784	,	O
1784	herd	O
1784	##eck	O
1784	##e	O
1784	,	O
1784	g	O
1784	##erman	O
1784	##y	O
1784	)	O
1784	,	O
1784	its	O
1784	k	O
1784	##5	O
1784	capsule	O
1784	mutant	O
1784	##s	O
1784	,	O
1784	[UNK]	O
1784	and	O
1784	[UNK]	O
1784	,	O
1784	and	O
1784	e	O
1784	.	O
1784	co	O
1784	##li	O
1784	k	O
1784	##12	O
1784	strain	O
1784	mg	O
1784	##16	O
1784	##55	O
1784	(	O
1784	c	O
1784	##gs	O
1784	##c	O
1784	##7	O
1784	##7	O
1784	##40	O
1784	)	O
1784	70	O
1784	were	O
1784	used	O
1784	in	O
1784	this	O
1784	study	O
1784	.	O
1784	[SEP]	O
1785	[CLS]	O
1785	the	O
1785	b	O
1785	##dd	O
1785	micro	O
1785	##ele	O
1785	##ct	O
1785	##rod	O
1785	##e	O
1785	potential	O
1785	was	O
1785	held	O
1785	over	O
1785	the	O
1785	tissue	O
1785	at	O
1785	+	O
1785	650	O
1785	m	O
1785	##v	O
1785	vs	O
1785	a	O
1785	##g	O
1785	|	O
1785	a	O
1785	##g	O
1785	##c	O
1785	##l	O
1785	which	O
1785	was	O
1785	sufficient	O
1785	to	O
1785	o	O
1785	##xi	O
1785	##di	O
1785	##ze	O
1785	se	O
1785	##rot	O
1785	##oni	O
1785	##n	O
1785	at	O
1785	a	O
1785	mass	O
1785	transfer	O
1785	limited	O
1785	rate	O
1785	##7	O
1785	##37	O
1785	##4	O
1785	.	O
1785	[SEP]	O
1786	[CLS]	O
1786	after	O
1786	der	O
1786	##iva	O
1786	##ti	O
1786	##zation	O
1786	,	O
1786	20	O
1786	μ	O
1786	##l	O
1786	of	O
1786	each	O
1786	s	O
1786	##c	O
1786	##fa	O
1786	standard	O
1786	and	O
1786	sample	O
1786	solution	O
1786	were	O
1786	injected	O
1786	onto	O
1786	a	O
1786	c	O
1786	##18	O
1786	column	O
1786	(	O
1786	fort	O
1786	##is	O
1786	150	O
1786	mm	O
1786	×	O
1786	##3	O
1786	mm	O
1786	,	O
1786	3	O
1786	μ	O
1786	##m	O
1786	;	O
1786	fort	O
1786	##is	O
1786	technologies	O
1786	l	O
1786	##t	O
1786	##d	O
1786	,	O
1786	ch	O
1786	##esh	O
1786	##ire	O
1786	,	O
1786	uk	O
1786	)	O
1786	at	O
1786	40	O
1786	°	O
1786	##c	O
1786	,	O
1786	with	O
1786	detection	O
1786	at	O
1786	λ	O
1786	=	O
1786	295	O
1786	nm	O
1786	.	O
1786	[SEP]	O
1787	[CLS]	O
1787	here	O
1787	,	O
1787	using	O
1787	stable	O
1787	,	O
1787	mon	O
1787	##os	O
1787	##ized	O
1787	,	O
1787	radio	O
1787	##la	O
1787	##bel	O
1787	##ed	O
1787	,	O
1787	me	O
1787	##so	O
1787	##por	O
1787	##ous	O
1787	si	O
1787	##lica	O
1787	na	O
1787	##no	O
1787	##par	O
1787	##tic	O
1787	##les	O
1787	(	O
1787	m	O
1787	##s	O
1787	##ns	O
1787	)	O
1787	,	O
1787	we	O
1787	apply	O
1787	an	O
1787	integrated	O
1787	s	O
1787	##pect	O
1787	/	O
1787	c	O
1787	##t	O
1787	imaging	O
1787	and	O
1787	mathematical	O
1787	modeling	O
1787	approach	O
1787	to	O
1787	understand	O
1787	the	O
1787	combined	O
1787	effects	O
1787	of	O
1787	m	O
1787	##s	O
1787	##n	O
1787	size	O
1787	,	O
1787	surface	O
1787	chemistry	O
1787	and	O
1787	routes	O
1787	of	O
1787	administration	O
1787	on	O
1787	bio	O
1787	##dis	O
1787	##tribution	O
1787	and	O
1787	clearance	B-PK
1787	kinetic	O
1787	##s	O
1787	in	O
1787	healthy	O
1787	rats	O
1787	.	O
1787	[SEP]	O
1788	[CLS]	O
1788	we	O
1788	show	O
1788	that	O
1788	increased	O
1788	particle	O
1788	size	O
1788	from	O
1788	~	O
1788	32	O
1788	-	O
1788	to	O
1788	~	O
1788	142	O
1788	-	O
1788	nm	O
1788	results	O
1788	in	O
1788	a	O
1788	mon	O
1788	##oto	O
1788	##nic	O
1788	decrease	O
1788	in	O
1788	systemic	B-PK
1788	bio	I-PK
1788	##ava	I-PK
1788	##ila	I-PK
1788	##bility	I-PK
1788	,	O
1788	i	O
1788	##rre	O
1788	##spective	O
1788	of	O
1788	route	O
1788	of	O
1788	administration	O
1788	,	O
1788	with	O
1788	corresponding	O
1788	accumulation	O
1788	in	O
1788	liver	O
1788	and	O
1788	s	O
1788	##ple	O
1788	##en	O
1788	.	O
1788	[SEP]	O
1789	[CLS]	O
1789	we	O
1789	then	O
1789	estimated	O
1789	area	B-PK
1789	under	I-PK
1789	the	I-PK
1789	curves	I-PK
1789	(	I-PK
1789	au	I-PK
1789	##c	I-PK
1789	##0	I-PK
1789	–	I-PK
1789	24	I-PK
1789	h	I-PK
1789	)	I-PK
1789	,	O
1789	up	B-PK
1789	##take	I-PK
1789	(	I-PK
1789	kin	I-PK
1789	)	I-PK
1789	and	O
1789	elimination	B-PK
1789	rate	I-PK
1789	constant	I-PK
1789	##s	I-PK
1789	(	I-PK
1789	k	I-PK
1789	##out	I-PK
1789	)	I-PK
1789	,	O
1789	and	O
1789	half	B-PK
1789	-	I-PK
1789	lives	I-PK
1789	(	I-PK
1789	t	I-PK
1789	##1	I-PK
1789	/	I-PK
1789	2	I-PK
1789	)	I-PK
1789	of	O
1789	individual	O
1789	curves	O
1789	from	O
1789	fi	O
1789	##g	O
1789	.	O
1789	4	O
1789	##a	O
1789	,	O
1789	b	O
1789	.	O
1789	[SEP]	O
1790	[CLS]	O
1790	as	O
1790	seen	O
1790	in	O
1790	fi	O
1790	##g	O
1790	.	O
1790	4	O
1790	##c	O
1790	,	O
1790	au	B-PK
1790	##c	I-PK
1790	##0	I-PK
1790	–	I-PK
1790	24	I-PK
1790	h	I-PK
1790	decreases	O
1790	mon	O
1790	##oto	O
1790	##nical	O
1790	##ly	O
1790	with	O
1790	an	O
1790	increase	O
1790	in	O
1790	particle	O
1790	size	O
1790	in	O
1790	the	O
1790	studied	O
1790	size	O
1790	range	O
1790	of	O
1790	~	O
1790	32	O
1790	to	O
1790	~	O
1790	142	O
1790	nm	O
1790	,	O
1790	i	O
1790	##rre	O
1790	##spective	O
1790	of	O
1790	the	O
1790	route	O
1790	of	O
1790	delivery	O
1790	,	O
1790	governed	O
1790	by	O
1790	the	O
1790	mathematical	O
1790	relation	O
1790	:	O
1790	au	O
1790	##c	O
1790	##0	O
1790	–	O
1790	24	O
1790	h	O
1790	=	O
1790	λ	O
1790	·	O
1790	size	O
1790	##−	O
1790	##n	O
1790	,	O
1790	where	O
1790	λ	O
1790	and	O
1790	n	O
1790	are	O
1790	fitted	O
1790	coefficients	O
1790	,	O
1790	and	O
1790	size	O
1790	refers	O
1790	to	O
1790	the	O
1790	core	O
1790	diameter	O
1790	of	O
1790	n	O
1790	##ps	O
1790	.	O
1790	[SEP]	O
1791	[CLS]	O
1791	further	O
1791	,	O
1791	the	O
1791	elimination	B-PK
1791	rate	I-PK
1791	constant	I-PK
1791	(	I-PK
1791	k	I-PK
1791	##out	I-PK
1791	)	I-PK
1791	increases	O
1791	(	O
1791	and	O
1791	thus	O
1791	t	B-PK
1791	##1	I-PK
1791	/	I-PK
1791	2	I-PK
1791	decreases	O
1791	)	O
1791	with	O
1791	an	O
1791	increase	O
1791	in	O
1791	size	O
1791	(	O
1791	see	O
1791	fi	O
1791	##g	O
1791	.	O
1791	4	O
1791	##e	O
1791	and	O
1791	table	O
1791	2	O
1791	)	O
1791	;	O
1791	however	O
1791	,	O
1791	one	O
1791	-	O
1791	way	O
1791	an	O
1791	##ova	O
1791	reveals	O
1791	no	O
1791	significant	O
1791	difference	O
1791	in	O
1791	the	O
1791	up	B-PK
1791	##take	I-PK
1791	rate	I-PK
1791	constant	I-PK
1791	(	I-PK
1791	kin	I-PK
1791	)	I-PK
1791	values	O
1791	across	O
1791	i	O
1791	.	O
1791	p	O
1791	.	O
1791	administered	O
1791	cases	O
1791	(	O
1791	p	O
1791	>	O
1791	0	O
1791	.	O
1791	05	O
1791	)	O
1791	(	O
1791	see	O
1791	fi	O
1791	##g	O
1791	.	O
1791	4	O
1791	##d	O
1791	)	O
1791	.	O
1791	[SEP]	O
1792	[CLS]	O
1792	this	O
1792	suggests	O
1792	that	O
1792	absorption	O
1792	of	O
1792	n	O
1792	##ps	O
1792	from	O
1792	per	O
1792	##ito	O
1792	##nea	O
1792	##l	O
1792	cavity	O
1792	in	O
1792	the	O
1792	studied	O
1792	size	O
1792	range	O
1792	is	O
1792	independent	O
1792	of	O
1792	particle	O
1792	size	O
1792	##37	O
1792	and	O
1792	that	O
1792	the	O
1792	systemic	B-PK
1792	bio	I-PK
1792	##ava	I-PK
1792	##ila	I-PK
1792	##bility	I-PK
1792	through	O
1792	either	O
1792	route	O
1792	of	O
1792	administration	O
1792	is	O
1792	primarily	O
1792	a	O
1792	function	O
1792	of	O
1792	the	O
1792	k	B-PK
1792	##out	I-PK
1792	parameter	O
1792	.	O
1792	[SEP]	O
1793	[CLS]	O
1793	thus	O
1793	,	O
1793	greater	O
1793	protection	O
1793	from	O
1793	the	O
1793	traps	O
1793	in	O
1793	micro	O
1793	##vas	O
1793	##cula	O
1793	##ture	O
1793	yields	O
1793	a	O
1793	higher	O
1793	systemic	B-PK
1793	bio	I-PK
1793	##ava	I-PK
1793	##ila	I-PK
1793	##bility	I-PK
1793	for	O
1793	smaller	O
1793	-	O
1793	sized	O
1793	particles	O
1793	.	O
1793	[SEP]	O
1794	[CLS]	O
1794	all	O
1794	of	O
1794	the	O
1794	above	O
1794	suggest	O
1794	that	O
1794	the	O
1794	effect	O
1794	of	O
1794	m	O
1794	##s	O
1794	##n	O
1794	p	O
1794	##hy	O
1794	##si	O
1794	##co	O
1794	##chemical	O
1794	properties	O
1794	and	O
1794	routes	O
1794	of	O
1794	administration	O
1794	on	O
1794	m	O
1794	##s	O
1794	##n	O
1794	disposition	O
1794	kinetic	O
1794	##s	O
1794	in	O
1794	source	O
1794	-	O
1794	like	O
1794	r	O
1794	##ois	O
1794	is	O
1794	similar	O
1794	to	O
1794	that	O
1794	in	O
1794	systemic	O
1794	kinetic	O
1794	##s	O
1794	.	O
1794	[SEP]	O
1795	[CLS]	O
1795	next	O
1795	looking	O
1795	at	O
1795	the	O
1795	effect	O
1795	of	O
1795	surface	O
1795	chemistry	O
1795	in	O
1795	fi	O
1795	##g	O
1795	.	O
1795	4	O
1795	##b	O
1795	,	O
1795	c	O
1795	,	O
1795	e	O
1795	and	O
1795	table	O
1795	2	O
1795	,	O
1795	p	O
1795	##ei	O
1795	##50	O
1795	(	O
1795	which	O
1795	has	O
1795	surface	O
1795	-	O
1795	exposed	O
1795	am	O
1795	##ines	O
1795	)	O
1795	has	O
1795	a	O
1795	~	O
1795	9	O
1795	-	O
1795	fold	O
1795	lesser	O
1795	au	B-PK
1795	##c	I-PK
1795	##0	I-PK
1795	–	I-PK
1795	24	I-PK
1795	h	I-PK
1795	(	O
1795	un	O
1795	##pair	O
1795	##ed	O
1795	t	O
1795	test	O
1795	,	O
1795	p	O
1795	<	O
1795	0	O
1795	.	O
1795	000	O
1795	##1	O
1795	)	O
1795	and	O
1795	half	O
1795	the	O
1795	t	B-PK
1795	##1	I-PK
1795	/	I-PK
1795	2	I-PK
1795	(	O
1795	un	O
1795	##pair	O
1795	##ed	O
1795	t	O
1795	test	O
1795	,	O
1795	p	O
1795	<	O
1795	0	O
1795	.	O
1795	05	O
1795	)	O
1795	relative	O
1795	to	O
1795	size	O
1795	-	O
1795	matched	O
1795	and	O
1795	z	O
1795	##eta	O
1795	potential	O
1795	-	O
1795	matched	O
1795	q	O
1795	##a	O
1795	##50	O
1795	(	O
1795	which	O
1795	has	O
1795	o	O
1795	##bs	O
1795	##truct	O
1795	##ed	O
1795	surface	O
1795	am	O
1795	##ines	O
1795	)	O
1795	.	O
1795	[SEP]	O
1796	[CLS]	O
1796	interesting	O
1796	##ly	O
1796	,	O
1796	we	O
1796	observed	O
1796	no	O
1796	significant	O
1796	effect	O
1796	of	O
1796	z	O
1796	##eta	O
1796	potential	O
1796	on	O
1796	the	O
1796	au	B-PK
1796	##c	I-PK
1796	##0	I-PK
1796	–	I-PK
1796	24	I-PK
1796	h	I-PK
1796	of	O
1796	size	O
1796	-	O
1796	matched	O
1796	and	O
1796	surface	O
1796	chemistry	O
1796	-	O
1796	matched	O
1796	,	O
1796	but	O
1796	differently	O
1796	charged	O
1796	t	O
1796	##ms	O
1796	##50	O
1796	and	O
1796	q	O
1796	##a	O
1796	##50	O
1796	particles	O
1796	(	O
1796	un	O
1796	##pair	O
1796	##ed	O
1796	t	O
1796	test	O
1796	,	O
1796	p	O
1796	>	O
1796	0	O
1796	.	O
1796	05	O
1796	)	O
1796	(	O
1796	see	O
1796	fi	O
1796	##g	O
1796	.	O
1796	4	O
1796	##c	O
1796	)	O
1796	,	O
1796	although	O
1796	the	O
1796	positively	O
1796	charged	O
1796	q	O
1796	##a	O
1796	##50	O
1796	has	O
1796	a	O
1796	slightly	O
1796	lesser	O
1796	k	B-PK
1796	##out	I-PK
1796	(	O
1796	hence	O
1796	slightly	O
1796	greater	O
1796	t	B-PK
1796	##1	I-PK
1796	/	I-PK
1796	2	I-PK
1796	)	O
1796	than	O
1796	neutral	O
1796	t	O
1796	##ms	O
1796	##50	O
1796	(	O
1796	un	O
1796	##pair	O
1796	##ed	O
1796	t	O
1796	test	O
1796	,	O
1796	p	O
1796	<	O
1796	0	O
1796	.	O
1796	05	O
1796	)	O
1796	(	O
1796	see	O
1796	fi	O
1796	##g	O
1796	.	O
1796	4	O
1796	##e	O
1796	and	O
1796	table	O
1796	2	O
1796	)	O
1796	.	O
1796	[SEP]	O
1797	[CLS]	O
1797	a	O
1797	change	O
1797	in	O
1797	the	O
1797	heart	O
1797	concentration	O
1797	of	O
1797	m	O
1797	##s	O
1797	##ns	O
1797	is	O
1797	reflected	O
1797	by	O
1797	a	O
1797	similar	O
1797	change	O
1797	in	O
1797	source	O
1797	-	O
1797	like	O
1797	r	O
1797	##ois	O
1797	,	O
1797	as	O
1797	is	O
1797	also	O
1797	evident	O
1797	from	O
1797	similarity	O
1797	in	O
1797	the	O
1797	k	B-PK
1797	##out	I-PK
1797	values	O
1797	of	O
1797	m	O
1797	##s	O
1797	##ns	O
1797	across	O
1797	r	O
1797	##ois	O
1797	(	O
1797	one	O
1797	-	O
1797	way	O
1797	an	O
1797	##ova	O
1797	,	O
1797	p	O
1797	>	O
1797	0	O
1797	.	O
1797	05	O
1797	)	O
1797	,	O
1797	except	O
1797	p	O
1797	##ei	O
1797	##50	O
1797	(	O
1797	one	O
1797	-	O
1797	way	O
1797	an	O
1797	##ova	O
1797	,	O
1797	p	O
1797	<	O
1797	0	O
1797	.	O
1797	05	O
1797	)	O
1797	(	O
1797	comparing	O
1797	fi	O
1797	##g	O
1797	.	O
1797	4	O
1797	##e	O
1797	and	O
1797	supplement	O
1797	##ary	O
1797	fi	O
1797	##gs	O
1797	.	O
1797	8	O
1797	##c	O
1797	,	O
1797	12	O
1797	##f	O
1797	,	O
1797	13	O
1797	##g	O
1797	,	O
1797	and	O
1797	14	O
1797	##g	O
1797	)	O
1797	.	O
1797	[SEP]	O
1798	[CLS]	O
1798	also	O
1798	,	O
1798	the	O
1798	mathematical	O
1798	relation	O
1798	au	O
1798	##c	O
1798	##0	O
1798	–	O
1798	24	O
1798	h	O
1798	=	O
1798	λ	O
1798	·	O
1798	size	O
1798	##−	O
1798	##n	O
1798	seems	O
1798	to	O
1798	hold	O
1798	true	O
1798	for	O
1798	all	O
1798	source	O
1798	-	O
1798	like	O
1798	r	O
1798	##ois	O
1798	,	O
1798	with	O
1798	values	O
1798	of	O
1798	power	O
1798	coefficient	O
1798	n	O
1798	ranging	O
1798	from	O
1798	0	O
1798	.	O
1798	5	O
1798	to	O
1798	0	O
1798	.	O
1798	9	O
1798	,	O
1798	suggesting	O
1798	a	O
1798	moderate	O
1798	to	O
1798	strongly	O
1798	negative	O
1798	linear	O
1798	dependence	O
1798	(	O
1798	fi	O
1798	##g	O
1798	.	O
1798	5	O
1798	##j	O
1798	,	O
1798	supplement	O
1798	##ary	O
1798	fi	O
1798	##gs	O
1798	.	O
1798	12	O
1798	##e	O
1798	,	O
1798	13	O
1798	##e	O
1798	,	O
1798	and	O
1798	14	O
1798	##e	O
1798	,	O
1798	and	O
1798	19	O
1798	##a	O
1798	,	O
1798	b	O
1798	,	O
1798	c	O
1798	,	O
1798	f	O
1798	)	O
1798	.	O
1798	[SEP]	O
1799	[CLS]	O
1799	m	O
1799	##s	O
1799	##n	O
1799	concentrations	O
1799	in	O
1799	these	O
1799	r	O
1799	##ois	O
1799	rise	O
1799	over	O
1799	time	O
1799	initially	O
1799	,	O
1799	followed	O
1799	by	O
1799	slow	O
1799	or	O
1799	no	O
1799	decline	O
1799	in	O
1799	concentration	O
1799	within	O
1799	24	O
1799	h	O
1799	,	O
1799	indicating	O
1799	the	O
1799	presence	O
1799	of	O
1799	traps	O
1799	causing	O
1799	m	O
1799	##s	O
1799	##n	O
1799	accumulation	O
1799	over	O
1799	time	O
1799	into	O
1799	the	O
1799	inter	O
1799	##st	O
1799	##iti	O
1799	##um	O
1799	(	O
1799	see	O
1799	fi	O
1799	##g	O
1799	.	O
1799	5	O
1799	##b	O
1799	,	O
1799	c	O
1799	,	O
1799	e	O
1799	,	O
1799	f	O
1799	and	O
1799	supplement	O
1799	##ary	O
1799	fi	O
1799	##g	O
1799	.	O
1799	11	O
1799	##a	O
1799	)	O
1799	.	O
1799	[SEP]	O
1800	[CLS]	O
1800	as	O
1800	a	O
1800	result	O
1800	in	O
1800	sink	O
1800	-	O
1800	like	O
1800	r	O
1800	##ois	O
1800	(	O
1800	fi	O
1800	##g	O
1800	.	O
1800	5	O
1800	##b	O
1800	,	O
1800	c	O
1800	,	O
1800	e	O
1800	,	O
1800	f	O
1800	and	O
1800	supplement	O
1800	##ary	O
1800	fi	O
1800	##g	O
1800	.	O
1800	11	O
1800	##a	O
1800	)	O
1800	,	O
1800	e	O
1800	##q	O
1800	.	O
1800	(	O
1800	4	O
1800	)	O
1800	or	O
1800	its	O
1800	adaptation	O
1800	,	O
1800	e	O
1800	##q	O
1800	.	O
1800	(	O
1800	5	O
1800	)	O
1800	,	O
1800	is	O
1800	fit	O
1800	to	O
1800	m	O
1800	##s	O
1800	##n	O
1800	concentration	O
1800	–	O
1800	time	O
1800	data	O
1800	(	O
1800	see	O
1800	supplement	O
1800	##ary	O
1800	tables	O
1800	4	O
1800	and	O
1800	5	O
1800	)	O
1800	.	O
1800	[SEP]	O
1801	[CLS]	O
1801	the	O
1801	mathematical	O
1801	relation	O
1801	between	O
1801	au	B-PK
1801	##c	I-PK
1801	##0	I-PK
1801	–	I-PK
1801	24	I-PK
1801	h	I-PK
1801	and	O
1801	particle	O
1801	size	O
1801	,	O
1801	au	O
1801	##c	O
1801	##0	O
1801	–	O
1801	24	O
1801	h	O
1801	=	O
1801	λ	O
1801	·	O
1801	size	O
1801	##n	O
1801	,	O
1801	is	O
1801	consistent	O
1801	across	O
1801	all	O
1801	sink	O
1801	-	O
1801	like	O
1801	r	O
1801	##ois	O
1801	with	O
1801	values	O
1801	of	O
1801	power	O
1801	coefficient	O
1801	n	O
1801	varying	O
1801	between	O
1801	0	O
1801	.	O
1801	4	O
1801	and	O
1801	1	O
1801	.	O
1801	2	O
1801	,	O
1801	suggesting	O
1801	a	O
1801	moderate	O
1801	to	O
1801	strongly	O
1801	positive	O
1801	linear	O
1801	dependence	O
1801	(	O
1801	see	O
1801	supplement	O
1801	##ary	O
1801	fi	O
1801	##g	O
1801	.	O
1801	19	O
1801	##d	O
1801	,	O
1801	g	O
1801	,	O
1801	h	O
1801	)	O
1801	.	O
1801	[SEP]	O
1802	[CLS]	O
1802	it	O
1802	is	O
1802	worth	O
1802	mentioning	O
1802	that	O
1802	t	O
1802	##ms	O
1802	##25	O
1802	(	O
1802	i	O
1802	.	O
1802	v	O
1802	.	O
1802	)	O
1802	and	O
1802	q	O
1802	##a	O
1802	##50	O
1802	(	O
1802	i	O
1802	.	O
1802	v	O
1802	.	O
1802	)	O
1802	,	O
1802	show	O
1802	a	O
1802	decline	O
1802	in	O
1802	concentration	O
1802	over	O
1802	time	O
1802	in	O
1802	the	O
1802	liver	O
1802	,	O
1802	in	O
1802	contrast	O
1802	to	O
1802	the	O
1802	other	O
1802	m	O
1802	##s	O
1802	##ns	O
1802	;	O
1802	hence	O
1802	,	O
1802	the	O
1802	mon	O
1802	##o	O
1802	-	O
1802	ex	O
1802	##po	O
1802	##nent	O
1802	##ial	O
1802	e	O
1802	##q	O
1802	.	O
1802	(	O
1802	6	O
1802	)	O
1802	was	O
1802	fit	O
1802	to	O
1802	their	O
1802	concentration	O
1802	–	O
1802	time	O
1802	course	O
1802	(	O
1802	fi	O
1802	##g	O
1802	.	O
1802	5	O
1802	##b	O
1802	,	O
1802	e	O
1802	)	O
1802	.	O
1802	[SEP]	O
1803	[CLS]	O
1803	this	O
1803	observation	O
1803	def	O
1803	##ies	O
1803	the	O
1803	often	O
1803	-	O
1803	quoted	O
1803	re	B-PK
1803	##nal	I-PK
1803	clearance	I-PK
1803	cut	O
1803	##off	O
1803	of	O
1803	~	O
1803	5	O
1803	.	O
1803	5	O
1803	nm	O
1803	##5	O
1803	.	O
1803	[SEP]	O
1804	[CLS]	O
1804	due	O
1804	to	O
1804	loss	O
1804	of	O
1804	activity	O
1804	from	O
1804	the	O
1804	bladder	O
1804	via	O
1804	u	O
1804	##rina	O
1804	##tion	O
1804	,	O
1804	the	O
1804	activity	O
1804	detected	O
1804	in	O
1804	the	O
1804	bladder	O
1804	at	O
1804	a	O
1804	given	O
1804	time	O
1804	point	O
1804	(	O
1804	fi	O
1804	##g	O
1804	.	O
1804	6	O
1804	##b	O
1804	,	O
1804	e	O
1804	)	O
1804	is	O
1804	not	O
1804	equivalent	O
1804	to	O
1804	the	O
1804	cumulative	O
1804	amount	O
1804	of	O
1804	re	O
1804	##nal	O
1804	ex	O
1804	##cre	O
1804	##tion	O
1804	.	O
1804	[SEP]	O
1805	[CLS]	O
1805	to	O
1805	enable	O
1805	detection	O
1805	by	O
1805	s	O
1805	##pect	O
1805	,	O
1805	mon	O
1805	##od	O
1805	##is	O
1805	##pers	O
1805	##e	O
1805	m	O
1805	##s	O
1805	##ns	O
1805	were	O
1805	co	O
1805	##valent	O
1805	##ly	O
1805	coupled	O
1805	to	O
1805	d	O
1805	##t	O
1805	##pa	O
1805	through	O
1805	is	O
1805	##oth	O
1805	##io	O
1805	##cy	O
1805	##ana	O
1805	##te	O
1805	and	O
1805	am	O
1805	##ine	O
1805	reactions	O
1805	to	O
1805	enable	O
1805	binding	O
1805	of	O
1805	111	O
1805	##in	O
1805	,	O
1805	a	O
1805	gamma	O
1805	-	O
1805	em	O
1805	##itting	O
1805	radio	O
1805	##is	O
1805	##oto	O
1805	##pe	O
1805	with	O
1805	a	O
1805	radioactive	O
1805	half	B-PK
1805	-	I-PK
1805	life	I-PK
1805	of	O
1805	2	O
1805	.	O
1805	8	O
1805	days	O
1805	##5	O
1805	##6	O
1805	.	O
1805	[SEP]	O
1806	[CLS]	O
1806	based	O
1806	on	O
1806	the	O
1806	nature	O
1806	of	O
1806	concentration	O
1806	–	O
1806	time	O
1806	curves	O
1806	of	O
1806	m	O
1806	##s	O
1806	##ns	O
1806	in	O
1806	the	O
1806	heart	O
1806	,	O
1806	we	O
1806	applied	O
1806	a	O
1806	one	O
1806	-	O
1806	compartment	O
1806	p	O
1806	##k	O
1806	model	O
1806	##36	O
1806	(	O
1806	same	O
1806	as	O
1806	e	O
1806	##q	O
1806	.	O
1806	(	O
1806	6	O
1806	)	O
1806	for	O
1806	i	O
1806	.	O
1806	v	O
1806	.	O
1806	delivery	O
1806	,	O
1806	and	O
1806	e	O
1806	##q	O
1806	.	O
1806	(	O
1806	4	O
1806	)	O
1806	for	O
1806	i	O
1806	.	O
1806	p	O
1806	.	O
1806	delivery	O
1806	)	O
1806	,	O
1806	and	O
1806	determined	O
1806	p	O
1806	##k	O
1806	parameters	O
1806	:	O
1806	(	O
1806	i	O
1806	)	O
1806	au	B-PK
1806	##c	I-PK
1806	from	I-PK
1806	0	I-PK
1806	to	I-PK
1806	24	I-PK
1806	h	I-PK
1806	(	I-PK
1806	au	I-PK
1806	##c	I-PK
1806	##0	I-PK
1806	–	I-PK
1806	24	I-PK
1806	h	I-PK
1806	)	I-PK
1806	,	O
1806	(	O
1806	ii	O
1806	)	O
1806	up	B-PK
1806	##take	I-PK
1806	rate	I-PK
1806	constant	I-PK
1806	(	I-PK
1806	kin	I-PK
1806	)	I-PK
1806	,	O
1806	(	O
1806	ii	O
1806	##i	O
1806	)	O
1806	elimination	B-PK
1806	rate	I-PK
1806	constant	I-PK
1806	(	I-PK
1806	k	I-PK
1806	##out	I-PK
1806	)	I-PK
1806	,	O
1806	and	O
1806	(	O
1806	i	O
1806	##v	O
1806	)	O
1806	half	B-PK
1806	-	I-PK
1806	life	I-PK
1806	(	I-PK
1806	t	I-PK
1806	##1	I-PK
1806	/	I-PK
1806	2	I-PK
1806	)	I-PK
1806	.	O
1806	[SEP]	O
1807	[CLS]	O
1807	au	B-PK
1807	##c	I-PK
1807	##0	I-PK
1807	–	I-PK
1807	24	I-PK
1807	h	I-PK
1807	represents	O
1807	the	O
1807	systemic	B-PK
1807	bio	I-PK
1807	##ava	I-PK
1807	##ila	I-PK
1807	##bility	I-PK
1807	of	O
1807	n	O
1807	##ps	O
1807	and	O
1807	is	O
1807	the	O
1807	definite	O
1807	integral	O
1807	of	O
1807	n	O
1807	##p	O
1807	concentration	O
1807	–	O
1807	time	O
1807	in	O
1807	plasma	O
1807	(	O
1807	heart	O
1807	,	O
1807	in	O
1807	this	O
1807	study	O
1807	)	O
1807	,	O
1807	determined	O
1807	analytical	O
1807	##ly	O
1807	.	O
1807	[SEP]	O
1808	[CLS]	O
1808	k	B-PK
1808	##out	I-PK
1808	is	O
1808	the	O
1808	slope	O
1808	of	O
1808	the	O
1808	curve	O
1808	on	O
1808	a	O
1808	semi	O
1808	-	O
1808	log	O
1808	plot	O
1808	between	O
1808	ch	O
1808	##ear	O
1808	##t	O
1808	and	O
1808	t	O
1808	,	O
1808	and	O
1808	represents	O
1808	the	O
1808	fraction	O
1808	of	O
1808	n	O
1808	##ps	O
1808	eliminated	O
1808	from	O
1808	plasma	O
1808	per	O
1808	unit	O
1808	time	O
1808	.	O
1808	[SEP]	O
1809	[CLS]	O
1809	the	O
1809	p	O
1809	##har	O
1809	##ma	O
1809	##co	O
1809	##kin	O
1809	##etics	O
1809	parameters	O
1809	including	O
1809	cm	B-PK
1809	##ax	I-PK
1809	,	O
1809	t	B-PK
1809	##max	I-PK
1809	,	O
1809	and	O
1809	au	B-PK
1809	##c	I-PK
1809	were	O
1809	determined	O
1809	for	O
1809	r	O
1809	##is	O
1809	##per	O
1809	##ido	O
1809	##ne	O
1809	and	O
1809	its	O
1809	active	O
1809	ingredient	O
1809	.	O
1809	[SEP]	O
1810	[CLS]	O
1810	the	O
1810	p	O
1810	##har	O
1810	##ma	O
1810	##co	O
1810	##kin	O
1810	##etics	O
1810	parameters	O
1810	(	O
1810	cm	B-PK
1810	##ax	I-PK
1810	,	O
1810	t	B-PK
1810	##max	I-PK
1810	,	O
1810	au	B-PK
1810	##c	I-PK
1810	##0	I-PK
1810	–	I-PK
1810	48	I-PK
1810	,	O
1810	and	O
1810	au	B-PK
1810	##c	I-PK
1810	##0	I-PK
1810	-	I-PK
1810	in	I-PK
1810	##f	I-PK
1810	)	O
1810	were	O
1810	calculated	O
1810	.	O
1810	[SEP]	O
1811	[CLS]	O
1811	for	O
1811	r	O
1811	##is	O
1811	##per	O
1811	##ido	O
1811	##ne	O
1811	,	O
1811	comparison	O
1811	of	O
1811	au	B-PK
1811	##c	I-PK
1811	##0	I-PK
1811	–	I-PK
1811	48	I-PK
1811	,	O
1811	au	B-PK
1811	##c	I-PK
1811	##0	I-PK
1811	-	I-PK
1811	in	I-PK
1811	##f	I-PK
1811	values	O
1811	across	O
1811	dose	O
1811	levels	O
1811	demonstrated	O
1811	linear	O
1811	##ity	O
1811	in	O
1811	the	O
1811	dose	O
1811	response	O
1811	for	O
1811	the	O
1811	parent	O
1811	drug	O
1811	,	O
1811	r	O
1811	##is	O
1811	##per	O
1811	##ido	O
1811	##ne	O
1811	,	O
1811	in	O
1811	low	O
1811	and	O
1811	middle	O
1811	doses	O
1811	.	O
1811	[SEP]	O
1812	[CLS]	O
1812	au	B-PK
1812	##c	I-PK
1812	##0	I-PK
1812	–	I-PK
1812	48	I-PK
1812	increased	O
1812	from	O
1812	101	O
1812	.	O
1812	81	O
1812	±	O
1812	8	O
1812	.	O
1812	5	O
1812	to	O
1812	1914	O
1812	.	O
1812	83	O
1812	±	O
1812	49	O
1812	.	O
1812	6	O
1812	(	O
1812	18	O
1812	.	O
1812	8	O
1812	-	O
1812	fold	O
1812	)	O
1812	and	O
1812	from	O
1812	126	O
1812	.	O
1812	01	O
1812	±	O
1812	12	O
1812	.	O
1812	2	O
1812	to	O
1812	30	O
1812	##9	O
1812	##4	O
1812	.	O
1812	49	O
1812	±	O
1812	360	O
1812	.	O
1812	4	O
1812	(	O
1812	24	O
1812	.	O
1812	5	O
1812	-	O
1812	fold	O
1812	)	O
1812	for	O
1812	au	B-PK
1812	##c	I-PK
1812	##0	I-PK
1812	-	I-PK
1812	in	I-PK
1812	##f	I-PK
1812	.	O
1812	[SEP]	O
1813	[CLS]	O
1813	difference	O
1813	in	O
1813	dose	O
1813	-	O
1813	dependent	O
1813	p	O
1813	##har	O
1813	##ma	O
1813	##co	O
1813	##kin	O
1813	##etic	O
1813	studies	O
1813	was	O
1813	also	O
1813	observed	O
1813	in	O
1813	cm	B-PK
1813	##ax	I-PK
1813	.	O
1813	[SEP]	O
1814	[CLS]	O
1814	for	O
1814	r	O
1814	##is	O
1814	##per	O
1814	##ido	O
1814	##ne	O
1814	meta	O
1814	##bol	O
1814	##ite	O
1814	,	O
1814	9	O
1814	-	O
1814	h	O
1814	##ydro	O
1814	##xy	O
1814	##ris	O
1814	##per	O
1814	##ido	O
1814	##ne	O
1814	,	O
1814	the	O
1814	values	O
1814	of	O
1814	au	B-PK
1814	##c	I-PK
1814	##0	I-PK
1814	–	I-PK
1814	48	I-PK
1814	and	O
1814	au	B-PK
1814	##c	I-PK
1814	##0	I-PK
1814	-	I-PK
1814	in	I-PK
1814	##f	I-PK
1814	increased	O
1814	by	O
1814	1	O
1814	.	O
1814	2	O
1814	-	O
1814	fold	O
1814	and	O
1814	0	O
1814	.	O
1814	95	O
1814	-	O
1814	fold	O
1814	,	O
1814	respectively	O
1814	,	O
1814	following	O
1814	increase	O
1814	in	O
1814	the	O
1814	doses	O
1814	from	O
1814	0	O
1814	.	O
1814	30	O
1814	to	O
1814	1	O
1814	.	O
1814	0	O
1814	mg	O
1814	/	O
1814	kg	O
1814	(	O
1814	3	O
1814	.	O
1814	3	O
1814	-	O
1814	fold	O
1814	)	O
1814	.	O
1814	[SEP]	O
1815	[CLS]	O
1815	after	O
1815	increase	O
1815	of	O
1815	the	O
1815	dose	O
1815	from	O
1815	1	O
1815	.	O
1815	0	O
1815	to	O
1815	6	O
1815	.	O
1815	0	O
1815	mg	O
1815	/	O
1815	kg	O
1815	(	O
1815	6	O
1815	-	O
1815	fold	O
1815	)	O
1815	,	O
1815	the	O
1815	value	O
1815	au	B-PK
1815	##c	I-PK
1815	##0	I-PK
1815	–	I-PK
1815	48	I-PK
1815	and	O
1815	au	B-PK
1815	##c	I-PK
1815	##0	I-PK
1815	-	I-PK
1815	in	I-PK
1815	##f	I-PK
1815	increased	O
1815	by	O
1815	1	O
1815	.	O
1815	25	O
1815	-	O
1815	fold	O
1815	and	O
1815	1	O
1815	.	O
1815	85	O
1815	-	O
1815	fold	O
1815	,	O
1815	respectively	O
1815	.	O
1815	[SEP]	O
1816	[CLS]	O
1816	cm	B-PK
1816	##ax	I-PK
1816	increased	O
1816	for	O
1816	about	O
1816	2	O
1816	-	O
1816	fold	O
1816	following	O
1816	increasing	O
1816	doses	O
1816	from	O
1816	0	O
1816	.	O
1816	3	O
1816	to	O
1816	1	O
1816	.	O
1816	0	O
1816	mg	O
1816	/	O
1816	kg	O
1816	(	O
1816	3	O
1816	fold	O
1816	)	O
1816	,	O
1816	while	O
1816	ins	O
1816	##ign	O
1816	##ificant	O
1816	##ly	O
1816	increased	O
1816	following	O
1816	raising	O
1816	doses	O
1816	from	O
1816	1	O
1816	.	O
1816	0	O
1816	to	O
1816	6	O
1816	.	O
1816	0	O
1816	mg	O
1816	/	O
1816	kg	O
1816	.	O
1816	[SEP]	O
1817	[CLS]	O
1817	there	O
1817	were	O
1817	no	O
1817	significant	O
1817	differences	O
1817	in	O
1817	r	O
1817	##os	O
1817	##c	O
1817	,	O
1817	maximum	B-PK
1817	concentration	I-PK
1817	;	O
1817	except	O
1817	at	O
1817	30	O
1817	s	O
1817	,	O
1817	and	O
1817	time	B-PK
1817	-	I-PK
1817	to	I-PK
1817	-	I-PK
1817	concentration	I-PK
1817	-	I-PK
1817	maximum	I-PK
1817	between	O
1817	the	O
1817	hi	O
1817	##o	O
1817	and	O
1817	i	O
1817	##v	O
1817	groups	O
1817	.	O
1817	[SEP]	O
1818	[CLS]	O
1818	•	O
1818	no	O
1818	difference	O
1818	in	O
1818	concentration	B-PK
1818	maximum	I-PK
1818	(	I-PK
1818	cm	I-PK
1818	##ax	I-PK
1818	)	I-PK
1818	and	O
1818	time	B-PK
1818	to	I-PK
1818	maximum	I-PK
1818	concentration	I-PK
1818	(	I-PK
1818	t	I-PK
1818	##max	I-PK
1818	)	I-PK
1818	in	O
1818	e	O
1818	##pine	O
1818	##ph	O
1818	##rine	O
1818	between	O
1818	hum	O
1818	##eral	O
1818	in	O
1818	##tra	O
1818	##oss	O
1818	##eous	O
1818	and	O
1818	in	O
1818	##tra	O
1818	##ven	O
1818	##ous	O
1818	routes	O
1818	of	O
1818	administration	O
1818	over	O
1818	time	O
1818	.	O
1818	•	O
1818	hum	O
1818	##eral	O
1818	in	O
1818	##tra	O
1818	##oss	O
1818	##eous	O
1818	delivers	O
1818	higher	O
1818	concentration	O
1818	than	O
1818	in	O
1818	##tra	O
1818	##ven	O
1818	##ous	O
1818	at	O
1818	30	O
1818	s	O
1818	after	O
1818	administration	O
1818	of	O
1818	e	O
1818	##pine	O
1818	##ph	O
1818	##rine	O
1818	.	O
1818	•	O
1818	hum	O
1818	##eral	O
1818	in	O
1818	##tra	O
1818	##oss	O
1818	##eous	O
1818	facilitate	O
1818	##s	O
1818	rapid	O
1818	delivery	O
1818	of	O
1818	e	O
1818	##pine	O
1818	##ph	O
1818	##rine	O
1818	during	O
1818	cardiac	O
1818	arrest	O
1818	.	O
1818	•	O
1818	use	O
1818	of	O
1818	hum	O
1818	##eral	O
1818	in	O
1818	##tra	O
1818	##oss	O
1818	##eous	O
1818	had	O
1818	higher	O
1818	number	O
1818	of	O
1818	subjects	O
1818	survived	O
1818	.	O
1818	[SEP]	O
1819	[CLS]	O
1819	no	O
1819	difference	O
1819	in	O
1819	concentration	B-PK
1819	maximum	I-PK
1819	(	I-PK
1819	cm	I-PK
1819	##ax	I-PK
1819	)	I-PK
1819	and	O
1819	time	B-PK
1819	to	I-PK
1819	maximum	I-PK
1819	concentration	I-PK
1819	(	I-PK
1819	t	I-PK
1819	##max	I-PK
1819	)	I-PK
1819	in	O
1819	e	O
1819	##pine	O
1819	##ph	O
1819	##rine	O
1819	between	O
1819	hum	O
1819	##eral	O
1819	in	O
1819	##tra	O
1819	##oss	O
1819	##eous	O
1819	and	O
1819	in	O
1819	##tra	O
1819	##ven	O
1819	##ous	O
1819	routes	O
1819	of	O
1819	administration	O
1819	over	O
1819	time	O
1819	.	O
1819	[SEP]	O
1820	[CLS]	O
1820	are	O
1820	there	O
1820	statistical	O
1820	##ly	O
1820	significant	O
1820	differences	O
1820	in	O
1820	cm	B-PK
1820	##ax	I-PK
1820	and	O
1820	t	B-PK
1820	##max	I-PK
1820	of	O
1820	e	O
1820	##pine	O
1820	##ph	O
1820	##rine	O
1820	between	O
1820	the	O
1820	hum	O
1820	##eral	O
1820	i	O
1820	##o	O
1820	,	O
1820	i	O
1820	##v	O
1820	,	O
1820	and	O
1820	control	O
1820	groups	O
1820	?	O
1820	[SEP]	O
1821	[CLS]	O
1821	the	O
1821	concentration	O
1821	is	O
1821	reported	O
1821	in	O
1821	ng	O
1821	per	O
1821	m	O
1821	##l	O
1821	.	O
1821	to	O
1821	evaluate	O
1821	potential	O
1821	differences	O
1821	in	O
1821	cm	B-PK
1821	##ax	I-PK
1821	by	O
1821	group	O
1821	(	O
1821	hi	O
1821	##o	O
1821	vs	O
1821	.	O
1821	i	O
1821	##v	O
1821	)	O
1821	,	O
1821	we	O
1821	ran	O
1821	w	O
1821	##il	O
1821	##co	O
1821	##xon	O
1821	signed	O
1821	ranks	O
1821	.	O
1821	[SEP]	O
1822	[CLS]	O
1822	the	O
1822	results	O
1822	were	O
1822	not	O
1822	statistical	O
1822	##ly	O
1822	significant	O
1822	(	O
1822	w	O
1822	=	O
1822	31	O
1822	.	O
1822	00	O
1822	,	O
1822	p	O
1822	=	O
1822	.	O
1822	45	O
1822	##5	O
1822	##7	O
1822	)	O
1822	(	O
1822	see	O
1822	fi	O
1822	##g	O
1822	.	O
1822	1	O
1822	for	O
1822	a	O
1822	side	O
1822	-	O
1822	by	O
1822	-	O
1822	side	O
1822	box	O
1822	##p	O
1822	##lot	O
1822	of	O
1822	cm	B-PK
1822	##ax	I-PK
1822	by	O
1822	group	O
1822	)	O
1822	.	O
1822	[SEP]	O
1823	[CLS]	O
1823	we	O
1823	performed	O
1823	this	O
1823	same	O
1823	analysis	O
1823	for	O
1823	t	B-PK
1823	##max	I-PK
1823	.	O
1823	[SEP]	O
1824	[CLS]	O
1824	the	O
1824	w	O
1824	##il	O
1824	##co	O
1824	##xon	O
1824	signed	O
1824	ranks	O
1824	test	O
1824	approaches	O
1824	significance	O
1824	(	O
1824	w	O
1824	=	O
1824	10	O
1824	.	O
1824	50	O
1824	,	O
1824	p	O
1824	=	O
1824	.	O
1824	06	O
1824	##2	O
1824	)	O
1824	(	O
1824	see	O
1824	fi	O
1824	##g	O
1824	.	O
1824	2	O
1824	is	O
1824	the	O
1824	side	O
1824	-	O
1824	by	O
1824	-	O
1824	side	O
1824	box	O
1824	##p	O
1824	##lot	O
1824	##s	O
1824	in	O
1824	maximum	O
1824	concentration	O
1824	in	O
1824	seconds	O
1824	)	O
1824	.	O
1824	[SEP]	O
1825	[CLS]	O
1825	no	O
1825	clinical	O
1825	##ly	O
1825	relevant	O
1825	increases	O
1825	in	O
1825	plasma	O
1825	um	O
1825	##ec	O
1825	##lid	O
1825	##ini	O
1825	##um	O
1825	or	O
1825	v	O
1825	##ila	O
1825	##nter	O
1825	##ol	O
1825	systemic	O
1825	exposure	O
1825	(	O
1825	area	B-PK
1825	under	I-PK
1825	the	I-PK
1825	curve	I-PK
1825	or	I-PK
1825	maximum	I-PK
1825	observed	I-PK
1825	plasma	I-PK
1825	concentration	I-PK
1825	)	O
1825	were	O
1825	observed	O
1825	following	O
1825	um	O
1825	##ec	O
1825	##lid	O
1825	##ini	O
1825	##um	O
1825	125	O
1825	μ	O
1825	##g	O
1825	or	O
1825	um	O
1825	##ec	O
1825	##lid	O
1825	##ini	O
1825	##um	O
1825	/	O
1825	v	O
1825	##ila	O
1825	##nter	O
1825	##ol	O
1825	125	O
1825	/	O
1825	25	O
1825	μ	O
1825	##g	O
1825	administration	O
1825	.	O
1825	[SEP]	O
1826	[CLS]	O
1826	the	O
1826	primary	O
1826	end	O
1826	##points	O
1826	were	O
1826	um	O
1826	##ec	O
1826	##lid	O
1826	##ini	O
1826	##um	O
1826	and	O
1826	v	O
1826	##ila	O
1826	##nter	O
1826	##ol	O
1826	plasma	O
1826	p	O
1826	##k	O
1826	parameters	O
1826	:	O
1826	area	B-PK
1826	under	I-PK
1826	the	I-PK
1826	curve	I-PK
1826	(	I-PK
1826	au	I-PK
1826	##c	I-PK
1826	)	I-PK
1826	(	I-PK
1826	0	I-PK
1826	–	I-PK
1826	0	I-PK
1826	.	I-PK
1826	25	I-PK
1826	##h	I-PK
1826	)	I-PK
1826	,	O
1826	au	B-PK
1826	##c	I-PK
1826	(	I-PK
1826	0	I-PK
1826	–	I-PK
1826	2	I-PK
1826	##h	I-PK
1826	)	I-PK
1826	,	O
1826	maximum	B-PK
1826	observed	I-PK
1826	plasma	I-PK
1826	concentration	I-PK
1826	(	I-PK
1826	cm	I-PK
1826	##ax	I-PK
1826	)	I-PK
1826	,	O
1826	time	B-PK
1826	to	I-PK
1826	cm	I-PK
1826	##ax	I-PK
1826	(	I-PK
1826	t	I-PK
1826	##max	I-PK
1826	)	I-PK
1826	,	O
1826	au	B-PK
1826	##c	I-PK
1826	(	I-PK
1826	0	I-PK
1826	–	I-PK
1826	24	I-PK
1826	##h	I-PK
1826	)	I-PK
1826	,	O
1826	au	B-PK
1826	##c	I-PK
1826	(	I-PK
1826	0	I-PK
1826	–	I-PK
1826	∞	I-PK
1826	)	I-PK
1826	,	O
1826	time	B-PK
1826	to	I-PK
1826	last	I-PK
1826	q	I-PK
1826	##uant	I-PK
1826	##ifiable	I-PK
1826	concentration	I-PK
1826	(	I-PK
1826	t	I-PK
1826	##last	I-PK
1826	)	I-PK
1826	,	O
1826	terminal	B-PK
1826	phase	I-PK
1826	half	I-PK
1826	-	I-PK
1826	life	I-PK
1826	(	I-PK
1826	t	I-PK
1826	##1	I-PK
1826	/	I-PK
1826	2	I-PK
1826	)	I-PK
1826	,	O
1826	and	O
1826	other	O
1826	p	O
1826	##k	O
1826	parameters	O
1826	as	O
1826	data	O
1826	permitted	O
1826	.	O
1826	[SEP]	O
1827	[CLS]	O
1827	the	O
1827	p	O
1827	##k	O
1827	parameters	O
1827	of	O
1827	au	B-PK
1827	##c	I-PK
1827	,	O
1827	cm	B-PK
1827	##ax	I-PK
1827	,	O
1827	and	O
1827	a	B-PK
1827	##e	I-PK
1827	(	I-PK
1827	0	I-PK
1827	–	I-PK
1827	24	I-PK
1827	##h	I-PK
1827	)	I-PK
1827	of	O
1827	um	O
1827	##ec	O
1827	##lid	O
1827	##ini	O
1827	##um	O
1827	and	O
1827	v	O
1827	##ila	O
1827	##nter	O
1827	##ol	O
1827	were	O
1827	log	O
1827	##e	O
1827	transformed	O
1827	and	O
1827	were	O
1827	analyzed	O
1827	separately	O
1827	.	O
1827	[SEP]	O
1828	[CLS]	O
1828	the	O
1828	au	B-PK
1828	##c	I-PK
1828	(	I-PK
1828	0	I-PK
1828	–	I-PK
1828	∞	I-PK
1828	)	I-PK
1828	and	O
1828	au	B-PK
1828	##c	I-PK
1828	(	I-PK
1828	0	I-PK
1828	–	I-PK
1828	24	I-PK
1828	##h	I-PK
1828	)	I-PK
1828	were	O
1828	non	O
1828	-	O
1828	ca	O
1828	##l	O
1828	##cula	O
1828	##ble	O
1828	due	O
1828	to	O
1828	non	O
1828	##qua	O
1828	##nti	O
1828	##fia	O
1828	##ble	O
1828	(	O
1828	n	O
1828	##q	O
1828	)	O
1828	plasma	O
1828	concentrations	O
1828	in	O
1828	the	O
1828	terminal	O
1828	phase	O
1828	;	O
1828	therefore	O
1828	,	O
1828	au	B-PK
1828	##c	I-PK
1828	(	I-PK
1828	0	I-PK
1828	–	I-PK
1828	0	I-PK
1828	.	I-PK
1828	25	I-PK
1828	##h	I-PK
1828	)	I-PK
1828	and	O
1828	au	B-PK
1828	##c	I-PK
1828	(	I-PK
1828	0	I-PK
1828	–	I-PK
1828	2	I-PK
1828	##h	I-PK
1828	)	I-PK
1828	for	O
1828	um	O
1828	##ec	O
1828	##lid	O
1828	##ini	O
1828	##um	O
1828	,	O
1828	and	O
1828	au	B-PK
1828	##c	I-PK
1828	(	I-PK
1828	0	I-PK
1828	–	I-PK
1828	0	I-PK
1828	.	I-PK
1828	25	I-PK
1828	##h	I-PK
1828	)	I-PK
1828	and	O
1828	au	B-PK
1828	##c	I-PK
1828	(	I-PK
1828	0	I-PK
1828	–	I-PK
1828	1	I-PK
1828	##h	I-PK
1828	)	I-PK
1828	for	O
1828	v	O
1828	##ila	O
1828	##nter	O
1828	##ol	O
1828	were	O
1828	derived	O
1828	and	O
1828	statistical	O
1828	##ly	O
1828	analyzed	O
1828	.	O
1828	[SEP]	O
1829	[CLS]	O
1829	um	O
1829	##ec	O
1829	##lid	O
1829	##ini	O
1829	##um	O
1829	was	O
1829	rapidly	O
1829	absorbed	O
1829	with	O
1829	median	O
1829	t	B-PK
1829	##max	I-PK
1829	of	O
1829	approximately	O
1829	5	O
1829	minutes	O
1829	post	O
1829	##dos	O
1829	##e	O
1829	.	O
1829	[SEP]	O
1830	[CLS]	O
1830	following	O
1830	administration	O
1830	of	O
1830	um	O
1830	##ec	O
1830	##lid	O
1830	##ini	O
1830	##um	O
1830	125	O
1830	μ	O
1830	##g	O
1830	or	O
1830	um	O
1830	##ec	O
1830	##lid	O
1830	##ini	O
1830	##um	O
1830	/	O
1830	v	O
1830	##ila	O
1830	##nter	O
1830	##ol	O
1830	125	O
1830	/	O
1830	25	O
1830	μ	O
1830	##g	O
1830	,	O
1830	there	O
1830	was	O
1830	no	O
1830	evidence	O
1830	of	O
1830	a	O
1830	clinical	O
1830	##ly	O
1830	relevant	O
1830	increase	O
1830	in	O
1830	um	O
1830	##ec	O
1830	##lid	O
1830	##ini	O
1830	##um	O
1830	plasma	O
1830	exposure	O
1830	,	O
1830	in	O
1830	terms	O
1830	of	O
1830	au	B-PK
1830	##c	I-PK
1830	(	I-PK
1830	0	I-PK
1830	–	I-PK
1830	2	I-PK
1830	##h	I-PK
1830	)	I-PK
1830	or	O
1830	cm	B-PK
1830	##ax	I-PK
1830	,	O
1830	for	O
1830	patients	O
1830	with	O
1830	severe	O
1830	re	O
1830	##nal	O
1830	imp	O
1830	##air	O
1830	##ment	O
1830	compared	O
1830	with	O
1830	healthy	O
1830	volunteers	O
1830	.	O
1830	[SEP]	O
1831	[CLS]	O
1831	for	O
1831	au	B-PK
1831	##c	I-PK
1831	(	I-PK
1831	0	I-PK
1831	–	I-PK
1831	2	I-PK
1831	##h	I-PK
1831	)	I-PK
1831	,	O
1831	there	O
1831	was	O
1831	an	O
1831	average	O
1831	10	O
1831	%	O
1831	decrease	O
1831	,	O
1831	with	O
1831	the	O
1831	true	O
1831	mean	O
1831	difference	O
1831	likely	O
1831	to	O
1831	be	O
1831	between	O
1831	36	O
1831	%	O
1831	lower	O
1831	and	O
1831	26	O
1831	%	O
1831	higher	O
1831	in	O
1831	patients	O
1831	with	O
1831	severe	O
1831	re	O
1831	##nal	O
1831	imp	O
1831	##air	O
1831	##ment	O
1831	compared	O
1831	with	O
1831	healthy	O
1831	volunteers	O
1831	following	O
1831	um	O
1831	##ec	O
1831	##lid	O
1831	##ini	O
1831	##um	O
1831	125	O
1831	μ	O
1831	##g	O
1831	administration	O
1831	.	O
1831	[SEP]	O
1832	[CLS]	O
1832	for	O
1832	cm	B-PK
1832	##ax	I-PK
1832	,	O
1832	there	O
1832	was	O
1832	an	O
1832	average	O
1832	11	O
1832	%	O
1832	decrease	O
1832	,	O
1832	with	O
1832	the	O
1832	true	O
1832	mean	O
1832	difference	O
1832	likely	O
1832	to	O
1832	be	O
1832	between	O
1832	42	O
1832	%	O
1832	lower	O
1832	and	O
1832	35	O
1832	%	O
1832	higher	O
1832	in	O
1832	patients	O
1832	with	O
1832	severe	O
1832	re	O
1832	##nal	O
1832	imp	O
1832	##air	O
1832	##ment	O
1832	compared	O
1832	with	O
1832	healthy	O
1832	volunteers	O
1832	following	O
1832	um	O
1832	##ec	O
1832	##lid	O
1832	##ini	O
1832	##um	O
1832	125	O
1832	μ	O
1832	##g	O
1832	administration	O
1832	.	O
1832	[SEP]	O
1833	[CLS]	O
1833	on	O
1833	average	O
1833	,	O
1833	um	O
1833	##ec	O
1833	##lid	O
1833	##ini	O
1833	##um	O
1833	urine	B-PK
1833	t	I-PK
1833	##1	I-PK
1833	/	I-PK
1833	2	I-PK
1833	was	O
1833	similar	O
1833	between	O
1833	patients	O
1833	with	O
1833	severe	O
1833	re	O
1833	##nal	O
1833	imp	O
1833	##air	O
1833	##ment	O
1833	and	O
1833	healthy	O
1833	volunteers	O
1833	.	O
1833	[SEP]	O
1834	[CLS]	O
1834	v	O
1834	##ila	O
1834	##nter	O
1834	##ol	O
1834	was	O
1834	rapidly	O
1834	absorbed	O
1834	with	O
1834	a	O
1834	median	O
1834	t	B-PK
1834	##max	I-PK
1834	occurring	O
1834	at	O
1834	approximately	O
1834	5	O
1834	minutes	O
1834	post	O
1834	##dos	O
1834	##e	O
1834	,	O
1834	following	O
1834	which	O
1834	plasma	O
1834	concentrations	O
1834	declined	O
1834	rapidly	O
1834	for	O
1834	both	O
1834	patients	O
1834	with	O
1834	severe	O
1834	re	O
1834	##nal	O
1834	imp	O
1834	##air	O
1834	##ment	O
1834	and	O
1834	healthy	O
1834	volunteers	O
1834	.	O
1834	[SEP]	O
1835	[CLS]	O
1835	for	O
1835	au	B-PK
1835	##c	I-PK
1835	(	I-PK
1835	0	I-PK
1835	–	I-PK
1835	1	I-PK
1835	##h	I-PK
1835	)	I-PK
1835	,	O
1835	there	O
1835	was	O
1835	an	O
1835	average	O
1835	21	O
1835	%	O
1835	increase	O
1835	,	O
1835	with	O
1835	the	O
1835	true	O
1835	mean	O
1835	increase	O
1835	likely	O
1835	to	O
1835	be	O
1835	between	O
1835	13	O
1835	%	O
1835	lower	O
1835	and	O
1835	70	O
1835	%	O
1835	higher	O
1835	in	O
1835	patients	O
1835	with	O
1835	severe	O
1835	re	O
1835	##nal	O
1835	imp	O
1835	##air	O
1835	##ment	O
1835	compared	O
1835	with	O
1835	healthy	O
1835	volunteers	O
1835	.	O
1835	[SEP]	O
1836	[CLS]	O
1836	neither	O
1836	a	O
1836	##e	O
1836	led	O
1836	to	O
1836	study	O
1836	withdrawal	O
1836	.	O
1836	[SEP]	O
1837	[CLS]	O
1837	when	O
1837	le	O
1837	##vo	O
1837	##bu	O
1837	##pi	O
1837	##va	O
1837	##ca	O
1837	##ine	O
1837	was	O
1837	used	O
1837	alone	O
1837	,	O
1837	the	O
1837	t	B-PK
1837	##max	I-PK
1837	in	O
1837	plasma	O
1837	was	O
1837	1	O
1837	.	O
1837	07	O
1837	±	O
1837	0	O
1837	.	O
1837	16	O
1837	h	O
1837	.	O
1837	interesting	O
1837	##ly	O
1837	,	O
1837	the	O
1837	t	B-PK
1837	##max	I-PK
1837	of	O
1837	le	O
1837	##vo	O
1837	##bu	O
1837	##pi	O
1837	##va	O
1837	##ca	O
1837	##ine	O
1837	in	O
1837	the	O
1837	plasma	O
1837	was	O
1837	increased	O
1837	by	O
1837	four	O
1837	times	O
1837	in	O
1837	combination	O
1837	with	O
1837	q	O
1837	##x	O
1837	-	O
1837	oh	O
1837	(	O
1837	4	O
1837	.	O
1837	11	O
1837	±	O
1837	0	O
1837	.	O
1837	39	O
1837	h	O
1837	)	O
1837	.	O
1837	[SEP]	O
1838	[CLS]	O
1838	according	O
1838	to	O
1838	the	O
1838	chin	O
1838	##a	O
1838	food	O
1838	and	O
1838	drug	O
1838	administration	O
1838	guidance	O
1838	for	O
1838	pre	O
1838	##c	O
1838	##lini	O
1838	##cal	O
1838	p	O
1838	##har	O
1838	##ma	O
1838	##co	O
1838	##kin	O
1838	##etic	O
1838	study	O
1838	,	O
1838	there	O
1838	should	O
1838	be	O
1838	more	O
1838	than	O
1838	three	O
1838	sampling	O
1838	points	O
1838	adjacent	O
1838	to	O
1838	the	O
1838	time	B-PK
1838	to	I-PK
1838	reach	I-PK
1838	the	I-PK
1838	maximum	I-PK
1838	concentration	I-PK
1838	.	O
1838	[SEP]	O
1839	[CLS]	O
1839	in	O
1839	our	O
1839	preliminary	O
1839	experiment	O
1839	,	O
1839	the	O
1839	time	B-PK
1839	to	I-PK
1839	maximum	I-PK
1839	concentration	I-PK
1839	of	O
1839	le	O
1839	##vo	O
1839	-	O
1839	b	O
1839	##up	O
1839	##i	O
1839	,	O
1839	as	O
1839	a	O
1839	single	O
1839	drug	O
1839	in	O
1839	the	O
1839	rat	O
1839	s	O
1839	##cia	O
1839	##tic	O
1839	nerve	O
1839	block	O
1839	,	O
1839	was	O
1839	0	O
1839	.	O
1839	5	O
1839	h	O
1839	.	O
1839	[SEP]	O
1840	[CLS]	O
1840	thus	O
1840	,	O
1840	to	O
1840	obtain	O
1840	an	O
1840	accurate	O
1840	value	O
1840	of	O
1840	the	O
1840	maximum	B-PK
1840	concentration	I-PK
1840	of	O
1840	le	O
1840	##vo	O
1840	-	O
1840	b	O
1840	##up	O
1840	##i	O
1840	,	O
1840	we	O
1840	added	O
1840	another	O
1840	time	O
1840	point	O
1840	at	O
1840	0	O
1840	.	O
1840	33	O
1840	h	O
1840	.	O
1840	[SEP]	O
1841	[CLS]	O
1841	in	O
1841	this	O
1841	study	O
1841	,	O
1841	the	O
1841	following	O
1841	p	O
1841	##har	O
1841	##ma	O
1841	##co	O
1841	##kin	O
1841	##etic	O
1841	parameters	O
1841	were	O
1841	calculated	O
1841	:	O
1841	the	O
1841	value	O
1841	of	O
1841	maximum	B-PK
1841	concentration	I-PK
1841	(	I-PK
1841	cm	I-PK
1841	##ax	I-PK
1841	)	I-PK
1841	and	O
1841	the	O
1841	time	B-PK
1841	to	I-PK
1841	acquire	I-PK
1841	(	I-PK
1841	t	I-PK
1841	##max	I-PK
1841	)	I-PK
1841	;	O
1841	the	O
1841	elimination	B-PK
1841	half	I-PK
1841	-	I-PK
1841	life	I-PK
1841	(	I-PK
1841	t	I-PK
1841	##1	I-PK
1841	/	I-PK
1841	2	I-PK
1841	)	I-PK
1841	;	O
1841	area	B-PK
1841	under	I-PK
1841	curve	I-PK
1841	(	I-PK
1841	au	I-PK
1841	##c	I-PK
1841	)	I-PK
1841	from	I-PK
1841	zero	I-PK
1841	to	I-PK
1841	the	I-PK
1841	last	I-PK
1841	time	I-PK
1841	point	I-PK
1841	(	I-PK
1841	au	I-PK
1841	##c	I-PK
1841	##0	I-PK
1841	–	I-PK
1841	last	I-PK
1841	)	I-PK
1841	and	I-PK
1841	from	I-PK
1841	zero	I-PK
1841	to	I-PK
1841	in	I-PK
1841	##finity	I-PK
1841	(	I-PK
1841	au	I-PK
1841	##c	I-PK
1841	##0	I-PK
1841	–	I-PK
1841	∞	I-PK
1841	)	I-PK
1841	;	O
1841	clearance	B-PK
1841	(	I-PK
1841	c	I-PK
1841	##l	I-PK
1841	/	I-PK
1841	f	I-PK
1841	)	I-PK
1841	,	O
1841	and	O
1841	volume	B-PK
1841	of	I-PK
1841	distribution	I-PK
1841	(	I-PK
1841	v	I-PK
1841	##d	I-PK
1841	/	I-PK
1841	f	I-PK
1841	)	I-PK
1841	.	O
1841	[SEP]	O
1842	[CLS]	O
1842	for	O
1842	the	O
1842	half	B-PK
1842	-	I-PK
1842	time	I-PK
1842	and	O
1842	time	O
1842	to	O
1842	block	O
1842	caps	O
1842	,	O
1842	it	O
1842	was	O
1842	conducted	O
1842	by	O
1842	k	O
1842	##rus	O
1842	##kal	O
1842	–	O
1842	wall	O
1842	##is	O
1842	test	O
1842	due	O
1842	to	O
1842	its	O
1842	une	O
1842	##qua	O
1842	##l	O
1842	variance	O
1842	,	O
1842	and	O
1842	the	O
1842	cm	B-PK
1842	##ax	I-PK
1842	,	O
1842	t	B-PK
1842	##max	I-PK
1842	and	O
1842	the	O
1842	cellular	O
1842	drug	O
1842	up	O
1842	##take	O
1842	ass	O
1842	##ay	O
1842	were	O
1842	statistical	O
1842	##ly	O
1842	analyzed	O
1842	using	O
1842	independent	O
1842	-	O
1842	sample	O
1842	t	O
1842	test	O
1842	.	O
1842	[SEP]	O
1843	[CLS]	O
1843	the	O
1843	cm	B-PK
1843	##ax	I-PK
1843	values	O
1843	of	O
1843	q	O
1843	##x	O
1843	-	O
1843	oh	O
1843	and	O
1843	le	O
1843	##vo	O
1843	-	O
1843	b	O
1843	##up	O
1843	##i	O
1843	were	O
1843	72	O
1843	##7	O
1843	.	O
1843	22	O
1843	±	O
1843	43	O
1843	.	O
1843	38	O
1843	and	O
1843	256	O
1843	.	O
1843	02	O
1843	±	O
1843	28	O
1843	.	O
1843	52	O
1843	μ	O
1843	##g	O
1843	/	O
1843	g	O
1843	in	O
1843	muscle	O
1843	,	O
1843	63	O
1843	##4	O
1843	.	O
1843	26	O
1843	±	O
1843	36	O
1843	.	O
1843	04	O
1843	and	O
1843	42	O
1843	##9	O
1843	.	O
1843	63	O
1843	±	O
1843	48	O
1843	.	O
1843	64	O
1843	μ	O
1843	##g	O
1843	/	O
1843	g	O
1843	in	O
1843	s	O
1843	##cia	O
1843	##tic	O
1843	nerve	O
1843	,	O
1843	and	O
1843	71	O
1843	##1	O
1843	.	O
1843	71	O
1843	±	O
1843	25	O
1843	.	O
1843	14	O
1843	and	O
1843	114	O
1843	.	O
1843	40	O
1843	±	O
1843	10	O
1843	.	O
1843	19	O
1843	ng	O
1843	/	O
1843	m	O
1843	##l	O
1843	in	O
1843	plasma	O
1843	,	O
1843	respectively	O
1843	.	O
1843	[SEP]	O
1844	[CLS]	O
1844	the	O
1844	cm	B-PK
1844	##ax	I-PK
1844	of	O
1844	q	O
1844	##x	O
1844	-	O
1844	oh	O
1844	in	O
1844	s	O
1844	##cia	O
1844	##tic	O
1844	nerve	O
1844	did	O
1844	not	O
1844	significantly	O
1844	differ	O
1844	from	O
1844	that	O
1844	in	O
1844	muscle	O
1844	(	O
1844	p	O
1844	=	O
1844	0	O
1844	.	O
1844	05	O
1844	##8	O
1844	)	O
1844	.	O
1844	[SEP]	O
1845	[CLS]	O
1845	in	O
1845	contrast	O
1845	,	O
1845	the	O
1845	cm	B-PK
1845	##ax	I-PK
1845	of	O
1845	le	O
1845	##vo	O
1845	-	O
1845	b	O
1845	##up	O
1845	##i	O
1845	was	O
1845	higher	O
1845	in	O
1845	s	O
1845	##cia	O
1845	##tic	O
1845	nerve	O
1845	(	O
1845	42	O
1845	##9	O
1845	.	O
1845	63	O
1845	±	O
1845	48	O
1845	.	O
1845	64	O
1845	μ	O
1845	##g	O
1845	/	O
1845	g	O
1845	)	O
1845	than	O
1845	that	O
1845	in	O
1845	muscle	O
1845	(	O
1845	256	O
1845	.	O
1845	02	O
1845	±	O
1845	28	O
1845	.	O
1845	52	O
1845	μ	O
1845	##g	O
1845	/	O
1845	g	O
1845	,	O
1845	p	O
1845	=	O
1845	0	O
1845	.	O
1845	00	O
1845	##8	O
1845	)	O
1845	.	O
1845	[SEP]	O
1846	[CLS]	O
1846	the	O
1846	com	O
1846	##puted	O
1846	au	B-PK
1846	##c	I-PK
1846	values	I-PK
1846	of	I-PK
1846	q	I-PK
1846	##x	I-PK
1846	-	I-PK
1846	oh	I-PK
1846	from	I-PK
1846	zero	I-PK
1846	to	I-PK
1846	the	I-PK
1846	last	I-PK
1846	time	I-PK
1846	point	I-PK
1846	were	O
1846	1	O
1846	,	O
1846	48	O
1846	##7	O
1846	.	O
1846	72	O
1846	±	O
1846	82	O
1846	.	O
1846	20	O
1846	μ	O
1846	##g	O
1846	*	O
1846	h	O
1846	/	O
1846	g	O
1846	in	O
1846	s	O
1846	##cia	O
1846	##tic	O
1846	nerve	O
1846	,	O
1846	1	O
1846	,	O
1846	188	O
1846	.	O
1846	29	O
1846	±	O
1846	62	O
1846	.	O
1846	38	O
1846	μ	O
1846	##g	O
1846	*	O
1846	h	O
1846	/	O
1846	g	O
1846	in	O
1846	muscle	O
1846	,	O
1846	and	O
1846	1	O
1846	,	O
1846	91	O
1846	##3	O
1846	.	O
1846	72	O
1846	±	O
1846	148	O
1846	.	O
1846	7	O
1846	ng	O
1846	*	O
1846	h	O
1846	/	O
1846	m	O
1846	##l	O
1846	in	O
1846	plasma	O
1846	.	O
1846	[SEP]	O
1847	[CLS]	O
1847	the	O
1847	au	B-PK
1847	##c	I-PK
1847	values	I-PK
1847	of	I-PK
1847	le	I-PK
1847	##vo	I-PK
1847	-	I-PK
1847	b	I-PK
1847	##up	I-PK
1847	##i	I-PK
1847	from	I-PK
1847	zero	I-PK
1847	to	I-PK
1847	the	I-PK
1847	last	I-PK
1847	time	I-PK
1847	point	I-PK
1847	were	O
1847	93	O
1847	##5	O
1847	.	O
1847	82	O
1847	±	O
1847	74	O
1847	.	O
1847	35	O
1847	μ	O
1847	##g	O
1847	*	O
1847	h	O
1847	/	O
1847	g	O
1847	in	O
1847	s	O
1847	##cia	O
1847	##tic	O
1847	nerve	O
1847	,	O
1847	41	O
1847	##7	O
1847	.	O
1847	58	O
1847	±	O
1847	43	O
1847	.	O
1847	46	O
1847	μ	O
1847	##g	O
1847	*	O
1847	h	O
1847	/	O
1847	g	O
1847	in	O
1847	muscle	O
1847	,	O
1847	and	O
1847	65	O
1847	##1	O
1847	.	O
1847	23	O
1847	±	O
1847	47	O
1847	.	O
1847	39	O
1847	ng	O
1847	*	O
1847	h	O
1847	/	O
1847	m	O
1847	##l	O
1847	in	O
1847	plasma	O
1847	.	O
1847	[SEP]	O
1848	[CLS]	O
1848	in	O
1848	a	O
1848	previous	O
1848	study	O
1848	(	O
1848	y	O
1848	##u	O
1848	et	O
1848	al	O
1848	.	O
1848	,	O
1848	2002	O
1848	)	O
1848	,	O
1848	the	O
1848	cm	B-PK
1848	##ax	I-PK
1848	of	O
1848	b	O
1848	##up	O
1848	##iva	O
1848	##ca	O
1848	##ine	O
1848	was	O
1848	reached	O
1848	at	O
1848	0	O
1848	.	O
1848	5	O
1848	h	O
1848	after	O
1848	sub	O
1848	##cut	O
1848	##aneous	O
1848	administration	O
1848	.	O
1848	[SEP]	O
1849	[CLS]	O
1849	however	O
1849	,	O
1849	the	O
1849	t	B-PK
1849	##max	I-PK
1849	of	O
1849	le	O
1849	##vo	O
1849	-	O
1849	b	O
1849	##up	O
1849	##i	O
1849	in	O
1849	ll	O
1849	-	O
1849	1	O
1849	was	O
1849	4	O
1849	.	O
1849	11	O
1849	±	O
1849	0	O
1849	.	O
1849	39	O
1849	h	O
1849	.	O
1849	[SEP]	O
1850	[CLS]	O
1850	when	O
1850	le	O
1850	##vo	O
1850	-	O
1850	b	O
1850	##up	O
1850	##i	O
1850	was	O
1850	used	O
1850	alone	O
1850	,	O
1850	the	O
1850	t	B-PK
1850	##max	I-PK
1850	in	O
1850	plasma	O
1850	was	O
1850	1	O
1850	.	O
1850	07	O
1850	±	O
1850	0	O
1850	.	O
1850	16	O
1850	h	O
1850	(	O
1850	figure	O
1850	2	O
1850	##a	O
1850	)	O
1850	.	O
1850	[SEP]	O
1851	[CLS]	O
1851	interesting	O
1851	##ly	O
1851	,	O
1851	the	O
1851	t	B-PK
1851	##max	I-PK
1851	of	O
1851	le	O
1851	##vo	O
1851	-	O
1851	b	O
1851	##up	O
1851	##i	O
1851	in	O
1851	the	O
1851	plasma	O
1851	was	O
1851	increased	O
1851	by	O
1851	four	O
1851	times	O
1851	in	O
1851	combination	O
1851	with	O
1851	q	O
1851	##x	O
1851	-	O
1851	oh	O
1851	(	O
1851	4	O
1851	.	O
1851	11	O
1851	±	O
1851	0	O
1851	.	O
1851	39	O
1851	h	O
1851	,	O
1851	p	O
1851	<	O
1851	0	O
1851	.	O
1851	00	O
1851	##1	O
1851	)	O
1851	.	O
1851	[SEP]	O
1852	[CLS]	O
1852	the	O
1852	cm	B-PK
1852	##ax	I-PK
1852	of	O
1852	le	O
1852	##vo	O
1852	-	O
1852	b	O
1852	##up	O
1852	##i	O
1852	,	O
1852	used	O
1852	alone	O
1852	,	O
1852	(	O
1852	142	O
1852	.	O
1852	45	O
1852	±	O
1852	13	O
1852	.	O
1852	04	O
1852	ng	O
1852	/	O
1852	m	O
1852	##l	O
1852	)	O
1852	did	O
1852	not	O
1852	significantly	O
1852	differ	O
1852	from	O
1852	that	O
1852	in	O
1852	ll	O
1852	-	O
1852	1	O
1852	(	O
1852	p	O
1852	=	O
1852	0	O
1852	.	O
1852	114	O
1852	)	O
1852	.	O
1852	[SEP]	O
1853	[CLS]	O
1853	in	O
1853	contrast	O
1853	,	O
1853	le	O
1853	##vo	O
1853	-	O
1853	b	O
1853	##up	O
1853	##i	O
1853	,	O
1853	used	O
1853	alone	O
1853	,	O
1853	had	O
1853	a	O
1853	faster	O
1853	elimination	O
1853	(	O
1853	c	B-PK
1853	##l	I-PK
1853	=	O
1853	1	O
1853	.	O
1853	32	O
1853	±	O
1853	0	O
1853	.	O
1853	08	O
1853	l	O
1853	/	O
1853	h	O
1853	,	O
1853	p	O
1853	=	O
1853	0	O
1853	.	O
1853	00	O
1853	##1	O
1853	;	O
1853	t	B-PK
1853	##1	I-PK
1853	/	I-PK
1853	2	I-PK
1853	=	O
1853	2	O
1853	.	O
1853	61	O
1853	±	O
1853	0	O
1853	.	O
1853	31	O
1853	h	O
1853	,	O
1853	p	O
1853	=	O
1853	0	O
1853	.	O
1853	199	O
1853	)	O
1853	.	O
1853	[SEP]	O
1854	[CLS]	O
1854	the	O
1854	op	O
1854	##ti	O
1854	##mized	O
1854	p	O
1854	##g	O
1854	:	O
1854	t	O
1854	##we	O
1854	##en	O
1854	80	O
1854	formulation	O
1854	significantly	O
1854	improved	O
1854	the	O
1854	p	O
1854	##har	O
1854	##ma	O
1854	##co	O
1854	##kin	O
1854	##etic	O
1854	parameters	O
1854	compared	O
1854	with	O
1854	the	O
1854	universal	O
1854	0	O
1854	.	O
1854	5	O
1854	%	O
1854	(	O
1854	w	O
1854	##t	O
1854	/	O
1854	vol	O
1854	)	O
1854	cm	O
1854	##c	O
1854	formulation	O
1854	,	O
1854	as	O
1854	evidenced	O
1854	by	O
1854	improved	O
1854	maximum	B-PK
1854	concentration	I-PK
1854	of	I-PK
1854	drug	I-PK
1854	in	I-PK
1854	serum	I-PK
1854	(	I-PK
1854	cm	I-PK
1854	##ax	I-PK
1854	)	I-PK
1854	(	O
1854	1	O
1854	.	O
1854	04	O
1854	versus	O
1854	0	O
1854	.	O
1854	15	O
1854	μ	O
1854	##g	O
1854	/	O
1854	m	O
1854	##l	O
1854	)	O
1854	and	O
1854	area	B-PK
1854	under	I-PK
1854	the	I-PK
1854	curve	I-PK
1854	to	I-PK
1854	the	I-PK
1854	last	I-PK
1854	me	I-PK
1854	##as	I-PK
1854	##urable	I-PK
1854	concentration	I-PK
1854	(	I-PK
1854	au	I-PK
1854	##c	I-PK
1854	##last	I-PK
1854	)	I-PK
1854	(	O
1854	6	O
1854	.	O
1854	56	O
1854	versus	O
1854	1	O
1854	.	O
1854	51	O
1854	h	O
1854	·	O
1854	μ	O
1854	##g	O
1854	/	O
1854	m	O
1854	##l	O
1854	)	O
1854	(	O
1854	table	O
1854	1	O
1854	)	O
1854	.	O
1854	[SEP]	O
1855	[CLS]	O
1855	to	O
1855	enhance	O
1855	oral	B-PK
1855	bio	I-PK
1855	##ava	I-PK
1855	##ila	I-PK
1855	##bility	I-PK
1855	,	O
1855	we	O
1855	developed	O
1855	a	O
1855	novel	O
1855	formulation	O
1855	for	O
1855	compound	O
1855	2	O
1855	in	O
1855	prop	O
1855	##yle	O
1855	##ne	O
1855	g	O
1855	##ly	O
1855	##co	O
1855	##l	O
1855	(	O
1855	p	O
1855	##g	O
1855	)	O
1855	:	O
1855	t	O
1855	##we	O
1855	##en	O
1855	80	O
1855	(	O
1855	4	O
1855	:	O
1855	1	O
1855	,	O
1855	vol	O
1855	/	O
1855	vol	O
1855	)	O
1855	.	O
1855	[SEP]	O
1856	[CLS]	O
1856	we	O
1856	compared	O
1856	the	O
1856	bio	B-PK
1856	##ava	I-PK
1856	##ila	I-PK
1856	##bility	I-PK
1856	of	O
1856	this	O
1856	new	O
1856	formulation	O
1856	with	O
1856	a	O
1856	previously	O
1856	reported	O
1856	formulation	O
1856	using	O
1856	0	O
1856	.	O
1856	5	O
1856	%	O
1856	(	O
1856	w	O
1856	##t	O
1856	/	O
1856	vol	O
1856	)	O
1856	car	O
1856	##box	O
1856	##yme	O
1856	##thy	O
1856	##l	O
1856	cell	O
1856	##ulos	O
1856	##e	O
1856	(	O
1856	cm	O
1856	##c	O
1856	)	O
1856	(	O
1856	19	O
1856	)	O
1856	.	O
1856	[SEP]	O
1857	[CLS]	O
1857	ed	B-PK
1857	##50	I-PK
1857	values	O
1857	were	O
1857	compared	O
1857	using	O
1857	the	O
1857	extra	O
1857	sum	O
1857	-	O
1857	of	O
1857	-	O
1857	squares	O
1857	f	O
1857	test	O
1857	.	O
1857	[SEP]	O
1858	[CLS]	O
1858	drug	O
1858	concentration	O
1858	over	O
1858	time	O
1858	was	O
1858	determined	O
1858	using	O
1858	liquid	O
1858	ch	O
1858	##roma	O
1858	##tography	O
1858	–	O
1858	mass	O
1858	s	O
1858	##pect	O
1858	##rome	O
1858	##try	O
1858	and	O
1858	total	O
1858	exposure	O
1858	(	O
1858	au	B-PK
1858	##c	I-PK
1858	##0	I-PK
1858	-	I-PK
1858	∞	I-PK
1858	)	O
1858	was	O
1858	estimated	O
1858	from	O
1858	the	O
1858	concentration	O
1858	-	O
1858	time	O
1858	profiles	O
1858	.	O
1858	[SEP]	O
1859	[CLS]	O
1859	au	B-PK
1859	##c	I-PK
1859	##0	I-PK
1859	-	I-PK
1859	∞	I-PK
1859	was	O
1859	the	O
1859	highest	O
1859	ever	O
1859	reported	O
1859	in	O
1859	human	O
1859	tissue	O
1859	(	O
1859	131	O
1859	##0	O
1859	##3	O
1859	(	O
1859	(	O
1859	m	O
1859	##c	O
1859	##g	O
1859	/	O
1859	g	O
1859	)	O
1859	.	O
1859	h	O
1859	##r	O
1859	)	O
1859	)	O
1859	.	O
1859	[SEP]	O
1860	[CLS]	O
1860	lip	O
1860	##ids	O
1860	were	O
1860	anal	O
1860	##ys	O
1860	##ed	O
1860	by	O
1860	electro	O
1860	##sp	O
1860	##ray	O
1860	ion	O
1860	##isation	O
1860	-	O
1860	mass	O
1860	s	O
1860	##pect	O
1860	##rome	O
1860	##try	O
1860	(	O
1860	es	O
1860	##i	O
1860	-	O
1860	m	O
1860	##s	O
1860	)	O
1860	using	O
1860	an	O
1860	a	O
1860	##gi	O
1860	##lent	O
1860	triple	O
1860	q	O
1860	##uad	O
1860	64	O
1860	##60	O
1860	.	O
1860	[SEP]	O
1861	[CLS]	O
1861	total	O
1861	drug	O
1861	exposure	O
1861	was	O
1861	measured	O
1861	as	O
1861	the	O
1861	area	B-PK
1861	under	I-PK
1861	the	I-PK
1861	concentration	I-PK
1861	-	I-PK
1861	time	I-PK
1861	curve	I-PK
1861	(	I-PK
1861	au	I-PK
1861	##c	I-PK
1861	)	I-PK
1861	from	I-PK
1861	time	I-PK
1861	zero	I-PK
1861	to	I-PK
1861	96	I-PK
1861	hours	I-PK
1861	(	I-PK
1861	au	I-PK
1861	##c	I-PK
1861	##0	I-PK
1861	-	I-PK
1861	96	I-PK
1861	)	I-PK
1861	and	O
1861	zero	O
1861	to	O
1861	in	O
1861	##finity	O
1861	(	O
1861	au	B-PK
1861	##c	I-PK
1861	##0	I-PK
1861	-	I-PK
1861	∞	I-PK
1861	)	O
1861	using	O
1861	cubic	O
1861	s	O
1861	##p	O
1861	##lines	O
1861	method	O
1861	and	O
1861	expressed	O
1861	as	O
1861	linear	O
1861	of	O
1861	log	O
1861	concentration	O
1861	.	O
1861	[SEP]	O
1862	[CLS]	O
1862	elimination	B-PK
1862	rate	I-PK
1862	constant	I-PK
1862	(	I-PK
1862	k	I-PK
1862	##e	I-PK
1862	)	I-PK
1862	and	O
1862	half	B-PK
1862	-	I-PK
1862	life	I-PK
1862	(	I-PK
1862	t	I-PK
1862	##1	I-PK
1862	/	I-PK
1862	2	I-PK
1862	)	I-PK
1862	,	O
1862	maximum	B-PK
1862	concentrations	I-PK
1862	(	I-PK
1862	cm	I-PK
1862	##ax	I-PK
1862	)	I-PK
1862	and	O
1862	time	B-PK
1862	to	I-PK
1862	cm	I-PK
1862	##ax	I-PK
1862	(	I-PK
1862	t	I-PK
1862	##max	I-PK
1862	)	I-PK
1862	were	O
1862	also	O
1862	estimated	O
1862	for	O
1862	each	O
1862	par	O
1862	##itic	O
1862	##ip	O
1862	##ant	O
1862	[SEP]	O
1863	[CLS]	O
1863	the	O
1863	estimated	O
1863	au	B-PK
1863	##c	I-PK
1863	##0	I-PK
1863	-	I-PK
1863	96	I-PK
1863	and	O
1863	au	B-PK
1863	##c	I-PK
1863	##0	I-PK
1863	-	I-PK
1863	∞	I-PK
1863	was	O
1863	36	O
1863	##44	O
1863	and	O
1863	131	O
1863	##0	O
1863	##3	O
1863	(	O
1863	(	O
1863	m	O
1863	##c	O
1863	##g	O
1863	/	O
1863	g	O
1863	)	O
1863	.	O
1863	h	O
1863	##r	O
1863	)	O
1863	respectively	O
1863	.	O
1863	[SEP]	O
1864	[CLS]	O
1864	the	O
1864	elimination	B-PK
1864	rate	I-PK
1864	constant	I-PK
1864	was	O
1864	0	O
1864	.	O
1864	00	O
1864	##8	O
1864	/	O
1864	hour	O
1864	.	O
1864	[SEP]	O
1865	[CLS]	O
1865	r	O
1865	##alo	O
1865	##xi	O
1865	##fen	O
1865	##e	O
1865	(	O
1865	r	O
1865	##x	O
1865	##f	O
1865	)	O
1865	is	O
1865	a	O
1865	hormone	O
1865	-	O
1865	like	O
1865	medication	O
1865	used	O
1865	for	O
1865	treating	O
1865	post	O
1865	##men	O
1865	##op	O
1865	##aus	O
1865	##al	O
1865	o	O
1865	##ste	O
1865	##op	O
1865	##oro	O
1865	##sis	O
1865	and	O
1865	est	O
1865	##rogen	O
1865	-	O
1865	dependent	O
1865	breast	O
1865	cancer	O
1865	,	O
1865	yet	O
1865	associated	O
1865	with	O
1865	bad	O
1865	low	O
1865	bio	B-PK
1865	##ava	I-PK
1865	##ila	I-PK
1865	##bility	I-PK
1865	due	O
1865	to	O
1865	poor	O
1865	so	O
1865	##lub	O
1865	##ility	O
1865	.	O
1865	[SEP]	O
1866	[CLS]	O
1866	this	O
1866	study	O
1866	was	O
1866	intended	O
1866	to	O
1866	develop	O
1866	c	O
1866	##y	O
1866	##c	O
1866	##lo	O
1866	##de	O
1866	##x	O
1866	##tri	O
1866	##n	O
1866	/	O
1866	ch	O
1866	##ito	O
1866	##san	O
1866	na	O
1866	##no	O
1866	##par	O
1866	##tic	O
1866	##les	O
1866	(	O
1866	cc	O
1866	##n	O
1866	##ps	O
1866	)	O
1866	for	O
1866	oral	O
1866	delivery	O
1866	of	O
1866	r	O
1866	##x	O
1866	##f	O
1866	in	O
1866	order	O
1866	to	O
1866	enhance	O
1866	the	O
1866	oral	B-PK
1866	bio	I-PK
1866	##ava	I-PK
1866	##ila	I-PK
1866	##bility	I-PK
1866	.	O
1866	[SEP]	O
1867	[CLS]	O
1867	the	O
1867	complex	O
1867	formation	O
1867	constant	O
1867	(	O
1867	k	O
1867	##f	O
1867	)	O
1867	was	O
1867	calculated	O
1867	based	O
1867	on	O
1867	the	O
1867	equation	O
1867	:	O
1867	k	O
1867	##f	O
1867	=	O
1867	s	O
1867	/	O
1867	s	O
1867	##0	O
1867	(	O
1867	1	O
1867	−	O
1867	s	O
1867	)	O
1867	,	O
1867	where	O
1867	s	O
1867	and	O
1867	s	O
1867	##0	O
1867	denote	O
1867	the	O
1867	slope	O
1867	of	O
1867	linear	O
1867	equation	O
1867	(	O
1867	if	O
1867	applicable	O
1867	)	O
1867	and	O
1867	drug	O
1867	so	O
1867	##lub	O
1867	##ility	O
1867	in	O
1867	the	O
1867	absence	O
1867	of	O
1867	s	O
1867	##be	O
1867	-	O
1867	β	O
1867	-	O
1867	c	O
1867	##d	O
1867	,	O
1867	respectively	O
1867	.	O
1867	[SEP]	O
1868	[CLS]	O
1868	thus	O
1868	,	O
1868	the	O
1868	calculated	O
1868	complex	O
1868	formation	O
1868	constant	O
1868	(	O
1868	k	O
1868	##f	O
1868	)	O
1868	was	O
1868	106	O
1868	.	O
1868	91	O
1868	l	O
1868	/	O
1868	m	O
1868	##ol	O
1868	.	O
1868	[SEP]	O
1869	[CLS]	O
1869	the	O
1869	k	O
1869	##f	O
1869	value	O
1869	was	O
1869	considerably	O
1869	large	O
1869	for	O
1869	an	O
1869	inclusion	O
1869	compound	O
1869	,	O
1869	demonstrating	O
1869	a	O
1869	stable	O
1869	complex	O
1869	##ation	O
1869	.	O
1869	[SEP]	O
1870	[CLS]	O
1870	for	O
1870	the	O
1870	formulation	O
1870	of	O
1870	r	O
1870	##x	O
1870	##f	O
1870	suspension	O
1870	##s	O
1870	,	O
1870	the	O
1870	drug	O
1870	absorption	O
1870	was	O
1870	relatively	O
1870	inadequate	O
1870	with	O
1870	the	O
1870	ma	B-PK
1870	##ximal	I-PK
1870	plasma	I-PK
1870	concentration	I-PK
1870	(	I-PK
1870	cm	I-PK
1870	##ax	I-PK
1870	)	I-PK
1870	of	O
1870	108	O
1870	.	O
1870	46	O
1870	ng	O
1870	/	O
1870	m	O
1870	##l	O
1870	.	O
1870	different	O
1870	from	O
1870	r	O
1870	##x	O
1870	##f	O
1870	suspension	O
1870	##s	O
1870	,	O
1870	r	O
1870	##x	O
1870	##f	O
1870	-	O
1870	sic	O
1870	##s	O
1870	solution	O
1870	gave	O
1870	rise	O
1870	to	O
1870	an	O
1870	elevated	O
1870	cm	B-PK
1870	##ax	I-PK
1870	,	O
1870	which	O
1870	was	O
1870	almost	O
1870	two	O
1870	times	O
1870	as	O
1870	high	O
1870	as	O
1870	that	O
1870	of	O
1870	r	O
1870	##x	O
1870	##f	O
1870	suspension	O
1870	##s	O
1870	.	O
1870	[SEP]	O
1871	[CLS]	O
1871	however	O
1871	,	O
1871	r	O
1871	##x	O
1871	##f	O
1871	-	O
1871	cc	O
1871	##n	O
1871	##ps	O
1871	resulted	O
1871	in	O
1871	a	O
1871	higher	O
1871	cm	B-PK
1871	##ax	I-PK
1871	,	O
1871	up	O
1871	to	O
1871	36	O
1871	##7	O
1871	.	O
1871	48	O
1871	ng	O
1871	/	O
1871	m	O
1871	##l	O
1871	.	O
1871	the	O
1871	time	B-PK
1871	to	I-PK
1871	cm	I-PK
1871	##ax	I-PK
1871	(	I-PK
1871	t	I-PK
1871	##max	I-PK
1871	)	I-PK
1871	and	O
1871	the	O
1871	terminal	B-PK
1871	half	I-PK
1871	-	I-PK
1871	life	I-PK
1871	(	I-PK
1871	t	I-PK
1871	##1	I-PK
1871	/	I-PK
1871	2	I-PK
1871	)	I-PK
1871	among	O
1871	three	O
1871	formulation	O
1871	##s	O
1871	appeared	O
1871	to	O
1871	be	O
1871	a	O
1871	little	O
1871	distinct	O
1871	.	O
1871	[SEP]	O
1872	[CLS]	O
1872	the	O
1872	formulation	O
1872	with	O
1872	good	O
1872	absorption	O
1872	possesses	O
1872	smaller	O
1872	t	B-PK
1872	##max	I-PK
1872	and	O
1872	shorter	O
1872	t	B-PK
1872	##1	I-PK
1872	/	I-PK
1872	2	I-PK
1872	,	O
1872	which	O
1872	is	O
1872	related	O
1872	to	O
1872	the	O
1872	fast	O
1872	drug	O
1872	disposition	O
1872	,	O
1872	including	O
1872	absorption	O
1872	and	O
1872	elimination	O
1872	.	O
1872	[SEP]	O
1873	[CLS]	O
1873	the	O
1873	area	B-PK
1873	under	I-PK
1873	plasma	I-PK
1873	drug	I-PK
1873	concentration	I-PK
1873	vs	I-PK
1873	.	I-PK
1873	time	I-PK
1873	curve	I-PK
1873	(	I-PK
1873	au	I-PK
1873	##c	I-PK
1873	##0	I-PK
1873	-	I-PK
1873	t	I-PK
1873	)	I-PK
1873	of	O
1873	r	O
1873	##x	O
1873	##f	O
1873	-	O
1873	cc	O
1873	##n	O
1873	##ps	O
1873	was	O
1873	up	O
1873	to	O
1873	240	O
1873	##0	O
1873	.	O
1873	78	O
1873	ng	O
1873	/	O
1873	m	O
1873	##l	O
1873	·	O
1873	h	O
1873	that	O
1873	was	O
1873	notably	O
1873	larger	O
1873	than	O
1873	that	O
1873	of	O
1873	r	O
1873	##x	O
1873	##f	O
1873	suspension	O
1873	##s	O
1873	and	O
1873	r	O
1873	##x	O
1873	##f	O
1873	-	O
1873	sic	O
1873	##s	O
1873	solution	O
1873	.	O
1873	[SEP]	O
1874	[CLS]	O
1874	the	O
1874	oral	B-PK
1874	bio	I-PK
1874	##ava	I-PK
1874	##ila	I-PK
1874	##bility	I-PK
1874	of	O
1874	r	O
1874	##x	O
1874	##f	O
1874	-	O
1874	cc	O
1874	##n	O
1874	##ps	O
1874	relative	O
1874	to	O
1874	r	O
1874	##x	O
1874	##f	O
1874	suspension	O
1874	##s	O
1874	was	O
1874	calculated	O
1874	to	O
1874	be	O
1874	360	O
1874	.	O
1874	76	O
1874	%	O
1874	,	O
1874	whereas	O
1874	it	O
1874	was	O
1874	just	O
1874	249	O
1874	.	O
1874	38	O
1874	%	O
1874	for	O
1874	r	O
1874	##x	O
1874	##f	O
1874	-	O
1874	sic	O
1874	##s	O
1874	solution	O
1874	.	O
1874	[SEP]	O
1875	[CLS]	O
1875	in	O
1875	our	O
1875	study	O
1875	,	O
1875	c	O
1875	##y	O
1875	##c	O
1875	##lo	O
1875	##de	O
1875	##x	O
1875	##tri	O
1875	##n	O
1875	inclusion	O
1875	complexes	O
1875	as	O
1875	a	O
1875	bio	B-PK
1875	##ava	I-PK
1875	##ila	I-PK
1875	##bility	I-PK
1875	enhance	O
1875	##r	O
1875	was	O
1875	verified	O
1875	again	O
1875	in	O
1875	the	O
1875	case	O
1875	of	O
1875	r	O
1875	##x	O
1875	##f	O
1875	-	O
1875	sic	O
1875	##s	O
1875	solution	O
1875	.	O
1875	[SEP]	O
1876	[CLS]	O
1876	our	O
1876	developed	O
1876	r	O
1876	##x	O
1876	##f	O
1876	-	O
1876	cc	O
1876	##n	O
1876	##ps	O
1876	is	O
1876	not	O
1876	only	O
1876	convenient	O
1876	for	O
1876	use	O
1876	,	O
1876	but	O
1876	also	O
1876	can	O
1876	enhance	O
1876	the	O
1876	oral	B-PK
1876	bio	I-PK
1876	##ava	I-PK
1876	##ila	I-PK
1876	##bility	I-PK
1876	of	O
1876	r	O
1876	##x	O
1876	##f	O
1876	.	O
1876	[SEP]	O
1877	[CLS]	O
1877	high	O
1877	cellular	O
1877	up	O
1877	##take	O
1877	guarantees	O
1877	good	O
1877	absorption	O
1877	and	O
1877	bio	B-PK
1877	##ava	I-PK
1877	##ila	I-PK
1877	##bility	I-PK
1877	.	O
1877	[SEP]	O
1878	[CLS]	O
1878	the	O
1878	low	O
1878	bio	B-PK
1878	##ava	I-PK
1878	##ila	I-PK
1878	##bility	I-PK
1878	of	O
1878	r	O
1878	##x	O
1878	##f	O
1878	is	O
1878	not	O
1878	only	O
1878	associated	O
1878	with	O
1878	its	O
1878	poor	O
1878	water	O
1878	so	O
1878	##lub	O
1878	##ility	O
1878	,	O
1878	but	O
1878	also	O
1878	has	O
1878	something	O
1878	to	O
1878	do	O
1878	with	O
1878	the	O
1878	in	O
1878	##test	O
1878	##inal	O
1878	metabolism	O
1878	and	O
1878	e	O
1878	##ff	O
1878	##lux	O
1878	[	O
1878	27	O
1878	]	O
1878	.	O
1878	[SEP]	O
1879	[CLS]	O
1879	l	O
1879	##ymph	O
1879	##atic	O
1879	transport	O
1879	can	O
1879	reduce	O
1879	the	O
1879	he	O
1879	##pa	O
1879	##tic	O
1879	first	O
1879	-	O
1879	pass	O
1879	effect	O
1879	,	O
1879	which	O
1879	further	O
1879	contributes	O
1879	the	O
1879	enhance	O
1879	##ment	O
1879	of	O
1879	oral	B-PK
1879	bio	I-PK
1879	##ava	I-PK
1879	##ila	I-PK
1879	##bility	I-PK
1879	.	O
1879	[SEP]	O
1880	[CLS]	O
1880	the	O
1880	oral	B-PK
1880	bio	I-PK
1880	##ava	I-PK
1880	##ila	I-PK
1880	##bility	I-PK
1880	was	O
1880	17	O
1880	.	O
1880	7	O
1880	–	O
1880	19	O
1880	.	O
1880	5	O
1880	%	O
1880	at	O
1880	20	O
1880	–	O
1880	60	O
1880	mg	O
1880	/	O
1880	kg	O
1880	doses	O
1880	in	O
1880	mice	O
1880	,	O
1880	<	O
1880	1	O
1880	.	O
1880	6	O
1880	%	O
1880	at	O
1880	100	O
1880	–	O
1880	2000	O
1880	mg	O
1880	/	O
1880	kg	O
1880	in	O
1880	rats	O
1880	,	O
1880	and	O
1880	11	O
1880	.	O
1880	2	O
1880	%	O
1880	at	O
1880	100	O
1880	mg	O
1880	/	O
1880	kg	O
1880	decreasing	O
1880	to	O
1880	3	O
1880	.	O
1880	45	O
1880	%	O
1880	at	O
1880	400	O
1880	mg	O
1880	/	O
1880	kg	O
1880	and	O
1880	1	O
1880	.	O
1880	11	O
1880	%	O
1880	at	O
1880	1500	O
1880	mg	O
1880	/	O
1880	kg	O
1880	in	O
1880	dogs	O
1880	.	O
1880	[SEP]	O
1881	[CLS]	O
1881	the	O
1881	disposition	O
1881	parameters	O
1881	were	O
1881	well	O
1881	correlated	O
1881	with	O
1881	the	O
1881	body	O
1881	weight	O
1881	for	O
1881	all	O
1881	species	O
1881	using	O
1881	the	O
1881	all	O
1881	##ometric	O
1881	equation	O
1881	,	O
1881	which	O
1881	predicted	O
1881	values	O
1881	of	O
1881	c	B-PK
1881	##l	I-PK
1881	(	O
1881	17	O
1881	.	O
1881	3	O
1881	l	O
1881	/	O
1881	h	O
1881	)	O
1881	,	O
1881	v	B-PK
1881	##1	I-PK
1881	(	O
1881	36	O
1881	.	O
1881	2	O
1881	l	O
1881	)	O
1881	,	O
1881	v	B-PK
1881	##2	I-PK
1881	(	O
1881	68	O
1881	.	O
1881	5	O
1881	l	O
1881	)	O
1881	and	O
1881	c	B-PK
1881	##ld	I-PK
1881	(	O
1881	15	O
1881	.	O
1881	2	O
1881	l	O
1881	/	O
1881	h	O
1881	)	O
1881	for	O
1881	a	O
1881	70	O
1881	-	O
1881	kg	O
1881	human	O
1881	.	O
1881	[SEP]	O
1882	[CLS]	O
1882	the	O
1882	oral	B-PK
1882	absorption	I-PK
1882	rate	I-PK
1882	and	O
1882	bio	B-PK
1882	##ava	I-PK
1882	##ila	I-PK
1882	##bility	I-PK
1882	of	O
1882	she	O
1882	##ta	O
1882	##2	O
1882	was	O
1882	highly	O
1882	dependent	O
1882	on	O
1882	species	O
1882	,	O
1882	doses	O
1882	,	O
1882	formulation	O
1882	##s	O
1882	,	O
1882	and	O
1882	possibly	O
1882	other	O
1882	factors	O
1882	.	O
1882	[SEP]	O
1883	[CLS]	O
1883	the	O
1883	limited	O
1883	bio	B-PK
1883	##ava	I-PK
1883	##ila	I-PK
1883	##bility	I-PK
1883	at	O
1883	high	O
1883	doses	O
1883	was	O
1883	taken	O
1883	into	O
1883	consideration	O
1883	for	O
1883	the	O
1883	suggested	O
1883	first	O
1883	-	O
1883	in	O
1883	-	O
1883	human	O
1883	dose	O
1883	,	O
1883	which	O
1883	was	O
1883	much	O
1883	lower	O
1883	than	O
1883	the	O
1883	dose	O
1883	estimated	O
1883	based	O
1883	on	O
1883	toxic	O
1883	##ology	O
1883	studies	O
1883	.	O
1883	[SEP]	O
1884	[CLS]	O
1884	the	O
1884	two	O
1884	-	O
1884	compartment	O
1884	model	O
1884	was	O
1884	parameter	O
1884	##ized	O
1884	with	O
1884	clearance	B-PK
1884	(	I-PK
1884	c	I-PK
1884	##l	I-PK
1884	)	I-PK
1884	,	O
1884	volume	B-PK
1884	of	I-PK
1884	distribution	I-PK
1884	in	I-PK
1884	the	I-PK
1884	central	I-PK
1884	(	I-PK
1884	v	I-PK
1884	##1	I-PK
1884	)	I-PK
1884	and	O
1884	peripheral	B-PK
1884	(	I-PK
1884	v	I-PK
1884	##2	I-PK
1884	)	I-PK
1884	compartment	I-PK
1884	,	O
1884	and	O
1884	distribution	B-PK
1884	clearance	I-PK
1884	(	I-PK
1884	c	I-PK
1884	##ld	I-PK
1884	)	I-PK
1884	between	O
1884	compartment	O
1884	##s	O
1884	.	O
1884	[SEP]	O
1885	[CLS]	O
1885	ka	B-PK
1885	is	O
1885	the	O
1885	first	B-PK
1885	-	I-PK
1885	order	I-PK
1885	absorption	I-PK
1885	rate	I-PK
1885	constant	I-PK
1885	and	O
1885	f	B-PK
1885	is	O
1885	oral	B-PK
1885	bio	I-PK
1885	##ava	I-PK
1885	##ila	I-PK
1885	##bility	I-PK
1885	.	O
1885	[SEP]	O
1886	[CLS]	O
1886	in	O
1886	this	O
1886	model	O
1886	,	O
1886	we	O
1886	assumed	O
1886	(	O
1886	a	O
1886	)	O
1886	the	O
1886	drug	O
1886	undergo	O
1886	##es	O
1886	transit	O
1886	through	O
1886	the	O
1886	in	O
1886	##test	O
1886	##ines	O
1886	with	O
1886	the	O
1886	first	B-PK
1886	-	I-PK
1886	order	I-PK
1886	transit	I-PK
1886	rate	I-PK
1886	constant	I-PK
1886	(	I-PK
1886	ka	I-PK
1886	##t	I-PK
1886	)	I-PK
1886	,	O
1886	which	O
1886	was	O
1886	assumed	O
1886	to	O
1886	be	O
1886	same	O
1886	through	O
1886	all	O
1886	compartment	O
1886	##s	O
1886	;	O
1886	(	O
1886	b	O
1886	)	O
1886	she	O
1886	##ta	O
1886	##2	O
1886	absorption	O
1886	from	O
1886	the	O
1886	first	O
1886	compartment	O
1886	(	O
1886	i	O
1886	.	O
1886	e	O
1886	.	O
1886	,	O
1886	stomach	O
1886	)	O
1886	is	O
1886	ins	O
1886	##ign	O
1886	##ificant	O
1886	;	O
1886	and	O
1886	(	O
1886	c	O
1886	)	O
1886	the	O
1886	absorption	O
1886	only	O
1886	occurs	O
1886	from	O
1886	the	O
1886	second	O
1886	(	O
1886	g	O
1886	##2	O
1886	)	O
1886	and	O
1886	last	O
1886	(	O
1886	g	O
1886	##7	O
1886	)	O
1886	segments	O
1886	with	O
1886	two	O
1886	different	O
1886	absorption	B-PK
1886	rate	I-PK
1886	constant	I-PK
1886	##s	I-PK
1886	(	O
1886	ka	B-PK
1886	and	O
1886	ka	B-PK
1886	##2	I-PK
1886	)	O
1886	,	O
1886	with	O
1886	no	O
1886	absorption	O
1886	from	O
1886	segments	O
1886	3	O
1886	–	O
1886	6	O
1886	.	O
1886	[SEP]	O
1887	[CLS]	O
1887	ka	B-PK
1887	and	O
1887	ka	B-PK
1887	##2	I-PK
1887	represent	O
1887	the	O
1887	first	B-PK
1887	-	I-PK
1887	order	I-PK
1887	absorption	I-PK
1887	rate	I-PK
1887	constant	I-PK
1887	from	I-PK
1887	the	I-PK
1887	second	I-PK
1887	(	O
1887	g	O
1887	##2	O
1887	)	O
1887	and	O
1887	last	B-PK
1887	(	O
1887	g	O
1887	##7	O
1887	)	O
1887	compartment	O
1887	##s	O
1887	,	O
1887	respectively	O
1887	.	O
1887	[SEP]	O
1888	[CLS]	O
1888	the	O
1888	plasma	O
1888	concentration	O
1888	-	O
1888	time	O
1888	data	O
1888	from	O
1888	both	O
1888	i	O
1888	##v	O
1888	and	O
1888	oral	O
1888	routes	O
1888	were	O
1888	fitted	O
1888	simultaneously	O
1888	with	O
1888	e	O
1888	##q	O
1888	##s	O
1888	1	O
1888	–	O
1888	3	O
1888	(	O
1888	fi	O
1888	##g	O
1888	2	O
1888	##a	O
1888	)	O
1888	to	O
1888	obtain	O
1888	the	O
1888	disposition	O
1888	(	O
1888	c	B-PK
1888	##l	I-PK
1888	,	O
1888	v	B-PK
1888	##1	I-PK
1888	,	O
1888	v	B-PK
1888	##2	I-PK
1888	,	O
1888	c	B-PK
1888	##ld	I-PK
1888	)	O
1888	and	O
1888	absorption	O
1888	parameters	O
1888	(	O
1888	ka	B-PK
1888	and	O
1888	f	B-PK
1888	)	O
1888	for	O
1888	mice	O
1888	and	O
1888	rats	O
1888	.	O
1888	[SEP]	O
1889	[CLS]	O
1889	similarly	O
1889	,	O
1889	the	O
1889	parameters	O
1889	for	O
1889	disposition	O
1889	and	O
1889	gas	O
1889	##tro	O
1889	##int	O
1889	##est	O
1889	##inal	O
1889	transit	O
1889	absorption	O
1889	process	O
1889	(	O
1889	ka	B-PK
1889	,	O
1889	ka	B-PK
1889	##2	I-PK
1889	,	O
1889	ka	B-PK
1889	##t	I-PK
1889	,	O
1889	and	O
1889	f	B-PK
1889	)	O
1889	were	O
1889	obtained	O
1889	by	O
1889	simultaneously	O
1889	fitting	O
1889	the	O
1889	i	O
1889	##v	O
1889	and	O
1889	oral	O
1889	data	O
1889	from	O
1889	dogs	O
1889	with	O
1889	e	O
1889	##q	O
1889	##s	O
1889	4	O
1889	–	O
1889	9	O
1889	(	O
1889	fi	O
1889	##g	O
1889	2	O
1889	##b	O
1889	)	O
1889	.	O
1889	[SEP]	O
1890	[CLS]	O
1890	the	O
1890	units	O
1890	of	O
1890	parameters	O
1890	are	O
1890	l	O
1890	/	O
1890	h	O
1890	for	O
1890	c	B-PK
1890	##l	I-PK
1890	and	O
1890	c	B-PK
1890	##ld	I-PK
1890	;	O
1890	l	O
1890	for	O
1890	v	B-PK
1890	##1	I-PK
1890	and	O
1890	v	B-PK
1890	##2	I-PK
1890	;	O
1890	and	O
1890	h	O
1890	-	O
1890	1	O
1890	for	O
1890	all	O
1890	first	B-PK
1890	-	I-PK
1890	order	I-PK
1890	rate	I-PK
1890	constant	I-PK
1890	##s	I-PK
1890	(	O
1890	e	O
1890	.	O
1890	g	O
1890	.	O
1890	,	O
1890	ka	B-PK
1890	,	O
1890	ka	B-PK
1890	##2	I-PK
1890	,	O
1890	ka	B-PK
1890	##t	I-PK
1890	)	O
1890	.	O
1890	[SEP]	O
1891	[CLS]	O
1891	for	O
1891	the	O
1891	population	O
1891	demographic	O
1891	,	O
1891	physiological	O
1891	,	O
1891	and	O
1891	other	O
1891	variables	O
1891	,	O
1891	we	O
1891	used	O
1891	the	O
1891	default	O
1891	values	O
1891	and	O
1891	var	O
1891	##iability	O
1891	(	O
1891	e	O
1891	.	O
1891	g	O
1891	.	O
1891	,	O
1891	40	O
1891	%	O
1891	for	O
1891	c	B-PK
1891	##l	I-PK
1891	and	O
1891	20	O
1891	%	O
1891	for	O
1891	v	B-PK
1891	##1	I-PK
1891	)	O
1891	provided	O
1891	in	O
1891	the	O
1891	program	O
1891	.	O
1891	[SEP]	O
1892	[CLS]	O
1892	the	O
1892	non	O
1892	##com	O
1892	##par	O
1892	##tment	O
1892	##al	O
1892	parameters	O
1892	included	O
1892	the	O
1892	area	B-PK
1892	under	I-PK
1892	the	I-PK
1892	plasma	I-PK
1892	-	I-PK
1892	concentration	I-PK
1892	curve	I-PK
1892	(	I-PK
1892	au	I-PK
1892	##c	I-PK
1892	##0	I-PK
1892	-	I-PK
1892	in	I-PK
1892	##f	I-PK
1892	)	I-PK
1892	,	O
1892	maximum	B-PK
1892	concentration	I-PK
1892	(	I-PK
1892	cm	I-PK
1892	##ax	I-PK
1892	)	I-PK
1892	,	O
1892	time	B-PK
1892	of	I-PK
1892	cm	I-PK
1892	##ax	I-PK
1892	(	I-PK
1892	t	I-PK
1892	##max	I-PK
1892	)	I-PK
1892	,	O
1892	and	O
1892	terminal	B-PK
1892	half	I-PK
1892	-	I-PK
1892	life	I-PK
1892	(	I-PK
1892	t	I-PK
1892	##1	I-PK
1892	/	I-PK
1892	2	I-PK
1892	)	I-PK
1892	.	O
1892	[SEP]	O
1893	[CLS]	O
1893	all	O
1893	##ometric	O
1893	s	O
1893	##cal	O
1893	##ing	O
1893	was	O
1893	applied	O
1893	to	O
1893	the	O
1893	disposition	O
1893	parameters	O
1893	,	O
1893	including	O
1893	clearance	B-PK
1893	(	I-PK
1893	c	I-PK
1893	##l	I-PK
1893	)	I-PK
1893	,	O
1893	central	B-PK
1893	(	I-PK
1893	v	I-PK
1893	##1	I-PK
1893	)	I-PK
1893	and	O
1893	peripheral	B-PK
1893	(	I-PK
1893	v	I-PK
1893	##2	I-PK
1893	)	I-PK
1893	distribution	I-PK
1893	##al	I-PK
1893	volumes	I-PK
1893	,	O
1893	and	O
1893	distribution	B-PK
1893	##al	I-PK
1893	clearance	I-PK
1893	(	I-PK
1893	c	I-PK
1893	##ld	I-PK
1893	)	I-PK
1893	,	O
1893	obtained	O
1893	from	O
1893	simultaneous	O
1893	fitting	O
1893	of	O
1893	oral	O
1893	and	O
1893	i	O
1893	##v	O
1893	plasma	O
1893	concentration	O
1893	-	O
1893	time	O
1893	data	O
1893	for	O
1893	each	O
1893	species	O
1893	.	O
1893	[SEP]	O
1894	[CLS]	O
1894	several	O
1894	studies	O
1894	have	O
1894	shown	O
1894	that	O
1894	modified	O
1894	s	O
1894	##cal	O
1894	##ing	O
1894	methods	O
1894	with	O
1894	a	O
1894	correction	O
1894	of	O
1894	maximum	O
1894	life	O
1894	-	O
1894	span	O
1894	potential	O
1894	(	O
1894	m	O
1894	##l	O
1894	##p	O
1894	)	O
1894	or	O
1894	brain	O
1894	weight	O
1894	(	O
1894	br	O
1894	##w	O
1894	)	O
1894	improve	O
1894	the	O
1894	accuracy	O
1894	of	O
1894	human	O
1894	c	B-PK
1894	##l	I-PK
1894	prediction	O
1894	[	O
1894	18	O
1894	–	O
1894	20	O
1894	]	O
1894	,	O
1894	as	O
1894	long	O
1894	##evity	O
1894	is	O
1894	frequently	O
1894	inverse	O
1894	##ly	O
1894	correlated	O
1894	with	O
1894	he	O
1894	##pa	O
1894	##tic	O
1894	c	O
1894	##yt	O
1894	##och	O
1894	##rome	O
1894	p	O
1894	##45	O
1894	##0	O
1894	drug	O
1894	oxidation	O
1894	rates	O
1894	[	O
1894	18	O
1894	,	O
1894	21	O
1894	]	O
1894	.	O
1894	[SEP]	O
1895	[CLS]	O
1895	therefore	O
1895	,	O
1895	in	O
1895	addition	O
1895	to	O
1895	simple	O
1895	all	O
1895	##ome	O
1895	##try	O
1895	,	O
1895	we	O
1895	applied	O
1895	the	O
1895	m	O
1895	##l	O
1895	##p	O
1895	correction	O
1895	in	O
1895	the	O
1895	prediction	O
1895	of	O
1895	she	O
1895	##ta	O
1895	##2	O
1895	clearance	B-PK
1895	in	O
1895	humans	O
1895	using	O
1895	c	O
1895	##l	O
1895	[UNK]	O
1895	m	O
1895	##l	O
1895	##p	O
1895	=	O
1895	a	O
1895	•	O
1895	b	O
1895	##w	O
1895	##b	O
1895	[	O
1895	20	O
1895	]	O
1895	.	O
1895	[SEP]	O
1896	[CLS]	O
1896	the	O
1896	input	O
1896	data	O
1896	for	O
1896	she	O
1896	##ta	O
1896	##2	O
1896	compound	O
1896	included	O
1896	(	O
1896	a	O
1896	)	O
1896	disposition	O
1896	p	O
1896	##k	O
1896	parameters	O
1896	from	O
1896	the	O
1896	all	O
1896	##ome	O
1896	##tically	O
1896	-	O
1896	scaled	O
1896	human	O
1896	values	O
1896	of	O
1896	c	B-PK
1896	##l	I-PK
1896	,	O
1896	v	B-PK
1896	##1	I-PK
1896	,	O
1896	v	B-PK
1896	##2	I-PK
1896	,	O
1896	and	O
1896	c	B-PK
1896	##ld	I-PK
1896	;	O
1896	(	O
1896	b	O
1896	)	O
1896	she	O
1896	##ta	O
1896	##2	O
1896	doses	O
1896	in	O
1896	mg	O
1896	;	O
1896	and	O
1896	(	O
1896	c	O
1896	)	O
1896	p	O
1896	##hy	O
1896	##si	O
1896	##co	O
1896	##chemical	O
1896	properties	O
1896	,	O
1896	including	O
1896	molecular	O
1896	structure	O
1896	(	O
1896	fi	O
1896	##g	O
1896	1	O
1896	)	O
1896	,	O
1896	experimental	O
1896	##ly	O
1896	calculated	O
1896	log	O
1896	p	O
1896	value	O
1896	of	O
1896	4	O
1896	.	O
1896	23	O
1896	[	O
1896	23	O
1896	]	O
1896	,	O
1896	per	B-PK
1896	##me	I-PK
1896	##ability	I-PK
1896	[	O
1896	24	O
1896	]	O
1896	,	O
1896	and	O
1896	experimental	O
1896	##ly	O
1896	calculated	O
1896	so	O
1896	##lub	O
1896	##ility	O
1896	of	O
1896	19	O
1896	.	O
1896	9	O
1896	μ	O
1896	##g	O
1896	/	O
1896	m	O
1896	##l	O
1896	in	O
1896	simulated	O
1896	gas	O
1896	##tro	O
1896	##int	O
1896	##est	O
1896	##inal	O
1896	fluid	O
1896	.	O
1896	[SEP]	O
1897	[CLS]	O
1897	she	O
1897	##ta	O
1897	##2	O
1897	appeared	O
1897	to	O
1897	be	O
1897	readily	O
1897	distributed	O
1897	into	O
1897	peripheral	O
1897	tissues	O
1897	,	O
1897	as	O
1897	indicated	O
1897	by	O
1897	a	O
1897	high	O
1897	extent	O
1897	of	O
1897	the	O
1897	volume	B-PK
1897	of	I-PK
1897	distribution	I-PK
1897	.	O
1897	[SEP]	O
1898	[CLS]	O
1898	the	O
1898	elimination	B-PK
1898	half	I-PK
1898	-	I-PK
1898	life	I-PK
1898	of	O
1898	she	O
1898	##ta	O
1898	##2	O
1898	after	O
1898	i	O
1898	##v	O
1898	administration	O
1898	in	O
1898	mice	O
1898	was	O
1898	much	O
1898	longer	O
1898	than	O
1898	it	O
1898	was	O
1898	in	O
1898	rats	O
1898	(	O
1898	1	O
1898	.	O
1898	16	O
1898	h	O
1898	)	O
1898	(	O
1898	table	O
1898	2	O
1898	)	O
1898	.	O
1898	[SEP]	O
1899	[CLS]	O
1899	this	O
1899	disposition	O
1899	pattern	O
1899	in	O
1899	non	O
1899	-	O
1899	tumor	O
1899	-	O
1899	bearing	O
1899	mice	O
1899	was	O
1899	also	O
1899	different	O
1899	from	O
1899	what	O
1899	our	O
1899	group	O
1899	observed	O
1899	for	O
1899	she	O
1899	##ta	O
1899	##2	O
1899	in	O
1899	tumor	O
1899	-	O
1899	bearing	O
1899	mice	O
1899	(	O
1899	t	B-PK
1899	##1	I-PK
1899	/	I-PK
1899	2	I-PK
1899	=	O
1899	4	O
1899	.	O
1899	5	O
1899	h	O
1899	)	O
1899	[	O
1899	23	O
1899	]	O
1899	.	O
1899	[SEP]	O
1900	[CLS]	O
1900	the	O
1900	oral	B-PK
1900	bio	I-PK
1900	##ava	I-PK
1900	##ila	I-PK
1900	##bility	I-PK
1900	was	O
1900	estimated	O
1900	to	O
1900	be	O
1900	17	O
1900	.	O
1900	7	O
1900	%	O
1900	and	O
1900	19	O
1900	.	O
1900	5	O
1900	%	O
1900	at	O
1900	20	O
1900	and	O
1900	60	O
1900	mg	O
1900	/	O
1900	kg	O
1900	.	O
1900	[SEP]	O
1901	[CLS]	O
1901	for	O
1901	oral	O
1901	administration	O
1901	in	O
1901	rats	O
1901	,	O
1901	the	O
1901	prolonged	O
1901	absorption	O
1901	kinetic	O
1901	##s	O
1901	were	O
1901	apparent	O
1901	at	O
1901	higher	O
1901	doses	O
1901	(	O
1901	500	O
1901	and	O
1901	2000	O
1901	mg	O
1901	/	O
1901	kg	O
1901	)	O
1901	,	O
1901	as	O
1901	evidenced	O
1901	by	O
1901	the	O
1901	estimated	O
1901	absorption	B-PK
1901	rate	I-PK
1901	constant	I-PK
1901	(	I-PK
1901	ka	I-PK
1901	)	I-PK
1901	of	O
1901	0	O
1901	.	O
1901	07	O
1901	##55	O
1901	h	O
1901	-	O
1901	1	O
1901	and	O
1901	a	O
1901	much	O
1901	slower	O
1901	decline	O
1901	of	O
1901	drug	O
1901	concentration	O
1901	following	O
1901	the	O
1901	oral	O
1901	dose	O
1901	compared	O
1901	with	O
1901	the	O
1901	i	O
1901	##v	O
1901	administration	O
1901	(	O
1901	i	O
1901	.	O
1901	e	O
1901	.	O
1901	,	O
1901	flip	O
1901	-	O
1901	fl	O
1901	##op	O
1901	kinetic	O
1901	##s	O
1901	)	O
1901	.	O
1901	[SEP]	O
1902	[CLS]	O
1902	the	O
1902	oral	B-PK
1902	bio	I-PK
1902	##ava	I-PK
1902	##ila	I-PK
1902	##bility	I-PK
1902	in	O
1902	rats	O
1902	was	O
1902	low	O
1902	,	O
1902	ranging	O
1902	from	O
1902	0	O
1902	.	O
1902	56	O
1902	–	O
1902	1	O
1902	.	O
1902	6	O
1902	%	O
1902	at	O
1902	all	O
1902	studied	O
1902	doses	O
1902	,	O
1902	and	O
1902	the	O
1902	increase	O
1902	in	O
1902	overall	O
1902	systemic	O
1902	exposure	O
1902	(	O
1902	cm	B-PK
1902	##ax	I-PK
1902	and	O
1902	au	B-PK
1902	##c	I-PK
1902	)	O
1902	was	O
1902	less	O
1902	than	O
1902	proportional	O
1902	at	O
1902	2000	O
1902	mg	O
1902	/	O
1902	kg	O
1902	(	O
1902	table	O
1902	3	O
1902	)	O
1902	.	O
1902	[SEP]	O
1903	[CLS]	O
1903	in	O
1903	dogs	O
1903	,	O
1903	the	O
1903	oral	O
1903	absorption	O
1903	was	O
1903	relatively	O
1903	fast	O
1903	,	O
1903	reaching	O
1903	the	O
1903	peak	B-PK
1903	concentration	I-PK
1903	within	O
1903	1	O
1903	–	O
1903	3	O
1903	h	O
1903	after	O
1903	dos	O
1903	##ing	O
1903	.	O
1903	[SEP]	O
1904	[CLS]	O
1904	the	O
1904	increases	O
1904	in	O
1904	cm	B-PK
1904	##ax	I-PK
1904	and	O
1904	au	B-PK
1904	##c	I-PK
1904	were	O
1904	less	O
1904	than	O
1904	proportional	O
1904	with	O
1904	increasing	O
1904	doses	O
1904	(	O
1904	table	O
1904	2	O
1904	)	O
1904	,	O
1904	indicating	O
1904	the	O
1904	non	O
1904	##linear	O
1904	p	O
1904	##k	O
1904	.	O
1904	[SEP]	O
1905	[CLS]	O
1905	the	O
1905	mean	O
1905	cm	B-PK
1905	##ax	I-PK
1905	observed	O
1905	at	O
1905	two	O
1905	high	O
1905	doses	O
1905	of	O
1905	400	O
1905	and	O
1905	1500	O
1905	mg	O
1905	/	O
1905	kg	O
1905	was	O
1905	smaller	O
1905	than	O
1905	that	O
1905	at	O
1905	100	O
1905	mg	O
1905	/	O
1905	kg	O
1905	.	O
1905	[SEP]	O
1906	[CLS]	O
1906	in	O
1906	this	O
1906	model	O
1906	,	O
1906	drug	O
1906	movement	O
1906	along	O
1906	the	O
1906	in	O
1906	##test	O
1906	##ine	O
1906	was	O
1906	modeled	O
1906	by	O
1906	a	O
1906	first	O
1906	-	O
1906	order	O
1906	process	O
1906	(	O
1906	ka	O
1906	##t	O
1906	)	O
1906	through	O
1906	seven	O
1906	transit	O
1906	compartment	O
1906	##s	O
1906	and	O
1906	drug	O
1906	absorption	O
1906	by	O
1906	two	O
1906	different	O
1906	first	B-PK
1906	-	I-PK
1906	order	I-PK
1906	rate	I-PK
1906	constant	I-PK
1906	##s	I-PK
1906	(	O
1906	ka	B-PK
1906	and	O
1906	ka	B-PK
1906	##2	I-PK
1906	)	O
1906	occurring	O
1906	from	O
1906	the	O
1906	g	O
1906	##2	O
1906	and	O
1906	g	O
1906	##7	O
1906	compartment	O
1906	##s	O
1906	.	O
1906	[SEP]	O
1907	[CLS]	O
1907	the	O
1907	magnitude	O
1907	and	O
1907	time	O
1907	of	O
1907	initial	O
1907	and	O
1907	/	O
1907	or	O
1907	second	O
1907	peak	O
1907	occurrence	O
1907	##s	O
1907	varied	O
1907	by	O
1907	doses	O
1907	after	O
1907	oral	O
1907	administration	O
1907	,	O
1907	and	O
1907	bio	B-PK
1907	##ava	I-PK
1907	##ila	I-PK
1907	##bility	I-PK
1907	(	I-PK
1907	f	I-PK
1907	)	I-PK
1907	was	O
1907	marked	O
1907	##ly	O
1907	reduced	O
1907	with	O
1907	increasing	O
1907	doses	O
1907	.	O
1907	[SEP]	O
1908	[CLS]	O
1908	this	O
1908	required	O
1908	the	O
1908	est	O
1908	##imation	O
1908	of	O
1908	the	O
1908	rate	O
1908	and	O
1908	extent	O
1908	of	O
1908	absorption	O
1908	kinetic	O
1908	parameters	O
1908	varying	O
1908	at	O
1908	different	O
1908	doses	O
1908	;	O
1908	those	O
1908	parameters	O
1908	included	O
1908	f	B-PK
1908	,	O
1908	ka	B-PK
1908	##t	I-PK
1908	,	O
1908	ka	B-PK
1908	,	O
1908	and	O
1908	ka	B-PK
1908	##2	I-PK
1908	.	O
1908	[SEP]	O
1909	[CLS]	O
1909	our	O
1909	results	O
1909	indicated	O
1909	that	O
1909	the	O
1909	drug	O
1909	absorption	O
1909	from	O
1909	the	O
1909	g	O
1909	##2	O
1909	compartment	O
1909	(	O
1909	ka	B-PK
1909	)	O
1909	was	O
1909	much	O
1909	slower	O
1909	at	O
1909	higher	O
1909	doses	O
1909	than	O
1909	at	O
1909	low	O
1909	doses	O
1909	(	O
1909	0	O
1909	.	O
1909	41	O
1909	##1	O
1909	vs	O
1909	.	O
1909	1	O
1909	.	O
1909	12	O
1909	h	O
1909	-	O
1909	1	O
1909	)	O
1909	,	O
1909	which	O
1909	contributed	O
1909	to	O
1909	the	O
1909	first	O
1909	peak	O
1909	being	O
1909	lower	O
1909	and	O
1909	delayed	O
1909	at	O
1909	higher	O
1909	doses	O
1909	.	O
1909	[SEP]	O
1910	[CLS]	O
1910	the	O
1910	oral	B-PK
1910	bio	I-PK
1910	##ava	I-PK
1910	##ila	I-PK
1910	##bility	I-PK
1910	of	O
1910	the	O
1910	she	O
1910	##ta	O
1910	##2	O
1910	formulation	O
1910	in	O
1910	dogs	O
1910	was	O
1910	reduced	O
1910	from	O
1910	11	O
1910	.	O
1910	2	O
1910	%	O
1910	at	O
1910	100	O
1910	mg	O
1910	/	O
1910	kg	O
1910	to	O
1910	3	O
1910	.	O
1910	45	O
1910	%	O
1910	at	O
1910	400	O
1910	mg	O
1910	/	O
1910	kg	O
1910	to	O
1910	1	O
1910	.	O
1910	11	O
1910	%	O
1910	at	O
1910	1500	O
1910	mg	O
1910	/	O
1910	kg	O
1910	.	O
1910	[SEP]	O
1911	[CLS]	O
1911	fi	O
1911	##g	O
1911	4	O
1911	shows	O
1911	the	O
1911	comparison	O
1911	of	O
1911	oral	B-PK
1911	bio	I-PK
1911	##ava	I-PK
1911	##ila	I-PK
1911	##bility	I-PK
1911	with	O
1911	respect	O
1911	to	O
1911	dose	O
1911	among	O
1911	mice	O
1911	,	O
1911	rats	O
1911	,	O
1911	and	O
1911	dogs	O
1911	.	O
1911	[SEP]	O
1912	[CLS]	O
1912	the	O
1912	oral	B-PK
1912	bio	I-PK
1912	##ava	I-PK
1912	##ila	I-PK
1912	##bility	I-PK
1912	(	O
1912	18	O
1912	.	O
1912	6	O
1912	%	O
1912	)	O
1912	in	O
1912	mice	O
1912	after	O
1912	20	O
1912	–	O
1912	60	O
1912	mg	O
1912	/	O
1912	kg	O
1912	was	O
1912	the	O
1912	highest	O
1912	among	O
1912	all	O
1912	pre	O
1912	##c	O
1912	##lini	O
1912	##cal	O
1912	studies	O
1912	.	O
1912	[SEP]	O
1913	[CLS]	O
1913	in	O
1913	dogs	O
1913	,	O
1913	bio	B-PK
1913	##ava	I-PK
1913	##ila	I-PK
1913	##bility	I-PK
1913	dose	O
1913	-	O
1913	dependent	O
1913	##ly	O
1913	decreased	O
1913	with	O
1913	increasing	O
1913	doses	O
1913	.	O
1913	[SEP]	O
1914	[CLS]	O
1914	compared	O
1914	with	O
1914	mice	O
1914	and	O
1914	dogs	O
1914	,	O
1914	oral	B-PK
1914	bio	I-PK
1914	##ava	I-PK
1914	##ila	I-PK
1914	##bility	I-PK
1914	in	O
1914	rats	O
1914	was	O
1914	generally	O
1914	low	O
1914	at	O
1914	all	O
1914	doses	O
1914	(	O
1914	f	O
1914	<	O
1914	1	O
1914	.	O
1914	6	O
1914	%	O
1914	)	O
1914	,	O
1914	which	O
1914	could	O
1914	be	O
1914	attributed	O
1914	to	O
1914	several	O
1914	factors	O
1914	,	O
1914	including	O
1914	different	O
1914	formulation	O
1914	used	O
1914	in	O
1914	rats	O
1914	,	O
1914	species	O
1914	differences	O
1914	in	O
1914	absorption	O
1914	through	O
1914	the	O
1914	gas	O
1914	##tro	O
1914	-	O
1914	in	O
1914	##test	O
1914	##inal	O
1914	tract	O
1914	and	O
1914	first	O
1914	-	O
1914	pass	O
1914	metabolism	O
1914	,	O
1914	and	O
1914	different	O
1914	diet	O
1914	##ary	O
1914	habits	O
1914	among	O
1914	species	O
1914	.	O
1914	[SEP]	O
1915	[CLS]	O
1915	inter	O
1915	##sp	O
1915	##ec	O
1915	##ies	O
1915	s	O
1915	##cal	O
1915	##ing	O
1915	was	O
1915	performed	O
1915	on	O
1915	the	O
1915	disposition	O
1915	parameters	O
1915	of	O
1915	clearance	B-PK
1915	(	I-PK
1915	c	I-PK
1915	##l	I-PK
1915	)	I-PK
1915	,	O
1915	central	B-PK
1915	(	I-PK
1915	v	I-PK
1915	##1	I-PK
1915	)	I-PK
1915	and	O
1915	peripheral	B-PK
1915	(	I-PK
1915	v	I-PK
1915	##2	I-PK
1915	)	I-PK
1915	distribution	I-PK
1915	##al	I-PK
1915	volumes	I-PK
1915	,	O
1915	and	O
1915	distribution	B-PK
1915	##al	I-PK
1915	clearance	I-PK
1915	(	I-PK
1915	c	I-PK
1915	##ld	I-PK
1915	;	O
1915	table	O
1915	3	O
1915	)	O
1915	.	O
1915	[SEP]	O
1916	[CLS]	O
1916	doses	O
1916	can	O
1916	be	O
1916	es	O
1916	##calated	O
1916	from	O
1916	2	O
1916	mg	O
1916	/	O
1916	kg	O
1916	to	O
1916	a	O
1916	point	O
1916	at	O
1916	which	O
1916	the	O
1916	peak	B-PK
1916	plasma	I-PK
1916	concentration	I-PK
1916	(	I-PK
1916	cm	I-PK
1916	##ax	I-PK
1916	)	I-PK
1916	reaches	O
1916	4	O
1916	μ	O
1916	##m	O
1916	(	O
1916	equivalent	O
1916	to	O
1916	1600	O
1916	ng	O
1916	/	O
1916	m	O
1916	##l	O
1916	)	O
1916	,	O
1916	the	O
1916	concentration	O
1916	that	O
1916	is	O
1916	sufficient	O
1916	to	O
1916	induce	O
1916	g	O
1916	##1	O
1916	cell	O
1916	cycle	O
1916	arrest	O
1916	within	O
1916	24	O
1916	hours	O
1916	and	O
1916	causes	O
1916	target	O
1916	m	O
1916	##od	O
1916	##ulation	O
1916	within	O
1916	4	O
1916	hours	O
1916	.	O
1916	[SEP]	O
1917	[CLS]	O
1917	the	O
1917	predicted	O
1917	human	O
1917	clearance	B-PK
1917	ranged	O
1917	from	O
1917	17	O
1917	.	O
1917	3	O
1917	l	O
1917	/	O
1917	h	O
1917	(	O
1917	m	O
1917	##l	O
1917	##p	O
1917	-	O
1917	based	O
1917	)	O
1917	to	O
1917	41	O
1917	.	O
1917	0	O
1917	l	O
1917	/	O
1917	h	O
1917	(	O
1917	simple	O
1917	all	O
1917	##ome	O
1917	##try	O
1917	)	O
1917	.	O
1917	[SEP]	O
1918	[CLS]	O
1918	following	O
1918	a	O
1918	single	O
1918	oral	O
1918	dose	O
1918	of	O
1918	0	O
1918	.	O
1918	25	O
1918	–	O
1918	2	O
1918	.	O
1918	0	O
1918	g	O
1918	di	O
1918	##c	O
1918	##lo	O
1918	##xa	O
1918	##ci	O
1918	##llin	O
1918	sodium	O
1918	,	O
1918	the	O
1918	maximum	B-PK
1918	plasma	I-PK
1918	drug	I-PK
1918	concentration	I-PK
1918	(	I-PK
1918	cm	I-PK
1918	##ax	I-PK
1918	)	I-PK
1918	and	O
1918	the	O
1918	corresponding	O
1918	values	O
1918	for	O
1918	the	O
1918	area	B-PK
1918	under	I-PK
1918	the	I-PK
1918	concentration	I-PK
1918	–	I-PK
1918	time	I-PK
1918	curve	I-PK
1918	from	I-PK
1918	0	I-PK
1918	to	I-PK
1918	10	I-PK
1918	hours	I-PK
1918	(	I-PK
1918	au	I-PK
1918	##c	I-PK
1918	##0	I-PK
1918	–	I-PK
1918	10	I-PK
1918	h	I-PK
1918	)	I-PK
1918	increased	O
1918	in	O
1918	a	O
1918	dose	O
1918	-	O
1918	proportional	O
1918	manner	O
1918	.	O
1918	[SEP]	O
1919	[CLS]	O
1919	for	O
1919	the	O
1919	disposition	O
1919	parameters	O
1919	,	O
1919	we	O
1919	used	O
1919	the	O
1919	all	O
1919	##ometric	O
1919	##ally	O
1919	scaled	O
1919	human	O
1919	p	O
1919	##k	O
1919	parameters	O
1919	v	B-PK
1919	##1	I-PK
1919	(	O
1919	36	O
1919	.	O
1919	2	O
1919	l	O
1919	)	O
1919	,	O
1919	v	B-PK
1919	##2	I-PK
1919	(	O
1919	68	O
1919	.	O
1919	5	O
1919	l	O
1919	)	O
1919	,	O
1919	c	B-PK
1919	##ld	I-PK
1919	(	O
1919	15	O
1919	.	O
1919	2	O
1919	l	O
1919	/	O
1919	h	O
1919	)	O
1919	,	O
1919	and	O
1919	m	B-PK
1919	##l	I-PK
1919	##p	I-PK
1919	-	I-PK
1919	based	I-PK
1919	c	I-PK
1919	##l	I-PK
1919	(	O
1919	17	O
1919	.	O
1919	3	O
1919	l	O
1919	/	O
1919	h	O
1919	)	O
1919	to	O
1919	predict	O
1919	the	O
1919	concentration	O
1919	-	O
1919	time	O
1919	profile	O
1919	of	O
1919	she	O
1919	##ta	O
1919	##2	O
1919	in	O
1919	humans	O
1919	.	O
1919	[SEP]	O
1920	[CLS]	O
1920	evaluation	O
1920	of	O
1920	absorption	B-PK
1920	rate	I-PK
1920	constant	I-PK
1920	(	I-PK
1920	ka	I-PK
1920	)	I-PK
1920	was	O
1920	difficult	O
1920	,	O
1920	as	O
1920	there	O
1920	was	O
1920	no	O
1920	correlation	O
1920	in	O
1920	ka	B-PK
1920	across	O
1920	different	O
1920	species	O
1920	(	O
1920	table	O
1920	3	O
1920	)	O
1920	.	O
1920	[SEP]	O
1921	[CLS]	O
1921	the	O
1921	mean	O
1921	predicted	B-PK
1921	bio	I-PK
1921	##ava	I-PK
1921	##ila	I-PK
1921	##bility	I-PK
1921	was	O
1921	18	O
1921	.	O
1921	8	O
1921	%	O
1921	(	O
1921	7	O
1921	.	O
1921	4	O
1921	–	O
1921	42	O
1921	%	O
1921	)	O
1921	which	O
1921	is	O
1921	very	O
1921	close	O
1921	to	O
1921	the	O
1921	maximum	O
1921	bio	B-PK
1921	##ava	I-PK
1921	##ila	I-PK
1921	##bility	I-PK
1921	(	O
1921	18	O
1921	.	O
1921	6	O
1921	%	O
1921	)	O
1921	observed	O
1921	from	O
1921	pre	O
1921	##c	O
1921	##lini	O
1921	##cal	O
1921	species	O
1921	at	O
1921	doses	O
1921	<	O
1921	100	O
1921	mg	O
1921	/	O
1921	kg	O
1921	.	O
1921	[SEP]	O
1922	[CLS]	O
1922	the	O
1922	prediction	O
1922	also	O
1922	suggested	O
1922	no	O
1922	significant	O
1922	difference	O
1922	in	O
1922	bio	B-PK
1922	##ava	I-PK
1922	##ila	I-PK
1922	##bility	I-PK
1922	from	O
1922	dos	O
1922	##ing	O
1922	under	O
1922	the	O
1922	fed	O
1922	state	O
1922	(	O
1922	18	O
1922	.	O
1922	1	O
1922	%	O
1922	)	O
1922	.	O
1922	[SEP]	O
1923	[CLS]	O
1923	the	O
1923	mean	O
1923	elimination	B-PK
1923	half	I-PK
1923	-	I-PK
1923	life	I-PK
1923	(	I-PK
1923	t	I-PK
1923	##1	I-PK
1923	/	I-PK
1923	2	I-PK
1923	)	I-PK
1923	was	O
1923	in	O
1923	the	O
1923	range	O
1923	of	O
1923	1	O
1923	.	O
1923	38	O
1923	–	O
1923	1	O
1923	.	O
1923	71	O
1923	hours	O
1923	.	O
1923	[SEP]	O
1924	[CLS]	O
1924	di	O
1924	##c	O
1924	##lo	O
1924	##xa	O
1924	##ci	O
1924	##llin	O
1924	was	O
1924	safe	O
1924	and	O
1924	well	O
1924	tolerate	O
1924	##d	O
1924	in	O
1924	the	O
1924	volunteers	O
1924	and	O
1924	displayed	O
1924	linear	O
1924	increases	O
1924	in	O
1924	the	O
1924	cm	B-PK
1924	##ax	I-PK
1924	and	O
1924	au	B-PK
1924	##c	I-PK
1924	##0	I-PK
1924	–	I-PK
1924	10	I-PK
1924	h	I-PK
1924	values	O
1924	.	O
1924	[SEP]	O
1925	[CLS]	O
1925	safety	O
1925	evaluation	O
1925	##s	O
1925	included	O
1925	adverse	O
1925	event	O
1925	(	O
1925	a	O
1925	##e	O
1925	)	O
1925	counts	O
1925	,	O
1925	monitoring	O
1925	for	O
1925	serious	O
1925	adverse	O
1925	events	O
1925	(	O
1925	sa	O
1925	##es	O
1925	)	O
1925	with	O
1925	the	O
1925	severity	O
1925	,	O
1925	and	O
1925	relationship	O
1925	to	O
1925	the	O
1925	study	O
1925	drug	O
1925	and	O
1925	regular	O
1925	monitoring	O
1925	of	O
1925	vital	O
1925	signs	O
1925	,	O
1925	physical	O
1925	condition	O
1925	,	O
1925	clinical	O
1925	laboratory	O
1925	tests	O
1925	(	O
1925	e	O
1925	##g	O
1925	,	O
1925	hem	O
1925	##ato	O
1925	##logy	O
1925	parameters	O
1925	,	O
1925	liver	O
1925	function	O
1925	tests	O
1925	[	O
1925	al	O
1925	##ani	O
1925	##ne	O
1925	trans	O
1925	##ami	O
1925	##nas	O
1925	##e	O
1925	(	O
1925	al	O
1925	##t	O
1925	)	O
1925	,	O
1925	as	O
1925	##par	O
1925	##tate	O
1925	amino	O
1925	##tra	O
1925	##ns	O
1925	##fer	O
1925	##ase	O
1925	(	O
1925	as	O
1925	##t	O
1925	)	O
1925	,	O
1925	and	O
1925	gamma	O
1925	-	O
1925	g	O
1925	##lut	O
1925	##am	O
1925	##yl	O
1925	transfer	O
1925	##ase	O
1925	]	O
1925	,	O
1925	kidney	O
1925	function	O
1925	tests	O
1925	[	O
1925	blood	O
1925	u	O
1925	##rea	O
1925	nitrogen	O
1925	and	O
1925	serum	O
1925	c	O
1925	##rea	O
1925	##tin	O
1925	##ine	O
1925	]	O
1925	,	O
1925	and	O
1925	urine	O
1925	analysis	O
1925	)	O
1925	,	O
1925	and	O
1925	12	O
1925	-	O
1925	lead	O
1925	electro	O
1925	##card	O
1925	##io	O
1925	##gram	O
1925	.	O
1925	[SEP]	O
1926	[CLS]	O
1926	the	O
1926	study	O
1926	was	O
1926	conducted	O
1926	in	O
1926	accordance	O
1926	with	O
1926	the	O
1926	principles	O
1926	of	O
1926	the	O
1926	current	O
1926	revision	O
1926	of	O
1926	the	O
1926	declaration	O
1926	of	O
1926	he	O
1926	##ls	O
1926	##ink	O
1926	##i	O
1926	concerning	O
1926	medical	O
1926	research	O
1926	in	O
1926	humans	O
1926	,	O
1926	19	O
1926	the	O
1926	international	O
1926	conference	O
1926	on	O
1926	harm	O
1926	##oni	O
1926	##zation	O
1926	guide	O
1926	##line	O
1926	for	O
1926	good	O
1926	clinical	O
1926	practice	O
1926	,	O
1926	20	O
1926	the	O
1926	guide	O
1926	##line	O
1926	for	O
1926	good	O
1926	clinical	O
1926	practice	O
1926	,	O
1926	and	O
1926	the	O
1926	guide	O
1926	##line	O
1926	for	O
1926	p	O
1926	##har	O
1926	##ma	O
1926	##co	O
1926	##kin	O
1926	##etics	O
1926	studies	O
1926	recommended	O
1926	by	O
1926	the	O
1926	chin	O
1926	##a	O
1926	food	O
1926	and	O
1926	drug	O
1926	administration	O
1926	.	O
1926	21	O
1926	,	O
1926	22	O
1926	[SEP]	O
1927	[CLS]	O
1927	the	O
1927	following	O
1927	p	O
1927	##har	O
1927	##ma	O
1927	##co	O
1927	##kin	O
1927	##etic	O
1927	parameters	O
1927	were	O
1927	obtained	O
1927	for	O
1927	part	O
1927	1	O
1927	:	O
1927	maximum	B-PK
1927	plasma	I-PK
1927	concentration	I-PK
1927	(	I-PK
1927	cm	I-PK
1927	##ax	I-PK
1927	)	I-PK
1927	,	O
1927	time	B-PK
1927	to	I-PK
1927	maximum	I-PK
1927	plasma	I-PK
1927	concentration	I-PK
1927	(	I-PK
1927	t	I-PK
1927	##max	I-PK
1927	)	I-PK
1927	,	O
1927	elimination	B-PK
1927	half	I-PK
1927	-	I-PK
1927	life	I-PK
1927	(	I-PK
1927	t	I-PK
1927	##1	I-PK
1927	/	I-PK
1927	2	I-PK
1927	)	I-PK
1927	,	O
1927	area	B-PK
1927	under	I-PK
1927	the	I-PK
1927	concentration	I-PK
1927	–	I-PK
1927	time	I-PK
1927	curve	I-PK
1927	from	I-PK
1927	time	I-PK
1927	zero	I-PK
1927	to	I-PK
1927	the	I-PK
1927	last	I-PK
1927	q	I-PK
1927	##uant	I-PK
1927	##ifiable	I-PK
1927	concentration	I-PK
1927	(	I-PK
1927	au	I-PK
1927	##c	I-PK
1927	##0	I-PK
1927	–	I-PK
1927	10	I-PK
1927	h	I-PK
1927	)	I-PK
1927	,	O
1927	au	B-PK
1927	##c	I-PK
1927	from	I-PK
1927	time	I-PK
1927	zero	I-PK
1927	extra	I-PK
1927	##pol	I-PK
1927	##ated	I-PK
1927	to	I-PK
1927	in	I-PK
1927	##finity	I-PK
1927	(	I-PK
1927	au	I-PK
1927	##c	I-PK
1927	##0	I-PK
1927	–	I-PK
1927	∞	I-PK
1927	)	I-PK
1927	,	O
1927	apparent	B-PK
1927	oral	I-PK
1927	clearance	I-PK
1927	(	I-PK
1927	c	I-PK
1927	##l	I-PK
1927	/	I-PK
1927	f	I-PK
1927	)	I-PK
1927	,	O
1927	apparent	B-PK
1927	volume	I-PK
1927	of	I-PK
1927	distribution	I-PK
1927	during	I-PK
1927	the	I-PK
1927	terminal	I-PK
1927	elimination	I-PK
1927	phase	I-PK
1927	following	I-PK
1927	extra	I-PK
1927	##vas	I-PK
1927	##cular	I-PK
1927	administration	I-PK
1927	(	I-PK
1927	v	I-PK
1927	##z	I-PK
1927	/	I-PK
1927	f	I-PK
1927	)	I-PK
1927	.	O
1927	[SEP]	O
1928	[CLS]	O
1928	t	B-PK
1928	##1	I-PK
1928	/	I-PK
1928	2	I-PK
1928	,	O
1928	c	B-PK
1928	##l	I-PK
1928	/	I-PK
1928	f	I-PK
1928	,	O
1928	and	O
1928	vs	B-PK
1928	##s	I-PK
1928	/	I-PK
1928	f	I-PK
1928	(	I-PK
1928	volume	I-PK
1928	of	I-PK
1928	distribution	I-PK
1928	at	I-PK
1928	the	I-PK
1928	steady	I-PK
1928	state	I-PK
1928	)	I-PK
1928	were	O
1928	calculated	O
1928	using	O
1928	the	O
1928	same	O
1928	method	O
1928	as	O
1928	for	O
1928	single	O
1928	-	O
1928	dose	O
1928	period	O
1928	.	O
1928	[SEP]	O
1929	[CLS]	O
1929	the	O
1929	accumulation	O
1929	ratio	O
1929	was	O
1929	calculated	O
1929	as	O
1929	the	O
1929	ratio	O
1929	of	O
1929	au	B-PK
1929	##c	I-PK
1929	##0	I-PK
1929	–	I-PK
1929	τ	I-PK
1929	,	I-PK
1929	s	I-PK
1929	##s	I-PK
1929	to	O
1929	au	B-PK
1929	##c	I-PK
1929	##0	I-PK
1929	–	I-PK
1929	τ	I-PK
1929	(	O
1929	single	O
1929	dose	O
1929	)	O
1929	,	O
1929	and	O
1929	the	O
1929	flu	B-PK
1929	##ct	I-PK
1929	##uation	I-PK
1929	ratio	I-PK
1929	was	O
1929	calculated	O
1929	by	O
1929	(	B-PK
1929	cm	I-PK
1929	##ax	I-PK
1929	,	I-PK
1929	s	I-PK
1929	##s	I-PK
1929	−	I-PK
1929	cm	I-PK
1929	##in	I-PK
1929	,	I-PK
1929	s	I-PK
1929	##s	I-PK
1929	)	I-PK
1929	/	I-PK
1929	ca	I-PK
1929	##v	I-PK
1929	##g	I-PK
1929	,	O
1929	where	O
1929	ca	B-PK
1929	##v	I-PK
1929	##g	I-PK
1929	is	O
1929	the	O
1929	average	B-PK
1929	steady	I-PK
1929	-	I-PK
1929	state	I-PK
1929	drug	I-PK
1929	concentration	I-PK
1929	during	O
1929	multiple	O
1929	dos	O
1929	##ing	O
1929	,	O
1929	which	O
1929	is	O
1929	calculated	O
1929	as	O
1929	au	B-PK
1929	##c	I-PK
1929	##0	I-PK
1929	–	I-PK
1929	τ	I-PK
1929	,	I-PK
1929	s	I-PK
1929	##s	I-PK
1929	/	I-PK
1929	τ	I-PK
1929	,	O
1929	where	O
1929	τ	O
1929	is	O
1929	the	O
1929	dos	O
1929	##ing	O
1929	interval	O
1929	(	O
1929	6	O
1929	hours	O
1929	)	O
1929	.	O
1929	[SEP]	O
1930	[CLS]	O
1930	in	O
1930	addition	O
1930	,	O
1930	the	O
1930	amount	O
1930	of	O
1930	drug	B-PK
1930	ex	I-PK
1930	##cre	I-PK
1930	##ted	I-PK
1930	into	I-PK
1930	the	I-PK
1930	urine	I-PK
1930	from	I-PK
1930	time	I-PK
1930	zero	I-PK
1930	to	I-PK
1930	time	I-PK
1930	24	I-PK
1930	hours	I-PK
1930	(	I-PK
1930	a	I-PK
1930	##e	I-PK
1930	##0	I-PK
1930	–	I-PK
1930	24	I-PK
1930	)	I-PK
1930	and	O
1930	re	B-PK
1930	##nal	I-PK
1930	clearance	I-PK
1930	were	O
1930	determined	O
1930	for	O
1930	each	O
1930	single	O
1930	-	O
1930	dose	O
1930	p	O
1930	##har	O
1930	##ma	O
1930	##co	O
1930	##kin	O
1930	##etic	O
1930	group	O
1930	from	O
1930	the	O
1930	urine	O
1930	drug	O
1930	concentration	O
1930	–	O
1930	time	O
1930	data	O
1930	.	O
1930	[SEP]	O
1931	[CLS]	O
1931	p	O
1931	##har	O
1931	##ma	O
1931	##co	O
1931	##kin	O
1931	##etic	O
1931	parameters	O
1931	were	O
1931	expressed	O
1931	using	O
1931	arithmetic	O
1931	means	O
1931	and	O
1931	standard	O
1931	de	O
1931	##viation	O
1931	##s	O
1931	,	O
1931	except	O
1931	for	O
1931	t	B-PK
1931	##max	I-PK
1931	,	O
1931	for	O
1931	which	O
1931	median	O
1931	values	O
1931	and	O
1931	ranges	O
1931	are	O
1931	reported	O
1931	.	O
1931	[SEP]	O
1932	[CLS]	O
1932	to	O
1932	test	O
1932	dose	O
1932	proportional	O
1932	##ity	O
1932	in	O
1932	the	O
1932	single	O
1932	-	O
1932	dose	O
1932	range	O
1932	studied	O
1932	,	O
1932	log	O
1932	-	O
1932	transformed	O
1932	p	O
1932	##har	O
1932	##ma	O
1932	##co	O
1932	##kin	O
1932	##etic	O
1932	parameters	O
1932	au	B-PK
1932	##c	I-PK
1932	and	O
1932	cm	B-PK
1932	##ax	I-PK
1932	were	O
1932	analyzed	O
1932	by	O
1932	using	O
1932	the	O
1932	power	O
1932	model	O
1932	,	O
1932	p	O
1932	##k	O
1932	=	O
1932	a	O
1932	×	O
1932	(	O
1932	dose	O
1932	)	O
1932	β	O
1932	,	O
1932	where	O
1932	p	O
1932	##k	O
1932	is	O
1932	the	O
1932	p	O
1932	##har	O
1932	##ma	O
1932	##co	O
1932	##kin	O
1932	##etic	O
1932	parameter	O
1932	,	O
1932	a	O
1932	is	O
1932	the	O
1932	intercept	O
1932	,	O
1932	and	O
1932	β	O
1932	is	O
1932	the	O
1932	dose	O
1932	-	O
1932	proportional	O
1932	##ity	O
1932	coefficient	O
1932	.	O
1932	[SEP]	O
1933	[CLS]	O
1933	the	O
1933	results	O
1933	for	O
1933	t	B-PK
1933	##max	I-PK
1933	were	O
1933	evaluated	O
1933	using	O
1933	the	O
1933	w	O
1933	##il	O
1933	##co	O
1933	##xon	O
1933	rank	O
1933	-	O
1933	sum	O
1933	analysis	O
1933	.	O
1933	[SEP]	O
1934	[CLS]	O
1934	no	O
1934	subjects	O
1934	experienced	O
1934	sa	O
1934	##es	O
1934	,	O
1934	or	O
1934	were	O
1934	withdrawn	O
1934	from	O
1934	the	O
1934	study	O
1934	after	O
1934	dos	O
1934	##ing	O
1934	due	O
1934	to	O
1934	an	O
1934	a	O
1934	##e	O
1934	.	O
1934	[SEP]	O
1935	[CLS]	O
1935	only	O
1935	one	O
1935	subject	O
1935	(	O
1935	1	O
1935	/	O
1935	16	O
1935	,	O
1935	6	O
1935	.	O
1935	25	O
1935	%	O
1935	)	O
1935	developed	O
1935	le	O
1935	##uc	O
1935	##ope	O
1935	##nia	O
1935	and	O
1935	ne	O
1935	##ut	O
1935	##rop	O
1935	##enia	O
1935	that	O
1935	were	O
1935	assessed	O
1935	as	O
1935	mild	O
1935	a	O
1935	##e	O
1935	;	O
1935	both	O
1935	were	O
1935	suspected	O
1935	to	O
1935	be	O
1935	related	O
1935	to	O
1935	the	O
1935	study	O
1935	drug	O
1935	.	O
1935	[SEP]	O
1936	[CLS]	O
1936	the	O
1936	mean	O
1936	cm	B-PK
1936	##ax	I-PK
1936	values	O
1936	for	O
1936	the	O
1936	0	O
1936	.	O
1936	25	O
1936	,	O
1936	0	O
1936	.	O
1936	5	O
1936	,	O
1936	1	O
1936	.	O
1936	0	O
1936	,	O
1936	and	O
1936	2	O
1936	.	O
1936	0	O
1936	g	O
1936	group	O
1936	were	O
1936	13	O
1936	.	O
1936	62	O
1936	µ	O
1936	##g	O
1936	·	O
1936	m	O
1936	##l	O
1936	##−	O
1936	##1	O
1936	,	O
1936	24	O
1936	.	O
1936	28	O
1936	µ	O
1936	##g	O
1936	·	O
1936	m	O
1936	##l	O
1936	##−	O
1936	##1	O
1936	,	O
1936	45	O
1936	.	O
1936	02	O
1936	µ	O
1936	##g	O
1936	·	O
1936	m	O
1936	##l	O
1936	##−	O
1936	##1	O
1936	,	O
1936	and	O
1936	79	O
1936	.	O
1936	97	O
1936	µ	O
1936	##g	O
1936	·	O
1936	m	O
1936	##l	O
1936	##−	O
1936	##1	O
1936	,	O
1936	respectively	O
1936	.	O
1936	[SEP]	O
1937	[CLS]	O
1937	the	O
1937	au	B-PK
1937	##c	I-PK
1937	##0	I-PK
1937	–	I-PK
1937	10	I-PK
1937	h	I-PK
1937	values	O
1937	were	O
1937	31	O
1937	.	O
1937	60	O
1937	µ	O
1937	##g	O
1937	·	O
1937	h	O
1937	·	O
1937	m	O
1937	##l	O
1937	##−	O
1937	##1	O
1937	,	O
1937	61	O
1937	.	O
1937	40	O
1937	µ	O
1937	##g	O
1937	·	O
1937	h	O
1937	·	O
1937	m	O
1937	##l	O
1937	##−	O
1937	##1	O
1937	,	O
1937	108	O
1937	.	O
1937	73	O
1937	µ	O
1937	##g	O
1937	·	O
1937	h	O
1937	·	O
1937	m	O
1937	##l	O
1937	##−	O
1937	##1	O
1937	,	O
1937	and	O
1937	203	O
1937	.	O
1937	29	O
1937	µ	O
1937	##g	O
1937	·	O
1937	h	O
1937	·	O
1937	m	O
1937	##l	O
1937	##−	O
1937	##1	O
1937	,	O
1937	respectively	O
1937	.	O
1937	[SEP]	O
1938	[CLS]	O
1938	plasma	B-PK
1938	t	I-PK
1938	##1	I-PK
1938	/	I-PK
1938	2	I-PK
1938	was	O
1938	independent	O
1938	of	O
1938	the	O
1938	dose	O
1938	,	O
1938	averaging	O
1938	1	O
1938	.	O
1938	51	O
1938	hours	O
1938	(	O
1938	0	O
1938	.	O
1938	92	O
1938	–	O
1938	2	O
1938	.	O
1938	56	O
1938	hours	O
1938	)	O
1938	.	O
1938	[SEP]	O
1939	[CLS]	O
1939	the	O
1939	trend	O
1939	for	O
1939	an	O
1939	increasing	O
1939	t	B-PK
1939	##1	I-PK
1939	/	I-PK
1939	2	I-PK
1939	with	O
1939	increasing	O
1939	dose	O
1939	has	O
1939	been	O
1939	observed	O
1939	,	O
1939	and	O
1939	at	O
1939	the	O
1939	highest	O
1939	dose	O
1939	of	O
1939	2	O
1939	.	O
1939	0	O
1939	g	O
1939	,	O
1939	t	B-PK
1939	##1	I-PK
1939	/	I-PK
1939	2	I-PK
1939	was	O
1939	in	O
1939	the	O
1939	range	O
1939	of	O
1939	1	O
1939	.	O
1939	13	O
1939	–	O
1939	2	O
1939	.	O
1939	56	O
1939	hours	O
1939	.	O
1939	[SEP]	O
1940	[CLS]	O
1940	the	O
1940	apparent	B-PK
1940	volume	I-PK
1940	of	I-PK
1940	distribution	I-PK
1940	and	O
1940	apparent	B-PK
1940	clearance	I-PK
1940	ranged	O
1940	between	O
1940	9	O
1940	.	O
1940	7	O
1940	and	O
1940	40	O
1940	.	O
1940	97	O
1940	l	O
1940	and	O
1940	5	O
1940	.	O
1940	33	O
1940	and	O
1940	16	O
1940	.	O
1940	89	O
1940	l	O
1940	·	O
1940	h	O
1940	##−	O
1940	##1	O
1940	,	O
1940	respectively	O
1940	,	O
1940	over	O
1940	the	O
1940	entire	O
1940	dose	O
1940	range	O
1940	.	O
1940	[SEP]	O
1941	[CLS]	O
1941	for	O
1941	the	O
1941	relationship	O
1941	between	O
1941	non	O
1941	-	O
1941	compartment	O
1941	##al	O
1941	parameters	O
1941	(	O
1941	au	B-PK
1941	##c	I-PK
1941	##0	I-PK
1941	–	I-PK
1941	∞	I-PK
1941	and	O
1941	/	O
1941	or	O
1941	au	B-PK
1941	##c	I-PK
1941	##0	I-PK
1941	–	I-PK
1941	10	I-PK
1941	h	I-PK
1941	and	O
1941	cm	B-PK
1941	##ax	I-PK
1941	)	O
1941	and	O
1941	dose	O
1941	,	O
1941	analysis	O
1941	results	O
1941	indicated	O
1941	that	O
1941	the	O
1941	estimated	O
1941	proportional	O
1941	##ity	O
1941	coefficients	O
1941	(	O
1941	β	O
1941	)	O
1941	for	O
1941	au	B-PK
1941	##c	I-PK
1941	##0	I-PK
1941	–	I-PK
1941	∞	I-PK
1941	,	O
1941	au	B-PK
1941	##c	I-PK
1941	##0	I-PK
1941	–	I-PK
1941	10	I-PK
1941	h	I-PK
1941	,	O
1941	and	O
1941	cm	B-PK
1941	##ax	I-PK
1941	were	O
1941	0	O
1941	.	O
1941	87	O
1941	##6	O
1941	(	O
1941	90	O
1941	%	O
1941	c	O
1941	##i	O
1941	:	O
1941	0	O
1941	.	O
1941	81	O
1941	##2	O
1941	–	O
1941	0	O
1941	.	O
1941	94	O
1941	##0	O
1941	)	O
1941	,	O
1941	0	O
1941	.	O
1941	88	O
1941	##1	O
1941	(	O
1941	90	O
1941	%	O
1941	c	O
1941	##i	O
1941	:	O
1941	0	O
1941	.	O
1941	81	O
1941	##6	O
1941	–	O
1941	0	O
1941	.	O
1941	94	O
1941	##5	O
1941	)	O
1941	,	O
1941	and	O
1941	0	O
1941	.	O
1941	82	O
1941	##8	O
1941	(	O
1941	90	O
1941	%	O
1941	c	O
1941	##i	O
1941	:	O
1941	0	O
1941	.	O
1941	70	O
1941	##9	O
1941	–	O
1941	0	O
1941	.	O
1941	94	O
1941	##8	O
1941	)	O
1941	,	O
1941	respectively	O
1941	.	O
1941	[SEP]	O
1942	[CLS]	O
1942	this	O
1942	indicated	O
1942	a	O
1942	slightly	O
1942	less	O
1942	than	O
1942	dose	O
1942	-	O
1942	proportional	O
1942	increase	O
1942	of	O
1942	au	B-PK
1942	##c	I-PK
1942	and	O
1942	cm	B-PK
1942	##ax	I-PK
1942	in	O
1942	the	O
1942	dose	O
1942	range	O
1942	of	O
1942	0	O
1942	.	O
1942	25	O
1942	–	O
1942	2	O
1942	.	O
1942	0	O
1942	g	O
1942	,	O
1942	with	O
1942	a	O
1942	slope	O
1942	β	O
1942	of	O
1942	slightly	O
1942	less	O
1942	than	O
1942	1	O
1942	.	O
1942	[SEP]	O
1943	[CLS]	O
1943	no	O
1943	significant	O
1943	differences	O
1943	in	O
1943	t	B-PK
1943	##max	I-PK
1943	,	O
1943	t	B-PK
1943	##1	I-PK
1943	/	I-PK
1943	2	I-PK
1943	,	O
1943	m	B-PK
1943	##rt	I-PK
1943	##0	I-PK
1943	–	I-PK
1943	10	I-PK
1943	h	I-PK
1943	,	O
1943	m	B-PK
1943	##rt	I-PK
1943	##0	I-PK
1943	–	I-PK
1943	∞	I-PK
1943	,	O
1943	cm	B-PK
1943	##ax	I-PK
1943	,	O
1943	c	B-PK
1943	##l	I-PK
1943	/	I-PK
1943	f	I-PK
1943	,	O
1943	v	B-PK
1943	##z	I-PK
1943	/	I-PK
1943	f	I-PK
1943	,	O
1943	au	B-PK
1943	##c	I-PK
1943	##0	I-PK
1943	–	I-PK
1943	10	I-PK
1943	h	I-PK
1943	,	O
1943	au	B-PK
1943	##c	I-PK
1943	##0	I-PK
1943	–	I-PK
1943	∞	I-PK
1943	,	O
1943	or	O
1943	a	B-PK
1943	##e	I-PK
1943	were	O
1943	detected	O
1943	between	O
1943	male	O
1943	and	O
1943	female	O
1943	subjects	O
1943	who	O
1943	received	O
1943	0	O
1943	.	O
1943	5	O
1943	,	O
1943	1	O
1943	.	O
1943	0	O
1943	,	O
1943	or	O
1943	2	O
1943	.	O
1943	0	O
1943	g	O
1943	di	O
1943	##c	O
1943	##lo	O
1943	##xa	O
1943	##ci	O
1943	##llin	O
1943	sodium	O
1943	.	O
1943	[SEP]	O
1944	[CLS]	O
1944	in	O
1944	subjects	O
1944	who	O
1944	received	O
1944	0	O
1944	.	O
1944	25	O
1944	g	O
1944	di	O
1944	##c	O
1944	##lo	O
1944	##xa	O
1944	##ci	O
1944	##llin	O
1944	sodium	O
1944	,	O
1944	significant	O
1944	differences	O
1944	in	O
1944	au	B-PK
1944	##c	I-PK
1944	##0	I-PK
1944	–	I-PK
1944	∞	I-PK
1944	(	O
1944	p	O
1944	=	O
1944	0	O
1944	.	O
1944	04	O
1944	##4	O
1944	)	O
1944	and	O
1944	c	B-PK
1944	##l	I-PK
1944	/	I-PK
1944	f	I-PK
1944	(	O
1944	p	O
1944	=	O
1944	0	O
1944	.	O
1944	02	O
1944	##6	O
1944	)	O
1944	were	O
1944	observed	O
1944	between	O
1944	the	O
1944	two	O
1944	sex	O
1944	.	O
1944	[SEP]	O
1945	[CLS]	O
1945	di	O
1945	##c	O
1945	##lo	O
1945	##xa	O
1945	##ci	O
1945	##llin	O
1945	at	O
1945	doses	O
1945	of	O
1945	0	O
1945	.	O
1945	25	O
1945	g	O
1945	q	O
1945	##6	O
1945	##h	O
1945	and	O
1945	0	O
1945	.	O
1945	5	O
1945	g	O
1945	q	O
1945	##6	O
1945	##h	O
1945	was	O
1945	rapidly	O
1945	absorbed	O
1945	,	O
1945	with	O
1945	t	B-PK
1945	##max	I-PK
1945	,	I-PK
1945	s	I-PK
1945	##s	I-PK
1945	ranging	O
1945	from	O
1945	0	O
1945	.	O
1945	33	O
1945	to	O
1945	3	O
1945	.	O
1945	0	O
1945	hours	O
1945	after	O
1945	dose	O
1945	across	O
1945	subjects	O
1945	on	O
1945	day	O
1945	3	O
1945	.	O
1945	[SEP]	O
1946	[CLS]	O
1946	the	O
1946	corresponding	O
1946	au	B-PK
1946	##c	I-PK
1946	##0	I-PK
1946	–	I-PK
1946	10	I-PK
1946	h	I-PK
1946	values	O
1946	on	O
1946	day	O
1946	3	O
1946	were	O
1946	33	O
1946	.	O
1946	72	O
1946	µ	O
1946	##g	O
1946	·	O
1946	h	O
1946	·	O
1946	m	O
1946	##l	O
1946	##−	O
1946	##1	O
1946	and	O
1946	62	O
1946	.	O
1946	06	O
1946	µ	O
1946	##g	O
1946	·	O
1946	h	O
1946	·	O
1946	m	O
1946	##l	O
1946	##−	O
1946	##1	O
1946	.	O
1946	[SEP]	O
1947	[CLS]	O
1947	the	O
1947	mean	O
1947	peak	B-PK
1947	plasma	I-PK
1947	concentrations	I-PK
1947	(	I-PK
1947	cm	I-PK
1947	##ax	I-PK
1947	)	I-PK
1947	after	O
1947	i	O
1947	.	O
1947	v	O
1947	.	O
1947	,	O
1947	i	O
1947	.	O
1947	m	O
1947	.	O
1947	,	O
1947	and	O
1947	p	O
1947	.	O
1947	o	O
1947	administration	O
1947	were	O
1947	2	O
1947	.	O
1947	60	O
1947	±	O
1947	0	O
1947	.	O
1947	10	O
1947	,	O
1947	2	O
1947	.	O
1947	59	O
1947	±	O
1947	0	O
1947	.	O
1947	12	O
1947	,	O
1947	and	O
1947	2	O
1947	.	O
1947	34	O
1947	±	O
1947	0	O
1947	.	O
1947	12	O
1947	µ	O
1947	##g	O
1947	/	O
1947	m	O
1947	##l	O
1947	at	O
1947	0	O
1947	.	O
1947	25	O
1947	±	O
1947	0	O
1947	.	O
1947	00	O
1947	,	O
1947	0	O
1947	.	O
1947	44	O
1947	±	O
1947	0	O
1947	.	O
1947	10	O
1947	,	O
1947	and	O
1947	1	O
1947	.	O
1947	58	O
1947	±	O
1947	0	O
1947	.	O
1947	40	O
1947	h	O
1947	,	O
1947	respectively	O
1947	.	O
1947	[SEP]	O
1948	[CLS]	O
1948	the	O
1948	area	B-PK
1948	under	I-PK
1948	the	I-PK
1948	plasma	I-PK
1948	concentration	I-PK
1948	-	I-PK
1948	time	I-PK
1948	curves	I-PK
1948	(	I-PK
1948	au	I-PK
1948	##c	I-PK
1948	##0	I-PK
1948	–	I-PK
1948	24	I-PK
1948	)	I-PK
1948	and	O
1948	elimination	B-PK
1948	half	I-PK
1948	-	I-PK
1948	lives	I-PK
1948	were	O
1948	24	O
1948	.	O
1948	80	O
1948	±	O
1948	0	O
1948	.	O
1948	90	O
1948	,	O
1948	25	O
1948	.	O
1948	80	O
1948	±	O
1948	1	O
1948	.	O
1948	40	O
1948	,	O
1948	and	O
1948	23	O
1948	.	O
1948	40	O
1948	±	O
1948	5	O
1948	.	O
1948	00	O
1948	h	O
1948	·	O
1948	μ	O
1948	##g	O
1948	/	O
1948	m	O
1948	##l	O
1948	and	O
1948	8	O
1948	.	O
1948	60	O
1948	±	O
1948	0	O
1948	.	O
1948	30	O
1948	,	O
1948	12	O
1948	.	O
1948	80	O
1948	±	O
1948	1	O
1948	.	O
1948	10	O
1948	,	O
1948	and	O
1948	8	O
1948	.	O
1948	60	O
1948	±	O
1948	0	O
1948	.	O
1948	00	O
1948	h	O
1948	,	O
1948	for	O
1948	i	O
1948	.	O
1948	v	O
1948	.	O
1948	,	O
1948	i	O
1948	.	O
1948	m	O
1948	.	O
1948	,	O
1948	and	O
1948	p	O
1948	.	O
1948	o	O
1948	.	O
1948	administration	O
1948	,	O
1948	corresponding	O
1948	##ly	O
1948	.	O
1948	[SEP]	O
1949	[CLS]	O
1949	the	O
1949	area	B-PK
1949	under	I-PK
1949	the	I-PK
1949	curve	I-PK
1949	(	I-PK
1949	au	I-PK
1949	##c	I-PK
1949	)	I-PK
1949	,	O
1949	peak	B-PK
1949	times	I-PK
1949	(	I-PK
1949	t	I-PK
1949	##max	I-PK
1949	)	I-PK
1949	,	O
1949	peak	B-PK
1949	plasma	I-PK
1949	concentrations	I-PK
1949	(	I-PK
1949	cm	I-PK
1949	##ax	I-PK
1949	)	I-PK
1949	,	O
1949	elimination	B-PK
1949	half	I-PK
1949	-	I-PK
1949	life	I-PK
1949	(	I-PK
1949	t	I-PK
1949	##1	I-PK
1949	/	I-PK
1949	2	I-PK
1949	)	I-PK
1949	,	O
1949	and	O
1949	absolute	B-PK
1949	bio	I-PK
1949	##ava	I-PK
1949	##ila	I-PK
1949	##bility	I-PK
1949	(	I-PK
1949	f	I-PK
1949	)	I-PK
1949	were	O
1949	calculated	O
1949	for	O
1949	p	O
1949	##har	O
1949	##ma	O
1949	##co	O
1949	##kin	O
1949	##etic	O
1949	determination	O
1949	using	O
1949	a	O
1949	non	O
1949	##com	O
1949	##par	O
1949	##tment	O
1949	##al	O
1949	analysis	O
1949	.	O
1949	[SEP]	O
1950	[CLS]	O
1950	the	O
1950	absolute	B-PK
1950	bio	I-PK
1950	##ava	I-PK
1950	##ila	I-PK
1950	##bility	I-PK
1950	for	O
1950	i	O
1950	.	O
1950	m	O
1950	.	O
1950	administration	O
1950	was	O
1950	determined	O
1950	with	O
1950	the	O
1950	formula	O
1950	f	O
1950	=	O
1950	(	O
1950	au	O
1950	##ci	O
1950	##m	O
1950	/	O
1950	au	O
1950	##ci	O
1950	##v	O
1950	)	O
1950	×	O
1950	100	O
1950	%	O
1950	.	O
1950	[SEP]	O
1951	[CLS]	O
1951	similarly	O
1951	,	O
1951	absolute	B-PK
1951	bio	I-PK
1951	##ava	I-PK
1951	##ila	I-PK
1951	##bility	I-PK
1951	was	O
1951	determined	O
1951	by	O
1951	f	O
1951	=	O
1951	(	O
1951	au	O
1951	##c	O
1951	##po	O
1951	/	O
1951	au	O
1951	##ci	O
1951	##v	O
1951	)	O
1951	×	O
1951	100	O
1951	%	O
1951	,	O
1951	in	O
1951	the	O
1951	case	O
1951	of	O
1951	p	O
1951	.	O
1951	o	O
1951	.	O
1951	administration	O
1951	.	O
1951	[SEP]	O
1952	[CLS]	O
1952	the	O
1952	peak	B-PK
1952	plasma	I-PK
1952	concentrations	I-PK
1952	(	I-PK
1952	cm	I-PK
1952	##ax	I-PK
1952	)	I-PK
1952	of	O
1952	ma	O
1952	##rb	O
1952	##of	O
1952	##lo	O
1952	##xa	O
1952	##cin	O
1952	were	O
1952	2	O
1952	.	O
1952	60	O
1952	±	O
1952	0	O
1952	.	O
1952	10	O
1952	μ	O
1952	##g	O
1952	/	O
1952	m	O
1952	##l	O
1952	,	O
1952	2	O
1952	.	O
1952	59	O
1952	±	O
1952	0	O
1952	.	O
1952	12	O
1952	μ	O
1952	##g	O
1952	/	O
1952	m	O
1952	##l	O
1952	,	O
1952	and	O
1952	2	O
1952	.	O
1952	34	O
1952	±	O
1952	0	O
1952	.	O
1952	12	O
1952	μ	O
1952	##g	O
1952	/	O
1952	m	O
1952	##l	O
1952	for	O
1952	i	O
1952	.	O
1952	v	O
1952	.	O
1952	,	O
1952	i	O
1952	.	O
1952	m	O
1952	.	O
1952	,	O
1952	and	O
1952	p	O
1952	.	O
1952	o	O
1952	.	O
1952	administration	O
1952	,	O
1952	respectively	O
1952	.	O
1952	[SEP]	O
1953	[CLS]	O
1953	the	O
1953	areas	B-PK
1953	under	I-PK
1953	the	I-PK
1953	plasma	I-PK
1953	concentration	I-PK
1953	-	I-PK
1953	time	I-PK
1953	curves	I-PK
1953	(	I-PK
1953	au	I-PK
1953	##c	I-PK
1953	##0	I-PK
1953	–	I-PK
1953	24	I-PK
1953	)	I-PK
1953	were	O
1953	24	O
1953	.	O
1953	80	O
1953	±	O
1953	0	O
1953	.	O
1953	90	O
1953	,	O
1953	25	O
1953	.	O
1953	80	O
1953	±	O
1953	1	O
1953	.	O
1953	40	O
1953	,	O
1953	and	O
1953	23	O
1953	.	O
1953	40	O
1953	±	O
1953	5	O
1953	.	O
1953	00	O
1953	h	O
1953	·	O
1953	μ	O
1953	##g	O
1953	/	O
1953	m	O
1953	##l	O
1953	for	O
1953	i	O
1953	.	O
1953	v	O
1953	.	O
1953	,	O
1953	i	O
1953	.	O
1953	m	O
1953	.	O
1953	,	O
1953	and	O
1953	p	O
1953	.	O
1953	o	O
1953	.	O
1953	administration	O
1953	,	O
1953	corresponding	O
1953	##ly	O
1953	.	O
1953	[SEP]	O
1954	[CLS]	O
1954	the	O
1954	elimination	B-PK
1954	half	I-PK
1954	-	I-PK
1954	life	I-PK
1954	(	I-PK
1954	t	I-PK
1954	##1	I-PK
1954	/	I-PK
1954	2	I-PK
1954	)	I-PK
1954	values	O
1954	were	O
1954	8	O
1954	.	O
1954	60	O
1954	±	O
1954	0	O
1954	.	O
1954	30	O
1954	,	O
1954	12	O
1954	.	O
1954	80	O
1954	±	O
1954	1	O
1954	.	O
1954	10	O
1954	,	O
1954	and	O
1954	8	O
1954	.	O
1954	60	O
1954	±	O
1954	0	O
1954	.	O
1954	00	O
1954	h	O
1954	,	O
1954	corresponding	O
1954	##ly	O
1954	in	O
1954	i	O
1954	.	O
1954	v	O
1954	.	O
1954	,	O
1954	i	O
1954	.	O
1954	m	O
1954	.	O
1954	,	O
1954	and	O
1954	p	O
1954	.	O
1954	o	O
1954	.	O
1954	administration	O
1954	.	O
1954	[SEP]	O
1955	[CLS]	O
1955	the	O
1955	in	O
1955	v	O
1955	##it	O
1955	##ro	O
1955	mi	O
1955	##c	O
1955	and	O
1955	m	O
1955	##b	O
1955	##c	O
1955	data	O
1955	were	O
1955	integrated	O
1955	with	O
1955	in	O
1955	v	O
1955	##ivo	O
1955	p	O
1955	##k	O
1955	data	O
1955	to	O
1955	determine	O
1955	the	O
1955	p	O
1955	##k	O
1955	/	O
1955	p	O
1955	##d	O
1955	in	O
1955	##dices	O
1955	such	O
1955	as	O
1955	au	B-PK
1955	##c	I-PK
1955	##0	I-PK
1955	–	I-PK
1955	24	I-PK
1955	/	I-PK
1955	mi	I-PK
1955	##c	I-PK
1955	,	O
1955	au	B-PK
1955	##c	I-PK
1955	##0	I-PK
1955	–	I-PK
1955	24	I-PK
1955	/	I-PK
1955	m	I-PK
1955	##b	I-PK
1955	##c	I-PK
1955	,	O
1955	cm	B-PK
1955	##ax	I-PK
1955	/	I-PK
1955	mi	I-PK
1955	##c	I-PK
1955	,	O
1955	cm	B-PK
1955	##ax	I-PK
1955	/	I-PK
1955	m	I-PK
1955	##b	I-PK
1955	##c	I-PK
1955	,	O
1955	t	O
1955	>	O
1955	mi	O
1955	##c	O
1955	,	O
1955	and	O
1955	au	B-PK
1955	##c	I-PK
1955	##0	I-PK
1955	–	I-PK
1955	24	I-PK
1955	>	O
1955	mi	O
1955	##c	O
1955	,	O
1955	which	O
1955	are	O
1955	presented	O
1955	in	O
1955	table	O
1955	5	O
1955	.	O
1955	[SEP]	O
1956	[CLS]	O
1956	absolute	O
1956	percentage	O
1956	##s	O
1956	of	O
1956	bio	B-PK
1956	##ava	I-PK
1956	##ila	I-PK
1956	##bility	I-PK
1956	(	I-PK
1956	f	I-PK
1956	)	I-PK
1956	of	O
1956	the	O
1956	ma	O
1956	##rb	O
1956	##of	O
1956	##lo	O
1956	##xa	O
1956	##cin	O
1956	in	O
1956	pig	O
1956	were	O
1956	104	O
1956	.	O
1956	60	O
1956	±	O
1956	5	O
1956	.	O
1956	70	O
1956	%	O
1956	and	O
1956	94	O
1956	.	O
1956	35	O
1956	±	O
1956	8	O
1956	.	O
1956	90	O
1956	%	O
1956	,	O
1956	respectively	O
1956	,	O
1956	in	O
1956	in	O
1956	##tra	O
1956	##mus	O
1956	##cular	O
1956	and	O
1956	per	O
1956	##oral	O
1956	routes	O
1956	compared	O
1956	to	O
1956	in	O
1956	##tra	O
1956	##ven	O
1956	##ous	O
1956	route	O
1956	.	O
1956	[SEP]	O
1957	[CLS]	O
1957	the	O
1957	au	B-PK
1957	##c	I-PK
1957	##0	I-PK
1957	–	I-PK
1957	24	I-PK
1957	/	I-PK
1957	mi	I-PK
1957	##c	I-PK
1957	,	O
1957	au	B-PK
1957	##c	I-PK
1957	##0	I-PK
1957	–	I-PK
1957	24	I-PK
1957	/	I-PK
1957	m	I-PK
1957	##b	I-PK
1957	##c	I-PK
1957	,	O
1957	cm	B-PK
1957	##ax	I-PK
1957	/	I-PK
1957	mi	I-PK
1957	##c	I-PK
1957	,	O
1957	and	O
1957	cm	B-PK
1957	##ax	I-PK
1957	/	I-PK
1957	m	I-PK
1957	##b	I-PK
1957	##c	I-PK
1957	values	O
1957	attained	O
1957	from	O
1957	the	O
1957	application	O
1957	of	O
1957	ma	O
1957	##rb	O
1957	##of	O
1957	##lo	O
1957	##xa	O
1957	##cin	O
1957	through	O
1957	p	O
1957	.	O
1957	o	O
1957	.	O
1957	route	O
1957	are	O
1957	significantly	O
1957	lower	O
1957	than	O
1957	i	O
1957	.	O
1957	v	O
1957	.	O
1957	and	O
1957	i	O
1957	.	O
1957	m	O
1957	.	O
1957	administration	O
1957	values	O
1957	.	O
1957	[SEP]	O
1958	[CLS]	O
1958	on	O
1958	the	O
1958	contrary	O
1958	,	O
1958	the	O
1958	au	B-PK
1958	##c	I-PK
1958	##0	I-PK
1958	–	I-PK
1958	24	I-PK
1958	>	O
1958	mi	O
1958	##c	O
1958	value	O
1958	with	O
1958	the	O
1958	administration	O
1958	of	O
1958	ma	O
1958	##rb	O
1958	##of	O
1958	##lo	O
1958	##xa	O
1958	##cin	O
1958	through	O
1958	p	O
1958	.	O
1958	o	O
1958	.	O
1958	route	O
1958	is	O
1958	significantly	O
1958	higher	O
1958	than	O
1958	the	O
1958	values	O
1958	obtained	O
1958	from	O
1958	i	O
1958	.	O
1958	v	O
1958	.	O
1958	and	O
1958	i	O
1958	.	O
1958	m	O
1958	.	O
1958	administration	O
1958	.	O
1958	[SEP]	O
1959	[CLS]	O
1959	single	O
1959	-	O
1959	chain	O
1959	f	O
1959	##v	O
1959	[SEP]	O
1960	[CLS]	O
1960	in	O
1960	contrast	O
1960	,	O
1960	the	O
1960	position	O
1960	of	O
1960	the	O
1960	s	O
1960	##c	O
1960	##d	O
1960	##b	O
1960	with	O
1960	respect	O
1960	to	O
1960	the	O
1960	f	O
1960	##c	O
1960	region	O
1960	did	O
1960	not	O
1960	influence	O
1960	the	O
1960	growth	O
1960	in	O
1960	##hibition	O
1960	effects	O
1960	;	O
1960	comparable	O
1960	results	O
1960	were	O
1960	observed	O
1960	for	O
1960	he	O
1960	##x	O
1960	##3	O
1960	-	O
1960	s	O
1960	##c	O
1960	##d	O
1960	##b	O
1960	-	O
1960	f	O
1960	##c	O
1960	-	O
1960	h	O
1960	##l	O
1960	and	O
1960	-	O
1960	h	O
1960	##l	O
1960	-	O
1960	re	O
1960	##v	O
1960	,	O
1960	and	O
1960	for	O
1960	he	O
1960	##x	O
1960	##3	O
1960	-	O
1960	s	O
1960	##c	O
1960	##d	O
1960	##b	O
1960	-	O
1960	f	O
1960	##c	O
1960	-	O
1960	l	O
1960	##h	O
1960	and	O
1960	-	O
1960	l	O
1960	##h	O
1960	-	O
1960	re	O
1960	##v	O
1960	,	O
1960	respectively	O
1960	.	O
1960	[SEP]	O
1961	[CLS]	O
1961	to	O
1961	investigate	O
1961	the	O
1961	effects	O
1961	of	O
1961	rear	O
1961	##rang	O
1961	##ing	O
1961	the	O
1961	domain	O
1961	order	O
1961	of	O
1961	he	O
1961	##x	O
1961	##3	O
1961	-	O
1961	d	O
1961	##b	O
1961	on	O
1961	the	O
1961	functions	O
1961	of	O
1961	its	O
1961	f	O
1961	##c	O
1961	fusion	O
1961	format	O
1961	,	O
1961	we	O
1961	prepared	O
1961	four	O
1961	types	O
1961	of	O
1961	he	O
1961	##x	O
1961	##3	O
1961	-	O
1961	s	O
1961	##c	O
1961	##d	O
1961	##b	O
1961	-	O
1961	f	O
1961	##c	O
1961	(	O
1961	including	O
1961	the	O
1961	original	O
1961	he	O
1961	##x	O
1961	##3	O
1961	-	O
1961	s	O
1961	##c	O
1961	##d	O
1961	##b	O
1961	-	O
1961	3	O
1961	##c	O
1961	-	O
1961	f	O
1961	##c	O
1961	[	O
1961	he	O
1961	##x	O
1961	##3	O
1961	-	O
1961	s	O
1961	##c	O
1961	##d	O
1961	##b	O
1961	-	O
1961	f	O
1961	##c	O
1961	-	O
1961	h	O
1961	##l	O
1961	]	O
1961	)	O
1961	,	O
1961	each	O
1961	with	O
1961	a	O
1961	different	O
1961	domain	O
1961	order	O
1961	,	O
1961	as	O
1961	described	O
1961	in	O
1961	experimental	O
1961	procedures	O
1961	.	O
1961	[SEP]	O
1962	[CLS]	O
1962	a	O
1962	lower	O
1962	di	O
1962	##sso	O
1962	##ciation	O
1962	rate	O
1962	caused	O
1962	by	O
1962	the	O
1962	bi	O
1962	##vale	O
1962	##ncy	O
1962	of	O
1962	he	O
1962	##x	O
1962	##3	O
1962	-	O
1962	s	O
1962	##c	O
1962	##d	O
1962	##b	O
1962	-	O
1962	f	O
1962	##cs	O
1962	contributed	O
1962	to	O
1962	their	O
1962	higher	O
1962	affinity	O
1962	for	O
1962	se	O
1962	##g	O
1962	##f	O
1962	##r	O
1962	than	O
1962	those	O
1962	of	O
1962	he	O
1962	##x	O
1962	##3	O
1962	-	O
1962	d	O
1962	##bs	O
1962	,	O
1962	he	O
1962	##x	O
1962	##3	O
1962	-	O
1962	h	O
1962	##l	O
1962	,	O
1962	and	O
1962	he	O
1962	##x	O
1962	##3	O
1962	-	O
1962	l	O
1962	##h	O
1962	,	O
1962	but	O
1962	no	O
1962	major	O
1962	differences	O
1962	between	O
1962	he	O
1962	##x	O
1962	##3	O
1962	-	O
1962	s	O
1962	##c	O
1962	##d	O
1962	##b	O
1962	-	O
1962	f	O
1962	##c	O
1962	-	O
1962	h	O
1962	##l	O
1962	and	O
1962	he	O
1962	##x	O
1962	##3	O
1962	-	O
1962	s	O
1962	##c	O
1962	##d	O
1962	##b	O
1962	-	O
1962	f	O
1962	##c	O
1962	-	O
1962	l	O
1962	##h	O
1962	were	O
1962	observed	O
1962	(	O
1962	table	O
1962	1	O
1962	)	O
1962	.	O
1962	[SEP]	O
1963	[CLS]	O
1963	the	O
1963	structure	O
1963	of	O
1963	he	O
1963	##x	O
1963	##3	O
1963	-	O
1963	s	O
1963	##c	O
1963	##d	O
1963	##b	O
1963	-	O
1963	f	O
1963	##c	O
1963	-	O
1963	l	O
1963	##h	O
1963	might	O
1963	be	O
1963	able	O
1963	to	O
1963	avoid	O
1963	s	O
1963	##ter	O
1963	##ic	O
1963	hind	O
1963	##rance	O
1963	with	O
1963	cell	O
1963	surface	O
1963	molecules	O
1963	,	O
1963	particularly	O
1963	those	O
1963	of	O
1963	t	O
1963	-	O
1963	la	O
1963	##k	O
1963	cells	O
1963	,	O
1963	and	O
1963	this	O
1963	feature	O
1963	might	O
1963	contribute	O
1963	to	O
1963	the	O
1963	increased	O
1963	c	O
1963	##yt	O
1963	##oto	O
1963	##xi	O
1963	##c	O
1963	effects	O
1963	of	O
1963	this	O
1963	b	O
1963	##sa	O
1963	##b	O
1963	,	O
1963	indicating	O
1963	that	O
1963	the	O
1963	characteristics	O
1963	of	O
1963	he	O
1963	##x	O
1963	##3	O
1963	-	O
1963	l	O
1963	##h	O
1963	are	O
1963	fully	O
1963	retained	O
1963	after	O
1963	f	O
1963	##c	O
1963	fusion	O
1963	.	O
1963	[SEP]	O
1964	[CLS]	O
1964	s	O
1964	##ds	O
1964	-	O
1964	page	O
1964	analysis	O
1964	identified	O
1964	these	O
1964	fraction	O
1964	##s	O
1964	as	O
1964	he	O
1964	##x	O
1964	##3	O
1964	-	O
1964	s	O
1964	##c	O
1964	##d	O
1964	##b	O
1964	-	O
1964	f	O
1964	##cs	O
1964	derivatives	O
1964	that	O
1964	had	O
1964	fragment	O
1964	##ed	O
1964	in	O
1964	the	O
1964	region	O
1964	of	O
1964	the	O
1964	connecting	O
1964	site	O
1964	of	O
1964	the	O
1964	f	O
1964	##c	O
1964	region	O
1964	during	O
1964	long	O
1964	-	O
1964	term	O
1964	storage	O
1964	;	O
1964	results	O
1964	for	O
1964	he	O
1964	##x	O
1964	##3	O
1964	-	O
1964	s	O
1964	##c	O
1964	##d	O
1964	##b	O
1964	-	O
1964	h	O
1964	##l	O
1964	are	O
1964	shown	O
1964	in	O
1964	figure	O
1964	6	O
1964	##bas	O
1964	a	O
1964	representative	O
1964	example	O
1964	.	O
1964	[SEP]	O
1965	[CLS]	O
1965	to	O
1965	evaluate	O
1965	in	O
1965	v	O
1965	##ivo	O
1965	stability	O
1965	,	O
1965	we	O
1965	measured	O
1965	the	O
1965	area	B-PK
1965	under	I-PK
1965	the	I-PK
1965	curve	I-PK
1965	(	I-PK
1965	au	I-PK
1965	##c	I-PK
1965	)	I-PK
1965	using	O
1965	radio	O
1965	##io	O
1965	##dine	O
1965	-	O
1965	labeled	O
1965	b	O
1965	##sa	O
1965	##bs	O
1965	.	O
1965	[SEP]	O
1966	[CLS]	O
1966	the	O
1966	au	B-PK
1966	##cs	I-PK
1966	(	I-PK
1966	1	I-PK
1966	.	I-PK
1966	5	I-PK
1966	–	I-PK
1966	8	I-PK
1966	h	I-PK
1966	)	I-PK
1966	of	O
1966	he	O
1966	##x	O
1966	##3	O
1966	-	O
1966	s	O
1966	##c	O
1966	##d	O
1966	##b	O
1966	-	O
1966	f	O
1966	##c	O
1966	-	O
1966	h	O
1966	##l	O
1966	and	O
1966	he	O
1966	##x	O
1966	##3	O
1966	-	O
1966	s	O
1966	##c	O
1966	##d	O
1966	##b	O
1966	-	O
1966	f	O
1966	##c	O
1966	-	O
1966	l	O
1966	##h	O
1966	were	O
1966	3	O
1966	.	O
1966	1	O
1966	-	O
1966	fold	O
1966	greater	O
1966	than	O
1966	those	O
1966	of	O
1966	their	O
1966	corresponding	O
1966	d	O
1966	##b	O
1966	formats	O
1966	,	O
1966	he	O
1966	##x	O
1966	##3	O
1966	-	O
1966	h	O
1966	##l	O
1966	and	O
1966	he	O
1966	##x	O
1966	##3	O
1966	-	O
1966	l	O
1966	##h	O
1966	,	O
1966	as	O
1966	a	O
1966	result	O
1966	of	O
1966	the	O
1966	increased	O
1966	molecular	O
1966	weight	O
1966	due	O
1966	to	O
1966	the	O
1966	f	O
1966	##c	O
1966	fusion	O
1966	(	O
1966	fi	O
1966	##g	O
1966	.	O
1966	6	O
1966	##c	O
1966	;	O
1966	table	O
1966	1	O
1966	)	O
1966	.	O
1966	[SEP]	O
1967	[CLS]	O
1967	to	O
1967	investigate	O
1967	whether	O
1967	the	O
1967	ad	O
1967	##cc	O
1967	activity	O
1967	contributed	O
1967	to	O
1967	the	O
1967	enhanced	O
1967	growth	O
1967	in	O
1967	##hibition	O
1967	effects	O
1967	of	O
1967	s	O
1967	##c	O
1967	##d	O
1967	##b	O
1967	-	O
1967	f	O
1967	##c	O
1967	,	O
1967	we	O
1967	constructed	O
1967	an	O
1967	he	O
1967	##x	O
1967	##3	O
1967	-	O
1967	s	O
1967	##c	O
1967	##d	O
1967	##b	O
1967	-	O
1967	f	O
1967	##c	O
1967	-	O
1967	l	O
1967	##h	O
1967	variant	O
1967	whose	O
1967	f	O
1967	##c	O
1967	region	O
1967	was	O
1967	derived	O
1967	from	O
1967	human	O
1967	i	O
1967	##gg	O
1967	##2	O
1967	(	O
1967	he	O
1967	##x	O
1967	##3	O
1967	-	O
1967	s	O
1967	##c	O
1967	##d	O
1967	##b	O
1967	-	O
1967	f	O
1967	##c	O
1967	-	O
1967	l	O
1967	##h	O
1967	-	O
1967	i	O
1967	##gg	O
1967	##2	O
1967	,	O
1967	figure	O
1967	7	O
1967	##a	O
1967	)	O
1967	.	O
1967	[SEP]	O
1968	[CLS]	O
1968	we	O
1968	previously	O
1968	described	O
1968	the	O
1968	construction	O
1968	of	O
1968	the	O
1968	ma	O
1968	##mmal	O
1968	##ian	O
1968	expression	O
1968	vector	O
1968	p	O
1968	##c	O
1968	##dn	O
1968	##a	O
1968	-	O
1968	he	O
1968	##x	O
1968	##3	O
1968	-	O
1968	s	O
1968	##c	O
1968	##d	O
1968	##b	O
1968	-	O
1968	3	O
1968	##c	O
1968	-	O
1968	f	O
1968	##c	O
1968	for	O
1968	he	O
1968	##x	O
1968	##3	O
1968	-	O
1968	s	O
1968	##c	O
1968	##d	O
1968	##b	O
1968	-	O
1968	3	O
1968	##c	O
1968	-	O
1968	f	O
1968	##c	O
1968	,	O
1968	in	O
1968	which	O
1968	a	O
1968	single	O
1968	-	O
1968	chain	O
1968	form	O
1968	of	O
1968	he	O
1968	##x	O
1968	##3	O
1968	-	O
1968	d	O
1968	##b	O
1968	was	O
1968	fused	O
1968	to	O
1968	a	O
1968	human	O
1968	i	O
1968	##gg	O
1968	##1	O
1968	f	O
1968	##c	O
1968	region	O
1968	via	O
1968	a	O
1968	recognition	O
1968	site	O
1968	(	O
1968	le	O
1968	##v	O
1968	##lf	O
1968	##q	O
1968	##g	O
1968	##p	O
1968	)	O
1968	for	O
1968	human	O
1968	r	O
1968	##hino	O
1968	##virus	O
1968	3	O
1968	##c	O
1968	(	O
1968	h	O
1968	##r	O
1968	##v	O
1968	##3	O
1968	##c	O
1968	)	O
1968	pro	O
1968	##te	O
1968	##ase	O
1968	.	O
1968	30	O
1968	because	O
1968	two	O
1968	ch	O
1968	##ime	O
1968	##ric	O
1968	single	O
1968	-	O
1968	chain	O
1968	components	O
1968	of	O
1968	he	O
1968	##x	O
1968	##3	O
1968	-	O
1968	d	O
1968	##b	O
1968	—	O
1968	ho	O
1968	##hh	O
1968	##5	O
1968	##l	O
1968	and	O
1968	h	O
1968	##5	O
1968	##hh	O
1968	##ol	O
1968	,	O
1968	both	O
1968	with	O
1968	a	O
1968	v	O
1968	##h	O
1968	–	O
1968	v	O
1968	##l	O
1968	order	O
1968	—	O
1968	were	O
1968	connected	O
1968	via	O
1968	a	O
1968	20	O
1968	–	O
1968	amino	O
1968	acid	O
1968	link	O
1968	##er	O
1968	(	O
1968	[	O
1968	g	O
1968	##gg	O
1968	##gs	O
1968	]	O
1968	4	O
1968	)	O
1968	in	O
1968	the	O
1968	ho	O
1968	##hh	O
1968	##5	O
1968	##l	O
1968	–	O
1968	h	O
1968	##5	O
1968	##hh	O
1968	##ol	O
1968	order	O
1968	,	O
1968	he	O
1968	##x	O
1968	##3	O
1968	-	O
1968	s	O
1968	##c	O
1968	##d	O
1968	##b	O
1968	-	O
1968	3	O
1968	##c	O
1968	-	O
1968	f	O
1968	##c	O
1968	was	O
1968	re	O
1968	-	O
1968	designated	O
1968	as	O
1968	he	O
1968	##x	O
1968	##3	O
1968	-	O
1968	s	O
1968	##c	O
1968	##d	O
1968	##b	O
1968	-	O
1968	f	O
1968	##c	O
1968	-	O
1968	h	O
1968	##l	O
1968	in	O
1968	this	O
1968	report	O
1968	for	O
1968	clarity	O
1968	.	O
1968	[SEP]	O
1969	[CLS]	O
1969	the	O
1969	expression	O
1969	vector	O
1969	p	O
1969	##c	O
1969	##dn	O
1969	##a	O
1969	-	O
1969	he	O
1969	##x	O
1969	##3	O
1969	-	O
1969	s	O
1969	##c	O
1969	##d	O
1969	##b	O
1969	-	O
1969	f	O
1969	##c	O
1969	-	O
1969	l	O
1969	##h	O
1969	for	O
1969	he	O
1969	##x	O
1969	##3	O
1969	-	O
1969	s	O
1969	##c	O
1969	##d	O
1969	##b	O
1969	-	O
1969	f	O
1969	##c	O
1969	-	O
1969	l	O
1969	##h	O
1969	with	O
1969	a	O
1969	v	O
1969	##l	O
1969	–	O
1969	v	O
1969	##h	O
1969	order	O
1969	(	O
1969	i	O
1969	.	O
1969	e	O
1969	.	O
1969	,	O
1969	a	O
1969	ho	O
1969	##l	O
1969	##h	O
1969	##5	O
1969	##h	O
1969	–	O
1969	h	O
1969	##5	O
1969	##l	O
1969	##ho	O
1969	##h	O
1969	–	O
1969	3	O
1969	##c	O
1969	–	O
1969	f	O
1969	##c	O
1969	order	O
1969	)	O
1969	,	O
1969	was	O
1969	constructed	O
1969	by	O
1969	using	O
1969	the	O
1969	overlap	O
1969	polymer	O
1969	##ase	O
1969	chain	O
1969	reaction	O
1969	.	O
1969	[SEP]	O
1970	[CLS]	O
1970	the	O
1970	leader	O
1970	p	O
1970	##eptide	O
1970	sequences	O
1970	for	O
1970	protein	O
1970	secret	O
1970	##ion	O
1970	were	O
1970	derived	O
1970	from	O
1970	the	O
1970	mouse	O
1970	ok	O
1970	##t	O
1970	##3	O
1970	heavy	O
1970	chain	O
1970	for	O
1970	the	O
1970	h	O
1970	##l	O
1970	-	O
1970	types	O
1970	and	O
1970	the	O
1970	light	O
1970	chain	O
1970	for	O
1970	the	O
1970	l	O
1970	##h	O
1970	-	O
1970	types	O
1970	,	O
1970	respectively	O
1970	.	O
1970	31	O
1970	to	O
1970	construct	O
1970	the	O
1970	expression	O
1970	vector	O
1970	p	O
1970	##c	O
1970	##dn	O
1970	##a	O
1970	-	O
1970	he	O
1970	##x	O
1970	##3	O
1970	-	O
1970	s	O
1970	##c	O
1970	##d	O
1970	##b	O
1970	-	O
1970	f	O
1970	##c	O
1970	-	O
1970	l	O
1970	##h	O
1970	-	O
1970	i	O
1970	##gg	O
1970	##2	O
1970	for	O
1970	he	O
1970	##x	O
1970	##3	O
1970	-	O
1970	s	O
1970	##c	O
1970	##d	O
1970	##b	O
1970	-	O
1970	f	O
1970	##c	O
1970	-	O
1970	l	O
1970	##h	O
1970	-	O
1970	i	O
1970	##gg	O
1970	##2	O
1970	,	O
1970	the	O
1970	gene	O
1970	for	O
1970	the	O
1970	human	O
1970	f	O
1970	##c	O
1970	region	O
1970	derived	O
1970	from	O
1970	the	O
1970	i	O
1970	##gg	O
1970	##2	O
1970	sub	O
1970	##c	O
1970	##lass	O
1970	was	O
1970	clone	O
1970	##d	O
1970	from	O
1970	peripheral	O
1970	blood	O
1970	mon	O
1970	##on	O
1970	##uc	O
1970	##lea	O
1970	##r	O
1970	cells	O
1970	(	O
1970	p	O
1970	##b	O
1970	##m	O
1970	##c	O
1970	)	O
1970	and	O
1970	then	O
1970	used	O
1970	to	O
1970	replace	O
1970	the	O
1970	i	O
1970	##gg	O
1970	##1	O
1970	f	O
1970	##c	O
1970	portion	O
1970	in	O
1970	p	O
1970	##c	O
1970	##dn	O
1970	##a	O
1970	-	O
1970	he	O
1970	##x	O
1970	##3	O
1970	-	O
1970	s	O
1970	##c	O
1970	##d	O
1970	##b	O
1970	-	O
1970	f	O
1970	##c	O
1970	-	O
1970	l	O
1970	##h	O
1970	.	O
1970	[SEP]	O
1971	[CLS]	O
1971	clearance	B-PK
1971	was	O
1971	1	O
1971	.	O
1971	10	O
1971	(	O
1971	root	O
1971	square	O
1971	error	O
1971	8	O
1971	%	O
1971	)	O
1971	l	O
1971	/	O
1971	h	O
1971	and	O
1971	v	B-PK
1971	##1	I-PK
1971	and	O
1971	v	B-PK
1971	##2	I-PK
1971	were	O
1971	17	O
1971	.	O
1971	6	O
1971	(	O
1971	root	O
1971	square	O
1971	error	O
1971	14	O
1971	%	O
1971	)	O
1971	and	O
1971	3	O
1971	.	O
1971	63	O
1971	(	O
1971	root	O
1971	square	O
1971	error	O
1971	8	O
1971	%	O
1971	)	O
1971	l	O
1971	,	O
1971	respectively	O
1971	.	O
1971	[SEP]	O
1972	[CLS]	O
1972	median	O
1972	area	B-PK
1972	under	I-PK
1972	the	I-PK
1972	concentration	I-PK
1972	–	I-PK
1972	time	I-PK
1972	curve	I-PK
1972	over	I-PK
1972	24	I-PK
1972	h	I-PK
1972	(	O
1972	inter	O
1972	##qua	O
1972	##rt	O
1972	##ile	O
1972	range	O
1972	)	O
1972	on	O
1972	day	O
1972	14	O
1972	for	O
1972	regime	O
1972	##ns	O
1972	i	O
1972	–	O
1972	v	O
1972	were	O
1972	91	O
1972	(	O
1972	67	O
1972	–	O
1972	122	O
1972	)	O
1972	,	O
1972	183	O
1972	(	O
1972	135	O
1972	–	O
1972	244	O
1972	)	O
1972	,	O
1972	91	O
1972	(	O
1972	67	O
1972	–	O
1972	122	O
1972	)	O
1972	,	O
1972	137	O
1972	(	O
1972	101	O
1972	–	O
1972	183	O
1972	)	O
1972	and	O
1972	183	O
1972	(	O
1972	135	O
1972	–	O
1972	244	O
1972	)	O
1972	mg	O
1972	h	O
1972	/	O
1972	l	O
1972	,	O
1972	respectively	O
1972	,	O
1972	for	O
1972	a	O
1972	typical	O
1972	patient	O
1972	of	O
1972	70	O
1972	kg	O
1972	.	O
1972	[SEP]	O
1973	[CLS]	O
1973	the	O
1973	primary	O
1973	p	O
1973	##k	O
1973	parameters	O
1973	were	O
1973	clearance	B-PK
1973	(	I-PK
1973	c	I-PK
1973	##l	I-PK
1973	)	I-PK
1973	and	O
1973	volume	B-PK
1973	of	I-PK
1973	distribution	I-PK
1973	(	I-PK
1973	v	I-PK
1973	)	I-PK
1973	.	O
1973	[SEP]	O
1974	[CLS]	O
1974	after	O
1974	selection	O
1974	of	O
1974	the	O
1974	base	O
1974	model	O
1974	,	O
1974	the	O
1974	following	O
1974	co	O
1974	##var	O
1974	##iate	O
1974	##s	O
1974	were	O
1974	tested	O
1974	on	O
1974	c	B-PK
1974	##l	I-PK
1974	and	O
1974	v	B-PK
1974	based	O
1974	on	O
1974	physiological	O
1974	p	O
1974	##laus	O
1974	##ibility	O
1974	:	O
1974	album	O
1974	##in	O
1974	,	O
1974	continuous	O
1974	ve	O
1974	##no	O
1974	-	O
1974	ve	O
1974	##nous	O
1974	hem	O
1974	##of	O
1974	##ilt	O
1974	##ration	O
1974	(	O
1974	c	O
1974	##v	O
1974	##v	O
1974	##h	O
1974	)	O
1974	and	O
1974	sofa	O
1974	.	O
1974	[SEP]	O
1975	[CLS]	O
1975	the	O
1975	effect	O
1975	of	O
1975	album	O
1975	##in	O
1975	was	O
1975	assessed	O
1975	on	O
1975	v	B-PK
1975	##1	I-PK
1975	and	O
1975	c	B-PK
1975	##l	I-PK
1975	.	O
1975	[SEP]	O
1976	[CLS]	O
1976	the	O
1976	differences	O
1976	observed	O
1976	between	O
1976	treatments	O
1976	could	O
1976	be	O
1976	attributed	O
1976	to	O
1976	a	O
1976	faster	O
1976	absorption	B-PK
1976	rate	I-PK
1976	which	O
1976	could	O
1976	in	O
1976	##hibit	O
1976	the	O
1976	release	O
1976	of	O
1976	inflammatory	O
1976	substances	O
1976	sooner	O
1976	in	O
1976	the	O
1976	inflammatory	O
1976	ca	O
1976	##sca	O
1976	##de	O
1976	,	O
1976	therefore	O
1976	affecting	O
1976	overall	O
1976	substance	O
1976	p	O
1976	concentrations	O
1976	.	O
1976	[SEP]	O
1977	[CLS]	O
1977	on	O
1977	the	O
1977	other	O
1977	hand	O
1977	,	O
1977	the	O
1977	t	B-PK
1977	##max	I-PK
1977	could	O
1977	explain	O
1977	the	O
1977	lower	O
1977	substance	O
1977	p	O
1977	concentrations	O
1977	,	O
1977	w	O
1977	##b	O
1977	##c	O
1977	counts	O
1977	and	O
1977	weight	O
1977	,	O
1977	as	O
1977	a	O
1977	faster	O
1977	onset	O
1977	of	O
1977	action	O
1977	from	O
1977	s	O
1977	##c	O
1977	me	O
1977	##lo	O
1977	##xi	O
1977	##cam	O
1977	administration	O
1977	could	O
1977	in	O
1977	##hibit	O
1977	the	O
1977	production	O
1977	of	O
1977	pro	O
1977	-	O
1977	inflammatory	O
1977	substances	O
1977	sooner	O
1977	in	O
1977	the	O
1977	inflammatory	O
1977	process	O
1977	which	O
1977	could	O
1977	consequently	O
1977	lead	O
1977	to	O
1977	a	O
1977	reduced	O
1977	magnitude	O
1977	of	O
1977	inflammation	O
1977	.	O
1977	[SEP]	O
1978	[CLS]	O
1978	the	O
1978	total	O
1978	volume	O
1978	of	O
1978	blood	O
1978	required	O
1978	for	O
1978	the	O
1978	hi	O
1978	##v	O
1978	r	O
1978	##na	O
1978	testing	O
1978	was	O
1978	approximately	O
1978	35	O
1978	m	O
1978	##l	O
1978	per	O
1978	patient	O
1978	.	O
1978	[SEP]	O
1979	[CLS]	O
1979	physiological	O
1979	parameters	O
1979	,	O
1979	like	O
1979	organ	O
1979	volumes	O
1979	,	O
1979	blood	B-PK
1979	flow	I-PK
1979	rates	I-PK
1979	,	O
1979	and	O
1979	surface	O
1979	per	O
1979	##me	O
1979	##abi	O
1979	##lities	O
1979	,	O
1979	are	O
1979	provided	O
1979	within	O
1979	the	O
1979	software	O
1979	.	O
1979	7	O
1979	absorption	O
1979	,	O
1979	distribution	O
1979	,	O
1979	metabolism	O
1979	,	O
1979	and	O
1979	ex	O
1979	##cre	O
1979	##tion	O
1979	‐	O
1979	relevant	O
1979	proteins	O
1979	reported	O
1979	to	O
1979	govern	O
1979	the	O
1979	p	O
1979	##k	O
1979	of	O
1979	a	O
1979	drug	O
1979	,	O
1979	such	O
1979	as	O
1979	meta	O
1979	##bol	O
1979	##izing	O
1979	enzymes	O
1979	,	O
1979	transport	O
1979	##ers	O
1979	,	O
1979	or	O
1979	binding	O
1979	partners	O
1979	,	O
1979	were	O
1979	implemented	O
1979	into	O
1979	the	O
1979	models	O
1979	and	O
1979	tested	O
1979	.	O
1979	[SEP]	O
1980	[CLS]	O
1980	fraction	O
1980	##al	O
1980	absorbed	O
1980	data	O
1980	for	O
1980	each	O
1980	subject	O
1980	and	O
1980	treatment	O
1980	was	O
1980	used	O
1980	for	O
1980	est	O
1980	##imation	O
1980	of	O
1980	the	O
1980	apparent	B-PK
1980	absorption	I-PK
1980	rate	I-PK
1980	constant	I-PK
1980	(	I-PK
1980	ka	I-PK
1980	)	I-PK
1980	.	O
1980	[SEP]	O
1981	[CLS]	O
1981	vascular	O
1981	-	O
1981	targeting	O
1981	p	O
1981	##dt	O
1981	has	O
1981	been	O
1981	reported	O
1981	to	O
1981	induce	O
1981	blood	B-PK
1981	flow	I-PK
1981	imp	O
1981	##air	O
1981	##ment	O
1981	and	O
1981	blood	O
1981	vessel	O
1981	destruction	O
1981	,	O
1981	resulting	O
1981	in	O
1981	tissue	O
1981	h	O
1981	##y	O
1981	##pox	O
1981	##ia	O
1981	,	O
1981	nut	O
1981	##rient	O
1981	de	O
1981	##p	O
1981	##ri	O
1981	##vation	O
1981	,	O
1981	and	O
1981	tumor	O
1981	destruction	O
1981	[	O
1981	34	O
1981	,	O
1981	36	O
1981	,	O
1981	37	O
1981	]	O
1981	.	O
1981	[SEP]	O
1982	[CLS]	O
1982	o	O
1982	##xy	O
1982	##co	O
1982	##don	O
1982	##e	O
1982	distribution	O
1982	was	O
1982	considered	O
1982	to	O
1982	be	O
1982	per	O
1982	##fusion	O
1982	-	O
1982	rate	O
1982	limited	O
1982	assuming	O
1982	that	O
1982	the	O
1982	diffusion	O
1982	through	O
1982	cap	O
1982	##illa	O
1982	##ry	O
1982	membrane	O
1982	occurs	O
1982	very	O
1982	quickly	O
1982	and	O
1982	the	O
1982	rate	O
1982	-	O
1982	limiting	O
1982	factor	O
1982	for	O
1982	distribution	O
1982	into	O
1982	tissues	O
1982	is	O
1982	the	O
1982	blood	B-PK
1982	flow	I-PK
1982	.	O
1982	[SEP]	O
1983	[CLS]	O
1983	the	O
1983	half	B-PK
1983	-	I-PK
1983	life	I-PK
1983	of	O
1983	each	O
1983	of	O
1983	these	O
1983	compounds	O
1983	in	O
1983	the	O
1983	silk	O
1983	##worm	O
1983	hem	O
1983	##oly	O
1983	##mp	O
1983	##h	O
1983	was	O
1983	18	O
1983	,	O
1983	26	O
1983	and	O
1983	34	O
1983	h	O
1983	,	O
1983	respectively	O
1983	.	O
1983	[SEP]	O
1984	[CLS]	O
1984	per	O
1984	protocol	O
1984	,	O
1984	subjects	O
1984	were	O
1984	categorized	O
1984	by	O
1984	b	O
1984	##w	O
1984	and	O
1984	b	O
1984	##mi	O
1984	(	O
1984	figure	O
1984	##1	O
1984	)	O
1984	.	O
1984	[SEP]	O
1985	[CLS]	O
1985	the	O
1985	re	O
1985	##comb	O
1985	##ina	O
1985	##nt	O
1985	hi	O
1985	##rud	O
1985	##ins	O
1985	in	O
1985	the	O
1985	plasma	O
1985	was	O
1985	analyzed	O
1985	by	O
1985	ch	O
1985	##rom	O
1985	##ogenic	O
1985	substrate	O
1985	ass	O
1985	##ay	O
1985	,	O
1985	enzyme	O
1985	-	O
1985	linked	O
1985	im	O
1985	##mu	O
1985	##nos	O
1985	##or	O
1985	##bent	O
1985	ass	O
1985	##ay	O
1985	(	O
1985	el	O
1985	##isa	O
1985	)	O
1985	,	O
1985	total	O
1985	radio	O
1985	##is	O
1985	##oto	O
1985	##pe	O
1985	ass	O
1985	##ay	O
1985	(	O
1985	r	O
1985	##a	O
1985	)	O
1985	and	O
1985	t	O
1985	##rich	O
1985	##lor	O
1985	##oa	O
1985	##ce	O
1985	##tic	O
1985	acid	O
1985	pre	O
1985	-	O
1985	treated	O
1985	total	O
1985	radio	O
1985	##is	O
1985	##oto	O
1985	##pe	O
1985	ass	O
1985	##ay	O
1985	(	O
1985	t	O
1985	##ca	O
1985	-	O
1985	r	O
1985	##a	O
1985	)	O
1985	.	O
1985	[SEP]	O
1986	[CLS]	O
1986	in	O
1986	conclusion	O
1986	,	O
1986	re	O
1986	##nal	O
1986	imp	O
1986	##air	O
1986	##ment	O
1986	impacted	O
1986	au	B-PK
1986	##c	I-PK
1986	,	O
1986	c	B-PK
1986	##l	I-PK
1986	,	O
1986	and	O
1986	t	B-PK
1986	##1	I-PK
1986	/	I-PK
1986	2	I-PK
1986	without	O
1986	affecting	O
1986	cm	B-PK
1986	##ax	I-PK
1986	.	O
1986	[SEP]	O
1987	[CLS]	O
1987	the	O
1987	blood	B-PK
1987	flow	I-PK
1987	rate	I-PK
1987	and	O
1987	the	O
1987	dial	O
1987	##ys	O
1987	##ate	O
1987	flow	O
1987	rate	O
1987	were	O
1987	400	O
1987	to	O
1987	500	O
1987	m	O
1987	##l	O
1987	/	O
1987	min	O
1987	and	O
1987	600	O
1987	to	O
1987	700	O
1987	m	O
1987	##l	O
1987	/	O
1987	min	O
1987	,	O
1987	respectively	O
1987	.	O
1987	[SEP]	O
1988	[CLS]	O
1988	for	O
1988	subjects	O
1988	on	O
1988	hem	O
1988	##od	O
1988	##ial	O
1988	##ys	O
1988	##is	O
1988	,	O
1988	cumulative	B-PK
1988	amount	I-PK
1988	of	I-PK
1988	drug	I-PK
1988	recovered	I-PK
1988	unchanged	I-PK
1988	in	I-PK
1988	dial	I-PK
1988	##ys	I-PK
1988	##ate	I-PK
1988	(	I-PK
1988	a	I-PK
1988	##r	I-PK
1988	)	I-PK
1988	,	O
1988	hem	B-PK
1988	##od	I-PK
1988	##ial	I-PK
1988	##ys	I-PK
1988	##is	I-PK
1988	clearance	I-PK
1988	(	I-PK
1988	c	I-PK
1988	##l	I-PK
1988	##h	I-PK
1988	##d	I-PK
1988	)	I-PK
1988	,	O
1988	and	O
1988	fraction	B-PK
1988	of	I-PK
1988	the	I-PK
1988	total	I-PK
1988	body	I-PK
1988	pool	I-PK
1988	of	I-PK
1988	drug	I-PK
1988	removed	I-PK
1988	by	I-PK
1988	hem	I-PK
1988	##od	I-PK
1988	##ial	I-PK
1988	##ys	I-PK
1988	##is	I-PK
1988	(	I-PK
1988	f	I-PK
1988	##r	I-PK
1988	)	I-PK
1988	were	O
1988	determined	O
1988	.	O
1988	10	O
1988	[SEP]	O
1989	[CLS]	O
1989	the	O
1989	t	B-PK
1989	##1	I-PK
1989	/	I-PK
1989	2	I-PK
1989	values	O
1989	in	O
1989	normal	O
1989	,	O
1989	mild	O
1989	,	O
1989	moderate	O
1989	,	O
1989	severe	O
1989	,	O
1989	and	O
1989	hem	O
1989	##od	O
1989	##ial	O
1989	##ys	O
1989	##is	O
1989	(	O
1989	dos	O
1989	##ing	O
1989	post	O
1989	##hem	O
1989	##od	O
1989	##ial	O
1989	##ys	O
1989	##is	O
1989	,	O
1989	without	O
1989	h	O
1989	##d	O
1989	)	O
1989	groups	O
1989	were	O
1989	2	O
1989	.	O
1989	8	O
1989	,	O
1989	3	O
1989	.	O
1989	0	O
1989	,	O
1989	4	O
1989	.	O
1989	1	O
1989	,	O
1989	6	O
1989	.	O
1989	9	O
1989	,	O
1989	and	O
1989	9	O
1989	.	O
1989	6	O
1989	hours	O
1989	,	O
1989	respectively	O
1989	.	O
1989	[SEP]	O
1990	[CLS]	O
1990	geometric	O
1990	mean	O
1990	(	O
1990	c	O
1990	##v	O
1990	%	O
1990	geometric	O
1990	mean	O
1990	)	O
1990	of	O
1990	a	O
1990	##r	O
1990	relative	O
1990	to	O
1990	c	O
1990	##ef	O
1990	##ider	O
1990	##oc	O
1990	##ol	O
1990	dose	O
1990	was	O
1990	56	O
1990	.	O
1990	1	O
1990	%	O
1990	(	O
1990	12	O
1990	.	O
1990	2	O
1990	%	O
1990	)	O
1990	,	O
1990	and	O
1990	f	B-PK
1990	##r	I-PK
1990	was	O
1990	62	O
1990	.	O
1990	3	O
1990	%	O
1990	(	O
1990	8	O
1990	.	O
1990	4	O
1990	%	O
1990	)	O
1990	,	O
1990	suggesting	O
1990	that	O
1990	intermittent	O
1990	h	O
1990	##d	O
1990	removed	O
1990	approximately	O
1990	60	O
1990	%	O
1990	of	O
1990	the	O
1990	c	O
1990	##ef	O
1990	##ider	O
1990	##oc	O
1990	##ol	O
1990	dose	O
1990	.	O
1990	[SEP]	O
1991	[CLS]	O
1991	v	O
1991	##al	O
1991	##p	O
1991	##roi	O
1991	##c	O
1991	acid	O
1991	β	O
1991	-	O
1991	d	O
1991	g	O
1991	##lu	O
1991	##cu	O
1991	##ron	O
1991	##ide	O
1991	(	O
1991	v	O
1991	##pa	O
1991	##g	O
1991	)	O
1991	was	O
1991	purchased	O
1991	from	O
1991	sa	O
1991	##nta	O
1991	c	O
1991	##ru	O
1991	##z	O
1991	bio	O
1991	##tech	O
1991	##nology	O
1991	,	O
1991	in	O
1991	##c	O
1991	.	O
1991	(	O
1991	sa	O
1991	##nta	O
1991	c	O
1991	##ru	O
1991	##z	O
1991	,	O
1991	ca	O
1991	,	O
1991	us	O
1991	##a	O
1991	)	O
1991	.	O
1991	[SEP]	O
1992	[CLS]	O
1992	it	O
1992	was	O
1992	in	O
1992	the	O
1992	order	O
1992	of	O
1992	0	O
1992	.	O
1992	1	O
1992	mm	O
1992	/	O
1992	s	O
1992	,	O
1992	yet	O
1992	faster	O
1992	than	O
1992	molecular	O
1992	diffusion	O
1992	of	O
1992	large	O
1992	molecules	O
1992	such	O
1992	as	O
1992	mon	O
1992	##oc	O
1992	##lon	O
1992	##al	O
1992	antibodies	O
1992	(	O
1992	m	O
1992	##w	O
1992	~	O
1992	150	O
1992	k	O
1992	##da	O
1992	)	O
1992	.	O
1992	[SEP]	O
1993	[CLS]	O
1993	equation	O
1993	(	O
1993	3	O
1993	)	O
1993	describes	O
1993	the	O
1993	rate	O
1993	of	O
1993	change	O
1993	of	O
1993	the	O
1993	amount	O
1993	of	O
1993	me	O
1993	##rop	O
1993	##ene	O
1993	##m	O
1993	(	O
1993	in	O
1993	mill	O
1993	##ig	O
1993	##rams	O
1993	)	O
1993	in	O
1993	the	O
1993	c	O
1993	##s	O
1993	##f	O
1993	compartment	O
1993	(	O
1993	x	O
1993	##3	O
1993	)	O
1993	.	O
1993	[SEP]	O
1994	[CLS]	O
1994	an	O
1994	important	O
1994	assumption	O
1994	of	O
1994	this	O
1994	multiple	O
1994	re	O
1994	##gression	O
1994	analysis	O
1994	is	O
1994	that	O
1994	the	O
1994	independent	O
1994	variables	O
1994	(	O
1994	au	B-PK
1994	##cs	I-PK
1994	)	O
1994	are	O
1994	not	O
1994	correlated	O
1994	.	O
1994	[SEP]	O
1995	[CLS]	O
1995	compared	O
1995	with	O
1995	dos	O
1995	##ing	O
1995	at	O
1995	fast	O
1995	##ed	O
1995	state	O
1995	,	O
1995	taking	O
1995	my	O
1995	##rt	O
1995	##ol	O
1995	standardized	O
1995	capsule	O
1995	##s	O
1995	after	O
1995	a	O
1995	meal	O
1995	achieve	O
1995	##s	O
1995	a	O
1995	delayed	O
1995	absorption	B-PK
1995	rate	I-PK
1995	and	O
1995	an	O
1995	increased	O
1995	absorption	O
1995	extent	O
1995	.	O
1995	[SEP]	O
1996	[CLS]	O
1996	spear	O
1996	##man	O
1996	rank	O
1996	test	O
1996	was	O
1996	used	O
1996	to	O
1996	assess	O
1996	correlation	O
1996	between	O
1996	al	O
1996	##t	O
1996	,	O
1996	al	O
1996	##p	O
1996	,	O
1996	total	O
1996	bi	O
1996	##li	O
1996	##ru	O
1996	##bin	O
1996	,	O
1996	album	O
1996	##in	O
1996	,	O
1996	and	O
1996	half	B-PK
1996	‐	I-PK
1996	life	I-PK
1996	.	O
1996	[SEP]	O
1997	[CLS]	O
1997	log	O
1997	##ari	O
1997	##th	O
1997	##mic	O
1997	transformation	O
1997	of	O
1997	au	B-PK
1997	##c	I-PK
1997	##0	I-PK
1997	-	I-PK
1997	24	I-PK
1997	,	O
1997	au	B-PK
1997	##c	I-PK
1997	##0	I-PK
1997	-	I-PK
1997	∞	I-PK
1997	,	O
1997	and	O
1997	cm	B-PK
1997	##ax	I-PK
1997	were	O
1997	compared	O
1997	by	O
1997	the	O
1997	analysis	O
1997	of	O
1997	variance	O
1997	(	O
1997	an	O
1997	##ova	O
1997	)	O
1997	for	O
1997	a	O
1997	crossover	O
1997	design	O
1997	followed	O
1997	by	O
1997	90	O
1997	%	O
1997	confidence	O
1997	interval	O
1997	test	O
1997	for	O
1997	the	O
1997	arithmetic	O
1997	mean	O
1997	p	O
1997	##har	O
1997	##ma	O
1997	##co	O
1997	##kin	O
1997	##etic	O
1997	parameters	O
1997	of	O
1997	c	O
1997	##tz	O
1997	formulation	O
1997	##s	O
1997	.	O
1997	[SEP]	O
1998	[CLS]	O
1998	similarly	O
1998	,	O
1998	the	O
1998	equation	O
1998	for	O
1998	i	O
1998	##rre	O
1998	##versible	O
1998	in	O
1998	##hibition	O
1998	is	O
1998	:	O
1998	(	O
1998	2	O
1998	)	O
1998	au	O
1998	##c	O
1998	′	O
1998	au	O
1998	##c	O
1998	=	O
1998	f	O
1998	##gi	O
1998	##f	O
1998	##g	O
1998	##×	O
1998	##1	O
1998	##f	O
1998	##m	O
1998	##cy	O
1998	##pi	O
1998	##1	O
1998	+	O
1998	kin	O
1998	##act	O
1998	##×	O
1998	##i	O
1998	/	O
1998	k	O
1998	##de	O
1998	##g	O
1998	##×	O
1998	##ka	O
1998	##pp	O
1998	+	O
1998	i	O
1998	+	O
1998	1	O
1998	##−	O
1998	##f	O
1998	##m	O
1998	##cy	O
1998	##pi	O
1998	##with	O
1998	kin	O
1998	##act	O
1998	as	O
1998	the	O
1998	ma	O
1998	##ximal	O
1998	in	O
1998	##act	O
1998	##ivation	O
1998	rate	O
1998	constant	O
1998	,	O
1998	ka	B-PK
1998	##pp	I-PK
1998	the	O
1998	inhibitor	O
1998	concentration	O
1998	at	O
1998	50	O
1998	%	O
1998	of	O
1998	kin	B-PK
1998	##act	I-PK
1998	,	O
1998	and	O
1998	k	B-PK
1998	##de	I-PK
1998	##g	I-PK
1998	the	O
1998	end	O
1998	##ogen	O
1998	##ous	O
1998	degradation	B-PK
1998	rate	I-PK
1998	constant	I-PK
1998	of	O
1998	the	O
1998	c	O
1998	##y	O
1998	##p	O
1998	enzyme	O
1998	.	O
1998	[SEP]	O
1999	[CLS]	O
1999	assuming	O
1999	a	O
1999	5	O
1999	‐	O
1999	fold	O
1999	accumulation	O
1999	of	O
1999	e	O
1999	##vo	O
1999	##fo	O
1999	##s	O
1999	##fa	O
1999	##mi	O
1999	##de	O
1999	in	O
1999	he	O
1999	##pa	O
1999	##to	O
1999	##cy	O
1999	##tes	O
1999	,	O
1999	the	O
1999	au	B-PK
1999	##c	I-PK
1999	ratio	I-PK
1999	was	O
1999	1	O
1999	.	O
1999	14	O
1999	(	O
1999	1	O
1999	.	O
1999	12	O
1999	;	O
1999	1	O
1999	.	O
1999	17	O
1999	)	O
1999	,	O
1999	again	O
1999	below	O
1999	the	O
1999	threshold	O
1999	of	O
1999	1	O
1999	.	O
1999	25	O
1999	.	O
1999	[SEP]	O
2000	[CLS]	O
2000	during	O
2000	follow	O
2000	-	O
2000	up	O
2000	,	O
2000	the	O
2000	child	O
2000	will	O
2000	have	O
2000	several	O
2000	cap	O
2000	##illa	O
2000	##ry	O
2000	blood	O
2000	collections	O
2000	that	O
2000	are	O
2000	not	O
2000	performed	O
2000	routinely	O
2000	,	O
2000	although	O
2000	the	O
2000	total	O
2000	blood	O
2000	volume	O
2000	sampled	O
2000	will	O
2000	be	O
2000	limited	O
2000	to	O
2000	under	O
2000	10	O
2000	m	O
2000	##l	O
2000	so	O
2000	is	O
2000	not	O
2000	associated	O
2000	with	O
2000	a	O
2000	particular	O
2000	risk	O
2000	.	O
2000	[SEP]	O
2001	[CLS]	O
2001	the	O
2001	half	B-PK
2001	-	I-PK
2001	lives	I-PK
2001	of	O
2001	compound	O
2001	a	O
2001	,	O
2001	b	O
2001	,	O
2001	and	O
2001	c	O
2001	at	O
2001	the	O
2001	second	O
2001	stage	O
2001	were	O
2001	estimated	O
2001	to	O
2001	be	O
2001	18	O
2001	,	O
2001	26	O
2001	,	O
2001	and	O
2001	34	O
2001	h	O
2001	##rs	O
2001	,	O
2001	respectively	O
2001	(	O
2001	figure	O
2001	4	O
2001	)	O
2001	.	O
2001	[SEP]	O
2002	[CLS]	O
2002	q	O
2002	##uad	O
2002	##rup	O
2002	##ole	O
2002	##s	O
2002	q	O
2002	##1	O
2002	and	O
2002	q	O
2002	##3	O
2002	were	O
2002	set	O
2002	on	O
2002	unit	O
2002	resolution	O
2002	.	O
2002	[SEP]	O
2003	[CLS]	O
2003	recover	O
2003	##ies	O
2003	of	O
2003	at	O
2003	##or	O
2003	##vas	O
2003	##tat	O
2003	##in	O
2003	,	O
2003	met	O
2003	##form	O
2003	##in	O
2003	,	O
2003	g	O
2003	##lim	O
2003	##ep	O
2003	##iri	O
2003	##de	O
2003	and	O
2003	is	O
2003	were	O
2003	determined	O
2003	by	O
2003	comparing	O
2003	the	O
2003	peak	O
2003	area	O
2003	of	O
2003	extracted	O
2003	anal	O
2003	##yte	O
2003	standard	O
2003	with	O
2003	the	O
2003	peak	O
2003	area	O
2003	of	O
2003	non	O
2003	-	O
2003	extracted	O
2003	standard	O
2003	.	O
2003	[SEP]	O
2004	[CLS]	O
2004	after	O
2004	s	O
2004	.	O
2004	c	O
2004	.	O
2004	administration	O
2004	of	O
2004	100	O
2004	mg	O
2004	an	O
2004	##aki	O
2004	##n	O
2004	##ra	O
2004	,	O
2004	the	O
2004	mean	O
2004	cm	B-PK
2004	##ax	I-PK
2004	value	O
2004	was	O
2004	46	O
2004	%	O
2004	lower	O
2004	and	O
2004	the	O
2004	mean	O
2004	au	B-PK
2004	##c	I-PK
2004	value	O
2004	was	O
2004	33	O
2004	%	O
2004	lower	O
2004	for	O
2004	subjects	O
2004	with	O
2004	b	O
2004	##w	O
2004	≥	O
2004	100	O
2004	kg	O
2004	than	O
2004	for	O
2004	subjects	O
2004	with	O
2004	b	O
2004	##w	O
2004	≤	O
2004	90	O
2004	kg	O
2004	.	O
2004	[SEP]	O
2005	[CLS]	O
2005	internal	O
2005	standard	O
2005	(	O
2005	13	O
2005	##c	O
2005	##6	O
2005	-	O
2005	d	O
2005	##c	O
2005	##f	O
2005	)	O
2005	was	O
2005	added	O
2005	to	O
2005	25	O
2005	µ	O
2005	##l	O
2005	co	O
2005	##culture	O
2005	medium	O
2005	to	O
2005	give	O
2005	a	O
2005	final	O
2005	concentration	O
2005	of	O
2005	20	O
2005	μ	O
2005	##m	O
2005	d	O
2005	##c	O
2005	##f	O
2005	when	O
2005	at	O
2005	50	O
2005	–	O
2005	100	O
2005	##×	O
2005	cm	B-PK
2005	##ax	I-PK
2005	(	O
2005	4	O
2005	.	O
2005	4	O
2005	µ	O
2005	##m	O
2005	was	O
2005	cm	B-PK
2005	##ax	I-PK
2005	for	O
2005	our	O
2005	study	O
2005	)	O
2005	,	O
2005	and	O
2005	2	O
2005	μ	O
2005	##m	O
2005	with	O
2005	d	O
2005	##c	O
2005	##f	O
2005	at	O
2005	1	O
2005	##×	O
2005	cm	B-PK
2005	##ax	I-PK
2005	of	O
2005	d	O
2005	##5	O
2005	-	O
2005	g	O
2005	##ca	O
2005	(	O
2005	0	O
2005	.	O
2005	5	O
2005	–	O
2005	1	O
2005	μ	O
2005	##m	O
2005	)	O
2005	was	O
2005	added	O
2005	as	O
2005	an	O
2005	internal	O
2005	standard	O
2005	prior	O
2005	to	O
2005	sample	O
2005	extraction	O
2005	for	O
2005	bi	O
2005	##le	O
2005	acid	O
2005	measurements	O
2005	.	O
2005	[SEP]	O
2006	[CLS]	O
2006	standard	O
2006	series	O
2006	of	O
2006	various	O
2006	concentrations	O
2006	were	O
2006	prepared	O
2006	with	O
2006	standard	O
2006	working	O
2006	solution	O
2006	,	O
2006	and	O
2006	the	O
2006	standard	O
2006	concentrations	O
2006	ranged	O
2006	from	O
2006	0	O
2006	.	O
2006	1	O
2006	to	O
2006	1000	O
2006	ng	O
2006	/	O
2006	m	O
2006	##l	O
2006	.	O
2006	the	O
2006	peak	O
2006	area	O
2006	was	O
2006	measured	O
2006	under	O
2006	the	O
2006	same	O
2006	condition	O
2006	as	O
2006	the	O
2006	tested	O
2006	blood	O
2006	sample	O
2006	.	O
2006	[SEP]	O
2007	[CLS]	O
2007	simulation	O
2007	##s	O
2007	of	O
2007	the	O
2007	time	O
2007	course	O
2007	of	O
2007	c	O
2007	##d	O
2007	##19	O
2007	+	O
2007	l	O
2007	##ymph	O
2007	##ocytes	O
2007	for	O
2007	the	O
2007	4	O
2007	dose	O
2007	regime	O
2007	##ns	O
2007	are	O
2007	shown	O
2007	in	O
2007	figure	O
2007	4	O
2007	,	O
2007	where	O
2007	a	O
2007	single	O
2007	in	O
2007	##fusion	O
2007	of	O
2007	375	O
2007	mg	O
2007	/	O
2007	m	O
2007	##2	O
2007	produced	O
2007	mostly	O
2007	identical	O
2007	effect	O
2007	on	O
2007	c	O
2007	##d	O
2007	##19	O
2007	+	O
2007	l	O
2007	##ymph	O
2007	##oc	O
2007	##yte	O
2007	suppression	O
2007	within	O
2007	10	O
2007	weeks	O
2007	and	O
2007	the	O
2007	effect	O
2007	remained	O
2007	similar	O
2007	after	O
2007	6	O
2007	months	O
2007	,	O
2007	in	O
2007	comparison	O
2007	to	O
2007	the	O
2007	highest	O
2007	suppression	O
2007	achieved	O
2007	by	O
2007	4	O
2007	weekly	O
2007	375	O
2007	mg	O
2007	/	O
2007	m	O
2007	##2	O
2007	in	O
2007	##fusion	O
2007	##s	O
2007	(	O
2007	6	O
2007	.	O
2007	2	O
2007	%	O
2007	vs	O
2007	3	O
2007	.	O
2007	3	O
2007	%	O
2007	of	O
2007	base	O
2007	##line	O
2007	c	O
2007	##d	O
2007	##19	O
2007	+	O
2007	l	O
2007	##ymph	O
2007	##oc	O
2007	##yte	O
2007	counts	O
2007	after	O
2007	6	O
2007	months	O
2007	)	O
2007	.	O
2007	[SEP]	O
2008	[CLS]	O
2008	d	O
2008	##na	O
2008	was	O
2008	analyzed	O
2008	by	O
2008	drop	O
2008	##let	O
2008	digital	O
2008	polymer	O
2008	##ase	O
2008	chain	O
2008	reaction	O
2008	(	O
2008	d	O
2008	##d	O
2008	##p	O
2008	##c	O
2008	##r	O
2008	;	O
2008	bio	O
2008	##rad	O
2008	,	O
2008	mountain	O
2008	view	O
2008	,	O
2008	ca	O
2008	)	O
2008	for	O
2008	copy	O
2008	number	O
2008	am	O
2008	##p	O
2008	##lification	O
2008	##s	O
2008	at	O
2008	the	O
2008	following	O
2008	12	O
2008	g	O
2008	##eni	O
2008	##c	O
2008	lo	O
2008	##ci	O
2008	:	O
2008	b	O
2008	##c	O
2008	##l	O
2008	##2	O
2008	,	O
2008	cc	O
2008	##nd	O
2008	##1	O
2008	,	O
2008	c	O
2008	##d	O
2008	##k	O
2008	##4	O
2008	,	O
2008	e	O
2008	##g	O
2008	##f	O
2008	##r	O
2008	,	O
2008	er	O
2008	##bb	O
2008	##2	O
2008	,	O
2008	f	O
2008	##g	O
2008	##f	O
2008	##r	O
2008	##1	O
2008	,	O
2008	f	O
2008	##g	O
2008	##f	O
2008	##r	O
2008	##2	O
2008	,	O
2008	f	O
2008	##g	O
2008	##f	O
2008	##r	O
2008	##3	O
2008	,	O
2008	f	O
2008	##g	O
2008	##f	O
2008	##r	O
2008	##4	O
2008	,	O
2008	met	O
2008	,	O
2008	p	O
2008	##d	O
2008	##g	O
2008	##fra	O
2008	,	O
2008	and	O
2008	p	O
2008	##ik	O
2008	##3	O
2008	##ca	O
2008	.	O
2008	[SEP]	O
2009	[CLS]	O
2009	subjects	O
2009	(	O
2009	n	O
2009	=	O
2009	119	O
2009	##6	O
2009	)	O
2009	,	O
2009	at	O
2009	least	O
2009	40	O
2009	years	O
2009	old	O
2009	,	O
2009	were	O
2009	current	O
2009	or	O
2009	ex	O
2009	-	O
2009	smoke	O
2009	##rs	O
2009	random	O
2009	##ized	O
2009	to	O
2009	twice	O
2009	-	O
2009	daily	O
2009	inhaled	O
2009	m	O
2009	##f	O
2009	/	O
2009	f	O
2009	400	O
2009	/	O
2009	10	O
2009	μ	O
2009	##g	O
2009	,	O
2009	m	O
2009	##f	O
2009	/	O
2009	f	O
2009	200	O
2009	/	O
2009	10	O
2009	μ	O
2009	##g	O
2009	,	O
2009	m	O
2009	##f	O
2009	400	O
2009	μ	O
2009	##g	O
2009	,	O
2009	f	O
2009	10	O
2009	μ	O
2009	##g	O
2009	,	O
2009	or	O
2009	place	O
2009	##bo	O
2009	.	O
2009	[SEP]	O
2010	[CLS]	O
2010	the	O
2010	effect	O
2010	of	O
2010	hem	O
2010	##od	O
2010	##ial	O
2010	##ys	O
2010	##is	O
2010	on	O
2010	the	O
2010	clearance	B-PK
2010	of	O
2010	c	O
2010	##ef	O
2010	##ider	O
2010	##oc	O
2010	##ol	O
2010	was	O
2010	also	O
2010	assessed	O
2010	.	O
2010	[SEP]	O
2011	[CLS]	O
2011	the	O
2011	terminal	B-PK
2011	elimination	I-PK
2011	half	I-PK
2011	‐	I-PK
2011	life	I-PK
2011	of	O
2011	c	O
2011	##ef	O
2011	##ider	O
2011	##oc	O
2011	##ol	O
2011	was	O
2011	1	O
2011	.	O
2011	98	O
2011	to	O
2011	2	O
2011	.	O
2011	74	O
2011	hours	O
2011	in	O
2011	these	O
2011	healthy	O
2011	volunteers	O
2011	.	O
2011	[SEP]	O
2012	[CLS]	O
2012	the	O
2012	composite	O
2012	samples	O
2012	were	O
2012	prepared	O
2012	by	O
2012	treating	O
2012	each	O
2012	matrix	O
2012	(	O
2012	plasma	O
2012	,	O
2012	urine	O
2012	,	O
2012	and	O
2012	dial	O
2012	##ys	O
2012	##ate	O
2012	)	O
2012	with	O
2012	a	O
2012	buffer	O
2012	(	O
2012	0	O
2012	.	O
2012	2	O
2012	m	O
2012	##ol	O
2012	/	O
2012	l	O
2012	am	O
2012	##mon	O
2012	##ium	O
2012	ace	O
2012	##tate	O
2012	,	O
2012	p	O
2012	##h	O
2012	5	O
2012	)	O
2012	in	O
2012	1	O
2012	:	O
2012	1	O
2012	volume	O
2012	ratio	O
2012	and	O
2012	used	O
2012	for	O
2012	measurement	O
2012	of	O
2012	c	O
2012	##ef	O
2012	##ider	O
2012	##oc	O
2012	##ol	O
2012	concentrations	O
2012	.	O
2012	[SEP]	O
2013	[CLS]	O
2013	the	O
2013	total	O
2013	volume	O
2013	of	O
2013	the	O
2013	c	O
2013	##s	O
2013	##f	O
2013	in	O
2013	humans	O
2013	is	O
2013	170	O
2013	m	O
2013	##l	O
2013	on	O
2013	average	O
2013	,	O
2013	of	O
2013	which	O
2013	approximately	O
2013	33	O
2013	%	O
2013	is	O
2013	found	O
2013	in	O
2013	##tra	O
2013	##c	O
2013	##rani	O
2013	##ally	O
2013	within	O
2013	the	O
2013	brain	O
2013	vent	O
2013	##ric	O
2013	##les	O
2013	[	O
2013	14	O
2013	]	O
2013	.	O
2013	[SEP]	O
2014	[CLS]	O
2014	since	O
2014	the	O
2014	c	O
2014	##rani	O
2014	##um	O
2014	is	O
2014	nearly	O
2014	rigid	O
2014	,	O
2014	the	O
2014	pu	O
2014	##ls	O
2014	##ation	O
2014	in	O
2014	blood	B-PK
2014	flow	I-PK
2014	must	O
2014	be	O
2014	accounted	O
2014	for	O
2014	.	O
2014	[SEP]	O
2015	[CLS]	O
2015	this	O
2015	q	O
2015	##sp	O
2015	model	O
2015	adequately	O
2015	captured	O
2015	the	O
2015	observed	O
2015	plasma	O
2015	and	O
2015	liver	O
2015	bio	O
2015	##mark	O
2015	##er	O
2015	behavior	O
2015	across	O
2015	a	O
2015	range	O
2015	of	O
2015	doses	O
2015	and	O
2015	dose	O
2015	regime	O
2015	##ns	O
2015	in	O
2015	gun	O
2015	##n	O
2015	rats	O
2015	.	O
2015	[SEP]	O
2016	[CLS]	O
2016	in	O
2016	a	O
2016	subsequent	O
2016	study	O
2016	(	O
2016	data	O
2016	not	O
2016	shown	O
2016	)	O
2016	similar	O
2016	behavior	O
2016	was	O
2016	observed	O
2016	in	O
2016	a	O
2016	larger	O
2016	set	O
2016	of	O
2016	animals	O
2016	that	O
2016	was	O
2016	seen	O
2016	to	O
2016	be	O
2016	an	O
2016	age	O
2016	effect	O
2016	,	O
2016	and	O
2016	part	O
2016	of	O
2016	the	O
2016	natural	O
2016	history	O
2016	of	O
2016	gun	O
2016	##n	O
2016	rats	O
2016	.	O
2016	[SEP]	O
2017	[CLS]	O
2017	on	O
2017	day	O
2017	22	O
2017	,	O
2017	inter	O
2017	-	O
2017	subject	O
2017	var	O
2017	##iability	O
2017	for	O
2017	p	O
2017	##f	O
2017	-	O
2017	06	O
2017	##64	O
2017	##9	O
2017	##75	O
2017	##1	O
2017	exposure	O
2017	,	O
2017	based	O
2017	on	O
2017	geometric	O
2017	%	O
2017	c	O
2017	##v	O
2017	,	O
2017	ranged	O
2017	from	O
2017	35	O
2017	%	O
2017	to	O
2017	61	O
2017	%	O
2017	for	O
2017	au	B-PK
2017	##ct	I-PK
2017	##au	I-PK
2017	and	O
2017	26	O
2017	%	O
2017	to	O
2017	46	O
2017	%	O
2017	for	O
2017	cm	B-PK
2017	##ax	I-PK
2017	across	O
2017	all	O
2017	co	O
2017	##hor	O
2017	##ts	O
2017	.	O
2017	[SEP]	O
2018	[CLS]	O
2018	supplement	O
2018	##ary	O
2018	material	O
2018	1	O
2018	(	O
2018	p	O
2018	##d	O
2018	##f	O
2018	90	O
2018	##7	O
2018	k	O
2018	##b	O
2018	)	O
2018	[SEP]	O
2019	[CLS]	O
2019	a	O
2019	micro	O
2019	##scopic	O
2019	examination	O
2019	including	O
2019	r	O
2019	##b	O
2019	##c	O
2019	,	O
2019	w	O
2019	##b	O
2019	##c	O
2019	,	O
2019	proteins	O
2019	,	O
2019	and	O
2019	casts	O
2019	was	O
2019	performed	O
2019	only	O
2019	when	O
2019	dip	O
2019	##stick	O
2019	evaluation	O
2019	was	O
2019	positive	O
2019	for	O
2019	w	O
2019	##b	O
2019	##c	O
2019	,	O
2019	or	O
2019	proteins	O
2019	,	O
2019	or	O
2019	blood	O
2019	.	O
2019	[SEP]	O
2020	[CLS]	O
2020	the	O
2020	following	O
2020	cell	O
2020	lines	O
2020	(	O
2020	at	O
2020	##cc	O
2020	,	O
2020	except	O
2020	where	O
2020	noted	O
2020	)	O
2020	were	O
2020	grown	O
2020	in	O
2020	culture	O
2020	medium	O
2020	supplemented	O
2020	with	O
2020	10	O
2020	%	O
2020	heat	O
2020	-	O
2020	inactivated	O
2020	f	O
2020	##etal	O
2020	b	O
2020	##ov	O
2020	##ine	O
2020	serum	O
2020	(	O
2020	f	O
2020	##bs	O
2020	,	O
2020	g	O
2020	##ib	O
2020	##co	O
2020	)	O
2020	,	O
2020	100	O
2020	units	O
2020	/	O
2020	m	O
2020	##l	O
2020	pen	O
2020	##ici	O
2020	##llin	O
2020	,	O
2020	100	O
2020	μ	O
2020	##g	O
2020	/	O
2020	m	O
2020	##l	O
2020	s	O
2020	##tre	O
2020	##pt	O
2020	##omy	O
2020	##cin	O
2020	(	O
2020	g	O
2020	##ib	O
2020	##co	O
2020	)	O
2020	,	O
2020	and	O
2020	1	O
2020	##x	O
2020	g	O
2020	##lut	O
2020	##ama	O
2020	##x	O
2020	(	O
2020	g	O
2020	##ib	O
2020	##co	O
2020	)	O
2020	(	O
2020	except	O
2020	where	O
2020	noted	O
2020	)	O
2020	,	O
2020	and	O
2020	maintained	O
2020	in	O
2020	a	O
2020	humid	O
2020	##ified	O
2020	in	O
2020	##cu	O
2020	##bat	O
2020	##or	O
2020	at	O
2020	37	O
2020	##°	O
2020	##c	O
2020	in	O
2020	5	O
2020	%	O
2020	co	O
2020	##2	O
2020	;	O
2020	re	O
2020	##v	O
2020	-	O
2020	g	O
2020	##f	O
2020	##p	O
2020	u	O
2020	##2	O
2020	##os	O
2020	[	O
2020	m	O
2020	##cco	O
2020	##y	O
2020	'	O
2020	s	O
2020	5	O
2020	##a	O
2020	,	O
2020	200	O
2020	u	O
2020	##g	O
2020	/	O
2020	m	O
2020	##l	O
2020	g	O
2020	##41	O
2020	##8	O
2020	(	O
2020	si	O
2020	##gma	O
2020	)	O
2020	]	O
2020	,	O
2020	mm	O
2020	.	O
2020	1	O
2020	##s	O
2020	(	O
2020	rpm	O
2020	##i	O
2020	)	O
2020	,	O
2020	m	O
2020	##v	O
2020	-	O
2020	4	O
2020	–	O
2020	11	O
2020	(	O
2020	im	O
2020	##d	O
2020	##m	O
2020	)	O
2020	,	O
2020	th	O
2020	##p	O
2020	-	O
2020	1	O
2020	(	O
2020	rpm	O
2020	##i	O
2020	)	O
2020	,	O
2020	h	O
2020	##ct	O
2020	-	O
2020	116	O
2020	(	O
2020	m	O
2020	##cco	O
2020	##y	O
2020	'	O
2020	s	O
2020	5	O
2020	##a	O
2020	)	O
2020	,	O
2020	am	O
2020	##l	O
2020	##2	O
2020	(	O
2020	d	O
2020	##sm	O
2020	##z	O
2020	,	O
2020	rpm	O
2020	##i	O
2020	)	O
2020	,	O
2020	am	O
2020	##l	O
2020	##3	O
2020	(	O
2020	d	O
2020	##sm	O
2020	##z	O
2020	,	O
2020	rpm	O
2020	##i	O
2020	)	O
2020	,	O
2020	h	O
2020	##t	O
2020	##10	O
2020	##80	O
2020	(	O
2020	em	O
2020	##em	O
2020	)	O
2020	,	O
2020	he	O
2020	##l	O
2020	(	O
2020	d	O
2020	##sm	O
2020	##z	O
2020	,	O
2020	rpm	O
2020	##i	O
2020	)	O
2020	,	O
2020	ka	O
2020	##su	O
2020	##mi	O
2020	-	O
2020	6	O
2020	(	O
2020	rpm	O
2020	##i	O
2020	,	O
2020	2	O
2020	mm	O
2020	l	O
2020	-	O
2020	g	O
2020	##lut	O
2020	##amine	O
2020	,	O
2020	1	O
2020	.	O
2020	5	O
2020	##g	O
2020	/	O
2020	l	O
2020	sodium	O
2020	bio	O
2020	##car	O
2020	##bon	O
2020	##ate	O
2020	,	O
2020	4	O
2020	.	O
2020	5	O
2020	g	O
2020	/	O
2020	l	O
2020	glucose	O
2020	,	O
2020	10	O
2020	mm	O
2020	he	O
2020	##pes	O
2020	,	O
2020	1	O
2020	.	O
2020	0	O
2020	mm	O
2020	sodium	O
2020	p	O
2020	##yr	O
2020	##u	O
2020	##vate	O
2020	,	O
2020	2	O
2020	ng	O
2020	/	O
2020	m	O
2020	##l	O
2020	g	O
2020	##m	O
2020	-	O
2020	c	O
2020	##s	O
2020	##f	O
2020	,	O
2020	20	O
2020	%	O
2020	f	O
2020	##bs	O
2020	)	O
2020	,	O
2020	sin	O
2020	##e	O
2020	compound	O
2020	resistant	O
2020	h	O
2020	##t	O
2020	##10	O
2020	##80	O
2020	(	O
2020	em	O
2020	##em	O
2020	,	O
2020	600	O
2020	nm	O
2020	k	O
2020	##pt	O
2020	-	O
2020	185	O
2020	)	O
2020	,	O
2020	a	O
2020	##5	O
2020	##4	O
2020	##9	O
2020	(	O
2020	rpm	O
2020	##i	O
2020	)	O
2020	,	O
2020	u	O
2020	##ch	O
2020	##1	O
2020	(	O
2020	4	O
2020	:	O
2020	1	O
2020	im	O
2020	##d	O
2020	##m	O
2020	:	O
2020	rpm	O
2020	##i	O
2020	)	O
2020	,	O
2020	u	O
2020	##ch	O
2020	##2	O
2020	(	O
2020	4	O
2020	:	O
2020	1	O
2020	im	O
2020	##d	O
2020	##m	O
2020	:	O
2020	rpm	O
2020	##i	O
2020	)	O
2020	,	O
2020	l	O
2020	##s	O
2020	##17	O
2020	##4	O
2020	##t	O
2020	(	O
2020	em	O
2020	##em	O
2020	)	O
2020	,	O
2020	and	O
2020	as	O
2020	##ps	O
2020	-	O
2020	k	O
2020	##y	O
2020	(	O
2020	gifted	O
2020	from	O
2020	a	O
2020	.	O
2020	og	O
2020	##ose	O
2020	,	O
2020	rpm	O
2020	##i	O
2020	)	O
2020	.	O
2020	[SEP]	O
2021	[CLS]	O
2021	el	O
2021	##uate	O
2021	##s	O
2021	and	O
2021	inputs	O
2021	were	O
2021	analyzed	O
2021	using	O
2021	a	O
2021	cap	O
2021	##illa	O
2021	##ry	O
2021	western	O
2021	method	O
2021	(	O
2021	p	O
2021	##eg	O
2021	##gy	O
2021	sue	O
2021	;	O
2021	protein	O
2021	simple	O
2021	)	O
2021	with	O
2021	the	O
2021	following	O
2021	primary	O
2021	antibodies	O
2021	:	O
2021	x	O
2021	##po	O
2021	##1	O
2021	(	O
2021	sa	O
2021	##nta	O
2021	c	O
2021	##ru	O
2021	##z	O
2021	)	O
2021	and	O
2021	β	O
2021	-	O
2021	act	O
2021	##in	O
2021	(	O
2021	sa	O
2021	##nta	O
2021	c	O
2021	##ru	O
2021	##z	O
2021	)	O
2021	.	O
2021	[SEP]	O
2022	[CLS]	O
2022	we	O
2022	set	O
2022	slope	O
2022	=	O
2022	0	O
2022	for	O
2022	subjects	O
2022	without	O
2022	ha	O
2022	##em	O
2022	##od	O
2022	##ial	O
2022	##ys	O
2022	##is	O
2022	or	O
2022	after	O
2022	volume	O
2022	recovery	O
2022	following	O
2022	ha	O
2022	##em	O
2022	##od	O
2022	##ial	O
2022	##ys	O
2022	##is	O
2022	;	O
2022	slope	O
2022	=	O
2022	vs	O
2022	##lop	O
2022	##e	O
2022	in	O
2022	subjects	O
2022	during	O
2022	ha	O
2022	##em	O
2022	##od	O
2022	##ial	O
2022	##ys	O
2022	##is	O
2022	and	O
2022	slope	O
2022	=	O
2022	−	O
2022	##v	O
2022	##s	O
2022	##lop	O
2022	##eu	O
2022	##p	O
2022	in	O
2022	subjects	O
2022	3	O
2022	h	O
2022	after	O
2022	ha	O
2022	##em	O
2022	##od	O
2022	##ial	O
2022	##ys	O
2022	##is	O
2022	,	O
2022	respectively	O
2022	.	O
2022	[SEP]	O
2023	[CLS]	O
2023	we	O
2023	illustrated	O
2023	this	O
2023	approach	O
2023	using	O
2023	a	O
2023	published	O
2023	human	O
2023	p	O
2023	##b	O
2023	##p	O
2023	##k	O
2023	model	O
2023	for	O
2023	ace	O
2023	##tam	O
2023	##ino	O
2023	##phe	O
2023	##n	O
2023	(	O
2023	a	O
2023	##pa	O
2023	##p	O
2023	)	O
2023	and	O
2023	its	O
2023	two	O
2023	primary	O
2023	meta	O
2023	##bol	O
2023	##ites	O
2023	a	O
2023	##pa	O
2023	##p	O
2023	-	O
2023	g	O
2023	##lu	O
2023	##cu	O
2023	##ron	O
2023	##ide	O
2023	and	O
2023	a	O
2023	##pa	O
2023	##p	O
2023	-	O
2023	su	O
2023	##lf	O
2023	##ate	O
2023	.	O
2023	[SEP]	O
2024	[CLS]	O
2024	the	O
2024	pure	O
2024	fraction	O
2024	##s	O
2024	of	O
2024	compound	O
2024	f	O
2024	were	O
2024	pool	O
2024	##ed	O
2024	and	O
2024	the	O
2024	solvent	O
2024	was	O
2024	e	O
2024	##va	O
2024	##porated	O
2024	under	O
2024	reduced	O
2024	pressure	O
2024	.	O
2024	[SEP]	O
2025	[CLS]	O
2025	compound	O
2025	f	O
2025	was	O
2025	dissolved	O
2025	in	O
2025	met	O
2025	##han	O
2025	##ol	O
2025	at	O
2025	a	O
2025	concentration	O
2025	of	O
2025	5	O
2025	µ	O
2025	##g	O
2025	/	O
2025	m	O
2025	##l	O
2025	and	O
2025	scanned	O
2025	for	O
2025	its	O
2025	flu	O
2025	##ores	O
2025	##cence	O
2025	spectrum	O
2025	from	O
2025	300	O
2025	to	O
2025	900	O
2025	nm	O
2025	in	O
2025	a	O
2025	flu	O
2025	##ores	O
2025	##cence	O
2025	s	O
2025	##pect	O
2025	##rop	O
2025	##hot	O
2025	##ometer	O
2025	(	O
2025	f	O
2025	-	O
2025	460	O
2025	##0	O
2025	,	O
2025	hit	O
2025	##achi	O
2025	high	O
2025	-	O
2025	technologies	O
2025	corporation	O
2025	,	O
2025	j	O
2025	##apa	O
2025	##n	O
2025	)	O
2025	to	O
2025	get	O
2025	its	O
2025	maximum	O
2025	flu	O
2025	##ores	O
2025	##cence	O
2025	ex	O
2025	##citation	O
2025	and	O
2025	absorption	O
2025	wavelength	O
2025	.	O
2025	[SEP]	O
2026	[CLS]	O
2026	twenty	O
2026	mill	O
2026	##ig	O
2026	##ram	O
2026	of	O
2026	compound	O
2026	f	O
2026	was	O
2026	dissolved	O
2026	in	O
2026	4	O
2026	m	O
2026	##l	O
2026	water	O
2026	.	O
2026	[SEP]	O
2027	[CLS]	O
2027	solutions	O
2027	of	O
2027	compound	O
2027	f	O
2027	(	O
2027	5	O
2027	.	O
2027	0	O
2027	mg	O
2027	/	O
2027	m	O
2027	##l	O
2027	)	O
2027	and	O
2027	camp	O
2027	##to	O
2027	##the	O
2027	##cin	O
2027	with	O
2027	a	O
2027	final	O
2027	concentration	O
2027	of	O
2027	1	O
2027	.	O
2027	0	O
2027	µ	O
2027	##g	O
2027	/	O
2027	m	O
2027	##l	O
2027	as	O
2027	an	O
2027	internal	O
2027	standard	O
2027	were	O
2027	added	O
2027	to	O
2027	5	O
2027	m	O
2027	##l	O
2027	human	O
2027	serum	O
2027	to	O
2027	give	O
2027	a	O
2027	final	O
2027	concentration	O
2027	of	O
2027	0	O
2027	.	O
2027	5	O
2027	mg	O
2027	/	O
2027	m	O
2027	##l	O
2027	and	O
2027	in	O
2027	##cu	O
2027	##bate	O
2027	##d	O
2027	at	O
2027	37	O
2027	##°	O
2027	##c	O
2027	.	O
2027	[SEP]	O
2028	[CLS]	O
2028	after	O
2028	entering	O
2028	tumor	O
2028	cells	O
2028	,	O
2028	the	O
2028	h	O
2028	##yd	O
2028	##raz	O
2028	##one	O
2028	bond	O
2028	in	O
2028	compound	O
2028	f	O
2028	is	O
2028	to	O
2028	r	O
2028	##up	O
2028	##ture	O
2028	to	O
2028	generate	O
2028	compound	O
2028	b	O
2028	and	O
2028	play	O
2028	efficacy	O
2028	so	O
2028	the	O
2028	release	O
2028	of	O
2028	compound	O
2028	b	O
2028	is	O
2028	important	O
2028	.	O
2028	[SEP]	O
2029	[CLS]	O
2029	the	O
2029	results	O
2029	showed	O
2029	that	O
2029	compound	O
2029	f	O
2029	had	O
2029	the	O
2029	strongest	O
2029	c	O
2029	##yt	O
2029	##oto	O
2029	##xi	O
2029	##city	O
2029	for	O
2029	the	O
2029	three	O
2029	cell	O
2029	lines	O
2029	.	O
2029	[SEP]	O
2030	[CLS]	O
2030	the	O
2030	concentrations	O
2030	of	O
2030	compound	O
2030	f	O
2030	in	O
2030	the	O
2030	plasma	O
2030	and	O
2030	tissues	O
2030	of	O
2030	heart	O
2030	,	O
2030	liver	O
2030	,	O
2030	s	O
2030	##ple	O
2030	##en	O
2030	,	O
2030	lung	O
2030	,	O
2030	kidney	O
2030	,	O
2030	brain	O
2030	,	O
2030	and	O
2030	tumor	O
2030	were	O
2030	measured	O
2030	after	O
2030	in	O
2030	##tra	O
2030	##ven	O
2030	##ous	O
2030	injection	O
2030	of	O
2030	compound	O
2030	f	O
2030	solution	O
2030	.	O
2030	[SEP]	O
2031	[CLS]	O
2031	it	O
2031	is	O
2031	suggested	O
2031	that	O
2031	compound	O
2031	f	O
2031	could	O
2031	c	O
2031	##ir	O
2031	##culate	O
2031	for	O
2031	a	O
2031	much	O
2031	longer	O
2031	time	O
2031	in	O
2031	the	O
2031	blood	O
2031	circulation	O
2031	system	O
2031	than	O
2031	10	O
2031	-	O
2031	h	O
2031	##c	O
2031	##pt	O
2031	solution	O
2031	,	O
2031	which	O
2031	would	O
2031	result	O
2031	in	O
2031	their	O
2031	higher	O
2031	affinity	O
2031	to	O
2031	the	O
2031	tumor	O
2031	cells	O
2031	or	O
2031	extra	O
2031	##cellular	O
2031	spaces	O
2031	.	O
2031	[SEP]	O
2032	[CLS]	O
2032	k	B-PK
2032	is	O
2032	the	O
2032	terminal	B-PK
2032	elimination	I-PK
2032	rate	I-PK
2032	constant	I-PK
2032	[SEP]	O
2033	[CLS]	O
2033	significant	O
2033	differences	O
2033	were	O
2033	observed	O
2033	for	O
2033	apparent	B-PK
2033	volume	I-PK
2033	of	I-PK
2033	distribution	I-PK
2033	(	O
2033	p	O
2033	=	O
2033	0	O
2033	.	O
2033	01	O
2033	##25	O
2033	)	O
2033	,	O
2033	and	O
2033	total	B-PK
2033	body	I-PK
2033	clearance	I-PK
2033	(	O
2033	p	O
2033	=	O
2033	0	O
2033	.	O
2033	02	O
2033	##01	O
2033	)	O
2033	in	O
2033	a	O
2033	##f	O
2033	##rica	O
2033	##ns	O
2033	and	O
2033	chin	O
2033	##ese	O
2033	.	O
2033	[SEP]	O
2034	[CLS]	O
2034	the	O
2034	relationship	O
2034	of	O
2034	gut	O
2034	micro	O
2034	##bio	O
2034	##ta	O
2034	with	O
2034	the	O
2034	p	O
2034	##k	O
2034	was	O
2034	plot	O
2034	##ted	O
2034	in	O
2034	a	O
2034	network	O
2034	by	O
2034	co	O
2034	##rrel	O
2034	##ating	O
2034	the	O
2034	bacterial	O
2034	o	O
2034	##tus	O
2034	with	O
2034	the	O
2034	au	B-PK
2034	##cs	I-PK
2034	of	O
2034	be	O
2034	##rber	O
2034	##ine	O
2034	in	O
2034	participants	O
2034	.	O
2034	[SEP]	O
2035	[CLS]	O
2035	non	O
2035	##com	O
2035	##par	O
2035	##tment	O
2035	##al	O
2035	analysis	O
2035	was	O
2035	applied	O
2035	to	O
2035	obtain	O
2035	the	O
2035	p	O
2035	##har	O
2035	##ma	O
2035	##co	O
2035	##kin	O
2035	##etic	O
2035	parameters	O
2035	using	O
2035	the	O
2035	win	O
2035	##non	O
2035	##lin	O
2035	##®	O
2035	software	O
2035	,	O
2035	version	O
2035	2	O
2035	.	O
2035	0	O
2035	(	O
2035	p	O
2035	##har	O
2035	##sight	O
2035	co	O
2035	##rp	O
2035	.	O
2035	,	O
2035	mountain	O
2035	view	O
2035	,	O
2035	ca	O
2035	,	O
2035	us	O
2035	##a	O
2035	)	O
2035	.	O
2035	[SEP]	O
2036	[CLS]	O
2036	the	O
2036	study	O
2036	was	O
2036	prospective	O
2036	##ly	O
2036	registered	O
2036	with	O
2036	the	O
2036	au	O
2036	##stra	O
2036	##lian	O
2036	drug	O
2036	regulatory	O
2036	authority	O
2036	,	O
2036	the	O
2036	therapeutic	O
2036	goods	O
2036	administration	O
2036	(	O
2036	t	O
2036	##ga	O
2036	)	O
2036	,	O
2036	clinical	O
2036	trial	O
2036	not	O
2036	##ification	O
2036	(	O
2036	c	O
2036	##t	O
2036	-	O
2036	2015	O
2036	-	O
2036	c	O
2036	##t	O
2036	##n	O
2036	-	O
2036	03	O
2036	##23	O
2036	##7	O
2036	-	O
2036	1	O
2036	v	O
2036	##2	O
2036	)	O
2036	in	O
2036	compliance	O
2036	with	O
2036	the	O
2036	requirements	O
2036	of	O
2036	the	O
2036	human	O
2036	ethics	O
2036	committee	O
2036	and	O
2036	retrospective	O
2036	##ly	O
2036	with	O
2036	the	O
2036	au	O
2036	##stra	O
2036	##lian	O
2036	new	O
2036	z	O
2036	##eal	O
2036	##and	O
2036	clinical	O
2036	trials	O
2036	registry	O
2036	(	O
2036	trial	O
2036	id	O
2036	:	O
2036	act	O
2036	##rn	O
2036	##12	O
2036	##6	O
2036	##16	O
2036	##00	O
2036	##16	O
2036	##6	O
2036	##64	O
2036	##15	O
2036	)	O
2036	.	O
2036	[SEP]	O
2037	[CLS]	O
2037	this	O
2037	physiological	O
2037	absorption	O
2037	model	O
2037	accounts	O
2037	for	O
2037	p	O
2037	##h	O
2037	,	O
2037	transit	O
2037	time	O
2037	,	O
2037	lengths	O
2037	and	O
2037	r	O
2037	##adi	O
2037	##i	O
2037	of	O
2037	each	O
2037	gas	O
2037	##tro	O
2037	##int	O
2037	##est	O
2037	##inal	O
2037	compartment	O
2037	,	O
2037	plasma	O
2037	protein	O
2037	binding	O
2037	,	O
2037	stomach	O
2037	volume	O
2037	,	O
2037	he	B-PK
2037	##pa	I-PK
2037	##tic	I-PK
2037	blood	I-PK
2037	flow	I-PK
2037	rate	I-PK
2037	,	O
2037	and	O
2037	gut	O
2037	enzyme	O
2037	and	O
2037	transport	O
2037	##er	O
2037	distribution	O
2037	.	O
2037	[SEP]	O
2038	[CLS]	O
2038	the	O
2038	second	O
2038	peak	O
2038	,	O
2038	which	O
2038	occurred	O
2038	at	O
2038	around	O
2038	9	O
2038	h	O
2038	,	O
2038	was	O
2038	depicted	O
2038	by	O
2038	a	O
2038	combination	O
2038	of	O
2038	varying	O
2038	transit	B-PK
2038	constant	I-PK
2038	(	I-PK
2038	ka	I-PK
2038	##t	I-PK
2038	;	O
2038	0	O
2038	.	O
2038	53	O
2038	##2	O
2038	–	O
2038	1	O
2038	.	O
2038	25	O
2038	h	O
2038	-	O
2038	1	O
2038	)	O
2038	and	O
2038	absorption	B-PK
2038	rate	I-PK
2038	constant	I-PK
2038	from	I-PK
2038	the	I-PK
2038	g	I-PK
2038	##7	I-PK
2038	compartment	I-PK
2038	(	I-PK
2038	ka	I-PK
2038	##2	I-PK
2038	;	O
2038	0	O
2038	.	O
2038	92	O
2038	##9	O
2038	–	O
2038	0	O
2038	.	O
2038	08	O
2038	##9	O
2038	##8	O
2038	h	O
2038	-	O
2038	1	O
2038	)	O
2038	at	O
2038	different	O
2038	doses	O
2038	(	O
2038	table	O
2038	3	O
2038	)	O
2038	.	O
2038	[SEP]	O
2039	[CLS]	O
2039	in	O
2039	mice	O
2039	,	O
2039	plasma	O
2039	concentrations	O
2039	reached	O
2039	the	O
2039	peak	O
2039	at	O
2039	2	O
2039	h	O
2039	after	O
2039	oral	O
2039	administration	O
2039	and	O
2039	declined	O
2039	in	O
2039	parallel	O
2039	with	O
2039	the	O
2039	terminal	B-PK
2039	slope	I-PK
2039	of	O
2039	the	O
2039	i	O
2039	##v	O
2039	profile	O
2039	,	O
2039	with	O
2039	elimination	B-PK
2039	half	I-PK
2039	-	I-PK
2039	lives	I-PK
2039	of	O
2039	7	O
2039	–	O
2039	11	O
2039	h	O
2039	.	O
2039	[SEP]	O
2040	[CLS]	O
2040	for	O
2040	both	O
2040	parts	O
2040	of	O
2040	this	O
2040	study	O
2040	,	O
2040	di	O
2040	##c	O
2040	##lo	O
2040	##xa	O
2040	##ci	O
2040	##llin	O
2040	sodium	O
2040	capsule	O
2040	##s	O
2040	(	O
2040	0	O
2040	.	O
2040	25	O
2040	g	O
2040	per	O
2040	capsule	O
2040	;	O
2040	lot	O
2040	91	O
2040	##30	O
2040	##5	O
2040	##7	O
2040	##4	O
2040	)	O
2040	were	O
2040	supplied	O
2040	by	O
2040	bright	O
2040	future	O
2040	pharmaceutical	O
2040	##s	O
2040	factory	O
2040	(	O
2040	y	O
2040	##uen	O
2040	long	O
2040	,	O
2040	n	O
2040	.	O
2040	t	O
2040	.	O
2040	,	O
2040	ho	O
2040	##ng	O
2040	k	O
2040	##ong	O
2040	)	O
2040	.	O
2040	[SEP]	O
2041	[CLS]	O
2041	for	O
2041	multiple	O
2041	-	O
2041	dose	O
2041	study	O
2041	,	O
2041	the	O
2041	time	B-PK
2041	to	I-PK
2041	reach	I-PK
2041	peak	I-PK
2041	concentration	I-PK
2041	(	I-PK
2041	t	I-PK
2041	##max	I-PK
2041	,	I-PK
2041	s	I-PK
2041	##s	I-PK
2041	)	I-PK
2041	and	O
2041	maximum	B-PK
2041	and	O
2041	minimum	B-PK
2041	plasma	I-PK
2041	concentration	I-PK
2041	at	I-PK
2041	the	I-PK
2041	steady	I-PK
2041	state	I-PK
2041	(	O
2041	cm	B-PK
2041	##ax	I-PK
2041	,	I-PK
2041	s	I-PK
2041	##s	I-PK
2041	and	O
2041	cm	B-PK
2041	##in	I-PK
2041	,	I-PK
2041	s	I-PK
2041	##s	I-PK
2041	)	O
2041	were	O
2041	determined	O
2041	directly	O
2041	from	O
2041	experimental	O
2041	observations	O
2041	.	O
2041	[SEP]	O
2042	[CLS]	O
2042	the	O
2042	cm	B-PK
2042	##ax	I-PK
2042	/	I-PK
2042	mi	I-PK
2042	##c	I-PK
2042	values	O
2042	were	O
2042	26	O
2042	.	O
2042	58	O
2042	±	O
2042	18	O
2042	.	O
2042	84	O
2042	,	O
2042	26	O
2042	.	O
2042	48	O
2042	±	O
2042	18	O
2042	.	O
2042	77	O
2042	,	O
2042	and	O
2042	23	O
2042	.	O
2042	94	O
2042	±	O
2042	16	O
2042	.	O
2042	97	O
2042	,	O
2042	and	O
2042	t	O
2042	>	O
2042	mi	O
2042	##cs	O
2042	were	O
2042	42	O
2042	.	O
2042	80	O
2042	±	O
2042	1	O
2042	.	O
2042	01	O
2042	,	O
2042	36	O
2042	.	O
2042	40	O
2042	±	O
2042	1	O
2042	.	O
2042	24	O
2042	,	O
2042	and	O
2042	38	O
2042	.	O
2042	60	O
2042	±	O
2042	1	O
2042	.	O
2042	18	O
2042	h	O
2042	,	O
2042	after	O
2042	i	O
2042	.	O
2042	v	O
2042	.	O
2042	,	O
2042	i	O
2042	.	O
2042	m	O
2042	.	O
2042	,	O
2042	and	O
2042	p	O
2042	.	O
2042	o	O
2042	.	O
2042	administration	O
2042	,	O
2042	respectively	O
2042	.	O
2042	[SEP]	O
2043	[CLS]	O
2043	the	O
2043	p	O
2043	##har	O
2043	##ma	O
2043	##co	O
2043	##kin	O
2043	##etic	O
2043	parameters	O
2043	of	O
2043	ma	O
2043	##rb	O
2043	##of	O
2043	##lo	O
2043	##xa	O
2043	##cin	O
2043	were	O
2043	analyzed	O
2043	by	O
2043	win	O
2043	##non	O
2043	##lin	O
2043	6	O
2043	.	O
2043	1	O
2043	software	O
2043	(	O
2043	p	O
2043	##har	O
2043	##sight	O
2043	corporation	O
2043	,	O
2043	mountain	O
2043	view	O
2043	,	O
2043	ca	O
2043	,	O
2043	us	O
2043	##a	O
2043	)	O
2043	.	O
2043	[SEP]	O
2044	[CLS]	O
2044	cultures	O
2044	(	O
2044	20	O
2044	μ	O
2044	##l	O
2044	)	O
2044	from	O
2044	all	O
2044	micro	O
2044	##well	O
2044	##s	O
2044	in	O
2044	96	O
2044	-	O
2044	well	O
2044	plates	O
2044	that	O
2044	showed	O
2044	no	O
2044	visible	O
2044	growth	O
2044	were	O
2044	spotted	O
2044	on	O
2044	try	O
2044	##ptic	O
2044	so	O
2044	##y	O
2044	a	O
2044	##gar	O
2044	(	O
2044	t	O
2044	##sa	O
2044	)	O
2044	plates	O
2044	and	O
2044	in	O
2044	##cu	O
2044	##bate	O
2044	##d	O
2044	for	O
2044	24	O
2044	h	O
2044	at	O
2044	35	O
2044	##°	O
2044	##c	O
2044	.	O
2044	[SEP]	O
2045	[CLS]	O
2045	each	O
2045	he	O
2045	##x	O
2045	##3	O
2045	-	O
2045	s	O
2045	##c	O
2045	##d	O
2045	##b	O
2045	-	O
2045	f	O
2045	##c	O
2045	predominantly	O
2045	formed	O
2045	mon	O
2045	##omer	O
2045	##s	O
2045	,	O
2045	which	O
2045	correspond	O
2045	##ed	O
2045	to	O
2045	the	O
2045	functional	O
2045	s	O
2045	##c	O
2045	##d	O
2045	##b	O
2045	-	O
2045	f	O
2045	##c	O
2045	fraction	O
2045	(	O
2045	[UNK]	O
2045	k	O
2045	##da	O
2045	)	O
2045	;	O
2045	however	O
2045	,	O
2045	small	O
2045	amounts	O
2045	of	O
2045	multi	O
2045	##mer	O
2045	##ic	O
2045	forms	O
2045	also	O
2045	appeared	O
2045	on	O
2045	the	O
2045	ch	O
2045	##roma	O
2045	##to	O
2045	##graphs	O
2045	(	O
2045	fi	O
2045	##g	O
2045	.	O
2045	1	O
2045	##c	O
2045	)	O
2045	.	O
2045	[SEP]	O
2046	[CLS]	O
2046	l	O
2046	##ymph	O
2046	##oki	O
2046	##ne	O
2046	-	O
2046	activated	O
2046	killer	O
2046	cells	O
2046	with	O
2046	the	O
2046	t	O
2046	-	O
2046	cell	O
2046	p	O
2046	##hen	O
2046	##otype	O
2046	(	O
2046	t	O
2046	-	O
2046	la	O
2046	##k	O
2046	)	O
2046	were	O
2046	induced	O
2046	as	O
2046	previously	O
2046	described	O
2046	.	O
2046	34	O
2046	in	O
2046	brief	O
2046	,	O
2046	p	O
2046	##b	O
2046	##m	O
2046	##c	O
2046	were	O
2046	culture	O
2046	##d	O
2046	for	O
2046	48	O
2046	h	O
2046	at	O
2046	a	O
2046	density	O
2046	of	O
2046	1	O
2046	×	O
2046	106	O
2046	cells	O
2046	/	O
2046	m	O
2046	##l	O
2046	in	O
2046	medium	O
2046	supplemented	O
2046	with	O
2046	100	O
2046	i	O
2046	##u	O
2046	/	O
2046	m	O
2046	##l	O
2046	of	O
2046	re	O
2046	##comb	O
2046	##ina	O
2046	##nt	O
2046	human	O
2046	il	O
2046	-	O
2046	2	O
2046	(	O
2046	s	O
2046	##hi	O
2046	##ono	O
2046	##gi	O
2046	pharmaceutical	O
2046	co	O
2046	.	O
2046	,	O
2046	o	O
2046	##sa	O
2046	##ka	O
2046	,	O
2046	j	O
2046	##apa	O
2046	##n	O
2046	)	O
2046	in	O
2046	a	O
2046	culture	O
2046	fl	O
2046	##ask	O
2046	(	O
2046	a	O
2046	/	O
2046	s	O
2046	nun	O
2046	##c	O
2046	,	O
2046	r	O
2046	##os	O
2046	##ki	O
2046	##lde	O
2046	,	O
2046	den	O
2046	##mark	O
2046	)	O
2046	that	O
2046	was	O
2046	pre	O
2046	##coat	O
2046	##ed	O
2046	with	O
2046	anti	O
2046	-	O
2046	c	O
2046	##d	O
2046	##3	O
2046	mon	O
2046	##oc	O
2046	##lon	O
2046	##al	O
2046	anti	O
2046	##body	O
2046	(	O
2046	10	O
2046	μ	O
2046	##g	O
2046	/	O
2046	m	O
2046	##l	O
2046	)	O
2046	.	O
2046	[SEP]	O
2047	[CLS]	O
2047	the	O
2047	effect	O
2047	of	O
2047	c	O
2047	##v	O
2047	##v	O
2047	##h	O
2047	was	O
2047	assessed	O
2047	on	O
2047	v	B-PK
2047	##1	I-PK
2047	(	O
2047	di	O
2047	##cho	O
2047	##tom	O
2047	##ous	O
2047	co	O
2047	##var	O
2047	##iate	O
2047	)	O
2047	.	O
2047	[SEP]	O
2048	[CLS]	O
2048	the	O
2048	sofa	O
2048	score	O
2048	was	O
2048	divided	O
2048	into	O
2048	a	O
2048	low	O
2048	score	O
2048	(	O
2048	<	O
2048	10	O
2048	)	O
2048	and	O
2048	a	O
2048	high	O
2048	score	O
2048	(	O
2048	>	O
2048	10	O
2048	)	O
2048	based	O
2048	on	O
2048	associated	O
2048	mortality	O
2048	risks	O
2048	[	O
2048	20	O
2048	,	O
2048	21	O
2048	]	O
2048	and	O
2048	was	O
2048	assessed	O
2048	as	O
2048	a	O
2048	cat	O
2048	##ego	O
2048	##rical	O
2048	co	O
2048	##var	O
2048	##iate	O
2048	on	O
2048	c	B-PK
2048	##l	I-PK
2048	and	O
2048	v	B-PK
2048	.	O
2048	[SEP]	O
2049	[CLS]	O
2049	ii	O
2049	##v	O
2049	on	O
2049	c	B-PK
2049	##l	I-PK
2049	and	O
2049	v	B-PK
2049	##1	I-PK
2049	further	O
2049	improved	O
2049	the	O
2049	model	O
2049	while	O
2049	data	O
2049	did	O
2049	not	O
2049	support	O
2049	the	O
2049	addition	O
2049	of	O
2049	ii	O
2049	##v	O
2049	on	O
2049	q	B-PK
2049	or	O
2049	v	B-PK
2049	##2	I-PK
2049	.	O
2049	[SEP]	O
2050	[CLS]	O
2050	allowing	O
2050	a	O
2050	correlation	O
2050	between	O
2050	ii	O
2050	##v	O
2050	of	O
2050	c	B-PK
2050	##l	I-PK
2050	and	O
2050	v	B-PK
2050	##1	I-PK
2050	further	O
2050	improved	O
2050	the	O
2050	model	O
2050	(	O
2050	difference	O
2050	of	O
2050	##v	O
2050	=	O
2050	13	O
2050	.	O
2050	98	O
2050	)	O
2050	.	O
2050	[SEP]	O
2051	[CLS]	O
2051	c	B-PK
2051	##l	I-PK
2051	,	O
2051	v	B-PK
2051	##1	I-PK
2051	,	O
2051	q	B-PK
2051	and	O
2051	v	B-PK
2051	##2	I-PK
2051	were	O
2051	estimated	O
2051	to	O
2051	be	O
2051	1	O
2051	.	O
2051	10	O
2051	l	O
2051	/	O
2051	h	O
2051	,	O
2051	17	O
2051	.	O
2051	6	O
2051	l	O
2051	,	O
2051	0	O
2051	.	O
2051	36	O
2051	##3	O
2051	l	O
2051	/	O
2051	h	O
2051	and	O
2051	3	O
2051	.	O
2051	63	O
2051	l	O
2051	.	O
2051	the	O
2051	ii	O
2051	##v	O
2051	on	O
2051	c	B-PK
2051	##l	I-PK
2051	and	O
2051	v	B-PK
2051	##1	I-PK
2051	were	O
2051	estimated	O
2051	to	O
2051	be	O
2051	40	O
2051	and	O
2051	73	O
2051	%	O
2051	c	O
2051	##v	O
2051	with	O
2051	et	O
2051	##a	O
2051	shrink	O
2051	##age	O
2051	of	O
2051	1	O
2051	.	O
2051	2	O
2051	and	O
2051	41	O
2051	%	O
2051	,	O
2051	respectively	O
2051	,	O
2051	while	O
2051	i	O
2051	##ov	O
2051	on	O
2051	v	B-PK
2051	##1	I-PK
2051	was	O
2051	estimated	O
2051	to	O
2051	be	O
2051	37	O
2051	%	O
2051	c	O
2051	##v	O
2051	.	O
2051	[SEP]	O
2052	[CLS]	O
2052	no	O
2052	co	O
2052	##var	O
2052	##iate	O
2052	##s	O
2052	were	O
2052	identified	O
2052	to	O
2052	significantly	O
2052	affect	O
2052	c	B-PK
2052	##l	I-PK
2052	or	O
2052	v	B-PK
2052	##1	I-PK
2052	.	O
2052	[SEP]	O
2053	[CLS]	O
2053	from	O
2053	the	O
2053	plasma	O
2053	profile	O
2053	,	O
2053	it	O
2053	was	O
2053	shown	O
2053	that	O
2053	the	O
2053	maximum	B-PK
2053	concentration	I-PK
2053	(	I-PK
2053	cm	I-PK
2053	##ax	I-PK
2053	)	I-PK
2053	values	O
2053	for	O
2053	b	O
2053	##ud	O
2053	suspension	O
2053	##s	O
2053	and	O
2053	b	O
2053	##ud	O
2053	micro	O
2053	##sp	O
2053	##here	O
2053	##s	O
2053	were	O
2053	8	O
2053	.	O
2053	41	O
2053	and	O
2053	4	O
2053	.	O
2053	57	O
2053	μ	O
2053	##g	O
2053	/	O
2053	m	O
2053	##l	O
2053	,	O
2053	respectively	O
2053	,	O
2053	and	O
2053	the	O
2053	time	B-PK
2053	to	I-PK
2053	reach	I-PK
2053	maximum	I-PK
2053	concentration	I-PK
2053	(	I-PK
2053	t	I-PK
2053	##max	I-PK
2053	)	I-PK
2053	values	O
2053	were	O
2053	1	O
2053	and	O
2053	6	O
2053	h	O
2053	,	O
2053	respectively	O
2053	.	O
2053	[SEP]	O
2054	[CLS]	O
2054	the	O
2054	t	B-PK
2054	##max	I-PK
2054	was	O
2054	6	O
2054	h	O
2054	for	O
2054	b	O
2054	##ud	O
2054	micro	O
2054	##sp	O
2054	##here	O
2054	##s	O
2054	,	O
2054	while	O
2054	it	O
2054	was	O
2054	1	O
2054	h	O
2054	for	O
2054	b	O
2054	##ud	O
2054	suspension	O
2054	##s	O
2054	.	O
2054	[SEP]	O
2055	[CLS]	O
2055	extra	B-PK
2055	##pol	I-PK
2055	##ation	I-PK
2055	to	I-PK
2055	infinite	I-PK
2055	time	I-PK
2055	(	I-PK
2055	au	I-PK
2055	##c	I-PK
2055	##0	I-PK
2055	–	I-PK
2055	∞	I-PK
2055	)	I-PK
2055	was	O
2055	calculated	O
2055	as	O
2055	follows	O
2055	:	O
2055	au	O
2055	##c	O
2055	##0	O
2055	–	O
2055	∞	O
2055	=	O
2055	au	O
2055	##c	O
2055	##0	O
2055	–	O
2055	t	O
2055	+	O
2055	c	O
2055	##t	O
2055	/	O
2055	k	O
2055	##e	O
2055	,	O
2055	where	O
2055	c	O
2055	##t	O
2055	is	O
2055	the	O
2055	last	O
2055	me	O
2055	##as	O
2055	##urable	O
2055	plasma	O
2055	concentration	O
2055	and	O
2055	k	B-PK
2055	##e	I-PK
2055	is	O
2055	the	O
2055	terminal	B-PK
2055	elimination	I-PK
2055	rate	I-PK
2055	constant	I-PK
2055	.	O
2055	[SEP]	O
2056	[CLS]	O
2056	the	O
2056	elimination	B-PK
2056	half	I-PK
2056	-	I-PK
2056	life	I-PK
2056	(	I-PK
2056	t	I-PK
2056	##1	I-PK
2056	/	I-PK
2056	2	I-PK
2056	)	I-PK
2056	was	O
2056	determined	O
2056	by	O
2056	linear	O
2056	re	O
2056	##gression	O
2056	of	O
2056	the	O
2056	terminal	O
2056	portion	O
2056	of	O
2056	the	O
2056	plasma	O
2056	concentration	O
2056	-	O
2056	time	O
2056	data	O
2056	.	O
2056	[SEP]	O
2057	[CLS]	O
2057	radio	B-PK
2057	##act	I-PK
2057	##ivity	I-PK
2057	was	O
2057	detected	O
2057	and	O
2057	q	O
2057	##uant	O
2057	##itated	O
2057	using	O
2057	a	O
2057	pack	O
2057	##ard	O
2057	fl	O
2057	##o	O
2057	-	O
2057	one	O
2057	/	O
2057	beta	O
2057	radio	O
2057	##matic	O
2057	detector	O
2057	a	O
2057	##500	O
2057	or	O
2057	a	O
2057	##25	O
2057	##0	O
2057	with	O
2057	a	O
2057	0	O
2057	.	O
2057	5	O
2057	m	O
2057	##l	O
2057	flow	O
2057	cell	O
2057	,	O
2057	a	O
2057	y	O
2057	##ts	O
2057	##i	O
2057	solid	O
2057	cell	O
2057	,	O
2057	or	O
2057	by	O
2057	collecting	O
2057	1	O
2057	minute	O
2057	fraction	O
2057	##s	O
2057	.	O
2057	[SEP]	O
2058	[CLS]	O
2058	extract	O
2058	##s	O
2058	from	O
2058	individual	O
2058	and	O
2058	pool	O
2058	##ed	O
2058	samples	O
2058	were	O
2058	applied	O
2058	to	O
2058	thin	O
2058	layer	O
2058	ch	O
2058	##roma	O
2058	##tography	O
2058	(	O
2058	t	O
2058	##l	O
2058	##c	O
2058	)	O
2058	plates	O
2058	and	O
2058	el	O
2058	##uted	O
2058	with	O
2058	a	O
2058	solvent	O
2058	consisting	O
2058	of	O
2058	di	O
2058	##ch	O
2058	##lor	O
2058	##ome	O
2058	##than	O
2058	##e	O
2058	,	O
2058	met	O
2058	##han	O
2058	##ol	O
2058	,	O
2058	and	O
2058	concentrated	O
2058	am	O
2058	##monia	O
2058	solution	O
2058	in	O
2058	a	O
2058	volume	O
2058	ratio	O
2058	of	O
2058	74	O
2058	:	O
2058	25	O
2058	:	O
2058	1	O
2058	.	O
2058	[SEP]	O
2059	[CLS]	O
2059	radio	O
2059	##la	O
2059	##bel	O
2059	##ed	O
2059	components	O
2059	were	O
2059	visual	O
2059	##ized	O
2059	by	O
2059	placing	O
2059	the	O
2059	t	O
2059	##l	O
2059	##c	O
2059	plates	O
2059	in	O
2059	contact	O
2059	with	O
2059	a	O
2059	b	O
2059	##as	O
2059	##20	O
2059	##00	O
2059	p	O
2059	##hos	O
2059	##ph	O
2059	##oi	O
2059	##maging	O
2059	plate	O
2059	(	O
2059	f	O
2059	##u	O
2059	##ji	O
2059	photo	O
2059	film	O
2059	co	O
2059	l	O
2059	##t	O
2059	##d	O
2059	,	O
2059	j	O
2059	##apa	O
2059	##n	O
2059	)	O
2059	,	O
2059	and	O
2059	the	O
2059	exposed	O
2059	plates	O
2059	were	O
2059	read	O
2059	with	O
2059	a	O
2059	f	O
2059	##u	O
2059	##ji	O
2059	##x	O
2059	b	O
2059	##as	O
2059	##20	O
2059	##00	O
2059	bio	O
2059	-	O
2059	imaging	O
2059	analyze	O
2059	##r	O
2059	(	O
2059	f	O
2059	##u	O
2059	##ji	O
2059	photo	O
2059	film	O
2059	co	O
2059	l	O
2059	##t	O
2059	##d	O
2059	,	O
2059	j	O
2059	##apa	O
2059	##n	O
2059	)	O
2059	.	O
2059	[SEP]	O
2060	[CLS]	O
2060	after	O
2060	cent	O
2060	##ri	O
2060	##fu	O
2060	##gation	O
2060	to	O
2060	remove	O
2060	part	O
2060	##iculate	O
2060	matter	O
2060	,	O
2060	25	O
2060	to	O
2060	50	O
2060	μ	O
2060	##l	O
2060	al	O
2060	##iq	O
2060	##uo	O
2060	##ts	O
2060	of	O
2060	urine	O
2060	were	O
2060	applied	O
2060	to	O
2060	commercially	O
2060	prepared	O
2060	0	O
2060	.	O
2060	25	O
2060	mm	O
2060	thick	O
2060	si	O
2060	##lica	O
2060	gel	O
2060	t	O
2060	##l	O
2060	##c	O
2060	plates	O
2060	with	O
2060	a	O
2060	60	O
2060	f	O
2060	##25	O
2060	##4	O
2060	coating	O
2060	(	O
2060	e	O
2060	.	O
2060	me	O
2060	##rc	O
2060	##k	O
2060	a	O
2060	##g	O
2060	,	O
2060	da	O
2060	##rms	O
2060	##tadt	O
2060	,	O
2060	g	O
2060	##erman	O
2060	##y	O
2060	)	O
2060	.	O
2060	[SEP]	O
2061	[CLS]	O
2061	all	O
2061	h	O
2061	##ydro	O
2061	##ly	O
2061	##zed	O
2061	samples	O
2061	were	O
2061	subsequently	O
2061	profile	O
2061	##d	O
2061	by	O
2061	t	O
2061	##l	O
2061	##c	O
2061	.	O
2061	[SEP]	O
2062	[CLS]	O
2062	samples	O
2062	were	O
2062	prepared	O
2062	by	O
2062	scraping	O
2062	the	O
2062	relevant	O
2062	regions	O
2062	of	O
2062	the	O
2062	t	O
2062	##l	O
2062	##c	O
2062	plates	O
2062	followed	O
2062	by	O
2062	extraction	O
2062	with	O
2062	met	O
2062	##han	O
2062	##ol	O
2062	and	O
2062	e	O
2062	##va	O
2062	##por	O
2062	##ation	O
2062	to	O
2062	dry	O
2062	##ness	O
2062	prior	O
2062	to	O
2062	trim	O
2062	##eth	O
2062	##yl	O
2062	##si	O
2062	##ly	O
2062	##l	O
2062	der	O
2062	##iva	O
2062	##ti	O
2062	##zation	O
2062	.	O
2062	[SEP]	O
2063	[CLS]	O
2063	the	O
2063	proportions	O
2063	of	O
2063	radioactive	O
2063	components	O
2063	recovered	O
2063	in	O
2063	urine	O
2063	,	O
2063	expressed	O
2063	as	O
2063	the	O
2063	percentage	O
2063	of	O
2063	administered	O
2063	dose	O
2063	,	O
2063	were	O
2063	generally	O
2063	in	O
2063	good	O
2063	agreement	O
2063	between	O
2063	t	O
2063	##l	O
2063	##c	O
2063	and	O
2063	hp	O
2063	##l	O
2063	##c	O
2063	(	O
2063	figure	O
2063	5	O
2063	)	O
2063	,	O
2063	and	O
2063	indicated	O
2063	the	O
2063	presence	O
2063	of	O
2063	three	O
2063	major	O
2063	radioactive	O
2063	components	O
2063	(	O
2063	m	O
2063	##1	O
2063	,	O
2063	m	O
2063	##2	O
2063	,	O
2063	and	O
2063	m	O
2063	##3	O
2063	)	O
2063	.	O
2063	[SEP]	O
2064	[CLS]	O
2064	on	O
2064	t	O
2064	##l	O
2064	##c	O
2064	,	O
2064	components	O
2064	m	O
2064	##1	O
2064	,	O
2064	m	O
2064	##2	O
2064	,	O
2064	and	O
2064	m	O
2064	##3	O
2064	el	O
2064	##uted	O
2064	with	O
2064	respective	O
2064	r	O
2064	##f	O
2064	values	O
2064	of	O
2064	0	O
2064	.	O
2064	41	O
2064	,	O
2064	0	O
2064	.	O
2064	57	O
2064	,	O
2064	and	O
2064	0	O
2064	.	O
2064	63	O
2064	to	O
2064	0	O
2064	.	O
2064	81	O
2064	.	O
2064	[SEP]	O
2065	[CLS]	O
2065	for	O
2065	each	O
2065	study	O
2065	,	O
2065	p	O
2065	##k	O
2065	parameters	O
2065	were	O
2065	calculated	O
2065	from	O
2065	the	O
2065	plasma	O
2065	concentration	O
2065	-	O
2065	time	O
2065	data	O
2065	using	O
2065	non	O
2065	##com	O
2065	##par	O
2065	##tment	O
2065	##al	O
2065	methods	O
2065	.	O
2065	22	O
2065	p	O
2065	##har	O
2065	##ma	O
2065	##co	O
2065	##kin	O
2065	##etic	O
2065	parameters	O
2065	included	O
2065	area	B-PK
2065	under	I-PK
2065	the	I-PK
2065	plasma	I-PK
2065	concentration	I-PK
2065	-	I-PK
2065	time	I-PK
2065	curve	I-PK
2065	from	I-PK
2065	time	I-PK
2065	zero	I-PK
2065	to	I-PK
2065	time	I-PK
2065	of	I-PK
2065	last	I-PK
2065	q	I-PK
2065	##uant	I-PK
2065	##ifiable	I-PK
2065	concentration	I-PK
2065	(	I-PK
2065	au	I-PK
2065	##c	I-PK
2065	##0	I-PK
2065	##−	I-PK
2065	##t	I-PK
2065	)	I-PK
2065	calculated	O
2065	using	O
2065	the	O
2065	linear	O
2065	trap	O
2065	##ez	O
2065	##oid	O
2065	##al	O
2065	rule	O
2065	,	O
2065	au	B-PK
2065	##c	I-PK
2065	from	I-PK
2065	time	I-PK
2065	zero	I-PK
2065	to	I-PK
2065	in	I-PK
2065	##finity	I-PK
2065	(	I-PK
2065	au	I-PK
2065	##c	I-PK
2065	##0	I-PK
2065	##−	I-PK
2065	##∞	I-PK
2065	)	I-PK
2065	calculated	O
2065	using	O
2065	the	O
2065	linear	O
2065	trap	O
2065	##ez	O
2065	##oid	O
2065	##al	O
2065	rule	O
2065	of	O
2065	sum	O
2065	##mation	O
2065	and	O
2065	extra	O
2065	##pol	O
2065	##ated	O
2065	to	O
2065	in	O
2065	##finity	O
2065	,	O
2065	maximum	B-PK
2065	observed	I-PK
2065	plasma	I-PK
2065	concentration	I-PK
2065	(	I-PK
2065	cm	I-PK
2065	##ax	I-PK
2065	)	I-PK
2065	,	O
2065	time	B-PK
2065	to	I-PK
2065	cm	I-PK
2065	##ax	I-PK
2065	(	I-PK
2065	t	I-PK
2065	##max	I-PK
2065	)	I-PK
2065	,	O
2065	and	O
2065	terminal	B-PK
2065	elimination	I-PK
2065	half	I-PK
2065	-	I-PK
2065	life	I-PK
2065	(	I-PK
2065	t	I-PK
2065	##1	I-PK
2065	/	I-PK
2065	2	I-PK
2065	)	I-PK
2065	.	O
2065	[SEP]	O
2066	[CLS]	O
2066	top	O
2066	##ira	O
2066	##mate	O
2066	au	B-PK
2066	##c	I-PK
2066	and	O
2066	cm	B-PK
2066	##ax	I-PK
2066	increased	O
2066	with	O
2066	ascending	O
2066	doses	O
2066	of	O
2066	us	O
2066	##l	O
2066	##25	O
2066	##5	O
2066	.	O
2066	[SEP]	O
2067	[CLS]	O
2067	the	O
2067	median	O
2067	t	B-PK
2067	##max	I-PK
2067	for	O
2067	us	O
2067	##l	O
2067	##25	O
2067	##5	O
2067	dos	O
2067	##ing	O
2067	groups	O
2067	ranged	O
2067	from	O
2067	16	O
2067	to	O
2067	23	O
2067	h	O
2067	.	O
2067	[SEP]	O
2068	[CLS]	O
2068	for	O
2068	participants	O
2068	who	O
2068	received	O
2068	at	O
2068	least	O
2068	three	O
2068	doses	O
2068	of	O
2068	us	O
2068	##l	O
2068	##25	O
2068	##5	O
2068	in	O
2068	study	O
2068	1	O
2068	,	O
2068	in	O
2068	##tras	O
2068	##ub	O
2068	##ject	O
2068	%	O
2068	c	O
2068	##v	O
2068	of	O
2068	dose	O
2068	-	O
2068	normal	O
2068	##ized	O
2068	mean	O
2068	au	B-PK
2068	##c	I-PK
2068	##0	I-PK
2068	##−	I-PK
2068	##t	I-PK
2068	,	O
2068	au	B-PK
2068	##c	I-PK
2068	##0	I-PK
2068	##−	I-PK
2068	##∞	I-PK
2068	,	O
2068	and	O
2068	cm	B-PK
2068	##ax	I-PK
2068	values	O
2068	were	O
2068	less	O
2068	than	O
2068	14	O
2068	%	O
2068	(	O
2068	%	O
2068	c	O
2068	##v	O
2068	:	O
2068	au	B-PK
2068	##c	I-PK
2068	##0	I-PK
2068	##−	I-PK
2068	##t	I-PK
2068	,	O
2068	10	O
2068	.	O
2068	8	O
2068	%	O
2068	;	O
2068	au	B-PK
2068	##c	I-PK
2068	##0	I-PK
2068	##−	I-PK
2068	##∞	I-PK
2068	,	O
2068	8	O
2068	.	O
2068	2	O
2068	%	O
2068	;	O
2068	cm	B-PK
2068	##ax	I-PK
2068	,	O
2068	13	O
2068	.	O
2068	2	O
2068	%	O
2068	)	O
2068	.	O
2068	[SEP]	O
2069	[CLS]	O
2069	both	O
2069	visual	O
2069	(	O
2069	parameter	O
2069	vs	O
2069	co	O
2069	##var	O
2069	##iate	O
2069	s	O
2069	##cat	O
2069	##ter	O
2069	plots	O
2069	)	O
2069	and	O
2069	numerical	O
2069	(	O
2069	generalized	O
2069	add	O
2069	##itive	O
2069	model	O
2069	in	O
2069	x	O
2069	##pose	O
2069	,	O
2069	version	O
2069	4	O
2069	.	O
2069	0	O
2069	.	O
2069	4	O
2069	)	O
2069	co	O
2069	##var	O
2069	##iate	O
2069	screening	O
2069	procedures	O
2069	were	O
2069	performed	O
2069	before	O
2069	adding	O
2069	each	O
2069	co	O
2069	##var	O
2069	##iate	O
2069	to	O
2069	the	O
2069	basic	O
2069	model	O
2069	.	O
2069	[SEP]	O
2070	[CLS]	O
2070	the	O
2070	distribution	O
2070	pattern	O
2070	of	O
2070	c	O
2070	##w	O
2070	##res	O
2070	at	O
2070	individual	O
2070	t	B-PK
2070	##max	I-PK
2070	also	O
2070	showed	O
2070	the	O
2070	out	O
2070	##per	O
2070	##form	O
2070	##ance	O
2070	of	O
2070	the	O
2070	transit	O
2070	compartment	O
2070	model	O
2070	(	O
2070	figure	O
2070	2	O
2070	)	O
2070	.	O
2070	[SEP]	O
2071	[CLS]	O
2071	the	O
2071	relative	B-PK
2071	bio	I-PK
2071	##ava	I-PK
2071	##ila	I-PK
2071	##bility	I-PK
2071	changes	O
2071	caused	O
2071	by	O
2071	meals	O
2071	were	O
2071	not	O
2071	considered	O
2071	in	O
2071	the	O
2071	model	O
2071	because	O
2071	the	O
2071	changes	O
2071	were	O
2071	not	O
2071	acknowledged	O
2071	in	O
2071	the	O
2071	statistical	O
2071	tests	O
2071	of	O
2071	linear	O
2071	-	O
2071	trap	O
2071	##ez	O
2071	##oid	O
2071	##al	O
2071	area	B-PK
2071	under	I-PK
2071	the	I-PK
2071	curves	I-PK
2071	(	I-PK
2071	au	I-PK
2071	##cs	I-PK
2071	;	O
2071	not	O
2071	shown	O
2071	in	O
2071	this	O
2071	report	O
2071	)	O
2071	.	O
2071	[SEP]	O
2072	[CLS]	O
2072	e	O
2072	is	O
2072	the	O
2072	m	O
2072	##olar	O
2072	a	O
2072	##bs	O
2072	##or	O
2072	##pt	O
2072	##ivity	O
2072	value	O
2072	of	O
2072	o	O
2072	##xy	O
2072	##hem	O
2072	##og	O
2072	##lo	O
2072	##bin	O
2072	at	O
2072	415	O
2072	nm	O
2072	,	O
2072	and	O
2072	1	O
2072	.	O
2072	65	O
2072	##5	O
2072	is	O
2072	the	O
2072	correction	O
2072	factor	O
2072	accounting	O
2072	for	O
2072	plasma	O
2072	t	O
2072	##ur	O
2072	##bid	O
2072	##ity	O
2072	.	O
2072	%	O
2072	hem	O
2072	##oly	O
2072	##sis	O
2072	=	O
2072	plasma	O
2072	h	O
2072	##b	O
2072	value	O
2072	of	O
2072	sample	O
2072	##to	O
2072	##tal	O
2072	h	O
2072	##b	O
2072	value	O
2072	of	O
2072	blood	O
2072	##×	O
2072	##100	O
2072	(	O
2072	7	O
2072	)	O
2072	[SEP]	O
2073	[CLS]	O
2073	the	O
2073	t	B-PK
2073	##max	I-PK
2073	,	O
2073	cm	B-PK
2073	##ax	I-PK
2073	,	O
2073	and	O
2073	c	B-PK
2073	##l	I-PK
2073	values	O
2073	changed	O
2073	minimal	O
2073	##ly	O
2073	throughout	O
2073	the	O
2073	two	O
2073	modes	O
2073	of	O
2073	in	O
2073	##tra	O
2073	##ven	O
2073	##ous	O
2073	administration	O
2073	.	O
2073	[SEP]	O
2074	[CLS]	O
2074	the	O
2074	t	B-PK
2074	##max	I-PK
2074	,	O
2074	t	B-PK
2074	##1	I-PK
2074	/	I-PK
2074	2	I-PK
2074	,	O
2074	and	O
2074	au	B-PK
2074	##c	I-PK
2074	##0	I-PK
2074	–	I-PK
2074	t	I-PK
2074	of	O
2074	pulmonary	O
2074	administration	O
2074	were	O
2074	significantly	O
2074	higher	O
2074	than	O
2074	those	O
2074	of	O
2074	combined	O
2074	or	O
2074	single	O
2074	in	O
2074	##tra	O
2074	##ven	O
2074	##ous	O
2074	administration	O
2074	(	O
2074	p	O
2074	<	O
2074	0	O
2074	.	O
2074	05	O
2074	)	O
2074	,	O
2074	whereas	O
2074	the	O
2074	c	B-PK
2074	##l	I-PK
2074	and	O
2074	cm	B-PK
2074	##ax	I-PK
2074	were	O
2074	lower	O
2074	than	O
2074	those	O
2074	of	O
2074	other	O
2074	groups	O
2074	.	O
2074	[SEP]	O
2075	[CLS]	O
2075	after	O
2075	pulmonary	O
2075	administration	O
2075	with	O
2075	pm	O
2075	##s	O
2075	,	O
2075	the	O
2075	postponed	O
2075	t	B-PK
2075	##max	I-PK
2075	demonstrated	O
2075	that	O
2075	the	O
2075	absorption	O
2075	of	O
2075	p	O
2075	##t	O
2075	##x	O
2075	slowed	O
2075	down	O
2075	.	O
2075	[SEP]	O
2076	[CLS]	O
2076	results	O
2076	showed	O
2076	that	O
2076	combined	O
2076	in	O
2076	##tra	O
2076	##ven	O
2076	##ous	O
2076	administration	O
2076	and	O
2076	pulmonary	O
2076	administration	O
2076	could	O
2076	improve	O
2076	the	O
2076	p	O
2076	##t	O
2076	##x	O
2076	absorption	B-PK
2076	rate	I-PK
2076	,	O
2076	amount	O
2076	,	O
2076	and	O
2076	p	O
2076	##har	O
2076	##ma	O
2076	##co	O
2076	##kin	O
2076	##etics	O
2076	.	O
2076	[SEP]	O
2077	[CLS]	O
2077	the	O
2077	bio	B-PK
2077	##ava	I-PK
2077	##ila	I-PK
2077	##bility	I-PK
2077	of	O
2077	p	O
2077	##t	O
2077	##x	O
2077	was	O
2077	significantly	O
2077	enhanced	O
2077	by	O
2077	the	O
2077	pulmonary	O
2077	administration	O
2077	of	O
2077	pm	O
2077	##s	O
2077	.	O
2077	[SEP]	O
2078	[CLS]	O
2078	the	O
2078	amount	O
2078	and	O
2078	time	O
2078	are	O
2078	used	O
2078	to	O
2078	calculate	O
2078	the	O
2078	rate	O
2078	(	O
2078	rate	O
2078	=	O
2078	am	O
2078	##t	O
2078	/	O
2078	time	O
2078	##h	O
2078	)	O
2078	.	O
2078	[SEP]	O
2079	[CLS]	O
2079	n	O
2079	##s	O
2079	##c	O
2079	##23	O
2079	##9	O
2079	##25	O
2079	##b	O
2079	concentrations	O
2079	declined	O
2079	bi	O
2079	##ex	O
2079	##po	O
2079	##nent	O
2079	##ially	O
2079	after	O
2079	the	O
2079	t	B-PK
2079	##max	I-PK
2079	with	O
2079	a	O
2079	mean	O
2079	terminal	B-PK
2079	elimination	I-PK
2079	half	I-PK
2079	-	I-PK
2079	life	I-PK
2079	of	O
2079	8	O
2079	.	O
2079	69	O
2079	±	O
2079	4	O
2079	.	O
2079	18	O
2079	hours	O
2079	for	O
2079	mice	O
2079	and	O
2079	9	O
2079	.	O
2079	24	O
2079	±	O
2079	3	O
2079	.	O
2079	77	O
2079	hours	O
2079	for	O
2079	rats	O
2079	.	O
2079	[SEP]	O
2080	[CLS]	O
2080	however	O
2080	,	O
2080	some	O
2080	of	O
2080	the	O
2080	p	O
2080	##har	O
2080	##ma	O
2080	##co	O
2080	##kin	O
2080	##etic	O
2080	parameters	O
2080	of	O
2080	ch	O
2080	##em	O
2080	##oth	O
2080	##era	O
2080	##pe	O
2080	##uti	O
2080	##c	O
2080	drug	O
2080	p	O
2080	##ac	O
2080	##lit	O
2080	##ax	O
2080	##el	O
2080	,	O
2080	such	O
2080	as	O
2080	v	B-PK
2080	##ds	I-PK
2080	##s	I-PK
2080	,	O
2080	t	B-PK
2080	##1	I-PK
2080	/	I-PK
2080	2	I-PK
2080	,	O
2080	k	B-PK
2080	##el	I-PK
2080	,	O
2080	m	B-PK
2080	##rt	I-PK
2080	##iv	I-PK
2080	,	O
2080	and	O
2080	au	B-PK
2080	##m	I-PK
2080	##c	I-PK
2080	##0	I-PK
2080	-	I-PK
2080	in	I-PK
2080	##f	I-PK
2080	were	O
2080	altered	O
2080	when	O
2080	combined	O
2080	with	O
2080	n	O
2080	##s	O
2080	##c	O
2080	##23	O
2080	##9	O
2080	##25	O
2080	##b	O
2080	in	O
2080	rats	O
2080	.	O
2080	[SEP]	O
2081	[CLS]	O
2081	as	O
2081	a	O
2081	result	O
2081	,	O
2081	a	O
2081	decrease	O
2081	of	O
2081	v	B-PK
2081	##ds	I-PK
2081	##s	I-PK
2081	in	O
2081	the	O
2081	absence	O
2081	of	O
2081	alter	O
2081	##ation	O
2081	in	O
2081	clearance	B-PK
2081	resulted	O
2081	in	O
2081	shorter	O
2081	t	B-PK
2081	##1	I-PK
2081	/	I-PK
2081	2	I-PK
2081	and	O
2081	larger	O
2081	k	B-PK
2081	##el	I-PK
2081	.	O
2081	[SEP]	O
2082	[CLS]	O
2082	v	B-PK
2082	##ds	I-PK
2082	##s	I-PK
2082	can	O
2082	change	O
2082	independent	O
2082	of	O
2082	clearance	B-PK
2082	.	O
2082	[SEP]	O
2083	[CLS]	O
2083	there	O
2083	were	O
2083	no	O
2083	significant	O
2083	changes	O
2083	among	O
2083	other	O
2083	p	O
2083	##har	O
2083	##ma	O
2083	##co	O
2083	##kin	O
2083	##etic	O
2083	parameters	O
2083	;	O
2083	for	O
2083	example	O
2083	,	O
2083	in	O
2083	the	O
2083	case	O
2083	of	O
2083	au	B-PK
2083	##c	I-PK
2083	##0	I-PK
2083	-	I-PK
2083	in	I-PK
2083	##f	I-PK
2083	(	I-PK
2083	the	I-PK
2083	area	I-PK
2083	under	I-PK
2083	the	I-PK
2083	plasma	I-PK
2083	concentration	I-PK
2083	versus	I-PK
2083	time	I-PK
2083	curve	I-PK
2083	)	I-PK
2083	,	O
2083	n	O
2083	##s	O
2083	##c	O
2083	##23	O
2083	##9	O
2083	##25	O
2083	##b	O
2083	only	O
2083	was	O
2083	170	O
2083	##1	O
2083	±	O
2083	130	O
2083	h	O
2083	·	O
2083	ng	O
2083	·	O
2083	m	O
2083	##l	O
2083	##−	O
2083	##1	O
2083	,	O
2083	combination	O
2083	n	O
2083	##s	O
2083	##c	O
2083	##23	O
2083	##9	O
2083	##25	O
2083	##b	O
2083	and	O
2083	p	O
2083	##ac	O
2083	##lit	O
2083	##ax	O
2083	##el	O
2083	was	O
2083	164	O
2083	##9	O
2083	±	O
2083	65	O
2083	.	O
2083	6	O
2083	h	O
2083	·	O
2083	ng	O
2083	·	O
2083	m	O
2083	##l	O
2083	##−	O
2083	##1	O
2083	,	O
2083	combination	O
2083	n	O
2083	##s	O
2083	##c	O
2083	##23	O
2083	##9	O
2083	##25	O
2083	##b	O
2083	and	O
2083	do	O
2083	##x	O
2083	##or	O
2083	##ubi	O
2083	##cin	O
2083	and	O
2083	1827	O
2083	±	O
2083	73	O
2083	.	O
2083	8	O
2083	h	O
2083	·	O
2083	ng	O
2083	·	O
2083	m	O
2083	##l	O
2083	##−	O
2083	##1	O
2083	.	O
2083	[SEP]	O
2084	[CLS]	O
2084	mean	O
2084	maximum	B-PK
2084	plasma	I-PK
2084	concentration	I-PK
2084	(	I-PK
2084	cm	I-PK
2084	##ax	I-PK
2084	)	I-PK
2084	of	O
2084	a	O
2084	##zi	O
2084	##ls	O
2084	##art	O
2084	##an	O
2084	was	O
2084	88	O
2084	##8	O
2084	.	O
2084	3	O
2084	and	O
2084	83	O
2084	##1	O
2084	.	O
2084	3	O
2084	ng	O
2084	/	O
2084	m	O
2084	##l	O
2084	and	O
2084	median	O
2084	time	B-PK
2084	to	I-PK
2084	maximum	I-PK
2084	concentration	I-PK
2084	(	I-PK
2084	t	I-PK
2084	##max	I-PK
2084	)	I-PK
2084	of	O
2084	unchanged	O
2084	a	O
2084	##zi	O
2084	##ls	O
2084	##art	O
2084	##an	O
2084	was	O
2084	3	O
2084	.	O
2084	0	O
2084	and	O
2084	4	O
2084	.	O
2084	0	O
2084	h	O
2084	,	O
2084	in	O
2084	the	O
2084	5	O
2084	-	O
2084	mg	O
2084	and	O
2084	10	O
2084	-	O
2084	mg	O
2084	groups	O
2084	,	O
2084	respectively	O
2084	.	O
2084	[SEP]	O
2085	[CLS]	O
2085	p	O
2085	##har	O
2085	##ma	O
2085	##co	O
2085	##kin	O
2085	##etic	O
2085	variables	O
2085	derived	O
2085	from	O
2085	a	O
2085	##zi	O
2085	##ls	O
2085	##art	O
2085	##an	O
2085	,	O
2085	m	O
2085	-	O
2085	i	O
2085	,	O
2085	and	O
2085	m	O
2085	-	O
2085	ii	O
2085	concentrations	O
2085	in	O
2085	plasma	O
2085	included	O
2085	area	B-PK
2085	under	I-PK
2085	the	I-PK
2085	plasma	I-PK
2085	concentration	I-PK
2085	–	I-PK
2085	time	I-PK
2085	curve	I-PK
2085	from	I-PK
2085	0	I-PK
2085	to	I-PK
2085	24	I-PK
2085	h	I-PK
2085	post	I-PK
2085	-	I-PK
2085	dose	I-PK
2085	(	I-PK
2085	au	I-PK
2085	##c	I-PK
2085	##0	I-PK
2085	–	I-PK
2085	24	I-PK
2085	)	I-PK
2085	and	I-PK
2085	from	I-PK
2085	0	I-PK
2085	h	I-PK
2085	to	I-PK
2085	in	I-PK
2085	##finity	I-PK
2085	(	I-PK
2085	au	I-PK
2085	##c	I-PK
2085	##0	I-PK
2085	–	I-PK
2085	in	I-PK
2085	##f	I-PK
2085	)	I-PK
2085	;	O
2085	maximum	B-PK
2085	observed	I-PK
2085	concentration	I-PK
2085	in	I-PK
2085	plasma	I-PK
2085	(	I-PK
2085	cm	I-PK
2085	##ax	I-PK
2085	)	I-PK
2085	;	O
2085	time	B-PK
2085	to	I-PK
2085	reach	I-PK
2085	cm	I-PK
2085	##ax	I-PK
2085	(	I-PK
2085	t	I-PK
2085	##max	I-PK
2085	)	I-PK
2085	;	O
2085	terminal	B-PK
2085	elimination	I-PK
2085	rate	I-PK
2085	constant	I-PK
2085	(	I-PK
2085	λ	I-PK
2085	##z	I-PK
2085	=	O
2085	negative	O
2085	slope	O
2085	of	O
2085	the	O
2085	log	O
2085	-	O
2085	linear	O
2085	re	O
2085	##gression	O
2085	of	O
2085	the	O
2085	natural	O
2085	log	O
2085	##ari	O
2085	##th	O
2085	##m	O
2085	concentration	O
2085	–	O
2085	time	O
2085	curve	O
2085	during	O
2085	the	O
2085	terminal	O
2085	phase	O
2085	)	O
2085	;	O
2085	terminal	B-PK
2085	elimination	I-PK
2085	half	I-PK
2085	-	I-PK
2085	life	I-PK
2085	(	I-PK
2085	t	I-PK
2085	##1	I-PK
2085	/	I-PK
2085	2	I-PK
2085	=	O
2085	l	O
2085	##n	O
2085	(	O
2085	2	O
2085	)	O
2085	/	O
2085	λ	O
2085	##z	O
2085	)	O
2085	;	O
2085	apparent	B-PK
2085	clearance	I-PK
2085	after	I-PK
2085	extra	I-PK
2085	##vas	I-PK
2085	##cular	I-PK
2085	administration	I-PK
2085	(	I-PK
2085	c	I-PK
2085	##l	I-PK
2085	/	I-PK
2085	f	I-PK
2085	=	O
2085	dose	B-PK
2085	/	I-PK
2085	au	I-PK
2085	##c	I-PK
2085	##0	I-PK
2085	–	I-PK
2085	in	I-PK
2085	##f	I-PK
2085	)	O
2085	;	O
2085	and	O
2085	apparent	B-PK
2085	volume	I-PK
2085	of	I-PK
2085	distribution	I-PK
2085	during	I-PK
2085	the	I-PK
2085	terminal	I-PK
2085	phase	I-PK
2085	(	I-PK
2085	v	I-PK
2085	##z	I-PK
2085	/	I-PK
2085	f	I-PK
2085	=	O
2085	[	B-PK
2085	c	I-PK
2085	##l	I-PK
2085	/	I-PK
2085	f	I-PK
2085	]	I-PK
2085	/	I-PK
2085	λ	I-PK
2085	##z	I-PK
2085	)	O
2085	.	O
2085	[SEP]	O
2086	[CLS]	O
2086	urine	O
2086	p	O
2086	##har	O
2086	##ma	O
2086	##co	O
2086	##kin	O
2086	##etic	O
2086	parameters	O
2086	included	O
2086	total	B-PK
2086	amount	I-PK
2086	ex	I-PK
2086	##cre	I-PK
2086	##ted	I-PK
2086	in	I-PK
2086	urine	I-PK
2086	from	I-PK
2086	0	I-PK
2086	to	I-PK
2086	24	I-PK
2086	h	I-PK
2086	post	I-PK
2086	-	I-PK
2086	dose	I-PK
2086	(	I-PK
2086	a	I-PK
2086	##e	I-PK
2086	##0	I-PK
2086	–	I-PK
2086	24	I-PK
2086	)	I-PK
2086	,	O
2086	fraction	B-PK
2086	ex	I-PK
2086	##cre	I-PK
2086	##ted	I-PK
2086	in	I-PK
2086	the	I-PK
2086	urine	I-PK
2086	(	I-PK
2086	f	I-PK
2086	##e	I-PK
2086	=	O
2086	[	O
2086	a	B-PK
2086	##e	I-PK
2086	##0	I-PK
2086	–	I-PK
2086	24	I-PK
2086	/	I-PK
2086	dose	I-PK
2086	]	O
2086	×	O
2086	100	O
2086	)	O
2086	,	O
2086	and	O
2086	re	B-PK
2086	##nal	I-PK
2086	clearance	I-PK
2086	(	I-PK
2086	c	I-PK
2086	##l	I-PK
2086	##r	I-PK
2086	=	O
2086	a	B-PK
2086	##e	I-PK
2086	##0	I-PK
2086	–	I-PK
2086	24	I-PK
2086	/	I-PK
2086	au	I-PK
2086	##c	I-PK
2086	##0	I-PK
2086	–	I-PK
2086	24	I-PK
2086	)	O
2086	.	O
2086	[SEP]	O
2087	[CLS]	O
2087	f	B-PK
2087	##e	I-PK
2087	estimates	O
2087	for	O
2087	a	O
2087	##zi	O
2087	##ls	O
2087	##art	O
2087	##an	O
2087	,	O
2087	m	O
2087	-	O
2087	i	O
2087	,	O
2087	and	O
2087	m	O
2087	-	O
2087	ii	O
2087	were	O
2087	adjusted	O
2087	for	O
2087	molecular	O
2087	weight	O
2087	.	O
2087	[SEP]	O
2088	[CLS]	O
2088	median	O
2088	a	O
2088	##zi	O
2088	##ls	O
2088	##art	O
2088	##an	O
2088	t	B-PK
2088	##max	I-PK
2088	was	O
2088	3	O
2088	h	O
2088	(	O
2088	range	O
2088	2	O
2088	.	O
2088	1	O
2088	–	O
2088	3	O
2088	.	O
2088	0	O
2088	h	O
2088	)	O
2088	in	O
2088	the	O
2088	5	O
2088	-	O
2088	mg	O
2088	group	O
2088	and	O
2088	4	O
2088	h	O
2088	(	O
2088	range	O
2088	2	O
2088	.	O
2088	1	O
2088	–	O
2088	4	O
2088	.	O
2088	0	O
2088	h	O
2088	)	O
2088	in	O
2088	the	O
2088	10	O
2088	-	O
2088	mg	O
2088	group	O
2088	,	O
2088	and	O
2088	mean	O
2088	a	O
2088	##zi	O
2088	##ls	O
2088	##art	O
2088	##an	O
2088	cm	B-PK
2088	##ax	I-PK
2088	was	O
2088	88	O
2088	##8	O
2088	.	O
2088	3	O
2088	and	O
2088	83	O
2088	##1	O
2088	.	O
2088	3	O
2088	ng	O
2088	/	O
2088	m	O
2088	##l	O
2088	,	O
2088	respectively	O
2088	.	O
2088	[SEP]	O
2089	[CLS]	O
2089	median	O
2089	t	B-PK
2089	##max	I-PK
2089	of	O
2089	the	O
2089	m	O
2089	-	O
2089	i	O
2089	meta	O
2089	##bol	O
2089	##ite	O
2089	was	O
2089	3	O
2089	.	O
2089	0	O
2089	h	O
2089	(	O
2089	range	O
2089	2	O
2089	.	O
2089	9	O
2089	–	O
2089	3	O
2089	.	O
2089	0	O
2089	h	O
2089	)	O
2089	and	O
2089	6	O
2089	.	O
2089	0	O
2089	h	O
2089	(	O
2089	range	O
2089	1	O
2089	.	O
2089	0	O
2089	–	O
2089	6	O
2089	.	O
2089	0	O
2089	h	O
2089	)	O
2089	in	O
2089	the	O
2089	5	O
2089	-	O
2089	mg	O
2089	and	O
2089	10	O
2089	-	O
2089	mg	O
2089	groups	O
2089	,	O
2089	respectively	O
2089	,	O
2089	and	O
2089	mean	O
2089	t	B-PK
2089	##1	I-PK
2089	/	I-PK
2089	2	I-PK
2089	was	O
2089	5	O
2089	.	O
2089	4	O
2089	h	O
2089	and	O
2089	5	O
2089	.	O
2089	9	O
2089	h	O
2089	in	O
2089	the	O
2089	5	O
2089	-	O
2089	and	O
2089	10	O
2089	-	O
2089	mg	O
2089	groups	O
2089	,	O
2089	respectively	O
2089	.	O
2089	[SEP]	O
2090	[CLS]	O
2090	median	O
2090	t	B-PK
2090	##max	I-PK
2090	of	O
2090	m	O
2090	-	O
2090	ii	O
2090	was	O
2090	5	O
2090	.	O
2090	9	O
2090	h	O
2090	(	O
2090	range	O
2090	4	O
2090	.	O
2090	0	O
2090	–	O
2090	6	O
2090	.	O
2090	0	O
2090	)	O
2090	in	O
2090	the	O
2090	5	O
2090	-	O
2090	mg	O
2090	group	O
2090	and	O
2090	8	O
2090	.	O
2090	0	O
2090	h	O
2090	(	O
2090	range	O
2090	6	O
2090	.	O
2090	0	O
2090	–	O
2090	24	O
2090	.	O
2090	1	O
2090	)	O
2090	in	O
2090	the	O
2090	10	O
2090	-	O
2090	mg	O
2090	group	O
2090	;	O
2090	t	B-PK
2090	##1	I-PK
2090	/	I-PK
2090	2	I-PK
2090	of	O
2090	m	O
2090	-	O
2090	ii	O
2090	could	O
2090	only	O
2090	be	O
2090	calculated	O
2090	in	O
2090	one	O
2090	patient	O
2090	in	O
2090	the	O
2090	5	O
2090	-	O
2090	mg	O
2090	group	O
2090	(	O
2090	5	O
2090	.	O
2090	5	O
2090	h	O
2090	)	O
2090	.	O
2090	[SEP]	O
2091	[CLS]	O
2091	for	O
2091	the	O
2091	m	O
2091	-	O
2091	i	O
2091	meta	O
2091	##bol	O
2091	##ite	O
2091	,	O
2091	both	O
2091	mean	O
2091	au	B-PK
2091	##c	I-PK
2091	##0	I-PK
2091	–	I-PK
2091	24	I-PK
2091	(	O
2091	5	O
2091	mg	O
2091	:	O
2091	159	O
2091	##2	O
2091	.	O
2091	7	O
2091	ng	O
2091	h	O
2091	/	O
2091	m	O
2091	##l	O
2091	;	O
2091	10	O
2091	mg	O
2091	:	O
2091	142	O
2091	##0	O
2091	.	O
2091	5	O
2091	ng	O
2091	h	O
2091	/	O
2091	m	O
2091	##l	O
2091	)	O
2091	and	O
2091	cm	B-PK
2091	##ax	I-PK
2091	(	O
2091	5	O
2091	mg	O
2091	:	O
2091	191	O
2091	.	O
2091	3	O
2091	ng	O
2091	/	O
2091	m	O
2091	##l	O
2091	;	O
2091	10	O
2091	mg	O
2091	:	O
2091	141	O
2091	.	O
2091	3	O
2091	ng	O
2091	/	O
2091	m	O
2091	##l	O
2091	)	O
2091	were	O
2091	lower	O
2091	than	O
2091	those	O
2091	observed	O
2091	for	O
2091	a	O
2091	##zi	O
2091	##ls	O
2091	##art	O
2091	##an	O
2091	;	O
2091	similar	O
2091	results	O
2091	were	O
2091	observed	O
2091	for	O
2091	the	O
2091	m	O
2091	-	O
2091	ii	O
2091	meta	O
2091	##bol	O
2091	##ite	O
2091	with	O
2091	au	B-PK
2091	##c	I-PK
2091	##0	I-PK
2091	–	I-PK
2091	24	I-PK
2091	values	O
2091	of	O
2091	1986	O
2091	.	O
2091	5	O
2091	ng	O
2091	h	O
2091	/	O
2091	m	O
2091	##l	O
2091	and	O
2091	35	O
2091	##26	O
2091	.	O
2091	0	O
2091	ng	O
2091	h	O
2091	/	O
2091	m	O
2091	##l	O
2091	and	O
2091	cm	B-PK
2091	##ax	I-PK
2091	values	O
2091	of	O
2091	227	O
2091	.	O
2091	7	O
2091	ng	O
2091	/	O
2091	m	O
2091	##l	O
2091	and	O
2091	179	O
2091	.	O
2091	3	O
2091	ng	O
2091	/	O
2091	m	O
2091	##l	O
2091	in	O
2091	the	O
2091	5	O
2091	-	O
2091	mg	O
2091	and	O
2091	10	O
2091	-	O
2091	mg	O
2091	groups	O
2091	,	O
2091	respectively	O
2091	.	O
2091	[SEP]	O
2092	[CLS]	O
2092	after	O
2092	obtaining	O
2092	the	O
2092	last	O
2092	blood	O
2092	sample	O
2092	,	O
2092	all	O
2092	rats	O
2092	were	O
2092	sacrificed	O
2092	and	O
2092	kidney	O
2092	##s	O
2092	and	O
2092	liver	O
2092	collected	O
2092	.	O
2092	[SEP]	O
2093	[CLS]	O
2093	half	B-PK
2093	-	I-PK
2093	life	I-PK
2093	(	I-PK
2093	t	I-PK
2093	##1	I-PK
2093	/	I-PK
2093	2	I-PK
2093	)	I-PK
2093	were	O
2093	calculated	O
2093	from	O
2093	the	O
2093	elimination	O
2093	phase	O
2093	.	O
2093	[SEP]	O
2094	[CLS]	O
2094	the	O
2094	half	B-PK
2094	-	I-PK
2094	life	I-PK
2094	(	I-PK
2094	t	I-PK
2094	##1	I-PK
2094	/	I-PK
2094	2	I-PK
2094	)	I-PK
2094	of	O
2094	s	O
2094	##k	O
2094	##14	O
2094	-	O
2094	06	O
2094	##1	O
2094	##a	O
2094	was	O
2094	about	O
2094	3	O
2094	.	O
2094	6	O
2094	h	O
2094	##r	O
2094	,	O
2094	with	O
2094	a	O
2094	time	B-PK
2094	to	I-PK
2094	reach	I-PK
2094	peak	I-PK
2094	plasma	I-PK
2094	concentration	I-PK
2094	(	I-PK
2094	t	I-PK
2094	##max	I-PK
2094	)	I-PK
2094	value	O
2094	of	O
2094	1	O
2094	.	O
2094	3	O
2094	h	O
2094	##r	O
2094	.	O
2094	[SEP]	O
2095	[CLS]	O
2095	j	O
2095	##ej	O
2095	##un	O
2095	##um	O
2095	>	O
2095	il	O
2095	##eum	O
2095	,	O
2095	with	O
2095	a	O
2095	rapid	O
2095	t	B-PK
2095	##max	I-PK
2095	value	O
2095	[	O
2095	13	O
2095	]	O
2095	.	O
2095	[SEP]	O
2096	[CLS]	O
2096	interesting	O
2096	##ly	O
2096	,	O
2096	the	O
2096	t	B-PK
2096	##max	I-PK
2096	of	O
2096	et	O
2096	##v	O
2096	was	O
2096	delayed	O
2096	when	O
2096	administered	O
2096	in	O
2096	combination	O
2096	with	O
2096	s	O
2096	##k	O
2096	##14	O
2096	-	O
2096	06	O
2096	##1	O
2096	##a	O
2096	(	O
2096	fi	O
2096	##g	O
2096	6	O
2096	##a	O
2096	,	O
2096	table	O
2096	3	O
2096	)	O
2096	.	O
2096	[SEP]	O
2097	[CLS]	O
2097	the	O
2097	t	B-PK
2097	##max	I-PK
2097	for	O
2097	s	O
2097	##k	O
2097	##14	O
2097	-	O
2097	06	O
2097	##1	O
2097	##a	O
2097	was	O
2097	also	O
2097	delayed	O
2097	in	O
2097	combination	O
2097	with	O
2097	et	O
2097	##v	O
2097	,	O
2097	as	O
2097	well	O
2097	as	O
2097	in	O
2097	the	O
2097	case	O
2097	of	O
2097	et	O
2097	##v	O
2097	.	O
2097	[SEP]	O
2098	[CLS]	O
2098	the	O
2098	data	O
2098	for	O
2098	dose	O
2098	responses	O
2098	were	O
2098	plot	O
2098	##ted	O
2098	as	O
2098	%	O
2098	in	O
2098	##hibition	O
2098	calculated	O
2098	with	O
2098	the	O
2098	data	O
2098	reduction	O
2098	formula	O
2098	:	O
2098	100	O
2098	×	O
2098	(	O
2098	1	O
2098	##−	O
2098	(	O
2098	u	O
2098	##1	O
2098	##−	O
2098	##c	O
2098	##2	O
2098	)	O
2098	/	O
2098	(	O
2098	c	O
2098	##1	O
2098	##−	O
2098	##c	O
2098	##2	O
2098	)	O
2098	)	O
2098	vs	O
2098	concentration	O
2098	of	O
2098	compound	O
2098	where	O
2098	u	O
2098	is	O
2098	the	O
2098	unknown	O
2098	value	O
2098	,	O
2098	c	O
2098	##1	O
2098	is	O
2098	the	O
2098	average	O
2098	control	O
2098	value	O
2098	obtained	O
2098	for	O
2098	1	O
2098	μ	O
2098	##l	O
2098	d	O
2098	##ms	O
2098	##o	O
2098	,	O
2098	and	O
2098	c	O
2098	##2	O
2098	is	O
2098	the	O
2098	average	O
2098	control	O
2098	value	O
2098	obtained	O
2098	for	O
2098	0	O
2098	.	O
2098	03	O
2098	##5	O
2098	m	O
2098	ed	O
2098	##ta	O
2098	.	O
2098	[SEP]	O
2099	[CLS]	O
2099	data	O
2099	were	O
2099	fitted	O
2099	with	O
2099	a	O
2099	curve	O
2099	described	O
2099	by	O
2099	:	O
2099	y	O
2099	=	O
2099	(	O
2099	(	O
2099	v	O
2099	##max	O
2099	×	O
2099	x	O
2099	)	O
2099	/	O
2099	(	O
2099	k	O
2099	+	O
2099	x	O
2099	)	O
2099	+	O
2099	y	O
2099	##2	O
2099	)	O
2099	,	O
2099	where	O
2099	v	B-PK
2099	##max	I-PK
2099	is	O
2099	the	O
2099	upper	O
2099	as	O
2099	##ym	O
2099	##pt	O
2099	##ote	O
2099	,	O
2099	y	O
2099	##2	O
2099	is	O
2099	the	O
2099	y	O
2099	intercept	O
2099	,	O
2099	and	O
2099	k	B-PK
2099	is	O
2099	the	O
2099	i	B-PK
2099	##c	I-PK
2099	##50	I-PK
2099	.	O
2099	[SEP]	O
2100	[CLS]	O
2100	data	O
2100	were	O
2100	fitted	O
2100	with	O
2100	a	O
2100	curve	O
2100	described	O
2100	by	O
2100	the	O
2100	equation	O
2100	,	O
2100	y	O
2100	=	O
2100	v	O
2100	##max	O
2100	×	O
2100	(	O
2100	1	O
2100	##−	O
2100	(	O
2100	x	O
2100	/	O
2100	(	O
2100	k	O
2100	+	O
2100	x	O
2100	)	O
2100	)	O
2100	)	O
2100	,	O
2100	where	O
2100	k	B-PK
2100	is	O
2100	equal	O
2100	to	O
2100	the	O
2100	i	B-PK
2100	##c	I-PK
2100	##50	I-PK
2100	.	O
2100	[SEP]	O
2101	[CLS]	O
2101	the	O
2101	f	O
2101	##ac	O
2101	##s	O
2101	data	O
2101	for	O
2101	four	O
2101	or	O
2101	five	O
2101	different	O
2101	t	O
2101	##umour	O
2101	samples	O
2101	for	O
2101	each	O
2101	x	O
2101	##eno	O
2101	##gra	O
2101	##ft	O
2101	was	O
2101	collected	O
2101	in	O
2101	four	O
2101	-	O
2101	decade	O
2101	mode	O
2101	,	O
2101	gate	O
2101	##d	O
2101	for	O
2101	single	O
2101	cells	O
2101	,	O
2101	anal	O
2101	##ys	O
2101	##ed	O
2101	to	O
2101	calculate	O
2101	the	O
2101	mean	O
2101	channel	O
2101	difference	O
2101	(	O
2101	m	O
2101	##d	O
2101	)	O
2101	,	O
2101	which	O
2101	represents	O
2101	the	O
2101	magnitude	O
2101	of	O
2101	difference	O
2101	between	O
2101	ve	O
2101	##g	O
2101	##f	O
2101	##r	O
2101	##2	O
2101	-	O
2101	specific	O
2101	stain	O
2101	##ing	O
2101	and	O
2101	non	O
2101	##sp	O
2101	##ec	O
2101	##ific	O
2101	is	O
2101	##otype	O
2101	stain	O
2101	##ing	O
2101	.	O
2101	[SEP]	O
2102	[CLS]	O
2102	in	O
2102	the	O
2102	p	O
2102	##k	O
2102	study	O
2102	,	O
2102	using	O
2102	an	O
2102	open	O
2102	,	O
2102	random	O
2102	##ized	O
2102	,	O
2102	crossover	O
2102	design	O
2102	,	O
2102	the	O
2102	dogs	O
2102	received	O
2102	1	O
2102	mg	O
2102	/	O
2102	kg	O
2102	q	O
2102	24	O
2102	hours	O
2102	of	O
2102	es	O
2102	##ome	O
2102	##pra	O
2102	##zo	O
2102	##le	O
2102	via	O
2102	i	O
2102	##v	O
2102	,	O
2102	s	O
2102	##c	O
2102	,	O
2102	and	O
2102	p	O
2102	##o	O
2102	administration	O
2102	.	O
2102	[SEP]	O
2103	[CLS]	O
2103	in	O
2103	the	O
2103	p	O
2103	##d	O
2103	study	O
2103	,	O
2103	the	O
2103	effect	O
2103	of	O
2103	es	O
2103	##ome	O
2103	##pra	O
2103	##zo	O
2103	##le	O
2103	on	O
2103	in	O
2103	##tra	O
2103	##gas	O
2103	##tric	O
2103	p	O
2103	##h	O
2103	was	O
2103	determined	O
2103	with	O
2103	a	O
2103	bra	O
2103	##vo	O
2103	##®	O
2103	p	O
2103	##h	O
2103	monitoring	O
2103	system	O
2103	.	O
2103	4	O
2103	using	O
2103	an	O
2103	open	O
2103	,	O
2103	random	O
2103	##ized	O
2103	,	O
2103	crossover	O
2103	design	O
2103	,	O
2103	in	O
2103	##tra	O
2103	##gas	O
2103	##tric	O
2103	p	O
2103	##h	O
2103	was	O
2103	recorded	O
2103	without	O
2103	medication	O
2103	(	O
2103	base	O
2103	##line	O
2103	p	O
2103	##h	O
2103	)	O
2103	and	O
2103	after	O
2103	the	O
2103	3	O
2103	dos	O
2103	##ing	O
2103	regime	O
2103	##ns	O
2103	:	O
2103	i	O
2103	##v	O
2103	,	O
2103	s	O
2103	##c	O
2103	,	O
2103	and	O
2103	p	O
2103	##o	O
2103	doses	O
2103	of	O
2103	es	O
2103	##ome	O
2103	##pra	O
2103	##zo	O
2103	##le	O
2103	(	O
2103	1	O
2103	mg	O
2103	/	O
2103	kg	O
2103	q	O
2103	24	O
2103	hours	O
2103	)	O
2103	.	O
2103	[SEP]	O
2104	[CLS]	O
2104	to	O
2104	estimate	O
2104	the	O
2104	p	O
2104	##k	O
2104	parameters	O
2104	of	O
2104	es	O
2104	##ome	O
2104	##pra	O
2104	##zo	O
2104	##le	O
2104	,	O
2104	plasma	O
2104	concentration	O
2104	‐	O
2104	time	O
2104	profiles	O
2104	were	O
2104	analyzed	O
2104	by	O
2104	a	O
2104	non	O
2104	##com	O
2104	##par	O
2104	##tment	O
2104	##al	O
2104	model	O
2104	analysis	O
2104	in	O
2104	win	O
2104	##non	O
2104	##lin	O
2104	##®	O
2104	software	O
2104	version	O
2104	4	O
2104	.	O
2104	1	O
2104	.	O
2104	11	O
2104	the	O
2104	terminal	B-PK
2104	half	I-PK
2104	‐	I-PK
2104	life	I-PK
2104	(	I-PK
2104	t	I-PK
2104	##1	I-PK
2104	/	I-PK
2104	2	I-PK
2104	)	I-PK
2104	was	O
2104	calculated	O
2104	as	O
2104	0	O
2104	.	O
2104	69	O
2104	##3	O
2104	/	O
2104	k	O
2104	##e	O
2104	,	O
2104	where	O
2104	elimination	B-PK
2104	rate	I-PK
2104	constant	I-PK
2104	(	I-PK
2104	k	I-PK
2104	##e	I-PK
2104	)	I-PK
2104	is	O
2104	the	O
2104	slope	O
2104	of	O
2104	the	O
2104	log	O
2104	‐	O
2104	linear	O
2104	portion	O
2104	of	O
2104	the	O
2104	concentration	O
2104	‐	O
2104	time	O
2104	profile	O
2104	.	O
2104	[SEP]	O
2105	[CLS]	O
2105	the	O
2105	c	B-PK
2105	##l	I-PK
2105	and	O
2105	vs	B-PK
2105	##s	I-PK
2105	for	O
2105	es	O
2105	##ome	O
2105	##pra	O
2105	##zo	O
2105	##le	O
2105	were	O
2105	calculated	O
2105	using	O
2105	the	O
2105	following	O
2105	equations	O
2105	:	O
2105	(	O
2105	1	O
2105	)	O
2105	c	O
2105	##l	O
2105	=	O
2105	dose	O
2105	##au	O
2105	##c	O
2105	##0	O
2105	##−	O
2105	##∞	O
2105	(	O
2105	2	O
2105	)	O
2105	vs	O
2105	##s	O
2105	=	O
2105	m	O
2105	##rt	O
2105	##c	O
2105	##l	O
2105	(	O
2105	3	O
2105	)	O
2105	m	O
2105	##rt	O
2105	=	O
2105	au	O
2105	##m	O
2105	##c	O
2105	##0	O
2105	##−	O
2105	##∞	O
2105	##au	O
2105	##c	O
2105	##0	O
2105	##−	O
2105	##∞	O
2105	[SEP]	O
2106	[CLS]	O
2106	the	O
2106	peak	B-PK
2106	plasma	I-PK
2106	concentration	I-PK
2106	(	I-PK
2106	cm	I-PK
2106	##ax	I-PK
2106	)	I-PK
2106	and	O
2106	the	O
2106	time	B-PK
2106	until	I-PK
2106	maximum	I-PK
2106	concentration	I-PK
2106	(	I-PK
2106	t	I-PK
2106	##max	I-PK
2106	)	I-PK
2106	were	O
2106	directly	O
2106	determined	O
2106	from	O
2106	the	O
2106	plasma	O
2106	concentration	O
2106	‐	O
2106	time	O
2106	curves	O
2106	.	O
2106	[SEP]	O
2107	[CLS]	O
2107	the	O
2107	bra	O
2107	##vo	O
2107	capsule	O
2107	##s	O
2107	were	O
2107	oral	O
2107	##ly	O
2107	inserted	O
2107	with	O
2107	a	O
2107	delivery	O
2107	system	O
2107	(	O
2107	80	O
2107	cm	O
2107	in	O
2107	length	O
2107	,	O
2107	with	O
2107	a	O
2107	diameter	O
2107	of	O
2107	6	O
2107	f	O
2107	##r	O
2107	.	O
2107	)	O
2107	.	O
2107	[SEP]	O
2108	[CLS]	O
2108	after	O
2108	repeated	O
2108	p	O
2108	##o	O
2108	administration	O
2108	##s	O
2108	of	O
2108	es	O
2108	##ome	O
2108	##pra	O
2108	##zo	O
2108	##le	O
2108	(	O
2108	1	O
2108	mg	O
2108	/	O
2108	kg	O
2108	,	O
2108	once	O
2108	daily	O
2108	)	O
2108	,	O
2108	the	O
2108	t	B-PK
2108	##max	I-PK
2108	on	O
2108	day	O
2108	5	O
2108	was	O
2108	2	O
2108	.	O
2108	23	O
2108	‐	O
2108	fold	O
2108	faster	O
2108	than	O
2108	on	O
2108	day	O
2108	1	O
2108	(	O
2108	0	O
2108	.	O
2108	81	O
2108	and	O
2108	1	O
2108	.	O
2108	81	O
2108	hours	O
2108	,	O
2108	respectively	O
2108	;	O
2108	p	O
2108	=	O
2108	.	O
2108	02	O
2108	##2	O
2108	)	O
2108	.	O
2108	[SEP]	O
2109	[CLS]	O
2109	the	O
2109	cm	B-PK
2109	##ax	I-PK
2109	of	O
2109	the	O
2109	p	O
2109	##o	O
2109	es	O
2109	##ome	O
2109	##pra	O
2109	##zo	O
2109	##le	O
2109	treatment	O
2109	was	O
2109	significantly	O
2109	lower	O
2109	than	O
2109	that	O
2109	of	O
2109	the	O
2109	i	O
2109	##v	O
2109	(	O
2109	p	O
2109	=	O
2109	.	O
2109	00	O
2109	##4	O
2109	)	O
2109	treatment	O
2109	,	O
2109	and	O
2109	the	O
2109	bio	B-PK
2109	##ava	I-PK
2109	##ila	I-PK
2109	##bility	I-PK
2109	was	O
2109	71	O
2109	.	O
2109	43	O
2109	%	O
2109	.	O
2109	[SEP]	O
2110	[CLS]	O
2110	eighteen	O
2110	mice	O
2110	were	O
2110	divided	O
2110	into	O
2110	six	O
2110	groups	O
2110	(	O
2110	a	O
2110	,	O
2110	b	O
2110	,	O
2110	c	O
2110	,	O
2110	d	O
2110	,	O
2110	e	O
2110	and	O
2110	f	O
2110	)	O
2110	,	O
2110	each	O
2110	group	O
2110	containing	O
2110	three	O
2110	mice	O
2110	.	O
2110	[SEP]	O
2111	[CLS]	O
2111	samples	O
2111	from	O
2111	groups	O
2111	a	O
2111	and	O
2111	d	O
2111	were	O
2111	collected	O
2111	at	O
2111	0	O
2111	min	O
2111	(	O
2111	0	O
2111	h	O
2111	)	O
2111	,	O
2111	30	O
2111	min	O
2111	(	O
2111	0	O
2111	.	O
2111	5	O
2111	h	O
2111	)	O
2111	,	O
2111	4	O
2111	h	O
2111	and	O
2111	24	O
2111	h	O
2111	.	O
2111	samples	O
2111	from	O
2111	groups	O
2111	b	O
2111	and	O
2111	e	O
2111	were	O
2111	collected	O
2111	at	O
2111	5	O
2111	min	O
2111	(	O
2111	0	O
2111	.	O
2111	08	O
2111	h	O
2111	)	O
2111	,	O
2111	1	O
2111	h	O
2111	and	O
2111	6	O
2111	h	O
2111	.	O
2111	samples	O
2111	from	O
2111	groups	O
2111	c	O
2111	and	O
2111	f	O
2111	were	O
2111	collected	O
2111	at	O
2111	15	O
2111	min	O
2111	(	O
2111	0	O
2111	.	O
2111	25	O
2111	h	O
2111	)	O
2111	,	O
2111	2	O
2111	h	O
2111	and	O
2111	8	O
2111	h	O
2111	.	O
2111	next	O
2111	,	O
2111	all	O
2111	of	O
2111	the	O
2111	blood	O
2111	samples	O
2111	were	O
2111	cent	O
2111	##ri	O
2111	##fu	O
2111	##ged	O
2111	for	O
2111	5	O
2111	min	O
2111	at	O
2111	800	O
2111	##0	O
2111	rpm	O
2111	,	O
2111	4	O
2111	°	O
2111	##c	O
2111	,	O
2111	and	O
2111	the	O
2111	plasma	O
2111	was	O
2111	collected	O
2111	in	O
2111	a	O
2111	96	O
2111	-	O
2111	well	O
2111	plate	O
2111	and	O
2111	stored	O
2111	at	O
2111	−	O
2111	##20	O
2111	°	O
2111	##c	O
2111	.	O
2111	[SEP]	O
2112	[CLS]	O
2112	d	O
2112	##sa	O
2112	2	O
2112	.	O
2112	0	O
2112	p	O
2112	##har	O
2112	##ma	O
2112	##co	O
2112	##kin	O
2112	##etic	O
2112	software	O
2112	(	O
2112	chin	O
2112	##a	O
2112	pharmaceutical	O
2112	university	O
2112	,	O
2112	chin	O
2112	##a	O
2112	)	O
2112	was	O
2112	used	O
2112	to	O
2112	calculate	O
2112	the	O
2112	main	O
2112	p	O
2112	##har	O
2112	##ma	O
2112	##co	O
2112	##kin	O
2112	##etic	O
2112	parameters	O
2112	,	O
2112	including	O
2112	the	O
2112	area	B-PK
2112	under	I-PK
2112	the	I-PK
2112	time	I-PK
2112	-	I-PK
2112	concentration	I-PK
2112	curve	I-PK
2112	(	I-PK
2112	au	I-PK
2112	##c	I-PK
2112	)	I-PK
2112	,	O
2112	half	B-PK
2112	-	I-PK
2112	life	I-PK
2112	(	I-PK
2112	t	I-PK
2112	##1	I-PK
2112	/	I-PK
2112	2	I-PK
2112	)	I-PK
2112	,	O
2112	the	O
2112	maximum	B-PK
2112	of	I-PK
2112	blood	I-PK
2112	concentration	I-PK
2112	(	I-PK
2112	cm	I-PK
2112	##ax	I-PK
2112	)	I-PK
2112	,	O
2112	blood	B-PK
2112	clearance	I-PK
2112	rate	I-PK
2112	(	I-PK
2112	c	I-PK
2112	##l	I-PK
2112	)	I-PK
2112	,	O
2112	apparent	B-PK
2112	volume	I-PK
2112	of	I-PK
2112	distribution	I-PK
2112	(	I-PK
2112	v	I-PK
2112	)	I-PK
2112	,	O
2112	and	O
2112	mean	B-PK
2112	retention	I-PK
2112	time	I-PK
2112	(	I-PK
2112	m	I-PK
2112	##rt	I-PK
2112	)	I-PK
2112	.	O
2112	[SEP]	O
2113	[CLS]	O
2113	bio	B-PK
2113	##ava	I-PK
2113	##ila	I-PK
2113	##bility	I-PK
2113	was	O
2113	calculated	O
2113	by	O
2113	absolute	O
2113	bio	O
2113	##ava	O
2113	##ila	O
2113	##bility	O
2113	=	O
2113	100	O
2113	%	O
2113	×	O
2113	au	O
2113	##c	O
2113	##po	O
2113	·	O
2113	di	O
2113	##v	O
2113	/	O
2113	(	O
2113	au	O
2113	##ci	O
2113	##v	O
2113	·	O
2113	d	O
2113	##po	O
2113	)	O
2113	,	O
2113	where	O
2113	au	B-PK
2113	##ci	I-PK
2113	##v	I-PK
2113	and	O
2113	au	B-PK
2113	##c	I-PK
2113	##po	I-PK
2113	are	O
2113	the	O
2113	au	B-PK
2113	##c	I-PK
2113	of	I-PK
2113	the	I-PK
2113	drug	I-PK
2113	from	I-PK
2113	(	I-PK
2113	0	I-PK
2113	–	I-PK
2113	∞	I-PK
2113	)	I-PK
2113	after	O
2113	in	O
2113	##tra	O
2113	##ven	O
2113	##ous	O
2113	and	O
2113	oral	O
2113	administration	O
2113	,	O
2113	and	O
2113	di	O
2113	##v	O
2113	and	O
2113	d	O
2113	##po	O
2113	are	O
2113	the	O
2113	single	O
2113	dos	O
2113	##age	O
2113	of	O
2113	t	O
2113	##b	O
2113	##ms	O
2113	-	O
2113	i	O
2113	for	O
2113	the	O
2113	in	O
2113	##tra	O
2113	##ven	O
2113	##ous	O
2113	and	O
2113	oral	O
2113	administration	O
2113	,	O
2113	respectively	O
2113	.	O
2113	[SEP]	O
2114	[CLS]	O
2114	the	O
2114	t	B-PK
2114	##max	I-PK
2114	was	O
2114	1	O
2114	.	O
2114	8	O
2114	±	O
2114	1	O
2114	.	O
2114	3	O
2114	h	O
2114	after	O
2114	oral	O
2114	administration	O
2114	.	O
2114	[SEP]	O
2115	[CLS]	O
2115	the	O
2115	non	O
2115	-	O
2115	ha	O
2115	##em	O
2115	##or	O
2115	##r	O
2115	##ha	O
2115	##gic	O
2115	group	O
2115	,	O
2115	where	O
2115	patients	O
2115	experience	O
2115	a	O
2115	bleeding	O
2115	volume	O
2115	of	O
2115	less	O
2115	than	O
2115	800	O
2115	m	O
2115	##l	O
2115	,	O
2115	is	O
2115	a	O
2115	reference	O
2115	group	O
2115	for	O
2115	biology	O
2115	and	O
2115	will	O
2115	be	O
2115	sampled	O
2115	to	O
2115	obtain	O
2115	a	O
2115	reference	O
2115	profile	O
2115	for	O
2115	the	O
2115	direct	O
2115	p	O
2115	##las	O
2115	##min	O
2115	generation	O
2115	test	O
2115	in	O
2115	c	O
2115	##s	O
2115	.	O
2115	[SEP]	O
2116	[CLS]	O
2116	secondary	O
2116	end	O
2116	##points	O
2116	will	O
2116	be	O
2116	measured	O
2116	before	O
2116	inclusion	O
2116	(	O
2116	t	O
2116	##0	O
2116	)	O
2116	and	O
2116	at	O
2116	t	O
2116	##30	O
2116	,	O
2116	t	O
2116	##60	O
2116	,	O
2116	t	O
2116	##12	O
2116	##0	O
2116	and	O
2116	t	O
2116	##36	O
2116	##0	O
2116	,	O
2116	respectively	O
2116	30	O
2116	,	O
2116	60	O
2116	,	O
2116	120	O
2116	and	O
2116	360	O
2116	min	O
2116	after	O
2116	inclusion	O
2116	and	O
2116	at	O
2116	day	O
2116	2	O
2116	(	O
2116	±	O
2116	##12	O
2116	h	O
2116	)	O
2116	[SEP]	O
2117	[CLS]	O
2117	the	O
2117	average	O
2117	of	O
2117	total	O
2117	bleeding	O
2117	was	O
2117	131	O
2117	##3	O
2117	±	O
2117	143	O
2117	##2	O
2117	m	O
2117	##l	O
2117	in	O
2117	the	O
2117	ta	O
2117	group	O
2117	vs	O
2117	208	O
2117	##9	O
2117	±	O
2117	155	O
2117	##6	O
2117	m	O
2117	##l	O
2117	in	O
2117	the	O
2117	place	O
2117	##bo	O
2117	group	O
2117	(	O
2117	p	O
2117	=	O
2117	0	O
2117	.	O
2117	03	O
2117	)	O
2117	.	O
2117	[SEP]	O
2118	[CLS]	O
2118	water	O
2118	used	O
2118	for	O
2118	the	O
2118	l	O
2118	##c	O
2118	–	O
2118	m	O
2118	##s	O
2118	/	O
2118	m	O
2118	##s	O
2118	analysis	O
2118	was	O
2118	prepared	O
2118	from	O
2118	mill	O
2118	##i	O
2118	q	O
2118	water	O
2118	pu	O
2118	##rification	O
2118	system	O
2118	pro	O
2118	##cure	O
2118	##d	O
2118	from	O
2118	mill	O
2118	##ip	O
2118	##ore	O
2118	(	O
2118	bang	O
2118	##alo	O
2118	##re	O
2118	,	O
2118	in	O
2118	##dia	O
2118	)	O
2118	.	O
2118	[SEP]	O
2119	[CLS]	O
2119	bench	O
2119	top	O
2119	stability	O
2119	(	O
2119	5	O
2119	h	O
2119	at	O
2119	ice	O
2119	water	O
2119	bath	O
2119	)	O
2119	,	O
2119	auto	O
2119	##sa	O
2119	##mple	O
2119	##r	O
2119	stability	O
2119	(	O
2119	46	O
2119	h	O
2119	)	O
2119	,	O
2119	freeze	O
2119	-	O
2119	th	O
2119	##aw	O
2119	stability	O
2119	(	O
2119	3	O
2119	cycles	O
2119	at	O
2119	ice	O
2119	water	O
2119	bath	O
2119	)	O
2119	,	O
2119	re	O
2119	##in	O
2119	##jection	O
2119	stability	O
2119	(	O
2119	26	O
2119	h	O
2119	)	O
2119	,	O
2119	wet	O
2119	extract	O
2119	stability	O
2119	(	O
2119	43	O
2119	h	O
2119	at	O
2119	2	O
2119	–	O
2119	8	O
2119	°	O
2119	##c	O
2119	)	O
2119	and	O
2119	long	O
2119	-	O
2119	term	O
2119	stability	O
2119	at	O
2119	−	O
2119	##70	O
2119	°	O
2119	##c	O
2119	for	O
2119	56	O
2119	day	O
2119	the	O
2119	mean	O
2119	%	O
2119	nominal	O
2119	values	O
2119	of	O
2119	the	O
2119	anal	O
2119	##yte	O
2119	##s	O
2119	were	O
2119	found	O
2119	to	O
2119	be	O
2119	within	O
2119	±	O
2119	##15	O
2119	%	O
2119	of	O
2119	the	O
2119	predicted	O
2119	concentrations	O
2119	for	O
2119	the	O
2119	anal	O
2119	##yte	O
2119	##s	O
2119	at	O
2119	their	O
2119	l	O
2119	##q	O
2119	##c	O
2119	and	O
2119	h	O
2119	##q	O
2119	##c	O
2119	levels	O
2119	(	O
2119	table	O
2119	2	O
2119	)	O
2119	.	O
2119	[SEP]	O
2120	[CLS]	O
2120	blood	O
2120	samples	O
2120	for	O
2120	assessment	O
2120	of	O
2120	the	O
2120	t	B-PK
2120	##rough	I-PK
2120	concentration	I-PK
2120	(	I-PK
2120	cm	I-PK
2120	##in	I-PK
2120	)	I-PK
2120	of	O
2120	r	O
2120	##ad	O
2120	##00	O
2120	##1	O
2120	were	O
2120	obtained	O
2120	immediately	O
2120	before	O
2120	administration	O
2120	of	O
2120	the	O
2120	next	O
2120	dose	O
2120	on	O
2120	days	O
2120	2	O
2120	,	O
2120	8	O
2120	,	O
2120	11	O
2120	,	O
2120	15	O
2120	and	O
2120	16	O
2120	of	O
2120	cycle	O
2120	1	O
2120	and	O
2120	on	O
2120	day	O
2120	1	O
2120	of	O
2120	cycle	O
2120	2	O
2120	as	O
2120	well	O
2120	as	O
2120	at	O
2120	the	O
2120	end	O
2120	of	O
2120	the	O
2120	study	O
2120	.	O
2120	[SEP]	O
2121	[CLS]	O
2121	the	O
2121	cm	B-PK
2121	##in	I-PK
2121	of	O
2121	r	O
2121	##ad	O
2121	##00	O
2121	##1	O
2121	indicated	O
2121	that	O
2121	a	O
2121	steady	O
2121	state	O
2121	was	O
2121	attained	O
2121	after	O
2121	[UNK]	O
2121	days	O
2121	of	O
2121	repeated	O
2121	once	O
2121	-	O
2121	daily	O
2121	oral	O
2121	dos	O
2121	##ing	O
2121	(	O
2121	fi	O
2121	##g	O
2121	.	O
2121	1	O
2121	##b	O
2121	)	O
2121	.	O
2121	[SEP]	O
2122	[CLS]	O
2122	the	O
2122	c	O
2122	##yt	O
2122	##oto	O
2122	##to	O
2122	##xi	O
2122	##city	O
2122	,	O
2122	serum	B-PK
2122	half	I-PK
2122	-	I-PK
2122	life	I-PK
2122	,	O
2122	and	O
2122	anti	O
2122	##tum	O
2122	##or	O
2122	effect	O
2122	of	O
2122	i	O
2122	##g	O
2122	##b	O
2122	##d	O
2122	-	O
2122	trail	O
2122	and	O
2122	a	O
2122	##b	O
2122	##d	O
2122	-	O
2122	trail	O
2122	were	O
2122	compared	O
2122	.	O
2122	[SEP]	O
2123	[CLS]	O
2123	to	O
2123	estimate	O
2123	the	O
2123	influence	O
2123	of	O
2123	i	O
2123	##gg	O
2123	and	O
2123	album	O
2123	##in	O
2123	binding	O
2123	on	O
2123	the	O
2123	c	O
2123	##yt	O
2123	##oto	O
2123	##xi	O
2123	##city	O
2123	of	O
2123	trail	O
2123	fusion	O
2123	proteins	O
2123	,	O
2123	i	O
2123	##gg	O
2123	or	O
2123	album	O
2123	##in	O
2123	were	O
2123	mixed	O
2123	with	O
2123	i	O
2123	##g	O
2123	##b	O
2123	##d	O
2123	-	O
2123	trail	O
2123	or	O
2123	a	O
2123	##b	O
2123	##d	O
2123	-	O
2123	trail	O
2123	at	O
2123	a	O
2123	molecular	O
2123	ratio	O
2123	of	O
2123	1	O
2123	:	O
2123	1	O
2123	and	O
2123	in	O
2123	##cu	O
2123	##bate	O
2123	##d	O
2123	at	O
2123	room	O
2123	temperature	O
2123	for	O
2123	0	O
2123	.	O
2123	5	O
2123	h	O
2123	,	O
2123	followed	O
2123	by	O
2123	addition	O
2123	into	O
2123	the	O
2123	cells	O
2123	.	O
2123	[SEP]	O
2124	[CLS]	O
2124	subsequently	O
2124	,	O
2124	the	O
2124	sensor	O
2124	was	O
2124	inserted	O
2124	into	O
2124	a	O
2124	solution	O
2124	containing	O
2124	different	O
2124	concentrations	O
2124	(	O
2124	0	O
2124	-	O
2124	2	O
2124	μ	O
2124	##m	O
2124	)	O
2124	of	O
2124	i	O
2124	##g	O
2124	##b	O
2124	##d	O
2124	-	O
2124	trail	O
2124	for	O
2124	300	O
2124	s	O
2124	to	O
2124	enable	O
2124	association	O
2124	,	O
2124	followed	O
2124	by	O
2124	di	O
2124	##sa	O
2124	##sso	O
2124	##ciation	O
2124	in	O
2124	p	O
2124	##bs	O
2124	for	O
2124	200	O
2124	s	O
2124	.	O
2124	the	O
2124	association	O
2124	constant	O
2124	ka	O
2124	,	O
2124	di	O
2124	##sa	O
2124	##sso	O
2124	##ciation	O
2124	constant	O
2124	k	O
2124	##d	O
2124	,	O
2124	and	O
2124	affinity	O
2124	k	O
2124	##d	O
2124	(	O
2124	k	O
2124	##d	O
2124	=	O
2124	k	O
2124	##d	O
2124	/	O
2124	ka	O
2124	)	O
2124	were	O
2124	calculated	O
2124	by	O
2124	using	O
2124	software	O
2124	for	O
2124	o	O
2124	##ct	O
2124	##et	O
2124	##®	O
2124	systems	O
2124	according	O
2124	to	O
2124	1	O
2124	:	O
2124	1	O
2124	binding	O
2124	model	O
2124	.	O
2124	[SEP]	O
2125	[CLS]	O
2125	in	O
2125	addition	O
2125	,	O
2125	a	O
2125	traditional	O
2125	radioactive	O
2125	method	O
2125	was	O
2125	also	O
2125	used	O
2125	to	O
2125	monitor	O
2125	the	O
2125	blood	B-PK
2125	clearance	I-PK
2125	of	O
2125	trail	O
2125	proteins	O
2125	and	O
2125	i	O
2125	##gg	O
2125	.	O
2125	i	O
2125	##13	O
2125	##1	O
2125	-	O
2125	label	O
2125	##ing	O
2125	was	O
2125	performed	O
2125	according	O
2125	to	O
2125	fan	O
2125	et	O
2125	al	O
2125	.	O
2125	40	O
2125	.	O
2125	[SEP]	O
2126	[CLS]	O
2126	to	O
2126	monitor	O
2126	the	O
2126	blood	B-PK
2126	clearance	I-PK
2126	,	O
2126	normal	O
2126	b	O
2126	##al	O
2126	##b	O
2126	/	O
2126	c	O
2126	mice	O
2126	(	O
2126	n	O
2126	=	O
2126	3	O
2126	for	O
2126	each	O
2126	time	O
2126	point	O
2126	)	O
2126	were	O
2126	in	O
2126	##tra	O
2126	##ven	O
2126	##ously	O
2126	injected	O
2126	with	O
2126	i	O
2126	##13	O
2126	##1	O
2126	-	O
2126	labeled	O
2126	trail	O
2126	proteins	O
2126	or	O
2126	i	O
2126	##gg	O
2126	pre	O
2126	##in	O
2126	##cu	O
2126	##bate	O
2126	##d	O
2126	with	O
2126	or	O
2126	without	O
2126	i	O
2126	##g	O
2126	##b	O
2126	##d	O
2126	-	O
2126	trail	O
2126	at	O
2126	a	O
2126	m	O
2126	##olar	O
2126	ratio	O
2126	of	O
2126	1	O
2126	:	O
2126	1	O
2126	(	O
2126	100	O
2126	μ	O
2126	##l	O
2126	,	O
2126	27	O
2126	.	O
2126	5	O
2126	k	O
2126	##b	O
2126	##q	O
2126	/	O
2126	g	O
2126	body	O
2126	weight	O
2126	)	O
2126	.	O
2126	[SEP]	O
2127	[CLS]	O
2127	the	O
2127	speed	O
2127	of	O
2127	the	O
2127	c	O
2127	##yt	O
2127	##oto	O
2127	##xi	O
2127	##city	O
2127	decrease	O
2127	reflects	O
2127	the	O
2127	protein	O
2127	clearance	B-PK
2127	rate	I-PK
2127	.	O
2127	[SEP]	O
2128	[CLS]	O
2128	bio	O
2128	##layer	O
2128	inter	O
2128	##fer	O
2128	##ome	O
2128	##try	O
2128	revealed	O
2128	that	O
2128	the	O
2128	affinity	O
2128	of	O
2128	a	O
2128	##b	O
2128	##d	O
2128	-	O
2128	trail	O
2128	for	O
2128	h	O
2128	##sa	O
2128	was	O
2128	1	O
2128	.	O
2128	68	O
2128	nm	O
2128	(	O
2128	figure	O
2128	6	O
2128	##b	O
2128	)	O
2128	.	O
2128	[SEP]	O
2129	[CLS]	O
2129	as	O
2129	shown	O
2129	in	O
2129	figure	O
2129	7	O
2129	##a	O
2129	,	O
2129	when	O
2129	injected	O
2129	at	O
2129	an	O
2129	early	O
2129	time	O
2129	post	O
2129	-	O
2129	in	O
2129	##oc	O
2129	##ulation	O
2129	(	O
2129	tumor	O
2129	volume	O
2129	~	O
2129	50	O
2129	mm	O
2129	##3	O
2129	)	O
2129	,	O
2129	a	O
2129	##b	O
2129	##d	O
2129	-	O
2129	trail	O
2129	showed	O
2129	greater	O
2129	tumor	O
2129	suppression	O
2129	than	O
2129	trail	O
2129	.	O
2129	[SEP]	O
2130	[CLS]	O
2130	con	O
2130	##clusive	O
2130	##ly	O
2130	,	O
2130	these	O
2130	data	O
2130	revealed	O
2130	that	O
2130	b	O
2130	##b	O
2130	##r	O
2130	can	O
2130	improve	O
2130	insulin	O
2130	sensitivity	O
2130	in	O
2130	d	O
2130	##b	O
2130	/	O
2130	d	O
2130	##b	O
2130	di	O
2130	##abe	O
2130	##tic	O
2130	mice	O
2130	,	O
2130	and	O
2130	the	O
2130	b	O
2130	##b	O
2130	##r	O
2130	-	O
2130	s	O
2130	##ln	O
2130	##s	O
2130	ex	O
2130	##ert	O
2130	##ed	O
2130	more	O
2130	potent	O
2130	effects	O
2130	than	O
2130	an	O
2130	equivalent	O
2130	dose	O
2130	of	O
2130	b	O
2130	##b	O
2130	##r	O
2130	,	O
2130	probably	O
2130	through	O
2130	increased	O
2130	absorption	O
2130	and	O
2130	/	O
2130	or	O
2130	bio	B-PK
2130	##ava	I-PK
2130	##ila	I-PK
2130	##bility	I-PK
2130	.	O
2130	[SEP]	O
2131	[CLS]	O
2131	ex	O
2131	##po	O
2131	##nent	O
2131	##iating	O
2131	the	O
2131	least	O
2131	-	O
2131	squares	O
2131	means	O
2131	(	O
2131	mean	O
2131	differences	O
2131	)	O
2131	and	O
2131	the	O
2131	lower	O
2131	and	O
2131	upper	O
2131	limits	O
2131	of	O
2131	these	O
2131	confidence	O
2131	intervals	O
2131	yielded	O
2131	estimates	O
2131	for	O
2131	the	O
2131	population	O
2131	geometric	O
2131	means	O
2131	(	O
2131	population	O
2131	geometric	O
2131	mean	O
2131	ratios	O
2131	)	O
2131	and	O
2131	confidence	O
2131	intervals	O
2131	for	O
2131	the	O
2131	geometric	O
2131	means	O
2131	(	O
2131	geometric	O
2131	mean	O
2131	ratios	O
2131	)	O
2131	on	O
2131	the	O
2131	original	O
2131	scale	O
2131	.	O
2131	[SEP]	O
2132	[CLS]	O
2132	a	O
2132	95	O
2132	%	O
2132	confidence	O
2132	interval	O
2132	(	O
2132	c	O
2132	##i	O
2132	)	O
2132	was	O
2132	constructed	O
2132	for	O
2132	the	O
2132	geometric	O
2132	means	O
2132	of	O
2132	the	O
2132	au	B-PK
2132	##cs	I-PK
2132	for	O
2132	the	O
2132	treatment	O
2132	arms	O
2132	.	O
2132	[SEP]	O
2133	[CLS]	O
2133	the	O
2133	median	O
2133	time	B-PK
2133	to	I-PK
2133	reach	I-PK
2133	cm	I-PK
2133	##ax	I-PK
2133	(	I-PK
2133	t	I-PK
2133	##max	I-PK
2133	)	I-PK
2133	was	O
2133	5	O
2133	h	O
2133	post	O
2133	-	O
2133	dose	O
2133	for	O
2133	the	O
2133	m	O
2133	##k	O
2133	-	O
2133	06	O
2133	##46	O
2133	alone	O
2133	treatment	O
2133	and	O
2133	3	O
2133	.	O
2133	5	O
2133	h	O
2133	post	O
2133	-	O
2133	dose	O
2133	for	O
2133	the	O
2133	m	O
2133	##k	O
2133	-	O
2133	06	O
2133	##46	O
2133	+	O
2133	c	O
2133	##et	O
2133	##ux	O
2133	##ima	O
2133	##b	O
2133	/	O
2133	i	O
2133	##rino	O
2133	##teca	O
2133	##n	O
2133	treatment	O
2133	.	O
2133	[SEP]	O
2134	[CLS]	O
2134	the	O
2134	co	O
2134	-	O
2134	administration	O
2134	of	O
2134	m	O
2134	##k	O
2134	-	O
2134	06	O
2134	##46	O
2134	with	O
2134	c	O
2134	##et	O
2134	##ux	O
2134	##ima	O
2134	##b	O
2134	/	O
2134	i	O
2134	##rino	O
2134	##teca	O
2134	##n	O
2134	produced	O
2134	a	O
2134	higher	O
2134	mean	O
2134	peak	B-PK
2134	c	I-PK
2134	##et	I-PK
2134	##ux	I-PK
2134	##ima	I-PK
2134	##b	I-PK
2134	concentration	I-PK
2134	(	O
2134	geometric	O
2134	mean	O
2134	of	O
2134	the	O
2134	cm	B-PK
2134	##ax	I-PK
2134	value	O
2134	of	O
2134	236	O
2134	.	O
2134	5	O
2134	vs	O
2134	.	O
2134	204	O
2134	.	O
2134	0	O
2134	μ	O
2134	##g	O
2134	/	O
2134	m	O
2134	##l	O
2134	without	O
2134	m	O
2134	##k	O
2134	-	O
2134	06	O
2134	##46	O
2134	co	O
2134	-	O
2134	administration	O
2134	)	O
2134	,	O
2134	which	O
2134	was	O
2134	reached	O
2134	earlier	O
2134	(	O
2134	median	O
2134	t	B-PK
2134	##max	I-PK
2134	value	O
2134	of	O
2134	2	O
2134	.	O
2134	0	O
2134	vs	O
2134	.	O
2134	7	O
2134	.	O
2134	9	O
2134	h	O
2134	without	O
2134	m	O
2134	##k	O
2134	-	O
2134	06	O
2134	##46	O
2134	co	O
2134	-	O
2134	administration	O
2134	)	O
2134	.	O
2134	[SEP]	O
2135	[CLS]	O
2135	the	O
2135	median	O
2135	t	B-PK
2135	##max	I-PK
2135	was	O
2135	the	O
2135	same	O
2135	for	O
2135	both	O
2135	treatments	O
2135	(	O
2135	1	O
2135	.	O
2135	0	O
2135	h	O
2135	)	O
2135	.	O
2135	[SEP]	O
2136	[CLS]	O
2136	the	O
2136	rate	B-PK
2136	constant	I-PK
2136	associated	I-PK
2136	with	I-PK
2136	the	I-PK
2136	terminal	I-PK
2136	elimination	I-PK
2136	phase	I-PK
2136	(	I-PK
2136	λ	I-PK
2136	)	I-PK
2136	was	O
2136	estimated	O
2136	by	O
2136	means	O
2136	of	O
2136	linear	O
2136	re	O
2136	##gression	O
2136	of	O
2136	the	O
2136	terminal	O
2136	phase	O
2136	of	O
2136	the	O
2136	log	O
2136	concentration	O
2136	-	O
2136	vs	O
2136	.	O
2136	-	O
2136	time	O
2136	curve	O
2136	,	O
2136	and	O
2136	the	O
2136	half	B-PK
2136	-	I-PK
2136	life	I-PK
2136	(	I-PK
2136	t	I-PK
2136	##1	I-PK
2136	/	I-PK
2136	2	I-PK
2136	)	I-PK
2136	and	O
2136	the	O
2136	volume	B-PK
2136	of	I-PK
2136	distribution	I-PK
2136	(	I-PK
2136	v	I-PK
2136	##d	I-PK
2136	)	I-PK
2136	associated	I-PK
2136	with	I-PK
2136	λ	I-PK
2136	(	I-PK
2136	v	I-PK
2136	##d	I-PK
2136	##λ	I-PK
2136	)	I-PK
2136	was	O
2136	calculated	O
2136	.	O
2136	[SEP]	O
2137	[CLS]	O
2137	for	O
2137	calculation	O
2137	of	O
2137	λ	B-PK
2137	after	O
2137	the	O
2137	in	O
2137	##tra	O
2137	##ven	O
2137	##ous	O
2137	and	O
2137	the	O
2137	in	O
2137	##tra	O
2137	##mus	O
2137	##cular	O
2137	administration	O
2137	all	O
2137	plasma	O
2137	samples	O
2137	from	O
2137	2	O
2137	.	O
2137	5	O
2137	h	O
2137	and	O
2137	onwards	O
2137	were	O
2137	included	O
2137	.	O
2137	[SEP]	O
2138	[CLS]	O
2138	differences	O
2138	between	O
2138	different	O
2138	routes	O
2138	of	O
2138	administration	O
2138	regarding	O
2138	the	O
2138	λ	B-PK
2138	and	O
2138	the	O
2138	effect	O
2138	duration	O
2138	were	O
2138	statistical	O
2138	##ly	O
2138	evaluated	O
2138	using	O
2138	the	O
2138	k	O
2138	##rus	O
2138	##kal	O
2138	-	O
2138	wall	O
2138	##is	O
2138	test	O
2138	by	O
2138	the	O
2138	use	O
2138	of	O
2138	mini	O
2138	##ta	O
2138	##b	O
2138	for	O
2138	windows	O
2138	95	O
2138	,	O
2138	release	O
2138	12	O
2138	(	O
2138	mini	O
2138	##nc	O
2138	,	O
2138	state	O
2138	college	O
2138	,	O
2138	p	O
2138	##a	O
2138	,	O
2138	us	O
2138	##a	O
2138	)	O
2138	.	O
2138	[SEP]	O
2139	[CLS]	O
2139	m	O
2139	##rt	O
2139	=	O
2139	au	O
2139	##m	O
2139	##cin	O
2139	##f	O
2139	/	O
2139	au	O
2139	##cin	O
2139	##f	O
2139	[SEP]	O
2140	[CLS]	O
2140	v	O
2140	##ds	O
2140	##s	O
2140	=	O
2140	dose	O
2140	×	O
2140	au	O
2140	##m	O
2140	##c	O
2140	/	O
2140	au	O
2140	##cin	O
2140	##f	O
2140	##2	O
2140	[SEP]	O
2141	[CLS]	O
2141	because	O
2141	the	O
2141	oral	B-PK
2141	bio	I-PK
2141	##ava	I-PK
2141	##ila	I-PK
2141	##bility	I-PK
2141	(	I-PK
2141	f	I-PK
2141	)	I-PK
2141	of	O
2141	e	O
2141	##fa	O
2141	##vir	O
2141	##en	O
2141	##z	O
2141	was	O
2141	not	O
2141	determined	O
2141	,	O
2141	c	B-PK
2141	##l	I-PK
2141	and	O
2141	v	B-PK
2141	##d	I-PK
2141	represented	O
2141	apparent	O
2141	values	O
2141	(	O
2141	i	O
2141	.	O
2141	e	O
2141	.	O
2141	,	O
2141	c	B-PK
2141	##l	I-PK
2141	/	I-PK
2141	f	I-PK
2141	and	O
2141	v	B-PK
2141	##d	I-PK
2141	/	I-PK
2141	f	I-PK
2141	,	O
2141	respectively	O
2141	)	O
2141	.	O
2141	[SEP]	O
2142	[CLS]	O
2142	we	O
2142	pre	O
2142	‐	O
2142	estimated	O
2142	ka	B-PK
2142	from	O
2142	nine	O
2142	subjects	O
2142	from	O
2142	source	O
2142	#	O
2142	2	O
2142	from	O
2142	whom	O
2142	intensive	O
2142	sampling	O
2142	during	O
2142	the	O
2142	absorption	O
2142	phase	O
2142	was	O
2142	available	O
2142	,	O
2142	and	O
2142	ka	B-PK
2142	was	O
2142	then	O
2142	fixed	O
2142	at	O
2142	the	O
2142	pre	O
2142	‐	O
2142	estimated	O
2142	value	O
2142	in	O
2142	subsequent	O
2142	model	O
2142	development	O
2142	.	O
2142	[SEP]	O
2143	[CLS]	O
2143	no	O
2143	co	O
2143	‐	O
2143	medications	O
2143	tested	O
2143	(	O
2143	see	O
2143	table	O
2143	##2	O
2143	)	O
2143	was	O
2143	found	O
2143	to	O
2143	influence	O
2143	c	B-PK
2143	##l	I-PK
2143	.	O
2143	[SEP]	O
2144	[CLS]	O
2144	further	O
2144	introduction	O
2144	of	O
2144	the	O
2144	add	O
2144	##itive	O
2144	error	O
2144	model	O
2144	to	O
2144	explain	O
2144	inter	O
2144	##ind	O
2144	##iv	O
2144	##id	O
2144	##ual	O
2144	var	O
2144	##iability	O
2144	in	O
2144	c	B-PK
2144	##l	I-PK
2144	did	O
2144	not	O
2144	improve	O
2144	the	O
2144	fit	O
2144	(	O
2144	δ	O
2144	##of	O
2144	=	O
2144	0	O
2144	.	O
2144	00	O
2144	)	O
2144	.	O
2144	[SEP]	O
2145	[CLS]	O
2145	in	O
2145	the	O
2145	final	O
2145	model	O
2145	,	O
2145	the	O
2145	typical	O
2145	c	B-PK
2145	##l	I-PK
2145	of	O
2145	e	O
2145	##fa	O
2145	##vir	O
2145	##en	O
2145	##z	O
2145	for	O
2145	g	O
2145	##g	O
2145	,	O
2145	g	O
2145	##t	O
2145	,	O
2145	and	O
2145	t	O
2145	##t	O
2145	carriers	O
2145	were	O
2145	estimated	O
2145	to	O
2145	be	O
2145	10	O
2145	.	O
2145	2	O
2145	,	O
2145	7	O
2145	.	O
2145	33	O
2145	,	O
2145	and	O
2145	2	O
2145	.	O
2145	38	O
2145	l	O
2145	/	O
2145	h	O
2145	,	O
2145	respectively	O
2145	.	O
2145	[SEP]	O
2146	[CLS]	O
2146	study	O
2146	highlights	O
2146	##w	O
2146	##hat	O
2146	is	O
2146	the	O
2146	current	O
2146	knowledge	O
2146	on	O
2146	the	O
2146	topic	O
2146	?	O
2146	[SEP]	O
2147	[CLS]	O
2147	absorption	O
2147	profile	O
2147	of	O
2147	s	O
2147	‐	O
2147	k	O
2147	##eta	O
2147	##mine	O
2147	was	O
2147	best	O
2147	described	O
2147	with	O
2147	a	O
2147	simple	O
2147	first	B-PK
2147	‐	I-PK
2147	order	I-PK
2147	absorption	I-PK
2147	rate	I-PK
2147	constant	I-PK
2147	(	I-PK
2147	ka	I-PK
2147	)	I-PK
2147	model	O
2147	in	O
2147	comparison	O
2147	to	O
2147	a	O
2147	transit	O
2147	compartment	O
2147	model	O
2147	or	O
2147	a	O
2147	single	O
2147	we	O
2147	##ib	O
2147	##ull	O
2147	absorption	O
2147	function	O
2147	.	O
2147	[SEP]	O
2148	[CLS]	O
2148	both	O
2148	of	O
2148	these	O
2148	processes	O
2148	were	O
2148	dependent	O
2148	on	O
2148	individually	O
2148	scaled	O
2148	blood	B-PK
2148	flow	I-PK
2148	levels	I-PK
2148	that	O
2148	,	O
2148	in	O
2148	turn	O
2148	,	O
2148	used	O
2148	the	O
2148	body	O
2148	weight	O
2148	as	O
2148	a	O
2148	subject	O
2148	specific	O
2148	parameter	O
2148	(	O
2148	table	O
2148	##1	O
2148	)	O
2148	.	O
2148	[SEP]	O
2149	[CLS]	O
2149	our	O
2149	results	O
2149	suggest	O
2149	that	O
2149	the	O
2149	gut	B-PK
2149	wall	I-PK
2149	clearance	I-PK
2149	of	O
2149	s	O
2149	‐	O
2149	k	O
2149	##eta	O
2149	##mine	O
2149	is	O
2149	very	O
2149	low	O
2149	in	O
2149	comparison	O
2149	to	O
2149	he	B-PK
2149	##pa	I-PK
2149	##tic	I-PK
2149	clearance	I-PK
2149	,	O
2149	and	O
2149	the	O
2149	ratio	B-PK
2149	between	I-PK
2149	these	I-PK
2149	two	I-PK
2149	clearance	I-PK
2149	##s	I-PK
2149	was	O
2149	~	O
2149	1	O
2149	:	O
2149	253	O
2149	(	O
2149	table	O
2149	##2	O
2149	)	O
2149	.	O
2149	[SEP]	O
2150	[CLS]	O
2150	all	O
2150	efforts	O
2150	to	O
2150	calculate	O
2150	the	O
2150	absorption	B-PK
2150	rate	I-PK
2150	constant	I-PK
2150	(	I-PK
2150	ka	I-PK
2150	,	I-PK
2150	t	I-PK
2150	##ic	I-PK
2150	)	I-PK
2150	freely	O
2150	in	O
2150	the	O
2150	model	O
2150	were	O
2150	unsuccessful	O
2150	and	O
2150	,	O
2150	therefore	O
2150	,	O
2150	ka	B-PK
2150	,	I-PK
2150	t	I-PK
2150	##ic	I-PK
2150	was	O
2150	fixed	O
2150	to	O
2150	a	O
2150	published	O
2150	value	O
2150	of	O
2150	3	O
2150	.	O
2150	3	O
2150	/	O
2150	h	O
2150	.	O
2150	8	O
2150	the	O
2150	absorption	O
2150	phase	O
2150	was	O
2150	adequately	O
2150	described	O
2150	by	O
2150	a	O
2150	transit	O
2150	compartment	O
2150	##al	O
2150	model	O
2150	.	O
2150	[SEP]	O
2151	[CLS]	O
2151	median	O
2151	t	B-PK
2151	##max	I-PK
2151	was	O
2151	reached	O
2151	between	O
2151	3	O
2151	and	O
2151	7	O
2151	hours	O
2151	after	O
2151	administration	O
2151	of	O
2151	single	O
2151	or	O
2151	multiple	O
2151	doses	O
2151	of	O
2151	g	O
2151	##ilt	O
2151	##eri	O
2151	##tin	O
2151	##ib	O
2151	(	O
2151	tables	O
2151	s	O
2151	##2	O
2151	and	O
2151	s	O
2151	##3	O
2151	)	O
2151	.	O
2151	[SEP]	O
2152	[CLS]	O
2152	after	O
2152	multiple	O
2152	dose	O
2152	administration	O
2152	,	O
2152	the	O
2152	mean	O
2152	half	B-PK
2152	‐	I-PK
2152	life	I-PK
2152	of	O
2152	g	O
2152	##ilt	O
2152	##eri	O
2152	##tin	O
2152	##ib	O
2152	was	O
2152	estimated	O
2152	to	O
2152	range	O
2152	from	O
2152	84	O
2152	to	O
2152	126	O
2152	hours	O
2152	,	O
2152	with	O
2152	an	O
2152	approximate	O
2152	8	O
2152	‐	O
2152	fold	O
2152	accumulation	O
2152	relative	O
2152	to	O
2152	base	O
2152	##line	O
2152	.	O
2152	[SEP]	O
2153	[CLS]	O
2153	paired	O
2153	observations	O
2153	of	O
2153	p	O
2153	##har	O
2153	##ma	O
2153	##co	O
2153	##kin	O
2153	##etic	O
2153	parameter	O
2153	values	O
2153	of	O
2153	sun	O
2153	##iti	O
2153	##ni	O
2153	##b	O
2153	and	O
2153	i	O
2153	##rino	O
2153	##teca	O
2153	##n	O
2153	alone	O
2153	vs	O
2153	the	O
2153	combination	O
2153	did	O
2153	not	O
2153	reveal	O
2153	significant	O
2153	drug	O
2153	–	O
2153	drug	O
2153	interactions	O
2153	.	O
2153	[SEP]	O
2154	[CLS]	O
2154	standard	O
2154	plasma	O
2154	p	O
2154	##har	O
2154	##ma	O
2154	##co	O
2154	##kin	O
2154	##etic	O
2154	parameters	O
2154	were	O
2154	used	O
2154	including	O
2154	the	O
2154	maximum	B-PK
2154	plasma	I-PK
2154	concentration	I-PK
2154	(	I-PK
2154	cm	I-PK
2154	##ax	I-PK
2154	)	I-PK
2154	,	O
2154	time	B-PK
2154	to	I-PK
2154	cm	I-PK
2154	##ax	I-PK
2154	(	I-PK
2154	t	I-PK
2154	##max	I-PK
2154	)	I-PK
2154	,	O
2154	area	B-PK
2154	under	I-PK
2154	the	I-PK
2154	plasma	I-PK
2154	concentration	I-PK
2154	–	I-PK
2154	time	I-PK
2154	curve	I-PK
2154	to	I-PK
2154	the	I-PK
2154	time	I-PK
2154	of	I-PK
2154	the	I-PK
2154	last	I-PK
2154	me	I-PK
2154	##as	I-PK
2154	##urable	I-PK
2154	concentration	I-PK
2154	(	I-PK
2154	au	I-PK
2154	##c	I-PK
2154	##0	I-PK
2154	–	I-PK
2154	last	I-PK
2154	)	I-PK
2154	or	I-PK
2154	in	I-PK
2154	##finity	I-PK
2154	(	I-PK
2154	au	I-PK
2154	##c	I-PK
2154	##0	I-PK
2154	–	I-PK
2154	∞	I-PK
2154	)	I-PK
2154	,	O
2154	clearance	B-PK
2154	,	O
2154	and	O
2154	terminal	B-PK
2154	elimination	I-PK
2154	half	I-PK
2154	-	I-PK
2154	life	I-PK
2154	(	I-PK
2154	t	I-PK
2154	##1	I-PK
2154	/	I-PK
2154	2	I-PK
2154	)	I-PK
2154	.	O
2154	[SEP]	O
2155	[CLS]	O
2155	plasma	O
2155	do	O
2155	##lut	O
2155	##eg	O
2155	##ra	O
2155	##vir	O
2155	au	B-PK
2155	##c	I-PK
2155	(	I-PK
2155	0	I-PK
2155	–	I-PK
2155	∞	I-PK
2155	)	I-PK
2155	,	O
2155	cm	B-PK
2155	##ax	I-PK
2155	,	O
2155	and	O
2155	c	O
2155	##24	O
2155	were	O
2155	reduced	O
2155	by	O
2155	39	O
2155	%	O
2155	,	O
2155	37	O
2155	%	O
2155	,	O
2155	and	O
2155	39	O
2155	%	O
2155	,	O
2155	respectively	O
2155	,	O
2155	when	O
2155	co	O
2155	-	O
2155	administered	O
2155	with	O
2155	calcium	O
2155	carbon	O
2155	##ate	O
2155	while	O
2155	fast	O
2155	##ing	O
2155	and	O
2155	were	O
2155	reduced	O
2155	by	O
2155	54	O
2155	%	O
2155	,	O
2155	57	O
2155	%	O
2155	,	O
2155	and	O
2155	56	O
2155	%	O
2155	,	O
2155	respectively	O
2155	,	O
2155	when	O
2155	co	O
2155	-	O
2155	administered	O
2155	with	O
2155	f	O
2155	##er	O
2155	##rous	O
2155	f	O
2155	##uma	O
2155	##rate	O
2155	while	O
2155	fast	O
2155	##ing	O
2155	.	O
2155	[SEP]	O
2156	[CLS]	O
2156	this	O
2156	study	O
2156	was	O
2156	planned	O
2156	to	O
2156	en	O
2156	##roll	O
2156	24	O
2156	eligible	O
2156	subjects	O
2156	who	O
2156	were	O
2156	random	O
2156	##ized	O
2156	into	O
2156	1	O
2156	of	O
2156	the	O
2156	2	O
2156	co	O
2156	##hor	O
2156	##ts	O
2156	(	O
2156	calcium	O
2156	or	O
2156	iron	O
2156	)	O
2156	(	O
2156	table	O
2156	##1	O
2156	)	O
2156	and	O
2156	received	O
2156	each	O
2156	of	O
2156	4	O
2156	treatments	O
2156	in	O
2156	a	O
2156	random	O
2156	##ized	O
2156	fashion	O
2156	:	O
2156	(	O
2156	1	O
2156	)	O
2156	a	O
2156	single	O
2156	dose	O
2156	of	O
2156	do	O
2156	##lut	O
2156	##eg	O
2156	##ra	O
2156	##vir	O
2156	50	O
2156	mg	O
2156	administered	O
2156	under	O
2156	fast	O
2156	##ed	O
2156	conditions	O
2156	(	O
2156	treatment	O
2156	a	O
2156	)	O
2156	;	O
2156	(	O
2156	2	O
2156	)	O
2156	a	O
2156	single	O
2156	dose	O
2156	of	O
2156	do	O
2156	##lut	O
2156	##eg	O
2156	##ra	O
2156	##vir	O
2156	50	O
2156	mg	O
2156	co	O
2156	-	O
2156	administered	O
2156	with	O
2156	a	O
2156	single	O
2156	dose	O
2156	of	O
2156	calcium	O
2156	carbon	O
2156	##ate	O
2156	(	O
2156	treatment	O
2156	b	O
2156	)	O
2156	or	O
2156	f	O
2156	##er	O
2156	##rous	O
2156	f	O
2156	##uma	O
2156	##rate	O
2156	(	O
2156	treatment	O
2156	e	O
2156	)	O
2156	under	O
2156	fast	O
2156	##ed	O
2156	conditions	O
2156	;	O
2156	(	O
2156	3	O
2156	)	O
2156	a	O
2156	single	O
2156	dose	O
2156	of	O
2156	do	O
2156	##lut	O
2156	##eg	O
2156	##ra	O
2156	##vir	O
2156	50	O
2156	mg	O
2156	co	O
2156	-	O
2156	administered	O
2156	with	O
2156	a	O
2156	single	O
2156	dose	O
2156	of	O
2156	calcium	O
2156	carbon	O
2156	##ate	O
2156	(	O
2156	treatment	O
2156	c	O
2156	)	O
2156	or	O
2156	f	O
2156	##er	O
2156	##rous	O
2156	f	O
2156	##uma	O
2156	##rate	O
2156	(	O
2156	treatment	O
2156	f	O
2156	)	O
2156	with	O
2156	a	O
2156	moderate	O
2156	-	O
2156	fat	O
2156	meal	O
2156	(	O
2156	approximately	O
2156	30	O
2156	%	O
2156	fat	O
2156	)	O
2156	;	O
2156	and	O
2156	(	O
2156	4	O
2156	)	O
2156	a	O
2156	single	O
2156	dose	O
2156	of	O
2156	do	O
2156	##lut	O
2156	##eg	O
2156	##ra	O
2156	##vir	O
2156	50	O
2156	mg	O
2156	administered	O
2156	under	O
2156	fast	O
2156	##ed	O
2156	conditions	O
2156	2	O
2156	hours	O
2156	prior	O
2156	to	O
2156	administration	O
2156	of	O
2156	a	O
2156	single	O
2156	dose	O
2156	of	O
2156	calcium	O
2156	carbon	O
2156	##ate	O
2156	(	O
2156	treatment	O
2156	d	O
2156	)	O
2156	or	O
2156	f	O
2156	##er	O
2156	##rous	O
2156	f	O
2156	##uma	O
2156	##rate	O
2156	(	O
2156	treatment	O
2156	g	O
2156	)	O
2156	.	O
2156	[SEP]	O
2157	[CLS]	O
2157	in	O
2157	a	O
2157	study	O
2157	with	O
2157	do	O
2157	##lut	O
2157	##eg	O
2157	##ra	O
2157	##vir	O
2157	,	O
2157	concurrent	O
2157	administration	O
2157	of	O
2157	maximum	O
2157	strength	O
2157	ma	O
2157	##alo	O
2157	##x	O
2157	##®	O
2157	(	O
2157	containing	O
2157	al	O
2157	##3	O
2157	+	O
2157	and	O
2157	mg	O
2157	##2	O
2157	+	O
2157	;	O
2157	no	O
2157	##var	O
2157	##tis	O
2157	consumer	O
2157	health	O
2157	,	O
2157	par	O
2157	##si	O
2157	##ppan	O
2157	##y	O
2157	,	O
2157	new	O
2157	jersey	O
2157	)	O
2157	under	O
2157	fast	O
2157	##ed	O
2157	conditions	O
2157	decreased	O
2157	do	O
2157	##lut	O
2157	##eg	O
2157	##ra	O
2157	##vir	O
2157	mean	O
2157	area	B-PK
2157	under	I-PK
2157	the	I-PK
2157	plasma	I-PK
2157	concentration	I-PK
2157	-	I-PK
2157	time	I-PK
2157	curve	I-PK
2157	(	I-PK
2157	au	I-PK
2157	##c	I-PK
2157	)	I-PK
2157	,	O
2157	maximum	B-PK
2157	observed	I-PK
2157	plasma	I-PK
2157	concentration	I-PK
2157	(	I-PK
2157	cm	I-PK
2157	##ax	I-PK
2157	)	I-PK
2157	,	O
2157	and	O
2157	plasma	O
2157	concentration	O
2157	at	O
2157	24	O
2157	hours	O
2157	post	O
2157	-	O
2157	dose	O
2157	(	O
2157	c	O
2157	##24	O
2157	)	O
2157	by	O
2157	74	O
2157	%	O
2157	,	O
2157	72	O
2157	%	O
2157	,	O
2157	and	O
2157	74	O
2157	%	O
2157	,	O
2157	respectively	O
2157	,	O
2157	and	O
2157	administration	O
2157	of	O
2157	ma	O
2157	##alo	O
2157	##x	O
2157	2	O
2157	hours	O
2157	after	O
2157	do	O
2157	##lut	O
2157	##eg	O
2157	##ra	O
2157	##vir	O
2157	administration	O
2157	decreased	O
2157	do	O
2157	##lut	O
2157	##eg	O
2157	##ra	O
2157	##vir	O
2157	mean	O
2157	au	B-PK
2157	##c	I-PK
2157	,	O
2157	cm	B-PK
2157	##ax	I-PK
2157	,	O
2157	and	O
2157	c	O
2157	##24	O
2157	by	O
2157	26	O
2157	%	O
2157	,	O
2157	18	O
2157	%	O
2157	,	O
2157	and	O
2157	30	O
2157	%	O
2157	,	O
2157	respectively	O
2157	.	O
2157	8	O
2157	these	O
2157	data	O
2157	resulted	O
2157	in	O
2157	the	O
2157	recommendation	O
2157	that	O
2157	con	O
2157	##com	O
2157	##ita	O
2157	##nt	O
2157	administration	O
2157	of	O
2157	do	O
2157	##lut	O
2157	##eg	O
2157	##ra	O
2157	##vir	O
2157	and	O
2157	ant	O
2157	##ac	O
2157	##ids	O
2157	should	O
2157	be	O
2157	avoided	O
2157	.	O
2157	[SEP]	O
2158	[CLS]	O
2158	p	O
2158	##har	O
2158	##ma	O
2158	##co	O
2158	##kin	O
2158	##etic	O
2158	parameters	O
2158	that	O
2158	were	O
2158	determined	O
2158	included	O
2158	cm	B-PK
2158	##ax	I-PK
2158	,	O
2158	au	B-PK
2158	##c	I-PK
2158	from	I-PK
2158	time	I-PK
2158	zero	I-PK
2158	to	I-PK
2158	the	I-PK
2158	time	I-PK
2158	of	I-PK
2158	last	I-PK
2158	q	I-PK
2158	##uant	I-PK
2158	##ifiable	I-PK
2158	concentration	I-PK
2158	(	I-PK
2158	au	I-PK
2158	##c	I-PK
2158	[	I-PK
2158	0	I-PK
2158	–	I-PK
2158	t	I-PK
2158	]	I-PK
2158	)	I-PK
2158	,	O
2158	au	B-PK
2158	##c	I-PK
2158	from	I-PK
2158	time	I-PK
2158	zero	I-PK
2158	extra	I-PK
2158	##pol	I-PK
2158	##ated	I-PK
2158	to	I-PK
2158	in	I-PK
2158	##finity	I-PK
2158	(	I-PK
2158	au	I-PK
2158	##c	I-PK
2158	[	I-PK
2158	0	I-PK
2158	–	I-PK
2158	∞	I-PK
2158	]	I-PK
2158	)	I-PK
2158	,	O
2158	c	O
2158	##24	O
2158	,	O
2158	and	O
2158	time	B-PK
2158	of	I-PK
2158	occurrence	I-PK
2158	of	I-PK
2158	cm	I-PK
2158	##ax	I-PK
2158	(	I-PK
2158	t	I-PK
2158	##max	I-PK
2158	)	I-PK
2158	.	O
2158	[SEP]	O
2159	[CLS]	O
2159	t	B-PK
2159	##max	I-PK
2159	was	O
2159	analyzed	O
2159	non	O
2159	##par	O
2159	##ame	O
2159	##tric	O
2159	##ally	O
2159	for	O
2159	the	O
2159	treatment	O
2159	differences	O
2159	of	O
2159	interest	O
2159	using	O
2159	the	O
2159	w	O
2159	##il	O
2159	##co	O
2159	##xon	O
2159	'	O
2159	s	O
2159	matched	O
2159	-	O
2159	pairs	O
2159	method	O
2159	.	O
2159	[SEP]	O
2160	[CLS]	O
2160	when	O
2160	compared	O
2160	to	O
2160	mice	O
2160	fed	O
2160	the	O
2160	standard	O
2160	rode	O
2160	##nt	O
2160	ch	O
2160	##ow	O
2160	diet	O
2160	(	O
2160	s	O
2160	##rc	O
2160	##d	O
2160	)	O
2160	,	O
2160	we	O
2160	found	O
2160	that	O
2160	mice	O
2160	fed	O
2160	the	O
2160	k	O
2160	##d	O
2160	were	O
2160	more	O
2160	sensitive	O
2160	to	O
2160	electro	O
2160	##con	O
2160	##vu	O
2160	##ls	O
2160	##ions	O
2160	as	O
2160	reflected	O
2160	by	O
2160	a	O
2160	significant	O
2160	decrease	O
2160	in	O
2160	seizure	O
2160	threshold	O
2160	(	O
2160	3	O
2160	.	O
2160	86	O
2160	ma	O
2160	in	O
2160	mice	O
2160	on	O
2160	the	O
2160	k	O
2160	##d	O
2160	vs	O
2160	7	O
2160	.	O
2160	29	O
2160	ma	O
2160	in	O
2160	mice	O
2160	on	O
2160	the	O
2160	s	O
2160	##rc	O
2160	##d	O
2160	;	O
2160	p	O
2160	<	O
2160	0	O
2160	.	O
2160	05	O
2160	)	O
2160	in	O
2160	the	O
2160	ma	O
2160	##ximal	O
2160	electro	O
2160	##sh	O
2160	##ock	O
2160	seizure	O
2160	threshold	O
2160	(	O
2160	me	O
2160	##st	O
2160	)	O
2160	test	O
2160	.	O
2160	[SEP]	O
2161	[CLS]	O
2161	the	O
2161	variables	O
2161	cm	B-PK
2161	##ax	I-PK
2161	and	O
2161	t	B-PK
2161	##max	I-PK
2161	were	O
2161	directly	O
2161	read	O
2161	from	O
2161	the	O
2161	plasma	O
2161	concentration	O
2161	–	O
2161	time	O
2161	profiles	O
2161	,	O
2161	au	B-PK
2161	##c	I-PK
2161	from	I-PK
2161	time	I-PK
2161	zero	I-PK
2161	to	I-PK
2161	the	I-PK
2161	time	I-PK
2161	of	I-PK
2161	the	I-PK
2161	last	I-PK
2161	me	I-PK
2161	##as	I-PK
2161	##urable	I-PK
2161	concentration	I-PK
2161	(	I-PK
2161	au	I-PK
2161	##c	I-PK
2161	##0	I-PK
2161	–	I-PK
2161	t	I-PK
2161	)	I-PK
2161	was	O
2161	calculated	O
2161	using	O
2161	the	O
2161	trap	O
2161	##ez	O
2161	##oid	O
2161	##al	O
2161	method	O
2161	[	O
2161	14	O
2161	]	O
2161	,	O
2161	and	O
2161	t	B-PK
2161	##½	I-PK
2161	was	O
2161	calculated	O
2161	as	O
2161	l	O
2161	##n	O
2161	2	O
2161	/	O
2161	λ	O
2161	##z	O
2161	,	O
2161	where	O
2161	λ	B-PK
2161	##z	I-PK
2161	is	O
2161	the	O
2161	terminal	B-PK
2161	elimination	I-PK
2161	rate	I-PK
2161	constant	I-PK
2161	estimated	O
2161	by	O
2161	log	O
2161	-	O
2161	linear	O
2161	re	O
2161	##gression	O
2161	analysis	O
2161	.	O
2161	[SEP]	O
2162	[CLS]	O
2162	p	O
2162	##har	O
2162	##ma	O
2162	##co	O
2162	##kin	O
2162	##etic	O
2162	variables	O
2162	were	O
2162	analyzed	O
2162	descriptive	O
2162	##ly	O
2162	,	O
2162	providing	O
2162	geometric	O
2162	means	O
2162	and	O
2162	95	O
2162	%	O
2162	confidence	O
2162	intervals	O
2162	(	O
2162	c	O
2162	##is	O
2162	)	O
2162	for	O
2162	cm	B-PK
2162	##ax	I-PK
2162	,	O
2162	au	B-PK
2162	##c	I-PK
2162	from	I-PK
2162	time	I-PK
2162	zero	I-PK
2162	to	I-PK
2162	in	I-PK
2162	##finity	I-PK
2162	(	I-PK
2162	au	I-PK
2162	##c	I-PK
2162	##0	I-PK
2162	–	I-PK
2162	in	I-PK
2162	##f	I-PK
2162	)	I-PK
2162	,	O
2162	au	B-PK
2162	##c	I-PK
2162	##0	I-PK
2162	–	I-PK
2162	t	I-PK
2162	(	O
2162	i	O
2162	.	O
2162	e	O
2162	.	O
2162	,	O
2162	au	B-PK
2162	##c	I-PK
2162	from	I-PK
2162	time	I-PK
2162	zero	I-PK
2162	to	I-PK
2162	144	I-PK
2162	h	I-PK
2162	[	I-PK
2162	au	I-PK
2162	##c	I-PK
2162	##0	I-PK
2162	–	I-PK
2162	144	I-PK
2162	##h	I-PK
2162	]	I-PK
2162	)	O
2162	,	O
2162	and	O
2162	t	B-PK
2162	##½	I-PK
2162	.	O
2162	for	O
2162	t	B-PK
2162	##max	I-PK
2162	,	O
2162	the	O
2162	median	O
2162	with	O
2162	minimum	O
2162	and	O
2162	maximum	O
2162	values	O
2162	were	O
2162	calculated	O
2162	and	O
2162	reported	O
2162	.	O
2162	[SEP]	O
2163	[CLS]	O
2163	differences	O
2163	in	O
2163	t	B-PK
2163	##max	I-PK
2163	were	O
2163	explored	O
2163	using	O
2163	the	O
2163	non	O
2163	##par	O
2163	##ame	O
2163	##tric	O
2163	w	O
2163	##il	O
2163	##co	O
2163	##xon	O
2163	signed	O
2163	-	O
2163	rank	O
2163	test	O
2163	.	O
2163	[SEP]	O
2164	[CLS]	O
2164	in	O
2164	study	O
2164	1	O
2164	,	O
2164	the	O
2164	plasma	O
2164	concentration	O
2164	–	O
2164	time	O
2164	profiles	O
2164	of	O
2164	p	O
2164	##ones	O
2164	##imo	O
2164	##d	O
2164	were	O
2164	characterized	O
2164	by	O
2164	a	O
2164	median	O
2164	t	B-PK
2164	##max	I-PK
2164	of	O
2164	4	O
2164	h	O
2164	for	O
2164	both	O
2164	p	O
2164	##oly	O
2164	##morphic	O
2164	forms	O
2164	in	O
2164	capsule	O
2164	##s	O
2164	(	O
2164	fi	O
2164	##g	O
2164	.	O
2164	1	O
2164	##a	O
2164	;	O
2164	table	O
2164	1	O
2164	)	O
2164	.	O
2164	[SEP]	O
2165	[CLS]	O
2165	the	O
2165	following	O
2165	p	O
2165	##har	O
2165	##ma	O
2165	##co	O
2165	##kin	O
2165	##etic	O
2165	parameters	O
2165	for	O
2165	h	O
2165	##ydro	O
2165	##co	O
2165	##don	O
2165	##e	O
2165	and	O
2165	h	O
2165	##ydro	O
2165	##mor	O
2165	##phone	O
2165	were	O
2165	calculated	O
2165	for	O
2165	each	O
2165	active	O
2165	treatment	O
2165	using	O
2165	non	O
2165	##com	O
2165	##par	O
2165	##tment	O
2165	##al	O
2165	analysis	O
2165	:	O
2165	maximum	B-PK
2165	plasma	I-PK
2165	drug	I-PK
2165	concentration	I-PK
2165	(	I-PK
2165	cm	I-PK
2165	##ax	I-PK
2165	;	O
2165	by	O
2165	inspection	O
2165	and	O
2165	without	O
2165	inter	O
2165	##pol	O
2165	##ation	O
2165	)	O
2165	,	O
2165	time	B-PK
2165	to	I-PK
2165	cm	I-PK
2165	##ax	I-PK
2165	(	I-PK
2165	t	I-PK
2165	##max	I-PK
2165	;	O
2165	by	O
2165	inspection	O
2165	)	O
2165	,	O
2165	area	B-PK
2165	under	I-PK
2165	the	I-PK
2165	plasma	I-PK
2165	concentration	I-PK
2165	-	I-PK
2165	time	I-PK
2165	curve	I-PK
2165	(	I-PK
2165	au	I-PK
2165	##c	I-PK
2165	)	I-PK
2165	from	I-PK
2165	0	I-PK
2165	to	I-PK
2165	0	I-PK
2165	.	I-PK
2165	75	I-PK
2165	hours	I-PK
2165	after	I-PK
2165	study	I-PK
2165	drug	I-PK
2165	administration	I-PK
2165	(	I-PK
2165	au	I-PK
2165	##c	I-PK
2165	##0	I-PK
2165	–	I-PK
2165	0	I-PK
2165	.	I-PK
2165	75	I-PK
2165	;	O
2165	closest	O
2165	sampling	O
2165	time	O
2165	to	O
2165	median	O
2165	t	O
2165	##max	O
2165	for	O
2165	h	O
2165	##ydro	O
2165	##co	O
2165	##don	O
2165	##e	O
2165	i	O
2165	##r	O
2165	)	O
2165	,	O
2165	au	B-PK
2165	##c	I-PK
2165	from	I-PK
2165	0	I-PK
2165	to	I-PK
2165	4	I-PK
2165	hours	I-PK
2165	(	I-PK
2165	au	I-PK
2165	##c	I-PK
2165	##0	I-PK
2165	-	I-PK
2165	4	I-PK
2165	;	O
2165	closest	O
2165	sampling	O
2165	time	O
2165	to	O
2165	median	O
2165	t	B-PK
2165	##max	I-PK
2165	for	O
2165	finely	O
2165	crushed	O
2165	h	O
2165	##ydro	O
2165	##co	O
2165	##don	O
2165	##e	O
2165	er	O
2165	)	O
2165	,	O
2165	au	B-PK
2165	##c	I-PK
2165	from	I-PK
2165	0	I-PK
2165	to	I-PK
2165	7	I-PK
2165	hours	I-PK
2165	(	I-PK
2165	au	I-PK
2165	##c	I-PK
2165	##0	I-PK
2165	–	I-PK
2165	7	I-PK
2165	;	O
2165	closest	O
2165	sampling	O
2165	time	O
2165	to	O
2165	median	O
2165	t	B-PK
2165	##max	I-PK
2165	for	O
2165	intact	O
2165	h	O
2165	##ydro	O
2165	##co	O
2165	##don	O
2165	##e	O
2165	er	O
2165	)	O
2165	,	O
2165	au	B-PK
2165	##c	I-PK
2165	from	I-PK
2165	time	I-PK
2165	0	I-PK
2165	to	I-PK
2165	the	I-PK
2165	time	I-PK
2165	of	I-PK
2165	the	I-PK
2165	last	I-PK
2165	me	I-PK
2165	##as	I-PK
2165	##urable	I-PK
2165	drug	I-PK
2165	concentration	I-PK
2165	(	I-PK
2165	au	I-PK
2165	##c	I-PK
2165	##0	I-PK
2165	–	I-PK
2165	t	I-PK
2165	)	I-PK
2165	,	O
2165	au	B-PK
2165	##c	I-PK
2165	from	I-PK
2165	time	I-PK
2165	0	I-PK
2165	to	I-PK
2165	in	I-PK
2165	##finity	I-PK
2165	(	I-PK
2165	au	I-PK
2165	##c	I-PK
2165	##0	I-PK
2165	–	I-PK
2165	∞	I-PK
2165	)	I-PK
2165	,	O
2165	apparent	B-PK
2165	plasma	I-PK
2165	terminal	I-PK
2165	elimination	I-PK
2165	rate	I-PK
2165	constant	I-PK
2165	(	I-PK
2165	λ	I-PK
2165	##z	I-PK
2165	)	I-PK
2165	,	O
2165	elimination	B-PK
2165	half	I-PK
2165	-	I-PK
2165	life	I-PK
2165	(	I-PK
2165	t	I-PK
2165	##1	I-PK
2165	/	I-PK
2165	2	I-PK
2165	)	I-PK
2165	,	O
2165	abuse	B-PK
2165	q	I-PK
2165	##uo	I-PK
2165	##tien	I-PK
2165	##t	I-PK
2165	(	O
2165	calculated	O
2165	as	O
2165	cm	B-PK
2165	##ax	I-PK
2165	/	I-PK
2165	t	I-PK
2165	##max	I-PK
2165	)	O
2165	,	O
2165	and	O
2165	percent	O
2165	extra	O
2165	##pol	O
2165	##ation	O
2165	(	O
2165	calculated	O
2165	as	O
2165	100	O
2165	x	O
2165	[	O
2165	au	O
2165	##c	O
2165	##0	O
2165	–	O
2165	∞	O
2165	–	O
2165	au	O
2165	##c	O
2165	##0	O
2165	–	O
2165	t	O
2165	]	O
2165	/	O
2165	au	O
2165	##c	O
2165	##0	O
2165	–	O
2165	∞	O
2165	)	O
2165	.	O
2165	[SEP]	O
2166	[CLS]	O
2166	significantly	O
2166	lower	O
2166	em	B-PK
2166	##ax	I-PK
2166	values	O
2166	for	O
2166	the	O
2166	l	O
2166	##s	O
2166	##d	O
2166	sub	O
2166	##sca	O
2166	##le	O
2166	of	O
2166	the	O
2166	arc	O
2166	##i	O
2166	were	O
2166	observed	O
2166	for	O
2166	intact	O
2166	and	O
2166	finely	O
2166	crushed	O
2166	h	O
2166	##ydro	O
2166	##co	O
2166	##don	O
2166	##e	O
2166	er	O
2166	compared	O
2166	with	O
2166	h	O
2166	##ydro	O
2166	##co	O
2166	##don	O
2166	##e	O
2166	i	O
2166	##r	O
2166	(	O
2166	4	O
2166	.	O
2166	4	O
2166	and	O
2166	4	O
2166	.	O
2166	7	O
2166	vs	O
2166	.	O
2166	6	O
2166	.	O
2166	2	O
2166	;	O
2166	p	O
2166	<	O
2166	0	O
2166	.	O
2166	00	O
2166	##1	O
2166	)	O
2166	;	O
2166	however	O
2166	,	O
2166	the	O
2166	au	O
2166	##ec	O
2166	for	O
2166	the	O
2166	l	O
2166	##s	O
2166	##d	O
2166	sub	O
2166	##sca	O
2166	##le	O
2166	was	O
2166	comparable	O
2166	across	O
2166	treatments	O
2166	,	O
2166	with	O
2166	no	O
2166	significant	O
2166	differences	O
2166	.	O
2166	[SEP]	O
2167	[CLS]	O
2167	cm	B-PK
2167	##ax	I-PK
2167	was	O
2167	lowest	O
2167	for	O
2167	intact	O
2167	h	O
2167	##ydro	O
2167	##co	O
2167	##don	O
2167	##e	O
2167	er	O
2167	(	O
2167	28	O
2167	.	O
2167	8	O
2167	ng	O
2167	/	O
2167	m	O
2167	##l	O
2167	)	O
2167	.	O
2167	[SEP]	O
2168	[CLS]	O
2168	the	O
2168	rate	B-PK
2168	of	I-PK
2168	absorption	I-PK
2168	of	O
2168	h	O
2168	##ydro	O
2168	##co	O
2168	##don	O
2168	##e	O
2168	was	O
2168	slow	O
2168	##est	O
2168	for	O
2168	intact	O
2168	h	O
2168	##ydro	O
2168	##co	O
2168	##don	O
2168	##e	O
2168	er	O
2168	,	O
2168	with	O
2168	a	O
2168	t	B-PK
2168	##max	I-PK
2168	of	O
2168	7	O
2168	.	O
2168	1	O
2168	hours	O
2168	,	O
2168	compared	O
2168	with	O
2168	the	O
2168	t	B-PK
2168	##max	I-PK
2168	for	O
2168	finely	O
2168	crushed	O
2168	h	O
2168	##ydro	O
2168	##co	O
2168	##don	O
2168	##e	O
2168	er	O
2168	(	O
2168	4	O
2168	.	O
2168	0	O
2168	hours	O
2168	)	O
2168	and	O
2168	h	O
2168	##ydro	O
2168	##co	O
2168	##don	O
2168	##e	O
2168	i	O
2168	##r	O
2168	(	O
2168	0	O
2168	.	O
2168	8	O
2168	hours	O
2168	)	O
2168	.	O
2168	[SEP]	O
2169	[CLS]	O
2169	exposure	O
2169	before	O
2169	t	B-PK
2169	##max	I-PK
2169	for	O
2169	h	O
2169	##ydro	O
2169	##co	O
2169	##don	O
2169	##e	O
2169	i	O
2169	##r	O
2169	(	O
2169	au	B-PK
2169	##c	I-PK
2169	##0	I-PK
2169	–	I-PK
2169	0	I-PK
2169	.	I-PK
2169	75	I-PK
2169	)	O
2169	and	O
2169	before	O
2169	t	B-PK
2169	##max	I-PK
2169	for	O
2169	intact	O
2169	h	O
2169	##ydro	O
2169	##co	O
2169	##don	O
2169	##e	O
2169	er	O
2169	(	O
2169	au	B-PK
2169	##c	I-PK
2169	##0	I-PK
2169	–	I-PK
2169	7	I-PK
2169	)	O
2169	was	O
2169	greatest	O
2169	for	O
2169	h	O
2169	##ydro	O
2169	##co	O
2169	##don	O
2169	##e	O
2169	i	O
2169	##r	O
2169	.	O
2169	[SEP]	O
2170	[CLS]	O
2170	mean	O
2170	au	B-PK
2170	##c	I-PK
2170	##0	I-PK
2170	–	I-PK
2170	0	I-PK
2170	.	I-PK
2170	75	I-PK
2170	and	O
2170	au	B-PK
2170	##c	I-PK
2170	##0	I-PK
2170	–	I-PK
2170	7	I-PK
2170	for	O
2170	intact	O
2170	h	O
2170	##ydro	O
2170	##co	O
2170	##don	O
2170	##e	O
2170	er	O
2170	were	O
2170	97	O
2170	%	O
2170	and	O
2170	72	O
2170	%	O
2170	lower	O
2170	,	O
2170	respectively	O
2170	,	O
2170	than	O
2170	for	O
2170	h	O
2170	##ydro	O
2170	##co	O
2170	##don	O
2170	##e	O
2170	i	O
2170	##r	O
2170	.	O
2170	[SEP]	O
2171	[CLS]	O
2171	the	O
2171	following	O
2171	relationships	O
2171	between	O
2171	the	O
2171	au	B-PK
2171	##c	I-PK
2171	of	O
2171	cape	O
2171	##ci	O
2171	##ta	O
2171	##bine	O
2171	meta	O
2171	##bol	O
2171	##ites	O
2171	and	O
2171	patient	O
2171	-	O
2171	reported	O
2171	symptoms	O
2171	measured	O
2171	during	O
2171	the	O
2171	same	O
2171	cycle	O
2171	were	O
2171	found	O
2171	:	O
2171	au	B-PK
2171	##c	I-PK
2171	5	O
2171	′	O
2171	-	O
2171	d	O
2171	##fu	O
2171	##r	O
2171	and	O
2171	weight	O
2171	loss	O
2171	(	O
2171	or	O
2171	1	O
2171	.	O
2171	10	O
2171	,	O
2171	95	O
2171	%	O
2171	c	O
2171	##i	O
2171	:	O
2171	1	O
2171	.	O
2171	01	O
2171	–	O
2171	1	O
2171	.	O
2171	19	O
2171	)	O
2171	,	O
2171	au	B-PK
2171	##c	I-PK
2171	f	O
2171	##bal	O
2171	and	O
2171	h	O
2171	##fs	O
2171	(	O
2171	or	O
2171	0	O
2171	.	O
2171	90	O
2171	,	O
2171	95	O
2171	%	O
2171	c	O
2171	##i	O
2171	:	O
2171	0	O
2171	.	O
2171	83	O
2171	–	O
2171	0	O
2171	.	O
2171	99	O
2171	)	O
2171	,	O
2171	au	B-PK
2171	##c	I-PK
2171	f	O
2171	##bal	O
2171	and	O
2171	r	O
2171	##hino	O
2171	##rr	O
2171	##hea	O
2171	(	O
2171	or	O
2171	1	O
2171	.	O
2171	21	O
2171	,	O
2171	95	O
2171	%	O
2171	c	O
2171	##i	O
2171	:	O
2171	1	O
2171	.	O
2171	03	O
2171	–	O
2171	1	O
2171	.	O
2171	42	O
2171	)	O
2171	,	O
2171	au	B-PK
2171	##c	I-PK
2171	f	O
2171	##bal	O
2171	and	O
2171	weight	O
2171	loss	O
2171	(	O
2171	or	O
2171	1	O
2171	.	O
2171	09	O
2171	,	O
2171	95	O
2171	%	O
2171	c	O
2171	##i	O
2171	:	O
2171	1	O
2171	.	O
2171	00	O
2171	–	O
2171	1	O
2171	.	O
2171	20	O
2171	)	O
2171	,	O
2171	and	O
2171	au	B-PK
2171	##c	I-PK
2171	f	O
2171	##bal	O
2171	and	O
2171	depression	O
2171	(	O
2171	or	O
2171	0	O
2171	.	O
2171	90	O
2171	,	O
2171	95	O
2171	%	O
2171	c	O
2171	##i	O
2171	:	O
2171	0	O
2171	.	O
2171	82	O
2171	–	O
2171	0	O
2171	.	O
2171	99	O
2171	)	O
2171	(	O
2171	p	O
2171	<	O
2171	0	O
2171	.	O
2171	05	O
2171	)	O
2171	(	O
2171	supplement	O
2171	##ary	O
2171	table	O
2171	s	O
2171	##5	O
2171	)	O
2171	.	O
2171	[SEP]	O
2172	[CLS]	O
2172	the	O
2172	oral	B-PK
2172	maximum	I-PK
2172	plasma	I-PK
2172	concentration	I-PK
2172	(	I-PK
2172	cm	I-PK
2172	##ax	I-PK
2172	)	I-PK
2172	was	O
2172	0	O
2172	.	O
2172	80	O
2172	##3	O
2172	mg	O
2172	/	O
2172	l	O
2172	,	O
2172	and	O
2172	t	B-PK
2172	##max	I-PK
2172	was	O
2172	4	O
2172	h	O
2172	.	O
2172	[SEP]	O
2173	[CLS]	O
2173	the	O
2173	oral	B-PK
2173	half	I-PK
2173	-	I-PK
2173	life	I-PK
2173	(	I-PK
2173	t	I-PK
2173	##1	I-PK
2173	/	I-PK
2173	2	I-PK
2173	)	I-PK
2173	was	O
2173	8	O
2173	.	O
2173	36	O
2173	##1	O
2173	h	O
2173	,	O
2173	and	O
2173	mean	B-PK
2173	residence	I-PK
2173	time	I-PK
2173	(	I-PK
2173	m	I-PK
2173	##rt	I-PK
2173	##0	I-PK
2173	-	I-PK
2173	t	I-PK
2173	)	I-PK
2173	was	O
2173	9	O
2173	.	O
2173	09	O
2173	##8	O
2173	h	O
2173	.	O
2173	in	O
2173	addition	O
2173	,	O
2173	r	O
2173	##ox	O
2173	##yl	O
2173	-	O
2173	z	O
2173	##h	O
2173	##c	O
2173	-	O
2173	84	O
2173	showed	O
2173	an	O
2173	oral	O
2173	apparent	B-PK
2173	distribution	I-PK
2173	volume	I-PK
2173	(	I-PK
2173	vs	I-PK
2173	##s	I-PK
2173	)	I-PK
2173	of	O
2173	12	O
2173	.	O
2173	142	O
2173	l	O
2173	/	O
2173	kg	O
2173	and	O
2173	a	O
2173	clearance	B-PK
2173	of	O
2173	1	O
2173	.	O
2173	02	O
2173	##7	O
2173	l	O
2173	/	O
2173	h	O
2173	/	O
2173	kg	O
2173	.	O
2173	[SEP]	O
2174	[CLS]	O
2174	determine	O
2174	the	O
2174	le	O
2174	##vo	O
2174	##f	O
2174	##lo	O
2174	##xa	O
2174	##cin	O
2174	au	B-PK
2174	##c	I-PK
2174	/	I-PK
2174	mi	I-PK
2174	##c	I-PK
2174	that	O
2174	provides	O
2174	the	O
2174	shortest	O
2174	time	O
2174	to	O
2174	s	O
2174	##put	O
2174	##um	O
2174	culture	O
2174	conversion	O
2174	on	O
2174	solid	O
2174	medium	O
2174	[SEP]	O
2175	[CLS]	O
2175	determine	O
2175	the	O
2175	highest	O
2175	le	O
2175	##vo	O
2175	##f	O
2175	##lo	O
2175	##xa	O
2175	##cin	O
2175	au	B-PK
2175	##c	I-PK
2175	that	O
2175	is	O
2175	both	O
2175	safe	O
2175	and	O
2175	associated	O
2175	with	O
2175	fewer	O
2175	than	O
2175	25	O
2175	%	O
2175	of	O
2175	patients	O
2175	disco	O
2175	##ntin	O
2175	##uing	O
2175	or	O
2175	reducing	O
2175	the	O
2175	dose	O
2175	of	O
2175	le	O
2175	##vo	O
2175	##f	O
2175	##lo	O
2175	##xa	O
2175	##cin	O
2175	[SEP]	O
2176	[CLS]	O
2176	a	O
2176	second	O
2176	sample	O
2176	size	O
2176	calculation	O
2176	was	O
2176	completed	O
2176	based	O
2176	on	O
2176	the	O
2176	log	O
2176	##istic	O
2176	re	O
2176	##gression	O
2176	of	O
2176	a	O
2176	binary	O
2176	response	O
2176	variable	O
2176	(	O
2176	whether	O
2176	the	O
2176	participant	O
2176	has	O
2176	completed	O
2176	6	O
2176	months	O
2176	of	O
2176	treatment	O
2176	with	O
2176	the	O
2176	assigned	O
2176	dose	O
2176	or	O
2176	not	O
2176	)	O
2176	on	O
2176	a	O
2176	continuous	O
2176	,	O
2176	normally	O
2176	distributed	O
2176	variable	O
2176	(	O
2176	au	B-PK
2176	##c	I-PK
2176	)	O
2176	.	O
2176	[SEP]	O
2177	[CLS]	O
2177	the	O
2177	estimated	O
2177	mean	O
2177	au	B-PK
2177	##c	I-PK
2177	will	O
2177	be	O
2177	140	O
2177	μ	O
2177	##g	O
2177	-	O
2177	h	O
2177	/	O
2177	m	O
2177	##l	O
2177	,	O
2177	with	O
2177	standard	O
2177	de	O
2177	##viation	O
2177	of	O
2177	about	O
2177	65	O
2177	μ	O
2177	##g	O
2177	-	O
2177	h	O
2177	/	O
2177	m	O
2177	##l	O
2177	,	O
2177	[	O
2177	14	O
2177	]	O
2177	giving	O
2177	a	O
2177	total	O
2177	of	O
2177	79	O
2177	e	O
2177	##val	O
2177	##ua	O
2177	##ble	O
2177	patients	O
2177	needed	O
2177	to	O
2177	detect	O
2177	an	O
2177	or	O
2177	of	O
2177	0	O
2177	.	O
2177	41	O
2177	##2	O
2177	between	O
2177	the	O
2177	proportion	O
2177	completing	O
2177	treatment	O
2177	at	O
2177	the	O
2177	mean	O
2177	au	B-PK
2177	##c	I-PK
2177	and	O
2177	the	O
2177	proportion	O
2177	completing	O
2177	treatment	O
2177	at	O
2177	the	O
2177	mean	O
2177	+	O
2177	1	O
2177	s	O
2177	##d	O
2177	au	B-PK
2177	##c	I-PK
2177	(	O
2177	205	O
2177	μ	O
2177	##g	O
2177	-	O
2177	h	O
2177	/	O
2177	m	O
2177	##l	O
2177	)	O
2177	.	O
2177	[SEP]	O
2178	[CLS]	O
2178	for	O
2178	the	O
2178	toxicity	O
2178	end	O
2178	##point	O
2178	,	O
2178	we	O
2178	estimated	O
2178	the	O
2178	power	O
2178	to	O
2178	detect	O
2178	a	O
2178	relationship	O
2178	between	O
2178	the	O
2178	au	B-PK
2178	##c	I-PK
2178	and	O
2178	frequency	O
2178	of	O
2178	grade	O
2178	3	O
2178	,	O
2178	4	O
2178	or	O
2178	5	O
2178	a	O
2178	##es	O
2178	,	O
2178	occurring	O
2178	up	O
2178	to	O
2178	and	O
2178	including	O
2178	the	O
2178	time	O
2178	on	O
2178	study	O
2178	drug	O
2178	plus	O
2178	4	O
2178	weeks	O
2178	post	O
2178	study	O
2178	drug	O
2178	completion	O
2178	.	O
2178	[SEP]	O
2179	[CLS]	O
2179	with	O
2179	79	O
2179	e	O
2179	##val	O
2179	##ua	O
2179	##ble	O
2179	participants	O
2179	,	O
2179	there	O
2179	will	O
2179	be	O
2179	80	O
2179	%	O
2179	power	O
2179	to	O
2179	detect	O
2179	an	O
2179	association	O
2179	if	O
2179	the	O
2179	proportion	O
2179	with	O
2179	a	O
2179	##es	O
2179	grade	O
2179	3	O
2179	or	O
2179	higher	O
2179	at	O
2179	mean	O
2179	au	B-PK
2179	##c	I-PK
2179	+	O
2179	1	O
2179	s	O
2179	##d	O
2179	is	O
2179	46	O
2179	%	O
2179	(	O
2179	p	O
2179	##2	O
2179	)	O
2179	and	O
2179	90	O
2179	%	O
2179	power	O
2179	if	O
2179	the	O
2179	proportion	O
2179	is	O
2179	49	O
2179	%	O
2179	.	O
2179	[SEP]	O
2180	[CLS]	O
2180	the	O
2180	number	O
2180	of	O
2180	adverse	O
2180	events	O
2180	grade	O
2180	3	O
2180	or	O
2180	higher	O
2180	will	O
2180	be	O
2180	plot	O
2180	##ted	O
2180	against	O
2180	the	O
2180	au	B-PK
2180	##c	I-PK
2180	of	O
2180	the	O
2180	individual	O
2180	in	O
2180	whom	O
2180	those	O
2180	events	O
2180	occurred	O
2180	.	O
2180	[SEP]	O
2181	[CLS]	O
2181	linear	O
2181	re	O
2181	##gression	O
2181	will	O
2181	be	O
2181	used	O
2181	to	O
2181	calculate	O
2181	the	O
2181	p	O
2181	##ear	O
2181	##son	O
2181	correlation	O
2181	coefficient	O
2181	between	O
2181	au	B-PK
2181	##c	I-PK
2181	and	O
2181	number	O
2181	and	O
2181	severity	O
2181	of	O
2181	events	O
2181	.	O
2181	[SEP]	O
2182	[CLS]	O
2182	if	O
2182	the	O
2182	distribution	O
2182	of	O
2182	the	O
2182	au	B-PK
2182	##c	I-PK
2182	is	O
2182	s	O
2182	##ke	O
2182	##wed	O
2182	,	O
2182	then	O
2182	the	O
2182	au	B-PK
2182	##c	I-PK
2182	will	O
2182	be	O
2182	log	O
2182	transformed	O
2182	.	O
2182	[SEP]	O
2183	[CLS]	O
2183	the	O
2183	resulting	O
2183	relationship	O
2183	will	O
2183	be	O
2183	used	O
2183	to	O
2183	identify	O
2183	an	O
2183	au	B-PK
2183	##c	I-PK
2183	at	O
2183	which	O
2183	more	O
2183	than	O
2183	25	O
2183	%	O
2183	of	O
2183	participants	O
2183	would	O
2183	be	O
2183	expected	O
2183	to	O
2183	have	O
2183	grade	O
2183	3	O
2183	,	O
2183	4	O
2183	,	O
2183	or	O
2183	5	O
2183	adverse	O
2183	events	O
2183	.	O
2183	[SEP]	O
2184	[CLS]	O
2184	for	O
2184	to	O
2184	##ler	O
2184	##ability	O
2184	,	O
2184	log	O
2184	##istic	O
2184	re	O
2184	##gression	O
2184	will	O
2184	be	O
2184	used	O
2184	to	O
2184	model	O
2184	the	O
2184	association	O
2184	between	O
2184	these	O
2184	variables	O
2184	with	O
2184	the	O
2184	au	B-PK
2184	##c	I-PK
2184	included	O
2184	as	O
2184	a	O
2184	continuous	O
2184	co	O
2184	##var	O
2184	##iate	O
2184	.	O
2184	[SEP]	O
2185	[CLS]	O
2185	the	O
2185	primary	O
2185	objective	O
2185	is	O
2185	to	O
2185	determine	O
2185	whether	O
2185	there	O
2185	is	O
2185	sufficient	O
2185	evidence	O
2185	to	O
2185	reject	O
2185	the	O
2185	null	O
2185	hypothesis	O
2185	that	O
2185	the	O
2185	odds	O
2185	ratio	O
2185	of	O
2185	disco	O
2185	##ntin	O
2185	##uation	O
2185	for	O
2185	a	O
2185	unit	O
2185	increase	O
2185	in	O
2185	the	O
2185	au	B-PK
2185	##c	I-PK
2185	is	O
2185	equal	O
2185	to	O
2185	1	O
2185	.	O
2185	[SEP]	O
2186	[CLS]	O
2186	using	O
2186	the	O
2186	fish	O
2186	##er	O
2186	transformation	O
2186	of	O
2186	the	O
2186	correlation	O
2186	coefficient	O
2186	,	O
2186	we	O
2186	estimated	O
2186	that	O
2186	62	O
2186	e	O
2186	##val	O
2186	##ua	O
2186	##ble	O
2186	patients	O
2186	would	O
2186	allow	O
2186	detection	O
2186	of	O
2186	moderate	O
2186	correlation	O
2186	(	O
2186	-	O
2186	0	O
2186	.	O
2186	40	O
2186	)	O
2186	between	O
2186	au	B-PK
2186	##c	I-PK
2186	/	I-PK
2186	mi	I-PK
2186	##c	I-PK
2186	and	O
2186	time	O
2186	to	O
2186	s	O
2186	##put	O
2186	##um	O
2186	-	O
2186	culture	O
2186	conversion	O
2186	with	O
2186	90	O
2186	%	O
2186	power	O
2186	and	O
2186	two	O
2186	-	O
2186	sided	O
2186	significance	O
2186	of	O
2186	5	O
2186	%	O
2186	.	O
2186	[SEP]	O
2187	[CLS]	O
2187	linear	O
2187	re	O
2187	##gression	O
2187	will	O
2187	be	O
2187	used	O
2187	to	O
2187	calculate	O
2187	the	O
2187	p	O
2187	##ear	O
2187	##son	O
2187	correlation	O
2187	coefficient	O
2187	between	O
2187	au	B-PK
2187	##c	I-PK
2187	/	I-PK
2187	mi	I-PK
2187	##c	I-PK
2187	and	O
2187	log	O
2187	-	O
2187	transformed	O
2187	time	O
2187	to	O
2187	culture	O
2187	conversion	O
2187	.	O
2187	[SEP]	O
2188	[CLS]	O
2188	the	O
2188	relationship	O
2188	will	O
2188	be	O
2188	plot	O
2188	##ted	O
2188	on	O
2188	a	O
2188	s	O
2188	##cat	O
2188	##ter	O
2188	plot	O
2188	of	O
2188	au	B-PK
2188	##c	I-PK
2188	/	I-PK
2188	mi	I-PK
2188	##c	I-PK
2188	against	O
2188	time	O
2188	to	O
2188	culture	O
2188	-	O
2188	conversion	O
2188	curve	O
2188	on	O
2188	the	O
2188	log	O
2188	scale	O
2188	.	O
2188	[SEP]	O
2189	[CLS]	O
2189	results	O
2189	:	O
2189	the	O
2189	peak	B-PK
2189	plasma	I-PK
2189	levels	I-PK
2189	of	I-PK
2189	v	I-PK
2189	##t	I-PK
2189	##b	I-PK
2189	(	I-PK
2189	cm	I-PK
2189	##ax	I-PK
2189	)	I-PK
2189	released	O
2189	from	O
2189	the	O
2189	various	O
2189	doses	O
2189	of	O
2189	verb	O
2189	ranged	O
2189	between	O
2189	6	O
2189	.	O
2189	19	O
2189	-	O
2189	17	O
2189	.	O
2189	3	O
2189	ng	O
2189	/	O
2189	m	O
2189	##l	O
2189	indicating	O
2189	a	O
2189	low	O
2189	systemic	O
2189	burst	O
2189	release	O
2189	.	O
2189	[SEP]	O
2190	[CLS]	O
2190	the	O
2190	plasma	O
2190	profile	O
2190	of	O
2190	v	O
2190	##t	O
2190	##b	O
2190	was	O
2190	consistent	O
2190	with	O
2190	a	O
2190	distribution	O
2190	phase	O
2190	up	O
2190	to	O
2190	6	O
2190	h	O
2190	after	O
2190	administration	O
2190	followed	O
2190	by	O
2190	elimination	O
2190	with	O
2190	a	O
2190	half	B-PK
2190	-	I-PK
2190	life	I-PK
2190	of	O
2190	20	O
2190	-	O
2190	23	O
2190	h	O
2190	.	O
2190	the	O
2190	au	B-PK
2190	##c	I-PK
2190	of	O
2190	v	O
2190	##t	O
2190	##b	O
2190	and	O
2190	its	O
2190	major	O
2190	meta	O
2190	##bol	O
2190	##ite	O
2190	n	O
2190	-	O
2190	des	O
2190	##met	O
2190	##hyl	O
2190	van	O
2190	##det	O
2190	##ani	O
2190	##b	O
2190	(	O
2190	n	O
2190	##d	O
2190	##m	O
2190	v	O
2190	##t	O
2190	##b	O
2190	)	O
2190	was	O
2190	approximately	O
2190	linear	O
2190	with	O
2190	the	O
2190	dose	O
2190	strength	O
2190	of	O
2190	verb	O
2190	.	O
2190	[SEP]	O
2191	[CLS]	O
2191	materials	O
2191	and	O
2191	methods	O
2191	:	O
2191	in	O
2191	a	O
2191	first	O
2191	phase	O
2191	,	O
2191	healthy	O
2191	s	O
2191	##wine	O
2191	were	O
2191	treated	O
2191	with	O
2191	he	O
2191	##pa	O
2191	##tic	O
2191	in	O
2191	##tra	O
2191	-	O
2191	art	O
2191	##erial	O
2191	administration	O
2191	of	O
2191	verb	O
2191	at	O
2191	target	O
2191	dose	O
2191	loading	O
2191	strengths	O
2191	of	O
2191	36	O
2191	mg	O
2191	/	O
2191	m	O
2191	##l	O
2191	(	O
2191	verb	O
2191	##36	O
2191	)	O
2191	,	O
2191	72	O
2191	mg	O
2191	/	O
2191	m	O
2191	##l	O
2191	(	O
2191	verb	O
2191	##7	O
2191	##2	O
2191	)	O
2191	and	O
2191	120	O
2191	mg	O
2191	/	O
2191	m	O
2191	##l	O
2191	(	O
2191	verb	O
2191	##12	O
2191	##0	O
2191	)	O
2191	.	O
2191	[SEP]	O
2192	[CLS]	O
2192	a	O
2192	4	O
2192	f	O
2192	##r	O
2192	co	O
2192	##bra	O
2192	2	O
2192	cat	O
2192	##he	O
2192	##ter	O
2192	(	O
2192	an	O
2192	##gio	O
2192	##dynamic	O
2192	##s	O
2192	in	O
2192	##c	O
2192	.	O
2192	)	O
2192	was	O
2192	then	O
2192	positioned	O
2192	in	O
2192	the	O
2192	c	O
2192	##eli	O
2192	##ac	O
2192	axis	O
2192	and	O
2192	a	O
2192	c	O
2192	##eli	O
2192	##ac	O
2192	an	O
2192	##gio	O
2192	##gram	O
2192	obtained	O
2192	by	O
2192	in	O
2192	##ject	O
2192	##ing	O
2192	contrast	O
2192	media	O
2192	.	O
2192	[SEP]	O
2193	[CLS]	O
2193	a	O
2193	2	O
2193	.	O
2193	7	O
2193	f	O
2193	##r	O
2193	micro	O
2193	##cat	O
2193	##he	O
2193	##ter	O
2193	(	O
2193	pro	O
2193	##g	O
2193	##rea	O
2193	##t	O
2193	##®	O
2193	,	O
2193	te	O
2193	##rum	O
2193	##o	O
2193	j	O
2193	##apa	O
2193	##n	O
2193	)	O
2193	was	O
2193	then	O
2193	advanced	O
2193	in	O
2193	the	O
2193	he	O
2193	##pa	O
2193	##tic	O
2193	artery	O
2193	branch	O
2193	chosen	O
2193	because	O
2193	it	O
2193	fed	O
2193	around	O
2193	50	O
2193	%	O
2193	of	O
2193	the	O
2193	liver	O
2193	volume	O
2193	.	O
2193	[SEP]	O
2194	[CLS]	O
2194	for	O
2194	each	O
2194	animal	O
2194	,	O
2194	the	O
2194	following	O
2194	toxic	O
2194	##oki	O
2194	##net	O
2194	##ic	O
2194	parameters	O
2194	were	O
2194	determined	O
2194	:	O
2194	maximum	B-PK
2194	observed	I-PK
2194	plasma	I-PK
2194	concentration	I-PK
2194	(	I-PK
2194	cm	I-PK
2194	##ax	I-PK
2194	)	I-PK
2194	,	O
2194	time	B-PK
2194	of	I-PK
2194	maximum	I-PK
2194	observed	I-PK
2194	plasma	I-PK
2194	concentration	I-PK
2194	(	I-PK
2194	t	I-PK
2194	##max	I-PK
2194	)	I-PK
2194	,	O
2194	and	O
2194	area	B-PK
2194	under	I-PK
2194	the	I-PK
2194	plasma	I-PK
2194	concentration	I-PK
2194	-	I-PK
2194	time	I-PK
2194	curve	I-PK
2194	(	I-PK
2194	au	I-PK
2194	##c	I-PK
2194	)	I-PK
2194	.	O
2194	[SEP]	O
2195	[CLS]	O
2195	half	B-PK
2195	-	I-PK
2195	life	I-PK
2195	values	I-PK
2195	(	I-PK
2195	t	I-PK
2195	##1	I-PK
2195	/	I-PK
2195	2	I-PK
2195	)	I-PK
2195	were	O
2195	reported	O
2195	for	O
2195	individual	O
2195	plasma	O
2195	concentration	O
2195	-	O
2195	time	O
2195	profiles	O
2195	that	O
2195	had	O
2195	sufficient	O
2195	plasma	O
2195	concentrations	O
2195	in	O
2195	the	O
2195	terminal	O
2195	elimination	O
2195	phase	O
2195	(	O
2195	at	O
2195	least	O
2195	three	O
2195	samples	O
2195	not	O
2195	including	O
2195	t	B-PK
2195	##max	I-PK
2195	)	O
2195	and	O
2195	an	O
2195	adjusted	O
2195	r	O
2195	##2	O
2195	of	O
2195	≥	O
2195	0	O
2195	.	O
2195	9	O
2195	.	O
2195	[SEP]	O
2196	[CLS]	O
2196	blood	O
2196	samples	O
2196	(	O
2196	approximately	O
2196	1	O
2196	m	O
2196	##l	O
2196	)	O
2196	were	O
2196	collected	O
2196	from	O
2196	all	O
2196	animals	O
2196	in	O
2196	phase	O
2196	one	O
2196	via	O
2196	the	O
2196	j	O
2196	##ug	O
2196	##ular	O
2196	or	O
2196	other	O
2196	suitable	O
2196	vein	O
2196	for	O
2196	determination	O
2196	of	O
2196	the	O
2196	plasma	O
2196	concentrations	O
2196	of	O
2196	the	O
2196	test	O
2196	article	O
2196	,	O
2196	van	O
2196	##det	O
2196	##ani	O
2196	##b	O
2196	(	O
2196	v	O
2196	##t	O
2196	##b	O
2196	)	O
2196	,	O
2196	and	O
2196	the	O
2196	meta	O
2196	##bol	O
2196	##ites	O
2196	,	O
2196	n	O
2196	‑	O
2196	des	O
2196	##met	O
2196	##hyl	O
2196	van	O
2196	##det	O
2196	##ani	O
2196	##b	O
2196	(	O
2196	n	O
2196	##d	O
2196	##m	O
2196	v	O
2196	##t	O
2196	##b	O
2196	)	O
2196	and	O
2196	van	O
2196	##det	O
2196	##ani	O
2196	##b	O
2196	n	O
2196	‑	O
2196	oxide	O
2196	(	O
2196	v	O
2196	##t	O
2196	##b	O
2196	-	O
2196	no	O
2196	)	O
2196	.	O
2196	[SEP]	O
2197	[CLS]	O
2197	individual	O
2197	v	O
2197	##t	O
2197	##b	O
2197	,	O
2197	n	O
2197	##d	O
2197	##m	O
2197	v	O
2197	##t	O
2197	##b	O
2197	,	O
2197	unknown	O
2197	meta	O
2197	##bol	O
2197	##ite	O
2197	,	O
2197	and	O
2197	v	O
2197	##t	O
2197	##b	O
2197	-	O
2197	no	O
2197	concentration	O
2197	-	O
2197	time	O
2197	profiles	O
2197	from	O
2197	o	O
2197	##v	O
2197	##t	O
2197	##b	O
2197	,	O
2197	verb	O
2197	##36	O
2197	,	O
2197	verb	O
2197	##7	O
2197	##2	O
2197	,	O
2197	or	O
2197	verb	O
2197	##12	O
2197	##0	O
2197	‑	O
2197	treated	O
2197	animals	O
2197	were	O
2197	analyzed	O
2197	using	O
2197	model	O
2197	-	O
2197	independent	O
2197	methods	O
2197	.	O
2197	[SEP]	O
2198	[CLS]	O
2198	additional	O
2198	toxic	O
2198	##oki	O
2198	##net	O
2198	##ic	O
2198	parameters	O
2198	calculated	O
2198	were	O
2198	clearance	B-PK
2198	(	I-PK
2198	c	I-PK
2198	##l	I-PK
2198	/	I-PK
2198	f	I-PK
2198	)	I-PK
2198	,	O
2198	and	O
2198	volume	B-PK
2198	of	I-PK
2198	distribution	I-PK
2198	(	I-PK
2198	v	I-PK
2198	##z	I-PK
2198	/	I-PK
2198	f	I-PK
2198	)	I-PK
2198	.	O
2198	[SEP]	O
2199	[CLS]	O
2199	following	O
2199	completion	O
2199	of	O
2199	em	O
2199	##bol	O
2199	##ization	O
2199	,	O
2199	vascular	B-PK
2199	blood	I-PK
2199	flow	I-PK
2199	within	O
2199	the	O
2199	treated	O
2199	lobe	O
2199	of	O
2199	the	O
2199	liver	O
2199	was	O
2199	assessed	O
2199	to	O
2199	evaluate	O
2199	level	O
2199	of	O
2199	vascular	O
2199	o	O
2199	##cc	O
2199	##lusion	O
2199	.	O
2199	[SEP]	O
2200	[CLS]	O
2200	figure	O
2200	1	O
2200	(	O
2200	a	O
2200	)	O
2200	shows	O
2200	that	O
2200	the	O
2200	t	B-PK
2200	##max	I-PK
2200	(	I-PK
2200	time	I-PK
2200	to	I-PK
2200	reach	I-PK
2200	cm	I-PK
2200	##ax	I-PK
2200	)	I-PK
2200	is	O
2200	achieved	O
2200	within	O
2200	approximately	O
2200	1	O
2200	hour	O
2200	of	O
2200	treatment	O
2200	administration	O
2200	for	O
2200	the	O
2200	verb	O
2200	groups	O
2200	and	O
2200	approximately	O
2200	2	O
2200	hours	O
2200	for	O
2200	o	O
2200	##v	O
2200	##t	O
2200	##b	O
2200	given	O
2200	the	O
2200	dose	O
2200	difference	O
2200	(	O
2200	21	O
2200	mg	O
2200	/	O
2200	kg	O
2200	)	O
2200	.	O
2200	[SEP]	O
2201	[CLS]	O
2201	plasma	O
2201	samples	O
2201	from	O
2201	the	O
2201	phase	O
2201	one	O
2201	study	O
2201	were	O
2201	successfully	O
2201	analyzed	O
2201	for	O
2201	concentrations	O
2201	of	O
2201	v	O
2201	##t	O
2201	##b	O
2201	,	O
2201	n	O
2201	##d	O
2201	##m	O
2201	v	O
2201	##t	O
2201	##b	O
2201	and	O
2201	v	O
2201	##t	O
2201	##b	O
2201	-	O
2201	no	O
2201	.	O
2201	[SEP]	O
2202	[CLS]	O
2202	the	O
2202	fraction	B-PK
2202	of	I-PK
2202	dose	I-PK
2202	absorbed	I-PK
2202	(	I-PK
2202	f	I-PK
2202	)	I-PK
2202	was	O
2202	not	O
2202	determined	O
2202	;	O
2202	therefore	O
2202	v	B-PK
2202	##z	I-PK
2202	/	I-PK
2202	f	I-PK
2202	and	O
2202	c	B-PK
2202	##l	I-PK
2202	/	I-PK
2202	f	I-PK
2202	were	O
2202	not	O
2202	normal	O
2202	##ized	O
2202	for	O
2202	the	O
2202	fraction	B-PK
2202	of	I-PK
2202	dose	I-PK
2202	absorbed	I-PK
2202	.	O
2202	[SEP]	O
2203	[CLS]	O
2203	figure	O
2203	1	O
2203	(	O
2203	b	O
2203	)	O
2203	shows	O
2203	that	O
2203	the	O
2203	values	O
2203	of	O
2203	the	O
2203	area	B-PK
2203	under	I-PK
2203	the	I-PK
2203	curve	I-PK
2203	(	O
2203	levels	O
2203	of	O
2203	drug	O
2203	in	O
2203	the	O
2203	plasma	O
2203	over	O
2203	time	O
2203	)	O
2203	measured	O
2203	after	O
2203	either	O
2203	24	O
2203	hours	O
2203	(	O
2203	au	B-PK
2203	##c	I-PK
2203	##0	I-PK
2203	-	I-PK
2203	24	I-PK
2203	)	O
2203	or	O
2203	until	O
2203	the	O
2203	last	O
2203	q	O
2203	##uant	O
2203	##ifiable	O
2203	measurement	O
2203	was	O
2203	made	O
2203	(	O
2203	au	B-PK
2203	##ct	I-PK
2203	##last	I-PK
2203	)	O
2203	,	O
2203	are	O
2203	linear	O
2203	##ly	O
2203	correlated	O
2203	for	O
2203	both	O
2203	v	O
2203	##t	O
2203	##b	O
2203	and	O
2203	n	O
2203	##d	O
2203	##m	O
2203	v	O
2203	##t	O
2203	##b	O
2203	with	O
2203	the	O
2203	dose	O
2203	of	O
2203	v	O
2203	##t	O
2203	##b	O
2203	administered	O
2203	in	O
2203	the	O
2203	beads	O
2203	.	O
2203	[SEP]	O
2204	[CLS]	O
2204	none	O
2204	of	O
2204	these	O
2204	treatment	O
2204	-	O
2204	related	O
2204	findings	O
2204	were	O
2204	present	O
2204	in	O
2204	the	O
2204	un	O
2204	##tre	O
2204	##ated	O
2204	liver	O
2204	section	O
2204	and	O
2204	are	O
2204	consistent	O
2204	with	O
2204	impaired	O
2204	blood	B-PK
2204	flow	I-PK
2204	with	O
2204	subsequent	O
2204	ne	O
2204	##c	O
2204	##rosis	O
2204	and	O
2204	regeneration	O
2204	.	O
2204	[SEP]	O
2205	[CLS]	O
2205	we	O
2205	h	O
2205	##y	O
2205	##pot	O
2205	##hes	O
2205	##ize	O
2205	that	O
2205	the	O
2205	observed	O
2205	trends	O
2205	after	O
2205	z	O
2205	##ea	O
2205	and	O
2205	t	O
2205	-	O
2205	2	O
2205	exposure	O
2205	are	O
2205	related	O
2205	to	O
2205	the	O
2205	c	O
2205	##yt	O
2205	##oto	O
2205	##xi	O
2205	##c	O
2205	effect	O
2205	of	O
2205	t	O
2205	-	O
2205	2	O
2205	,	O
2205	resulting	O
2205	in	O
2205	an	O
2205	increased	O
2205	absorption	B-PK
2205	rate	I-PK
2205	constant	I-PK
2205	ka	I-PK
2205	.	O
2205	[SEP]	O
2206	[CLS]	O
2206	however	O
2206	,	O
2206	oral	O
2206	plasma	O
2206	concentration	O
2206	-	O
2206	time	O
2206	profiles	O
2206	showed	O
2206	quantitative	O
2206	differences	O
2206	in	O
2206	absolute	B-PK
2206	oral	I-PK
2206	bio	I-PK
2206	##ava	I-PK
2206	##ila	I-PK
2206	##bility	I-PK
2206	f	I-PK
2206	[	O
2206	p	O
2206	-	O
2206	value	O
2206	(	O
2206	an	O
2206	##ova	O
2206	)	O
2206	=	O
2206	0	O
2206	.	O
2206	02	O
2206	##2	O
2206	]	O
2206	,	O
2206	au	B-PK
2206	##c	I-PK
2206	_	I-PK
2206	0	I-PK
2206	-	I-PK
2206	in	I-PK
2206	##f	I-PK
2206	(	O
2206	μ	O
2206	##g	O
2206	##∗	O
2206	##h	O
2206	/	O
2206	l	O
2206	)	O
2206	[	O
2206	p	O
2206	-	O
2206	value	O
2206	(	O
2206	an	O
2206	##ova	O
2206	)	O
2206	=	O
2206	0	O
2206	.	O
2206	02	O
2206	##3	O
2206	]	O
2206	,	O
2206	k	B-PK
2206	##e	I-PK
2206	(	O
2206	1	O
2206	/	O
2206	h	O
2206	)	O
2206	[	O
2206	p	O
2206	-	O
2206	value	O
2206	(	O
2206	an	O
2206	##ova	O
2206	)	O
2206	=	O
2206	0	O
2206	.	O
2206	00	O
2206	##4	O
2206	]	O
2206	,	O
2206	and	O
2206	ka	B-PK
2206	(	O
2206	1	O
2206	/	O
2206	h	O
2206	)	O
2206	[	O
2206	p	O
2206	-	O
2206	value	O
2206	(	O
2206	an	O
2206	##ova	O
2206	)	O
2206	=	O
2206	0	O
2206	.	O
2206	03	O
2206	##1	O
2206	]	O
2206	.	O
2206	[SEP]	O
2207	[CLS]	O
2207	although	O
2207	only	O
2207	differences	O
2207	in	O
2207	k	B-PK
2207	##e	I-PK
2207	estimates	O
2207	after	O
2207	oral	O
2207	administration	O
2207	reached	O
2207	significance	O
2207	in	O
2207	the	O
2207	post	O
2207	ho	O
2207	##c	O
2207	analysis	O
2207	due	O
2207	to	O
2207	inequality	O
2207	of	O
2207	the	O
2207	variance	O
2207	##s	O
2207	.	O
2207	[SEP]	O
2208	[CLS]	O
2208	oral	B-PK
2208	c	I-PK
2208	##l	I-PK
2208	and	O
2208	v	B-PK
2208	##d	I-PK
2208	were	O
2208	corrected	O
2208	for	O
2208	the	O
2208	bio	B-PK
2208	##ava	I-PK
2208	##ila	I-PK
2208	##bility	I-PK
2208	f	B-PK
2208	.	O
2208	[SEP]	O
2209	[CLS]	O
2209	a	O
2209	non	O
2209	-	O
2209	compartment	O
2209	##al	O
2209	analysis	O
2209	(	O
2209	n	O
2209	##ca	O
2209	)	O
2209	was	O
2209	performed	O
2209	to	O
2209	calculate	O
2209	the	O
2209	area	B-PK
2209	under	I-PK
2209	the	I-PK
2209	plasma	I-PK
2209	concentration	I-PK
2209	-	I-PK
2209	time	I-PK
2209	curve	I-PK
2209	(	I-PK
2209	au	I-PK
2209	##c	I-PK
2209	_	I-PK
2209	0	I-PK
2209	-	I-PK
2209	in	I-PK
2209	##f	I-PK
2209	)	I-PK
2209	,	O
2209	clearance	B-PK
2209	(	I-PK
2209	c	I-PK
2209	##l	I-PK
2209	)	I-PK
2209	,	O
2209	volume	B-PK
2209	of	I-PK
2209	distribution	I-PK
2209	(	I-PK
2209	v	I-PK
2209	##d	I-PK
2209	)	I-PK
2209	,	O
2209	and	O
2209	the	O
2209	elimination	B-PK
2209	rate	I-PK
2209	constant	I-PK
2209	(	I-PK
2209	k	I-PK
2209	##e	I-PK
2209	)	I-PK
2209	after	O
2209	i	O
2209	##v	O
2209	dos	O
2209	##ing	O
2209	.	O
2209	[SEP]	O
2210	[CLS]	O
2210	au	B-PK
2210	##c	I-PK
2210	_	I-PK
2210	0	I-PK
2210	-	I-PK
2210	in	I-PK
2210	##f	I-PK
2210	,	O
2210	c	B-PK
2210	##l	I-PK
2210	,	O
2210	v	B-PK
2210	##d	I-PK
2210	,	O
2210	cm	B-PK
2210	##ax	I-PK
2210	(	I-PK
2210	ma	I-PK
2210	##ximal	I-PK
2210	plasma	I-PK
2210	concentration	I-PK
2210	)	I-PK
2210	,	O
2210	t	B-PK
2210	##max	I-PK
2210	(	I-PK
2210	time	I-PK
2210	to	I-PK
2210	cm	I-PK
2210	##ax	I-PK
2210	)	I-PK
2210	,	O
2210	k	B-PK
2210	##e	I-PK
2210	,	O
2210	absorption	B-PK
2210	rate	I-PK
2210	constant	I-PK
2210	(	I-PK
2210	ka	I-PK
2210	)	I-PK
2210	,	O
2210	and	O
2210	f	B-PK
2210	(	I-PK
2210	absolute	I-PK
2210	oral	I-PK
2210	bio	I-PK
2210	##ava	I-PK
2210	##ila	I-PK
2210	##bility	I-PK
2210	)	I-PK
2210	were	O
2210	calculated	O
2210	after	O
2210	p	O
2210	##o	O
2210	dos	O
2210	##ing	O
2210	.	O
2210	[SEP]	O
2211	[CLS]	O
2211	in	O
2211	this	O
2211	table	O
2211	,	O
2211	the	O
2211	v	B-PK
2211	##max	I-PK
2211	,	O
2211	and	O
2211	km	B-PK
2211	values	O
2211	are	O
2211	the	O
2211	values	O
2211	corresponding	O
2211	to	O
2211	an	O
2211	inhibitor	O
2211	concentration	O
2211	of	O
2211	zero	O
2211	.	O
2211	[SEP]	O
2212	[CLS]	O
2212	of	O
2212	notice	O
2212	are	O
2212	the	O
2212	results	O
2212	for	O
2212	c	B-PK
2212	##l	I-PK
2212	,	O
2212	v	B-PK
2212	##d	I-PK
2212	,	O
2212	and	O
2212	k	B-PK
2212	##e	I-PK
2212	amongst	O
2212	the	O
2212	three	O
2212	groups	O
2212	,	O
2212	with	O
2212	nearly	O
2212	identical	O
2212	estimates	O
2212	,	O
2212	which	O
2212	suggest	O
2212	equal	O
2212	elimination	O
2212	characteristics	O
2212	.	O
2212	[SEP]	O
2213	[CLS]	O
2213	considering	O
2213	this	O
2213	similar	O
2213	c	B-PK
2213	##l	I-PK
2213	and	O
2213	lower	O
2213	v	B-PK
2213	##d	I-PK
2213	,	O
2213	the	O
2213	t	O
2213	-	O
2213	2	O
2213	group	O
2213	showed	O
2213	a	O
2213	statistical	O
2213	significant	O
2213	higher	O
2213	k	B-PK
2213	##e	I-PK
2213	estimate	O
2213	(	O
2213	p	O
2213	=	O
2213	0	O
2213	.	O
2213	00	O
2213	##4	O
2213	)	O
2213	,	O
2213	highlighting	O
2213	a	O
2213	potential	O
2213	different	O
2213	elimination	B-PK
2213	half	I-PK
2213	-	I-PK
2213	life	I-PK
2213	in	O
2213	the	O
2213	t	O
2213	-	O
2213	2	O
2213	group	O
2213	.	O
2213	[SEP]	O
2214	[CLS]	O
2214	further	O
2214	##more	O
2214	,	O
2214	the	O
2214	average	O
2214	ka	B-PK
2214	of	O
2214	the	O
2214	t	O
2214	-	O
2214	2	O
2214	group	O
2214	was	O
2214	about	O
2214	2	O
2214	.	O
2214	5	O
2214	times	O
2214	higher	O
2214	compared	O
2214	to	O
2214	the	O
2214	control	O
2214	group	O
2214	.	O
2214	[SEP]	O
2215	[CLS]	O
2215	a	O
2215	change	O
2215	in	O
2215	ka	B-PK
2215	should	O
2215	result	O
2215	in	O
2215	a	O
2215	change	O
2215	in	O
2215	t	B-PK
2215	##max	I-PK
2215	values	O
2215	.	O
2215	[SEP]	O
2216	[CLS]	O
2216	however	O
2216	,	O
2216	this	O
2216	was	O
2216	not	O
2216	reflected	O
2216	in	O
2216	the	O
2216	average	O
2216	t	B-PK
2216	##max	I-PK
2216	for	O
2216	the	O
2216	t	O
2216	-	O
2216	2	O
2216	group	O
2216	.	O
2216	[SEP]	O
2217	[CLS]	O
2217	the	O
2217	reason	O
2217	is	O
2217	that	O
2217	one	O
2217	pig	O
2217	showed	O
2217	a	O
2217	t	B-PK
2217	##max	I-PK
2217	of	O
2217	4	O
2217	h	O
2217	,	O
2217	while	O
2217	the	O
2217	other	O
2217	t	B-PK
2217	##max	I-PK
2217	values	O
2217	ranged	O
2217	between	O
2217	0	O
2217	.	O
2217	16	O
2217	and	O
2217	1	O
2217	.	O
2217	5	O
2217	h	O
2217	.	O
2217	in	O
2217	the	O
2217	control	O
2217	group	O
2217	this	O
2217	range	O
2217	was	O
2217	between	O
2217	0	O
2217	.	O
2217	67	O
2217	and	O
2217	2	O
2217	h	O
2217	.	O
2217	removing	O
2217	the	O
2217	observation	O
2217	from	O
2217	the	O
2217	analysis	O
2217	resulted	O
2217	in	O
2217	a	O
2217	mean	O
2217	t	B-PK
2217	##max	I-PK
2217	value	O
2217	of	O
2217	0	O
2217	.	O
2217	71	O
2217	##4	O
2217	±	O
2217	0	O
2217	.	O
2217	55	O
2217	##9	O
2217	h	O
2217	.	O
2217	however	O
2217	,	O
2217	the	O
2217	result	O
2217	was	O
2217	not	O
2217	significantly	O
2217	different	O
2217	amongst	O
2217	the	O
2217	groups	O
2217	(	O
2217	p	O
2217	=	O
2217	0	O
2217	.	O
2217	170	O
2217	)	O
2217	.	O
2217	[SEP]	O
2218	[CLS]	O
2218	thin	O
2218	layer	O
2218	ch	O
2218	##roma	O
2218	##tography	O
2218	(	O
2218	t	O
2218	##l	O
2218	##c	O
2218	)	O
2218	was	O
2218	performed	O
2218	using	O
2218	pre	O
2218	##coat	O
2218	##ed	O
2218	si	O
2218	##lica	O
2218	gel	O
2218	60	O
2218	f	O
2218	##25	O
2218	##4	O
2218	plates	O
2218	and	O
2218	visual	O
2218	##ized	O
2218	using	O
2218	an	O
2218	##isa	O
2218	##lde	O
2218	##hy	O
2218	##de	O
2218	solution	O
2218	,	O
2218	heat	O
2218	,	O
2218	and	O
2218	u	O
2218	##v	O
2218	light	O
2218	(	O
2218	254	O
2218	nm	O
2218	)	O
2218	.	O
2218	[SEP]	O
2219	[CLS]	O
2219	the	O
2219	following	O
2219	abbreviation	O
2219	##s	O
2219	were	O
2219	used	O
2219	to	O
2219	describe	O
2219	peak	O
2219	splitting	O
2219	patterns	O
2219	:	O
2219	br	O
2219	=	O
2219	broad	O
2219	,	O
2219	s	O
2219	=	O
2219	single	O
2219	##t	O
2219	,	O
2219	d	O
2219	=	O
2219	double	O
2219	##t	O
2219	,	O
2219	t	O
2219	=	O
2219	triple	O
2219	##t	O
2219	,	O
2219	q	O
2219	=	O
2219	quartet	O
2219	,	O
2219	m	O
2219	=	O
2219	multiple	O
2219	##t	O
2219	,	O
2219	d	O
2219	##d	O
2219	=	O
2219	double	O
2219	##t	O
2219	of	O
2219	double	O
2219	##ts	O
2219	,	O
2219	t	O
2219	##d	O
2219	=	O
2219	triple	O
2219	##t	O
2219	of	O
2219	double	O
2219	##ts	O
2219	,	O
2219	d	O
2219	##dd	O
2219	=	O
2219	double	O
2219	##t	O
2219	of	O
2219	double	O
2219	##ts	O
2219	of	O
2219	double	O
2219	##ts	O
2219	.	O
2219	[SEP]	O
2220	[CLS]	O
2220	for	O
2220	protein	O
2220	fraction	O
2220	##ation	O
2220	,	O
2220	brain	O
2220	tissues	O
2220	were	O
2220	ho	O
2220	##mo	O
2220	##gen	O
2220	##ized	O
2220	with	O
2220	ice	O
2220	cold	O
2220	t	O
2220	##bs	O
2220	-	O
2220	containing	O
2220	protein	O
2220	##ase	O
2220	inhibitor	O
2220	##s	O
2220	,	O
2220	followed	O
2220	by	O
2220	cent	O
2220	##ri	O
2220	##fu	O
2220	##gation	O
2220	(	O
2220	100	O
2220	k	O
2220	##×	O
2220	##g	O
2220	,	O
2220	30	O
2220	min	O
2220	)	O
2220	.	O
2220	[SEP]	O
2221	[CLS]	O
2221	a	O
2221	##β	O
2221	##o	O
2221	(	O
2221	0	O
2221	.	O
2221	1	O
2221	μ	O
2221	##m	O
2221	,	O
2221	45	O
2221	min	O
2221	per	O
2221	##fusion	O
2221	)	O
2221	alone	O
2221	significantly	O
2221	decreased	O
2221	the	O
2221	magnitude	O
2221	of	O
2221	h	O
2221	##lt	O
2221	##p	O
2221	(	O
2221	145	O
2221	.	O
2221	3	O
2221	##±	O
2221	##10	O
2221	.	O
2221	9	O
2221	%	O
2221	)	O
2221	,	O
2221	and	O
2221	this	O
2221	effect	O
2221	was	O
2221	prevented	O
2221	by	O
2221	co	O
2221	-	O
2221	application	O
2221	of	O
2221	t	O
2221	##p	O
2221	##70	O
2221	(	O
2221	1	O
2221	μ	O
2221	##m	O
2221	,	O
2221	45	O
2221	min	O
2221	treatment	O
2221	prior	O
2221	to	O
2221	recordings	O
2221	;	O
2221	fi	O
2221	##g	O
2221	.	O
2221	5	O
2221	##d	O
2221	,	O
2221	e	O
2221	)	O
2221	.	O
2221	[SEP]	O
2222	[CLS]	O
2222	h	O
2222	##lt	O
2222	##p	O
2222	is	O
2222	a	O
2222	well	O
2222	-	O
2222	established	O
2222	cellular	O
2222	model	O
2222	of	O
2222	learning	O
2222	and	O
2222	memory	O
2222	and	O
2222	has	O
2222	been	O
2222	shown	O
2222	to	O
2222	be	O
2222	impaired	O
2222	in	O
2222	several	O
2222	ad	O
2222	models	O
2222	associated	O
2222	with	O
2222	a	O
2222	##β	O
2222	toxicity	O
2222	.	O
2222	[SEP]	O
2223	[CLS]	O
2223	in	O
2223	addition	O
2223	,	O
2223	week	O
2223	16	O
2223	data	O
2223	values	O
2223	were	O
2223	included	O
2223	from	O
2223	a	O
2223	sub	O
2223	##st	O
2223	##ud	O
2223	##y	O
2223	(	O
2223	n	O
2223	=	O
2223	52	O
2223	;	O
2223	50	O
2223	maximum	B-PK
2223	concentration	I-PK
2223	[	I-PK
2223	cm	I-PK
2223	##ax	I-PK
2223	]	I-PK
2223	values	O
2223	available	O
2223	)	O
2223	in	O
2223	which	O
2223	subjects	O
2223	who	O
2223	administered	O
2223	l	O
2223	##ira	O
2223	##g	O
2223	##lut	O
2223	##ide	O
2223	in	O
2223	the	O
2223	evening	O
2223	had	O
2223	blood	O
2223	drawn	O
2223	for	O
2223	l	O
2223	##ira	O
2223	##g	O
2223	##lut	O
2223	##ide	O
2223	bio	O
2223	##ana	O
2223	##lysis	O
2223	at	O
2223	approximately	O
2223	10	O
2223	,	O
2223	11	O
2223	,	O
2223	12	O
2223	and	O
2223	14	O
2223	h	O
2223	after	O
2223	dos	O
2223	##ing	O
2223	,	O
2223	to	O
2223	obtain	O
2223	exposure	O
2223	values	O
2223	around	O
2223	cm	B-PK
2223	##ax	I-PK
2223	for	O
2223	l	O
2223	##ira	O
2223	##g	O
2223	##lut	O
2223	##ide	O
2223	3	O
2223	.	O
2223	0	O
2223	mg	O
2223	.	O
2223	[SEP]	O
2224	[CLS]	O
2224	to	O
2224	ensure	O
2224	id	O
2224	##ent	O
2224	##if	O
2224	##iability	O
2224	of	O
2224	the	O
2224	model	O
2224	with	O
2224	the	O
2224	sparse	O
2224	##ly	O
2224	sampled	O
2224	data	O
2224	,	O
2224	the	O
2224	l	O
2224	##ira	O
2224	##g	O
2224	##lut	O
2224	##ide	O
2224	absorption	B-PK
2224	rate	I-PK
2224	constant	I-PK
2224	was	O
2224	set	O
2224	to	O
2224	a	O
2224	value	O
2224	(	O
2224	0	O
2224	.	O
2224	08	O
2224	##0	O
2224	##6	O
2224	l	O
2224	/	O
2224	h	O
2224	##−	O
2224	##1	O
2224	)	O
2224	estimated	O
2224	from	O
2224	a	O
2224	population	O
2224	p	O
2224	##har	O
2224	##ma	O
2224	##co	O
2224	##kin	O
2224	##etic	O
2224	model	O
2224	based	O
2224	on	O
2224	a	O
2224	multiple	O
2224	-	O
2224	dose	O
2224	clinical	O
2224	p	O
2224	##har	O
2224	##ma	O
2224	##cology	O
2224	study	O
2224	in	O
2224	o	O
2224	##bes	O
2224	##e	O
2224	subjects	O
2224	(	O
2224	[	O
2224	8	O
2224	]	O
2224	;	O
2224	data	O
2224	on	O
2224	file	O
2224	)	O
2224	,	O
2224	and	O
2224	the	O
2224	assumption	O
2224	that	O
2224	this	O
2224	parameter	O
2224	can	O
2224	be	O
2224	fixed	O
2224	without	O
2224	affecting	O
2224	the	O
2224	conclusions	O
2224	was	O
2224	verified	O
2224	by	O
2224	sensitivity	O
2224	analyses	O
2224	.	O
2224	[SEP]	O
2225	[CLS]	O
2225	graphical	O
2225	data	O
2225	quality	O
2225	analyses	O
2225	,	O
2225	including	O
2225	goodness	O
2225	-	O
2225	of	O
2225	-	O
2225	fit	O
2225	plots	O
2225	,	O
2225	were	O
2225	conducted	O
2225	prior	O
2225	to	O
2225	performing	O
2225	the	O
2225	population	O
2225	p	O
2225	##har	O
2225	##ma	O
2225	##co	O
2225	##kin	O
2225	##etic	O
2225	analysis	O
2225	,	O
2225	as	O
2225	described	O
2225	in	O
2225	the	O
2225	online	O
2225	resource	O
2225	(	O
2225	sect	O
2225	.	O
2225	[SEP]	O
2226	[CLS]	O
2226	compared	O
2226	with	O
2226	a	O
2226	reference	O
2226	subject	O
2226	weighing	O
2226	100	O
2226	kg	O
2226	,	O
2226	higher	O
2226	body	O
2226	weight	O
2226	was	O
2226	associated	O
2226	with	O
2226	decreased	O
2226	l	O
2226	##ira	O
2226	##g	O
2226	##lut	O
2226	##ide	O
2226	exposure	O
2226	,	O
2226	and	O
2226	lower	O
2226	body	O
2226	weight	O
2226	was	O
2226	associated	O
2226	with	O
2226	increased	O
2226	exposure	O
2226	;	O
2226	for	O
2226	a	O
2226	234	O
2226	kg	O
2226	subject	O
2226	(	O
2226	the	O
2226	highest	O
2226	observed	O
2226	body	O
2226	weight	O
2226	in	O
2226	the	O
2226	data	O
2226	##set	O
2226	)	O
2226	,	O
2226	l	O
2226	##ira	O
2226	##g	O
2226	##lut	O
2226	##ide	O
2226	exposure	O
2226	was	O
2226	44	O
2226	%	O
2226	lower	O
2226	(	O
2226	78	O
2226	%	O
2226	higher	O
2226	c	B-PK
2226	##l	I-PK
2226	/	I-PK
2226	f	I-PK
2226	)	O
2226	.	O
2226	[SEP]	O
2227	[CLS]	O
2227	the	O
2227	time	B-PK
2227	to	I-PK
2227	reach	I-PK
2227	the	I-PK
2227	maximum	I-PK
2227	peak	I-PK
2227	plasma	I-PK
2227	concentration	I-PK
2227	of	O
2227	a	O
2227	drug	O
2227	after	O
2227	administration	O
2227	in	O
2227	biological	O
2227	systems	O
2227	can	O
2227	be	O
2227	used	O
2227	as	O
2227	an	O
2227	index	O
2227	of	O
2227	the	O
2227	drug	B-PK
2227	absorption	I-PK
2227	rate	I-PK
2227	.	O
2227	[SEP]	O
2228	[CLS]	O
2228	in	O
2228	our	O
2228	research	O
2228	,	O
2228	in	O
2228	oral	O
2228	administration	O
2228	groups	O
2228	,	O
2228	the	O
2228	t	B-PK
2228	##max	I-PK
2228	values	O
2228	range	O
2228	from	O
2228	22	O
2228	to	O
2228	200	O
2228	min	O
2228	.	O
2228	[SEP]	O
2229	[CLS]	O
2229	although	O
2229	the	O
2229	t	B-PK
2229	##max	I-PK
2229	and	O
2229	the	O
2229	m	B-PK
2229	##rt	I-PK
2229	of	O
2229	oral	O
2229	##ly	O
2229	given	O
2229	s	O
2229	##chi	O
2229	##zan	O
2229	##dr	O
2229	##in	O
2229	group	O
2229	were	O
2229	shorter	O
2229	than	O
2229	that	O
2229	of	O
2229	s	O
2229	.	O
2229	chin	O
2229	##ensis	O
2229	(	O
2229	p	O
2229	<	O
2229	0	O
2229	.	O
2229	05	O
2229	)	O
2229	groups	O
2229	,	O
2229	there	O
2229	were	O
2229	no	O
2229	significant	O
2229	differences	O
2229	in	O
2229	the	O
2229	clearance	B-PK
2229	##s	I-PK
2229	among	O
2229	the	O
2229	three	O
2229	groups	O
2229	.	O
2229	[SEP]	O
2230	[CLS]	O
2230	our	O
2230	findings	O
2230	indicated	O
2230	that	O
2230	the	O
2230	t	B-PK
2230	##max	I-PK
2230	and	O
2230	m	B-PK
2230	##rt	I-PK
2230	values	O
2230	of	O
2230	oral	O
2230	##ly	O
2230	ing	O
2230	##est	O
2230	##ing	O
2230	s	O
2230	.	O
2230	chin	O
2230	##ensis	O
2230	products	O
2230	are	O
2230	larger	O
2230	than	O
2230	that	O
2230	of	O
2230	the	O
2230	dos	O
2230	##ing	O
2230	single	O
2230	component	O
2230	s	O
2230	##chi	O
2230	##zan	O
2230	##dr	O
2230	##in	O
2230	,	O
2230	which	O
2230	also	O
2230	matches	O
2230	fear	O
2230	##y	O
2230	’	O
2230	s	O
2230	study	O
2230	[	O
2230	34	O
2230	]	O
2230	.	O
2230	[SEP]	O
2231	[CLS]	O
2231	according	O
2231	to	O
2231	the	O
2231	comparative	O
2231	p	O
2231	##har	O
2231	##ma	O
2231	##co	O
2231	##kin	O
2231	##etics	O
2231	results	O
2231	shown	O
2231	in	O
2231	table	O
2231	4	O
2231	,	O
2231	the	O
2231	cm	B-PK
2231	##ax	I-PK
2231	and	O
2231	t	B-PK
2231	##max	I-PK
2231	of	O
2231	pharmaceutical	O
2231	industry	O
2231	s	O
2231	.	O
2231	chin	O
2231	##ensis	O
2231	products	O
2231	were	O
2231	significantly	O
2231	different	O
2231	from	O
2231	that	O
2231	of	O
2231	single	O
2231	ing	O
2231	##est	O
2231	##ion	O
2231	group	O
2231	.	O
2231	[SEP]	O
2232	[CLS]	O
2232	the	O
2232	s	O
2232	##chi	O
2232	##zan	O
2232	##dr	O
2232	##in	O
2232	levels	O
2232	in	O
2232	the	O
2232	plasma	O
2232	of	O
2232	rats	O
2232	given	O
2232	the	O
2232	commercial	O
2232	pharmaceutical	O
2232	products	O
2232	showed	O
2232	a	O
2232	later	O
2232	t	B-PK
2232	##max	I-PK
2232	and	O
2232	longer	O
2232	per	O
2232	##sistence	O
2232	than	O
2232	the	O
2232	levels	O
2232	in	O
2232	rats	O
2232	given	O
2232	the	O
2232	pure	O
2232	compound	O
2232	.	O
2232	[SEP]	O
2233	[CLS]	O
2233	he	O
2233	##pa	O
2233	##tic	O
2233	first	O
2233	-	O
2233	pass	O
2233	and	O
2233	in	O
2233	##test	O
2233	##inal	O
2233	effects	O
2233	are	O
2233	widely	O
2233	acknowledged	O
2233	to	O
2233	be	O
2233	responsible	O
2233	for	O
2233	the	O
2233	low	O
2233	oral	B-PK
2233	bio	I-PK
2233	##ava	I-PK
2233	##ila	I-PK
2233	##bility	I-PK
2233	of	O
2233	s	O
2233	##chi	O
2233	##zan	O
2233	##dr	O
2233	##in	O
2233	.	O
2233	[SEP]	O
2234	[CLS]	O
2234	the	O
2234	p	O
2234	##har	O
2234	##ma	O
2234	##co	O
2234	##kin	O
2234	##etic	O
2234	parameters	O
2234	of	O
2234	in	O
2234	##tra	O
2234	##ven	O
2234	##ous	O
2234	group	O
2234	revealed	O
2234	the	O
2234	half	B-PK
2234	-	I-PK
2234	life	I-PK
2234	(	I-PK
2234	t	I-PK
2234	##1	I-PK
2234	/	I-PK
2234	2	I-PK
2234	)	I-PK
2234	,	O
2234	clearance	B-PK
2234	(	I-PK
2234	c	I-PK
2234	##l	I-PK
2234	)	I-PK
2234	,	O
2234	mean	B-PK
2234	residence	I-PK
2234	time	I-PK
2234	(	I-PK
2234	m	I-PK
2234	##rt	I-PK
2234	)	I-PK
2234	,	O
2234	area	B-PK
2234	under	I-PK
2234	the	I-PK
2234	concentration	I-PK
2234	-	I-PK
2234	time	I-PK
2234	curve	I-PK
2234	(	I-PK
2234	au	I-PK
2234	##c	I-PK
2234	)	I-PK
2234	and	O
2234	volume	B-PK
2234	of	I-PK
2234	distribution	I-PK
2234	(	I-PK
2234	v	I-PK
2234	##d	I-PK
2234	)	I-PK
2234	.	O
2234	[SEP]	O
2235	[CLS]	O
2235	the	O
2235	p	O
2235	##har	O
2235	##ma	O
2235	##co	O
2235	##kin	O
2235	##etic	O
2235	parameter	O
2235	for	O
2235	m	B-PK
2235	##rt	I-PK
2235	was	O
2235	34	O
2235	.	O
2235	80	O
2235	min	O
2235	,	O
2235	the	O
2235	c	B-PK
2235	##l	I-PK
2235	was	O
2235	0	O
2235	.	O
2235	09	O
2235	l	O
2235	/	O
2235	min	O
2235	,	O
2235	and	O
2235	the	O
2235	au	B-PK
2235	##c	I-PK
2235	was	O
2235	43	O
2235	.	O
2235	11	O
2235	min	O
2235	ng	O
2235	/	O
2235	m	O
2235	##l	O
2235	,	O
2235	suggesting	O
2235	that	O
2235	the	O
2235	elimination	O
2235	process	O
2235	is	O
2235	rapid	O
2235	.	O
2235	[SEP]	O
2236	[CLS]	O
2236	the	O
2236	short	O
2236	half	B-PK
2236	-	I-PK
2236	life	I-PK
2236	,	O
2236	short	O
2236	mean	B-PK
2236	residence	I-PK
2236	time	I-PK
2236	and	O
2236	high	O
2236	clearance	B-PK
2236	rate	I-PK
2236	of	O
2236	s	O
2236	##chi	O
2236	##zan	O
2236	##dr	O
2236	##in	O
2236	imply	O
2236	that	O
2236	the	O
2236	elimination	O
2236	process	O
2236	might	O
2236	be	O
2236	rapid	O
2236	.	O
2236	[SEP]	O
2237	[CLS]	O
2237	bio	B-PK
2237	##ava	I-PK
2237	##ila	I-PK
2237	##bility	I-PK
2237	was	O
2237	calculated	O
2237	using	O
2237	the	O
2237	following	O
2237	formula	O
2237	:	O
2237	f	O
2237	(	O
2237	%	O
2237	)	O
2237	=	O
2237	100	O
2237	×	O
2237	(	O
2237	au	O
2237	##cor	O
2237	##al	O
2237	/	O
2237	do	O
2237	##ral	O
2237	)	O
2237	/	O
2237	(	O
2237	au	O
2237	##ci	O
2237	##v	O
2237	/	O
2237	di	O
2237	##v	O
2237	)	O
2237	.	O
2237	[SEP]	O
2238	[CLS]	O
2238	in	O
2238	our	O
2238	study	O
2238	,	O
2238	we	O
2238	used	O
2238	the	O
2238	au	B-PK
2238	##ci	I-PK
2238	##v	I-PK
2238	value	O
2238	of	O
2238	s	O
2238	##chi	O
2238	##zan	O
2238	##dr	O
2238	##in	O
2238	to	O
2238	calculate	O
2238	the	O
2238	bio	B-PK
2238	##ava	I-PK
2238	##ila	I-PK
2238	##bility	I-PK
2238	of	O
2238	s	O
2238	##chi	O
2238	##zan	O
2238	##dr	O
2238	##in	O
2238	and	O
2238	s	O
2238	.	O
2238	chin	O
2238	##ensis	O
2238	(	O
2238	3	O
2238	g	O
2238	/	O
2238	kg	O
2238	and	O
2238	10	O
2238	g	O
2238	/	O
2238	kg	O
2238	)	O
2238	.	O
2238	[SEP]	O
2239	[CLS]	O
2239	finally	O
2239	,	O
2239	traditional	O
2239	chin	O
2239	##ese	O
2239	medicines	O
2239	have	O
2239	been	O
2239	used	O
2239	for	O
2239	thousands	O
2239	of	O
2239	years	O
2239	in	O
2239	as	O
2239	##ia	O
2239	,	O
2239	and	O
2239	there	O
2239	is	O
2239	still	O
2239	a	O
2239	large	O
2239	amount	O
2239	of	O
2239	empirical	O
2239	information	O
2239	awaiting	O
2239	new	O
2239	scientific	O
2239	explanations	O
2239	.	O
2239	[SEP]	O
2240	[CLS]	O
2240	stability	O
2240	was	O
2240	evaluated	O
2240	under	O
2240	four	O
2240	conditions	O
2240	:	O
2240	short	O
2240	-	O
2240	term	O
2240	stability	O
2240	kept	O
2240	at	O
2240	room	O
2240	temperature	O
2240	for	O
2240	6	O
2240	h	O
2240	;	O
2240	post	O
2240	-	O
2240	pre	O
2240	##par	O
2240	##ative	O
2240	stability	O
2240	kept	O
2240	in	O
2240	the	O
2240	auto	O
2240	##sa	O
2240	##mple	O
2240	##r	O
2240	at	O
2240	8	O
2240	°	O
2240	##c	O
2240	for	O
2240	6	O
2240	h	O
2240	;	O
2240	long	O
2240	-	O
2240	term	O
2240	stability	O
2240	kept	O
2240	at	O
2240	−	O
2240	##80	O
2240	°	O
2240	##c	O
2240	for	O
2240	1	O
2240	month	O
2240	;	O
2240	and	O
2240	freeze	O
2240	-	O
2240	th	O
2240	##aw	O
2240	stability	O
2240	:	O
2240	three	O
2240	samples	O
2240	were	O
2240	frozen	O
2240	and	O
2240	stored	O
2240	at	O
2240	−	O
2240	##20	O
2240	°	O
2240	##c	O
2240	for	O
2240	24	O
2240	h	O
2240	and	O
2240	then	O
2240	th	O
2240	##awed	O
2240	at	O
2240	room	O
2240	temperature	O
2240	.	O
2240	[SEP]	O
2241	[CLS]	O
2241	recovery	O
2241	(	O
2241	%	O
2241	)	O
2241	and	O
2241	matrix	O
2241	effects	O
2241	(	O
2241	%	O
2241	)	O
2241	were	O
2241	calculated	O
2241	by	O
2241	using	O
2241	the	O
2241	peak	O
2241	area	O
2241	of	O
2241	set	O
2241	2	O
2241	/	O
2241	set	O
2241	1	O
2241	and	O
2241	set	O
2241	3	O
2241	/	O
2241	set	O
2241	2	O
2241	,	O
2241	respectively	O
2241	.	O
2241	[SEP]	O
2242	[CLS]	O
2242	in	O
2242	v	O
2242	##it	O
2242	##ro	O
2242	release	O
2242	and	O
2242	p	O
2242	##har	O
2242	##ma	O
2242	##co	O
2242	##kin	O
2242	##etics	O
2242	studies	O
2242	were	O
2242	used	O
2242	to	O
2242	evaluate	O
2242	the	O
2242	dissolution	O
2242	and	O
2242	bio	B-PK
2242	##ava	I-PK
2242	##ila	I-PK
2242	##bility	I-PK
2242	of	O
2242	g	O
2242	##ps	O
2242	.	O
2242	[SEP]	O
2243	[CLS]	O
2243	a	O
2243	p	O
2243	##har	O
2243	##ma	O
2243	##co	O
2243	##kin	O
2243	##etic	O
2243	analysis	O
2243	revealed	O
2243	an	O
2243	8	O
2243	.	O
2243	5	O
2243	-	O
2243	fold	O
2243	increase	O
2243	of	O
2243	bio	B-PK
2243	##ava	I-PK
2243	##ila	I-PK
2243	##bility	I-PK
2243	of	O
2243	the	O
2243	g	O
2243	##ps	O
2243	-	O
2243	s	O
2243	##g	O
2243	##c	O
2243	-	O
2243	n	O
2243	##l	O
2243	##cs	O
2243	compared	O
2243	with	O
2243	g	O
2243	##ps	O
2243	powder	O
2243	.	O
2243	[SEP]	O
2244	[CLS]	O
2244	initially	O
2244	,	O
2244	each	O
2244	sample	O
2244	was	O
2244	di	O
2244	##lut	O
2244	##ed	O
2244	with	O
2244	appropriate	O
2244	volume	O
2244	of	O
2244	di	O
2244	##st	O
2244	##ille	O
2244	##d	O
2244	water	O
2244	and	O
2244	a	O
2244	drop	O
2244	was	O
2244	added	O
2244	to	O
2244	a	O
2244	film	O
2244	-	O
2244	coated	O
2244	copper	O
2244	grid	O
2244	(	O
2244	z	O
2244	##hong	O
2244	ji	O
2244	##ng	O
2244	k	O
2244	##e	O
2244	y	O
2244	##i	O
2244	technology	O
2244	in	O
2244	##c	O
2244	.	O
2244	,	O
2244	be	O
2244	##iji	O
2244	##ng	O
2244	,	O
2244	chin	O
2244	##a	O
2244	)	O
2244	and	O
2244	air	O
2244	dried	O
2244	for	O
2244	about	O
2244	20	O
2244	minutes	O
2244	.	O
2244	[SEP]	O
2245	[CLS]	O
2245	the	O
2245	three	O
2245	independent	O
2245	variables	O
2245	were	O
2245	the	O
2245	total	O
2245	lip	O
2245	##id	O
2245	concentration	O
2245	(	O
2245	solid	O
2245	and	O
2245	liquid	O
2245	lip	O
2245	##ids	O
2245	,	O
2245	x	O
2245	##1	O
2245	)	O
2245	,	O
2245	the	O
2245	ratio	O
2245	of	O
2245	liquid	O
2245	lip	O
2245	##id	O
2245	to	O
2245	total	O
2245	lip	O
2245	##id	O
2245	(	O
2245	x	O
2245	##2	O
2245	)	O
2245	,	O
2245	and	O
2245	the	O
2245	surf	O
2245	##act	O
2245	##ant	O
2245	concentration	O
2245	(	O
2245	x	O
2245	##3	O
2245	)	O
2245	.	O
2245	[SEP]	O
2246	[CLS]	O
2246	maximum	B-PK
2246	concentration	I-PK
2246	(	I-PK
2246	cm	I-PK
2246	##ax	I-PK
2246	)	I-PK
2246	,	O
2246	time	B-PK
2246	of	I-PK
2246	cm	I-PK
2246	##ax	I-PK
2246	(	I-PK
2246	t	I-PK
2246	##max	I-PK
2246	)	I-PK
2246	,	O
2246	and	O
2246	mean	B-PK
2246	residence	I-PK
2246	time	I-PK
2246	(	I-PK
2246	m	I-PK
2246	##rt	I-PK
2246	)	I-PK
2246	were	O
2246	determined	O
2246	from	O
2246	the	O
2246	raw	O
2246	data	O
2246	.	O
2246	[SEP]	O
2247	[CLS]	O
2247	p	B-PK
2247	##ap	I-PK
2247	##p	I-PK
2247	was	O
2247	calculated	O
2247	using	O
2247	the	O
2247	following	O
2247	equation	O
2247	:	O
2247	p	O
2247	##ap	O
2247	##p	O
2247	=	O
2247	q	O
2247	##ln	O
2247	(	O
2247	co	O
2247	##ut	O
2247	##q	O
2247	##out	O
2247	##cin	O
2247	##qi	O
2247	##n	O
2247	)	O
2247	2	O
2247	##π	O
2247	##rl	O
2247	(	O
2247	3	O
2247	)	O
2247	where	O
2247	q	O
2247	##in	O
2247	and	O
2247	q	O
2247	##out	O
2247	are	O
2247	the	O
2247	volume	O
2247	of	O
2247	the	O
2247	inlet	O
2247	and	O
2247	outlet	O
2247	per	O
2247	##fu	O
2247	##sat	O
2247	##es	O
2247	,	O
2247	respectively	O
2247	;	O
2247	c	O
2247	##in	O
2247	and	O
2247	co	O
2247	##ut	O
2247	are	O
2247	the	O
2247	drug	O
2247	concentrations	O
2247	of	O
2247	the	O
2247	inlet	O
2247	and	O
2247	outlet	O
2247	per	O
2247	##fu	O
2247	##sat	O
2247	##es	O
2247	,	O
2247	respectively	O
2247	;	O
2247	q	O
2247	is	O
2247	the	O
2247	flow	O
2247	rate	O
2247	;	O
2247	l	O
2247	and	O
2247	r	O
2247	are	O
2247	the	O
2247	length	O
2247	and	O
2247	radius	O
2247	of	O
2247	the	O
2247	in	O
2247	##test	O
2247	##ine	O
2247	,	O
2247	respectively	O
2247	.	O
2247	[SEP]	O
2248	[CLS]	O
2248	in	O
2248	addition	O
2248	,	O
2248	the	O
2248	particle	O
2248	size	O
2248	decreases	O
2248	with	O
2248	an	O
2248	increase	O
2248	in	O
2248	the	O
2248	ratio	O
2248	of	O
2248	liquid	O
2248	lip	O
2248	##id	O
2248	to	O
2248	total	O
2248	lip	O
2248	##id	O
2248	.	O
2248	[SEP]	O
2249	[CLS]	O
2249	as	O
2249	shown	O
2249	in	O
2249	table	O
2249	4	O
2249	,	O
2249	the	O
2249	absorption	O
2249	of	O
2249	g	O
2249	##ps	O
2249	powder	O
2249	suspension	O
2249	(	O
2249	t	B-PK
2249	##max	I-PK
2249	=	O
2249	0	O
2249	.	O
2249	79	O
2249	##2	O
2249	hour	O
2249	)	O
2249	was	O
2249	shorter	O
2249	than	O
2249	that	O
2249	of	O
2249	g	O
2249	##ps	O
2249	-	O
2249	n	O
2249	##l	O
2249	##cs	O
2249	(	O
2249	t	B-PK
2249	##max	I-PK
2249	=	O
2249	1	O
2249	.	O
2249	41	O
2249	##7	O
2249	hour	O
2249	)	O
2249	and	O
2249	g	O
2249	##ps	O
2249	-	O
2249	s	O
2249	##g	O
2249	##c	O
2249	-	O
2249	n	O
2249	##l	O
2249	##cs	O
2249	(	O
2249	t	B-PK
2249	##max	I-PK
2249	=	O
2249	2	O
2249	.	O
2249	250	O
2249	hour	O
2249	)	O
2249	,	O
2249	suggesting	O
2249	that	O
2249	g	O
2249	##ps	O
2249	powder	O
2249	suspension	O
2249	was	O
2249	absorbed	O
2249	more	O
2249	rapidly	O
2249	than	O
2249	n	O
2249	##l	O
2249	##cs	O
2249	,	O
2249	with	O
2249	g	O
2249	##ps	O
2249	-	O
2249	s	O
2249	##g	O
2249	##c	O
2249	-	O
2249	n	O
2249	##l	O
2249	##cs	O
2249	displaying	O
2249	the	O
2249	longest	O
2249	absorption	O
2249	.	O
2249	[SEP]	O
2250	[CLS]	O
2250	the	O
2250	results	O
2250	of	O
2250	t	B-PK
2250	##max	I-PK
2250	and	O
2250	m	B-PK
2250	##rt	I-PK
2250	indicate	O
2250	that	O
2250	the	O
2250	drug	O
2250	in	O
2250	g	O
2250	##ps	O
2250	-	O
2250	s	O
2250	##g	O
2250	##c	O
2250	-	O
2250	n	O
2250	##l	O
2250	##cs	O
2250	remains	O
2250	in	O
2250	circulation	O
2250	for	O
2250	a	O
2250	significantly	O
2250	longer	O
2250	period	O
2250	of	O
2250	time	O
2250	.	O
2250	[SEP]	O
2251	[CLS]	O
2251	the	O
2251	stab	O
2251	##ili	O
2251	##zing	O
2251	effect	O
2251	might	O
2251	extend	O
2251	the	O
2251	resident	B-PK
2251	time	I-PK
2251	of	O
2251	g	O
2251	##ps	O
2251	-	O
2251	s	O
2251	##g	O
2251	##c	O
2251	-	O
2251	n	O
2251	##l	O
2251	##cs	O
2251	in	O
2251	the	O
2251	gas	O
2251	##tro	O
2251	##int	O
2251	##est	O
2251	##inal	O
2251	tract	O
2251	,	O
2251	18	O
2251	resulting	O
2251	in	O
2251	longer	O
2251	t	B-PK
2251	##max	I-PK
2251	and	O
2251	m	B-PK
2251	##rt	I-PK
2251	compared	O
2251	with	O
2251	that	O
2251	of	O
2251	g	O
2251	##ps	O
2251	powder	O
2251	suspension	O
2251	and	O
2251	g	O
2251	##ps	O
2251	-	O
2251	n	O
2251	##l	O
2251	##cs	O
2251	.	O
2251	[SEP]	O
2252	[CLS]	O
2252	the	O
2252	s	O
2252	##g	O
2252	##c	O
2252	-	O
2252	n	O
2252	##l	O
2252	##cs	O
2252	could	O
2252	significantly	O
2252	enhance	O
2252	the	O
2252	absorption	O
2252	of	O
2252	drugs	O
2252	with	O
2252	the	O
2252	excellent	O
2252	bio	O
2252	##com	O
2252	##pa	O
2252	##ti	O
2252	##bility	O
2252	of	O
2252	n	O
2252	##l	O
2252	##cs	O
2252	and	O
2252	by	O
2252	promoting	O
2252	the	O
2252	trans	O
2252	##me	O
2252	##mb	O
2252	##rane	O
2252	transportation	O
2252	of	O
2252	s	O
2252	##g	O
2252	##c	O
2252	,	O
2252	which	O
2252	would	O
2252	result	O
2252	in	O
2252	a	O
2252	greater	O
2252	improvement	O
2252	of	O
2252	drug	O
2252	bio	B-PK
2252	##ava	I-PK
2252	##ila	I-PK
2252	##bility	I-PK
2252	.	O
2252	[SEP]	O
2253	[CLS]	O
2253	the	O
2253	model	O
2253	parameters	O
2253	were	O
2253	v	B-PK
2253	/	I-PK
2253	f	I-PK
2253	,	O
2253	which	O
2253	is	O
2253	the	O
2253	ratio	O
2253	between	O
2253	volume	B-PK
2253	and	O
2253	the	O
2253	bio	B-PK
2253	##ava	I-PK
2253	##ila	I-PK
2253	##bility	I-PK
2253	,	O
2253	t	O
2253	and	O
2253	t	B-PK
2253	##lag	I-PK
2253	represent	O
2253	time	O
2253	and	O
2253	the	O
2253	la	B-PK
2253	##g	I-PK
2253	time	I-PK
2253	,	O
2253	respectively	O
2253	,	O
2253	and	O
2253	ka	B-PK
2253	and	O
2253	k	B-PK
2253	are	O
2253	the	O
2253	absorption	B-PK
2253	rate	I-PK
2253	constant	I-PK
2253	and	O
2253	the	O
2253	elimination	B-PK
2253	rate	I-PK
2253	constant	I-PK
2253	,	O
2253	respectively	O
2253	.	O
2253	[SEP]	O
2254	[CLS]	O
2254	the	O
2254	following	O
2254	p	O
2254	##k	O
2254	parameters	O
2254	were	O
2254	determined	O
2254	:	O
2254	maximum	B-PK
2254	observed	I-PK
2254	serum	I-PK
2254	concentration	I-PK
2254	(	I-PK
2254	cm	I-PK
2254	##ax	I-PK
2254	)	I-PK
2254	,	O
2254	cm	B-PK
2254	##ax	I-PK
2254	/	I-PK
2254	dose	I-PK
2254	,	O
2254	area	B-PK
2254	under	I-PK
2254	the	I-PK
2254	serum	I-PK
2254	concentration	I-PK
2254	-	I-PK
2254	time	I-PK
2254	curve	I-PK
2254	from	I-PK
2254	time	I-PK
2254	zero	I-PK
2254	(	I-PK
2254	pre	I-PK
2254	-	I-PK
2254	dose	I-PK
2254	)	I-PK
2254	extra	I-PK
2254	##pol	I-PK
2254	##ated	I-PK
2254	to	I-PK
2254	infinite	I-PK
2254	time	I-PK
2254	(	I-PK
2254	au	I-PK
2254	##c	I-PK
2254	##0	I-PK
2254	–	I-PK
2254	∞	I-PK
2254	)	I-PK
2254	,	O
2254	au	B-PK
2254	##c	I-PK
2254	##0	I-PK
2254	–	I-PK
2254	∞	I-PK
2254	/	I-PK
2254	dose	I-PK
2254	,	O
2254	distribution	B-PK
2254	phase	I-PK
2254	half	I-PK
2254	-	I-PK
2254	life	I-PK
2254	(	I-PK
2254	t	I-PK
2254	##½	I-PK
2254	,	I-PK
2254	α	I-PK
2254	)	I-PK
2254	,	O
2254	terminal	B-PK
2254	phase	I-PK
2254	half	I-PK
2254	-	I-PK
2254	life	I-PK
2254	(	I-PK
2254	t	I-PK
2254	##½	I-PK
2254	,	I-PK
2254	β	I-PK
2254	)	I-PK
2254	,	O
2254	systemic	B-PK
2254	clearance	I-PK
2254	of	I-PK
2254	parent	I-PK
2254	drug	I-PK
2254	(	I-PK
2254	c	I-PK
2254	##l	I-PK
2254	)	I-PK
2254	,	O
2254	volume	B-PK
2254	of	I-PK
2254	distribution	I-PK
2254	for	I-PK
2254	the	I-PK
2254	central	I-PK
2254	compartment	I-PK
2254	(	I-PK
2254	v	I-PK
2254	##1	I-PK
2254	)	I-PK
2254	,	O
2254	volume	B-PK
2254	of	I-PK
2254	distribution	I-PK
2254	at	I-PK
2254	steady	I-PK
2254	state	I-PK
2254	(	I-PK
2254	vs	I-PK
2254	##s	I-PK
2254	)	I-PK
2254	and	O
2254	mean	B-PK
2254	residence	I-PK
2254	time	I-PK
2254	(	I-PK
2254	m	I-PK
2254	##rt	I-PK
2254	)	I-PK
2254	.	O
2254	[SEP]	O
2255	[CLS]	O
2255	blood	O
2255	samples	O
2255	were	O
2255	evaluated	O
2255	for	O
2255	anti	O
2255	-	O
2255	be	O
2255	##lim	O
2255	##uma	O
2255	##b	O
2255	antibodies	O
2255	at	O
2255	pre	O
2255	-	O
2255	dose	O
2255	,	O
2255	and	O
2255	days	O
2255	14	O
2255	and	O
2255	84	O
2255	.	O
2255	[SEP]	O
2256	[CLS]	O
2256	no	O
2256	significant	O
2256	difference	O
2256	was	O
2256	found	O
2256	in	O
2256	terms	O
2256	of	O
2256	the	O
2256	p	O
2256	##har	O
2256	##ma	O
2256	##co	O
2256	##kin	O
2256	##etic	O
2256	parameters	O
2256	of	O
2256	to	O
2256	##l	O
2256	##but	O
2256	##ami	O
2256	##de	O
2256	(	O
2256	au	B-PK
2256	##c	I-PK
2256	(	I-PK
2256	0	I-PK
2256	##→	I-PK
2256	##t	I-PK
2256	)	I-PK
2256	,	O
2256	au	B-PK
2256	##c	I-PK
2256	(	I-PK
2256	0	I-PK
2256	-	I-PK
2256	∞	I-PK
2256	)	I-PK
2256	,	O
2256	t	B-PK
2256	##1	I-PK
2256	/	I-PK
2256	2	I-PK
2256	,	O
2256	t	B-PK
2256	##max	I-PK
2256	,	O
2256	cm	B-PK
2256	##ax	I-PK
2256	,	O
2256	and	O
2256	c	B-PK
2256	##l	I-PK
2256	)	O
2256	between	O
2256	lent	O
2256	##ina	O
2256	##n	O
2256	and	O
2256	b	O
2256	##c	O
2256	##g	O
2256	groups	O
2256	.	O
2256	[SEP]	O
2257	[CLS]	O
2257	interesting	O
2257	##ly	O
2257	,	O
2257	as	O
2257	the	O
2257	dose	O
2257	of	O
2257	lent	O
2257	##ina	O
2257	##n	O
2257	increased	O
2257	,	O
2257	au	B-PK
2257	##c	I-PK
2257	(	I-PK
2257	0	I-PK
2257	##→	I-PK
2257	##t	I-PK
2257	)	I-PK
2257	,	O
2257	au	B-PK
2257	##c	I-PK
2257	(	I-PK
2257	0	I-PK
2257	-	I-PK
2257	∞	I-PK
2257	)	I-PK
2257	,	O
2257	t	B-PK
2257	##1	I-PK
2257	/	I-PK
2257	2	I-PK
2257	,	O
2257	t	B-PK
2257	##max	I-PK
2257	,	O
2257	cm	B-PK
2257	##ax	I-PK
2257	and	O
2257	c	B-PK
2257	##l	I-PK
2257	of	O
2257	o	O
2257	##me	O
2257	##pra	O
2257	##zo	O
2257	##le	O
2257	in	O
2257	m	O
2257	##t	O
2257	##g	O
2257	and	O
2257	h	O
2257	##t	O
2257	##g	O
2257	showed	O
2257	no	O
2257	obvious	O
2257	changes	O
2257	from	O
2257	the	O
2257	b	O
2257	##c	O
2257	##g	O
2257	group	O
2257	.	O
2257	[SEP]	O
2258	[CLS]	O
2258	c	B-PK
2258	##l	I-PK
2258	(	I-PK
2258	plasma	I-PK
2258	clearance	I-PK
2258	)	I-PK
2258	of	O
2258	p	O
2258	##hen	O
2258	##ace	O
2258	##tin	O
2258	was	O
2258	remarkably	O
2258	elevated	O
2258	(	O
2258	p	O
2258	<	O
2258	0	O
2258	.	O
2258	05	O
2258	)	O
2258	.	O
2258	[SEP]	O
2259	[CLS]	O
2259	we	O
2259	therefore	O
2259	hypothesis	O
2259	##ed	O
2259	that	O
2259	co	O
2259	##ad	O
2259	##mini	O
2259	##stra	O
2259	##tion	O
2259	of	O
2259	im	O
2259	##ati	O
2259	##ni	O
2259	##b	O
2259	,	O
2259	as	O
2259	an	O
2259	inhibitor	O
2259	of	O
2259	the	O
2259	micro	O
2259	##so	O
2259	##mal	O
2259	c	O
2259	##y	O
2259	##p	O
2259	##3	O
2259	##a	O
2259	##4	O
2259	enzyme	O
2259	system	O
2259	,	O
2259	could	O
2259	affect	O
2259	the	O
2259	elimination	B-PK
2259	rate	I-PK
2259	of	O
2259	si	O
2259	##m	O
2259	##vas	O
2259	##tat	O
2259	##in	O
2259	.	O
2259	[SEP]	O
2260	[CLS]	O
2260	the	O
2260	present	O
2260	study	O
2260	was	O
2260	undertaken	O
2260	to	O
2260	assess	O
2260	this	O
2260	potential	O
2260	p	O
2260	##har	O
2260	##ma	O
2260	##co	O
2260	##kin	O
2260	##etic	O
2260	interaction	O
2260	by	O
2260	evaluation	O
2260	of	O
2260	the	O
2260	si	O
2260	##m	O
2260	##vas	O
2260	##tat	O
2260	##in	O
2260	plasma	O
2260	concentration	O
2260	vs	O
2260	time	O
2260	profiles	O
2260	after	O
2260	co	O
2260	##ad	O
2260	##mini	O
2260	##stra	O
2260	##tion	O
2260	with	O
2260	im	O
2260	##ati	O
2260	##ni	O
2260	##b	O
2260	(	O
2260	us	O
2260	department	O
2260	of	O
2260	health	O
2260	and	O
2260	human	O
2260	services	O
2260	,	O
2260	1999	O
2260	)	O
2260	and	O
2260	its	O
2260	effects	O
2260	on	O
2260	safety	O
2260	and	O
2260	to	O
2260	##ler	O
2260	##ability	O
2260	in	O
2260	patients	O
2260	with	O
2260	chronic	O
2260	my	O
2260	##elo	O
2260	##id	O
2260	le	O
2260	##uka	O
2260	##emia	O
2260	(	O
2260	cm	O
2260	##l	O
2260	)	O
2260	.	O
2260	[SEP]	O
2261	[CLS]	O
2261	for	O
2261	plasma	O
2261	concentrations	O
2261	of	O
2261	si	O
2261	##m	O
2261	##vas	O
2261	##tat	O
2261	##in	O
2261	the	O
2261	following	O
2261	parameters	O
2261	were	O
2261	determined	O
2261	:	O
2261	au	B-PK
2261	##c	I-PK
2261	(	I-PK
2261	0	I-PK
2261	–	I-PK
2261	t	I-PK
2261	)	I-PK
2261	(	I-PK
2261	area	I-PK
2261	under	I-PK
2261	the	I-PK
2261	concentration	I-PK
2261	–	I-PK
2261	time	I-PK
2261	curve	I-PK
2261	from	I-PK
2261	time	I-PK
2261	zero	I-PK
2261	to	I-PK
2261	t	I-PK
2261	)	I-PK
2261	,	O
2261	au	B-PK
2261	##c	I-PK
2261	(	I-PK
2261	0	I-PK
2261	–	I-PK
2261	∞	I-PK
2261	)	I-PK
2261	(	I-PK
2261	area	I-PK
2261	under	I-PK
2261	the	I-PK
2261	concentration	I-PK
2261	–	I-PK
2261	time	I-PK
2261	curve	I-PK
2261	from	I-PK
2261	time	I-PK
2261	zero	I-PK
2261	to	I-PK
2261	in	I-PK
2261	##finity	I-PK
2261	)	I-PK
2261	,	O
2261	cm	B-PK
2261	##ax	I-PK
2261	(	I-PK
2261	maximum	I-PK
2261	plasma	I-PK
2261	drug	I-PK
2261	concentration	I-PK
2261	)	I-PK
2261	,	O
2261	t	B-PK
2261	##max	I-PK
2261	(	I-PK
2261	time	I-PK
2261	to	I-PK
2261	reach	I-PK
2261	maximum	I-PK
2261	concentration	I-PK
2261	following	I-PK
2261	drug	I-PK
2261	administration	I-PK
2261	)	I-PK
2261	,	O
2261	t	B-PK
2261	##1	I-PK
2261	/	I-PK
2261	2	I-PK
2261	(	I-PK
2261	elimination	I-PK
2261	half	I-PK
2261	-	I-PK
2261	life	I-PK
2261	associated	I-PK
2261	with	I-PK
2261	terminal	I-PK
2261	slope	I-PK
2261	of	I-PK
2261	a	I-PK
2261	semi	I-PK
2261	##log	I-PK
2261	##ari	I-PK
2261	##th	I-PK
2261	##mic	I-PK
2261	concentration	I-PK
2261	–	I-PK
2261	time	I-PK
2261	curve	I-PK
2261	)	I-PK
2261	,	O
2261	v	B-PK
2261	##z	I-PK
2261	/	I-PK
2261	f	I-PK
2261	(	I-PK
2261	apparent	I-PK
2261	volume	I-PK
2261	of	I-PK
2261	distribution	I-PK
2261	based	I-PK
2261	on	I-PK
2261	terminal	I-PK
2261	phase	I-PK
2261	of	I-PK
2261	plasma	I-PK
2261	concentration	I-PK
2261	–	I-PK
2261	time	I-PK
2261	curves	I-PK
2261	)	I-PK
2261	and	O
2261	c	B-PK
2261	##l	I-PK
2261	/	I-PK
2261	f	I-PK
2261	(	I-PK
2261	total	I-PK
2261	body	I-PK
2261	clearance	I-PK
2261	of	I-PK
2261	drug	I-PK
2261	from	I-PK
2261	the	I-PK
2261	plasma	I-PK
2261	)	I-PK
2261	,	O
2261	in	O
2261	order	O
2261	to	O
2261	assess	O
2261	the	O
2261	effects	O
2261	of	O
2261	im	O
2261	##ati	O
2261	##ni	O
2261	##b	O
2261	on	O
2261	the	O
2261	p	O
2261	##k	O
2261	of	O
2261	si	O
2261	##m	O
2261	##vas	O
2261	##tat	O
2261	##in	O
2261	.	O
2261	[SEP]	O
2262	[CLS]	O
2262	the	O
2262	following	O
2262	p	O
2262	##har	O
2262	##ma	O
2262	##co	O
2262	##kin	O
2262	##etic	O
2262	parameters	O
2262	were	O
2262	used	O
2262	to	O
2262	assess	O
2262	an	O
2262	interaction	O
2262	of	O
2262	im	O
2262	##ati	O
2262	##ni	O
2262	##b	O
2262	on	O
2262	si	O
2262	##m	O
2262	##vas	O
2262	##tat	O
2262	##in	O
2262	:	O
2262	au	B-PK
2262	##cin	I-PK
2262	##f	I-PK
2262	,	O
2262	au	B-PK
2262	##cal	I-PK
2262	##l	I-PK
2262	,	O
2262	cm	B-PK
2262	##ax	I-PK
2262	,	O
2262	v	B-PK
2262	##z	I-PK
2262	/	I-PK
2262	f	I-PK
2262	,	O
2262	c	B-PK
2262	##l	I-PK
2262	/	I-PK
2262	f	I-PK
2262	,	O
2262	t	B-PK
2262	##1	I-PK
2262	/	I-PK
2262	2	I-PK
2262	and	O
2262	t	B-PK
2262	##max	I-PK
2262	.	O
2262	[SEP]	O
2263	[CLS]	O
2263	with	O
2263	the	O
2263	exception	O
2263	of	O
2263	t	B-PK
2263	##1	I-PK
2263	/	I-PK
2263	2	I-PK
2263	and	O
2263	t	B-PK
2263	##max	I-PK
2263	,	O
2263	parameters	O
2263	were	O
2263	l	O
2263	##n	O
2263	-	O
2263	transformed	O
2263	prior	O
2263	to	O
2263	analysis	O
2263	.	O
2263	[SEP]	O
2264	[CLS]	O
2264	t	B-PK
2264	##max	I-PK
2264	was	O
2264	anal	O
2264	##ys	O
2264	##ed	O
2264	non	O
2264	##par	O
2264	##ame	O
2264	##tric	O
2264	##ally	O
2264	.	O
2264	[SEP]	O
2265	[CLS]	O
2265	following	O
2265	im	O
2265	##ati	O
2265	##ni	O
2265	##b	O
2265	co	O
2265	##ad	O
2265	##mini	O
2265	##stra	O
2265	##tion	O
2265	,	O
2265	the	O
2265	mean	O
2265	si	O
2265	##m	O
2265	##vas	O
2265	##tat	O
2265	##in	O
2265	cm	B-PK
2265	##ax	I-PK
2265	,	O
2265	au	B-PK
2265	##c	I-PK
2265	(	I-PK
2265	0	I-PK
2265	–	I-PK
2265	all	I-PK
2265	)	I-PK
2265	and	O
2265	au	B-PK
2265	##c	I-PK
2265	(	I-PK
2265	0	I-PK
2265	–	I-PK
2265	∞	I-PK
2265	)	I-PK
2265	increased	O
2265	significantly	O
2265	by	O
2265	two	O
2265	-	O
2265	to	O
2265	-	O
2265	three	O
2265	-	O
2265	fold	O
2265	(	O
2265	p	O
2265	<	O
2265	0	O
2265	.	O
2265	00	O
2265	##1	O
2265	)	O
2265	.	O
2265	[SEP]	O
2266	[CLS]	O
2266	extra	B-PK
2266	##pol	I-PK
2266	##ation	I-PK
2266	to	I-PK
2266	time	I-PK
2266	in	I-PK
2266	##finity	I-PK
2266	(	I-PK
2266	au	I-PK
2266	##c	I-PK
2266	##0	I-PK
2266	–	I-PK
2266	∞	I-PK
2266	)	I-PK
2266	was	O
2266	calculated	O
2266	as	O
2266	follows	O
2266	:	O
2266	au	O
2266	##c	O
2266	##0	O
2266	–	O
2266	∞	O
2266	=	O
2266	au	O
2266	##c	O
2266	##0	O
2266	–	O
2266	t	O
2266	+	O
2266	c	O
2266	##t	O
2266	/	O
2266	k	O
2266	##e	O
2266	,	O
2266	(	O
2266	3	O
2266	)	O
2266	where	O
2266	c	B-PK
2266	##t	I-PK
2266	was	O
2266	the	O
2266	last	B-PK
2266	me	I-PK
2266	##as	I-PK
2266	##urable	I-PK
2266	plasma	I-PK
2266	concentration	I-PK
2266	and	O
2266	k	B-PK
2266	##e	I-PK
2266	was	O
2266	the	O
2266	terminal	B-PK
2266	elimination	I-PK
2266	rate	I-PK
2266	constant	I-PK
2266	.	O
2266	[SEP]	O
2267	[CLS]	O
2267	results	O
2267	of	O
2267	drug	O
2267	loading	O
2267	and	O
2267	en	O
2267	##cap	O
2267	##sul	O
2267	##ation	O
2267	efficiency	O
2267	indicated	O
2267	that	O
2267	1	O
2267	:	O
2267	5	O
2267	(	O
2267	l	O
2267	##v	O
2267	##t	O
2267	:	O
2267	p	O
2267	##la	O
2267	)	O
2267	was	O
2267	the	O
2267	optimal	O
2267	ratio	O
2267	.	O
2267	[SEP]	O
2268	[CLS]	O
2268	an	O
2268	experiment	O
2268	comparing	O
2268	bi	O
2268	##ab	O
2268	-	O
2268	mediated	O
2268	p	O
2268	##ha	O
2268	##go	O
2268	##cy	O
2268	##tosis	O
2268	of	O
2268	wild	O
2268	-	O
2268	type	O
2268	(	O
2268	double	O
2268	-	O
2268	positive	O
2268	)	O
2268	r	O
2268	##aj	O
2268	##i	O
2268	cells	O
2268	with	O
2268	engineered	O
2268	r	O
2268	##aj	O
2268	##i	O
2268	c	O
2268	##d	O
2268	##19	O
2268	knockout	O
2268	cells	O
2268	supports	O
2268	this	O
2268	idea	O
2268	.	O
2268	[SEP]	O
2269	[CLS]	O
2269	at	O
2269	52	O
2269	weeks	O
2269	,	O
2269	mean	O
2269	(	O
2269	standard	O
2269	error	O
2269	)	O
2269	h	O
2269	##ba	O
2269	##1	O
2269	##c	O
2269	was	O
2269	7	O
2269	.	O
2269	38	O
2269	(	O
2269	0	O
2269	.	O
2269	03	O
2269	)	O
2269	%	O
2269	with	O
2269	bi	O
2269	##l	O
2269	and	O
2269	7	O
2269	.	O
2269	61	O
2269	(	O
2269	0	O
2269	.	O
2269	04	O
2269	)	O
2269	%	O
2269	with	O
2269	g	O
2269	##l	O
2269	{	O
2269	difference	O
2269	−	O
2269	##0	O
2269	.	O
2269	22	O
2269	%	O
2269	[	O
2269	95	O
2269	%	O
2269	confidence	O
2269	interval	O
2269	(	O
2269	c	O
2269	##i	O
2269	)	O
2269	−	O
2269	##0	O
2269	.	O
2269	32	O
2269	,	O
2269	−	O
2269	##0	O
2269	.	O
2269	12	O
2269	]	O
2269	;	O
2269	p	O
2269	<	O
2269	0	O
2269	.	O
2269	00	O
2269	##1	O
2269	}	O
2269	.	O
2269	at	O
2269	52	O
2269	weeks	O
2269	more	O
2269	bi	O
2269	##l	O
2269	‐	O
2269	treated	O
2269	patients	O
2269	reached	O
2269	h	O
2269	##ba	O
2269	##1	O
2269	##c	O
2269	<	O
2269	7	O
2269	%	O
2269	(	O
2269	35	O
2269	%	O
2269	vs	O
2269	26	O
2269	%	O
2269	;	O
2269	p	O
2269	<	O
2269	0	O
2269	.	O
2269	00	O
2269	##1	O
2269	)	O
2269	,	O
2269	the	O
2269	no	O
2269	##cturnal	O
2269	h	O
2269	##y	O
2269	##po	O
2269	##gly	O
2269	##ca	O
2269	##emia	O
2269	rate	O
2269	was	O
2269	47	O
2269	%	O
2269	lower	O
2269	(	O
2269	p	O
2269	<	O
2269	0	O
2269	.	O
2269	00	O
2269	##1	O
2269	)	O
2269	and	O
2269	the	O
2269	total	O
2269	h	O
2269	##y	O
2269	##po	O
2269	##gly	O
2269	##ca	O
2269	##emia	O
2269	rate	O
2269	was	O
2269	11	O
2269	%	O
2269	higher	O
2269	(	O
2269	p	O
2269	=	O
2269	0	O
2269	.	O
2269	00	O
2269	##2	O
2269	)	O
2269	than	O
2269	in	O
2269	g	O
2269	##l	O
2269	‐	O
2269	treated	O
2269	patients	O
2269	,	O
2269	and	O
2269	there	O
2269	was	O
2269	no	O
2269	difference	O
2269	in	O
2269	severe	O
2269	h	O
2269	##y	O
2269	##po	O
2269	##gly	O
2269	##ca	O
2269	##emia	O
2269	rate	O
2269	.	O
2269	[SEP]	O
2270	[CLS]	O
2270	investigators	O
2270	were	O
2270	permitted	O
2270	to	O
2270	make	O
2270	further	O
2270	insulin	O
2270	adjustments	O
2270	at	O
2270	any	O
2270	point	O
2270	,	O
2270	depending	O
2270	on	O
2270	clinical	O
2270	circumstances	O
2270	(	O
2270	e	O
2270	.	O
2270	g	O
2270	.	O
2270	h	O
2270	##y	O
2270	##po	O
2270	##gly	O
2270	##ca	O
2270	##emia	O
2270	)	O
2270	.	O
2270	[SEP]	O
2271	[CLS]	O
2271	the	O
2271	proportion	O
2271	of	O
2271	patients	O
2271	with	O
2271	total	O
2271	bi	O
2271	##li	O
2271	##ru	O
2271	##bin	O
2271	≥	O
2271	##2	O
2271	×	O
2271	ul	O
2271	##n	O
2271	at	O
2271	any	O
2271	time	O
2271	after	O
2271	base	O
2271	##line	O
2271	was	O
2271	higher	O
2271	with	O
2271	g	O
2271	##l	O
2271	treatment	O
2271	(	O
2271	g	O
2271	##l	O
2271	0	O
2271	.	O
2271	9	O
2271	%	O
2271	vs	O
2271	bi	O
2271	##l	O
2271	0	O
2271	%	O
2271	;	O
2271	p	O
2271	=	O
2271	0	O
2271	.	O
2271	02	O
2271	##7	O
2271	)	O
2271	.	O
2271	[SEP]	O
2272	[CLS]	O
2272	g	O
2272	–	O
2272	a	O
2272	is	O
2272	the	O
2272	most	O
2272	abundant	O
2272	an	O
2272	##xi	O
2272	##oly	O
2272	##tic	O
2272	compound	O
2272	in	O
2272	this	O
2272	plant	O
2272	,	O
2272	while	O
2272	gal	O
2272	##phi	O
2272	##mine	O
2272	-	O
2272	e	O
2272	(	O
2272	g	O
2272	–	O
2272	e	O
2272	)	O
2272	is	O
2272	the	O
2272	most	O
2272	abundant	O
2272	gal	O
2272	##phi	O
2272	##mine	O
2272	,	O
2272	but	O
2272	inactive	O
2272	.	O
2272	[SEP]	O
2273	[CLS]	O
2273	g	O
2273	–	O
2273	e	O
2273	was	O
2273	transformed	O
2273	chemical	O
2273	##ly	O
2273	into	O
2273	g	O
2273	–	O
2273	a	O
2273	.	O
2273	the	O
2273	p	O
2273	##har	O
2273	##ma	O
2273	##co	O
2273	##kin	O
2273	##etic	O
2273	study	O
2273	was	O
2273	carried	O
2273	out	O
2273	in	O
2273	i	O
2273	##c	O
2273	##r	O
2273	mice	O
2273	,	O
2273	which	O
2273	were	O
2273	oral	O
2273	##ly	O
2273	administered	O
2273	a	O
2273	single	O
2273	200	O
2273	mg	O
2273	/	O
2273	kg	O
2273	dose	O
2273	of	O
2273	g	O
2273	–	O
2273	a	O
2273	.	O
2273	samples	O
2273	of	O
2273	blood	O
2273	and	O
2273	brain	O
2273	were	O
2273	taken	O
2273	at	O
2273	different	O
2273	times	O
2273	after	O
2273	administration	O
2273	of	O
2273	g	O
2273	–	O
2273	a	O
2273	.	O
2273	previously	O
2273	,	O
2273	we	O
2273	established	O
2273	the	O
2273	valid	O
2273	##ation	O
2273	of	O
2273	methods	O
2273	for	O
2273	determining	O
2273	the	O
2273	concentration	O
2273	of	O
2273	g	O
2273	–	O
2273	a	O
2273	.	O
2273	the	O
2273	g	O
2273	–	O
2273	a	O
2273	was	O
2273	detected	O
2273	in	O
2273	plasma	O
2273	5	O
2273	min	O
2273	after	O
2273	oral	O
2273	administration	O
2273	,	O
2273	and	O
2273	its	O
2273	concentration	O
2273	reached	O
2273	2	O
2273	.	O
2273	47	O
2273	μ	O
2273	##g	O
2273	/	O
2273	m	O
2273	##l	O
2273	.	O
2273	data	O
2273	from	O
2273	concentration	O
2273	-	O
2273	time	O
2273	curves	O
2273	allowed	O
2273	us	O
2273	to	O
2273	establish	O
2273	the	O
2273	main	O
2273	p	O
2273	##har	O
2273	##ma	O
2273	##co	O
2273	##kin	O
2273	##etic	O
2273	parameters	O
2273	in	O
2273	two	O
2273	models	O
2273	:	O
2273	one	O
2273	-	O
2273	and	O
2273	/	O
2273	or	O
2273	two	O
2273	-	O
2273	compartment	O
2273	.	O
2273	[SEP]	O
2274	[CLS]	O
2274	the	O
2274	g	O
2274	–	O
2274	a	O
2274	in	O
2274	brain	O
2274	tissue	O
2274	was	O
2274	noted	O
2274	to	O
2274	cross	O
2274	the	O
2274	blood	O
2274	-	O
2274	brain	O
2274	barrier	O
2274	,	O
2274	reaching	O
2274	cm	B-PK
2274	##ax	I-PK
2274	2	O
2274	.	O
2274	74	O
2274	μ	O
2274	##g	O
2274	/	O
2274	m	O
2274	##l	O
2274	,	O
2274	t	B-PK
2274	##max	I-PK
2274	81	O
2274	.	O
2274	6	O
2274	min	O
2274	,	O
2274	and	O
2274	then	O
2274	drop	O
2274	gradually	O
2274	to	O
2274	0	O
2274	.	O
2274	32	O
2274	μ	O
2274	##g	O
2274	/	O
2274	m	O
2274	##l	O
2274	detected	O
2274	at	O
2274	24	O
2274	h	O
2274	.	O
2274	the	O
2274	presence	O
2274	of	O
2274	g	O
2274	–	O
2274	a	O
2274	in	O
2274	brain	O
2274	tissue	O
2274	,	O
2274	confirmed	O
2274	that	O
2274	this	O
2274	an	O
2274	##xi	O
2274	##oly	O
2274	##tic	O
2274	compound	O
2274	can	O
2274	access	O
2274	the	O
2274	target	O
2274	organ	O
2274	and	O
2274	acts	O
2274	directly	O
2274	on	O
2274	the	O
2274	c	O
2274	##ns	O
2274	.	O
2274	[SEP]	O
2275	[CLS]	O
2275	figure	O
2275	2	O
2275	,	O
2275	panels	O
2275	(	O
2275	a	O
2275	)	O
2275	and	O
2275	(	O
2275	b	O
2275	)	O
2275	illustrate	O
2275	the	O
2275	ch	O
2275	##roma	O
2275	##to	O
2275	##graphic	O
2275	profile	O
2275	of	O
2275	g	O
2275	–	O
2275	a	O
2275	and	O
2275	g	O
2275	–	O
2275	e	O
2275	.	O
2275	retention	O
2275	times	O
2275	(	O
2275	r	O
2275	##t	O
2275	)	O
2275	for	O
2275	g	O
2275	–	O
2275	a	O
2275	and	O
2275	g	O
2275	–	O
2275	e	O
2275	were	O
2275	7	O
2275	.	O
2275	12	O
2275	and	O
2275	8	O
2275	.	O
2275	29	O
2275	min	O
2275	,	O
2275	respectively	O
2275	.	O
2275	[SEP]	O
2276	[CLS]	O
2276	the	O
2276	presence	O
2276	of	O
2276	the	O
2276	ace	O
2276	##tate	O
2276	group	O
2276	at	O
2276	the	O
2276	c	O
2276	##7	O
2276	position	O
2276	of	O
2276	g	O
2276	–	O
2276	e	O
2276	increased	O
2276	the	O
2276	retention	O
2276	time	O
2276	;	O
2276	this	O
2276	fact	O
2276	was	O
2276	useful	O
2276	in	O
2276	order	O
2276	to	O
2276	monitor	O
2276	the	O
2276	transformation	O
2276	of	O
2276	g	O
2276	–	O
2276	e	O
2276	to	O
2276	g	O
2276	–	O
2276	a	O
2276	.	O
2276	due	O
2276	to	O
2276	this	O
2276	difference	O
2276	in	O
2276	r	O
2276	##t	O
2276	,	O
2276	g	O
2276	–	O
2276	a	O
2276	of	O
2276	high	O
2276	purity	O
2276	was	O
2276	later	O
2276	obtained	O
2276	.	O
2276	[SEP]	O
2277	[CLS]	O
2277	regarding	O
2277	the	O
2277	performance	O
2277	of	O
2277	g	O
2277	–	O
2277	a	O
2277	in	O
2277	the	O
2277	brain	O
2277	compartment	O
2277	,	O
2277	it	O
2277	reached	O
2277	cm	B-PK
2277	##ax	I-PK
2277	of	O
2277	2	O
2277	.	O
2277	74	O
2277	μ	O
2277	##g	O
2277	/	O
2277	m	O
2277	##l	O
2277	,	O
2277	t	B-PK
2277	##max	I-PK
2277	81	O
2277	.	O
2277	6	O
2277	min	O
2277	(	O
2277	table	O
2277	6	O
2277	)	O
2277	,	O
2277	and	O
2277	then	O
2277	dropped	O
2277	gradually	O
2277	to	O
2277	0	O
2277	.	O
2277	32	O
2277	μ	O
2277	##g	O
2277	/	O
2277	m	O
2277	##l	O
2277	detected	O
2277	at	O
2277	24	O
2277	h	O
2277	.	O
2277	such	O
2277	a	O
2277	good	O
2277	distribution	O
2277	of	O
2277	g	O
2277	–	O
2277	a	O
2277	in	O
2277	the	O
2277	brain	O
2277	is	O
2277	certainly	O
2277	a	O
2277	result	O
2277	of	O
2277	the	O
2277	lip	O
2277	##op	O
2277	##hil	O
2277	##ic	O
2277	properties	O
2277	of	O
2277	the	O
2277	molecule	O
2277	,	O
2277	which	O
2277	allows	O
2277	it	O
2277	to	O
2277	easily	O
2277	cross	O
2277	the	O
2277	blood	O
2277	-	O
2277	brain	O
2277	barrier	O
2277	.	O
2277	[SEP]	O
2278	[CLS]	O
2278	the	O
2278	equations	O
2278	describing	O
2278	the	O
2278	compartment	O
2278	##s	O
2278	are	O
2278	as	O
2278	follows	O
2278	:	O
2278	c	O
2278	##p	O
2278	=	O
2278	c	O
2278	##1	O
2278	##e	O
2278	##−	O
2278	##k	O
2278	##dt	O
2278	+	O
2278	c	O
2278	##2	O
2278	##e	O
2278	##−	O
2278	##kat	O
2278	(	O
2278	one	O
2278	compartment	O
2278	model	O
2278	)	O
2278	c	O
2278	##p	O
2278	=	O
2278	c	O
2278	##1	O
2278	##e	O
2278	##−	O
2278	##α	O
2278	##t	O
2278	+	O
2278	c	O
2278	##2	O
2278	##e	O
2278	##−	O
2278	##β	O
2278	##t	O
2278	+	O
2278	c	O
2278	##3	O
2278	##e	O
2278	##−	O
2278	##k	O
2278	##dt	O
2278	(	O
2278	two	O
2278	compartment	O
2278	mode	O
2278	)	O
2278	where	O
2278	c	O
2278	##p	O
2278	is	O
2278	the	O
2278	plasma	O
2278	concentration	O
2278	(	O
2278	μ	O
2278	##g	O
2278	/	O
2278	m	O
2278	##l	O
2278	)	O
2278	;	O
2278	k	B-PK
2278	##d	I-PK
2278	,	I-PK
2278	β	I-PK
2278	,	I-PK
2278	disposition	I-PK
2278	rate	I-PK
2278	constant	I-PK
2278	(	O
2278	min	O
2278	##−	O
2278	##1	O
2278	)	O
2278	;	O
2278	ka	B-PK
2278	,	I-PK
2278	absorption	I-PK
2278	rate	I-PK
2278	constant	I-PK
2278	(	O
2278	min	O
2278	##−	O
2278	##1	O
2278	)	O
2278	;	O
2278	c	O
2278	##1	O
2278	,	O
2278	c	O
2278	##2	O
2278	and	O
2278	c	O
2278	##3	O
2278	,	O
2278	coefficients	O
2278	(	O
2278	µ	O
2278	##g	O
2278	/	O
2278	m	O
2278	##l	O
2278	)	O
2278	.	O
2278	[SEP]	O
2279	[CLS]	O
2279	the	O
2279	plasma	B-PK
2279	area	I-PK
2279	under	I-PK
2279	the	I-PK
2279	g	I-PK
2279	–	I-PK
2279	a	I-PK
2279	concentration	I-PK
2279	time	I-PK
2279	curve	I-PK
2279	throughout	O
2279	the	O
2279	measurement	O
2279	period	O
2279	reached	O
2279	values	O
2279	of	O
2279	2	O
2279	,	O
2279	170	O
2279	and	O
2279	2	O
2279	,	O
2279	03	O
2279	##0	O
2279	μ	O
2279	##g	O
2279	·	O
2279	min	O
2279	·	O
2279	m	O
2279	##l	O
2279	##−	O
2279	##1	O
2279	.	O
2279	[SEP]	O
2280	[CLS]	O
2280	the	O
2280	area	B-PK
2280	under	I-PK
2280	the	I-PK
2280	curve	I-PK
2280	for	O
2280	g	O
2280	–	O
2280	a	O
2280	was	O
2280	comparable	O
2280	in	O
2280	the	O
2280	two	O
2280	models	O
2280	analyzed	O
2280	compared	O
2280	to	O
2280	the	O
2280	au	B-PK
2280	##c	I-PK
2280	##0	I-PK
2280	##→	I-PK
2280	##∞	I-PK
2280	found	O
2280	for	O
2280	oral	O
2280	administration	O
2280	of	O
2280	g	O
2280	##ly	O
2280	##cy	O
2280	##rr	O
2280	##he	O
2280	##tin	O
2280	##ic	O
2280	acid	O
2280	in	O
2280	mice	O
2280	:	O
2280	2	O
2280	,	O
2280	45	O
2280	##4	O
2280	µ	O
2280	##g	O
2280	·	O
2280	min	O
2280	·	O
2280	m	O
2280	##l	O
2280	##−	O
2280	##1	O
2280	[	O
2280	10	O
2280	]	O
2280	.	O
2280	[SEP]	O
2281	[CLS]	O
2281	to	O
2281	transform	O
2281	the	O
2281	obtained	O
2281	g	O
2281	–	O
2281	e	O
2281	into	O
2281	g	O
2281	–	O
2281	a	O
2281	,	O
2281	the	O
2281	dried	O
2281	product	O
2281	containing	O
2281	g	O
2281	–	O
2281	e	O
2281	was	O
2281	dissolved	O
2281	in	O
2281	a	O
2281	saturated	O
2281	k	O
2281	##h	O
2281	##co	O
2281	##3	O
2281	solution	O
2281	(	O
2281	2	O
2281	mg	O
2281	/	O
2281	m	O
2281	##l	O
2281	of	O
2281	g	O
2281	–	O
2281	e	O
2281	)	O
2281	.	O
2281	[SEP]	O
2282	[CLS]	O
2282	g	O
2282	–	O
2282	a	O
2282	concentration	O
2282	was	O
2282	obtained	O
2282	by	O
2282	comparison	O
2282	with	O
2282	a	O
2282	pre	O
2282	-	O
2282	built	O
2282	ca	O
2282	##li	O
2282	##bra	O
2282	##tion	O
2282	curve	O
2282	at	O
2282	λ	O
2282	=	O
2282	220	O
2282	nm	O
2282	.	O
2282	[SEP]	O
2283	[CLS]	O
2283	consequently	O
2283	,	O
2283	r	O
2283	##ge	O
2283	did	O
2283	not	O
2283	in	O
2283	##hibit	O
2283	the	O
2283	o	O
2283	##ct	O
2283	##1	O
2283	-	O
2283	and	O
2283	o	O
2283	##ct	O
2283	##2	O
2283	-	O
2283	mediated	O
2283	met	O
2283	##form	O
2283	##in	O
2283	up	O
2283	##take	O
2283	up	O
2283	to	O
2283	500	O
2283	µ	O
2283	##g	O
2283	/	O
2283	m	O
2283	##l	O
2283	of	O
2283	r	O
2283	##ge	O
2283	treatment	O
2283	(	O
2283	figure	O
2283	1	O
2283	##e	O
2283	,	O
2283	f	O
2283	)	O
2283	.	O
2283	[SEP]	O
2284	[CLS]	O
2284	the	O
2284	results	O
2284	suggested	O
2284	that	O
2284	the	O
2284	absorption	O
2284	of	O
2284	met	O
2284	##form	O
2284	##in	O
2284	from	O
2284	the	O
2284	duo	O
2284	##den	O
2284	##um	O
2284	and	O
2284	il	O
2284	##eum	O
2284	was	O
2284	enhanced	O
2284	by	O
2284	the	O
2284	repeated	O
2284	administration	O
2284	of	O
2284	r	O
2284	##ge	O
2284	without	O
2284	altering	O
2284	the	O
2284	absorption	O
2284	of	O
2284	glucose	O
2284	and	O
2284	cell	O
2284	integrity	O
2284	,	O
2284	which	O
2284	could	O
2284	consequently	O
2284	cause	O
2284	the	O
2284	increased	O
2284	absorption	O
2284	and	O
2284	plasma	O
2284	concentrations	O
2284	of	O
2284	met	O
2284	##form	O
2284	##in	O
2284	,	O
2284	including	O
2284	cm	B-PK
2284	##ax	I-PK
2284	and	O
2284	au	B-PK
2284	##c	I-PK
2284	value	O
2284	.	O
2284	[SEP]	O
2285	[CLS]	O
2285	however	O
2285	,	O
2285	in	O
2285	the	O
2285	repeated	O
2285	r	O
2285	##ge	O
2285	treatment	O
2285	group	O
2285	(	O
2285	1	O
2285	##w	O
2285	##ra	O
2285	)	O
2285	,	O
2285	the	O
2285	elimination	B-PK
2285	half	I-PK
2285	-	I-PK
2285	life	I-PK
2285	(	I-PK
2285	t	I-PK
2285	##1	I-PK
2285	/	I-PK
2285	2	I-PK
2285	)	I-PK
2285	,	O
2285	cm	B-PK
2285	##ax	I-PK
2285	,	O
2285	au	B-PK
2285	##c	I-PK
2285	,	O
2285	and	O
2285	fraction	B-PK
2285	of	I-PK
2285	the	I-PK
2285	met	I-PK
2285	##form	I-PK
2285	##in	I-PK
2285	dose	I-PK
2285	ex	I-PK
2285	##cre	I-PK
2285	##ted	I-PK
2285	into	I-PK
2285	urine	I-PK
2285	as	I-PK
2285	unchanged	I-PK
2285	drug	I-PK
2285	(	I-PK
2285	a	I-PK
2285	##e	I-PK
2285	##24	I-PK
2285	##h	I-PK
2285	)	I-PK
2285	were	O
2285	increased	O
2285	compared	O
2285	with	O
2285	those	O
2285	in	O
2285	control	O
2285	group	O
2285	(	O
2285	table	O
2285	3	O
2285	)	O
2285	.	O
2285	[SEP]	O
2286	[CLS]	O
2286	p	O
2286	##k	O
2286	parameters	O
2286	included	O
2286	:	O
2286	maximum	B-PK
2286	plasma	I-PK
2286	concentration	I-PK
2286	(	I-PK
2286	cm	I-PK
2286	##ax	I-PK
2286	)	I-PK
2286	,	O
2286	time	B-PK
2286	to	I-PK
2286	cm	I-PK
2286	##ax	I-PK
2286	(	I-PK
2286	t	I-PK
2286	##max	I-PK
2286	)	I-PK
2286	,	O
2286	area	B-PK
2286	under	I-PK
2286	the	I-PK
2286	plasma	I-PK
2286	concentration	I-PK
2286	versus	I-PK
2286	time	I-PK
2286	curve	I-PK
2286	from	I-PK
2286	zero	I-PK
2286	to	I-PK
2286	in	I-PK
2286	##finity	I-PK
2286	(	I-PK
2286	au	I-PK
2286	##c	I-PK
2286	##0	I-PK
2286	–	I-PK
2286	∞	I-PK
2286	)	I-PK
2286	,	O
2286	au	B-PK
2286	##c	I-PK
2286	##0	I-PK
2286	-	I-PK
2286	τ	I-PK
2286	(	O
2286	where	O
2286	τ	O
2286	=	O
2286	24	O
2286	h	O
2286	)	O
2286	and	O
2286	half	B-PK
2286	–	I-PK
2286	life	I-PK
2286	(	I-PK
2286	t	I-PK
2286	##1	I-PK
2286	/	I-PK
2286	2	I-PK
2286	)	I-PK
2286	.	O
2286	[SEP]	O
2287	[CLS]	O
2287	both	O
2287	criteria	O
2287	were	O
2287	met	O
2287	by	O
2287	r	O
2287	##up	O
2287	##ata	O
2287	##dine	O
2287	and	O
2287	u	O
2287	##r	O
2287	-	O
2287	127	O
2287	##90	O
2287	for	O
2287	cm	B-PK
2287	##ax	I-PK
2287	,	O
2287	au	B-PK
2287	##c	I-PK
2287	##0	I-PK
2287	-	I-PK
2287	∞	I-PK
2287	on	O
2287	day	O
2287	1	O
2287	and	O
2287	cm	B-PK
2287	##ax	I-PK
2287	,	O
2287	au	B-PK
2287	##c	I-PK
2287	##0	I-PK
2287	-	I-PK
2287	τ	I-PK
2287	on	O
2287	day	O
2287	5	O
2287	.	O
2287	[SEP]	O
2288	[CLS]	O
2288	unlike	O
2288	higher	O
2288	doses	O
2288	,	O
2288	r	O
2288	##up	O
2288	##ata	O
2288	##dine	O
2288	10	O
2288	mg	O
2288	rapid	O
2288	visual	O
2288	processing	O
2288	(	O
2288	r	O
2288	##v	O
2288	##p	O
2288	)	O
2288	assessment	O
2288	scores	O
2288	were	O
2288	comparable	O
2288	with	O
2288	the	O
2288	place	O
2288	##bo	O
2288	treatment	O
2288	group	O
2288	at	O
2288	1	O
2288	h	O
2288	of	O
2288	drug	O
2288	administration	O
2288	,	O
2288	the	O
2288	time	O
2288	correspondent	O
2288	to	O
2288	r	O
2288	##up	O
2288	##ata	O
2288	##dine	O
2288	t	B-PK
2288	##max	I-PK
2288	(	O
2288	fi	O
2288	##g	O
2288	4	O
2288	##a	O
2288	)	O
2288	.	O
2288	[SEP]	O
2289	[CLS]	O
2289	these	O
2289	findings	O
2289	suggest	O
2289	that	O
2289	the	O
2289	effects	O
2289	on	O
2289	cognitive	O
2289	function	O
2289	appear	O
2289	to	O
2289	be	O
2289	dose	O
2289	dependent	O
2289	and	O
2289	more	O
2289	pronounced	O
2289	at	O
2289	around	O
2289	t	B-PK
2289	##max	I-PK
2289	on	O
2289	days	O
2289	1	O
2289	and	O
2289	5	O
2289	at	O
2289	high	O
2289	doses	O
2289	with	O
2289	some	O
2289	development	O
2289	of	O
2289	r	O
2289	##up	O
2289	##ata	O
2289	##dine	O
2289	tolerance	O
2289	after	O
2289	multiple	O
2289	doses	O
2289	.	O
2289	[SEP]	O
2290	[CLS]	O
2290	le	O
2290	##uk	O
2290	##ope	O
2290	##nia	O
2290	was	O
2290	not	O
2290	significantly	O
2290	correlated	O
2290	with	O
2290	p	O
2290	##har	O
2290	##ma	O
2290	##co	O
2290	##kin	O
2290	##etic	O
2290	parameters	O
2290	,	O
2290	including	O
2290	time	B-PK
2290	above	I-PK
2290	a	I-PK
2290	threshold	I-PK
2290	concentration	I-PK
2290	or	O
2290	the	O
2290	area	B-PK
2290	under	I-PK
2290	the	I-PK
2290	tune	I-PK
2290	‐	I-PK
2290	concentration	I-PK
2290	curve	I-PK
2290	.	O
2290	[SEP]	O
2291	[CLS]	O
2291	there	O
2291	was	O
2291	a	O
2291	significant	O
2291	difference	O
2291	in	O
2291	the	O
2291	cellular	O
2291	d	O
2291	##n	O
2291	##r	O
2291	and	O
2291	do	O
2291	##l	O
2291	au	B-PK
2291	##c	I-PK
2291	between	O
2291	respond	O
2291	##ers	O
2291	and	O
2291	non	O
2291	-	O
2291	respond	O
2291	##ers	O
2291	(	O
2291	p	O
2291	<	O
2291	0	O
2291	.	O
2291	02	O
2291	)	O
2291	.	O
2291	[SEP]	O
2292	[CLS]	O
2292	there	O
2292	were	O
2292	no	O
2292	significant	O
2292	differences	O
2292	between	O
2292	patients	O
2292	who	O
2292	went	O
2292	into	O
2292	complete	O
2292	re	O
2292	##mission	O
2292	(	O
2292	12	O
2292	/	O
2292	23	O
2292	)	O
2292	compared	O
2292	with	O
2292	those	O
2292	who	O
2292	did	O
2292	not	O
2292	respond	O
2292	for	O
2292	the	O
2292	following	O
2292	p	O
2292	##har	O
2292	##ma	O
2292	##co	O
2292	##kin	O
2292	##etic	O
2292	parameters	O
2292	:	O
2292	d	O
2292	##n	O
2292	##r	O
2292	and	O
2292	do	O
2292	##l	O
2292	plasma	B-PK
2292	au	I-PK
2292	##c	I-PK
2292	(	I-PK
2292	area	I-PK
2292	under	I-PK
2292	the	I-PK
2292	curve	I-PK
2292	)	I-PK
2292	and	O
2292	d	O
2292	##n	O
2292	##r	O
2292	plasma	B-PK
2292	half	I-PK
2292	-	I-PK
2292	life	I-PK
2292	and	O
2292	clearance	B-PK
2292	.	O
2292	[SEP]	O
2293	[CLS]	O
2293	v	O
2293	##l	O
2293	was	O
2293	assessed	O
2293	at	O
2293	each	O
2293	visit	O
2293	using	O
2293	co	O
2293	##bas	O
2293	##®	O
2293	am	O
2293	##p	O
2293	##lip	O
2293	##re	O
2293	##p	O
2293	/	O
2293	co	O
2293	##bas	O
2293	##®	O
2293	ta	O
2293	##q	O
2293	##man	O
2293	##®	O
2293	hi	O
2293	##v	O
2293	-	O
2293	1	O
2293	test	O
2293	,	O
2293	v	O
2293	##2	O
2293	.	O
2293	0	O
2293	(	O
2293	r	O
2293	##och	O
2293	##e	O
2293	diagnostic	O
2293	##s	O
2293	,	O
2293	base	O
2293	##l	O
2293	,	O
2293	s	O
2293	##witz	O
2293	##erland	O
2293	)	O
2293	.	O
2293	[SEP]	O
2294	[CLS]	O
2294	ad	O
2294	##herence	O
2294	was	O
2294	lower	O
2294	in	O
2294	patients	O
2294	with	O
2294	base	O
2294	##line	O
2294	v	O
2294	##l	O
2294	[UNK]	O
2294	50	O
2294	copies	O
2294	/	O
2294	m	O
2294	##l	O
2294	than	O
2294	<	O
2294	50	O
2294	copies	O
2294	/	O
2294	m	O
2294	##l	O
2294	(	O
2294	47	O
2294	%	O
2294	(	O
2294	69	O
2294	/	O
2294	148	O
2294	)	O
2294	vs	O
2294	57	O
2294	%	O
2294	(	O
2294	30	O
2294	/	O
2294	53	O
2294	)	O
2294	,	O
2294	respectively	O
2294	)	O
2294	.	O
2294	[SEP]	O
2295	[CLS]	O
2295	when	O
2295	the	O
2295	a	O
2295	##pta	O
2295	##mers	O
2295	were	O
2295	administered	O
2295	sub	O
2295	##cut	O
2295	##aneous	O
2295	##ly	O
2295	,	O
2295	the	O
2295	t	B-PK
2295	##max	I-PK
2295	of	O
2295	s	O
2295	##b	O
2295	##c	O
2295	-	O
2295	p	O
2295	##eg	O
2295	##yla	O
2295	##ted	O
2295	17	O
2295	##m	O
2295	-	O
2295	38	O
2295	##2	O
2295	was	O
2295	3	O
2295	.	O
2295	8	O
2295	times	O
2295	longer	O
2295	than	O
2295	that	O
2295	of	O
2295	p	O
2295	##eg	O
2295	##yla	O
2295	##ted	O
2295	17	O
2295	##m	O
2295	-	O
2295	38	O
2295	##2	O
2295	.	O
2295	[SEP]	O
2296	[CLS]	O
2296	the	O
2296	t	B-PK
2296	##max	I-PK
2296	was	O
2296	recorded	O
2296	as	O
2296	the	O
2296	time	B-PK
2296	at	I-PK
2296	which	I-PK
2296	cm	I-PK
2296	##ax	I-PK
2296	occurred	I-PK
2296	.	O
2296	[SEP]	O
2297	[CLS]	O
2297	half	B-PK
2297	-	I-PK
2297	life	I-PK
2297	(	I-PK
2297	t	I-PK
2297	##1	I-PK
2297	/	I-PK
2297	2	I-PK
2297	)	I-PK
2297	was	O
2297	calculated	O
2297	as	O
2297	l	O
2297	##n	O
2297	(	O
2297	2	O
2297	)	O
2297	/	O
2297	λ	O
2297	##z	O
2297	.	O
2297	[SEP]	O
2298	[CLS]	O
2298	the	O
2298	t	B-PK
2298	##max	I-PK
2298	for	O
2298	plasma	O
2298	free	O
2298	p	O
2298	##hen	O
2298	##yt	O
2298	##oi	O
2298	##n	O
2298	was	O
2298	generally	O
2298	shorter	O
2298	than	O
2298	that	O
2298	for	O
2298	plasma	O
2298	total	O
2298	p	O
2298	##hen	O
2298	##yt	O
2298	##oi	O
2298	##n	O
2298	.	O
2298	[SEP]	O
2299	[CLS]	O
2299	the	O
2299	mean	O
2299	au	B-PK
2299	##ct	I-PK
2299	/	I-PK
2299	kg	I-PK
2299	weight	O
2299	increased	O
2299	slightly	O
2299	more	O
2299	than	O
2299	proportional	O
2299	to	O
2299	the	O
2299	administered	O
2299	dose	O
2299	(	O
2299	α	O
2299	=	O
2299	−	O
2299	##9	O
2299	##6	O
2299	.	O
2299	2	O
2299	,	O
2299	β	O
2299	=	O
2299	34	O
2299	.	O
2299	0	O
2299	,	O
2299	r	O
2299	=	O
2299	0	O
2299	.	O
2299	95	O
2299	over	O
2299	a	O
2299	30	O
2299	-	O
2299	min	O
2299	in	O
2299	##fusion	O
2299	)	O
2299	,	O
2299	whereas	O
2299	the	O
2299	mean	O
2299	c	B-PK
2299	##l	I-PK
2299	decreased	O
2299	with	O
2299	increasing	O
2299	dose	O
2299	.	O
2299	[SEP]	O
2300	[CLS]	O
2300	the	O
2300	w	O
2300	##ista	O
2300	##r	O
2300	rat	O
2300	eyes	O
2300	treated	O
2300	with	O
2300	g	O
2300	##c	O
2300	##m	O
2300	showed	O
2300	significant	O
2300	increase	O
2300	in	O
2300	g	O
2300	##an	O
2300	##ci	O
2300	##c	O
2300	##lov	O
2300	##ir	O
2300	au	B-PK
2300	##c	I-PK
2300	(	O
2300	~	O
2300	4	O
2300	.	O
2300	99	O
2300	-	O
2300	fold	O
2300	)	O
2300	and	O
2300	cm	B-PK
2300	##ax	I-PK
2300	(	O
2300	2	O
2300	.	O
2300	69	O
2300	-	O
2300	fold	O
2300	)	O
2300	in	O
2300	a	O
2300	##que	O
2300	##ous	O
2300	humor	O
2300	compared	O
2300	to	O
2300	g	O
2300	##an	O
2300	##ci	O
2300	##c	O
2300	##lov	O
2300	##ir	O
2300	solution	O
2300	and	O
2300	delay	O
2300	in	O
2300	t	B-PK
2300	##max	I-PK
2300	.	O
2300	[SEP]	O
2301	[CLS]	O
2301	additionally	O
2301	,	O
2301	g	O
2301	##an	O
2301	##ci	O
2301	##c	O
2301	##lov	O
2301	##ir	O
2301	half	B-PK
2301	life	I-PK
2301	(	I-PK
2301	t	I-PK
2301	##1	I-PK
2301	/	I-PK
2301	2	I-PK
2301	)	I-PK
2301	,	O
2301	relative	B-PK
2301	bio	I-PK
2301	##ava	I-PK
2301	##ila	I-PK
2301	##bility	I-PK
2301	,	O
2301	the	O
2301	maximum	B-PK
2301	peak	I-PK
2301	concentration	I-PK
2301	(	I-PK
2301	cm	I-PK
2301	##ax	I-PK
2301	)	I-PK
2301	and	O
2301	time	B-PK
2301	to	I-PK
2301	achieve	I-PK
2301	maximum	I-PK
2301	peak	I-PK
2301	concentration	I-PK
2301	(	I-PK
2301	t	I-PK
2301	##max	I-PK
2301	)	I-PK
2301	was	O
2301	also	O
2301	calculated	O
2301	.	O
2301	[SEP]	O
2302	[CLS]	O
2302	the	O
2302	terminal	B-PK
2302	rate	I-PK
2302	constant	I-PK
2302	(	I-PK
2302	k	I-PK
2302	##e	I-PK
2302	)	I-PK
2302	and	O
2302	apparent	B-PK
2302	absorption	I-PK
2302	rate	I-PK
2302	(	I-PK
2302	ka	I-PK
2302	)	I-PK
2302	of	O
2302	g	O
2302	##an	O
2302	##ci	O
2302	##c	O
2302	##lov	O
2302	##ir	O
2302	from	O
2302	a	O
2302	##que	O
2302	##ous	O
2302	humor	O
2302	was	O
2302	estimated	O
2302	from	O
2302	the	O
2302	terminal	O
2302	portions	O
2302	of	O
2302	the	O
2302	respective	O
2302	log	O
2302	(	O
2302	a	O
2302	##que	O
2302	##ous	O
2302	humor	O
2302	concentration	O
2302	)	O
2302	vs	O
2302	.	O
2302	time	O
2302	linear	O
2302	re	O
2302	##gression	O
2302	plots	O
2302	[	O
2302	28	O
2302	]	O
2302	.	O
2302	[SEP]	O
2303	[CLS]	O
2303	the	O
2303	o	O
2303	##cular	O
2303	irritation	O
2303	test	O
2303	showed	O
2303	that	O
2303	the	O
2303	g	O
2303	##c	O
2303	##m	O
2303	sample	O
2303	(	O
2303	12	O
2303	.	O
2303	0	O
2303	±	O
2303	1	O
2303	.	O
2303	0	O
2303	vs	O
2303	g	O
2303	##an	O
2303	##ci	O
2303	##c	O
2303	##lov	O
2303	##ir	O
2303	solution	O
2303	10	O
2303	.	O
2303	0	O
2303	±	O
2303	1	O
2303	.	O
2303	0	O
2303	)	O
2303	was	O
2303	well	O
2303	tolerate	O
2303	##d	O
2303	.	O
2303	[SEP]	O
2304	[CLS]	O
2304	subsequently	O
2304	,	O
2304	the	O
2304	terminal	B-PK
2304	rate	I-PK
2304	constant	I-PK
2304	(	I-PK
2304	k	I-PK
2304	##e	I-PK
2304	)	I-PK
2304	and	O
2304	t	B-PK
2304	##1	I-PK
2304	/	I-PK
2304	2	I-PK
2304	did	O
2304	not	O
2304	alter	O
2304	much	O
2304	.	O
2304	[SEP]	O
2305	[CLS]	O
2305	the	O
2305	cm	B-PK
2305	##ax	I-PK
2305	of	O
2305	g	O
2305	##c	O
2305	##m	O
2305	was	O
2305	2	O
2305	.	O
2305	69	O
2305	-	O
2305	fold	O
2305	of	O
2305	the	O
2305	g	O
2305	##an	O
2305	##ci	O
2305	##c	O
2305	##lov	O
2305	##ir	O
2305	group	O
2305	(	O
2305	p	O
2305	<	O
2305	0	O
2305	.	O
2305	000	O
2305	##1	O
2305	)	O
2305	and	O
2305	the	O
2305	delay	O
2305	in	O
2305	t	B-PK
2305	##max	I-PK
2305	in	O
2305	##fers	O
2305	the	O
2305	sustained	O
2305	release	O
2305	of	O
2305	the	O
2305	g	O
2305	##c	O
2305	##m	O
2305	.	O
2305	[SEP]	O
2306	[CLS]	O
2306	in	O
2306	this	O
2306	study	O
2306	,	O
2306	the	O
2306	cm	B-PK
2306	##ax	I-PK
2306	/	I-PK
2306	mi	I-PK
2306	##c	I-PK
2306	##90	I-PK
2306	and	O
2306	au	B-PK
2306	##c	I-PK
2306	##0	I-PK
2306	–	I-PK
2306	24	I-PK
2306	/	I-PK
2306	mi	I-PK
2306	##c	I-PK
2306	##90	I-PK
2306	of	O
2306	g	O
2306	##c	O
2306	##m	O
2306	were	O
2306	maintained	O
2306	higher	O
2306	than	O
2306	the	O
2306	g	O
2306	##an	O
2306	##ci	O
2306	##c	O
2306	##lov	O
2306	##ir	O
2306	solution	O
2306	.	O
2306	[SEP]	O
2307	[CLS]	O
2307	k	O
2307	##1	O
2307	##g	O
2307	(	O
2307	t	O
2307	)	O
2307	+	O
2307	k	O
2307	##2	O
2307	##k	O
2307	##1	O
2307	##g	O
2307	(	O
2307	t	O
2307	)	O
2307	+	O
2307	k	O
2307	##2	O
2307	,	O
2307	um	O
2307	##in	O
2307	##≤	O
2307	##k	O
2307	##1	O
2307	##g	O
2307	(	O
2307	t	O
2307	)	O
2307	+	O
2307	k	O
2307	##2	O
2307	##≤	O
2307	##uma	O
2307	##x	O
2307	##uma	O
2307	##x	O
2307	,	O
2307	um	O
2307	##ax	O
2307	<	O
2307	k	O
2307	##1	O
2307	##g	O
2307	(	O
2307	t	O
2307	)	O
2307	+	O
2307	k	O
2307	##2	O
2307	[SEP]	O
2308	[CLS]	O
2308	g	O
2308	##a	O
2308	is	O
2308	a	O
2308	significant	O
2308	un	O
2308	##met	O
2308	need	O
2308	,	O
2308	affecting	O
2308	more	O
2308	than	O
2308	5	O
2308	million	O
2308	people	O
2308	worldwide	O
2308	,	O
2308	with	O
2308	devastating	O
2308	effects	O
2308	on	O
2308	patients	O
2308	'	O
2308	visual	O
2308	function	O
2308	and	O
2308	quality	O
2308	of	O
2308	life	O
2308	.	O
2308	1	O
2308	,	O
2308	2	O
2308	g	O
2308	##a	O
2308	is	O
2308	characterized	O
2308	by	O
2308	extensive	O
2308	loss	O
2308	of	O
2308	the	O
2308	ch	O
2308	##orio	O
2308	##cap	O
2308	##illa	O
2308	##ris	O
2308	and	O
2308	the	O
2308	overly	O
2308	##ing	O
2308	re	O
2308	##tina	O
2308	##l	O
2308	pig	O
2308	##ment	O
2308	e	O
2308	##pit	O
2308	##hel	O
2308	##ium	O
2308	(	O
2308	r	O
2308	##pe	O
2308	)	O
2308	,	O
2308	and	O
2308	accounts	O
2308	for	O
2308	26	O
2308	%	O
2308	of	O
2308	legal	O
2308	blind	O
2308	##ness	O
2308	in	O
2308	the	O
2308	united	O
2308	kingdom	O
2308	.	O
2308	3	O
2308	–	O
2308	6	O
2308	currently	O
2308	,	O
2308	there	O
2308	are	O
2308	no	O
2308	licensed	O
2308	the	O
2308	##rap	O
2308	##ies	O
2308	to	O
2308	prevent	O
2308	the	O
2308	progression	O
2308	of	O
2308	g	O
2308	##a	O
2308	and	O
2308	the	O
2308	associated	O
2308	decrease	O
2308	in	O
2308	visual	O
2308	function	O
2308	.	O
2308	7	O
2308	[SEP]	O
2309	[CLS]	O
2309	v	O
2309	##vi	O
2309	##tr	O
2309	and	O
2309	v	B-PK
2309	##c	I-PK
2309	are	O
2309	the	O
2309	v	O
2309	##it	O
2309	##re	O
2309	##ous	O
2309	humor	O
2309	and	O
2309	serum	B-PK
2309	volumes	I-PK
2309	,	O
2309	respectively	O
2309	;	O
2309	r	O
2309	##aq	O
2309	is	O
2309	the	O
2309	total	O
2309	c	O
2309	##f	O
2309	##d	O
2309	concentration	O
2309	in	O
2309	a	O
2309	##que	O
2309	##ous	O
2309	humor	O
2309	;	O
2309	k	B-PK
2309	##out	I-PK
2309	and	O
2309	k	B-PK
2309	##out	I-PK
2309	##c	I-PK
2309	denote	O
2309	the	O
2309	elimination	B-PK
2309	rate	I-PK
2309	constant	I-PK
2309	##s	I-PK
2309	of	O
2309	the	O
2309	un	O
2309	##bound	O
2309	lamp	O
2309	##ali	O
2309	##zu	O
2309	##ma	O
2309	##b	O
2309	and	O
2309	lamp	O
2309	##ali	O
2309	##zu	O
2309	##ma	O
2309	##b	O
2309	–	O
2309	c	O
2309	##f	O
2309	##d	O
2309	complex	O
2309	,	O
2309	respectively	O
2309	.	O
2309	[SEP]	O
2310	[CLS]	O
2310	only	O
2310	three	O
2310	random	O
2310	effect	O
2310	parameters	O
2310	(	O
2310	k	B-PK
2310	##out	I-PK
2310	,	O
2310	k	B-PK
2310	,	O
2310	and	O
2310	λ	B-PK
2310	##a	I-PK
2310	)	O
2310	were	O
2310	significantly	O
2310	different	O
2310	from	O
2310	1	O
2310	%	O
2310	.	O
2310	[SEP]	O
2311	[CLS]	O
2311	after	O
2311	the	O
2311	base	O
2311	model	O
2311	was	O
2311	developed	O
2311	,	O
2311	effects	O
2311	of	O
2311	age	O
2311	,	O
2311	sex	O
2311	,	O
2311	and	O
2311	anti	O
2311	##ther	O
2311	##ap	O
2311	##eu	O
2311	##tic	O
2311	antibodies	O
2311	(	O
2311	at	O
2311	##a	O
2311	)	O
2311	status	O
2311	on	O
2311	k	B-PK
2311	##out	I-PK
2311	and	O
2311	k	B-PK
2311	were	O
2311	added	O
2311	to	O
2311	the	O
2311	model	O
2311	.	O
2311	[SEP]	O
2312	[CLS]	O
2312	therefore	O
2312	,	O
2312	co	O
2312	##var	O
2312	##iate	O
2312	effects	O
2312	were	O
2312	tested	O
2312	only	O
2312	on	O
2312	o	O
2312	##cular	O
2312	(	O
2312	k	B-PK
2312	##out	I-PK
2312	)	O
2312	and	O
2312	systemic	B-PK
2312	elimination	I-PK
2312	rate	I-PK
2312	constant	I-PK
2312	##s	I-PK
2312	(	I-PK
2312	k	I-PK
2312	)	I-PK
2312	,	O
2312	which	O
2312	are	O
2312	the	O
2312	main	O
2312	parameters	O
2312	that	O
2312	govern	O
2312	the	O
2312	o	O
2312	##cular	O
2312	and	O
2312	systemic	O
2312	p	O
2312	##har	O
2312	##ma	O
2312	##co	O
2312	##kin	O
2312	##etics	O
2312	,	O
2312	respectively	O
2312	.	O
2312	[SEP]	O
2313	[CLS]	O
2313	systemic	B-PK
2313	half	I-PK
2313	-	I-PK
2313	life	I-PK
2313	was	O
2313	estimated	O
2313	to	O
2313	be	O
2313	9	O
2313	hours	O
2313	(	O
2313	k	B-PK
2313	=	O
2313	1	O
2313	.	O
2313	89	O
2313	day	O
2313	##−	O
2313	##1	O
2313	,	O
2313	table	O
2313	##1	O
2313	)	O
2313	when	O
2313	using	O
2313	the	O
2313	combined	O
2313	o	O
2313	##cular	O
2313	/	O
2313	serum	O
2313	model	O
2313	,	O
2313	and	O
2313	was	O
2313	in	O
2313	agreement	O
2313	with	O
2313	the	O
2313	population	O
2313	serum	O
2313	p	O
2313	##k	O
2313	model	O
2313	(	O
2313	t	B-PK
2313	##1	I-PK
2313	/	I-PK
2313	2	I-PK
2313	=	O
2313	7	O
2313	.	O
2313	4	O
2313	hours	O
2313	,	O
2313	k	B-PK
2313	=	O
2313	2	O
2313	.	O
2313	23	O
2313	day	O
2313	##−	O
2313	##1	O
2313	,	O
2313	supplement	O
2313	##al	O
2313	table	O
2313	2	O
2313	)	O
2313	.	O
2313	[SEP]	O
2314	[CLS]	O
2314	also	O
2314	in	O
2314	agreement	O
2314	with	O
2314	the	O
2314	serum	O
2314	population	O
2314	p	O
2314	##k	O
2314	model	O
2314	,	O
2314	o	O
2314	##cular	O
2314	-	O
2314	to	O
2314	-	O
2314	systemic	O
2314	absorption	B-PK
2314	half	I-PK
2314	-	I-PK
2314	life	I-PK
2314	was	O
2314	estimated	O
2314	to	O
2314	be	O
2314	5	O
2314	.	O
2314	9	O
2314	days	O
2314	(	O
2314	k	B-PK
2314	##out	I-PK
2314	=	O
2314	0	O
2314	.	O
2314	117	O
2314	day	O
2314	##−	O
2314	##1	O
2314	)	O
2314	.	O
2314	[SEP]	O
2315	[CLS]	O
2315	at	O
2315	steady	O
2315	-	O
2315	state	O
2315	,	O
2315	lamp	O
2315	##ali	O
2315	##zu	O
2315	##ma	O
2315	##b	O
2315	v	O
2315	##it	O
2315	##re	O
2315	##ous	O
2315	humor	O
2315	exposure	O
2315	was	O
2315	greater	O
2315	than	O
2315	11	O
2315	,	O
2315	000	O
2315	-	O
2315	fold	O
2315	higher	O
2315	than	O
2315	serum	O
2315	exposure	O
2315	based	O
2315	on	O
2315	serum	O
2315	and	O
2315	v	O
2315	##it	O
2315	##re	O
2315	##ous	O
2315	humor	O
2315	cm	B-PK
2315	##ax	I-PK
2315	,	O
2315	minimum	B-PK
2315	concentrations	I-PK
2315	(	I-PK
2315	cm	I-PK
2315	##in	I-PK
2315	)	I-PK
2315	,	O
2315	or	O
2315	cumulative	B-PK
2315	area	I-PK
2315	under	I-PK
2315	the	I-PK
2315	concentration	I-PK
2315	–	I-PK
2315	time	I-PK
2315	curve	I-PK
2315	(	I-PK
2315	au	I-PK
2315	##c	I-PK
2315	##0	I-PK
2315	-	I-PK
2315	72	I-PK
2315	##w	I-PK
2315	##k	I-PK
2315	)	I-PK
2315	(	O
2315	supplement	O
2315	##al	O
2315	table	O
2315	3	O
2315	)	O
2315	.	O
2315	[SEP]	O
2316	[CLS]	O
2316	additionally	O
2316	,	O
2316	with	O
2316	all	O
2316	three	O
2316	dos	O
2316	##ing	O
2316	schedules	O
2316	,	O
2316	the	O
2316	5th	O
2316	percent	O
2316	##ile	O
2316	of	O
2316	v	O
2316	##it	O
2316	##re	O
2316	##ous	O
2316	humor	O
2316	cm	B-PK
2316	##in	I-PK
2316	values	O
2316	for	O
2316	10	O
2316	mg	O
2316	per	O
2316	eye	O
2316	were	O
2316	above	O
2316	the	O
2316	median	B-PK
2316	inhibitor	I-PK
2316	##y	I-PK
2316	concentration	I-PK
2316	(	I-PK
2316	i	I-PK
2316	##c	I-PK
2316	##50	I-PK
2316	)	I-PK
2316	(	O
2316	[UNK]	O
2316	.	O
2316	2	O
2316	μ	O
2316	##g	O
2316	/	O
2316	m	O
2316	##l	O
2316	or	O
2316	4	O
2316	nm	O
2316	)	O
2316	of	O
2316	alternative	O
2316	complement	O
2316	in	O
2316	##hibition	O
2316	(	O
2316	figure	O
2316	##4	O
2316	##a	O
2316	and	O
2316	supplement	O
2316	##al	O
2316	table	O
2316	3	O
2316	)	O
2316	based	O
2316	on	O
2316	a	O
2316	serum	O
2316	hem	O
2316	##oly	O
2316	##tic	O
2316	cell	O
2316	-	O
2316	based	O
2316	ass	O
2316	##ay	O
2316	,	O
2316	11	O
2316	while	O
2316	the	O
2316	95	O
2316	##th	O
2316	percent	O
2316	##ile	O
2316	of	O
2316	serum	O
2316	cm	B-PK
2316	##ax	I-PK
2316	values	O
2316	for	O
2316	10	O
2316	mg	O
2316	per	O
2316	eye	O
2316	were	O
2316	below	O
2316	2	O
2316	μ	O
2316	##g	O
2316	/	O
2316	m	O
2316	##l	O
2316	or	O
2316	42	O
2316	nm	O
2316	(	O
2316	figure	O
2316	##4	O
2316	##b	O
2316	and	O
2316	supplement	O
2316	##al	O
2316	table	O
2316	3	O
2316	)	O
2316	,	O
2316	the	O
2316	minimum	O
2316	level	O
2316	needed	O
2316	to	O
2316	in	O
2316	##hibit	O
2316	alternative	O
2316	complement	O
2316	pathway	O
2316	in	O
2316	the	O
2316	serum	O
2316	.	O
2316	10	O
2316	,	O
2316	11	O
2316	our	O
2316	simulation	O
2316	##s	O
2316	showed	O
2316	that	O
2316	in	O
2316	##tra	O
2316	##vi	O
2316	##tre	O
2316	##ally	O
2316	administered	O
2316	lamp	O
2316	##ali	O
2316	##zu	O
2316	##ma	O
2316	##b	O
2316	results	O
2316	in	O
2316	high	O
2316	local	O
2316	o	O
2316	##cular	O
2316	drug	O
2316	concentrations	O
2316	while	O
2316	mini	O
2316	##mizing	O
2316	systemic	O
2316	drug	O
2316	concentrations	O
2316	and	O
2316	potential	O
2316	systemic	O
2316	adverse	O
2316	events	O
2316	.	O
2316	[SEP]	O
2317	[CLS]	O
2317	older	O
2317	patients	O
2317	also	O
2317	tended	O
2317	to	O
2317	have	O
2317	a	O
2317	slower	O
2317	o	B-PK
2317	##cular	I-PK
2317	elimination	I-PK
2317	constant	I-PK
2317	(	I-PK
2317	k	I-PK
2317	##out	I-PK
2317	)	I-PK
2317	and	O
2317	longer	O
2317	o	B-PK
2317	##cular	I-PK
2317	half	I-PK
2317	-	I-PK
2317	life	I-PK
2317	(	O
2317	supplement	O
2317	##al	O
2317	figure	O
2317	3	O
2317	##b	O
2317	)	O
2317	.	O
2317	[SEP]	O
2318	[CLS]	O
2318	to	O
2318	examine	O
2318	the	O
2318	impact	O
2318	of	O
2318	age	O
2318	and	O
2318	sex	O
2318	on	O
2318	the	O
2318	clinical	O
2318	##ly	O
2318	relevant	O
2318	o	O
2318	##cular	O
2318	and	O
2318	systemic	O
2318	exposure	O
2318	##s	O
2318	,	O
2318	the	O
2318	magnitude	O
2318	of	O
2318	their	O
2318	co	O
2318	##var	O
2318	##iate	O
2318	effect	O
2318	on	O
2318	o	B-PK
2318	##cular	I-PK
2318	cm	I-PK
2318	##in	I-PK
2318	,	O
2318	cumulative	B-PK
2318	au	I-PK
2318	##c	I-PK
2318	,	O
2318	serum	B-PK
2318	cm	I-PK
2318	##ax	I-PK
2318	,	O
2318	and	O
2318	cumulative	B-PK
2318	au	I-PK
2318	##c	I-PK
2318	was	O
2318	examined	O
2318	(	O
2318	figure	O
2318	##5	O
2318	)	O
2318	.	O
2318	[SEP]	O
2319	[CLS]	O
2319	despite	O
2319	the	O
2319	statistical	O
2319	##ly	O
2319	significant	O
2319	impact	O
2319	of	O
2319	age	O
2319	and	O
2319	sex	O
2319	on	O
2319	k	B-PK
2319	and	O
2319	age	O
2319	on	O
2319	k	B-PK
2319	##out	I-PK
2319	,	O
2319	the	O
2319	magnitude	O
2319	of	O
2319	the	O
2319	co	O
2319	##var	O
2319	##iate	O
2319	effects	O
2319	was	O
2319	relatively	O
2319	small	O
2319	compared	O
2319	to	O
2319	the	O
2319	inter	O
2319	##su	O
2319	##bject	O
2319	var	O
2319	##iability	O
2319	and	O
2319	was	O
2319	not	O
2319	expected	O
2319	to	O
2319	be	O
2319	clinical	O
2319	##ly	O
2319	relevant	O
2319	.	O
2319	[SEP]	O
2320	[CLS]	O
2320	comparison	O
2320	of	O
2320	v	O
2320	##pa	O
2320	c	B-PK
2320	##l	I-PK
2320	/	I-PK
2320	f	I-PK
2320	values	O
2320	between	O
2320	e	O
2320	##pile	O
2320	##ptic	O
2320	and	O
2320	man	O
2320	##ic	O
2320	patients	O
2320	[SEP]	O
2321	[CLS]	O
2321	v	O
2321	##pa	O
2321	c	B-PK
2321	##l	I-PK
2321	/	I-PK
2321	f	I-PK
2321	between	O
2321	these	O
2321	two	O
2321	groups	O
2321	was	O
2321	compared	O
2321	and	O
2321	v	O
2321	##pa	O
2321	clearance	B-PK
2321	was	O
2321	significantly	O
2321	higher	O
2321	in	O
2321	patients	O
2321	with	O
2321	acute	O
2321	man	O
2321	##ia	O
2321	.	O
2321	[SEP]	O
2322	[CLS]	O
2322	comparison	O
2322	of	O
2322	v	O
2322	##pa	O
2322	c	B-PK
2322	##l	I-PK
2322	/	I-PK
2322	f	I-PK
2322	values	O
2322	between	O
2322	male	O
2322	and	O
2322	female	O
2322	[SEP]	O
2323	[CLS]	O
2323	v	O
2323	##pa	O
2323	c	B-PK
2323	##l	I-PK
2323	/	I-PK
2323	f	I-PK
2323	values	O
2323	between	O
2323	male	O
2323	and	O
2323	female	O
2323	were	O
2323	compared	O
2323	and	O
2323	no	O
2323	significant	O
2323	difference	O
2323	was	O
2323	noted	O
2323	.	O
2323	[SEP]	O
2324	[CLS]	O
2324	v	O
2324	##pa	O
2324	apparent	B-PK
2324	oral	I-PK
2324	clearance	I-PK
2324	(	I-PK
2324	c	I-PK
2324	##l	I-PK
2324	/	I-PK
2324	f	I-PK
2324	)	I-PK
2324	values	O
2324	were	O
2324	calculated	O
2324	and	O
2324	compared	O
2324	between	O
2324	these	O
2324	two	O
2324	groups	O
2324	.	O
2324	[SEP]	O
2325	[CLS]	O
2325	where	O
2325	c	B-PK
2325	##l	I-PK
2325	is	O
2325	the	O
2325	total	B-PK
2325	body	I-PK
2325	clearance	I-PK
2325	of	O
2325	drug	O
2325	,	O
2325	f	B-PK
2325	is	O
2325	the	O
2325	oral	B-PK
2325	bio	I-PK
2325	##ava	I-PK
2325	##ila	I-PK
2325	##bility	I-PK
2325	and	O
2325	c	B-PK
2325	##ss	I-PK
2325	reflected	B-PK
2325	t	I-PK
2325	##rough	I-PK
2325	concentrations	I-PK
2325	,	O
2325	and	O
2325	so	O
2325	calculated	O
2325	c	B-PK
2325	##l	I-PK
2325	/	I-PK
2325	f	I-PK
2325	may	O
2325	represent	O
2325	over	O
2325	##est	O
2325	##imate	O
2325	##s	O
2325	of	O
2325	the	O
2325	actual	O
2325	values	O
2325	.	O
2325	[SEP]	O
2326	[CLS]	O
2326	after	O
2326	i	O
2326	.	O
2326	v	O
2326	.	O
2326	administration	O
2326	of	O
2326	n	O
2326	##f	O
2326	##l	O
2326	##x	O
2326	##ga	O
2326	,	O
2326	the	O
2326	distribution	O
2326	(	O
2326	t	B-PK
2326	##1	I-PK
2326	/	I-PK
2326	2	I-PK
2326	##α	I-PK
2326	)	O
2326	and	O
2326	elimination	B-PK
2326	half	I-PK
2326	-	I-PK
2326	life	I-PK
2326	(	I-PK
2326	t	I-PK
2326	##1	I-PK
2326	/	I-PK
2326	2	I-PK
2326	##β	I-PK
2326	)	I-PK
2326	were	O
2326	0	O
2326	.	O
2326	36	O
2326	±	O
2326	0	O
2326	.	O
2326	07	O
2326	h	O
2326	and	O
2326	7	O
2326	.	O
2326	42	O
2326	±	O
2326	3	O
2326	.	O
2326	55	O
2326	h	O
2326	,	O
2326	respectively	O
2326	.	O
2326	[SEP]	O
2327	[CLS]	O
2327	after	O
2327	p	O
2327	.	O
2327	o	O
2327	.	O
2327	administration	O
2327	of	O
2327	n	O
2327	##f	O
2327	##l	O
2327	##x	O
2327	##ga	O
2327	,	O
2327	the	O
2327	ma	B-PK
2327	##ximal	I-PK
2327	absorption	I-PK
2327	concentration	I-PK
2327	(	I-PK
2327	cm	I-PK
2327	##ax	I-PK
2327	)	I-PK
2327	was	O
2327	0	O
2327	.	O
2327	43	O
2327	±	O
2327	0	O
2327	.	O
2327	06	O
2327	µ	O
2327	##g	O
2327	/	O
2327	m	O
2327	##l	O
2327	at	O
2327	1	O
2327	.	O
2327	36	O
2327	±	O
2327	0	O
2327	.	O
2327	39	O
2327	h	O
2327	(	O
2327	t	B-PK
2327	##max	I-PK
2327	)	O
2327	.	O
2327	[SEP]	O
2328	[CLS]	O
2328	the	O
2328	mean	O
2328	systemic	B-PK
2328	bio	I-PK
2328	##ava	I-PK
2328	##ila	I-PK
2328	##bility	I-PK
2328	(	I-PK
2328	f	I-PK
2328	)	I-PK
2328	after	O
2328	p	O
2328	.	O
2328	o	O
2328	.	O
2328	administration	O
2328	was	O
2328	31	O
2328	.	O
2328	10	O
2328	±	O
2328	15	O
2328	.	O
2328	16	O
2328	%	O
2328	.	O
2328	[SEP]	O
2329	[CLS]	O
2329	following	O
2329	p	O
2329	.	O
2329	o	O
2329	.	O
2329	administration	O
2329	,	O
2329	the	O
2329	bio	B-PK
2329	##ava	I-PK
2329	##ila	I-PK
2329	##bility	I-PK
2329	f	I-PK
2329	was	O
2329	calculated	O
2329	according	O
2329	to	O
2329	the	O
2329	equation	O
2329	:	O
2329	[SEP]	O
2330	[CLS]	O
2330	the	O
2330	serum	O
2330	concentration	O
2330	of	O
2330	nor	O
2330	##f	O
2330	##lo	O
2330	##xa	O
2330	##cin	O
2330	reached	O
2330	a	O
2330	maximum	O
2330	level	O
2330	(	O
2330	cm	B-PK
2330	##ax	I-PK
2330	)	O
2330	of	O
2330	0	O
2330	.	O
2330	43	O
2330	±	O
2330	0	O
2330	.	O
2330	06	O
2330	µ	O
2330	##g	O
2330	/	O
2330	m	O
2330	##l	O
2330	at	O
2330	1	O
2330	.	O
2330	36	O
2330	±	O
2330	0	O
2330	.	O
2330	39	O
2330	h	O
2330	(	O
2330	t	B-PK
2330	##max	I-PK
2330	)	O
2330	,	O
2330	and	O
2330	the	O
2330	absorption	B-PK
2330	half	I-PK
2330	-	I-PK
2330	life	I-PK
2330	(	I-PK
2330	t	I-PK
2330	##1	I-PK
2330	/	I-PK
2330	2	I-PK
2330	##ka	I-PK
2330	)	I-PK
2330	was	O
2330	0	O
2330	.	O
2330	78	O
2330	±	O
2330	0	O
2330	.	O
2330	27	O
2330	h	O
2330	after	O
2330	p	O
2330	.	O
2330	o	O
2330	.	O
2330	administration	O
2330	in	O
2330	pigs	O
2330	.	O
2330	[SEP]	O
2331	[CLS]	O
2331	the	O
2331	aim	O
2331	of	O
2331	the	O
2331	analysis	O
2331	was	O
2331	to	O
2331	character	O
2331	##ize	O
2331	the	O
2331	population	O
2331	p	O
2331	##har	O
2331	##ma	O
2331	##co	O
2331	##kin	O
2331	##etics	O
2331	(	O
2331	p	O
2331	##ks	O
2331	)	O
2331	and	O
2331	exposure	O
2331	–	O
2331	response	O
2331	(	O
2331	e	O
2331	–	O
2331	r	O
2331	)	O
2331	for	O
2331	efficacy	O
2331	(	O
2331	fast	O
2331	##ing	O
2331	plasma	O
2331	glucose	O
2331	,	O
2331	g	O
2331	##ly	O
2331	##cated	O
2331	hem	O
2331	##og	O
2331	##lo	O
2331	##bin	O
2331	)	O
2331	and	O
2331	safety	O
2331	/	O
2331	to	O
2331	##ler	O
2331	##ability	O
2331	[	O
2331	h	O
2331	##y	O
2331	##po	O
2331	##gly	O
2331	##ce	O
2331	##mia	O
2331	,	O
2331	g	O
2331	##eni	O
2331	##tal	O
2331	infections	O
2331	,	O
2331	u	O
2331	##rina	O
2331	##ry	O
2331	tract	O
2331	infection	O
2331	(	O
2331	u	O
2331	##ti	O
2331	)	O
2331	,	O
2331	and	O
2331	volume	O
2331	de	O
2331	##ple	O
2331	##tion	O
2331	]	O
2331	of	O
2331	the	O
2331	sodium	O
2331	glucose	O
2331	co	O
2331	##tra	O
2331	##ns	O
2331	##port	O
2331	##er	O
2331	2	O
2331	inhibitor	O
2331	,	O
2331	em	O
2331	##pa	O
2331	##gli	O
2331	##f	O
2331	##lo	O
2331	##zin	O
2331	,	O
2331	in	O
2331	patients	O
2331	with	O
2331	type	O
2331	2	O
2331	diabetes	O
2331	me	O
2331	##lli	O
2331	##tus	O
2331	.	O
2331	[SEP]	O
2332	[CLS]	O
2332	population	O
2332	p	O
2332	##har	O
2332	##ma	O
2332	##co	O
2332	##kin	O
2332	##etic	O
2332	and	O
2332	e	O
2332	–	O
2332	r	O
2332	models	O
2332	were	O
2332	developed	O
2332	based	O
2332	on	O
2332	two	O
2332	phase	O
2332	i	O
2332	,	O
2332	four	O
2332	phase	O
2332	ii	O
2332	,	O
2332	and	O
2332	four	O
2332	phase	O
2332	ii	O
2332	##i	O
2332	studies	O
2332	.	O
2332	[SEP]	O
2333	[CLS]	O
2333	based	O
2333	on	O
2333	the	O
2333	results	O
2333	from	O
2333	the	O
2333	p	O
2333	##k	O
2333	and	O
2333	e	O
2333	–	O
2333	r	O
2333	analysis	O
2333	,	O
2333	no	O
2333	dose	O
2333	adjustment	O
2333	is	O
2333	required	O
2333	for	O
2333	em	O
2333	##pa	O
2333	##gli	O
2333	##f	O
2333	##lo	O
2333	##zin	O
2333	in	O
2333	the	O
2333	patient	O
2333	population	O
2333	for	O
2333	which	O
2333	the	O
2333	drug	O
2333	is	O
2333	approved	O
2333	.	O
2333	[SEP]	O
2334	[CLS]	O
2334	the	O
2334	influence	O
2334	of	O
2334	age	O
2334	,	O
2334	sex	O
2334	,	O
2334	race	O
2334	,	O
2334	total	O
2334	protein	O
2334	,	O
2334	and	O
2334	b	O
2334	##mi	O
2334	was	O
2334	assessed	O
2334	for	O
2334	the	O
2334	volumes	B-PK
2334	of	I-PK
2334	distribution	I-PK
2334	[	O
2334	apparent	B-PK
2334	central	I-PK
2334	volume	I-PK
2334	of	I-PK
2334	distribution	I-PK
2334	(	I-PK
2334	v	I-PK
2334	##2	I-PK
2334	/	I-PK
2334	f	I-PK
2334	)	I-PK
2334	,	O
2334	apparent	B-PK
2334	peripheral	I-PK
2334	volume	I-PK
2334	of	I-PK
2334	distribution	I-PK
2334	(	I-PK
2334	v	I-PK
2334	##3	I-PK
2334	/	I-PK
2334	f	I-PK
2334	)	I-PK
2334	]	O
2334	,	O
2334	and	O
2334	age	O
2334	,	O
2334	sex	O
2334	,	O
2334	and	O
2334	race	O
2334	were	O
2334	evaluated	O
2334	for	O
2334	influence	O
2334	on	O
2334	the	O
2334	absorption	B-PK
2334	rate	I-PK
2334	constant	I-PK
2334	(	I-PK
2334	ka	I-PK
2334	)	I-PK
2334	(	O
2334	table	O
2334	s	O
2334	##1	O
2334	in	O
2334	the	O
2334	supplement	O
2334	##ary	O
2334	material	O
2334	)	O
2334	.	O
2334	[SEP]	O
2335	[CLS]	O
2335	the	O
2335	co	O
2335	##var	O
2335	##iate	O
2335	##s	O
2335	were	O
2335	chosen	O
2335	based	O
2335	on	O
2335	one	O
2335	or	O
2335	a	O
2335	combination	O
2335	of	O
2335	the	O
2335	following	O
2335	:	O
2335	findings	O
2335	from	O
2335	previous	O
2335	analysis	O
2335	(	O
2335	c	B-PK
2335	##l	I-PK
2335	/	I-PK
2335	f	I-PK
2335	:	O
2335	age	O
2335	,	O
2335	b	O
2335	##mi	O
2335	,	O
2335	race	O
2335	,	O
2335	total	O
2335	protein	O
2335	,	O
2335	e	O
2335	##g	O
2335	##f	O
2335	##r	O
2335	;	O
2335	v	B-PK
2335	##2	I-PK
2335	/	I-PK
2335	f	I-PK
2335	:	O
2335	sex	O
2335	,	O
2335	race	O
2335	,	O
2335	total	O
2335	protein	O
2335	,	O
2335	b	O
2335	##mi	O
2335	;	O
2335	ka	B-PK
2335	:	O
2335	race	O
2335	)	O
2335	,	O
2335	scientific	O
2335	interest	O
2335	and	O
2335	relevance	O
2335	to	O
2335	the	O
2335	development	O
2335	programme	O
2335	(	O
2335	v	B-PK
2335	##2	I-PK
2335	/	I-PK
2335	f	I-PK
2335	:	O
2335	age	O
2335	,	O
2335	race	O
2335	;	O
2335	ka	B-PK
2335	:	O
2335	sex	O
2335	)	O
2335	,	O
2335	physiological	O
2335	/	O
2335	me	O
2335	##chan	O
2335	##istic	O
2335	p	O
2335	##laus	O
2335	##ibility	O
2335	(	O
2335	c	B-PK
2335	##l	I-PK
2335	/	I-PK
2335	f	I-PK
2335	:	O
2335	e	O
2335	##g	O
2335	##f	O
2335	##r	O
2335	;	O
2335	ka	B-PK
2335	:	O
2335	age	O
2335	)	O
2335	.	O
2335	[SEP]	O
2336	[CLS]	O
2336	patient	O
2336	-	O
2336	level	O
2336	random	O
2336	effects	O
2336	were	O
2336	included	O
2336	for	O
2336	c	B-PK
2336	##l	I-PK
2336	/	I-PK
2336	f	I-PK
2336	,	O
2336	ka	B-PK
2336	,	O
2336	and	O
2336	v	B-PK
2336	##3	I-PK
2336	/	I-PK
2336	f	I-PK
2336	;	O
2336	these	O
2336	parameters	O
2336	were	O
2336	assumed	O
2336	to	O
2336	be	O
2336	log	O
2336	-	O
2336	normal	O
2336	distributed	O
2336	.	O
2336	[SEP]	O
2337	[CLS]	O
2337	in	O
2337	addition	O
2337	,	O
2337	mon	O
2337	##te	O
2337	car	O
2337	##lo	O
2337	simulation	O
2337	##s	O
2337	were	O
2337	performed	O
2337	to	O
2337	evaluate	O
2337	the	O
2337	predict	O
2337	##ive	O
2337	performance	O
2337	of	O
2337	the	O
2337	population	O
2337	p	O
2337	##k	O
2337	model	O
2337	for	O
2337	dose	O
2337	-	O
2337	normal	O
2337	##ized	O
2337	maximum	B-PK
2337	and	O
2337	minimum	B-PK
2337	concentration	I-PK
2337	(	O
2337	cm	B-PK
2337	##ax	I-PK
2337	and	O
2337	cm	B-PK
2337	##in	I-PK
2337	,	O
2337	respectively	O
2337	)	O
2337	.	O
2337	[SEP]	O
2338	[CLS]	O
2338	the	O
2338	safety	O
2338	/	O
2338	to	O
2338	##ler	O
2338	##ability	O
2338	end	O
2338	##points	O
2338	investigated	O
2338	in	O
2338	the	O
2338	e	O
2338	–	O
2338	r	O
2338	analysis	O
2338	were	O
2338	confirmed	O
2338	h	O
2338	##y	O
2338	##po	O
2338	##gly	O
2338	##ce	O
2338	##mic	O
2338	adverse	O
2338	events	O
2338	(	O
2338	a	O
2338	##es	O
2338	)	O
2338	(	O
2338	plasma	O
2338	glucose	O
2338	<	O
2338	3	O
2338	.	O
2338	9	O
2338	mm	O
2338	and	O
2338	/	O
2338	or	O
2338	assistance	O
2338	required	O
2338	)	O
2338	,	O
2338	events	O
2338	consistent	O
2338	with	O
2338	u	O
2338	##rina	O
2338	##ry	O
2338	tract	O
2338	infection	O
2338	(	O
2338	u	O
2338	##ti	O
2338	;	O
2338	using	O
2338	a	O
2338	prospective	O
2338	##ly	O
2338	defined	O
2338	search	O
2338	of	O
2338	73	O
2338	preferred	O
2338	terms	O
2338	)	O
2338	,	O
2338	events	O
2338	consistent	O
2338	with	O
2338	g	O
2338	##eni	O
2338	##tal	O
2338	infection	O
2338	(	O
2338	using	O
2338	a	O
2338	prospective	O
2338	##ly	O
2338	defined	O
2338	search	O
2338	of	O
2338	89	O
2338	preferred	O
2338	terms	O
2338	)	O
2338	,	O
2338	and	O
2338	events	O
2338	consistent	O
2338	with	O
2338	volume	O
2338	de	O
2338	##ple	O
2338	##tion	O
2338	(	O
2338	all	O
2338	on	O
2338	-	O
2338	treatment	O
2338	a	O
2338	##es	O
2338	,	O
2338	using	O
2338	eight	O
2338	preferred	O
2338	terms	O
2338	)	O
2338	.	O
2338	[SEP]	O
2339	[CLS]	O
2339	the	O
2339	safety	O
2339	/	O
2339	to	O
2339	##ler	O
2339	##ability	O
2339	end	O
2339	##points	O
2339	considered	O
2339	in	O
2339	the	O
2339	e	O
2339	–	O
2339	r	O
2339	analysis	O
2339	were	O
2339	included	O
2339	as	O
2339	di	O
2339	##cho	O
2339	##tom	O
2339	##ous	O
2339	end	O
2339	##points	O
2339	(	O
2339	i	O
2339	.	O
2339	e	O
2339	.	O
2339	,	O
2339	participant	O
2339	-	O
2339	reported	O
2339	a	O
2339	##es	O
2339	:	O
2339	any	O
2339	a	O
2339	##e	O
2339	during	O
2339	study	O
2339	,	O
2339	single	O
2339	yes	O
2339	/	O
2339	no	O
2339	data	O
2339	##point	O
2339	)	O
2339	,	O
2339	and	O
2339	were	O
2339	analyzed	O
2339	using	O
2339	a	O
2339	log	O
2339	##istic	O
2339	re	O
2339	##gression	O
2339	model	O
2339	[	O
2339	19	O
2339	,	O
2339	22	O
2339	]	O
2339	.	O
2339	[SEP]	O
2340	[CLS]	O
2340	typical	O
2340	population	O
2340	p	O
2340	##k	O
2340	parameters	O
2340	(	O
2340	95	O
2340	%	O
2340	c	O
2340	##i	O
2340	,	O
2340	based	O
2340	on	O
2340	non	O
2340	-	O
2340	para	O
2340	##metric	O
2340	boots	O
2340	##tra	O
2340	##p	O
2340	)	O
2340	given	O
2340	the	O
2340	reference	O
2340	co	O
2340	##var	O
2340	##iate	O
2340	##s	O
2340	(	O
2340	50	O
2340	-	O
2340	year	O
2340	-	O
2340	old	O
2340	,	O
2340	non	O
2340	-	O
2340	smoking	O
2340	male	O
2340	,	O
2340	non	O
2340	-	O
2340	as	O
2340	##ian	O
2340	race	O
2340	;	O
2340	b	O
2340	##mi	O
2340	,	O
2340	25	O
2340	kg	O
2340	/	O
2340	m	O
2340	##2	O
2340	;	O
2340	e	O
2340	##g	O
2340	##f	O
2340	##r	O
2340	,	O
2340	100	O
2340	m	O
2340	##l	O
2340	/	O
2340	min	O
2340	/	O
2340	1	O
2340	.	O
2340	73	O
2340	m	O
2340	##2	O
2340	;	O
2340	total	O
2340	protein	O
2340	,	O
2340	70	O
2340	g	O
2340	/	O
2340	d	O
2340	##l	O
2340	;	O
2340	al	O
2340	##t	O
2340	,	O
2340	20	O
2340	u	O
2340	/	O
2340	l	O
2340	;	O
2340	as	O
2340	##t	O
2340	,	O
2340	20	O
2340	u	O
2340	/	O
2340	l	O
2340	;	O
2340	a	O
2340	##p	O
2340	,	O
2340	70	O
2340	u	O
2340	/	O
2340	l	O
2340	;	O
2340	and	O
2340	l	O
2340	##dh	O
2340	,	O
2340	160	O
2340	u	O
2340	/	O
2340	l	O
2340	)	O
2340	were	O
2340	:	O
2340	c	B-PK
2340	##l	I-PK
2340	/	I-PK
2340	f	I-PK
2340	,	O
2340	10	O
2340	.	O
2340	6	O
2340	l	O
2340	/	O
2340	h	O
2340	(	O
2340	10	O
2340	.	O
2340	1	O
2340	,	O
2340	11	O
2340	.	O
2340	1	O
2340	)	O
2340	;	O
2340	v	B-PK
2340	##2	I-PK
2340	/	I-PK
2340	f	I-PK
2340	,	O
2340	3	O
2340	.	O
2340	14	O
2340	l	O
2340	(	O
2340	0	O
2340	.	O
2340	00	O
2340	##12	O
2340	##8	O
2340	,	O
2340	4	O
2340	.	O
2340	03	O
2340	)	O
2340	;	O
2340	apparent	B-PK
2340	inter	I-PK
2340	##com	I-PK
2340	##par	I-PK
2340	##tment	I-PK
2340	##al	I-PK
2340	clearance	I-PK
2340	(	I-PK
2340	q	I-PK
2340	/	I-PK
2340	f	I-PK
2340	)	I-PK
2340	,	O
2340	6	O
2340	.	O
2340	34	O
2340	l	O
2340	/	O
2340	h	O
2340	(	O
2340	5	O
2340	.	O
2340	72	O
2340	,	O
2340	6	O
2340	.	O
2340	91	O
2340	)	O
2340	;	O
2340	v	B-PK
2340	##3	I-PK
2340	/	I-PK
2340	f	I-PK
2340	,	O
2340	70	O
2340	.	O
2340	6	O
2340	l	O
2340	(	O
2340	64	O
2340	.	O
2340	4	O
2340	,	O
2340	76	O
2340	.	O
2340	6	O
2340	)	O
2340	;	O
2340	and	O
2340	first	B-PK
2340	-	I-PK
2340	order	I-PK
2340	ka	I-PK
2340	,	O
2340	0	O
2340	.	O
2340	196	O
2340	l	O
2340	/	O
2340	h	O
2340	(	O
2340	0	O
2340	.	O
2340	185	O
2340	,	O
2340	0	O
2340	.	O
2340	208	O
2340	)	O
2340	.	O
2340	[SEP]	O
2341	[CLS]	O
2341	estimated	O
2341	co	O
2341	##var	O
2341	##iate	O
2341	effects	O
2341	on	O
2341	parameters	O
2341	not	O
2341	affecting	O
2341	au	B-PK
2341	##cs	I-PK
2341	##s	I-PK
2341	(	O
2341	v	B-PK
2341	##2	I-PK
2341	/	I-PK
2341	f	I-PK
2341	,	O
2341	v	B-PK
2341	##3	I-PK
2341	/	I-PK
2341	f	I-PK
2341	,	O
2341	and	O
2341	ka	B-PK
2341	)	O
2341	are	O
2341	included	O
2341	in	O
2341	table	O
2341	s	O
2341	##1	O
2341	in	O
2341	the	O
2341	supplement	O
2341	##ary	O
2341	material	O
2341	.	O
2341	[SEP]	O
2342	[CLS]	O
2342	fast	O
2342	##ing	O
2342	plasma	O
2342	glucose	O
2342	measurements	O
2342	from	O
2342	the	O
2342	same	O
2342	studies	O
2342	were	O
2342	used	O
2342	to	O
2342	develop	O
2342	the	O
2342	e	O
2342	–	O
2342	r	O
2342	model	O
2342	for	O
2342	f	O
2342	##p	O
2342	##g	O
2342	(	O
2342	42	O
2342	##8	O
2342	##9	O
2342	patients	O
2342	)	O
2342	,	O
2342	including	O
2342	patients	O
2342	receiving	O
2342	em	O
2342	##pa	O
2342	##gli	O
2342	##f	O
2342	##lo	O
2342	##zin	O
2342	or	O
2342	place	O
2342	##bo	O
2342	.	O
2342	[SEP]	O
2343	[CLS]	O
2343	based	O
2343	on	O
2343	parameter	O
2343	estimates	O
2343	for	O
2343	the	O
2343	final	O
2343	h	O
2343	##ba	O
2343	##1	O
2343	##c	O
2343	e	O
2343	–	O
2343	r	O
2343	model	O
2343	,	O
2343	targets	O
2343	of	O
2343	80	O
2343	%	O
2343	and	O
2343	90	O
2343	%	O
2343	were	O
2343	obtained	O
2343	for	O
2343	the	O
2343	ma	O
2343	##ximal	O
2343	response	O
2343	for	O
2343	f	O
2343	##p	O
2343	##g	O
2343	and	O
2343	h	O
2343	##ba	O
2343	##1	O
2343	##c	O
2343	after	O
2343	24	O
2343	weeks	O
2343	of	O
2343	treatment	O
2343	with	O
2343	once	O
2343	daily	O
2343	em	O
2343	##pa	O
2343	##gli	O
2343	##f	O
2343	##lo	O
2343	##zin	O
2343	doses	O
2343	of	O
2343	approximately	O
2343	10	O
2343	and	O
2343	25	O
2343	mg	O
2343	,	O
2343	respectively	O
2343	(	O
2343	table	O
2343	s	O
2343	##4	O
2343	in	O
2343	the	O
2343	supplement	O
2343	##ary	O
2343	material	O
2343	)	O
2343	.	O
2343	[SEP]	O
2344	[CLS]	O
2344	to	O
2344	investigate	O
2344	the	O
2344	influence	O
2344	of	O
2344	e	O
2344	##g	O
2344	##f	O
2344	##r	O
2344	and	O
2344	age	O
2344	on	O
2344	h	O
2344	##ba	O
2344	##1	O
2344	##c	O
2344	lowering	O
2344	,	O
2344	de	O
2344	##ter	O
2344	##mini	O
2344	##stic	O
2344	simulation	O
2344	##s	O
2344	were	O
2344	performed	O
2344	to	O
2344	illustrate	O
2344	the	O
2344	e	O
2344	–	O
2344	r	O
2344	after	O
2344	24	O
2344	weeks	O
2344	of	O
2344	treatment	O
2344	(	O
2344	fi	O
2344	##g	O
2344	.	O
2344	s	O
2344	##8	O
2344	in	O
2344	the	O
2344	supplement	O
2344	##ary	O
2344	material	O
2344	)	O
2344	.	O
2344	[SEP]	O
2345	[CLS]	O
2345	however	O
2345	,	O
2345	the	O
2345	magnitude	O
2345	##s	O
2345	of	O
2345	these	O
2345	co	O
2345	##var	O
2345	##iate	O
2345	effects	O
2345	were	O
2345	minor	O
2345	,	O
2345	with	O
2345	differences	O
2345	within	O
2345	these	O
2345	co	O
2345	##var	O
2345	##iate	O
2345	groups	O
2345	between	O
2345	0	O
2345	.	O
2345	8	O
2345	and	O
2345	1	O
2345	.	O
2345	25	O
2345	of	O
2345	the	O
2345	normal	O
2345	##ized	O
2345	c	B-PK
2345	##l	I-PK
2345	/	I-PK
2345	f	I-PK
2345	or	O
2345	au	B-PK
2345	##cs	I-PK
2345	##s	I-PK
2345	at	O
2345	the	O
2345	extreme	O
2345	co	O
2345	##var	O
2345	##iate	O
2345	levels	O
2345	(	O
2345	fi	O
2345	##g	O
2345	.	O
2345	1	O
2345	)	O
2345	.	O
2345	[SEP]	O
2346	[CLS]	O
2346	g	O
2346	##ly	O
2346	##cated	O
2346	hem	O
2346	##og	O
2346	##lo	O
2346	##bin	O
2346	half	B-PK
2346	-	I-PK
2346	life	I-PK
2346	(	O
2346	calculated	O
2346	from	O
2346	k	O
2346	##h	O
2346	##ba	O
2346	##1	O
2346	##c	O
2346	,	O
2346	out	O
2346	)	O
2346	was	O
2346	approximately	O
2346	2	O
2346	.	O
2346	6	O
2346	weeks	O
2346	(	O
2346	95	O
2346	%	O
2346	c	O
2346	##i	O
2346	1	O
2346	.	O
2346	7	O
2346	,	O
2346	3	O
2346	.	O
2346	9	O
2346	)	O
2346	,	O
2346	indicating	O
2346	that	O
2346	maximum	O
2346	changes	O
2346	in	O
2346	h	O
2346	##ba	O
2346	##1	O
2346	##c	O
2346	are	O
2346	reached	O
2346	by	O
2346	around	O
2346	12	O
2346	weeks	O
2346	(	O
2346	>	O
2346	3	O
2346	half	B-PK
2346	-	I-PK
2346	lives	I-PK
2346	)	O
2346	of	O
2346	em	O
2346	##pa	O
2346	##gli	O
2346	##f	O
2346	##lo	O
2346	##zin	O
2346	therapy	O
2346	,	O
2346	and	O
2346	was	O
2346	almost	O
2346	entirely	O
2346	achieved	O
2346	by	O
2346	24	O
2346	weeks	O
2346	(	O
2346	>	O
2346	6	O
2346	half	B-PK
2346	-	I-PK
2346	lives	I-PK
2346	)	O
2346	.	O
2346	[SEP]	O
2347	[CLS]	O
2347	for	O
2347	patients	O
2347	receiving	O
2347	em	O
2347	##pa	O
2347	##gli	O
2347	##f	O
2347	##lo	O
2347	##zin	O
2347	treatment	O
2347	,	O
2347	increases	O
2347	in	O
2347	em	O
2347	##pa	O
2347	##gli	O
2347	##f	O
2347	##lo	O
2347	##zin	O
2347	au	B-PK
2347	##cs	I-PK
2347	##si	I-PK
2347	[	O
2347	or	O
2347	(	O
2347	95	O
2347	%	O
2347	c	O
2347	##i	O
2347	)	O
2347	for	O
2347	au	B-PK
2347	##c	I-PK
2347	normal	O
2347	##ized	O
2347	to	O
2347	350	O
2347	##0	O
2347	nm	O
2347	*	O
2347	h	O
2347	increase	O
2347	in	O
2347	au	B-PK
2347	##cs	I-PK
2347	##s	I-PK
2347	]	O
2347	produced	O
2347	no	O
2347	significant	O
2347	increase	O
2347	in	O
2347	incidence	O
2347	rates	O
2347	of	O
2347	confirmed	O
2347	h	O
2347	##y	O
2347	##po	O
2347	##gly	O
2347	##ce	O
2347	##mic	O
2347	a	O
2347	##es	O
2347	[	O
2347	0	O
2347	.	O
2347	98	O
2347	##8	O
2347	(	O
2347	0	O
2347	.	O
2347	86	O
2347	##3	O
2347	,	O
2347	1	O
2347	.	O
2347	13	O
2347	)	O
2347	]	O
2347	,	O
2347	events	O
2347	consistent	O
2347	with	O
2347	volume	O
2347	de	O
2347	##ple	O
2347	##tion	O
2347	[	O
2347	0	O
2347	.	O
2347	77	O
2347	##0	O
2347	(	O
2347	0	O
2347	.	O
2347	45	O
2347	##4	O
2347	,	O
2347	1	O
2347	.	O
2347	30	O
2347	)	O
2347	]	O
2347	,	O
2347	events	O
2347	consistent	O
2347	with	O
2347	u	O
2347	##ti	O
2347	[	O
2347	1	O
2347	.	O
2347	06	O
2347	(	O
2347	0	O
2347	.	O
2347	93	O
2347	##5	O
2347	,	O
2347	1	O
2347	.	O
2347	20	O
2347	)	O
2347	]	O
2347	,	O
2347	or	O
2347	events	O
2347	consistent	O
2347	with	O
2347	g	O
2347	##eni	O
2347	##tal	O
2347	infection	O
2347	[	O
2347	0	O
2347	.	O
2347	74	O
2347	##4	O
2347	(	O
2347	0	O
2347	.	O
2347	57	O
2347	##4	O
2347	,	O
2347	0	O
2347	.	O
2347	96	O
2347	##5	O
2347	)	O
2347	]	O
2347	.	O
2347	[SEP]	O
2348	[CLS]	O
2348	the	O
2348	main	O
2348	co	O
2348	##var	O
2348	##iate	O
2348	influences	O
2348	accounted	O
2348	for	O
2348	in	O
2348	the	O
2348	e	O
2348	–	O
2348	r	O
2348	analyses	O
2348	were	O
2348	con	O
2348	##com	O
2348	##ita	O
2348	##nt	O
2348	insulin	O
2348	therapy	O
2348	for	O
2348	confirmed	O
2348	h	O
2348	##y	O
2348	##po	O
2348	##gly	O
2348	##ce	O
2348	##mic	O
2348	events	O
2348	[	O
2348	or	O
2348	48	O
2348	.	O
2348	7	O
2348	(	O
2348	95	O
2348	%	O
2348	c	O
2348	##i	O
2348	26	O
2348	.	O
2348	5	O
2348	,	O
2348	89	O
2348	.	O
2348	5	O
2348	)	O
2348	]	O
2348	;	O
2348	female	O
2348	sex	O
2348	for	O
2348	u	O
2348	##ti	O
2348	[	O
2348	or	O
2348	6	O
2348	.	O
2348	14	O
2348	(	O
2348	4	O
2348	.	O
2348	60	O
2348	,	O
2348	8	O
2348	.	O
2348	19	O
2348	)	O
2348	]	O
2348	,	O
2348	and	O
2348	g	O
2348	##eni	O
2348	##tal	O
2348	infection	O
2348	[	O
2348	or	O
2348	2	O
2348	.	O
2348	28	O
2348	(	O
2348	1	O
2348	.	O
2348	55	O
2348	,	O
2348	3	O
2348	.	O
2348	35	O
2348	)	O
2348	]	O
2348	;	O
2348	and	O
2348	re	O
2348	##nal	O
2348	imp	O
2348	##air	O
2348	##ment	O
2348	[	O
2348	e	O
2348	##g	O
2348	##f	O
2348	##r	O
2348	60	O
2348	–	O
2348	90	O
2348	m	O
2348	##l	O
2348	/	O
2348	min	O
2348	/	O
2348	1	O
2348	.	O
2348	73	O
2348	m	O
2348	##2	O
2348	;	O
2348	or	O
2348	1	O
2348	.	O
2348	75	O
2348	(	O
2348	0	O
2348	.	O
2348	61	O
2348	##7	O
2348	,	O
2348	4	O
2348	.	O
2348	96	O
2348	)	O
2348	]	O
2348	;	O
2348	e	O
2348	##g	O
2348	##f	O
2348	##r	O
2348	<	O
2348	60	O
2348	m	O
2348	##l	O
2348	/	O
2348	min	O
2348	/	O
2348	1	O
2348	.	O
2348	73	O
2348	m	O
2348	##2	O
2348	;	O
2348	or	O
2348	2	O
2348	.	O
2348	78	O
2348	(	O
2348	0	O
2348	.	O
2348	82	O
2348	##9	O
2348	,	O
2348	9	O
2348	.	O
2348	34	O
2348	)	O
2348	,	O
2348	and	O
2348	insulin	O
2348	therapy	O
2348	[	O
2348	or	O
2348	,	O
2348	2	O
2348	.	O
2348	60	O
2348	(	O
2348	1	O
2348	.	O
2348	21	O
2348	,	O
2348	5	O
2348	.	O
2348	61	O
2348	)	O
2348	]	O
2348	for	O
2348	volume	O
2348	de	O
2348	##ple	O
2348	##tion	O
2348	.	O
2348	[SEP]	O
2349	[CLS]	O
2349	n	O
2349	##uc	O
2349	##leo	O
2349	##tide	O
2349	substitution	O
2349	##s	O
2349	in	O
2349	the	O
2349	amino	O
2349	acids	O
2349	e	O
2349	##5	O
2349	##42	O
2349	(	O
2349	k	O
2349	)	O
2349	,	O
2349	e	O
2349	##5	O
2349	##45	O
2349	(	O
2349	a	O
2349	,	O
2349	g	O
2349	,	O
2349	d	O
2349	,	O
2349	or	O
2349	k	O
2349	)	O
2349	,	O
2349	q	O
2349	##5	O
2349	##46	O
2349	(	O
2349	e	O
2349	,	O
2349	k	O
2349	,	O
2349	l	O
2349	,	O
2349	or	O
2349	r	O
2349	)	O
2349	,	O
2349	and	O
2349	h	O
2349	##10	O
2349	##47	O
2349	(	O
2349	l	O
2349	,	O
2349	r	O
2349	,	O
2349	or	O
2349	y	O
2349	)	O
2349	or	O
2349	the	O
2349	wild	O
2349	-	O
2349	type	O
2349	all	O
2349	##ele	O
2349	##s	O
2349	were	O
2349	detected	O
2349	.	O
2349	[SEP]	O
2350	[CLS]	O
2350	fifty	O
2350	-	O
2350	eight	O
2350	(	O
2350	84	O
2350	.	O
2350	1	O
2350	%	O
2350	)	O
2350	patients	O
2350	were	O
2350	included	O
2350	in	O
2350	the	O
2350	efficacy	O
2350	-	O
2350	e	O
2350	##val	O
2350	##ua	O
2350	##ble	O
2350	population	O
2350	for	O
2350	or	O
2350	##r	O
2350	analysis	O
2350	.	O
2350	[SEP]	O
2351	[CLS]	O
2351	major	O
2351	p	O
2351	##har	O
2351	##ma	O
2351	##co	O
2351	##kin	O
2351	##etic	O
2351	parameters	O
2351	included	O
2351	cm	B-PK
2351	##ax	I-PK
2351	,	O
2351	time	B-PK
2351	to	I-PK
2351	reach	I-PK
2351	cm	I-PK
2351	##ax	I-PK
2351	(	I-PK
2351	t	I-PK
2351	##max	I-PK
2351	)	I-PK
2351	,	O
2351	terminal	B-PK
2351	-	I-PK
2351	phase	I-PK
2351	half	I-PK
2351	-	I-PK
2351	life	I-PK
2351	(	I-PK
2351	t	I-PK
2351	##1	I-PK
2351	/	I-PK
2351	2	I-PK
2351	)	I-PK
2351	,	O
2351	au	B-PK
2351	##c	I-PK
2351	from	I-PK
2351	time	I-PK
2351	zero	I-PK
2351	to	I-PK
2351	the	I-PK
2351	last	I-PK
2351	me	I-PK
2351	##as	I-PK
2351	##urable	I-PK
2351	concentration	I-PK
2351	(	I-PK
2351	au	I-PK
2351	##ct	I-PK
2351	)	I-PK
2351	,	O
2351	au	B-PK
2351	##c	I-PK
2351	from	I-PK
2351	time	I-PK
2351	zero	I-PK
2351	to	I-PK
2351	in	I-PK
2351	##finity	I-PK
2351	(	I-PK
2351	au	I-PK
2351	##c	I-PK
2351	##∞	I-PK
2351	)	I-PK
2351	,	O
2351	cumulative	B-PK
2351	u	I-PK
2351	##rina	I-PK
2351	##ry	I-PK
2351	ex	I-PK
2351	##cre	I-PK
2351	##tion	I-PK
2351	as	I-PK
2351	a	I-PK
2351	percentage	I-PK
2351	of	I-PK
2351	administered	I-PK
2351	dose	I-PK
2351	(	I-PK
2351	f	I-PK
2351	##e	I-PK
2351	)	I-PK
2351	,	O
2351	and	O
2351	re	B-PK
2351	##nal	I-PK
2351	clearance	I-PK
2351	(	I-PK
2351	c	I-PK
2351	##l	I-PK
2351	##r	I-PK
2351	)	I-PK
2351	.	O
2351	[SEP]	O
2352	[CLS]	O
2352	the	O
2352	observed	O
2352	median	O
2352	dig	O
2352	##ox	O
2352	##in	O
2352	t	B-PK
2352	##max	I-PK
2352	was	O
2352	identical	O
2352	when	O
2352	co	O
2352	-	O
2352	administered	O
2352	with	O
2352	either	O
2352	le	O
2352	##nal	O
2352	##ido	O
2352	##mi	O
2352	##de	O
2352	or	O
2352	place	O
2352	##bo	O
2352	(	O
2352	1	O
2352	h	O
2352	;	O
2352	range	O
2352	1	O
2352	–	O
2352	3	O
2352	h	O
2352	)	O
2352	.	O
2352	[SEP]	O
2353	[CLS]	O
2353	there	O
2353	was	O
2353	no	O
2353	difference	O
2353	in	O
2353	t	B-PK
2353	##max	I-PK
2353	and	O
2353	terminal	B-PK
2353	t	I-PK
2353	##1	I-PK
2353	/	I-PK
2353	2	I-PK
2353	of	O
2353	te	O
2353	##ms	O
2353	##iro	O
2353	##lim	O
2353	##us	O
2353	or	O
2353	sir	O
2353	##oli	O
2353	##mus	O
2353	between	O
2353	treatments	O
2353	(	O
2353	table	O
2353	1	O
2353	)	O
2353	.	O
2353	[SEP]	O
2354	[CLS]	O
2354	the	O
2354	t	B-PK
2354	##max	I-PK
2354	for	O
2354	e	O
2354	##va	O
2354	##ce	O
2354	##tra	O
2354	##pi	O
2354	##b	O
2354	was	O
2354	analyzed	O
2354	using	O
2354	a	O
2354	w	O
2354	##il	O
2354	##co	O
2354	##xon	O
2354	sign	O
2354	rank	O
2354	test	O
2354	.	O
2354	[SEP]	O
2355	[CLS]	O
2355	there	O
2355	was	O
2355	no	O
2355	difference	O
2355	in	O
2355	median	O
2355	t	B-PK
2355	##max	I-PK
2355	between	O
2355	treatments	O
2355	.	O
2355	[SEP]	O
2356	[CLS]	O
2356	there	O
2356	was	O
2356	no	O
2356	significant	O
2356	difference	O
2356	in	O
2356	median	O
2356	t	B-PK
2356	##max	I-PK
2356	.	O
2356	[SEP]	O
2357	[CLS]	O
2357	the	O
2357	au	B-PK
2357	##c	I-PK
2357	and	O
2357	cm	B-PK
2357	##ax	I-PK
2357	ratios	I-PK
2357	were	O
2357	2	O
2357	.	O
2357	37	O
2357	and	O
2357	1	O
2357	.	O
2357	94	O
2357	,	O
2357	and	O
2357	the	O
2357	90	O
2357	%	O
2357	c	O
2357	##is	O
2357	did	O
2357	not	O
2357	include	O
2357	unity	O
2357	.	O
2357	[SEP]	O
2358	[CLS]	O
2358	the	O
2358	p	O
2358	##k	O
2358	parameters	O
2358	calculated	O
2358	for	O
2358	the	O
2358	meta	O
2358	##bol	O
2358	##ite	O
2358	included	O
2358	:	O
2358	au	B-PK
2358	##c	I-PK
2358	##0	I-PK
2358	→	I-PK
2358	∞	I-PK
2358	,	O
2358	peak	B-PK
2358	concentration	I-PK
2358	(	I-PK
2358	cm	I-PK
2358	##ax	I-PK
2358	;	O
2358	μ	O
2358	##g	O
2358	/	O
2358	m	O
2358	##l	O
2358	)	O
2358	,	O
2358	and	O
2358	time	B-PK
2358	at	I-PK
2358	which	I-PK
2358	maximum	I-PK
2358	concentration	I-PK
2358	occurs	I-PK
2358	(	I-PK
2358	t	I-PK
2358	##max	I-PK
2358	;	O
2358	h	O
2358	)	O
2358	.	O
2358	[SEP]	O
2359	[CLS]	O
2359	the	O
2359	her	O
2359	##ita	O
2359	##bility	O
2359	estimate	O
2359	for	O
2359	t	B-PK
2359	##max	I-PK
2359	for	O
2359	the	O
2359	meta	O
2359	##bol	O
2359	##ite	O
2359	for	O
2359	flu	O
2359	##ni	O
2359	##xin	O
2359	me	O
2359	##g	O
2359	##lum	O
2359	##ine	O
2359	was	O
2359	outside	O
2359	the	O
2359	bounds	O
2359	and	O
2359	therefore	O
2359	was	O
2359	not	O
2359	shown	O
2359	.	O
2359	[SEP]	O
2360	[CLS]	O
2360	the	O
2360	mean	O
2360	im	O
2360	##ati	O
2360	##ni	O
2360	##b	O
2360	cm	B-PK
2360	##in	I-PK
2360	value	O
2360	of	O
2360	the	O
2360	18	O
2360	patients	O
2360	was	O
2360	1841	O
2360	ng	O
2360	/	O
2360	m	O
2360	##l	O
2360	(	O
2360	101	O
2360	##8	O
2360	–	O
2360	38	O
2360	##9	O
2360	##7	O
2360	ng	O
2360	/	O
2360	m	O
2360	##l	O
2360	)	O
2360	.	O
2360	[SEP]	O
2361	[CLS]	O
2361	the	O
2361	difference	O
2361	between	O
2361	the	O
2361	patients	O
2361	treated	O
2361	with	O
2361	400	O
2361	mg	O
2361	/	O
2361	d	O
2361	(	O
2361	n	O
2361	=	O
2361	9	O
2361	)	O
2361	and	O
2361	those	O
2361	treated	O
2361	with	O
2361	300	O
2361	mg	O
2361	/	O
2361	d	O
2361	(	O
2361	n	O
2361	=	O
2361	9	O
2361	)	O
2361	,	O
2361	which	O
2361	have	O
2361	im	O
2361	##ati	O
2361	##ni	O
2361	##b	O
2361	cm	B-PK
2361	##in	I-PK
2361	values	O
2361	of	O
2361	212	O
2361	##2	O
2361	##±	O
2361	##100	O
2361	##3	O
2361	ng	O
2361	/	O
2361	m	O
2361	##l	O
2361	and	O
2361	155	O
2361	##9	O
2361	##±	O
2361	##47	O
2361	##8	O
2361	ng	O
2361	/	O
2361	m	O
2361	##l	O
2361	,	O
2361	respectively	O
2361	,	O
2361	was	O
2361	not	O
2361	significant	O
2361	(	O
2361	p	O
2361	=	O
2361	0	O
2361	.	O
2361	148	O
2361	)	O
2361	.	O
2361	[SEP]	O
2362	[CLS]	O
2362	patients	O
2362	with	O
2362	g	O
2362	##ist	O
2362	who	O
2362	exhibited	O
2362	into	O
2362	##ler	O
2362	##ance	O
2362	to	O
2362	the	O
2362	standard	O
2362	dose	O
2362	of	O
2362	im	O
2362	##ati	O
2362	##ni	O
2362	##b	O
2362	(	O
2362	400	O
2362	mg	O
2362	/	O
2362	d	O
2362	)	O
2362	,	O
2362	a	O
2362	lower	O
2362	dose	O
2362	of	O
2362	300	O
2362	mg	O
2362	/	O
2362	d	O
2362	could	O
2362	provide	O
2362	not	O
2362	only	O
2362	sufficient	O
2362	plasma	B-PK
2362	cm	I-PK
2362	##in	I-PK
2362	and	O
2362	good	O
2362	disease	O
2362	control	O
2362	but	O
2362	also	O
2362	the	O
2362	all	O
2362	##ev	O
2362	##iation	O
2362	of	O
2362	the	O
2362	side	O
2362	effects	O
2362	.	O
2362	[SEP]	O
2363	[CLS]	O
2363	im	O
2363	cm	B-PK
2363	##in	I-PK
2363	was	O
2363	measured	O
2363	in	O
2363	j	O
2363	##anu	O
2363	##ary	O
2363	2015	O
2363	.	O
2363	[SEP]	O
2364	[CLS]	O
2364	each	O
2364	patient	O
2364	received	O
2364	a	O
2364	dose	O
2364	of	O
2364	im	O
2364	regularly	O
2364	at	O
2364	12	O
2364	am	O
2364	daily	O
2364	for	O
2364	at	O
2364	least	O
2364	4	O
2364	months	O
2364	by	O
2364	the	O
2364	time	O
2364	of	O
2364	cm	B-PK
2364	##in	I-PK
2364	assessment	O
2364	.	O
2364	[SEP]	O
2365	[CLS]	O
2365	the	O
2365	im	O
2365	cm	B-PK
2365	##in	I-PK
2365	in	O
2365	5	O
2365	patients	O
2365	was	O
2365	measured	O
2365	twice	O
2365	on	O
2365	different	O
2365	days	O
2365	,	O
2365	and	O
2365	then	O
2365	the	O
2365	mean	O
2365	of	O
2365	the	O
2365	2	O
2365	values	O
2365	were	O
2365	used	O
2365	for	O
2365	analysis	O
2365	.	O
2365	[SEP]	O
2366	[CLS]	O
2366	meanwhile	O
2366	,	O
2366	the	O
2366	im	O
2366	cm	B-PK
2366	##in	I-PK
2366	in	O
2366	the	O
2366	other	O
2366	patients	O
2366	was	O
2366	measured	O
2366	once	O
2366	and	O
2366	the	O
2366	resulting	O
2366	value	O
2366	was	O
2366	used	O
2366	for	O
2366	analysis	O
2366	.	O
2366	[SEP]	O
2367	[CLS]	O
2367	the	O
2367	w	O
2367	##il	O
2367	##co	O
2367	##xon	O
2367	rank	O
2367	test	O
2367	was	O
2367	used	O
2367	to	O
2367	compare	O
2367	the	O
2367	means	O
2367	of	O
2367	the	O
2367	im	O
2367	cm	B-PK
2367	##in	I-PK
2367	of	O
2367	patients	O
2367	treated	O
2367	with	O
2367	different	O
2367	doses	O
2367	of	O
2367	im	O
2367	.	O
2367	[SEP]	O
2368	[CLS]	O
2368	the	O
2368	value	O
2368	of	O
2368	im	O
2368	cm	B-PK
2368	##in	I-PK
2368	was	O
2368	log	O
2368	-	O
2368	transformed	O
2368	for	O
2368	the	O
2368	linear	O
2368	re	O
2368	##gression	O
2368	analysis	O
2368	in	O
2368	order	O
2368	to	O
2368	identify	O
2368	the	O
2368	correlation	O
2368	##s	O
2368	between	O
2368	the	O
2368	im	O
2368	cm	B-PK
2368	##in	I-PK
2368	and	O
2368	the	O
2368	co	O
2368	##var	O
2368	##iate	O
2368	##s	O
2368	,	O
2368	such	O
2368	as	O
2368	age	O
2368	,	O
2368	sex	O
2368	,	O
2368	body	O
2368	weight	O
2368	,	O
2368	b	O
2368	##sa	O
2368	,	O
2368	duration	O
2368	of	O
2368	im	O
2368	use	O
2368	,	O
2368	hem	O
2368	##og	O
2368	##lo	O
2368	##bin	O
2368	,	O
2368	w	O
2368	##b	O
2368	##c	O
2368	,	O
2368	an	O
2368	##c	O
2368	,	O
2368	plate	O
2368	##lets	O
2368	,	O
2368	album	O
2368	##in	O
2368	,	O
2368	and	O
2368	c	O
2368	##rea	O
2368	##tin	O
2368	##ine	O
2368	clearance	O
2368	.	O
2368	[SEP]	O
2369	[CLS]	O
2369	im	O
2369	cm	B-PK
2369	##in	I-PK
2369	was	O
2369	measured	O
2369	twice	O
2369	in	O
2369	4	O
2369	patients	O
2369	treated	O
2369	with	O
2369	300	O
2369	mg	O
2369	/	O
2369	d	O
2369	im	O
2369	and	O
2369	1	O
2369	patient	O
2369	treated	O
2369	with	O
2369	400	O
2369	mg	O
2369	/	O
2369	d	O
2369	im	O
2369	.	O
2369	[SEP]	O
2370	[CLS]	O
2370	im	O
2370	cm	B-PK
2370	##in	I-PK
2370	in	O
2370	all	O
2370	18	O
2370	patients	O
2370	reached	O
2370	over	O
2370	1000	O
2370	ng	O
2370	/	O
2370	m	O
2370	##l	O
2370	,	O
2370	and	O
2370	the	O
2370	mean	O
2370	cm	B-PK
2370	##in	I-PK
2370	was	O
2370	1841	O
2370	ng	O
2370	/	O
2370	m	O
2370	##l	O
2370	(	O
2370	101	O
2370	##8	O
2370	–	O
2370	38	O
2370	##9	O
2370	##7	O
2370	ng	O
2370	/	O
2370	m	O
2370	##l	O
2370	)	O
2370	.	O
2370	[SEP]	O
2371	[CLS]	O
2371	distribution	O
2371	of	O
2371	im	O
2371	cm	B-PK
2371	##in	I-PK
2371	had	O
2371	between	O
2371	sex	O
2371	and	O
2371	ages	O
2371	and	O
2371	primary	O
2371	sites	O
2371	of	O
2371	tumors	O
2371	(	O
2371	table	O
2371	1	O
2371	)	O
2371	.	O
2371	[SEP]	O
2372	[CLS]	O
2372	in	O
2372	un	O
2372	##iva	O
2372	##ria	O
2372	##te	O
2372	analysis	O
2372	,	O
2372	we	O
2372	failed	O
2372	to	O
2372	reveal	O
2372	the	O
2372	association	O
2372	between	O
2372	im	O
2372	cm	B-PK
2372	##in	I-PK
2372	and	O
2372	factors	O
2372	including	O
2372	b	O
2372	##mi	O
2372	,	O
2372	hem	O
2372	##og	O
2372	##lo	O
2372	##bin	O
2372	level	O
2372	,	O
2372	w	O
2372	##b	O
2372	##c	O
2372	,	O
2372	c	O
2372	##rea	O
2372	##tin	O
2372	##ine	O
2372	clearance	O
2372	,	O
2372	or	O
2372	album	O
2372	##in	O
2372	level	O
2372	.	O
2372	[SEP]	O
2373	[CLS]	O
2373	the	O
2373	mean	O
2373	of	O
2373	im	O
2373	cm	B-PK
2373	##in	I-PK
2373	in	O
2373	patients	O
2373	receiving	O
2373	300	O
2373	mg	O
2373	daily	O
2373	dose	O
2373	was	O
2373	155	O
2373	##9	O
2373	##±	O
2373	##47	O
2373	##8	O
2373	ng	O
2373	/	O
2373	m	O
2373	##l	O
2373	(	O
2373	median	O
2373	141	O
2373	##2	O
2373	ng	O
2373	/	O
2373	m	O
2373	##l	O
2373	,	O
2373	range	O
2373	101	O
2373	##8	O
2373	–	O
2373	238	O
2373	##7	O
2373	ng	O
2373	/	O
2373	m	O
2373	##l	O
2373	)	O
2373	.	O
2373	[SEP]	O
2374	[CLS]	O
2374	in	O
2374	contrast	O
2374	to	O
2374	patients	O
2374	treated	O
2374	with	O
2374	400	O
2374	mg	O
2374	/	O
2374	d	O
2374	,	O
2374	the	O
2374	cm	B-PK
2374	##in	I-PK
2374	in	O
2374	patients	O
2374	receiving	O
2374	300	O
2374	mg	O
2374	/	O
2374	d	O
2374	decreased	O
2374	,	O
2374	but	O
2374	not	O
2374	significantly	O
2374	(	O
2374	212	O
2374	##2	O
2374	##±	O
2374	##100	O
2374	##3	O
2374	ng	O
2374	/	O
2374	m	O
2374	##l	O
2374	vs	O
2374	155	O
2374	##9	O
2374	##±	O
2374	##47	O
2374	##8	O
2374	ng	O
2374	/	O
2374	m	O
2374	##l	O
2374	,	O
2374	p	O
2374	=	O
2374	0	O
2374	.	O
2374	148	O
2374	,	O
2374	fi	O
2374	##g	O
2374	.	O
2374	2	O
2374	)	O
2374	.	O
2374	[SEP]	O
2375	[CLS]	O
2375	the	O
2375	mean	O
2375	of	O
2375	im	O
2375	cm	B-PK
2375	##in	I-PK
2375	was	O
2375	226	O
2375	##2	O
2375	##±	O
2375	##100	O
2375	##9	O
2375	ng	O
2375	/	O
2375	m	O
2375	##l	O
2375	and	O
2375	159	O
2375	##6	O
2375	##±	O
2375	##4	O
2375	##9	O
2375	##6	O
2375	ng	O
2375	/	O
2375	m	O
2375	##l	O
2375	(	O
2375	p	O
2375	=	O
2375	0	O
2375	.	O
2375	174	O
2375	)	O
2375	.	O
2375	[SEP]	O
2376	[CLS]	O
2376	the	O
2376	mean	O
2376	(	O
2376	±	O
2376	##stand	O
2376	##ard	O
2376	de	O
2376	##viation	O
2376	)	O
2376	im	O
2376	cm	B-PK
2376	##in	I-PK
2376	was	O
2376	2011	O
2376	##±	O
2376	##11	O
2376	##0	O
2376	##3	O
2376	ng	O
2376	/	O
2376	m	O
2376	##l	O
2376	,	O
2376	the	O
2376	median	O
2376	follow	O
2376	up	O
2376	was	O
2376	14	O
2376	months	O
2376	(	O
2376	7	O
2376	–	O
2376	18	O
2376	months	O
2376	)	O
2376	,	O
2376	and	O
2376	4	O
2376	p	O
2376	##r	O
2376	and	O
2376	1	O
2376	s	O
2376	##d	O
2376	were	O
2376	observed	O
2376	.	O
2376	[SEP]	O
2377	[CLS]	O
2377	only	O
2377	1	O
2377	of	O
2377	the	O
2377	6	O
2377	patients	O
2377	received	O
2377	300	O
2377	mg	O
2377	/	O
2377	d	O
2377	im	O
2377	,	O
2377	the	O
2377	cm	B-PK
2377	##in	I-PK
2377	was	O
2377	125	O
2377	##8	O
2377	ng	O
2377	/	O
2377	m	O
2377	##l	O
2377	,	O
2377	and	O
2377	the	O
2377	tumor	O
2377	size	O
2377	continued	O
2377	to	O
2377	decrease	O
2377	until	O
2377	the	O
2377	last	O
2377	follow	O
2377	up	O
2377	(	O
2377	13	O
2377	months	O
2377	)	O
2377	.	O
2377	[SEP]	O
2378	[CLS]	O
2378	the	O
2378	frequency	O
2378	of	O
2378	toxicity	O
2378	was	O
2378	lower	O
2378	(	O
2378	88	O
2378	.	O
2378	9	O
2378	%	O
2378	vs	O
2378	44	O
2378	.	O
2378	4	O
2378	%	O
2378	,	O
2378	p	O
2378	=	O
2378	0	O
2378	.	O
2378	02	O
2378	##3	O
2378	)	O
2378	in	O
2378	9	O
2378	patients	O
2378	treated	O
2378	with	O
2378	300	O
2378	mg	O
2378	/	O
2378	d	O
2378	im	O
2378	(	O
2378	table	O
2378	3	O
2378	)	O
2378	.	O
2378	[SEP]	O
2379	[CLS]	O
2379	patients	O
2379	with	O
2379	grade	O
2379	3	O
2379	–	O
2379	4	O
2379	toxic	O
2379	##ities	O
2379	did	O
2379	not	O
2379	differ	O
2379	from	O
2379	patients	O
2379	with	O
2379	zero	O
2379	or	O
2379	mild	O
2379	toxic	O
2379	##ities	O
2379	in	O
2379	terms	O
2379	of	O
2379	im	O
2379	cm	B-PK
2379	##in	I-PK
2379	(	O
2379	1875	O
2379	##±	O
2379	##17	O
2379	##3	O
2379	vs	O
2379	1834	O
2379	##±	O
2379	##8	O
2379	##9	O
2379	##6	O
2379	,	O
2379	p	O
2379	=	O
2379	0	O
2379	.	O
2379	94	O
2379	##0	O
2379	)	O
2379	.	O
2379	[SEP]	O
2380	[CLS]	O
2380	this	O
2380	study	O
2380	prospective	O
2380	##ly	O
2380	valid	O
2380	##ated	O
2380	a	O
2380	new	O
2380	van	O
2380	##com	O
2380	##y	O
2380	##cin	O
2380	dos	O
2380	##ing	O
2380	no	O
2380	##mo	O
2380	##gram	O
2380	based	O
2380	on	O
2380	the	O
2380	8	O
2380	-	O
2380	hours	O
2380	re	B-PK
2380	##nal	I-PK
2380	clearance	I-PK
2380	of	O
2380	c	O
2380	##rea	O
2380	##tin	O
2380	##ine	O
2380	and	O
2380	demonstrated	O
2380	that	O
2380	it	O
2380	is	O
2380	possible	O
2380	to	O
2380	increase	O
2380	the	O
2380	likelihood	O
2380	of	O
2380	target	O
2380	attain	O
2380	##ment	O
2380	in	O
2380	the	O
2380	first	O
2380	24	O
2380	h	O
2380	of	O
2380	treatment	O
2380	,	O
2380	particularly	O
2380	in	O
2380	patients	O
2380	with	O
2380	augmented	O
2380	re	B-PK
2380	##nal	I-PK
2380	clearance	I-PK
2380	[SEP]	O
2381	[CLS]	O
2381	the	O
2381	improved	O
2381	anti	O
2381	##no	O
2381	##ci	O
2381	##ceptive	O
2381	activity	O
2381	of	O
2381	a	O
2381	##c	O
2381	na	O
2381	##no	O
2381	##c	O
2381	##ry	O
2381	##stal	O
2381	##s	O
2381	was	O
2381	shown	O
2381	at	O
2381	much	O
2381	lower	O
2381	doses	O
2381	as	O
2381	compared	O
2381	to	O
2381	un	O
2381	##p	O
2381	##ro	O
2381	##cess	O
2381	##ed	O
2381	drug	O
2381	,	O
2381	which	O
2381	is	O
2381	purely	O
2381	because	O
2381	of	O
2381	na	O
2381	##non	O
2381	##ization	O
2381	which	O
2381	may	O
2381	be	O
2381	attributed	O
2381	to	O
2381	improved	O
2381	so	O
2381	##lub	O
2381	##ility	O
2381	and	O
2381	dissolution	O
2381	rate	O
2381	of	O
2381	a	O
2381	##c	O
2381	,	O
2381	ultimately	O
2381	resulting	O
2381	in	O
2381	its	O
2381	faster	O
2381	rate	B-PK
2381	of	I-PK
2381	absorption	I-PK
2381	.	O
2381	[SEP]	O
2382	[CLS]	O
2382	the	O
2382	obtained	O
2382	residue	O
2382	was	O
2382	re	O
2382	##c	O
2382	##ry	O
2382	##stal	O
2382	##li	O
2382	##zed	O
2382	by	O
2382	is	O
2382	##op	O
2382	##rop	O
2382	##ano	O
2382	##l	O
2382	several	O
2382	times	O
2382	until	O
2382	the	O
2382	re	O
2382	##age	O
2382	##nts	O
2382	and	O
2382	un	O
2382	##co	O
2382	##up	O
2382	##led	O
2382	5	O
2382	-	O
2382	f	O
2382	##a	O
2382	were	O
2382	totally	O
2382	removed	O
2382	(	O
2382	monitored	O
2382	by	O
2382	t	O
2382	##l	O
2382	##c	O
2382	and	O
2382	hp	O
2382	##l	O
2382	##c	O
2382	)	O
2382	,	O
2382	then	O
2382	dried	O
2382	in	O
2382	vacuum	O
2382	at	O
2382	40	O
2382	##°	O
2382	##c	O
2382	overnight	O
2382	.	O
2382	[SEP]	O
2383	[CLS]	O
2383	as	O
2383	the	O
2383	molecular	O
2383	weight	O
2383	increases	O
2383	,	O
2383	the	O
2383	in	O
2383	v	O
2383	##ivo	O
2383	clearance	B-PK
2383	rate	I-PK
2383	decreases	O
2383	.	O
2383	[SEP]	O
2384	[CLS]	O
2384	after	O
2384	administration	O
2384	in	O
2384	##tra	O
2384	##ven	O
2384	##ously	O
2384	,	O
2384	5	O
2384	-	O
2384	f	O
2384	##a	O
2384	was	O
2384	rapidly	O
2384	eliminated	O
2384	from	O
2384	the	O
2384	blood	O
2384	circulation	O
2384	,	O
2384	which	O
2384	led	O
2384	to	O
2384	a	O
2384	complete	O
2384	removal	O
2384	at	O
2384	[UNK]	O
2384	h	O
2384	after	O
2384	administration	O
2384	,	O
2384	whereas	O
2384	the	O
2384	elimination	B-PK
2384	rate	I-PK
2384	of	O
2384	5	O
2384	-	O
2384	f	O
2384	##a	O
2384	-	O
2384	p	O
2384	##ae	O
2384	was	O
2384	much	O
2384	lower	O
2384	than	O
2384	that	O
2384	of	O
2384	5	O
2384	-	O
2384	f	O
2384	##a	O
2384	,	O
2384	and	O
2384	the	O
2384	blood	O
2384	retention	O
2384	time	O
2384	of	O
2384	this	O
2384	mac	O
2384	##rom	O
2384	##ole	O
2384	##cular	O
2384	pro	O
2384	##dr	O
2384	##ug	O
2384	reached	O
2384	more	O
2384	than	O
2384	96	O
2384	h	O
2384	(	O
2384	figure	O
2384	3	O
2384	)	O
2384	.	O
2384	[SEP]	O
2385	[CLS]	O
2385	some	O
2385	p	O
2385	##har	O
2385	##ma	O
2385	##co	O
2385	##kin	O
2385	##etic	O
2385	parameters	O
2385	,	O
2385	such	O
2385	as	O
2385	the	O
2385	area	B-PK
2385	under	I-PK
2385	the	I-PK
2385	curve	I-PK
2385	(	I-PK
2385	au	I-PK
2385	##c	I-PK
2385	)	I-PK
2385	,	O
2385	the	O
2385	mean	B-PK
2385	retention	I-PK
2385	time	I-PK
2385	(	I-PK
2385	m	I-PK
2385	##rt	I-PK
2385	)	I-PK
2385	and	O
2385	the	O
2385	elimination	B-PK
2385	half	I-PK
2385	-	I-PK
2385	life	I-PK
2385	(	I-PK
2385	t	I-PK
2385	##1	I-PK
2385	/	I-PK
2385	2	I-PK
2385	)	I-PK
2385	of	O
2385	5	O
2385	-	O
2385	f	O
2385	##a	O
2385	-	O
2385	p	O
2385	##ae	O
2385	were	O
2385	much	O
2385	higher	O
2385	than	O
2385	those	O
2385	of	O
2385	5	O
2385	-	O
2385	f	O
2385	##a	O
2385	,	O
2385	i	O
2385	.	O
2385	e	O
2385	.	O
2385	,	O
2385	25	O
2385	.	O
2385	6	O
2385	times	O
2385	for	O
2385	au	B-PK
2385	##c	I-PK
2385	(	O
2385	54	O
2385	##6	O
2385	.	O
2385	6	O
2385	##±	O
2385	##36	O
2385	.	O
2385	7	O
2385	µ	O
2385	##g	O
2385	/	O
2385	m	O
2385	##l	O
2385	·	O
2385	h	O
2385	vs	O
2385	21	O
2385	.	O
2385	37	O
2385	##±	O
2385	##4	O
2385	.	O
2385	36	O
2385	µ	O
2385	##g	O
2385	/	O
2385	m	O
2385	##l	O
2385	·	O
2385	h	O
2385	)	O
2385	,	O
2385	11	O
2385	.	O
2385	7	O
2385	times	O
2385	for	O
2385	m	B-PK
2385	##rt	I-PK
2385	(	O
2385	7	O
2385	.	O
2385	96	O
2385	##2	O
2385	##±	O
2385	##0	O
2385	.	O
2385	400	O
2385	h	O
2385	vs	O
2385	0	O
2385	.	O
2385	67	O
2385	##9	O
2385	##±	O
2385	##0	O
2385	.	O
2385	142	O
2385	h	O
2385	)	O
2385	and	O
2385	14	O
2385	.	O
2385	4	O
2385	times	O
2385	for	O
2385	t	B-PK
2385	##1	I-PK
2385	/	I-PK
2385	2	I-PK
2385	(	O
2385	22	O
2385	.	O
2385	10	O
2385	##±	O
2385	##5	O
2385	.	O
2385	92	O
2385	h	O
2385	vs	O
2385	1	O
2385	.	O
2385	53	O
2385	##8	O
2385	##±	O
2385	##0	O
2385	.	O
2385	41	O
2385	##9	O
2385	h	O
2385	)	O
2385	,	O
2385	indicating	O
2385	a	O
2385	much	O
2385	longer	O
2385	blood	O
2385	circulation	O
2385	times	O
2385	and	O
2385	a	O
2385	remarkably	O
2385	enhanced	O
2385	bio	B-PK
2385	##ava	I-PK
2385	##ila	I-PK
2385	##bility	I-PK
2385	of	O
2385	the	O
2385	mac	O
2385	##rom	O
2385	##ole	O
2385	##cular	O
2385	pro	O
2385	##dr	O
2385	##ug	O
2385	(	O
2385	table	O
2385	3	O
2385	)	O
2385	.	O
2385	[SEP]	O
2386	[CLS]	O
2386	crushed	O
2386	or	O
2386	##f	O
2386	administration	O
2386	yielded	O
2386	reduced	O
2386	o	O
2386	##xy	O
2386	##co	O
2386	##don	O
2386	##e	O
2386	cm	B-PK
2386	##ax	I-PK
2386	and	O
2386	increased	O
2386	t	B-PK
2386	##max	I-PK
2386	versus	O
2386	crushed	O
2386	o	O
2386	##c	O
2386	and	O
2386	o	O
2386	##xy	O
2386	a	O
2386	##pi	O
2386	.	O
2386	[SEP]	O
2387	[CLS]	O
2387	p	O
2387	##har	O
2387	##ma	O
2387	##co	O
2387	##kin	O
2387	##etic	O
2387	metric	O
2387	##s	O
2387	were	O
2387	:	O
2387	maximum	B-PK
2387	plasma	I-PK
2387	concentration	I-PK
2387	(	I-PK
2387	cm	I-PK
2387	##ax	I-PK
2387	)	I-PK
2387	,	O
2387	time	B-PK
2387	to	I-PK
2387	maximum	I-PK
2387	plasma	I-PK
2387	concentration	I-PK
2387	(	I-PK
2387	t	I-PK
2387	##max	I-PK
2387	)	I-PK
2387	,	O
2387	area	B-PK
2387	under	I-PK
2387	the	I-PK
2387	concentration	I-PK
2387	time	I-PK
2387	curve	I-PK
2387	from	I-PK
2387	time	I-PK
2387	zero	I-PK
2387	to	I-PK
2387	in	I-PK
2387	##finity	I-PK
2387	(	I-PK
2387	au	I-PK
2387	##cin	I-PK
2387	##f	I-PK
2387	)	I-PK
2387	,	O
2387	and	O
2387	terminal	B-PK
2387	half	I-PK
2387	-	I-PK
2387	life	I-PK
2387	(	I-PK
2387	t	I-PK
2387	##1	I-PK
2387	/	I-PK
2387	2	I-PK
2387	)	I-PK
2387	.	O
2387	[SEP]	O
2388	[CLS]	O
2388	median	O
2388	t	B-PK
2388	##max	I-PK
2388	values	O
2388	for	O
2388	finely	O
2388	and	O
2388	coarse	O
2388	##ly	O
2388	crushed	O
2388	or	O
2388	##f	O
2388	were	O
2388	approximately	O
2388	twice	O
2388	as	O
2388	long	O
2388	as	O
2388	those	O
2388	observed	O
2388	for	O
2388	o	O
2388	##c	O
2388	and	O
2388	o	O
2388	##xy	O
2388	a	O
2388	##pi	O
2388	.	O
2388	[SEP]	O
2389	[CLS]	O
2389	the	O
2389	p	O
2389	##k	O
2389	parameters	O
2389	for	O
2389	analysis	O
2389	included	O
2389	maximum	B-PK
2389	serum	I-PK
2389	concentration	I-PK
2389	(	I-PK
2389	cm	I-PK
2389	##ax	I-PK
2389	)	I-PK
2389	,	O
2389	minimum	B-PK
2389	serum	I-PK
2389	concentration	I-PK
2389	(	I-PK
2389	cm	I-PK
2389	##in	I-PK
2389	)	I-PK
2389	,	O
2389	time	B-PK
2389	of	I-PK
2389	maximum	I-PK
2389	serum	I-PK
2389	concentration	I-PK
2389	(	I-PK
2389	t	I-PK
2389	##max	I-PK
2389	)	I-PK
2389	,	O
2389	systemic	B-PK
2389	clearance	I-PK
2389	(	I-PK
2389	c	I-PK
2389	##l	I-PK
2389	)	I-PK
2389	,	O
2389	volume	B-PK
2389	of	I-PK
2389	distribution	I-PK
2389	at	I-PK
2389	steady	I-PK
2389	state	I-PK
2389	(	I-PK
2389	vs	I-PK
2389	##s	I-PK
2389	)	I-PK
2389	,	O
2389	elimination	B-PK
2389	half	I-PK
2389	-	I-PK
2389	life	I-PK
2389	(	I-PK
2389	t	I-PK
2389	##1	I-PK
2389	/	I-PK
2389	2	I-PK
2389	)	I-PK
2389	,	O
2389	area	B-PK
2389	under	I-PK
2389	the	I-PK
2389	serum	I-PK
2389	concentration	I-PK
2389	versus	I-PK
2389	time	I-PK
2389	curve	I-PK
2389	over	I-PK
2389	the	I-PK
2389	dos	I-PK
2389	##ing	I-PK
2389	interval	I-PK
2389	(	I-PK
2389	au	I-PK
2389	##c	I-PK
2389	##0	I-PK
2389	–	I-PK
2389	τ	I-PK
2389	)	I-PK
2389	,	O
2389	and	O
2389	the	O
2389	average	B-PK
2389	serum	I-PK
2389	concentration	I-PK
2389	over	I-PK
2389	the	I-PK
2389	dos	I-PK
2389	##ing	I-PK
2389	interval	I-PK
2389	(	I-PK
2389	ca	I-PK
2389	##v	I-PK
2389	,	I-PK
2389	τ	I-PK
2389	)	I-PK
2389	for	O
2389	l	O
2389	##y	O
2389	##31	O
2389	##64	O
2389	##53	O
2389	##0	O
2389	.	O
2389	[SEP]	O
2390	[CLS]	O
2390	k	O
2390	##ras	O
2390	and	O
2390	e	O
2390	##g	O
2390	##f	O
2390	##r	O
2390	so	O
2390	##matic	O
2390	mutations	O
2390	were	O
2390	also	O
2390	assessed	O
2390	using	O
2390	the	O
2390	##ras	O
2390	##cre	O
2390	##en	O
2390	##®	O
2390	k	O
2390	##ras	O
2390	and	O
2390	e	O
2390	##g	O
2390	##f	O
2390	##r	O
2390	rotor	O
2390	-	O
2390	gene	O
2390	q	O
2390	p	O
2390	##c	O
2390	##r	O
2390	ass	O
2390	##ays	O
2390	.	O
2390	[SEP]	O
2391	[CLS]	O
2391	the	O
2391	cm	B-PK
2391	##ax	I-PK
2391	occurred	O
2391	at	O
2391	~	O
2391	3	O
2391	h	O
2391	(	O
2391	t	B-PK
2391	##max	I-PK
2391	)	O
2391	following	O
2391	the	O
2391	start	O
2391	of	O
2391	in	O
2391	##fusion	O
2391	,	O
2391	and	O
2391	serum	O
2391	concentrations	O
2391	declined	O
2391	in	O
2391	a	O
2391	mon	O
2391	##oe	O
2391	##x	O
2391	##po	O
2391	##nent	O
2391	##ial	O
2391	manner	O
2391	(	O
2391	fi	O
2391	##g	O
2391	.	O
2391	2	O
2391	)	O
2391	.	O
2391	[SEP]	O
2392	[CLS]	O
2392	however	O
2392	,	O
2392	the	O
2392	minimum	B-PK
2392	serum	I-PK
2392	concentration	I-PK
2392	over	I-PK
2392	the	I-PK
2392	dos	I-PK
2392	##ing	I-PK
2392	interval	I-PK
2392	(	I-PK
2392	cm	I-PK
2392	##in	I-PK
2392	,	I-PK
2392	τ	I-PK
2392	)	I-PK
2392	following	O
2392	1000	O
2392	mg	O
2392	on	O
2392	schedule	O
2392	1	O
2392	of	O
2392	l	O
2392	##y	O
2392	##31	O
2392	##64	O
2392	##53	O
2392	##0	O
2392	in	O
2392	cycles	O
2392	1	O
2392	and	O
2392	2	O
2392	(	O
2392	mean	O
2392	cm	B-PK
2392	##in	I-PK
2392	,	I-PK
2392	τ	I-PK
2392	range	O
2392	17	O
2392	.	O
2392	6	O
2392	–	O
2392	40	O
2392	.	O
2392	8	O
2392	µ	O
2392	##g	O
2392	/	O
2392	m	O
2392	##l	O
2392	)	O
2392	was	O
2392	lower	O
2392	than	O
2392	the	O
2392	met	O
2392	e	B-PK
2392	##c	I-PK
2392	##50	I-PK
2392	(	O
2392	79	O
2392	.	O
2392	5	O
2392	µ	O
2392	##g	O
2392	/	O
2392	m	O
2392	##l	O
2392	)	O
2392	,	O
2392	which	O
2392	is	O
2392	the	O
2392	predicted	O
2392	target	O
2392	concentration	O
2392	to	O
2392	maintain	O
2392	throughout	O
2392	the	O
2392	dos	O
2392	##ing	O
2392	interval	O
2392	to	O
2392	achieve	O
2392	the	O
2392	p	O
2392	##har	O
2392	##ma	O
2392	##co	O
2392	##log	O
2392	##ic	O
2392	activity	O
2392	of	O
2392	l	O
2392	##y	O
2392	##31	O
2392	##64	O
2392	##53	O
2392	##0	O
2392	.	O
2392	[SEP]	O
2393	[CLS]	O
2393	therefore	O
2393	,	O
2393	a	O
2393	weekly	O
2393	schedule	O
2393	of	O
2393	administration	O
2393	(	O
2393	schedule	O
2393	2	O
2393	)	O
2393	was	O
2393	tested	O
2393	to	O
2393	try	O
2393	to	O
2393	minimize	O
2393	the	O
2393	flu	O
2393	##ct	O
2393	##uation	O
2393	between	O
2393	the	O
2393	cm	B-PK
2393	##in	I-PK
2393	and	O
2393	cm	B-PK
2393	##ax	I-PK
2393	and	O
2393	thereby	O
2393	sustain	O
2393	a	O
2393	higher	O
2393	and	O
2393	more	O
2393	consistent	O
2393	level	O
2393	of	O
2393	in	O
2393	##hibition	O
2393	of	O
2393	both	O
2393	e	O
2393	##g	O
2393	##f	O
2393	##r	O
2393	and	O
2393	met	O
2393	.	O
2393	[SEP]	O
2394	[CLS]	O
2394	the	O
2394	cm	B-PK
2394	##ax	I-PK
2394	occurred	O
2394	at	O
2394	~	O
2394	2	O
2394	h	O
2394	(	O
2394	t	B-PK
2394	##max	I-PK
2394	)	O
2394	following	O
2394	the	O
2394	start	O
2394	of	O
2394	in	O
2394	##fusion	O
2394	of	O
2394	500	O
2394	and	O
2394	600	O
2394	mg	O
2394	doses	O
2394	,	O
2394	and	O
2394	serum	O
2394	concentrations	O
2394	declined	O
2394	in	O
2394	a	O
2394	mon	O
2394	##oe	O
2394	##x	O
2394	##po	O
2394	##nent	O
2394	##ial	O
2394	manner	O
2394	.	O
2394	[SEP]	O
2395	[CLS]	O
2395	the	O
2395	principal	O
2395	drugs	O
2395	tested	O
2395	,	O
2395	ve	O
2395	##rap	O
2395	##ami	O
2395	##l	O
2395	and	O
2395	ni	O
2395	##fe	O
2395	##di	O
2395	##pine	O
2395	,	O
2395	were	O
2395	found	O
2395	to	O
2395	increase	O
2395	significantly	O
2395	plasma	O
2395	dig	O
2395	##ox	O
2395	##in	O
2395	levels	O
2395	mainly	O
2395	by	O
2395	reducing	O
2395	dig	O
2395	##ox	O
2395	##in	O
2395	total	B-PK
2395	clearance	I-PK
2395	.	O
2395	[SEP]	O
2396	[CLS]	O
2396	p	O
2396	##har	O
2396	##ma	O
2396	##co	O
2396	##kin	O
2396	##etic	O
2396	parameters	O
2396	au	B-PK
2396	##c	I-PK
2396	(	I-PK
2396	0	I-PK
2396	-	I-PK
2396	t	I-PK
2396	)	I-PK
2396	,	O
2396	au	B-PK
2396	##c	I-PK
2396	(	I-PK
2396	0	I-PK
2396	-	I-PK
2396	alpha	I-PK
2396	)	I-PK
2396	,	O
2396	c	B-PK
2396	(	I-PK
2396	ma	I-PK
2396	##x	I-PK
2396	)	I-PK
2396	,	O
2396	t	B-PK
2396	(	I-PK
2396	ma	I-PK
2396	##x	I-PK
2396	)	I-PK
2396	,	O
2396	k	B-PK
2396	(	I-PK
2396	e	I-PK
2396	)	I-PK
2396	,	O
2396	m	B-PK
2396	##rt	I-PK
2396	and	O
2396	t	B-PK
2396	(	I-PK
2396	1	I-PK
2396	/	I-PK
2396	2	I-PK
2396	)	I-PK
2396	were	O
2396	determined	O
2396	from	O
2396	plasma	O
2396	concentrations	O
2396	of	O
2396	both	O
2396	formulation	O
2396	##s	O
2396	,	O
2396	resulting	O
2396	in	O
2396	a	O
2396	c	B-PK
2396	(	I-PK
2396	ma	I-PK
2396	##x	I-PK
2396	)	I-PK
2396	120	O
2396	%	O
2396	larger	O
2396	than	O
2396	and	O
2396	a	O
2396	t	B-PK
2396	(	I-PK
2396	ma	I-PK
2396	##x	I-PK
2396	)	I-PK
2396	65	O
2396	%	O
2396	faster	O
2396	than	O
2396	those	O
2396	reported	O
2396	in	O
2396	other	O
2396	populations	O
2396	.	O
2396	[SEP]	O
2397	[CLS]	O
2397	this	O
2397	decrease	O
2397	was	O
2397	accompanied	O
2397	by	O
2397	a	O
2397	di	O
2397	##sp	O
2397	##rop	O
2397	##ort	O
2397	##ion	O
2397	##ate	O
2397	increase	O
2397	in	O
2397	the	O
2397	value	O
2397	of	O
2397	au	B-PK
2397	##c	I-PK
2397	from	O
2397	25	O
2397	.	O
2397	4	O
2397	+	O
2397	-	O
2397	5	O
2397	.	O
2397	9	O
2397	to	O
2397	112	O
2397	##8	O
2397	.	O
2397	6	O
2397	+	O
2397	-	O
2397	57	O
2397	##5	O
2397	.	O
2397	7	O
2397	micro	O
2397	##gram	O
2397	##s	O
2397	x	O
2397	min	O
2397	x	O
2397	m	O
2397	##l	O
2397	-	O
2397	1	O
2397	,	O
2397	elimination	B-PK
2397	half	I-PK
2397	-	I-PK
2397	life	I-PK
2397	from	O
2397	33	O
2397	.	O
2397	2	O
2397	+	O
2397	-	O
2397	10	O
2397	.	O
2397	7	O
2397	to	O
2397	41	O
2397	##3	O
2397	.	O
2397	0	O
2397	+	O
2397	-	O
2397	239	O
2397	.	O
2397	3	O
2397	min	O
2397	,	O
2397	and	O
2397	volume	B-PK
2397	of	I-PK
2397	distribution	I-PK
2397	from	O
2397	54	O
2397	##7	O
2397	.	O
2397	7	O
2397	+	O
2397	-	O
2397	153	O
2397	.	O
2397	1	O
2397	to	O
2397	148	O
2397	##9	O
2397	.	O
2397	0	O
2397	+	O
2397	-	O
2397	249	O
2397	.	O
2397	0	O
2397	m	O
2397	##l	O
2397	.	O
2397	[SEP]	O
2398	[CLS]	O
2398	peak	B-PK
2398	concentrations	I-PK
2398	,	O
2398	evening	B-PK
2398	t	I-PK
2398	##rough	I-PK
2398	##s	I-PK
2398	,	O
2398	and	O
2398	au	B-PK
2398	##c	I-PK
2398	##0	I-PK
2398	-	I-PK
2398	12	I-PK
2398	h	I-PK
2398	were	O
2398	entered	O
2398	into	O
2398	linear	O
2398	and	O
2398	log	O
2398	##10	O
2398	-	O
2398	log	O
2398	##10	O
2398	linear	O
2398	re	O
2398	##gression	O
2398	models	O
2398	to	O
2398	determine	O
2398	the	O
2398	best	O
2398	correlation	O
2398	with	O
2398	l	O
2398	##p	O
2398	##v	O
2398	and	O
2398	r	O
2398	##t	O
2398	##v	O
2398	plasma	O
2398	concentrations	O
2398	using	O
2398	a	O
2398	maximum	O
2398	of	O
2398	2	O
2398	time	O
2398	points	O
2398	.	O
2398	[SEP]	O
2399	[CLS]	O
2399	the	O
2399	values	O
2399	of	O
2399	the	O
2399	kinetic	O
2399	parameters	O
2399	were	O
2399	:	O
2399	ka	B-PK
2399	:	O
2399	6	O
2399	.	O
2399	9	O
2399	(	O
2399	h	O
2399	(	O
2399	-	O
2399	1	O
2399	)	O
2399	)	O
2399	,	O
2399	t	B-PK
2399	##1	I-PK
2399	/	I-PK
2399	2	I-PK
2399	,	O
2399	8	O
2399	.	O
2399	5	O
2399	(	O
2399	h	O
2399	)	O
2399	,	O
2399	au	B-PK
2399	##c	I-PK
2399	:	O
2399	74	O
2399	##1	O
2399	(	O
2399	p	O
2399	##g	O
2399	x	O
2399	h	O
2399	(	O
2399	-	O
2399	1	O
2399	)	O
2399	x	O
2399	l	O
2399	(	O
2399	-	O
2399	1	O
2399	)	O
2399	,	O
2399	v	B-PK
2399	(	I-PK
2399	area	I-PK
2399	/	I-PK
2399	f	I-PK
2399	)	I-PK
2399	:	O
2399	147	O
2399	##0	O
2399	(	O
2399	l	O
2399	)	O
2399	.	O
2399	[SEP]	O
2400	[CLS]	O
2400	the	O
2400	ch	O
2400	##ime	O
2400	##ric	O
2400	anti	O
2400	-	O
2400	il	O
2400	##6	O
2400	ma	O
2400	##bs	O
2400	have	O
2400	a	O
2400	long	O
2400	half	B-PK
2400	-	I-PK
2400	life	I-PK
2400	time	I-PK
2400	,	O
2400	a	O
2400	low	O
2400	im	O
2400	##mu	O
2400	##no	O
2400	##genic	O
2400	##ity	O
2400	,	O
2400	and	O
2400	are	O
2400	able	O
2400	to	O
2400	block	O
2400	il	O
2400	##6	O
2400	-	O
2400	dependent	O
2400	processes	O
2400	in	O
2400	v	O
2400	##ivo	O
2400	.	O
2400	[SEP]	O
2401	[CLS]	O
2401	no	O
2401	statistical	O
2401	##ly	O
2401	significant	O
2401	differences	O
2401	were	O
2401	obtained	O
2401	between	O
2401	the	O
2401	two	O
2401	products	O
2401	with	O
2401	respect	O
2401	to	O
2401	the	O
2401	mean	O
2401	concentration	O
2401	-	O
2401	time	O
2401	profiles	O
2401	or	O
2401	in	O
2401	the	O
2401	p	O
2401	##har	O
2401	##ma	O
2401	##co	O
2401	##kin	O
2401	##etic	O
2401	parameters	O
2401	,	O
2401	including	O
2401	the	O
2401	area	B-PK
2401	under	I-PK
2401	the	I-PK
2401	serum	I-PK
2401	concentration	I-PK
2401	-	I-PK
2401	time	I-PK
2401	curve	I-PK
2401	from	O
2401	the	O
2401	present	O
2401	study	O
2401	.	O
2401	[SEP]	O
2402	[CLS]	O
2402	clearance	B-PK
2402	was	O
2402	35	O
2402	(	O
2402	14	O
2402	-	O
2402	121	O
2402	)	O
2402	m	O
2402	##l	O
2402	/	O
2402	min	O
2402	and	O
2402	was	O
2402	weakly	O
2402	but	O
2402	significantly	O
2402	correlated	O
2402	with	O
2402	c	O
2402	##rea	O
2402	##tin	O
2402	##ine	O
2402	clearance	O
2402	.	O
2402	[SEP]	O
2403	[CLS]	O
2403	when	O
2403	g	O
2403	##em	O
2403	##fi	O
2403	##bro	O
2403	##zi	O
2403	##l	O
2403	was	O
2403	taken	O
2403	0	O
2403	,	O
2403	1	O
2403	,	O
2403	3	O
2403	,	O
2403	or	O
2403	6	O
2403	h	O
2403	before	O
2403	re	O
2403	##pa	O
2403	##gli	O
2403	##ni	O
2403	##de	O
2403	,	O
2403	the	O
2403	geometric	O
2403	mean	O
2403	ratio	O
2403	relative	O
2403	to	O
2403	control	O
2403	(	O
2403	90	O
2403	%	O
2403	confidence	O
2403	interval	O
2403	(	O
2403	c	O
2403	##i	O
2403	)	O
2403	)	O
2403	of	O
2403	re	O
2403	##pa	O
2403	##gli	O
2403	##ni	O
2403	##de	O
2403	area	B-PK
2403	under	I-PK
2403	the	I-PK
2403	plasma	I-PK
2403	concentration	I-PK
2403	-	I-PK
2403	time	I-PK
2403	curve	I-PK
2403	(	I-PK
2403	au	I-PK
2403	##c	I-PK
2403	(	I-PK
2403	0	I-PK
2403	-	I-PK
2403	∞	I-PK
2403	)	I-PK
2403	)	I-PK
2403	was	O
2403	5	O
2403	.	O
2403	0	O
2403	-	O
2403	fold	O
2403	(	O
2403	4	O
2403	.	O
2403	3	O
2403	-	O
2403	5	O
2403	.	O
2403	7	O
2403	-	O
2403	fold	O
2403	)	O
2403	,	O
2403	6	O
2403	.	O
2403	3	O
2403	-	O
2403	fold	O
2403	(	O
2403	5	O
2403	.	O
2403	4	O
2403	-	O
2403	7	O
2403	.	O
2403	5	O
2403	-	O
2403	fold	O
2403	)	O
2403	,	O
2403	6	O
2403	.	O
2403	6	O
2403	-	O
2403	fold	O
2403	(	O
2403	5	O
2403	.	O
2403	6	O
2403	-	O
2403	7	O
2403	.	O
2403	7	O
2403	-	O
2403	fold	O
2403	)	O
2403	,	O
2403	and	O
2403	5	O
2403	.	O
2403	4	O
2403	-	O
2403	fold	O
2403	(	O
2403	4	O
2403	.	O
2403	8	O
2403	-	O
2403	6	O
2403	.	O
2403	1	O
2403	-	O
2403	fold	O
2403	)	O
2403	,	O
2403	respectively	O
2403	(	O
2403	p	O
2403	<	O
2403	0	O
2403	.	O
2403	00	O
2403	##1	O
2403	vs	O
2403	.	O
2403	control	O
2403	)	O
2403	.	O
2403	[SEP]	O
2404	[CLS]	O
2404	the	O
2404	exposure	O
2404	##s	O
2404	[	O
2404	maximum	B-PK
2404	plasma	I-PK
2404	concentration	I-PK
2404	(	I-PK
2404	cm	I-PK
2404	##ax	I-PK
2404	)	I-PK
2404	and	O
2404	area	B-PK
2404	under	I-PK
2404	the	I-PK
2404	plasma	I-PK
2404	concentration	I-PK
2404	-	I-PK
2404	time	I-PK
2404	curve	I-PK
2404	(	I-PK
2404	au	I-PK
2404	##c	I-PK
2404	)	I-PK
2404	]	O
2404	of	O
2404	the	O
2404	components	O
2404	of	O
2404	the	O
2404	3	O
2404	##d	O
2404	regime	O
2404	##n	O
2404	were	O
2404	comparable	O
2404	(	O
2404	<	O
2404	20	O
2404	%	O
2404	difference	O
2404	)	O
2404	in	O
2404	healthy	O
2404	chin	O
2404	##ese	O
2404	subjects	O
2404	residing	O
2404	in	O
2404	chin	O
2404	##a	O
2404	or	O
2404	the	O
2404	united	O
2404	states	O
2404	.	O
2404	[SEP]	O
2405	[CLS]	O
2405	plasma	O
2405	p	O
2405	##har	O
2405	##ma	O
2405	##co	O
2405	##kin	O
2405	##etics	O
2405	of	O
2405	at	O
2405	##or	O
2405	##vas	O
2405	##tat	O
2405	##in	O
2405	as	O
2405	measured	O
2405	by	O
2405	ma	B-PK
2405	##ximal	I-PK
2405	plasma	I-PK
2405	concentration	I-PK
2405	(	I-PK
2405	cm	I-PK
2405	##ax	I-PK
2405	)	I-PK
2405	and	O
2405	area	B-PK
2405	under	I-PK
2405	the	I-PK
2405	curve	I-PK
2405	(	I-PK
2405	au	I-PK
2405	##c	I-PK
2405	)	I-PK
2405	(	I-PK
2405	0	I-PK
2405	-	I-PK
2405	24	I-PK
2405	h	I-PK
2405	)	I-PK
2405	.	O
2405	[SEP]	O
2406	[CLS]	O
2406	prediction	O
2406	of	O
2406	liver	O
2406	volume	O
2406	-	O
2406	a	O
2406	population	O
2406	-	O
2406	based	O
2406	approach	O
2406	to	O
2406	meta	O
2406	-	O
2406	analysis	O
2406	of	O
2406	p	O
2406	##ae	O
2406	##dia	O
2406	##tric	O
2406	,	O
2406	adult	O
2406	and	O
2406	g	O
2406	##eria	O
2406	##tric	O
2406	populations	O
2406	-	O
2406	an	O
2406	update	O
2406	.	O
2406	[SEP]	O
2407	[CLS]	O
2407	the	O
2407	before	O
2407	:	O
2407	after	O
2407	food	O
2407	ratios	O
2407	of	O
2407	the	O
2407	au	B-PK
2407	##c	I-PK
2407	values	O
2407	were	O
2407	1	O
2407	.	O
2407	51	O
2407	for	O
2407	cape	O
2407	##ci	O
2407	##ta	O
2407	##bine	O
2407	,	O
2407	1	O
2407	.	O
2407	26	O
2407	for	O
2407	5	O
2407	'	O
2407	-	O
2407	d	O
2407	##f	O
2407	##c	O
2407	##r	O
2407	,	O
2407	1	O
2407	.	O
2407	15	O
2407	for	O
2407	5	O
2407	'	O
2407	-	O
2407	d	O
2407	##fu	O
2407	##r	O
2407	,	O
2407	1	O
2407	.	O
2407	13	O
2407	for	O
2407	5	O
2407	-	O
2407	f	O
2407	##u	O
2407	,	O
2407	1	O
2407	.	O
2407	07	O
2407	for	O
2407	f	O
2407	##uh	O
2407	##2	O
2407	,	O
2407	and	O
2407	1	O
2407	.	O
2407	04	O
2407	for	O
2407	f	O
2407	##bal	O
2407	.	O
2407	[SEP]	O
2408	[CLS]	O
2408	but	O
2408	no	O
2408	significant	O
2408	difference	O
2408	were	O
2408	found	O
2408	to	O
2408	t	B-PK
2408	##max	I-PK
2408	in	O
2408	a	O
2408	##que	O
2408	##ous	O
2408	humor	O
2408	and	O
2408	corn	O
2408	##ea	O
2408	between	O
2408	lip	O
2408	##oso	O
2408	##me	O
2408	and	O
2408	eyed	O
2408	##rop	O
2408	,	O
2408	t	B-PK
2408	(	I-PK
2408	1	I-PK
2408	/	I-PK
2408	2	I-PK
2408	)	I-PK
2408	of	O
2408	di	O
2408	##c	O
2408	##lo	O
2408	##fen	O
2408	##ac	O
2408	in	O
2408	a	O
2408	##que	O
2408	##ous	O
2408	humor	O
2408	and	O
2408	corn	O
2408	##ea	O
2408	with	O
2408	lip	O
2408	##oso	O
2408	##ine	O
2408	were	O
2408	longer	O
2408	than	O
2408	that	O
2408	with	O
2408	eye	O
2408	-	O
2408	drop	O
2408	solution	O
2408	.	O
2408	[SEP]	O
2409	[CLS]	O
2409	p	O
2409	##har	O
2409	##ma	O
2409	##co	O
2409	##kin	O
2409	##etic	O
2409	modeling	O
2409	demonstrated	O
2409	a	O
2409	significant	O
2409	influence	O
2409	of	O
2409	c	O
2409	##p	O
2409	##b	O
2409	on	O
2409	the	O
2409	volume	B-PK
2409	of	I-PK
2409	distribution	I-PK
2409	and	O
2409	elimination	O
2409	of	O
2409	c	O
2409	##ef	O
2409	##az	O
2409	##olin	O
2409	.	O
2409	[SEP]	O
2410	[CLS]	O
2410	in	O
2410	some	O
2410	of	O
2410	the	O
2410	patients	O
2410	,	O
2410	chiefly	O
2410	infants	O
2410	with	O
2410	severe	O
2410	re	O
2410	##nal	O
2410	ins	O
2410	##uff	O
2410	##iciency	O
2410	,	O
2410	the	O
2410	var	O
2410	##ea	O
2410	was	O
2410	larger	O
2410	than	O
2410	normal	O
2410	.	O
2410	[SEP]	O
2411	[CLS]	O
2411	for	O
2411	standard	O
2411	-	O
2411	dose	O
2411	p	O
2411	##ali	O
2411	##fer	O
2411	##min	O
2411	,	O
2411	mean	O
2411	values	O
2411	for	O
2411	area	B-PK
2411	under	I-PK
2411	the	I-PK
2411	serum	I-PK
2411	concentration	I-PK
2411	-	I-PK
2411	time	I-PK
2411	curve	I-PK
2411	(	I-PK
2411	au	I-PK
2411	##c	I-PK
2411	)	I-PK
2411	were	O
2411	within	O
2411	15	O
2411	%	O
2411	between	O
2411	doses	O
2411	1	O
2411	and	O
2411	3	O
2411	and	O
2411	within	O
2411	1	O
2411	%	O
2411	between	O
2411	doses	O
2411	1	O
2411	and	O
2411	4	O
2411	.	O
2411	[SEP]	O
2412	[CLS]	O
2412	the	O
2412	plasma	O
2412	p	O
2412	##y	O
2412	##y	O
2412	concentration	O
2412	reached	O
2412	its	O
2412	peak	O
2412	at	O
2412	10	O
2412	min	O
2412	following	O
2412	pulmonary	O
2412	delivery	O
2412	with	O
2412	12	O
2412	-	O
2412	14	O
2412	%	O
2412	of	O
2412	bio	B-PK
2412	##ava	I-PK
2412	##ila	I-PK
2412	##bility	I-PK
2412	.	O
2412	[SEP]	O
2413	[CLS]	O
2413	le	O
2413	##vo	O
2413	##do	O
2413	##pa	O
2413	plasma	O
2413	levels	O
2413	were	O
2413	further	O
2413	measured	O
2413	with	O
2413	hp	O
2413	##l	O
2413	##c	O
2413	method	O
2413	,	O
2413	then	O
2413	giving	O
2413	the	O
2413	following	O
2413	variables	O
2413	:	O
2413	cm	B-PK
2413	##ax	I-PK
2413	(	I-PK
2413	peak	I-PK
2413	concentration	I-PK
2413	)	I-PK
2413	,	O
2413	t	B-PK
2413	##max	I-PK
2413	(	I-PK
2413	time	I-PK
2413	corresponding	I-PK
2413	to	I-PK
2413	cm	I-PK
2413	##ax	I-PK
2413	)	I-PK
2413	,	O
2413	au	B-PK
2413	##c	I-PK
2413	(	I-PK
2413	area	I-PK
2413	under	I-PK
2413	curve	I-PK
2413	)	I-PK
2413	.	O
2413	[SEP]	O
2414	[CLS]	O
2414	the	O
2414	mean	O
2414	r	O
2414	##if	O
2414	##ab	O
2414	##uti	O
2414	##n	O
2414	area	B-PK
2414	under	I-PK
2414	the	I-PK
2414	concentration	I-PK
2414	-	I-PK
2414	time	I-PK
2414	curve	I-PK
2414	(	I-PK
2414	au	I-PK
2414	##c	I-PK
2414	(	I-PK
2414	0	I-PK
2414	-	I-PK
2414	24	I-PK
2414	)	I-PK
2414	)	I-PK
2414	increased	O
2414	20	O
2414	%	O
2414	from	O
2414	the	O
2414	base	O
2414	##line	O
2414	value	O
2414	(	O
2414	geometric	O
2414	mean	O
2414	,	O
2414	5	O
2414	.	O
2414	0	O
2414	vs	O
2414	.	O
2414	4	O
2414	.	O
2414	2	O
2414	micro	O
2414	##g	O
2414	.	O
2414	h	O
2414	/	O
2414	m	O
2414	##l	O
2414	;	O
2414	ratio	O
2414	of	O
2414	geometric	O
2414	means	O
2414	,	O
2414	1	O
2414	.	O
2414	2	O
2414	[	O
2414	90	O
2414	%	O
2414	confidence	O
2414	interval	O
2414	,	O
2414	1	O
2414	.	O
2414	0	O
2414	-	O
2414	1	O
2414	.	O
2414	4	O
2414	]	O
2414	)	O
2414	.	O
2414	[SEP]	O
2415	[CLS]	O
2415	when	O
2415	given	O
2415	separately	O
2415	,	O
2415	there	O
2415	were	O
2415	significant	O
2415	differences	O
2415	in	O
2415	the	O
2415	values	O
2415	of	O
2415	au	B-PK
2415	##c	I-PK
2415	(	I-PK
2415	0	I-PK
2415	-	I-PK
2415	in	I-PK
2415	##finity	I-PK
2415	)	I-PK
2415	and	O
2415	c	B-PK
2415	##l	I-PK
2415	between	O
2415	on	O
2415	##z	O
2415	en	O
2415	##anti	O
2415	##omer	O
2415	##s	O
2415	(	O
2415	p	O
2415	<	O
2415	0	O
2415	.	O
2415	05	O
2415	)	O
2415	,	O
2415	indicating	O
2415	that	O
2415	elimination	O
2415	of	O
2415	(	O
2415	+	O
2415	)	O
2415	-	O
2415	on	O
2415	##z	O
2415	was	O
2415	more	O
2415	rapid	O
2415	than	O
2415	that	O
2415	of	O
2415	(	O
2415	-	O
2415	)	O
2415	-	O
2415	on	O
2415	##z	O
2415	.	O
2415	[SEP]	O
2416	[CLS]	O
2416	when	O
2416	2	O
2416	##cc	O
2416	##pa	O
2416	was	O
2416	administered	O
2416	in	O
2416	##tra	O
2416	##per	O
2416	##ito	O
2416	##nea	O
2416	##lly	O
2416	to	O
2416	mice	O
2416	at	O
2416	a	O
2416	dose	O
2416	of	O
2416	1	O
2416	.	O
2416	6	O
2416	mg	O
2416	/	O
2416	kg	O
2416	,	O
2416	the	O
2416	half	B-PK
2416	-	I-PK
2416	life	I-PK
2416	of	O
2416	2	O
2416	##cc	O
2416	##pa	O
2416	in	O
2416	plasma	O
2416	was	O
2416	16	O
2416	min	O
2416	.	O
2416	[SEP]	O
2417	[CLS]	O
2417	except	O
2417	for	O
2417	terminal	B-PK
2417	elimination	I-PK
2417	half	I-PK
2417	-	I-PK
2417	life	I-PK
2417	,	O
2417	which	O
2417	was	O
2417	10	O
2417	%	O
2417	shorter	O
2417	in	O
2417	women	O
2417	,	O
2417	no	O
2417	other	O
2417	p	O
2417	##har	O
2417	##ma	O
2417	##co	O
2417	##kin	O
2417	##etic	O
2417	values	O
2417	were	O
2417	significantly	O
2417	different	O
2417	between	O
2417	gender	O
2417	##s	O
2417	.	O
2417	[SEP]	O
2418	[CLS]	O
2418	however	O
2418	,	O
2418	in	O
2418	v	O
2418	##ivo	O
2418	studies	O
2418	in	O
2418	p	O
2418	-	O
2418	g	O
2418	##p	O
2418	knockout	O
2418	mice	O
2418	versus	O
2418	wild	O
2418	-	O
2418	type	O
2418	mice	O
2418	showed	O
2418	no	O
2418	difference	O
2418	in	O
2418	the	O
2418	amount	O
2418	of	O
2418	das	O
2418	##ati	O
2418	##ni	O
2418	##b	O
2418	remaining	O
2418	un	O
2418	##ab	O
2418	##sor	O
2418	##bed	O
2418	in	O
2418	the	O
2418	gas	O
2418	##tro	O
2418	##int	O
2418	##est	O
2418	##inal	O
2418	tract	O
2418	,	O
2418	suggesting	O
2418	that	O
2418	p	O
2418	-	O
2418	g	O
2418	##p	O
2418	may	O
2418	not	O
2418	be	O
2418	responsible	O
2418	for	O
2418	the	O
2418	incomplete	O
2418	bio	B-PK
2418	##ava	I-PK
2418	##ila	I-PK
2418	##bility	I-PK
2418	.	O
2418	[SEP]	O
2419	[CLS]	O
2419	the	O
2419	mean	O
2419	(	O
2419	s	O
2419	##d	O
2419	)	O
2419	terminal	B-PK
2419	half	I-PK
2419	-	I-PK
2419	life	I-PK
2419	of	O
2419	sa	O
2419	##p	O
2419	##rop	O
2419	##ter	O
2419	##in	O
2419	was	O
2419	6	O
2419	.	O
2419	69	O
2419	(	O
2419	2	O
2419	.	O
2419	29	O
2419	)	O
2419	hours	O
2419	and	O
2419	there	O
2419	was	O
2419	little	O
2419	evidence	O
2419	of	O
2419	accumulation	O
2419	,	O
2419	even	O
2419	at	O
2419	the	O
2419	highest	O
2419	dose	O
2419	.	O
2419	[SEP]	O
2420	[CLS]	O
2420	the	O
2420	bio	B-PK
2420	##ava	I-PK
2420	##ila	I-PK
2420	##bility	I-PK
2420	of	O
2420	que	O
2420	##rc	O
2420	##eti	O
2420	##n	O
2420	in	O
2420	pigs	O
2420	depends	O
2420	on	O
2420	the	O
2420	g	O
2420	##ly	O
2420	##cos	O
2420	##ide	O
2420	m	O
2420	##oi	O
2420	##ety	O
2420	and	O
2420	on	O
2420	diet	O
2420	##ary	O
2420	factors	O
2420	.	O
2420	[SEP]	O
2421	[CLS]	O
2421	in	O
2421	t	O
2421	##2	O
2421	##d	O
2421	patients	O
2421	,	O
2421	a	O
2421	protein	O
2421	and	O
2421	lip	O
2421	##id	O
2421	pre	O
2421	##load	O
2421	improve	O
2421	##s	O
2421	glucose	O
2421	tolerance	O
2421	throughout	O
2421	the	O
2421	whole	O
2421	post	O
2421	-	O
2421	a	O
2421	##bs	O
2421	##or	O
2421	##pt	O
2421	##ive	O
2421	phase	O
2421	mainly	O
2421	by	O
2421	reducing	O
2421	the	O
2421	appearance	O
2421	of	O
2421	oral	O
2421	glucose	O
2421	,	O
2421	and	O
2421	improving	O
2421	both	O
2421	beta	O
2421	-	O
2421	cell	O
2421	function	O
2421	and	O
2421	insulin	O
2421	bio	B-PK
2421	##ava	I-PK
2421	##ila	I-PK
2421	##bility	I-PK
2421	.	O
2421	[SEP]	O
2422	[CLS]	O
2422	in	O
2422	contrast	O
2422	to	O
2422	other	O
2422	papers	O
2422	,	O
2422	we	O
2422	found	O
2422	that	O
2422	m	O
2422	##ox	O
2422	##if	O
2422	##lo	O
2422	##xa	O
2422	##cin	O
2422	p	O
2422	##k	O
2422	were	O
2422	best	O
2422	described	O
2422	by	O
2422	a	O
2422	three	O
2422	compartment	O
2422	##al	O
2422	model	O
2422	using	O
2422	lean	O
2422	body	O
2422	mass	O
2422	(	O
2422	lb	O
2422	##m	O
2422	)	O
2422	as	O
2422	a	O
2422	predict	O
2422	##or	O
2422	for	O
2422	m	O
2422	##ox	O
2422	##if	O
2422	##lo	O
2422	##xa	O
2422	##cin	O
2422	clearance	B-PK
2422	.	O
2422	[SEP]	O
2423	[CLS]	O
2423	our	O
2423	major	O
2423	finding	O
2423	was	O
2423	that	O
2423	missing	O
2423	body	O
2423	weights	O
2423	minimal	O
2423	##ly	O
2423	affect	O
2423	population	O
2423	estimates	O
2423	of	O
2423	p	O
2423	##har	O
2423	##ma	O
2423	##co	O
2423	##kin	O
2423	##etic	O
2423	parameters	O
2423	but	O
2423	do	O
2423	affect	O
2423	the	O
2423	co	O
2423	##var	O
2423	##iate	O
2423	relationship	O
2423	parameters	O
2423	,	O
2423	particularly	O
2423	the	O
2423	one	O
2423	describing	O
2423	dependence	O
2423	of	O
2423	clearance	B-PK
2423	on	O
2423	body	O
2423	weight	O
2423	.	O
2423	[SEP]	O
2424	[CLS]	O
2424	met	O
2424	##had	O
2424	##one	O
2424	is	O
2424	a	O
2424	potent	O
2424	,	O
2424	long	O
2424	acting	O
2424	na	O
2424	##rc	O
2424	##otic	O
2424	anal	O
2424	##ges	O
2424	##ic	O
2424	which	O
2424	can	O
2424	be	O
2424	oral	O
2424	##ly	O
2424	administered	O
2424	due	O
2424	to	O
2424	its	O
2424	almost	O
2424	complete	O
2424	bio	B-PK
2424	##ava	I-PK
2424	##ila	I-PK
2424	##bility	I-PK
2424	.	O
2424	[SEP]	O
2425	[CLS]	O
2425	patients	O
2425	with	O
2425	a	O
2425	raised	O
2425	bi	O
2425	##li	O
2425	##ru	O
2425	##bin	O
2425	level	O
2425	had	O
2425	reduced	O
2425	do	O
2425	##x	O
2425	##or	O
2425	##ubi	O
2425	##cin	O
2425	clearance	B-PK
2425	,	O
2425	but	O
2425	there	O
2425	was	O
2425	no	O
2425	clear	O
2425	relationship	O
2425	between	O
2425	the	O
2425	extent	O
2425	of	O
2425	this	O
2425	elevation	O
2425	and	O
2425	the	O
2425	reduction	O
2425	in	O
2425	do	O
2425	##x	O
2425	##or	O
2425	##ubi	O
2425	##cin	O
2425	clearance	B-PK
2425	.	O
2425	[SEP]	O
2426	[CLS]	O
2426	the	O
2426	values	O
2426	of	O
2426	[	O
2426	formula	O
2426	:	O
2426	see	O
2426	text	O
2426	]	O
2426	,	O
2426	t	B-PK
2426	##max	I-PK
2426	and	O
2426	au	B-PK
2426	##c	I-PK
2426	##0	I-PK
2426	-	I-PK
2426	∞	I-PK
2426	of	O
2426	en	O
2426	##ro	O
2426	##f	O
2426	##lo	O
2426	##xa	O
2426	##cin	O
2426	were	O
2426	non	O
2426	##sign	O
2426	##ificant	O
2426	##ly	O
2426	increased	O
2426	by	O
2426	17	O
2426	%	O
2426	,	O
2426	26	O
2426	%	O
2426	and	O
2426	17	O
2426	%	O
2426	in	O
2426	a	O
2426	##f	O
2426	##lat	O
2426	##ox	O
2426	##in	O
2426	-	O
2426	exposed	O
2426	br	O
2426	##oil	O
2426	##er	O
2426	chickens	O
2426	,	O
2426	respectively	O
2426	.	O
2426	[SEP]	O
2427	[CLS]	O
2427	a	O
2427	total	O
2427	of	O
2427	85	O
2427	patients	O
2427	received	O
2427	am	O
2427	##ika	O
2427	##cin	O
2427	treatment	O
2427	,	O
2427	of	O
2427	whom	O
2427	71	O
2427	(	O
2427	83	O
2427	.	O
2427	5	O
2427	%	O
2427	)	O
2427	achieved	O
2427	a	O
2427	cm	B-PK
2427	##ax	I-PK
2427	/	I-PK
2427	mi	I-PK
2427	##c	I-PK
2427	>	O
2427	6	O
2427	,	O
2427	66	O
2427	(	O
2427	77	O
2427	.	O
2427	6	O
2427	%	O
2427	)	O
2427	a	O
2427	cm	B-PK
2427	##ax	I-PK
2427	/	I-PK
2427	mi	I-PK
2427	##c	I-PK
2427	>	O
2427	8	O
2427	,	O
2427	64	O
2427	(	O
2427	75	O
2427	.	O
2427	3	O
2427	%	O
2427	)	O
2427	a	O
2427	cm	B-PK
2427	##ax	I-PK
2427	/	I-PK
2427	mi	I-PK
2427	##c	I-PK
2427	>	O
2427	10	O
2427	and	O
2427	72	O
2427	(	O
2427	84	O
2427	.	O
2427	7	O
2427	%	O
2427	)	O
2427	an	O
2427	au	B-PK
2427	##c	I-PK
2427	/	I-PK
2427	mi	I-PK
2427	##c	I-PK
2427	>	O
2427	65	O
2427	.	O
2427	[SEP]	O
2428	[CLS]	O
2428	dose	O
2428	-	O
2428	normal	O
2428	##ized	O
2428	total	B-PK
2428	au	I-PK
2428	##c	I-PK
2428	values	O
2428	were	O
2428	used	O
2428	to	O
2428	calculate	O
2428	de	O
2428	##x	O
2428	##med	O
2428	##eto	O
2428	##mi	O
2428	##dine	O
2428	bio	B-PK
2428	##ava	I-PK
2428	##ila	I-PK
2428	##bility	I-PK
2428	.	O
2428	[SEP]	O
2429	[CLS]	O
2429	the	O
2429	oral	B-PK
2429	clearance	I-PK
2429	(	I-PK
2429	c	I-PK
2429	##l	I-PK
2429	/	I-PK
2429	f	I-PK
2429	)	I-PK
2429	of	O
2429	met	O
2429	##op	O
2429	##rol	O
2429	##ol	O
2429	was	O
2429	positively	O
2429	correlated	O
2429	with	O
2429	the	O
2429	apparent	B-PK
2429	volume	I-PK
2429	of	I-PK
2429	distribution	I-PK
2429	(	I-PK
2429	v	I-PK
2429	/	I-PK
2429	f	I-PK
2429	)	I-PK
2429	,	O
2429	suggesting	O
2429	the	O
2429	residual	O
2429	var	O
2429	##iability	O
2429	of	O
2429	f	B-PK
2429	.	O
2429	the	O
2429	up	O
2429	##take	O
2429	of	O
2429	met	O
2429	##op	O
2429	##rol	O
2429	##ol	O
2429	into	O
2429	l	O
2429	##s	O
2429	##18	O
2429	##0	O
2429	cells	O
2429	was	O
2429	significantly	O
2429	decreased	O
2429	by	O
2429	the	O
2429	acid	O
2429	##ification	O
2429	of	O
2429	extra	O
2429	##cellular	O
2429	medium	O
2429	p	O
2429	##h	O
2429	,	O
2429	and	O
2429	was	O
2429	dependent	O
2429	on	O
2429	temperature	O
2429	and	O
2429	in	O
2429	##tra	O
2429	##cellular	O
2429	p	O
2429	##h	O
2429	.	O
2429	further	O
2429	##more	O
2429	,	O
2429	the	O
2429	cellular	O
2429	up	O
2429	##take	O
2429	of	O
2429	met	O
2429	##op	O
2429	##rol	O
2429	##ol	O
2429	was	O
2429	sat	O
2429	##urable	O
2429	,	O
2429	and	O
2429	was	O
2429	significantly	O
2429	decreased	O
2429	in	O
2429	the	O
2429	presence	O
2429	of	O
2429	h	O
2429	##ydro	O
2429	##phobic	O
2429	cat	O
2429	##ion	O
2429	##ic	O
2429	drugs	O
2429	such	O
2429	as	O
2429	dip	O
2429	##hen	O
2429	##hy	O
2429	##dra	O
2429	##mine	O
2429	,	O
2429	pro	O
2429	##ca	O
2429	##ina	O
2429	##mi	O
2429	##de	O
2429	,	O
2429	bi	O
2429	##so	O
2429	##p	O
2429	##rol	O
2429	##ol	O
2429	,	O
2429	and	O
2429	q	O
2429	##uin	O
2429	##id	O
2429	##ine	O
2429	.	O
2429	[SEP]	O
2430	[CLS]	O
2430	the	O
2430	primary	O
2430	objectives	O
2430	were	O
2430	to	O
2430	assess	O
2430	the	O
2430	safety	O
2430	of	O
2430	de	O
2430	##ci	O
2430	##ta	O
2430	##bine	O
2430	plus	O
2430	c	O
2430	##eda	O
2430	##zu	O
2430	##rid	O
2430	##ine	O
2430	,	O
2430	and	O
2430	to	O
2430	determine	O
2430	the	O
2430	dose	O
2430	of	O
2430	each	O
2430	drug	O
2430	needed	O
2430	to	O
2430	achieve	O
2430	a	O
2430	mean	O
2430	au	B-PK
2430	##c	I-PK
2430	for	O
2430	de	O
2430	##ci	O
2430	##ta	O
2430	##bine	O
2430	exposure	O
2430	similar	O
2430	to	O
2430	that	O
2430	for	O
2430	in	O
2430	##tra	O
2430	##ven	O
2430	##ous	O
2430	de	O
2430	##ci	O
2430	##ta	O
2430	##bine	O
2430	exposure	O
2430	.	O
2430	[SEP]	O
2431	[CLS]	O
2431	in	O
2431	the	O
2431	nine	O
2431	non	O
2431	-	O
2431	ch	O
2431	##ole	O
2431	##static	O
2431	patients	O
2431	,	O
2431	u	O
2431	##d	O
2431	##c	O
2431	reduced	O
2431	the	O
2431	absorption	B-PK
2431	rate	I-PK
2431	and	O
2431	the	O
2431	bio	B-PK
2431	##ava	I-PK
2431	##ila	I-PK
2431	##bility	I-PK
2431	of	O
2431	c	O
2431	##sa	O
2431	without	O
2431	modify	O
2431	##ing	O
2431	the	O
2431	elimination	B-PK
2431	rate	I-PK
2431	constant	I-PK
2431	of	O
2431	c	O
2431	##sa	O
2431	and	O
2431	the	O
2431	c	O
2431	##sa	O
2431	pre	O
2431	-	O
2431	drug	O
2431	levels	O
2431	.	O
2431	[SEP]	O
2432	[CLS]	O
2432	the	O
2432	elimination	B-PK
2432	half	I-PK
2432	-	I-PK
2432	life	I-PK
2432	(	I-PK
2432	t	I-PK
2432	##1	I-PK
2432	/	I-PK
2432	2	I-PK
2432	)	I-PK
2432	of	O
2432	the	O
2432	##op	O
2432	##hyl	O
2432	##line	O
2432	was	O
2432	increased	O
2432	by	O
2432	20	O
2432	%	O
2432	.	O
2432	[SEP]	O
2433	[CLS]	O
2433	these	O
2433	correlation	O
2433	##s	O
2433	suggest	O
2433	that	O
2433	the	O
2433	t	O
2433	##g	O
2433	##32	O
2433	hem	O
2433	##i	O
2433	mouse	O
2433	model	O
2433	,	O
2433	which	O
2433	is	O
2433	both	O
2433	convenient	O
2433	and	O
2433	cost	O
2433	-	O
2433	effective	O
2433	,	O
2433	can	O
2433	offer	O
2433	value	O
2433	in	O
2433	predict	O
2433	##ing	O
2433	anti	O
2433	##body	O
2433	half	B-PK
2433	-	I-PK
2433	life	I-PK
2433	and	O
2433	clearance	B-PK
2433	in	O
2433	p	O
2433	##rima	O
2433	##tes	O
2433	.	O
2433	[SEP]	O
2434	[CLS]	O
2434	all	O
2434	the	O
2434	parameters	O
2434	of	O
2434	c	O
2434	##ip	O
2434	##ro	O
2434	##f	O
2434	##lo	O
2434	##xa	O
2434	##cin	O
2434	bio	B-PK
2434	##ava	I-PK
2434	##ila	I-PK
2434	##bility	I-PK
2434	i	O
2434	.	O
2434	e	O
2434	.	O
2434	,	O
2434	t	B-PK
2434	##max	I-PK
2434	,	O
2434	cm	B-PK
2434	##ax	I-PK
2434	,	O
2434	au	B-PK
2434	##c	I-PK
2434	and	O
2434	absorption	B-PK
2434	rate	I-PK
2434	constant	I-PK
2434	(	I-PK
2434	ka	I-PK
2434	)	I-PK
2434	showed	O
2434	no	O
2434	significant	O
2434	correlation	O
2434	with	O
2434	dissolution	O
2434	rates	O
2434	at	O
2434	t	O
2434	##30	O
2434	%	O
2434	,	O
2434	t	O
2434	##50	O
2434	%	O
2434	,	O
2434	t	O
2434	##90	O
2434	%	O
2434	and	O
2434	dissolution	O
2434	at	O
2434	30	O
2434	min	O
2434	##s	O
2434	with	O
2434	aims	O
2434	as	O
2434	in	O
2434	-	O
2434	v	O
2434	##ivo	O
2434	bio	O
2434	##e	O
2434	##q	O
2434	##u	O
2434	##valence	O
2434	wa	O
2434	##iver	O
2434	.	O
2434	[SEP]	O
2435	[CLS]	O
2435	mac	O
2435	##imo	O
2435	##rel	O
2435	##in	O
2435	au	B-PK
2435	##c	I-PK
2435	and	O
2435	cm	B-PK
2435	##ax	I-PK
2435	showed	O
2435	less	O
2435	than	O
2435	dose	O
2435	-	O
2435	proportional	O
2435	increases	O
2435	following	O
2435	administration	O
2435	of	O
2435	0	O
2435	.	O
2435	5	O
2435	and	O
2435	1	O
2435	.	O
2435	0	O
2435	mg	O
2435	/	O
2435	kg	O
2435	.	O
2435	[SEP]	O
2436	[CLS]	O
2436	the	O
2436	volume	B-PK
2436	of	I-PK
2436	distribution	I-PK
2436	at	I-PK
2436	steady	I-PK
2436	state	I-PK
2436	,	O
2436	systemic	B-PK
2436	clearance	I-PK
2436	and	O
2436	elimination	B-PK
2436	half	I-PK
2436	-	I-PK
2436	life	I-PK
2436	was	O
2436	5	O
2436	.	O
2436	90	O
2436	±	O
2436	0	O
2436	.	O
2436	200	O
2436	l	O
2436	/	O
2436	kg	O
2436	,	O
2436	30	O
2436	.	O
2436	7	O
2436	±	O
2436	0	O
2436	.	O
2436	166	O
2436	m	O
2436	##l	O
2436	/	O
2436	min	O
2436	/	O
2436	kg	O
2436	and	O
2436	4	O
2436	.	O
2436	84	O
2436	±	O
2436	0	O
2436	.	O
2436	83	O
2436	h	O
2436	respectively	O
2436	.	O
2436	[SEP]	O
2437	[CLS]	O
2437	the	O
2437	cm	B-PK
2437	##ax	I-PK
2437	of	O
2437	c	O
2437	##y	O
2437	##c	O
2437	##los	O
2437	##por	O
2437	##ine	O
2437	in	O
2437	c	O
2437	##y	O
2437	##p	O
2437	##3	O
2437	##a	O
2437	##4	O
2437	##∗	O
2437	##1	O
2437	/	O
2437	∗	O
2437	##1	O
2437	was	O
2437	significantly	O
2437	greater	O
2437	than	O
2437	that	O
2437	in	O
2437	c	O
2437	##y	O
2437	##p	O
2437	##3	O
2437	##a	O
2437	##4	O
2437	##∗	O
2437	##1	O
2437	/	O
2437	∗	O
2437	##18	O
2437	##b	O
2437	in	O
2437	the	O
2437	male	O
2437	group	O
2437	(	O
2437	p	O
2437	=	O
2437	0	O
2437	.	O
2437	02	O
2437	##3	O
2437	)	O
2437	,	O
2437	but	O
2437	not	O
2437	the	O
2437	female	O
2437	group	O
2437	.	O
2437	[SEP]	O
2438	[CLS]	O
2438	c	O
2438	##y	O
2438	##c	O
2438	##los	O
2438	##por	O
2438	##ine	O
2438	co	O
2438	##ad	O
2438	##mini	O
2438	##stra	O
2438	##tion	O
2438	did	O
2438	not	O
2438	appear	O
2438	to	O
2438	affect	O
2438	apparent	O
2438	sit	O
2438	##ag	O
2438	##lip	O
2438	##tin	O
2438	re	B-PK
2438	##nal	I-PK
2438	clearance	I-PK
2438	,	O
2438	t	B-PK
2438	(	I-PK
2438	1	I-PK
2438	/	I-PK
2438	2	I-PK
2438	)	I-PK
2438	,	O
2438	or	O
2438	c	O
2438	(	O
2438	24	O
2438	h	O
2438	)	O
2438	,	O
2438	suggesting	O
2438	that	O
2438	effects	O
2438	of	O
2438	these	O
2438	high	O
2438	doses	O
2438	of	O
2438	c	O
2438	##y	O
2438	##c	O
2438	##los	O
2438	##por	O
2438	##ine	O
2438	are	O
2438	more	O
2438	likely	O
2438	due	O
2438	to	O
2438	enhanced	O
2438	absorption	O
2438	of	O
2438	sit	O
2438	##ag	O
2438	##lip	O
2438	##tin	O
2438	,	O
2438	potentially	O
2438	through	O
2438	in	O
2438	##hibition	O
2438	of	O
2438	in	O
2438	##test	O
2438	##inal	O
2438	p	O
2438	-	O
2438	g	O
2438	##ly	O
2438	##co	O
2438	##p	O
2438	##rote	O
2438	##in	O
2438	.	O
2438	[SEP]	O
2439	[CLS]	O
2439	a	O
2439	significant	O
2439	difference	O
2439	was	O
2439	observed	O
2439	in	O
2439	au	B-PK
2439	##c	I-PK
2439	(	I-PK
2439	0	I-PK
2439	-	I-PK
2439	1	I-PK
2439	)	I-PK
2439	(	O
2439	45	O
2439	##31	O
2439	.	O
2439	28	O
2439	+	O
2439	-	O
2439	214	O
2439	##7	O
2439	vs	O
2439	162	O
2439	##9	O
2439	.	O
2439	1	O
2439	+	O
2439	-	O
2439	100	O
2439	##6	O
2439	ng	O
2439	x	O
2439	h	O
2439	x	O
2439	m	O
2439	##l	O
2439	(	O
2439	-	O
2439	1	O
2439	)	O
2439	,	O
2439	p	O
2439	<	O
2439	0	O
2439	.	O
2439	000	O
2439	##1	O
2439	)	O
2439	,	O
2439	au	B-PK
2439	##c	I-PK
2439	(	I-PK
2439	0	I-PK
2439	-	I-PK
2439	in	I-PK
2439	##finity	I-PK
2439	)	I-PK
2439	(	O
2439	46	O
2439	##32	O
2439	.	O
2439	42	O
2439	+	O
2439	-	O
2439	222	O
2439	##1	O
2439	.	O
2439	75	O
2439	vs	O
2439	162	O
2439	##9	O
2439	.	O
2439	46	O
2439	+	O
2439	-	O
2439	101	O
2439	##2	O
2439	.	O
2439	61	O
2439	ng	O
2439	x	O
2439	h	O
2439	x	O
2439	m	O
2439	##l	O
2439	(	O
2439	-	O
2439	1	O
2439	)	O
2439	,	O
2439	p	O
2439	=	O
2439	0	O
2439	.	O
2439	000	O
2439	##6	O
2439	)	O
2439	,	O
2439	cm	B-PK
2439	##ax	I-PK
2439	(	O
2439	54	O
2439	##4	O
2439	.	O
2439	89	O
2439	+	O
2439	-	O
2439	27	O
2439	##3	O
2439	.	O
2439	91	O
2439	vs	O
2439	238	O
2439	.	O
2439	61	O
2439	+	O
2439	-	O
2439	146	O
2439	.	O
2439	34	O
2439	ng	O
2439	/	O
2439	m	O
2439	##l	O
2439	,	O
2439	p	O
2439	=	O
2439	0	O
2439	.	O
2439	04	O
2439	)	O
2439	,	O
2439	t	O
2439	(	O
2439	1	O
2439	/	O
2439	2	O
2439	)	O
2439	(	O
2439	9	O
2439	.	O
2439	3	O
2439	+	O
2439	-	O
2439	3	O
2439	.	O
2439	58	O
2439	vs	O
2439	4	O
2439	.	O
2439	0	O
2439	+	O
2439	-	O
2439	1	O
2439	.	O
2439	43	O
2439	h	O
2439	,	O
2439	p	O
2439	=	O
2439	0	O
2439	.	O
2439	03	O
2439	##17	O
2439	)	O
2439	and	O
2439	c	B-PK
2439	##l	I-PK
2439	/	I-PK
2439	f	I-PK
2439	(	O
2439	43	O
2439	.	O
2439	14	O
2439	+	O
2439	-	O
2439	36	O
2439	.	O
2439	23	O
2439	vs	O
2439	122	O
2439	.	O
2439	85	O
2439	+	O
2439	-	O
2439	95	O
2439	l	O
2439	x	O
2439	h	O
2439	(	O
2439	-	O
2439	1	O
2439	)	O
2439	,	O
2439	p	O
2439	<	O
2439	0	O
2439	.	O
2439	000	O
2439	##1	O
2439	)	O
2439	of	O
2439	c	O
2439	##ele	O
2439	##co	O
2439	##xi	O
2439	##b	O
2439	administered	O
2439	before	O
2439	and	O
2439	after	O
2439	r	O
2439	##if	O
2439	##amp	O
2439	##ici	O
2439	##n	O
2439	pre	O
2439	##tre	O
2439	##at	O
2439	##ment	O
2439	.	O
2439	[SEP]	O
2440	[CLS]	O
2440	suspension	O
2440	##s	O
2440	of	O
2440	small	O
2440	drug	O
2440	particles	O
2440	can	O
2440	be	O
2440	used	O
2440	to	O
2440	improve	O
2440	the	O
2440	bio	B-PK
2440	##ava	I-PK
2440	##ila	I-PK
2440	##bility	I-PK
2440	.	O
2440	[SEP]	O
2441	[CLS]	O
2441	after	O
2441	in	O
2441	##tra	O
2441	##ven	O
2441	##ous	O
2441	administration	O
2441	,	O
2441	vs	B-PK
2441	##s	I-PK
2441	(	O
2441	1	O
2441	.	O
2441	39	O
2441	l	O
2441	/	O
2441	kg	O
2441	)	O
2441	and	O
2441	extremely	O
2441	low	O
2441	c	B-PK
2441	##l	I-PK
2441	(	O
2441	0	O
2441	.	O
2441	08	O
2441	l	O
2441	/	O
2441	kg	O
2441	/	O
2441	h	O
2441	)	O
2441	were	O
2441	observed	O
2441	.	O
2441	[SEP]	O
2442	[CLS]	O
2442	this	O
2442	study	O
2442	was	O
2442	conducted	O
2442	to	O
2442	evaluate	O
2442	the	O
2442	potential	O
2442	adverse	O
2442	effects	O
2442	of	O
2442	et	O
2442	##hyl	O
2442	##ben	O
2442	##zen	O
2442	##e	O
2442	(	O
2442	e	O
2442	##b	O
2442	)	O
2442	on	O
2442	reproductive	O
2442	capability	O
2442	from	O
2442	whole	O
2442	-	O
2442	body	O
2442	in	O
2442	##hala	O
2442	##tion	O
2442	exposure	O
2442	of	O
2442	f	O
2442	##0	O
2442	and	O
2442	f	O
2442	##1	O
2442	parental	O
2442	animals	O
2442	.	O
2442	[SEP]	O
2443	[CLS]	O
2443	the	O
2443	m	O
2443	##pa	O
2443	exposure	O
2443	expressed	O
2443	by	O
2443	the	O
2443	au	B-PK
2443	##c	I-PK
2443	appears	O
2443	to	O
2443	be	O
2443	higher	O
2443	in	O
2443	his	O
2443	##pan	O
2443	##ic	O
2443	patients	O
2443	than	O
2443	those	O
2443	reported	O
2443	in	O
2443	other	O
2443	ethnic	O
2443	groups	O
2443	,	O
2443	which	O
2443	may	O
2443	be	O
2443	the	O
2443	result	O
2443	of	O
2443	various	O
2443	factors	O
2443	such	O
2443	as	O
2443	difference	O
2443	of	O
2443	the	O
2443	u	O
2443	##rid	O
2443	##ine	O
2443	dip	O
2443	##hos	O
2443	##phate	O
2443	g	O
2443	##lu	O
2443	##cu	O
2443	##ron	O
2443	##osy	O
2443	##lt	O
2443	##ran	O
2443	##s	O
2443	##fer	O
2443	##ase	O
2443	enzyme	O
2443	g	O
2443	##eno	O
2443	##type	O
2443	##s	O
2443	,	O
2443	but	O
2443	gas	O
2443	##tro	O
2443	##int	O
2443	##est	O
2443	##inal	O
2443	side	O
2443	effects	O
2443	were	O
2443	acceptable	O
2443	and	O
2443	the	O
2443	cm	B-PK
2443	##ax	I-PK
2443	or	O
2443	au	B-PK
2443	##c	I-PK
2443	of	O
2443	m	O
2443	##pa	O
2443	##g	O
2443	showed	O
2443	correlation	O
2443	##s	O
2443	with	O
2443	gas	O
2443	##tro	O
2443	##int	O
2443	##est	O
2443	##inal	O
2443	symptoms	O
2443	.	O
2443	[SEP]	O
2444	[CLS]	O
2444	following	O
2444	the	O
2444	administration	O
2444	of	O
2444	o	O
2444	##xa	O
2444	##tom	O
2444	##ide	O
2444	1	O
2444	mg	O
2444	/	O
2444	kg	O
2444	,	O
2444	the	O
2444	peak	B-PK
2444	plasma	I-PK
2444	concentration	I-PK
2444	(	I-PK
2444	cm	I-PK
2444	##ax	I-PK
2444	)	I-PK
2444	,	O
2444	the	O
2444	elimination	B-PK
2444	half	I-PK
2444	-	I-PK
2444	life	I-PK
2444	(	I-PK
2444	t	I-PK
2444	##1	I-PK
2444	/	I-PK
2444	2	I-PK
2444	)	I-PK
2444	,	O
2444	the	O
2444	volume	B-PK
2444	of	I-PK
2444	distribution	I-PK
2444	(	I-PK
2444	v	I-PK
2444	##d	I-PK
2444	)	I-PK
2444	,	O
2444	and	O
2444	the	O
2444	area	B-PK
2444	under	I-PK
2444	the	I-PK
2444	curve	I-PK
2444	(	I-PK
2444	au	I-PK
2444	##c	I-PK
2444	)	I-PK
2444	0	I-PK
2444	-	I-PK
2444	36	I-PK
2444	h	I-PK
2444	were	O
2444	measured	O
2444	and	O
2444	the	O
2444	following	O
2444	results	O
2444	were	O
2444	obtained	O
2444	:	O
2444	42	O
2444	.	O
2444	2	O
2444	+	O
2444	-	O
2444	15	O
2444	ng	O
2444	/	O
2444	m	O
2444	##l	O
2444	at	O
2444	2	O
2444	h	O
2444	after	O
2444	o	O
2444	##xa	O
2444	##tom	O
2444	##ide	O
2444	administration	O
2444	,	O
2444	41	O
2444	.	O
2444	4	O
2444	+	O
2444	-	O
2444	2	O
2444	.	O
2444	0	O
2444	h	O
2444	,	O
2444	37	O
2444	.	O
2444	4	O
2444	+	O
2444	-	O
2444	4	O
2444	.	O
2444	2	O
2444	l	O
2444	/	O
2444	kg	O
2444	,	O
2444	and	O
2444	46	O
2444	##8	O
2444	+	O
2444	-	O
2444	52	O
2444	ng	O
2444	/	O
2444	m	O
2444	##l	O
2444	/	O
2444	h	O
2444	,	O
2444	respectively	O
2444	.	O
2444	[SEP]	O
2445	[CLS]	O
2445	the	O
2445	steady	O
2445	-	O
2445	state	O
2445	13	O
2445	-	O
2445	sample	O
2445	24	O
2445	-	O
2445	hour	O
2445	au	B-PK
2445	##c	I-PK
2445	value	O
2445	was	O
2445	correlated	O
2445	highly	O
2445	with	O
2445	the	O
2445	average	O
2445	9	O
2445	-	O
2445	sample	O
2445	au	B-PK
2445	##c	I-PK
2445	value	O
2445	after	O
2445	the	O
2445	2	O
2445	single	O
2445	doses	O
2445	(	O
2445	r	O
2445	=	O
2445	0	O
2445	.	O
2445	81	O
2445	;	O
2445	p	O
2445	=	O
2445	.	O
2445	000	O
2445	##2	O
2445	)	O
2445	.	O
2445	[SEP]	O
2446	[CLS]	O
2446	bus	O
2446	##ulf	O
2446	##an	O
2446	clearance	B-PK
2446	and	O
2446	area	B-PK
2446	under	I-PK
2446	concentration	I-PK
2446	time	I-PK
2446	-	I-PK
2446	curve	I-PK
2446	(	I-PK
2446	au	I-PK
2446	##c	I-PK
2446	)	I-PK
2446	were	O
2446	determined	O
2446	after	O
2446	the	O
2446	first	O
2446	dose	O
2446	using	O
2446	a	O
2446	one	O
2446	-	O
2446	compartment	O
2446	p	O
2446	##har	O
2446	##ma	O
2446	##co	O
2446	##kin	O
2446	##etic	O
2446	(	O
2446	p	O
2446	##k	O
2446	)	O
2446	model	O
2446	with	O
2446	first	O
2446	-	O
2446	order	O
2446	absorption	O
2446	.	O
2446	[SEP]	O
2447	[CLS]	O
2447	these	O
2447	findings	O
2447	suggest	O
2447	that	O
2447	newborn	O
2447	##s	O
2447	have	O
2447	increased	O
2447	try	O
2447	##ps	O
2447	##in	O
2447	up	O
2447	##take	O
2447	,	O
2447	and	O
2447	the	O
2447	try	O
2447	##ps	O
2447	##in	O
2447	initially	O
2447	binds	O
2447	to	O
2447	alpha	O
2447	1	O
2447	-	O
2447	inhibitor	O
2447	3	O
2447	before	O
2447	being	O
2447	transferred	O
2447	to	O
2447	alpha	O
2447	-	O
2447	mac	O
2447	##rog	O
2447	##lo	O
2447	##bul	O
2447	##in	O
2447	for	O
2447	clearance	B-PK
2447	.	O
2447	[SEP]	O
2448	[CLS]	O
2448	regarding	O
2448	the	O
2448	influence	O
2448	of	O
2448	au	B-PK
2448	##c	I-PK
2448	variation	O
2448	on	O
2448	au	O
2448	##ec	O
2448	variation	O
2448	,	O
2448	the	O
2448	total	B-PK
2448	clearance	I-PK
2448	value	O
2448	was	O
2448	changed	O
2448	from	O
2448	80	O
2448	%	O
2448	to	O
2448	120	O
2448	%	O
2448	.	O
2448	[SEP]	O
2449	[CLS]	O
2449	the	O
2449	au	B-PK
2449	##c	I-PK
2449	##0	I-PK
2449	-	I-PK
2449	in	I-PK
2449	##finity	I-PK
2449	and	O
2449	cm	B-PK
2449	##ax	I-PK
2449	values	O
2449	were	O
2449	proportional	O
2449	to	O
2449	doses	O
2449	(	O
2449	mg	O
2449	or	O
2449	mg	O
2449	/	O
2449	kg	O
2449	,	O
2449	p	O
2449	less	O
2449	than	O
2449	.	O
2449	00	O
2449	##1	O
2449	)	O
2449	.	O
2449	[SEP]	O
2450	[CLS]	O
2450	he	O
2450	##pa	O
2450	##tic	O
2450	ve	O
2450	##si	O
2450	##cular	O
2450	ion	O
2450	-	O
2450	trapping	O
2450	,	O
2450	intrinsic	B-PK
2450	elimination	I-PK
2450	clearance	I-PK
2450	,	O
2450	per	B-PK
2450	##me	I-PK
2450	##ability	I-PK
2450	-	O
2450	surface	O
2450	area	O
2450	product	O
2450	,	O
2450	and	O
2450	in	O
2450	##tra	O
2450	##cellular	O
2450	binding	O
2450	were	O
2450	derived	O
2450	using	O
2450	a	O
2450	physiological	O
2450	##ly	O
2450	based	O
2450	p	O
2450	##har	O
2450	##ma	O
2450	##co	O
2450	##kin	O
2450	##etic	O
2450	model	O
2450	.	O
2450	[SEP]	O
2451	[CLS]	O
2451	the	O
2451	oral	B-PK
2451	bio	I-PK
2451	##ava	I-PK
2451	##ila	I-PK
2451	##bility	I-PK
2451	of	O
2451	em	O
2451	##d	O
2451	570	O
2451	##33	O
2451	,	O
2451	a	O
2451	calcium	O
2451	se	O
2451	##ns	O
2451	##iti	O
2451	##zing	O
2451	agent	O
2451	with	O
2451	poor	O
2451	so	O
2451	##lub	O
2451	##ility	O
2451	,	O
2451	was	O
2451	compared	O
2451	in	O
2451	dogs	O
2451	using	O
2451	four	O
2451	solid	O
2451	dos	O
2451	##age	O
2451	form	O
2451	formulation	O
2451	approaches	O
2451	:	O
2451	a	O
2451	physical	O
2451	blend	O
2451	of	O
2451	the	O
2451	drug	O
2451	with	O
2451	ex	O
2451	##ci	O
2451	##pie	O
2451	##nts	O
2451	,	O
2451	micro	O
2451	##ni	O
2451	##zation	O
2451	of	O
2451	the	O
2451	drug	O
2451	,	O
2451	preparation	O
2451	of	O
2451	co	O
2451	##ground	O
2451	mixture	O
2451	##s	O
2451	and	O
2451	spray	O
2451	-	O
2451	drying	O
2451	of	O
2451	the	O
2451	drug	O
2451	from	O
2451	a	O
2451	na	O
2451	##no	O
2451	##c	O
2451	##ry	O
2451	##stal	O
2451	##line	O
2451	suspension	O
2451	.	O
2451	[SEP]	O
2452	[CLS]	O
2452	t	B-PK
2452	(	I-PK
2452	1	I-PK
2452	/	I-PK
2452	2	I-PK
2452	)	I-PK
2452	k	B-PK
2452	(	I-PK
2452	e	I-PK
2452	##o	I-PK
2452	)	I-PK
2452	for	O
2452	heart	O
2452	rate	O
2452	was	O
2452	17	O
2452	min	O
2452	,	O
2452	sa	O
2452	##cca	O
2452	##dic	O
2452	eye	O
2452	movements	O
2452	and	O
2452	adaptive	O
2452	tracking	O
2452	1	O
2452	-	O
2452	1	O
2452	.	O
2452	5	O
2452	h	O
2452	,	O
2452	body	O
2452	sway	O
2452	,	O
2452	smooth	O
2452	pursuit	O
2452	,	O
2452	visual	O
2452	analogue	O
2452	scales	O
2452	alert	O
2452	##ness	O
2452	and	O
2452	psychedelic	O
2452	2	O
2452	.	O
2452	5	O
2452	-	O
2452	3	O
2452	.	O
2452	5	O
2452	h	O
2452	,	O
2452	pupil	O
2452	size	O
2452	,	O
2452	finger	O
2452	tapping	O
2452	and	O
2452	visual	O
2452	analogue	O
2452	scales	O
2452	feeling	O
2452	high	O
2452	more	O
2452	than	O
2452	8	O
2452	h	O
2452	.	O
2452	s	O
2452	##co	O
2452	##pol	O
2452	##amine	O
2452	affected	O
2452	different	O
2452	c	O
2452	##ns	O
2452	functions	O
2452	in	O
2452	a	O
2452	concentration	O
2452	-	O
2452	dependent	O
2452	manner	O
2452	,	O
2452	which	O
2452	based	O
2452	on	O
2452	their	O
2452	distinct	O
2452	p	O
2452	##k	O
2452	-	O
2452	p	O
2452	##d	O
2452	characteristics	O
2452	seemed	O
2452	to	O
2452	reflect	O
2452	multiple	O
2452	distinct	O
2452	functional	O
2452	pathways	O
2452	of	O
2452	the	O
2452	ch	O
2452	##olin	O
2452	##ergic	O
2452	system	O
2452	.	O
2452	[SEP]	O
2453	[CLS]	O
2453	the	O
2453	data	O
2453	obtained	O
2453	fitted	O
2453	a	O
2453	two	O
2453	-	O
2453	compartment	O
2453	open	O
2453	model	O
2453	,	O
2453	and	O
2453	the	O
2453	mean	O
2453	t	B-PK
2453	##1	I-PK
2453	/	I-PK
2453	2	I-PK
2453	beta	I-PK
2453	value	O
2453	was	O
2453	39	O
2453	.	O
2453	8	O
2453	+	O
2453	-	O
2453	10	O
2453	.	O
2453	8	O
2453	min	O
2453	.	O
2453	[SEP]	O
2454	[CLS]	O
2454	in	O
2454	hospital	O
2454	##ized	O
2454	f	O
2454	##oa	O
2454	##ls	O
2454	,	O
2454	se	O
2454	##psis	O
2454	score	O
2454	,	O
2454	serum	O
2454	c	O
2454	##rea	O
2454	##tin	O
2454	##ine	O
2454	concentration	O
2454	,	O
2454	area	B-PK
2454	under	I-PK
2454	the	I-PK
2454	curve	I-PK
2454	,	O
2454	area	B-PK
2454	under	I-PK
2454	the	I-PK
2454	moment	I-PK
2454	curve	I-PK
2454	,	O
2454	and	O
2454	mean	B-PK
2454	residence	I-PK
2454	time	I-PK
2454	were	O
2454	greater	O
2454	,	O
2454	and	O
2454	total	B-PK
2454	clearance	I-PK
2454	was	O
2454	decreased	O
2454	,	O
2454	compared	O
2454	with	O
2454	values	O
2454	in	O
2454	clinical	O
2454	##ly	O
2454	normal	O
2454	f	O
2454	##oa	O
2454	##ls	O
2454	.	O
2454	[SEP]	O
2455	[CLS]	O
2455	t	O
2455	##ts	O
2455	were	O
2455	significantly	O
2455	higher	O
2455	than	O
2455	base	O
2455	##line	O
2455	at	O
2455	15	O
2455	minutes	O
2455	after	O
2455	l	O
2455	##d	O
2455	for	O
2455	f	O
2455	##3	O
2455	and	O
2455	f	O
2455	##5	O
2455	.	O
2455	[SEP]	O
2456	[CLS]	O
2456	clearance	B-PK
2456	decreased	O
2456	rapidly	O
2456	as	O
2456	the	O
2456	effective	O
2456	molecular	O
2456	size	O
2456	increased	O
2456	from	O
2456	19	O
2456	.	O
2456	5	O
2456	to	O
2456	70	O
2456	k	O
2456	##da	O
2456	,	O
2456	whereas	O
2456	above	O
2456	70	O
2456	k	O
2456	##da	O
2456	the	O
2456	clearance	B-PK
2456	decreased	O
2456	more	O
2456	slowly	O
2456	.	O
2456	[SEP]	O
2457	[CLS]	O
2457	the	O
2457	increased	O
2457	bio	B-PK
2457	##ava	I-PK
2457	##ila	I-PK
2457	##bility	I-PK
2457	of	O
2457	ni	O
2457	##fe	O
2457	##di	O
2457	##pine	O
2457	in	O
2457	the	O
2457	presence	O
2457	of	O
2457	p	O
2457	##io	O
2457	##gli	O
2457	##ta	O
2457	##zone	O
2457	may	O
2457	be	O
2457	due	O
2457	to	O
2457	an	O
2457	in	O
2457	##hibition	O
2457	of	O
2457	the	O
2457	p	O
2457	-	O
2457	g	O
2457	##p	O
2457	-	O
2457	mediated	O
2457	e	O
2457	##ff	O
2457	##lux	O
2457	transport	O
2457	##er	O
2457	in	O
2457	the	O
2457	small	O
2457	in	O
2457	##test	O
2457	##ine	O
2457	and	O
2457	to	O
2457	the	O
2457	in	O
2457	##hibition	O
2457	of	O
2457	the	O
2457	metabolism	O
2457	by	O
2457	in	O
2457	##hibition	O
2457	of	O
2457	c	O
2457	##y	O
2457	##p	O
2457	##3	O
2457	##a	O
2457	##4	O
2457	in	O
2457	the	O
2457	small	O
2457	in	O
2457	##test	O
2457	##ine	O
2457	and	O
2457	/	O
2457	or	O
2457	the	O
2457	liver	O
2457	,	O
2457	and	O
2457	/	O
2457	or	O
2457	to	O
2457	a	O
2457	reduction	O
2457	of	O
2457	c	B-PK
2457	##l	I-PK
2457	/	I-PK
2457	f	I-PK
2457	of	O
2457	ni	O
2457	##fe	O
2457	##di	O
2457	##pine	O
2457	by	O
2457	p	O
2457	##io	O
2457	##gli	O
2457	##ta	O
2457	##zone	O
2457	.	O
2457	[SEP]	O
2458	[CLS]	O
2458	the	O
2458	da	O
2458	##uno	O
2458	##ru	O
2458	##bic	O
2458	##in	O
2458	peak	B-PK
2458	concentrations	I-PK
2458	,	O
2458	clearance	B-PK
2458	##s	I-PK
2458	and	O
2458	elimination	B-PK
2458	half	I-PK
2458	-	I-PK
2458	lives	I-PK
2458	were	O
2458	(	O
2458	means	O
2458	+	O
2458	-	O
2458	s	O
2458	##d	O
2458	)	O
2458	:	O
2458	16	O
2458	.	O
2458	3	O
2458	+	O
2458	-	O
2458	2	O
2458	.	O
2458	8	O
2458	micro	O
2458	##g	O
2458	/	O
2458	m	O
2458	##l	O
2458	,	O
2458	0	O
2458	.	O
2458	3	O
2458	+	O
2458	-	O
2458	0	O
2458	.	O
2458	1	O
2458	l	O
2458	/	O
2458	h	O
2458	per	O
2458	m	O
2458	##2	O
2458	and	O
2458	5	O
2458	.	O
2458	6	O
2458	+	O
2458	-	O
2458	2	O
2458	.	O
2458	6	O
2458	h	O
2458	after	O
2458	da	O
2458	##uno	O
2458	##x	O
2458	##ome	O
2458	alone	O
2458	;	O
2458	15	O
2458	.	O
2458	1	O
2458	+	O
2458	-	O
2458	4	O
2458	.	O
2458	9	O
2458	micro	O
2458	##g	O
2458	/	O
2458	m	O
2458	##l	O
2458	,	O
2458	0	O
2458	.	O
2458	5	O
2458	+	O
2458	-	O
2458	0	O
2458	.	O
2458	3	O
2458	l	O
2458	/	O
2458	h	O
2458	per	O
2458	m	O
2458	##2	O
2458	and	O
2458	5	O
2458	.	O
2458	8	O
2458	+	O
2458	-	O
2458	2	O
2458	.	O
2458	1	O
2458	h	O
2458	after	O
2458	the	O
2458	combination	O
2458	with	O
2458	in	O
2458	##dina	O
2458	##vir	O
2458	;	O
2458	and	O
2458	14	O
2458	.	O
2458	5	O
2458	+	O
2458	-	O
2458	2	O
2458	.	O
2458	8	O
2458	micro	O
2458	##g	O
2458	/	O
2458	m	O
2458	##l	O
2458	,	O
2458	0	O
2458	.	O
2458	4	O
2458	+	O
2458	-	O
2458	0	O
2458	.	O
2458	2	O
2458	l	O
2458	/	O
2458	h	O
2458	per	O
2458	m	O
2458	##2	O
2458	and	O
2458	6	O
2458	.	O
2458	5	O
2458	+	O
2458	-	O
2458	3	O
2458	.	O
2458	9	O
2458	h	O
2458	after	O
2458	the	O
2458	combination	O
2458	with	O
2458	r	O
2458	##ito	O
2458	##na	O
2458	##vir	O
2458	.	O
2458	[SEP]	O
2459	[CLS]	O
2459	the	O
2459	mean	O
2459	(	O
2459	±	O
2459	##s	O
2459	##d	O
2459	)	O
2459	ni	O
2459	##cot	O
2459	##ine	O
2459	elimination	B-PK
2459	half	I-PK
2459	-	I-PK
2459	life	I-PK
2459	was	O
2459	136	O
2459	min	O
2459	(	O
2459	±	O
2459	##33	O
2459	.	O
2459	5	O
2459	)	O
2459	,	O
2459	clearance	B-PK
2459	was	O
2459	123	O
2459	##7	O
2459	m	O
2459	##l	O
2459	/	O
2459	min	O
2459	(	O
2459	±	O
2459	##33	O
2459	##1	O
2459	)	O
2459	,	O
2459	and	O
2459	vs	B-PK
2459	##s	I-PK
2459	was	O
2459	204	O
2459	l	O
2459	(	O
2459	±	O
2459	##6	O
2459	##6	O
2459	)	O
2459	,	O
2459	or	O
2459	2	O
2459	.	O
2459	6	O
2459	l	O
2459	/	O
2459	kg	O
2459	(	O
2459	±	O
2459	##0	O
2459	.	O
2459	7	O
2459	)	O
2459	.	O
2459	[SEP]	O
2460	[CLS]	O
2460	g	O
2460	##ena	O
2460	##cona	O
2460	##zo	O
2460	##le	O
2460	at	O
2460	20	O
2460	mg	O
2460	/	O
2460	kg	O
2460	and	O
2460	the	O
2460	r	O
2460	##r	O
2460	(	O
2460	s	O
2460	##ch	O
2460	42	O
2460	##42	O
2460	##7	O
2460	)	O
2460	en	O
2460	##anti	O
2460	##omer	O
2460	at	O
2460	10	O
2460	mg	O
2460	/	O
2460	kg	O
2460	had	O
2460	very	O
2460	similar	O
2460	serum	O
2460	concentration	O
2460	-	O
2460	time	O
2460	profiles	O
2460	and	O
2460	c	B-PK
2460	(	I-PK
2460	ma	I-PK
2460	##x	I-PK
2460	)	I-PK
2460	,	O
2460	au	B-PK
2460	##c	I-PK
2460	(	I-PK
2460	i	I-PK
2460	)	I-PK
2460	,	O
2460	and	O
2460	t	B-PK
2460	(	I-PK
2460	1	I-PK
2460	/	I-PK
2460	2	I-PK
2460	)	I-PK
2460	values	O
2460	for	O
2460	the	O
2460	r	O
2460	##r	O
2460	en	O
2460	##anti	O
2460	##omer	O
2460	in	O
2460	both	O
2460	rats	O
2460	and	O
2460	monkeys	O
2460	,	O
2460	indicating	O
2460	that	O
2460	the	O
2460	two	O
2460	treatments	O
2460	were	O
2460	equivalent	O
2460	with	O
2460	respect	O
2460	to	O
2460	the	O
2460	bio	B-PK
2460	##ava	I-PK
2460	##ila	I-PK
2460	##bility	I-PK
2460	of	O
2460	the	O
2460	r	O
2460	##r	O
2460	en	O
2460	##anti	O
2460	##omer	O
2460	.	O
2460	[SEP]	O
2461	[CLS]	O
2461	implementation	O
2461	of	O
2461	the	O
2461	m	O
2461	##p	O
2461	##b	O
2461	##p	O
2461	##k	O
2461	model	O
2461	enables	O
2461	us	O
2461	to	O
2461	analyze	O
2461	the	O
2461	relationships	O
2461	of	O
2461	age	O
2461	,	O
2461	weight	O
2461	,	O
2461	f	O
2461	##c	O
2461	##rn	O
2461	,	O
2461	er	O
2461	and	O
2461	k	O
2461	##sy	O
2461	##n	O
2461	in	O
2461	both	O
2461	adult	O
2461	and	O
2461	p	O
2461	##ediatric	O
2461	subject	O
2461	.	O
2461	[SEP]	O
2462	[CLS]	O
2462	population	O
2462	p	O
2462	##k	O
2462	analysis	O
2462	was	O
2462	performed	O
2462	by	O
2462	non	O
2462	##linear	O
2462	mixed	O
2462	-	O
2462	effects	O
2462	modeling	O
2462	(	O
2462	non	O
2462	##me	O
2462	##m	O
2462	)	O
2462	to	O
2462	estimate	O
2462	and	O
2462	identify	O
2462	different	O
2462	factors	O
2462	that	O
2462	could	O
2462	affect	O
2462	carved	O
2462	##ilo	O
2462	##l	O
2462	c	B-PK
2462	##l	I-PK
2462	.	O
2462	[SEP]	O
2463	[CLS]	O
2463	predict	O
2463	##ing	O
2463	the	O
2463	oral	B-PK
2463	bio	I-PK
2463	##ava	I-PK
2463	##ila	I-PK
2463	##bility	I-PK
2463	of	O
2463	19	O
2463	-	O
2463	nor	O
2463	##test	O
2463	##osterone	O
2463	pro	O
2463	##ges	O
2463	##tin	O
2463	##s	O
2463	in	O
2463	v	O
2463	##ivo	O
2463	from	O
2463	their	O
2463	metabolic	O
2463	stability	O
2463	in	O
2463	human	O
2463	liver	O
2463	micro	O
2463	##so	O
2463	##mal	O
2463	preparations	O
2463	in	O
2463	v	O
2463	##it	O
2463	##ro	O
2463	.	O
2463	[SEP]	O
2464	[CLS]	O
2464	however	O
2464	,	O
2464	due	O
2464	to	O
2464	poor	O
2464	water	O
2464	so	O
2464	##lub	O
2464	##ility	O
2464	,	O
2464	oral	B-PK
2464	bio	I-PK
2464	##ava	I-PK
2464	##ila	I-PK
2464	##bility	I-PK
2464	of	O
2464	the	O
2464	drug	O
2464	was	O
2464	relatively	O
2464	low	O
2464	.	O
2464	[SEP]	O
2465	[CLS]	O
2465	the	O
2465	calculations	O
2465	predicted	O
2465	that	O
2465	the	O
2465	agreement	O
2465	between	O
2465	single	O
2465	-	O
2465	and	O
2465	cumulative	O
2465	-	O
2465	dose	O
2465	techniques	O
2465	would	O
2465	be	O
2465	improved	O
2465	if	O
2465	(	O
2465	1	O
2465	)	O
2465	the	O
2465	dose	O
2465	in	O
2465	##cre	O
2465	##ment	O
2465	was	O
2465	increased	O
2465	,	O
2465	(	O
2465	2	O
2465	)	O
2465	the	O
2465	elimination	B-PK
2465	half	I-PK
2465	-	I-PK
2465	life	I-PK
2465	was	O
2465	increased	O
2465	above	O
2465	20	O
2465	minutes	O
2465	,	O
2465	or	O
2465	(	O
2465	3	O
2465	)	O
2465	an	O
2465	in	O
2465	##fusion	O
2465	was	O
2465	added	O
2465	.	O
2465	(	O
2465	abstract	O
2465	t	O
2465	##runcated	O
2465	at	O
2465	250	O
2465	words	O
2465	)	O
2465	[SEP]	O
2466	[CLS]	O
2466	it	O
2466	is	O
2466	hoped	O
2466	that	O
2466	more	O
2466	distinct	O
2466	and	O
2466	sufficient	O
2466	descriptions	O
2466	on	O
2466	the	O
2466	u	O
2466	##rina	O
2466	##ry	O
2466	ex	O
2466	##cre	O
2466	##tion	O
2466	and	O
2466	bio	B-PK
2466	##ava	I-PK
2466	##ila	I-PK
2466	##bility	I-PK
2466	will	O
2466	be	O
2466	associated	O
2466	to	O
2466	the	O
2466	package	O
2466	insert	O
2466	##s	O
2466	and	O
2466	the	O
2466	interview	O
2466	forms	O
2466	in	O
2466	future	O
2466	,	O
2466	for	O
2466	safe	O
2466	and	O
2466	efficient	O
2466	use	O
2466	of	O
2466	prescription	O
2466	drugs	O
2466	.	O
2466	[SEP]	O
2467	[CLS]	O
2467	however	O
2467	,	O
2467	despite	O
2467	advantage	O
2467	##ous	O
2467	p	O
2467	##har	O
2467	##ma	O
2467	##co	O
2467	##log	O
2467	##ic	O
2467	and	O
2467	formulation	O
2467	(	O
2467	e	O
2467	.	O
2467	g	O
2467	.	O
2467	long	O
2467	half	B-PK
2467	-	I-PK
2467	life	I-PK
2467	,	O
2467	quicker	O
2467	time	O
2467	to	O
2467	onset	O
2467	,	O
2467	and	O
2467	lack	O
2467	of	O
2467	first	O
2467	-	O
2467	pass	O
2467	he	O
2467	##pa	O
2467	##tic	O
2467	metabolism	O
2467	)	O
2467	profiles	O
2467	,	O
2467	there	O
2467	seems	O
2467	to	O
2467	be	O
2467	significant	O
2467	risk	O
2467	of	O
2467	in	O
2467	##fusion	O
2467	-	O
2467	related	O
2467	h	O
2467	##yper	O
2467	##sen	O
2467	##si	O
2467	##ti	O
2467	##vity	O
2467	reactions	O
2467	associated	O
2467	with	O
2467	the	O
2467	administration	O
2467	of	O
2467	in	O
2467	##tra	O
2467	##ven	O
2467	##ous	O
2467	r	O
2467	##ola	O
2467	##pit	O
2467	##ant	O
2467	.	O
2467	[SEP]	O
2468	[CLS]	O
2468	the	O
2468	test	O
2468	for	O
2468	proportional	O
2468	##ity	O
2468	indicated	O
2468	that	O
2468	cm	B-PK
2468	##ax	I-PK
2468	and	O
2468	au	B-PK
2468	##c	I-PK
2468	##0	I-PK
2468	-	I-PK
2468	12	I-PK
2468	increased	O
2468	proportional	O
2468	##ly	O
2468	with	O
2468	an	O
2468	increase	O
2468	in	O
2468	dose	O
2468	(	O
2468	p	O
2468	greater	O
2468	than	O
2468	0	O
2468	.	O
2468	05	O
2468	)	O
2468	.	O
2468	[SEP]	O
2469	[CLS]	O
2469	the	O
2469	half	B-PK
2469	-	I-PK
2469	life	I-PK
2469	of	O
2469	r	O
2469	-	O
2469	fl	O
2469	##eca	O
2469	##ini	O
2469	##de	O
2469	(	O
2469	12	O
2469	.	O
2469	9	O
2469	h	O
2469	)	O
2469	was	O
2469	longer	O
2469	(	O
2469	p	O
2469	less	O
2469	than	O
2469	0	O
2469	.	O
2469	03	O
2469	)	O
2469	than	O
2469	that	O
2469	of	O
2469	s	O
2469	-	O
2469	fl	O
2469	##eca	O
2469	##ini	O
2469	##de	O
2469	(	O
2469	9	O
2469	.	O
2469	8	O
2469	h	O
2469	)	O
2469	.	O
2469	[SEP]	O
2470	[CLS]	O
2470	the	O
2470	increase	O
2470	in	O
2470	bio	B-PK
2470	##ava	I-PK
2470	##ila	I-PK
2470	##bility	I-PK
2470	was	O
2470	not	O
2470	linear	O
2470	##ly	O
2470	related	O
2470	with	O
2470	the	O
2470	fat	O
2470	content	O
2470	of	O
2470	the	O
2470	meal	O
2470	.	O
2470	[SEP]	O
2471	[CLS]	O
2471	significant	O
2471	decrease	O
2471	in	O
2471	au	B-PK
2471	##c	I-PK
2471	,	O
2471	marked	O
2471	decrease	O
2471	in	O
2471	distribution	B-PK
2471	volume	I-PK
2471	and	O
2471	total	B-PK
2471	body	I-PK
2471	clearance	I-PK
2471	following	O
2471	lid	O
2471	##oc	O
2471	##aine	O
2471	and	O
2471	prop	O
2471	##rano	O
2471	##lo	O
2471	##l	O
2471	were	O
2471	noted	O
2471	.	O
2471	[SEP]	O
2472	[CLS]	O
2472	there	O
2472	were	O
2472	no	O
2472	differences	O
2472	between	O
2472	groups	O
2472	with	O
2472	respect	O
2472	to	O
2472	the	O
2472	elimination	B-PK
2472	half	I-PK
2472	-	I-PK
2472	life	I-PK
2472	(	O
2472	awake	O
2472	group	O
2472	:	O
2472	207	O
2472	min	O
2472	;	O
2472	an	O
2472	##ae	O
2472	##st	O
2472	##he	O
2472	##tized	O
2472	group	O
2472	:	O
2472	153	O
2472	min	O
2472	)	O
2472	,	O
2472	volume	B-PK
2472	of	I-PK
2472	distribution	I-PK
2472	at	I-PK
2472	steady	I-PK
2472	state	I-PK
2472	(	O
2472	awake	O
2472	:	O
2472	147	O
2472	litre	O
2472	;	O
2472	an	O
2472	##ae	O
2472	##st	O
2472	##he	O
2472	##tized	O
2472	:	O
2472	128	O
2472	litre	O
2472	)	O
2472	,	O
2472	or	O
2472	clearance	B-PK
2472	(	O
2472	awake	O
2472	:	O
2472	58	O
2472	##7	O
2472	m	O
2472	##l	O
2472	min	O
2472	-	O
2472	1	O
2472	;	O
2472	an	O
2472	##ae	O
2472	##st	O
2472	##he	O
2472	##tized	O
2472	:	O
2472	76	O
2472	##6	O
2472	m	O
2472	##l	O
2472	min	O
2472	-	O
2472	1	O
2472	)	O
2472	.	O
2472	[SEP]	O
2473	[CLS]	O
2473	the	O
2473	p	O
2473	##har	O
2473	##ma	O
2473	##co	O
2473	##kin	O
2473	##etic	O
2473	parameters	O
2473	au	B-PK
2473	##c	I-PK
2473	and	O
2473	cm	B-PK
2473	##ax	I-PK
2473	were	O
2473	tested	O
2473	for	O
2473	bio	O
2473	##e	O
2473	##qui	O
2473	##valence	O
2473	after	O
2473	log	O
2473	-	O
2473	transformation	O
2473	of	O
2473	data	O
2473	,	O
2473	differences	O
2473	of	O
2473	t	B-PK
2473	##max	I-PK
2473	were	O
2473	evaluated	O
2473	non	O
2473	##par	O
2473	##ame	O
2473	##tric	O
2473	##ally	O
2473	.	O
2473	[SEP]	O
2474	[CLS]	O
2474	objective	O
2474	:	O
2474	this	O
2474	study	O
2474	aims	O
2474	to	O
2474	detect	O
2474	the	O
2474	enhance	O
2474	##ment	O
2474	in	O
2474	the	O
2474	oral	B-PK
2474	bio	I-PK
2474	##ava	I-PK
2474	##ila	I-PK
2474	##bility	I-PK
2474	of	O
2474	a	O
2474	poorly	O
2474	water	O
2474	-	O
2474	soluble	O
2474	anti	O
2474	##hy	O
2474	##pert	O
2474	##ens	O
2474	##ive	O
2474	drug	O
2474	o	O
2474	##lm	O
2474	##es	O
2474	##art	O
2474	##an	O
2474	me	O
2474	##dox	O
2474	##omi	O
2474	##l	O
2474	(	O
2474	o	O
2474	##m	O
2474	)	O
2474	due	O
2474	to	O
2474	the	O
2474	formulation	O
2474	of	O
2474	l	O
2474	##yo	O
2474	##phi	O
2474	##li	O
2474	##zed	O
2474	oil	O
2474	##y	O
2474	-	O
2474	core	O
2474	na	O
2474	##no	O
2474	##cap	O
2474	##sul	O
2474	##es	O
2474	.	O
2474	[SEP]	O
2475	[CLS]	O
2475	using	O
2475	win	O
2475	##non	O
2475	##lin	O
2475	p	O
2475	##har	O
2475	##ma	O
2475	##co	O
2475	##kin	O
2475	##etic	O
2475	data	O
2475	analysis	O
2475	software	O
2475	,	O
2475	pu	O
2475	##era	O
2475	##rin	O
2475	was	O
2475	found	O
2475	to	O
2475	be	O
2475	rapidly	O
2475	absorbed	O
2475	via	O
2475	the	O
2475	oral	O
2475	route	O
2475	,	O
2475	reach	O
2475	peak	B-PK
2475	levels	I-PK
2475	at	O
2475	2	O
2475	hours	O
2475	,	O
2475	and	O
2475	have	O
2475	a	O
2475	half	B-PK
2475	-	I-PK
2475	life	I-PK
2475	of	O
2475	approximately	O
2475	4	O
2475	.	O
2475	3	O
2475	hours	O
2475	.	O
2475	[SEP]	O
2476	[CLS]	O
2476	this	O
2476	non	O
2476	##linear	O
2476	##ity	O
2476	was	O
2476	due	O
2476	to	O
2476	sat	O
2476	##urable	O
2476	total	B-PK
2476	body	I-PK
2476	clearance	I-PK
2476	and	O
2476	volume	B-PK
2476	of	I-PK
2476	distribution	I-PK
2476	of	O
2476	p	O
2476	##ac	O
2476	##lit	O
2476	##ax	O
2476	##el	O
2476	(	O
2476	p	O
2476	<	O
2476	0	O
2476	.	O
2476	00	O
2476	##1	O
2476	)	O
2476	.	O
2476	[SEP]	O
2477	[CLS]	O
2477	the	O
2477	p	O
2477	##hy	O
2477	##tate	O
2477	/	O
2477	z	O
2477	##n	O
2477	m	O
2477	##olar	O
2477	ratio	O
2477	is	O
2477	a	O
2477	useful	O
2477	index	O
2477	of	O
2477	z	O
2477	##n	O
2477	bio	B-PK
2477	##ava	I-PK
2477	##ila	I-PK
2477	##bility	I-PK
2477	.	O
2477	[SEP]	O
2478	[CLS]	O
2478	this	O
2478	study	O
2478	was	O
2478	aimed	O
2478	to	O
2478	develop	O
2478	s	O
2478	##ln	O
2478	##s	O
2478	and	O
2478	n	O
2478	##s	O
2478	of	O
2478	sa	O
2478	##quin	O
2478	##avi	O
2478	##r	O
2478	(	O
2478	sq	O
2478	)	O
2478	for	O
2478	improvement	O
2478	in	O
2478	bio	B-PK
2478	##ava	I-PK
2478	##ila	I-PK
2478	##bility	I-PK
2478	.	O
2478	[SEP]	O
2479	[CLS]	O
2479	peak	B-PK
2479	serum	I-PK
2479	levels	I-PK
2479	of	O
2479	r	O
2479	##omi	O
2479	##p	O
2479	##los	O
2479	##ti	O
2479	##m	O
2479	in	O
2479	t	O
2479	##bi	O
2479	mice	O
2479	occurred	O
2479	4	O
2479	-	O
2479	24	O
2479	h	O
2479	(	O
2479	t	B-PK
2479	##max	I-PK
2479	)	O
2479	after	O
2479	injection	O
2479	with	O
2479	a	O
2479	t	B-PK
2479	##1	I-PK
2479	/	I-PK
2479	2	I-PK
2479	of	O
2479	[UNK]	O
2479	h	O
2479	.	O
2479	cm	B-PK
2479	##ax	I-PK
2479	values	O
2479	were	O
2479	at	O
2479	[UNK]	O
2479	ng	O
2479	/	O
2479	m	O
2479	##l	O
2479	after	O
2479	30	O
2479	µ	O
2479	##g	O
2479	/	O
2479	kg	O
2479	±	O
2479	t	O
2479	##bi	O
2479	and	O
2479	[UNK]	O
2479	ng	O
2479	/	O
2479	m	O
2479	##l	O
2479	after	O
2479	300	O
2479	µ	O
2479	##g	O
2479	/	O
2479	kg	O
2479	.	O
2479	[SEP]	O
2480	[CLS]	O
2480	de	O
2480	##xa	O
2480	##met	O
2480	##has	O
2480	##one	O
2480	significantly	O
2480	increased	O
2480	the	O
2480	terminal	B-PK
2480	elimination	I-PK
2480	half	I-PK
2480	-	I-PK
2480	life	I-PK
2480	of	O
2480	en	O
2480	##ro	O
2480	##f	O
2480	##lo	O
2480	##xa	O
2480	##cin	O
2480	.	O
2480	[SEP]	O
2481	[CLS]	O
2481	double	O
2481	log	O
2481	##ari	O
2481	##th	O
2481	##mic	O
2481	plots	O
2481	of	O
2481	c	B-PK
2481	##l	I-PK
2481	and	O
2481	distribution	B-PK
2481	volume	I-PK
2481	at	I-PK
2481	the	I-PK
2481	steady	I-PK
2481	-	I-PK
2481	state	I-PK
2481	(	I-PK
2481	vs	I-PK
2481	##s	I-PK
2481	)	I-PK
2481	vs	O
2481	.	O
2481	body	O
2481	weight	O
2481	in	O
2481	four	O
2481	animal	O
2481	species	O
2481	were	O
2481	linear	O
2481	with	O
2481	high	O
2481	correlation	O
2481	coefficients	O
2481	;	O
2481	and	O
2481	the	O
2481	predicted	O
2481	c	B-PK
2481	##l	I-PK
2481	and	O
2481	vs	B-PK
2481	##s	I-PK
2481	values	O
2481	in	O
2481	humans	O
2481	agreed	O
2481	well	O
2481	with	O
2481	the	O
2481	observed	O
2481	values	O
2481	after	O
2481	administration	O
2481	of	O
2481	c	O
2481	##s	O
2481	-	O
2481	02	O
2481	##3	O
2481	by	O
2481	an	O
2481	in	O
2481	##tra	O
2481	##ven	O
2481	##ous	O
2481	d	O
2481	##rip	O
2481	in	O
2481	##fusion	O
2481	for	O
2481	30	O
2481	min	O
2481	.	O
2481	[SEP]	O
2482	[CLS]	O
2482	an	O
2482	##ato	O
2482	##mic	O
2482	##al	O
2482	and	O
2482	physiological	O
2482	basis	O
2482	for	O
2482	the	O
2482	all	O
2482	##ometric	O
2482	s	O
2482	##cal	O
2482	##ing	O
2482	of	O
2482	c	O
2482	##is	O
2482	##p	O
2482	##lat	O
2482	##in	O
2482	clearance	B-PK
2482	in	O
2482	dogs	O
2482	.	O
2482	[SEP]	O
2483	[CLS]	O
2483	our	O
2483	results	O
2483	revealed	O
2483	no	O
2483	considerable	O
2483	differences	O
2483	in	O
2483	clearance	B-PK
2483	##s	I-PK
2483	among	O
2483	the	O
2483	components	O
2483	.	O
2483	[SEP]	O
2484	[CLS]	O
2484	m	O
2484	##od	O
2484	##ulation	O
2484	of	O
2484	p	O
2484	-	O
2484	g	O
2484	##ly	O
2484	##co	O
2484	##p	O
2484	##rote	O
2484	##in	O
2484	with	O
2484	c	O
2484	##y	O
2484	##c	O
2484	##los	O
2484	##por	O
2484	##in	O
2484	a	O
2484	caused	O
2484	a	O
2484	5	O
2484	-	O
2484	to	O
2484	10	O
2484	-	O
2484	fold	O
2484	increase	O
2484	in	O
2484	the	O
2484	up	O
2484	##take	O
2484	of	O
2484	[	O
2484	18	O
2484	##f	O
2484	]	O
2484	m	O
2484	##pp	O
2484	##f	O
2484	.	O
2484	[SEP]	O
2485	[CLS]	O
2485	an	O
2485	ultra	O
2485	-	O
2485	high	O
2485	performance	O
2485	liquid	O
2485	ch	O
2485	##roma	O
2485	##tography	O
2485	/	O
2485	tandem	O
2485	mass	O
2485	s	O
2485	##pect	O
2485	##rome	O
2485	##try	O
2485	(	O
2485	up	O
2485	##l	O
2485	##c	O
2485	-	O
2485	m	O
2485	##s	O
2485	/	O
2485	m	O
2485	##s	O
2485	)	O
2485	method	O
2485	for	O
2485	the	O
2485	simultaneous	O
2485	determination	O
2485	of	O
2485	(	O
2485	4	O
2485	##s	O
2485	,	O
2485	5	O
2485	##r	O
2485	)	O
2485	-	O
2485	5	O
2485	-	O
2485	[	O
2485	3	O
2485	,	O
2485	5	O
2485	-	O
2485	bi	O
2485	##s	O
2485	(	O
2485	t	O
2485	##ri	O
2485	##f	O
2485	##lu	O
2485	##oro	O
2485	##met	O
2485	##hyl	O
2485	)	O
2485	p	O
2485	##hen	O
2485	##yl	O
2485	]	O
2485	-	O
2485	3	O
2485	-	O
2485	{	O
2485	[	O
2485	4	O
2485	'	O
2485	-	O
2485	flu	O
2485	##oro	O
2485	-	O
2485	5	O
2485	'	O
2485	-	O
2485	is	O
2485	##op	O
2485	##rop	O
2485	##yl	O
2485	-	O
2485	2	O
2485	'	O
2485	-	O
2485	met	O
2485	##ho	O
2485	##xy	O
2485	-	O
2485	4	O
2485	-	O
2485	(	O
2485	t	O
2485	##ri	O
2485	##f	O
2485	##lu	O
2485	##oro	O
2485	##met	O
2485	##hyl	O
2485	)	O
2485	bi	O
2485	##phe	O
2485	##ny	O
2485	##l	O
2485	-	O
2485	2	O
2485	-	O
2485	y	O
2485	##l	O
2485	]	O
2485	met	O
2485	##hyl	O
2485	}	O
2485	-	O
2485	4	O
2485	-	O
2485	met	O
2485	##hyl	O
2485	-	O
2485	1	O
2485	,	O
2485	3	O
2485	-	O
2485	o	O
2485	##xa	O
2485	##zo	O
2485	##lid	O
2485	##in	O
2485	-	O
2485	2	O
2485	-	O
2485	one	O
2485	(	O
2485	an	O
2485	##ace	O
2485	##tra	O
2485	##pi	O
2485	##b	O
2485	,	O
2485	i	O
2485	)	O
2485	and	O
2485	[	O
2485	(	O
2485	13	O
2485	)	O
2485	c	O
2485	##5	O
2485	(	O
2485	15	O
2485	)	O
2485	n	O
2485	]	O
2485	-	O
2485	an	O
2485	##ace	O
2485	##tra	O
2485	##pi	O
2485	##b	O
2485	,	O
2485	ii	O
2485	in	O
2485	human	O
2485	plasma	O
2485	has	O
2485	been	O
2485	developed	O
2485	to	O
2485	support	O
2485	a	O
2485	clinical	O
2485	study	O
2485	to	O
2485	determine	O
2485	the	O
2485	absolute	B-PK
2485	bio	I-PK
2485	##ava	I-PK
2485	##ila	I-PK
2485	##bility	I-PK
2485	of	O
2485	i	O
2485	.	O
2485	the	O
2485	anal	O
2485	##yte	O
2485	##s	O
2485	and	O
2485	the	O
2485	stable	O
2485	-	O
2485	is	O
2485	##oto	O
2485	##pe	O
2485	labeled	O
2485	internal	O
2485	standard	O
2485	(	O
2485	[	O
2485	(	O
2485	13	O
2485	)	O
2485	c	O
2485	##7	O
2485	(	O
2485	15	O
2485	)	O
2485	n	O
2485	(	O
2485	2	O
2485	)	O
2485	h	O
2485	##7	O
2485	]	O
2485	-	O
2485	an	O
2485	##ace	O
2485	##tra	O
2485	##pi	O
2485	##b	O
2485	,	O
2485	ii	O
2485	##i	O
2485	)	O
2485	were	O
2485	extracted	O
2485	from	O
2485	100	O
2485	##μ	O
2485	##l	O
2485	of	O
2485	human	O
2485	plasma	O
2485	by	O
2485	liquid	O
2485	-	O
2485	liquid	O
2485	extraction	O
2485	using	O
2485	20	O
2485	/	O
2485	80	O
2485	is	O
2485	##op	O
2485	##rop	O
2485	##yl	O
2485	alcohol	O
2485	/	O
2485	he	O
2485	##xa	O
2485	##ne	O
2485	(	O
2485	v	O
2485	/	O
2485	v	O
2485	)	O
2485	.	O
2485	[SEP]	O
2486	[CLS]	O
2486	compared	O
2486	with	O
2486	the	O
2486	patients	O
2486	receiving	O
2486	v	O
2486	##c	O
2486	##r	O
2486	,	O
2486	the	O
2486	patients	O
2486	treated	O
2486	with	O
2486	vs	O
2486	##li	O
2486	displayed	O
2486	an	O
2486	increase	O
2486	in	O
2486	the	O
2486	area	B-PK
2486	under	I-PK
2486	the	I-PK
2486	plasma	I-PK
2486	concentration	I-PK
2486	vs	I-PK
2486	time	I-PK
2486	curve	I-PK
2486	(	I-PK
2486	au	I-PK
2486	##c	I-PK
2486	)	I-PK
2486	,	O
2486	and	O
2486	a	O
2486	decrease	O
2486	in	O
2486	plasma	B-PK
2486	clearance	I-PK
2486	rates	I-PK
2486	.	O
2486	[SEP]	O
2487	[CLS]	O
2487	since	O
2487	et	O
2487	##op	O
2487	##os	O
2487	##ide	O
2487	was	O
2487	con	O
2487	##com	O
2487	##ita	O
2487	##ntly	O
2487	administered	O
2487	,	O
2487	we	O
2487	can	O
2487	formula	O
2487	##te	O
2487	the	O
2487	conclusion	O
2487	as	O
2487	follows	O
2487	:	O
2487	no	O
2487	""""	O
2487	objective	O
2487	""""	O
2487	response	O
2487	was	O
2487	observed	O
2487	in	O
2487	the	O
2487	patients	O
2487	with	O
2487	low	O
2487	t	O
2487	##p	O
2487	plasma	O
2487	concentrations	O
2487	and	O
2487	au	B-PK
2487	##c	I-PK
2487	##0	I-PK
2487	-	I-PK
2487	120	I-PK
2487	h	I-PK
2487	.	O
2487	[SEP]	O
2488	[CLS]	O
2488	the	O
2488	effect	O
2488	of	O
2488	acute	O
2488	withdrawal	O
2488	from	O
2488	cigarette	O
2488	smoking	O
2488	on	O
2488	in	O
2488	##do	O
2488	##cy	O
2488	##ani	O
2488	##ne	O
2488	green	O
2488	and	O
2488	anti	O
2488	##py	O
2488	##rine	O
2488	clearance	B-PK
2488	.	O
2488	[SEP]	O
2489	[CLS]	O
2489	however	O
2489	,	O
2489	during	O
2489	c	O
2489	##v	O
2489	##v	O
2489	##h	O
2489	##d	O
2489	,	O
2489	membrane	O
2489	dependence	O
2489	of	O
2489	van	O
2489	##com	O
2489	##y	O
2489	##cin	O
2489	clearance	B-PK
2489	was	O
2489	noted	O
2489	at	O
2489	a	O
2489	q	O
2489	(	O
2489	di	O
2489	)	O
2489	greater	O
2489	than	O
2489	16	O
2489	.	O
2489	7	O
2489	m	O
2489	##l	O
2489	/	O
2489	min	O
2489	;	O
2489	van	O
2489	##com	O
2489	##y	O
2489	##cin	O
2489	clearance	B-PK
2489	with	O
2489	pm	O
2489	##ma	O
2489	at	O
2489	a	O
2489	q	O
2489	(	O
2489	di	O
2489	)	O
2489	of	O
2489	25	O
2489	m	O
2489	##l	O
2489	/	O
2489	min	O
2489	was	O
2489	66	O
2489	%	O
2489	and	O
2489	43	O
2489	%	O
2489	greater	O
2489	than	O
2489	that	O
2489	with	O
2489	the	O
2489	an	O
2489	##6	O
2489	##9	O
2489	and	O
2489	ps	O
2489	filters	O
2489	,	O
2489	respectively	O
2489	.	O
2489	[SEP]	O
2490	[CLS]	O
2490	the	O
2490	bio	B-PK
2490	##ava	I-PK
2490	##ila	I-PK
2490	##bility	I-PK
2490	was	O
2490	116	O
2490	%	O
2490	relative	O
2490	to	O
2490	re	O
2490	##len	O
2490	##za	O
2490	##®	O
2490	.	O
2490	[SEP]	O
2491	[CLS]	O
2491	the	O
2491	effectiveness	O
2491	of	O
2491	p	O
2491	##ta	O
2491	##u	O
2491	in	O
2491	improving	O
2491	the	O
2491	oral	B-PK
2491	bio	I-PK
2491	##ava	I-PK
2491	##ila	I-PK
2491	##bility	I-PK
2491	of	O
2491	u	O
2491	##rid	O
2491	##ine	O
2491	could	O
2491	be	O
2491	useful	O
2491	in	O
2491	the	O
2491	rescue	O
2491	or	O
2491	protection	O
2491	from	O
2491	host	O
2491	toxic	O
2491	##ities	O
2491	of	O
2491	various	O
2491	ch	O
2491	##em	O
2491	##oth	O
2491	##era	O
2491	##pe	O
2491	##uti	O
2491	##c	O
2491	p	O
2491	##yr	O
2491	##im	O
2491	##id	O
2491	##ine	O
2491	analogue	O
2491	##s	O
2491	as	O
2491	well	O
2491	as	O
2491	in	O
2491	the	O
2491	management	O
2491	of	O
2491	medical	O
2491	disorders	O
2491	that	O
2491	are	O
2491	re	O
2491	##med	O
2491	##ied	O
2491	by	O
2491	administration	O
2491	of	O
2491	u	O
2491	##rid	O
2491	##ine	O
2491	.	O
2491	[SEP]	O
2492	[CLS]	O
2492	consistent	O
2492	with	O
2492	the	O
2492	cell	O
2492	culture	O
2492	model	O
2492	results	O
2492	,	O
2492	we	O
2492	observed	O
2492	that	O
2492	the	O
2492	degree	O
2492	and	O
2492	rate	O
2492	of	O
2492	drug	O
2492	transfer	O
2492	into	O
2492	human	O
2492	blood	O
2492	was	O
2492	more	O
2492	pronounced	O
2492	for	O
2492	c	O
2492	##sa	O
2492	-	O
2492	p	O
2492	##g	O
2492	than	O
2492	for	O
2492	l	O
2492	-	O
2492	c	O
2492	##sa	O
2492	with	O
2492	the	O
2492	area	B-PK
2492	under	I-PK
2492	the	I-PK
2492	curve	I-PK
2492	(	I-PK
2492	au	I-PK
2492	##c	I-PK
2492	)	I-PK
2492	of	O
2492	c	O
2492	##sa	O
2492	-	O
2492	p	O
2492	##g	O
2492	being	O
2492	about	O
2492	1	O
2492	.	O
2492	6	O
2492	times	O
2492	higher	O
2492	than	O
2492	for	O
2492	the	O
2492	l	O
2492	-	O
2492	c	O
2492	##sa	O
2492	formulation	O
2492	.	O
2492	[SEP]	O
2493	[CLS]	O
2493	the	O
2493	structure	O
2493	could	O
2493	explain	O
2493	the	O
2493	shorter	O
2493	terminal	B-PK
2493	half	I-PK
2493	-	I-PK
2493	life	I-PK
2493	of	O
2493	t	O
2493	-	O
2493	d	O
2493	##m	O
2493	##1	O
2493	relative	O
2493	to	O
2493	t	O
2493	##t	O
2493	##ma	O
2493	##b	O
2493	.	O
2493	[SEP]	O
2494	[CLS]	O
2494	as	O
2494	compared	O
2494	with	O
2494	the	O
2494	au	B-PK
2494	##c	I-PK
2494	in	O
2494	subjects	O
2494	who	O
2494	were	O
2494	administered	O
2494	l	O
2494	##w	O
2494	de	O
2494	##co	O
2494	##ction	O
2494	,	O
2494	the	O
2494	au	B-PK
2494	##c	I-PK
2494	in	O
2494	those	O
2494	taken	O
2494	l	O
2494	##w	O
2494	+	O
2494	p	O
2494	##v	O
2494	de	O
2494	##co	O
2494	##ction	O
2494	was	O
2494	lower	O
2494	[	O
2494	(	O
2494	157	O
2494	##34	O
2494	.	O
2494	88	O
2494	+	O
2494	-	O
2494	77	O
2494	##37	O
2494	.	O
2494	97	O
2494	)	O
2494	ng	O
2494	/	O
2494	(	O
2494	min	O
2494	.	O
2494	m	O
2494	##l	O
2494	)	O
2494	vs	O
2494	(	O
2494	57	O
2494	##17	O
2494	.	O
2494	92	O
2494	+	O
2494	-	O
2494	61	O
2494	##24	O
2494	.	O
2494	63	O
2494	)	O
2494	ng	O
2494	/	O
2494	(	O
2494	min	O
2494	.	O
2494	m	O
2494	##l	O
2494	)	O
2494	]	O
2494	,	O
2494	p	O
2494	<	O
2494	0	O
2494	.	O
2494	05	O
2494	)	O
2494	,	O
2494	while	O
2494	that	O
2494	in	O
2494	those	O
2494	taken	O
2494	ch	O
2494	-	O
2494	ii	O
2494	was	O
2494	relatively	O
2494	higher	O
2494	[	O
2494	(	O
2494	80	O
2494	##7	O
2494	##2	O
2494	.	O
2494	00	O
2494	+	O
2494	-	O
2494	44	O
2494	##24	O
2494	.	O
2494	31	O
2494	)	O
2494	ng	O
2494	/	O
2494	(	O
2494	min	O
2494	.	O
2494	m	O
2494	##l	O
2494	)	O
2494	,	O
2494	p	O
2494	>	O
2494	0	O
2494	.	O
2494	05	O
2494	)	O
2494	]	O
2494	.	O
2494	[SEP]	O
2495	[CLS]	O
2495	in	O
2495	addition	O
2495	,	O
2495	b	O
2495	##ms	O
2495	-	O
2495	3	O
2495	could	O
2495	be	O
2495	meta	O
2495	##bol	O
2495	##ized	O
2495	by	O
2495	both	O
2495	c	O
2495	##y	O
2495	##p	O
2495	##2	O
2495	##c	O
2495	##9	O
2495	and	O
2495	c	O
2495	##y	O
2495	##p	O
2495	##3	O
2495	##a	O
2495	##4	O
2495	,	O
2495	thus	O
2495	avoiding	O
2495	the	O
2495	reliance	O
2495	on	O
2495	a	O
2495	single	O
2495	p	O
2495	##45	O
2495	##0	O
2495	enzyme	O
2495	for	O
2495	metabolic	B-PK
2495	clearance	I-PK
2495	.	O
2495	[SEP]	O
2496	[CLS]	O
2496	based	O
2496	on	O
2496	the	O
2496	results	O
2496	,	O
2496	both	O
2496	formulation	O
2496	##s	O
2496	of	O
2496	am	O
2496	##ox	O
2496	##ici	O
2496	##llin	O
2496	evaluated	O
2496	in	O
2496	this	O
2496	study	O
2496	were	O
2496	considered	O
2496	bio	O
2496	##e	O
2496	##qui	O
2496	##valent	O
2496	according	O
2496	to	O
2496	f	O
2496	##da	O
2496	and	O
2496	an	O
2496	##vis	O
2496	##a	O
2496	/	O
2496	bra	O
2496	##zi	O
2496	##l	O
2496	criteria	O
2496	.	O
2496	[SEP]	O
2497	[CLS]	O
2497	micro	O
2497	##dos	O
2497	##e	O
2497	:	O
2497	c	B-PK
2497	##l	I-PK
2497	13	O
2497	##l	O
2497	/	O
2497	h	O
2497	,	O
2497	c	B-PK
2497	##l	I-PK
2497	(	I-PK
2497	r	I-PK
2497	)	I-PK
2497	4	O
2497	.	O
2497	1	O
2497	##l	O
2497	/	O
2497	h	O
2497	,	O
2497	v	B-PK
2497	(	I-PK
2497	s	I-PK
2497	##s	I-PK
2497	)	I-PK
2497	54	O
2497	##l	O
2497	,	O
2497	t	B-PK
2497	(	I-PK
2497	1	I-PK
2497	/	I-PK
2497	2	I-PK
2497	)	I-PK
2497	16	O
2497	##h	O
2497	;	O
2497	therapeutic	O
2497	dose	O
2497	:	O
2497	c	B-PK
2497	##l	I-PK
2497	16	O
2497	##l	O
2497	/	O
2497	h	O
2497	,	O
2497	c	B-PK
2497	##l	I-PK
2497	(	I-PK
2497	r	I-PK
2497	)	I-PK
2497	6	O
2497	.	O
2497	2	O
2497	##l	O
2497	/	O
2497	h	O
2497	,	O
2497	v	B-PK
2497	(	I-PK
2497	s	I-PK
2497	##s	I-PK
2497	)	I-PK
2497	64	O
2497	##l	O
2497	,	O
2497	t	B-PK
2497	(	I-PK
2497	1	I-PK
2497	/	I-PK
2497	2	I-PK
2497	)	I-PK
2497	12	O
2497	##h	O
2497	.	O
2497	[SEP]	O
2498	[CLS]	O
2498	the	O
2498	c	O
2498	##v	O
2498	##v	O
2498	##h	O
2498	##d	O
2498	##f	O
2498	yielded	O
2498	a	O
2498	mean	O
2498	line	O
2498	##zo	O
2498	##lid	O
2498	clearance	B-PK
2498	of	O
2498	36	O
2498	.	O
2498	5	O
2498	m	O
2498	##l	O
2498	/	O
2498	minute	O
2498	and	O
2498	an	O
2498	elimination	B-PK
2498	half	I-PK
2498	-	I-PK
2498	life	I-PK
2498	of	O
2498	7	O
2498	.	O
2498	5	O
2498	hours	O
2498	.	O
2498	[SEP]	O
2499	[CLS]	O
2499	absolute	B-PK
2499	bio	I-PK
2499	##ava	I-PK
2499	##ila	I-PK
2499	##bility	I-PK
2499	was	O
2499	determined	O
2499	from	O
2499	the	O
2499	ratios	B-PK
2499	of	I-PK
2499	the	I-PK
2499	areas	I-PK
2499	under	I-PK
2499	the	I-PK
2499	serum	I-PK
2499	concentration	I-PK
2499	-	I-PK
2499	time	I-PK
2499	curves	I-PK
2499	after	O
2499	intake	O
2499	of	O
2499	the	O
2499	tablet	O
2499	and	O
2499	after	O
2499	in	O
2499	##tra	O
2499	##ven	O
2499	##ous	O
2499	in	O
2499	##fusion	O
2499	of	O
2499	amino	O
2499	##phy	O
2499	##llin	O
2499	##e	O
2499	in	O
2499	the	O
2499	same	O
2499	patient	O
2499	.	O
2499	[SEP]	O
2500	[CLS]	O
2500	a	O
2500	comparison	O
2500	of	O
2500	the	O
2500	in	O
2500	v	O
2500	##ivo	O
2500	and	O
2500	in	O
2500	v	O
2500	##it	O
2500	##ro	O
2500	results	O
2500	demonstrated	O
2500	a	O
2500	definite	O
2500	rank	O
2500	-	O
2500	order	O
2500	correlation	O
2500	between	O
2500	the	O
2500	dissolution	O
2500	performance	O
2500	of	O
2500	the	O
2500	two	O
2500	suspension	O
2500	##s	O
2500	and	O
2500	the	O
2500	in	O
2500	v	O
2500	##ivo	O
2500	parameters	O
2500	reflecting	O
2500	the	O
2500	absorption	B-PK
2500	rate	I-PK
2500	.	O
2500	[SEP]	O
2501	[CLS]	O
2501	results	O
2501	we	O
2501	showed	O
2501	that	O
2501	there	O
2501	were	O
2501	no	O
2501	significant	O
2501	differences	O
2501	in	O
2501	p	O
2501	##har	O
2501	##ma	O
2501	##co	O
2501	##kin	O
2501	##etic	O
2501	parameters	O
2501	(	O
2501	half	B-PK
2501	-	I-PK
2501	life	I-PK
2501	,	O
2501	area	B-PK
2501	under	I-PK
2501	the	I-PK
2501	curve	I-PK
2501	,	O
2501	peak	B-PK
2501	concentrations	I-PK
2501	,	O
2501	time	B-PK
2501	to	I-PK
2501	reach	I-PK
2501	maximum	I-PK
2501	concentration	I-PK
2501	,	O
2501	elimination	B-PK
2501	rate	I-PK
2501	constant	I-PK
2501	)	O
2501	of	O
2501	am	O
2501	##ox	O
2501	##ici	O
2501	##llin	O
2501	between	O
2501	the	O
2501	pro	O
2501	##biotic	O
2501	treated	O
2501	and	O
2501	un	O
2501	##tre	O
2501	##ated	O
2501	control	O
2501	groups	O
2501	.	O
2501	[SEP]	O
2502	[CLS]	O
2502	significant	O
2502	inter	O
2502	##ind	O
2502	##iv	O
2502	##id	O
2502	##ual	O
2502	var	O
2502	##iability	O
2502	was	O
2502	found	O
2502	in	O
2502	time	B-PK
2502	to	I-PK
2502	peak	I-PK
2502	concentration	I-PK
2502	(	O
2502	30	O
2502	-	O
2502	180	O
2502	min	O
2502	)	O
2502	,	O
2502	peak	B-PK
2502	concentration	I-PK
2502	(	O
2502	0	O
2502	.	O
2502	41	O
2502	-	O
2502	2	O
2502	.	O
2502	77	O
2502	micro	O
2502	##m	O
2502	)	O
2502	,	O
2502	and	O
2502	to	O
2502	a	O
2502	lesser	O
2502	extent	O
2502	the	O
2502	half	B-PK
2502	-	I-PK
2502	lives	I-PK
2502	(	I-PK
2502	t	I-PK
2502	##1	I-PK
2502	/	I-PK
2502	2	I-PK
2502	alpha	I-PK
2502	:	O
2502	32	O
2502	.	O
2502	8	O
2502	-	O
2502	86	O
2502	.	O
2502	1	O
2502	min	O
2502	;	O
2502	t	B-PK
2502	##1	I-PK
2502	/	I-PK
2502	2	I-PK
2502	beta	I-PK
2502	:	O
2502	43	O
2502	.	O
2502	6	O
2502	-	O
2502	350	O
2502	.	O
2502	0	O
2502	min	O
2502	;	O
2502	t	B-PK
2502	##1	I-PK
2502	/	I-PK
2502	2	I-PK
2502	absorption	I-PK
2502	:	O
2502	25	O
2502	.	O
2502	2	O
2502	-	O
2502	60	O
2502	.	O
2502	3	O
2502	min	O
2502	)	O
2502	and	O
2502	plasma	B-PK
2502	area	I-PK
2502	under	I-PK
2502	the	I-PK
2502	concentration	I-PK
2502	-	I-PK
2502	time	I-PK
2502	curve	I-PK
2502	from	I-PK
2502	zero	I-PK
2502	to	I-PK
2502	in	I-PK
2502	##finity	I-PK
2502	(	O
2502	195	O
2502	.	O
2502	6	O
2502	-	O
2502	81	O
2502	##8	O
2502	.	O
2502	5	O
2502	micro	O
2502	##m	O
2502	.	O
2502	min	O
2502	)	O
2502	.	O
2502	[SEP]	O
2503	[CLS]	O
2503	changes	O
2503	in	O
2503	c	O
2503	##po	O
2503	##4	O
2503	and	O
2503	ch	O
2503	##co	O
2503	##3	O
2503	were	O
2503	not	O
2503	detected	O
2503	.	O
2503	[SEP]	O
2504	[CLS]	O
2504	the	O
2504	bio	O
2504	##dis	O
2504	##tribution	O
2504	and	O
2504	p	O
2504	##har	O
2504	##ma	O
2504	##co	O
2504	##kin	O
2504	##etic	O
2504	data	O
2504	suggest	O
2504	that	O
2504	the	O
2504	product	O
2504	can	O
2504	be	O
2504	further	O
2504	tested	O
2504	for	O
2504	molecular	O
2504	radio	O
2504	##ther	O
2504	##ap	O
2504	##y	O
2504	of	O
2504	c	O
2504	##ea	O
2504	+	O
2504	tumors	O
2504	.	O
2504	[SEP]	O
2505	[CLS]	O
2505	bio	B-PK
2505	##ava	I-PK
2505	##ila	I-PK
2505	##bility	I-PK
2505	was	O
2505	assessed	O
2505	by	O
2505	comparison	O
2505	of	O
2505	peak	B-PK
2505	concentration	I-PK
2505	,	O
2505	time	B-PK
2505	to	I-PK
2505	peak	I-PK
2505	concentration	I-PK
2505	,	O
2505	area	B-PK
2505	under	I-PK
2505	the	I-PK
2505	curve	I-PK
2505	,	O
2505	and	O
2505	time	O
2505	spent	O
2505	over	O
2505	0	O
2505	.	O
2505	5	O
2505	micro	O
2505	##gram	O
2505	##s	O
2505	/	O
2505	m	O
2505	##l	O
2505	.	O
2505	[SEP]	O
2506	[CLS]	O
2506	in	O
2506	the	O
2506	single	O
2506	-	O
2506	dose	O
2506	study	O
2506	,	O
2506	the	O
2506	mean	O
2506	t	B-PK
2506	(	I-PK
2506	1	I-PK
2506	/	I-PK
2506	2	I-PK
2506	)	I-PK
2506	for	O
2506	a	O
2506	##rani	O
2506	##di	O
2506	##pine	O
2506	5	O
2506	,	O
2506	10	O
2506	,	O
2506	and	O
2506	20	O
2506	mg	O
2506	was	O
2506	3	O
2506	.	O
2506	0	O
2506	(	O
2506	2	O
2506	.	O
2506	7	O
2506	)	O
2506	,	O
2506	2	O
2506	.	O
2506	7	O
2506	(	O
2506	1	O
2506	.	O
2506	1	O
2506	)	O
2506	,	O
2506	and	O
2506	3	O
2506	.	O
2506	1	O
2506	(	O
2506	2	O
2506	.	O
2506	2	O
2506	)	O
2506	hours	O
2506	,	O
2506	respectively	O
2506	;	O
2506	mean	O
2506	t	B-PK
2506	(	I-PK
2506	ma	I-PK
2506	##x	I-PK
2506	)	I-PK
2506	was	O
2506	4	O
2506	.	O
2506	9	O
2506	(	O
2506	0	O
2506	.	O
2506	4	O
2506	)	O
2506	,	O
2506	4	O
2506	.	O
2506	4	O
2506	(	O
2506	1	O
2506	.	O
2506	0	O
2506	)	O
2506	,	O
2506	and	O
2506	4	O
2506	.	O
2506	3	O
2506	(	O
2506	0	O
2506	.	O
2506	9	O
2506	)	O
2506	hours	O
2506	;	O
2506	mean	O
2506	c	B-PK
2506	(	I-PK
2506	ma	I-PK
2506	##x	I-PK
2506	)	I-PK
2506	was	O
2506	1	O
2506	.	O
2506	1	O
2506	(	O
2506	0	O
2506	.	O
2506	6	O
2506	)	O
2506	,	O
2506	2	O
2506	.	O
2506	4	O
2506	(	O
2506	0	O
2506	.	O
2506	8	O
2506	)	O
2506	,	O
2506	and	O
2506	4	O
2506	.	O
2506	0	O
2506	(	O
2506	2	O
2506	.	O
2506	0	O
2506	)	O
2506	micro	O
2506	##g	O
2506	/	O
2506	l	O
2506	;	O
2506	and	O
2506	mean	O
2506	au	B-PK
2506	##c	I-PK
2506	(	I-PK
2506	last	I-PK
2506	)	I-PK
2506	was	O
2506	4	O
2506	.	O
2506	1	O
2506	(	O
2506	1	O
2506	.	O
2506	4	O
2506	)	O
2506	,	O
2506	10	O
2506	.	O
2506	3	O
2506	(	O
2506	2	O
2506	.	O
2506	3	O
2506	)	O
2506	,	O
2506	and	O
2506	20	O
2506	.	O
2506	9	O
2506	(	O
2506	4	O
2506	.	O
2506	2	O
2506	)	O
2506	micro	O
2506	##g	O
2506	.	O
2506	[SEP]	O
2507	[CLS]	O
2507	the	O
2507	p	O
2507	##eo	O
2507	-	O
2507	b	O
2507	-	O
2507	p	O
2507	##c	O
2507	##l	O
2507	mice	O
2507	##lles	O
2507	also	O
2507	significantly	O
2507	decreased	O
2507	the	O
2507	volume	B-PK
2507	of	I-PK
2507	distribution	I-PK
2507	(	I-PK
2507	v	I-PK
2507	##d	I-PK
2507	(	I-PK
2507	s	I-PK
2507	##s	I-PK
2507	)	I-PK
2507	)	I-PK
2507	and	O
2507	clearance	B-PK
2507	(	I-PK
2507	c	I-PK
2507	##l	I-PK
2507	)	I-PK
2507	of	O
2507	v	O
2507	##als	O
2507	##po	O
2507	##dar	O
2507	by	O
2507	nearly	O
2507	49	O
2507	%	O
2507	and	O
2507	34	O
2507	%	O
2507	,	O
2507	respectively	O
2507	.	O
2507	[SEP]	O
2508	[CLS]	O
2508	the	O
2508	results	O
2508	indicated	O
2508	that	O
2508	the	O
2508	extent	O
2508	of	O
2508	bio	B-PK
2508	##ava	I-PK
2508	##ila	I-PK
2508	##bility	I-PK
2508	of	O
2508	c	O
2508	##ef	O
2508	##ota	O
2508	##xi	O
2508	##me	O
2508	was	O
2508	increased	O
2508	approximately	O
2508	2	O
2508	.	O
2508	7	O
2508	and	O
2508	2	O
2508	.	O
2508	3	O
2508	times	O
2508	compared	O
2508	with	O
2508	that	O
2508	of	O
2508	the	O
2508	a	O
2508	##que	O
2508	##ous	O
2508	solution	O
2508	and	O
2508	the	O
2508	physical	O
2508	mixture	O
2508	,	O
2508	respectively	O
2508	.	O
2508	[SEP]	O
2509	[CLS]	O
2509	the	O
2509	distribution	B-PK
2509	volume	I-PK
2509	at	I-PK
2509	steady	I-PK
2509	state	I-PK
2509	was	O
2509	1	O
2509	.	O
2509	4	O
2509	l	O
2509	kg	O
2509	-	O
2509	1	O
2509	,	O
2509	implying	O
2509	a	O
2509	low	O
2509	tendency	O
2509	for	O
2509	distribution	O
2509	to	O
2509	ad	O
2509	##ip	O
2509	##ose	O
2509	tissue	O
2509	.	O
2509	[SEP]	O
2510	[CLS]	O
2510	decreases	O
2510	in	O
2510	the	O
2510	area	B-PK
2510	under	I-PK
2510	the	I-PK
2510	blood	I-PK
2510	concentration	I-PK
2510	-	I-PK
2510	time	I-PK
2510	curves	I-PK
2510	were	O
2510	greatest	O
2510	following	O
2510	oral	O
2510	dos	O
2510	##ing	O
2510	,	O
2510	intermediate	O
2510	following	O
2510	in	O
2510	##tra	O
2510	##port	O
2510	##al	O
2510	dos	O
2510	##ing	O
2510	,	O
2510	and	O
2510	least	O
2510	following	O
2510	i	O
2510	##v	O
2510	dos	O
2510	##ing	O
2510	.	O
2510	[SEP]	O
2511	[CLS]	O
2511	on	O
2511	day	O
2511	7	O
2511	,	O
2511	14	O
2511	,	O
2511	and	O
2511	21	O
2511	after	O
2511	my	O
2511	##oc	O
2511	##ard	O
2511	##ial	O
2511	is	O
2511	##che	O
2511	##mia	O
2511	anti	O
2511	##py	O
2511	##rine	O
2511	t	B-PK
2511	##1	I-PK
2511	/	I-PK
2511	2	I-PK
2511	increased	O
2511	considerably	O
2511	,	O
2511	and	O
2511	anti	O
2511	##py	O
2511	##rine	O
2511	c	B-PK
2511	##l	I-PK
2511	and	O
2511	k	B-PK
2511	##el	I-PK
2511	decreased	O
2511	.	O
2511	[SEP]	O
2512	[CLS]	O
2512	the	O
2512	t	B-PK
2512	##max	I-PK
2512	of	O
2512	fur	O
2512	##ox	O
2512	##ime	O
2512	was	O
2512	faster	O
2512	than	O
2512	z	O
2512	##inn	O
2512	##at	O
2512	with	O
2512	the	O
2512	mean	O
2512	(	O
2512	90	O
2512	%	O
2512	c	O
2512	##i	O
2512	)	O
2512	of	O
2512	difference	O
2512	in	O
2512	t	B-PK
2512	##max	I-PK
2512	of	O
2512	-	O
2512	0	O
2512	.	O
2512	5	O
2512	[	O
2512	(	O
2512	-	O
2512	1	O
2512	.	O
2512	01	O
2512	)	O
2512	-	O
2512	0	O
2512	.	O
2512	01	O
2512	]	O
2512	h	O
2512	.	O
2512	bio	O
2512	##e	O
2512	##qui	O
2512	##valence	O
2512	analysis	O
2512	showed	O
2512	that	O
2512	the	O
2512	au	B-PK
2512	##c	I-PK
2512	(	I-PK
2512	0	I-PK
2512	-	I-PK
2512	in	I-PK
2512	##finity	I-PK
2512	)	I-PK
2512	and	O
2512	the	O
2512	cm	B-PK
2512	##ax	I-PK
2512	of	O
2512	the	O
2512	two	O
2512	products	O
2512	were	O
2512	not	O
2512	significantly	O
2512	different	O
2512	.	O
2512	[SEP]	O
2513	[CLS]	O
2513	au	B-PK
2513	##c	I-PK
2513	,	O
2513	cm	B-PK
2513	##ax	I-PK
2513	and	O
2513	cm	B-PK
2513	##in	I-PK
2513	of	O
2513	both	O
2513	total	O
2513	and	O
2513	un	O
2513	##bound	O
2513	re	O
2513	##mo	O
2513	##xi	O
2513	##p	O
2513	##ride	O
2513	increased	O
2513	with	O
2513	increasing	O
2513	age	O
2513	.	O
2513	[SEP]	O
2514	[CLS]	O
2514	in	O
2514	h	O
2514	##n	O
2514	##f	O
2514	##1	O
2514	##a	O
2514	(	O
2514	-	O
2514	/	O
2514	-	O
2514	)	O
2514	mice	O
2514	,	O
2514	serum	O
2514	concentrations	O
2514	and	O
2514	half	B-PK
2514	-	I-PK
2514	life	I-PK
2514	of	O
2514	su	O
2514	##lf	O
2514	##ony	O
2514	##lu	O
2514	##rea	O
2514	derivatives	O
2514	are	O
2514	strongly	O
2514	increased	O
2514	.	O
2514	[SEP]	O
2515	[CLS]	O
2515	from	O
2515	the	O
2515	above	O
2515	results	O
2515	,	O
2515	it	O
2515	was	O
2515	concluded	O
2515	that	O
2515	o	O
2515	##la	O
2515	na	O
2515	##no	O
2515	-	O
2515	formulation	O
2515	##s	O
2515	can	O
2515	be	O
2515	an	O
2515	alternative	O
2515	to	O
2515	enhance	O
2515	the	O
2515	oral	B-PK
2515	bio	I-PK
2515	##ava	I-PK
2515	##ila	I-PK
2515	##bility	I-PK
2515	and	O
2515	to	O
2515	reduce	O
2515	the	O
2515	ha	O
2515	##ema	O
2515	##to	O
2515	##logical	O
2515	toxicity	O
2515	of	O
2515	o	O
2515	##la	O
2515	.	O
2515	[SEP]	O
2516	[CLS]	O
2516	d	O
2516	##n	O
2516	##v	O
2516	au	B-PK
2516	##c	I-PK
2516	##0	I-PK
2516	-	I-PK
2516	∞	I-PK
2516	,	O
2516	cm	B-PK
2516	##ax	I-PK
2516	and	O
2516	c	O
2516	##12	O
2516	##h	O
2516	g	O
2516	##m	O
2516	##r	O
2516	%	O
2516	(	O
2516	90	O
2516	%	O
2516	c	O
2516	##i	O
2516	)	O
2516	with	O
2516	ran	O
2516	##iti	O
2516	##dine	O
2516	:	O
2516	81	O
2516	.	O
2516	9	O
2516	(	O
2516	68	O
2516	.	O
2516	3	O
2516	-	O
2516	98	O
2516	.	O
2516	1	O
2516	)	O
2516	,	O
2516	104	O
2516	(	O
2516	86	O
2516	.	O
2516	9	O
2516	-	O
2516	123	O
2516	)	O
2516	and	O
2516	87	O
2516	.	O
2516	5	O
2516	(	O
2516	69	O
2516	.	O
2516	3	O
2516	-	O
2516	111	O
2516	)	O
2516	,	O
2516	and	O
2516	with	O
2516	o	O
2516	##me	O
2516	##pra	O
2516	##zo	O
2516	##le	O
2516	:	O
2516	83	O
2516	.	O
2516	0	O
2516	(	O
2516	67	O
2516	.	O
2516	4	O
2516	-	O
2516	102	O
2516	)	O
2516	,	O
2516	92	O
2516	.	O
2516	7	O
2516	(	O
2516	70	O
2516	.	O
2516	6	O
2516	-	O
2516	122	O
2516	)	O
2516	and	O
2516	93	O
2516	.	O
2516	3	O
2516	(	O
2516	65	O
2516	.	O
2516	6	O
2516	-	O
2516	133	O
2516	)	O
2516	.	O
2516	[SEP]	O
2517	[CLS]	O
2517	mean	O
2517	ratios	O
2517	of	O
2517	au	B-PK
2517	##cin	I-PK
2517	##f	I-PK
2517	,	O
2517	au	B-PK
2517	##c	I-PK
2517	##0	I-PK
2517	-	I-PK
2517	t	I-PK
2517	,	O
2517	and	O
2517	cm	B-PK
2517	##ax	I-PK
2517	for	O
2517	f	O
2517	##d	O
2517	##c	O
2517	or	O
2517	single	O
2517	-	O
2517	component	O
2517	da	O
2517	##pa	O
2517	##gli	O
2517	##f	O
2517	##lo	O
2517	##zin	O
2517	and	O
2517	met	O
2517	##form	O
2517	##in	O
2517	tablets	O
2517	were	O
2517	close	O
2517	to	O
2517	unity	O
2517	.	O
2517	[SEP]	O
2518	[CLS]	O
2518	there	O
2518	were	O
2518	no	O
2518	significant	O
2518	differences	O
2518	in	O
2518	maximum	B-PK
2518	concentration	I-PK
2518	and	O
2518	area	B-PK
2518	under	I-PK
2518	the	I-PK
2518	curve	I-PK
2518	(	I-PK
2518	au	I-PK
2518	##c	I-PK
2518	)	I-PK
2518	for	O
2518	serum	O
2518	total	O
2518	and	O
2518	free	O
2518	test	O
2518	##osterone	O
2518	(	O
2518	t	O
2518	)	O
2518	between	O
2518	the	O
2518	t	O
2518	##u	O
2518	750	O
2518	and	O
2518	1000	O
2518	mg	O
2518	groups	O
2518	,	O
2518	i	O
2518	##rre	O
2518	##spective	O
2518	of	O
2518	whether	O
2518	t	O
2518	##u	O
2518	was	O
2518	administered	O
2518	with	O
2518	200	O
2518	mg	O
2518	of	O
2518	net	O
2518	##e	O
2518	.	O
2518	[SEP]	O
2519	[CLS]	O
2519	after	O
2519	a	O
2519	single	O
2519	oral	O
2519	dose	O
2519	of	O
2519	20	O
2519	mg	O
2519	/	O
2519	kg	O
2519	of	O
2519	b	O
2519	##a	O
2519	,	O
2519	the	O
2519	mean	O
2519	peak	B-PK
2519	plasma	I-PK
2519	concentration	I-PK
2519	(	I-PK
2519	c	I-PK
2519	(	I-PK
2519	ma	I-PK
2519	##x	I-PK
2519	)	I-PK
2519	)	I-PK
2519	of	O
2519	b	O
2519	##a	O
2519	was	O
2519	234	O
2519	.	O
2519	7	O
2519	±	O
2519	161	O
2519	ng	O
2519	/	O
2519	m	O
2519	##l	O
2519	at	O
2519	0	O
2519	.	O
2519	25	O
2519	h	O
2519	.	O
2519	the	O
2519	area	B-PK
2519	under	I-PK
2519	the	I-PK
2519	plasma	I-PK
2519	concentration	I-PK
2519	-	I-PK
2519	time	I-PK
2519	curve	I-PK
2519	(	I-PK
2519	au	I-PK
2519	##c	I-PK
2519	(	I-PK
2519	0	I-PK
2519	-	I-PK
2519	24	I-PK
2519	h	I-PK
2519	)	I-PK
2519	)	I-PK
2519	was	O
2519	53	O
2519	##5	O
2519	.	O
2519	8	O
2519	±	O
2519	223	O
2519	.	O
2519	7	O
2519	h	O
2519	·	O
2519	ng	O
2519	/	O
2519	m	O
2519	##l	O
2519	,	O
2519	and	O
2519	the	O
2519	elimination	B-PK
2519	half	I-PK
2519	-	I-PK
2519	life	I-PK
2519	(	I-PK
2519	t	I-PK
2519	(	I-PK
2519	1	I-PK
2519	/	I-PK
2519	2	I-PK
2519	)	I-PK
2519	)	I-PK
2519	was	O
2519	5	O
2519	.	O
2519	0	O
2519	±	O
2519	0	O
2519	.	O
2519	36	O
2519	h	O
2519	.	O
2519	in	O
2519	case	O
2519	of	O
2519	in	O
2519	##tra	O
2519	##ven	O
2519	##ous	O
2519	administration	O
2519	of	O
2519	b	O
2519	##a	O
2519	at	O
2519	a	O
2519	dos	O
2519	##age	O
2519	of	O
2519	2	O
2519	mg	O
2519	/	O
2519	kg	O
2519	,	O
2519	the	O
2519	area	B-PK
2519	under	I-PK
2519	the	I-PK
2519	plasma	I-PK
2519	concentration	I-PK
2519	-	I-PK
2519	time	I-PK
2519	curve	I-PK
2519	(	I-PK
2519	au	I-PK
2519	##c	I-PK
2519	(	I-PK
2519	0	I-PK
2519	-	I-PK
2519	24	I-PK
2519	h	I-PK
2519	)	I-PK
2519	)	I-PK
2519	was	O
2519	34	O
2519	##2	O
2519	±	O
2519	98	O
2519	h	O
2519	##⋅	O
2519	##ng	O
2519	/	O
2519	m	O
2519	##l	O
2519	,	O
2519	and	O
2519	the	O
2519	elimination	B-PK
2519	half	I-PK
2519	-	I-PK
2519	life	I-PK
2519	(	I-PK
2519	t	I-PK
2519	(	I-PK
2519	1	I-PK
2519	/	I-PK
2519	2	I-PK
2519	)	I-PK
2519	)	I-PK
2519	was	O
2519	5	O
2519	.	O
2519	8	O
2519	±	O
2519	0	O
2519	.	O
2519	7	O
2519	h	O
2519	.	O
2519	[SEP]	O
2520	[CLS]	O
2520	hence	O
2520	,	O
2520	it	O
2520	can	O
2520	be	O
2520	concluded	O
2520	that	O
2520	the	O
2520	natural	O
2520	da	O
2520	##uc	O
2520	##us	O
2520	car	O
2520	##ota	O
2520	extract	O
2520	can	O
2520	be	O
2520	the	O
2520	better	O
2520	alternative	O
2520	source	O
2520	for	O
2520	the	O
2520	preparation	O
2520	of	O
2520	solid	O
2520	di	O
2520	##sper	O
2520	##sion	O
2520	and	O
2520	/	O
2520	or	O
2520	other	O
2520	dos	O
2520	##age	O
2520	forms	O
2520	for	O
2520	improving	O
2520	so	O
2520	##lub	O
2520	##ility	O
2520	and	O
2520	bio	B-PK
2520	##ava	I-PK
2520	##ila	I-PK
2520	##bility	I-PK
2520	.	O
2520	[SEP]	O
2521	[CLS]	O
2521	the	O
2521	bio	B-PK
2521	##ava	I-PK
2521	##ila	I-PK
2521	##bility	I-PK
2521	of	O
2521	e	O
2521	##ico	O
2521	##sa	O
2521	##pent	O
2521	##aen	O
2521	##oi	O
2521	##c	O
2521	acid	O
2521	from	O
2521	re	O
2521	##con	O
2521	##stituted	O
2521	t	O
2521	##rig	O
2521	##ly	O
2521	##cer	O
2521	##ide	O
2521	fish	O
2521	oil	O
2521	is	O
2521	higher	O
2521	than	O
2521	that	O
2521	obtained	O
2521	from	O
2521	the	O
2521	t	O
2521	##rig	O
2521	##ly	O
2521	##cer	O
2521	##ide	O
2521	and	O
2521	mon	O
2521	##og	O
2521	##ly	O
2521	##cer	O
2521	##ide	O
2521	forms	O
2521	.	O
2521	[SEP]	O
2522	[CLS]	O
2522	solid	O
2522	di	O
2522	##sper	O
2522	##sions	O
2522	using	O
2522	p	O
2522	##lu	O
2522	##ronic	O
2522	f	O
2522	-	O
2522	68	O
2522	as	O
2522	a	O
2522	carrier	O
2522	were	O
2522	studied	O
2522	for	O
2522	improving	O
2522	the	O
2522	dissolution	O
2522	and	O
2522	bio	B-PK
2522	##ava	I-PK
2522	##ila	I-PK
2522	##bility	I-PK
2522	of	O
2522	a	O
2522	##bt	O
2522	-	O
2522	96	O
2522	##3	O
2522	,	O
2522	a	O
2522	poorly	O
2522	water	O
2522	-	O
2522	soluble	O
2522	compound	O
2522	.	O
2522	[SEP]	O
2523	[CLS]	O
2523	the	O
2523	mean	O
2523	cm	B-PK
2523	##ax	I-PK
2523	and	O
2523	au	B-PK
2523	##c	I-PK
2523	##0	I-PK
2523	-	I-PK
2523	in	I-PK
2523	##finity	I-PK
2523	of	O
2523	s	O
2523	##ta	O
2523	##vu	O
2523	##dine	O
2523	increased	O
2523	in	O
2523	a	O
2523	dose	O
2523	-	O
2523	proportional	O
2523	manner	O
2523	.	O
2523	[SEP]	O
2524	[CLS]	O
2524	following	O
2524	a	O
2524	single	O
2524	dose	O
2524	the	O
2524	cm	B-PK
2524	##ax	I-PK
2524	was	O
2524	0	O
2524	.	O
2524	82	O
2524	+	O
2524	-	O
2524	0	O
2524	.	O
2524	15	O
2524	micro	O
2524	##gram	O
2524	##s	O
2524	/	O
2524	m	O
2524	##l	O
2524	,	O
2524	the	O
2524	t	B-PK
2524	##max	I-PK
2524	was	O
2524	achieved	O
2524	at	O
2524	6	O
2524	.	O
2524	1	O
2524	+	O
2524	-	O
2524	3	O
2524	.	O
2524	5	O
2524	h	O
2524	,	O
2524	the	O
2524	elimination	B-PK
2524	half	I-PK
2524	life	I-PK
2524	was	O
2524	65	O
2524	.	O
2524	7	O
2524	+	O
2524	-	O
2524	17	O
2524	.	O
2524	6	O
2524	h	O
2524	,	O
2524	the	O
2524	c	B-PK
2524	##lt	I-PK
2524	/	I-PK
2524	f	I-PK
2524	was	O
2524	2	O
2524	.	O
2524	04	O
2524	+	O
2524	-	O
2524	0	O
2524	.	O
2524	53	O
2524	m	O
2524	##l	O
2524	/	O
2524	min	O
2524	,	O
2524	the	O
2524	v	B-PK
2524	##d	I-PK
2524	/	I-PK
2524	f	I-PK
2524	was	O
2524	11	O
2524	.	O
2524	0	O
2524	+	O
2524	-	O
2524	1	O
2524	.	O
2524	7	O
2524	l	O
2524	and	O
2524	the	O
2524	au	B-PK
2524	##c	I-PK
2524	in	I-PK
2524	##finity	I-PK
2524	was	O
2524	86	O
2524	.	O
2524	9	O
2524	+	O
2524	-	O
2524	24	O
2524	.	O
2524	6	O
2524	mug	O
2524	##h	O
2524	/	O
2524	m	O
2524	##l	O
2524	,	O
2524	which	O
2524	was	O
2524	similar	O
2524	to	O
2524	results	O
2524	reported	O
2524	in	O
2524	other	O
2524	study	O
2524	from	O
2524	p	O
2524	##iro	O
2524	##xi	O
2524	##cam	O
2524	(	O
2524	10	O
2524	mg	O
2524	)	O
2524	.	O
2524	[SEP]	O
2525	[CLS]	O
2525	the	O
2525	geometric	O
2525	mean	O
2525	±	O
2525	s	O
2525	##d	O
2525	area	B-PK
2525	under	I-PK
2525	the	I-PK
2525	plasma	I-PK
2525	concentration	I-PK
2525	-	I-PK
2525	time	I-PK
2525	curve	I-PK
2525	(	I-PK
2525	au	I-PK
2525	##c	I-PK
2525	)	I-PK
2525	following	O
2525	i	O
2525	##v	O
2525	injection	O
2525	was	O
2525	26	O
2525	,	O
2525	82	O
2525	##0	O
2525	.	O
2525	59	O
2525	±	O
2525	9	O
2525	,	O
2525	03	O
2525	##3	O
2525	.	O
2525	88	O
2525	and	O
2525	51	O
2525	##1	O
2525	.	O
2525	83	O
2525	±	O
2525	213	O
2525	.	O
2525	98	O
2525	h	O
2525	##r	O
2525	ng	O
2525	/	O
2525	m	O
2525	##l	O
2525	for	O
2525	t	O
2525	##d	O
2525	route	O
2525	.	O
2525	[SEP]	O
2526	[CLS]	O
2526	the	O
2526	ch	O
2526	##em	O
2526	##ose	O
2526	##ns	O
2526	##iti	O
2526	##zing	O
2526	sur	O
2526	##ami	O
2526	##n	O
2526	dose	O
2526	showed	O
2526	a	O
2526	terminal	B-PK
2526	half	I-PK
2526	-	I-PK
2526	life	I-PK
2526	of	O
2526	202	O
2526	h	O
2526	and	O
2526	a	O
2526	total	B-PK
2526	body	I-PK
2526	clearance	I-PK
2526	of	O
2526	0	O
2526	.	O
2526	02	O
2526	##9	O
2526	l	O
2526	h	O
2526	(	O
2526	-	O
2526	1	O
2526	)	O
2526	m	O
2526	(	O
2526	-	O
2526	2	O
2526	)	O
2526	(	O
2526	higher	O
2526	than	O
2526	the	O
2526	0	O
2526	.	O
2526	01	O
2526	##3	O
2526	l	O
2526	h	O
2526	(	O
2526	-	O
2526	1	O
2526	)	O
2526	m	O
2526	(	O
2526	-	O
2526	2	O
2526	)	O
2526	value	O
2526	for	O
2526	m	O
2526	##t	O
2526	##d	O
2526	of	O
2526	sur	O
2526	##ami	O
2526	##n	O
2526	)	O
2526	.	O
2526	[SEP]	O
2527	[CLS]	O
2527	the	O
2527	t	B-PK
2527	##max	I-PK
2527	obtained	O
2527	ranged	O
2527	from	O
2527	3	O
2527	to	O
2527	10	O
2527	min	O
2527	.	O
2527	[SEP]	O
2528	[CLS]	O
2528	p	O
2528	##har	O
2528	##ma	O
2528	##co	O
2528	##kin	O
2528	##etic	O
2528	parameters	O
2528	following	O
2528	in	O
2528	##tra	O
2528	##mus	O
2528	##cular	O
2528	versus	O
2528	re	O
2528	##ct	O
2528	##al	O
2528	administration	O
2528	were	O
2528	the	O
2528	following	O
2528	:	O
2528	area	B-PK
2528	under	I-PK
2528	the	I-PK
2528	curve	I-PK
2528	59	O
2528	##16	O
2528	vs	O
2528	.	O
2528	52	O
2528	##53	O
2528	mum	O
2528	##ol	O
2528	.	O
2528	h	O
2528	/	O
2528	l	O
2528	;	O
2528	half	B-PK
2528	-	I-PK
2528	life	I-PK
2528	112	O
2528	vs	O
2528	.	O
2528	113	O
2528	h	O
2528	;	O
2528	time	B-PK
2528	to	I-PK
2528	maximum	I-PK
2528	concentration	I-PK
2528	2	O
2528	.	O
2528	1	O
2528	vs	O
2528	.	O
2528	4	O
2528	.	O
2528	4	O
2528	h	O
2528	;	O
2528	and	O
2528	maximum	B-PK
2528	serum	I-PK
2528	concentration	I-PK
2528	36	O
2528	.	O
2528	2	O
2528	vs	O
2528	.	O
2528	31	O
2528	.	O
2528	4	O
2528	mum	O
2528	##ol	O
2528	/	O
2528	l	O
2528	.	O
2528	mean	O
2528	relative	B-PK
2528	bio	I-PK
2528	##ava	I-PK
2528	##ila	I-PK
2528	##bility	I-PK
2528	for	O
2528	re	O
2528	##ct	O
2528	##al	O
2528	p	O
2528	##hen	O
2528	##ob	O
2528	##ar	O
2528	##bit	O
2528	##al	O
2528	was	O
2528	90	O
2528	percent	O
2528	.	O
2528	[SEP]	O
2529	[CLS]	O
2529	when	O
2529	et	O
2529	##op	O
2529	##os	O
2529	##ide	O
2529	was	O
2529	administered	O
2529	in	O
2529	combination	O
2529	with	O
2529	r	O
2529	##hul	O
2529	##t	O
2529	,	O
2529	the	O
2529	concentration	O
2529	of	O
2529	et	O
2529	##op	O
2529	##os	O
2529	##ide	O
2529	in	O
2529	tumor	O
2529	tissue	O
2529	after	O
2529	60	O
2529	to	O
2529	240	O
2529	minutes	O
2529	was	O
2529	significantly	O
2529	higher	O
2529	than	O
2529	when	O
2529	et	O
2529	##op	O
2529	##os	O
2529	##ide	O
2529	was	O
2529	given	O
2529	alone	O
2529	,	O
2529	and	O
2529	the	O
2529	area	B-PK
2529	under	I-PK
2529	the	I-PK
2529	concentration	I-PK
2529	versus	I-PK
2529	time	I-PK
2529	curve	I-PK
2529	was	O
2529	also	O
2529	greater	O
2529	for	O
2529	the	O
2529	tumors	O
2529	of	O
2529	mice	O
2529	with	O
2529	combination	O
2529	treatment	O
2529	.	O
2529	[SEP]	O
2530	[CLS]	O
2530	apparent	B-PK
2530	oral	I-PK
2530	clearance	I-PK
2530	was	O
2530	significantly	O
2530	reduced	O
2530	(	O
2530	p	O
2530	less	O
2530	than	O
2530	0	O
2530	.	O
2530	01	O
2530	)	O
2530	in	O
2530	the	O
2530	elderly	O
2530	.	O
2530	[SEP]	O
2531	[CLS]	O
2531	de	O
2531	##uter	O
2531	##ium	O
2531	-	O
2531	labeled	O
2531	te	O
2531	##rb	O
2531	##uta	O
2531	##line	O
2531	can	O
2531	be	O
2531	used	O
2531	,	O
2531	in	O
2531	##tra	O
2531	##ven	O
2531	##ously	O
2531	or	O
2531	oral	O
2531	##ly	O
2531	,	O
2531	as	O
2531	an	O
2531	absolute	O
2531	reference	O
2531	in	O
2531	bio	B-PK
2531	##ava	I-PK
2531	##ila	I-PK
2531	##bility	I-PK
2531	studies	O
2531	on	O
2531	te	O
2531	##rb	O
2531	##uta	O
2531	##line	O
2531	.	O
2531	[SEP]	O
2532	[CLS]	O
2532	this	O
2532	study	O
2532	showed	O
2532	that	O
2532	similar	O
2532	levels	O
2532	of	O
2532	a	O
2532	##a	O
2532	and	O
2532	f	O
2532	##a	O
2532	bio	B-PK
2532	##ava	I-PK
2532	##ila	I-PK
2532	##bility	I-PK
2532	can	O
2532	be	O
2532	attained	O
2532	through	O
2532	ing	O
2532	##est	O
2532	##ion	O
2532	of	O
2532	100	O
2532	%	O
2532	o	O
2532	##j	O
2532	and	O
2532	a	O
2532	fortified	O
2532	beverage	O
2532	.	O
2532	[SEP]	O
2533	[CLS]	O
2533	the	O
2533	te	O
2533	##rta	O
2533	##to	O
2533	##lo	O
2533	##l	O
2533	elimination	B-PK
2533	half	I-PK
2533	-	I-PK
2533	life	I-PK
2533	was	O
2533	9	O
2533	.	O
2533	0	O
2533	+	O
2533	-	O
2533	7	O
2533	.	O
2533	1	O
2533	hours	O
2533	.	O
2533	[SEP]	O
2534	[CLS]	O
2534	p	O
2534	##har	O
2534	##ma	O
2534	##co	O
2534	##kin	O
2534	##etic	O
2534	studies	O
2534	revealed	O
2534	that	O
2534	all	O
2534	-	O
2534	trans	O
2534	-	O
2534	rag	O
2534	was	O
2534	extensively	O
2534	h	O
2534	##ydro	O
2534	##ly	O
2534	##zed	O
2534	to	O
2534	all	O
2534	-	O
2534	trans	O
2534	-	O
2534	r	O
2534	##a	O
2534	and	O
2534	that	O
2534	the	O
2534	plasma	B-PK
2534	area	I-PK
2534	under	I-PK
2534	the	I-PK
2534	concentration	I-PK
2534	-	I-PK
2534	time	I-PK
2534	curve	I-PK
2534	(	I-PK
2534	au	I-PK
2534	##c	I-PK
2534	)	I-PK
2534	of	O
2534	all	O
2534	-	O
2534	trans	O
2534	-	O
2534	r	O
2534	##a	O
2534	following	O
2534	all	O
2534	-	O
2534	trans	O
2534	-	O
2534	rag	O
2534	application	O
2534	exceeded	O
2534	the	O
2534	plasma	B-PK
2534	au	I-PK
2534	##c	I-PK
2534	value	O
2534	of	O
2534	all	O
2534	-	O
2534	trans	O
2534	-	O
2534	r	O
2534	##a	O
2534	following	O
2534	application	O
2534	of	O
2534	all	O
2534	-	O
2534	trans	O
2534	-	O
2534	r	O
2534	##a	O
2534	.	O
2534	[SEP]	O
2535	[CLS]	O
2535	the	O
2535	population	O
2535	mean	O
2535	clearance	B-PK
2535	of	O
2535	at	O
2535	##v	O
2535	/	O
2535	r	O
2535	was	O
2535	4	O
2535	.	O
2535	93	O
2535	l	O
2535	/	O
2535	h	O
2535	in	O
2535	female	O
2535	patients	O
2535	and	O
2535	was	O
2535	28	O
2535	.	O
2535	7	O
2535	%	O
2535	higher	O
2535	in	O
2535	male	O
2535	patients	O
2535	.	O
2535	[SEP]	O
2536	[CLS]	O
2536	to	O
2536	identify	O
2536	appropriate	O
2536	species	O
2536	for	O
2536	predict	O
2536	##ing	O
2536	human	O
2536	in	O
2536	v	O
2536	##ivo	O
2536	clearance	B-PK
2536	by	O
2536	single	O
2536	-	O
2536	species	O
2536	s	O
2536	##cal	O
2536	##ing	O
2536	(	O
2536	s	O
2536	##ss	O
2536	)	O
2536	or	O
2536	multi	O
2536	##sp	O
2536	##ec	O
2536	##ies	O
2536	all	O
2536	##ome	O
2536	##try	O
2536	(	O
2536	ma	O
2536	)	O
2536	,	O
2536	we	O
2536	scaled	O
2536	in	O
2536	v	O
2536	##it	O
2536	##ro	O
2536	intrinsic	B-PK
2536	clearance	I-PK
2536	(	I-PK
2536	c	I-PK
2536	##lint	I-PK
2536	)	I-PK
2536	of	O
2536	five	O
2536	a	O
2536	##o	O
2536	substrates	O
2536	obtained	O
2536	from	O
2536	he	O
2536	##pa	O
2536	##tic	O
2536	s	O
2536	##9	O
2536	of	O
2536	mouse	O
2536	,	O
2536	rat	O
2536	,	O
2536	g	O
2536	##uin	O
2536	##ea	O
2536	pig	O
2536	,	O
2536	monkey	O
2536	and	O
2536	mini	O
2536	##pi	O
2536	##g	O
2536	to	O
2536	human	O
2536	in	O
2536	v	O
2536	##it	O
2536	##ro	O
2536	c	B-PK
2536	##lint	I-PK
2536	.	O
2536	[SEP]	O
2537	[CLS]	O
2537	this	O
2537	results	O
2537	in	O
2537	considerable	O
2537	error	O
2537	if	O
2537	the	O
2537	free	O
2537	i	O
2537	##od	O
2537	##ine	O
2537	in	O
2537	the	O
2537	nuclear	O
2537	drug	O
2537	is	O
2537	not	O
2537	taken	O
2537	into	O
2537	account	O
2537	in	O
2537	the	O
2537	clearance	B-PK
2537	calculation	O
2537	.	O
2537	[SEP]	O
2538	[CLS]	O
2538	these	O
2538	results	O
2538	demonstrate	O
2538	a	O
2538	significant	O
2538	improvement	O
2538	in	O
2538	target	O
2538	au	B-PK
2538	##c	I-PK
2538	attain	O
2538	##ment	O
2538	and	O
2538	less	O
2538	inter	O
2538	##patient	O
2538	var	O
2538	##iability	O
2538	with	O
2538	p	O
2538	##k	O
2538	-	O
2538	guided	O
2538	dos	O
2538	##ing	O
2538	using	O
2538	a	O
2538	test	O
2538	dose	O
2538	strategy	O
2538	compared	O
2538	with	O
2538	weight	O
2538	-	O
2538	based	O
2538	dos	O
2538	##ing	O
2538	.	O
2538	[SEP]	O
2539	[CLS]	O
2539	the	O
2539	apparent	B-PK
2539	volume	I-PK
2539	of	I-PK
2539	the	I-PK
2539	central	I-PK
2539	compartment	I-PK
2539	(	I-PK
2539	v	I-PK
2539	(	I-PK
2539	c	I-PK
2539	)	I-PK
2539	)	I-PK
2539	was	O
2539	found	O
2539	to	O
2539	be	O
2539	1	O
2539	.	O
2539	38	O
2539	##3	O
2539	,	O
2539	0	O
2539	.	O
2539	69	O
2539	##9	O
2539	and	O
2539	0	O
2539	.	O
2539	143	O
2539	l	O
2539	/	O
2539	kg	O
2539	respectively	O
2539	.	O
2539	[SEP]	O
2540	[CLS]	O
2540	the	O
2540	mean	O
2540	elimination	B-PK
2540	half	I-PK
2540	-	I-PK
2540	life	I-PK
2540	of	O
2540	54	O
2540	.	O
2540	8	O
2540	h	O
2540	determined	O
2540	by	O
2540	model	O
2540	dependent	O
2540	analysis	O
2540	was	O
2540	similar	O
2540	to	O
2540	the	O
2540	mean	O
2540	elimination	B-PK
2540	half	I-PK
2540	-	I-PK
2540	life	I-PK
2540	of	O
2540	59	O
2540	.	O
2540	9	O
2540	h	O
2540	determined	O
2540	by	O
2540	model	O
2540	independent	O
2540	analysis	O
2540	.	O
2540	[SEP]	O
2541	[CLS]	O
2541	with	O
2541	ha	O
2541	##lot	O
2541	##hane	O
2541	,	O
2541	v	B-PK
2541	##c	I-PK
2541	was	O
2541	decreased	O
2541	and	O
2541	t	B-PK
2541	##1	I-PK
2541	/	I-PK
2541	2	I-PK
2541	alpha	I-PK
2541	was	O
2541	shortened	O
2541	.	O
2541	[SEP]	O
2542	[CLS]	O
2542	the	O
2542	primary	O
2542	de	O
2542	##ter	O
2542	##mina	O
2542	##nts	O
2542	of	O
2542	drug	O
2542	interaction	O
2542	were	O
2542	the	O
2542	l	O
2542	##n	O
2542	-	O
2542	transformed	O
2542	area	B-PK
2542	under	I-PK
2542	the	I-PK
2542	plasma	I-PK
2542	concentration	I-PK
2542	versus	I-PK
2542	time	I-PK
2542	curve	I-PK
2542	[	I-PK
2542	au	I-PK
2542	##c	I-PK
2542	(	I-PK
2542	t	I-PK
2542	(	I-PK
2542	s	I-PK
2542	##s	I-PK
2542	)	I-PK
2542	)	I-PK
2542	]	I-PK
2542	over	O
2542	the	O
2542	final	O
2542	(	O
2542	day	O
2542	14	O
2542	)	O
2542	24	O
2542	h	O
2542	dos	O
2542	##ing	O
2542	interval	O
2542	and	O
2542	maximum	B-PK
2542	measured	I-PK
2542	steady	I-PK
2542	-	I-PK
2542	state	I-PK
2542	plasma	I-PK
2542	r	I-PK
2542	##os	I-PK
2542	##u	I-PK
2542	##vas	I-PK
2542	##tat	I-PK
2542	##in	I-PK
2542	concentration	I-PK
2542	[	I-PK
2542	c	I-PK
2542	(	I-PK
2542	ma	I-PK
2542	##x	I-PK
2542	(	I-PK
2542	s	I-PK
2542	##s	I-PK
2542	)	I-PK
2542	)	I-PK
2542	]	I-PK
2542	on	O
2542	day	O
2542	14	O
2542	.	O
2542	[SEP]	O
2543	[CLS]	O
2543	m	O
2543	##ox	O
2543	##if	O
2543	##lo	O
2543	##xa	O
2543	##cin	O
2543	regime	O
2543	##ns	O
2543	produced	O
2543	a	O
2543	range	O
2543	of	O
2543	area	B-PK
2543	under	I-PK
2543	the	I-PK
2543	concentration	I-PK
2543	-	I-PK
2543	time	I-PK
2543	curve	I-PK
2543	(	I-PK
2543	au	I-PK
2543	##c	I-PK
2543	)	I-PK
2543	/	I-PK
2543	mi	I-PK
2543	##c	I-PK
2543	ratios	I-PK
2543	ranging	O
2543	from	O
2543	9	O
2543	.	O
2543	2	O
2543	to	O
2543	44	O
2543	##4	O
2543	and	O
2543	peak	B-PK
2543	/	I-PK
2543	mi	I-PK
2543	##c	I-PK
2543	ratios	I-PK
2543	ranging	O
2543	from	O
2543	1	O
2543	.	O
2543	3	O
2543	to	O
2543	102	O
2543	.	O
2543	[SEP]	O
2544	[CLS]	O
2544	in	O
2544	addition	O
2544	,	O
2544	the	O
2544	relative	B-PK
2544	bio	I-PK
2544	##ava	I-PK
2544	##ila	I-PK
2544	##bility	I-PK
2544	of	O
2544	the	O
2544	nm	O
2544	##d	O
2544	-	O
2544	s	O
2544	##s	O
2544	##c	O
2544	(	O
2544	test	O
2544	)	O
2544	and	O
2544	ni	O
2544	##moto	O
2544	##p	O
2544	(	O
2544	reference	O
2544	)	O
2544	was	O
2544	determined	O
2544	in	O
2544	be	O
2544	##ag	O
2544	##le	O
2544	dogs	O
2544	after	O
2544	a	O
2544	single	O
2544	dose	O
2544	(	O
2544	120	O
2544	##m	O
2544	##g	O
2544	nm	O
2544	##d	O
2544	)	O
2544	in	O
2544	a	O
2544	random	O
2544	##ized	O
2544	crossover	O
2544	,	O
2544	own	O
2544	-	O
2544	control	O
2544	study	O
2544	.	O
2544	[SEP]	O
2545	[CLS]	O
2545	a	O
2545	positive	O
2545	correlation	O
2545	was	O
2545	found	O
2545	between	O
2545	forced	O
2545	ex	O
2545	##pi	O
2545	##rator	O
2545	##y	O
2545	volume	O
2545	in	O
2545	1	O
2545	s	O
2545	(	O
2545	f	O
2545	##ev	O
2545	##1	O
2545	)	O
2545	in	O
2545	per	O
2545	cent	O
2545	predicted	O
2545	and	O
2545	both	O
2545	au	B-PK
2545	##c	I-PK
2545	and	O
2545	ma	B-PK
2545	##ximal	I-PK
2545	co	I-PK
2545	##list	I-PK
2545	##in	I-PK
2545	concentrations	I-PK
2545	in	I-PK
2545	serum	I-PK
2545	(	I-PK
2545	cm	I-PK
2545	##ax	I-PK
2545	)	I-PK
2545	.	O
2545	[SEP]	O
2546	[CLS]	O
2546	to	O
2546	##l	O
2546	##cap	O
2546	##one	O
2546	had	O
2546	similar	O
2546	effects	O
2546	on	O
2546	plasma	O
2546	le	O
2546	##vo	O
2546	##do	O
2546	##pa	O
2546	concentrations	O
2546	with	O
2546	the	O
2546	standard	O
2546	-	O
2546	release	O
2546	formulation	O
2546	##s	O
2546	:	O
2546	half	B-PK
2546	-	I-PK
2546	life	I-PK
2546	and	O
2546	bio	B-PK
2546	##ava	I-PK
2546	##ila	I-PK
2546	##bility	I-PK
2546	increased	O
2546	approximately	O
2546	2	O
2546	-	O
2546	fold	O
2546	compared	O
2546	with	O
2546	place	O
2546	##bo	O
2546	,	O
2546	and	O
2546	maximum	B-PK
2546	plasma	I-PK
2546	concentration	I-PK
2546	(	I-PK
2546	cm	I-PK
2546	##ax	I-PK
2546	)	I-PK
2546	and	O
2546	time	B-PK
2546	to	I-PK
2546	cm	I-PK
2546	##ax	I-PK
2546	(	I-PK
2546	t	I-PK
2546	##max	I-PK
2546	)	I-PK
2546	were	O
2546	un	O
2546	##af	O
2546	##fected	O
2546	,	O
2546	except	O
2546	for	O
2546	a	O
2546	slight	O
2546	increase	O
2546	in	O
2546	cm	B-PK
2546	##ax	I-PK
2546	with	O
2546	the	O
2546	le	O
2546	##vo	O
2546	##do	O
2546	##pa	O
2546	/	O
2546	ben	O
2546	##ser	O
2546	##azi	O
2546	##de	O
2546	200	O
2546	/	O
2546	50	O
2546	mg	O
2546	formulation	O
2546	.	O
2546	[SEP]	O
2547	[CLS]	O
2547	the	O
2547	area	B-PK
2547	under	I-PK
2547	the	I-PK
2547	concentration	I-PK
2547	v	I-PK
2547	.	I-PK
2547	time	I-PK
2547	curve	I-PK
2547	(	I-PK
2547	au	I-PK
2547	##c	I-PK
2547	)	I-PK
2547	was	O
2547	162	O
2547	+	O
2547	-	O
2547	27	O
2547	(	O
2547	se	O
2547	##m	O
2547	)	O
2547	times	O
2547	larger	O
2547	in	O
2547	c	O
2547	##s	O
2547	##f	O
2547	than	O
2547	in	O
2547	plasma	O
2547	.	O
2547	[SEP]	O
2548	[CLS]	O
2548	p	O
2548	##har	O
2548	##ma	O
2548	##co	O
2548	##kin	O
2548	##etic	O
2548	(	O
2548	p	O
2548	##k	O
2548	)	O
2548	parameters	O
2548	,	O
2548	including	O
2548	t	B-PK
2548	<	I-PK
2548	sub	I-PK
2548	>	I-PK
2548	ma	I-PK
2548	##x	I-PK
2548	<	I-PK
2548	/	I-PK
2548	sub	I-PK
2548	>	I-PK
2548	,	O
2548	c	B-PK
2548	<	I-PK
2548	sub	I-PK
2548	>	I-PK
2548	ma	I-PK
2548	##x	I-PK
2548	<	I-PK
2548	/	I-PK
2548	sub	I-PK
2548	>	I-PK
2548	,	O
2548	and	O
2548	au	B-PK
2548	##c	I-PK
2548	<	I-PK
2548	sub	I-PK
2548	>	I-PK
2548	last	I-PK
2548	<	I-PK
2548	/	I-PK
2548	sub	I-PK
2548	>	I-PK
2548	were	O
2548	calculated	O
2548	by	O
2548	non	O
2548	##com	O
2548	##par	O
2548	##tment	O
2548	##al	O
2548	methods	O
2548	.	O
2548	[SEP]	O
2549	[CLS]	O
2549	p	O
2549	##har	O
2549	##ma	O
2549	##co	O
2549	##dynamic	O
2549	measurement	O
2549	versus	O
2549	p	O
2549	##har	O
2549	##ma	O
2549	##co	O
2549	##kin	O
2549	##etics	O
2549	revealed	O
2549	a	O
2549	significant	O
2549	inverse	O
2549	relationship	O
2549	between	O
2549	p	O
2549	##asi	O
2549	score	O
2549	and	O
2549	m	O
2549	##t	O
2549	##x	O
2549	au	B-PK
2549	##c	I-PK
2549	(	O
2549	r	O
2549	##s	O
2549	=	O
2549	-	O
2549	0	O
2549	.	O
2549	91	O
2549	##2	O
2549	,	O
2549	p	O
2549	<	O
2549	0	O
2549	.	O
2549	00	O
2549	##2	O
2549	)	O
2549	and	O
2549	between	O
2549	p	O
2549	##asi	O
2549	score	O
2549	and	O
2549	er	O
2549	##yt	O
2549	##hr	O
2549	##oc	O
2549	##ytic	O
2549	m	O
2549	##t	O
2549	##x	O
2549	(	O
2549	r	O
2549	##s	O
2549	=	O
2549	-	O
2549	0	O
2549	.	O
2549	98	O
2549	##8	O
2549	,	O
2549	p	O
2549	<	O
2549	0	O
2549	.	O
2549	00	O
2549	##2	O
2549	)	O
2549	.	O
2549	[SEP]	O
2550	[CLS]	O
2550	area	B-PK
2550	under	I-PK
2550	the	I-PK
2550	curve	I-PK
2550	est	O
2550	##imation	O
2550	##s	O
2550	were	O
2550	consistent	O
2550	with	O
2550	an	O
2550	m	O
2550	##t	O
2550	##x	O
2550	exposure	O
2550	of	O
2550	30	O
2550	%	O
2550	and	O
2550	46	O
2550	%	O
2550	for	O
2550	the	O
2550	muscle	O
2550	and	O
2550	liver	O
2550	as	O
2550	compared	O
2550	with	O
2550	the	O
2550	circulation	O
2550	.	O
2550	[SEP]	O
2551	[CLS]	O
2551	volume	B-PK
2551	of	I-PK
2551	distribution	I-PK
2551	terms	O
2551	for	O
2551	a	O
2551	drug	O
2551	(	O
2551	c	O
2551	##ef	O
2551	##tri	O
2551	##ax	O
2551	##one	O
2551	)	O
2551	exhibiting	O
2551	concentration	O
2551	-	O
2551	dependent	O
2551	protein	O
2551	binding	O
2551	.	O
2551	[SEP]	O
2552	[CLS]	O
2552	the	O
2552	mean	O
2552	+	O
2552	-	O
2552	s	O
2552	##d	O
2552	volume	B-PK
2552	of	I-PK
2552	distribution	I-PK
2552	was	O
2552	0	O
2552	.	O
2552	39	O
2552	+	O
2552	-	O
2552	0	O
2552	.	O
2552	15	O
2552	l	O
2552	/	O
2552	kg	O
2552	ideal	O
2552	body	O
2552	weight	O
2552	,	O
2552	and	O
2552	elimination	B-PK
2552	half	I-PK
2552	-	I-PK
2552	life	I-PK
2552	during	O
2552	dial	O
2552	##ys	O
2552	##is	O
2552	was	O
2552	4	O
2552	.	O
2552	2	O
2552	+	O
2552	-	O
2552	2	O
2552	.	O
2552	3	O
2552	hours	O
2552	.	O
2552	[SEP]	O
2553	[CLS]	O
2553	the	O
2553	90	O
2553	%	O
2553	confidence	O
2553	interval	O
2553	(	O
2553	c	O
2553	##i	O
2553	)	O
2553	of	O
2553	the	O
2553	ratios	O
2553	(	O
2553	test	O
2553	/	O
2553	reference	O
2553	)	O
2553	of	O
2553	atom	O
2553	##ox	O
2553	##eti	O
2553	##ne	O
2553	for	O
2553	au	B-PK
2553	##c	I-PK
2553	##0	I-PK
2553	-	I-PK
2553	24	I-PK
2553	,	O
2553	au	B-PK
2553	##c	I-PK
2553	##0	I-PK
2553	-	I-PK
2553	∞	I-PK
2553	and	O
2553	cm	B-PK
2553	##ax	I-PK
2553	were	O
2553	100	O
2553	.	O
2553	9	O
2553	%	O
2553	(	O
2553	93	O
2553	.	O
2553	6	O
2553	-	O
2553	108	O
2553	.	O
2553	8	O
2553	%	O
2553	)	O
2553	,	O
2553	103	O
2553	.	O
2553	1	O
2553	%	O
2553	(	O
2553	95	O
2553	.	O
2553	1	O
2553	-	O
2553	111	O
2553	.	O
2553	7	O
2553	%	O
2553	)	O
2553	and	O
2553	105	O
2553	.	O
2553	2	O
2553	%	O
2553	(	O
2553	92	O
2553	.	O
2553	8	O
2553	-	O
2553	119	O
2553	.	O
2553	4	O
2553	%	O
2553	)	O
2553	,	O
2553	respectively	O
2553	,	O
2553	which	O
2553	fell	O
2553	within	O
2553	the	O
2553	interval	O
2553	of	O
2553	80	O
2553	-	O
2553	125	O
2553	%	O
2553	and	O
2553	75	O
2553	-	O
2553	133	O
2553	%	O
2553	.	O
2553	[SEP]	O
2554	[CLS]	O
2554	with	O
2554	increasing	O
2554	the	O
2554	length	O
2554	of	O
2554	in	O
2554	##fusion	O
2554	##s	O
2554	to	O
2554	3	O
2554	,	O
2554	4	O
2554	,	O
2554	and	O
2554	5	O
2554	hours	O
2554	,	O
2554	simulation	O
2554	studies	O
2554	showed	O
2554	that	O
2554	the	O
2554	cm	B-PK
2554	##ax	I-PK
2554	decreased	O
2554	to	O
2554	128	O
2554	%	O
2554	,	O
2554	113	O
2554	%	O
2554	,	O
2554	and	O
2554	102	O
2554	%	O
2554	of	O
2554	the	O
2554	oral	B-PK
2554	cm	I-PK
2554	##ax	I-PK
2554	.	O
2554	[SEP]	O
2555	[CLS]	O
2555	the	O
2555	results	O
2555	of	O
2555	the	O
2555	study	O
2555	indicate	O
2555	that	O
2555	c	O
2555	##p	O
2555	##l	O
2555	##x	O
2555	shows	O
2555	improved	O
2555	dissolution	O
2555	properties	O
2555	and	O
2555	a	O
2555	higher	O
2555	relative	O
2555	oral	B-PK
2555	bio	I-PK
2555	##ava	I-PK
2555	##ila	I-PK
2555	##bility	I-PK
2555	compared	O
2555	with	O
2555	p	O
2555	##hy	O
2555	##s	O
2555	and	O
2555	mi	O
2555	##co	O
2555	.	O
2555	[SEP]	O
2556	[CLS]	O
2556	in	O
2556	conclusion	O
2556	,	O
2556	it	O
2556	is	O
2556	suggested	O
2556	that	O
2556	the	O
2556	therapeutic	O
2556	effects	O
2556	and	O
2556	side	O
2556	effects	O
2556	of	O
2556	v	O
2556	##c	O
2556	##m	O
2556	should	O
2556	be	O
2556	actively	O
2556	monitored	O
2556	using	O
2556	t	O
2556	##d	O
2556	##m	O
2556	,	O
2556	because	O
2556	concentrations	O
2556	may	O
2556	decrease	O
2556	when	O
2556	c	B-PK
2556	##l	I-PK
2556	increases	O
2556	in	O
2556	v	O
2556	##c	O
2556	##m	O
2556	therapy	O
2556	for	O
2556	elderly	O
2556	patients	O
2556	with	O
2556	ma	O
2556	##li	O
2556	##gnant	O
2556	tumors	O
2556	.	O
2556	[SEP]	O
2557	[CLS]	O
2557	the	O
2557	su	O
2557	##lf	O
2557	##adi	O
2557	##mi	O
2557	##dine	O
2557	half	B-PK
2557	-	I-PK
2557	lives	I-PK
2557	in	O
2557	male	O
2557	s	O
2557	##pra	O
2557	##gue	O
2557	-	O
2557	da	O
2557	##wley	O
2557	and	O
2557	w	O
2557	##ista	O
2557	##r	O
2557	rat	O
2557	are	O
2557	similar	O
2557	.	O
2557	[SEP]	O
2558	[CLS]	O
2558	subjects	O
2558	with	O
2558	the	O
2558	c	O
2558	.	O
2558	42	O
2558	##1	O
2558	##aa	O
2558	g	O
2558	##eno	O
2558	##type	O
2558	(	O
2558	n	O
2558	=	O
2558	4	O
2558	)	O
2558	had	O
2558	a	O
2558	72	O
2558	%	O
2558	larger	O
2558	mean	O
2558	area	B-PK
2558	under	I-PK
2558	the	I-PK
2558	plasma	I-PK
2558	at	I-PK
2558	##or	I-PK
2558	##vas	I-PK
2558	##tat	I-PK
2558	##in	I-PK
2558	concentration	I-PK
2558	-	I-PK
2558	time	I-PK
2558	curve	I-PK
2558	from	I-PK
2558	time	I-PK
2558	0	I-PK
2558	to	I-PK
2558	in	I-PK
2558	##finity	I-PK
2558	(	I-PK
2558	au	I-PK
2558	##c	I-PK
2558	(	I-PK
2558	0	I-PK
2558	-	I-PK
2558	in	I-PK
2558	##finity	I-PK
2558	)	I-PK
2558	)	I-PK
2558	than	O
2558	individuals	O
2558	with	O
2558	the	O
2558	c	O
2558	.	O
2558	42	O
2558	##1	O
2558	##cc	O
2558	g	O
2558	##eno	O
2558	##type	O
2558	had	O
2558	(	O
2558	n	O
2558	=	O
2558	16	O
2558	;	O
2558	p	O
2558	=	O
2558	0	O
2558	.	O
2558	04	O
2558	##9	O
2558	)	O
2558	.	O
2558	[SEP]	O
2559	[CLS]	O
2559	the	O
2559	maximum	O
2559	number	O
2559	of	O
2559	binding	O
2559	sites	O
2559	(	O
2559	b	O
2559	##max	O
2559	)	O
2559	for	O
2559	the	O
2559	partial	O
2559	ago	O
2559	##nist	O
2559	t	O
2559	##rit	O
2559	##iated	O
2559	c	O
2559	##lon	O
2559	##id	O
2559	##ine	O
2559	was	O
2559	significantly	O
2559	lower	O
2559	for	O
2559	both	O
2559	patient	O
2559	groups	O
2559	than	O
2559	for	O
2559	normal	O
2559	subjects	O
2559	,	O
2559	and	O
2559	the	O
2559	b	O
2559	##max	O
2559	for	O
2559	the	O
2559	antagonist	O
2559	t	O
2559	##rit	O
2559	##iated	O
2559	yo	O
2559	##him	O
2559	##bine	O
2559	was	O
2559	significantly	O
2559	lower	O
2559	for	O
2559	panic	O
2559	patients	O
2559	.	O
2559	[SEP]	O
2560	[CLS]	O
2560	for	O
2560	the	O
2560	c	O
2560	##is	O
2560	-	O
2560	trans	O
2560	group	O
2560	,	O
2560	the	O
2560	apparent	B-PK
2560	elimination	I-PK
2560	half	I-PK
2560	-	I-PK
2560	life	I-PK
2560	and	O
2560	clearance	B-PK
2560	were	O
2560	17	O
2560	.	O
2560	7	O
2560	+	O
2560	-	O
2560	1	O
2560	.	O
2560	8	O
2560	min	O
2560	and	O
2560	9	O
2560	.	O
2560	0	O
2560	+	O
2560	-	O
2560	1	O
2560	.	O
2560	0	O
2560	m	O
2560	##l	O
2560	.	O
2560	kg	O
2560	-	O
2560	1	O
2560	.	O
2560	min	O
2560	-	O
2560	1	O
2560	,	O
2560	but	O
2560	these	O
2560	figures	O
2560	require	O
2560	care	O
2560	in	O
2560	interpretation	O
2560	,	O
2560	as	O
2560	this	O
2560	is	O
2560	##omer	O
2560	group	O
2560	contains	O
2560	is	O
2560	##omer	O
2560	##s	O
2560	of	O
2560	widely	O
2560	varying	O
2560	rates	O
2560	of	O
2560	decomposition	O
2560	.	O
2560	(	O
2560	abstract	O
2560	t	O
2560	##runcated	O
2560	at	O
2560	250	O
2560	words	O
2560	)	O
2560	[SEP]	O
2561	[CLS]	O
2561	the	O
2561	high	O
2561	systemic	O
2561	absorption	O
2561	of	O
2561	g	O
2561	##ent	O
2561	##ami	O
2561	##cin	O
2561	in	O
2561	patients	O
2561	with	O
2561	per	O
2561	##ito	O
2561	##ni	O
2561	##tis	O
2561	and	O
2561	prolonged	O
2561	plasma	B-PK
2561	elimination	I-PK
2561	half	I-PK
2561	-	I-PK
2561	life	I-PK
2561	may	O
2561	lead	O
2561	to	O
2561	drug	O
2561	accumulation	O
2561	in	O
2561	the	O
2561	systemic	O
2561	circulation	O
2561	,	O
2561	increasing	O
2561	the	O
2561	risk	O
2561	of	O
2561	toxicity	O
2561	.	O
2561	[SEP]	O
2562	[CLS]	O
2562	apparent	O
2562	v	O
2562	##pa	O
2562	oral	B-PK
2562	clearance	I-PK
2562	(	I-PK
2562	c	I-PK
2562	##l	I-PK
2562	/	I-PK
2562	f	I-PK
2562	)	I-PK
2562	calculated	O
2562	for	O
2562	each	O
2562	elderly	O
2562	patient	O
2562	was	O
2562	compared	O
2562	with	O
2562	that	O
2562	determined	O
2562	in	O
2562	an	O
2562	equal	O
2562	number	O
2562	of	O
2562	v	O
2562	##pa	O
2562	-	O
2562	treated	O
2562	controls	O
2562	aged	O
2562	20	O
2562	-	O
2562	50	O
2562	years	O
2562	and	O
2562	matched	O
2562	for	O
2562	gender	O
2562	,	O
2562	body	O
2562	weight	O
2562	and	O
2562	anti	O
2562	##ep	O
2562	##ile	O
2562	##ptic	O
2562	drug	O
2562	(	O
2562	a	O
2562	##ed	O
2562	)	O
2562	comedic	O
2562	##ation	O
2562	.	O
2562	[SEP]	O
2563	[CLS]	O
2563	the	O
2563	point	O
2563	est	O
2563	##imator	O
2563	##s	O
2563	for	O
2563	au	B-PK
2563	##c	I-PK
2563	(	I-PK
2563	0	I-PK
2563	-	I-PK
2563	in	I-PK
2563	##f	I-PK
2563	)	I-PK
2563	and	O
2563	cm	B-PK
2563	##ax	I-PK
2563	were	O
2563	found	O
2563	to	O
2563	be	O
2563	99	O
2563	.	O
2563	7	O
2563	%	O
2563	and	O
2563	85	O
2563	.	O
2563	9	O
2563	%	O
2563	,	O
2563	respectively	O
2563	.	O
2563	[SEP]	O
2564	[CLS]	O
2564	the	O
2564	au	B-PK
2564	##c	I-PK
2564	of	O
2564	ed	O
2564	##d	O
2564	##p	O
2564	increased	O
2564	significantly	O
2564	,	O
2564	by	O
2564	35	O
2564	%	O
2564	.	O
2564	[SEP]	O
2565	[CLS]	O
2565	no	O
2565	difference	O
2565	was	O
2565	seen	O
2565	between	O
2565	the	O
2565	acid	O
2565	and	O
2565	al	O
2565	##kal	O
2565	##ine	O
2565	condition	O
2565	for	O
2565	do	O
2565	##x	O
2565	or	O
2565	do	O
2565	##x	O
2565	##or	O
2565	##ubi	O
2565	##cin	O
2565	##ol	O
2565	with	O
2565	regard	O
2565	to	O
2565	clearance	B-PK
2565	from	I-PK
2565	blood	I-PK
2565	plasma	I-PK
2565	,	O
2565	area	B-PK
2565	under	I-PK
2565	the	I-PK
2565	curve	I-PK
2565	,	O
2565	re	B-PK
2565	##nal	I-PK
2565	clearance	I-PK
2565	,	O
2565	re	B-PK
2565	##nal	I-PK
2565	drug	I-PK
2565	clearance	I-PK
2565	/	I-PK
2565	re	I-PK
2565	##nal	I-PK
2565	c	O
2565	##rea	O
2565	##tin	O
2565	##ine	O
2565	clearance	O
2565	.	O
2565	[SEP]	O
2566	[CLS]	O
2566	ma	O
2566	##gnesium	O
2566	bio	B-PK
2566	##ava	I-PK
2566	##ila	I-PK
2566	##bility	I-PK
2566	from	O
2566	ma	O
2566	##gnesium	O
2566	c	O
2566	##it	O
2566	##rate	O
2566	and	O
2566	ma	O
2566	##gnesium	O
2566	oxide	O
2566	.	O
2566	[SEP]	O
2567	[CLS]	O
2567	bio	B-PK
2567	##ava	I-PK
2567	##ila	I-PK
2567	##bility	I-PK
2567	and	O
2567	p	O
2567	##har	O
2567	##ma	O
2567	##co	O
2567	##kin	O
2567	##etics	O
2567	of	O
2567	met	O
2567	##oc	O
2567	##lop	O
2567	##ram	O
2567	##ide	O
2567	in	O
2567	cattle	O
2567	.	O
2567	[SEP]	O
2568	[CLS]	O
2568	with	O
2568	a	O
2568	specific	O
2568	radio	O
2568	##im	O
2568	##mu	O
2568	##no	O
2568	##ass	O
2568	##ay	O
2568	the	O
2568	p	O
2568	##har	O
2568	##ma	O
2568	##co	O
2568	##kin	O
2568	##etics	O
2568	and	O
2568	relative	B-PK
2568	bio	I-PK
2568	##ava	I-PK
2568	##ila	I-PK
2568	##bility	I-PK
2568	of	O
2568	es	O
2568	##cin	O
2568	was	O
2568	measured	O
2568	after	O
2568	administration	O
2568	of	O
2568	different	O
2568	formulation	O
2568	##s	O
2568	containing	O
2568	a	O
2568	##escu	O
2568	##lus	O
2568	-	O
2568	extract	O
2568	.	O
2568	[SEP]	O
2569	[CLS]	O
2569	in	O
2569	the	O
2569	presence	O
2569	of	O
2569	k	O
2569	##eto	O
2569	##cona	O
2569	##zo	O
2569	##le	O
2569	,	O
2569	inter	O
2569	-	O
2569	individual	O
2569	var	O
2569	##iability	O
2569	in	O
2569	clearance	B-PK
2569	and	O
2569	au	B-PK
2569	##c	I-PK
2569	,	O
2569	expressed	O
2569	as	O
2569	coefficient	O
2569	of	O
2569	variation	O
2569	,	O
2569	was	O
2569	increased	O
2569	from	O
2569	41	O
2569	.	O
2569	6	O
2569	to	O
2569	49	O
2569	.	O
2569	5	O
2569	%	O
2569	and	O
2569	from	O
2569	28	O
2569	.	O
2569	0	O
2569	to	O
2569	35	O
2569	.	O
2569	1	O
2569	%	O
2569	,	O
2569	respectively	O
2569	,	O
2569	and	O
2569	not	O
2569	,	O
2569	as	O
2569	we	O
2569	had	O
2569	h	O
2569	##y	O
2569	##pot	O
2569	##hes	O
2569	##ized	O
2569	,	O
2569	reduced	O
2569	.	O
2569	[SEP]	O
2570	[CLS]	O
2570	e	O
2570	##pi	O
2570	-	O
2570	m	O
2570	##n	O
2570	##ps	O
2570	showed	O
2570	1	O
2570	.	O
2570	18	O
2570	folds	O
2570	higher	O
2570	bio	B-PK
2570	##ava	I-PK
2570	##ila	I-PK
2570	##bility	I-PK
2570	and	O
2570	better	O
2570	tumor	O
2570	suppression	O
2570	than	O
2570	e	O
2570	##pi	O
2570	-	O
2570	p	O
2570	##n	O
2570	##ps	O
2570	.	O
2570	[SEP]	O
2571	[CLS]	O
2571	a	O
2571	comprehensive	O
2571	study	O
2571	of	O
2571	the	O
2571	bio	B-PK
2571	##ava	I-PK
2571	##ila	I-PK
2571	##bility	I-PK
2571	of	O
2571	oral	O
2571	##ly	O
2571	administered	O
2571	silver	O
2571	na	O
2571	##no	O
2571	##par	O
2571	##tic	O
2571	##les	O
2571	(	O
2571	a	O
2571	##gn	O
2571	##ps	O
2571	)	O
2571	was	O
2571	carried	O
2571	out	O
2571	using	O
2571	a	O
2571	rat	O
2571	model	O
2571	.	O
2571	[SEP]	O
2572	[CLS]	O
2572	a	O
2572	man	O
2572	##n	O
2572	-	O
2572	w	O
2572	##hit	O
2572	##ney	O
2572	test	O
2572	indicated	O
2572	statistical	O
2572	##ly	O
2572	significant	O
2572	differences	O
2572	in	O
2572	au	B-PK
2572	##c	I-PK
2572	(	O
2572	p	O
2572	=	O
2572	0	O
2572	.	O
2572	01	O
2572	)	O
2572	and	O
2572	c	B-PK
2572	##l	I-PK
2572	/	I-PK
2572	f	I-PK
2572	(	O
2572	p	O
2572	=	O
2572	0	O
2572	.	O
2572	04	O
2572	)	O
2572	between	O
2572	groups	O
2572	.	O
2572	[SEP]	O
2573	[CLS]	O
2573	p	O
2573	##har	O
2573	##ma	O
2573	##co	O
2573	##kin	O
2573	##etics	O
2573	was	O
2573	assessed	O
2573	using	O
2573	the	O
2573	standard	O
2573	measurements	O
2573	of	O
2573	maximum	B-PK
2573	plasma	I-PK
2573	concentration	I-PK
2573	(	I-PK
2573	cm	I-PK
2573	##ax	I-PK
2573	)	I-PK
2573	,	O
2573	time	B-PK
2573	to	I-PK
2573	cm	I-PK
2573	##ax	I-PK
2573	,	O
2573	area	B-PK
2573	under	I-PK
2573	the	I-PK
2573	curve	I-PK
2573	(	I-PK
2573	au	I-PK
2573	##c	I-PK
2573	)	I-PK
2573	,	O
2573	and	O
2573	elimination	B-PK
2573	half	I-PK
2573	-	I-PK
2573	life	I-PK
2573	(	I-PK
2573	t	I-PK
2573	##1	I-PK
2573	/	I-PK
2573	2	I-PK
2573	)	I-PK
2573	.	O
2573	[SEP]	O
2574	[CLS]	O
2574	no	O
2574	significant	O
2574	difference	O
2574	between	O
2574	both	O
2574	in	O
2574	##tra	O
2574	-	O
2574	art	O
2574	##erial	O
2574	administration	O
2574	##s	O
2574	in	O
2574	elimination	B-PK
2574	half	I-PK
2574	-	I-PK
2574	life	I-PK
2574	(	O
2574	50	O
2574	-	O
2574	223	O
2574	h	O
2574	at	O
2574	2	O
2574	h	O
2574	in	O
2574	##fusion	O
2574	,	O
2574	58	O
2574	-	O
2574	246	O
2574	h	O
2574	at	O
2574	24	O
2574	h	O
2574	in	O
2574	##fusion	O
2574	)	O
2574	and	O
2574	area	B-PK
2574	under	I-PK
2574	the	I-PK
2574	plasma	I-PK
2574	concentration	I-PK
2574	-	I-PK
2574	time	I-PK
2574	curve	I-PK
2574	(	I-PK
2574	au	I-PK
2574	##c	I-PK
2574	##0	I-PK
2574	-	I-PK
2574	72	I-PK
2574	=	O
2574	11	O
2574	.	O
2574	6	O
2574	micro	O
2574	##gram	O
2574	##s	O
2574	/	O
2574	m	O
2574	##l	O
2574	.	O
2574	h	O
2574	for	O
2574	2	O
2574	h	O
2574	in	O
2574	##fusion	O
2574	,	O
2574	au	B-PK
2574	##c	I-PK
2574	##0	I-PK
2574	-	I-PK
2574	72	I-PK
2574	=	O
2574	11	O
2574	.	O
2574	2	O
2574	micro	O
2574	##gram	O
2574	##s	O
2574	/	O
2574	m	O
2574	##l	O
2574	.	O
2574	h	O
2574	for	O
2574	24	O
2574	h	O
2574	in	O
2574	##fusion	O
2574	)	O
2574	could	O
2574	be	O
2574	found	O
2574	.	O
2574	[SEP]	O
2575	[CLS]	O
2575	bio	B-PK
2575	##ava	I-PK
2575	##ila	I-PK
2575	##bility	I-PK
2575	of	O
2575	two	O
2575	brands	O
2575	of	O
2575	q	O
2575	##uin	O
2575	##id	O
2575	##ine	O
2575	g	O
2575	##lu	O
2575	##cona	O
2575	##te	O
2575	administered	O
2575	on	O
2575	a	O
2575	multiple	O
2575	-	O
2575	dose	O
2575	regime	O
2575	##n	O
2575	.	O
2575	[SEP]	O
2576	[CLS]	O
2576	plasma	O
2576	the	O
2576	##op	O
2576	##hyl	O
2576	##line	O
2576	concentrations	O
2576	were	O
2576	measured	O
2576	before	O
2576	and	O
2576	1	O
2576	,	O
2576	2	O
2576	,	O
2576	3	O
2576	,	O
2576	4	O
2576	,	O
2576	6	O
2576	,	O
2576	8	O
2576	,	O
2576	10	O
2576	,	O
2576	12	O
2576	,	O
2576	16	O
2576	and	O
2576	24	O
2576	h	O
2576	after	O
2576	the	O
2576	morning	O
2576	dose	O
2576	of	O
2576	arm	O
2576	##op	O
2576	##hyl	O
2576	##line	O
2576	on	O
2576	the	O
2576	fourth	O
2576	day	O
2576	of	O
2576	each	O
2576	treatment	O
2576	period	O
2576	;	O
2576	the	O
2576	maximum	B-PK
2576	plasma	I-PK
2576	concentration	I-PK
2576	(	I-PK
2576	cm	I-PK
2576	##ax	I-PK
2576	)	I-PK
2576	,	O
2576	and	O
2576	time	B-PK
2576	to	I-PK
2576	cm	I-PK
2576	##ax	I-PK
2576	(	I-PK
2576	t	I-PK
2576	##max	I-PK
2576	)	I-PK
2576	were	O
2576	noted	O
2576	,	O
2576	and	O
2576	the	O
2576	area	B-PK
2576	under	I-PK
2576	the	I-PK
2576	24	I-PK
2576	-	I-PK
2576	h	I-PK
2576	time	I-PK
2576	-	I-PK
2576	concentration	I-PK
2576	curve	I-PK
2576	(	I-PK
2576	au	I-PK
2576	##c	I-PK
2576	##0	I-PK
2576	-	I-PK
2576	24	I-PK
2576	)	I-PK
2576	and	O
2576	mean	O
2576	plasma	B-PK
2576	concentration	I-PK
2576	(	I-PK
2576	cm	I-PK
2576	##ean	I-PK
2576	)	I-PK
2576	were	O
2576	com	O
2576	##puted	O
2576	.	O
2576	[SEP]	O
2577	[CLS]	O
2577	there	O
2577	were	O
2577	no	O
2577	significant	O
2577	differences	O
2577	in	O
2577	bio	B-PK
2577	##ava	I-PK
2577	##ila	I-PK
2577	##bility	I-PK
2577	of	O
2577	rib	O
2577	##of	O
2577	##lav	O
2577	##in	O
2577	and	O
2577	p	O
2577	##yr	O
2577	##ido	O
2577	##xin	O
2577	##e	O
2577	h	O
2577	##ydro	O
2577	##ch	O
2577	##lor	O
2577	##ide	O
2577	between	O
2577	the	O
2577	se	O
2577	##g	O
2577	formulation	O
2577	and	O
2577	the	O
2577	tablet	O
2577	albeit	O
2577	a	O
2577	trend	O
2577	toward	O
2577	consistent	O
2577	absorption	O
2577	was	O
2577	seen	O
2577	from	O
2577	the	O
2577	se	O
2577	##g	O
2577	formulation	O
2577	.	O
2577	[SEP]	O
2578	[CLS]	O
2578	steady	B-PK
2578	-	I-PK
2578	state	I-PK
2578	volume	I-PK
2578	of	I-PK
2578	distribution	I-PK
2578	ranged	O
2578	from	O
2578	0	O
2578	.	O
2578	80	O
2578	to	O
2578	1	O
2578	.	O
2578	26	O
2578	l	O
2578	/	O
2578	kg	O
2578	but	O
2578	did	O
2578	not	O
2578	differ	O
2578	among	O
2578	the	O
2578	groups	O
2578	.	O
2578	[SEP]	O
2579	[CLS]	O
2579	after	O
2579	an	O
2579	in	O
2579	##tra	O
2579	##ven	O
2579	##ous	O
2579	dose	O
2579	of	O
2579	met	O
2579	##form	O
2579	##in	O
2579	,	O
2579	a	O
2579	2	O
2579	-	O
2579	fold	O
2579	decrease	O
2579	in	O
2579	the	O
2579	apparent	B-PK
2579	volume	I-PK
2579	of	I-PK
2579	distribution	I-PK
2579	and	O
2579	clearance	B-PK
2579	was	O
2579	observed	O
2579	in	O
2579	knockout	O
2579	compared	O
2579	with	O
2579	wild	O
2579	-	O
2579	type	O
2579	mice	O
2579	(	O
2579	p	O
2579	<	O
2579	0	O
2579	.	O
2579	00	O
2579	##1	O
2579	)	O
2579	,	O
2579	indicating	O
2579	an	O
2579	important	O
2579	role	O
2579	of	O
2579	o	O
2579	##ct	O
2579	##3	O
2579	in	O
2579	tissue	O
2579	distribution	O
2579	and	O
2579	elimination	O
2579	of	O
2579	the	O
2579	drug	O
2579	.	O
2579	[SEP]	O
2580	[CLS]	O
2580	et	O
2580	##od	O
2580	##ola	O
2580	##c	O
2580	is	O
2580	characterised	O
2580	by	O
2580	a	O
2580	high	O
2580	oral	B-PK
2580	bio	I-PK
2580	##ava	I-PK
2580	##ila	I-PK
2580	##bility	I-PK
2580	,	O
2580	low	O
2580	clearance	B-PK
2580	,	O
2580	a	O
2580	small	O
2580	volume	B-PK
2580	of	I-PK
2580	distribution	I-PK
2580	,	O
2580	and	O
2580	a	O
2580	7	O
2580	-	O
2580	hour	O
2580	half	B-PK
2580	-	I-PK
2580	life	I-PK
2580	.	O
2580	[SEP]	O
2581	[CLS]	O
2581	control	O
2581	and	O
2581	prevention	O
2581	of	O
2581	bleeding	O
2581	events	O
2581	in	O
2581	such	O
2581	patients	O
2581	with	O
2581	re	O
2581	##comb	O
2581	##ina	O
2581	##nt	O
2581	factor	O
2581	v	O
2581	##ii	O
2581	##a	O
2581	(	O
2581	r	O
2581	##f	O
2581	##vi	O
2581	##ia	O
2581	)	O
2581	is	O
2581	limited	O
2581	by	O
2581	the	O
2581	short	O
2581	half	B-PK
2581	-	I-PK
2581	life	I-PK
2581	of	O
2581	the	O
2581	available	O
2581	product	O
2581	.	O
2581	[SEP]	O
2582	[CLS]	O
2582	current	O
2582	published	O
2582	dos	O
2582	##ing	O
2582	regime	O
2582	##ns	O
2582	result	O
2582	in	O
2582	sub	O
2582	##ther	O
2582	##ap	O
2582	##eu	O
2582	##tic	O
2582	concentrations	O
2582	in	O
2582	the	O
2582	early	O
2582	period	O
2582	of	O
2582	se	O
2582	##psis	O
2582	due	O
2582	to	O
2582	augmented	O
2582	re	B-PK
2582	##nal	I-PK
2582	clearance	I-PK
2582	,	O
2582	which	O
2582	risks	O
2582	clinical	O
2582	failure	O
2582	in	O
2582	critically	O
2582	ill	O
2582	children	O
2582	,	O
2582	and	O
2582	therefore	O
2582	need	O
2582	to	O
2582	be	O
2582	updated	O
2582	.	O
2582	[SEP]	O
2583	[CLS]	O
2583	in	O
2583	the	O
2583	present	O
2583	work	O
2583	we	O
2583	investigated	O
2583	the	O
2583	possibility	O
2583	of	O
2583	improving	O
2583	de	O
2583	##hy	O
2583	##dr	O
2583	##oe	O
2583	##pian	O
2583	##dr	O
2583	##osterone	O
2583	(	O
2583	d	O
2583	##hea	O
2583	)	O
2583	so	O
2583	##lub	O
2583	##ility	O
2583	and	O
2583	bio	B-PK
2583	##ava	I-PK
2583	##ila	I-PK
2583	##bility	I-PK
2583	by	O
2583	high	O
2583	-	O
2583	energy	O
2583	co	O
2583	##g	O
2583	##rin	O
2583	##ding	O
2583	with	O
2583	alpha	O
2583	-	O
2583	c	O
2583	##y	O
2583	##c	O
2583	##lo	O
2583	##de	O
2583	##x	O
2583	##tri	O
2583	##n	O
2583	(	O
2583	alpha	O
2583	-	O
2583	c	O
2583	##d	O
2583	)	O
2583	in	O
2583	the	O
2583	presence	O
2583	or	O
2583	absence	O
2583	of	O
2583	different	O
2583	auxiliary	O
2583	substances	O
2583	(	O
2583	g	O
2583	##ly	O
2583	##cine	O
2583	,	O
2583	bio	O
2583	##mal	O
2583	##to	O
2583	##de	O
2583	##x	O
2583	##tri	O
2583	##n	O
2583	,	O
2583	p	O
2583	##oly	O
2583	(	O
2583	vinyl	O
2583	p	O
2583	##yr	O
2583	##rol	O
2583	##ido	O
2583	##ne	O
2583	)	O
2583	,	O
2583	p	O
2583	##oly	O
2583	(	O
2583	et	O
2583	##hyl	O
2583	##ene	O
2583	g	O
2583	##ly	O
2583	##co	O
2583	##l	O
2583	)	O
2583	400	O
2583	)	O
2583	.	O
2583	[SEP]	O
2584	[CLS]	O
2584	the	O
2584	oral	B-PK
2584	absorption	I-PK
2584	rate	I-PK
2584	as	O
2584	measured	O
2584	by	O
2584	the	O
2584	observed	O
2584	time	B-PK
2584	to	I-PK
2584	peak	I-PK
2584	concentration	I-PK
2584	was	O
2584	not	O
2584	significantly	O
2584	altered	O
2584	by	O
2584	food	O
2584	.	O
2584	[SEP]	O
2585	[CLS]	O
2585	the	O
2585	ma	B-PK
2585	##ximal	I-PK
2585	plasma	I-PK
2585	bi	I-PK
2585	##per	I-PK
2585	##iden	I-PK
2585	concentration	I-PK
2585	(	O
2585	34	O
2585	.	O
2585	4	O
2585	ng	O
2585	/	O
2585	m	O
2585	##l	O
2585	)	O
2585	in	O
2585	seizure	O
2585	-	O
2585	terminated	O
2585	animals	O
2585	occurred	O
2585	at	O
2585	26	O
2585	.	O
2585	3	O
2585	min	O
2585	.	O
2585	[SEP]	O
2586	[CLS]	O
2586	in	O
2586	v	O
2586	##it	O
2586	##ro	O
2586	release	O
2586	study	O
2586	of	O
2586	am	O
2586	-	O
2586	s	O
2586	##ln	O
2586	##s	O
2586	showed	O
2586	9	O
2586	.	O
2586	23	O
2586	%	O
2586	±	O
2586	2	O
2586	.	O
2586	72	O
2586	%	O
2586	and	O
2586	92	O
2586	.	O
2586	09	O
2586	%	O
2586	±	O
2586	3	O
2586	.	O
2586	40	O
2586	%	O
2586	release	O
2586	of	O
2586	am	O
2586	in	O
2586	p	O
2586	##h	O
2586	1	O
2586	.	O
2586	2	O
2586	medium	O
2586	and	O
2586	phosphate	O
2586	buffer	O
2586	p	O
2586	##h	O
2586	6	O
2586	.	O
2586	8	O
2586	,	O
2586	respectively	O
2586	,	O
2586	indicating	O
2586	higher	O
2586	potential	O
2586	of	O
2586	l	O
2586	##ymph	O
2586	##atic	O
2586	up	O
2586	##take	O
2586	.	O
2586	[SEP]	O
2587	[CLS]	O
2587	the	O
2587	value	O
2587	of	O
2587	the	O
2587	apparent	B-PK
2587	distribution	I-PK
2587	volume	I-PK
2587	in	O
2587	the	O
2587	central	O
2587	compartment	O
2587	was	O
2587	0	O
2587	.	O
2587	38	O
2587	m	O
2587	##l	O
2587	/	O
2587	kg	O
2587	and	O
2587	that	O
2587	of	O
2587	the	O
2587	stationary	B-PK
2587	and	O
2587	kinetic	B-PK
2587	distribution	I-PK
2587	volumes	I-PK
2587	was	O
2587	1	O
2587	.	O
2587	37	O
2587	and	O
2587	3	O
2587	.	O
2587	06	O
2587	1	O
2587	/	O
2587	kg	O
2587	respectively	O
2587	.	O
2587	[SEP]	O
2588	[CLS]	O
2588	bio	B-PK
2588	##ava	I-PK
2588	##ila	I-PK
2588	##bility	I-PK
2588	studies	O
2588	with	O
2588	dig	O
2588	##ox	O
2588	##in	O
2588	-	O
2588	sand	O
2588	##oz	O
2588	and	O
2588	la	O
2588	##no	O
2588	##xin	O
2588	.	O
2588	[SEP]	O
2589	[CLS]	O
2589	mean	O
2589	value	O
2589	(	O
2589	between	O
2589	-	O
2589	patients	O
2589	var	O
2589	##iability	O
2589	)	O
2589	for	O
2589	c	B-PK
2589	##l	I-PK
2589	,	O
2589	v	B-PK
2589	##1	I-PK
2589	,	O
2589	q	B-PK
2589	,	O
2589	and	O
2589	v	B-PK
2589	##2	I-PK
2589	were	O
2589	4	O
2589	.	O
2589	3	O
2589	l	O
2589	/	O
2589	h	O
2589	(	O
2589	31	O
2589	%	O
2589	)	O
2589	,	O
2589	15	O
2589	.	O
2589	9	O
2589	l	O
2589	(	O
2589	22	O
2589	%	O
2589	)	O
2589	,	O
2589	12	O
2589	.	O
2589	1	O
2589	l	O
2589	/	O
2589	h	O
2589	(	O
2589	27	O
2589	%	O
2589	)	O
2589	,	O
2589	and	O
2589	21	O
2589	.	O
2589	4	O
2589	l	O
2589	(	O
2589	47	O
2589	%	O
2589	)	O
2589	,	O
2589	respectively	O
2589	.	O
2589	[SEP]	O
2590	[CLS]	O
2590	the	O
2590	predominant	O
2590	effect	O
2590	of	O
2590	s	O
2590	##v	O
2590	loaded	O
2590	n	O
2590	##l	O
2590	##cs	O
2590	may	O
2590	be	O
2590	attributed	O
2590	to	O
2590	the	O
2590	enhance	O
2590	##ment	O
2590	of	O
2590	absorption	O
2590	,	O
2590	prolonged	O
2590	duration	O
2590	and	O
2590	improvement	O
2590	of	O
2590	bio	B-PK
2590	##ava	I-PK
2590	##ila	I-PK
2590	##bility	I-PK
2590	of	O
2590	s	O
2590	##v	O
2590	.	O
2590	[SEP]	O
2591	[CLS]	O
2591	in	O
2591	conclusion	O
2591	,	O
2591	our	O
2591	r	O
2591	##op	O
2591	##ini	O
2591	##rol	O
2591	##e	O
2591	oral	O
2591	film	O
2591	improved	O
2591	bio	B-PK
2591	##ava	I-PK
2591	##ila	I-PK
2591	##bility	I-PK
2591	after	O
2591	sub	O
2591	##ling	O
2591	##ual	O
2591	or	O
2591	b	O
2591	##uc	O
2591	##cal	O
2591	administration	O
2591	.	O
2591	[SEP]	O
2592	[CLS]	O
2592	mean	O
2592	half	B-PK
2592	-	I-PK
2592	lives	I-PK
2592	of	O
2592	s	O
2592	##bt	O
2592	and	O
2592	a	O
2592	##b	O
2592	##p	O
2592	##c	O
2592	in	O
2592	the	O
2592	serum	O
2592	following	O
2592	oral	O
2592	administration	O
2592	were	O
2592	about	O
2592	1	O
2592	.	O
2592	33	O
2592	and	O
2592	1	O
2592	.	O
2592	61	O
2592	hours	O
2592	respectively	O
2592	.	O
2592	[SEP]	O
2593	[CLS]	O
2593	weight	O
2593	-	O
2593	corrected	O
2593	volume	B-PK
2593	of	I-PK
2593	distribution	I-PK
2593	and	O
2593	total	B-PK
2593	body	I-PK
2593	clearance	I-PK
2593	were	O
2593	significantly	O
2593	lower	O
2593	in	O
2593	o	O
2593	##bes	O
2593	##e	O
2593	compared	O
2593	with	O
2593	lean	O
2593	rats	O
2593	;	O
2593	no	O
2593	differences	O
2593	were	O
2593	found	O
2593	in	O
2593	absolute	B-PK
2593	clearance	I-PK
2593	or	O
2593	volume	B-PK
2593	.	O
2593	[SEP]	O
2594	[CLS]	O
2594	si	O
2594	##lde	O
2594	##na	O
2594	##fi	O
2594	##l	O
2594	cm	B-PK
2594	##ax	I-PK
2594	(	O
2594	156	O
2594	.	O
2594	8	O
2594	±	O
2594	124	O
2594	.	O
2594	5	O
2594	ng	O
2594	/	O
2594	m	O
2594	##l	O
2594	)	O
2594	was	O
2594	elevated	O
2594	in	O
2594	66	O
2594	%	O
2594	of	O
2594	patients	O
2594	,	O
2594	with	O
2594	a	O
2594	two	O
2594	to	O
2594	five	O
2594	##fold	O
2594	increase	O
2594	over	O
2594	the	O
2594	upper	O
2594	limit	O
2594	of	O
2594	the	O
2594	reference	O
2594	range	O
2594	in	O
2594	25	O
2594	%	O
2594	of	O
2594	patients	O
2594	.	O
2594	[SEP]	O
2595	[CLS]	O
2595	c	O
2595	##v	O
2595	##v	O
2595	##h	O
2595	has	O
2595	no	O
2595	clinical	O
2595	##ly	O
2595	relevant	O
2595	contribution	O
2595	to	O
2595	total	B-PK
2595	clearance	I-PK
2595	.	O
2595	[SEP]	O
2596	[CLS]	O
2596	influence	O
2596	of	O
2596	the	O
2596	chemical	O
2596	form	O
2596	on	O
2596	the	O
2596	plasma	B-PK
2596	clearance	I-PK
2596	of	O
2596	r	O
2596	##uth	O
2596	##eni	O
2596	##um	O
2596	in	O
2596	humans	O
2596	.	O
2596	[SEP]	O
2597	[CLS]	O
2597	the	O
2597	similarity	O
2597	of	O
2597	systemic	O
2597	kinetic	O
2597	parameters	O
2597	(	O
2597	volume	B-PK
2597	of	I-PK
2597	distribution	I-PK
2597	;	O
2597	mi	O
2597	##cha	O
2597	##eli	O
2597	##s	O
2597	-	O
2597	men	O
2597	##ten	O
2597	elimination	O
2597	parameters	O
2597	,	O
2597	v	B-PK
2597	##max	I-PK
2597	and	O
2597	km	B-PK
2597	)	O
2597	between	O
2597	in	O
2597	##hala	O
2597	##tion	O
2597	exposure	O
2597	and	O
2597	i	O
2597	##v	O
2597	and	O
2597	p	O
2597	##o	O
2597	routes	O
2597	of	O
2597	administration	O
2597	was	O
2597	verified	O
2597	.	O
2597	[SEP]	O
2598	[CLS]	O
2598	the	O
2598	terminal	B-PK
2598	half	I-PK
2598	-	I-PK
2598	lives	I-PK
2598	of	O
2598	filter	O
2598	##able	O
2598	and	O
2598	total	O
2598	platinum	O
2598	were	O
2598	similar	O
2598	to	O
2598	the	O
2598	ones	O
2598	observed	O
2598	after	O
2598	the	O
2598	test	O
2598	dose	O
2598	,	O
2598	i	O
2598	.	O
2598	e	O
2598	.	O
2598	0	O
2598	.	O
2598	36	O
2598	h	O
2598	and	O
2598	86	O
2598	h	O
2598	,	O
2598	respectively	O
2598	.	O
2598	[SEP]	O
2599	[CLS]	O
2599	g	O
2599	##ef	O
2599	##iti	O
2599	##ni	O
2599	##b	O
2599	was	O
2599	rapidly	O
2599	absorbed	O
2599	and	O
2599	showed	O
2599	a	O
2599	mon	O
2599	##oe	O
2599	##x	O
2599	##po	O
2599	##nent	O
2599	##ial	O
2599	decline	O
2599	with	O
2599	an	O
2599	elimination	B-PK
2599	half	I-PK
2599	-	I-PK
2599	life	I-PK
2599	of	O
2599	3	O
2599	.	O
2599	7	O
2599	-	O
2599	4	O
2599	.	O
2599	1	O
2599	h	O
2599	.	O
2599	the	O
2599	p	O
2599	##har	O
2599	##ma	O
2599	##co	O
2599	##kin	O
2599	##etics	O
2599	of	O
2599	g	O
2599	##ef	O
2599	##iti	O
2599	##ni	O
2599	##b	O
2599	was	O
2599	not	O
2599	affected	O
2599	by	O
2599	g	O
2599	##p	O
2599	##d	O
2599	pre	O
2599	##tre	O
2599	##at	O
2599	##ment	O
2599	.	O
2599	[SEP]	O
2600	[CLS]	O
2600	maximum	B-PK
2600	concentration	I-PK
2600	of	O
2600	ni	O
2600	##cot	O
2600	##ine	O
2600	,	O
2600	8	O
2600	.	O
2600	1	O
2600	+	O
2600	-	O
2600	3	O
2600	.	O
2600	5	O
2600	ng	O
2600	/	O
2600	m	O
2600	##l	O
2600	,	O
2600	in	O
2600	the	O
2600	16	O
2600	subjects	O
2600	occurred	O
2600	after	O
2600	a	O
2600	median	O
2600	of	O
2600	60	O
2600	minutes	O
2600	(	O
2600	range	O
2600	,	O
2600	30	O
2600	to	O
2600	180	O
2600	minutes	O
2600	)	O
2600	;	O
2600	maximum	B-PK
2600	co	I-PK
2600	##tin	I-PK
2600	##ine	I-PK
2600	concentrations	I-PK
2600	of	O
2600	60	O
2600	.	O
2600	4	O
2600	+	O
2600	-	O
2600	11	O
2600	.	O
2600	5	O
2600	ng	O
2600	/	O
2600	m	O
2600	##l	O
2600	occurred	O
2600	after	O
2600	4	O
2600	hours	O
2600	.	O
2600	[SEP]	O
2601	[CLS]	O
2601	min	O
2601	-	O
2601	1	O
2601	,	O
2601	p	O
2601	less	O
2601	than	O
2601	0	O
2601	.	O
2601	01	O
2601	)	O
2601	and	O
2601	the	O
2601	elimination	B-PK
2601	half	I-PK
2601	-	I-PK
2601	life	I-PK
2601	was	O
2601	significantly	O
2601	prolonged	O
2601	(	O
2601	11	O
2601	.	O
2601	4	O
2601	vs	O
2601	.	O
2601	6	O
2601	.	O
2601	0	O
2601	h	O
2601	,	O
2601	p	O
2601	less	O
2601	than	O
2601	0	O
2601	.	O
2601	01	O
2601	)	O
2601	.	O
2601	[SEP]	O
2602	[CLS]	O
2602	preliminary	O
2602	studies	O
2602	of	O
2602	j	O
2602	##p	O
2602	##c	O
2602	-	O
2602	29	O
2602	##9	O
2602	##7	O
2602	in	O
2602	mice	O
2602	show	O
2602	linear	O
2602	p	O
2602	##har	O
2602	##ma	O
2602	##co	O
2602	##kin	O
2602	##etics	O
2602	over	O
2602	the	O
2602	range	O
2602	2	O
2602	.	O
2602	5	O
2602	to	O
2602	40	O
2602	mg	O
2602	/	O
2602	kg	O
2602	,	O
2602	a	O
2602	low	O
2602	clearance	B-PK
2602	of	O
2602	0	O
2602	.	O
2602	22	O
2602	liter	O
2602	##s	O
2602	/	O
2602	h	O
2602	/	O
2602	kg	O
2602	,	O
2602	a	O
2602	volume	B-PK
2602	of	I-PK
2602	distribution	I-PK
2602	of	O
2602	15	O
2602	.	O
2602	6	O
2602	liter	O
2602	##s	O
2602	/	O
2602	kg	O
2602	,	O
2602	and	O
2602	an	O
2602	elimination	B-PK
2602	half	I-PK
2602	-	I-PK
2602	life	I-PK
2602	of	O
2602	49	O
2602	.	O
2602	8	O
2602	h	O
2602	.	O
2602	the	O
2602	high	O
2602	in	O
2602	v	O
2602	##ivo	O
2602	pot	O
2602	##ency	O
2602	data	O
2602	and	O
2602	lengthy	O
2602	elimination	B-PK
2602	half	I-PK
2602	-	I-PK
2602	life	I-PK
2602	of	O
2602	j	O
2602	##p	O
2602	##c	O
2602	-	O
2602	29	O
2602	##9	O
2602	##7	O
2602	suggest	O
2602	that	O
2602	it	O
2602	is	O
2602	worthy	O
2602	of	O
2602	further	O
2602	pre	O
2602	##c	O
2602	##lini	O
2602	##cal	O
2602	assessment	O
2602	as	O
2602	a	O
2602	partner	O
2602	drug	O
2602	.	O
2602	[SEP]	O
2603	[CLS]	O
2603	the	O
2603	clearance	B-PK
2603	at	O
2603	treatment	O
2603	week	O
2603	4	O
2603	was	O
2603	42	O
2603	.	O
2603	3	O
2603	l	O
2603	day	O
2603	(	O
2603	-	O
2603	1	O
2603	)	O
2603	(	O
2603	patients	O
2603	with	O
2603	c	O
2603	##l	O
2603	##c	O
2603	##r	O
2603	120	O
2603	m	O
2603	##l	O
2603	min	O
2603	(	O
2603	-	O
2603	1	O
2603	)	O
2603	)	O
2603	with	O
2603	inter	O
2603	##patient	O
2603	var	O
2603	##iability	O
2603	30	O
2603	%	O
2603	.	O
2603	[SEP]	O
2604	[CLS]	O
2604	p	O
2604	##har	O
2604	##ma	O
2604	##co	O
2604	##kin	O
2604	##etic	O
2604	profile	O
2604	of	O
2604	t	O
2604	##m	O
2604	##x	O
2604	after	O
2604	en	O
2604	##cap	O
2604	##sul	O
2604	##ation	O
2604	was	O
2604	improved	O
2604	giving	O
2604	3	O
2604	-	O
2604	fold	O
2604	higher	O
2604	au	B-PK
2604	##c	I-PK
2604	;	O
2604	extended	O
2604	mean	B-PK
2604	residence	I-PK
2604	time	I-PK
2604	is	O
2604	improving	O
2604	chances	O
2604	of	O
2604	na	O
2604	##nov	O
2604	##esi	O
2604	##cle	O
2604	to	O
2604	extra	O
2604	##vas	O
2604	##ate	O
2604	in	O
2604	tumor	O
2604	via	O
2604	e	O
2604	##p	O
2604	##r	O
2604	effect	O
2604	.	O
2604	[SEP]	O
2605	[CLS]	O
2605	cm	B-PK
2605	##ax	I-PK
2605	and	O
2605	area	B-PK
2605	under	I-PK
2605	the	I-PK
2605	curve	I-PK
2605	(	O
2605	au	B-PK
2605	##c	I-PK
2605	(	I-PK
2605	0	I-PK
2605	-	I-PK
2605	t	I-PK
2605	)	I-PK
2605	and	O
2605	au	B-PK
2605	##c	I-PK
2605	(	I-PK
2605	0	I-PK
2605	-	I-PK
2605	∞	I-PK
2605	)	I-PK
2605	)	O
2605	were	O
2605	calculated	O
2605	and	O
2605	compared	O
2605	between	O
2605	groups	O
2605	using	O
2605	the	O
2605	paired	O
2605	t	O
2605	test	O
2605	.	O
2605	[SEP]	O
2606	[CLS]	O
2606	the	O
2606	serum	B-PK
2606	half	I-PK
2606	-	I-PK
2606	life	I-PK
2606	of	O
2606	the	O
2606	slow	O
2606	disposition	O
2606	phase	O
2606	was	O
2606	1	O
2606	.	O
2606	75	O
2606	h	O
2606	in	O
2606	patients	O
2606	with	O
2606	normal	O
2606	re	O
2606	##nal	O
2606	function	O
2606	.	O
2606	[SEP]	O
2607	[CLS]	O
2607	after	O
2607	oral	O
2607	administration	O
2607	,	O
2607	area	B-PK
2607	under	I-PK
2607	serum	I-PK
2607	concentration	I-PK
2607	-	I-PK
2607	time	I-PK
2607	curve	I-PK
2607	(	I-PK
2607	au	I-PK
2607	##c	I-PK
2607	)	I-PK
2607	was	O
2607	about	O
2607	35	O
2607	-	O
2607	fold	O
2607	higher	O
2607	in	O
2607	female	O
2607	rats	O
2607	than	O
2607	in	O
2607	male	O
2607	rats	O
2607	,	O
2607	and	O
2607	absolute	B-PK
2607	bio	I-PK
2607	##ava	I-PK
2607	##ila	I-PK
2607	##bility	I-PK
2607	was	O
2607	about	O
2607	5	O
2607	.	O
2607	8	O
2607	-	O
2607	fold	O
2607	higher	O
2607	in	O
2607	female	O
2607	rats	O
2607	than	O
2607	in	O
2607	male	O
2607	rats	O
2607	.	O
2607	[SEP]	O
2608	[CLS]	O
2608	lead	O
2608	compounds	O
2608	30	O
2608	and	O
2608	58	O
2608	exhibited	O
2608	good	O
2608	exposure	O
2608	and	O
2608	oral	B-PK
2608	bio	I-PK
2608	##ava	I-PK
2608	##ila	I-PK
2608	##bility	I-PK
2608	in	O
2608	mouse	O
2608	p	O
2608	##har	O
2608	##ma	O
2608	##co	O
2608	##kin	O
2608	##etic	O
2608	(	O
2608	p	O
2608	##k	O
2608	)	O
2608	study	O
2608	.	O
2608	[SEP]	O
2609	[CLS]	O
2609	additionally	O
2609	,	O
2609	the	O
2609	area	B-PK
2609	under	I-PK
2609	the	I-PK
2609	plasma	I-PK
2609	concentration	I-PK
2609	-	I-PK
2609	time	I-PK
2609	curve	I-PK
2609	from	I-PK
2609	zero	I-PK
2609	to	I-PK
2609	in	I-PK
2609	##finity	I-PK
2609	(	I-PK
2609	au	I-PK
2609	##c	I-PK
2609	(	I-PK
2609	0	I-PK
2609	-	I-PK
2609	in	I-PK
2609	##finity	I-PK
2609	)	I-PK
2609	)	I-PK
2609	and	O
2609	the	O
2609	elimination	B-PK
2609	half	I-PK
2609	-	I-PK
2609	life	I-PK
2609	of	O
2609	(	O
2609	r	O
2609	)	O
2609	-	O
2609	war	O
2609	##fari	O
2609	##n	O
2609	in	O
2609	pm	O
2609	##s	O
2609	were	O
2609	significantly	O
2609	greater	O
2609	than	O
2609	those	O
2609	in	O
2609	h	O
2609	##me	O
2609	##ms	O
2609	(	O
2609	p	O
2609	=	O
2609	0	O
2609	.	O
2609	000	O
2609	##5	O
2609	and	O
2609	p	O
2609	=	O
2609	0	O
2609	.	O
2609	01	O
2609	##01	O
2609	respectively	O
2609	)	O
2609	.	O
2609	[SEP]	O
2610	[CLS]	O
2610	half	B-PK
2610	-	I-PK
2610	lives	I-PK
2610	(	I-PK
2610	t	I-PK
2610	1	I-PK
2610	/	I-PK
2610	2	I-PK
2610	)	I-PK
2610	in	O
2610	c	O
2610	##s	O
2610	##f	O
2610	and	O
2610	c	B-PK
2610	##s	I-PK
2610	##f	I-PK
2610	/	I-PK
2610	serum	I-PK
2610	ratios	I-PK
2610	of	I-PK
2610	t	I-PK
2610	1	I-PK
2610	/	I-PK
2610	2	I-PK
2610	were	O
2610	52	O
2610	minutes	O
2610	and	O
2610	2	O
2610	.	O
2610	1	O
2610	for	O
2610	am	O
2610	##pic	O
2610	##ill	O
2610	##in	O
2610	and	O
2610	23	O
2610	minutes	O
2610	and	O
2610	1	O
2610	.	O
2610	3	O
2610	for	O
2610	car	O
2610	##ben	O
2610	##ici	O
2610	##llin	O
2610	,	O
2610	respectively	O
2610	.	O
2610	[SEP]	O
2611	[CLS]	O
2611	p	O
2611	##har	O
2611	##ma	O
2611	##co	O
2611	##kin	O
2611	##etics	O
2611	and	O
2611	bio	B-PK
2611	##ava	I-PK
2611	##ila	I-PK
2611	##bility	I-PK
2611	of	O
2611	r	O
2611	##if	O
2611	##amp	O
2611	##in	O
2611	in	O
2611	adult	O
2611	sheep	O
2611	were	O
2611	investigated	O
2611	by	O
2611	use	O
2611	of	O
2611	high	O
2611	-	O
2611	performance	O
2611	liquid	O
2611	ch	O
2611	##roma	O
2611	##tography	O
2611	for	O
2611	determination	O
2611	of	O
2611	serum	O
2611	concentrations	O
2611	.	O
2611	[SEP]	O
2612	[CLS]	O
2612	analysis	O
2612	of	O
2612	co	O
2612	##var	O
2612	##iance	O
2612	models	O
2612	with	O
2612	adjustment	O
2612	for	O
2612	age	O
2612	and	O
2612	ad	O
2612	##herence	O
2612	and	O
2612	all	O
2612	##ometric	O
2612	adjustment	O
2612	of	O
2612	c	B-PK
2612	##l	I-PK
2612	were	O
2612	used	O
2612	to	O
2612	assess	O
2612	associations	O
2612	between	O
2612	studied	O
2612	p	O
2612	##oly	O
2612	##mor	O
2612	##phism	O
2612	##s	O
2612	and	O
2612	au	B-PK
2612	##c	I-PK
2612	,	O
2612	c	B-PK
2612	##l	I-PK
2612	,	O
2612	and	O
2612	hi	O
2612	##v	O
2612	r	O
2612	##na	O
2612	.	O
2612	[SEP]	O
2613	[CLS]	O
2613	volumes	B-PK
2613	of	I-PK
2613	distribution	I-PK
2613	in	I-PK
2613	the	I-PK
2613	central	I-PK
2613	compartment	I-PK
2613	as	O
2613	well	O
2613	as	O
2613	tissue	O
2613	distribution	O
2613	studies	O
2613	in	O
2613	all	O
2613	three	O
2613	species	O
2613	indicated	O
2613	a	O
2613	rapid	O
2613	up	O
2613	##take	O
2613	and	O
2613	significant	O
2613	concentration	O
2613	of	O
2613	the	O
2613	drug	O
2613	with	O
2613	long	O
2613	elimination	B-PK
2613	half	I-PK
2613	-	I-PK
2613	lives	I-PK
2613	in	O
2613	a	O
2613	deep	O
2613	compartment	O
2613	.	O
2613	[SEP]	O
2614	[CLS]	O
2614	sparse	O
2614	sampling	O
2614	can	O
2614	accurately	O
2614	estimate	O
2614	au	B-PK
2614	##cs	I-PK
2614	and	O
2614	can	O
2614	be	O
2614	implemented	O
2614	in	O
2614	rode	O
2614	##nt	O
2614	toxic	O
2614	##ology	O
2614	studies	O
2614	to	O
2614	significantly	O
2614	reduce	O
2614	the	O
2614	number	O
2614	of	O
2614	animals	O
2614	for	O
2614	t	O
2614	##k	O
2614	evaluation	O
2614	##s	O
2614	.	O
2614	[SEP]	O
2615	[CLS]	O
2615	increased	O
2615	gas	O
2615	##tric	O
2615	p	O
2615	##h	O
2615	and	O
2615	the	O
2615	bio	B-PK
2615	##ava	I-PK
2615	##ila	I-PK
2615	##bility	I-PK
2615	of	O
2615	flu	O
2615	##cona	O
2615	##zo	O
2615	##le	O
2615	and	O
2615	k	O
2615	##eto	O
2615	##cona	O
2615	##zo	O
2615	##le	O
2615	.	O
2615	[SEP]	O
2616	[CLS]	O
2616	ad	O
2616	##junct	O
2616	##ive	O
2616	se	O
2616	##rt	O
2616	##ral	O
2616	##ine	O
2616	significantly	O
2616	increased	O
2616	c	O
2616	##s	O
2616	##f	O
2616	fun	O
2616	##gal	O
2616	clearance	B-PK
2616	rate	I-PK
2616	compared	O
2616	to	O
2616	coat	O
2616	trial	O
2616	and	O
2616	se	O
2616	##rt	O
2616	##ral	O
2616	##ine	O
2616	effect	O
2616	was	O
2616	dose	O
2616	-	O
2616	independent	O
2616	with	O
2616	no	O
2616	co	O
2616	##var	O
2616	##iate	O
2616	found	O
2616	to	O
2616	affect	O
2616	fun	O
2616	##gal	O
2616	clearance	B-PK
2616	including	O
2616	art	O
2616	.	O
2616	[SEP]	O
2617	[CLS]	O
2617	since	O
2617	p	O
2617	##hen	O
2617	##yt	O
2617	##oi	O
2617	##n	O
2617	obey	O
2617	##s	O
2617	mi	O
2617	##chel	O
2617	##es	O
2617	men	O
2617	##tens	O
2617	kinetic	O
2617	##s	O
2617	,	O
2617	the	O
2617	au	B-PK
2617	##c	I-PK
2617	methodology	O
2617	used	O
2617	for	O
2617	comparison	O
2617	would	O
2617	give	O
2617	only	O
2617	an	O
2617	approximate	O
2617	indication	O
2617	of	O
2617	relative	B-PK
2617	bio	I-PK
2617	##ava	I-PK
2617	##ila	I-PK
2617	##bility	I-PK
2617	.	O
2617	[SEP]	O
2618	[CLS]	O
2618	p	O
2618	##har	O
2618	##ma	O
2618	##co	O
2618	##kin	O
2618	##etic	O
2618	parameter	O
2618	estimates	O
2618	(	O
2618	au	B-PK
2618	##c	I-PK
2618	(	I-PK
2618	0	I-PK
2618	-	I-PK
2618	t	I-PK
2618	last	I-PK
2618	)	I-PK
2618	,	O
2618	c	B-PK
2618	(	I-PK
2618	ma	I-PK
2618	##x	I-PK
2618	)	I-PK
2618	,	O
2618	and	O
2618	t	B-PK
2618	(	I-PK
2618	ma	I-PK
2618	##x	I-PK
2618	)	I-PK
2618	)	O
2618	and	O
2618	in	O
2618	##hibition	O
2618	of	O
2618	plate	O
2618	##let	O
2618	a	O
2618	##gg	O
2618	##regation	O
2618	(	O
2618	i	O
2618	##pa	O
2618	)	O
2618	by	O
2618	light	O
2618	transmission	O
2618	a	O
2618	##gg	O
2618	##re	O
2618	##go	O
2618	##metry	O
2618	were	O
2618	assessed	O
2618	at	O
2618	multiple	O
2618	time	O
2618	points	O
2618	after	O
2618	the	O
2618	l	O
2618	##d	O
2618	and	O
2618	final	O
2618	m	O
2618	##d	O
2618	.	O
2618	[SEP]	O
2619	[CLS]	O
2619	however	O
2619	there	O
2619	was	O
2619	a	O
2619	correlation	O
2619	between	O
2619	basal	O
2619	plasma	O
2619	c	O
2619	##rea	O
2619	##tin	O
2619	##ine	O
2619	values	O
2619	and	O
2619	plasma	O
2619	cap	O
2619	##top	O
2619	##ril	O
2619	t	B-PK
2619	##1	I-PK
2619	/	I-PK
2619	2	I-PK
2619	,	O
2619	p	O
2619	##cea	O
2619	blockade	O
2619	(	O
2619	au	B-PK
2619	##c	I-PK
2619	)	O
2619	and	O
2619	overall	O
2619	anti	O
2619	##hy	O
2619	##pert	O
2619	##ens	O
2619	##ive	O
2619	effect	O
2619	(	O
2619	au	B-PK
2619	##c	I-PK
2619	)	O
2619	.	O
2619	[SEP]	O
2620	[CLS]	O
2620	the	O
2620	inter	O
2620	##fer	O
2620	##on	O
2620	treatment	O
2620	had	O
2620	no	O
2620	influence	O
2620	on	O
2620	the	O
2620	p	O
2620	##har	O
2620	##ma	O
2620	##co	O
2620	##kin	O
2620	##etics	O
2620	of	O
2620	e	O
2620	##pi	O
2620	##ru	O
2620	##bic	O
2620	##in	O
2620	(	O
2620	au	B-PK
2620	##c	I-PK
2620	,	O
2620	cm	B-PK
2620	##ax	I-PK
2620	,	O
2620	terminal	B-PK
2620	half	I-PK
2620	life	I-PK
2620	)	O
2620	.	O
2620	[SEP]	O
2621	[CLS]	O
2621	he	O
2621	##pa	O
2621	##to	O
2621	##bil	O
2621	##iary	O
2621	disposition	O
2621	of	O
2621	at	O
2621	##ova	O
2621	##q	O
2621	##uo	O
2621	##ne	O
2621	:	O
2621	a	O
2621	case	O
2621	of	O
2621	me	O
2621	##chan	O
2621	##istic	O
2621	##ally	O
2621	unusual	O
2621	bi	O
2621	##lia	O
2621	##ry	O
2621	clearance	B-PK
2621	.	O
2621	[SEP]	O
2622	[CLS]	O
2622	all	O
2622	tested	O
2622	p	O
2622	##har	O
2622	##ma	O
2622	##co	O
2622	##kin	O
2622	##etic	O
2622	parameters	O
2622	(	O
2622	au	B-PK
2622	##c	I-PK
2622	(	I-PK
2622	in	I-PK
2622	##f	I-PK
2622	)	I-PK
2622	,	O
2622	au	B-PK
2622	##c	I-PK
2622	(	I-PK
2622	in	I-PK
2622	##f	I-PK
2622	)	I-PK
2622	(	I-PK
2622	n	I-PK
2622	##l	I-PK
2622	##70	I-PK
2622	)	I-PK
2622	,	O
2622	cm	B-PK
2622	##ax	I-PK
2622	,	O
2622	cm	B-PK
2622	##ax	I-PK
2622	(	I-PK
2622	n	I-PK
2622	##l	I-PK
2622	##70	I-PK
2622	)	I-PK
2622	,	O
2622	t	B-PK
2622	(	I-PK
2622	1	I-PK
2622	/	I-PK
2622	2	I-PK
2622	)	I-PK
2622	,	O
2622	and	O
2622	te	B-PK
2622	##c	I-PK
2622	)	O
2622	were	O
2622	significantly	O
2622	different	O
2622	among	O
2622	four	O
2622	different	O
2622	g	O
2622	##eno	O
2622	##ty	O
2622	##pic	O
2622	groups	O
2622	.	O
2622	[SEP]	O
2623	[CLS]	O
2623	the	O
2623	systemic	B-PK
2623	bio	I-PK
2623	##ava	I-PK
2623	##ila	I-PK
2623	##bility	I-PK
2623	of	O
2623	g	O
2623	##eni	O
2623	##stein	O
2623	[	O
2623	mean	O
2623	au	B-PK
2623	##c	I-PK
2623	=	O
2623	4	O
2623	.	O
2623	54	O
2623	micro	O
2623	##g	O
2623	/	O
2623	(	O
2623	m	O
2623	##l	O
2623	x	O
2623	h	O
2623	)	O
2623	]	O
2623	is	O
2623	much	O
2623	greater	O
2623	than	O
2623	that	O
2623	of	O
2623	da	O
2623	##id	O
2623	##ze	O
2623	##in	O
2623	[	O
2623	mean	O
2623	au	B-PK
2623	##c	I-PK
2623	=	O
2623	2	O
2623	.	O
2623	94	O
2623	micro	O
2623	##g	O
2623	/	O
2623	(	O
2623	m	O
2623	##l	O
2623	x	O
2623	h	O
2623	)	O
2623	]	O
2623	,	O
2623	and	O
2623	bio	B-PK
2623	##ava	I-PK
2623	##ila	I-PK
2623	##bility	I-PK
2623	of	O
2623	these	O
2623	is	O
2623	##of	O
2623	##lav	O
2623	##ones	O
2623	is	O
2623	greater	O
2623	when	O
2623	ing	O
2623	##ested	O
2623	as	O
2623	beta	O
2623	-	O
2623	g	O
2623	##ly	O
2623	##cos	O
2623	##ides	O
2623	rather	O
2623	than	O
2623	a	O
2623	##gly	O
2623	##con	O
2623	##es	O
2623	as	O
2623	measured	O
2623	from	O
2623	the	O
2623	area	B-PK
2623	under	I-PK
2623	the	I-PK
2623	curve	I-PK
2623	of	I-PK
2623	the	I-PK
2623	plasma	I-PK
2623	appearance	I-PK
2623	and	I-PK
2623	disappearance	I-PK
2623	concentrations	I-PK
2623	.	O
2623	[SEP]	O
2624	[CLS]	O
2624	10	O
2624	the	O
2624	two	O
2624	methods	O
2624	provided	O
2624	similar	O
2624	values	O
2624	for	O
2624	the	O
2624	metabolic	B-PK
2624	clearance	I-PK
2624	rate	I-PK
2624	(	I-PK
2624	m	I-PK
2624	##c	I-PK
2624	##r	I-PK
2624	)	I-PK
2624	when	O
2624	,	O
2624	after	O
2624	the	O
2624	single	O
2624	injection	O
2624	,	O
2624	the	O
2624	m	B-PK
2624	##c	I-PK
2624	##r	I-PK
2624	was	O
2624	estimated	O
2624	by	O
2624	integrating	O
2624	the	O
2624	area	B-PK
2624	under	I-PK
2624	each	I-PK
2624	disappearance	I-PK
2624	curve	I-PK
2624	of	O
2624	radioactive	O
2624	co	O
2624	##rt	O
2624	##ico	O
2624	##id	O
2624	.	O
2624	[SEP]	O
2625	[CLS]	O
2625	the	O
2625	probability	O
2625	of	O
2625	attain	O
2625	##ing	O
2625	the	O
2625	target	O
2625	,	O
2625	t	O
2625	>	O
2625	mi	O
2625	##c	O
2625	of	O
2625	100	O
2625	%	O
2625	,	O
2625	was	O
2625	higher	O
2625	for	O
2625	3	O
2625	-	O
2625	hour	O
2625	in	O
2625	##fusion	O
2625	regime	O
2625	##ns	O
2625	compared	O
2625	with	O
2625	30	O
2625	-	O
2625	minute	O
2625	in	O
2625	##fusion	O
2625	regime	O
2625	##ns	O
2625	for	O
2625	all	O
2625	ranges	O
2625	of	O
2625	c	O
2625	##l	O
2625	##cre	O
2625	##at	O
2625	.	O
2625	[SEP]	O
2626	[CLS]	O
2626	in	O
2626	part	O
2626	1	O
2626	,	O
2626	co	O
2626	-	O
2626	administration	O
2626	of	O
2626	p	O
2626	##imo	O
2626	##di	O
2626	##vir	O
2626	with	O
2626	o	O
2626	##sel	O
2626	##tam	O
2626	##iv	O
2626	##ir	O
2626	increased	O
2626	the	O
2626	cm	B-PK
2626	##ax	I-PK
2626	of	O
2626	p	O
2626	##imo	O
2626	##di	O
2626	##vir	O
2626	by	O
2626	31	O
2626	%	O
2626	(	O
2626	90	O
2626	%	O
2626	c	O
2626	##i	O
2626	:	O
2626	0	O
2626	.	O
2626	92	O
2626	-	O
2626	1	O
2626	.	O
2626	85	O
2626	)	O
2626	with	O
2626	no	O
2626	change	O
2626	in	O
2626	cm	B-PK
2626	##in	I-PK
2626	or	O
2626	au	B-PK
2626	##c	I-PK
2626	##12	I-PK
2626	##h	I-PK
2626	.	O
2626	[SEP]	O
2627	[CLS]	O
2627	co	O
2627	##ad	O
2627	##mini	O
2627	##stra	O
2627	##tion	O
2627	with	O
2627	er	O
2627	##yt	O
2627	##hr	O
2627	##omy	O
2627	##cin	O
2627	resulted	O
2627	in	O
2627	a	O
2627	1	O
2627	.	O
2627	6	O
2627	-	O
2627	fold	O
2627	increase	O
2627	in	O
2627	the	O
2627	cm	B-PK
2627	##ax	I-PK
2627	of	O
2627	m	O
2627	##osa	O
2627	##p	O
2627	##ride	O
2627	and	O
2627	pro	O
2627	##long	O
2627	##ation	O
2627	of	O
2627	t	B-PK
2627	(	I-PK
2627	1	I-PK
2627	/	I-PK
2627	2	I-PK
2627	)	I-PK
2627	from	O
2627	1	O
2627	.	O
2627	6	O
2627	to	O
2627	2	O
2627	.	O
2627	4	O
2627	hours	O
2627	,	O
2627	indicating	O
2627	the	O
2627	in	O
2627	##hibition	O
2627	of	O
2627	m	O
2627	##osa	O
2627	##p	O
2627	##ride	O
2627	metabolism	O
2627	.	O
2627	[SEP]	O
2628	[CLS]	O
2628	p	O
2628	##iva	O
2628	##mp	O
2628	##ici	O
2628	##llin	O
2628	was	O
2628	absorbed	O
2628	well	O
2628	in	O
2628	non	O
2628	-	O
2628	fast	O
2628	##ed	O
2628	horses	O
2628	with	O
2628	an	O
2628	oral	B-PK
2628	bio	I-PK
2628	##ava	I-PK
2628	##ila	I-PK
2628	##bility	I-PK
2628	of	O
2628	36	O
2628	%	O
2628	.	O
2628	[SEP]	O
2629	[CLS]	O
2629	the	O
2629	following	O
2629	mean	O
2629	values	O
2629	were	O
2629	obtained	O
2629	after	O
2629	intake	O
2629	of	O
2629	16	O
2629	mg	O
2629	lo	O
2629	##per	O
2629	##ami	O
2629	##de	O
2629	as	O
2629	film	O
2629	coated	O
2629	tablets	O
2629	:	O
2629	au	O
2629	##c	O
2629	##0	O
2629	in	O
2629	##finity	O
2629	62	O
2629	.	O
2629	04	O
2629	ng	O
2629	##h	O
2629	/	O
2629	m	O
2629	##l	O
2629	,	O
2629	cm	B-PK
2629	##ax	I-PK
2629	3	O
2629	.	O
2629	35	O
2629	ng	O
2629	/	O
2629	m	O
2629	##l	O
2629	,	O
2629	t	B-PK
2629	##max	I-PK
2629	4	O
2629	.	O
2629	08	O
2629	h	O
2629	,	O
2629	t	B-PK
2629	##1	I-PK
2629	/	I-PK
2629	2	I-PK
2629	19	O
2629	.	O
2629	66	O
2629	h	O
2629	and	O
2629	after	O
2629	administration	O
2629	of	O
2629	the	O
2629	capsule	O
2629	##s	O
2629	:	O
2629	au	B-PK
2629	##c	I-PK
2629	##0	I-PK
2629	in	I-PK
2629	##finity	I-PK
2629	66	O
2629	.	O
2629	56	O
2629	ng	O
2629	##h	O
2629	/	O
2629	m	O
2629	##l	O
2629	,	O
2629	cm	B-PK
2629	##ax	I-PK
2629	3	O
2629	.	O
2629	98	O
2629	ng	O
2629	/	O
2629	m	O
2629	##l	O
2629	,	O
2629	t	B-PK
2629	##max	I-PK
2629	4	O
2629	.	O
2629	38	O
2629	h	O
2629	,	O
2629	t	B-PK
2629	##1	I-PK
2629	/	I-PK
2629	2	I-PK
2629	18	O
2629	.	O
2629	43	O
2629	h	O
2629	.	O
2629	[SEP]	O
2630	[CLS]	O
2630	for	O
2630	the	O
2630	total	O
2630	group	O
2630	,	O
2630	l	O
2630	##p	O
2630	##v	O
2630	geometric	O
2630	mean	O
2630	au	B-PK
2630	##c	I-PK
2630	##0	I-PK
2630	-	I-PK
2630	12	I-PK
2630	,	O
2630	cm	B-PK
2630	##ax	I-PK
2630	and	O
2630	c	O
2630	##12	O
2630	were	O
2630	106	O
2630	.	O
2630	9	O
2630	h	O
2630	×	O
2630	mg	O
2630	/	O
2630	l	O
2630	,	O
2630	12	O
2630	.	O
2630	0	O
2630	mg	O
2630	/	O
2630	l	O
2630	and	O
2630	4	O
2630	.	O
2630	9	O
2630	mg	O
2630	/	O
2630	l	O
2630	,	O
2630	respectively	O
2630	.	O
2630	[SEP]	O
2631	[CLS]	O
2631	t	B-PK
2631	(	I-PK
2631	1	I-PK
2631	/	I-PK
2631	2	I-PK
2631	)	I-PK
2631	of	O
2631	br	O
2631	##ev	O
2631	##is	O
2631	##cap	O
2631	##ine	O
2631	lip	O
2631	##oso	O
2631	##mes	O
2631	and	O
2631	commercial	O
2631	injection	O
2631	were	O
2631	23	O
2631	.	O
2631	13	O
2631	+	O
2631	-	O
2631	7	O
2631	.	O
2631	71	O
2631	and	O
2631	6	O
2631	.	O
2631	27	O
2631	+	O
2631	-	O
2631	1	O
2631	.	O
2631	84	O
2631	##min	O
2631	,	O
2631	respectively	O
2631	.	O
2631	[SEP]	O
2632	[CLS]	O
2632	the	O
2632	terminal	B-PK
2632	elimination	I-PK
2632	half	I-PK
2632	-	I-PK
2632	life	I-PK
2632	(	I-PK
2632	t	I-PK
2632	(	I-PK
2632	1	I-PK
2632	/	I-PK
2632	2	I-PK
2632	)	I-PK
2632	)	I-PK
2632	of	O
2632	para	O
2632	##ce	O
2632	##tam	O
2632	##ol	O
2632	was	O
2632	1	O
2632	.	O
2632	6	O
2632	(	O
2632	c	O
2632	##i	O
2632	1	O
2632	.	O
2632	4	O
2632	-	O
2632	2	O
2632	.	O
2632	0	O
2632	)	O
2632	and	O
2632	1	O
2632	.	O
2632	9	O
2632	(	O
2632	c	O
2632	##i	O
2632	1	O
2632	.	O
2632	5	O
2632	-	O
2632	2	O
2632	.	O
2632	4	O
2632	)	O
2632	h	O
2632	##r	O
2632	for	O
2632	50	O
2632	and	O
2632	25	O
2632	g	O
2632	,	O
2632	respectively	O
2632	(	O
2632	n	O
2632	##s	O
2632	)	O
2632	,	O
2632	and	O
2632	2	O
2632	.	O
2632	5	O
2632	(	O
2632	c	O
2632	##i	O
2632	1	O
2632	.	O
2632	8	O
2632	-	O
2632	3	O
2632	.	O
2632	0	O
2632	)	O
2632	h	O
2632	##r	O
2632	for	O
2632	the	O
2632	5	O
2632	-	O
2632	g	O
2632	dose	O
2632	(	O
2632	p	O
2632	=	O
2632	0	O
2632	.	O
2632	00	O
2632	##3	O
2632	)	O
2632	.	O
2632	[SEP]	O
2633	[CLS]	O
2633	cocaine	O
2633	was	O
2633	rapidly	O
2633	distributed	O
2633	(	O
2633	t	B-PK
2633	##1	I-PK
2633	/	I-PK
2633	2	I-PK
2633	##bet	I-PK
2633	##a	I-PK
2633	=	O
2633	1	O
2633	.	O
2633	09	O
2633	min	O
2633	)	O
2633	and	O
2633	eliminated	O
2633	(	O
2633	t	B-PK
2633	##1	I-PK
2633	/	I-PK
2633	2	I-PK
2633	##al	I-PK
2633	##pha	I-PK
2633	=	O
2633	14	O
2633	.	O
2633	93	O
2633	min	O
2633	)	O
2633	.	O
2633	[SEP]	O
2634	[CLS]	O
2634	in	O
2634	v	O
2634	##ivo	O
2634	oral	B-PK
2634	bio	I-PK
2634	##ava	I-PK
2634	##ila	I-PK
2634	##bility	I-PK
2634	studies	O
2634	of	O
2634	op	O
2634	##ti	O
2634	##mized	O
2634	cc	O
2634	na	O
2634	##no	O
2634	##c	O
2634	##ry	O
2634	##stal	O
2634	##s	O
2634	in	O
2634	m	O
2634	##uri	O
2634	##ne	O
2634	model	O
2634	revealed	O
2634	3	O
2634	.	O
2634	8	O
2634	-	O
2634	fold	O
2634	increase	O
2634	in	O
2634	the	O
2634	oral	B-PK
2634	bio	I-PK
2634	##ava	I-PK
2634	##ila	I-PK
2634	##bility	I-PK
2634	and	O
2634	twice	O
2634	the	O
2634	c	B-PK
2634	ma	I-PK
2634	##x	I-PK
2634	as	O
2634	compared	O
2634	with	O
2634	the	O
2634	free	O
2634	cc	O
2634	when	O
2634	administered	O
2634	oral	O
2634	##ly	O
2634	.	O
2634	[SEP]	O
2635	[CLS]	O
2635	biological	O
2635	studies	O
2635	carried	O
2635	out	O
2635	in	O
2635	normal	O
2635	w	O
2635	##ista	O
2635	##r	O
2635	rats	O
2635	exhibited	O
2635	no	O
2635	significant	O
2635	accumulation	O
2635	of	O
2635	activity	O
2635	in	O
2635	any	O
2635	of	O
2635	the	O
2635	vital	O
2635	organs	O
2635	/	O
2635	tissue	O
2635	except	O
2635	in	O
2635	kidney	O
2635	##s	O
2635	and	O
2635	non	O
2635	-	O
2635	accumulated	O
2635	activity	O
2635	showed	O
2635	major	O
2635	re	B-PK
2635	##nal	I-PK
2635	clearance	I-PK
2635	.	O
2635	[SEP]	O
2636	[CLS]	O
2636	the	O
2636	objective	O
2636	was	O
2636	to	O
2636	improve	O
2636	the	O
2636	o	O
2636	##cular	O
2636	residence	O
2636	time	O
2636	of	O
2636	ha	O
2636	,	O
2636	by	O
2636	providing	O
2636	sustained	O
2636	o	O
2636	##cular	O
2636	ha	O
2636	delivery	O
2636	through	O
2636	imp	O
2636	##lant	O
2636	contact	O
2636	lenses	O
2636	for	O
2636	the	O
2636	treatment	O
2636	of	O
2636	dry	O
2636	eye	O
2636	syndrome	O
2636	.	O
2636	[SEP]	O
2637	[CLS]	O
2637	these	O
2637	values	O
2637	are	O
2637	considerably	O
2637	lower	O
2637	than	O
2637	the	O
2637	half	B-PK
2637	-	I-PK
2637	lives	I-PK
2637	previously	O
2637	published	O
2637	for	O
2637	dogs	O
2637	(	O
2637	133	O
2637	h	O
2637	)	O
2637	and	O
2637	cats	O
2637	(	O
2637	166	O
2637	h	O
2637	)	O
2637	.	O
2637	[SEP]	O
2638	[CLS]	O
2638	the	O
2638	results	O
2638	indicated	O
2638	that	O
2638	the	O
2638	reason	O
2638	which	O
2638	delay	O
2638	the	O
2638	elimination	O
2638	of	O
2638	p	O
2638	##ae	O
2638	##oni	O
2638	##f	O
2638	##lor	O
2638	##in	O
2638	and	O
2638	enhance	O
2638	its	O
2638	bio	B-PK
2638	##ava	I-PK
2638	##ila	I-PK
2638	##bility	I-PK
2638	might	O
2638	be	O
2638	some	O
2638	ingredients	O
2638	in	O
2638	cortex	O
2638	m	O
2638	##out	O
2638	##an	O
2638	extract	O
2638	.	O
2638	[SEP]	O
2639	[CLS]	O
2639	k	O
2639	##eto	O
2639	##cona	O
2639	##zo	O
2639	##le	O
2639	in	O
2639	##hibit	O
2639	##s	O
2639	the	O
2639	clearance	B-PK
2639	of	O
2639	met	O
2639	##hyl	O
2639	##p	O
2639	##red	O
2639	##nis	O
2639	##olo	O
2639	##ne	O
2639	by	O
2639	60	O
2639	percent	O
2639	and	O
2639	extends	O
2639	co	O
2639	##rt	O
2639	##is	O
2639	##ol	O
2639	suppression	O
2639	beyond	O
2639	that	O
2639	produced	O
2639	by	O
2639	met	O
2639	##hyl	O
2639	##p	O
2639	##red	O
2639	##nis	O
2639	##olo	O
2639	##ne	O
2639	alone	O
2639	.	O
2639	[SEP]	O
2640	[CLS]	O
2640	the	O
2640	mean	O
2640	(	O
2640	c	O
2640	##v	O
2640	)	O
2640	half	B-PK
2640	-	I-PK
2640	life	I-PK
2640	at	I-PK
2640	alpha	I-PK
2640	phase	I-PK
2640	(	I-PK
2640	t	I-PK
2640	##1	I-PK
2640	/	I-PK
2640	2	I-PK
2640	##α	I-PK
2640	)	I-PK
2640	,	O
2640	t	B-PK
2640	##1	I-PK
2640	/	I-PK
2640	2	I-PK
2640	##β	I-PK
2640	,	O
2640	and	O
2640	t	B-PK
2640	##1	I-PK
2640	/	I-PK
2640	2	I-PK
2640	##γ	I-PK
2640	were	O
2640	2	O
2640	.	O
2640	29	O
2640	(	O
2640	49	O
2640	.	O
2640	8	O
2640	%	O
2640	)	O
2640	,	O
2640	13	O
2640	.	O
2640	4	O
2640	(	O
2640	10	O
2640	.	O
2640	5	O
2640	%	O
2640	)	O
2640	,	O
2640	and	O
2640	245	O
2640	(	O
2640	14	O
2640	.	O
2640	9	O
2640	%	O
2640	)	O
2640	hours	O
2640	,	O
2640	respectively	O
2640	.	O
2640	[SEP]	O
2641	[CLS]	O
2641	mean	O
2641	disposition	B-PK
2641	half	I-PK
2641	-	I-PK
2641	lives	I-PK
2641	across	O
2641	treatments	O
2641	were	O
2641	1	O
2641	.	O
2641	2	O
2641	-	O
2641	1	O
2641	.	O
2641	4	O
2641	h	O
2641	for	O
2641	t	B-PK
2641	##1	I-PK
2641	/	I-PK
2641	2	I-PK
2641	alpha	I-PK
2641	and	O
2641	10	O
2641	.	O
2641	7	O
2641	-	O
2641	13	O
2641	.	O
2641	8	O
2641	h	O
2641	for	O
2641	the	O
2641	t	B-PK
2641	##1	I-PK
2641	/	I-PK
2641	2	I-PK
2641	beta	I-PK
2641	.	O
2641	[SEP]	O
2642	[CLS]	O
2642	mon	O
2642	##te	O
2642	car	O
2642	##lo	O
2642	simulation	O
2642	##s	O
2642	were	O
2642	performed	O
2642	to	O
2642	compare	O
2642	the	O
2642	maximum	B-PK
2642	concentrations	I-PK
2642	(	I-PK
2642	cm	I-PK
2642	##ax	I-PK
2642	)	I-PK
2642	,	O
2642	minimum	B-PK
2642	concentrations	I-PK
2642	(	I-PK
2642	cm	I-PK
2642	##in	I-PK
2642	)	I-PK
2642	,	O
2642	and	O
2642	area	B-PK
2642	under	I-PK
2642	the	I-PK
2642	curve	I-PK
2642	(	I-PK
2642	au	I-PK
2642	##c	I-PK
2642	)	I-PK
2642	with	O
2642	the	O
2642	standard	O
2642	da	O
2642	##pt	O
2642	##omy	O
2642	##cin	O
2642	6	O
2642	mg	O
2642	/	O
2642	kg	O
2642	/	O
2642	day	O
2642	dose	O
2642	or	O
2642	a	O
2642	500	O
2642	-	O
2642	mg	O
2642	daily	O
2642	fixed	O
2642	dose	O
2642	in	O
2642	o	O
2642	##bes	O
2642	##e	O
2642	and	O
2642	non	O
2642	##obe	O
2642	##se	O
2642	subjects	O
2642	.	O
2642	[SEP]	O
2643	[CLS]	O
2643	values	O
2643	of	O
2643	absorption	B-PK
2643	half	I-PK
2643	-	I-PK
2643	life	I-PK
2643	averaged	O
2643	25	O
2643	min	O
2643	(	O
2643	range	O
2643	10	O
2643	.	O
2643	3	O
2643	-	O
2643	42	O
2643	.	O
2643	7	O
2643	min	O
2643	)	O
2643	,	O
2643	and	O
2643	elimination	B-PK
2643	half	I-PK
2643	-	I-PK
2643	life	I-PK
2643	(	I-PK
2643	t	I-PK
2643	##1	I-PK
2643	/	I-PK
2643	2	I-PK
2643	beta	I-PK
2643	)	I-PK
2643	averaged	O
2643	14	O
2643	.	O
2643	2	O
2643	h	O
2643	##r	O
2643	(	O
2643	range	O
2643	8	O
2643	.	O
2643	4	O
2643	-	O
2643	23	O
2643	.	O
2643	9	O
2643	h	O
2643	##r	O
2643	)	O
2643	.	O
2643	[SEP]	O
2644	[CLS]	O
2644	following	O
2644	oral	O
2644	administration	O
2644	to	O
2644	man	O
2644	,	O
2644	absorption	O
2644	was	O
2644	rapid	O
2644	with	O
2644	a	O
2644	mean	O
2644	value	O
2644	for	O
2644	t	B-PK
2644	##max	I-PK
2644	of	O
2644	1	O
2644	h	O
2644	,	O
2644	and	O
2644	cm	B-PK
2644	##ax	I-PK
2644	'	I-PK
2644	s	I-PK
2644	ranging	O
2644	non	O
2644	-	O
2644	linear	O
2644	##ly	O
2644	from	O
2644	90	O
2644	to	O
2644	210	O
2644	##0	O
2644	ng	O
2644	/	O
2644	m	O
2644	##l	O
2644	following	O
2644	dos	O
2644	##ing	O
2644	at	O
2644	12	O
2644	.	O
2644	5	O
2644	to	O
2644	150	O
2644	mg	O
2644	respectively	O
2644	.	O
2644	[SEP]	O
2645	[CLS]	O
2645	the	O
2645	t	B-PK
2645	(	I-PK
2645	1	I-PK
2645	/	I-PK
2645	2	I-PK
2645	)	I-PK
2645	,	O
2645	t	B-PK
2645	##max	I-PK
2645	,	O
2645	cm	B-PK
2645	##ax	I-PK
2645	,	O
2645	m	B-PK
2645	##rt	I-PK
2645	,	O
2645	au	B-PK
2645	##c	I-PK
2645	(	I-PK
2645	0	I-PK
2645	-	I-PK
2645	-	I-PK
2645	>	I-PK
2645	24	I-PK
2645	h	I-PK
2645	)	I-PK
2645	of	O
2645	o	O
2645	##xy	O
2645	##mat	O
2645	##rine	O
2645	were	O
2645	(	O
2645	5	O
2645	.	O
2645	5	O
2645	+	O
2645	-	O
2645	1	O
2645	.	O
2645	58	O
2645	)	O
2645	h	O
2645	,	O
2645	(	O
2645	1	O
2645	.	O
2645	0	O
2645	+	O
2645	-	O
2645	0	O
2645	.	O
2645	30	O
2645	)	O
2645	h	O
2645	,	O
2645	(	O
2645	241	O
2645	##8	O
2645	.	O
2645	3	O
2645	+	O
2645	-	O
2645	97	O
2645	##0	O
2645	.	O
2645	78	O
2645	)	O
2645	ng	O
2645	x	O
2645	m	O
2645	##l	O
2645	(	O
2645	-	O
2645	1	O
2645	)	O
2645	,	O
2645	(	O
2645	3	O
2645	.	O
2645	2	O
2645	+	O
2645	-	O
2645	0	O
2645	.	O
2645	64	O
2645	)	O
2645	h	O
2645	,	O
2645	(	O
2645	57	O
2645	##9	O
2645	##7	O
2645	.	O
2645	4	O
2645	+	O
2645	-	O
2645	90	O
2645	##8	O
2645	.	O
2645	16	O
2645	)	O
2645	ng	O
2645	x	O
2645	m	O
2645	##l	O
2645	(	O
2645	-	O
2645	1	O
2645	)	O
2645	x	O
2645	h	O
2645	accordingly	O
2645	.	O
2645	[SEP]	O
2646	[CLS]	O
2646	time	B-PK
2646	to	I-PK
2646	peak	I-PK
2646	plasma	I-PK
2646	concentration	I-PK
2646	(	I-PK
2646	t	I-PK
2646	##max	I-PK
2646	)	I-PK
2646	and	O
2646	area	B-PK
2646	under	I-PK
2646	curve	I-PK
2646	(	I-PK
2646	au	I-PK
2646	##c	I-PK
2646	)	I-PK
2646	averaged	O
2646	0	O
2646	.	O
2646	7	O
2646	+	O
2646	-	O
2646	0	O
2646	.	O
2646	2	O
2646	h	O
2646	and	O
2646	305	O
2646	+	O
2646	-	O
2646	115	O
2646	mg	O
2646	.	O
2646	h	O
2646	/	O
2646	l	O
2646	,	O
2646	respectively	O
2646	.	O
2646	[SEP]	O
2647	[CLS]	O
2647	elimination	B-PK
2647	half	I-PK
2647	-	I-PK
2647	life	I-PK
2647	was	O
2647	prolonged	O
2647	but	O
2647	the	O
2647	difference	O
2647	did	O
2647	not	O
2647	reach	O
2647	statistical	O
2647	significance	O
2647	due	O
2647	to	O
2647	the	O
2647	wide	O
2647	variation	O
2647	of	O
2647	the	O
2647	values	O
2647	in	O
2647	the	O
2647	elderly	O
2647	.	O
2647	[SEP]	O
2648	[CLS]	O
2648	final	O
2648	parameter	O
2648	estimates	O
2648	were	O
2648	as	O
2648	follow	O
2648	c	B-PK
2648	##l	I-PK
2648	,	O
2648	5	O
2648	.	O
2648	77	O
2648	liter	O
2648	##s	O
2648	/	O
2648	h	O
2648	/	O
2648	70	O
2648	kg	O
2648	;	O
2648	central	B-PK
2648	volume	I-PK
2648	of	I-PK
2648	distribution	I-PK
2648	,	O
2648	21	O
2648	.	O
2648	6	O
2648	liter	O
2648	##s	O
2648	/	O
2648	70	O
2648	kg	O
2648	;	O
2648	peripheral	B-PK
2648	volume	I-PK
2648	of	I-PK
2648	distribution	I-PK
2648	,	O
2648	13	O
2648	.	O
2648	8	O
2648	liter	O
2648	##s	O
2648	/	O
2648	70	O
2648	kg	O
2648	;	O
2648	and	O
2648	inter	B-PK
2648	##com	I-PK
2648	##par	I-PK
2648	##tment	I-PK
2648	##al	I-PK
2648	clearance	I-PK
2648	,	O
2648	0	O
2648	.	O
2648	62	O
2648	liter	O
2648	/	O
2648	h	O
2648	/	O
2648	70	O
2648	kg	O
2648	.	O
2648	[SEP]	O
2649	[CLS]	O
2649	it	O
2649	exhibits	O
2649	greater	O
2649	efficacy	O
2649	but	O
2649	requires	O
2649	higher	O
2649	dose	O
2649	than	O
2649	other	O
2649	ɑ	O
2649	##1	O
2649	-	O
2649	ad	O
2649	##ren	O
2649	##oc	O
2649	##ept	O
2649	##or	O
2649	block	O
2649	##ers	O
2649	because	O
2649	of	O
2649	its	O
2649	poor	O
2649	bio	B-PK
2649	##ava	I-PK
2649	##ila	I-PK
2649	##bility	I-PK
2649	.	O
2649	[SEP]	O
2650	[CLS]	O
2650	co	O
2650	-	O
2650	administration	O
2650	of	O
2650	can	O
2650	##des	O
2650	##art	O
2650	##an	O
2650	c	O
2650	##ile	O
2650	##xe	O
2650	##til	O
2650	with	O
2650	h	O
2650	##ct	O
2650	##z	O
2650	produced	O
2650	a	O
2650	statistical	O
2650	##ly	O
2650	significant	O
2650	increase	O
2650	in	O
2650	the	O
2650	bio	B-PK
2650	##ava	I-PK
2650	##ila	I-PK
2650	##bility	I-PK
2650	and	O
2650	cm	B-PK
2650	##ax	I-PK
2650	values	O
2650	for	O
2650	can	O
2650	##des	O
2650	##art	O
2650	##an	O
2650	(	O
2650	18	O
2650	%	O
2650	and	O
2650	25	O
2650	%	O
2650	,	O
2650	respectively	O
2650	)	O
2650	.	O
2650	[SEP]	O
2651	[CLS]	O
2651	longer	O
2651	sampling	O
2651	also	O
2651	improved	O
2651	p	O
2651	##k	O
2651	accuracy	O
2651	for	O
2651	o	O
2651	##bes	O
2651	##e	O
2651	women	O
2651	(	O
2651	excess	O
2651	au	B-PK
2651	##c	I-PK
2651	20	O
2651	%	O
2651	)	O
2651	as	O
2651	compared	O
2651	to	O
2651	both	O
2651	normal	O
2651	and	O
2651	o	O
2651	##bes	O
2651	##e	O
2651	controls	O
2651	undergoing	O
2651	shorter	O
2651	sampling	O
2651	times	O
2651	(	O
2651	48	O
2651	h	O
2651	)	O
2651	with	O
2651	excess	O
2651	au	B-PK
2651	##cs	I-PK
2651	of	O
2651	25	O
2651	%	O
2651	and	O
2651	50	O
2651	%	O
2651	,	O
2651	respectively	O
2651	.	O
2651	[SEP]	O
2652	[CLS]	O
2652	to	O
2652	investigate	O
2652	three	O
2652	different	O
2652	modelling	O
2652	strategies	O
2652	in	O
2652	co	O
2652	##var	O
2652	##iate	O
2652	model	O
2652	building	O
2652	using	O
2652	do	O
2652	##fe	O
2652	##til	O
2652	##ide	O
2652	as	O
2652	an	O
2652	example	O
2652	:	O
2652	(	O
2652	1	O
2652	)	O
2652	using	O
2652	statistical	O
2652	criteria	O
2652	only	O
2652	or	O
2652	in	O
2652	combination	O
2652	with	O
2652	clinical	O
2652	i	O
2652	##rrel	O
2652	##eva	O
2652	##nce	O
2652	criteria	O
2652	for	O
2652	co	O
2652	##var	O
2652	##iate	O
2652	selection	O
2652	,	O
2652	(	O
2652	2	O
2652	)	O
2652	applying	O
2652	co	O
2652	##var	O
2652	##iate	O
2652	effects	O
2652	on	O
2652	total	B-PK
2652	clearance	I-PK
2652	or	O
2652	separately	O
2652	on	O
2652	non	B-PK
2652	-	I-PK
2652	re	I-PK
2652	##nal	I-PK
2652	and	I-PK
2652	re	I-PK
2652	##nal	I-PK
2652	clearance	I-PK
2652	##s	I-PK
2652	and	O
2652	(	O
2652	3	O
2652	)	O
2652	using	O
2652	separate	O
2652	data	O
2652	sets	O
2652	for	O
2652	co	O
2652	##var	O
2652	##iate	O
2652	selection	O
2652	and	O
2652	parameter	O
2652	est	O
2652	##imation	O
2652	.	O
2652	[SEP]	O
2653	[CLS]	O
2653	for	O
2653	sa	O
2653	##b	O
2653	,	O
2653	the	O
2653	p	O
2653	##har	O
2653	##ma	O
2653	##co	O
2653	##kin	O
2653	##etics	O
2653	parameters	O
2653	t	B-PK
2653	##max	I-PK
2653	,	O
2653	cm	B-PK
2653	##ax	I-PK
2653	,	O
2653	au	B-PK
2653	##c	I-PK
2653	##0	I-PK
2653	-	I-PK
2653	t	I-PK
2653	,	O
2653	m	B-PK
2653	##rt	I-PK
2653	##last	I-PK
2653	in	O
2653	the	O
2653	plasma	O
2653	were	O
2653	(	O
2653	1	O
2653	.	O
2653	08	O
2653	##±	O
2653	##0	O
2653	.	O
2653	20	O
2653	)	O
2653	h	O
2653	,	O
2653	(	O
2653	21	O
2653	.	O
2653	09	O
2653	##±	O
2653	##4	O
2653	.	O
2653	850	O
2653	)	O
2653	ng	O
2653	•	O
2653	g	O
2653	##⁻	O
2653	##¹	O
2653	,	O
2653	(	O
2653	14	O
2653	.	O
2653	83	O
2653	##±	O
2653	##3	O
2653	.	O
2653	160	O
2653	)	O
2653	ng	O
2653	•	O
2653	h	O
2653	•	O
2653	g	O
2653	##⁻	O
2653	##¹	O
2653	and	O
2653	(	O
2653	0	O
2653	.	O
2653	99	O
2653	##±	O
2653	##0	O
2653	.	O
2653	08	O
2653	)	O
2653	h	O
2653	,	O
2653	respectively	O
2653	.	O
2653	[SEP]	O
2654	[CLS]	O
2654	following	O
2654	in	O
2654	##tra	O
2654	##gas	O
2654	##tric	O
2654	administration	O
2654	,	O
2654	le	O
2654	##vet	O
2654	##ira	O
2654	##ce	O
2654	##tam	O
2654	had	O
2654	a	O
2654	peak	B-PK
2654	concentration	I-PK
2654	of	O
2654	38	O
2654	.	O
2654	34	O
2654	±	O
2654	7	O
2654	.	O
2654	42	O
2654	mg	O
2654	/	O
2654	l	O
2654	and	O
2654	time	B-PK
2654	to	I-PK
2654	achieve	I-PK
2654	peak	I-PK
2654	concentration	I-PK
2654	was	O
2654	0	O
2654	.	O
2654	87	O
2654	##5	O
2654	(	O
2654	0	O
2654	.	O
2654	5	O
2654	-	O
2654	1	O
2654	.	O
2654	5	O
2654	)	O
2654	h	O
2654	.	O
2654	mean	O
2654	bio	B-PK
2654	##ava	I-PK
2654	##ila	I-PK
2654	##bility	I-PK
2654	for	O
2654	i	O
2654	##g	O
2654	administration	O
2654	was	O
2654	excellent	O
2654	(	O
2654	103	O
2654	.	O
2654	04	O
2654	±	O
2654	14	O
2654	.	O
2654	51	O
2654	%	O
2654	)	O
2654	.	O
2654	[SEP]	O
2655	[CLS]	O
2655	both	O
2655	peak	B-PK
2655	concentrations	I-PK
2655	and	O
2655	area	B-PK
2655	under	I-PK
2655	the	I-PK
2655	curve	I-PK
2655	increased	O
2655	linear	O
2655	##ly	O
2655	with	O
2655	an	O
2655	increase	O
2655	in	O
2655	dose	O
2655	,	O
2655	whereas	O
2655	time	B-PK
2655	to	I-PK
2655	reach	I-PK
2655	peak	I-PK
2655	serum	I-PK
2655	concentrations	I-PK
2655	did	O
2655	not	O
2655	vary	O
2655	significantly	O
2655	between	O
2655	doses	O
2655	.	O
2655	[SEP]	O
2656	[CLS]	O
2656	typical	O
2656	values	O
2656	for	O
2656	the	O
2656	absorption	B-PK
2656	rate	I-PK
2656	constant	I-PK
2656	(	I-PK
2656	k	I-PK
2656	(	I-PK
2656	a	I-PK
2656	)	I-PK
2656	)	I-PK
2656	,	O
2656	elimination	B-PK
2656	rate	I-PK
2656	constant	I-PK
2656	(	I-PK
2656	k	I-PK
2656	(	I-PK
2656	el	I-PK
2656	)	I-PK
2656	)	I-PK
2656	,	O
2656	apparent	B-PK
2656	volume	I-PK
2656	of	I-PK
2656	distribution	I-PK
2656	for	I-PK
2656	the	I-PK
2656	central	I-PK
2656	compartment	I-PK
2656	(	I-PK
2656	v	I-PK
2656	##d	I-PK
2656	/	I-PK
2656	f	I-PK
2656	)	I-PK
2656	,	O
2656	and	O
2656	oral	B-PK
2656	clearance	I-PK
2656	(	I-PK
2656	c	I-PK
2656	##l	I-PK
2656	/	I-PK
2656	f	I-PK
2656	)	I-PK
2656	calculated	O
2656	by	O
2656	population	O
2656	p	O
2656	##har	O
2656	##ma	O
2656	##co	O
2656	##kin	O
2656	##etic	O
2656	analysis	O
2656	were	O
2656	2	O
2656	.	O
2656	16	O
2656	hours	O
2656	(	O
2656	-	O
2656	1	O
2656	)	O
2656	,	O
2656	0	O
2656	.	O
2656	54	O
2656	##7	O
2656	hours	O
2656	(	O
2656	-	O
2656	1	O
2656	)	O
2656	,	O
2656	43	O
2656	.	O
2656	3	O
2656	l	O
2656	,	O
2656	and	O
2656	23	O
2656	.	O
2656	7	O
2656	l	O
2656	/	O
2656	h	O
2656	,	O
2656	respectively	O
2656	.	O
2656	[SEP]	O
2657	[CLS]	O
2657	in	O
2657	##dom	O
2657	##eth	O
2657	##ac	O
2657	##in	O
2657	,	O
2657	however	O
2657	,	O
2657	was	O
2657	shown	O
2657	to	O
2657	have	O
2657	a	O
2657	higher	O
2657	up	B-PK
2657	##take	I-PK
2657	clearance	I-PK
2657	(	O
2657	59	O
2657	##9	O
2657	+	O
2657	-	O
2657	101	O
2657	micro	O
2657	##l	O
2657	/	O
2657	min	O
2657	/	O
2657	10	O
2657	(	O
2657	6	O
2657	)	O
2657	cells	O
2657	)	O
2657	than	O
2657	at	O
2657	##or	O
2657	##vas	O
2657	##tat	O
2657	##in	O
2657	(	O
2657	375	O
2657	+	O
2657	-	O
2657	45	O
2657	micro	O
2657	##l	O
2657	/	O
2657	min	O
2657	/	O
2657	10	O
2657	(	O
2657	6	O
2657	)	O
2657	cells	O
2657	)	O
2657	and	O
2657	c	O
2657	##eri	O
2657	##vas	O
2657	##tat	O
2657	##in	O
2657	(	O
2657	41	O
2657	##3	O
2657	+	O
2657	-	O
2657	47	O
2657	micro	O
2657	##l	O
2657	/	O
2657	min	O
2657	/	O
2657	10	O
2657	(	O
2657	6	O
2657	)	O
2657	cells	O
2657	)	O
2657	.	O
2657	[SEP]	O
2658	[CLS]	O
2658	cm	B-PK
2658	##ax	I-PK
2658	was	O
2658	improved	O
2658	by	O
2658	1	O
2658	.	O
2658	26	O
2658	fold	O
2658	and	O
2658	t	B-PK
2658	##max	I-PK
2658	was	O
2658	decreased	O
2658	by	O
2658	2	O
2658	##h	O
2658	after	O
2658	comparing	O
2658	with	O
2658	control	O
2658	indicating	O
2658	improved	O
2658	absorption	O
2658	.	O
2658	[SEP]	O
2659	[CLS]	O
2659	in	O
2659	conclusion	O
2659	,	O
2659	re	O
2659	##s	O
2659	##ver	O
2659	##at	O
2659	##rol	O
2659	significantly	O
2659	increased	O
2659	the	O
2659	bio	B-PK
2659	##ava	I-PK
2659	##ila	I-PK
2659	##bility	I-PK
2659	of	O
2659	di	O
2659	##lt	O
2659	##ia	O
2659	##ze	O
2659	##m	O
2659	due	O
2659	to	O
2659	the	O
2659	in	O
2659	##hibition	O
2659	of	O
2659	both	O
2659	the	O
2659	c	O
2659	##yt	O
2659	##och	O
2659	##rome	O
2659	p	O
2659	##45	O
2659	##0	O
2659	(	O
2659	c	O
2659	##y	O
2659	##p	O
2659	)	O
2659	3	O
2659	##a	O
2659	##4	O
2659	-	O
2659	mediated	O
2659	metabolism	O
2659	and	O
2659	the	O
2659	e	O
2659	##ff	O
2659	##lux	O
2659	pump	O
2659	p	O
2659	-	O
2659	g	O
2659	##ly	O
2659	##co	O
2659	##p	O
2659	##rote	O
2659	##in	O
2659	(	O
2659	p	O
2659	-	O
2659	g	O
2659	##p	O
2659	)	O
2659	in	O
2659	the	O
2659	in	O
2659	##test	O
2659	##ine	O
2659	and	O
2659	/	O
2659	or	O
2659	liver	O
2659	.	O
2659	[SEP]	O
2660	[CLS]	O
2660	the	O
2660	bio	B-PK
2660	##ava	I-PK
2660	##ila	I-PK
2660	##bility	I-PK
2660	of	O
2660	v	O
2660	##al	O
2660	##p	O
2660	##roa	O
2660	##te	O
2660	from	O
2660	s	O
2660	##h	O
2660	##d	O
2660	enter	O
2660	##ic	O
2660	-	O
2660	coated	O
2660	tablets	O
2660	(	O
2660	e	O
2660	##pi	O
2660	##val	O
2660	,	O
2660	abbot	O
2660	##t	O
2660	-	O
2660	50	O
2660	##7	O
2660	##11	O
2660	)	O
2660	and	O
2660	from	O
2660	sodium	O
2660	v	O
2660	##al	O
2660	##p	O
2660	##roa	O
2660	##te	O
2660	enter	O
2660	##ic	O
2660	-	O
2660	coated	O
2660	tablets	O
2660	(	O
2660	er	O
2660	##geny	O
2660	##l	O
2660	)	O
2660	was	O
2660	compared	O
2660	in	O
2660	a	O
2660	single	O
2660	-	O
2660	dose	O
2660	,	O
2660	double	O
2660	-	O
2660	blind	O
2660	,	O
2660	crossover	O
2660	study	O
2660	.	O
2660	[SEP]	O
2661	[CLS]	O
2661	in	O
2661	particular	O
2661	,	O
2661	re	B-PK
2661	##nal	I-PK
2661	clearance	I-PK
2661	was	O
2661	not	O
2661	significantly	O
2661	different	O
2661	(	O
2661	48	O
2661	##8	O
2661	+	O
2661	-	O
2661	95	O
2661	m	O
2661	##l	O
2661	/	O
2661	min	O
2661	without	O
2661	probe	O
2661	##ne	O
2661	##cid	O
2661	vs	O
2661	.	O
2661	47	O
2661	##8	O
2661	+	O
2661	-	O
2661	69	O
2661	m	O
2661	##l	O
2661	/	O
2661	min	O
2661	in	O
2661	the	O
2661	presence	O
2661	of	O
2661	probe	O
2661	##ne	O
2661	##cid	O
2661	)	O
2661	.	O
2661	[SEP]	O
2662	[CLS]	O
2662	patients	O
2662	with	O
2662	advanced	O
2662	h	O
2662	##cc	O
2662	had	O
2662	lower	O
2662	initial	O
2662	serum	O
2662	concentration	O
2662	,	O
2662	larger	O
2662	volume	B-PK
2662	of	I-PK
2662	distribution	I-PK
2662	and	O
2662	more	O
2662	rapid	O
2662	clearance	B-PK
2662	than	O
2662	patients	O
2662	with	O
2662	other	O
2662	ma	O
2662	##li	O
2662	##gna	O
2662	##ncies	O
2662	and	O
2662	normal	O
2662	liver	O
2662	function	O
2662	.	O
2662	[SEP]	O
2663	[CLS]	O
2663	in	O
2663	cats	O
2663	with	O
2663	liver	O
2663	failure	O
2663	,	O
2663	plasma	B-PK
2663	clearance	I-PK
2663	was	O
2663	significantly	O
2663	less	O
2663	and	O
2663	mean	B-PK
2663	residence	I-PK
2663	time	I-PK
2663	greater	O
2663	than	O
2663	in	O
2663	control	O
2663	cats	O
2663	(	O
2663	2	O
2663	.	O
2663	8	O
2663	+	O
2663	-	O
2663	0	O
2663	.	O
2663	6	O
2663	vs	O
2663	.	O
2663	14	O
2663	.	O
2663	1	O
2663	+	O
2663	-	O
2663	6	O
2663	.	O
2663	5	O
2663	m	O
2663	##l	O
2663	.	O
2663	kg	O
2663	-	O
2663	1	O
2663	.	O
2663	min	O
2663	-	O
2663	1	O
2663	and	O
2663	33	O
2663	##4	O
2663	+	O
2663	-	O
2663	225	O
2663	vs	O
2663	.	O
2663	49	O
2663	+	O
2663	-	O
2663	29	O
2663	min	O
2663	,	O
2663	mean	O
2663	+	O
2663	-	O
2663	s	O
2663	##d	O
2663	,	O
2663	respectively	O
2663	)	O
2663	.	O
2663	[SEP]	O
2664	[CLS]	O
2664	dig	O
2664	##ox	O
2664	##in	O
2664	solution	O
2664	was	O
2664	s	O
2664	##p	O
2664	##rinkled	O
2664	directly	O
2664	over	O
2664	the	O
2664	surface	O
2664	of	O
2664	the	O
2664	duo	O
2664	##den	O
2664	##um	O
2664	using	O
2664	an	O
2664	end	O
2664	##os	O
2664	##cope	O
2664	,	O
2664	and	O
2664	its	O
2664	absorption	B-PK
2664	rate	I-PK
2664	was	O
2664	evaluated	O
2664	by	O
2664	serial	O
2664	monitoring	O
2664	of	O
2664	the	O
2664	serum	O
2664	concentration	O
2664	and	O
2664	by	O
2664	analysis	O
2664	of	O
2664	its	O
2664	initial	O
2664	15	O
2664	-	O
2664	min	O
2664	increasing	O
2664	phase	O
2664	.	O
2664	[SEP]	O
2665	[CLS]	O
2665	au	B-PK
2665	##cs	I-PK
2665	(	I-PK
2665	area	I-PK
2665	under	I-PK
2665	the	I-PK
2665	drug	I-PK
2665	concentration	I-PK
2665	-	I-PK
2665	time	I-PK
2665	curve	I-PK
2665	)	I-PK
2665	were	O
2665	34	O
2665	##6	O
2665	to	O
2665	89	O
2665	##6	O
2665	micro	O
2665	##gram	O
2665	##s	O
2665	.	O
2665	min	O
2665	/	O
2665	m	O
2665	##l	O
2665	and	O
2665	they	O
2665	were	O
2665	the	O
2665	equivalent	O
2665	of	O
2665	in	O
2665	v	O
2665	##it	O
2665	##ro	O
2665	cell	O
2665	kills	O
2665	in	O
2665	excess	O
2665	of	O
2665	3	O
2665	logs	O
2665	for	O
2665	rat	O
2665	9	O
2665	##l	O
2665	g	O
2665	##lio	O
2665	##sar	O
2665	##com	O
2665	##a	O
2665	and	O
2665	human	O
2665	g	O
2665	##lio	O
2665	##ma	O
2665	126	O
2665	cells	O
2665	.	O
2665	[SEP]	O
2666	[CLS]	O
2666	ben	O
2666	##az	O
2666	##ep	O
2666	##ril	O
2666	##at	O
2666	concentrations	O
2666	accumulated	O
2666	moderately	O
2666	with	O
2666	repeated	O
2666	administration	O
2666	,	O
2666	with	O
2666	a	O
2666	peak	B-PK
2666	concentration	I-PK
2666	that	O
2666	was	O
2666	23	O
2666	%	O
2666	higher	O
2666	and	O
2666	an	O
2666	area	B-PK
2666	under	I-PK
2666	the	I-PK
2666	concentration	I-PK
2666	-	I-PK
2666	time	I-PK
2666	curve	I-PK
2666	that	O
2666	was	O
2666	34	O
2666	%	O
2666	higher	O
2666	after	O
2666	the	O
2666	15th	O
2666	dose	O
2666	of	O
2666	ben	O
2666	##az	O
2666	##ep	O
2666	##ril	O
2666	,	O
2666	compared	O
2666	with	O
2666	values	O
2666	after	O
2666	a	O
2666	single	O
2666	dose	O
2666	.	O
2666	[SEP]	O
2667	[CLS]	O
2667	the	O
2667	initial	O
2667	volume	B-PK
2667	of	I-PK
2667	distribution	I-PK
2667	(	I-PK
2667	v	I-PK
2667	##1	I-PK
2667	)	I-PK
2667	correspond	O
2667	##ed	O
2667	to	O
2667	the	O
2667	vascular	O
2667	compartment	O
2667	whereas	O
2667	the	O
2667	volume	B-PK
2667	of	I-PK
2667	distribution	I-PK
2667	at	I-PK
2667	steady	I-PK
2667	state	I-PK
2667	(	I-PK
2667	vs	I-PK
2667	##s	I-PK
2667	)	I-PK
2667	was	O
2667	somewhat	O
2667	larger	O
2667	.	O
2667	[SEP]	O
2668	[CLS]	O
2668	cm	B-PK
2668	##ax	I-PK
2668	and	O
2668	au	B-PK
2668	##c	I-PK
2668	were	O
2668	half	O
2668	of	O
2668	these	O
2668	values	O
2668	after	O
2668	administration	O
2668	of	O
2668	250	O
2668	mg	O
2668	.	O
2668	[SEP]	O
2669	[CLS]	O
2669	the	O
2669	primary	O
2669	objective	O
2669	of	O
2669	the	O
2669	study	O
2669	was	O
2669	to	O
2669	estimate	O
2669	the	O
2669	population	O
2669	p	O
2669	##har	O
2669	##ma	O
2669	##co	O
2669	##kin	O
2669	##etic	O
2669	parameters	O
2669	for	O
2669	it	O
2669	##rac	O
2669	##ona	O
2669	##zo	O
2669	##le	O
2669	and	O
2669	h	O
2669	##ydro	O
2669	##xy	O
2669	-	O
2669	it	O
2669	##rac	O
2669	##ona	O
2669	##zo	O
2669	##le	O
2669	,	O
2669	in	O
2669	particular	O
2669	,	O
2669	the	O
2669	relative	B-PK
2669	oral	I-PK
2669	bio	I-PK
2669	##ava	I-PK
2669	##ila	I-PK
2669	##bility	I-PK
2669	of	O
2669	the	O
2669	capsule	O
2669	compared	O
2669	with	O
2669	solution	O
2669	in	O
2669	adult	O
2669	c	O
2669	##ys	O
2669	##tic	O
2669	fi	O
2669	##bro	O
2669	##sis	O
2669	patients	O
2669	,	O
2669	in	O
2669	order	O
2669	to	O
2669	develop	O
2669	new	O
2669	dos	O
2669	##ing	O
2669	guidelines	O
2669	.	O
2669	[SEP]	O
2670	[CLS]	O
2670	comparative	O
2670	bio	B-PK
2670	##ava	I-PK
2670	##ila	I-PK
2670	##bility	I-PK
2670	of	O
2670	two	O
2670	z	O
2670	##ol	O
2670	##pid	O
2670	##em	O
2670	hem	O
2670	##ita	O
2670	##rt	O
2670	##rate	O
2670	formulation	O
2670	##s	O
2670	in	O
2670	healthy	O
2670	human	O
2670	bra	O
2670	##zi	O
2670	##lian	O
2670	volunteers	O
2670	using	O
2670	high	O
2670	-	O
2670	performance	O
2670	liquid	O
2670	ch	O
2670	##roma	O
2670	##tography	O
2670	coupled	O
2670	to	O
2670	tandem	O
2670	mass	O
2670	s	O
2670	##pect	O
2670	##rome	O
2670	##try	O
2670	.	O
2670	[SEP]	O
2671	[CLS]	O
2671	no	O
2671	significant	O
2671	difference	O
2671	in	O
2671	the	O
2671	apparent	B-PK
2671	volume	I-PK
2671	of	I-PK
2671	distribution	I-PK
2671	of	O
2671	anti	O
2671	##py	O
2671	##rine	O
2671	was	O
2671	observed	O
2671	.	O
2671	[SEP]	O
2672	[CLS]	O
2672	in	O
2672	##hibition	O
2672	of	O
2672	pu	O
2672	##rom	O
2672	##y	O
2672	##cin	O
2672	-	O
2672	induced	O
2672	re	O
2672	##nal	O
2672	injury	O
2672	by	O
2672	a	O
2672	super	O
2672	##oxide	O
2672	di	O
2672	##sm	O
2672	##uta	O
2672	##se	O
2672	derivative	O
2672	with	O
2672	prolonged	O
2672	in	O
2672	v	O
2672	##ivo	O
2672	half	B-PK
2672	-	I-PK
2672	life	I-PK
2672	.	O
2672	[SEP]	O
2673	[CLS]	O
2673	net	O
2673	##ih	O
2673	##er	O
2673	di	O
2673	##lt	O
2673	##ia	O
2673	##ze	O
2673	##m	O
2673	or	O
2673	is	O
2673	##oso	O
2673	##rb	O
2673	##ide	O
2673	din	O
2673	##it	O
2673	##rate	O
2673	significantly	O
2673	altered	O
2673	the	O
2673	time	B-PK
2673	to	I-PK
2673	reach	I-PK
2673	maximum	I-PK
2673	serum	I-PK
2673	dig	I-PK
2673	##ox	I-PK
2673	##in	I-PK
2673	concentration	I-PK
2673	.	O
2673	[SEP]	O
2674	[CLS]	O
2674	production	O
2674	of	O
2674	f	O
2674	##b	O
2674	##z	O
2674	was	O
2674	enhanced	O
2674	as	O
2674	reflected	O
2674	by	O
2674	increased	O
2674	(	O
2674	>	O
2674	60	O
2674	%	O
2674	)	O
2674	au	B-PK
2674	##c	I-PK
2674	,	O
2674	delayed	O
2674	t	B-PK
2674	(	I-PK
2674	ma	I-PK
2674	##x	I-PK
2674	)	I-PK
2674	and	O
2674	a	O
2674	significantly	O
2674	delayed	O
2674	(	O
2674	>	O
2674	45	O
2674	%	O
2674	)	O
2674	elimination	O
2674	(	O
2674	t	B-PK
2674	(	I-PK
2674	1	I-PK
2674	/	I-PK
2674	2	I-PK
2674	)	I-PK
2674	(	I-PK
2674	el	I-PK
2674	)	I-PK
2674	)	O
2674	.	O
2674	[SEP]	O
2675	[CLS]	O
2675	co	O
2675	##list	O
2675	##in	O
2675	elimination	O
2675	is	O
2675	not	O
2675	limited	O
2675	by	O
2675	the	O
2675	formation	O
2675	rate	O
2675	because	O
2675	its	O
2675	half	B-PK
2675	-	I-PK
2675	life	I-PK
2675	(	O
2675	3	O
2675	h	O
2675	)	O
2675	is	O
2675	longer	O
2675	than	O
2675	that	O
2675	of	O
2675	cm	O
2675	##s	O
2675	.	O
2675	[SEP]	O
2676	[CLS]	O
2676	the	O
2676	half	B-PK
2676	-	I-PK
2676	life	I-PK
2676	for	O
2676	36	O
2676	##c	O
2676	##l	O
2676	-	O
2676	absorption	O
2676	from	O
2676	plasma	O
2676	was	O
2676	19	O
2676	.	O
2676	2	O
2676	h	O
2676	corresponding	O
2676	to	O
2676	a	O
2676	rate	B-PK
2676	constant	I-PK
2676	of	O
2676	0	O
2676	.	O
2676	03	O
2676	##6	O
2676	##1	O
2676	h	O
2676	-	O
2676	1	O
2676	,	O
2676	while	O
2676	the	O
2676	half	B-PK
2676	-	I-PK
2676	life	I-PK
2676	for	O
2676	36	O
2676	##c	O
2676	##l	O
2676	-	O
2676	elimination	O
2676	from	O
2676	plasma	O
2676	was	O
2676	51	O
2676	.	O
2676	9	O
2676	h	O
2676	,	O
2676	corresponding	O
2676	to	O
2676	a	O
2676	rate	B-PK
2676	constant	I-PK
2676	of	O
2676	0	O
2676	.	O
2676	01	O
2676	##34	O
2676	h	O
2676	-	O
2676	1	O
2676	.	O
2676	[SEP]	O
2677	[CLS]	O
2677	the	O
2677	drug	O
2677	was	O
2677	immediately	O
2677	converted	O
2677	to	O
2677	di	O
2677	##hy	O
2677	##dr	O
2677	##oar	O
2677	##tem	O
2677	##isi	O
2677	##nin	O
2677	(	O
2677	d	O
2677	##ha	O
2677	)	O
2677	,	O
2677	with	O
2677	elimination	B-PK
2677	half	I-PK
2677	-	I-PK
2677	lives	I-PK
2677	ranging	O
2677	0	O
2677	.	O
2677	12	O
2677	-	O
2677	0	O
2677	.	O
2677	24	O
2677	and	O
2677	1	O
2677	.	O
2677	15	O
2677	-	O
2677	2	O
2677	.	O
2677	37	O
2677	hours	O
2677	for	O
2677	as	O
2677	and	O
2677	d	O
2677	##ha	O
2677	,	O
2677	respectively	O
2677	.	O
2677	[SEP]	O
2678	[CLS]	O
2678	self	O
2678	-	O
2678	na	O
2678	##no	O
2678	##em	O
2678	##ul	O
2678	##si	O
2678	##fying	O
2678	drug	O
2678	delivery	O
2678	system	O
2678	for	O
2678	enhanced	O
2678	bio	B-PK
2678	##ava	I-PK
2678	##ila	I-PK
2678	##bility	I-PK
2678	and	O
2678	improved	O
2678	he	O
2678	##pa	O
2678	##top	O
2678	##rote	O
2678	##ctive	O
2678	activity	O
2678	of	O
2678	bi	O
2678	##phe	O
2678	##ny	O
2678	##l	O
2678	dim	O
2678	##eth	O
2678	##yl	O
2678	di	O
2678	##car	O
2678	##box	O
2678	##yla	O
2678	##te	O
2678	.	O
2678	[SEP]	O
2679	[CLS]	O
2679	it	O
2679	was	O
2679	concluded	O
2679	that	O
2679	delta	O
2679	##met	O
2679	##hr	O
2679	##in	O
2679	was	O
2679	rapidly	O
2679	but	O
2679	incomplete	O
2679	##ly	O
2679	absorbed	O
2679	after	O
2679	in	O
2679	##tra	O
2679	##c	O
2679	##rop	O
2679	administration	O
2679	and	O
2679	bio	B-PK
2679	##ava	I-PK
2679	##ila	I-PK
2679	##bility	I-PK
2679	was	O
2679	at	O
2679	a	O
2679	low	O
2679	level	O
2679	.	O
2679	[SEP]	O
2680	[CLS]	O
2680	another	O
2680	random	O
2680	##ized	O
2680	,	O
2680	open	O
2680	,	O
2680	three	O
2680	-	O
2680	way	O
2680	crossover	O
2680	study	O
2680	was	O
2680	conducted	O
2680	in	O
2680	12	O
2680	healthy	O
2680	male	O
2680	volunteers	O
2680	to	O
2680	investigate	O
2680	the	O
2680	effect	O
2680	of	O
2680	food	O
2680	in	O
2680	the	O
2680	gas	O
2680	##tro	O
2680	##int	O
2680	##est	O
2680	##inal	O
2680	tract	O
2680	on	O
2680	the	O
2680	bio	B-PK
2680	##ava	I-PK
2680	##ila	I-PK
2680	##bility	I-PK
2680	of	O
2680	t	O
2680	##rov	O
2680	##af	O
2680	##lo	O
2680	##xa	O
2680	##cin	O
2680	.	O
2680	[SEP]	O
2681	[CLS]	O
2681	the	O
2681	valid	O
2681	##ated	O
2681	method	O
2681	has	O
2681	been	O
2681	successfully	O
2681	applied	O
2681	to	O
2681	the	O
2681	p	O
2681	##har	O
2681	##ma	O
2681	##co	O
2681	##kin	O
2681	##etics	O
2681	study	O
2681	of	O
2681	g	O
2681	##w	O
2681	##9	O
2681	##50	O
2681	##8	O
2681	in	O
2681	rat	O
2681	plasma	O
2681	,	O
2681	and	O
2681	our	O
2681	results	O
2681	demonstrated	O
2681	that	O
2681	g	O
2681	##w	O
2681	##9	O
2681	##50	O
2681	##8	O
2681	showed	O
2681	low	O
2681	clearance	B-PK
2681	,	O
2681	moderate	O
2681	half	B-PK
2681	-	I-PK
2681	life	I-PK
2681	and	O
2681	ideal	O
2681	bio	B-PK
2681	##ava	I-PK
2681	##ila	I-PK
2681	##bility	I-PK
2681	(	O
2681	54	O
2681	.	O
2681	88	O
2681	%	O
2681	)	O
2681	.	O
2681	[SEP]	O
2682	[CLS]	O
2682	after	O
2682	in	O
2682	##tra	O
2682	##ven	O
2682	##ous	O
2682	d	O
2682	##rip	O
2682	in	O
2682	##fusion	O
2682	for	O
2682	60	O
2682	minutes	O
2682	,	O
2682	tissue	O
2682	level	O
2682	reached	O
2682	to	O
2682	the	O
2682	maximum	O
2682	during	O
2682	1	O
2682	.	O
2682	01	O
2682	-	O
2682	1	O
2682	.	O
2682	82	O
2682	hours	O
2682	with	O
2682	half	B-PK
2682	-	I-PK
2682	life	I-PK
2682	of	O
2682	0	O
2682	.	O
2682	65	O
2682	-	O
2682	1	O
2682	.	O
2682	4	O
2682	hours	O
2682	and	O
2682	au	B-PK
2682	##c	I-PK
2682	of	O
2682	tissue	O
2682	concentration	O
2682	achieved	O
2682	about	O
2682	20	O
2682	-	O
2682	57	O
2682	%	O
2682	of	O
2682	that	O
2682	of	O
2682	u	O
2682	##ter	O
2682	##ine	O
2682	artery	O
2682	.	O
2682	[SEP]	O
2683	[CLS]	O
2683	me	O
2683	##l	O
2683	##pha	O
2683	##lan	O
2683	au	B-PK
2683	##c	I-PK
2683	ranged	O
2683	from	O
2683	4	O
2683	.	O
2683	9	O
2683	to	O
2683	24	O
2683	.	O
2683	6	O
2683	mg	O
2683	l	O
2683	(	O
2683	-	O
2683	1	O
2683	)	O
2683	h	O
2683	,	O
2683	median	O
2683	12	O
2683	.	O
2683	84	O
2683	mg	O
2683	l	O
2683	(	O
2683	-	O
2683	1	O
2683	)	O
2683	h	O
2683	.	O
2683	me	O
2683	##l	O
2683	##pha	O
2683	##lan	O
2683	au	B-PK
2683	##c	I-PK
2683	above	O
2683	the	O
2683	median	O
2683	was	O
2683	a	O
2683	risk	O
2683	factor	O
2683	for	O
2683	severe	O
2683	m	O
2683	##uc	O
2683	##os	O
2683	##itis	O
2683	(	O
2683	h	O
2683	##r	O
2683	1	O
2683	.	O
2683	21	O
2683	,	O
2683	95	O
2683	%	O
2683	c	O
2683	##i	O
2683	1	O
2683	.	O
2683	06	O
2683	,	O
2683	1	O
2683	.	O
2683	38	O
2683	,	O
2683	p	O
2683	=	O
2683	0	O
2683	.	O
2683	00	O
2683	##4	O
2683	)	O
2683	but	O
2683	was	O
2683	also	O
2683	associated	O
2683	with	O
2683	significantly	O
2683	improved	O
2683	overall	O
2683	survival	O
2683	(	O
2683	o	O
2683	##s	O
2683	)	O
2683	(	O
2683	h	O
2683	##r	O
2683	0	O
2683	.	O
2683	40	O
2683	,	O
2683	95	O
2683	%	O
2683	c	O
2683	##i	O
2683	0	O
2683	.	O
2683	20	O
2683	,	O
2683	0	O
2683	.	O
2683	81	O
2683	,	O
2683	p	O
2683	=	O
2683	0	O
2683	.	O
2683	00	O
2683	##1	O
2683	)	O
2683	,	O
2683	with	O
2683	an	O
2683	estimated	O
2683	median	O
2683	survival	O
2683	of	O
2683	8	O
2683	.	O
2683	50	O
2683	years	O
2683	vs	O
2683	.	O
2683	5	O
2683	.	O
2683	38	O
2683	years	O
2683	for	O
2683	high	O
2683	vs	O
2683	.	O
2683	low	O
2683	au	B-PK
2683	##c	I-PK
2683	groups	O
2683	.	O
2683	[SEP]	O
2684	[CLS]	O
2684	multiple	O
2684	re	O
2684	##gression	O
2684	analysis	O
2684	showed	O
2684	that	O
2684	the	O
2684	variables	O
2684	with	O
2684	the	O
2684	greatest	O
2684	predict	O
2684	##ive	O
2684	value	O
2684	for	O
2684	clearance	B-PK
2684	in	O
2684	into	O
2684	##xi	O
2684	##cated	O
2684	patients	O
2684	were	O
2684	age	O
2684	and	O
2684	re	O
2684	##nal	O
2684	function	O
2684	.	O
2684	[SEP]	O
2685	[CLS]	O
2685	from	O
2685	the	O
2685	results	O
2685	of	O
2685	re	B-PK
2685	##nal	I-PK
2685	clearance	I-PK
2685	experiments	O
2685	,	O
2685	tub	O
2685	##ular	O
2685	secret	O
2685	##ion	O
2685	appeared	O
2685	to	O
2685	be	O
2685	the	O
2685	predominant	O
2685	mechanism	O
2685	of	O
2685	re	O
2685	##nal	O
2685	elimination	O
2685	for	O
2685	these	O
2685	three	O
2685	drugs	O
2685	.	O
2685	[SEP]	O
2686	[CLS]	O
2686	for	O
2686	plasma	O
2686	total	O
2686	cap	O
2686	##top	O
2686	##ril	O
2686	(	O
2686	the	O
2686	sum	O
2686	of	O
2686	free	O
2686	unchanged	O
2686	cap	O
2686	##top	O
2686	##ril	O
2686	and	O
2686	its	O
2686	di	O
2686	##sul	O
2686	##fi	O
2686	##de	O
2686	compounds	O
2686	)	O
2686	the	O
2686	values	O
2686	were	O
2686	time	B-PK
2686	to	I-PK
2686	ma	I-PK
2686	##ximal	I-PK
2686	concentration	I-PK
2686	3	O
2686	.	O
2686	5	O
2686	+	O
2686	-	O
2686	0	O
2686	.	O
2686	6	O
2686	h	O
2686	and	O
2686	ma	B-PK
2686	##ximal	I-PK
2686	plasma	I-PK
2686	concentration	I-PK
2686	2	O
2686	,	O
2686	77	O
2686	##7	O
2686	+	O
2686	-	O
2686	42	O
2686	##9	O
2686	ng	O
2686	x	O
2686	m	O
2686	##l	O
2686	-	O
2686	1	O
2686	.	O
2686	[SEP]	O
2687	[CLS]	O
2687	the	O
2687	p	O
2687	##k	O
2687	parameters	O
2687	were	O
2687	maximum	B-PK
2687	plasma	I-PK
2687	concentration	I-PK
2687	(	I-PK
2687	cm	I-PK
2687	##ax	I-PK
2687	)	I-PK
2687	,	O
2687	time	B-PK
2687	at	I-PK
2687	which	I-PK
2687	the	I-PK
2687	cm	I-PK
2687	##ax	I-PK
2687	occurred	I-PK
2687	(	I-PK
2687	t	I-PK
2687	##max	I-PK
2687	)	I-PK
2687	,	O
2687	and	O
2687	area	B-PK
2687	under	I-PK
2687	the	I-PK
2687	plasma	I-PK
2687	concentration	I-PK
2687	-	I-PK
2687	time	I-PK
2687	data	I-PK
2687	from	I-PK
2687	time	I-PK
2687	0	I-PK
2687	to	I-PK
2687	selected	I-PK
2687	time	I-PK
2687	point	I-PK
2687	(	I-PK
2687	t	I-PK
2687	)	I-PK
2687	(	I-PK
2687	au	I-PK
2687	##c	I-PK
2687	##0	I-PK
2687	-	I-PK
2687	t	I-PK
2687	)	I-PK
2687	.	O
2687	[SEP]	O
2688	[CLS]	O
2688	because	O
2688	of	O
2688	an	O
2688	influence	O
2688	of	O
2688	body	O
2688	weight	O
2688	on	O
2688	the	O
2688	clearance	B-PK
2688	of	O
2688	a	O
2688	##po	O
2688	##a	O
2688	-	O
2688	i	O
2688	,	O
2688	p	O
2688	##har	O
2688	##ma	O
2688	##co	O
2688	##kin	O
2688	##etics	O
2688	modeling	O
2688	of	O
2688	the	O
2688	phase	O
2688	1	O
2688	sad	O
2688	study	O
2688	data	O
2688	predicted	O
2688	that	O
2688	fixed	O
2688	doses	O
2688	would	O
2688	result	O
2688	in	O
2688	less	O
2688	var	O
2688	##iability	O
2688	in	O
2688	a	O
2688	##po	O
2688	##a	O
2688	-	O
2688	i	O
2688	exposure	O
2688	at	O
2688	extreme	O
2688	##s	O
2688	of	O
2688	the	O
2688	body	O
2688	weight	O
2688	range	O
2688	.	O
2688	19	O
2688	consequently	O
2688	,	O
2688	fixed	O
2688	doses	O
2688	of	O
2688	c	O
2688	##s	O
2688	##l	O
2688	##11	O
2688	##2	O
2688	were	O
2688	used	O
2688	in	O
2688	the	O
2688	phase	O
2688	1	O
2688	mad	O
2688	and	O
2688	phase	O
2688	2	O
2688	##a	O
2688	studies	O
2688	.	O
2688	[SEP]	O
2689	[CLS]	O
2689	throughout	O
2689	the	O
2689	dose	O
2689	range	O
2689	in	O
2689	the	O
2689	current	O
2689	study	O
2689	and	O
2689	throughout	O
2689	the	O
2689	hours	O
2689	after	O
2689	in	O
2689	##fusion	O
2689	,	O
2689	a	O
2689	similar	O
2689	proportion	O
2689	of	O
2689	the	O
2689	in	O
2689	##fused	O
2689	a	O
2689	##po	O
2689	##a	O
2689	-	O
2689	i	O
2689	appeared	O
2689	as	O
2689	pre	O
2689	–	O
2689	β	O
2689	##1	O
2689	-	O
2689	h	O
2689	##dl	O
2689	such	O
2689	that	O
2689	the	O
2689	relationship	O
2689	between	O
2689	a	O
2689	##po	O
2689	##a	O
2689	-	O
2689	i	O
2689	au	B-PK
2689	##c	I-PK
2689	##0	I-PK
2689	–	I-PK
2689	24	I-PK
2689	and	O
2689	pre	O
2689	–	O
2689	β	O
2689	##1	O
2689	-	O
2689	h	O
2689	##dl	O
2689	area	O
2689	under	O
2689	the	O
2689	effect	O
2689	curve	O
2689	0	O
2689	to	O
2689	24	O
2689	hours	O
2689	(	O
2689	au	O
2689	##ec	O
2689	##0	O
2689	–	O
2689	24	O
2689	)	O
2689	seems	O
2689	linear	O
2689	(	O
2689	figure	O
2689	1	O
2689	##d	O
2689	)	O
2689	.	O
2689	[SEP]	O
2690	[CLS]	O
2690	in	O
2690	addition	O
2690	,	O
2690	the	O
2690	maximum	B-PK
2690	plasma	I-PK
2690	concentration	I-PK
2690	(	I-PK
2690	cm	I-PK
2690	##ax	I-PK
2690	)	I-PK
2690	and	O
2690	the	O
2690	time	B-PK
2690	to	I-PK
2690	reach	I-PK
2690	the	I-PK
2690	maximum	I-PK
2690	plasma	I-PK
2690	concentration	I-PK
2690	(	I-PK
2690	t	I-PK
2690	##max	I-PK
2690	)	I-PK
2690	were	O
2690	obtained	O
2690	from	O
2690	the	O
2690	plasma	O
2690	concentration	O
2690	-	O
2690	time	O
2690	data	O
2690	.	O
2690	[SEP]	O
2691	[CLS]	O
2691	a	O
2691	and	O
2691	b	O
2691	:	O
2691	g	O
2691	–	O
2691	a	O
2691	plasma	O
2691	concentration	O
2691	in	O
2691	central	O
2691	and	O
2691	peripheral	O
2691	compartment	O
2691	,	O
2691	respectively	O
2691	;	O
2691	ka	B-PK
2691	:	O
2691	apparent	B-PK
2691	first	I-PK
2691	-	I-PK
2691	order	I-PK
2691	absorption	I-PK
2691	rate	I-PK
2691	constant	I-PK
2691	;	O
2691	k	B-PK
2691	##10	I-PK
2691	:	O
2691	apparent	B-PK
2691	first	I-PK
2691	-	I-PK
2691	order	I-PK
2691	elimination	I-PK
2691	rate	I-PK
2691	constant	I-PK
2691	from	I-PK
2691	central	I-PK
2691	compartment	I-PK
2691	;	O
2691	k	B-PK
2691	##12	I-PK
2691	:	O
2691	apparent	B-PK
2691	first	I-PK
2691	-	I-PK
2691	order	I-PK
2691	transfer	I-PK
2691	rate	I-PK
2691	constant	I-PK
2691	from	I-PK
2691	central	I-PK
2691	compartment	I-PK
2691	to	I-PK
2691	peripheral	I-PK
2691	compartment	I-PK
2691	;	O
2691	k	B-PK
2691	##21	I-PK
2691	:	O
2691	apparent	B-PK
2691	first	I-PK
2691	-	I-PK
2691	order	I-PK
2691	transfer	I-PK
2691	rate	I-PK
2691	constant	I-PK
2691	from	I-PK
2691	peripheral	I-PK
2691	compartment	I-PK
2691	to	I-PK
2691	central	I-PK
2691	compartment	I-PK
2691	;	O
2691	t	B-PK
2691	##1	I-PK
2691	/	I-PK
2691	2	I-PK
2691	##ka	I-PK
2691	:	O
2691	absorption	B-PK
2691	half	I-PK
2691	time	I-PK
2691	;	O
2691	α	O
2691	and	O
2691	β	O
2691	:	O
2691	empirical	O
2691	constant	O
2691	##s	O
2691	corresponding	O
2691	to	O
2691	the	O
2691	coefficients	O
2691	of	O
2691	the	O
2691	ex	O
2691	##ponents	O
2691	of	O
2691	the	O
2691	values	O
2691	of	O
2691	a	O
2691	and	O
2691	b	O
2691	;	O
2691	v	B-PK
2691	/	I-PK
2691	f	I-PK
2691	:	O
2691	apparent	B-PK
2691	volume	I-PK
2691	of	I-PK
2691	distribution	I-PK
2691	;	O
2691	c	B-PK
2691	##l	I-PK
2691	/	I-PK
2691	f	I-PK
2691	:	B-PK
2691	apparent	I-PK
2691	clearance	I-PK
2691	;	O
2691	t	B-PK
2691	##max	I-PK
2691	:	O
2691	time	B-PK
2691	to	I-PK
2691	ma	I-PK
2691	##ximal	I-PK
2691	concentration	I-PK
2691	;	O
2691	cm	B-PK
2691	##ax	I-PK
2691	:	O
2691	ma	B-PK
2691	##ximal	I-PK
2691	concentration	I-PK
2691	;	O
2691	au	B-PK
2691	##c	I-PK
2691	##0	I-PK
2691	##→	I-PK
2691	##∞	I-PK
2691	y	O
2691	au	B-PK
2691	##c	I-PK
2691	##0	I-PK
2691	-	I-PK
2691	144	I-PK
2691	##0	I-PK
2691	min	I-PK
2691	:	O
2691	area	B-PK
2691	under	I-PK
2691	the	I-PK
2691	plasma	I-PK
2691	concentration	I-PK
2691	curve	I-PK
2691	from	I-PK
2691	0	I-PK
2691	to	I-PK
2691	in	I-PK
2691	##finity	I-PK
2691	and	I-PK
2691	form	I-PK
2691	0	I-PK
2691	to	I-PK
2691	144	I-PK
2691	##0	I-PK
2691	min	I-PK
2691	,	O
2691	respectively	O
2691	;	O
2691	m	B-PK
2691	##rt	I-PK
2691	:	O
2691	mean	B-PK
2691	residence	I-PK
2691	time	I-PK
2691	;	O
2691	s	O
2691	##s	O
2691	:	O
2691	sum	O
2691	of	O
2691	square	O
2691	;	O
2691	r	O
2691	##2	O
2691	:	O
2691	correlation	O
2691	index	O
2691	;	O
2691	a	O
2691	##ic	O
2691	:	O
2691	aka	O
2691	##ike	O
2691	information	O
2691	criteria	O
2691	;	O
2691	s	O
2691	##c	O
2691	:	O
2691	s	O
2691	##ch	O
2691	##war	O
2691	##z	O
2691	criterion	O
2691	.	O
2691	[SEP]	O
2692	[CLS]	O
2692	however	O
2692	,	O
2692	the	O
2692	difference	O
2692	in	O
2692	t	B-PK
2692	##max	I-PK
2692	,	O
2692	v	B-PK
2692	##d	I-PK
2692	,	O
2692	and	O
2692	t	B-PK
2692	##1	I-PK
2692	/	I-PK
2692	2	I-PK
2692	between	O
2692	groups	O
2692	did	O
2692	not	O
2692	reach	O
2692	statistical	O
2692	significance	O
2692	,	O
2692	except	O
2692	c	B-PK
2692	##l	I-PK
2692	was	O
2692	significantly	O
2692	decreased	O
2692	to	O
2692	58	O
2692	%	O
2692	by	O
2692	pre	O
2692	##tre	O
2692	##at	O
2692	##ment	O
2692	with	O
2692	20	O
2692	mg	O
2692	/	O
2692	kg	O
2692	of	O
2692	pipe	O
2692	##rine	O
2692	.	O
2692	[SEP]	O
2693	[CLS]	O
2693	the	O
2693	dose	O
2693	-	O
2693	dependent	O
2693	relationships	O
2693	of	O
2693	cm	B-PK
2693	##ax	I-PK
2693	,	O
2693	t	B-PK
2693	##max	I-PK
2693	,	O
2693	and	O
2693	au	B-PK
2693	##c	I-PK
2693	##0	I-PK
2693	–	I-PK
2693	∞	I-PK
2693	are	O
2693	depicted	O
2693	in	O
2693	figure	O
2693	4	O
2693	.	O
2693	[SEP]	O
2694	[CLS]	O
2694	in	O
2694	the	O
2694	control	O
2694	group	O
2694	given	O
2694	pu	O
2694	##era	O
2694	##rin	O
2694	only	O
2694	,	O
2694	the	O
2694	p	O
2694	##har	O
2694	##ma	O
2694	##co	O
2694	##kin	O
2694	##etic	O
2694	parameters	O
2694	of	O
2694	pu	O
2694	##era	O
2694	##rin	O
2694	in	O
2694	our	O
2694	study	O
2694	was	O
2694	partially	O
2694	consistent	O
2694	with	O
2694	the	O
2694	result	O
2694	of	O
2694	ji	O
2694	##ang	O
2694	et	O
2694	al	O
2694	.	O
2694	[	O
2694	21	O
2694	]	O
2694	,	O
2694	in	O
2694	which	O
2694	pu	O
2694	##era	O
2694	##rin	O
2694	also	O
2694	displayed	O
2694	a	O
2694	low	O
2694	cm	B-PK
2694	##ax	I-PK
2694	,	O
2694	short	O
2694	t	B-PK
2694	##1	I-PK
2694	/	I-PK
2694	2	I-PK
2694	,	O
2694	and	O
2694	high	O
2694	c	B-PK
2694	##l	I-PK
2694	after	O
2694	oral	O
2694	administration	O
2694	.	O
2694	[SEP]	O
2695	[CLS]	O
2695	also	O
2695	,	O
2695	a	O
2695	2	O
2695	-	O
2695	to	O
2695	4	O
2695	-	O
2695	fold	O
2695	greater	O
2695	dose	B-PK
2695	-	I-PK
2695	normal	I-PK
2695	##ized	I-PK
2695	peak	I-PK
2695	plasma	I-PK
2695	concentration	I-PK
2695	(	I-PK
2695	cm	I-PK
2695	##ax	I-PK
2695	)	I-PK
2695	was	O
2695	observed	O
2695	for	O
2695	the	O
2695	dog	O
2695	compared	O
2695	to	O
2695	the	O
2695	other	O
2695	species	O
2695	as	O
2695	listed	O
2695	in	O
2695	table	O
2695	2	O
2695	.	O
2695	[SEP]	O
2696	[CLS]	O
2696	the	O
2696	mouse	O
2696	showed	O
2696	the	O
2696	highest	O
2696	dose	B-PK
2696	-	I-PK
2696	normal	I-PK
2696	##ized	I-PK
2696	au	I-PK
2696	##c	I-PK
2696	,	O
2696	which	O
2696	was	O
2696	2	O
2696	-	O
2696	fold	O
2696	greater	O
2696	than	O
2696	that	O
2696	for	O
2696	the	O
2696	rabbit	O
2696	and	O
2696	monkey	O
2696	both	O
2696	of	O
2696	which	O
2696	,	O
2696	by	O
2696	approximation	O
2696	showed	O
2696	the	O
2696	lowest	O
2696	dose	B-PK
2696	-	I-PK
2696	normal	I-PK
2696	##ized	I-PK
2696	au	I-PK
2696	##c	I-PK
2696	value	O
2696	,	O
2696	as	O
2696	shown	O
2696	in	O
2696	table	O
2696	2	O
2696	.	O
2696	[SEP]	O
2697	[CLS]	O
2697	the	O
2697	skin	O
2697	micro	O
2697	##dial	O
2697	##ys	O
2697	##is	O
2697	study	O
2697	indicated	O
2697	p	O
2697	##ae	O
2697	-	O
2697	l	O
2697	##c	O
2697	##n	O
2697	##ps	O
2697	have	O
2697	good	O
2697	trans	O
2697	##der	O
2697	##mal	O
2697	per	B-PK
2697	##me	I-PK
2697	##ability	I-PK
2697	and	O
2697	efficacy	O
2697	.	O
2697	[SEP]	O
2698	[CLS]	O
2698	modified	O
2698	dos	O
2698	##age	O
2698	formulation	O
2698	##s	O
2698	commonly	O
2698	cause	O
2698	flip	O
2698	-	O
2698	fl	O
2698	##op	O
2698	;	O
2698	however	O
2698	,	O
2698	formulation	O
2698	characteristics	O
2698	,	O
2698	such	O
2698	as	O
2698	the	O
2698	drugs	O
2698	per	O
2698	se	O
2698	or	O
2698	the	O
2698	ex	O
2698	##ci	O
2698	##pie	O
2698	##nts	O
2698	,	O
2698	can	O
2698	also	O
2698	trigger	O
2698	flip	O
2698	-	O
2698	fl	O
2698	##op	O
2698	.	O
2698	63	O
2698	drugs	O
2698	,	O
2698	the	O
2698	oral	O
2698	absorption	O
2698	of	O
2698	which	O
2698	is	O
2698	limited	O
2698	by	O
2698	the	O
2698	per	B-PK
2698	##me	I-PK
2698	##ability	I-PK
2698	rate	I-PK
2698	,	O
2698	are	O
2698	most	O
2698	likely	O
2698	to	O
2698	exhibit	O
2698	flip	O
2698	-	O
2698	fl	O
2698	##op	O
2698	p	O
2698	##har	O
2698	##ma	O
2698	##co	O
2698	##kin	O
2698	##etics	O
2698	.	O
2698	64	O
2698	thus	O
2698	,	O
2698	oral	O
2698	hp	O
2698	-	O
2698	beta	O
2698	-	O
2698	c	O
2698	##d	O
2698	/	O
2698	pm	O
2698	##x	O
2698	/	O
2698	d	O
2698	##ck	O
2698	/	O
2698	p	O
2698	##18	O
2698	##8	O
2698	-	O
2698	ne	O
2698	would	O
2698	be	O
2698	expected	O
2698	to	O
2698	exhibit	O
2698	rapid	O
2698	onset	O
2698	action	O
2698	and	O
2698	a	O
2698	sustained	O
2698	therapeutic	O
2698	effect	O
2698	compared	O
2698	with	O
2698	i	O
2698	##v	O
2698	or	O
2698	oral	O
2698	pm	O
2698	##x	O
2698	alone	O
2698	.	O
2698	[SEP]	O
2699	[CLS]	O
2699	cm	B-PK
2699	##ax	I-PK
2699	and	O
2699	au	B-PK
2699	##c	I-PK
2699	of	O
2699	a	O
2699	##can	O
2699	##th	O
2699	##op	O
2699	##ana	O
2699	##x	O
2699	sent	O
2699	##ico	O
2699	##sus	O
2699	p	O
2699	##oly	O
2699	##sa	O
2699	##cc	O
2699	##hari	O
2699	##des	O
2699	(	O
2699	as	O
2699	##ps	O
2699	)	O
2699	were	O
2699	significantly	O
2699	reduced	O
2699	in	O
2699	radiation	O
2699	-	O
2699	injured	O
2699	mice	O
2699	,	O
2699	suggesting	O
2699	that	O
2699	the	O
2699	blood	B-PK
2699	flow	I-PK
2699	of	O
2699	mouse	O
2699	was	O
2699	blocked	O
2699	or	O
2699	slowed	O
2699	,	O
2699	due	O
2699	to	O
2699	the	O
2699	path	O
2699	##ological	O
2699	state	O
2699	of	O
2699	is	O
2699	##che	O
2699	##mia	O
2699	and	O
2699	h	O
2699	##y	O
2699	##pox	O
2699	##ia	O
2699	,	O
2699	which	O
2699	are	O
2699	caused	O
2699	by	O
2699	radiation	O
2699	.	O
2699	[SEP]	O
2700	[CLS]	O
2700	average	B-PK
2700	concentrations	I-PK
2700	of	O
2700	da	O
2700	##ct	O
2700	in	O
2700	plasma	O
2700	,	O
2700	and	O
2700	to	O
2700	a	O
2700	greater	O
2700	extent	O
2700	in	O
2700	urine	O
2700	,	O
2700	were	O
2700	sensitive	O
2700	to	O
2700	v	B-PK
2700	##max	I-PK
2700	and	O
2700	km	B-PK
2700	for	O
2700	metabolism	O
2700	of	O
2700	de	O
2700	##a	O
2700	to	O
2700	da	O
2700	##ct	O
2700	.	O
2700	[SEP]	O
2701	[CLS]	O
2701	in	O
2701	general	O
2701	,	O
2701	the	O
2701	average	B-PK
2701	concentration	I-PK
2701	of	O
2701	at	O
2701	##z	O
2701	and	O
2701	its	O
2701	meta	O
2701	##bol	O
2701	##ites	O
2701	in	O
2701	plasma	O
2701	and	O
2701	urine	O
2701	was	O
2701	sensitive	O
2701	to	O
2701	the	O
2701	rate	O
2701	constant	O
2701	##s	O
2701	for	O
2701	metabolism	O
2701	or	O
2701	clearance	B-PK
2701	of	O
2701	each	O
2701	specific	O
2701	ch	O
2701	##lor	O
2701	##ot	O
2701	##ria	O
2701	##zine	O
2701	.	O
2701	[SEP]	O
2702	[CLS]	O
2702	corresponding	O
2702	##ly	O
2702	,	O
2702	the	O
2702	model	O
2702	‐	O
2702	derived	O
2702	mean	O
2702	estimate	O
2702	of	O
2702	au	B-PK
2702	##c	I-PK
2702	##0	I-PK
2702	‐	I-PK
2702	24	I-PK
2702	##h	I-PK
2702	at	I-PK
2702	steady	I-PK
2702	state	I-PK
2702	following	O
2702	last	O
2702	dose	O
2702	was	O
2702	higher	O
2702	in	O
2702	children	O
2702	compared	O
2702	with	O
2702	adolescent	O
2702	##s	O
2702	and	O
2702	adults	O
2702	(	O
2702	table	O
2702	4	O
2702	)	O
2702	.	O
2702	[SEP]	O
2703	[CLS]	O
2703	in	O
2703	study	O
2703	part	O
2703	5	O
2703	,	O
2703	dose	O
2703	proportional	O
2703	##ity	O
2703	for	O
2703	up	O
2703	##ada	O
2703	##ci	O
2703	##tin	O
2703	##ib	O
2703	exposure	O
2703	was	O
2703	tested	O
2703	for	O
2703	the	O
2703	natural	O
2703	log	O
2703	##ari	O
2703	##th	O
2703	##ms	O
2703	of	O
2703	dose	B-PK
2703	‐	I-PK
2703	normal	I-PK
2703	##ized	I-PK
2703	cm	I-PK
2703	##ax	I-PK
2703	and	O
2703	au	B-PK
2703	##c	I-PK
2703	##0	I-PK
2703	–	I-PK
2703	24	I-PK
2703	after	O
2703	the	O
2703	last	O
2703	dose	O
2703	on	O
2703	day	O
2703	7	O
2703	.	O
2703	[SEP]	O
2704	[CLS]	O
2704	the	O
2704	proportion	O
2704	of	O
2704	radio	B-PK
2704	##act	I-PK
2704	##ivity	I-PK
2704	for	O
2704	meta	O
2704	##bol	O
2704	##ite	O
2704	vs	O
2704	.	O
2704	total	B-PK
2704	radio	I-PK
2704	##act	I-PK
2704	##ivity	I-PK
2704	in	O
2704	the	O
2704	plasma	O
2704	samples	O
2704	was	O
2704	estimated	O
2704	and	O
2704	meta	O
2704	##bol	O
2704	##ite	O
2704	concentrations	O
2704	calculated	O
2704	and	O
2704	expressed	O
2704	in	O
2704	u	O
2704	##g	O
2704	e	O
2704	##qui	O
2704	##v	O
2704	/	O
2704	m	O
2704	##l	O
2704	.	O
2704	au	B-PK
2704	##c	I-PK
2704	values	O
2704	for	O
2704	the	O
2704	meta	O
2704	##bol	O
2704	##ite	O
2704	(	O
2704	s	O
2704	)	O
2704	were	O
2704	estimated	O
2704	based	O
2704	on	O
2704	plasma	B-PK
2704	radio	I-PK
2704	##act	I-PK
2704	##ivity	I-PK
2704	vs	O
2704	.	O
2704	time	O
2704	data	O
2704	.	O
2704	[SEP]	O
2705	[CLS]	O
2705	do	O
2705	##ca	O
2705	is	O
2705	known	O
2705	to	O
2705	m	O
2705	##od	O
2705	##ulate	O
2705	or	O
2705	increase	O
2705	in	O
2705	##test	O
2705	##inal	O
2705	para	O
2705	##cellular	O
2705	per	B-PK
2705	##me	I-PK
2705	##ability	I-PK
2705	via	O
2705	e	O
2705	##pit	O
2705	##hel	O
2705	##ial	O
2705	growth	O
2705	factor	O
2705	receptor	O
2705	(	O
2705	e	O
2705	##g	O
2705	##f	O
2705	##r	O
2705	)	O
2705	auto	O
2705	-	O
2705	p	O
2705	##hos	O
2705	##ph	O
2705	##ory	O
2705	##lation	O
2705	,	O
2705	o	O
2705	##cc	O
2705	##lu	O
2705	##din	O
2705	de	O
2705	##ph	O
2705	##os	O
2705	##ph	O
2705	##ory	O
2705	##lation	O
2705	,	O
2705	and	O
2705	rear	O
2705	##rang	O
2705	##ement	O
2705	at	O
2705	the	O
2705	tight	O
2705	junction	O
2705	level	O
2705	.	O
2705	34	O
2705	,	O
2705	51	O
2705	it	O
2705	was	O
2705	also	O
2705	reported	O
2705	that	O
2705	p	O
2705	##18	O
2705	##8	O
2705	can	O
2705	change	O
2705	the	O
2705	lateral	O
2705	packing	O
2705	density	O
2705	of	O
2705	membrane	O
2705	##s	O
2705	by	O
2705	insertion	O
2705	into	O
2705	the	O
2705	lip	O
2705	##id	O
2705	layers	O
2705	.	O
2705	52	O
2705	further	O
2705	##more	O
2705	,	O
2705	na	O
2705	##no	O
2705	##em	O
2705	##ul	O
2705	##sions	O
2705	en	O
2705	##tra	O
2705	##pping	O
2705	the	O
2705	hp	O
2705	-	O
2705	beta	O
2705	-	O
2705	c	O
2705	##d	O
2705	/	O
2705	pm	O
2705	##x	O
2705	/	O
2705	d	O
2705	##ck	O
2705	/	O
2705	p	O
2705	##18	O
2705	##8	O
2705	demonstrated	O
2705	a	O
2705	significant	O
2705	increase	O
2705	in	O
2705	p	B-PK
2705	##ap	I-PK
2705	##p	I-PK
2705	across	O
2705	a	O
2705	ca	O
2705	##co	O
2705	-	O
2705	2	O
2705	cell	O
2705	mon	O
2705	##ola	O
2705	##yer	O
2705	by	O
2705	1	O
2705	.	O
2705	15	O
2705	-	O
2705	and	O
2705	9	O
2705	.	O
2705	82	O
2705	-	O
2705	fold	O
2705	compared	O
2705	with	O
2705	those	O
2705	of	O
2705	hp	O
2705	-	O
2705	beta	O
2705	-	O
2705	c	O
2705	##d	O
2705	/	O
2705	pm	O
2705	##x	O
2705	/	O
2705	d	O
2705	##ck	O
2705	and	O
2705	free	O
2705	pm	O
2705	##x	O
2705	,	O
2705	respectively	O
2705	,	O
2705	further	O
2705	implying	O
2705	enhanced	O
2705	oral	B-PK
2705	bio	I-PK
2705	##ava	I-PK
2705	##ila	I-PK
2705	##bility	I-PK
2705	.	O
2705	[SEP]	O
2706	[CLS]	O
2706	me	O
2706	##chan	O
2706	##istic	O
2706	study	O
2706	demonstrated	O
2706	that	O
2706	lab	O
2706	##ras	O
2706	##ol	O
2706	can	O
2706	disrupt	O
2706	tight	O
2706	junction	O
2706	##s	O
2706	at	O
2706	the	O
2706	molecular	O
2706	level	O
2706	,	O
2706	including	O
2706	the	O
2706	loss	O
2706	of	O
2706	junction	O
2706	integrity	O
2706	via	O
2706	changes	O
2706	in	O
2706	f	O
2706	-	O
2706	act	O
2706	##in	O
2706	ring	O
2706	and	O
2706	red	O
2706	##ist	O
2706	##ri	O
2706	##but	O
2706	##ion	O
2706	of	O
2706	z	O
2706	##on	O
2706	##ula	O
2706	o	O
2706	##cc	O
2706	##lude	O
2706	##ns	O
2706	-	O
2706	1	O
2706	(	O
2706	z	O
2706	##o	O
2706	-	O
2706	1	O
2706	)	O
2706	,	O
2706	leading	O
2706	them	O
2706	to	O
2706	act	O
2706	as	O
2706	potential	O
2706	absorption	O
2706	enhance	O
2706	##rs	O
2706	of	O
2706	h	O
2706	##ydro	O
2706	##phi	O
2706	##lic	O
2706	drugs	O
2706	.	O
2706	54	O
2706	,	O
2706	55	O
2706	based	O
2706	on	O
2706	the	O
2706	results	O
2706	of	O
2706	the	O
2706	in	O
2706	v	O
2706	##it	O
2706	##ro	O
2706	artificial	O
2706	in	O
2706	##test	O
2706	##inal	O
2706	membrane	O
2706	and	O
2706	ca	O
2706	##co	O
2706	-	O
2706	2	O
2706	cell	O
2706	mon	O
2706	##ola	O
2706	##yer	O
2706	per	B-PK
2706	##me	I-PK
2706	##ability	I-PK
2706	analyses	O
2706	,	O
2706	further	O
2706	experiments	O
2706	,	O
2706	including	O
2706	those	O
2706	on	O
2706	the	O
2706	in	O
2706	v	O
2706	##ivo	O
2706	oral	O
2706	absorption	O
2706	in	O
2706	rats	O
2706	and	O
2706	tumor	O
2706	growth	O
2706	suppression	O
2706	efficacy	O
2706	in	O
2706	mice	O
2706	,	O
2706	were	O
2706	carried	O
2706	out	O
2706	using	O
2706	hp	O
2706	-	O
2706	beta	O
2706	-	O
2706	c	O
2706	##d	O
2706	/	O
2706	pm	O
2706	##x	O
2706	/	O
2706	d	O
2706	##ck	O
2706	/	O
2706	p	O
2706	##18	O
2706	##8	O
2706	-	O
2706	ne	O
2706	.	O
2706	[SEP]	O
2707	[CLS]	O
2707	in	O
2707	male	O
2707	subjects	O
2707	,	O
2707	there	O
2707	were	O
2707	no	O
2707	significant	O
2707	changes	O
2707	in	O
2707	overall	O
2707	exposure	O
2707	(	O
2707	au	B-PK
2707	##c	I-PK
2707	)	O
2707	;	O
2707	however	O
2707	,	O
2707	there	O
2707	were	O
2707	significant	O
2707	increases	O
2707	in	O
2707	t	B-PK
2707	##max	I-PK
2707	and	O
2707	t	B-PK
2707	##½	I-PK
2707	##β	I-PK
2707	,	O
2707	and	O
2707	a	O
2707	decrease	O
2707	in	O
2707	cm	B-PK
2707	##ax	I-PK
2707	.	O
2707	[SEP]	O
2708	[CLS]	O
2708	the	O
2708	predicted	O
2708	free	B-PK
2708	au	I-PK
2708	##c	I-PK
2708	/	I-PK
2708	mi	I-PK
2708	##c	I-PK
2708	level	O
2708	was	O
2708	more	O
2708	sensitive	O
2708	to	O
2708	changes	O
2708	in	O
2708	free	B-PK
2708	fraction	I-PK
2708	levels	O
2708	when	O
2708	compared	O
2708	to	O
2708	the	O
2708	total	B-PK
2708	au	I-PK
2708	##c	I-PK
2708	/	I-PK
2708	mi	I-PK
2708	##c	I-PK
2708	(	O
2708	figure	O
2708	##6	O
2708	##c	O
2708	,	O
2708	right	O
2708	)	O
2708	.	O
2708	[SEP]	O
2709	[CLS]	O
2709	to	O
2709	si	O
2709	##mu	O
2709	##late	O
2709	the	O
2709	terminal	B-PK
2709	clearance	I-PK
2709	of	O
2709	total	B-PK
2709	radio	I-PK
2709	##act	I-PK
2709	##ivity	I-PK
2709	from	O
2709	rat	O
2709	plasma	O
2709	,	O
2709	a	O
2709	rate	O
2709	of	O
2709	reaction	O
2709	with	O
2709	album	O
2709	##in	O
2709	was	O
2709	estimated	O
2709	to	O
2709	provide	O
2709	sufficient	O
2709	album	O
2709	##in	O
2709	-	O
2709	bound	O
2709	14	O
2709	##c	O
2709	-	O
2709	at	O
2709	##z	O
2709	equivalent	O
2709	##s	O
2709	in	O
2709	plasma	O
2709	(	O
2709	t	O
2709	##im	O
2709	##chal	O
2709	##k	O
2709	et	O
2709	al	O
2709	.	O
2709	,	O
2709	1990	O
2709	)	O
2709	,	O
2709	with	O
2709	the	O
2709	terminal	B-PK
2709	clearance	I-PK
2709	time	I-PK
2709	based	O
2709	on	O
2709	the	O
2709	turnover	O
2709	of	O
2709	serum	O
2709	album	O
2709	##in	O
2709	in	O
2709	rats	O
2709	.	O
2709	[SEP]	O
2710	[CLS]	O
2710	as	O
2710	expected	O
2710	,	O
2710	th	O
2710	##c	O
2710	,	O
2710	11	O
2710	‐	O
2710	oh	O
2710	‐	O
2710	th	O
2710	##c	O
2710	,	O
2710	and	O
2710	11	O
2710	‐	O
2710	co	O
2710	##oh	O
2710	‐	O
2710	th	O
2710	##c	O
2710	plasma	O
2710	concentrations	O
2710	were	O
2710	low	O
2710	or	O
2710	below	O
2710	the	O
2710	level	O
2710	of	O
2710	q	O
2710	##uant	O
2710	##ification	O
2710	throughout	O
2710	the	O
2710	trial	O
2710	and	O
2710	therefore	O
2710	the	O
2710	steady	O
2710	‐	O
2710	state	O
2710	mean	O
2710	th	O
2710	##c	O
2710	exposure	O
2710	(	O
2710	cm	B-PK
2710	##ax	I-PK
2710	)	O
2710	was	O
2710	consistently	O
2710	low	O
2710	across	O
2710	co	O
2710	##hor	O
2710	##ts	O
2710	(	O
2710	data	O
2710	not	O
2710	shown	O
2710	)	O
2710	.	O
2710	[SEP]	O
2711	[CLS]	O
2711	c	B-PK
2711	##ss	I-PK
2711	(	I-PK
2711	ma	I-PK
2711	##x	I-PK
2711	)	I-PK
2711	and	O
2711	c	B-PK
2711	##ss	I-PK
2711	(	I-PK
2711	min	I-PK
2711	)	I-PK
2711	the	O
2711	maximum	B-PK
2711	and	O
2711	minimum	B-PK
2711	plasma	I-PK
2711	concentrations	I-PK
2711	at	I-PK
2711	steady	I-PK
2711	state	I-PK
2711	were	O
2711	calculated	O
2711	by	O
2711	the	O
2711	following	O
2711	equation	O
2711	by	O
2711	sub	O
2711	##stituting	O
2711	respective	O
2711	time	O
2711	points	O
2711	and	O
2711	rate	O
2711	constant	O
2711	##s	O
2711	.	O
2711	[SEP]	O
2712	[CLS]	O
2712	both	O
2712	peak	O
2712	exposure	O
2712	(	O
2712	cm	B-PK
2712	##ax	I-PK
2712	)	O
2712	and	O
2712	total	O
2712	exposure	O
2712	(	O
2712	au	B-PK
2712	##c	I-PK
2712	##last	I-PK
2712	)	O
2712	increased	O
2712	with	O
2712	increasing	O
2712	dose	O
2712	from	O
2712	0	O
2712	.	O
2712	75	O
2712	mg	O
2712	to	O
2712	9	O
2712	mg	O
2712	,	O
2712	and	O
2712	the	O
2712	increases	O
2712	appeared	O
2712	to	O
2712	be	O
2712	dose	O
2712	proportional	O
2712	as	O
2712	evidenced	O
2712	by	O
2712	similar	O
2712	dose	B-PK
2712	-	I-PK
2712	normal	I-PK
2712	##ized	I-PK
2712	au	I-PK
2712	##c	I-PK
2712	##last	I-PK
2712	and	O
2712	cm	B-PK
2712	##ax	I-PK
2712	across	O
2712	all	O
2712	doses	O
2712	.	O
2712	[SEP]	O
2713	[CLS]	O
2713	au	B-PK
2713	##c	I-PK
2713	/	I-PK
2713	mi	I-PK
2713	##c	I-PK
2713	,	O
2713	meant	O
2713	the	O
2713	targeted	O
2713	end	O
2713	##point	O
2713	for	O
2713	optimal	O
2713	efficacy	O
2713	;	O
2713	mi	O
2713	##c	O
2713	,	O
2713	meant	O
2713	minimum	O
2713	inhibitor	O
2713	##y	O
2713	concentration	O
2713	;	O
2713	c	B-PK
2713	##l	I-PK
2713	,	O
2713	meant	O
2713	clearance	B-PK
2713	per	I-PK
2713	day	I-PK
2713	;	O
2713	f	B-PK
2713	##u	I-PK
2713	,	O
2713	meant	O
2713	the	O
2713	free	B-PK
2713	fraction	I-PK
2713	of	I-PK
2713	drug	I-PK
2713	in	I-PK
2713	plasma	I-PK
2713	,	O
2713	ignoring	O
2713	if	O
2713	there	O
2713	was	O
2713	minimal	O
2713	binding	O
2713	;	O
2713	f	B-PK
2713	,	O
2713	meant	O
2713	the	O
2713	bio	B-PK
2713	##ava	I-PK
2713	##ila	I-PK
2713	##bility	I-PK
2713	.	O
2713	[SEP]	O
2714	[CLS]	O
2714	the	O
2714	radio	B-PK
2714	##act	I-PK
2714	##ivity	I-PK
2714	concentration	O
2714	in	O
2714	bi	O
2714	##le	O
2714	at	O
2714	0	O
2714	.	O
2714	08	O
2714	##3	O
2714	h	O
2714	post	O
2714	##dos	O
2714	##e	O
2714	was	O
2714	100	O
2714	-	O
2714	fold	O
2714	higher	O
2714	than	O
2714	that	O
2714	in	O
2714	blood	O
2714	(	O
2714	maximum	B-PK
2714	concentration	I-PK
2714	[	I-PK
2714	cm	I-PK
2714	##ax	I-PK
2714	]	I-PK
2714	,	O
2714	1	O
2714	,	O
2714	570	O
2714	ng	O
2714	·	O
2714	e	O
2714	##q	O
2714	/	O
2714	m	O
2714	##l	O
2714	)	O
2714	but	O
2714	was	O
2714	not	O
2714	me	O
2714	##as	O
2714	##urable	O
2714	at	O
2714	24	O
2714	h	O
2714	.	O
2714	[SEP]	O
2715	[CLS]	O
2715	the	O
2715	radio	B-PK
2715	##act	I-PK
2715	##ivity	I-PK
2715	concentration	O
2715	in	O
2715	me	O
2715	##as	O
2715	##urable	O
2715	tissues	O
2715	was	O
2715	higher	O
2715	than	O
2715	in	O
2715	blood	O
2715	(	O
2715	cm	B-PK
2715	##ax	I-PK
2715	=	O
2715	125	O
2715	ng	O
2715	·	O
2715	e	O
2715	##q	O
2715	/	O
2715	m	O
2715	##l	O
2715	)	O
2715	,	O
2715	except	O
2715	in	O
2715	brain	O
2715	,	O
2715	spinal	O
2715	cord	O
2715	,	O
2715	and	O
2715	eyes	O
2715	(	O
2715	table	O
2715	2	O
2715	and	O
2715	table	O
2715	3	O
2715	)	O
2715	.	O
2715	[SEP]	O
2716	[CLS]	O
2716	the	O
2716	tissue	B-PK
2716	-	I-PK
2716	to	I-PK
2716	-	I-PK
2716	blood	I-PK
2716	concentration	I-PK
2716	ratios	I-PK
2716	of	O
2716	1	O
2716	.	O
2716	37	O
2716	(	O
2716	based	O
2716	on	O
2716	cm	B-PK
2716	##ax	I-PK
2716	)	O
2716	and	O
2716	0	O
2716	.	O
2716	37	O
2716	(	O
2716	based	O
2716	on	O
2716	au	B-PK
2716	##c	I-PK
2716	)	O
2716	suggested	O
2716	moderate	O
2716	distribution	O
2716	of	O
2716	drug	O
2716	-	O
2716	related	O
2716	radio	B-PK
2716	##act	I-PK
2716	##ivity	I-PK
2716	to	O
2716	the	O
2716	test	O
2716	##is	O
2716	(	O
2716	table	O
2716	3	O
2716	)	O
2716	.	O
2716	[SEP]	O
2717	[CLS]	O
2717	the	O
2717	concentration	O
2717	profiles	O
2717	of	O
2717	the	O
2717	radio	B-PK
2717	##act	I-PK
2717	##ivity	I-PK
2717	of	O
2717	o	O
2717	##mada	O
2717	##cy	O
2717	##cline	O
2717	in	O
2717	blood	O
2717	and	O
2717	plasma	O
2717	were	O
2717	analyzed	O
2717	using	O
2717	win	O
2717	##non	O
2717	##lin	O
2717	and	O
2717	the	O
2717	p	O
2717	##har	O
2717	##ma	O
2717	##co	O
2717	##kin	O
2717	##etic	O
2717	parameters	O
2717	,	O
2717	including	O
2717	the	O
2717	area	B-PK
2717	under	I-PK
2717	the	I-PK
2717	concentration	I-PK
2717	curve	I-PK
2717	from	I-PK
2717	h	I-PK
2717	0	I-PK
2717	to	I-PK
2717	in	I-PK
2717	##finity	I-PK
2717	(	I-PK
2717	au	I-PK
2717	##c	I-PK
2717	##0	I-PK
2717	–	I-PK
2717	∞	I-PK
2717	)	I-PK
2717	,	O
2717	and	O
2717	the	O
2717	terminal	B-PK
2717	half	I-PK
2717	-	I-PK
2717	lives	I-PK
2717	were	O
2717	estimated	O
2717	by	O
2717	a	O
2717	non	O
2717	##com	O
2717	##par	O
2717	##tment	O
2717	##al	O
2717	analysis	O
2717	.	O
2717	[SEP]	O
2718	[CLS]	O
2718	the	O
2718	fraction	O
2718	or	O
2718	percentage	O
2718	of	O
2718	the	O
2718	dose	O
2718	absorbed	O
2718	was	O
2718	calculated	O
2718	based	O
2718	on	O
2718	blood	B-PK
2718	or	O
2718	plasma	B-PK
2718	radio	I-PK
2718	##act	I-PK
2718	##ivity	I-PK
2718	data	O
2718	,	O
2718	assuming	O
2718	a	O
2718	proportional	O
2718	relationship	O
2718	between	O
2718	au	B-PK
2718	##c	I-PK
2718	and	O
2718	dose	O
2718	.	O
2718	[SEP]	O
2719	[CLS]	O
2719	next	O
2719	,	O
2719	as	O
2719	seen	O
2719	in	O
2719	fi	O
2719	##g	O
2719	.	O
2719	2d	O
2719	–	O
2719	f	O
2719	,	O
2719	i	O
2719	.	O
2719	p	O
2719	.	O
2719	injection	O
2719	of	O
2719	p	O
2719	##eg	O
2719	-	O
2719	t	O
2719	##ms	O
2719	-	O
2719	coated	O
2719	m	O
2719	##s	O
2719	##ns	O
2719	shows	O
2719	a	O
2719	pu	O
2719	##nc	O
2719	##tate	O
2719	bio	O
2719	##dis	O
2719	##tribution	O
2719	pattern	O
2719	throughout	O
2719	the	O
2719	abdomen	O
2719	at	O
2719	the	O
2719	initial	O
2719	time	O
2719	point	O
2719	of	O
2719	30	O
2719	min	O
2719	that	O
2719	seems	O
2719	to	O
2719	map	O
2719	the	O
2719	abdominal	O
2719	l	O
2719	##ymph	O
2719	c	O
2719	##ir	O
2719	##cula	O
2719	##tory	O
2719	network	O
2719	##29	O
2719	,	O
2719	with	O
2719	media	O
2719	##st	O
2719	##inal	O
2719	l	O
2719	##ymph	O
2719	nodes	O
2719	in	O
2719	the	O
2719	th	O
2719	##orax	O
2719	(	O
2719	see	O
2719	r	O
2719	##oi	O
2719	map	O
2719	fi	O
2719	##g	O
2719	.	O
2719	1	O
2719	##c	O
2719	)	O
2719	being	O
2719	an	O
2719	important	O
2719	site	O
2719	of	O
2719	radio	B-PK
2719	##act	I-PK
2719	##ivity	I-PK
2719	(	O
2719	see	O
2719	fi	O
2719	##gs	O
2719	.	O
2719	2d	O
2719	–	O
2719	f	O
2719	,	O
2719	3	O
2719	##b	O
2719	)	O
2719	.	O
2719	[SEP]	O
2720	[CLS]	O
2720	given	O
2720	that	O
2720	the	O
2720	i	O
2720	.	O
2720	v	O
2720	.	O
2720	injected	O
2720	m	O
2720	##s	O
2720	##ns	O
2720	are	O
2720	100	O
2720	%	O
2720	bio	O
2720	##ava	O
2720	##ila	O
2720	##ble	O
2720	,	O
2720	the	O
2720	bio	B-PK
2720	##ava	I-PK
2720	##ila	I-PK
2720	##bility	I-PK
2720	fraction	I-PK
2720	(	O
2720	calculated	O
2720	as	O
2720	the	O
2720	ratio	O
2720	of	O
2720	dose	B-PK
2720	normal	I-PK
2720	##ized	I-PK
2720	au	I-PK
2720	##c	I-PK
2720	##0	I-PK
2720	–	I-PK
2720	24	I-PK
2720	h	I-PK
2720	of	O
2720	i	O
2720	.	O
2720	p	O
2720	.	O
2720	to	O
2720	au	B-PK
2720	##c	I-PK
2720	##0	I-PK
2720	–	I-PK
2720	24	I-PK
2720	h	I-PK
2720	of	O
2720	i	O
2720	.	O
2720	v	O
2720	.	O
2720	)	O
2720	of	O
2720	i	O
2720	.	O
2720	p	O
2720	.	O
2720	administered	O
2720	t	O
2720	##ms	O
2720	##25	O
2720	,	O
2720	t	O
2720	##ms	O
2720	##50	O
2720	,	O
2720	and	O
2720	t	O
2720	##ms	O
2720	##15	O
2720	##0	O
2720	m	O
2720	##s	O
2720	##ns	O
2720	is	O
2720	72	O
2720	.	O
2720	8	O
2720	,	O
2720	66	O
2720	.	O
2720	6	O
2720	,	O
2720	and	O
2720	79	O
2720	.	O
2720	6	O
2720	%	O
2720	,	O
2720	respectively	O
2720	,	O
2720	thus	O
2720	q	O
2720	##uant	O
2720	##ifying	O
2720	the	O
2720	incomplete	O
2720	absorption	O
2720	of	O
2720	m	O
2720	##s	O
2720	##ns	O
2720	from	O
2720	the	O
2720	per	O
2720	##ito	O
2720	##nea	O
2720	##l	O
2720	cavity	O
2720	into	O
2720	blood	O
2720	.	O
2720	[SEP]	O
2721	[CLS]	O
2721	for	O
2721	the	O
2721	p	O
2721	##ei	O
2721	##50	O
2721	m	O
2721	##s	O
2721	##ns	O
2721	with	O
2721	surface	O
2721	-	O
2721	exposed	O
2721	am	O
2721	##ines	O
2721	,	O
2721	s	O
2721	##ple	O
2721	##en	O
2721	and	O
2721	liver	O
2721	are	O
2721	the	O
2721	prime	O
2721	sites	O
2721	of	O
2721	radio	B-PK
2721	##act	I-PK
2721	##ivity	I-PK
2721	,	O
2721	unlike	O
2721	the	O
2721	size	O
2721	-	O
2721	matched	O
2721	and	O
2721	z	O
2721	##eta	O
2721	potential	O
2721	-	O
2721	matched	O
2721	counterpart	O
2721	,	O
2721	q	O
2721	##a	O
2721	##50	O
2721	,	O
2721	with	O
2721	o	O
2721	##bs	O
2721	##truct	O
2721	##ed	O
2721	am	O
2721	##ines	O
2721	(	O
2721	see	O
2721	fi	O
2721	##gs	O
2721	.	O
2721	3	O
2721	##a	O
2721	,	O
2721	5	O
2721	##e	O
2721	,	O
2721	f	O
2721	)	O
2721	.	O
2721	[SEP]	O
2722	[CLS]	O
2722	the	O
2722	presence	O
2722	of	O
2722	radio	B-PK
2722	##act	I-PK
2722	##ivity	I-PK
2722	in	O
2722	the	O
2722	u	O
2722	##rina	O
2722	##ry	O
2722	bladder	O
2722	r	O
2722	##oi	O
2722	indicates	O
2722	that	O
2722	some	O
2722	111	O
2722	##in	O
2722	-	O
2722	d	O
2722	##t	O
2722	##pa	O
2722	is	O
2722	reaching	O
2722	the	O
2722	bladder	O
2722	(	O
2722	fi	O
2722	##gs	O
2722	.	O
2722	2	O
2722	,	O
2722	3	O
2722	,	O
2722	6	O
2722	##b	O
2722	,	O
2722	e	O
2722	)	O
2722	.	O
2722	[SEP]	O
2723	[CLS]	O
2723	the	O
2723	effective	B-PK
2723	per	I-PK
2723	##me	I-PK
2723	##ability	I-PK
2723	coefficient	I-PK
2723	(	I-PK
2723	p	I-PK
2723	##ef	I-PK
2723	##f	I-PK
2723	)	I-PK
2723	was	O
2723	calculated	O
2723	with	O
2723	the	O
2723	following	O
2723	equation	O
2723	:	O
2723	p	O
2723	##ef	O
2723	##f	O
2723	=	O
2723	q	O
2723	##2	O
2723	##π	O
2723	##rl	O
2723	##ln	O
2723	##co	O
2723	##ut	O
2723	##cin	O
2723	##where	O
2723	q	O
2723	represents	O
2723	the	O
2723	flow	O
2723	rate	O
2723	(	O
2723	0	O
2723	.	O
2723	2	O
2723	m	O
2723	##l	O
2723	/	O
2723	min	O
2723	)	O
2723	,	O
2723	r	O
2723	and	O
2723	l	O
2723	denote	O
2723	the	O
2723	radius	O
2723	and	O
2723	length	O
2723	of	O
2723	the	O
2723	per	O
2723	##fused	O
2723	in	O
2723	##test	O
2723	##inal	O
2723	segment	O
2723	(	O
2723	cm	O
2723	)	O
2723	,	O
2723	c	O
2723	##in	O
2723	and	O
2723	co	O
2723	##ut	O
2723	are	O
2723	the	O
2723	inlet	O
2723	and	O
2723	outlet	O
2723	concentration	O
2723	of	O
2723	r	O
2723	##x	O
2723	##f	O
2723	,	O
2723	respectively	O
2723	.	O
2723	[SEP]	O
2724	[CLS]	O
2724	weight	O
2724	,	O
2724	height	O
2724	,	O
2724	and	O
2724	many	O
2724	physiological	O
2724	parameters	O
2724	,	O
2724	such	O
2724	as	O
2724	organ	O
2724	volumes	O
2724	,	O
2724	blood	B-PK
2724	flow	I-PK
2724	rates	I-PK
2724	,	O
2724	and	O
2724	gas	O
2724	##tro	O
2724	##int	O
2724	##est	O
2724	##inal	O
2724	characteristics	O
2724	,	O
2724	were	O
2724	varied	O
2724	according	O
2724	to	O
2724	published	O
2724	data	O
2724	##7	O
2724	as	O
2724	implemented	O
2724	into	O
2724	the	O
2724	software	O
2724	.	O
2724	9	O
2724	in	O
2724	addition	O
2724	to	O
2724	the	O
2724	var	O
2724	##iability	O
2724	in	O
2724	drug	O
2724	p	O
2724	##k	O
2724	that	O
2724	results	O
2724	from	O
2724	these	O
2724	physiological	O
2724	differences	O
2724	within	O
2724	the	O
2724	virtual	O
2724	populations	O
2724	,	O
2724	the	O
2724	expression	O
2724	levels	O
2724	of	O
2724	the	O
2724	implemented	O
2724	drug	O
2724	meta	O
2724	##bol	O
2724	##izing	O
2724	enzymes	O
2724	,	O
2724	transport	O
2724	##ers	O
2724	,	O
2724	and	O
2724	protein	O
2724	binding	O
2724	partners	O
2724	were	O
2724	varied	O
2724	around	O
2724	their	O
2724	reference	O
2724	values	O
2724	.	O
2724	[SEP]	O
2725	[CLS]	O
2725	to	O
2725	minimize	O
2725	an	O
2725	##eus	O
2725	##omy	O
2725	at	O
2725	the	O
2725	reference	O
2725	lo	O
2725	##ci	O
2725	,	O
2725	the	O
2725	reference	O
2725	lo	O
2725	##cus	O
2725	(	O
2725	r	O
2725	##pp	O
2725	##30	O
2725	,	O
2725	c	O
2725	.	O
2725	16	O
2725	_	O
2725	c	O
2725	.	O
2725	77	O
2725	,	O
2725	ch	O
2725	##r	O
2725	##10	O
2725	##q	O
2725	##23	O
2725	)	O
2725	was	O
2725	inter	O
2725	##rogate	O
2725	##d	O
2725	against	O
2725	two	O
2725	additional	O
2725	reference	O
2725	lo	O
2725	##ci	O
2725	(	O
2725	a	O
2725	##p	O
2725	##3	O
2725	##b	O
2725	##1	O
2725	,	O
2725	c	O
2725	.	O
2725	257	O
2725	##8	O
2725	–	O
2725	236	O
2725	##0	O
2725	##5	O
2725	_	O
2725	c	O
2725	.	O
2725	257	O
2725	##8	O
2725	_	O
2725	235	O
2725	##43	O
2725	,	O
2725	ch	O
2725	##r	O
2725	##5	O
2725	##q	O
2725	##14	O
2725	;	O
2725	n	O
2725	##fa	O
2725	##t	O
2725	##5	O
2725	,	O
2725	c	O
2725	.	O
2725	32	O
2725	##7	O
2725	_	O
2725	c	O
2725	.	O
2725	395	O
2725	,	O
2725	ch	O
2725	##r	O
2725	##16	O
2725	##q	O
2725	##22	O
2725	)	O
2725	such	O
2725	that	O
2725	each	O
2725	target	O
2725	lo	O
2725	##cus	O
2725	was	O
2725	normal	O
2725	##ized	O
2725	to	O
2725	the	O
2725	average	B-PK
2725	concentration	I-PK
2725	of	O
2725	the	O
2725	three	O
2725	reference	O
2725	lo	O
2725	##ci	O
2725	.	O
2725	[SEP]	O
2726	[CLS]	O
2726	drug	O
2726	-	O
2726	related	O
2726	radio	B-PK
2726	##act	I-PK
2726	##ivity	I-PK
2726	after	O
2726	a	O
2726	90	O
2726	mg	O
2726	/	O
2726	kg	O
2726	oral	O
2726	dose	O
2726	of	O
2726	14	O
2726	##c	O
2726	-	O
2726	o	O
2726	##mada	O
2726	##cy	O
2726	##cline	O
2726	showed	O
2726	a	O
2726	low	O
2726	distribution	O
2726	to	O
2726	the	O
2726	central	O
2726	nervous	O
2726	system	O
2726	(	O
2726	brain	O
2726	and	O
2726	spinal	O
2726	cord	O
2726	)	O
2726	,	O
2726	since	O
2726	the	O
2726	concentrations	O
2726	were	O
2726	low	O
2726	(	O
2726	<	O
2726	80	O
2726	ng	O
2726	·	O
2726	e	O
2726	##q	O
2726	/	O
2726	g	O
2726	)	O
2726	and	O
2726	<	O
2726	ll	O
2726	##o	O
2726	##q	O
2726	for	O
2726	most	O
2726	time	O
2726	points	O
2726	,	O
2726	although	O
2726	the	O
2726	tissue	B-PK
2726	-	I-PK
2726	to	I-PK
2726	-	I-PK
2726	blood	I-PK
2726	concentration	I-PK
2726	ratios	I-PK
2726	were	O
2726	0	O
2726	.	O
2726	62	O
2726	(	O
2726	based	O
2726	on	O
2726	cm	B-PK
2726	##ax	I-PK
2726	)	O
2726	and	O
2726	[UNK]	O
2726	.	O
2726	19	O
2726	(	O
2726	based	O
2726	on	O
2726	au	B-PK
2726	##c	I-PK
2726	)	O
2726	.	O
2726	[SEP]	O
2727	[CLS]	O
2727	the	O
2727	profile	O
2727	of	O
2727	radio	B-PK
2727	##act	I-PK
2727	##ivity	I-PK
2727	in	O
2727	each	O
2727	el	O
2727	##uted	O
2727	sample	O
2727	was	O
2727	obtained	O
2727	using	O
2727	a	O
2727	berth	O
2727	##old	O
2727	t	O
2727	##l	O
2727	##c	O
2727	linear	O
2727	analyze	O
2727	##r	O
2727	(	O
2727	model	O
2727	lb	O
2727	##28	O
2727	##42	O
2727	and	O
2727	lb	O
2727	##28	O
2727	##32	O
2727	;	O
2727	labor	O
2727	##ator	O
2727	##ium	O
2727	pro	O
2727	##f	O
2727	.	O
2727	d	O
2727	##r	O
2727	.	O
2727	berth	O
2727	##old	O
2727	,	O
2727	wild	O
2727	##bad	O
2727	,	O
2727	g	O
2727	##erman	O
2727	##y	O
2727	)	O
2727	.	O
2727	[SEP]	O
2728	[CLS]	O
2728	blood	O
2728	loss	O
2728	volume	O
2728	(	O
2728	m	O
2728	##l	O
2728	)	O
2728	is	O
2728	measured	O
2728	in	O
2728	the	O
2728	surgical	O
2728	or	O
2728	cell	O
2728	-	O
2728	save	O
2728	##r	O
2728	as	O
2728	##piration	O
2728	bag	O
2728	,	O
2728	in	O
2728	the	O
2728	delivery	O
2728	bag	O
2728	collecting	O
2728	v	B-PK
2728	##agi	I-PK
2728	##nal	I-PK
2728	blood	I-PK
2728	flow	I-PK
2728	during	O
2728	c	O
2728	##s	O
2728	and	O
2728	by	O
2728	weighing	O
2728	d	O
2728	##rap	O
2728	##es	O
2728	and	O
2728	pads	O
2728	(	O
2728	conversion	O
2728	factor	O
2728	for	O
2728	blood	O
2728	density	O
2728	=	O
2728	1	O
2728	.	O
2728	06	O
2728	)	O
2728	.	O
2728	[SEP]	O
2729	[CLS]	O
2729	au	B-PK
2729	##c	I-PK
2729	##0	I-PK
2729	–	I-PK
2729	4	I-PK
2729	(	O
2729	exposure	O
2729	before	O
2729	t	B-PK
2729	##max	I-PK
2729	for	O
2729	intact	O
2729	h	O
2729	##ydro	O
2729	##co	O
2729	##don	O
2729	##e	O
2729	er	O
2729	)	O
2729	was	O
2729	57	O
2729	%	O
2729	lower	O
2729	for	O
2729	finely	O
2729	crushed	O
2729	h	O
2729	##ydro	O
2729	##co	O
2729	##don	O
2729	##e	O
2729	er	O
2729	than	O
2729	for	O
2729	h	O
2729	##ydro	O
2729	##co	O
2729	##don	O
2729	##e	O
2729	i	O
2729	##r	O
2729	.	O
2729	[SEP]	O
2730	[CLS]	O
2730	the	O
2730	study	O
2730	aims	O
2730	to	O
2730	determine	O
2730	the	O
2730	area	B-PK
2730	under	I-PK
2730	the	I-PK
2730	curve	I-PK
2730	(	I-PK
2730	au	I-PK
2730	##c	I-PK
2730	)	I-PK
2730	of	O
2730	the	O
2730	le	O
2730	##vo	O
2730	##f	O
2730	##lo	O
2730	##xa	O
2730	##cin	O
2730	serum	O
2730	concentration	O
2730	in	O
2730	the	O
2730	24	O
2730	hours	O
2730	after	O
2730	dos	O
2730	##ing	O
2730	divided	O
2730	by	O
2730	the	O
2730	minimal	O
2730	inhibitor	O
2730	##y	O
2730	concentration	O
2730	of	O
2730	the	O
2730	patient	O
2730	’	O
2730	s	O
2730	my	O
2730	##co	O
2730	##ba	O
2730	##cter	O
2730	##ium	O
2730	tuberculosis	O
2730	is	O
2730	##olate	O
2730	that	O
2730	in	O
2730	##hibit	O
2730	##s	O
2730	>	O
2730	90	O
2730	%	O
2730	of	O
2730	organisms	O
2730	(	O
2730	au	B-PK
2730	##c	I-PK
2730	/	I-PK
2730	mi	I-PK
2730	##c	I-PK
2730	)	O
2730	that	O
2730	ma	O
2730	##xi	O
2730	##mize	O
2730	##s	O
2730	efficacy	O
2730	and	O
2730	the	O
2730	au	B-PK
2730	##c	I-PK
2730	that	O
2730	ma	O
2730	##xi	O
2730	##mize	O
2730	##s	O
2730	safety	O
2730	and	O
2730	to	O
2730	##ler	O
2730	##ability	O
2730	in	O
2730	the	O
2730	context	O
2730	of	O
2730	an	O
2730	m	O
2730	##dr	O
2730	-	O
2730	t	O
2730	##b	O
2730	treatment	O
2730	regime	O
2730	##n	O
2730	.	O
2730	[SEP]	O
2731	[CLS]	O
2731	the	O
2731	absorption	B-PK
2731	rate	I-PK
2731	constant	I-PK
2731	(	I-PK
2731	ka	I-PK
2731	)	I-PK
2731	data	O
2731	showed	O
2731	that	O
2731	the	O
2731	g	O
2731	##c	O
2731	##m	O
2731	trans	O
2731	-	O
2731	corn	O
2731	##eal	O
2731	per	B-PK
2731	##me	I-PK
2731	##ability	I-PK
2731	was	O
2731	enhanced	O
2731	and	O
2731	was	O
2731	statistical	O
2731	##ly	O
2731	significant	O
2731	than	O
2731	the	O
2731	g	O
2731	##an	O
2731	##ci	O
2731	##c	O
2731	##lov	O
2731	##ir	O
2731	solution	O
2731	.	O
2731	[SEP]	O
2732	[CLS]	O
2732	steady	B-PK
2732	-	I-PK
2732	state	I-PK
2732	im	I-PK
2732	##ati	I-PK
2732	##ni	I-PK
2732	##b	I-PK
2732	t	I-PK
2732	##rough	I-PK
2732	concentration	I-PK
2732	(	I-PK
2732	cm	I-PK
2732	##in	I-PK
2732	)	I-PK
2732	values	O
2732	in	O
2732	18	O
2732	patients	O
2732	with	O
2732	g	O
2732	##ist	O
2732	who	O
2732	were	O
2732	taking	O
2732	300	O
2732	mg	O
2732	/	O
2732	d	O
2732	or	O
2732	400	O
2732	mg	O
2732	/	O
2732	d	O
2732	im	O
2732	##ati	O
2732	##ni	O
2732	##b	O
2732	were	O
2732	measured	O
2732	.	O
2732	[SEP]	O
2733	[CLS]	O
2733	distribution	O
2733	of	O
2733	im	O
2733	cm	B-PK
2733	##in	I-PK
2733	at	I-PK
2733	steady	I-PK
2733	state	I-PK
2733	for	O
2733	300	O
2733	mg	O
2733	/	O
2733	d	O
2733	and	O
2733	400	O
2733	mg	O
2733	/	O
2733	d	O
2733	are	O
2733	displayed	O
2733	in	O
2733	fi	O
2733	##g	O
2733	.	O
2733	1	O
2733	.	O
2733	[SEP]	O
2734	[CLS]	O
2734	the	O
2734	dos	O
2734	##ing	O
2734	method	O
2734	based	O
2734	on	O
2734	clearance	B-PK
2734	values	O
2734	obtained	O
2734	by	O
2734	non	O
2734	##me	O
2734	##m	O
2734	analysis	O
2734	allowed	O
2734	the	O
2734	prediction	O
2734	of	O
2734	the	O
2734	steady	B-PK
2734	-	I-PK
2734	state	I-PK
2734	concentration	I-PK
2734	as	O
2734	a	O
2734	function	O
2734	of	O
2734	maintenance	O
2734	dose	O
2734	with	O
2734	acceptable	O
2734	error	O
2734	for	O
2734	therapeutic	O
2734	drug	O
2734	monitoring	O
2734	.	O
2734	[SEP]	O
2735	[CLS]	O
2735	greater	O
2735	que	O
2735	##rc	O
2735	##eti	O
2735	##n	O
2735	absorption	O
2735	and	O
2735	bio	B-PK
2735	##ava	I-PK
2735	##ila	I-PK
2735	##bility	I-PK
2735	may	O
2735	be	O
2735	associated	O
2735	with	O
2735	poor	O
2735	vitamin	O
2735	c	O
2735	status	O
2735	and	O
2735	increased	O
2735	in	O
2735	##test	O
2735	##inal	O
2735	per	B-PK
2735	##me	I-PK
2735	##ability	I-PK
2735	in	O
2735	healthy	O
2735	adults	O
2735	.	O
2735	[SEP]	O
2736	[CLS]	O
2736	parameters	O
2736	were	O
2736	included	O
2736	into	O
2736	the	O
2736	analysis	O
2736	if	O
2736	they	O
2736	have	O
2736	been	O
2736	op	O
2736	##ti	O
2736	##mized	O
2736	,	O
2736	if	O
2736	they	O
2736	might	O
2736	have	O
2736	a	O
2736	strong	O
2736	influence	O
2736	due	O
2736	to	O
2736	calculation	O
2736	methods	O
2736	used	O
2736	in	O
2736	the	O
2736	model	O
2736	(	O
2736	e	O
2736	.	O
2736	g	O
2736	.	O
2736	,	O
2736	lip	O
2736	##op	O
2736	##hil	O
2736	##icit	O
2736	##y	O
2736	and	O
2736	fraction	B-PK
2736	un	I-PK
2736	##bound	I-PK
2736	)	O
2736	,	O
2736	if	O
2736	they	O
2736	are	O
2736	related	O
2736	to	O
2736	op	O
2736	##ti	O
2736	##mized	O
2736	parameters	O
2736	,	O
2736	or	O
2736	if	O
2736	they	O
2736	had	O
2736	significant	O
2736	impact	O
2736	in	O
2736	other	O
2736	models	O
2736	(	O
2736	e	O
2736	.	O
2736	g	O
2736	.	O
2736	,	O
2736	so	O
2736	##lub	O
2736	##ility	O
2736	and	O
2736	blood	B-PK
2736	/	I-PK
2736	plasma	I-PK
2736	concentration	I-PK
2736	ratio	I-PK
2736	)	O
2736	.	O
2736	[SEP]	O
2737	[CLS]	O
2737	standard	O
2737	methods	O
2737	were	O
2737	used	O
2737	to	O
2737	determine	O
2737	the	O
2737	log	O
2737	of	O
2737	o	O
2737	##ct	O
2737	##ano	O
2737	##l	O
2737	/	O
2737	water	O
2737	partition	O
2737	coefficient	O
2737	(	O
2737	log	O
2737	##p	O
2737	)	O
2737	,	O
2737	the	O
2737	blood	B-PK
2737	‐	I-PK
2737	plasma	I-PK
2737	concentration	I-PK
2737	ratio	I-PK
2737	,	O
2737	and	O
2737	the	O
2737	fraction	B-PK
2737	un	I-PK
2737	##bound	I-PK
2737	in	I-PK
2737	plasma	I-PK
2737	.	O
2737	[SEP]	O
2738	[CLS]	O
2738	fraction	B-PK
2738	##s	I-PK
2738	escaping	I-PK
2738	gut	I-PK
2738	metabolism	I-PK
2738	in	O
2738	the	O
2738	presence	O
2738	and	O
2738	absence	O
2738	of	O
2738	inhibitor	O
2738	##s	O
2738	were	O
2738	set	O
2738	to	O
2738	unity	O
2738	for	O
2738	c	O
2738	##y	O
2738	##p	O
2738	##2	O
2738	##b	O
2738	##6	O
2738	and	O
2738	2d	O
2738	##6	O
2738	,	O
2738	because	O
2738	expression	O
2738	of	O
2738	these	O
2738	enzymes	O
2738	in	O
2738	the	O
2738	gas	O
2738	##tro	O
2738	##int	O
2738	##est	O
2738	##inal	O
2738	tract	O
2738	is	O
2738	ne	O
2738	##gli	O
2738	##gible	O
2738	,	O
2738	36	O
2738	and	O
2738	to	O
2738	unity	O
2738	and	O
2738	0	O
2738	.	O
2738	57	O
2738	for	O
2738	mid	O
2738	##az	O
2738	##ola	O
2738	##m	O
2738	in	O
2738	line	O
2738	with	O
2738	the	O
2738	prominent	O
2738	gut	O
2738	expression	O
2738	of	O
2738	c	O
2738	##y	O
2738	##p	O
2738	##3	O
2738	##a	O
2738	.	O
2738	37	O
2738	the	O
2738	static	O
2738	equation	O
2738	for	O
2738	a	O
2738	single	O
2738	c	O
2738	##y	O
2738	##p	O
2738	is	O
2738	##oz	O
2738	##yme	O
2738	si	O
2738	##mp	O
2738	##li	O
2738	##fies	O
2738	to	O
2738	:	O
2738	(	O
2738	1	O
2738	)	O
2738	au	O
2738	##c	O
2738	′	O
2738	au	O
2738	##c	O
2738	=	O
2738	f	O
2738	##gi	O
2738	##f	O
2738	##g	O
2738	##×	O
2738	##1	O
2738	##f	O
2738	##m	O
2738	##cy	O
2738	##pi	O
2738	##1	O
2738	+	O
2738	i	O
2738	/	O
2738	k	O
2738	##i	O
2738	+	O
2738	1	O
2738	##−	O
2738	##f	O
2738	##m	O
2738	##cy	O
2738	##pi	O
2738	##where	O
2738	[UNK]	B-PK
2738	and	O
2738	au	B-PK
2738	##c	I-PK
2738	are	O
2738	the	O
2738	area	B-PK
2738	under	I-PK
2738	the	I-PK
2738	concentration	I-PK
2738	time	I-PK
2738	curve	I-PK
2738	in	O
2738	the	O
2738	presence	O
2738	and	O
2738	absence	O
2738	of	O
2738	the	O
2738	inhibitor	O
2738	,	O
2738	f	B-PK
2738	##gi	I-PK
2738	and	O
2738	f	B-PK
2738	##g	I-PK
2738	are	O
2738	the	O
2738	fraction	B-PK
2738	##s	I-PK
2738	escaping	I-PK
2738	gut	I-PK
2738	metabolism	I-PK
2738	in	O
2738	the	O
2738	presence	O
2738	and	O
2738	absence	O
2738	of	O
2738	inhibitor	O
2738	,	O
2738	[	B-PK
2738	i	I-PK
2738	]	I-PK
2738	is	O
2738	the	O
2738	estimated	B-PK
2738	un	I-PK
2738	##bound	I-PK
2738	inhibitor	I-PK
2738	concentration	I-PK
2738	as	O
2738	discussed	O
2738	below	O
2738	,	O
2738	k	B-PK
2738	##i	I-PK
2738	is	O
2738	the	O
2738	re	B-PK
2738	##versible	I-PK
2738	in	I-PK
2738	##hibition	I-PK
2738	constant	I-PK
2738	,	O
2738	and	O
2738	f	B-PK
2738	##m	I-PK
2738	##cy	I-PK
2738	##pi	I-PK
2738	represents	O
2738	the	O
2738	fraction	B-PK
2738	of	I-PK
2738	the	I-PK
2738	probe	I-PK
2738	drug	I-PK
2738	meta	I-PK
2738	##bol	I-PK
2738	##ized	I-PK
2738	by	O
2738	c	O
2738	##y	O
2738	##pi	O
2738	.	O
2738	[SEP]	O
2739	[CLS]	O
2739	the	O
2739	highest	O
2739	tissue	B-PK
2739	-	I-PK
2739	to	I-PK
2739	-	I-PK
2739	blood	I-PK
2739	concentration	I-PK
2739	ratios	I-PK
2739	(	O
2739	t	O
2739	/	O
2739	b	O
2739	>	O
2739	5	O
2739	)	O
2739	,	O
2739	calculated	O
2739	as	O
2739	values	O
2739	corresponding	O
2739	to	O
2739	the	O
2739	area	B-PK
2739	under	I-PK
2739	the	I-PK
2739	concentration	I-PK
2739	-	I-PK
2739	time	I-PK
2739	curve	I-PK
2739	(	I-PK
2739	au	I-PK
2739	##c	I-PK
2739	)	I-PK
2739	,	O
2739	were	O
2739	observed	O
2739	in	O
2739	bone	O
2739	mineral	O
2739	,	O
2739	harder	O
2739	##ian	O
2739	g	O
2739	##land	O
2739	,	O
2739	liver	O
2739	,	O
2739	s	O
2739	##ple	O
2739	##en	O
2739	,	O
2739	and	O
2739	sa	O
2739	##liva	O
2739	##ry	O
2739	g	O
2739	##land	O
2739	(	O
2739	table	O
2739	3	O
2739	)	O
2739	.	O
2739	[SEP]	O
2740	[CLS]	O
2740	though	O
2740	the	O
2740	initial	O
2740	concentration	O
2740	and	O
2740	tumor	B-PK
2740	/	I-PK
2740	blood	I-PK
2740	concentration	I-PK
2740	ratio	I-PK
2740	of	O
2740	5	O
2740	-	O
2740	f	O
2740	##a	O
2740	were	O
2740	higher	O
2740	than	O
2740	5	O
2740	-	O
2740	f	O
2740	##a	O
2740	-	O
2740	p	O
2740	##ae	O
2740	,	O
2740	a	O
2740	high	O
2740	elimination	B-PK
2740	rate	I-PK
2740	of	O
2740	5	O
2740	-	O
2740	f	O
2740	##a	O
2740	severely	O
2740	limited	O
2740	its	O
2740	therapeutic	O
2740	effect	O
2740	in	O
2740	clinic	O
2740	.	O
2740	[SEP]	O
2741	[CLS]	O
2741	the	O
2741	results	O
2741	predicted	O
2741	e	O
2741	##vo	O
2741	##fo	O
2741	##s	O
2741	##fa	O
2741	##mi	O
2741	##de	O
2741	as	O
2741	a	O
2741	border	O
2741	##line	O
2741	weak	O
2741	inhibitor	O
2741	based	O
2741	on	O
2741	the	O
2741	maximum	O
2741	inhibitor	O
2741	concentration	O
2741	with	O
2741	a	O
2741	ratio	O
2741	of	O
2741	1	O
2741	.	O
2741	32	O
2741	,	O
2741	whereas	O
2741	the	O
2741	calculation	O
2741	based	O
2741	on	O
2741	the	O
2741	average	B-PK
2741	concentration	I-PK
2741	yielded	O
2741	an	O
2741	au	B-PK
2741	##c	I-PK
2741	ratio	I-PK
2741	of	O
2741	1	O
2741	.	O
2741	00	O
2741	##2	O
2741	,	O
2741	making	O
2741	a	O
2741	clinical	O
2741	##ly	O
2741	relevant	O
2741	d	O
2741	##di	O
2741	again	O
2741	very	O
2741	unlikely	O
2741	.	O
2741	[SEP]	O
2742	[CLS]	O
2742	all	O
2742	other	O
2742	formulation	O
2742	##s	O
2742	produced	O
2742	similar	O
2742	exposure	O
2742	##s	O
2742	between	O
2742	11	O
2742	–	O
2742	16	O
2742	%	O
2742	of	O
2742	i	O
2742	##v	O
2742	and	O
2742	90	O
2742	–	O
2742	129	O
2742	%	O
2742	of	O
2742	re	O
2742	##ct	O
2742	##al	O
2742	suspension	O
2742	(	O
2742	as	O
2742	shown	O
2742	in	O
2742	au	B-PK
2742	##c	I-PK
2742	##0	I-PK
2742	##−	I-PK
2742	##24	I-PK
2742	h	I-PK
2742	,	O
2742	table	O
2742	3	O
2742	)	O
2742	.	O
2742	[SEP]	O
2743	[CLS]	O
2743	other	O
2743	p	O
2743	##k	O
2743	parameters	O
2743	,	O
2743	including	O
2743	t	B-PK
2743	##1	I-PK
2743	/	I-PK
2743	2	I-PK
2743	,	O
2743	area	B-PK
2743	under	I-PK
2743	the	I-PK
2743	curve	I-PK
2743	(	I-PK
2743	au	I-PK
2743	##c	I-PK
2743	)	I-PK
2743	0	I-PK
2743	##−	I-PK
2743	##t	I-PK
2743	,	O
2743	au	B-PK
2743	##c	I-PK
2743	##0	I-PK
2743	##−	I-PK
2743	##∞	I-PK
2743	,	O
2743	clearance	B-PK
2743	(	I-PK
2743	c	I-PK
2743	##l	I-PK
2743	/	I-PK
2743	f	I-PK
2743	)	I-PK
2743	,	O
2743	volume	B-PK
2743	of	I-PK
2743	distribution	I-PK
2743	(	I-PK
2743	v	I-PK
2743	##d	I-PK
2743	/	I-PK
2743	f	I-PK
2743	)	I-PK
2743	,	O
2743	and	O
2743	mean	B-PK
2743	residence	I-PK
2743	time	I-PK
2743	(	I-PK
2743	m	I-PK
2743	##rt	I-PK
2743	)	I-PK
2743	,	O
2743	were	O
2743	calculated	O
2743	by	O
2743	a	O
2743	non	O
2743	-	O
2743	compartment	O
2743	##al	O
2743	model	O
2743	with	O
2743	win	O
2743	##non	O
2743	##lin	O
2743	v	O
2743	##6	O
2743	.	O
2743	4	O
2743	(	O
2743	p	O
2743	##har	O
2743	##sight	O
2743	co	O
2743	##rp	O
2743	.	O
2743	,	O
2743	mountain	O
2743	view	O
2743	,	O
2743	ca	O
2743	,	O
2743	us	O
2743	##a	O
2743	)	O
2743	.	O
2743	[SEP]	O
2744	[CLS]	O
2744	this	O
2744	difference	O
2744	,	O
2744	however	O
2744	,	O
2744	does	O
2744	not	O
2744	cause	O
2744	variation	O
2744	in	O
2744	the	O
2744	systemic	B-PK
2744	bio	I-PK
2744	##ava	I-PK
2744	##ila	I-PK
2744	##bility	I-PK
2744	of	O
2744	the	O
2744	two	O
2744	particles	O
2744	as	O
2744	indicated	O
2744	by	O
2744	similar	O
2744	values	O
2744	of	O
2744	au	B-PK
2744	##c	I-PK
2744	##0	I-PK
2744	–	I-PK
2744	24	I-PK
2744	h	I-PK
2744	.	O
2744	[SEP]	O
2745	[CLS]	O
2745	since	O
2745	she	O
2745	##ta	O
2745	##2	O
2745	has	O
2745	limited	O
2745	a	O
2745	##que	O
2745	##ous	O
2745	so	O
2745	##lub	O
2745	##ility	O
2745	,	O
2745	which	O
2745	may	O
2745	contribute	O
2745	to	O
2745	its	O
2745	low	O
2745	,	O
2745	dose	O
2745	-	O
2745	dependent	O
2745	bio	B-PK
2745	##ava	I-PK
2745	##ila	I-PK
2745	##bility	I-PK
2745	,	O
2745	we	O
2745	compared	O
2745	the	O
2745	bio	B-PK
2745	##ava	I-PK
2745	##ila	I-PK
2745	##bility	I-PK
2745	of	O
2745	she	O
2745	##ta	O
2745	##2	O
2745	with	O
2745	respect	O
2745	to	O
2745	doses	O
2745	across	O
2745	species	O
2745	and	O
2745	estimated	O
2745	the	O
2745	dose	O
2745	at	O
2745	which	O
2745	sat	O
2745	##uration	O
2745	in	O
2745	absorption	O
2745	may	O
2745	occur	O
2745	.	O
2745	[SEP]	O
2746	[CLS]	O
2746	i	O
2746	##ov	O
2746	was	O
2746	considered	O
2746	on	O
2746	c	B-PK
2746	##l	I-PK
2746	and	O
2746	v	B-PK
2746	.	O
2746	structural	O
2746	model	O
2746	selection	O
2746	was	O
2746	guided	O
2746	by	O
2746	objective	O
2746	function	O
2746	value	O
2746	(	O
2746	of	O
2746	##v	O
2746	)	O
2746	as	O
2746	com	O
2746	##puted	O
2746	by	O
2746	non	O
2746	##me	O
2746	##m	O
2746	,	O
2746	corresponding	O
2746	to	O
2746	minus	O
2746	twice	O
2746	the	O
2746	log	O
2746	-	O
2746	likelihood	O
2746	(	O
2746	a	O
2746	δ	O
2746	of	O
2746	−	O
2746	##3	O
2746	.	O
2746	84	O
2746	with	O
2746	1	O
2746	degree	O
2746	of	O
2746	freedom	O
2746	,	O
2746	ch	O
2746	##i	O
2746	-	O
2746	squared	O
2746	distribution	O
2746	,	O
2746	corresponds	O
2746	to	O
2746	a	O
2746	significance	O
2746	level	O
2746	of	O
2746	p	O
2746	=	O
2746	0	O
2746	.	O
2746	05	O
2746	)	O
2746	goodness	O
2746	-	O
2746	of	O
2746	-	O
2746	fit	O
2746	plots	O
2746	and	O
2746	physiological	O
2746	p	O
2746	##laus	O
2746	##ibility	O
2746	.	O
2746	[SEP]	O
2747	[CLS]	O
2747	g	O
2747	##w	O
2747	##65	O
2747	##46	O
2747	##5	O
2747	##2	O
2747	was	O
2747	a	O
2747	potent	O
2747	inhibitor	O
2747	of	O
2747	the	O
2747	h	O
2747	##t	O
2747	##29	O
2747	,	O
2747	h	O
2747	##ct	O
2747	##11	O
2747	##6	O
2747	and	O
2747	h	O
2747	##n	O
2747	##5	O
2747	x	O
2747	##eno	O
2747	##gra	O
2747	##fts	O
2747	with	O
2747	an	O
2747	ed	B-PK
2747	##50	I-PK
2747	ranging	O
2747	from	O
2747	20	O
2747	to	O
2747	28	O
2747	mg	O
2747	kg	O
2747	##−	O
2747	##1	O
2747	.	O
2747	[SEP]	O
2748	[CLS]	O
2748	sex	O
2748	,	O
2748	age	O
2748	,	O
2748	and	O
2748	at	O
2748	##a	O
2748	status	O
2748	were	O
2748	tested	O
2748	as	O
2748	co	O
2748	##var	O
2748	##iate	O
2748	##s	O
2748	on	O
2748	k	B-PK
2748	##out	I-PK
2748	and	O
2748	k	B-PK
2748	.	O
2748	at	O
2748	##a	O
2748	status	O
2748	was	O
2748	not	O
2748	a	O
2748	statistical	O
2748	##ly	O
2748	significant	O
2748	co	O
2748	##var	O
2748	##iate	O
2748	for	O
2748	either	O
2748	k	B-PK
2748	##out	I-PK
2748	or	O
2748	k	B-PK
2748	.	O
2748	age	O
2748	was	O
2748	found	O
2748	to	O
2748	be	O
2748	a	O
2748	statistical	O
2748	##ly	O
2748	significant	O
2748	co	O
2748	##var	O
2748	##iate	O
2748	explaining	O
2748	inter	O
2748	##su	O
2748	##bject	O
2748	var	O
2748	##iability	O
2748	for	O
2748	both	O
2748	k	B-PK
2748	##out	I-PK
2748	(	O
2748	3	O
2748	.	O
2748	6	O
2748	%	O
2748	)	O
2748	and	O
2748	k	B-PK
2748	(	O
2748	7	O
2748	.	O
2748	6	O
2748	%	O
2748	)	O
2748	,	O
2748	whereas	O
2748	sex	O
2748	was	O
2748	a	O
2748	statistical	O
2748	##ly	O
2748	significant	O
2748	co	O
2748	##var	O
2748	##iate	O
2748	explaining	O
2748	inter	O
2748	##su	O
2748	##bject	O
2748	var	O
2748	##iability	O
2748	for	O
2748	k	B-PK
2748	##out	I-PK
2748	(	O
2748	11	O
2748	.	O
2748	5	O
2748	%	O
2748	)	O
2748	.	O
2748	[SEP]	O
2749	[CLS]	O
2749	log	O
2749	-	O
2749	log	O
2749	re	O
2749	##gression	O
2749	analysis	O
2749	(	O
2749	the	O
2749	power	O
2749	model	O
2749	)	O
2749	revealed	O
2749	that	O
2749	the	O
2749	steady	B-PK
2749	-	I-PK
2749	state	I-PK
2749	area	I-PK
2749	under	I-PK
2749	the	I-PK
2749	curve	I-PK
2749	(	I-PK
2749	au	I-PK
2749	##c	I-PK
2749	(	I-PK
2749	s	I-PK
2749	##s	I-PK
2749	)	I-PK
2749	)	I-PK
2749	and	O
2749	the	O
2749	maximum	B-PK
2749	,	O
2749	minimum	B-PK
2749	,	O
2749	and	O
2749	average	B-PK
2749	concentrations	I-PK
2749	at	I-PK
2749	steady	I-PK
2749	state	I-PK
2749	(	O
2749	c	B-PK
2749	(	I-PK
2749	ma	I-PK
2749	##x	I-PK
2749	,	I-PK
2749	s	I-PK
2749	##s	I-PK
2749	)	O
2749	,	O
2749	c	B-PK
2749	(	I-PK
2749	min	I-PK
2749	,	I-PK
2749	s	I-PK
2749	##s	I-PK
2749	)	I-PK
2749	,	O
2749	and	O
2749	c	B-PK
2749	(	I-PK
2749	a	I-PK
2749	##v	I-PK
2749	##g	I-PK
2749	,	I-PK
2749	s	I-PK
2749	##s	I-PK
2749	)	I-PK
2749	,	O
2749	respectively	O
2749	)	O
2749	increased	O
2749	in	O
2749	a	O
2749	dose	O
2749	-	O
2749	proportional	O
2749	manner	O
2749	over	O
2749	the	O
2749	300	O
2749	-	O
2749	to	O
2749	1	O
2749	,	O
2749	200	O
2749	-	O
2749	mg	O
2749	dose	O
2749	range	O
2749	.	O
2749	[SEP]	O
2750	[CLS]	O
2750	this	O
2750	study	O
2750	was	O
2750	approved	O
2750	by	O
2750	the	O
2750	may	O
2750	##o	O
2750	foundation	O
2750	institutional	O
2750	review	O
2750	board	O
2750	,	O
2750	and	O
2750	written	O
2750	informed	O
2750	consent	O
2750	was	O
2750	obtained	O
2750	from	O
2750	each	O
2750	patient	O
2750	prior	O
2750	to	O
2750	study	O
2750	participation	O
2750	.	O
2750	[SEP]	O
2751	[CLS]	O
2751	the	O
2751	con	O
2751	##stan	O
2751	##cy	O
2751	of	O
2751	the	O
2751	half	B-PK
2751	-	I-PK
2751	life	I-PK
2751	,	O
2751	c	B-PK
2751	##l	I-PK
2751	,	O
2751	and	O
2751	vs	B-PK
2751	##s	I-PK
2751	with	O
2751	increasing	O
2751	dose	O
2751	indicates	O
2751	dose	O
2751	-	O
2751	independent	O
2751	disposition	O
2751	for	O
2751	de	O
2751	##x	O
2751	##raz	O
2751	##ox	O
2751	##ane	O
2751	.	O
2751	[SEP]	O
2752	[CLS]	O
2752	tore	O
2752	##mi	O
2752	##fen	O
2752	##e	O
2752	c	O
2752	##it	O
2752	##rate	O
2752	in	O
2752	##hibit	O
2752	##ed	O
2752	e	O
2752	##bo	O
2752	##v	O
2752	replication	O
2752	with	O
2752	i	B-PK
2752	##c	I-PK
2752	##50	I-PK
2752	##s	I-PK
2752	ranging	O
2752	from	O
2752	2	O
2752	.	O
2752	1	O
2752	to	O
2752	4	O
2752	.	O
2752	5	O
2752	μ	O
2752	##m	O
2752	(	O
2752	table	O
2752	1	O
2752	)	O
2752	,	O
2752	and	O
2752	c	O
2752	##yt	O
2752	##oto	O
2752	##xi	O
2752	##city	O
2752	increased	O
2752	at	O
2752	doses	O
2752	of	O
2752	10	O
2752	μ	O
2752	##m	O
2752	and	O
2752	above	O
2752	in	O
2752	the	O
2752	72	O
2752	-	O
2752	h	O
2752	ass	O
2752	##ay	O
2752	(	O
2752	fi	O
2752	##g	O
2752	3	O
2752	##f	O
2752	)	O
2752	.	O
2752	[SEP]	O
2753	[CLS]	O
2753	the	O
2753	inter	O
2753	##patient	O
2753	var	O
2753	##iability	O
2753	,	O
2753	however	O
2753	,	O
2753	supports	O
2753	the	O
2753	need	O
2753	for	O
2753	monitoring	O
2753	of	O
2753	plasma	O
2753	ch	O
2753	##lora	O
2753	##mp	O
2753	##hen	O
2753	##ico	O
2753	##l	O
2753	concentrations	O
2753	,	O
2753	especially	O
2753	in	O
2753	newborn	O
2753	infants	O
2753	,	O
2753	persons	O
2753	with	O
2753	liver	O
2753	disease	O
2753	,	O
2753	or	O
2753	those	O
2753	receiving	O
2753	other	O
2753	medications	O
2753	that	O
2753	alter	O
2753	ch	O
2753	##lora	O
2753	##mp	O
2753	##hen	O
2753	##ico	O
2753	##l	O
2753	metabolism	O
2753	.	O
2753	[SEP]	O
2754	[CLS]	O
2754	non	O
2754	-	O
2754	toxic	O
2754	doses	O
2754	in	O
2754	4	O
2754	-	O
2754	week	O
2754	toxicity	O
2754	studies	O
2754	in	O
2754	rats	O
2754	are	O
2754	>	O
2754	or	O
2754	=	O
2754	3000	O
2754	mg	O
2754	/	O
2754	kg	O
2754	/	O
2754	d	O
2754	and	O
2754	500	O
2754	mg	O
2754	/	O
2754	kg	O
2754	/	O
2754	d	O
2754	for	O
2754	s	O
2754	-	O
2754	and	O
2754	r	O
2754	-	O
2754	p	O
2754	##azi	O
2754	##nac	O
2754	##lone	O
2754	,	O
2754	respectively	O
2754	;	O
2754	the	O
2754	corresponding	O
2754	doses	O
2754	in	O
2754	dogs	O
2754	are	O
2754	10	O
2754	and	O
2754	4	O
2754	mg	O
2754	/	O
2754	kg	O
2754	/	O
2754	d	O
2754	,	O
2754	respectively	O
2754	.	O
2754	[SEP]	O
2755	[CLS]	O
2755	ch	O
2755	##lor	O
2755	##o	O
2755	##quin	O
2755	##e	O
2755	(	O
2755	c	O
2755	##q	O
2755	)	O
2755	is	O
2755	an	O
2755	important	O
2755	anti	O
2755	##mal	O
2755	##aria	O
2755	##l	O
2755	drug	O
2755	for	O
2755	the	O
2755	treatment	O
2755	of	O
2755	special	O
2755	patient	O
2755	groups	O
2755	and	O
2755	as	O
2755	a	O
2755	com	O
2755	##par	O
2755	##ator	O
2755	for	O
2755	pre	O
2755	##c	O
2755	##lini	O
2755	##cal	O
2755	testing	O
2755	of	O
2755	new	O
2755	drugs	O
2755	.	O
2755	[SEP]	O
2756	[CLS]	O
2756	three	O
2756	of	O
2756	the	O
2756	20	O
2756	patients	O
2756	documented	O
2756	to	O
2756	have	O
2756	progressive	O
2756	disease	O
2756	on	O
2756	p	O
2756	##ac	O
2756	##lit	O
2756	##ax	O
2756	##el	O
2756	alone	O
2756	had	O
2756	partial	O
2756	responses	O
2756	when	O
2756	high	O
2756	-	O
2756	dose	O
2756	pro	O
2756	##ges	O
2756	##tero	O
2756	##ne	O
2756	was	O
2756	added	O
2756	to	O
2756	the	O
2756	p	O
2756	##ac	O
2756	##lit	O
2756	##ax	O
2756	##el	O
2756	regime	O
2756	##n	O
2756	.	O
2756	[SEP]	O
2757	[CLS]	O
2757	pit	O
2757	##falls	O
2757	and	O
2757	valid	O
2757	approaches	O
2757	to	O
2757	p	O
2757	##har	O
2757	##ma	O
2757	##co	O
2757	##kin	O
2757	##etic	O
2757	analysis	O
2757	of	O
2757	mean	O
2757	concentration	O
2757	data	O
2757	following	O
2757	in	O
2757	##tra	O
2757	##ven	O
2757	##ous	O
2757	administration	O
2757	.	O
2757	[SEP]	O
2758	[CLS]	O
2758	the	O
2758	methods	O
2758	were	O
2758	also	O
2758	applied	O
2758	to	O
2758	q	O
2758	##uant	O
2758	##ification	O
2758	of	O
2758	t	O
2758	##ica	O
2758	##g	O
2758	##rel	O
2758	##or	O
2758	,	O
2758	a	O
2758	##r	O
2758	-	O
2758	c	O
2758	##12	O
2758	##4	O
2758	##9	O
2758	##10	O
2758	##x	O
2758	##x	O
2758	and	O
2758	a	O
2758	##r	O
2758	-	O
2758	c	O
2758	##13	O
2758	##39	O
2758	##13	O
2758	##x	O
2758	##x	O
2758	in	O
2758	rabbit	O
2758	,	O
2758	rat	O
2758	,	O
2758	mouse	O
2758	and	O
2758	ma	O
2758	##rm	O
2758	##ose	O
2758	##t	O
2758	,	O
2758	using	O
2758	25	O
2758	micro	O
2758	##l	O
2758	of	O
2758	animal	O
2758	plasma	O
2758	.	O
2758	[SEP]	O
2759	[CLS]	O
2759	ch	O
2759	##roma	O
2759	##to	O
2759	##graphic	O
2759	separation	O
2759	was	O
2759	operated	O
2759	on	O
2759	an	O
2759	ultimate	O
2759	##®	O
2759	x	O
2759	##b	O
2759	-	O
2759	c	O
2759	##18	O
2759	column	O
2759	(	O
2759	2	O
2759	.	O
2759	1	O
2759	×	O
2759	50	O
2759	mm	O
2759	,	O
2759	3	O
2759	.	O
2759	5	O
2759	μ	O
2759	##m	O
2759	,	O
2759	we	O
2759	##l	O
2759	##ch	O
2759	)	O
2759	with	O
2759	a	O
2759	flow	O
2759	rate	O
2759	of	O
2759	0	O
2759	.	O
2759	400	O
2759	m	O
2759	##l	O
2759	/	O
2759	min	O
2759	,	O
2759	using	O
2759	a	O
2759	gradient	O
2759	el	O
2759	##ution	O
2759	with	O
2759	ace	O
2759	##ton	O
2759	##it	O
2759	##ril	O
2759	##e	O
2759	and	O
2759	water	O
2759	which	O
2759	contained	O
2759	2	O
2759	mm	O
2759	am	O
2759	##mon	O
2759	##ium	O
2759	ace	O
2759	##tate	O
2759	and	O
2759	0	O
2759	.	O
2759	1	O
2759	%	O
2759	form	O
2759	##ic	O
2759	acid	O
2759	as	O
2759	the	O
2759	mobile	O
2759	phase	O
2759	.	O
2759	[SEP]	O
2760	[CLS]	O
2760	in	O
2760	first	O
2760	step	O
2760	,	O
2760	the	O
2760	model	O
2760	that	O
2760	gives	O
2760	the	O
2760	most	O
2760	drop	O
2760	of	O
2760	objective	O
2760	value	O
2760	is	O
2760	retained	O
2760	and	O
2760	taken	O
2760	forward	O
2760	to	O
2760	the	O
2760	next	O
2760	step	O
2760	.	O
2760	[SEP]	O
2761	[CLS]	O
2761	the	O
2761	p	O
2761	##har	O
2761	##ma	O
2761	##co	O
2761	##kin	O
2761	##etics	O
2761	of	O
2761	a	O
2761	single	O
2761	400	O
2761	mg	O
2761	oral	O
2761	dose	O
2761	of	O
2761	fl	O
2761	##ero	O
2761	##xa	O
2761	##cin	O
2761	and	O
2761	p	O
2761	##ef	O
2761	##lo	O
2761	##xa	O
2761	##cin	O
2761	were	O
2761	evaluated	O
2761	in	O
2761	ten	O
2761	healthy	O
2761	male	O
2761	volunteers	O
2761	in	O
2761	a	O
2761	random	O
2761	##ized	O
2761	cross	O
2761	-	O
2761	over	O
2761	study	O
2761	.	O
2761	[SEP]	O
2762	[CLS]	O
2762	the	O
2762	resulting	O
2762	lower	O
2762	-	O
2762	than	O
2762	-	O
2762	expected	O
2762	magnitude	O
2762	of	O
2762	systemic	O
2762	a	O
2762	##z	O
2762	##d	O
2762	##31	O
2762	##9	O
2762	##9	O
2762	exposure	O
2762	in	O
2762	cop	O
2762	##d	O
2762	patients	O
2762	was	O
2762	positively	O
2762	noteworthy	O
2762	from	O
2762	a	O
2762	to	O
2762	##ler	O
2762	##ability	O
2762	perspective	O
2762	,	O
2762	whereas	O
2762	differences	O
2762	v	O
2762	##is	O
2762	-	O
2762	a	O
2762	-	O
2762	v	O
2762	##is	O
2762	healthy	O
2762	ca	O
2762	##uca	O
2762	##sian	O
2762	volunteers	O
2762	were	O
2762	clinical	O
2762	##ly	O
2762	of	O
2762	minor	O
2762	importance	O
2762	with	O
2762	respect	O
2762	to	O
2762	the	O
2762	healthy	O
2762	j	O
2762	##apa	O
2762	##nese	O
2762	men	O
2762	and	O
2762	patients	O
2762	with	O
2762	as	O
2762	##th	O
2762	##ma	O
2762	(	O
2762	figure	O
2762	2	O
2762	)	O
2762	.	O
2762	[SEP]	O
2763	[CLS]	O
2763	however	O
2763	,	O
2763	the	O
2763	degree	O
2763	of	O
2763	correlation	O
2763	across	O
2763	various	O
2763	regions	O
2763	was	O
2763	observed	O
2763	to	O
2763	vary	O
2763	(	O
2763	s	O
2763	##5	O
2763	fi	O
2763	##g	O
2763	)	O
2763	.	O
2763	[SEP]	O
2764	[CLS]	O
2764	the	O
2764	second	O
2764	patient	O
2764	with	O
2764	low	O
2764	risk	O
2764	,	O
2764	stage	O
2764	4	O
2764	##s	O
2764	ne	O
2764	##uro	O
2764	##blast	O
2764	##oma	O
2764	died	O
2764	prior	O
2764	to	O
2764	car	O
2764	##bo	O
2764	##p	O
2764	##lat	O
2764	##in	O
2764	treatment	O
2764	on	O
2764	day	O
2764	2	O
2764	of	O
2764	the	O
2764	first	O
2764	course	O
2764	of	O
2764	treatment	O
2764	due	O
2764	to	O
2764	complications	O
2764	relating	O
2764	to	O
2764	t	O
2764	##umour	O
2764	burden	O
2764	.	O
2764	[SEP]	O
2765	[CLS]	O
2765	data	O
2765	were	O
2765	derived	O
2765	from	O
2765	a	O
2765	phase	O
2765	i	O
2765	study	O
2765	of	O
2765	26	O
2765	patients	O
2765	receiving	O
2765	huh	O
2765	##m	O
2765	##f	O
2765	##g	O
2765	##1	O
2765	at	O
2765	doses	O
2765	ranging	O
2765	from	O
2765	1	O
2765	to	O
2765	16	O
2765	mg	O
2765	kg	O
2765	##−	O
2765	##1	O
2765	.	O
2765	[SEP]	O
2766	[CLS]	O
2766	the	O
2766	time	O
2766	duration	O
2766	at	O
2766	which	O
2766	the	O
2766	the	O
2766	##op	O
2766	##hyl	O
2766	##line	O
2766	plasma	O
2766	levels	O
2766	remain	O
2766	higher	O
2766	than	O
2766	75	O
2766	%	O
2766	of	O
2766	the	O
2766	maximum	B-PK
2766	steady	I-PK
2766	-	I-PK
2766	state	I-PK
2766	levels	I-PK
2766	,	O
2766	following	O
2766	12	O
2766	-	O
2766	h	O
2766	dos	O
2766	##ing	O
2766	interval	O
2766	,	O
2766	was	O
2766	evaluated	O
2766	:	O
2766	for	O
2766	the	O
2766	sustained	O
2766	-	O
2766	release	O
2766	micro	O
2766	##en	O
2766	##cap	O
2766	##sul	O
2766	##ated	O
2766	formulation	O
2766	##s	O
2766	this	O
2766	time	O
2766	duration	O
2766	reaches	O
2766	100	O
2766	%	O
2766	of	O
2766	the	O
2766	dos	O
2766	##ing	O
2766	interval	O
2766	.	O
2766	[SEP]	O
2767	[CLS]	O
2767	[	O
2767	re	O
2767	##ct	O
2767	##al	O
2767	fluid	O
2767	t	O
2767	##f	O
2767	##v	O
2767	]	O
2767	for	O
2767	predict	O
2767	##ing	O
2767	re	O
2767	##ct	O
2767	##al	O
2767	tissue	O
2767	t	O
2767	##f	O
2767	##v	O
2767	,	O
2767	β	O
2767	##1	O
2767	,	O
2767	t	O
2767	##f	O
2767	##v	O
2767	=	O
2767	0	O
2767	.	O
2767	63	O
2767	##4	O
2767	(	O
2767	±	O
2767	##0	O
2767	.	O
2767	07	O
2767	##7	O
2767	##7	O
2767	)	O
2767	(	O
2767	p	O
2767	<	O
2767	0	O
2767	.	O
2767	00	O
2767	##1	O
2767	)	O
2767	and	O
2767	β	O
2767	##0	O
2767	,	O
2767	t	O
2767	##f	O
2767	##v	O
2767	=	O
2767	−	O
2767	##2	O
2767	.	O
2767	43	O
2767	(	O
2767	±	O
2767	##0	O
2767	.	O
2767	335	O
2767	)	O
2767	.	O
2767	[SEP]	O
2768	[CLS]	O
2768	patients	O
2768	for	O
2768	whom	O
2768	m	O
2768	##ri	O
2768	scanning	O
2768	is	O
2768	con	O
2768	##tra	O
2768	##ind	O
2768	##ica	O
2768	##ted	O
2768	(	O
2768	e	O
2768	.	O
2768	g	O
2768	.	O
2768	pace	O
2768	##maker	O
2768	,	O
2768	heart	O
2768	valve	O
2768	replacement	O
2768	)	O
2768	were	O
2768	also	O
2768	excluded	O
2768	.	O
2768	[SEP]	O
2769	[CLS]	O
2769	the	O
2769	maximum	B-PK
2769	concentration	I-PK
2769	(	I-PK
2769	cm	I-PK
2769	##ax	I-PK
2769	)	I-PK
2769	and	O
2769	area	B-PK
2769	under	I-PK
2769	the	I-PK
2769	concentration	I-PK
2769	-	I-PK
2769	time	I-PK
2769	curve	I-PK
2769	(	I-PK
2769	au	I-PK
2769	##c	I-PK
2769	)	I-PK
2769	for	O
2769	total	B-PK
2769	radio	I-PK
2769	##act	I-PK
2769	##ivity	I-PK
2769	were	O
2769	higher	O
2769	in	O
2769	plasma	O
2769	compared	O
2769	with	O
2769	blood	O
2769	.	O
2769	[SEP]	O
2770	[CLS]	O
2770	the	O
2770	amount	B-PK
2770	of	I-PK
2770	total	I-PK
2770	radio	I-PK
2770	##act	I-PK
2770	##ivity	I-PK
2770	(	I-PK
2770	ng	I-PK
2770	##e	I-PK
2770	##q	I-PK
2770	)	I-PK
2770	in	O
2770	urine	O
2770	and	O
2770	f	O
2770	##ec	O
2770	##es	O
2770	was	O
2770	determined	O
2770	by	O
2770	multi	O
2770	##p	O
2770	##lying	O
2770	the	O
2770	volume	O
2770	or	O
2770	weight	O
2770	of	O
2770	the	O
2770	samples	O
2770	by	O
2770	the	O
2770	radio	B-PK
2770	##act	I-PK
2770	##ivity	I-PK
2770	concentration	O
2770	.	O
2770	[SEP]	O
2771	[CLS]	O
2771	tissue	O
2771	fraction	O
2771	##ation	O
2771	of	O
2771	liver	O
2771	,	O
2771	19	O
2771	min	O
2771	after	O
2771	injection	O
2771	of	O
2771	labeled	O
2771	enzyme	O
2771	,	O
2771	indicated	O
2771	that	O
2771	the	O
2771	radio	B-PK
2771	##act	I-PK
2771	##ivity	I-PK
2771	was	O
2771	present	O
2771	both	O
2771	in	O
2771	end	O
2771	##oso	O
2771	##mes	O
2771	and	O
2771	in	O
2771	l	O
2771	##ys	O
2771	##oso	O
2771	##mes	O
2771	,	O
2771	suggesting	O
2771	up	O
2771	##take	O
2771	by	O
2771	end	O
2771	##oc	O
2771	##yt	O
2771	##osis	O
2771	,	O
2771	followed	O
2771	by	O
2771	breakdown	O
2771	in	O
2771	the	O
2771	l	O
2771	##ys	O
2771	##oso	O
2771	##mes	O
2771	.	O
2771	[SEP]	O
2772	[CLS]	O
2772	compared	O
2772	with	O
2772	(	O
2772	64	O
2772	)	O
2772	cu	O
2772	-	O
2772	dot	O
2772	##a	O
2772	-	O
2772	r	O
2772	##g	O
2772	##d	O
2772	,	O
2772	this	O
2772	trace	O
2772	##r	O
2772	showed	O
2772	improved	O
2772	in	O
2772	v	O
2772	##ivo	O
2772	kinetic	O
2772	##s	O
2772	,	O
2772	with	O
2772	significantly	O
2772	reduced	O
2772	liver	O
2772	up	O
2772	##take	O
2772	(	O
2772	0	O
2772	.	O
2772	99	O
2772	+	O
2772	-	O
2772	0	O
2772	.	O
2772	08	O
2772	%	O
2772	id	O
2772	/	O
2772	g	O
2772	vs	O
2772	.	O
2772	1	O
2772	.	O
2772	73	O
2772	+	O
2772	-	O
2772	0	O
2772	.	O
2772	39	O
2772	%	O
2772	id	O
2772	/	O
2772	g	O
2772	at	O
2772	30	O
2772	min	O
2772	after	O
2772	injection	O
2772	and	O
2772	0	O
2772	.	O
2772	58	O
2772	+	O
2772	-	O
2772	0	O
2772	.	O
2772	07	O
2772	%	O
2772	id	O
2772	/	O
2772	g	O
2772	vs	O
2772	.	O
2772	2	O
2772	.	O
2772	57	O
2772	+	O
2772	-	O
2772	0	O
2772	.	O
2772	49	O
2772	%	O
2772	id	O
2772	/	O
2772	g	O
2772	at	O
2772	4	O
2772	h	O
2772	after	O
2772	injection	O
2772	)	O
2772	.	O
2772	[SEP]	O
2773	[CLS]	O
2773	the	O
2773	distribution	O
2773	of	O
2773	radio	B-PK
2773	##act	I-PK
2773	##ivity	I-PK
2773	into	O
2773	er	O
2773	##yt	O
2773	##hr	O
2773	##ocytes	O
2773	averaged	O
2773	from	O
2773	44	O
2773	to	O
2773	36	O
2773	%	O
2773	of	O
2773	the	O
2773	whole	O
2773	blood	B-PK
2773	radio	I-PK
2773	##act	I-PK
2773	##ivity	I-PK
2773	from	O
2773	0	O
2773	.	O
2773	25	O
2773	to	O
2773	12	O
2773	h	O
2773	post	O
2773	##dos	O
2773	##e	O
2773	.	O
2773	[SEP]	O
2774	[CLS]	O
2774	on	O
2774	day	O
2774	1	O
2774	,	O
2774	all	O
2774	patients	O
2774	had	O
2774	taken	O
2774	let	O
2774	##ro	O
2774	##zo	O
2774	##le	O
2774	for	O
2774	at	O
2774	least	O
2774	28	O
2774	days	O
2774	and	O
2774	had	O
2774	steady	B-PK
2774	-	I-PK
2774	state	I-PK
2774	plasma	I-PK
2774	concentrations	I-PK
2774	.	O
2774	[SEP]	O
2775	[CLS]	O
2775	the	O
2775	tumors	O
2775	and	O
2775	various	O
2775	other	O
2775	tissues	O
2775	were	O
2775	removed	O
2775	,	O
2775	weighed	O
2775	,	O
2775	and	O
2775	assessed	O
2775	for	O
2775	radio	B-PK
2775	##act	I-PK
2775	##ivity	I-PK
2775	using	O
2775	a	O
2775	co	O
2775	##bra	O
2775	auto	O
2775	##gam	O
2775	##ma	O
2775	counter	O
2775	.	O
2775	[SEP]	O
2776	[CLS]	O
2776	p	O
2776	##har	O
2776	##ma	O
2776	##co	O
2776	##kin	O
2776	##etic	O
2776	tests	O
2776	in	O
2776	b	O
2776	##al	O
2776	##b	O
2776	/	O
2776	c	O
2776	##j	O
2776	mice	O
2776	show	O
2776	blood	O
2776	d	O
2776	##t	O
2776	##g	O
2776	levels	O
2776	at	O
2776	,	O
2776	or	O
2776	above	O
2776	,	O
2776	its	O
2776	inhibitor	O
2776	##y	O
2776	concentration	O
2776	##90	O
2776	of	O
2776	64	O
2776	ng	O
2776	/	O
2776	m	O
2776	##l	O
2776	for	O
2776	56	O
2776	days	O
2776	,	O
2776	and	O
2776	tissue	O
2776	d	O
2776	##t	O
2776	##g	O
2776	levels	O
2776	for	O
2776	28	O
2776	days	O
2776	.	O
2776	[SEP]	O
2777	[CLS]	O
2777	mean	B-PK
2777	serum	I-PK
2777	concentrations	I-PK
2777	exceeded	O
2777	a	O
2777	target	O
2777	peak	O
2777	of	O
2777	32	O
2777	.	O
2777	0	O
2777	micro	O
2777	##gram	O
2777	##s	O
2777	/	O
2777	m	O
2777	##l	O
2777	and	O
2777	remained	O
2777	above	O
2777	an	O
2777	estimated	O
2777	inhibitor	O
2777	##y	O
2777	concentration	O
2777	of	O
2777	8	O
2777	.	O
2777	0	O
2777	micro	O
2777	##gram	O
2777	##s	O
2777	/	O
2777	m	O
2777	##l	O
2777	for	O
2777	approximately	O
2777	12	O
2777	h	O
2777	##r	O
2777	.	O
2777	[SEP]	O
2778	[CLS]	O
2778	after	O
2778	oral	O
2778	administration	O
2778	,	O
2778	n	O
2778	##b	O
2778	##d	O
2778	c	O
2778	##6	O
2778	-	O
2778	c	O
2778	##era	O
2778	##mi	O
2778	##de	O
2778	rapidly	O
2778	rose	O
2778	to	O
2778	peak	B-PK
2778	plasma	I-PK
2778	concentrations	I-PK
2778	within	O
2778	the	O
2778	first	O
2778	90	O
2778	min	O
2778	,	O
2778	distributed	O
2778	to	O
2778	tissues	O
2778	,	O
2778	and	O
2778	remained	O
2778	in	O
2778	v	O
2778	##ivo	O
2778	for	O
2778	more	O
2778	than	O
2778	24	O
2778	h	O
2778	.	O
2778	t	O
2778	##iss	O
2778	##ular	O
2778	levels	O
2778	of	O
2778	n	O
2778	##b	O
2778	##d	O
2778	c	O
2778	##6	O
2778	-	O
2778	c	O
2778	##era	O
2778	##mi	O
2778	##de	O
2778	from	O
2778	high	O
2778	to	O
2778	low	O
2778	were	O
2778	associated	O
2778	with	O
2778	heart	O
2778	,	O
2778	lung	O
2778	,	O
2778	c	O
2778	##ere	O
2778	##bell	O
2778	##um	O
2778	,	O
2778	test	O
2778	##icle	O
2778	,	O
2778	s	O
2778	##ple	O
2778	##en	O
2778	,	O
2778	liver	O
2778	,	O
2778	kidney	O
2778	,	O
2778	and	O
2778	brain	O
2778	.	O
2778	[SEP]	O
2779	[CLS]	O
2779	the	O
2779	low	O
2779	concentrations	O
2779	in	O
2779	serum	O
2779	were	O
2779	caused	O
2779	by	O
2779	more	O
2779	rapid	O
2779	u	O
2779	##rina	O
2779	##ry	O
2779	ex	O
2779	##cre	O
2779	##tion	O
2779	of	O
2779	the	O
2779	anti	O
2779	##biotic	O
2779	,	O
2779	with	O
2779	rates	B-PK
2779	of	I-PK
2779	re	I-PK
2779	##nal	I-PK
2779	clearance	I-PK
2779	averaging	O
2779	425	O
2779	m	O
2779	##l	O
2779	/	O
2779	min	O
2779	per	O
2779	1	O
2779	.	O
2779	73	O
2779	m	O
2779	##2	O
2779	in	O
2779	the	O
2779	patients	O
2779	with	O
2779	c	O
2779	##f	O
2779	and	O
2779	36	O
2779	##2	O
2779	m	O
2779	##l	O
2779	/	O
2779	min	O
2779	per	O
2779	1	O
2779	.	O
2779	73	O
2779	m	O
2779	##2	O
2779	in	O
2779	the	O
2779	normal	O
2779	subjects	O
2779	.	O
2779	[SEP]	O
2780	[CLS]	O
2780	est	O
2780	##imating	O
2780	the	O
2780	var	O
2780	##iability	O
2780	in	O
2780	fraction	B-PK
2780	absorbed	I-PK
2780	as	O
2780	a	O
2780	paradigm	O
2780	for	O
2780	informing	O
2780	formulation	O
2780	development	O
2780	in	O
2780	early	O
2780	clinical	O
2780	drug	O
2780	development	O
2780	.	O
2780	[SEP]	O
2781	[CLS]	O
2781	the	O
2781	existence	O
2781	of	O
2781	one	O
2781	or	O
2781	two	O
2781	half	B-PK
2781	-	I-PK
2781	lives	I-PK
2781	for	O
2781	the	O
2781	rate	B-PK
2781	of	I-PK
2781	disappearance	I-PK
2781	was	O
2781	assessed	O
2781	.	O
2781	[SEP]	O
2782	[CLS]	O
2782	geometric	O
2782	mean	O
2782	(	O
2782	g	O
2782	##me	O
2782	##an	O
2782	)	O
2782	and	O
2782	coefficient	O
2782	of	O
2782	variation	O
2782	(	O
2782	c	O
2782	##v	O
2782	)	O
2782	are	O
2782	presented	O
2782	for	O
2782	cm	B-PK
2782	##ax	I-PK
2782	,	O
2782	au	B-PK
2782	##c	I-PK
2782	(	I-PK
2782	0	I-PK
2782	-	I-PK
2782	t	I-PK
2782	)	I-PK
2782	,	O
2782	au	B-PK
2782	##c	I-PK
2782	(	I-PK
2782	in	I-PK
2782	##f	I-PK
2782	)	I-PK
2782	,	O
2782	a	B-PK
2782	##i	I-PK
2782	_	I-PK
2782	au	I-PK
2782	##c	I-PK
2782	,	O
2782	cm	B-PK
2782	##in	I-PK
2782	,	O
2782	and	O
2782	au	B-PK
2782	##c	I-PK
2782	(	I-PK
2782	ta	I-PK
2782	##u	I-PK
2782	)	I-PK
2782	;	O
2782	arithmetic	O
2782	mean	O
2782	and	O
2782	standard	O
2782	de	O
2782	##viation	O
2782	(	O
2782	s	O
2782	##d	O
2782	)	O
2782	are	O
2782	presented	O
2782	for	O
2782	t	B-PK
2782	##1	I-PK
2782	/	I-PK
2782	2	I-PK
2782	;	O
2782	and	O
2782	median	O
2782	and	O
2782	range	O
2782	are	O
2782	presented	O
2782	for	O
2782	t	B-PK
2782	##max	I-PK
2782	.	O
2782	[SEP]	O
2783	[CLS]	O
2783	therefore	O
2783	,	O
2783	the	O
2783	decrease	O
2783	in	O
2783	dig	O
2783	##ox	O
2783	##in	O
2783	oral	B-PK
2783	clearance	I-PK
2783	previously	O
2783	observed	O
2783	in	O
2783	ch	O
2783	##f	O
2783	patients	O
2783	receiving	O
2783	e	O
2783	##pop	O
2783	##ros	O
2783	##ten	O
2783	##ol	O
2783	may	O
2783	be	O
2783	as	O
2783	##cribed	O
2783	to	O
2783	increases	O
2783	in	O
2783	dig	O
2783	##ox	O
2783	##in	O
2783	bio	B-PK
2783	##ava	I-PK
2783	##ila	I-PK
2783	##bility	I-PK
2783	,	O
2783	secondary	O
2783	to	O
2783	e	O
2783	##pop	O
2783	##ros	O
2783	##ten	O
2783	##ol	O
2783	-	O
2783	induced	O
2783	increases	O
2783	in	O
2783	q	B-PK
2783	##g	I-PK
2783	.	O
2783	[SEP]	O
2784	[CLS]	O
2784	during	O
2784	the	O
2784	continuous	O
2784	in	O
2784	##fusion	O
2784	##s	O
2784	,	O
2784	plateau	B-PK
2784	levels	I-PK
2784	of	O
2784	i	O
2784	##r	O
2784	-	O
2784	g	O
2784	##n	O
2784	##r	O
2784	##h	O
2784	between	O
2784	2	O
2784	and	O
2784	6	O
2784	h	O
2784	were	O
2784	34	O
2784	%	O
2784	lower	O
2784	with	O
2784	s	O
2784	##c	O
2784	delivery	O
2784	(	O
2784	67	O
2784	.	O
2784	5	O
2784	vs	O
2784	.	O
2784	102	O
2784	.	O
2784	4	O
2784	p	O
2784	##g	O
2784	/	O
2784	m	O
2784	##l	O
2784	)	O
2784	,	O
2784	indicating	O
2784	i	O
2784	##rre	O
2784	##versible	O
2784	losses	O
2784	of	O
2784	about	O
2784	one	O
2784	third	O
2784	of	O
2784	g	O
2784	##n	O
2784	##r	O
2784	##h	O
2784	injected	O
2784	s	O
2784	##c	O
2784	.	O
2784	[SEP]	O
2785	[CLS]	O
2785	to	O
2785	allow	O
2785	calculation	O
2785	of	O
2785	cell	O
2785	-	O
2785	to	O
2785	-	O
2785	medium	O
2785	met	O
2785	##f	O
2785	concentration	O
2785	ratios	O
2785	,	O
2785	average	O
2785	cell	O
2785	volume	O
2785	was	O
2785	determined	O
2785	in	O
2785	a	O
2785	separate	O
2785	series	O
2785	of	O
2785	experiments	O
2785	by	O
2785	simultaneous	O
2785	determination	O
2785	of	O
2785	cell	O
2785	number	O
2785	and	O
2785	packed	O
2785	cell	O
2785	volume	O
2785	using	O
2785	special	O
2785	cent	O
2785	##ri	O
2785	##fu	O
2785	##gation	O
2785	tubes	O
2785	(	O
2785	tech	O
2785	##no	O
2785	plastic	O
2785	products	O
2785	a	O
2785	##g	O
2785	,	O
2785	t	O
2785	##ras	O
2785	##ading	O
2785	##en	O
2785	,	O
2785	s	O
2785	##witz	O
2785	##erland	O
2785	)	O
2785	.	O
2785	[SEP]	O
2786	[CLS]	O
2786	however	O
2786	,	O
2786	respond	O
2786	##ers	O
2786	showed	O
2786	lower	O
2786	plasma	O
2786	concentrations	O
2786	of	O
2786	the	O
2786	parent	O
2786	compound	O
2786	r	O
2786	##is	O
2786	as	O
2786	well	O
2786	as	O
2786	lower	O
2786	metabolic	B-PK
2786	ratios	I-PK
2786	r	O
2786	##is	O
2786	/	O
2786	9	O
2786	-	O
2786	oh	O
2786	-	O
2786	r	O
2786	##is	O
2786	than	O
2786	non	O
2786	-	O
2786	respond	O
2786	##ers	O
2786	(	O
2786	p	O
2786	=	O
2786	0	O
2786	.	O
2786	01	O
2786	##7	O
2786	and	O
2786	p	O
2786	=	O
2786	0	O
2786	.	O
2786	03	O
2786	##4	O
2786	)	O
2786	.	O
2786	[SEP]	O
2787	[CLS]	O
2787	below	O
2787	500	O
2787	micro	O
2787	##gram	O
2787	##s	O
2787	/	O
2787	kg	O
2787	/	O
2787	h	O
2787	the	O
2787	d	O
2787	##s	O
2787	and	O
2787	c	O
2787	##y	O
2787	216	O
2787	plateau	B-PK
2787	concentrations	I-PK
2787	were	O
2787	higher	O
2787	than	O
2787	that	O
2787	of	O
2787	s	O
2787	##h	O
2787	while	O
2787	above	O
2787	this	O
2787	dose	O
2787	the	O
2787	s	O
2787	##h	O
2787	concentration	O
2787	was	O
2787	higher	O
2787	than	O
2787	that	O
2787	of	O
2787	d	O
2787	##s	O
2787	and	O
2787	c	O
2787	##y	O
2787	216	O
2787	.	O
2787	[SEP]	O
2788	[CLS]	O
2788	ex	B-PK
2788	##cre	I-PK
2788	##ted	I-PK
2788	amount	I-PK
2788	of	O
2788	ca	O
2788	##de	O
2788	in	O
2788	urine	O
2788	constituted	O
2788	about	O
2788	1	O
2788	.	O
2788	1	O
2788	%	O
2788	after	O
2788	i	O
2788	##v	O
2788	in	O
2788	##fusion	O
2788	and	O
2788	4	O
2788	.	O
2788	7	O
2788	%	O
2788	after	O
2788	oral	O
2788	c	O
2788	##da	O
2788	treatment	O
2788	.	O
2788	[SEP]	O
2789	[CLS]	O
2789	the	O
2789	clearance	B-PK
2789	(	O
2789	studied	O
2789	in	O
2789	two	O
2789	groups	O
2789	)	O
2789	of	O
2789	org	O
2789	94	O
2789	##8	O
2789	##8	O
2789	was	O
2789	1	O
2789	.	O
2789	28	O
2789	and	O
2789	1	O
2789	.	O
2789	06	O
2789	m	O
2789	##l	O
2789	x	O
2789	kg	O
2789	(	O
2789	-	O
2789	1	O
2789	)	O
2789	x	O
2789	min	O
2789	(	O
2789	-	O
2789	1	O
2789	)	O
2789	with	O
2789	an	O
2789	ex	B-PK
2789	##cre	I-PK
2789	##tion	I-PK
2789	fraction	I-PK
2789	in	I-PK
2789	the	I-PK
2789	urine	I-PK
2789	of	O
2789	51	O
2789	.	O
2789	9	O
2789	%	O
2789	and	O
2789	53	O
2789	.	O
2789	5	O
2789	%	O
2789	,	O
2789	respectively	O
2789	.	O
2789	[SEP]	O
2790	[CLS]	O
2790	a	O
2790	prolonged	O
2790	p	O
2790	##t	O
2790	and	O
2790	a	O
2790	r	O
2790	##iva	O
2790	##ro	O
2790	##xa	O
2790	##ban	O
2790	t	B-PK
2790	##rough	I-PK
2790	level	I-PK
2790	greater	O
2790	than	O
2790	eight	O
2790	times	O
2790	that	O
2790	predicted	O
2790	from	O
2790	p	O
2790	##har	O
2790	##ma	O
2790	##co	O
2790	##kin	O
2790	##etic	O
2790	modelling	O
2790	suggests	O
2790	that	O
2790	bleeding	O
2790	was	O
2790	due	O
2790	to	O
2790	increased	O
2790	exposure	O
2790	to	O
2790	r	O
2790	##iva	O
2790	##ro	O
2790	##xa	O
2790	##ban	O
2790	,	O
2790	probably	O
2790	due	O
2790	to	O
2790	an	O
2790	interaction	O
2790	with	O
2790	r	O
2790	##ito	O
2790	##na	O
2790	##vir	O
2790	and	O
2790	da	O
2790	##run	O
2790	##avi	O
2790	##r	O
2790	.	O
2790	[SEP]	O
2791	[CLS]	O
2791	in	O
2791	a	O
2791	model	O
2791	with	O
2791	log	O
2791	(	O
2791	doses	O
2791	per	O
2791	week	O
2791	)	O
2791	and	O
2791	log	O
2791	(	O
2791	au	B-PK
2791	##c	I-PK
2791	)	O
2791	as	O
2791	predict	O
2791	##ors	O
2791	,	O
2791	a	O
2791	log	O
2791	-	O
2791	linear	O
2791	relationship	O
2791	was	O
2791	seen	O
2791	between	O
2791	doses	O
2791	per	O
2791	week	O
2791	and	O
2791	t	O
2791	##f	O
2791	##v	O
2791	scalp	O
2791	hair	O
2791	level	O
2791	,	O
2791	with	O
2791	an	O
2791	estimated	O
2791	76	O
2791	%	O
2791	(	O
2791	95	O
2791	%	O
2791	c	O
2791	##i	O
2791	60	O
2791	–	O
2791	93	O
2791	%	O
2791	,	O
2791	p	O
2791	<	O
2791	0	O
2791	.	O
2791	000	O
2791	##1	O
2791	)	O
2791	increase	O
2791	in	O
2791	hair	O
2791	level	O
2791	per	O
2791	2	O
2791	-	O
2791	fold	O
2791	dose	O
2791	increase	O
2791	.	O
2791	[SEP]	O
2792	[CLS]	O
2792	the	O
2792	difference	O
2792	between	O
2792	the	O
2792	exit	O
2792	and	O
2792	input	O
2792	micro	B-PK
2792	##scopic	I-PK
2792	rate	I-PK
2792	constant	I-PK
2792	,	I-PK
2792	k	I-PK
2792	##12	I-PK
2792	-	I-PK
2792	k	I-PK
2792	##21	I-PK
2792	,	O
2792	was	O
2792	much	O
2792	larger	O
2792	in	O
2792	the	O
2792	young	O
2792	patients	O
2792	(	O
2792	p	O
2792	less	O
2792	than	O
2792	0	O
2792	.	O
2792	00	O
2792	##1	O
2792	)	O
2792	.	O
2792	[SEP]	O
2793	[CLS]	O
2793	the	O
2793	t	B-PK
2793	##max	I-PK
2793	of	O
2793	l	O
2793	##ume	O
2793	##fant	O
2793	##rine	O
2793	after	O
2793	oral	O
2793	administration	O
2793	was	O
2793	found	O
2793	to	O
2793	be	O
2793	in	O
2793	the	O
2793	range	O
2793	of	O
2793	2	O
2793	-	O
2793	8	O
2793	h	O
2793	.	O
2793	the	O
2793	reason	O
2793	for	O
2793	longer	O
2793	t	B-PK
2793	##max	I-PK
2793	seems	O
2793	to	O
2793	be	O
2793	the	O
2793	low	O
2793	a	O
2793	##que	O
2793	##ous	O
2793	so	O
2793	##lub	O
2793	##ility	O
2793	of	O
2793	l	O
2793	##ume	O
2793	##fant	O
2793	##rine	O
2793	since	O
2793	,	O
2793	l	O
2793	##ume	O
2793	##fant	O
2793	##rine	O
2793	displayed	O
2793	high	O
2793	per	B-PK
2793	##me	I-PK
2793	##ability	I-PK
2793	in	O
2793	the	O
2793	in	O
2793	-	O
2793	sit	O
2793	##u	O
2793	per	B-PK
2793	##me	I-PK
2793	##ability	I-PK
2793	study	O
2793	.	O
2793	[SEP]	O
2794	[CLS]	O
2794	68	O
2794	##ga	O
2794	-	O
2794	dot	O
2794	##a	O
2794	-	O
2794	j	O
2794	##r	O
2794	##11	O
2794	demonstrated	O
2794	rapid	O
2794	tumor	O
2794	up	O
2794	##take	O
2794	,	O
2794	high	O
2794	tumor	B-PK
2794	/	I-PK
2794	background	I-PK
2794	ratios	I-PK
2794	,	O
2794	and	O
2794	rapid	O
2794	clearance	B-PK
2794	from	I-PK
2794	blood	I-PK
2794	.	O
2794	[SEP]	O
2795	[CLS]	O
2795	more	O
2795	detailed	O
2795	characteristics	O
2795	of	O
2795	this	O
2795	central	O
2795	alpha	O
2795	-	O
2795	ad	O
2795	##ren	O
2795	##oc	O
2795	##ept	O
2795	##or	O
2795	emerged	O
2795	from	O
2795	correlation	O
2795	studies	O
2795	in	O
2795	which	O
2795	new	O
2795	ed	B-PK
2795	##30	I-PK
2795	values	O
2795	,	O
2795	associated	O
2795	with	O
2795	brain	O
2795	concentrations	O
2795	,	O
2795	were	O
2795	employed	O
2795	.	O
2795	[SEP]	O
2796	[CLS]	O
2796	co	O
2796	-	O
2796	administration	O
2796	of	O
2796	do	O
2796	##lut	O
2796	##eg	O
2796	##ra	O
2796	##vir	O
2796	with	O
2796	calcium	O
2796	carbon	O
2796	##ate	O
2796	or	O
2796	f	O
2796	##er	O
2796	##rous	O
2796	f	O
2796	##uma	O
2796	##rate	O
2796	had	O
2796	no	O
2796	effect	O
2796	on	O
2796	t	B-PK
2796	##max	I-PK
2796	of	O
2796	do	O
2796	##lut	O
2796	##eg	O
2796	##ra	O
2796	##vir	O
2796	(	O
2796	tables	O
2796	##2	O
2796	and	O
2796	3	O
2796	)	O
2796	.	O
2796	[SEP]	O
2797	[CLS]	O
2797	this	O
2797	analysis	O
2797	demonstrates	O
2797	the	O
2797	influence	O
2797	of	O
2797	the	O
2797	25	O
2797	(	O
2797	oh	O
2797	)	O
2797	d	O
2797	reference	O
2797	value	O
2797	on	O
2797	the	O
2797	au	B-PK
2797	##c	I-PK
2797	.	O
2797	[SEP]	O
2798	[CLS]	O
2798	as	O
2798	compared	O
2798	to	O
2798	oral	O
2798	administration	O
2798	,	O
2798	the	O
2798	su	O
2798	##pp	O
2798	##os	O
2798	##itor	O
2798	##ies	O
2798	produced	O
2798	a	O
2798	lower	O
2798	cm	B-PK
2798	##ax	I-PK
2798	and	O
2798	a	O
2798	delayed	O
2798	t	B-PK
2798	##max	I-PK
2798	,	O
2798	although	O
2798	au	B-PK
2798	##c	I-PK
2798	##0	I-PK
2798	-	I-PK
2798	24	I-PK
2798	values	O
2798	were	O
2798	comparable	O
2798	.	O
2798	[SEP]	O
2799	[CLS]	O
2799	although	O
2799	0	O
2799	.	O
2799	02	O
2799	μ	O
2799	##g	O
2799	of	O
2799	he	O
2799	##x	O
2799	##3	O
2799	-	O
2799	s	O
2799	##c	O
2799	##d	O
2799	##b	O
2799	-	O
2799	f	O
2799	##c	O
2799	-	O
2799	h	O
2799	##l	O
2799	and	O
2799	he	O
2799	##x	O
2799	##3	O
2799	-	O
2799	l	O
2799	##h	O
2799	without	O
2799	the	O
2799	f	O
2799	##c	O
2799	region	O
2799	produced	O
2799	no	O
2799	substantial	O
2799	differences	O
2799	compared	O
2799	with	O
2799	the	O
2799	p	O
2799	##bs	O
2799	control	O
2799	,	O
2799	the	O
2799	same	O
2799	dose	O
2799	of	O
2799	he	O
2799	##x	O
2799	##3	O
2799	-	O
2799	s	O
2799	##c	O
2799	##d	O
2799	##b	O
2799	-	O
2799	f	O
2799	##c	O
2799	-	O
2799	l	O
2799	##h	O
2799	significantly	O
2799	in	O
2799	##hibit	O
2799	##ed	O
2799	tumor	O
2799	growth	O
2799	in	O
2799	the	O
2799	s	O
2799	##cid	O
2799	mice	O
2799	(	O
2799	fi	O
2799	##g	O
2799	.	O
2799	8	O
2799	##a	O
2799	)	O
2799	.	O
2799	[SEP]	O
